PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Walker, RL; Clark, ME; Sanders, SH				Walker, Robyn L.; Clark, Michael E.; Sanders, Steven H.			The "Postdeployment Multi-Symptom Disorder": An Emerging Syndrome in Need of a New Treatment Paradigm	PSYCHOLOGICAL SERVICES			English	Article						chronic pain; postconcussive syndrome; posttraumatic stress disorder; treatment	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; OPERATIONS ENDURING FREEDOM; CHRONIC PAIN; VETERANS; WAR; POLYTRAUMA; SOLDIERS; BLAST; CARE	Many veterans of Operation Enduring Freedom and Operation Iraqi Freedom have incurred blast related injuries during deployment. One of the most common blast related injuries is mild traumatic brain injury, with the long-term consequences known as postconcussive Syndrome (PCS). Because of frequent combat related injuries and lengthy deployments, many OEF/OIF returnees also report ongoing pain problems and symptoms of posttraumatic stress disorder (PTSD). A substantial percentage of these returning service members present to Department of Veterans Affairs facilities with multiple comorbid symptoms of PCS, pain, and PTSD, which we have termed "Post-deployment Multi-Symptom Disorder." Despite the recent clinical literature suggesting that this clinical triad of symptoms appears to be a common phenomenon that may be resistant to current treatments, there has been no guidance toward how to best manage these problems. This article introduces the conceptualization of this new "disorder" comprised of the clinical triad of PCS, pain, and PTSD symptoms, and proposes an integrated treatment model based on the current empirically supported treatments for each of these conditions.	[Walker, Robyn L.; Clark, Michael E.; Sanders, Steven H.] James A Haley Vet Affairs Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL USA; [Clark, Michael E.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA	Walker, RL (corresponding author), Chron Pain Rehabil Program 2CW, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Robyn.Walker2@va.gov					American Psychiatric Association, 2004, PRACT GUID TREATM PA; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 2009, VA DOD CLIN PRACT GU; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; BENEDEK DM, 2009, GUIDELINE WATCH PRAC; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; Commission on Accreditation of Rehabilitation Facilities. (CARF), 2009, MED REH STAND MAN; Foa E.B., 2008, EFFECTIVE TREATMENTS; Gallagher R, 2006, J AM MED DIR ASSOC, V7, P432, DOI 10.1016/j.jamda.2006.04.010; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; HICKLING EJ, 1992, J ANXIETY DISORD, V6, P285, DOI 10.1016/0887-6185(92)90040-E; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Institute of Medicine, 2007, TREATM PTSD ASS EV; Kalra R, 2008, FED PRACT, V25, P36; Kang HK, 2005, NEW ENGL J MED, V352, P1289, DOI 10.1056/NEJMp058024; Keane TM., 2002, ANXIETY ITS DISORDER, P418; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Marlatt GA, 1996, ADDICT BEHAV, V21, P779, DOI 10.1016/0306-4603(96)00042-1; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Merskey H., 1994, IASP TASK FORCE TAXO, P209; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MUSE M, 1986, PAIN, V25, P389, DOI 10.1016/0304-3959(86)90243-5; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Otis J. D., 2008, S COND VISN 21 POST; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Otis JD, 2009, PAIN MED, V10, P1300, DOI 10.1111/j.1526-4637.2009.00715.x; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sanders Steven H, 2005, Pain Pract, V5, P303, DOI 10.1111/j.1533-2500.2005.00033.x; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Turk D. C., INTERDISCIP IN PRESS; Veterans Health Administration, 2003, NAT PAIN MAN STRAT; Veterans Health Administration, 2006, VHA HDB 2A, P1; Veterans Health Administration Department of Defense, 2007, VA DOD CLIN PRACT GU; Veterans Health Administration Department of Defense, 2003, VA DOD CLIN PRACT GU; Veterans Health Administration Department of Defense, 2004, VA DOD CLIN PRACT GU; Warden DL, 2005, J NEUROTRAUM, V22, P1178; World Health Organization, 1994, WHO AN PAIN MAN LADD	62	37	37	0	5	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1541-1559	1939-148X		PSYCHOL SERV	Psychol. Serv.	AUG	2010	7	3					136	147		10.1037/a0019684			12	Psychology, Clinical	Psychology	789QG	WOS:000292529800005					2021-06-18	
J	Malec, JF; Brown, AW; Moessner, AM; Stump, TE; Monahan, P				Malec, James F.; Brown, Allen W.; Moessner, Anne M.; Stump, Timothy E.; Monahan, Patrick			A Preliminary Model for Posttraumatic Brain Injury Depression	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Rehabilitation	IMPAIRED SELF-AWARENESS; CLOSED-HEAD-INJURY; MOOD DISORDERS; INDIVIDUALS; INVENTORY; SEQUELAE; PERSONALITY; SEVERITY; SCALE	Malec JF, Brown AW, Moessner AM, Stump TE, Monahan P. A preliminary model for posttraumatic brain injury depression. Arch Phys Med Rehabil 2010;91:1087-97. Objective: To develop, based on previous research, and evaluate a model for depression after traumatic brain injury (TBI). Design: Cross-sectional structural equation modeling (SEM) of data from consecutively recruited patients. Setting: Acute hospital and inpatient rehabilitation units. Participants: Adult patients (N=158) after hospital admission for moderate to severe TBI. Interventions: Not applicable. Main Outcome Measures: External appraisal of ability in participants was measured by the Mayo-Portland Adaptability Inventory (MPAI-4) Ability Index completed by a TBI clinical nurse specialist. Patient self-appraisal of post-TBI ability and depression were measured by the Awareness Questionnaire and Beck Depression Inventory-II. Functional outcome 1 year after injury was assessed with the MPAI-4 Participation Index. Results: Successive SEM resulted in a parsimonious model with excellent fit. Consistent with prior research, a moderately strong association between self-appraisal of post-TBI ability and depression was found. Injury severity, as measured by the duration of posttraumatic amnesia (PTA), was not significantly associated with post-TBI depression. The 1-year functional outcome was associated with depression and TBI severity. Conclusions: The strong association between self-appraisal of post-TBI ability and depression is consistent with the cognitive-behavioral model of depression and recommends consideration and further study of cognitive-behavioral therapy for post-TBI depression. The lack of association between TBI severity and depression may represent the indirect and proxy nature of current measures of TBI severity such as PTA. Emerging neuroimaging techniques (eg, diffusion tensor imaging, magnetic resonance imaging spectroscopy) may provide the more direct measures of disruption of brain function after TBI that are needed to advance this line of research.	[Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN 46077 USA; [Malec, James F.] Indiana Univ, Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Stump, Timothy E.; Monahan, Patrick] Indiana Univ, Sch Med, Div Biostat, Indianapolis, IN USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Moessner, Anne M.] Mayo Clin, Dept Nursing, Rochester, MN USA	Malec, JF (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46077 USA.	jmalec@rhin.com		Brown, Allen W./0000-0001-7228-3351	National Institute for Disability and Rehabilitation Research [H133A020507]	Supported by the National Institute for Disability and Rehabilitation Research (FBI Model System grant no. H133A020507).	Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Beck AT, 1967, DEPRESSION CAUSES TR; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF, MANUAL MAYO PORTLAND; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PHATAK VS, 2007, 35 ANN M INT NEUR SO; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Wallace CA, 2000, BRAIN INJURY, V14, P549; WITOL AD, 1996, J VOCATIONAL REHABIL, V7, P159	55	37	37	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2010	91	7					1087	1097		10.1016/j.apmr.2010.04.002			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	625PM	WOS:000279907400013	20599048				2021-06-18	
J	Dhawan, J; Benveniste, H; Nawrocky, M; Smith, SD; Biegon, A				Dhawan, Jasbeer; Benveniste, Helene; Nawrocky, Marta; Smith, S. David; Biegon, Anat			Transient focal ischemia results in persistent and widespread neuroinflammation and loss of glutamate NMDA receptors	NEUROIMAGE			English	Article						Stroke; Autoradiography; beta-imager; [H-3]PK11195; [H-3]MK801; Microglia; Neuroinflammation	MIDDLE CEREBRAL-ARTERY; METHYL-D-ASPARTATE; CLOSED-HEAD INJURY; PERIPHERAL BENZODIAZEPINE-RECEPTORS; POSITRON-EMISSION-TOMOGRAPHY; BINDING-SITES; IN-VIVO; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; BRAIN-LESIONS	Stroke is accompanied by neuroinflammation in humans and animal models. To examine the temporal and anatomical profile of neuroinflammation and NMDA receptors (NMDAR) in a stroke model, rats (N=17) were subjected to a 90 min occlusion of the middle cerebral artery (MCAO) and compared to sham (N=5) and intact (N=4) controls. Striatal and parietal cortical infarction was confirmed by MRI 24 h after reperfusion. Animals were killed 14 or 30-40 days later and consecutive coronal cryostat sections were processed for quantitative autoradiography with the neuroinflammation marker [H-3]PK11195 and the NMDAR antagonist [H-3]MK801. Significantly increased specific binding of [H-3]PK11195 relative to nonischemic controls was observed in the ipsilateral striatum (>3 fold, p 0.0001), substantia innominata (>2 fold) with smaller (20%-80%) but statistically significant (p = 0.002-0.04) ipsilateral increases in other regions partially involved in the infarct such as the parietal and piriform cortex, and in the lateral septum, which was not involved in the infarct. Trends for increases in PBR density were also observed in the contralateral hemisphere. In the same animals, NMDAR specific binding was significantly decreased bilaterally in the septum, substantia innominata and ventral pallidum. Significant decreases were also seen in the ipsilateral striatum, accumbens, frontal and parietal cortex. The different anatomical distribution of the two phenomena suggests that neuroinflammation does not cause the observed reduction in NMDAR, though loss of NMDAR may be locally augmented in ipsilateral regions with intense neuroinflammation. Persistent, bilateral loss of NMDAR, probably reflecting receptor down regulation and internalization, may be responsible for some of the effects of stroke on cognitive function which cannot be explained by infarction alone. Published by Elsevier Inc.	[Dhawan, Jasbeer; Benveniste, Helene; Nawrocky, Marta; Smith, S. David; Biegon, Anat] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; [Benveniste, Helene] SUNY Stony Brook, Dept Anesthesia, Stony Brook, NY 11794 USA	Biegon, A (corresponding author), Brookhaven Natl Lab, Dept Med, Bldg 490, Upton, NY 11973 USA.	biegon@bnl.gov			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 N5050285]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER	Supported in part by NIH RO1 N5050285 to Anat Biegon.	Bal-Price A, 2001, J NEUROSCI, V21, P6480; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; BENAVIDES J, 1983, J NEUROCHEM, V41, P1744, DOI 10.1111/j.1471-4159.1983.tb00888.x; BENVENISTE H, 1991, STROKE, V22, P259, DOI 10.1161/01.STR.22.2.259; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; Candelario-Jalil E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-3; Dalkara T, 1996, STROKE, V27, P127, DOI 10.1161/01.STR.27.1.127; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; Emsley HCA, 2008, NEUROCRIT CARE, V9, P125, DOI 10.1007/s12028-007-9035-x; FIORELLI M, 1991, J NEUROL SCI, V104, P135, DOI 10.1016/0022-510X(91)90302-N; Gerhard A, 2000, NEUROREPORT, V11, P2957, DOI 10.1097/00001756-200009110-00025; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; HAEFELIN TN, 2000, STROKE, V31, P1965; Hochstenbach J, 1998, CLIN REHABIL, V12, P514, DOI 10.1191/026921598666870672; IZQUIERDO I, 1991, TRENDS PHARMACOL SCI, V12, P128, DOI 10.1016/0165-6147(91)90527-Y; Koizumi J., 1986, NOSOTCHU, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; Li S, 2010, NEUROSCI LETT, V470, P106, DOI 10.1016/j.neulet.2009.12.064; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219; MEMEZAWA H, 1992, EXP BRAIN RES, V89, P67; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; OGAWA N, 1991, NEUROCHEM RES, V16, P519, DOI 10.1007/BF00974869; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; PENNEY JB, 1990, J NEUROL NEUROSUR PS, V53, P314, DOI 10.1136/jnnp.53.4.314; Pera J, 2004, J NEUROSCI RES, V78, P132, DOI 10.1002/jnr.20232; Peters O, 1998, J CEREBR BLOOD F MET, V18, P196, DOI 10.1097/00004647-199802000-00011; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; RAMSAY SC, 1992, LANCET, V339, P1054, DOI 10.1016/0140-6736(92)90576-O; Rojas S, 2007, J CEREBR BLOOD F MET, V27, P1975, DOI 10.1038/sj.jcbfm.9600500; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Rossini PM, 2003, LANCET NEUROL, V2, P493, DOI 10.1016/S1474-4422(03)00485-X; RYCK MD, 2000, NEUROPHARMACOLOGY, V39, P691; Schroeter M, 2009, J CEREBR BLOOD F MET, V29, P1216, DOI 10.1038/jcbfm.2009.36; SETTE G, 1993, STROKE, V24, P2046, DOI 10.1161/01.STR.24.12.2046; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Sobesky J, 2005, J CEREBR BLOOD F MET, V25, P1685, DOI 10.1038/sj.jcbfm.9600162; Spratt NJ, 2006, J NEUROSCI METH, V155, P285, DOI 10.1016/j.jneumeth.2006.01.020; Sunderland A, 1999, STROKE, V30, P949, DOI 10.1161/01.STR.30.5.949; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tsubokawa T, 2006, J NEUROSCI RES, V84, P832, DOI 10.1002/jnr.20977; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; WANG KM, 2000, STROKE, V31, P2055; Weber R, 2006, J CEREBR BLOOD F MET, V26, P591, DOI 10.1038/sj.jcbfm.9600241; Wiart M, 2007, STROKE, V38, P131, DOI 10.1161/01.STR.0000252159.05702.00; Wu O, 2007, J CEREBR BLOOD F MET, V27, P196, DOI 10.1038/sj.jcbfm.9600328; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhu DM, 2005, J NEUROSCI RES, V80, P104, DOI 10.1002/jnr.20422	57	37	43	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUN	2010	51	2					599	605		10.1016/j.neuroimage.2010.02.073			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	589IT	WOS:000277141200010	20206701	Green Accepted			2021-06-18	
J	Jungner, M; Grande, PO; Mattiasson, G; Bentzer, P				Jungner, Marten; Grande, Per-Olof; Mattiasson, Gustav; Bentzer, Peter			Effects on Brain Edema of Crystalloid and Albumin Fluid Resuscitation after Brain Trauma and Hemorrhage in the Rat	ANESTHESIOLOGY			English	Article							COLLOID ONCOTIC PRESSURE; CLOSED-HEAD TRAUMA; CEREBRAL BLOOD-FLOW; INTRACRANIAL-PRESSURE; HYPERTONIC SALINE; PLASMA OSMOLALITY; CRYOGENIC INJURY; VOLUME; PERMEABILITY; HETASTARCH	Background: It has been hypothesized that resuscitation with crystalloids after brain trauma increases brain edema compared with colloids, but previous studies on the subject have been inconclusive. To test this hypothesis, the authors compared groups resuscitated with either colloid or crystalloid. Methods: After fluid percussion injury, rats were subjected to a controlled hemorrhage of 20 ml/kg and were randomized to 5% albumin at 20 ml/kg (A20), isotonic Ringer's acetate at 50 ml/kg (C50), or 90 ml/kg (C90). After 3 or 24 h, water content in the injured cortex was determined using a wet/dry weight method. Blood volume was calculated from plasma volume, measured by I-125-albumin dilution, and hematocrit. Oncotic pressure and osmolality were measured with osmometers. Results: At 3 h, blood volume was equal in the A20 and C90 groups and lower in the C50 group. Oncotic pressure was reduced by 35-40% in the crystalloid groups and unchanged in the albumin group. Cortical water content in the A20 group was lower than in the C90 group (81.3 +/- 0.5% vs. 82.1 +/- 1.1%, P < 0.05), but it was not different from the C50 group (81.8 +/- 1.1%). At 24 h, oncotic pressure and blood volume were normalized in all groups, and cortical water content was significantly lower in the albumin group than in the crystalloid groups. Osmolality and arterial pressure were equal in all groups throughout the experiment. Conclusions: When given to the same intravascular volume expansion, isotonic crystalloids caused greater posttraumatic brain edema than 5% albumin at 3 and 24 h after trauma.	[Jungner, Marten; Grande, Per-Olof; Mattiasson, Gustav; Bentzer, Peter] Univ Lund Hosp, Dept Anesthesiol & Intens Care, SE-22185 Lund, Sweden	Jungner, M (corresponding author), Univ Lund Hosp, Dept Anesthesiol & Intens Care, SE-22185 Lund, Sweden.	marten.jungner@med.lu.se			Swedish Research Council (Stockholm, Sweden)Swedish Research Council [11581]; Medical Faculty of Lund University (Lund, Sweden); Region Skane (ALF) (Lund, Sweden); Anna and Edwin Berger Foundation (Lidingo, Sweden)	Received from the Department of Anesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden. Submitted for publication July 13, 2009. Accepted for publication December 30, 2009. Supported by grants from the Swedish Research Council (grant 11581) (Stockholm, Sweden), the Medical Faculty of Lund University (Lund, Sweden), Region Skane (ALF) (Lund, Sweden), and the Anna and Edwin Berger Foundation (Lidingo, Sweden).	Beaumont A, 2002, ACT NEUR S, V81, P217; Bentzer P, 2003, J NEUROTRAUM, V20, P447, DOI 10.1089/089771503765355522; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Bernard F, 2008, J TRAUMA, V64, P872, DOI 10.1097/TA.0b013e31803428cc; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chorny I, 1999, J NEUROSURG ANESTH, V11, P273, DOI 10.1097/00008506-199910000-00008; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; Dubniks M, 2007, INTENS CARE MED, V33, P2192, DOI 10.1007/s00134-007-0756-2; Eilig I, 2001, ANESTH ANALG, V92, P669, DOI 10.1213/00000539-200103000-00023; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; FALK JL, 1984, ACUTE CARE, V10, P59; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; FENSTERMACHER JD, 1981, PHARMACOL THERAPEUT, V14, P217, DOI 10.1016/0163-7258(81)90062-0; FENSTERMACHER JD, 1984, VOLUME REGULATION CE, P384; Grande PO, 2008, ACTA ANAESTH SCAND, V52, P738, DOI 10.1111/j.1399-6576.2008.01688.x; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P554, DOI 10.1097/00000542-198910000-00013; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; LAMKE L-O, 1976, Resuscitation, V5, P93, DOI 10.1016/0300-9572(76)90029-0; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Oqvist BW, 1999, NEPHROL DIAL TRANSPL, V14, P1898, DOI 10.1093/ndt/14.8.1898; Persson J, 2005, INTENS CARE MED, V31, P296, DOI 10.1007/s00134-004-2510-3; PODUSLO JF, 1994, P NATL ACAD SCI USA, V91, P5705, DOI 10.1073/pnas.91.12.5705; Rise IR, 1998, J NEUROSURG, V89, P454, DOI 10.3171/jns.1998.89.3.0454; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Talmor D, 1998, ANESTH ANALG, V86, P1225, DOI 10.1097/00000539-199806000-00017; TOMITA H, 1994, ACTA NEUROCHIR, P547; Unterberg AW, 1997, ACT NEUR S, V70, P106; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	39	37	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2010	112	5					1194	1203		10.1097/ALN.0b013e3181d94d6e			10	Anesthesiology	Anesthesiology	591FL	WOS:000277284800024	20395822	Bronze			2021-06-18	
J	van Kessel, ME; van Nes, IJW; Brouwer, WH; Geurts, ACH; Fasotti, L				van Kessel, Marlies E.; van Nes, Ilse J. W.; Brouwer, Wiebo H.; Geurts, Alexander C. H.; Fasotti, Luciano			Visuospatial asymmetry and non-spatial attention in subacute stroke patients with and without neglect	CORTEX			English	Article						Hemi-inattention; Behavioural Inattention Task; Reaction time task; General attention	UNILATERAL SPATIAL NEGLECT; CLOSED-HEAD-INJURY; HEMISPATIAL NEGLECT; SUSTAINED ATTENTION; REACTION-TIME; DIVIDED ATTENTION; VISUAL NEGLECT; BRAIN-DAMAGE; REHABILITATION; DEFICITS	Asymmetry in performance and an association with non-lateralized attention are often mentioned as two important aspects of the clinical manifestation of visuospatial neglect. Both these aspects were investigated in 21 left (LH) and 24 right hemisphere (RH) stroke patients and in 20 healthy subjects. The letter and star cancellation subtests of the Behavioural Inattention Task (BIT) and a computerized visual reaction time task (CVRT) with stimuli presented either left, central or right in extrapersonal space were administered. In LH patients, the calculation of BIT asymmetry scores allowed a better distinction between patients with and without neglect than raw omission scores. However, in RH patients, raw and asymmetry scores led to similar classifications. In the CVRT, raw and asymmetry scores for the number of omissions also produced identical classifications. Thus, the computation of asymmetry scores for omissions did not substantially refine the diagnosis of neglect. On the other hand, more patients were classified as neglect patients by using CVRT reaction time (RT) asymmetry scores than by using BIT or CVRT omission scores. Ipsilesional RT's were chosen as a measure of general, non-lateralized attention. The ipsilesional RT's of the LH and RH patients did not differ from the healthy subjects' lateral RT's. However, within the RH group, patients with both RT asymmetries and BIT scores above cut-off level showed longer ipsilesional RT's than patients with defective RT asymmetries but normal BIT scores. This supports the idea of an interaction between lateralized and non-lateralized attentional components in neglect, in which the presence of general attentional deficits exacerbates the severity of neglect symptoms. RT tasks may contribute to the detection of asymmetries in visuospatial attention in patients with subclinical neglect symptoms, who might compensate for their lateralized deficit in paper-and-pencil tasks employing intact general attention. (C) 2009 Elsevier Srl. All rights reserved.	[van Kessel, Marlies E.; van Nes, Ilse J. W.; Geurts, Alexander C. H.; Fasotti, Luciano] Sint Maartensklin Res Dev & Educ, NL-6500 GM Nijmegen, Netherlands; [Fasotti, Luciano] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands; [Brouwer, Wiebo H.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Geurts, Alexander C. H.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands	van Kessel, ME (corresponding author), Sint Maartensklin Res Dev & Educ, POB 9011, NL-6500 GM Nijmegen, Netherlands.	m.vankessel@maartenskliniek.nl	Geurts, Alexander/H-8032-2014	Geurts, Alexander/0000-0001-7478-1119; van Nes, Ilse/0000-0003-3249-3789	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [14350009]	This research was supported by Research Grant 14350009 from the Netherlands Organisation for Health Research and Development.	Anderson B, 2000, NEUROPSYCHOLOGIA, V38, P785, DOI 10.1016/S0028-3932(99)00137-2; Azouvi P, 2002, J NEUROL NEUROSUR PS, V73, P160, DOI 10.1136/jnnp.73.2.160; Bartolomeo P, 1999, NEUROLOGY, V53, P2023, DOI 10.1212/WNL.53.9.2023; BARTOLOMEO P, 1994, NEUROLOGY, V44, P1710, DOI 10.1212/WNL.44.9.1710; Bartolomeo P, 2002, NEUROSCI BIOBEHAV R, V26, P217, DOI 10.1016/S0149-7634(01)00065-3; Bowen A, 1999, STROKE, V30, P1196, DOI 10.1161/01.STR.30.6.1196; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Deouell LY, 2005, J INT NEUROPSYCH SOC, V11, P697, DOI 10.1017/S13556177050824; DERME P, 1992, NEUROPSYCHOLOGIA, V30, P989, DOI 10.1016/0028-3932(92)90050-V; GAINOTTI G, 1991, J NEUROL NEUROSUR PS, V54, P1082, DOI 10.1136/jnnp.54.12.1082; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Halligan P, 1990, Int Disabil Stud, V12, P95; Heilman K.M.V.E., 1993, CLIN NEUROPSYCHOLOGY; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1979, ANN NEUROL, V5, P166, DOI 10.1002/ana.410050210; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; KAIZER F, 1988, STROKE, V19, P335, DOI 10.1161/01.STR.19.3.335; KARNATH HO, 1988, NEUROPSYCHOLOGIA, V26, P27, DOI 10.1016/0028-3932(88)90028-0; Kinsbourne M., 1993, UNILATERAL NEGLECT C; LADAVAS E, 1990, CORTEX, V26, P307, DOI 10.1016/S0010-9452(13)80083-4; Luaute J, 2006, NEUROSCI BIOBEHAV R, V30, P961, DOI 10.1016/j.neubiorev.2006.03.001; Malhotra P, 2006, CURR OPIN NEUROL, V19, P14, DOI 10.1097/01.wco.0000198101.87670.7e; Manly T, 2002, NEUROPSYCHOL REHABIL, V12, P289, DOI 10.1080/0960201044000101; MATTINGLEY JB, 1994, J NEUROL NEUROSUR PS, V57, P597, DOI 10.1136/jnnp.57.5.597; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; PONDS RW, 1988, J GERONTOL, V436, P151; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBERTSON I, 1992, INT J NEUROSCI, V62, P45; ROBERTSON I, 2004, COGNITIVE NEURAL BAS; Robertson IH, 2001, NEUROIMAGE, V14, pS85, DOI 10.1006/nimg.2001.0838; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P1527, DOI 10.1016/S0028-3932(97)00084-5; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; ROBERTSON IH, 1989, NEUROPSYCHOLOGIA, V272, P157; Samuelsson H, 1998, J CLIN EXP NEUROPSYC, V20, P73, DOI 10.1076/jcen.20.1.73.1481; Schendel KL, 2002, J CLIN EXP NEUROPSYC, V24, P941, DOI 10.1076/jcen.24.7.941.8390; SCHMIDT IW, 1996, APPL NEUROPSYCHOL, V34, P155; Vallar G, 1998, TRENDS COGN SCI, V2, P87, DOI 10.1016/S1364-6613(98)01145-0; Vallar Giuseppe, 2003, Adv Neurol, V93, P293; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wilson B., 1987, BEHAV INATTENTION TE	46	37	37	0	4	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	MAY	2010	46	5					602	612		10.1016/j.cortex.2009.06.004			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	581TN	WOS:000276547600003	19591978				2021-06-18	
J	Levy, AS; Salottolo, K; Bar-Or, R; Offner, P; Mains, C; Sullivan, M; Bar-Or, D				Levy, Andrew Stewart; Salottolo, Kristin; Bar-Or, Raphael; Offner, Patrick; Mains, Charles; Sullivan, Michael; Bar-Or, David			Pharmacologic Thromboprophylaxis Is a Risk Factor for Hemorrhage Progression in a Subset of Patients With Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Prophylaxis; Traumatic brain injury; Thromboembolism; Lovenox; Intracranial hemorrhage	VENOUS THROMBOEMBOLISM PROPHYLAXIS; MOLECULAR-WEIGHT HEPARIN; HEAD COMPUTED-TOMOGRAPHY; NONOPERATIVE MANAGEMENT; ENOXAPARIN PROPHYLAXIS; 1602 EPISODES; DATA-BANK; SAFETY; PATTERNS; FAILURE	Background: Pharmacologic thromboprophylaxis (PTP) may exacerbate intracranial hemorrhage (ICH) in patients with traumatic brain injury (TBI). We examined risk factors for hemorrhage progression in patients with blunt TBI and hypothesized that PTP would increase ICH progression in a subset of these patients. Methods: We retrospectively studied patients with TBI admitted to our level I trauma center during 19 months. Progression of hemorrhage was examined in two populations: patients with a stable initial follow-up (F/U) computed tomography (CT) and patients with hemorrhage progression on initial F/U CT. Risk factors potentially associated with hemorrhage progression were analyzed using logistic regression. Timing of PTP was defined two ways: exposed to PTP versus not exposed; early (<72 hours), late (>= 72 hours), or no PTP. Results: Three hundred forty patients with TBI were reviewed and hemorrhage progression occurred in 32.4% (n = 110) of patients of which 59.1% were considered clinically significant. In patients with ICH progression on initial F/U CT, predictors of subsequent hemorrhage progression include exposure to PTP (odds ratio [OR]: 13.07, p = 0.01), extradural/subdural hemorrhage (OR: 5.15, p = 0.03), Glasgow Coma Score 3-8 (OR: 4.64, p = 0.03), and body mass index >= 25 (OR = 4.32, p = 0.03). PTP was not significantly associated with hemorrhage progression in patients with a stable initial F/U CT. Conclusions: These findings suggest that PTP use is associated with a 13-fold increased odds of further hemorrhage progression in patients whose F/U CT within 1 day of admission showed ICH progression; 16% of this risk can be attributed to receiving PTP. Conversely, PTP may be safe in a subgroup of patients with TBI with no ICH progression on initial F/U CT.	[Salottolo, Kristin; Bar-Or, Raphael; Sullivan, Michael; Bar-Or, David] Swedish Med Ctr, Trauma Res Dept, Englewood, CO 80113 USA; [Salottolo, Kristin; Bar-Or, Raphael; Offner, Patrick; Mains, Charles; Sullivan, Michael; Bar-Or, David] St Anthony Cent Hosp, Trauma Res Dept, Denver, CO USA; [Offner, Patrick; Mains, Charles] St Anthony Cent Hosp, Trauma Serv Dept, Denver, CO USA; [Mains, Charles; Bar-Or, David] Rocky Vista Univ, Aurora, CO USA	Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave,Room 4-454, Englewood, CO 80113 USA.	dbaror@dmibio.com	Bar-Or, David/AAE-9328-2020				*BRAIN TRAUM FDN A, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Depew AJ, 2008, AM SURGEON, V74, P906; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Peitzman A, 2000, J TRAUMA, V48, P374; Rogers SO, 2007, J TRAUMA, V62, P562; Shackford SR, 2004, ANN SURG, V240, P496; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	20	37	38	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					886	892		10.1097/TA.0b013e3181d27dd5			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	583GY	WOS:000276663100026	20386284				2021-06-18	
J	Walker, AJ; Nott, MT; Doyle, M; Onus, M; McCarthy, K; Baguley, IJ				Walker, Alexandra J.; Nott, Melissa T.; Doyle, Margaret; Onus, Margaret; McCarthy, Kathleen; Baguley, Ian J.			Effectiveness of a group anger management programme after severe traumatic brain injury	BRAIN INJURY			English	Article						Anger management; cognitive behaviour therapy; group intervention; acquired brain injury; challenging behaviour	AGGRESSIVE-BEHAVIOR; CHALLENGING BEHAVIORS; COMMUNITY SETTINGS; ADJUSTMENT; REDUCTION; PEOPLE; BURDEN; ADULTS; TBI	Primary objective: This study examined the effectiveness of a group approach to the treatment of anger management difficulties for people with severe traumatic brain injury (TBI). Research design: Repeated-measures design with convenience sampling. Method and procedure: Participants were community living clients of a tertiary brain injury service. The group programme consisted of 12 weekly sessions based on a cognitive behavioural therapy (CBT) model, with modifications to incorporate compensations for TBI-related cognitive impairment. Treatment effectiveness was measured using the State-Trait Anger Expression Inventory (STAXI), at pre-treatment, post-treatment and follow-up. Main outcomes and results: The programme was completed by 52 people across nine groups over the years 1998-2006 and 31 of these attended a follow-up session. Completion of the programme was associated with significant decreases in self-reported frequency with which anger was experienced (STAXI Trait Anger) and frequency of expression of anger (Anger Expression-Out), as well as a significant increase in reported attempts to control feelings of anger (Anger Control); changes were maintained at follow-up assessment. Conclusions: A group CBT approach shows promise as an effective community-based treatment for anger control issues after severe TBI. Future research directions should include a wait-list control group and objective rating of anger expression.	[Walker, Alexandra J.; Nott, Melissa T.; Doyle, Margaret; Onus, Margaret; McCarthy, Kathleen; Baguley, Ian J.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia	Walker, AJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	awalker@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Nott, Melissa T/M-6778-2018; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Nott, Melissa T/0000-0001-7088-5826; 			Alderman N, 1999, BRAIN INJURY, V13, P669; ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; DAWSON H, 1993, ANGER MANAGEMENT MAN; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Demark J, 2002, BRAIN INJURY, V16, P91, DOI 10.1080/02699050110102059; FELD M, 2007, DISS ABSTR INT B, V68, P1302; Hagiliassis N, 2005, J INTELLECT DEV DIS, V30, P86, DOI 10.1080/13668250500124950; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kelly G., 2004, BRAIN IMPAIR, V5, DOI [10.1375/brim.5.1.42.35398, DOI 10.1375/brim.5.1.42.35398]; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Mela M, 2008, J FORENSIC PSYCHI PS, V19, P396, DOI 10.1080/14789940802164090; Novaco R.W., 1975, ANGER CONTROL DEV EV; NOVACO RW, 1976, J CONSULT CLIN PSYCH, V44, P681, DOI 10.1037/0022-006X.44.4.681; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; OROZCO M, 2005, DISS ABSTR INT B, V66, P2313; PEAT J, 2005, MED STAT GUID DAT AN; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; SCHMITZ MJ, 2006, DISS ABSTR INT B, V66, P4500; Speilberger C. D., 1988, STATE TRAIT ANGER EX; SPEILBERGER CD, 1979, STATE TRAIT ANGER EX; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Whitehouse A. M., 1994, J COGN PSYCHOTHER, V8, P141; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	34	37	38	0	12	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2010	24	3					517	524		10.3109/02699051003601721			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800007	20184408				2021-06-18	
J	Bener, A; Omar, AOK; Ahmad, AE; Al-Mulla, FH; Rahman, YSA				Bener, Abdulbari; Omar, Azhar O. Kh.; Ahmad, Amal E.; Al-Mulla, Fatma H.; Rahman, Yassir S. Abdul			The pattern of traumatic brain injuries: A country undergoing rapid development	BRAIN INJURY			English	Article						Epidemiology and incidence; traumatic brain injury; morbidity; rehabilitation; mortality	EPIDEMIOLOGY	Background: Traumatic brain injuries (TBIs) remain an important public health problem in most industrial developed and especially in developing countries. This may also result in temporary or permanent disability. Objective: The aim of this study was to examine the trends in the distribution of traumatic brain injuries by gender, age, severity of injury and outcome and describe the incidence in the injury patterns. Design: This is a retrospective, descriptive, hospital-based study that included all cases of TBI during the period from January 2003 to December 2007. Patients and methods: This study is a retrospective analysis of 1919 patients with traumatic brain injury attended and treated at the Accident and Emergency Department of the Hamad General Hospital and other Trauma Centers of the Hamad Medical Corporation. Details of all TBI cases were extracted from the database of the Emergency Medical Services (EMS). Severity of TBI was assessed by Glasgow Coma Scale (GCS). Results: This study was based on 1919 patients suffering from traumatic brain injury, where 154 died and 97 (5.1%) of them died in the intensive care unit. The number of TBI cases increased remarkably in 2007 by 69.7%. However, the incidence rate was nearly stable across the years (4.2-4.9/10000 population). Of the total TBI cases, the majority of them were non-Qataris (72.7%) and men (88.6%). There was a significant increase in number of TBI cases between 2003 and 2007 in terms of age group (p = 0.003), nationality (p = 0.004) and severity of injuries (p = 0.05). The highest peak rate of TBI cases was observed among the population over 65 years old, followed by 15-24 year olds. Falls caused most TBIs in the 1-14 years age group, road traffic accidents in the age group 15-24 years and sports and recreation in the age group 25-34 years. Conclusion: The present study findings revealed that traumatic brain injury is a major public health problem, especially among young adults and older people. Although there was a sharp increase found in the number of TBI cases, the incidence rate of TBI took a stable trend during the study period.	[Bener, Abdulbari] Hamad Med Corp, Dept Epidemiol & Med Stat, Weill Cornell Med Coll, Hamad Gen Hosp, Doha, Qatar; [Bener, Abdulbari] Univ Manchester, Dept Evidence Populat Hlth Unit, Sch Epidemiol & Hlth Sci, Manchester, Lancs, England; [Omar, Azhar O. Kh.; Al-Mulla, Fatma H.] Hamad Med Corp, Dept Pediat, Doha, Qatar; [Ahmad, Amal E.] Hamad Med Corp, Speech Therapy Unit, Rehabil Dept, Doha, Qatar; [Rahman, Yassir S. Abdul] Hamad Med Corp, Dept Trauma Surg, Doha, Qatar	Bener, A (corresponding author), Hamad Med Corp, Dept Epidemiol & Med Stat, Weill Cornell Med Coll, Hamad Gen Hosp, POB 3050, Doha, Qatar.	abener@hmc.org.qa	BENER, ABDULBARI/AAC-4436-2020				Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bener Abdulbari, 2009, Int Emerg Nurs, V17, P52, DOI 10.1016/j.ienj.2008.07.007; Bener Abdulbari, 2007, Int J Inj Contr Saf Promot, V14, P103, DOI 10.1080/17457300701212033; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; HAMAD BA, 2008, ANN HLTH REPORT; Hannay HJ, 2004, NEUROPHYSIOLOGICAL A, P158; HANNAY HJ, NEUROPSYCHOLOGICAL A; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KLAUBER MR, 1978, AM J EPIDEMIOL, V1981, P500; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Melo JRT, 2004, ARQ NEURO-PSIQUIAT, V62, P711, DOI 10.1590/S0004-282X2004000400027; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Thurman DJ., 1995, GUIDELINES SURVEILLA; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Tsai WC, 2004, J CLIN NEUROSCI, V11, P126, DOI 10.1016/S0967-5868(03)00156-5; *US DEP HHS, 1997, INT CLASS DIS; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zitnay GA, 2005, ACT NEUR S, V93, P131	25	37	38	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	2					74	80		10.3109/02699050903508192			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500002	20085444				2021-06-18	
J	Ekmark-Lewen, S; Lewen, A; Israelsson, C; Li, GL; Farooque, M; Olsson, Y; Ebendal, T; Hillered, L				Ekmark-Lewen, Sara; Lewen, Anders; Israelsson, Charlotte; Li, Gui Lin; Farooque, Mohammad; Olsson, Yngve; Ebendal, Ted; Hillered, Lars			Vimentin and GFAP responses in astrocytes after contusion trauma to the murine brain	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; rat; mouse; astrocytes; gliosis	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; GLIAL REACTION; INJURY; RAT; IMMUNOREACTIVITY; PROLIFERATION; ALPHA	Purpose: Astroglial responses after traumatic brain injury are difficult to detect with routine morphological methods. The aims for this study were to compare the temporal and spatial expression pattern of vimentin-and glial fibrillary acidic protein (GFAP) in a weight drop model of mild cerebral contusion injury in the rat. We also wanted to study the vimentin response with immunohistochemistry and vimentin mRNA RT-PCR analysis in severe cortical contusion injury produced by the controlled cortical impact in the mouse. Methods: Vimentin and GFAP immunohistochemistry (1day, 3 days and 7 days) combined with vimentin mRNA RT-PCR analysis (1 h, 4 h, 22 h, 3 days and 7 days) were used after experimental traumatic brain injury in the rat and mouse. Results: Increases in post-traumatic vimentin mRNA levels in the cortex and in the hippocampus appeared together with vimentin immunoreactivity in astrocytes in the perimeter of the cortical lesion, in the subcortical white matter and in the hippocampus starting at one day after severe trauma. GFAP immunostaining revealed hypertrophic astrocytes peaking at day 3 in the perifocal cortical region. There was no significant increase in GFAP immunoreactivity in the white matter in the rat. However, in the mouse there was a slight increase in the number of GFAP positive cells in this region, 3 days after trauma. Overall the pattern of vimentin immunoreactivity was very similar in the rat and mouse. Conclusions: Vimentin immunoreactivity was more sensitive than the GFAP staining method to demonstrate the distribution and time course of astrocyte reactions after a contusion injury, especially in the white matter distant from the cortical lesion.	[Ekmark-Lewen, Sara; Lewen, Anders; Hillered, Lars] Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden; [Israelsson, Charlotte; Ebendal, Ted] Uppsala Univ, Dept Neurosci, Biomed Ctr, SE-75185 Uppsala, Sweden; [Li, Gui Lin; Farooque, Mohammad; Olsson, Yngve] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden	Lewen, A (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden.	anders.lewen@neurokir.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Hillered, Lars/0000-0002-2808-9292	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [7888, 0320]; Swedish Brain Foundation; Fredrik and Ingrid Thuring's Foundation; Swedish Association of Neurologically Disabled; Tore Nilsson's Foundation; A. Wiberg's Foundation; Ahlen's Foundation; Emil and Wera Cornell Foundation; Laerdal Foundation for Acute Medicine; O E and Edla Johansson's Foundation; King Gustaf V and Queen Victorias Foundation; Foundation for Stroke Research	We would like to thank Madeleine Jarild, Gunilla Tibbling, Khaled Ahmad Ata and Ulla Karlsson for their excellent technical help. Supported by grants from the Swedish Medical Research Council (projects no. 7888 and 0320), The Swedish Brain Foundation, Fredrik and Ingrid Thuring's Foundation, The Swedish Association of Neurologically Disabled, Tore Nilsson's Foundation, A. Wiberg's Foundation, Ahlen's Foundation, Emil and Wera Cornell Foundation, the Laerdal Foundation for Acute Medicine, O E and Edla Johansson's Foundation, King Gustaf V and Queen Victorias Foundation, and 1987 Foundation for Stroke Research.	Baldwin SA, 1996, GLIA, V16, P266; Bignami A., 1991, DISCUSS NEUROSCI, V111, P9; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; DAHL D, 1981, EXP NEUROL, V73, P496, DOI 10.1016/0014-4886(81)90283-1; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; ENG LF, 1992, PROGR BRAIN RES, V94; GIULIAN D, 1988, J NEUROSCI, V8, P709; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Motohashi O, 1997, J NEUROTRAUM, V14, P747, DOI 10.1089/neu.1997.14.747; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SELMAJ K, 1991, J NEUROCHEM, V57, P823, DOI 10.1111/j.1471-4159.1991.tb08225.x; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4	25	37	42	1	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2010	28	3					311	321		10.3233/RNN-2010-0529			11	Neurosciences	Neurosciences & Neurology	606QP	WOS:000278442500002	20479526				2021-06-18	
J	McCauley, SR; Wilde, EA; Merkley, TL; Schnelle, KP; Bigler, ED; Hunter, JV; Chu, ZL; Vasquez, AC; Levin, HS				McCauley, Stephen R.; Wilde, Elisabeth A.; Merkley, Tricia L.; Schnelle, Kathleen P.; Bigler, Erin D.; Hunter, Jill V.; Chu, Zili; Vasquez, Ana C.; Levin, Harvey S.			Patterns of Cortical Thinning in Relation to Event-Based Prospective Memory Performance Three Months after Moderate to Severe Traumatic Brain Injury in Children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							SURFACE-BASED ANALYSIS; CEREBRAL-CORTEX; GEOMETRICALLY ACCURATE; PREFRONTAL CORTEX; HEAD-INJURY; MRI; THICKNESS; REGIONS; SEGMENTATION; IMPAIRMENTS	While event-based prospective memory (EB-PM) tasks are a familiar part of daily life for children, currently no data exists concerning the relation between EB-PM performance and brain volumetrics after traumatic brain injury (TBI). This study investigated EB-PM in children (7 to 17 years) with moderate to severe TBI or orthopedic injuries. Participants performed an EB-PM task and concurrently underwent neuroimaging at three months postinjury. Surface reconstruction and cortical thickness analysis were performed using FreeSurfer software. Cortical thickness was significantly correlated with EB-PM (adjusting for age). Significant thinning in the left (dorsolateral and inferior prefrontal cortex, anterior and posterior cingulate, temporal lobe, fusiform, and parahippocampal gyri), and right hemispheres (dorsolateral, inferior, and medial prefrontal cortex, cingulate, and temporal lobe) correlated positively and significantly with EB-PM performance; findings are comparable to those of functional neuroimaging and lesion studies of EB-PM.	[McCauley, Stephen R.] Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, Hematol Oncol Sect, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Schnelle, Kathleen P.; Vasquez, Ana C.; Levin, Harvey S.] Univ Texas Houston Med Sch, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Merkley, Tricia L.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, Hematol Oncol Sect, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	mccauley@bcm.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Center for Medical Rehabilitation Research [K23-HD40896]; National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD040896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was presented (in part) at the 7th annual meeting of the North American Brain Injury Society, Austin, Texas, October 2009 and was supported by National Center for Medical Rehabilitation Research grant K23-HD40896 ("Prospective memory in normal and head-injured children," McCauley, PI) and National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Medical Rehabilitation Research or the National Institutes of Health.	Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Athinoula A., 2005, FREESURFER; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Cheng HD, 2008, BRAIN INJURY, V22, P697, DOI 10.1080/02699050802263035; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; DAUM I, 1994, INT J NEUROSCI, V77, P187, DOI 10.3109/00207459408986030; Daum I, 2000, BEHAV NEUROL, V12, P161, DOI 10.1155/2000/327304; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Eschen A, 2007, INT J PSYCHOPHYSIOL, V64, P259, DOI 10.1016/j.ijpsycho.2006.09.005; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; HAUSER RM, 1997, SOCIOECONOMIC INDEXE; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Herrmann D., 1999, HDB APPL COGNITION, P377; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; LOUDA J, 2007, Z NEUROPSYCHOL, V18, P91; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; Meacham J. A., 1982, MEMORY OBSERVED REME, P327; MEACHAM JA, 1976, 1284 MS; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Okuda J, 2007, INT J PSYCHOPHYSIOL, V64, P233, DOI 10.1016/j.ijpsycho.2006.09.009; Palmer HM, 2000, BRAIN COGNITION, V44, P103; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; TEASDALE G, 1974, LANCET, V2, P81; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; WILKINS AJ, 1978, PRACTICAL ASPECTS ME, P27; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	69	37	37	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2010	35	3					318	332	PII 921878856	10.1080/87565641003696866			15	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	594EX	WOS:000277518100006	20446135	Green Accepted			2021-06-18	
J	Mehta, A; Kochanek, PM; Tyler-Kabara, E; Adelson, PD; Wisniewski, SR; Berger, RP; Sidoni, MD; Bell, RL; Clark, RSB; Bell, MJ				Mehta, Amit; Kochanek, Patrick M.; Tyler-Kabara, Elizabeth; Adelson, P. David; Wisniewski, Stephen R.; Berger, Rachel P.; Sidoni, Maria D.; Bell, Rachelle L.; Clark, Robert S. B.; Bell, Michael J.			Relationship of Intracranial Pressure and Cerebral Perfusion Pressure with Outcome in Young Children after Severe Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Intracranial hypertension; Neurotrauma database; Glasgow Outcome Scale; Physiologic parameters; Childhood neurotrauma, inflicted	SEVERE HEAD-INJURY; IMPACT; NEUROPATHOLOGY; EPIDEMIOLOGY	Traumatic brain injury (TBI) is the most common cause of death for children less than 18 years of age. Current standards of care for children with severe TBI include monitoring of intracranial pressure (ICP), and goal-directed therapies to minimize ICP and optimize cerebral perfusion pressure (CPP; the mathematical difference between the mean arterial pressure and ICP). Current guidelines for ICP and CPP thresholds suggest that age-based thresholds should be adopted, but few studies have included the youngest children affected by TBI (those <2 years of age). We performed a retrospective analysis of our pediatric neurotrauma database to determine if ICP and CPP thresholds associated with favorable neurological outcome could be determined, or if the number of episodic alterations in the parameters (ICP >15 or >20 mm Hg; CPP <40 mm Hg, <45 mm Hg or <50 mm Hg) was different between children with favorable and unfavorable outcomes (based on dichotomous Glasgow Outcome Scale score at 6 months after TBI). Data from 22 children (of whom 81% had suffered from inflicted childhood neurotrauma) were analyzed in the first 7 days. Children with unfavorable outcome had more hourly readings of CPP of <45 mm Hg compared to children with favorable outcome [median (25-75%): 2 (1-31) vs. 0 (0-2); p < 0.05]. There was no difference between the number of hourly readings of ICP of >20 mm Hg between the outcome groups [median (25-75%): favorable 0 (0-1) vs. unfavorable 1 (0-4); p = 0.17]. To our knowledge, this is the first exploratory report to test if CPP and ICP thresholds can be established for this young population of children after TBI, and it suggests a CPP target threshold of 45 mm Hg. Despite good ICP control in this population, there was still a 50% incidence of unfavorable outcome, suggesting that there may be unique physiologic parameters that need to be targeted in infants with severe TBI. A prospective study is needed to fully determine what goals should be targeted for this vulnerable population. Copyright (C) 2010 S. Karger AG, Basel	[Mehta, Amit] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Tyler-Kabara, Elizabeth; Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Adelson, P. David] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA	Mehta, A (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	amit.mehta@chp.edu	Tyler-Kabara, Elizabeth/H-4930-2013; Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Heron M, 2010, PEDIATRICS, V125, P4, DOI 10.1542/peds.2009-2416; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Pearl GS, 1998, CLIN LAB MED, V18, P39; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037	24	37	40	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					413	419		10.1159/000316804			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900009	20847542				2021-06-18	
J	Tay, SY; Ang, BT; Lau, XY; Meyyappan, A; Collinson, SL				Tay, Sze Yan; Ang, Beng Ti; Lau, Xin Yin; Meyyappan, Amutha; Collinson, Simon Lowes			Chronic Impairment of Prospective Memory after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive functioning; mild traumatic brain injury; prospective memory	CLOSED-HEAD INJURY; COMPLEX INTENTIONS; UNITED-STATES; MODERATE; REALIZATION; PERFORMANCE; SYMPTOMS; DISEASE; EVENT; TIME	Prospective memory (PM), the ability to recall future intentions, is crucial for independent living. Impairment of PM is a common complaint following head injury and is a significant impediment to good recovery, yet no studies have explored PM in mild traumatic brain injury (mTBI). In this study, prospective memory was examined in 31 mTBI patients and matched controls within a month of injury and 3 months after. mTBI patients performed more poorly than controls on the MIST task (Raskin, 2004) within the first month following injury, indicating that PM impairment is part of the acute cognitive sequelae of mTBI. These problems persisted beyond 3 months post-injury, suggesting that PM may be a sensitive indicator of cerebral compromise in mild brain injuries.	[Tay, Sze Yan; Meyyappan, Amutha; Collinson, Simon Lowes] Natl Univ Singapore, Dept Psychol, Fac Arts & Social Sci, Singapore 117570, Singapore; [Tay, Sze Yan] Singapore Gen Hosp, Dept Neurol, Brain Ctr, Singapore 0316, Singapore; [Ang, Beng Ti] Natl Inst Neurosci, Dept Neurosurg, Singapore, Singapore; [Lau, Xin Yin] Macquarie Univ, Dept Psychol, Ctr Emot Hlth, Sydney, NSW 2109, Australia	Tay, SY (corresponding author), Natl Univ Singapore, Dept Psychol, Fac Arts & Social Sci, Block AS4,02-07,9 Arts Link, Singapore 117570, Singapore.	tay.sze.yan@sgh.com.sg		Collinson, Simon Lowes/0000-0001-9232-9732			Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beck A, 1996, BECKS DEPRESSION INV, V2nd; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Burgess P.W., 2008, PROSPECTIVE MEMORY C, P235; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; CURRY LM, 1991, PHILADELPHIA HEAD IN; DIETER JNI, 1999, WHIPLASH RELATED HEA, P879; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Heng K. W. J., 2007, SMJ Singapore Medical Journal, V48, P1107; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jennett B, 1981, MANAGEMENT HEAD INJU; Jones S, 2006, NEUROPSYCHOLOGY, V20, P144, DOI 10.1037/0894-4105.20.2.144; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Karantzoulis S, 2009, J INT NEUROPSYCH SOC, V15, P407, DOI 10.1017/S1355617709090596; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2005, J NEUROL NEUROSUR PS, V76, P1501, DOI 10.1136/jnnp.2004.051268; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M, 2003, INT J PSYCHOL, V38, P193, DOI 10.1080/00207590344000114; Kliegel M., 2008, PROSPECTIVE MEMORY C, P283; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McHugh T, 2006, BRAIN COGNITION, V60, P209; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; PERINI S, 1984, NEUROL CLIN, V2, P719, DOI 10.1016/S0733-8619(18)31071-5; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Raskin SA, 2009, BRAIN IMPAIR, V10, P23, DOI 10.1375/brim.10.1.23; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Stein S. C., 1996, NEUROTRAUMA, P31; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tombaugh TN, 1996, TEST MEMORY MALINGER; Umile EM, 1998, BRAIN INJURY, V12, P577; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WRIGHTON P, 1999, MILD HEAD INJURY GUI	52	37	37	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					77	83		10.1089/neu.2009.1074			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200006	19698071				2021-06-18	
J	Jacobsson, LJ; Westerberg, M; Soderberg, S; Lexell, J				Jacobsson, L. J.; Westerberg, M.; Soderberg, S.; Lexell, J.			Functioning and disability 6-15 years after traumatic brain injuries in northern Sweden	ACTA NEUROLOGICA SCANDINAVICA			English	Article						disability evaluation; Glasgow Outcome Scale; outcome; recovery of function; traumatic brain injury; questionnaires	COMMUNITY INTEGRATION QUESTIONNAIRE; FOLLOW-UP; PRACTICAL SCALE; REHABILITATION; ADULTS; COMA; ADJUSTMENT; MODERATE; LIFE	Objectives - To assess long-term functioning and disability after traumatic brain injury (TBI). Material and methods - Individuals (n = 88) in Norrbotten, northern Sweden, who had been transferred for neurosurgical care were assessed with internationally established TBI outcome measures 6-15 years post-injury. Results - There was an improvement in overall outcome from discharge from inpatient rehabilitation to follow-up. Many individuals had a high degree of motor and cognitive functioning, which enabled them to live independently in their own home without assistance, but there remained a disability related to community reintegration and social participation. This affected their productivity and to some degree their marital stability. The remaining disability and reduced productivity were related to the age at injury and the injury severity. Conclusions Our data showed that individuals with a TBI can achieve and maintain a high degree of functioning many years after the injury. Increasing age and a greater injury severity contributed to their long-term disability.	[Jacobsson, L. J.] Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden; [Jacobsson, L. J.; Soderberg, S.; Lexell, J.] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; [Westerberg, M.] Lulea Univ Technol, Dept Business Adm & Social Sci, S-95187 Lulea, Sweden; [Lexell, J.] Univ Lund Hosp, Dept Rehabil Med, S-22185 Lund, Sweden; [Lexell, J.] Lund Univ, Dept Clin Sci, Div Rehabil Med, Lund, Sweden	Jacobsson, LJ (corresponding author), Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden.	lars.jacobsson@nll.se	Westerberg, Mats/C-3300-2012	Westerberg, Mats/0000-0001-5464-9292; Lexell, Jan/0000-0001-5294-3332; Jacobsson, Lars/0000-0002-1127-1178	Norrbacka-Eugenia Foundation; Cancer and Traffic Injury Fund; Norrbotten County Council; Swedish Association	This study was supported by grants from the Norrbacka-Eugenia Foundation, the Cancer and Traffic Injury Fund, Norrbotten County Council, the Swedish Association of Brain Injured and their Families and Skane county councils research and development foundation.	Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson I, 1996, CHILD NERV SYST, V12, P460, DOI 10.1007/BF00261625; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; JENNETT B, 1975, LANCET, V1, P480; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; KIM JA, 1997, OCCUPATIONAL THERAPY, V4, P178; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Sorbo AK, 2009, INT J REHABIL RES, V32, P139, DOI 10.1097/MRR.0b013e328325a5d1; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	33	37	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	DEC	2009	120	6					389	395		10.1111/j.1600-0404.2009.01238.x			7	Clinical Neurology	Neurosciences & Neurology	519IH	WOS:000271758800003	19922583				2021-06-18	
J	Castellani, C; Bimbashi, P; Ruttenstock, E; Sacherer, P; Stojakovic, T; Weinberg, AM				Castellani, C.; Bimbashi, P.; Ruttenstock, E.; Sacherer, P.; Stojakovic, T.; Weinberg, A-M			Neuroprotein s-100B-a useful parameter in paediatric patients with mild traumatic brain injury?	ACTA PAEDIATRICA			English	Article						Children; Mild traumatic brain injury; Neuroprotein; Neurotrauma; S-100	MINOR HEAD-INJURY; GLASGOW COMA SCALE; PROTEIN MEASUREMENTS; COMPUTED-TOMOGRAPHY; SERUM S100B; MANAGEMENT; DAMAGE	Aims: To examine the correlation of S-100B to cranial computerized tomography (CCT) scan results in children after mild traumatic brain injury (MTBI). Methods: One hundred and nine paediatric patients (0-18 years) with MTBI were included in this prospective single-centre study. Serum was collected within 6 h of trauma for determination of serum S-100B. The upper reference of S-100B was set to 0.16 mu g/L. A CCT scan was performed in all patients and the results were correlated to the S-100B values. Results: Computerized tomography was abnormal in 36 patients showing intracerebral haemorrhages and/or skull fractures. Serum S-100B level was significantly higher in patients with a pathological condition as shown in CT scan results (p = 0.003). There were no false negative, but 42 false positive test results for S-100B. This resulted in a sensitivity of 1.00, specificity of 0.42, positive predictive value of 0.46 and negative predictive value of 1.00. An area under the receiver operating curve of 0.68 was calculated. Conclusion: S-100B is a valuable tool to rule out patients with pathological CCT findings in a collective of paediatric patients with MTBI. Elevations of S-100B do not necessarily lead to a pathological finding in the CT scan, but values below the cut-off safely rule out the evidence of intracranial lesions.	[Castellani, C.; Bimbashi, P.; Ruttenstock, E.; Sacherer, P.; Weinberg, A-M] Med Univ Graz, Dept Pediat Surg, A-8036 Graz, Austria; [Stojakovic, T.] Med Univ Graz, Dept Med & Chem Diagnost, A-8036 Graz, Austria	Weinberg, AM (corresponding author), Med Univ Graz, Dept Pediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria.	annelie.weinberg@t-online.de					Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Eide PK, 2003, ACTA NEUROCHIR, V145, P171, DOI 10.1007/s00701-002-1062-y; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; *ROCH DIAGN CORP, 2007, ROCH D EL R S100 PRO; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Stein SC, 1996, NEUROSURG QUART, V6, P108, DOI 10.1097/00013414-199606000-00004; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Vos PE, 2002, SHOCK, V18, P481, DOI 10.1097/00024382-200211000-00017	26	37	40	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	OCT	2009	98	10					1607	1612		10.1111/j.1651-2227.2009.01423.x			6	Pediatrics	Pediatrics	490HP	WOS:000269491100016	19843022				2021-06-18	
J	Derrett, S; Black, J; Herbison, GP				Derrett, Sarah; Black, James; Herbison, G. Peter			Outcome After Injury-A Systematic Literature Search of Studies Using the EQ-5D	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	25th Plenary Scientific Meeting of the EuroQol-Group	SEP, 2008	Maggiore, ITALY	EuroQol Grp		Wounds and injuries; Quality of life; EQ-5D	QUALITY-OF-LIFE; FEMORAL-NECK FRACTURES; RANDOMIZED CONTROLLED-TRIAL; PREVALENT VERTEBRAL FRACTURES; NOTTINGHAM HEALTH PROFILE; TRAUMATIC BRAIN-INJURY; TOTAL HIP-ARTHROPLASTY; INTERNAL-FIXATION; ELDERLY-PATIENTS; MAJOR TRAUMA	Purpose: Information is required about recovery after injury, including general health measures such as the EQ-5D. This project aimed to: (1) search for studies of injury outcome using the EQ-5D, (2) describe EQ-5D administration and analysis, (3) summarize reliability and validity, and (4) report EQ-5D outcomes. Methods: A systematic search was undertaken for publications (January 1990 to May 2008). Studies were excluded if the EQ-5D was not used or if injury was a secondary outcome or resulted from a degenerative condition. Results: Of 79 potentially eligible articles retrieved, 35 were excluded and 44 remained. Sample sizes ranged between n = 14 and n = 3,231. Two thirds of studies described injury outcomes, the remainder focused on specific treatments after injury. Of studies reporting EQ-513 index scores, most used the UK value set, and 29% did not specify a value set. In 16 studies, the EQ-5D was self-completed by participants, and in others, administration was by interviewer, proxy, or unspecified. Time of administration varied between 6 days and 7 years after injury. The absence of a cognitive dimension in the EQ-513 was a concern. Discussion: Given the global impact of injury-related disability, our search supports calls for comprehensive population-level research exploring outcomes. Many studies considered only specific treatments after injury, had small sample sizes, or were undertaken in wealthy countries. Although noting reservations about the EQ-51), such as the absence of a cognitive dimension; the EQ-SD being freely available to nonprofit-making organizations, and with many language versions available, seems suitable for studies in wealthy and poorer nations alike.	[Derrett, Sarah; Black, James] Univ Otago, Dunedin Sch Med, Injury Prevent Res Unit, Dunedin 9054, New Zealand; [Herbison, G. Peter] Univ Otago, Dunedin Sch Med, Dept Preventat & Social Med, Dunedin 9054, New Zealand	Black, J (corresponding author), Univ Otago, Dunedin Sch Med, Injury Prevent Res Unit, POB 913, Dunedin 9054, New Zealand.	james.black@otago.ac.nz	Black, James A/A-5917-2010	Black, James A/0000-0002-2200-3179; Herbison, Graham Peter/0000-0002-5684-024X; Derrett, Sarah/0000-0003-2867-0498			Alderman N, 2001, NEUROPSYCHOL REHABIL, V11, P529, DOI 10.1080/09602010042000231; Sanchez JLA, 2007, ARCH SURG-CHICAGO, V142, P50, DOI 10.1001/archsurg.142.1.50; Badia X, 2001, QUAL LIFE RES, V10, P307, DOI 10.1023/A:1012200508847; Badia X, 2001, INTENS CARE MED, V27, P1901, DOI 10.1007/s00134-001-1137-x; Badia Xavier, 2004, Health Qual Life Outcomes, V2, P41; Bahena-Salgado Yadira, 2007, Acta Ortop Mex, V21, P3; Bakar I, 2008, INJURY EXTRA, V39, P179; Baker SP, 1992, THE INJURY FACT BOOK; Barker M, 1996, ARCH DIS CHILD, V75, P156, DOI 10.1136/adc.75.2.156; BARNES J, 2006, EXPLORATORY STUDY RO, P354; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Blomfeldt R, 2005, J BONE JOINT SURG BR, V87B, P523, DOI 10.1302/0301-620X.87B4; Blomfeldt R, 2006, ACTA ORTHOP, V77, P638, DOI 10.1080/17453670610012728; Borgstrom F, 2006, OSTEOPOROSIS INT, V17, P1781, DOI 10.1007/s00198-006-0193-z; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; BRAZIER J, 1993, QUAL LIFE RES, V2, P169, DOI 10.1007/BF00435221; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Bryan S, 2004, INT J TECHNOL ASSESS, V20, P222, DOI 10.1017/S026646230400100X; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Burton DJC, 2005, INJURY, V36, P1190, DOI 10.1016/j.injury.2005.05.030; Chung B, 2004, AM J SPORT MED, V32, P1660, DOI 10.1177/0363546503262806; Cockerill W, 2004, OSTEOPOROSIS INT, V15, P113, DOI 10.1007/s00198-003-1547-4; Cryer C, 2008, INJURY PREV, V14, P74, DOI 10.1136/ip.2007.017327; deLateur BJ, 1997, ARCH PHYS MED REHAB, V78, P237, DOI 10.1016/S0003-9993(97)90026-5; Derrett S, 2005, INT J TECHNOL ASSESS, V21, P359, DOI 10.1017/S0266462305050476; Dhillon V, 2005, OSTEOPOROSIS INT, V16, P483, DOI 10.1007/s00198-004-1705-3; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Dolan P, 1999, OSTEOPOROSIS INT, V9, P196, DOI 10.1007/s001980050136; Dolan P, 1995, SOCIAL TARIFF EUROQO; ELVIK R, 1995, SOC SCI MED, V40, P1385, DOI 10.1016/0277-9536(94)00264-T; Enocson AG, 2006, ACTA ORTHOP, V77, P87, DOI 10.1080/17453670610045731; EssinkBot ML, 1997, MED CARE, V35, P522, DOI 10.1097/00005650-199705000-00008; Fingerhut LA, 2004, INJURY PREV, V10, P264, DOI 10.1136/ip.2004.007047; Frankema SPG, 2005, J TRAUMA, V58, P596, DOI 10.1097/01.TA.0000152551.39400.6F; Frihagen F, 2007, BMJ-BRIT MED J, V335, P1251, DOI 10.1136/bmj.39399.456551.25; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Garratt AM, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-48; *GBD INJ EXP GROUP, GBD INJ EXP GROUP HO; Giannoudis PV, 2002, INJURY, V33, P117, DOI 10.1016/S0020-1383(01)00073-0; Gobbi A, 2006, AM J SPORT MED, V34, P1763, DOI 10.1177/0363546506288853; Goodwin PC, 2003, PHYS THER, V83, P520, DOI 10.1093/ptj/83.6.520; Gopal S, 2004, J BONE JOINT SURG BR, V86B, P861, DOI 10.1302/0301-620X.86B6.13400; Haddon W., 1964, ACCIDENT RES METHODS; Holder Y, 2001, INJURY SURVEILLANCE; HOLLINGWORTH W, 1995, QUAL LIFE RES, V4, P325, DOI 10.1007/BF01593885; Holtslag HR, 2008, B WORLD HEALTH ORGAN, V86, P111, DOI 10.2471/BLT.06.033803; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Jagodic HK, 2006, CRIT CARE, V10, DOI 10.1186/cc5047; Jakob F, 2006, QJM-INT J MED, V99, P531, DOI 10.1093/qjmed/hcl073; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Keating J F, 2005, Health Technol Assess, V9, piii; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Kovacs FM, 2005, SPINE, V30, P1786, DOI 10.1097/01.brs.0000172159.47152.dc; Kumar K, 2005, CAN J NEUROL SCI, V32, P487, DOI 10.1017/S0317167100004492; Lash N, 2002, ANZ J SURG, V72, P724, DOI 10.1046/j.1445-2197.2002.02530.x; Laukontaus SJ, 2006, ANN VASC SURG, V20, P42, DOI 10.1007/s10016-005-9283-1; LEE AY, SINGA; Lindahl H, 2006, J BONE JOINT SURG AM, V88A, P1215, DOI 10.2106/JBJS.E.00457; Lips P, 2005, OSTEOPOROSIS INT, V16, P447, DOI 10.1007/s00198-004-1762-7; Lyons RA, 2008, INJURY PREV, V14, P3, DOI 10.1136/ip.2007.018192; Madhu TS, 2007, INJURY, V38, P598, DOI 10.1016/j.injury.2006.11.005; Marcacci M, 2005, CLIN ORTHOP RELAT R, P96, DOI 10.1097/01.blo.0000165737.87628.5b; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Miedel R, 2005, J BONE JOINT SURG BR, V87B, P68; Morrissey MC, 2006, AM J PHYS MED REHAB, V85, P490, DOI 10.1097/01.phm.0000219280.06297.bd; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P87; Neugebauer E, 2006, EUROPEAN J TRAUMA, V32, P44, DOI [10.1007/s00068-006-0150-8, DOI 10.1007/S00068-006-0150-8]; Nikken JJ, 2005, RADIOLOGY, V236, P958, DOI 10.1148/radiol.2362041130; Oleksik A, 2000, J BONE MINER RES, V15, P1384, DOI 10.1359/jbmr.2000.15.7.1384; Oppe S, 2001, ACCIDENT ANAL PREV, V33, P129, DOI 10.1016/S0001-4575(00)00023-3; Pearn J, 2004, SCI BASIS INJURY PRE, P5; Peolsson M, 2004, J REHABIL MED, V36, P28, DOI 10.1080/11026480310015530; Pirente N, 2002, UNFALLCHIRURG, V105, P413; Pirente N, 2001, UNFALLCHIRURG, V104, P57, DOI 10.1007/s001130050688; Polinder S, 2005, PEDIATRICS, V116, pE810, DOI 10.1542/peds.2005-1035; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Pollard TCB, 2006, J BONE JOINT SURG BR, V88B, P592, DOI 10.1302/0301-620X.88B5.17354; Priestley M., 2003, DISABILITY LIFE COUR; Rajzbaum G, 2008, CURR MED RES OPIN, V24, P377, DOI 10.1185/030079908X261087; RAMAN R, 2008, INJURY EXTRA, V39, P200; Ryan T, 2006, CLIN REHABIL, V20, P123, DOI 10.1191/0269215506cr933oa; Salaffi F, 2007, CLIN EXP RHEUMATOL, V25, P390; Salkeld G, 2000, BMJ-BRIT MED J, V320, P341, DOI 10.1136/bmj.320.7231.341; Sluiter JK, 2008, INT ARCH OCC ENV HEA, V81, P495, DOI 10.1007/s00420-007-0222-z; Szende A, 2004, MEASURING SELF REPOR; Tidermark J, 2003, QUAL LIFE RES, V12, P1069, DOI 10.1023/A:1026193812514; Tidermark J, 2003, ACTA ORTHOP SCAND, V74, P2; Tidermark J, 2003, J BONE JOINT SURG BR, V85B, P380, DOI 10.1302/0301-620X.85B3.13609; Tidermark J, 2003, J ORTHOP TRAUMA, V17, P193, DOI 10.1097/00005131-200303000-00007; Tidermark J, 2002, QUAL LIFE RES, V11, P473, DOI 10.1023/A:1015632114068; Tidermark J, 2002, J ORTHOP TRAUMA, V16, P34, DOI 10.1097/00005131-200201000-00008; Tidermark J, 2007, QUAL LIFE RES, V16, P321, DOI 10.1007/s11136-006-9004-4; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Tosteson ANA, 2002, PHARMACOECONOMICS, V20, P289, DOI 10.2165/00019053-200220050-00001; Townend W, 2001, J NEUROL NEUROSUR PS, V70, P267; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; van Baar ME, 2006, J BURN CARE RES, V27, P790, DOI 10.1097/01.BCR.0000245434.76697.56; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; WHO, 2008, GLOB BURD DIS 2004; Xie F, 2006, OSTEOARTHR CARTILAGE, V14, P1098, DOI 10.1016/j.joca.2006.05.005; Yoh K, 2005, J BONE MINER METAB, V23, P167, DOI 10.1007/s00774-004-0556-5	103	37	37	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					883	890		10.1097/TA.0b013e3181ae6409			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	506BE	WOS:000270747000034	19820601				2021-06-18	
J	Fingas, M; Penner, M; Silasi, G; Colbourne, F				Fingas, Matthew; Penner, Mark; Silasi, Gergely; Colbourne, Frederick			Treatment of intracerebral hemorrhage in rats with 12 h, 3 days and 6 days of selective brain hypothermia	EXPERIMENTAL NEUROLOGY			English	Article						Stroke; Intracerebral hemorrhage; Striatum; Temperature; Hypothermia; Rat; Neuroprotection	PROLONGED HYPOTHERMIA; CARDIAC-ARREST; ANIMAL-MODELS; STROKE; ISCHEMIA; INJURY; COLLAGENASE; RECOVERY; IMPROVE; LESIONS	Intracerebral hemorrhage (ICH) is a devastating stroke with no proven treatment to reduce brain injury. In this study we modeled ICH by injecting 100 mu L of autologous blood into the striatum of rats. We then tested whether hypothermia would reduce brain injury and improve recovery as has been repeatedly observed for ischemic and traumatic brain damage. Aside from reducing blood-brain barrier disruption, inflammation and edema, hypothermia has not consistently improved behavioral or histological outcome after ICH in animal studies. As this might relate to the choice of cooling method and the duration of hypothermia, we used a system that selectively cooled the injured hemisphere to similar to 32 degrees C (striatum) while the body remained normothermic. Cooling (vs. normothermia) started 1 h after ICH and lasted for 12 h, 3 days or 6 days followed by slow re-warming (similar to 1 degrees C/h). Functional impairment was evaluated from 2 to 3 weeks post-ICH at which time brain injury was determined. The ICH caused significant impairment on a neurological deficit scale and in tests of walking (horizontal ladder), skilled reaching (tray task) and spontaneous limb usage (cylinder test). Only the limb use asymmetry deficit was significantly mitigated by hypothermia, and then only by the longest treatment. Lesion volume, which averaged 16.9 mm(3), was not affected. These results, in conjunction with earlier studies, suggest that prolonged mild hypothermia will not be a profound neuroprotectant for patients with striatal ICH, but it may nonetheless improve functional recovery in addition to its use for treating cerebral edema. (C) 2009 Elsevier Inc. All rights reserved.	[Penner, Mark; Colbourne, Frederick] Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; [Fingas, Matthew; Silasi, Gergely; Colbourne, Frederick] Univ Alberta, Ctr Neurosci, Edmonton, AB T6G 2E9, Canada	Colbourne, F (corresponding author), Univ Alberta, Dept Psychol, P217 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.	fcolbour@ualberta.ca	Colbourne, Frederick/ABB-7774-2020	Colbourne, Frederick/0000-0002-9567-2082; Silasi, Gergely/0000-0003-1036-1304	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research	Research supported by a grant from the Canadian Institutes of Health Research to FC, who is supported by an Alberta Heritage Foundation for Medical Research senior medical scholar award. The authors thank N. Cumby, Lindsey Warkentin and Shannon Wowk for technical assistance and Dr. C. MacLellan for helpful comments on the manuscript.	Berger C, 2007, EXP NEUROL, V204, P131, DOI 10.1016/j.expneurol.2006.10.002; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BRODERICK JP, 1994, HDB NEUROEPIDEMIOLOG, P141; Clark DL, 2008, EXP NEUROL, V212, P386, DOI 10.1016/j.expneurol.2008.04.016; Clark DL, 2007, J CEREBR BLOOD F MET, V27, P115, DOI 10.1038/sj.jcbfm.9600327; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; DeBow S, 2003, METHODS, V30, P167, DOI 10.1016/S1046-2023(03)00080-X; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Feng Honglin, 2002, Zhonghua Yi Xue Za Zhi, V82, P1622; Fingas M, 2007, EXP NEUROL, V208, P277, DOI 10.1016/j.expneurol.2007.08.018; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kawai N, 2001, BRAIN RES, V895, P50, DOI 10.1016/S0006-8993(01)02026-1; Kawanishi Masahiko, 2008, J Stroke Cerebrovasc Dis, V17, P187, DOI 10.1016/j.jstrokecerebrovasdis.2008.01.003; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; MacLellan CL, 2005, BRAIN RES, V1063, P40, DOI 10.1016/j.brainres.2005.09.027; MacLellan CL, 2004, J CEREBR BLOOD F MET, V24, P432, DOI 10.1097/00004647-200404000-00008; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mendelow AD, 2005, LANCET, V365, P387; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Nguyen AP, 2008, CURR NEUROVASC RES, V5, P171, DOI 10.2174/156720208785425710; Nguyen AP, 2008, BRAIN RES, V1193, P109, DOI 10.1016/j.brainres.2007.11.054; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; SACCO S, 2008, STROKE; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Ueda Y, 2004, STROKE, V35, P601, DOI 10.1161/01.STR.0000113693.56783.73; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; Wagner KR, 2006, ACTA NEUROCHIR SUPPL, V96, P177; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xue Mengzhou, 2003, J Stroke Cerebrovasc Dis, V12, P152, DOI 10.1016/S1052-3057(03)00036-3; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	43	37	37	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2009	219	1			SI		156	162		10.1016/j.expneurol.2009.05.007			7	Neurosciences	Neurosciences & Neurology	489CZ	WOS:000269398600020	19445934				2021-06-18	
J	Patel, CB; Cohen, DM; Ahobila-Vajjula, P; Sundberg, LM; Chacko, T; Narayana, PA				Patel, Chirag B.; Cohen, David M.; Ahobila-Vajjula, Pallavi; Sundberg, Laura M.; Chacko, Tessy; Narayana, Ponnada A.			Effect of VEGF Treatment on the Blood-Spinal Cord Barrier Permeability in Experimental Spinal Cord Injury: Dynamic Contrast-Enhanced Magnetic Resonance Imaging	JOURNAL OF NEUROTRAUMA			English	Article						BBB score; blood-spinal cord barrier; DCE-MRI; spinal cord injury; VEGF	ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; CONTUSION INJURY; ADULT-RAT; MICROVASCULAR HYPERPERMEABILITY; HIPPOCAMPAL-NEURONS; TEMPORAL EVOLUTION; ANGIOGENESIS; BRAIN; MRI	Compromised blood-spinal cord barrier (BSCB) is a factor in the outcome following traumatic spinal cord injury (SCI). Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis and vascular permeability. The role of VEGF in SCI is controversial. Relatively little is known about the spatial and temporal changes in the BSCB permeability following administration of VEGF in experimental SCI. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies were performed to noninvasively follow spatial and temporal changes in the BSCB permeability following acute administration of VEGF in experimental SCI over a post-injury period of 56 days. The DCE-MRI data was analyzed using a two-compartment pharmacokinetic model. Animals were assessed for open field locomotion using the Basso-Beattie-Bresnahan score. These studies demonstrate that the BSCB permeability was greater at all time points in the VEGF-treated animals compared to saline controls, most significantly in the epicenter region of injury. Although a significant temporal reduction in the BSCB permeability was observed in the VEGF-treated animals, BSCB permeability remained elevated even during the chronic phase. VEGF treatment resulted in earlier improvement in locomotor ability during the chronic phase of SCI. This study suggests a beneficial role of acutely administered VEGF in hastening neurobehavioral recovery after SCI.	[Patel, Chirag B.; Ahobila-Vajjula, Pallavi; Sundberg, Laura M.; Chacko, Tessy; Narayana, Ponnada A.] Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [Cohen, David M.] Anaplerosis Associates Inc, Omaha, NE USA	Narayana, PA (corresponding author), Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St, Houston, TX 77030 USA.	Ponnada.A.Narayana@uth.tmc.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045624]; NIH/NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10 RR17205-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045624] Funding Source: NIH RePORTER	We thank Shi-Jie Liu, M. D., for expert animal surgeries and assistance with animal work and Chul Ahn, Ph.D., for expert statistical advice. These studies were supported by NIH/NINDS ( grant NS045624 to P.A.N.). The 7-Tesla MRI scanner was funded by NIH/NCRR under the High End Instrumentation Program ( grant S10 RR17205-01 to P.A.N.).	Ankeny DP, 2001, EXP NEUROL, V170, P85, DOI 10.1006/exnr.2001.7699; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; Bilgen M, 2002, MAGN RESON IMAGING, V20, P337, DOI 10.1016/S0730-725X(02)00504-0; Bilgen M, 2001, MAGNET RESON MED, V45, P614, DOI 10.1002/mrm.1083; Bilgen M, 2001, MAGN RESON MED, V46, P1099, DOI 10.1002/mrm.1305; Bilgen M, 2000, MAGN RESON MED, V43, P594; Bilgen M, 2007, MAGN RESON IMAGING, V25, P657, DOI 10.1016/j.mri.2006.10.009; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Bocker-Meffert S, 2002, INVEST OPHTH VIS SCI, V43, P2021; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Cain LD, 2007, J NEUROSCI RES, V85, P1558, DOI 10.1002/jnr.21265; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Choi BH, 2007, J NEUROSURG-SPINE, V7, P54, DOI 10.3171/SPI-07/07/054; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; Fenyes DA, 1998, MAGN RESON IMAGING, V16, P1249, DOI 10.1016/S0730-725X(98)00093-9; Gordh T, 2006, PAIN, V124, P211, DOI 10.1016/j.pain.2006.05.020; Harrigan MR, 2002, NEUROSURGERY, V50, P589, DOI 10.1097/00006123-200203000-00030; Jakeman LB, 1998, EXP NEUROL, V154, P170, DOI 10.1006/exnr.1998.6924; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kao CH, 2008, SHOCK, V29, P49, DOI 10.1097/shk.0b013c31805cddce; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Maikos JT, 2007, J NEUROTRAUM, V24, P492, DOI 10.1089/neu.2006.0149; Matsuzaki H, 2001, FASEB J, V15, P1218; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; Mills CD, 2001, J NEUROTRAUM, V18, P743, DOI 10.1089/089771501316919111; Narayana P, 1999, MAGN RESON MED, V41, P315, DOI 10.1002/(SICI)1522-2594(199902)41:2<315::AID-MRM15>3.0.CO;2-B; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Rossignol S, 2007, J NEUROSCI, V27, P11782, DOI 10.1523/JNEUROSCI.3444-07.2007; Runge VM, 1997, INVEST RADIOL, V32, P105, DOI 10.1097/00004424-199702000-00006; Sakanaka M, 2007, J NEUROTRAUM, V24, P1037, DOI 10.1089/neu.2006.0182; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Sharma HS, 2006, J NEURAL TRANSM, V113, P463, DOI 10.1007/s00702-005-0404-3; SHINGU H, 1989, PARAPLEGIA, V27, P182, DOI 10.1038/sc.1989.27; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Sledge GW, 2002, SEMIN ONCOL, V29, P104, DOI 10.1053/sonc.2002.34062; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; Twisk J, 2002, J CLIN EPIDEMIOL, V55, P329, DOI 10.1016/S0895-4356(01)00476-0; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Westergren H, 2001, SPINAL CORD, V39, P74, DOI 10.1038/sj.sc.3101127; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Xiaowei H, 2006, SPINAL CORD, V44, P35, DOI 10.1038/sj.sc.3101813; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com	63	37	44	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1005	1016		10.1089/neu.2008.0860			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500006	19226205	Green Published			2021-06-18	
J	Cooper, Z; Rivara, FP; Wang, J; MacKenzie, EJ; Jurkovich, GJ				Cooper, Zara; Rivara, Frederick P.; Wang, Jin; MacKenzie, Ellen J.; Jurkovich, Gregory J.			Withdrawal of Life-Sustaining Therapy in Injured Patients: Variations Between Trauma Centers and Nontrauma Centers	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Withdrawal of care; Trauma centers; End-of-life care; Elderly trauma	INTENSIVE-CARE-UNIT; DECISION-MAKING; PALLIATIVE CARE; SERIOUSLY ILL; END; SUPPORT; IMPACT; PROGNOSTICATION; PREFERENCES; COMPLETION	Background: We sought to identify patient and institutional variables predictive of a withdrawal of care order (WOCO) in trauma patients. We hypothesized that the frequency of WOCO would be higher at trauma centers. Methods: Data from the National Study on the Costs and Outcomes of Trauma were used to determine associations between WOCO status and patient characteristics, institutional characteristics, and hospital course. chi(2), t tests, and multivariate analysis were used to identify variables predictive of WOCO. Results: Of 14,190 patients, 618 (4.4%) had WOCO, which accounted for 60.9% of patients who died in hospital. Age (p = <0.001), race (p = <0.001), comorbidity (p = <0.001), and injury mechanism were associated with WOCO (p = 0.03). WOCO patients had higher New Injury Severity Score (p = <0.001), lower Glasgow Coma Scale motor scores (p = <0.001), and higher incidence of midline shift on head computed tomography (p = 11.01). Trauma center status (odds ratio, 1.56; 95% confidence interval, 1.06-2.30) and closed intensive care units (odds ratio, 1.53; 95% confidence interval, 1.03-2.25) were also predictive of a WOCO. There was a sizable variation (0%-16%) in the percentage of patients with WOCO across centers. Conclusion: Most trauma patients who die in hospital do so after a WOCO. Although trauma center status and closed intensive care units are predictive of a WOCO, variation in the percentage of patients with WOCO across all centers speaks to the complexity of these decisions. Further investigation is needed to understand how a WOCO is applied to trauma patients.	[Cooper, Zara] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Div Trauma Burns & Crit Care, Boston, MA 02115 USA; [Rivara, Frederick P.; Wang, Jin] Univ Washington, Sch Med, Harborview Injury Prevent Ctr, Seattle, WA USA; [Jurkovich, Gregory J.] Univ Washington, Harborview Med Ctr, Sch Med, Dept Surg, Seattle, WA 98104 USA; [MacKenzie, Ellen J.] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA	Cooper, Z (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Div Trauma Burns & Crit Care, 75 Francis St, Boston, MA 02115 USA.	zcooper@partners.org			National Center for Injury Prevention and Control of the Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR316840]; National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01/AG20361]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020261] Funding Source: NIH RePORTER	Supported by grant (R49/CCR316840) from the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention and grant (R01/AG20361) from the National Institute on Aging of the National Institutes of Health.	Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Campbell ML, 1997, CRIT CARE MED, V25, P197, DOI 10.1097/00003246-199701000-00034; Charles C, 1999, BRIT MED J, V319, P780, DOI 10.1136/bmj.319.7212.780; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; *DEP VET AFF VPHS, 2000, ADV HEALTHC PLANN AD, pR1; Duffield P, 1996, J FAM PRACTICE, V42, P378; Finlayson EVA, 2002, SURGERY, V132, P787, DOI 10.1067/msy.2002.126509; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Hopp FP, 2000, J AM GERIATR SOC, V48, P658, DOI 10.1111/j.1532-5415.2000.tb04724.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kwak J, 2005, GERONTOLOGIST, V45, P634, DOI 10.1093/geront/45.5.634; Lloyd CB, 2004, CRIT CARE MED, V32, P649, DOI 10.1097/01.CCM.0000115636.29294.2F; Luce JM, 2007, AM J RESP CRIT CARE, V175, P1104, DOI 10.1164/rccm.200609-1397CP; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Manara AR, 1998, ANAESTHESIA, V53, P523, DOI 10.1046/j.1365-2044.1998.t01-1-00407.x; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; Morrison RS, 1998, ARCH INTERN MED, V158, P2493, DOI 10.1001/archinte.158.22.2493; Mosenthal AC, 2005, SURG CLIN N AM, V85, P303, DOI 10.1016/j.suc.2005.01.001; Mosenthal AC, 2003, J AM COLL SURGEONS, V197, P509, DOI 10.1016/S1072-7515(03)00651-3; Murphy DJ, 1998, ARCH FAM MED, V7, P484, DOI 10.1001/archfami.7.5.484; Nathens AB, 2008, J TRAUMA, V64, P81, DOI 10.1097/TA.0b013e31815dd4d7; Nathens AB, 2006, ANN SURG, V244, P545, DOI 10.1097/01.sla.0000239005.26353.49; Nolin T, 2003, ACTA ANAESTH SCAND, V47, P501, DOI 10.1034/j.1399-6576.2003.00128.x; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Perkins HS, 2002, J GEN INTERN MED, V17, P48, DOI 10.1046/j.1525-1497.2002.01032.x; Plaisier BR, 2002, AM SURGEON, V68, P159; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Puntillo K A, 2001, Am J Crit Care, V10, P216; Reilly P, 2008, J TRAUMA, V64, P88; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; THELEN M, 2005, CRIT CARE NURSE, V25, P38; Thelen Mary, 2005, Crit Care Nurse, V25, P28; TILDEN VP, 1995, ARCH INTERN MED, V155, P633, DOI 10.1001/archinte.155.6.633; *TRAUM ACOSCO, 2006, RES OPT CAR INJ PAT; Trunkey DD, 2000, ARCH SURG-CHICAGO, V135, P34, DOI 10.1001/archsurg.135.1.34; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Walter SD, 1998, CRIT CARE MED, V26, P44, DOI 10.1097/00003246-199801000-00015; White DB, 2007, CRIT CARE MED, V35, P442, DOI 10.1097/01.CCM.0000254723.28270.14	47	37	37	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2009	66	5					1327	1335		10.1097/TA.0b013e31819ea047			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	445AJ	WOS:000266021700013	19430235	Green Accepted			2021-06-18	
J	Frascarelli, F; Masia, L; Di Rosa, G; Cappa, P; Petrarca, M; Castelli, E; Krebs, HI				Frascarelli, F.; Masia, L.; Di Rosa, G.; Cappa, P.; Petrarca, M.; Castelli, E.; Krebs, H. I.			The impact of robotic rehabilitation in children with acquired or congenital movement disorders	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Rehabilitation; Cerebral palsy; Brain injuries; Stroke; Movement disorders	UPPER-LIMB; ASSISTED THERAPY; SINGLE-BLIND; STROKE; RECOVERY; ARM; REORGANIZATION; COORDINATION; HEMIPARESIS; IMPAIRMENT	Aim. The aim of this study was to evaluate if the robot-mediated therapy (RMT) can yield positive outcomes in children with acquired or congenital upper extremity movement disorders. Methods. This was an uncontrolled pilot study with pre-post treatment outcome comparison carried out by the Pediatric Rehabilitation Department of a Children's Hospital. The study enrolled 12 children, aged 5 to 15 years, suffering from acquired (at least 12 months post-onset) or congenital upper limb motor impairment. Etiology. 4 stroke, 6 traumatic brain injuries, and 2 hemiplegic cerebral palsy. RMT was provided 3 dines a week for an hour during 6 weeks for a total of 18 robot therapy sessions. The Melbourne Scale (MS) and the upper-extremity subsection of the Fugl-Meyer Assessment (FMA) were used for measurement of impairment. Secondary outcome measurements were made through the Modified Ashworth Scale (MAS); the Reaching Performance Scale (RPS); Parent's Questionnaire, and robot-based evaluation measurements. Specifically, authors compared the smoothness, as measured by the jerk metric, and average speed of unconstrained reaching movements. Results. Pre-post clinical evaluation revealed statistically significant gains for all primary and secondary metrics. In addition, significant improvement of robot-based metrics was observed. The primary outcome measurement mean (SEM) gains were 6.71 (1.29) for MS and 3.33 (0.80) for the FMA. RMT led to spasticity decreases in chronic cases, as shown by die reduction of MAS. It led to improved trunk-upper extremity postural attitude as demonstrated by improved RPS, and it was well accepted by parents and children as observed in the Parent's Questionnaire. Conclusion. This study suggests that RMT may hold rehabilitative benefits in children suffering from acquired and congenital hemiparesis.	[Frascarelli, F.; Di Rosa, G.; Cappa, P.; Petrarca, M.; Castelli, E.] Childrens Hosp Bambino Gesu, Pediat Rehabil Dept, Rome, Italy; [Masia, L.] Italian Inst Technol, Genoa, Italy; [Cappa, P.] Univ Roma La Sapienza, Dept Mech & Aeronaut, I-00184 Rome, Italy; [Krebs, H. I.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Krebs, H. I.] Cornell Univ, Weill Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY USA; [Krebs, H. I.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA	Frascarelli, F (corresponding author), Childrens Hosp Bambino Gesu, Pediat Rehabil Dept, Via Torre Palidoro 0050, Rome, Italy.	flaminiafrascarelli@opbg.net	Castelli, Enrico/J-1887-2012; MASIA, LORENZO/D-9385-2014; petrarca, maurizio/B-4181-2019	petrarca, maurizio/0000-0002-7330-3569; Cappa, Paolo/0000-0002-4898-9589	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD-045343]; NYSCORE; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045343] Funding Source: NIH RePORTER	This work has been in part supported by a grant from the Italian Ministry of University and Research ("Robotic systems for the rehabilitation" - year 2003/05) and by a grant from the Italian Ministry of Health ("Pilot study on a new class of medical devices: robotic systems for the rehabilitation and the tele-rellabilitation " - year 2007). Dr. Krebs is Supported in part by NIH Grant #R01-HD-045343 and by the NYSCORE.	Aisen ML, 1997, ARCH NEUROL-CHICAGO, V54, P443, DOI 10.1001/archneur.1997.00550160075019; Barreca S, 2003, NEUROREHAB NEURAL RE, V17, P220, DOI 10.1177/0888439003259415; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Braun C, 2001, BRAIN, V124, P2259, DOI 10.1093/brain/124.11.2259; CAO Y, 1994, P NATL ACAD SCI USA, V91, P9612, DOI 10.1073/pnas.91.20.9612; CARR LJ, 1993, BRAIN, V116, P1223, DOI 10.1093/brain/116.5.1223; Chang JJ, 2005, CLIN BIOMECH, V20, P381, DOI 10.1016/j.clinbiomech.2004.11.015; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Colombo R, 2008, NEUROREHAB NEURAL RE, V22, P50, DOI 10.1177/1545968307303401; FARMER SF, 1991, NEUROLOGY, V41, P1505, DOI 10.1212/WNL.41.9.1505; Fasoli SE, 2003, ARCH PHYS MED REHAB, V84, P477, DOI 10.1053/apmr.2003.50110; Fasoli SE, 2008, AM J PHYS MED REHAB, V87, P929, DOI 10.1097/PHM.0b013e31818a6aa4; Fasoli Susan E, 2004, Top Stroke Rehabil, V11, P11; Ferraro M, 2003, NEUROLOGY, V61, P1604, DOI 10.1212/01.WNL.0000095963.00970.68; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; FLASH T, 1991, J COGNITIVE NEUROSCI, V3, P220, DOI 10.1162/jocn.1991.3.3.220; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gunal I, 1996, J BONE JOINT SURG AM, V78A, P1401, DOI 10.2106/00004623-199609000-00017; KELSO JAS, 1981, J MOTOR BEHAV, V13, P226; KLINGELS H, 2006, GAIT POSTURE, V24, pS245; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; Krebs HI, 2008, IEEE ENG MED BIOL, V27, P61, DOI 10.1109/MEMB.2008.919498; Krebs HI, 2008, NEUROREHABILITATION, V23, P81; Krebs HI, 2006, P IEEE, V94, P1727, DOI 10.1109/JPROC.2006.880721; Krebs HI, 2000, J REHABIL RES DEV, V37, P639; Krebs HI, 2003, AUTON ROBOT, V15, P7, DOI 10.1023/A:1024494031121; Krebs HI, 1999, P NATL ACAD SCI USA, V96, P4645, DOI 10.1073/pnas.96.8.4645; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Levin MF, 2004, PHYS THER, V84, P8, DOI 10.1093/ptj/84.1.8; Liebermann DG, 2006, CLIN BIOMECH, V21, P8, DOI 10.1016/j.clinbiomech.2005.08.006; Masiero S, 2007, ARCH PHYS MED REHAB, V88, P142, DOI 10.1016/j.apmr.2006.10.032; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; PAGE SJ, 2004, CRIT REV PHYS REHABI, V16, P31, DOI DOI 10.1615/CRITREVPHYSREHABILMED.V16.I1.20; Patton JL, 2004, IEEE T BIO-MED ENG, V51, P636, DOI 10.1109/TBME.2003.821035; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Reid Denise T, 2002, Pediatr Rehabil, V5, P141, DOI 10.1080/1363849021000039344; Rohrer B, 2002, J NEUROSCI, V22, P8297; Shepherd Roberta B., 2001, Neural Plasticity, V8, P121, DOI 10.1155/NP.2001.121; Stein J, 2004, AM J PHYS MED REHAB, V83, P720, DOI 10.1097/01.PHM.0000137313.14480.CE; Sterr A, 2004, NEUROLOGY, V63, P2176, DOI 10.1212/01.WNL.0000145605.20476.07; TURVEY MT, 1989, NEUROSCIENCE, V33, P1, DOI 10.1016/0306-4522(89)90305-9; Volpe BT, 2001, CURR OPIN NEUROL, V14, P745, DOI 10.1097/00019052-200112000-00011; Volpe BT, 2001, NEUROL CLIN, V19, P903, DOI 10.1016/S0733-8619(05)70053-0; Woodworth W M, 1898, Science, V8, P302, DOI 10.1126/science.8.192.302	46	37	37	1	21	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	1973-9087	1973-9095		EUR J PHYS REHAB MED	Eur. J. Phys. Rehabil. Med.	MAR	2009	45	1					135	141					7	Rehabilitation	Rehabilitation	421VO	WOS:000264386600019	19293759				2021-06-18	
J	Griesbach, GS; Sutton, RL; Hovda, DA; Ying, Z; Gomez-Pinilla, F				Griesbach, Grace Sophia; Sutton, Richard L.; Hovda, David A.; Ying, Zhe; Gomez-Pinilla, Fernando			Controlled Contusion Injury Alters Molecular Systems Associated With Cognitive Performance	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						BDNF; injury; synapsin I; CREB; CAMKII; rat	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; DEPENDENT PROTEIN-KINASE; HIPPOCAMPAL EXCITATORY SYNAPSES; NEUROTROPHIC FACTOR INCREASES; OUTCOME FOLLOWING MODERATE; SPATIAL MEMORY DEFICITS; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; VOLUNTARY EXERCISE	We investigated whether a learning impairment after a controlled cortical impact (CCI) injury was associated with alterations in molecules involved in synaptic plasticity and learning and memory. Adult male rats with moderate CCI to the left parietal cortex, tested in a Morris water maze (MWM) beginning at postinjury day 10, showed impaired cognitive performance compared with sham-treated rats. Tissue was extracted for mRNA analysis on postinjury day 21. The expression of brain-derived neurotrophic factor (BDNF), synapsin 1, cyclic-AMP response element binding protein (CREB), and calcium-calmodulin-dependent protein kinase 11 (alpha-CAMKII) were all significantly decreased compared with sham injury levels within the ipsilateral hippocampus after CCI. No significant molecular level changes were found in the contralateral hippocampus. Decreased expression of BDNF and synapsin I was also found within the ipsilateral parietal cortex of CCI-injured rats compared with shams. However, BDNF and synapsin I expressions were significantly increased in the contralateral parietal cortex of the CCI rats. CREB expression was significantly decreased within the contralateral cortex of the CCI group. These findings show enduring reductions in the expression of BDNF, synapsin 1, CREB, and alpha-CAMKII ipsilateral to a CCI injury, which seem associated with the spatial learning deficits observed in this injury model. In addition, the delayed increase in the expression of BDNF and synapsin I within the cortex contralateral to CCI may reflect restorative processes in areas homotypical to the injury. (C) 2008 Wiley-Liss, Inc.	[Griesbach, Grace Sophia] Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90024 USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; [Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90024 USA.	ggriesbach@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS048535, R21 NS048535-02, NS27544, R01 NS027544] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NSO48535] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS048535, R01NS027544] Funding Source: NIH RePORTER		Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Ashman TA, 2006, MT SINAI J MED, V73, P999; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Babcock AM, 2002, J NEUROSCI RES, V67, P804, DOI 10.1002/jnr.10169; Babcock AM, 1995, BRAIN RES, V705, P307, DOI 10.1016/0006-8993(95)01155-2; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cammarota M, 2002, CELL MOL NEUROBIOL, V22, P259, DOI 10.1023/A:1020763716886; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DASH PK, 1995, J NEUROSCI, V15, P2030; de Hoz L, 2005, EUR J NEUROSCI, V22, P745, DOI 10.1111/j.1460-9568.2005.04255.x; Desmurget M, 2007, BRAIN, V130, P898, DOI 10.1093/brain/awl300; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Faddis BT, 1997, J NEUROSCI, V17, P951; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukunaga K, 1999, JPN J PHARMACOL, V79, P7, DOI 10.1254/jjp.79.7; Fukunaga K, 2000, NEUROSCI RES, V38, P3, DOI 10.1016/S0168-0102(00)00139-5; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Glazner GW, 2000, EXP NEUROL, V161, P442, DOI 10.1006/exnr.1999.7242; Gorski JA, 2003, J NEUROSCI, V23, P6856; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAN HQ, 1994, P NATL ACAD SCI USA, V91, P8557, DOI 10.1073/pnas.91.18.8557; Hanover JL, 1999, J NEUROSCI, V19, part. no.; Harris SE, 2006, MOL PSYCHIATR, V11, P505, DOI 10.1038/sj.mp.4001799; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Huh GY, 2001, NEUROSCI LETT, V316, P41, DOI 10.1016/S0304-3940(01)02371-0; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Larsson E, 2002, EXP NEUROL, V177, P1, DOI 10.1006/exnr.2002.7992; Lauterborn JC, 2007, J NEUROSCI, V27, P10685, DOI 10.1523/JNEUROSCI.2624-07.2007; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Liang ZH, 2007, J NEUROCHEM, V103, P2462, DOI 10.1111/j.1471-4159.2007.04942.x; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; Nagy Zoltan, 2002, Ideggyogy Sz, V55, P73; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Save E, 1996, BEHAV NEUROSCI, V110, P74; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Takei N, 1997, J NEUROCHEM, V68, P370; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Tully T, 2003, NAT REV DRUG DISCOV, V2, P267, DOI 10.1038/nrd1061; Tyler WJ, 2006, J PHYSIOL-LONDON, V574, P787, DOI 10.1113/jphysiol.2006.111310; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	95	37	40	0	2	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	FEB 15	2009	87	3					795	805		10.1002/jnr.21893			11	Neurosciences	Neurosciences & Neurology	404YX	WOS:000263190100022	18831070	Green Accepted			2021-06-18	
J	Freilich, D; Pearce, LB; Pitman, A; Greenburg, G; Berzins, M; Bebris, L; Ahlers, S; McCarron, R				Freilich, Daniel; Pearce, L. Bruce; Pitman, Arkadiy; Greenburg, Gerson; Berzins, Mara; Bebris, Lolita; Ahlers, Steven; McCarron, Richard			HBOC-201 Vasoactivity in a Phase III Clinical Trial in Orthopedic Surgery Subjects-Extrapolation of Potential Risk for Acute Trauma Trials	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Hemoglobin-based oxygen carrier; HBOC-201; Blood substitute; Blood pressure; Vasoactivity; Adverse events; Clinical trial; Serious adverse events; Cardiac biomarkers; Troponin; Trauma; Hemorrhagic shock.	CARDIAC TROPONIN-I; ACUTE CORONARY SYNDROMES; PERIOPERATIVE MYOCARDIAL-INFARCTION; POLYMERIZED HEMOGLOBIN HBOC-201; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; HEMORRHAGIC-SHOCK; BRAIN-INJURY; OXYGEN CARRIER; CREATINE-KINASE	Background: Vasoactivity has hampered progress of hemoglobin-based oxygen carriers (HBOCs) due to concern for adverse blood pressure responses and secondary complications. A recent formulation, highly polymerized HBOC-201 (Biopure, Cambridge, MA), has been found to be less vasoactive than prior less polymerized formulations, and to improve outcome in animal models of hemorrhagic shock (HS) compared with standard resuscitation fluids. HBOCs are envisioned to have life-saving potential for severe trauma patients for whom death due to HS is common despite transport to level I trauma centers. As part of a benefit:risk analysis for a proposed clinical trial of HBOC-201 in patients with traumatic HS, we analyzed data from a previoms phase III clinical trial of this HBOC that involved orthopedic surgery patients, for vasoactivity and related effects, with focus on patients more representative of the trauma population. Study Design: In a previous phase III study involving orthopedic surgery patients, HEM-0115, consented/stabilized patients were randomized to receive HBOC-201 (N = 350) (up to ten 30 g Hb units) or red blood cells (RBC) (N = 338) (up to 9 units) at the first transfusion decision. Systolic blood pressure (SBP) responses, key system and individual adverse events (AEs) and serious adverse events, and cardiac biomarker elevation incidences, were compared in the overall population and subpopulations: with stable trauma, hypotension, and with age stratification (Student's t and Fisher's exact tests, significance p < 0.05). Results: Mild to moderate peak SBP responses were common in HBOC-201 subjects and more common than with RBC in the overall population (mean, 60.8 years old), but less frequent in HBOC-201 subjects with stable trauma, younger age (<50 years old), and hypotension, in whom group differences were narrowed. SBP A responses were more common with HBOC-201 than RBC in the overall population, but not in subjects with stable trauma and <50 year olds, in whom response rates were lower. In the overall population, AEs were more common than with RBC in most systems (also, hypertension and stroke); only cardiac system serious adverse events were more common with HBOC-201. In contrast, there were few significant group differences in stable trauma, hypotensive, and <70 and especially <50-year-old subjects, in whom AE incidences were generally lower. A disproportionate number of key AEs occurred in elderly subjects. Troponin (but not CK-MB) elevation was; more frequent with HBOC-201 than RBC in the overall population but not in <50 year olds, and was not associated with acute coronary syndrome (ACS) or death. Conclusion: Our limited HEM-0115 safety analysis shows that key potentially vasoactivity- related adverse safety signals were more frequent with HBOC-201 than RBC in older patients undergoing orthopedic surgery with rapid access to safe blood transfusions. That incidences of these safety signals were generally lower and group differences narrowed in subpopulations with stable trauma, hypotension, and younger age, suggests an acceptable safety profile in younger acute trauma populations, especially in settings where rapid access to safe blood transfusions is unavailable; confirmation in controlled clinical trials is urgently warranted.	[Freilich, Daniel; Pearce, L. Bruce; Pitman, Arkadiy; Greenburg, Gerson; Berzins, Mara; Bebris, Lolita; Ahlers, Steven; McCarron, Richard] USN, Med Res Ctr, Hematomimet Program, Trauma & Resuscitat Med Dept, Silver Spring, MD USA	Freilich, D (corresponding author), 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	daniel.freilich@med.navy.mil			Biopure Corporation; the U.S. Government [A0315]; Naval Medical Research Center (NMRC) and Biopure Corp; Greenbung, were employees of Biopure Corp.	The HEM-0115 trial was funded and conducted by Biopure Corporation. Salary support for the safety analyses described herein was entirely funded by the U.S. Government (Office of Naval Research Work Unit Number A0315). Naval Medical Research Center (NMRC) and Biopure Corp. have a Cooperative Research and Development Agreement for evaluation of HBOC-201 in trauma clinical trials. No NMRC authors have Financial or other competing interests related to this article. There were no transfers, of funds in any of these agreements. L.B. Pearce, A. Pitman, and G. Greenbung, were employees of Biopure Corp. and may have Financial interest in the subject material, HBOC-201. Their contribution to this manuscript was limited to provision of data tables and editorial review.	ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Ammann P, 2003, J AM COLL CARDIOL, V41, P2004, DOI 10.1016/S0735-1097(03)00421-2; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 1997, CLIN CHEM, V43, P2047; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; Burhop K, 2004, ARTIF CELL BLOOD SUB, V32, P353, DOI 10.1081/LABB-200027429; Cavallini C, 2005, EUR HEART J, V26, P1494, DOI 10.1093/eurheartj/ehi173; Feinstein AJ, 2005, J TRAUMA, V59, P876, DOI 10.1097/01.ta.0000187654.24146.22; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; George I, 2006, AM J PHYSIOL-HEART C, V291, pH1126, DOI 10.1152/ajpheart.00076.2006; GUEST TM, 1995, JAMA-J AM MED ASSOC, V273, P1945, DOI 10.1001/jama.273.24.1945; Gurney J, 2004, J TRAUMA, V57, P726, DOI 10.1097/01.TA.0000147520.84792.B4; Jaffe AS, 2000, CIRCULATION, V102, P1216, DOI 10.1161/01.CIR.102.11.1216; Jahr JS, 2008, J TRAUMA, V64, P1484, DOI 10.1097/TA.0b013e318173a93f; Jeremias A, 2005, ANN INTERN MED, V142, P786, DOI 10.7326/0003-4819-142-9-200505030-00015; Johnson T, 2006, CRIT CARE MED, V34, P1464, DOI 10.1097/01.CCM.0000215824.85190.89; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; Kerby JD, 2007, SHOCK, V27, P652, DOI 10.1097/01.shk.0000248584.10400.dc; Kim LJ, 2002, CIRCULATION, V106, P2366, DOI 10.1161/01.CIR.0000036016.52396.BB; LaMuraglia GM, 2000, J VASC SURG, V31, P299, DOI 10.1016/S0741-5214(00)90161-7; Landesberg G, 2005, CRIT CARE MED, V33, P1281, DOI 10.1097/01.CCM.0000166607.22550.87; LENKE LG, 1994, J SPINAL DISORD, V7, P70, DOI 10.1097/00002517-199407010-00010; Levy JH, 2002, J THORAC CARDIOV SUR, V124, P35, DOI 10.1067/mtc.2002.121505; Lim W, 2005, CRIT CARE, V9, pR636, DOI 10.1186/cc3816; Lin JC, 2004, CLIN CHEM, V50, P333, DOI 10.1373/clinchem.2003.026708; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; Martinez EA, 2005, J CARDIOTHOR VASC AN, V19, P577, DOI 10.1053/j.jvca.2005.07.002; Millham FH, 2004, J TRAUMA, V56, P1090, DOI 10.1097/01.TA.0000119689.81910.06; Ng SM, 2001, AM J CARDIOL, V87, P994, DOI 10.1016/S0002-9149(01)01436-9; Noble JS, 1999, BRIT J ANAESTH, V82, P41; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Reid TJ, 2003, TRANSFUSION, V43, P280, DOI 10.1046/j.1537-2995.2003.00314.x; Rice J, 2008, J TRAUMA, V64, P1240, DOI 10.1097/TA.0b013e318058245e; Rice J, 2006, J TRAUMA, V61, P1085, DOI 10.1097/01.ta.0000236640.62893.fa; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Sprung J, 2002, ANESTH ANALG, V94, P799, DOI 10.1097/00000539-200204000-00006; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5; Wong CK, 2005, POSTGRAD MED J, V81, P552, DOI 10.1136/pgmj.2005.035071; WUKICH DK, 1989, J TRAUMA, V29, P375, DOI 10.1097/00005373-198903000-00017	43	37	37	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2009	66	2					365	376		10.1097/TA.0b013e3181820d5c			12	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	408NX	WOS:000263442800011	19204509				2021-06-18	
J	Resch, JA; Villarreal, V; Johnson, CL; Elliott, TR; Kwok, OM; Berry, JW; Underhill, AT				Resch, J. Aaron; Villarreal, Victor; Johnson, Caitlin L.; Elliott, Timothy R.; Kwok, Oi-Man; Berry, Jack W.; Underhill, Andrea T.			Trajectories of Life Satisfaction in the First 5 Years Following Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; life satisfaction; functional independence; hierarchical linear modeling; multilevel modeling	QUALITY-OF-LIFE; GENDER-DIFFERENCES; PUBLIC-HEALTH; UNITED-STATES; OUTCOMES; MILD; VALIDATION; DEPRESSION; MODERATE; WOMEN	Objectives: The trajectories of life satisfaction for 609 individuals who sustained a traumatic brain injury (TBI) were studied. Hierarchical linear modeling analysis examined individual level growth trends over the first 5 years following TBI using gender, functional independence, age, and time to estimate life satisfaction trajectories. Measures: Participants completed the Functional Independence Measure and the Life Satisfaction Inventory at years 1, 2, 4, and 5 after sustaining TBI. Results: Participants who reported higher functional independence at year I also had higher life satisfaction at year 1. Participants with lower functional independence across the 5-year period had life satisfaction trajectories that decreased at significantly greater rates than the individuals with more functional independence. The life satisfaction trajectory declined for the sample, but participants reporting lower cognitive and motor functional independence had significantly greater declines in life satisfaction trajectories. Age and gender were not significant factors in predicting life satisfaction trajectories following TBI. Implications: Individuals with greater cognitive and motor impairments following TBI are likely to experience significant declines in life satisfaction within 5 years of living with TBI.	[Resch, J. Aaron; Villarreal, Victor; Johnson, Caitlin L.; Elliott, Timothy R.; Kwok, Oi-Man] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77845 USA; [Berry, Jack W.; Underhill, Andrea T.] Univ Alabama Birmingham, Injury Control Res Ctr, Birmingham, AL USA	Elliott, TR (corresponding author), Texas A&M Univ, Dept Educ Psychol, 4225 TAMU, College Stn, TX 77845 USA.	telliott@tamu.edu	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714; Kwok, Oiman/0000-0002-4617-4562	NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER; NCIPC CDC HHS [R49-CE000191] Funding Source: Medline		ADAMS DL, 1969, J GERONTOL, V24, P470, DOI 10.1093/geronj/24.4.470; Bond T.G., 2001, APPL RASCH MODEL FUN; Brossart DF, 2002, J PEDIATR PSYCHOL, V27, P97, DOI 10.1093/jpepsy/27.1.97; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CHANG WC, 1995, ARCH PHYS MED REHAB, V76, P934, DOI 10.1016/S0003-9993(95)80070-0; *COMM INJ SCAL, 1985, ABBR INJ SCAL 1985 R; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Elliott T. R., 2002, HDB POSITIVE PSYCHOL, P687; Elliott T. R., 2004, COUNSELING DIVERSE P, P151; ELLIOTT TR, 2007, PSYCHOL MANAGEMENT P, P16; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fisher G. H., 1976, ADV PSYCHOL ED MEASU, P97; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; Glass TA, 2006, SOC SCI MED, V62, P1650, DOI 10.1016/j.socscimed.2005.08.044; Good GE, 2008, REHABIL PSYCHOL, V53, P39, DOI 10.1037/0090-5550.53.1.39; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hox J.J., 2010, MULTILEVEL ANAL TECH, V2nd ed.; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; KAPLAN RM, 1994, HEALTH PSYCHOL, V13, P451, DOI 10.1037/0278-6133.13.6.451; Kaplan RM, 2002, ARCH PHYS MED REHAB, V83, pS44, DOI 10.1053/apmr.2002.36955; Kaplan RM, 2005, ANNU REV CLIN PSYCHO, V1, P525, DOI 10.1146/annurev.clinpsy.1.102803.144118; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Linacre JM, 2003, USERS GUIDE WINSTEPS; Lollar DJ, 2003, ANNU REV PUBL HEALTH, V24, P195, DOI 10.1146/annurev.publhealth.24.100901.140844; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Niemeier JP, 2008, DISABIL REHABIL, V30, P166, DOI 10.1080/09638280701532169; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nosek MA, 2008, DISABIL REHABIL, V30, P174, DOI 10.1080/09638280701532219; Peterson David B., 2008, HDB COUNSELING PSYCH, P212; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; RAO VN, 1998, INT J AGING HUM DEV, V14, P55; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Snijders T.A.B., 1999, MULTILEVEL ANAL INTR; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tucker JA, 2008, REHABIL PSYCHOL, V53, P279, DOI 10.1037/a0012963; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Wallace KA, 2002, EDUC PSYCHOL MEAS, V62, P674, DOI 10.1177/0013164402062004009; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Wright B. D, 2003, RAS MEAS T, V17, P905	55	37	37	0	12	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2009	54	1					51	59		10.1037/a0015051			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	410WJ	WOS:000263608700006	19618703				2021-06-18	
J	Chiaravalloti, N; Balzano, J; Moore, N; DeLuca, J				Chiaravalloti, Nancy D.; Balzano, Julie; Moore, Nancy B.; DeLuca, John			[image omitted]The Open-Trial Selective Reminding Test (OT-SRT) as a Tool for the Assessment of Learning and Memory	CLINICAL NEUROPSYCHOLOGIST			English	Article						Learning; Memory; Neuropsychological assessment; Multiple sclerosis; Selective reminding test	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; COGNITIVE DYSFUNCTION; RETRIEVAL; ACQUISITION; DEFICITS; NEUROPSYCHOLOGY; CONSOLIDATION; PERFORMANCE; STORAGE	The Open Trial Selective Reminding Test (OT-SRT) is a modification of the SRT that also evaluates new learning abilities. The examinee is asked to learn a list of 10 words over a maximum of 15 trials. Using a criterion-referenced approach, the list is repeatedly administered until a criterion of complete recall on two consecutive trials is achieved. Training to criterion provides a better assessment of learning ability than the traditional fixed trial list-learning paradigm. Recall and recognition is then tested 30 and 90 minutes following the learning trials. This paper presents normative data on the OT-SRT for 117 healthy controls (Study 1) and 151 participants with clinically definite multiple sclerosis (Study 2).	[Chiaravalloti, Nancy D.; Balzano, Julie; Moore, Nancy B.; DeLuca, John] Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; [Chiaravalloti, Nancy D.; DeLuca, John] UMDNJ New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [DeLuca, John] UMDNJ New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA	Chiaravalloti, N (corresponding author), Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	nchiaravalloti@kmrrec.org			National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [PP0752, RG 2596B2, RG2596A]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD 38249]; UMDNJ Foundation [411-68-0527]; Henry H. Kessler Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038249] Funding Source: NIH RePORTER	Funded in part by Grant # PP0752, Grant # RG 2596B2, and Grant # RG2596A from the National Multiple Sclerosis Society; Grant # R01 HD 38249 from the National Institutes of Health; Grant # 411-68-0527 from the UMDNJ Foundation, and the Henry H. Kessler Foundation.	Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; BAHRICK HP, 1984, J EXP PSYCHOL GEN, V113, P1, DOI 10.1037/0096-3445.113.1.1; BAHRICK HP, 1975, J EXP PSYCHOL GEN, V104, P54, DOI 10.1037/0096-3445.104.1.54; BAHRICK HP, 1991, J EXP PSYCHOL GEN, V120, P20, DOI 10.1037/0096-3445.120.1.20; Bahrick HP, 2000, OXFORD HDB MEMORY, P347; BANKS PG, 1987, EXP AGING RES, V13, P203; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CAINE ED, 1986, ARCH NEUROL-CHICAGO, V43, P249, DOI 10.1001/archneur.1986.00520030039009; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Deluca J., 2004, COMPREHENSIVE HDB PS, P217; Demaree HA, 2000, J CLIN EXP NEUROPSYC, V22, P865, DOI 10.1076/jcen.22.6.865.961; DUQUETTE P, 1992, CAN J NEUROL SCI, V19, P466, DOI 10.1017/S0317167100041664; ERICKSON RC, 1977, PSYCHOL BULL, V84, P1130, DOI 10.1037/0033-2909.84.6.1130; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Grafman J, 1990, NEUROBEHAVIORAL ASPE, P102; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hart R. P., 1994, NEUROPSYCHOLOGY, V8, P325, DOI [10.1037/0894-4105.8.3.325, DOI 10.1037/0894-4105.8.3.325]; Hochstenbach J, 1998, J CLIN EXP NEUROPSYC, V20, P503, DOI 10.1076/jcen.20.4.503.1471; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; LORING DW, 1987, J CLIN EXP NEUROPSYC, V9, P340, DOI 10.1080/01688638708405055; MARKOWITSCH HJ, 2000, OXFORD HDB MEMORY, P465; MASUR DM, 1990, J CLIN EXP NEUROPSYC, V12, P529, DOI 10.1080/01688639008400999; MASUR DM, 1989, J CLIN EXP NEUROPSYC, V11, P615, DOI 10.1080/01688638908400920; McKinlay W, 1999, COGNITIVE BEHAV EFFE, P74; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P699, DOI 10.1080/01688638908400926; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; RUFF RM, 1989, J CLIN EXP NEUROPSYC, V11, P539, DOI 10.1080/01688638908400912; Solari A, 2002, MULT SCLER, V8, P169, DOI 10.1191/1352458502ms780oa; Spreen O., 1991, COMPENDIUM NEUROPSYC; Squire L. R., 1983, MEMORY CONSOLIDATION, P185; SQUIRE LR, 1987, MEMORY BRAIN; THAL LJ, 1983, NEW ENGL J MED, V308, P720; Torres A, 2006, ACTAS ESP PSIQUIATRI, V34, P408; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0; WIEDERHOLT WC, 1993, J AM GERIATR SOC, V41, P639, DOI 10.1111/j.1532-5415.1993.tb06738.x; WILLIAMS JM, 1991, COGNITIVE BEHAV RATI	53	37	37	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					231	254	PII 793866766	10.1080/13854040802121158			24	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000003	18609311				2021-06-18	
J	Colantonio, A; McVittie, D; Lewko, J; Yin, JL				Colantonio, Angela; McVittie, Doug; Lewko, John; Yin, Junlang			Traumatic brain injuries in the construction industry	BRAIN INJURY			English	Article						Traumatic brain injury; construction	SERIOUS INJURIES; WORK; SLEEPINESS; PERFORMANCE; POPULATION; PREVALENCE; FATALITIES; COSTS; STATE; TIME	Objective: This study analyses factors associated with work-related traumatic brain injury (TBI), specifically in the construction industry in Ontario, Canada. Methods: This cross-sectional study utilized data extracted from the Ontario Workplace Safety and Insurance Board (WSIB) records indicating concussion/intracranial injury that resulted in days off work in 2004-2005. Results: Analyses of 218 TBI cases revealed that falls were the most common cause of injury, followed by being struck by or against an object. Mechanisms of injury and the temporal profile of injury also varied by age. For instance, a significantly higher proportion of injuries occurred in the mornings for young workers compared to older workers. Conclusions: The results of this study provide important information for prevention of TBI which suggest important age-specific strategies for workers in the construction industry.	[Colantonio, Angela] Univ Toronto, Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, Toronto, ON M5G 1V7, Canada; [McVittie, Doug] Construct Safety Assoc, Toronto, ON, Canada; [Lewko, John] Laurentian Univ, Sudbury, ON P3E 2C6, Canada	Colantonio, A (corresponding author), Univ Toronto, Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, 500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	Ontario Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute and the Toronto Rehabilitation Institute Foundation	We would like to acknowledge Jennifer Fergenbaum and Michelle Mohan for their help with this manuscript. The authors also wish to acknowledge the Ontario MOHLTC's grant to Toronto Rehabilitation Institute. This project was funded by a grant from the Ontario Neurotrauma Foundation. We acknowledge the support of the Construction Safety Association, a grant from the Ontario Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute and the Toronto Rehabilitation Institute Foundation.	Breslau N, 1997, AM J PUBLIC HEALTH, V87, P1649, DOI 10.2105/AJPH.87.10.1649; DERMOLEN H, 2007, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD006251.PUB2; Dinges DF, 1997, SLEEP, V20, P267; Folkard S, 2003, OCCUP MED-OXFORD, V53, P95, DOI 10.1093/occmed/kqg047; Goldenhar LM, 2003, J SAFETY RES, V34, P215, DOI 10.1016/S0022-4375(03)00010-0; Haslam RA, 2005, APPL ERGON, V36, P401, DOI 10.1016/j.apergo.2004.12.002; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Janicak CA, 1998, J OCCUP ENVIRON MED, V40, P347, DOI 10.1097/00043764-199804000-00009; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kim JA, 1997, OCCUPATIONAL THERAPY, V4, P180; Kines P, 2002, J SAFETY RES, V33, P195, DOI 10.1016/S0022-4375(02)00019-1; Kristman VL, 2008, BRAIN INJURY, V22, P51, DOI 10.1080/02699050701849991; MCCLURE R, 2005, COCHRANE DATABASE SY, V25; MCVITTIE DJ, 1995, OCCUP MED, V10, P285; Menard MR, 1996, J OCCUP ENVIRON MED, V38, P1161, DOI 10.1097/00043764-199611000-00017; Mittelmann M, 1991, J Insur Med, V23, P55; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ricci JA, 2007, J OCCUP ENVIRON MED, V49, P1, DOI 10.1097/01.jom.0000249782.60321.2a; RIVARA F, 2000, AM J PREV MED, V18, pS4; Sallinen M, 2004, J SLEEP RES, V13, P285, DOI 10.1111/j.1365-2869.2004.00425.x; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; *STAT CAN, LAB FORC SURV EST N; Statistics Canada, 2008, IND N AM IND CLASS S; Tricco AC, 2006, BRAIN INJURY, V20, P719, DOI 10.1080/02699050600664640; Waehrer GM, 2007, J OCCUP ENVIRON MED, V49, P1218, DOI 10.1097/JOM.0b013e318156ed24; Wrona RM, 2006, J SAFETY RES, V37, P75, DOI 10.1016/j.jsr.2005.08.008	26	37	38	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	11					873	878	PII 915243067	10.1080/02699050903036033			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300003	20100123				2021-06-18	
J	Stewart, C; Haitsma, I; Zador, Z; Hemphill, JC; Morabito, D; Manley, G; Rosenthal, G				Stewart, Campbell; Haitsma, Iain; Zador, Zsolt; Hemphill, J. Claude, III; Morabito, Diane; Manley, Geoffrey; Rosenthal, Guy			THE NEW LICOX COMBINED BRAIN TISSUE OXYGEN AND BRAIN TEMPERATURE MONITOR: ASSESSMENT OF IN VITRO ACCURACY AND CLINICAL EXPERIENCE IN SEVERE TRAUMATIC BRAIN INJURY	NEUROSURGERY			English	Article						Brain temperature; Brain tissue oxygen tension; Clinical evaluation; In vitro accuracy; Technology assessment	SEVERE HEAD-INJURY; TENSION; PROBES	OBJECTIVE: Monitoring of brain tissue oxygen tension is increasingly being used to monitor patients after severe traumatic brain injury and to guide therapies aimed at maintaining brain tissue oxygen tension above threshold levels. The new Licox PMO combined oxygen and temperature catheter (Integra LifeSciences, Plainsboro, NJ) combines measurements of oxygen tension and temperature in a single probe inserted through a bolt mechanism. In this study, we sought to evaluate the accuracy of the new Licox PMO probe under controlled laboratory conditions and to assess the accuracy of oxygen tension and temperature measurements and the new automated card calibration system. We also describe our clinical experience with the Licox PMO probe. METHODS: Oxygen tension was measured in a 2-chambered apparatus at different oxygen tensions and temperatures. The new card calibration system was compared with a manually calibrated system. Rates of hematoma, infection, and dislodgement in Our clinical experience were recorded. RESULTS: The new Licox PMO probe accurately measures oxygen tension over a wide range of oxygen concentrations and physiological temperatures, but it does have a small tendency to underestimate oxygen tension (mean error, -3.8 +/- 3.5%) that is more pronounced between the temperatures of 33 and 39 degrees C. The thermistor of the PMO probe also has a tendency to underestimate temperature when compared with a resistance thermometer (mean error, -0.67 +/- 0.22 degrees C). The card calibration system was also found to introduce some variability in measurements of oxygen tension when compared with a manually calibrated system. Clinical experience with the new probe indicates good placement within the white matter using the improved bolt system and low rates of hematoma (2.9%), infection (0%), and dislodgement (5.9%). CONCLUSION: The new Licox PMO probe is accurate but has a small, consistent tendency to under-read oxygen tension that is more pronounced at higher temperatures. The probe tends to under-read temperature by 0.5 to 0.8 degrees C across temperatures, suggesting that caution should be used when brain temperature is measured with the Licox PMO probe and used to guide tempera tu re-directed treatment strategies. The Licox PMO probe improves upon previous models in allowing consistent and accurate placement in the white matter and obviating the need for placement of 2 separate probes to measure oxygen tension and temperature.	[Zador, Zsolt; Morabito, Diane; Manley, Geoffrey; Rosenthal, Guy] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94110 USA; [Stewart, Campbell] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94110 USA; [Haitsma, Iain] Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands; [Hemphill, J. Claude, III] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands	Manley, G (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525; zador, zsolt/0000-0003-4297-616X; Zador, Zsolt/0000-0001-9767-3372			Alessandri B, 2004, J NEUROSCI METH, V139, P161, DOI 10.1016/j.jneumeth.2004.04.021; Charbel FT, 2000, SURG NEUROL, V54, P432, DOI 10.1016/S0090-3019(00)00340-2; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 1998, ACT NEUR S, V71, P162; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vath A, 2002, ACT NEUR S, V81, P307	11	37	39	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2008	63	6					1159	1164		10.1227/01.NEU.0000333265.19131.7C			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	382ZH	WOS:000261643400047	19057329				2021-06-18	
J	Shores, EA; Lammel, A; Hullick, C; Sheedy, J; Flynn, M; Levick, W; Batchelor, J				Shores, E. A.; Lammel, A.; Hullick, C.; Sheedy, J.; Flynn, M.; Levick, W.; Batchelor, J.			The diagnostic accuracy of the Revised Westmead PTA Scale as an adjunct to the Glasgow Coma Scale in the early identification of cognitive impairment in patients with mild traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							BLUNT HEAD-INJURY; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; CONSCIOUSNESS; DURATION	Background: Assessment of patients with mild traumatic brain injury (mTBI) is predominantly done using the Glasgow Coma Scale (GCS). While the GCS is universally accepted for assessment of severity of traumatic brain injury, it may not be appropriate to rely on the GCS alone when assessing patients with mTBI in prehospital settings and emergency departments. Objective: To determine whether administering the Revised Westmead Post-traumatic Amnesia (PTA) Scale (R-WPTAS) in addition to the GCS would increase diagnostic accuracy in the early identification of cognitive impairment in patients with mTBI. Methods: Data were collected from 82 consecutive participants with mTBI who presented to the emergency department of a level 1 trauma centre in Australia. A matched sample of 88 control participants who attended the emergency department for reasons other than head trauma was also assessed. All patients were assessed using the GCS, R-WPTAS and a battery of neuropsychological tests. Results: Patients with mTBI scored poorly compared with control patients on all measures. The R-WPTAS showed greater concurrent validity with the neuropsychological measures than the GCS and significantly increased prediction of group membership of patients with mTBI with cognitive impairment. Conclusions: The R-WPTAS significantly improves diagnostic accuracy in identifying patients with mTBI who may be in PTA. Administration takes less than 1 min, and since early identification of a patient's cognitive status facilitates management decisions, it is recommended for routine use whenever the GCS is used.	[Shores, E. A.; Lammel, A.; Batchelor, J.] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Hullick, C.; Levick, W.] John Hunter Hosp, Div Emergency Med, New Lambton, Australia; [Sheedy, J.] St Vincents Hosp, Trauma Serv, Sydney, NSW 2010, Australia; [Flynn, M.] Ambulance Serv NSW, Sydney, NSW, Australia	Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	ashores@psy.mq.edu.au	hullick, Carolyn/H-7116-2019; Hullick, Carolyn/AAA-3334-2020	hullick, Carolyn/0000-0002-6157-8880; Hullick, Carolyn/0000-0002-6157-8880; Batchelor, Jennifer/0000-0003-4438-4993; Shores, Edwin A/0000-0003-1553-5131	Ambulance Service of New South Wales' Hamilton station; Rehabilitation Grant from the Motor Accident Authority of New South Wales [04/239]; Collaborative Research Grant from Macquarie University, Sydney, Australia [A006079]	The authors thank the clinical staff at the John Hunter Hospital Emergency Department and the paramedics and ambulance officers of the Ambulance Service of New South Wales' Hamilton station for their support in having made this study possible.; This study was funded by a Rehabilitation Grant from the Motor Accident Authority of New South Wales (Grant Ref: 04/239) and a Collaborative Research Grant from Macquarie University, Sydney, Australia (Grant Ref: A006079). The funding sources had no role in the study design, data collection and analysis, interpretation of the data, writing or any decision to submit to the Journal of Neurology, Neurosurgery and Psychiatry.	Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; DEVILLY GJ, 2005, CLIN TOOLS SOFTWARE; Geffen G., 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; Greenwood R, 1997, LANCET, V349, P1041, DOI 10.1016/S0140-6736(05)62288-X; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Laureys S, 2005, LANCET NEUROL, V4, P789, DOI 10.1016/S1474-4422(05)70230-1; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; LOVELL MR, 2004, IMPACT TRAUMA; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; *MEDCALC WIND, 2009, V 9 2 0 1; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Sackett D. L., 2000, EVIDENCE BASED MED P, V2nd; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHORES A, 1990, AUST NZ J PSYCHIAT, V24, P133, DOI 10.3109/00048679009062895; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198	26	37	37	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2008	79	10					1100	1106		10.1136/jnnp.2007.132571			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	348XG	WOS:000259242800004	18223020				2021-06-18	
J	Figaji, AA; Fieggen, AG; Argent, AC; LeRoux, PD; Peter, JC				Figaji, Anthony A.; Fieggen, A. Graham; Argent, Andrew C.; LeRoux, Peter D.; Peter, Jonathan C.			Does adherence to treatment targets in children with severe traumatic brain injury avoid brain hypoxia? A brain tissue oxygenation study	NEUROSURGERY			English	Article						brain hypoxia; cerebral ischemia; cerebral oxygenation; cerebral perfusion pressure; children; head injury; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURIES; INTRACRANIAL-PRESSURE; BLOOD-FLOW; INITIAL-EXPERIENCE; SUBSTRATE DELIVERY; PEDIATRIC-PATIENTS; INSPIRED OXYGEN; LOWER LIMIT; TRANSFUSION	OBJECTIVE: Most physicians rely on conventional treatment targets for intracranial pressure, cerebral perfusion pressure, systemic oxygenation, and hemoglobin to direct management of traumatic brain injury (TBI) in children. In this study, we used brain tissue oxygen tension (PbtO(2)) monitoring to examine the association between PbtO(2) values and Outcome in pediatric severe TBI and to determine the incidence of compromised PbtO(2) in patients for whom acceptable treatment targets had been achieved. METHODS: In this prospective observational study, 26 children with severe TBI and a median postresuscitation Glasgow Coma Scale score of 5 were managed with continuous PbtO(2) monitoring. The relationships between outcome and the 6-hour period of lowest PbtO(2) values and the length of time that PbtO(2) was less than 20, 15, 10, and 5 mmHg were examined. The incidence of reduced PbtO(2) for each threshold was evaluated where the following targets were met: intracranial pressure less than 20 mmHg, cerebral perfusion pressure greater than 50 mmHg, arterial oxygen tension greater than 60 mmHg (and peripheral oxygen saturation > 90%), and hemoglobin greater than 8 g/dl. RESULTS:There was a significant association between poor outcome and the 6-hour period of lowest PbtO(2) and length of time that PbtO(2) was less than 15 and 10 mmHg. Multiple logistic regression analysis showed that low PbtO(2) had an independent association with poor outcome. Despite achieving the management targets described above, 80% of patients experienced one or more episodes of compromised PbtO(2) (< 20 mmHg), and almost one-third experienced episodes of brain hypoxia (PbtO(2) < 10 mmHg). CONCLUSION: Reduced PbtO(2) is associated with poor outcome in pediatric severe TBI. In addition, many patients experience episodes of compromised PbtO(2) despite achieving acceptable treatment targets.	[Figaji, Anthony A.] Univ Cape Town, Red Cross Childrens Hosp, Div Neurosurg, Sch Child & Adolescent Hlth,Inst Child Hlth 617, ZA-7700 Rondebosch, South Africa; [Argent, Andrew C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Pediat Crit Care, ZA-7700 Rondebosch, South Africa; [LeRoux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Figaji, AA (corresponding author), Univ Cape Town, Red Cross Childrens Hosp, Div Neurosurg, Sch Child & Adolescent Hlth,Inst Child Hlth 617, Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	anthony.figaji@uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Fieggen, Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Arias Elizabeth, 2003, Natl Vital Stat Rep, V52, P1; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; *CDC NAT CTR INJ P, WEB BAS INJ STAT QUE; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chiaretti A, 2002, CHILD NERV SYST, V18, P54, DOI 10.1007/s00381-001-0533-4; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Doppenberg EMR, 1997, J NEUROSURG, V87, P809, DOI 10.3171/jns.1997.87.6.0809; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Haque IU, 2007, PEDIATR CRIT CARE ME, V8, P138, DOI 10.1097/01.PCC.0000257039.32593.DC; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Reiles E, 2007, CRIT CARE, V11, DOI 10.1186/cc5936; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9987; Thees C, 2003, INTENS CARE MED, V29, P386, DOI 10.1007/s00134-002-1625-7; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	55	37	37	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2008	63	1					83	91		10.1227/01.NEU.0000335074.39728.00			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	341LM	WOS:000258716000019	18728572				2021-06-18	
J	Fillpovic, R; Zecevic, N				Fillpovic, Radmila; Zecevic, Nada			Neuroprotective role of minocycline in co-cultures of human fetal neurons and microglia	EXPERIMENTAL NEUROLOGY			English	Article						LPS; ameboid microglia; neuroprotection; Bcl-2; bax; TLR4	CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTORS; SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; MULTIPLE-SCLEROSIS; MOLECULAR-MECHANISMS; PROTEIN-KINASES; INNATE IMMUNITY; MOUSE MODEL	Bacterial infections during pregnancy often result in premature birth and neonatal white matter damage. During these infections, microglia, the resident immune cells of the CNS, undergo activation and contribute to further neuronal damage of the CNS. Minocycline, a second-generation tetracycline antibiotic, inhibits microglial activation and protects neurons in rodents but data about its effects on human cells are limited. We studied the mechanism of the neuroprotective effect of minocycline in either purified cell cultures or co-cultures of microglia and neurons from human fetal brain during inflammation induced by lipopolysaccharide (LPS). In neuron/microglial co-cultures, minocycline treatment prevented activation and proliferation of microglia and protected neurons as demonstrated by decreased neuronal cell death and a shift of Bcl-2 family proteins toward anti-apoptotic ratio. Notably, neither minocycline nor LPS had an effect on neurons in purified neuronal cultures. The ability of minocycline to regulate activation of human fetal microglia might be relevant in therapies used towards treating neonatal CNS infections. (C) 2008 Elsevier Inc. All rights reserved.	[Fillpovic, Radmila; Zecevic, Nada] Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	Fillpovic, R (corresponding author), Univ Connecticut, Dept Physiol & Neurobiol, 75 N Eagleville Rd,U-3156, Storrs, CT 06269 USA.	radmila.filipovic@uconn.edu; nzecevic@neuron.uchc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041489] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041489] Funding Source: NIH RePORTER		Ackman JB, 2006, J NEUROSCI, V26, P11413, DOI 10.1523/JNEUROSCI.3340-06.2006; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Andjelkovic AV, 1998, BRAIN RES, V814, P13, DOI 10.1016/S0006-8993(98)00830-0; Back SA, 2004, SEMIN PERINATOL, V28, P405, DOI 10.1053/j.semperi.2004.10.010; BARZA M, 1975, ANTIMICROB AGENTS CH, V8, P713, DOI 10.1128/AAC.8.6.713; Bonelli RM, 2003, J PSYCHOPHARMACOL, V17, P461, DOI 10.1177/0269881103174008; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Bsibsi M, 2006, GLIA, V53, P688, DOI 10.1002/glia.20328; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Chechneva O, 2006, NEUROBIOL DIS, V23, P247, DOI 10.1016/j.nbd.2006.02.015; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; CHOI BH, 1981, J COMP NEUROL, V196, P683, DOI 10.1002/cne.901960412; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; Dammann O, 2001, EARLY HUM DEV, V64, P79, DOI 10.1016/S0378-3782(01)00183-9; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Familian A, 2006, GLIA, V53, P233, DOI 10.1002/glia.20268; Fan LW, 2005, NEUROSCIENCE, V133, P159, DOI 10.1016/j.neuroscience.2005.02.016; Ferrer I, 2003, BRAIN PATHOL, V13, P62; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Filipovic R, 2002, J NEUROIMMUNOL, V127, P1, DOI 10.1016/S0165-5728(02)00070-X; Filipovic R, 2008, GLIA, V56, P1, DOI 10.1002/glia.20582; HASSAN NF, 1991, NEUROSCIENCE, V41, P149, DOI 10.1016/0306-4522(91)90205-3; HETZMAN M, 2004, EUR J BIOCHEM, V271, P2050; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320; Kaftan H, 1998, SEMIN PERINATOL, V22, P15, DOI 10.1016/S0146-0005(98)80004-9; Karlsson M, 1996, ANTIMICROB AGENTS CH, V40, P1104, DOI 10.1128/AAC.40.5.1104; Kerfoot SM, 2004, J IMMUNOL, V173, P7070, DOI 10.4049/jimmunol.173.11.7070; Kerkovich DM, 1999, INT J DEV NEUROSCI, V17, P347, DOI 10.1016/S0736-5748(99)00036-2; Kloppenburg M, 1996, ANTIMICROB AGENTS CH, V40, P934, DOI 10.1128/AAC.40.4.934; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lai AY, 2006, GLIA, V53, P809, DOI 10.1002/glia.20335; Lauro GM, 1995, INT J DEV NEUROSCI, V13, P739, DOI 10.1016/0736-5748(95)00059-3; Lee SM, 2004, J NEUROCHEM, V91, P568, DOI 10.1111/j.1471-4159.2004.02780.x; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Leviton A, 2005, ANN NEUROL, V58, P821, DOI 10.1002/ana.20662; Li WW, 2005, J NEUROIMMUNOL, V158, P58, DOI 10.1016/j.jneuroim.2004.08.011; Lott Judy Wright, 2003, Crit Care Nurs Clin North Am, V15, P35; Maier K, 2007, NEUROBIOL DIS, V25, P514, DOI 10.1016/j.nbd.2006.10.022; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Metz LM, 2004, ANN NEUROL, V55, P756, DOI 10.1002/ana.20111; Monier A, 2006, J COMP NEUROL, V499, P565, DOI 10.1002/cne.21123; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; Nikodemova M, 2007, J BIOL CHEM, V282, P15208, DOI 10.1074/jbc.M611907200; Noseworthy JH, 1999, CURR OPIN NEUROL, V12, P279, DOI 10.1097/00019052-199906000-00007; Penfield W., 1932, CYTOLOGY CELLULAR PA, P483; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Ravina BM, 2003, NEUROLOGY, V60, P1234, DOI 10.1212/01.WNL.0000058760.13152.1A; Rezaie P, 2005, CEREB CORTEX, V15, P938, DOI 10.1093/cercor/bhh194; REZAIE P, 2003, NEUROEMBRYOLOGY, V2, P18, DOI DOI 10.1159/000068498; Romero R, 1998, AM J OBSTET GYNECOL, V179, P186, DOI 10.1016/S0002-9378(98)70271-6; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; Schwartz ML, 2004, SEMIN PERINATOL, V28, P379, DOI 10.1053/j.semperi.2004.10.009; Shankaran M, 2007, J NEUROSCI RES, V85, P2374, DOI 10.1002/jnr.21389; Slevin M, 2000, NEUROREPORT, V11, P2759, DOI 10.1097/00001756-200008210-00030; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Suk K, 2004, NEUROSCI LETT, V366, P167, DOI 10.1016/j.neulet.2004.05.038; Tanaka J, 1996, EXP NEUROL, V137, P367, DOI 10.1006/exnr.1996.0038; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zecevic N, 1998, DEV BRAIN RES, V105, P97, DOI 10.1016/S0165-3806(97)00176-4; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	82	37	37	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2008	211	1					41	51		10.1016/j.expneurol.2007.12.024			11	Neurosciences	Neurosciences & Neurology	298ZM	WOS:000255725600007	18359018				2021-06-18	
J	Schubert, GA; Poli, S; Mendelowitsch, A; Schilling, L; Thome, C				Schubert, Gerrit Alexander; Poli, Sven; Mendelowitsch, Aminadav; Schilling, Lothar; Thome, Claudius			Hypothermia reduces early hypoperfusion and metabolic alterations during the acute phase of massive subarachnoid hemorrhage: A Laser-Doppler-flowmetry and microdialysis study in rats	JOURNAL OF NEUROTRAUMA			English	Article						CBF autoregulation; hypothermia; metabolism; microdialysis; subarachnoid hemorrhage	CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; MILD HYPOTHERMIA; ACUTE VASOCONSTRICTION; BEDSIDE MICRODIALYSIS; MODERATE HYPOTHERMIA; ENERGY-METABOLISM; AMINO-ACIDS; IN-VIVO	Morbidity and mortality of subarachnoid hemorrhage (SAH) are correlated with the severity of the patient's acute neurological deficit. This initial presentation has been attributed to cerebral hypoperfusion in the acute phase, and we investigated the impact of moderate hypothermia on the early changes in perfusion and metabolism following massive experimental SAH. SAH was induced in 61 anesthetized rats by rapid injection of 0.5 mL of arterial blood into the cisterna magna. In normothermia (NT), animals were kept at 37 degrees C, while in the primary hypothermia (pHT) group, temperature was lowered to 32 degrees C prior to SAH, and in the secondary hypothermia (sHT) group, cooling was started immediately after SAH. From 30 min prior to 180 min after SAH, Laser-Doppler-flowmetry (LDF) probes allowed online recording of cerebral blood flow (CBF) while parenchymal dialysate was collected by microdialysis probes within the frontoparietal cortex. In NT, the acute phase was characterized by impaired autoregulation and prolonged hypoperfusion. In pHT and sHT, autoregulation was preserved and acute hypoperfusion rapidly improved. SAH also caused a highly significant reduction in glucose in NT only. pHT significantly reduced accumulation of lactate, glutamate, and aspartate. Comparable trends were present for histidine, GABA, and taurine, while glutamine consumption was ameliorated. Early perfusion deficits caused by acute hypoperfusion and disruption of cerebral autoregulation can be ameliorated by hypothermia. Also, the acute phase of experimental SAH is characterized by glucose depletion, lactate accumulation, and release of excitatory amino acids, which can be influenced favorably by hypothermia.	[Schubert, Gerrit Alexander; Poli, Sven; Thome, Claudius] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; [Mendelowitsch, Aminadav] Cranio Facial Ctr Hirslanden, Neurosurg Clin, Aarau, Switzerland; [Schilling, Lothar] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg Res, D-68167 Mannheim, Germany	Schubert, GA (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	gerrit.schubert@nch.ma.uni-heidelberg.de	Schubert, Gerrit Alexander/Q-9192-2017	Schubert, Gerrit Alexander/0000-0001-9135-6042			Baldwin ME, 2004, STROKE, V35, P2506, DOI 10.1161/01.STR.0000144654.79393.cf; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Cambj-Sapunar L, 2003, STROKE, V34, P1269, DOI 10.1161/01.STR.0000065829.45234.69; De Micheli E, 2000, ADV EXP MED BIOL, V483, P595; DELGADO TJ, 1985, STROKE, V16, P595, DOI 10.1161/01.STR.16.4.595; Eddy VA, 2000, SURG CLIN N AM, V80, P845, DOI 10.1016/S0039-6109(05)70099-2; El Idrissi A, 2003, ADV EXP MED BIOL, V526, P515; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Fujisawa H, 1999, J NEUROTRAUM, V16, P1083, DOI 10.1089/neu.1999.16.1083; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; JAKOBSEN J, 1992, ACTA NEUROL SCAND, V86, P1, DOI 10.1111/j.1600-0404.1992.tb08044.x; Karibe H, 2000, NEUROSURGERY, V47, P594, DOI 10.1097/00006123-200009000-00012; Khan SNH, 2000, NEUROCHEM RES, V25, P217, DOI 10.1023/A:1007519419342; Kollmar R, 2002, ANESTHESIOLOGY, V97, P868, DOI 10.1097/00000542-200210000-00018; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Morgan ME, 1996, J PHARMACOL EXP THER, V277, P1167; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; OKAMOTO K, 1983, BRAIN RES, V260, P249, DOI 10.1016/0006-8993(83)90678-9; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; Preisman S, 2005, BRIT J ANAESTH, V95, P207, DOI 10.1093/bja/aei147; PROUST F, 1995, STROKE, V26, P1553, DOI 10.1161/01.STR.26.9.1553; Ratsep T, 2001, J NEUROSURG, V95, P393, DOI 10.3171/jns.2001.95.3.0393; ROSENSTEIN J, 1984, NEUROSURGERY, V15, P519, DOI 10.1227/00006123-198410000-00008; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; Scheller D, 2000, NEUROCHEM RES, V25, P801, DOI 10.1023/A:1007513423270; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Sehba FA, 1999, STROKE, V30, P1955, DOI 10.1161/01.STR.30.9.1955; Shuaib A, 1996, ACT NEUR S, V67, P53; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Thome C, 2001, ACTA NEUROCHIR SUPPL, V77, P255; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919; Yamaguchi S, 2000, NEUROL RES, V22, P657; Zuccarello M, 2001, ACTA NEUROCHIR SUPPL, V77, P61	42	37	38	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2008	25	5					539	548		10.1089/neu.2007.0500			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	303PY	WOS:000256054100010	18352824				2021-06-18	
J	von Arx, T; Flury, R; Tschan, J; Buergin, W; Geiser, T				von Arx, T.; Flury, R.; Tschan, J.; Buergin, W.; Geiser, T.			Exercise capacity in athletes with mouthguards	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						spiroergometry; exercise capacity; mouthguard; athlete; breathing; performance	OROFACIAL INJURIES; CUSTOM-MADE; DENTAL INJURIES; MOUTH GUARDS; CONCUSSIONS; SPORTS	The objective of this study was to determine the effect of wearing a mouthguard on maximal exercise capacity and cardiopulmonary parameters at peak workload, and to assess the athletes' attitudes toward wearing a mouthguard. Thirteen volunteer male athletes (18 to 27 years old) were interviewed before and after delivery of a custom-made laminated mouthguard. A visual analogue scale (VAS, 0-100 mm) was used for judgment of interference with breathing, speaking, concentration and athletic performance. In addition, the athletes were subjected to a cardiorespiratory examination on a cycle ergometer with and without mouthguards. Subjectively, the athletes rated the mean interference with performance to be 37 mm VAS at the beginning of the study. Mean scores of impairment decreased to 23 mm VAS (p = 0.081) after wearing the mouthguard for four weeks, and further improved to 12 mm VAS (p < 0.001) after the test on the cycle ergometer. Objectively, the maximum workload during spiroergometry was even slightly elevated during exercise with the mouthguard (330.2 W) compared to exercise without the mouthguard (314.5 W). Peak minute ventilation and oxygen uptake were not different during exercise with and without the mouthguard. The present study demonstrated that a custom-made mouthguard does not significantly affect or reduce maximum exercise performance of athletes.	[von Arx, T.; Tschan, J.; Buergin, W.] Univ Bern, Dept Oral Surg & Stomatol, CH-3010 Bern, Switzerland; [Flury, R.; Geiser, T.] Univ Bern, Dept Pulm Med, CH-3010 Bern, Switzerland	von Arx, T (corresponding author), Univ Bern, Dept Oral Surg & Stomatol, Freiburgstr 7, CH-3010 Bern, Switzerland.	thomas.vonarx@zmk.unibe.ch					Amis T, 2000, MED SCI SPORT EXER, V32, P284, DOI 10.1097/00005768-200002000-00006; Brunner E., 2002, NONPARAMETRIC ANAL L; Chapman PJ, 1996, AUST DENT J, V41, P252, DOI 10.1111/j.1834-7819.1996.tb04869.x; Cornwell H, 2003, DENT TRAUMATOL, V19, P193, DOI 10.1034/j.1600-9657.2003.00202.x; Delaney JS, 2005, CLIN J SPORT MED, V15, P154, DOI 10.1097/01.jsm.0000158256.85664.8d; DEYOUNG AK, 1994, J AM DENT ASSOC, V125, P1112, DOI 10.14219/jada.archive.1994.0121; Eroglu E, 2006, DENT TRAUMATOL, V22, P193, DOI 10.1111/j.1600-9657.2006.00385.x; FLANDERS RA, 1995, J AM DENT ASSOC, V126, P491, DOI 10.14219/jada.archive.1995.0213; Francis K T, 1991, Br J Sports Med, V25, P227; Kececi AD, 2005, DENT TRAUMATOL, V21, P276, DOI 10.1111/j.1600-9657.2005.00354.x; Kvittem B, 1998, J PUBLIC HEALTH DENT, V58, P288, DOI 10.1111/j.1752-7325.1998.tb03011.x; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Lieger O, 2006, DENT TRAUMATOL, V22, P1, DOI 10.1111/j.1600-9657.2006.00328.x; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; MORROW RM, 1991, J ATHL TRAINING, V26, P344; SCOTT J, 1994, BRIT DENT J, V176, P310, DOI 10.1038/sj.bdj.4808433; SEALS RR, 1985, J AM DENT ASSOC, V110, P904, DOI 10.14219/jada.archive.1985.0005; Takeda T, 2005, DENT TRAUMATOL, V21, P134, DOI 10.1111/j.1600-9657.2005.00320.x; Tschan Jorg D, 2003, Schweiz Monatsschr Zahnmed, V113, P20; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Woodmansey KF, 1997, J AM COLL HEALTH, V45, P179, DOI 10.1080/07448481.1997.9936880; Yamada T, 1998, ENDOD DENT TRAUMATOL, V14, P84	22	37	37	0	10	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	MAY	2008	29	5					435	438		10.1055/s-2007-965341			4	Sport Sciences	Sport Sciences	306GV	WOS:000256237200015	17614035				2021-06-18	
J	Sorani, MD; Morabito, D; Rosenthal, G; Giacomini, KM; Manley, GT				Sorani, Marco D.; Morabito, Diane; Rosenthal, Guy; Giacomini, Kathleen M.; Manley, Geoffrey T.			Characterizing the dose-response relationship between mannitol and intracranial pressure in traumatic brain injury patients using a high-frequency physiological data collection system	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; brain injuries; dose-response relationship; intracranial pressure; mannitol	HYPERTONIC MANNITOL; 20-PERCENT MANNITOL; HEAD-INJURIES; HYPERTENSION; OSMOTHERAPY; MANAGEMENT; MECHANISM; OUTCOMES; SALINE; TRIAL	Despite the widespread use of mannitol to treat elevated intracranial pressure (ICP), there is no consensus regarding the optimal dosage. The objective of this study was to retrospectively characterize the dose-response relationship between mannitol and ICP using data collected with a continuous high-frequency physiological data collection system. To this end, we measured ICP continuously in 28 patients with traumatic brain injury (TBI) who were given at least one dose of mannitol. Twenty TBI patients were given a total of 85 doses of 50 g of mannitol, and 18 patients were given 50 doses of 100 g. Some patients received both amounts. Cerebral perfusion pressure was maintained above 60 mm Hg. The average ICP was 22.0 +/- 10.6 mm Hg when mannitol was administered, fell immediately after dosing, and continued falling for approximately 30 min to 15.7 +/- 8.1 mm Hg across all patients. After 30 min, ICP was equal in the 100-g group (15.6 +/- 10.9) versus the 50-g group (15.7 +/- 6.3). However, at 100 min, ICP had increased in the 50-g group to nearly its initial value but was still lower in the 100-g group (18.6 +/- 7.6 vs. 14.2 +/- 6.7 mm Hg; p = 0.001). Osmotic agents such as mannitol have been used for decades to treat cerebral edema, but there has been no definitive quantitative information regarding the dosing of mannitol. In a large, retrospective study of high-frequency ICP data, we have quantitatively shown that mannitol's effect on ICP is dose-dependent and that higher doses provide a more durable reduction in ICP.	[Morabito, Diane; Rosenthal, Guy; Manley, Geoffrey T.] San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94117 USA; [Sorani, Marco D.] Univ Calif San Francisco, Program Biol & Med Informat, San Francisco, CA 94143 USA; [Giacomini, Kathleen M.] San Francisco Gen Hosp, Dept Biopharmaceut Sci, San Francisco, CA 94117 USA	Manley, GT (corresponding author), San Francisco Gen Hosp, Dept Neurosurg, Bldg 1,Room 101,1001 Potrero Ave, San Francisco, CA 94117 USA.	manleyg@neurosurg.ucsf.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS049691, R01NS050173] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049691, NS050173] Funding Source: Medline		ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERECZKI D, 2001, COCHRANE DB SYST REV, V1; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Biestro A, 1997, ACTA NEUROCHIR, V139, P725, DOI 10.1007/BF01420045; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1995, New Horiz, V3, P448; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; Gondim FDA, 2005, J NEUROSURG, V103, P444; Hartl R, 1997, ACT NEUR S, V70, P40; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; Kirkpatrick PJ, 1996, NEUROSURGERY, V39, P714, DOI 10.1097/00006123-199610000-00013; Lang E W, 1995, New Horiz, V3, P400; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MCGRAW CP, 1978, SURG NEUROL, V10, P127; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Palma L, 2006, J Neurosurg Sci, V50, P63; POLLAY M, 1983, J NEUROSURG, V59, P945, DOI 10.3171/jns.1983.59.6.0945; Rapoport SI, 2000, CELL MOL NEUROBIOL, V20, P217, DOI 10.1023/A:1007049806660; REILLY MJ, 1976, POCKET CONSULT DIURE; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Weed LH, 1919, AM J PHYSIOL, V48, P531	33	37	39	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2008	25	4					291	298		10.1089/neu.2007.0411			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	282PL	WOS:000254579600002	18373479				2021-06-18	
J	Adembri, C; Massagrande, A; Tani, A; Miranda, M; Margheri, M; De Gaudio, R; Pellegrini-Giampietro, DE				Adembri, Chiara; Massagrande, Alessandra; Tani, Alessia; Miranda, Marco; Margheri, Martina; De Gaudio, Raffaele; Pellegrini-Giampietro, Domenico E.			Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						erythropoietin; carbamylated erythropoietin; neuro-protection; organotypic hippocampal slices; propidium iodide; traumatic brain injury		Objective: The well-documented neuroprotective effects of recombinant human erythropoietin (rhEPO) are commonly associated with untoward erythrocyte-stimulating effects (polycythemia), with subsequent risk of thromboembolic complications. A carbamylated-rhEPO (CEPO) derivative, which is neuroprotective but lacks hematopoietic activity, has been recently developed. In this study, we evaluated the neuroprotective capability of CEPO in an in vitro model of cerebral trauma in which rhEPO was previously shown to reduce posttraumatic cell death. Design: Prospective, controlled experiment. Setting: Animal, basic science laboratory. Subjects: Wistar rats, 8 days old. Interventions: Organotypic hippocampal slices, obtained from rat brains, were subjected to a well-characterized model of mechanical injury followed by addition of 10 IU/mL rhEPO, 10-100 IU/mL CEPO, or vehicle (injured control) to the incubation medium at different times to assess the temporal window of therapeutic neuroprotection. Measurements and Main Results, Posttraumatic cell death was quantified at 12, 24, or 48 hrs after injury by measuring propidium iodide fluorescence in the selectively vulnerable CA1 hippocampal area. Posttraumatic injury, observed in injured, vehicle-treated hippocampal slices, was significantly attenuated by addition of either 10 IU/mL rhEPO or 10 IU/mL CEPO. The neuroprotective efficacy of 10 IU/mL rhEPO or CEPO remained intact even when administration was delayed 1 hr after trauma. Qualitative microscopy in semithin sections showed that both rhEPO and CEPO exerted a marked pyramidal neuron-sparing effect. Conclusion: Our study shows that 10 IU/mL CEPO exerts neuroprotective effects comparable with those of rhEPO in an in vitro model of mechanical cerebral trauma. Because CEPO lacks hematopoietic effects and seems to possess a prolonged therapeutic time window, this erythropoietin derivative may represent an exciting new pharmacologic tool in treating patients with mechanical injury to the brain.	[Adembri, Chiara; Massagrande, Alessandra; Miranda, Marco; De Gaudio, Raffaele] Univ Florence, Sect Anesthesiol & Intens Care, Dept Crit Care Med, Florence, Italy; [Tani, Alessia; Margheri, Martina] Univ Florence, Dept Anat Histol & Forens Med, Florence, Italy; [Pellegrini-Giampietro, Domenico E.] Univ Florence, Dept Preclin & Clin Pharmacol, Florence, Italy	Adembri, C (corresponding author), Univ Florence, Sect Anesthesiol & Intens Care, Dept Crit Care Med, Florence, Italy.	chiara.adembri@unifi.it		Pellegrini-Giampietro, Domenico E./0000-0002-3920-2297			Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Montero M, 2007, EXP NEUROL, V204, P106, DOI 10.1016/j.expneurol.2006.09.026; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285	10	37	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2008	36	3					975	978		10.1097/CCM.0B013E3181644343			4	Critical Care Medicine	General & Internal Medicine	266QD	WOS:000253450500044	18176311				2021-06-18	
J	Lopresti, EF; Bodine, C; Lewis, C				Lopresti, Edmund F.; Bodine, Cathy; Lewis, Clayton			Assistive technology for cognition	IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-RETARDATION; IMPAIRMENTS; PEOPLE; REHABILITATION; OUTCOMES; CHILDREN; SPEECH; SYSTEM		[Lopresti, Edmund F.] AT Sci, LLC, Pittsburgh, PA 15213 USA; [Bodine, Cathy] Univ Colorado, Dept Rehabil Med, Boulder, CO 80309 USA; [Lewis, Clayton] Univ Colorado, Dept Comp Sci, Boulder, CO 80309 USA	Lopresti, EF (corresponding author), AT Sci, LLC, 160N Craig St,Suite 117, Pittsburgh, PA 15213 USA.	edlopresti@at-sciences.com					ABRAMSON R, 2000, IND STANDARD; Alzheimer's Association, 2005, BAS ALZH DIS; *AM PSYCH ASS TASK, 2000, DIAGN STAT MAN MENT, V33, P943; *AM STROKE ASS, 2006, IMP STROK; ARKELL H, 1997, INTRO DYSLEXIA DYSLE; BAECKER RM, 1995, READINGS HUMAN COMPU, P187; BANJA J, NIH CONS DEV C REH P; Bohman P., 2004, COGNITIVE DISABILI 1; Braddock D., 2004, Journal of Special Education Technology, V19, P49; Carey AC, 2005, MENT RETARD, V43, P322; Carmien S., 2005, ACM Transactions on Computer-Human Interaction, V12, P233, DOI 10.1145/1067860.1067865; CARMIEN S, 2003, 2 INT WORKSH UB COMP; Cole E, 1999, NEUROREHABILITATION, V12, P39; Cole E, 1994, NeuroRehabilitation, V4, P174, DOI 10.3233/NRE-1994-4308; COLE E, 2000, P REH ENG SOC N AM R, P31; COLE E, SIGCHI B, V20, P32; *COMM CLIN RES INV, 2004, ETH COND CLIN RES IN, P43; Cushman L A, 1996, Assist Technol, V8, P103; Davies DK, 2003, RES PRACT PERS SEV D, V28, P182, DOI 10.2511/rpsd.28.4.182; Davies DK, 2002, EDUC TRAIN MENT RET, V37, P209; DAVIES DK, 2004, ABLELINK INSTRUCTION; DENNETT B, 2001, HDB ACTION RES HLTH, P116; *DEV IND WORK GROU, 2005, DEV IND ACC MULT INT; DOE T, PARTICIPATORY ACTION; Eyde Lorraine D., 2000, ETHICS RES HUMAN PAR, P61; FICKAS S, 2005, CHI 2005 WORKSH ENG; FISCHMAN MW, 2000, ETHICS RES HUMAN PAR, P35; FRANCIK E, 1999, TELECOMMUNICATIONS P; FRIEDMAN M, 1993, P REH SOC N AM RESNA, P199; Gillette Y, 2004, NEUROREHABILITATION, V19, P233; GILLETTE Y, P CSUN 2005 C; GOLINKER L, 2001, KEY QUESTIONS MEDICA; Gorman P, 2003, NEUROREHABILITATION, V18, P57; Gould JD, 1983, P SIGCHI C HUM FACT, V28, P50, DOI [10.1145/800045.801579, DOI 10.1145/800045.801579]; GRANHOLM NA, 1992, LUPUS, V1, P63, DOI 10.1177/096120339200100203; Gregor P., 2000, ANN ACM C ASS TECHN, P85, DOI [10.1145/354324.354347, DOI 10.1145/354324.354347]; Gronbaek K., 1997, COMPUTERS DESIGN CON, P201; Hagenmeyer V., 2004, Automatisierungstechnik, V52, P3, DOI 10.1524/auto.52.1.3.25428; Hagerman RJ, 1999, DEV COGN NEUROSCI, P27; HAGERMAN RJ, 1999, NEURODEVELOPMENTAL D, P3173; HAGERMAN RJ, 1996, FRAGILE X SYNDROME D, P3; HAGERMAN RJ, 1999, DEV PERSP PSYCHIAT, P3; Happe F, 2001, J CHILD PSYCHOL PSYC, V42, P299, DOI 10.1111/1469-7610.00723; HART M, P ASSETS 2005, P136; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Henry S.L., 2007, JUST ASK INTEGRATING; Howell JD, 2003, USEFUL BODIES: HUMANS IN THE SERVICE OF MEDICAL SCIENCE IN THE TWENTIETH CENTURY, P190; JACOBS S, WORLD BANK 2004 INT; Jinks A., 1997, Proceedings of the RESNA '97 Annual Conference. Let's Tango - Partnering People and Technology, P526; KAYE HS, 2000, 13 DIS STAT US DEP E; Keates S., 2000, ACM SIGACCESS C COMP, P129; Kime SK, 1996, BRAIN INJURY, V10, P17; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; KOPPEL R, 2002, DIS COSTS US BUSINES, P1; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KUTIYANAWALA A, 2006, P ACM SIGACCESS, P245; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; LOPRESTI EF, 2005, P RESNA; MA J, 2002, P INT C SPOK LANG PR, P197; Mann WC, 2002, ASSIST TECHNOL, V14, P130, DOI 10.1080/10400435.2002.10132062; Mihailidis A, 2001, ASSIST TECHNOL, V13, P23, DOI 10.1080/10400435.2001.10132031; Namioka A., 1993, PARTICIPATORY DESIGN, P157; *NAT COUNC DIS, 2004, DES INCL CREAT NEW M; NAT'L BIOETHICS ADVISORY COMM'N, 1998, RES INV PERS MENT DI; *NCDRR STAFF, 2002, NAT CTR DISSEM DIDAB, V7; OCH F, 2005, GOOGLE BLOG; Philipose M, 2004, IEEE PERVAS COMPUT, V3, P50, DOI 10.1109/MPRV.2004.7; RASKIND MH, 1995, LEARN DISABILITY Q, V18, P141, DOI 10.2307/1511201; SALES B, 1979, ETHICS RES HUMAN P B; Scharfenaker S., 2002, FRAGILE X SYNDROME D, P363; SEELMAN KD, 1998, DISABILITYS NEW PARA; SILVER LB, 2006, WHAT ARE LEARNING DI; Stock S.E., 2003, J VOCAT REHABIL, V19, P95; Stringer E. T., 1999, ACTION RES; STROCK M, 1996, ATTENTION DEFICIT HY; SVENSK A, 1997, P 4 EUR C ADV ASS TE, P432; Todis B, 2005, BRAIN INJURY, V19, P389, DOI 10.1080/02699050400003957; *US DEP COMM, 2003, TECHN ASS US ASS TEC; VANDERHEIDEN G, 2005, INTERFACE SOCKETS RE; Wehmeyer M, 1997, EXCEPT CHILDREN, V63, P245, DOI 10.1177/001440299706300207; Wehmeyer ML, 1998, MENT RETARD, V36, P44, DOI 10.1352/0047-6765(1998)036<0044:NSOTUO>2.0.CO;2; WEHMEYER ML, 1999, J SPECIAL ED TECHNOL, V14, P48; Whyte W F, 1984, LEARNING FIELD GUIDE; Whyte WF., 1943, STREET CORNER SOC; WHYTE WF, 1997, CREATIVE PROBLEM SOL; WILLIAMS M, 2004, COMMUNICATION; WILLIAMS M, 2004, CAPE ARGUS      0617, P1; WILLOWS DM, 1993, VISUAL PROCESSES REA; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; WINTER R, 2001, HDB ACTION RES HLTH, P3; WONG TM, 1998, AVOIDING ETHICAL MIS, P187; 2005, SABE SUMMIT STATEMEN	96	37	37	0	4	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0739-5175	1937-4186		IEEE ENG MED BIOL	IEEE Eng. Med. Biol. Mag.	MAR-APR	2008	27	2					29	39		10.1109/EMB.2007.907396			11	Engineering, Biomedical; Medical Informatics	Engineering; Medical Informatics	277NT	WOS:000254220900007	18463019				2021-06-18	
J	Naunheim, RS; Matero, D; Fucetola, R				Naunheim, Rosanne S.; Matero, David; Fucetola, Robert			Assessment of patients with mild concussion in the emergency department	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	23rd Annual National-Neurotrauma-Society Symposium	NOV 10-11, 2005	Washington, DC	Natl Neurotrauma Soc		concussion; head injury; neurocognitive testing	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYNDROME; NEUROPSYCHOLOGICAL ASSESSMENT; SPORTS CONCUSSION; IMPACT; SPECIFICITY; SENSITIVITY; SYMPTOMS; HEALTH	Objectives: (1) to test the validity of the Standardized Assessment of Concussion (SAC) in characterizing the early evolution of concussion-related symptoms and mental status changes in the emergency department (ED) setting and (2) to compare it to the Conner's Continuous Performance Test 2nd Edition (CPT-II). Design: Prospective within-subject (repeated measures) design. Participants: Sixty-two persons with concussion (Glasgow Coma Scale = 15) and negative head computed tomographic scan results were examined on arrival in the ED and 3 and 6 hours later. Setting: A large urban, tertiary medical center ED. Main Outcome Measures: SAC; CPT-II; Post-Concussion Symptom Scale-Revised (PCS-R). Results: SAC and CPT-II scores improved significantly over the time course in the ED. Symptoms did not correlate with improvement, with many subjects complaining of headache or nausea after their scores improved. The average initial score on the SAC was 21 +/- 5.4/30. Conclusion: The SAC appears sensitive to the acute changes following concussion. It may be a useful tool for clinicians in detecting mental status changes after a concussion, when Glasgow Coma Scale and radiologic findings are normal.	[Naunheim, Rosanne S.] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO 63110 USA; [Fucetola, Robert] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Matero, David] Univ Colorado, Hlth Sci Ctr, Div Emergency Med, Denver, CO USA	Naunheim, RS (corresponding author), Washington Univ, Sch Med, Div Emergency Med, 660 So Euclid,Box 8072, St Louis, MO 63110 USA.						Amenta F, 2002, J NEUROL SCI, V203, P147, DOI 10.1016/S0022-510X(02)00281-2; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; Conners C, 2002, MANUAL CONNERS CONTI; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Epstein JN, 2001, J CLIN EXP NEUROPSYC, V23, P362, DOI 10.1076/jcen.23.3.362.1186; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Iverson GL, 2004, PSYCHOL REP, V95, P1241, DOI 10.2466/pr0.95.3f.1241-1247; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; RUTHERFORD WH, 1977, LANCET, V1, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Tinius TP, 2003, ARCH CLIN NEUROPSYCH, V18, P199, DOI 10.1016/S0887-6177(01)00196-2; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514	31	37	37	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					116	122		10.1097/01.HTR.0000314530.30401.70			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700006	18362765				2021-06-18	
J	Knight, C; Alderman, N; Johnson, C; Green, S; Birkett-Swan, L; Yorstan, G				Knight, Caroline; Alderman, Nick; Johnson, Chrissie; Green, Sharon; Birkett-Swan, Louise; Yorstan, Graeme			The St Andrew's Sexual Behaviour Assessment (SASBA): Development of a standardised recording instrument for the measurement and assessment of challenging sexual behaviour in people with progressive and acquired neurological impairment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						sexual; behaviour; assessment; neurological; impairment	NEUROBEHAVIORAL REHABILITATION SERVICE; TRAUMATIC BRAIN-INJURY; AGGRESSIVE-BEHAVIOR; OVERT AGGRESSION; OAS-MNR; DEMENTIA; MANAGEMENT; REDUCTION; ISSUES; SCALE	Inappropriate sexual behaviour (ISB) as a sequela of neurological impairment is often overlooked in comparison to other challenging behaviours such as agitation and aggression, yet the impact on patients and carers can be equally significant and pervasive. Inconsistencies in terminology and lack of standardised measurement tools for ISB limit the degree to which such behaviour can be objectively and consistently identified, reported and managed within and between services. This paper proposes a new ISB scale, the St Andrew's Sexual Behaviour Assessment (SASBA) based on the Overt Aggression Scale - Modified for Neurorehabilitation (OAS-MNR: Alderman, Knight, Morgan, 1997). The validity and reliability of the SASBA for use with people who have both progressive neurological conditions and acquired brain injury admitted to in-patient services is explored. This scale allows continuous observations of four categories of ISB, each of which has four levels of severity, that were developed with reference to relevant literature (Johnson, Knight, Alderman, 2006). Statistical properties of the scale were obtained using written descriptions and video enactments of ISB generated by clinicians. Results indicate strong construct and content validity, and good inter-rater and test-retest reliability. Some preliminary field data are presented with 924 incidents of challenging behaviour captured by the OAS-MNR and SASBA over a 10-week period for 36 patients; 16.34% of incidents were sexual behaviour. Clinical uses of the scale and perceived concerns or benefits for staff are discussed.	[Knight, Caroline; Alderman, Nick; Johnson, Chrissie; Green, Sharon; Birkett-Swan, Louise; Yorstan, Graeme] St Andrews Healthcare, Northampton NN1 5DG, England	Knight, C (corresponding author), St Andrews Healthcare, Billing Rd, Northampton NN1 5DG, England.	cknight@standrew.co.uk		Alderman, Nick/0000-0002-8523-4142			Alagiakrishnan K, 2005, POSTGRAD MED J, V81, P463, DOI 10.1136/pgmj.2004.028043; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 2001, BRAIN DAM B, P175; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1999, NEUROPSYCHOL REHABIL, V9, P385, DOI 10.1080/096020199389455; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 2007, BRAIN INJURY, V21, P891, DOI 10.1080/02699050701543560; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bezeau SC, 2004, BRAIN INJURY, V18, P299, DOI 10.1080/02699050310001617398; Braun UK, 2004, GERIATRICS, V59, P32; Britton KR, 1998, BRAIN INJURY, V12, P703, DOI 10.1080/026990598122269; BURNS A, 1990, BRIT J PSYCHIAT, V157, P86, DOI 10.1192/bjp.157.1.86; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77; Cubit K, 2007, AUSTRALAS J AGEING, V26, P64, DOI 10.1111/j.1741-6612.2007.00217.x; Devanand D P, 1992, Int Psychogeriatr, V4 Suppl 2, P161; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Gwet K., 2001, STAT TABLES INTER RA; Haboubi NHJ, 2003, DISABIL REHABIL, V25, P291, DOI 10.1080/0963828021000031188; Harris L, 1998, SEX DISABIL, V16, P205, DOI 10.1023/A:1023099109976; Hashmi F. H., 2000, CLIN GERIATRICS, V8, P61; Howell D. C., 1997, STAT METHODS PSYCHOL; HUGHES GV, 2005, J SEX AGGRESS, V11, P95, DOI DOI 10.1080/13552600410001731803; Johnson C, 2006, BRAIN INJURY, V20, P687, DOI 10.1080/02699050600744137; Jones NT, 2007, J SEX AGGRESS, V13, P51; KAY SR, 1988, J NERV MENT DIS, V176, P539, DOI 10.1097/00005053-198809000-00007; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; LANDIS JR, 1977, BIOMETRICS, V33, P174; Lawrie Barbara, 2004, Rehabil Nurs, V29, P9; MAYERS KS, 1994, SEX DISABIL, V12, P207, DOI 10.1007/BF02547907; Nagaratnam N, 2002, ARCH GERONTOL GERIAT, V35, P195, DOI 10.1016/S0167-4943(02)00026-2; Philo S W, 1996, J Gerontol Nurs, V22, P17; Ryden M B, 1988, Alzheimer Dis Assoc Disord, V2, P342, DOI 10.1097/00002093-198802040-00003; RYDEN MB, 1991, RES NURS HEALTH, V14, P87, DOI 10.1002/nur.4770140203; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Swan L, 2004, BRAIN INJURY, V18, P143, DOI 10.1080/02699050310001596923; Tsai SJ, 1999, ALZ DIS ASSOC DIS, V13, P60, DOI 10.1097/00002093-199903000-00009; Voyer Philippe, 2005, BMC Geriatr, V5, P13, DOI 10.1186/1471-2318-5-13; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163; ZUIDEMA S, 2004, J GERIATR PSYCHIAT, V20, P41	43	37	37	0	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	2					129	159		10.1080/09602010701822381			31	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	276HD	WOS:000254131000001	18350412				2021-06-18	
J	Ponsford, JL; Myles, PS; Cooper, DJ; Mcdermott, FT; Murray, LJ; Laidlaw, J; Cooper, G; Tremayne, AB; Bernard, SA				Ponsford, Jennie L.; Myles, Paul S.; Cooper, D. James; Mcdermott, Francis T.; Murray, Lynnette J.; Laidlaw, John; Cooper, Gregory; Tremayne, Ann B.; Bernard, Stephen A.			Gender differences in outcome in patients with hypotension and severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						traumatic brain injury; gender; outcome	SEVERE HEAD-INJURY; RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; SEX-RELATED DIFFERENCES; POSTMENOPAUSAL WOMEN; FEMALE RATS; REHABILITATION; EXPERIENCE; HORMONES	Background: Animal studies have identified hormonal influences on responses to injury and recovery, creating a potential gender effect on outcome. Progesterone and oestrogen are thought to afford protection in the immediate post-injury period, suggesting females have an advantage, although there has been Limited evidence of this in human outcome studies. Methods: This study examined the influence of gender on outcome in 229 adults (151 males), aged > 17 years, with severe blunt head trauma, initial GCS < 9 and hypotension, recruited into a randomised controlled trial of pre-hospital, hypertonic saline resuscitation versus conventional fluid management. Outcome was measured by survival and Glasgow Outcome Scale-Extended version (GOS-E) scores at 6 months post-injury. Results: Females recruited into the study had a higher mean age. Females were more likely to be injured as passengers and pedestrians and mates as drivers or motorcyclists. There were no gender differences in GCS or injury severity scores, ICP, cerebral perfusion pressure, gas exchange (PaO2/FiO(2) ratio), or duration of mechanical ventilation. After controlling for GCS, age and cause of injury, females had a lower rate of survival. They also showed a lower rate of good outcome (GOS-E score > 4) at 6 months, but this appeared to reflect the lower rate of initial survival. Those females surviving had similar outcomes to mates. Conclusions: The study provides no evidence that females fare better than mates following severe TBI, suggesting rather that females may fare worse. (c) 2007 Elsevier Ltd. All rights reserved.	[Ponsford, Jennie L.] Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia; [Myles, Paul S.] Monash Univ, Alfred Hosp, Dept Anesthesia, Clayton, Vic 3168, Australia; [Cooper, D. James; Murray, Lynnette J.] Monash Univ, Alfred Hosp, Dept Intens Care, Clayton, Vic 3168, Australia; [Laidlaw, John] Royal Melbourne Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Cooper, Gregory; Bernard, Stephen A.] Metropolitan Ambulance Serv, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au; p.myles@alfred.org.au; j.cooper@alfred.com.au; mcdf@ozemail.com.au; l.murray@alfred.org.au; John.Laidlaw@mh.org.au; Greg.cooper@mas.vic.gov.au; annt2@bigpond.com; Stephen.bernard@dhs.vic.gov.au	Cooper, D. James/G-7961-2013; Myles, Paul/AAU-9524-2020	Cooper, D. James/0000-0002-5872-9051; Myles, Paul/0000-0002-3324-5456			Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Forgie ML, 2003, BEHAV NEUROSCI, V117, P257, DOI 10.1037/0735-7044.117.2.257; Forgie ML, 1998, BEHAV NEUROSCI, V112, P141, DOI 10.1037/0735-7044.112.1.141; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HUNT J, 1995, AUST NZ J SURG, V65, P83, DOI 10.1111/j.1445-2197.1995.tb07266.x; Juraska JM, 1990, CEREBRAL CORTEX RAT, P483; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; KRAUS JF, 2000, NEUROSURG FOCUS ARTI, V5, P8; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; STEWART J, 1994, BRAIN RES, V654, P149, DOI 10.1016/0006-8993(94)91581-4; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	33	37	39	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2008	39	1					67	76		10.1016/j.injury.2007.08.028			10	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	264GE	WOS:000253274700010	18164301				2021-06-18	
S	Ratan, RR; Siddiq, A; Aminova, L; Langley, B; McConoughey, S; Karpisheva, K; Lee, HH; Carmichael, T; Kornblum, H; Coppola, G; Geschwind, DH; Hoke, A; Smirnova, N; Rink, C; Roy, S; Sen, C; Beattie, MS; Hart, RP; Grumet, M; Sun, DM; Freeman, RS; Semenza, GL; Gazaryan, I		Gibson, GE; Ratan, RR; Beal, MF		Ratan, Rajiv R.; Siddiq, Ambreena; Aminova, Leila; Langley, Brett; McConoughey, Stephen; Karpisheva, Ksenia; Lee, Hsin-Hwa; Carmichael, Thomas; Kornblum, Harley; Coppola, Giovanni; Geschwind, Daniel H.; Hoke, Ahmet; Smirnova, Natalya; Rink, Cameron; Roy, Sashwati; Sen, Chandan; Beattie, Michael S.; Hart, Ron P.; Grumet, Martin; Sun, Dongming; Freeman, Robert S.; Semenza, Gregg L.; Gazaryan, Irina			Small Molecule Activation of Adaptive Gene Expression Tilorone or Its Analogs Are Novel Potent Activators of Hypoxia Inducible Factor-1 That Provide Prophylaxis against Stroke and Spinal Cord Injury	MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Mitochondria and Oxisative Stress in Neurodegenerative Disorders	SEP 26-29, 2007	New York Acad Sci, New York, NY	Weill Med Coll, Cornell Univ, Grad Sch Med Sci, Ellison Med Fdn, Burke Med Res Inst	New York Acad Sci	homeostasis; hypoxia; hypoxia inducible factor; iron; hypoxia response element; erythropoietin; vascular endothelial growth factor; tilorone; desferrioxamine; prolyl hydroxylase	FOCAL CEREBRAL-ISCHEMIA; SIGNALING PATHWAY; INHIBITION; RATS; NEUROPROTECTION; HYDROCHLORIDE; INFARCTION; RECOVERY; DAMAGE	A major challenge for neurological therapeutics is the development of small molecule drugs that can activate a panoply of downstream pathways without toxicity. Over the past decade our group has shown that a family of enzymes that regulate posttranscriptional and transcriptional adaptive responses to hypoxia are viable targets for neuronal protection and repair. The family is a group of iron, oxygen, and 2-oxoglutarate-dependent dioxygenases, known as the HIF prolyl 4-hydroxylases (HIF PHDs). We have previously shown that pluripotent protection offered by iron chelators is mediated, in part, via the ability of these agents to inhibit the HIF PHDs. Our group and others have implicated the transcriptional activator HIF-1 in some of the salutary effects of iron chelation-induced PHD inhibition. While some iron chelators are currently employed in humans for conditions such as hemochromatosis, the diverse utilization of iron in physiological processes in the brain makes the development of HIF activators that do not bind iron a high priority. Here we report the development of a high throughput screen to develop novel HIF activators and/or PHD inhibitors for therapeutic use in the central nervous system (CNS). We show that tilorone, a low-molecular weight, antiviral, immunomodulatory agent is the most effective activator of the HIF pathway in a neuronal line. We also show that tilorone enhances HIF protein levels and increases the expression of downstream target genes independent of iron chelation and HIF PHD inhibition in vitro. We further demonstrate that tilorone can activate an HIF-regulated reporter gene in the CNS. These studies confirm that tilorone can penetrate the blood-brain barrier to activate HIF in the CNS. As expected from these findings, we show that tilorone provides effective prophylaxis against permanent ischemic stroke and traumatic spinal cord injury in male rodents. Altogether these findings identify tilorone as a novel and potent modulator of HIF-mediated gene expression in neurons with neuroprotective properties.	[Ratan, Rajiv R.; Siddiq, Ambreena; Langley, Brett; McConoughey, Stephen; Karpisheva, Ksenia; Lee, Hsin-Hwa; Smirnova, Natalya; Gazaryan, Irina] Cornell Univ, Weill Med Coll, Burke Cornell Med Res Inst, White Plains, NY USA; [Aminova, Leila] Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA; [Carmichael, Thomas; Kornblum, Harley; Coppola, Giovanni; Geschwind, Daniel H.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Hoke, Ahmet] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Rink, Cameron; Roy, Sashwati; Sen, Chandan] Ohio State Univ, Heart Blood & Lung Inst, Columbus, OH 43210 USA; [Hart, Ron P.; Grumet, Martin; Sun, Dongming] Rutgers State Univ, Keck Ctr Collaborat Neurosci, Piscataway, NJ 08855 USA; [Freeman, Robert S.] Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Genet, Inst Cell Engn, Baltimore, MD USA; [Ratan, Rajiv R.; Siddiq, Ambreena; Langley, Brett; McConoughey, Stephen; Karpisheva, Ksenia; Lee, Hsin-Hwa; Smirnova, Natalya; Gazaryan, Irina] New York State Ctr Res Excellence Spinal Cord Inj, New York, NY USA; [Beattie, Michael S.] Univ Calif San Francisco, Brain & Spinal Cord Injury Ctr, San Francisco, CA 94143 USA; [Aminova, Leila] Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	Ratan, RR (corresponding author), Cornell Univ, Weill Med Coll, Burke Cornell Med Res Inst, 785 Mamaroneck Ave, White Plains, NY USA.		Beattie, Michael S/A-8953-2009; Hart, Ronald/G-6530-2019; Rink, Cameron/AAA-4484-2021; Gazaryan, Irina G/T-8578-2017; Hart, Ronald/D-5219-2009; grumet, martin/ABC-6462-2020; Langley, Brett C/P-7207-2017; Rink, Cameron/E-3954-2011	Hart, Ronald/0000-0003-4836-8712; Gazaryan, Irina G/0000-0002-9670-5579; Langley, Brett C/0000-0003-4009-2109; Rink, Cameron/0000-0002-3149-3624; Carmichael, S Thomas/0000-0002-1169-9203; Hoke, Ahmet/0000-0003-1215-3373	New York State Department of Health [CO 19972]; Center for Research Excellence in Spinal Cord Injury; Adelson Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058868, P01NS045242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG014930] Funding Source: NIH RePORTER	We would like to gratefully acknowledge the technical and intellectual input of Dr. Juan Chavez who contributed several figures to this manuscript and Dr. Joe LaManna. The work was funded by New York State Department of Health Contract (CO 19972); the Center for Research Excellence in Spinal Cord Injury, and the Adelson Foundation for Neurorehabilitation and Repair.	Alcaro S, 2005, J CHEM INF MODEL, V45, P602, DOI 10.1021/ci0496595; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; BELAYEV L, 1996, STROKE, V27, P1623; Briggs CA, 2008, BRIT J PHARMACOL, V153, P1054, DOI 10.1038/sj.bjp.0707649; Chandra P, 1977, Top Curr Chem, V72, P125; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Freeman RS, 2005, CNS NEUROL DISORD-DR, V4, P85, DOI 10.2174/1568007053005154; Freret T, 2006, EUR J NEUROSCI, V23, P1757, DOI 10.1111/j.1460-9568.2006.04699.x; Ghosh P, 2004, EUR J CELL BIOL, V83, P257, DOI 10.1078/0171-9335-00374; Hashimoto M, 2007, J NEUROSCI, V27, P3603, DOI 10.1523/JNEUROSCI.4805-06.2007; Heemskerk Jill, 2002, Trends in Neurosciences, V25, P494, DOI 10.1016/S0166-2236(02)02236-1; KRUEGER RF, 1970, SCIENCE, V169, P1213, DOI 10.1126/science.169.3951.1213; MURPHY TH, 1990, FASEB J, V4, P1624; Nishi K, 2008, ANTIOXID REDOX SIGN, V10, P983, DOI 10.1089/ars.2007.1825; POLLACK A, 1980, CYTOMETRY, V1, P57, DOI 10.1002/cyto.990010112; Ratan RR, 2007, J MOL MED, V85, P1331, DOI 10.1007/s00109-007-0283-1; Ratan RR, 2004, STROKE, V35, P2687, DOI 10.1161/01.STR.0000143216.85349.9e; Savitz SI, 2007, ANN NEUROL, V61, P396, DOI 10.1002/ana.21127; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 2007, SCI STKE, pCM8, DOI DOI 10.1126/STKE.4072007CM8; Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; Siddiq A, 2007, NEUROCHEM RES, V32, P931, DOI 10.1007/s11064-006-9268-7; Stolze IP, 2006, NOVART FDN SYMP, V272, P25; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Woo KJ, 2006, BIOCHEM BIOPH RES CO, V343, P8, DOI 10.1016/j.bbrc.2006.02.116	29	37	39	0	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-713-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2008	1147						383	394		10.1196/annals.1427.033			12	Cell Biology; Multidisciplinary Sciences; Neurosciences; Physiology	Cell Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Physiology	BIR99	WOS:000262397800034	19076458	Green Accepted			2021-06-18	
J	Zampolini, M; Todeschini, E; Guitart, MB; Hermens, H; Ilsbroukx, S; Macellari, V; Magni, R; Rogante, M; Marchese, SS; Vollenbroek, M; Giacomozzi, C				Zampolini, Mauro; Todeschini, Elisabetta; Bernabeu Guitart, Montserrat; Hermens, Hermie; Ilsbroukx, Stephan; Macellari, Velio; Magni, Riccardo; Rogante, Marco; Marchese, Sandro Scattareggia; Vollenbroek, Miriam; Giacomozzi, Claudia			Tele-rehabilitation: present and future	ANNALI DELL ISTITUTO SUPERIORE DI SANITA			English	Article						stroke; multiple sclerosis; traumatic brain injury; tele-rehabilitation; upper limb; home rehabilitation	INDUCED MOVEMENT THERAPY; RANDOMIZED CLINICAL-TRIAL; UPPER EXTREMITY FUNCTION; MIRROR NEURON SYSTEM; VIRTUAL-REALITY; STROKE REHABILITATION; TELEREHABILITATION SYSTEM; SELF-EFFICACY; SPECIAL NEEDS; BRAIN-INJURY	During the last decade we assisted to relevant progress in rehabilitation studies and in technological development. From the combination of these issues rises the tele-rehabilitation - a subfield of telemedicine consisting of a system to control rehabilitation "at distance" - as an actual possibility of application and a promising development in the future. The present paper offers a short review of the state of the art in the field of tele-rehabilitation, with a special focus on upper limb tele-rehabilitation. The experience is also briefly reported of the preliminary application of the H-CAD (home care activity desk) system and the HELLODOC (Healthcare service linking tele-rehabilitation to disabled people and clinicians) tele-rehabilitation service, conducted by the authors within two European projects in the period 2003-2005 and 2005-2007 respectively.	[Zampolini, Mauro; Todeschini, Elisabetta] ASL 3, Unita Organ Riabilitaz Intens Neuromotoria, Perugia, Italy; [Bernabeu Guitart, Montserrat] Fundacio Inst Guttmann, Barcelona, Spain; [Hermens, Hermie; Vollenbroek, Miriam] Roessingh Res & Dev BV, Enschede, Netherlands; [Ilsbroukx, Stephan] Natl Multiple Sclerosis Ctr, Melsbroek, Belgium; [Macellari, Velio; Rogante, Marco; Giacomozzi, Claudia] Ist Super Sanita, Dipartimento Tecnol & Salute, I-00161 Rome, Italy; [Magni, Riccardo] Pragma Engn Srl, Perugia, Italy; [Marchese, Sandro Scattareggia] Signo Motus Srl, Messina, Italy	Zampolini, M (corresponding author), Dipartimento Riabilitaz ASL3 Reg Umbria, Piazza Garibaldi 5, I-06039 Perugia, Italy.	marco.roganti@iss.it	Zampolini, Mauro/B-7749-2009; Giacomozzi, Claudia/G-5018-2016; Giacomozzi, Claudia/AAH-1640-2021	Giacomozzi, Claudia/0000-0001-6950-4934; Giacomozzi, Claudia/0000-0001-6950-4934; Vollenbroek-Hutten, Miriam/0000-0001-8730-1487			Baheux K, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-27; Binkofski F, 1999, EXP BRAIN RES, V128, P210, DOI 10.1007/s002210050838; Blanton S, 1999, PHYS THER, V79, P847, DOI 10.1093/ptj/79.9.847; Boniver R, 2006, B-ENT, V2, P147; Burdea G, 2000, IEEE T REHABIL ENG, V8, P430, DOI 10.1109/86.867886; Burdea GC, 2003, METHOD INFORM MED, V42, P519; Burns RB, 1998, ASSIST TECHNOL, V10, P126, DOI 10.1080/10400435.1998.10131970; Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381; Carey LM, 2005, AM J PHYS MED REHAB, V84, P428, DOI 10.1097/01.PHM.0000159971.12096.7F; Carignan CR, 2006, J REHABIL RES DEV, V43, P695, DOI 10.1682/JRRD.2005.05.0085; Chumbler NR, 2004, TELEMED J E-HEALTH, V10, P129, DOI 10.1089/1530562041641200; Colombo R, 2005, IEEE T NEUR SYS REH, V13, P311, DOI 10.1109/TNSRE.2005.848352; DAWSON SJ, 1999, PHYSICAL THERAPY CAS, V3, P84; Dawson Steve, 2002, Telemed Today, V9, P8; DeChant H K, 1996, Telemed J, V2, P303, DOI 10.1089/tmj.1.1996.2.303; Diamond BJ, 2003, NEUROREHABILITATION, V18, P171; Ferris Daniel P, 2005, Top Spinal Cord Inj Rehabil, V11, P34; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Galea M, 2006, TELEMED J E-HEALTH, V12, P160, DOI 10.1089/tmj.2006.12.160; Gazzola V, 2007, NEUROIMAGE, V35, P1674, DOI 10.1016/j.neuroimage.2007.02.003; Girone M, 2000, Stud Health Technol Inform, V70, P89; Gourlay D, 2000, STUD HEALTH TECHNOL, V77, P1181; Hauber RP, 2002, J HEAD TRAUMA REHAB, V17, P535, DOI 10.1097/00001199-200212000-00005; Henderson A, 2007, TOP STROKE REHABIL, V14, P52, DOI 10.1310/tsr1402-52; Heuser A, 2007, IEEE T NEUR SYS REH, V15, P43, DOI 10.1109/TNSRE.2007.891393; Higgins J, 2006, CLIN REHABIL, V20, P296, DOI 10.1191/0269215505cr943oa; Hill AJ, 2006, AM J SPEECH-LANG PAT, V15, P45, DOI 10.1044/1058-0360(2006/006); Holden MK, 2007, IEEE T NEUR SYS REH, V15, P36, DOI 10.1109/TNSRE.2007.891388; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; JEROME L, 1993, HOSP COMMUNITY PSYCH, V44, P81; Johnson MJ, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-29; Kahn LE, 2006, J REHABIL RES DEV, V43, P619, DOI 10.1682/JRRD.2005.03.0056; Kalra L, 2007, J REHABIL MED, V39, P97, DOI 10.2340/16501977-0043; KETELAER P, 2001, INT MS J, V8, P10; Kuttuva M, 2006, CYBERPSYCHOL BEHAV, V9, P148, DOI 10.1089/cpb.2006.9.148; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Lum PS, 2006, J REHABIL RES DEV, V43, P391, DOI 10.1682/JRRD.2005.02.0042; Masiero S, 2006, AGING CLIN EXP RES, V18, P531; McClellan R, 2004, AUST J PHYSIOTHER, V50, P163, DOI 10.1016/S0004-9514(14)60154-9; Monger C, 2002, CLIN REHABIL, V16, P361, DOI 10.1191/0269215502cr506oa; Ozdemir F, 2001, ARCH PHYS MED REHAB, V82, P1375, DOI 10.1053/apmr.2001.25973; Page SJ, 2007, ARCH PHYS MED REHAB, V88, P922, DOI 10.1016/j.apmr.2007.03.038; Page SJ, 2007, STROKE, V38, P1293, DOI 10.1161/01.STR.0000260205.67348.2b; Piron L, 2004, MED INFORM INTERNET, V29, P119, DOI 10.1080/14639230410001723428; Piron L, 2001, ST HEAL T, V81, P386; PLACIDI G, 2006, COMPUT BIOL MED; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Ricker JH, 2003, NEUROREHABILITATION, V18, P179; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Rintala DH, 2004, J REHABIL RES DEV, V41, P481, DOI 10.1682/JRRD.2004.03.0481; Rizzolatti G, 2005, CURR OPIN NEUROBIOL, V15, P623, DOI 10.1016/j.conb.2005.10.018; Rizzolatti G, 2005, ANAT EMBRYOL, V210, P419, DOI 10.1007/s00429-005-0039-z; Robinson SS, 2003, TELEMED J E-HEALTH, V9, P57, DOI 10.1089/153056203763317657; Rodriguez-Ascaso A, 2002, J TELEMED TELECARE, V8, P72, DOI 10.1258/135763302320302109; Romano DM, 2005, DEV MED CHILD NEUROL, V47, P580, DOI 10.1017/S0012162205001143; Russell TG, 2002, J TELEMED TELECARE, V8, P50, DOI 10.1258/13576330260440853; Salbach NM, 2005, J AM GERIATR SOC, V53, P576, DOI 10.1111/j.1532-5415.2005.53203.x; Sanford JA, 2004, ASSIST TECHNOL, V16, P43, DOI 10.1080/10400435.2004.10132073; Sanford JA, 2006, J AM GERIATR SOC, V54, P1641, DOI 10.1111/j.1532-5415.2006.00913.x; Savard L, 2003, NEUROREHABILITATION, V18, P93; Simon AM, 2007, J BIOMECH, V40, P1286, DOI 10.1016/j.jbiomech.2006.05.021; Stein J, 2004, AM J PHYS MED REHAB, V83, P720, DOI 10.1097/01.PHM.0000137313.14480.CE; Sugarman H, 2006, CYBERPSYCHOL BEHAV, V9, P178, DOI 10.1089/cpb.2006.9.178; Tam Sing-Fai, 2003, Occup Ther Int, V10, P20, DOI 10.1002/oti.175; Torsney K, 2003, NEUROREHABILITATION, V18, P183; Vitali P, 2007, NEUROREHAB NEURAL RE, V21, P152, DOI 10.1177/1545968306294735; Volpe BT, 2000, NEUROLOGY, V54, P1938, DOI 10.1212/WNL.54.10.1938; Wakeford Linn, 2005, Am J Occup Ther, V59, P656; Walker MF, 2007, J REHABIL MED, V39, P193, DOI 10.2340/16501977-0063; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; Winters JM, 2004, P ANN INT IEEE EMBS, V26, P4777; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wolff JL, 2005, J AM GERIATR SOC, V53, P851, DOI 10.1111/j.1532-5415.2005.53262.x; YALONCHAMOVITZ S, 2007, RES DEV DISABIL	77	37	38	1	14	EDITRICE KURTIS S R L	MILAN	VIA LUIGI ZOJA 30, 20153 MILAN, ITALY	0021-2571			ANN I SUPER SANITA	Ann. Ist. Super. Sanita		2008	44	2					125	134					10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	V15PB	WOS:000207812800002	18660562	DOAJ Gold			2021-06-18	
J	Cullen, DK; Stabenfeldt, SE; Simon, CM; Tate, CC; LaPlaca, MC				Cullen, D. Kacy; Stabenfeldt, Sarah E.; Simon, Crystal M.; Tate, Ciara C.; LaPlaca, Michelle C.			In vitro neural injury model for optimization of tissue-engineered constructs	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						transplantation; apoptosis; laminin; neural stem cells	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; STEM-CELLS; HIPPOCAMPAL-NEURONS; PRIMARY CULTURES; GLIAL SCAR; RAT; ASTROCYTES	Stem cell transplantation is a promising approach for the treatment of traumatic brain injury, although the therapeutic benefits are limited by a high degree of donor cell death. Tissue engineering is a strategy to improve donor cell survival by providing structural and adhesive support. However, optimization prior to clinical implementation requires expensive and time-consuming in vivo studies. Accordingly, we have developed a three-dimensional (3-D) in vitro model of the injured host-transplant interface that can be used as a test bed for high-throughput evaluation of tissue-engineered strategies. The neuronal-astrocytic cocultures in 3-D were subjected to mechanical loading (inducing cell death and specific astrogliotic alterations) or to treatment with transforming growth factor-beta 1 (TGF-beta l), inducing astrogliosis without affecting viability. Neural stem cells (NSCs) were then delivered to the cocultures. A sharp increase in the number of TUNEL+ donor cells was observed in the injured cocultures compared to that in the TGF-beta 1-treated and control cocultures, suggesting that factors related to mechanical injury, but not strictly astrogliosis, were detrimental to donor cell survival. We then utilized the mechanically injured cocultures to evaluate a methylcellulose-laminin (MC-LN) scaffold designed to reduce apoptosis. When NSCs were codelivered with MC alone or MC-LN to the injured cocultures, the number of caspase(+) donor cells significantly decreased compared to that with vehicle delivery (medium). Collectively, these results demonstrate the utility of an in vitro model as a preanimal test bed and support further investigation of a tissue-engineering approach for chaperoned NSC delivery targeted to improve donor cell survival in neural transplantation. (C) 2007 Wiley-Liss, Inc.	[Cullen, D. Kacy; Stabenfeldt, Sarah E.; Simon, Crystal M.; Tate, Ciara C.; LaPlaca, Michelle C.] Emory Univ, Georgia Inst Technol, Dept Biomed Engn Inst Bioengn & Biosci, Lab Neuroengn, Atlanta, GA 30322 USA	LaPlaca, MC (corresponding author), GT Emory Coulter Dept BME, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F32 NS 054527] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS054527] Funding Source: NIH RePORTER		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Asher RA, 2000, J NEUROSCI, V20, P2427; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Braitenberg V, 2001, J COMPUT NEUROSCI, V10, P71, DOI 10.1023/A:1008920127052; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Conti AC, 1998, J NEUROSCI, V18, P5663; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Evans MS, 1998, J NEUROSCI METH, V79, P37, DOI 10.1016/S0165-0270(97)00159-3; Faijerson J, 2006, J NEUROSCI RES, V84, P1415, DOI 10.1002/jnr.21044; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FERREIRA A, 1987, DEV BRAIN RES, V34, P9, DOI 10.1016/0165-3806(87)90191-X; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GABBOTT PLA, 1987, NEUROSCIENCE, V21, P833, DOI 10.1016/0306-4522(87)90040-6; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gary DS, 2003, J NEUROCHEM, V84, P878, DOI 10.1046/j.1471-4159.2003.01579.x; Gary DS, 2001, J NEUROCHEM, V76, P1485, DOI 10.1046/j.1471-4159.2001.00173.x; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Irvin DK, 2003, DEV NEUROSCI-BASEL, V25, P162, DOI 10.1159/000072265; Kanelos SK, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199812000-00003; Kobayashi K, 1999, MACROMOLECULES, V32, P7070, DOI 10.1021/ma990242n; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; KOLLER H, 1990, SYNAPSE, V5, P59, DOI 10.1002/syn.890050105; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Leone DP, 2005, J CELL SCI, V118, P2589, DOI 10.1242/jcs.02396; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1999, SECONDARY BRAIN INJU; McKeon RJ, 1999, J NEUROSCI, V19, P10778; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Micci MA, 2005, NEUROGASTROENT MOTIL, V17, P557, DOI 10.1111/j.1365-2982.2005.00702.x; Mondal D, 2004, CANCER INVEST, V22, P925, DOI 10.1081/CNV-200039679; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; PASSAQUIN AC, 1994, INT J DEV NEUROSCI, V12, P363, DOI 10.1016/0736-5748(94)90086-8; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; PIZZI M, 1995, MOL BRAIN RES, V34, P38, DOI 10.1016/0169-328X(95)00129-G; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao MS, 1999, ANAT RECORD, V257, P137; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; SANTAOLALLA J, 1995, J NEUROSCI RES, V42, P172, DOI 10.1002/jnr.490420204; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; Stabenfeldt SE, 2006, J BIOMED MATER RES A, V77A, P718, DOI 10.1002/jbm.a.30638; Steinschneider R, 1996, DEV BRAIN RES, V95, P15, DOI 10.1016/0165-3806(96)00052-1; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Whittemore SR, 1999, J NEUROTRAUM, V16, P667, DOI 10.1089/neu.1999.16.667; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001	70	37	38	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC	2007	85	16					3642	3651		10.1002/jnr.21434			10	Neurosciences	Neurosciences & Neurology	243EP	WOS:000251778200015	17671988				2021-06-18	
J	Larson, MJ; Kaufman, DAS; Schmalfuss, IM; Perlstein, WM				Larson, Michael J.; Kaufman, David A. S.; Schmalfuss, Ilona M.; Perlstein, William M.			Performance monitoring, error processing, and evaluative control following severe TBI	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; event-related potentials; error-related negativity; stroop; cognitive control; error monitoring	ANTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSIVE DISORDER; EVENT-RELATED POTENTIALS; MEDIAL FRONTAL-CORTEX; CLOSED-HEAD INJURY; COGNITIVE CONTROL; PREFRONTAL CORTEX; WORKING-MEMORY; FUNCTIONAL-SIGNIFICANCE	Patients with severe traumatic brain injury (TBI) often demonstrate impairments in performance monitoring - an evaluative control process that can be measured using the error-negativity/error-related negativity (Ne/ERN) and post-error positivity (Pe). The Ne/ERN and Pe are event-related potential (ERP) components generated following errors, with current theories suggesting the Ne/ERN reflects automatic performance monitoring and the Pe reflects error processing and awareness. To elucidate the electrophysiological mechanisms of performance monitoring deficits following severe TBI, behavioral and ERP measurements were obtained, whereas participants with severe TBI and neurologically-healthy comparison participants performed a modified color-naming version of the Stroop task. Behaviorally, both groups demonstrated robust response-time (RT) and error-rate interference. Participants with TBI exhibited generalized RT slowing; no significant between-groups interactions were present for RTs or error rates. ERP results indicate Ne/ERN amplitude was attenuated in participants with TBI, whereas the pattern of Pe amplitude did not clearly differentiate groups. Findings suggest the Ne/ERN as a potential electrophysiological marker of evaluative control/performance monitoring impairment following TBI. Implications for future research and potential clinical application as well as potential limitations in conducting electrophysiological research in neurologically-impaired populations are discussed.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; N Florida S Georgia Vet Adm Hosp, Gainesville, FL USA; Univ Florida, Dept Med, Gainesville, FL USA; Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL USA	Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@phhp.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 MH073076, K01 MH01857] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS053335] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH073076, K01MH001857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS053335] Funding Source: NIH RePORTER		Beck A. T., 1996, BECK DEPRESSION INVE, VII; Benton A., 1976, MULTILINGUAL APHASIA; BERTRAND O, 1985, ELECTROEN CLIN NEURO, V62, P462, DOI 10.1016/0168-5597(85)90058-9; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brandt J., 2001, HOPKINS VERBAL LEARN; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; CLARK JH, 1924, J PHYSL OPTICS, V5, P269; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dias R, 2000, EUR J NEUROSCI, V12, P4457, DOI 10.1046/j.0953-816X.2000.01323.x; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; FONTAINE A, 1996, P AUST BRAIN INJ SOC, V1, P98; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Hajcak G, 2003, PSYCHOPHYSIOLOGY, V40, P895, DOI 10.1111/1469-8986.00107; Hajcak G, 2003, BIOL PSYCHOL, V64, P77, DOI 10.1016/S0301-0511(03)00103-0; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Larson MJ, 2006, NEUROREPORT, V17, P329, DOI 10.1097/01.wnr.0000199461.01542.db; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Mathalon DH, 2002, J ABNORM PSYCHOL, V111, P22, DOI 10.1037//0021-843X.111.1.22; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; MOCKS J, 1988, PSYCHOPHYSIOLOGY, V25, P217; Neter J., 1985, APPL LINEAR STAT MOD; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Picton T., 1995, HDB NEUROPHYSIOLOGY, P3; RABBITT PMA, 1968, Q J EXP PSYCHOL, V20, P179, DOI 10.1080/14640746808400146; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ruchsow M, 2006, J PSYCHIATR RES, V40, P37, DOI 10.1016/j.jpsychires.2005.02.002; Ruchsow M, 2004, PSYCHOPHYSIOLOGY, V41, P833, DOI 10.1111/j.1469-8986.2004.00237.x; Rushworth MFS, 2003, J COGNITIVE NEUROSCI, V15, P338, DOI 10.1162/089892903321593072; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Speilberger C. D., 1983, MANUAL STATE TRAIT A; Stemmer B, 2004, NEUROPSYCHOLOGIA, V42, P118, DOI 10.1016/S0028-3932(03)00121-0; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; TEASDALE G, 1974, LANCET, V2, P81; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; Walton ME, 2003, J NEUROSCI, V23, P6475; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; WOODY CD, 1967, MED BIOL ENG, V5, P539, DOI 10.1007/BF02474247; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x	69	37	38	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2007	13	6					961	971		10.1017/S1355617707071305			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	227GK	WOS:000250645000006	17942014				2021-06-18	
J	Pearson, BC; Armitage, KR; Horner, CWM; Carpenter, RHS				Pearson, B. C.; Armitage, K. R.; Horner, C. W. M.; Carpenter, R. H. S.			Saccadometry: the possible application of latency distribution measurement for monitoring concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CLOSED-HEAD INJURY; EYE-MOVEMENTS; RECOVERY; SACCADES; DEFICITS	Premature return to play after concussion may have debilitating or even fatal consequences. Computerised neuropsychological test batteries are widely used to monitor recovery, but none meet all specified criteria. One possible alternative is to measure saccadic reaction time or latency. Latency reflects the operation of cerebral decision mechanisms, and is strongly influenced by many agents that impair cortical function. A portable, micro-miniature device ( saccadometer) was used to record the eye movements of amateur boxers before and after competitive bouts. Individual latency distributions were significantly affected after blows to the head, though the effects seemed to be reversible, with recovery over a few days. This quantitative, objective and easy to use technique should perhaps be deployed more widely to evaluate its potential in monitoring the effects of sports-related head injuries.	Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England	Pearson, BC (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.	bcp22@cam.ac.uk		Carpenter, Roger/0000-0003-2572-1448			Ali FR, 2006, EXP BRAIN RES, V169, P237, DOI 10.1007/s00221-005-0143-6; CARPENTER RHS, 1995, NATURE, V377, P59, DOI 10.1038/377059a0; CARPENTER RHS, 1994, J PHYSL, V480, P4; CARPENTER RHS, 2006, LATER; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Leigh RJ, 2004, BRAIN, V127, P460, DOI 10.1093/brain/awh035; Nouraei SAR, 2003, BRIT J ANAESTH, V91, P175, DOI 10.1093/bja/aeg158; Ober JK, 2003, MODELLING MEASUREMEN, P187; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reddi BAJ, 2000, NAT NEUROSCI, V3, P827; Williams IM, 1997, J CLIN NEUROSCI, V4, P186, DOI 10.1016/S0967-5868(97)90072-2	13	37	37	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2007	41	9							610	10.1136/bjsm.2007.036731			3	Sport Sciences	Sport Sciences	204VP	WOS:000249072400021	17496064	Green Published			2021-06-18	
J	Zhang, ZY; Zhang, ZR; Artelt, M; Burnet, M; Schluesener, HJ				Zhang, Zhiyuan; Zhang, Zhiren; Artelt, Matthias; Burnet, Michael; Schluesener, Hermann J.			Dexamethasone attenuates early expression of three molecules associated with microglia/macrophages activation following rat traumatic brain injury	ACTA NEUROPATHOLOGICA			English	Article						dexamethasone; traumatic brain injury; EMAP-II; P2X4R; AIF-1; microglia/macrophages	INFLAMMATORY FACTOR-I; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; MICROGLIAL CELLS; POLYPEPTIDE-II; MACROPHAGES/MICROGLIAL CELLS; RECEPTOR ACTIVATION; LESIONAL EXPRESSION	Corticosteroids have been used in the treatment of human traumatic brain injury ( TBI), which is a leading cause of death and disability, but their efficiency is still a matter of debate. Dexamethasone was considered to delay post-traumatic inflammation and retard neuronal degeneration, resulting in attenuation of secondary injury following experimental TBI. In a rat TBI model, we have investigated the effects of dexamethasone on expression patterns of markers of inflammatory activation of microglia/macrophages by immunohistochemistry. Endothelial-monocyte activating polypeptide II (EMAP-II), P2X4 receptor (P2X4R) and allograft-inflammatory factor-1 (AIF-1) were reported to be associated with the activation of microglia/macrophages post central nervous system (CNS) injury and may play roles in inflammatory cascades of secondary brain damage. Dexamethasone significantly suppressed the accumulation of EMAP-II+, P2X4R(+) or AIF(+) cells at Day-1 and 2 post-brain-trauma but not on Days 4 and 6, which is in accordance with the reported short- but not long-term protective effects of dexamethasone in TBI. These findings indicate a rather rapid but transient anti-inflammatory effect of dexamethasone in TBI.	Univ Tubingen, Brain Res Inst, D-72076 Tubingen, Germany; Synovo GmbH, D-72076 Tubingen, Germany	Zhang, ZY (corresponding author), Univ Tubingen, Brain Res Inst, Calwer Str 3, D-72076 Tubingen, Germany.	zhangzy@gmx.de	zhang, zhiren/I-1046-2014; Burnet, Michael/AAB-2958-2019; Zhang, Zhiren/O-1012-2019	zhang, zhiren/0000-0002-5238-2835; Zhang, Zhiren/0000-0002-5238-2835			Adelson PD, 1998, ACT NEUR S, V71, P104; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; BOSSCHER KD, 1997, P NATL ACAD SCI USA, V94, P13504; Brough D, 2002, MOL CELL NEUROSCI, V19, P272, DOI 10.1006/mcne.2001.1054; CARLOS TM, 1994, BLOOD, V84, P2068; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colton CA, 1996, NEUROCHEM INT, V29, P43, DOI 10.1016/0197-0186(95)00139-5; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; Deininger MH, 2000, ACTA NEUROPATHOL, V100, P673, DOI 10.1007/s004010000233; Deininger MH, 2002, FEBS LETT, V514, P115, DOI 10.1016/S0014-5793(02)02430-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fauser S, 2001, ACTA NEUROPATHOL, V101, P565; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Gahm C, 2005, ACTA NEUROCHIR, V147, P1071, DOI 10.1007/s00701-005-0590-7; Gendron FP, 2003, J NEUROCHEM, V87, P344, DOI 10.1046/j.1471-4159.2003.01995.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Gottschall PE, 1996, NEUROREPORT, V7, P3077, DOI 10.1097/00001756-199611250-00057; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; Haynes LE, 2001, NEUROSCIENCE, V104, P57, DOI 10.1016/S0306-4522(01)00070-7; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KAO J, 1992, J BIOL CHEM, V267, P20239; KIEFER R, 1991, J NEUROIMMUNOL, V34, P99, DOI 10.1016/0165-5728(91)90119-R; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Lehrmann E, 1997, J COMP NEUROL, V386, P461; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mitchell IJ, 1998, NEUROSCIENCE, V84, P489, DOI 10.1016/S0306-4522(97)00534-4; MORI N, 1992, EPILEPSIA, V33, P994, DOI 10.1111/j.1528-1157.1992.tb01749.x; Mueller CA, 2003, J NEUROTRAUM, V20, P1007, DOI 10.1089/089771503770195858; Mueller CA, 2003, J NEUROIMMUNOL, V135, P1, DOI 10.1016/S0165-5728(02)00427-7; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Postler E, 2000, J NEUROIMMUNOL, V104, P85, DOI 10.1016/S0165-5728(99)00222-2; Pulliam L, 1998, J NEUROSCI RES, V54, P530, DOI 10.1002/(SICI)1097-4547(19981115)54:4<530::AID-JNR10>3.0.CO;2-1; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schluesener HJ, 2001, J NEUROIMMUNOL, V113, P89, DOI 10.1016/S0165-5728(00)00428-8; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Schwab JM, 2001, J NEUROIMMUNOL, V119, P214, DOI 10.1016/S0165-5728(01)00375-7; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Tanaka J, 1997, GLIA, V20, P23, DOI 10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.0.CO;2-6; Tanaka S, 1998, J NEUROSCI, V18, P6358; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Utans U, 1996, TRANSPLANTATION, V61, P1387, DOI 10.1097/00007890-199605150-00018; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang XQ, 2006, PLASMA SCI TECHNOL, V8, P141, DOI 10.1088/1009-0630/8/2/04; Zhang ZR, 2006, EXP NEUROL, V197, P252, DOI 10.1016/j.expneurol.2005.09.015	67	37	37	0	10	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2007	113	6					675	682		10.1007/s00401-007-0195-8			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	171IO	WOS:000246729600006	17265048				2021-06-18	
J	Zimmerman, RA; Bilaniuk, LT; Farina, L				Zimmerman, R. A.; Bilaniuk, L. T.; Farina, L.			Non-accidental brain trauma in infants: diffusion imaging, contributions to understanding the injury process	JOURNAL OF NEURORADIOLOGY			English	Article						Non-accidental trauma; imaging; child abuse; MRI; MRI diffusion imaging; traumatic	SHAKEN-BABY SYNDROME; HEAD-INJURY; SPECTROSCOPY; CHILDREN; STROKE	Analysis of MRI diffusion images from 33 infants suffering from non-accidental trauma reveals five patterns of injury. These are diffuse supratentorial hypoxic ischemic, watershed hypoxic ischemic, venous infarction, diffuse axonat injury and contusion. (c) 2007 Elsevier Masson SAS. All rights reserved.	Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA; Ist Nazl Neurol Carlo Besta, Milan, Italy	Zimmerman, RA (corresponding author), Childrens Hosp Philadelphia, Dept Radiol, Wood Room 2115,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zimmerman@email.chop.edu					Barkovich AJ, 2001, AM J NEURORADIOL, V22, P1786; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Erdem E, 2001, NEURORADIOLOGY, V43, P927, DOI 10.1007/s002340100603; Farina L, 2004, NEURORADIOLOGY, V46, P251, DOI 10.1007/s00234-003-1122-x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Jan W, 2003, NEURORADIOLOGY, V45, P393, DOI 10.1007/s00234-003-0955-7; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Wolf RL, 2001, RADIOLOGY, V218, P825, DOI 10.1148/radiology.218.3.r01fe47825; ZIMMERMAN RA, 2002, P C HELD BETH MD OCT	13	37	37	0	3	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0150-9861			J NEURORADIOLOGY	J. Neuroradiol.	MAY	2007	34	2					109	114		10.1016/j.neurad.2007.01.124			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	179CJ	WOS:000247266600005	17445894				2021-06-18	
J	Drew, AS; Langan, J; Halterman, C; Osternig, LR; Chou, LS; van Donkelaar, P				Drew, Anthony S.; Langan, Jeanne; Halterman, Charlene; Osternig, Louis R.; Chou, Li-Shan; van Donkelaar, Paul			Attentional disengagement dysfunction following mTBI assessed with the gap saccade task	NEUROSCIENCE LETTERS			English	Article						mild traumatic brain injury; saccade; attention	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; POSITRON-EMISSION-TOMOGRAPHY; NEURONAL-ACTIVITY; FIXATION POINT; EYE-MOVEMENTS; REACTION-TIME; DEFICITS; CONCUSSION; INITIATION	Concussion, or mild traumatic brain injury (mTBI), leads to a number of cognitive, attentional, and sensorimotor deficits that can last a surprisingly long time after the initial injury. We have previously shown that the ability to orient visuospatial attention is deficient in participants with mTBI within 2 days of their injury, but then recovers to normal levels within a week. Orienting attention requires disengagement from the point of fixation, movement of attention to the location of interest, and reengagement at that location. Deficits in any or all of these processes could lead to the difficulties with orienting attention that we have observed in mTBI. To address this issue, we tested participants with mTBI using a gap saccade task. Because this task manipulates the temporal gap between the offset of the fixation target and the appearance of the peripheral saccade target, it isolates the contribution of the disengagement process to saccadic reaction time. We found that participants with mTBI had significantly longer saccadic reaction times than controls when the temporal gap was short but not when it was long. This gap-dependent difference in saccadic reaction time was present within 2 days of the injury and resolved within 1 week. This pattern of results suggests that as the contribution of the disengagement process is reduced, so too is the extent of the reaction time deficit in the participants with mTBI. Taken together, this is consistent with the idea that the deficits in orienting visuospatial attention in participants with mTBI are fully accounted for by difficulties with the initial disengagement process. (c) 2007 Published by Elsevier Ireland Ltd.	Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	van Donkelaar, P (corresponding author), Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	paulvd@uoregon.edu		Langan, Jeanne/0000-0003-1417-2180	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 021735, CCR 023203] Funding Source: Medline		Abrams RA, 1998, PERCEPT PSYCHOPHYS, V60, P201, DOI 10.3758/BF03206029; Biscaldi M, 1996, J NEUROPHYSIOL, V76, P199; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Connolly JD, 2005, J NEUROPHYSIOL, V94, P605, DOI 10.1152/jn.00830.2004; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; Dorris MC, 1997, J NEUROSCI, V17, P8566; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Forbes K, 1996, J COGNITIVE NEUROSCI, V8, P344, DOI 10.1162/jocn.1996.8.4.344; Giza CC, 2001, J ATHL TRAINING, V36, P228; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kelly JP, 1997, NEUROLOGY, V48, P581; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; KLEIN R, 1993, BEHAV BRAIN SCI, V16, P583, DOI 10.1017/S0140525X00031769; Krauzlis RJ, 2003, J NEUROSCI, V23, P4333; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Neggers SFW, 2005, EUR J NEUROSCI, V21, P2853, DOI 10.1111/j.1460-9568.2005.04129.x; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; Pratt J, 1999, ACTA PSYCHOL, V102, P1, DOI 10.1016/S0001-6918(99)00014-1; REUTERLORENZ PA, 1991, PERCEPT PSYCHOPHYS, V49, P167, DOI 10.3758/BF03205036; Ruff RM, 1999, BRAIN INJURY, V13, P943; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860	36	37	37	0	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	APR 24	2007	417	1					61	65		10.1016/j.neulet.2007.02.038			5	Neurosciences	Neurosciences & Neurology	167ZR	WOS:000246492000013	17363165				2021-06-18	
J	Hellmich, HL; Eidson, KA; Capra, BA; Garcia, JM; Boone, DR; Hawkins, BE; Uchida, T; DeWitt, DS; Prough, DS				Hellmich, Helen L.; Eidson, Kristine A.; Capra, Bridget A.; Garcia, Jeanna M.; Boone, Deborah R.; Hawkins, Bridget E.; Uchida, Tatsuo; DeWitt, Douglas S.; Prough, Donald S.			Injured Fluoro-Jade-positive hippocampal neurons contain high levels of zinc after traumatic brain injury	BRAIN RESEARCH			English	Article						zinc neurotoxicity; Fluoro-Jade; Newport Green; traumatic brain injury; hippocampal injury; gene expression	RAT; CONTRIBUTES; DYSFUNCTION; RESPONSES; ISCHEMIA; RELEASE	Hippocampal damage contributes to cognitive dysfunction after traumatic brain injury (TBI). We previously showed that Fluoro-Jade, a fluorescent stain that labels injured, degenerating brain neurons, quantifies the extent of hippocampal injury after experimental fluid percussion TBI in rats. Coincidentally, we observed that injured neurons in the rat hippocampus also stained with Newport Green, a fluorescent dye specific for free ionic zinc. Here, we show that, regardless of injury severity or therapeutic intervention, the post-TBI population of injured neurons in rat hippocampal subfields CA1, CA3 and dentate gyrus is indistinguishable, both in numbers and anatomical distribution, from the population of neurons containing high levels of zinc. Treatment with lamotrigine, which inhibits presynaptic release of glutamate and presumably zinc that is co-localized with glutamate, reduced numbers of Fluoro-Jade-positive and Newport Green-positive neurons equally as did treatment with nicardipine, which blocks voltage-gated calcium channels through which zinc enters neurons. To confirm using molecular techniques that Fluoro-Jade and Newport Green-positive neurons are equivalent populations, we isolated total RNA from 25 Fluoro-Jade-positive and 25 Newport Green-positive pyramidal neurons obtained by laser capture microdissection (LCM) from the CA3 subfield, linearly amplified the mRNA and used quantitative ribonuclease protection analysis to demonstrate similar expression of mRNA for selected TBI-induced genes. Our data suggest that therapeutic interventions aimed at reducing neurotoxic zinc levels after TBI may reduce hippocampal neuronal injury. (c) 2006 Elsevier B.V. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013; Hawkins, Bridget/H-4933-2015	Prough, Donald S/0000-0001-7994-532X; Hawkins, Bridget/0000-0002-1887-3657	NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32 ES007254] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042849-01A1, R01 NS042849, R01 NS042849-04] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER		Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Canzoniero LMT, 1999, J NEUROSCI, V19; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duckworth EAM, 2005, BRAIN RES, V1042, P29, DOI 10.1016/j.brainres.2005.02.021; FREDERICKSON CJ, 1988, NUTRITIONAL MODULATI, P289; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hinkle DA, 2003, BIOL PSYCHIAT, V54, P413, DOI 10.1016/S0006-3223(03)00322-6; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *SAS I I, 1999, SAS STAT US GUID VER; Schiff ND, 2002, NEUROL RES, V24, P116, DOI 10.1179/016164102101199576; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Thompson K, 2001, N C Med J, V62, P376; Thompson RB, 2002, J NEUROSCI METH, V118, P63, DOI 10.1016/S0165-0270(02)00144-9; Thompson RB, 2002, J BIOMED OPT, V7, P555, DOI 10.1117/1.1501886; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wei G, 2004, NEUROSCI LETT, V370, P118, DOI 10.1016/j.neulet.2004.08.027; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	36	37	38	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 5	2007	1127	1					119	126		10.1016/j.brainres.2006.09.094			8	Neurosciences	Neurosciences & Neurology	130VP	WOS:000243827400015	17109824	Green Accepted			2021-06-18	
J	Chen, G; Shi, JX; Ding, YS; Yin, HX; Hang, CH				Chen, Gang; Shi, Jinxin; Ding, Yasuo; Yin, Hongxia; Hang, Chunhua			Progesterone prevents traumatic brain injury-induced intestinal nuclear factor kappa B activation and proinflammatory cytokines expression in male rats	MEDIATORS OF INFLAMMATION			English	Article							ALPHA; ALLOPREGNANOLONE; INACTIVATION; INFLAMMATION; REPRESSION; MECHANISM; SUBUNIT; MUCOSA; CELLS; GUT	We have previously shown that traumatic brain injury (TBI) can induce an upregulation of nuclear factor kappa B (NF-kappa B) and proinflammatory cytokines in the gut, which play an important role in the pathogenesis of acute gut mucosal injury mediated by inflammation. In this work, we investigated whether progesterone administration modulated intestinal NF-kappa B activity and proinflammatory cytokines expression after TBI in male rats. As a result, we found that administration of progesterone following TBI could decrease NF-kappa B binding activity, NF-kappa B p65 protein expression, and concentrations of interleukin-1 beta (IL-1 beta), and tumor necrosis factor-alpha ( TNF-alpha) in the gut. TBI-induced damages of gut structure were ameliorated after progesterone injections. The results of the present study suggest that the therapeutic benefit of post-TBI progesterone injections might be due to its inhibitory effects on intestinal NF-kappa B activation and proinflammatory cytokines expression.	Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	nju_neurosurgery@163.com	Yin, Hong/AAC-5784-2020	Chen, Gang/0000-0002-0758-1907			Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Castro-Caldas M, 2003, MEDIAT INFLAMM, V12, P37, DOI 10.1080/0962935031000096953; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Claud EC, 2007, AM J PHYSIOL-GASTR L, V292, pG1411, DOI 10.1152/ajpgi.00557.2006; Davies S, 2004, GYNECOL ONCOL, V94, P463, DOI 10.1016/j.ygyno.2004.05.028; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Gotkin JL, 2006, AM J OBSTET GYNECOL, V195, P1015, DOI 10.1016/j.ajog.2006.07.002; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Homaidan FR, 2003, MEDIAT INFLAMM, V12, P277, DOI 10.1080/09629350310001619681; Horie S, 2005, FERTIL STERIL, V83, P1530, DOI 10.1016/j.fertnstert.2004.11.042; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kurachi O, 2001, J CLIN ENDOCR METAB, V86, P2275, DOI 10.1210/jc.86.5.2275; Lee JW, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93148; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pritts TA, 1998, ARCH SURG-CHICAGO, V133, P1311, DOI 10.1001/archsurg.133.12.1311; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Shields AD, 2005, AM J OBSTET GYNECOL, V193, P1144, DOI 10.1016/j.ajog.2005.05.046; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	32	37	38	0	3	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2007	2007								93431	10.1155/2007/93431			7	Cell Biology; Immunology	Cell Biology; Immunology	211OG	WOS:000249532500001	18274644	DOAJ Gold, Green Published			2021-06-18	
J	Fiorello, CA; Hale, JB; Holdnack, JA; Kavanagh, JA; Terrell, J; Long, L				Fiorello, Catherine A.; Hale, James B.; Holdnack, James A.; Kavanagh, Jack A.; Terrell, Joy; Long, Lisa			Interpreting intelligence test results for children with disabilities: Is global intelligence relevant?	APPLIED NEUROPSYCHOLOGY			English	Article						ADHD; general intelligence; IQ; LD; profile analysis; TBI; test interpretation	SUBTEST ANALYSIS; FACTOR SCORES; IQ; ACHIEVEMENT; DISCREPANCY; PROFILES; AGE	School psychological and neuropsychological evaluations typically include intellectual and other standardized assessment tools in the identification of children with disabilities. The clinical utility of intellectual assessment in the identification and treatment of these children has been repeatedly challenged, with alternatives such as a response to intervention or global intelligence score interpretation offered to replace the long-held tradition of idiographic interpretation of intellectual factors or subtests for the purpose of differential diagnosis and individualized intervention. Replicating previous work, this study examined the structure of intellectual functioning for children diagnosed with Learning Disability (LD; n = 128), Attention-Deficit/Hyperactivity Disorder (ADHD; n = 71), and traumatic brain injury (TBI; n = 29) using regression commonality analysis. Across groups, results provide substantial evidence for a multifactorial representation of intellectual functioning for children with LD, ADHD, or TBI, with little shared variance among factor predictors of FSIQ in each analysis. As global intellectual functioning, represented by the shared variance among all predictors, was largely absent and instead composed of several discrete elements with the requisite specificity for individual interpretation, idiographic interpretation appears to be warranted for children with disabilities.	Temple Univ, Sch Psychol Program, Philadelphia, PA 19122 USA; Philadelphia Coll Osteopath Med, Philadelphia, PA USA; Psychol Corp, San Antonio, TX USA; Loyola Univ, Chicago, IL 60611 USA; SUNY Coll Plattsburgh, Plattsburgh, NY 12901 USA	Fiorello, CA (corresponding author), Temple Univ, Sch Psychol Program, RA 269,1301 Cecil B Moore Ave, Philadelphia, PA 19122 USA.	catherine.fiorello@temple.edu	Berger, Emily/N-7268-2017	Berger, Emily/0000-0001-5550-807X; Fiorello, Catherine/0000-0002-9938-0407			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barkley R. A., 1997, ADHD NATURE SELF CON; BERNINGER V, 1992, LEARN DISABILITY Q, V15, P103, DOI 10.2307/1511012; Bowman DB, 2001, LEARN INDIVID DIFFER, V13, P127, DOI 10.1016/S1041-6080(02)00076-6; Bryan KL, 2001, J INT NEUROPSYCH SOC, V7, P655, DOI 10.1017/S1355617701766015; CRONBACH LJ, 1975, AM PSYCHOL, V30, P1; Daniel MH, 1997, AM PSYCHOL, V52, P1038; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; FENNELL EB, 1997, HDB CLIN CHILD NEURO, P204; Fiorello CA, 2001, LEARN INDIVID DIFFER, V13, P115, DOI 10.1016/S1041-6080(02)00075-4; FLANAGAN DP, 2004, ESSENTIALS WISC IV A; FLETCHER JM, 1994, J EDUC PSYCHOL, V86, P6, DOI 10.1037//0022-0663.86.1.6; Georgas J., 2003, CULTURE CHILDRENS IN, P277, DOI [10.1016/B978-012280055-9/50021-7, DOI 10.1016/B978-012280055-9/50021-7]; Glutting JJ, 1997, PSYCHOL ASSESSMENT, V9, P295, DOI 10.1037/1040-3590.9.3.295; Glutting JJ, 1997, SCHOOL PSYCHOL REV, V26, P176; Glutting JJ, 1998, SCHOOL PSYCHOL REV, V27, P599; Goldberg E, 2001, EXECUTIVE BRAIN FRON; GOLDBERG E, 2001, EXECUTIVE BRAIN FROT; Gottfredson LS, 1997, INTELLIGENCE, V24, P79, DOI 10.1016/S0160-2896(97)90014-3; Gresham FM, 1997, SCHOOL PSYCHOL QUART, V12, P249, DOI 10.1037/h0088961; Groth-Marnat G., 2000, NEUROPSYCHOLOGICAL A, P129; Hale J. B., 2004, SCH NEUROPSYCHOLOGY; Hale JB, 2001, SCHOOL PSYCHOL QUART, V16, P31, DOI 10.1521/scpq.16.1.31.19158; HALE JB, 2003, SCH PSYCHOL, V58, P6; HORN JL, 1967, ACTA PSYCHOL, V26, P107, DOI 10.1016/0001-6918(67)90011-X; Jensen A. R., 1998, G FACTOR SCI MENTAL; KAMPHAUS RW, 2001, CLIN ASSESSMENT CHIL; KAVALE KA, 2003, NAT RES CTR LEARN DI; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mayes SD, 2003, AUTISM, V7, P65, DOI 10.1177/1362361303007001006; MCDERMOTT PA, 1992, J SPEC EDUC, V25, P504, DOI 10.1177/002246699202500407; MCDERMOTT PA, 1990, J PSYCHOEDUC ASSESS, V8, P290, DOI 10.1177/073428299000800307; MCGHEE RL, 2002, LEARN INDIVID DIFFER, V13, P197; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Pedhazur E.J., 1997, MULTIPLE REGRESSION, V3rd ed.; Pfeiffer SI, 2000, SCHOOL PSYCHOL QUART, V15, P376, DOI 10.1037/h0088795; RESCHLY DJ, 2002, BEST PRACTICES SCH P, V1, P3; Reynolds C. R., 1997, HDB CLIN CHILD NEURO, P180; Riccio CA, 2000, SCHOOL PSYCHOL QUART, V15, P386, DOI 10.1037/h0088796; ROID GH, 1993, J PSYCHOEDUC ASSESS, P6; ROURKE BP, 1994, FRAMES REFERENCE ASS, P475; Sattler J.M., 2001, ASSESSMENT CHILDREN, V4th edn; Siegel LS, 2003, J LEARN DISABIL-US, V36, P2, DOI 10.1177/00222194030360010101; Spearman C, 1904, AM J PSYCHOL, V15, P201, DOI 10.2307/1412107; Sternberg RJ, 2001, MERRILL PALMER QUART, V47, P1, DOI 10.1353/mpq.2001.0005; Thurstone L. L., 1938, PRIMARY MENTAL ABILI; Tulsky D.S., 2003, CLIN INTERPRETATION; Watkins MW, 2004, PSYCHOL ASSESSMENT, V16, P133, DOI 10.1037/1040-3590.16.2.133; Watkins MW, 2000, SCHOOL PSYCHOL QUART, V15, P465, DOI 10.1037/h0088802; WECHSLER D, 1975, AM PSYCHOL, V30, P135, DOI 10.1037/h0076868; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 1991, WECHSLER INTELLIGENC; YSSELDYKE JE, 1973, ACAD THER, V8, P415, DOI 10.1177/105345127300800407	53	37	37	1	15	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2007	14	1					2	12		10.1080/09084280701280338			11	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	171JA	WOS:000246730800002	17439365				2021-06-18	
J	Leon-Carrion, J; Leal-Cerro, A; Murillo Cabezas, F; Atutxa, AM; Gomez, SG; Cordero, JMF; Moreno, AS; Ferrari, MDR; Dominguez-Morales, MR				Leon-Carrion, J.; Leal-Cerro, A.; Murillo Cabezas, F.; Atutxa, A. Madrazo; Gomez, S. Garcia; Cordero, J. M. Flores; Moreno, A. Soto; Ferrari, M. D. Rincon; Dominguez-Morales, M. R.			Cognitive deterioration due to GH deficiency in patients with traumatic brain injury: A preliminary report	BRAIN INJURY			English	Article						hypopituitarism; brain injury; cognitive disorder; hormonal deficiency; emotional disorder	QUALITY-OF-LIFE; GROWTH-HORMONE DEFICIENCY; ADULTS; HYPOPITUITARISM; DYSFUNCTION; THERAPY; IMPACT	Primary objective: To determine whether cognitive and behavioural disorders observed in TBI patients are due to hormonal deficits or to the brain injury itself. Research design: Transversal, between-group design. Methods and procedures: Studied 22 severe TBI patients (GCS < 8): 11 had isolated GH deficiency and 11 did not. Prepared detailed clinical reports on patients and performed physical examinations, standard biochemical and full blood count analysis. Patients underwent neuropsychological assessment and hormonal evaluation 6 months after TBI diagnosis. Results: TBI patients with GH deficiency show greater deficits in attention, executive functioning, memory and emotion than those without GH deficiency. Conclusions: Results show GH-related cognitive impairment in patients who develop GH deficiency after TBI and suggest that treatment of GH deficiency would improve cognition. The clinical importance of these findings should be established to better understand the nature, magnitude and meaning of GH-related cognitive impairment in patients who develop GH deficiency after TBI.	Univ Seville, Dept Expt Psychol, Human Neuropsychol Lab, Seville, Spain; Univ Hosp Virgen Rocio, Div Endocrinol, Seville, Spain; Univ Hosp Virgen Rocio, Crit Care & Emergency Dept, Seville, Spain; Ctr Brain Injury Rehabil CRECER, Seville, Spain	Leon-Carrion, J (corresponding author), Univ Seville, Dept Expt Sychol, Human Neuropsychol Lab, C Camilo, Seville, Spain.	leoncarrion@us.es	IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021				Aleman A, 2000, NEUROPSYCHOBIOLOGY, V41, P73, DOI 10.1159/000026636; Arwert LI, 2005, NEUROENDOCRINOLOGY, V82, P32, DOI 10.1159/000090123; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Bennett PA, 2000, CONT ENDOCRINOL, V19, P145; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Burman P, 1998, PSYCHOTHER PSYCHOSOM, V67, P154, DOI 10.1159/000012276; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; CARRION JL, 1998, NEUROREHABILITATION, V11, P11129; Deijen J. B., 1999, Journal of Endocrinological Investigation, V22, P127; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Dik MG, 2003, NEUROBIOL AGING, V24, P573, DOI 10.1016/S0197-4580(02)00136-7; Fiasche R, 1995, PSYCHONEUROENDOCRINO, V20, P727, DOI 10.1016/0306-4530(95)00027-5; FISHER DA, 1998, QUEST DIAGNOSTIC MAN, P312; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; HOWLETT TA, 1997, DIAGNOSIS TREATMENT, P81; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon Carrion J, 1997, NEUROPSYCHOLOGICAL R; Leon-Carrion J, 2006, BRAIN INJURY TREATME; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; LEONCARRION J, 2006, BRAIN INJURY GUIDE F; LEONCARRION JL, 1998, BATERIA NEUROPSICOLO; Nyberg F, 1996, HORM RES, V45, P18, DOI 10.1159/000184753; Popovic V, 2005, FRONT HORM RES, V33, P33, DOI 10.1159/000088399; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Stabler B, 2001, HORM RES, V56, P55, DOI 10.1159/000048136; TOOGOOD AA, 1994, CLIN ENDOCRINOL, V41, P511, DOI 10.1111/j.1365-2265.1994.tb02583.x; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Wiren L, 2001, J CLIN ENDOCR METAB, V86, P3494, DOI 10.1210/jc.86.8.3494	33	37	38	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	8					871	875		10.1080/02699050701484849			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202YZ	WOS:000248942400008	17676444				2021-06-18	
J	Tate, CC; Tate, MC; LaPlaca, MC				Tate, Ciara C.; Tate, Matthew C.; LaPlaca, Michelle C.			Fibronectin and laminin increase in the mouse brain after controlled cortical impact injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; fibronectin; laminin; mouse; traumatic brain injury	EXTRACELLULAR-MATRIX PROTEINS; FOCAL CEREBRAL-ISCHEMIA; PLASMA FIBRONECTIN; GROWTH-FACTOR; BASAL LAMINA; INTEGRIN; RAT; EXPRESSION; BARRIER; TRAUMA	The complex environment of the traumatically injured brain exhibits aspects of inhibition and ongoing cell death together with attempts at repair and regeneration. Elucidating these events and exploiting those factors involved in endogenous repair and regeneration may aid in developing more effective treatments for traumatic brain injury. Two extracellular matrix proteins critical to neural development-fibronectin and laminin-may also play a protective or reparative role in the injury response. While both of these proteins have been found to increase following human brain injury, the presence of these proteins has not been studied in a clinically-relevant animal model of blunt head trauma. In this study, we examined the spatiotemporal profile of both fibronectin and laminin in the mouse brain following controlled cortical impact injury. Fibronectin and laminin reactivity was localized to the injury penumbra up to 14 days post-injury and was significantly higher than uninjured controls at 3 days post-injury. Upon examining the spatial relationship of fibronectin and laminin to support cells, we found macrophages/activated microglia prominently present in the fibronectin-rich tissue, consistent with a role for fibronectin in facilitating debris clearing. Furthermore, reactive astrocyte processes were found sheathing laminin positive vasculature, suggesting that laminin may play a role in repairing the blood-brain barrier. These and other hypothesized reparative roles for fibronectin and laminin after traumatic brain injury are discussed.	Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Lab Neuroengn, Atlanta, GA 30322 USA	LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Lab Neuroengn, 313 Ferst Dr, Atlanta, GA 30322 USA.	michelle.laplaca@bme.gatech.edu					Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bi XN, 2001, J COMP NEUROL, V435, P184, DOI 10.1002/cne.1201; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EGAN RA, 1991, BRAIN RES, V568, P330, DOI 10.1016/0006-8993(91)91421-V; Einheber S, 1996, J COMP NEUROL, V370, P105; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Fukai F, 1998, EXP CELL RES, V242, P92, DOI 10.1006/excr.1998.4076; Gibson RM, 2005, MOL CELL NEUROSCI, V28, P588, DOI 10.1016/j.mcn.2004.11.004; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRANT DS, 1990, ANN NY ACAD SCI, V588, P61, DOI 10.1111/j.1749-6632.1990.tb13197.x; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; LANGLIOS JA, 2004, TRAUMATIC BRAIN INJU; Lariviere B, 2003, WOUND REPAIR REGEN, V11, P79, DOI 10.1046/j.1524-475X.2003.11112.x; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; MARTIN DE, 1988, ARCH DERMATOL, V124, P226, DOI 10.1001/archderm.124.2.226; MIZUTANI K, 1987, ACTA HISTOCHEM CYTOC, V20, P87, DOI 10.1267/ahc.20.87; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SUZUKI M, 1990, ACTA NEUROPATHOL, V80, P355, DOI 10.1007/BF00307687; Szabo A, 2004, NEUROPATH APPL NEURO, V30, P169, DOI 10.1046/j.0305-1846.2003.00524.x; Tsuru A, 1996, EARLY HUM DEV, V45, P93, DOI 10.1016/0378-3782(95)01724-0; Yanaka K, 1996, J NEUROSURG, V85, P125, DOI 10.3171/jns.1996.85.1.0125; Yanaka K, 1997, J CEREBR BLOOD F MET, V17, P605; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	33	37	41	2	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					226	230		10.1089/neu.2006.0043			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100022	17263686				2021-06-18	
J	Kukacka, J; Vajtr, D; Huska, D; Prusa, R; Houstava, L; Samal, F; Diopan, V; Kotaska, K; Kizek, R				Kukacka, Jiri; Vajtr, David; Huska, Dalibor; Prusa, Richard; Houstava, Ladislav; Samal, Filip; Diopan, Vaclav; Kotaska, Karel; Kizek, Rene			Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic brain injury	NEUROENDOCRINOLOGY LETTERS			English	Article; Proceedings Paper	11th Interdisciplinary Slovak-Czech Toxicological Conference	JUN 05-07, 2006	Trencianske Teplice, SLOVAKIA	Slovak Acad Sci, Inst Expt Pharmaccol, Slovak Toxicol Soc, Czech Soc Expt & Clin Pharmacol, Czech Med Assoc JE Purkyne, Slovak Assoc Lab Anim Sci		metallothionein; contusion; diffuse axonal injury; Glasgow Coma Score; neuron specific enolase; S100B protein; oxidative stress; Brdicka reaction; differential pulse voltammetry	SEVERE HEAD-INJURY; PATHOLOGY; RELEASE	OBJECTIVES: The aim of this study was to evaluate the correlation of neuron specific enolase (NSE), protein S100B and time-profile of Glasgow Coma Score (GCS) development with metallothionein (MT) blood levels in patients with traumatic brain injury (TBI) during 10 days of hospitalization. Patients were divided into 2 groups with respect to NSE and S100B levels-with (group 1) and without (group II) GCS improvement. METHODS: Serum NSE and S100B concentrations were measured by immunochemical methods; serum metallothionein concentration by electrochemical technique. Cortical biopsies were investigated immunohistochemically and by electron microscope. A cDNA microarray containing 700 gene probes was used to study the changes in gene expression in the ipsilateral cortex. RESULTS: Values of MT in the blood of group I showed a non-significant decrease compared to group II during 1-3 days after admission. There was an increase of MT during 4-8 days in comparison with values of 1-3 days. The highest value of MT during hospitalization was found in a patient with diffuse axonal injury (group 11). The data of cDNA microarray suggested an increase in expression of gene transcripts for oxygen free radical scavenger proteins corresponding with the increase of MT during 4-8 days in both groups. CONCLUSIONS: The experimental data indicate that monitoring the content of MT in patients with trauma brain injury would be a suitable approach to evaluate the degree of injury or duration of prolonging unconsciousness, particularly in diagnosis of diffuse axonal injury.	Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Sch Med 2, CZ-15006 Prague 5, Czech Republic; Univ Hosp Motol, CZ-15006 Prague, Czech Republic; Charles Univ Prague, Inst Forens Med & Toxicol, Sch Med 1, CZ-15006 Prague 5, Czech Republic; Charles Univ Prague, Clin Neurosurg, Med Sch 3, CZ-15006 Prague 5, Czech Republic; Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, Brno, Czech Republic	Kukacka, J (corresponding author), Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Sch Med 2, Uvalu 84, CZ-15006 Prague 5, Czech Republic.	jiri.kukacka@lf2.cuni.cz	Kukacka, Jiri/C-4770-2013; Huska, Dalibor/J-9493-2018; Kizek, Rene/D-7748-2012; Huska, Dalibor/M-8285-2019; Kotaska, Karel/A-3830-2008	Huska, Dalibor/0000-0003-3852-8751; Kizek, Rene/0000-0002-0467-6169			Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; ILARIA R, 1985, J NEUROSCI METH, V15, P165, DOI 10.1016/0165-0270(85)90053-6; Kukacka J, 2006, FASEB J, V20, pA75; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2006, FEBS J, V273, P1857, DOI 10.1111/j.1742-4658.2006.05207.x; Petrlova J, 2006, ELECTROCHIM ACTA, V51, P5112, DOI 10.1016/j.electacta.2006.03.078; Prusa R, 2006, CLIN CHEM, V52, pA175; Prusa R, 2004, MOL BIOL CELL, V15, p249A; Vajtr D, 2006, Soud Lek, V51, P36; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 2002, J CLIN NEUROSCI, V9, P51, DOI 10.1054/jocn.2001.0904; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	18	37	41	0	4	MAGHIRA & MAAS PUBLICATIONS	STOCKHOLM	PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN	0172-780X			NEUROENDOCRINOL LETT	Neuroendocrinol. Lett.	DEC	2006	27			2			116	120					5	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	153NQ	WOS:000245442600028	17159794				2021-06-18	
J	Levchakov, A; Linder-Ganz, E; Raghupathi, R; Margulies, SS; Gefen, A				Levchakov, Anna; Linder-Ganz, Eran; Raghupathi, Ramesh; Margulies, Susan S.; Gefen, Amit			Computational studies of strain exposures in neonate and mature rat brains during closed head impact	JOURNAL OF NEUROTRAUMA			English	Article						finite element model; strain and stress distributions; tissue mechanical properties; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; AXONAL INJURY; AGE; RESPONSES	Traumatic brain injury (TBI) is the most common cause of death in childhood, and the majority of fatal cases are due to motor vehicle accidents, falls, sport-related accidents, and child abuse. Rodents and particularly rats became a commonly used animal model of TBI in childhood as well as in adults, and different techniques are described in the literature to induce the brain injury. However, findings reported in the last decade regarding the increased stiffness of brain tissue in young animals, including rats, are not considered in experimental designs of TBI studies, and this may seriously bias the results when TBI effects are compared across different animal ages. In this study, we determined the strain and stress distributions in neonatal (post-natal-day [PND] 13-17) and mature (PND 43 and 90) rat brains during a closed head injury, using age-specific finite element (FE) models. The FE simulations indicated that for identical cortical displacements, the neonatal brain may be exposed to larger peak stress magnitudes compared with a mature brain due to stiffer tissue properties in the neonate, as well as larger strain magnitudes due to its smaller size. The brain volume subjected to a certain strain level was greater in the neonate brain compared with the adult models for all indentation depths greater than 1 mm. In conclusion, our present findings allow better design of closed head impact experiments which involve an age factor. Additionally, the larger peak stresses and larger strain volumetric exposures observed in the neonatal brain support the hypothesis that the smaller size and stiffer tissue of the infant brain makes it more susceptible to TBI.	Tel Aviv Univ, Fac Engn, Dept Biomed Engn, IL-69978 Tel Aviv, Israel; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA USA; Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA	Gefen, A (corresponding author), Tel Aviv Univ, Fac Engn, Dept Biomed Engn, Ramat Aviv Campus, IL-69978 Tel Aviv, Israel.	gefen@eng.tau.ac.il	Gefen, Amit/M-4720-2015	Gefen, Amit/0000-0002-0223-7218; Linder-Ganz, Eran/0000-0001-6309-3505	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-41562] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041562] Funding Source: NIH RePORTER		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; Bandak F, 1994, 38 STAPP CAR CRASH C; BRUCE D, 1990, HEAD INJURIES PEDIAT; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; DEJEAMMES M, 1984, SAE T, P427; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbing J, 1981, SCI F PAEDIATRICS, P744; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fisher M D, 1997, Crit Care Nurs Q, V20, P36; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Griesbach G. S., 2000, Journal of Neurotrauma, V17, P986; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOHAN D, 1979, J BIOMECH ENG-T ASME, V101, P250, DOI 10.1115/1.3426254; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Ommaya AK, 1967, 11 STAPP CAR CRASH C; PASCUCCI RC, 1998, CARE MED, V14, P185; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pena A, 2005, ACT NEUR S, V95, P333; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 2001, SUMM BIOENG C ASME B; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; RUAN JS, 1993, SAE T; STURTZ G, 1980, SAE T, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; ZHOU C, 1994, SAE T; ZHOU C, 1995, SAE T	48	37	37	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1570	1580		10.1089/neu.2006.23.1570			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500016	17020491				2021-06-18	
J	Ezaki, Y; Tsutsumi, K; Morikawa, M; Nagata, I				Ezaki, Y.; Tsutsumi, K.; Morikawa, M.; Nagata, I.			Role of diffusion-weighted magnetic resonance imaging in diffuse axonal injury	ACTA RADIOLOGICA			English	Article						diffuse axonal injury; diffusion-weighted imaging; head injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; MR; CT; SEVERITY; HUMANS	Purpose: To determine whether the signal changes on magnetic resonance imaging (MRI), including fluid attenuated inversion recovery ( FLAIR), T2*-weighted gradient echo (GE) imaging, and diffusion-weighted imaging (DWI) in diffuse axonal injury (DAI) patients correlate with the clinical outcome. Material and Methods: We diagnosed patients with DAI based on the following criteria: 1) a loss of consciousness from the time of injury that persisted beyond 6 h; 2) no apparent hemorrhagic contusion on computed tomography (CT); 3) the presence of white matter injury on MRI. Twenty-one DAI patients were analyzed ( 19 M, 2 F, mean age 34 years) with MRI ( FLAIR, T2*-weighted GE imaging, and DWI). Results: 325 abnormalities were detected by MRI within a week after injury. The T2*weighted GE imaging was significantly more sensitive than FLAIR and DWI in diagnosing DAI. DWI detected only 32% of all lesions, but could depict additional shearing injuries not visible on either T2*-weighted GE imaging or FLAIR. The mean number of lesions in brainstem detected by DWI in the favorable group ( good recovery/ moderately disabled) was significantly smaller than in the unfavorable group ( severely disabled/vegetative survival/death). This trend was not observed on the T2*-weighted GE imaging and FLAIR findings. Conclusion: DWI cannot detect all DAI-related lesions, but is a potentially useful imaging modality for both diagnosing and assessing patients with DAI.	Nagasaki Univ, Grad Sch Med, Dept Neurosurg, Nagasaki 852, Japan; Nagasaki Univ, Grad Sch Med, Dept Radiol, Nagasaki 852, Japan	Ezaki, Y (corresponding author), Sasebo City Gen Hosp, Dept Neurosurg, 9-3 Hirasemachi, Sasebo 8578511, Japan.	ezaki-nsu@umin.ac.jp					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	24	37	46	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	SEP	2006	47	7					733	740		10.1080/02841850600771486			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	080GK	WOS:000240235700024	16950714				2021-06-18	
J	Basso, D; Lotze, M; Vitale, L; Ferreri, F; Bisiacchi, P; Belardinelli, MO; Rossini, PM; Birbaumer, N				Basso, D; Lotze, M; Vitale, L; Ferreri, F; Bisiacchi, P; Belardinelli, MO; Rossini, PM; Birbaumer, N			The role of prefrontal cortex in visuo-spatial planning: a repetitive TMS study	EXPERIMENTAL BRAIN RESEARCH			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; HUMAN CORTICOSPINAL EXCITABILITY; RTMS; SAFETY; MODEL	The visuo-spatial planning process is based on an "opportunistic" combination of heuristics and strategies, carried out in small units during the execution of plans. In order to investigate the functional role of the prefrontal cortex in heuristic switching, 42 healthy controls performed a labyrinth crossing task (the Maps Test). During this computerized version of the Travelling Salesperson Problem, subjects had to decide which order of locations optimizes total travel time and distance. This task was performed with and without 1 Hz repetitive transcranial magnetic stimulation (rTMS), which exerts an inhibitory action on the targeted area, applied during the task over bilateral frontal sites (active stimulation) and parieto-occipital site (sham stimulation). Only repetitive bilateral rTMS over F3 and F4 significantly decreased the number of strategies with changes of heuristics, and increased the number of movements required to solve the task. This behaviour contrasts with the performance of healthy subjects in the planning task, but is consistent with the performance of frontal traumatic brain injury patients. The results indicate that, in a visuo-spatial problem-solving task, the prefrontal cortex is involved in the switching between heuristics during the execution of a plan.	Interuniv Ctr Res Cognit Proc Nat & Artificial Sy, ECONA, I-00185 Rome, Italy; Inst Med Psychol & Verhaltensneurobiol, Tubingen, Germany; Univ Roma La Sapienza, Dept Psychol, Rome, Italy; Neurol, Rome, Italy; Univ Padua, Dept Gen Psychol, Padua, Italy; IRCCS, Ctr S Giovanni di Dio Fatebenefratelli, Brescia, Italy	Basso, D (corresponding author), Interuniv Ctr Res Cognit Proc Nat & Artificial Sy, ECONA, Via Marsi,78,Stanza 16,2 Piano, I-00185 Rome, Italy.	demis.basso@uniroma1.it	Lotze, Martin/D-2964-2012; BISIACCHI, PATRIZIA/B-8976-2008; Basso, Demis/Q-4782-2017; Rossini, Paolo M./D-4994-2013; Olivetti, Marta/T-4540-2017	Lotze, Martin/0000-0003-4519-4956; BISIACCHI, PATRIZIA/0000-0003-2760-8000; Basso, Demis/0000-0002-4595-3513; Rossini, Paolo M./0000-0003-2665-534X; Olivetti, Marta/0000-0003-3169-3359; Birbaumer, Niels/0000-0002-6786-5127; Ferreri, Florinda/0000-0002-7938-905X			Basso D, 2001, BRAIN COGNITION, V46, P38, DOI 10.1016/S0278-2626(01)80029-4; BASSO D, 2005, THESIS U ROME DEP PS; BISIACCHI PS, 2002, IAPS B PEOPLE ENV ST, V21, P1; Boroojerdi B, 2001, NEUROLOGY, V56, P526, DOI 10.1212/WNL.56.4.526; CADWALLADER M, 1975, ECON GEOGR, V51, P339, DOI 10.2307/142918; Chen R, 1997, ELECTROMYOGR MOTOR C, V105, P415, DOI 10.1016/S0924-980X(97)00036-2; Cisek P., 2005, COGN PROCESS, V6, P15; Cohen G, 1989, MEMORY REAL WORLD; Dehaene S, 1991, CEREB CORTEX, V1, P62, DOI 10.1093/cercor/1.1.62; Fitzgerald PB, 2002, CLIN NEUROPHYSIOL, V113, P1136, DOI 10.1016/S1388-2457(02)00145-1; Graham SM, 2000, MEM COGNITION, V28, P1191, DOI 10.3758/BF03211820; HAYES-ROTH B, 1979, Cognitive Science, V3, P275, DOI 10.1016/S0364-0213(79)80010-5; HIRTLE SC, 1992, GEOFORUM, V23, P227, DOI 10.1016/0016-7185(92)90019-Z; Karim AA, 2003, SUPPL CLIN NEUROPHYS, V56, P331; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Leocani L, 2000, BRAIN, V123, P1161, DOI 10.1093/brain/123.6.1161; MacGregor JN, 2004, MEM COGNITION, V32, P260, DOI 10.3758/BF03196857; McKeefry DJ, 1997, NEUROIMAGE, V5, P1, DOI 10.1006/nimg.1996.0246; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MORRIS RG, 1993, NEUROPSYCHOLOGIA, V31, P1367, DOI 10.1016/0028-3932(93)90104-8; Phillips LH, 2001, Q J EXP PSYCHOL-A, V54, P579, DOI 10.1080/02724980042000237; Rossi S, 2000, CEREB CORTEX, V10, P802, DOI 10.1093/cercor/10.8.802; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Vandenberghe R, 1996, NATURE, V383, P254, DOI 10.1038/383254a0; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8	27	37	37	0	7	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	MAY	2006	171	3					411	415		10.1007/s00221-006-0457-z			5	Neurosciences	Neurosciences & Neurology	044HC	WOS:000237662000012	16710684				2021-06-18	
J	Bergfeldt, U; Borg, K; Kullander, K; Julin, P				Bergfeldt, U; Borg, K; Kullander, K; Julin, P			Focal spasticity therapy with botulinum toxin: Effects on function, activities of daily living and pain in 100 adult patients	JOURNAL OF REHABILITATION MEDICINE			English	Article						botulinum toxin; spasticity; adults; cerebral palsy; stroke; traumatic injury	PLACEBO-CONTROLLED TRIAL; UPPER-LIMB SPASTICITY; UPPER EXTREMITY SPASTICITY; DOUBLE-BLIND; STROKE; MANAGEMENT; EFFICACY; SAFETY; FOOT	Objective: Analysis of the effects of a comprehensive focal spasticity program in adult patients. Design: Retrospective study of an out-patient cohort. Patients: One hundred patients were enrolled in the study (54 men and 46 women, mean age 41 years (SD 14). Cerebral palsy and stroke were equally common (80% in total). The remaining patients had miscellaneous diagnoses, including traumatic brain injury. Methods: On average 230 units (SD 101) of botulinum toxin A Botox((R)) was given for 227 principal therapy targets chosen by the patient or the caregiver. One patient could have several targets for therapy. Administration of botulinum toxin was combined with 260 additional therapeutic interventions, most of which were forms of physical therapy. The effects were assessed after 6 weeks and compared with baseline functional abilities 1 - 2 weeks prior to therapy. Results: Improvement was observed for 211 (93%) therapy targets, no change in 15 (7%), and impairment in 1, corresponding to an overall improvement in 90 patients (90%), 9 unchanged (9%) and worsening in 1. Spasticity assessment (Ashworth scale 0 - 4; 30 patients) showed a statistically significant improvement (median at baseline was 3 vs 2 after therapy, mean difference 1.2, p < 0.001). Conclusion: Improvement was observed in >= 90% of patients and in their principal therapeutic targets in a cohort receiving their first focal spasticity treatment with botulinum toxin A and additional therapy. A strict strategy for patient selection and comprehensive management was followed.	Stockholm Univ, Rehabil Med Clin, Karolinska Inst, SE-14186 Stockholm, Sweden	Bergfeldt, U (corresponding author), Stockholm Univ, Rehabil Med Clin, Karolinska Inst, SE-14186 Stockholm, Sweden.	ulla.bergfeldt@ds.se					ALBANY K, 2002, SPASTICITY ETIOLOGY, P166; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Bakheit AMO, 2001, EUR J NEUROL, V8, P559, DOI 10.1046/j.1468-1331.2001.00277.x; Bhakta BB, 2000, J NEUROL NEUROSUR PS, V69, P217, DOI 10.1136/jnnp.69.2.217; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; BRIN MF, 1997, MUSCLE NERVE SPAST S, V6; BRIN MF, 1997, MUSCLE NERVE       S, V6, P208; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; CHAMBERS HG, 2002, SPASTICITY ETIOLOGY, P94; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DENGLER R, 1992, J NEUROL, V239, P375; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; GARCIES JM, 2002, SPASTICITY ETIOLOGY, P44; GRACIES JM, 2002, SPASTICITY ETIOLOGY, P65; Lance JW., 1980, SPASTICITY DISORDERE, P185; Landau WM, 2003, NEW ENGL J MED, V348, P258; LEACH J, 2002, SPASTICITY ETIOLOGY, P143; LENTNER C, 1982, GEIGY SCI TABLES, V2, P89; Mayer NH, 2002, SPASTICITY ETIOLOGY, P154; Moore AP, 2002, EUR J NEUROL, V9, P42, DOI 10.1046/j.1468-1331.2002.0090s1042.x; OBRIEN CF, 1997, MUSCLE NERVE       S, V6, P176; PIERSON S, 1997, MUSCLE NERVE       S, V6, P36; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Pittock SJ, 2003, CEREBROVASC DIS, V15, P289, DOI 10.1159/000069495; Reichel G, 2001, J NEUROL, V248, pS25; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Richardson D, 1999, PHYSIOTHERAPY, V85, P541; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; TURNERSTOKES L, 2002, GUIDELINES USE BOTUL; Wade DT, 1992, MEASUREMENT NEUROLOG, p[15, 35]; Ward AB, 2002, EUR J NEUROL, V9, P48, DOI 10.1046/j.1468-1331.2002.0090s1048.x; Wissel J, 2000, J PAIN SYMPTOM MANAG, V20, P44, DOI 10.1016/S0885-3924(00)00146-9; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	35	37	38	0	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2006	38	3					166	171		10.1080/16501970500415348			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	039QS	WOS:000237321900004	16702083	DOAJ Gold			2021-06-18	
J	McCauley, SR; Pedroza, C; Brown, SA; Boake, C; Levin, HS; Goodman, HS; Merritt, SG				McCauley, SR; Pedroza, C; Brown, SA; Boake, C; Levin, HS; Goodman, HS; Merritt, SG			Confirmatory factor structure of the Center for Epidemiologic Studies-Depression scale (CES-D) in mild-to-moderate traumatic brain injury	BRAIN INJURY			English	Article						Center for Epidemiologic Studies-Depression Scale (CES-D); traumatic brain injury (TBI); depression; prediction	CLOSED-HEAD INJURY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; AXIS-I; EMOTIONAL DISTURBANCE; MULTIPLE-SCLEROSIS; COMMUNITY SAMPLE; AMERICAN ADULTS; MOOD DISORDERS; FOLLOW-UP	Primary objective: The Center for Epidemiologic Studies Depression scale (CES-D) is a frequently-used self-report measure of depressive symptom severity. Brief depression screening measures can be important in the identification and prediction of depression following traumatic brain injury. The objective of this study was to investigate the validity of the CES-D in measuring depressive symptoms in patients with mild-to-moderate TBI as it has been rarely used in neurologically compromised populations. Research design: Inception cohort. Methods and procedures: The CES-D was administered to 340 participants with mild-to-moderate TBI at 3-months post-injury. Main outcomes and results: Confirmatory factor analysis of the CES-D indicated that the data are a reasonable fit similar to that of Radloff's original 4-factor model. Conclusions: These findings suggest that the CES- D may be appropriate for use in patients with mild-to-moderate TBI.	Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; Univ Texas, Sch Med, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mccauley@bcm.edu		Pedroza, Claudia/0000-0003-4235-1282	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR612707] Funding Source: Medline		Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; *ASS ADV AUT MED, 1990, COMMINJ SCAL ABBR IN; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Beals J., 1991, PSYCHOL ASSESSMENT, V3, P623, DOI [10.1037/1040-3590.3.4.623, DOI 10.1037/1040-3590.3.4.623]; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boisvert JA, 2003, DEPRESS ANXIETY, V17, P19, DOI 10.1002/da.10080; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Bowen A, 1999, BRAIN INJURY, V13, P547; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; CALLAHAN CM, 1994, MED CARE, V32, P341, DOI 10.1097/00005650-199404000-00003; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Chwastiak L, 2002, AM J PSYCHIAT, V159, P1862, DOI 10.1176/appi.ajp.159.11.1862; CLARK VA, 1981, PSYCHIAT RES, V5, P171, DOI 10.1016/0165-1781(81)90047-0; CRAIG TJ, 1985, AM J PSYCHIAT, V142, P1272; da Silveira DX, 2002, PSYCHOL REP, V91, P865, DOI 10.2466/pr0.2002.91.3.865; DAVIDSON H, 1994, J GERONTOL, V49, pP159, DOI 10.1093/geronj/49.4.P159; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Edman JL, 1999, SOC PSYCH PSYCH EPID, V34, P211, DOI 10.1007/s001270050135; Falcon LM, 2000, J GERONTOL B-PSYCHOL, V55, pS108, DOI 10.1093/geronb/55.2.S108; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; GARCIA M, 1989, PSYCHIAT RES, V27, P137, DOI 10.1016/0165-1781(89)90129-7; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GOLDING JM, 1989, PSYCHOL ASSESSMENT, V0001; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Grant MM, 2000, ANN BEHAV MED, V22, P149, DOI 10.1007/BF02895779; Gualtari CT, 1991, BRAIN INJURY, V5, P219; GUARNACCIA PJ, 1989, SOC SCI MED, V29, P85, DOI 10.1016/0277-9536(89)90131-7; Haarasilta L, 2001, PSYCHOL MED, V31, P1169, DOI 10.1017/S0033291701004573; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jonas BS, 2003, SOC PSYCH PSYCH EPID, V38, P618, DOI 10.1007/s00127-003-0682-8; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kanetani Kouichi, 2003, Journal of Nippon Medical School, V70, P313; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KUO WH, 1984, J NERV MENT DIS, V172, P449, DOI 10.1097/00005053-198408000-00002; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MANSON SM, 1990, PSYCHOL ASSESSMENT, V2, P231, DOI DOI 10.1037/1040-3590.2.3.231; McCallion P, 2000, J MENTAL HLTH AGING, V6, P325; MEYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; Miller TQ, 1997, J GERONTOL B-PSYCHOL, V52, pS259, DOI 10.1093/geronb/52B.5.S259; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Muthen L. K., 2004, MPLUS USERS GUIDE, V3rd; *NAT CTR INJ PREV, TRAUM BRAIN INJ; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Paterniti S, 2002, BRIT J PSYCHIAT, V181, P111; Perna RB, 2003, J HEAD TRAUMA REHAB, V18, P201; Posner SF, 2001, ETHNIC HEALTH, V6, P137, DOI 10.1080/13557850120068469; RADLOFF LS, 1977, APPL PSYCH MEAS, V3, P385; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Roberts RE, 1990, PSYCHOL ASSESS J CON, V2, P122, DOI DOI 10.1037/1040-3590.2.2.122; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Sapolsky RM, 2001, P NATL ACAD SCI USA, V98, P12320, DOI 10.1073/pnas.231475998; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; *SAS I INC, 2003, STAT AN SOFTW WIND; SHEEHAN TJ, 1995, J PERS ASSESS, V64, P507, DOI 10.1207/s15327752jpa6403_9; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; STOMMEL M, 1993, PSYCHIAT RES, V49, P239, DOI 10.1016/0165-1781(93)90064-N; Stroup-Benham CA, 2000, J AM GERIATR SOC, V48, P250, DOI 10.1111/j.1532-5415.2000.tb02642.x; TEASDALE G, 1974, LANCET, V2, P84; THORSON JA, 1993, B PSYCHONOMIC SOC, V31, P577, DOI 10.3758/BF03337359; Vedhara K, 1999, BEHAV MED, V25, P43, DOI 10.1080/08964289909596738; Verdier-Taillefer MH, 2001, NEUROEPIDEMIOLOGY, V20, P262, DOI 10.1159/000054800; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; YING YW, 1988, J CLIN PSYCHOL, V44, P739, DOI 10.1002/1097-4679(198809)44:5<739::AID-JCLP2270440512>3.0.CO;2-0; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2	92	37	37	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2006	20	5					519	527		10.1080/02699050600676651			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800008	16716998				2021-06-18	
J	Naeimi, ZS; Weinhofer, A; Sarahrudi, K; Heinz, T; Vecsei, V				Naeimi, ZS; Weinhofer, A; Sarahrudi, K; Heinz, T; Vecsei, V			Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use	BRAIN INJURY			English	Article						S100B; NSE; traumatic brain injury; Marshall	MINOR HEAD-INJURY; CALCIUM-BINDING PROTEINS; NEUROBIOCHEMICAL MARKERS; NERVOUS-SYSTEM; S100 PROTEINS; TUMOR-MARKERS; SERUM MARKER; RELEASE; AGE; EXPRESSION	Objective: S-100B and NSE proteins are considered to be neurobiochemical markers for the brain damage. The aim of this study was to consider the diagnostic and prognostic validity of the initial serum levels of S-100B and NSE in clinical use. Methods: Forty-five patients with traumatic brain injury were included in this prospective study. Neurologic examination and CCT-scan were performed. S-100B and NSE were analysed. Patients were divided in two groups depending on the severity of injury. Results: The results showed a significant difference between the S-100B serum concentration and the two groups-minor head injuries and severe head injuries. A statistically significant correlation was observed between an increase of S-100B and NSE serum values and a cerebral pathological finding in CT scans. Conclusion: The clear correlation between S-100B and NSE serum concentrations and CCT findings does not validate both markers as an independent predictor of diagnosis and prognosis of brain injury.	Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria	Naeimi, ZS (corresponding author), Med Univ Vienna, Dept Traumatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	zahra.naeimi@meduniwien.ac.at					Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; COOPER EH, 1987, BRIT J CANCER, V56, P65, DOI 10.1038/bjc.1987.155; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; GERBITZ KD, 1986, J CLIN CHEM CLIN BIO, V24, P1009; GERBITZ KD, 1989, TUMORDIAGN THER, V10, P45; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; HULLIN DA, 1980, BIOCHIM BIOPHYS ACTA, V628, P98, DOI 10.1016/0304-4165(80)90355-4; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; ISHIGURO Y, 1983, CANCER RES, V43, P6080; JENNETT B, 1975, LANCET, V2, P480; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Lara DR, 2001, J PSYCHIATR RES, V35, P11, DOI 10.1016/S0022-3956(01)00003-6; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sheng JG, 1996, NEUROBIOL AGING, V17, P359, DOI 10.1016/0197-4580(96)00037-1; Stein S. C., 1996, NEUROTRAUMA, P31; Taggart DP, 1997, ANN THORAC SURG, V63, P492; Walz R, 2000, NEUROLOGY, V54, P2021, DOI 10.1212/WNL.54.10.2021; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	46	37	44	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2006	20	5					463	468		10.1080/02699050600664418			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800002	16716992				2021-06-18	
J	Popma, A; Raine, A				Popma, A; Raine, A			Will future forensic assessment be neurobiologic?	CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article							TRAUMATIC BRAIN-INJURY; LOW SALIVARY CORTISOL; HEART-RATE LEVEL; AGE 11 YEARS; ANTISOCIAL-BEHAVIOR; AGGRESSIVE-BEHAVIOR; ADOLESCENTS; CHILDREN; VIOLENCE; GENE	During the past two decades, research on the role of biologic factors in antisocial behavior has made great progress. This article discusses recent findings and their possible implications for future forensic assessment and treatment. In addition, some relevant philosophical, ethical, and political questions are brought forward.	Vrije Univ Amsterdam, Med Ctr, Dept Child & Adolescent Psychiat, NL-1115 ZG Amsterdam, Netherlands; Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA	Popma, A (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Child & Adolescent Psychiat, P-A Bascule,Rijksstraatweg 145PB, NL-1115 ZG Amsterdam, Netherlands.	a.popma@debascule.com					ARCHER J, 1991, BRIT J PSYCHOL, V82, P1, DOI 10.1111/j.2044-8295.1991.tb02379.x; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Button TMM, 2005, BEHAV GENET, V35, P115, DOI 10.1007/s10519-004-0826-y; Cacioppo JT, 2000, PSYCHOL BULL, V126, P829, DOI 10.1037//0033-2909.126.6.829; Cacioppo JT, 2003, J PERS SOC PSYCHOL, V85, P650, DOI 10.1037/0022-3514.85.4.650; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; CLONINGER CR, 1982, ARCH GEN PSYCHIAT, V39, P1242; Coccaro EF, 1997, PSYCHIAT RES, V73, P1, DOI 10.1016/S0165-1781(97)00108-X; Connor D. F., 2002, AGGRESSION ANTISOCIA; CRISTIANSEN KO, 1977, BIOSOCIAL BASIS CRIM, P89; DAHL RE, 1998, ANN PROGR CHILD PSYC, P3; Damasio A., 1994, DESCARTESERROR EMOTI; Eley TC, 2003, DEV PSYCHOPATHOL, V15, P383, DOI 10.1017/S095457940300021X; Eysenck H.J., 1977, CRIME PERSONALITY; Farrington DP, 1997, NATO ADV SCI I A-LIF, V292, P89; FISHER PA, 2002, INT C INF STUD TOR O; Foley DL, 2004, ARCH GEN PSYCHIAT, V61, P738, DOI 10.1001/archpsyc.61.7.738; FOWLES DC, 1993, ELECTRODERMAL ACTIVI; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Grisso T., 2004, DOUBLE JEOPARDY ADOL; Haberstick BC, 2005, AM J MED GENET B, V135B, P59, DOI 10.1002/ajmg.b.30176; Hugdahl K, 1998, PSYCHOPHYSIOLOGY, V35, P170; Hux D, 1998, BRAIN INJURY, V12, P667; Ishikawa SS, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P277; Kendler KS, 2005, AM J PSYCHIAT, V162, P433, DOI 10.1176/appi.ajp.162.3.433; Kendler KS, 2005, AM J PSYCHIAT, V162, P1243, DOI 10.1176/appi.ajp.162.7.1243; Kruesi MJP, 2004, PSYCHIAT RES-NEUROIM, V132, P1, DOI 10.1016/j.pscychresns.2004.07.002; LAHEY BB, 1995, CONDUCT DISORDERS CH; Lee TMC, 2002, HUM BRAIN MAPP, V15, P157, DOI 10.1002/hbm.10020; Lorber MF, 2004, PSYCHOL BULL, V130, P531, DOI 10.1037/0033-2909.130.4.531; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; McBurnett K, 2000, ARCH GEN PSYCHIAT, V57, P38, DOI 10.1001/archpsyc.57.1.38; McBurnett K, 2005, BIOL PSYCHIAT, V57, P1109, DOI 10.1016/j.biopsych.2005.01.041; Mednick S, 1977, BIOSOCIAL BASES CRIM, P1; Mitchell Sandra D., 2003, BIOL COMPLEXITY INTE; Moffitt TE, 2001, DEV PSYCHOPATHOL, V13, P355, DOI 10.1017/S0954579401002097; Monastra VJ, 2005, APPL PSYCHOPHYS BIOF, V30, P95, DOI 10.1007/s10484-005-4305-x; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Newman TK, 2005, BIOL PSYCHIAT, V57, P167, DOI 10.1016/j.biopsych.2004.10.012; OCONNOR K, 1985, BRIT J PSYCHOL, V76, P187, DOI 10.1111/j.2044-8295.1985.tb01942.x; Ortiz J, 2004, J AM ACAD CHILD PSY, V43, P154, DOI 10.1097/00004583-200402000-00010; PARKER LS, 1995, TRENDS GENET, V11, P520, DOI 10.1016/S0168-9525(00)89164-7; Plomin R, 2003, ANNU REV PSYCHOL, V54, P205, DOI 10.1146/annurev.psych.54.101601.145108; Porter RJ, 2003, PSYCHOPHARMACOLOGY, V165, P216, DOI 10.1007/s00213-002-1282-0; Prichep LS, 2002, CLIN ELECTROENCEPHAL, V33, P8, DOI 10.1177/155005940203300104; QUAY HC, 1965, AM J PSYCHIAT, V122, P180, DOI 10.1176/ajp.122.2.180; RAINE A, 1984, BIOL PSYCHOL, V18, P123, DOI 10.1016/0301-0511(84)90015-2; Raine A, 2002, J ABNORM CHILD PSYCH, V30, P311, DOI 10.1023/A:1015754122318; Raine A, 1997, J AM ACAD CHILD PSY, V36, P1457, DOI 10.1097/00004583-199710000-00029; Raine A, 2003, AM J PSYCHIAT, V160, P1627, DOI 10.1176/appi.ajp.160.9.1627; RAINE A, 1990, AM J PSYCHIAT, V147, P933; Raine A, 2001, AGGRESSIVE BEHAV, V27, P111, DOI 10.1002/ab.4; Raine A, 2001, PSYCHOPHYSIOLOGY, V38, P254, DOI 10.1111/1469-8986.3820254; RAINE A, 1990, PSYCHIAT RES, V31, P85, DOI 10.1016/0165-1781(90)90111-H; Raine A., 1993, PSYCHOPATHOLOGY CRIM; RAINE A, 1997, BIOSOCIAL BASES VIOL; RAINE A, 1999, CEREBRUM, V1, P15; Rhee SH, 2002, PSYCHOL BULL, V128, P490, DOI 10.1037//0033-2909.128.3.490; ROWE DC, 2001, BIOL CRIME; Rutter ML, 1997, AM PSYCHOL, V52, P390; Sapolsky RM, 2004, PHILOS T R SOC B, V359, P1787, DOI 10.1098/rstb.2004.1547; Scarpa A, 2003, J COMMUNITY PSYCHOL, V31, P321, DOI 10.1002/jcop.10058; Shirtcliff EA, 2005, DEV PSYCHOPATHOL, V17, P167, DOI 10.1017/S0954579405050091; Shoal GD, 2003, J AM ACAD CHILD PSY, V42, P1101, DOI 10.1097/01.CHI.0000070246.24125.6D; Sterzer P, 2005, BIOL PSYCHIAT, V57, P7, DOI 10.1016/j.biopsych.2004.10.008; Susman EJ, 1996, ANN NY ACAD SCI, V794, P18, DOI 10.1111/j.1749-6632.1996.tb32506.x; van de Wiel NMH, 2004, J AM ACAD CHILD PSY, V43, P1011, DOI 10.1097/01.chi.0000126976.56955.43; van Goozen SHM, 2000, J AM ACAD CHILD PSY, V39, P1438, DOI 10.1097/00004583-200011000-00019; Vermeiren R, 2003, CLIN PSYCHOL REV, V23, P277, DOI 10.1016/S0272-7358(02)00227-1; Volavka J, 1999, J NEUROPSYCH CLIN N, V11, P307, DOI 10.1176/jnp.11.3.307; Yang YL, 2005, BRIT J PSYCHIAT, V187, P320, DOI 10.1192/bjp.187.4.320	72	37	39	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1056-4993	1558-0490		CHILD ADOL PSYCH CL	Child Adolesc. Psychiatr. N. Am.	APR	2006	15	2					429	+		10.1016/j.chc.2005.11.004			17	Psychiatry	Psychiatry	028YE	WOS:000236523900010	16527664				2021-06-18	
J	Engberg, AW; Liebach, A; Nordenbo, A				Engberg, AW; Liebach, A; Nordenbo, A			Centralized rehabilitation after severe traumatic brain injury - a population-based study	ACTA NEUROLOGICA SCANDINAVICA			English	Article						centralized; population-based; rehabilitation; severe traumatic brain injury	SEVERE HEAD-INJURY; STROKE UNIT; SCALE	Objectives - To present results from the first 3 years of centralized subacute rehabilitation after very severe traumatic brain injury (TBI), and to compare results of centralized versus decentralized rehabilitation. Material and methods - Prospectively, the most severely injured group of adults from an uptake area of 2.4 million in Denmark were included at admission to a regional brain injury unit (BIU), on average 19 days after injury. Patients in the retrospective study used for comparison were randomly chosen from the national hospital register. Results and conclusions - Out of 117 patients in the prospective study, six died, and 92 (1.27 per 100,000 population per year) survived after a post-traumatic amnesia (PTA) period of at least 28 days. All 19 patients with PTA 7-27 days and 48% of survivors with PTA at least 4 weeks were discharged directly home. The incidence of patients vegetative at 1 month post-trauma was 0.29, and at 1 year 0.055 per 100,000 population. By comparison of 39 patients from the centralized unit injured in 2000-2003 with 21 patients injured in 1982, 1987 or 1992 and with similar PTA- and age distributions and male/female ratio, Glasgow Outcome Scale score at discharge was significantly better for the former group.	Univ Copenhagen, Hvidovre Hosp, Dept Neurol Rehabil 354, Brain Injury Unit, DK-2650 Hvidovre, Denmark	Engberg, AW (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Neurol Rehabil 354, Brain Injury Unit, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	aae@dadlnet.dk					AFFOLTER F, 1980, INT REHABIL MED, V3, P3; *AM ASS ADV AUT ME, 1990, ABBR INJ SCAL PLAIN; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; AZOUVI P, 1996, BRAIN INJURY, V10, P849; COOMBES K, 1996, ERNAHRUNGSSONDE ESSE, P137; DAVIES PM, 1994, STARTING AGAIN EARLY; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; GREENBLATT R, 1961, JAMA-J AM MED ASSOC, V178, P101, DOI 10.1001/jama.1961.03040410001001; HARRADINE PG, 2004, MED J AUSTRALIA, V3, P130; HOLLAND AD, 1984, LANGUAGE DISORDERS A, P245; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 2002, VEGETATIVE STATE; JORGENSEN HS, 1995, STROKE, V26, P1178, DOI 10.1161/01.STR.26.7.1178; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LINN S, 1995, INJURY SEVERITY SCOR, V5, P440; LIPP B, 1996, WEGE ANFANG FRUHREHA; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; ODDY M, 1984, CLOSED HEAD INJURY P, P108; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SAZBON I, 1990, J NEUROSURG, V73, P479; *SUND NAT BOARD HL, 1997, BEH TRAUM HJERN TILG	25	37	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	MAR	2006	113	3					178	184		10.1111/j.1600-0404.2005.00570.x			7	Clinical Neurology	Neurosciences & Neurology	006SP	WOS:000234917700006	16441248				2021-06-18	
J	Gemmell, C; Leathem, JM				Gemmell, C; Leathem, JM			A study investigating the effects of Tai Chi Chuan: Individuals with traumatic brain injury compared to controls	BRAIN INJURY			English	Article						Tai Chi; traumatic brain injury; rehabilitation	CARDIORESPIRATORY FUNCTION; AEROBIC EXERCISE; BALANCE; STRENGTH; REHABILITATION; PRACTITIONERS; RESPONSES; STRESS; WOMEN; TRIAL	Objective: To explore the effects of a 6-week course in Tai Chi associated with traumatic brain injury (TBI) symptoms. Method: Eighteen participants, with TBI assigned to a control (waiting list) group (n = 9) or Tai Chi group (n = 9) completed the Medical Outcome Scale Short Form 36 (SF-36) and Rosenberg Self-Esteem Scale (RSES) before, during, immediately after and 3 weeks after completion of the Tai Chi course. The Tai Chi group completed the Visual Analogue Mood Scales (VAMS) before and after each class. Results: Tai Chi was associated with significant improvement on all VAMS scores (except fatigue) with decreases in sadness, confusion, anger, tension, fear and increases in energy and happiness. There were no significant between-group differences on the SF-36 or RSES. Conclusions: Tai Chi provides short-term benefits after TBI, with rigorous outcome measurement needed to examine long-term benefits.	Massey Univ, Sch Psychol, Wellington, New Zealand	Leathem, JM (corresponding author), Massey Univ, Sch Psychol, POB 756, Wellington, New Zealand.	j.m.leathem@massey.ac.nz					ALDER P, 2000, J NURS SCHOLARSHIP, V32, P377; ARRUDA JE, 1997, J NEUROPSYCHIATRY CL, V9, P152; BROWN DD, 1989, RES Q EXERCISE SPORT, V60, P246, DOI 10.1080/02701367.1989.10607447; Chan KM, 2004, ARCH PHYS MED REHAB, V85, P717, DOI 10.1016/j.apmr.2003.08.091; Channer KS, 1996, POSTGRAD MED J, V72, P349, DOI 10.1136/pgmj.72.848.349; Chen K M, 1999, J Holist Nurs, V17, P267, DOI 10.1177/089801019901700304; FUZHONG L, 2001, PREV SCI, V2, P229; FUZHONG L, 2004, J AM GERIATR SOC, V52, P892; GEMMELL R, 1992, REELING SILK GUIDE T; Jacobson BH, 1997, PERCEPT MOTOR SKILL, V84, P27, DOI 10.2466/pms.1997.84.1.27; JIN P, 1989, J PSYCHOSOM RES, V33, P197, DOI 10.1016/0022-3999(89)90047-0; JIN PT, 1992, J PSYCHOSOM RES, V36, P361, DOI 10.1016/0022-3999(92)90072-A; KIRSTEINS AE, 1991, AM J PHYS MED REHAB, V70, P136, DOI 10.1097/00002060-199106000-00005; Kutner NG, 1997, J GERONTOL B-PSYCHOL, V52, pP242, DOI 10.1093/geronb/52B.5.P242; LAI JS, 1995, J AM GERIATR SOC, V43, P1222, DOI 10.1111/j.1532-5415.1995.tb07397.x; Lan C, 1998, MED SCI SPORT EXER, V30, P345, DOI 10.1097/00005768-199803000-00003; Lan C, 2000, ARCH PHYS MED REHAB, V81, P604, DOI 10.1053/mr.2000.3849; Lan C, 1996, ARCH PHYS MED REHAB, V77, P612, DOI 10.1016/S0003-9993(96)90305-6; LAN C, 1993, J FORMOS MED ASSOC, V92, P894; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187; McGibbon CA, 2004, J VESTIBUL RES-EQUIL, V14, P467; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Sandlund ES, 2000, INT J STRESS MANAGE, V7, P139, DOI 10.1023/A:1009536319034; Song R, 2003, J RHEUMATOL, V30, P2039; Stern R. A., 1997, VISUAL ANALOGUE MOOD; Taylor SK, 2003, TECHNIQUES ORTHOPAED, V18, P110; Taylor-Piliae Ruth E, 2003, J Cardiopulm Rehabil, V23, P90; Tsang WWN, 2004, MED SCI SPORT EXER, V36, P658, DOI 10.1249/01.MSS.0000122077.87090.2E; WAN Q, 1989, TAI CHI CHUAN J, V63, P33; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Wayne PM, 2004, ARCH PHYS MED REHAB, V85, P142, DOI 10.1016/S0003-9993(03)00652-X; Wolf SL, 1997, ARCH PHYS MED REHAB, V78, P886, DOI 10.1016/S0003-9993(97)90206-9; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x; Yan JH, 1998, J AGING PHYS ACTIV, V6, P350, DOI 10.1123/japa.6.4.350; YAN JH, 1999, J GERONTOL A-BIOL, V54, P1; YANG JM, 1990, C KUNG HLTH MARTIAL; Young DR, 1999, J AM GERIATR SOC, V47, P277, DOI 10.1111/j.1532-5415.1999.tb02989.x; ZHOU H, 1994, MAGIC Q GONG	43	37	37	1	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2006	20	2					151	156		10.1080/02699050500442998			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700004	16421063				2021-06-18	
J	Hewitt, J; Evans, JJ; Dritschel, B				Hewitt, J.; Evans, J. J.; Dritschel, B.			Theory driven rehabilitation of executive functioning: Improving planning skills in people with traumatic brain injury through the use of an autobiographical episodic memory cueing procedure	NEUROPSYCHOLOGIA			English	Article						traumatic brain injury; rehabilitation; executive dysfunction; planning; problem solving	AMNESIA	Traumatic brain injury (TBI) frequently leads to the development of a 'dysexecutive syndrome'. The associated difficulties with problem solving (including specific impairments in planning, initiation/plan-implementation and self-monitoring) represent a major challenge to functional recovery and adaptation following brain injury and serve as an important target for rehabilitation. Previous research suggests that one reason people with TBI are poor at everyday planning is that they fail to spontaneously use specific autobiographical memories to support planning in unstructured situations. In this study, we examined whether a self-instructional technique involving self-cueing to recall specific autobiographical experiences would improve performance on a planning task. Two groups of 15 participants who had suffered a closed traumatic brain injury carried out the Everyday Descriptions Task (Dritschel, B. (1991). The role of autobiographical memory in describing how to perform everyday activities. In Paper presented at the European Cognitive Society Conference.), in which they were asked to describe how they would plan eight common unstructured activities, i.e. activities that could be solved in a variety of ways. Group 1 was then asked to describe how to plan a second set of eight unstructured activities. Prior to completing their second set of eight activities, Group 2 underwent training in a procedure aimed at prompting the retrieval of specific memories to support planning. The results suggested that the intervention was effective at increasing the number of specific memories recalled, with a corresponding increase in the effectiveness of the plan and number of relevant steps in the plan. Potential applications of the technique are discussed. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland; Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland	Evans, JJ (corresponding author), Gartnavel Royal Hosp, Sch Psychol Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	jonathan.evans@clinmed.gla.ac.uk		Dritschel, Barbara/0000-0002-0909-6323			BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM; Barsalou L. W., 1988, REMEMBERING RECONSID; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; BURGESS PW, 1996, COGNITIVE MODELS MEM; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CONWAY MA, 1987, MEM COGNITION, V15, P119, DOI 10.3758/BF03197023; CONWAY MA, 1993, THEORIES REMEMBERING; DECOSTELLO AL, 1989, CORTEX, V29, P105; DRITSCHEL B, 1991, EUR COGN SOC C; Dritschel BH, 1998, BRAIN INJURY, V12, P875; EVANS J, 1992, PSYCHOL MED, V22, P399, DOI 10.1017/S0033291700030348; EVANS JJ, 2001, NEUROBEHAVIORAL DISA; GOODARD L, 1996, J ABNORM PSYCHOL, V36, P449; Kopelman M. D., 1990, AUTOBIOGRAPHICAL MEM; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; MARX EM, 1992, J ABNORM PSYCHOL, V101, P78, DOI 10.1037/0021-843X.101.1.78; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; ROSS BH, 1984, COGNITIVE PSYCHOL, V16, P371, DOI 10.1016/0010-0285(84)90014-8; SEIFERT C, 1994, ANALOGY METAPHOR REM, P95; Shallice, 1997, HAYLING BRIXTON TEST; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1998, PREFRONTAL CORTEX EX; WILLIAMS JMG, 1996, STUDIES AUTOBIOGRAPH, P271; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	28	37	38	1	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	8					1468	1474		10.1016/j.neuropsychologia.2005.11.016			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	049JG	WOS:000238011700021	16384587				2021-06-18	
J	von Steinbuechel, N; Richter, S; Morawetz, C; Riemsma, R				von Steinbuechel, N; Richter, S; Morawetz, C; Riemsma, R			Assessment of subjective health and health-related quality of life in persons with acquired or degenerative brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						acquired brain injury; cognitive impairment; dementia; disease-specific; generic; health-related quality of life; health status; outcome; Parkinson's disease; stroke; traumatic brain injury	PARKINSONS-DISEASE PATIENTS; RANDOMIZED CONTROLLED-TRIAL; EXPERIENCING WEARING-OFF; STROKE SURVIVORS; OUTCOME MEASURES; DOUBLE-BLIND; DEMENTIA; RELIABILITY; SATISFACTION; ENTACAPONE	Purpose of review Health-related quality of life is a new outcome variable in neurology. Several generic measures aim at assessing this variable in adults with neurological diseases. Disease-specific measures are still rare; however, individuals with neurological diseases frequently suffer from cognitive impairment, yet are often excluded from health-related quality of life investigations. When included in such studies, cognitive functioning is not monitored via neuropsychological evaluation, possibly leading to methodological problems. Papers from May 2004 until July 2005 are reviewed with respect to psychometric quality and information about persons after traumatic brain injury, stroke, Parkinson's disease or dementia. Recent findings Several new cross-sectional and longitudinal outcome studies are reviewed. The Medical Outcome Study Short Form with 36 items, the Sickness Impact Profile and the Nottingham Health Profile were identified as the most frequently used measures in neurology. For traumatic brain injury, two new generic instrument validations (Life Satisfaction Index-A, Subjective Quality of Life Profile) and one internationally validated disease-specific development (Quality of Life after Brain Injury) were found; for stroke, one disease-specific tool (Burden of Stroke Scale) was identified, In Parkinson's disease, the disease-specific health-related quality of life measure Parkinson's Disease Questionnaire-39 is well validated. In dementia, three dementia-specific instruments (Quality of Life for Dementia, Quality of Life in Late-Stage Dementia Scale and Quality of Life in Alzheimer's Disease Scale) seem to be valid. Summary In neurology, only a few measures have been developed and validated for respondents with cognitive impairment, often showing poorer validity results than studies involving healthy persons. Health-related quality of life assessment should therefore be validated in the specific diseases and, if necessary, combined with a neuropsychological evaluation and a disease-specific health-related quality of life measure.	Univ Gottingen, MR Res Neurol & Psychiat, D-37073 Gottingen, Germany; Univ Gottingen, Fac Psychol & Gerontopsychol, D-37073 Gottingen, Germany; Univ Clin, Dept Psychogeriatr, Geneva, Switzerland; Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England	von Steinbuechel, N (corresponding author), Univ Gottingen, MR Res Neurol & Psychiat, Waldweg 37, D-37073 Gottingen, Germany.	nvsteinbuechel@med.uni-goettingen.de	Riemsma, Rob/E-2319-2016; Morawetz, Carmen/G-9485-2017	Riemsma, Rob/0000-0001-8892-0861; Morawetz, Carmen/0000-0003-3607-7627			Ahmed S, 2005, QUAL LIFE RES, V14, P611, DOI 10.1007/s11136-004-3708-0; Andersen Christian K, 2004, Health Qual Life Outcomes, V2, P52, DOI 10.1186/1477-7525-2-52; Behari A, 2005, PARKINSONISM RELAT D, V11, P221, DOI 10.1016/j.parkreldis.2004.12.005; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bluvol A, 2004, J ADV NURS, V48, P322, DOI 10.1111/j.1365-2648.2004.03004.x; Bohannon RW, 2004, INT J REHABIL RES, V27, P151, DOI 10.1097/01.mrr.0000127349.25287.de; Bohannon RW, 2004, INT J REHABIL RES, V27, P149, DOI 10.1097/01.mrr.0000127350.25287.08; Boter H, 2004, STROKE, V35, P2867, DOI 10.1161/01.STR.0000147717.57531.e5; Boyer F, 2004, INT J GERIATR PSYCH, V19, P1026, DOI 10.1002/gps.1191; Bullinger M, 2001, CURR PROB E, V16, P277; Callahan CD, 2005, REHABIL PSYCHOL, V50, P65, DOI 10.1037/0090-5550.50.1.65; Carlsson GE, 2004, DISABIL REHABIL, V26, P1373, DOI 10.1080/09638280400000211; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chapuis S, 2005, MOVEMENT DISORD, V20, P224, DOI 10.1002/mds.20279; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Clarke CE, 2004, MOVEMENT DISORD, V19, P491, DOI 10.1002/mds.20057; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; De Leo D, 1998, BEHAV MED, V24, P17, DOI 10.1080/08964289809596377; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Doyle PJ, 2004, J CLIN EPIDEMIOL, V57, P997, DOI 10.1016/j.jclinepi.2003.11.016; Edelman P, 2004, AGING MENT HEALTH, V8, P514, DOI 10.1080/13607860412331303801; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Erola T, 2005, PARKINSONISM RELAT D, V11, P89, DOI 10.1016/j.parkreldis.2004.08.006; Ettema TP, 2005, QUAL LIFE RES, V14, P675, DOI 10.1007/s11136-004-1258-0; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finlayson TL, 2004, AM J MANAG CARE, V10, P336; Fjaertoft H, 2004, CLIN REHABIL, V18, P580, DOI 10.1191/0269215504cr773oa; Foerch C, 2004, J NEUROL NEUROSUR PS, V75, P988, DOI 10.1136/jnnp.2003.021014; Gallien P., 2005, Annales de Readaptation et de Medecine Physique, V48, P225, DOI 10.1016/j.annrmp.2005.02.001; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; Goetz CG, 2004, MOVEMENT DISORD, V19, P1020, DOI 10.1002/mds.20213; Gokkaya NKO, 2005, INT J REHABIL RES, V28, P229, DOI 10.1097/00004356-200509000-00005; Haapaniemi TH, 2004, J NEUROL NEUROSUR PS, V75, P976, DOI 10.1136/jnnp.2003.015693; HEEL S, 2000, LEBENSQUALITAT GESUN, P243; HENRY JD, IN PRESS NEUROPSYCHO; Hoe J, 2005, AGE AGEING, V34, P130, DOI 10.1093/ageing/afi030; James BD, 2005, AM J GERIAT PSYCHIAT, V13, P484, DOI 10.1176/appi.ajgp.13.6.484; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Jonsson AC, 2005, STROKE, V36, P803, DOI 10.1161/01.STR.0000160873.32791.20; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Kapapa T, 2005, NEUROL REHABIL, V11, P21; Kern RZ, 2004, J CLIN EPIDEMIOL, V57, P1033, DOI 10.1016/j.jclinepi.2004.03.004; Kim DH, 2005, STROKE, V36, P792, DOI 10.1161/01.STR.0000157594.58180.97; Koller W, 2005, J NEURAL TRANSM, V112, P221, DOI 10.1007/s00702-004-0184-1; Lai JCK, 2004, J TELEMED TELECARE, V10, P199, DOI 10.1258/1357633041424340; Leeds L, 2004, CLIN REHABIL, V18, P924, DOI 10.1191/0269215504cr807oa; Lezcano E, 2004, EUR J NEUROL, V11, P451, DOI 10.1111/j.1468-1331.2004.00804.x; Lobello SG, 2004, BRAIN INJURY, V18, P1127, DOI 10.1080/02699050410001672378; Ma HI, 2005, QUAL LIFE RES, V14, P565, DOI 10.1007/s11136-004-0687-0; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Martin-Cook K, 2005, DEMENT GERIATR COGN, V19, P82, DOI 10.1159/000082353; McMillan AS, 2005, J ORAL REHABIL, V32, P495, DOI 10.1111/j.1365-2842.2005.01451.x; McRae C, 2004, ARCH GEN PSYCHIAT, V61, P412, DOI 10.1001/archpsyc.61.4.412; Merchant C, 2004, J CLIN NURS, V13, P105, DOI 10.1111/j.1365-2702.2004.01050.x; Meyers AR, 2000, ARCH NEUROL-CHICAGO, V57, P1224, DOI 10.1001/archneur.57.8.1224; Moon YS, 2004, J NEUROL SCI, V224, P37, DOI 10.1016/j.jns.2004.05.018; Muller-Nordhorn J, 2005, NEUROEPIDEMIOLOGY, V24, P196, DOI 10.1159/000084712; Murrell R, 1999, NEUROPSYCHOL REV, V9, P209, DOI 10.1023/A:1021686606648; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Nyholm D, 2005, NEUROLOGY, V64, P216, DOI 10.1212/01.WNL.0000149637.70961.4C; Olanow CW, 2004, ARCH NEUROL-CHICAGO, V61, P1563, DOI 10.1001/archneur.61.10.1563; Onofrj M, 2004, J NEURAL TRANSM, V111, P1053, DOI 10.1007/s00702-004-0149-4; Perry J, 2005, AM J MENT RETARD, V110, P121, DOI 10.1352/0895-8017(2005)110<121:FAWOIC>2.0.CO;2; PICKARD SA, 2005, QUAL LIFE RES, V14, P207; Quittenbam BH, 2004, PARKINSONISM RELAT D, V10, P129, DOI 10.1016/j.parkreldis.2003.12.001; Reichmann H, 2005, ACTA NEUROL SCAND, V111, P21, DOI 10.1111/j.1600-0404.2004.00363.x; Riemsma R P, 2001, Health Technol Assess, V5, P1; Saeki Satoru, 2005, Journal of UOEH, V27, P171; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Salter K, 2005, DISABIL REHABIL, V27, P507, DOI 10.1080/0963828040008552; Samsa GP, 2004, J REHABIL RES DEV, V41, P279, DOI 10.1682/JRRD.2003.08.0117; Sands LP, 2004, AM J GERIAT PSYCHIAT, V12, P272, DOI 10.1176/appi.ajgp.12.3.272; Schielke E, 2005, J NEUROL, V252, P648, DOI 10.1007/s00415-005-0711-5; Selwood A, 2005, INT J GERIATR PSYCH, V20, P232, DOI 10.1002/gps.1271; Serrano-Duenas M, 2004, PARKINSONISM RELAT D, V10, P433, DOI 10.1016/j.parkreldis.2004.05.002; Smith KW, 1999, QUAL LIFE RES, V8, P447, DOI 10.1023/A:1008928518577; Smith SC, 2005, HEALTH TECHNOL ASSES, V9, P1; Studenski S, 2005, STROKE, V36, P1764, DOI 10.1161/01.STR.0000174192.87887.70; Sturm JW, 2004, STROKE, V35, P2340, DOI 10.1161/01.STR.0000141977.18520.3b; Tan LCS, 2004, PARKINSONISM RELAT D, V10, P493, DOI 10.1016/j.parkreldis.2004.05.007; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; The WHOQOL Group, 1993, QUAL LIFE RES, V2, P153, DOI DOI 10.1007/BF00435734; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; VONSTEINBUECHEL N, 1998, NEUE HERAUSFORDERUNG, V7, P50; WARE JE, 1995, INT J TECHNOL ASSESS, V11, P525, DOI 10.1017/S0266462300008710; Widar M, 2004, J CLIN NURS, V13, P497, DOI 10.1046/j.1365-2702.2003.00815.x; Zimmerman GJ, 2004, ACTA NEUROCHIR, V146, P1293, DOI 10.1007/s00701-004-0385-2	90	37	37	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2005	18	6					681	691		10.1097/01.wco.0000194140.56429.75			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	989MT	WOS:000233678800010	16280680				2021-06-18	
J	Avesani, R; Salvi, L; Rigoli, G; Gambini, MG				Avesani, R; Salvi, L; Rigoli, G; Gambini, MG			Reintegration after severe brain injury: A retrospective study	BRAIN INJURY			English	Article							FINNISH PATIENTS 5; ACUTE PREDICTORS; RETURN; WORK; REHABILITATION; EMPLOYMENT; REEMPLOYMENT; PROGRAM	Primary objective: The evaluation of school and work reintegration of patients following severe brain injury and of the relationship between the most common (early and late) prognostic indicators and reintegration itself. Research design: A retrospective study on a population of 353 patients consecutively admitted to an intensive rehabilitation unit (S. Cuore Hospital, Negrar, Italy) from 1991-1999. Methods and procedures: Evaluation of school and work outcome in this population up to December 2001 (follow-up from 2-10 years post-trauma). Data collection was made using the EBIS (European Brain Injury Society) protocol. Results: In December 2001, 53% of those previously working had returned to competitive work; 76.5% of students were continuing with their studies or had progressed into work. There was a significant difference between employed and non-employed groups in terms of GCS, post-traumatic amnesia (PTA), in-patient rehabilitation length of stay (LOS) and GOS at 6 and at 12 months post-injury. Conclusions: The data confirm the predictive value of the indices used regarding work reintegration in TBI patients. Nevertheless, prolonged and intensive rehabilitation programmes can lead to high re-employment rates in patients whose initial prognosis seemed very poor.	Don Calabria Hosp, Rehabil Serv, I-37024 Verona, Italy	Salvi, L (corresponding author), Don Calabria Hosp, Rehabil Serv, Via Don Sempreboni 5, I-37024 Verona, Italy.	lukesalvi@libero.it		Gambini, Maria Grazia/0000-0002-6211-2169			Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Avesani R, 2002, ACT NEUR S, V79, P45; BROOKS DN, 1995, DOCUMENT EUROPEEN EV; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PITIDIS A, 1998, C MEAS BURD INJ ECOS; PITIDIS A, 1997, HLTH ORG, V3, P102; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; 2003, OFFICIAL GAZETT 0312	21	37	38	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					933	939		10.1080/02699050400002371			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500008	16299934				2021-06-18	
J	Da Rocha, AB; Zanoni, C; De Freitas, GR; Himelfarb, S; Schneider, RF; Grivicich, I; Borges, L; Schwartsmann, G; Kaufmann, M; Regner, A				Da Rocha, AB; Zanoni, C; De Freitas, GR; Himelfarb, S; Schneider, RF; Grivicich, I; Borges, L; Schwartsmann, G; Kaufmann, M; Regner, A			Serum Hsp70 as an early predictor of fatal outcome after severe traumatic brain injury in males	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; heat shock proteins; humans; outcome; traumatic brain injury	HEAT-SHOCK PROTEINS; CEREBRAL-CORTEX; CELL-DEATH; HEAT-SHOCK-PROTEIN-70; EXPRESSION; APOPTOSIS; CHAPERONE; STRESS; PROTECTION; REGULATORS	Severe traumatic brain injury (TBI) is associated with a 35-70% mortality rate. Biochemical markers of cellular stress/injury have been proposed to indicate outcome after head injury. Therefore, our aim was to determine whether Hsp70 could be detected in the serum of patients after severe TBI and whether serum levels of Hsp70 correlate with primary outcome in severe TBI. Twenty consecutive male patients, victims of severe TBI (GCS 3-8), were enrolled in this prospective study. Clinical outcome variables of severe TBI comprised: survival, time for ICU discharge, and neurological assessment using the Glasgow Outcome Scale (GOS) at the ICU discharge. Venous blood samples were taken at admission in the ICU (study entry), 24 h later, and 7 days later. A control group consisting of eight healthy male volunteers was also included. Serum Hsp70 levels were measured by an enzyme-linked immunosorbent assay. Mean serum Hsp70 concentrations were significantly increased in the TBI (97.6, 48.1, and 39.2 ng/mL, at study entry, 24 h later, and 7 days later, respectively) compared with the control group (12.2 ng/mL). Severe TBI was associated with a 50% mortality rate. On study entry (mean time 10.8 h after injury), a higher proportion of patients with fatal outcome had elevated serum Hsp70 (mean 143.5 ng/mL) concentrations when compared with survivors (mean 51.6 ng/mL). There was a significant correlation between higher initial serum Hsp70 concentrations and fatal outcome. The sensitivity of serum Hsp70 predicting mortality according to the cutoff of 62 ng/mL is 70% within 20 h after injury. Increased serum Hsp70 levels may constitute an early predictor of unfavorable outcome in severe TBI in males.	ULBRA, Lab Marcadores Estresse Celular, Ctr Pesquisas Ciencias Med, BR-92420280 Canoas, RS, Brazil; ULBRA, Programa Posgrad Diagnost Genet & Mol, BR-92420280 Canoas, RS, Brazil; Fed Univ Rio De Janeiro, Serv Neurol, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; S Amer Off Drug Dev, Porto Alegre, RS, Brazil; Hosp Cristo Redentor, Unidade Terapia Intensiva, Porto Alegre, RS, Brazil; Hosp Municipal Pronto Socorro, SAMU, Porto Alegre, RS, Brazil	Regner, A (corresponding author), ULBRA, Lab Marcadores Estresse Celular, Ctr Pesquisas Ciencias Med, Miguel Tostes 101,Predio 22,5 Andar, BR-92420280 Canoas, RS, Brazil.	regner@uol.com.br	Grivicich, Ivana/A-6777-2013; Schwartsmann, Gilberto/G-4256-2016; Regner, Andrea/M-2596-2014	Grivicich, Ivana/0000-0001-9820-5730; Schwartsmann, Gilberto/0000-0002-7850-1644; Regner, Andrea/0000-0002-6657-7991			Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Calabrese V, 2000, J NEUROSCI RES, V60, P613, DOI 10.1002/(SICI)1097-4547(20000601)60:5<613::AID-JNR6>3.0.CO;2-8; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Dinh HKB, 2001, PHYSIOL GENOMICS, V7, P3; Duff D, 2003, AXONE, V23, P18; Dutcher SA, 1998, J NEUROTRAUM, V15, P421, DOI 10.1089/neu.1998.15.421; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; JACQUIERSARLIN MR, 1994, EXPERIENTIA, V50, P1031, DOI 10.1007/BF01923458; KRAUS JF, 1996, NEUROTRAUMA, P13; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Okada M, 2004, J BIOL CHEM, V279, P4221, DOI 10.1074/jbc.M309014200; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Reynolds LPR, 2003, CEREBELLUM, V2, P171, DOI 10.1080/14734220310016114; Rokutan Kazuhito, 1998, Journal of Medical Investigation, V44, P137; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.3.CO;2-8; Seidberg NA, 2003, J NEUROCHEM, V84, P514, DOI 10.1046/j.1471-4159.2003.01547.x; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; Todryk SM, 2003, IMMUNOLOGY, V110, P1, DOI 10.1046/j.1365-2567.2003.01725.x; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; YUAN XQ, 1996, NEUROENDOCRINOLOGY, V12, P209; ZAGARA G, 1992, J NEUROSURG SCI, V35, P77; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zugel U, 1999, CLIN MICROBIOL REV, V12, P19, DOI 10.1128/CMR.12.1.19; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	45	37	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					966	977		10.1089/neu.2005.22.966			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600004	16156712				2021-06-18	
J	Childs, C; Vail, A; Protheroe, R; King, AT; Dark, PM				Childs, C; Vail, A; Protheroe, R; King, AT; Dark, PM			Differences between brain and rectal temperatures during routine critical care of patients with severe traumatic brain injury	ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the Society-of-British-Neurological-Surgeons	SEP 17-19, 2003	Cardiff, WALES	Soc British Neurol Surg			SEVERE SUBARACHNOID HEMORRHAGE; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; INTENSIVE-CARE; SYSTEMIC TEMPERATURE; BODY-TEMPERATURE; ACUTE STROKE; HYPERTHERMIA; ISCHEMIA; WORSENS	Theoretical models suggest that small differences only exist between brain and body temperature in health. Once the brain is injured, brain temperature is generally regarded to rise above body temperature. However, since reports of the magnitude of the temperature gradient between brain and body vary, it is still not clear whether conventional body temperature monitoring accurately predicts brain temperature at all times. In this prospective, descriptive study, 20 adults with severe primary brain trauma were studied during their stay in the neurointensive care unit. Brain temperature ranged from 33.4 to 39.9 degrees C. Comparisons between paired brain and rectal temperature measurements revealed no evidence of a systematic difference [mean difference -0.04 degrees C (range -0.13 to 0.05 degrees C, 95% CI), p = 0.39]. Contrary to popular belief, brain temperature did not exceed systemic temperature in this relatively homogeneous patient series. The mean values masked inconsistent and unpredictable individual brain-rectal temperature differences (range 1.8 to -2.9 degrees C) and reversal of the brain-body temperature gradient occurred in some patients. Brain temperature could not be predicted from body temperature at all times.	Univ Manchester, Hope Hosp, Div Med & Neurosci, Salford M6 8HD, Lancs, England; Univ Manchester, Biostat Grp, Salford M6 8HD, Lancs, England; Hope Hosp, Dept Neurosurg, Salford M6 8HD, Lancs, England	Childs, C (corresponding author), Univ Manchester, Hope Hosp, Div Med & Neurosci, Salford M6 8HD, Lancs, England.	cchilds@manchester.ac.uk	Childs, Charmaine/G-9928-2012; King, Andrew/AAR-1656-2020	Dark, Paul/0000-0003-3309-0164; Vail, Andy/0000-0001-8274-2726; King, Andrew/0000-0002-6546-7248			*ASS ADV AUT MED, 1998, ABBR INJ SCAL 1990 R; Awaya S, 1993, Nihon Ika Daigaku Zasshi, V60, P37; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bommadevara M, 2002, BIOMECH MODEL MECHAN, V1, P137, DOI 10.1007/s10237-002-0011-2; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Childs C, 2004, ANAESTHESIA, V59, P192, DOI 10.1111/j.1365-2044.2003.03638.x; Childs C, 1999, ARCH DIS CHILD, V80, P262, DOI 10.1136/adc.80.3.262; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Fountas KN, 2003, J NEUROSURG ANESTH, V15, P87, DOI 10.1097/00008506-200304000-00004; GRAF W, 1959, ACTA PHYSL SCAND, V46, P38; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Lefrant JY, 2003, INTENS CARE MED, V29, P414, DOI 10.1007/s00134-002-1619-5; Mcilvoy Laura, 2004, J Neurosci Nurs, V36, P23; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Otawara Y, 2003, SURG NEUROL, V60, P549, DOI 10.1016/S0090-3019(03)00293-3; Otawara Y, 2003, SURG NEUROL, V60, P159, DOI 10.1016/S0090-3019(03)00083-1; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Sakurai A, 2003, ACTA NEUROCHIR SUPPL, V86, P251; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Zhu L, 2001, MED BIOL ENG COMPUT, V39, P681, DOI 10.1007/BF02345442	33	37	39	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	AUG	2005	60	8					759	765		10.1111/j.1365-2044.2005.04193.x			7	Anesthesiology	Anesthesiology	945HL	WOS:000230493500005	16029224	Bronze			2021-06-18	
J	Belanger, HG; Scott, SG; Scholten, J; Curtiss, G; Vanderploeg, RD				Belanger, HG; Scott, SG; Scholten, J; Curtiss, G; Vanderploeg, RD			Utility of mechanism-of-injury-based assessment and treatment: Blast Injury Program case illustration	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast injury; case-finding; diagnosis; mechanism; parallel; prevention; rehabilitation; sequential; traumatic brain injury; veteran	TRAUMATIC BRAIN-INJURY; SECONDARY PREVENTION; MILD; INVOLVEMENT; DECISION; HISTORY; FACTS	While medicine typically proceeds in a sequential fashion based on primary symptoms, sometimes relying on a parallel, mechanism-of-injury-based approach is advantageous, particularly when the mechanism of injury is associated with a variety of known sequelae. A mechanism-of-injury-based approach relies on knowledge of the typical sequelae associated with that mechanism Of injury to guide assessment and treatment. Thus, it represents an active, rather than passive, case-finding approach. This article describes an example of a mechanism-of-injury-based program, namely, a Blast Injury Program at the James A. Haley Veterans Hospital in Tampa, Florida. Case examples illustrate the utility of this approach with regard to more comprehensive assessment and treatment, as well as the possibility for secondary prevention.	James A Haley Vet Hosp, Dept Vet Affairs VA, Tampa, FL 33612 USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Henry M Jackson Fdn Adv Mil Med, Rockville, MD USA; Def & Vet Brain Injury Ctr, Washington, DC USA; Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33612 USA	Belanger, HG (corresponding author), James A Haley Vet Hosp, Dept Vet Affairs VA, Tampa, FL 33612 USA.	Heather.Belanger@med.va.gov	Curtiss, Glenn/ABB-5566-2020				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arlinger S., 2003, INT J AUDIOL S2, V42; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Gonzalez D, 2002, CALCIFIED TISSUE INT, V71, P141, DOI 10.1007/s00223-001-1027-9; Guy R J, 2000, J R Nav Med Serv, V86, P27; Hafner H, 2004, EUR ARCH PSY CLIN N, V254, P117, DOI 10.1007/s00406-004-0508-z; Helgason CM, 2002, THROMB HAEMOSTASIS, V88, P210; HILL JF, 1979, ANN ROY COLL SURG, V61, P4; Ho PM, 2004, J AM COLL CARDIOL, V43, P1517, DOI 10.1016/j.jacc.2003.12.037; Hull JB, 1996, J TRAUMA, V40, pS198, DOI 10.1097/00005373-199603001-00044; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; KUIPERS B, 1984, COGNITIVE SCI, V8, P363; Marks D, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI [DOI 10.3310/HTA4290, 10.3310/hta4290]; MARTINO RL, 1994, SCIENCE, V265, P902, DOI 10.1126/science.8052847; McSherry D, 1997, ARTIF INTELL MED, V10, P269, DOI 10.1016/S0933-3657(97)00396-5; Norman A, 2001, CAN FAM PHYSICIAN, V47, P2009; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; Sosin DM, 1996, BRAIN INJURY, V10, P47; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zunic G, 2000, NITRIC OXIDE-BIOL CH, V4, P123, DOI 10.1006/niox.2000.0276	30	37	37	0	2	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	JUL-AUG	2005	42	4					403	411		10.1682/JRRD.2004.08.0095			9	Rehabilitation	Rehabilitation	995NB	WOS:000234105900005	16320137				2021-06-18	
J	Majetschak, M; King, DR; Krehmeier, U; Busby, LT; Thome, C; Vajkoczy, S; Proctor, KG				Majetschak, M; King, DR; Krehmeier, U; Busby, LT; Thome, C; Vajkoczy, S; Proctor, KG			Ubiquitin immunoreactivity in cerebrospinal fluid after traumatic brain injury: Clinical and experimental findings	CRITICAL CARE MEDICINE			English	Article						ubiquitin; cerebrospinal fluid; traumatic brain injury; nontraumatic subarachnoid hemorrhage; hemolysis; swine	EXTRACELLULAR UBIQUITIN; EXOGENOUS UBIQUITIN; RESUSCITATION; APOPTOSIS; CELLS; PRESSURE; DISEASE; BLOOD; CSF	Objective: Recent data indicate that ubiquitin is increased in serum after trauma and might regulate immune functions. Its cellular source is unknown. Because there have been no previous studies after traumatic brain injury (TBI), we determined whether ubiquitin immunoreactivity is increased in cerebrospinal fluid (CSF) after TBI. Design and Setting: Prospective observational study of patients, with a subsequent interventional study of animals. Subjects: The subjects were 14 patients with TBI, five patients with nontraumatic subarachnoid hemorrhage, ten nonneurologic controls, and seven cross-bred swine. Interventions: Standardized TBI. Measurements and Main Results: Ubiquitin immunoreactivity was analyzed by enzyme-linked immunosorbent assay and immunoblotting. Hemolysis was assessed spectrophotometrically. CSF ubiquitin levels (mean +/- SD) were 19 +/- 3 ng/mL in nonneurologic control patients, 81 +/- 48 ng/mL at 7 +/- 2 hrs after TBI (p = .002), and at the end of operation in patients with nontraumatic subarachnoid hemorrhage they were 104 68 ng/mL (p = .001). CSF and serum ubiquitin were measured for 7 days in six patients with TBI. In survivors (n = 3), CSF ubiquitin levels progressively recovered, whereas in nonsurvivors (n = 3), the levels increased until death. There was no difference in serum ubiquitin levels between survivors/nonsurvivors and there was no correlation between serum and CSF ubiquitin levels. In swine, CSF ubiquitin levels peaked at 8- to 30-fold higher than baseline at 60 min post-TBI and then declined with a half-life of 1.3 hrs. In CSF with hemolysis, peak ubiquitin levels were five-fold higher than without hemolysis (p < .05). Ubiquitin and hemoglobin correlations in CSF and after in vitro lysis of erythrocytes suggested that erythrolysis could account for no more than 23 +/- 16% of the CSF ubiquitin. Conclusions: CSF ubiquitin levels are increased more than four-fold in patients after TBI and nontraumatic subarachnoid hemorrhage. Peak CSF ubiquitin measurements in patients with TBI probably underestimated the actual peak, on the basis of data from the animal model. The progressive rise in CSF ubiquitin in patients with TBI who died suggests that lack of clearance could reflect lethal progression to irreversible brain damage. Erythrolysis is one potential source of CSF ubiquitin.	Univ Miami, Miller Sch Med, Div Trauma, DeWitt Daughtry Family Dept Surg, Miami, FL USA; Univ Miami, Miller Sch Med, Div Surg Crit Care, DeWitt Daughtry Family Dept Surg, Miami, FL USA; Univ Heidelberg Hosp, Dept Trauma Surg, D-68135 Mannheim, Germany; Univ Heidelberg Hosp, Dept Neurosurg, D-68135 Mannheim, Germany; Univ Heidelberg Hosp, Dept Anaesthesiol, D-68135 Mannheim, Germany; Univ Heidelberg, Heidelberg, Germany	Majetschak, M (corresponding author), Univ Miami, Miller Sch Med, Div Trauma, DeWitt Daughtry Family Dept Surg, Miami, FL USA.			King, David/0000-0003-1028-1478			Cruickshank AM, 2001, J CLIN PATHOL, V54, P827, DOI 10.1136/jcp.54.11.827; Daino H, 2000, BLOOD, V95, P2577; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; GOETZ CG, 2003, TXB CLIN NEUROLOGY, P513; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4; Kurimura M, 1997, Rinsho Shinkeigaku, V37, P963; Majetschak M, 2004, SURGERY, V135, P536, DOI 10.1016/j.surg.2003.09.006; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; Majetschak M, 2003, BLOOD, V101, P1882, DOI 10.1182/blood-2002-03-0918; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Moore DJ, 2003, NEUROMOL MED, V4, P95, DOI 10.1385/NMM:4:1-2:95; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Ohe Y, 1996, J NEUROCHEM, V67, P964; *ROYAL SWED AC SCI, 2004, ADV INF NOB PRIZ CHE; Takada K, 1997, CLIN CHEM, V43, P1188; Yin W, 2002, J CLIN NEUROSCI, V9, P425, DOI 10.1054/jocn.2001.0968	23	37	38	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUL	2005	33	7					1589	1594		10.1097/01.CCM.0000169883.41245.23			6	Critical Care Medicine	General & Internal Medicine	947GB	WOS:000230630300017	16003067				2021-06-18	
J	McAdoo, JD; Warner, DS; Goldberg, RN; Vitek, MP; Pearlstein, R; Laskowitz, DT				McAdoo, JD; Warner, DS; Goldberg, RN; Vitek, MP; Pearlstein, R; Laskowitz, DT			Intrathecal. administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury	NEUROSCIENCE LETTERS			English	Article						apolipoprotein E; neuroprotection; hypoxia-ischemia; MK-801; perinatal hypoxia-ischemia	E-DEFICIENT MICE; APOLIPOPROTEIN-E POLYMORPHISM; GLIAL CELL-CULTURES; CLOSED-HEAD INJURY; BRAIN-INJURY; CEREBRAL-ISCHEMIA; MIMETIC PEPTIDES; E PROTECTS; RAT; EXCITOTOXICITY	Perinatal hypoxic-ischemic brain injury remains a significant clinical problem for which there remains no adequate therapeutic intervention. Apolipoprotein E (apoE) is a 299 amino acid protein that has been demonstrated to modify functional recovery following acute ischemic and traumatic brain injury. The aim of the current study was to evaluate whether administration of an apoE-derived peptide could reduce CNS injury in a rodent model of perinatal hypoxia and ischemia. We found that intrathecal delivery of an apoE-mimetic peptide caused a significant reduction in post-ischemic brain necrosis, as reflected by decreased reduction in ipsilateral brain weight 7 days following hypoxic-ischemic injury. These results suggest that administration of an apoE-derived therapeutic peptide represents a novel therapeutic strategy in the clinical setting of perinatal hypoxic-ischemic injury. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Duke Univ, Med Ctr, Neonatal Perinatal Res Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Cognosci Inc, Res Triangle Pk, NC 27709 USA	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Neonatal Perinatal Res Inst, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD043494] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD043494] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS4487-01, R01NS38994-01A1] Funding Source: Medline		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GIDDAY JM, 1994, NEUROSCI LETT, V168, P221, DOI 10.1016/0304-3940(94)90455-3; GOLDSTEIN RF, 2001, PEDIATR RES, V49, P352; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3	22	37	39	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 24	2005	381	3					305	308		10.1016/j.neulet.2005.02.036			4	Neurosciences	Neurosciences & Neurology	932MR	WOS:000229558300021	15896489				2021-06-18	
J	Nguyen, XV; Masse, J; Kumar, A; Vijitruth, R; Kulik, C; Liu, M; Choi, DY; Foster, TC; Usynin, I; Bakalkin, G; Bing, GY				Nguyen, XV; Masse, J; Kumar, A; Vijitruth, R; Kulik, C; Liu, M; Choi, DY; Foster, TC; Usynin, I; Bakalkin, G; Bing, GY			Prodynorphin knockout mice demonstrate diminished age-associated impairment in spatial water maze performance	BEHAVIOURAL BRAIN RESEARCH			English	Article						dynorphin; opioid; aging; Morris water maze; learning; memory; spatial; knockout mice	KAPPA-OPIOID RECEPTOR; GUINEA-PIG HIPPOCAMPUS; DENTATE GYRUS; DYNORPHIN PEPTIDES; SPINAL-CORD; RATS; MEMORY; EXPRESSION; BRAIN; BLOCK	Dynorphins, endogenous kappa-opioid agonists widely expressed in the central nervous system, have been reported to increase following diverse pathophysiological processes, including excitotoxicity, chronic inflammation. and traumatic injury. These peptides have been implicated in cognitive impairment, especially that associated with aging. To determine whether absence of dynorphin confers any beneficial effect on spatial learning and memory, knockout mice lacking the coding exons of the gene encoding its precursor prodynorphin (Pdyn) were tested in a water maze task. Learning and memory assessment using a 3-day water maze protocol demonstrated that aged Pdyn knockout mice (13-17 months) perform comparatively better than similarly aged wild-type (WT) mice, based on acquisition and retention probe trial indices. There was no genotype effect on performance in the cued version of the swim task nor on average swim speed, suggesting the observed genotype effects are likely attributable to differences in cognitive rather than motor function. Young (3-6 months) mice performed significantly better than aged mice, but in young mice, no genotype difference was observed. To investigate the relationship between aging and brain dynorphin expression in mice, we examined dynorphin peptide levels at varying ages in hippocampus and frontal cortex of WT 129SvEv mice. Quantitative radioimmunoassay demonstrated that dynorphin A levels in frontal cortex, but not hippocampus, of 12- and 24-month mice were significantly elevated compared to 3-month mice. Although the underlying mechanisms have yet to be elucidated, the results suggest that chronic increases in endogenous dynorphin expression with age, especially in frontal cortex, may adversely affect learning and memory. (c) 2005 Elsevier B.V. All rights reserved.	Univ Kentucky, Ctr Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden	Bing, GY (corresponding author), Univ Kentucky, Ctr Med, Dept Anat & Neurobiol, 800 Rose St,310 Whitney Henrickson Facil, Lexington, KY 40536 USA.	gbing@uky.edu	bing, guoying/F-7084-2012; Usynin, Ivan F/A-4945-2017; Nguyen, Xuan V/G-5532-2012	Nguyen, Xuan V/0000-0002-2617-1938; Bakalkin, Georgy/0000-0002-8074-9833; Usynin, Ivan/0000-0003-1752-9034; Bing, Guoying/0000-0003-0609-8152	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F30MH065055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG014979] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG14979] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65055-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 044157] Funding Source: Medline		CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHEN L, 1995, J PHYSIOL-LONDON, V482, P575, DOI 10.1113/jphysiol.1995.sp020541; Chen L, 1998, J PHARMACOL EXP THER, V284, P826; CHEN L, 1995, J NEUROSCI, V15, P4602; CHRISTENSSONNYLANDER I, 1985, NEUROPEPTIDES, V6, P391, DOI 10.1016/0143-4179(85)90137-4; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; Croll SD, 1999, PHARMACOL BIOCHEM BE, V64, P625, DOI 10.1016/S0091-3057(99)00122-7; Diez M, 2000, NEUROSCIENCE, V100, P259, DOI 10.1016/S0306-4522(00)00261-X; Foster TC, 1999, BRAIN RES REV, V30, P236, DOI 10.1016/S0165-0173(99)00017-X; Fugger HN, 1998, HORM BEHAV, V34, P163, DOI 10.1006/hbeh.1998.1475; GAGE FH, 1984, NEUROBIOL AGING, V5, P43, DOI 10.1016/0197-4580(84)90084-8; GALLAGHER M, 1993, BEHAV BRAIN RES, V57, P155, DOI 10.1016/0166-4328(93)90131-9; GARZON J, 1984, BRAIN RES, V302, P392, DOI 10.1016/0006-8993(84)90256-7; Hauser KF, 1999, EXP NEUROL, V160, P361, DOI 10.1006/exnr.1999.7235; Heron A, 1996, NEUROPEPTIDES, V30, P355, DOI 10.1016/S0143-4179(96)90024-4; HILLER JM, 1987, BRAIN RES, V406, P17, DOI 10.1016/0006-8993(87)90764-5; Hurd YL, 1999, ANN NY ACAD SCI, V877, P499, DOI 10.1111/j.1749-6632.1999.tb09285.x; INTROINICOLLISON IB, 1987, PSYCHOBIOLOGY, V15, P171; JARRARD LE, 1978, J COMP PHYSIOL PSYCH, V92, P1119, DOI 10.1037/h0077516; JIANG HK, 1989, P NATL ACAD SCI USA, V86, P2948, DOI 10.1073/pnas.86.8.2948; Kessels RPC, 2000, NEUROPSYCHOL REV, V10, P101, DOI 10.1023/A:1009016820717; KHACHATURIAN H, 1982, PEPTIDES, V3, P941, DOI 10.1016/0196-9781(82)90063-8; Kotz CM, 2004, NEUROBIOL AGING, V25, P1343, DOI 10.1016/j.neurobiolaging.2004.02.025; Magnusson KR, 2003, BEHAV NEUROSCI, V117, P485, DOI 10.1037/0735-7044.117.3.485; MCDANIEL KL, 1990, PHARMACOL BIOCHEM BE, V35, P429, DOI 10.1016/0091-3057(90)90180-P; MCGINTY JF, 1983, P NATL ACAD SCI-BIOL, V80, P589, DOI 10.1073/pnas.80.2.589; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NYLANDER I, 1991, NEUROPHARMACOLOGY, V30, P1219, DOI 10.1016/0028-3908(91)90168-B; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; Pliakas AM, 2001, J NEUROSCI, V21, P7397, DOI 10.1523/JNEUROSCI.21-18-07397.2001; Ploj K, 2001, PHARMACOL BIOCHEM BE, V69, P173, DOI 10.1016/S0091-3057(01)00511-1; RAPP PR, 1987, BEHAV NEUROSCI, V101, P3, DOI 10.1037/0735-7044.101.1.3; Redell JB, 2003, EXP BIOL MED, V228, P261; REISBERG B, 1983, NEW ENGL J MED, V308, P721; Risser D, 1996, NEUROSCI LETT, V203, P111, DOI 10.1016/0304-3940(95)12275-3; Sandin J, 1998, NEUROSCIENCE, V85, P375, DOI 10.1016/S0306-4522(97)00605-2; Sharifi N, 2001, MOL BRAIN RES, V86, P70, DOI 10.1016/S0169-328X(00)00264-3; Tan-No K, 2001, EXP CELL RES, V269, P54, DOI 10.1006/excr.2001.5309; Tang QB, 1999, J PHARMACOL EXP THER, V291, P760; TERMAN GW, 1994, J NEUROSCI, V14, P4740; Terman GW, 2000, J NEUROSCI, V20, P4379, DOI 10.1523/JNEUROSCI.20-12-04379.2000; WAGNER JJ, 1993, NATURE, V363, P451, DOI 10.1038/363451a0; WAGNER JJ, 1992, J NEUROSCI, V12, P132; WATSON SJ, 1982, LIFE SCI, V31, P1773, DOI 10.1016/0024-3205(82)90207-7; WATSON SJ, 1982, SCIENCE, V218, P1134, DOI 10.1126/science.6128790; WEISSKOPF MG, 1993, NATURE, V365, P188, DOI 10.1038/365188a0; Woods A, 2001, NEUROCHEM RES, V26, P395, DOI 10.1023/A:1010903215566; ZAMIR N, 1985, NEUROSCIENCE, V15, P1025, DOI 10.1016/0306-4522(85)90251-9	50	37	38	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 20	2005	161	2					254	262		10.1016/j.bbr.2005.02.010			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	935UT	WOS:000229809600011	15922052				2021-06-18	
J	Fu, ES; Tummala, RP				Fu, Eugene S.; Tummala, Ramachandra P.			Neuroprotection in brain and spinal cord trauma	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						neuroprotection; neurotrauma; spinal cord injury; traumatic brain injury		Purpose of review Traumatic brain and spinal cord injuries continue to be a public health problem. These types of injuries often occur in early adulthood and have a major impact for society. This review discusses strategies and therapeutic agents for perioperative neuroprotection in the management of brain and spinal cord trauma. Recent findings There are no definitive drugs or strategies that can be utilized to provide perioperative neuroprotection in brain and spinal cord trauma patients. Phase III trials of several pharmacologic agents, including inhibitors of oxidative and excitotoxic injury, have been unable to demonstrate clinical efficacy. Although experimental animal data for hypothermia have been promising over the years, clinical application of therapeutic hypothermia cannot be recommended for routine use in neurotrauma patients. Administration of methylprednisolone, which has become common practice in acute spinal cord injury, has come under close scrutiny. Various experimental animal investigations suggest that potential therapeutic agents include estrogen, progesterone, minocycline, erythropoietin, and magnesium. Summary The main priority in the initial treatment of brain and spinal cord trauma is to maintain oxygenation and perfusion in order to avoid aggravating secondary injury. Future progress will depend on the translation of neuroprotective strategies into well designed clinical trials with promising outcomes.	[Fu, Eugene S.] Univ Miami, Dept Anesthesiol, Sch Med, Miami, FL 33136 USA; [Tummala, Ramachandra P.] Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA	Fu, ES (corresponding author), Univ Miami, Dept Anesthesiol, Sch Med, 1611 NW 12th Ave,C-301, Miami, FL 33136 USA.	efu@med.miami.edu					*AM ASS NEUR SURG, 2002, NEUROSURGERY S, V50, P63; Baughman Verna L, 2002, Anesthesiol Clin North Am, V20, P315, DOI 10.1016/S0889-8537(01)00004-9; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bedell Eric, 2002, Anesthesiol Clin North Am, V20, P417, DOI 10.1016/S0889-8537(01)00010-4; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kaptanoglu E, 2003, J CLIN NEUROSCI, V10, P329, DOI 10.1016/S0967-5868(03)00031-6; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Kramer JH, 2003, EXP BIOL MED, V228, P665; Lee JS, 2004, J NEUROTRAUM, V21, P549, DOI 10.1089/089771504774129883; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Limmroth V, 1996, BRIT J PHARMACOL, V117, P99, DOI 10.1111/j.1476-5381.1996.tb15160.x; Liu XZ, 1997, J NEUROSCI, V17, P5395; Maas AIR, 2004, ACT NEUR S, V89, P113; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Sasaki R, 2003, INTERNAL MED, V42, P142, DOI 10.2169/internalmedicine.42.142; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Short D, 2001, CURR OPIN NEUROL, V14, P759, DOI 10.1097/00019052-200112000-00013; Stevens RD, 2003, J NEUROSURG ANESTH, V15, P215, DOI 10.1097/00008506-200307000-00009; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suzer T, 1999, SPINAL CORD, V37, P480, DOI 10.1038/sj.sc.3100874; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Vink R, 2004, J AM COLL NUTR, V23, p538S, DOI 10.1080/07315724.2004.10719398; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Weissner C, 2001, J CEREB BLOOD FLOW M, V21, P857; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	59	37	44	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2005	18	2					181	187		10.1097/01.aco.0000162838.56344.88			7	Anesthesiology	Anesthesiology	V40ZO	WOS:000209516700012	16534336				2021-06-18	
J	Trentz, OA; Handschin, AE; Bestmann, L; Hoerstrup, SP; Trentz, OL; Platz, A				Trentz, OA; Handschin, AE; Bestmann, L; Hoerstrup, SP; Trentz, OL; Platz, A			Influence of brain injury on early posttraumatic bone metabolism	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; heterotopic ossification; osteocalcin; bone markers	CARBOXY-TERMINAL TELOPEPTIDE; PARATHYROID-HORMONE; HETEROTOPIC OSSIFICATION; ALKALINE-PHOSPHATASE; BIOCHEMICAL MARKERS; ENHANCED OSTEOGENESIS; GLUTAMATE RECEPTORS; SIGNALING PATHWAYS; NERVOUS-SYSTEM; HEAD-INJURY	Background. Various clinical studies and observations demonstrate enhanced osteogenesis in patients sustaining traumatic brain injury. It is presumed that the induction of this process starts early after trauma. The purpose of our study was to investigate humoral markers of bone metabolism during the early posttraumatic period, with special regard to traumatic brain injury. Methods. Serum concentrations of biochemical markers of bone metabolism (calcium, inorganic phosphorus, carboxyl-terminal propeptide of type 1 procollagen, pyridinoline cross-linked telopeptide domain of type 1 collagen, Ostase, osteocalcin, intact parathyroid hormone, and calcitonin) were measured in three different groups of 80 patients during the first posttraumatic week. Patients were categorized into three groups: group 1, fractures only; group II, isolated traumatic brain injury; and group III, traumatic brain injury in combination with fractures. Results. Osteocalcin levels were significantly lower in the presence of traumatic brain injury (p < .05). Elevated pyridinoline cross-linked telopeptide domain of type 1 collagen levels expressed enhanced bone resorption in all groups, but levels were significantly higher in the absence of traumatic brain injury (P < .05). Intact parathyroid hormone levels were significantly higher on days 0 and 1 in the combined presence of traumatic brain injury plus fractures. Conclusion: These results demonstrate an imbalance of bone formation and resorption parameters in patients with traumatic brain injury during the early posttraumatic period, suggesting a central regulation in bone formation. The lower levels of osteocalcin detected in this study may play an important role in patients with brain injury and the later development of posttraumatic heterotopic ossification.	Univ Zurich, Div Res, Zurich, Switzerland; Univ Zurich, Inst Clin Chem, Div Trauma Surg, Zurich, Switzerland; Univ Zurich, Inst Clin Chem, Cardiovasc Surg Clin, Zurich, Switzerland; Univ Zurich, Inst Clin Chem, Dept Surg, Zurich, Switzerland	Trentz, OA (corresponding author), Univ Zurich, Div Res, Zurich, Switzerland.						Ahmad AM, 2003, BONE, V32, P170, DOI 10.1016/S8756-3282(02)00952-3; Ahmed MAAS, 2000, J CELL PHYSIOL, V183, P163; Banovac K, 1997, SPINAL CORD, V35, P158, DOI 10.1038/sj.sc.3100380; Banse X, 2002, BONE, V31, P70, DOI 10.1016/S8756-3282(02)00800-1; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Broyles DL, 1998, CLIN CHEM, V44, P2139; Calvo MS, 1996, ENDOCR REV, V17, P333, DOI 10.1210/er.17.4.333; CHENU C, 1994, J CELL BIOL, V127, P1149, DOI 10.1083/jcb.127.4.1149; Chenu C, 2002, MICROSC RES TECHNIQ, V58, P70, DOI 10.1002/jemt.10120; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009-9120(97)00113-6; Cornish J, 1999, J BONE MINER RES, V14, P915, DOI 10.1359/jbmr.1999.14.6.915; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; ENGLAND TE, 1994, CLIN BIOCHEM, V27, P187, DOI 10.1016/0009-9120(94)90054-X; Fuller K, 1998, J ENDOCRINOL, V158, P341, DOI 10.1677/joe.0.1580341; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Goodman TA, 1997, ARTHRITIS RHEUM, V40, P1619, DOI 10.1002/art.1780400911; Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218; JENSEN LL, 1987, AM J PHYS MED REHAB, V66, P351; KERET D, 1990, CLIN ORTHOP RELAT R, V25, P254; Konttinen YT, 1996, ACTA ORTHOP SCAND, V67, P632, DOI 10.3109/17453679608997772; Li W, 2001, BONE, V29, P231, DOI 10.1016/S8756-3282(01)00572-5; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Merle B, 2003, J CELL BIOCHEM, V90, P424, DOI 10.1002/jcb.10625; Miyakawa M, 1996, ENDOCR J, V43, P701, DOI 10.1507/endocrj.43.701; RISTELI J, 1993, CLIN CHEM, V39, P635; ROACH HI, 1994, CELL BIOL INT, V18, P617, DOI 10.1006/cbir.1994.1088; Seibel MJ, 1999, J CLIN DENSITOM, V2, P299, DOI 10.1385/JCD:2:3:299; Sexton PM, 1999, CURR MED CHEM, V6, P1067; Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Takahashi M, 2003, J CLIN DENSITOM, V6, P211, DOI 10.1385/JCD:6:3:211; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Taniguchi T, 2003, INJURY, V34, P477, DOI 10.1016/S0020-1383(02)00380-7; TEASDALE G, 1974, LANCET, V2, P81; TRENTZ OA, 2001, EUR J TRAUMA, V2, P34; Watts NB, 1999, CLIN CHEM, V45, P1359; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wu YH, 2000, J BONE MINER RES, V15, P879, DOI 10.1359/jbmr.2000.15.5.879; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zaidi M, 2002, J CLIN INVEST, V110, P1769, DOI 10.1172/JCI200217425	44	37	46	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2005	33	2					399	406		10.1097/01.CCM.0000152221.87477.21			8	Critical Care Medicine	General & Internal Medicine	898LE	WOS:000227077500016	15699845				2021-06-18	
J	Hemphill, JC; Morabito, D; Farrant, M; Manley, GT				Hemphill, JC; Morabito, D; Farrant, M; Manley, GT			Brain tissue oxygen monitoring in intracerebral hemorrhage	NEUROCRITICAL CARE			English	Article						intracerebral hemorrhage; brain tissue oxygen tension; translational research; swine model	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW; BEDSIDE MICRODIALYSIS; NO EVIDENCE; TENSION; EDEMA; PO(2); AUTOREGULATION; GUIDELINES; VARIABLES	Introduction: Brain tissue oxygen (PbrO2) monitoring is an emerging technique for detection of secondary brain injury in neurocritical care. Although it has been extensively reported in traumatic brain injury and aneurysmal subarachnoid hemorrhage, its use in nontraumatic intracerebral hemorrhage (ICH) has not been well described. We report complementary preliminary studies in a large animal model and in patients that demonstrate the feasibility of PbrO2 monitoring after ICH. Methods: To assess early events after ICH, Licox Clark-type oxygen probes were inserted in the bilateral frontal white matter of four anesthetized swine that subsequently underwent right parietal hematoma formation in an experimental model of ICH. Intracranial pressure (ICP) was monitored as well. Seven patients with acute ICH, who were undergoing ICP monitoring as part of standard neurocritical care, had placement of a frontal oxygen probe, with subsequent monitoring for up to 7 days. Results: In the swine ICH model, a rise in ICP early after hematoma formation was accompanied by a decrease in ipsilateral and contralateral PbrO2. Secondary increases in hematoma volume resulted in further decreases in PbrO2 over the first hour after ICH. In patients undergoing oxygen monitoring, low PbrO2 (<15 mmHg) was common. In these patients, changes in FiO2, mean arterial pressure, and cerebral perfusion pressure (but not ICP) predicted subsequent change in PbrO2. Conclusion: Brain tissue oxygen monitoring is feasible in ICH patients, as well as in a swine model of ICH. Translational research that emphasizes complementary information derived from human and animal studies may yield additional insights not available from either alone.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; San Francisco Injury Ctr, San Francisco, CA USA	Hemphill, JC (corresponding author), San Francisco Gen Hosp, Dept Neurol, Room 4M62,1001 Potrero Ave, San Francisco, CA 94110 USA.	jchiii@itsa.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS41420] Funding Source: Medline; ODCDC CDC HHS [R49CCR903697] Funding Source: Medline		Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; BULLOCK R, 1988, SURG NEUROL, V29, P101, DOI 10.1016/0090-3019(88)90065-1; Burbridge B, 2004, CAN ASSOC RADIOL J, V55, P326; Charbel FT, 2000, SURG NEUROL, V54, P432, DOI 10.1016/S0090-3019(00)00340-2; De Georgia Michael A, 2004, Cleve Clin J Med, V71 Suppl 1, pS16; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hirano T, 1999, NEUROLOGY, V53, P2179, DOI 10.1212/WNL.53.9.2179; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JUVELA S, 1995, ARCH NEUROL-CHICAGO, V52, P1193, DOI 10.1001/archneur.1995.00540360071018; Kazui S, 1996, STROKE, V27, P1783, DOI 10.1161/01.STR.27.10.1783; Kett-White R, 2002, ADV TECH STAND NEUR, V27, P87; Kidwell CS, 2001, NEUROLOGY, V57, P1611, DOI 10.1212/WNL.57.9.1611; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kitaoka T, 2003, ACT NEUR S, V86, P457; Kobayashi M, 2001, STROKE, V32, P2237, DOI 10.1161/hs1001.096621; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LISK DR, 1994, NEUROLOGY, V44, P133, DOI 10.1212/WNL.44.1.133; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2003, STROKE, V34, P224, DOI 10.1161/01.STR.0000046458.67968.E4; Mayer SA, 1998, STROKE, V29, P1791, DOI 10.1161/01.STR.29.9.1791; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MENDELOW AD, 1993, STROKE, V24, pI115; Menzel M, 2003, J NEUROSURG ANESTH, V15, P33, DOI 10.1097/00008506-200301000-00006; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2003, NEUROSURGERY, V52, P1041, DOI 10.1227/01.NEU.0000057694.96978.BC; Qureshi AI, 1999, NEUROLOGY, V52, P266, DOI 10.1212/WNL.52.2.266; Rossi S, 2000, ACTA NEUROCHIR SUPPL, V76, P243; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Steiner T, 2001, STROKE, V32, P2500, DOI 10.1161/hs1101.097400; Stocchetti N, 1998, ACT NEUR S, V71, P162; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Tang S, 2004, CHINESE J ORG CHEM, V24, P1133; Tuhrim S, 1999, CRIT CARE MED, V27, P617, DOI 10.1097/00003246-199903000-00045; TUHRIM S, 1995, CRIT CARE MED, V23, P950, DOI 10.1097/00003246-199505000-00026; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vath A, 2002, ACT NEUR S, V81, P307; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Xi G, 2002, ACT NEUR S, V81, P253; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	55	37	37	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	3	3					260	270		10.1385/NCC:3:3:260			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	995PG	WOS:000234115700014	16377842				2021-06-18	
J	Komjati, K; Besson, VC; Szabo, C				Komjati, Katalin; Besson, Valerie C.; Szabo, Csaba			Poly (ADP-Ribose) Polymerase Inhibitors as Potential Therapeutic Agents in Stroke and Neurotrauma	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Poly(ADP-ribose) polymerase; ischemia; necrosis; apoptosis; inflammation; CNS; stroke; spinal cord injury	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE; INDUCED CELL-DEATH; POLY(ADP-RIBOSE) SYNTHETASE ACTIVATION; DIABETIC ENDOTHELIAL DYSFUNCTION; FLUID PERCUSSION INJURY; CORTICAL IMPACT INJURY	Poly (ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding protein that is primarily activated by nicks in the DNA molecule. It regulates the activity of various enzymes - including itself- that are involved in the control of DNA metabolism. Upon binding to DNA breaks, activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes the latter on nuclear acceptor proteins including histones, transcription factors and PARP itself. Poly(ADP-ribosylation) contributes to DNA repair and to the maintenance of genomic stability. Evidence obtained with pharmacological PARP inhibitors of various structural classes, as well as animals lacking the PARP-1 enzyme indicate that PARP plays an important role in cerebral ischemia/reperfusion, stroke and neurotrauma. Overactivation of PARP consumes NAD(+) and ATP culminating in cell dysfunction and necrosis. PARP activation can also act as a signal that initiates cell death programs, for instance through AIF (apoptosis inducing factor) translocation. PARP has also been shown to associate with and regulate the function of several transcription factors. Of special interest is the enhancement by PARP of NF-kappa B-mediated transcription, which plays a central role in the expression of inflammatory cytokines, chemokines, adhesion molecules and inflammatory mediators. Via this mechanism, PARP is involved in the up-regulation of numerous pro-inflammatory genes that play a pathogenetic role in the later stage of stroke and neurotrauma. Here we review the roles of PARP in DNA damage signaling and cell death, and summarize the pathogenetic role of PARP in stroke and neurotrauma.	[Komjati, Katalin; Szabo, Csaba] Inotek Pharmaceut Corp, Beverly, MA 01915 USA; [Besson, Valerie C.] Univ Rene Decartes, Lab Pharmacol Circulat Cerebrale, Paris, France; [Szabo, Csaba] Semmelweis Univ, Dept Human Physiol & Clin Expt Res, Budapest, Hungary	Szabo, C (corresponding author), INOTEK Pharmaceut, 100 Cummings Ctr,Suite 419E, Beverly, MA 01915 USA.	szabocsaba@aol.com	BESSON, VALERIE/AAZ-9989-2020; besson, valerie C/L-7388-2017	BESSON, VALERIE/0000-0002-1491-2380; besson, valerie C/0000-0002-1491-2380	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Hungarian Ministry of Health	The work in the authors' laboratories is supported by grants from the National Institutes of Health and the Hungarian Ministry of Health.	Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Affar E, 2002, P NATL ACAD SCI USA, V99, P245, DOI 10.1073/pnas.012460399; Aito H, 2004, BRAIN RES, V1013, P117, DOI 10.1016/j.brainres.2004.04.014; Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Barc S, 2001, NEUROSCI LETT, V314, P82, DOI 10.1016/S0304-3940(01)02273-X; Beneke S, 2004, INT J CANCER, V111, P813, DOI 10.1002/ijc.20342; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Chiang SKS, 2000, INVEST OPHTH VIS SCI, V41, P3210; Chiarugi A, 2003, J PHARMACOL EXP THER, V305, P943, DOI 10.1124/jpet.103.048934; Chikawa T, 2001, J NEUROTRAUM, V18, P93, DOI 10.1089/089771501750055802; Colak A, 2003, J NEUROSURG, V98, P275, DOI 10.3171/spi.2003.98.3.0275; Cole KK, 2002, J NEUROCHEM, V82, P19, DOI 10.1046/j.1471-4159.2002.00935.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cosi C, 2002, EXPERT OPIN THER PAT, V12, P1047, DOI 10.1517/13543776.12.7.1047; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/S0006-8993(96)00571-9; Couturier JY, 2003, EXP NEUROL, V184, P973, DOI 10.1016/S0014-4886(03)00367-4; Cuzzocrea S, 2004, CURR MED CHEM, V9, P1147; Czapski GA, 2004, NEUROSCI LETT, V356, P45, DOI 10.1016/j.neulet.2003.11.022; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; DEMURCIA G, 2000, DNA DAMAGE STRESS SI; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Diaz-Ruiz A, 2002, NEUROSCI LETT, V319, P129, DOI 10.1016/S0304-3940(01)02540-X; Didier M, 1996, J NEUROSCI, V16, P2238; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Dyker AG, 1998, STROKE, V29, P535, DOI 10.1161/01.STR.29.2.535; Ehrlich W, 1995, RHEUMATOL INT, V15, P171, DOI 10.1007/BF00301776; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; FAGNI L, 1994, PROG BRAIN RES, V103, P381; Falsig J, 2004, EUR J PHARMACOL, V497, P7, DOI 10.1016/j.ejphar.2004.06.042; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Ferraris D, 2003, BIOORGAN MED CHEM, V11, P3695, DOI 10.1016/S0968-0896(03)00333-X; Flentjar NJ, 2002, EXP NEUROL, V177, P9, DOI 10.1006/exnr.2002.7927; Genovese T, 2005, J PHARMACOL EXP THER, V312, P449, DOI 10.1124/jpet.104.076711; Giovanelli L, J CEREB BLOOD FLOW M, V22, P697; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; GROTTA J, 1994, CEREBROVASC DIS, V4, P115, DOI 10.1159/000108466; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Gupta S, 2004, NEUROL RES, V26, P103, DOI 10.1179/016164104773026624; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; HAMMER B, 1993, NEUROREPORT, V5, P72, DOI 10.1097/00001756-199310000-00018; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HIROMATSU Y, 1992, CLIN ENDOCRINOL, V36, P91, DOI 10.1111/j.1365-2265.1992.tb02907.x; Hivert B, 1998, NEUROREPORT, V9, P1835, DOI 10.1097/00001756-199806010-00031; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Hortobagyi T, 2003, NEUROSCIENCE, V121, P983, DOI 10.1016/S0306-4522(03)00482-2; Huang FN, 2004, BRAIN RES, V997, P79, DOI 10.1016/j.brainres.2003.10.051; Hung TH, 2002, CIRC RES, V90, P1274, DOI 10.1161/01.RES.0000024411.22110.AA; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Iwashita A, 2004, J PHARMACOL EXP THER, V310, P425, DOI 10.1124/jpet.104.066944; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Kabra DG, 2004, BRAIN RES BULL, V62, P425, DOI 10.1016/j.brainresbull.2003.11.001; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kaminski S.G, 1999, NEUROREPORT, V10, P3347; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; Klaidman LK, 2001, BBA-GEN SUBJECTS, V1525, P136, DOI 10.1016/S0304-4165(00)00181-1; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Koh SH, 2004, EUR J NEUROSCI, V20, P1461, DOI 10.1111/j.1460-9568.2004.03632.x; Komjati K, 2004, INT J MOL MED, V13, P373; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Lacza Z, 2003, INT J MOL MED, V12, P153; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Lee YS, 2004, FREE RADICAL BIO MED, V36, P330, DOI 10.1016/j.freeradbiomed.2003.11.006; Lee YW, 2001, NEUROCHEM RES, V26, P337, DOI 10.1023/A:1010993428770; Lees K.R., 2002, CEREBROVASC DIS, P430; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li F, 2004, DIABETOLOGIA, V47, P710, DOI 10.1007/s00125-004-1356-0; Lin SH, 2000, J CEREBR BLOOD F MET, V20, P1380, DOI 10.1097/00004647-200009000-00013; Liu CL, 2002, CHINESE MED J-PEKING, V115, P740; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Lu XCM, 2003, BRAIN RES, V978, P99, DOI 10.1016/S0006-8993(03)02774-4; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mao JR, 1997, PAIN, V72, P355, DOI 10.1016/S0304-3959(97)00063-8; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; MAYNARD KI, 2002, SCI MED          SEP, P260; Mazzon E, 2001, EUR J PHARMACOL, V415, P85, DOI 10.1016/S0014-2999(01)00809-3; McCulloch J, 2002, CEREBROVASC DIS, P404; Meier HL, 1999, ANN NY ACAD SCI, V890, P330, DOI 10.1111/j.1749-6632.1999.tb08010.x; Meli E, 2004, MOL CELL NEUROSCI, V25, P172, DOI 10.1016/j.mcn.2003.09.016; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mesenge C, 1999, J CEREB BLOOD FLOW M, V19, pS390; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Minchenko AG, 2003, FASEB J, V17, P1514, DOI 10.1096/fj.03-0013fje; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Nakahara S, 2002, J NEUROTRAUM, V19, P1467, DOI 10.1089/089771502320914697; Nakajima H, 2005, J PHARMACOL EXP THER, V312, P472, DOI 10.1124/jpet.104.075465; Nishio S, 1997, ACT NEUR S, V70, P84; Nucci C, 2000, BIOCHEM BIOPH RES CO, V278, P360, DOI 10.1006/bbrc.2000.3811; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; OIKAWA A, 1980, BIOCHEM BIOPH RES CO, V97, P1311, DOI 10.1016/S0006-291X(80)80009-X; Oka M, 2000, NEUROPHARMACOLOGY, V39, P1319, DOI 10.1016/S0028-3908(99)00197-5; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; Pacher P, 2002, BIOCHEM PHARMACOL, V64, P1785, DOI 10.1016/S0006-2952(02)01421-1; Pacher P, 2002, BRIT J PHARMACOL, V135, P1347, DOI 10.1038/sj.bjp.0704627; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Pacher P, 2002, J PHARMACOL EXP THER, V300, P862, DOI 10.1124/jpet.300.3.862; Pacher P, 2002, INT J MOL MED, V9, P659; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; PARK SD, 1983, ENVIRON MUTAGEN, V5, P515, DOI 10.1002/em.2860050402; Park WS, 2001, NEUROL RES, V23, P410, DOI 10.1179/016164101101198640; Paschen W, 2000, J NEUROCHEM, V75, P1675, DOI 10.1046/j.1471-4159.2000.0751675.x; PAYAN HM, 1977, STROKE, V8, P194, DOI 10.1161/01.STR.8.2.194; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pineda JA, 2001, J NEUROTRAUM, V18, P625, DOI 10.1089/089771501750291864; Plaschke K, 2000, NEUROSCI LETT, V284, P109, DOI 10.1016/S0304-3940(00)00988-5; Plaschke K, 2000, ANN NY ACAD SCI, V903, P299, DOI 10.1111/j.1749-6632.2000.tb06380.x; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; RINK A, 1995, AM J PATHOL, V147, P1575; Rudat V, 1998, INT J RADIAT BIOL, V73, P325, DOI 10.1080/095530098142428; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Satoh M, 2001, STROKE, V32, P225, DOI 10.1161/01.STR.32.1.225; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Scott GS, 2004, J NEUROTRAUM, V21, P1255, DOI 10.1089/neu.2004.21.1255; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sharma HS, 2003, ACT NEUR S, V86, P415; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Shimoda K, 2003, AM J PHYSIOL-LUNG C, V285, pL240, DOI 10.1152/ajplung.00319.2002; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 2001, NUCLEIC ACIDS RES, V29, P841, DOI 10.1093/nar/29.3.841; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Snyder SH, 1996, NAT MED, V2, P965, DOI 10.1038/nm0996-965; Sonee M, 2002, NEUROTOX RES, V4, P595, DOI 10.1080/1029842021000045480; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Soriano FG, 2001, CIRC RES, V89, P684, DOI 10.1161/hh2001.097797; Soriano FG, 2001, NAT MED, V7, P108; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sugawara T, 2002, FASEB J, V16, P1997, DOI 10.1096/fj.02-0251fje; Suh SW, 2003, J NEUROSCI, V23, P10681; Sun AY, 1998, ACTA PHARMACOL SIN, V19, P104; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 2003, INTENS CARE MED, V29, P863, DOI 10.1007/s00134-003-1737-8; Szabo C, 2002, CIRCULATION, V106, P2680, DOI 10.1161/01.CIR.0000038365.78031.9C; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; SZABO C, 2000, CELL DEATH ROLE PARP; Szabo E, 2001, FASEB J, V15, pA942; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Tabuchi K, 2001, ANN OTO RHINOL LARYN, V110, P118; Takahashi G, 2003, J THORAC CARDIOV SUR, V126, P1461, DOI 10.1016/S0022-5223(03)00693-7; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Tasker RC, 1998, J CEREBR BLOOD F MET, V18, P1346, DOI 10.1097/00004647-199812000-00009; Tentori L, 2002, PHARMACOL RES, V45, P73, DOI 10.1006/phrs.2001.0935; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Ullrich O, 2000, FREE RADICAL BIO MED, V29, P995, DOI 10.1016/S0891-5849(00)00399-3; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Vaziri ND, 2004, BRAIN RES, V995, P76, DOI 10.1016/j.brainres.2003.09.056; Verrecchia C, 2000, RECENT RES DEV NEURO, V3, P237; Virag L, 1999, MOL PHARMACOL, V56, P824; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WALLIS RA, 1993, NEUROREPORT, V5, P245; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Williams L., 1999, Society for Neuroscience Abstracts, V25, P1061; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; Wullner U, 1997, NEUROSCIENCE, V81, P721, DOI 10.1016/S0306-4522(97)00181-4; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; YAMANAKA K, 1995, NEUROSCI LETT, V194, P124, DOI 10.1016/0304-3940(95)11715-9; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZHANG J, 2002, THERAPEUTIC IMPLICAT; Zhang YM, 2004, EUR J NEUROSCI, V20, P1727, DOI 10.1111/j.1460-9568.2004.03651.x; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	239	37	42	0	2	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2005	4	2					179	194		10.2174/1568007053544138			16	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5XF	WOS:000497842000010	15857303				2021-06-18	
J	Neary, JT; Kang, Y				Neary, JT; Kang, Y			Signaling from P2 nucleotide receptors to protein kinase cascades induced by CNS injury - Implications for reactive gliosis and neurodegeneration	MOLECULAR NEUROBIOLOGY			English	Article; Proceedings Paper	Satellite Symposium on Oxidative Mechanisms in Neurodegenerative Disorder	FEB 07-11, 2004	Guilin, PEOPLES R CHINA			Purinergic receptors; ATP; protein kinases; gliosis; trauma; ERK; Akt	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; STRETCH-INDUCED INJURY; RAT CORTICAL ASTROCYTES; PURINERGIC RECEPTORS; EXTRACELLULAR ATP; REGULATED KINASE; MESSENGER-RNA; ASTROGLIAL ACTIVATION; CULTURED ASTROCYTES	Gliosis is a hypertrophic and hyperplastic response to many types of central nervous system injury, including trauma, stroke, seizure, as well as neurodegenerative and demyelinating disorders. Reactive astrocytes, a major component of the glial scar, express molecules that can both inhibit and promote axonal regeneration. ATP, which is released upon traumatic injury, hypoxia, and cell death, contributes to the gliotic response by binding to specific cell surface astrocytic P2 nucleotide receptors and evoking characteristic features of gliosis such as increased expression of glial fibrillary acidic protein (GFAP), generation and elongation of astrocytic processes, and cellular proliferation. Here, we review recent studies that demonstrate that (1) metabotropic, P2Y, and ionotropic, P2X, receptors expressed in astrocytes are coupled to protein kinase signaling pathways that regulate cellular proliferation, differentiation, and survival such as ERK and protein kinase B/Akt and (2) these P2 receptor/protein kinase cascades are activated after trauma induced by mechanical strain. We suggest that P2 receptor/protein kinase signaling pathways might provide novel therapeutic targets to regulate the formation of reactive astrocytes and the production of molecules that affect axonal regeneration and neurodegeneration.	Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Pathol, Miami, FL 33152 USA; Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Biochem, Miami, FL 33152 USA; Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Mol Biol, Miami, FL 33152 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33152 USA	Neary, JT (corresponding author), Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Pathol, Miami, FL 33152 USA.	jneary@med.miami.edu					ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bhat NR, 1998, J NEUROSCI, V18, P1633; BODIN P, 1992, P ROY SOC B-BIOL SCI, V247, P131, DOI 10.1098/rspb.1992.0019; Bolego C, 1997, BRIT J PHARMACOL, V121, P1692, DOI 10.1038/sj.bjp.0701294; Brambilla R, 2002, J NEUROCHEM, V83, P1285, DOI 10.1046/j.1471-4159.2002.01239.x; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Chang-Liao KS, 2001, ELEC SOC S, V2001, P1; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Eng LF, 1987, PROG BRAIN RES <D>, V71, P439; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Floyd CL, 2004, J NEUROTRAUM, V21, P205, DOI 10.1089/089771504322778668; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Frank C, 1999, J Sci Med Sport, V2, P190, DOI 10.1016/S1440-2440(99)80173-X; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Gendron Fernand-Pierre, 2003, Biomedical Research (Aligarh), V14, P47; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HOU YJ, 1995, J NEUROSCI RES, V40, P359, DOI 10.1002/jnr.490400310; HU B, 2001, J NEUROTRAUM, V18, P1161; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Janes KA, 2003, MOL CELL PROTEOMICS, V2, P463, DOI 10.1074/mcp.M300045-MCP200; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/S0306-4522(96)00209-6; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MILLS CD, 2001, J NEUROTRAUM, V18, P1182; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Namikawa K, 2000, J NEUROSCI, V20, P2875; Neary JT, 1996, NEUROREPORT, V7, P2893, DOI 10.1097/00001756-199611250-00017; Neary JT, 1999, PROG BRAIN RES, V120, P323; Neary JT, 2004, J NEUROTRAUM, V21, P1283; Neary JT, 2003, J NEUROTRAUM, V20, P1104; NEARY JT, 1994, NEUROREPORT, V5, P1617, DOI 10.1097/00001756-199408150-00019; NEARY JT, 1994, J NEUROCHEM, V63, P490; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; NEARY JT, 1994, J NEUROCHEM, V63, P2021; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; NEARY JT, 2004, SOC NEUR ABSTR; NEARY JT, 2003, J REHABIL RES DEV, V40, P58; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Ralevic V, 1998, PHARMACOL REV, V50, P413; RATHBONE MP, 1992, NEUROSCI RES, V13, P1, DOI 10.1016/0168-0102(92)90030-G; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; SEGER R, 1995, FASEB J, V9, P726; SHREIBER D, 1995, P 1995 INT RES C BIO, P233; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	67	37	42	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.		2005	31	1-3					95	103		10.1385/MN:31:1-3:095			9	Neurosciences	Neurosciences & Neurology	940BY	WOS:000230119900008	15953814				2021-06-18	
J	Wong, J; Hoe, NW; Feng, ZW; Ng, I				Wong, J; Hoe, NW; Feng, ZW; Ng, I			Apoptosis and traumatic brain injury	NEUROCRITICAL CARE			English	Article						traumatic brain injury; apoptosis; Fas; caspases; Bcl-2 family; therapeutic intervention	CEREBRAL PERFUSION-PRESSURE; DNA STRAND BREAKS; CYTOCHROME-C; TEMPORAL PROFILE; FACTOR AIF; FAS; FRAGMENTATION; EXPRESSION; RELEASE; CASPASE-3	Traumatic brain injury is a cause of high mortality and morbidity and is an area of intense research. Apoptosis plays a crucial role in the pathogenesis of head injury, and the inhibition of apoptosis can potentially reverse the deleterious effects and lead to better functional outcome. Elucidation of the apoptotic pathway and its role in traumatic brain injury will provide potential targets for therapeutic intervention. This article aims to review the current wealth of literature on apoptosis and traumatic head injury and explores the current status of therapeutic strategies available.	Natl Inst Neurosci, Dept Neurosurg, Clin Staff Off, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Natl Inst Neurosci, Dept Res, Singapore 308433, Singapore	Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Clin Staff Off, Acute Brain Injury Res Lab, Singapore 11,Jalan Tan Tock Seng,Level 3, Singapore 308433, Singapore.	ivan_ng@nni.com.sg					ALBERTS B, 2002, MOL BIOL CELL, P983; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Czosnyka M, 2003, ACT NEUR S, V86, P581; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DEXTER TM, 1995, ROLE APOPTOSIS DEV T, P1; EASTMAN P, 2003, NEUROL TODAY     AUG; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Furth PA, 1997, APOPTOSIS, V2, P19, DOI 10.1023/A:1026454207398; GORCZYCA W, 1994, CYTOMETRY, V15, P169, DOI 10.1002/cyto.990150211; GORCZYCA W, 1993, CANCER RES, V53, P1945; Grodzicky T, 2002, MT SINAI J MED, V69, P208; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lallemend F, 2003, J NEUROCHEM, V87, P508, DOI 10.1046/j.1471-4159.2003.02014.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; LODISH H, 2000, MOL CELL BIOL, P1054; Maecker HL, 2000, CANCER RES, V60, P4638; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sachs LM, 1997, FASEB J, V11, P801; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SUVILLIAN PG, 2000, NEUROSCIENCE, V101, P289; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; SZABO I, 1991, J BIOL CHEM, V266, P3376; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zuzarte-Luis V, 2002, INT J DEV BIOL, V46, P871	58	37	39	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	3	2					177	182		10.1385/NCC:3:2:177			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	973UD	WOS:000232547200016	16174891				2021-06-18	
J	Hlatky, R; Valadka, AB; Goodman, JC; Robertson, CS				Hlatky, R; Valadka, AB; Goodman, JC; Robertson, CS			Evolution of brain tissue injury after evacuation of acute traumatic subdural hematomas	NEUROSURGERY			English	Article						brain tissue oxygen tension; lactate; microdialysis; subdural hematoma; traumatic brain injury	HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; INSPIRED OXYGEN; CT-SCAN; MORTALITY; ISCHEMIA; RAT; REDUCTION; REMOVAL; RELEASE	OBJECTIVE: Acute traumatic subdural hematoma complicated by brain parenchymal injury is associated with a 60 to 90% mortality rate. Early surgical evacuation of the mass lesion is essential for a favorable outcome, but the severity of the underlying brain injury determines the outcome, even when surgery has been prompt. The purpose of this study was to analyze tissue biochemical patterns in the brain underlying an evacuated acute subdural hematoma to identify a characteristic pattern of changes that might indicate evolving brain injury. METHODS: Prospectively collected data from 33 patients after surgical evacuation of acute subdural hematoma were analyzed. Both a brain tissue oxygen tension probe and an intracerebral microdialysis probe were placed in brain tissue exposed at surgery. On the basis of the postoperative clinical course, the patients were divided into three groups: patients with early intractable intracranial hypertension, patients with evolution of delayed traumatic injury (DTI), and patients with an uncomplicated course (the no-DTI group). RESULTS: The overall mortality rate was 46%, with 100% mortality in the intracranial hypertension group (five patients). Mortality in the DTI group was 53% compared with only 9% in the no-DTI group (P = 0.002). There were no significant differences in the initial computed tomographic scan characteristics such as thickness of the subdural hematoma or amount of midline shift, among the three groups. Physiological variables, as well as the microdialysate measures of brain biochemistry, were markedly different in the intracranial hypertension group compared with the other groups. Differences between the other two groups were more subtle but were significant. Significantly lower values of brain tissue oxygen tension (14 +/- 8 mm Hg versus 27 +/- 14 mm Hg) and higher dialysate values of lactate and pyruvate were documented in patients who developed a delayed injury compared with patients with uncomplicated courses (4.1 +/- 2.3 mmol/L versus 1.7 +/- 0.7 mmol/L for lactate, and 104 +/- 47 mumol/L versus 73 +/- 54 mumol/L for pyruvate at 24 h after injury). CONCLUSION: Evolution of DTI in the area of brain underlying an evacuated subdural hematoma is associated with a significant increase in mortality. Postoperatively decreasing brain tissue oxygen tension and increasing dialysate concentrations of lactate and pyruvate in this area may warn of evolving brain injury and evoke further diagnostic and therapeutic activity.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Charles Univ, Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHAMBERS JW, 1951, J NEUROSURG, V8, P263, DOI 10.3171/jns.1951.8.3.0263; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Reinert M, 2002, NEUROL RES, V24, P601, DOI 10.1179/016164102101200438; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; RICHARDS T, 1974, SURGERY, V75, P253; Robertson CS, 1998, NEUROL RES, V20, pS91; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Yilmazlar S, 1997, J Neurosurg Sci, V41, P379	31	37	37	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2004	55	6					1318	1324		10.1227/01.NEU.0000143029.42638.2C			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	878CB	WOS:000225623000010	15574213				2021-06-18	
J	Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Hovda, DA; Bergsneider, M				Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Hovda, DA; Bergsneider, M			Subcortical white matter metabolic chances remote from focal hemorrhagic lesions suggest diffuse injury after human traumatic brain injury	NEUROSURGERY			English	Article						diffuse axonal injury; hyperglycolysis; oxidative metabolism; reactive gliosis	CEREBRAL BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE SPECTROSCOPY; AXONAL INJURY; HEAD-INJURY; GLUCOSE-UTILIZATION; OXYGEN UTILIZATION; PRACTICAL SCALE; CYCLOSPORINE-A; NORMAL VALUES	OBJECTIVE: We used positron emission tomographic studies to prospectively examine the relationship between glucose and oxidative metabolism in the subcortical white matter (WM) acutely after traumatic brain injury (TBI). The objective was to determine the nature, extent, and degree of metabolic abnormalities in subcortical brain regions remote from hemorrhagic lesions. METHODS: Sixteen normal volunteers and 10 TBI patients (Glasgow Coma Scale score, 4-10; age, 17-64 yr; 6 with focal and 4 with diffuse injury) were studied. Each subject underwent dynamic positron emission tomographic studies using [O-15]CO, O-15(2), [O-15]H2O, and fluorodeoxyglucose plus a magnetic resonance imaging scan acutely after TBI. Parametric images of the metabolic rate of oxygen and metabolic rate of glucose were generated, and a molar oxygen-to-glucose utilization ratio was calculated. Data from gray matter and WM remote from hemorrhagic lesions, plus whole brain, were analyzed. RESULTS: There was a significant reduction in the subcortical WM oxygen-to-glucose utilization ratio after TBI compared with normal values (3.99 +/- 0.77 versus 5.37 +/- 1.00; P < 0.01), whereas the mean cortical gray matter and whole-brain values remained unchanged. WM metabolic changes, which were diffuse throughout the hemispheres, were characterized by a reduction in the metabolic rate of oxygen without a concomitant drop in the metabolic rate of glucose. CONCLUSION: The extent and degree of subcortical WM metabolic abnormalities after moderate and severe TBI suggest that diffuse WM injury is a general phenomenon after such injuries. This pervasive finding may indicate that the concept of focal traumatic injury, although valid from a computed tomographic imaging standpoint, may be misleading when considering metabolic derangements associated with TBI.	Univ Calif Los Angeles, Daivd Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, DOE Ctr Mol Med, Los Angeles, CA 90095 USA	Bergsneider, M (corresponding author), Univ Calif Los Angeles, Daivd Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, 10833 Leconte Ave,Room 74-134 CHS,Mail Code 95690, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu	Hattori, Naoya/G-2298-2012; Hattori, Naoya/AAR-6405-2020	Glenn, Thomas/0000-0003-4273-3408	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [Z01DE000387] Funding Source: NIH RePORTER; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [DE-FC0387-ER60615, DE-FC03-02ER63420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline		Alkire MT, 1997, ANESTHESIOLOGY, V86, P549, DOI 10.1097/00000542-199703000-00006; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brix G, 1997, J NUCL MED, V38, P1614; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Byas-Smith Michael, 2002, Mol Imaging Biol, V4, P139, DOI 10.1016/S1536-1632(01)00006-3; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183; DASTUR DK, 1963, USPHS PUBLICATION, V986, P59; DESPOPOULOS A, 1991, COLOR ATLAS PHYSL; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GJEDDE A, 1982, BRAIN RES REV, V4, P237, DOI 10.1016/0165-0173(82)90018-2; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; HATTORI N, IN PRESS J NUCL MED; HUANG SC, 1983, J CEREBR BLOOD F MET, V3, P141, DOI 10.1038/jcbfm.1983.21; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; JENNETT B, 1975, LANCET, V1, P480; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; Liu YY, 2001, NEUROREPORT, V12, P3239, DOI 10.1097/00001756-200110290-00019; MINTUN MA, 1984, J NUCL MED, V25, P177; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NAKAI H, 1987, STROKE, V18, P158, DOI 10.1161/01.STR.18.1.158; Nakao Y, 2001, P NATL ACAD SCI USA, V98, P7593, DOI 10.1073/pnas.121179898; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oehler R, 2000, BLOOD, V95, P1086, DOI 10.1182/blood.V95.3.1086.003k09_1086_1092; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P179, DOI 10.1038/jcbfm.1992.28; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PHELPS ME, 1979, J NUCL MED, V20, P328; Povlishock JT, 1999, ACT NEUR S, V73, P15; RISCHKE R, 1991, J CEREBR BLOOD F MET, V11, P106, DOI 10.1038/jcbfm.1991.12; Sanchez-Abarca LI, 2001, GLIA, V36, P321, DOI 10.1002/glia.1119; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Soares HD, 1995, J NEUROSCI, V15, P8223; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEWART L, 1994, ACTA NEUROCHIR, P544; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; WU HM, 2003, MOL IMAGING BIOL, V4, P1; WU HM, 2002, BRAIN IMAGING USING, P147; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zhou Y, 2001, IEEE T NUCL SCI, V48, P125, DOI 10.1109/23.910842	58	37	40	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2004	55	6					1306	1317		10.1227/01.NEU.0000143028.08719.42			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	878CB	WOS:000225623000009	15574212				2021-06-18	
J	Corrigan, JD; Bogner, J				Corrigan, JD; Bogner, J			Latent factors in measures of rehabilitation outcomes after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						outcomes measurement; rehabilitation; traumatic brain injury	FUNCTIONAL ASSESSMENT SCALES; QUALITY-OF-LIFE; COMMUNITY INTEGRATION QUESTIONNAIRE; HEALTH SURVEY QUESTIONNAIRE; SYSTEMATIC BIAS; BREAST-CANCER; SURVEY SF-36; FOLLOW-UP; SATISFACTION; INDIVIDUALS	Objectives: To determine whether there is a latent structure among measures used to evaluate rehabilitation outcomes for persons with traumatic brain injury and if the construct of participation is discernible within this structure. Design: Exploratory factor analyses of 2 cross-sectional cohorts of rehabilitation patients who sustained a traumatic brain injury up to 5 years prior to assessment. Primary Measures: Community Integration Questionnaire (CIQ), Craig Handicap Assessment and Reporting Technique (CHART), Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), and the Satisfaction With Life Scale (SWLS). Results: Both factor analyses suggested a latent structure composed of 3 factors that were interpreted as representing the Activities and Participation dimensions of the World Health Organization's International Classification of Functioning, Disability and Health (ICF), and a third representing Subjective Well-Being. Low to moderate correlations were found between factors. Conclusions: The World Health Organization's ICF excludes subjective well-being; however the factor analyses indicate that it is a distinct domain not incorporated into Activities and Participation. The SF-36, CIQ, and CHART can, in combination, evaluate all 3 domains, but not alone. The SF-36 appears to be sensitive to the affective, but not the cognitive, aspect of Subjective Well-Being. A measure of life satisfaction would be a useful supplement to traditional measures of rehabilitation outcome.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; BRUIN AF, 2002, SOC SCI MED, V35, P1003; Carlsson M, 1996, QUAL LIFE RES, V5, P265, DOI 10.1007/BF00434748; Carlsson M, 1999, QUAL LIFE RES, V8, P245, DOI 10.1023/A:1008875306645; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIJKERS M, 1997, ASSESSING MED REHABI, P153; DIJKERS M, 2003, COMMUNITY INTEGRATIO, V2; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FREDERICK S, 1999, SUBJECTIVE WELL BEIN, P303; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GORDON WA, 1998, LIVING LIFE TRAUMATI; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; GRANT JP, 1986, NUTR CLIN PRACT, V1, P3; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; *HLTH ASS LAB, 2000, PART MEAS POST AC CA; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; POPE AM, 1991, DISABILITY AM NATL A; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SOKOL K, 1999, ARCH PHYS MED REHAB, V80, P974; US Department of Education Office of Special Education and Rehabilitative Services National Institute on Disability and Rehabilitation Research, 2000, LONG RANG PLAN 1999; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1980, INT CLASS FUNCT DIS; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355; WILLER B, 1997, ASSESSING MED REHABI, P127; World Health Organization, 2001, INT CLASS FUNCT DIS; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	47	37	37	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2004	19	6					445	458		10.1097/00001199-200411000-00003			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	873LZ	WOS:000225283100003	15602308				2021-06-18	
J	Hillard, VH; Peng, H; Zhang, Y; Das, K; Murali, R; Etlinger, JD; Zeman, RJ				Hillard, VH; Peng, H; Zhang, Y; Das, K; Murali, R; Etlinger, JD; Zeman, RJ			Tempol, a nitroxide antioxidant, improves locomotor and histological outcomes after spinal cord contusion in rats	JOURNAL OF NEUROTRAUMA			English	Article						cavitation; contusion; locomotor function; spinal cord injury; tempol; white matter	TRANSIENT FOCAL ISCHEMIA; CLOSED-HEAD INJURY; STABLE NITROXIDE; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; BLOOD-PRESSURE; BRAIN-INJURY; MODEL; METHYLPREDNISOLONE; RECOVERY	We have determined whether the nitroxide antioxidant, tempol, can oppose tissue loss and improve recovery of locomotor function following contusion injury of the spinal cord. Contusion injury was produced in rats at the level of T10 with a weight-drop device and locomotor recovery was determined with the 21-point Basso, Beattie and Bresnahan (BBB) scale. Locomotor function recovered progressively during the 6-week postinjury observation period and was significantly greater in tempol-treated (275 mg/kg ip, 20 min postinjury) compared to vehicle-treated rats (final BBB scores: 9.1 versus 6.4). Similarly enhanced locomotor recovery was observed with doses of tempol in the range of 138-550, but not 69 mg/kg, and with injection at 48 h postinjury indicating a therapeutic time-window of at least several days. The extent of recovery correlated with measurements of sparing of spinal cord white matter in a region several millimeters in length extending rostrally from the contusion epicenter. In contrast, loss of gray matter was unaffected by tempol treatment. Since tempol acts by scavenging reactive oxygen species (ROS) such as superoxide and hydroxyl radicals, the improved locomotor recovery and spared spinal cord tissue following contusion injury provides evidence of a direct role of ROS-mediated neurodegeneration in spinal cord injury.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Neurosurg, Valhalla, NY 10595 USA; MotoGen Inc, Mt Kisco, NY USA	Zeman, RJ (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.	zeman@nymc.edu		Hillard, Virany Huynh/0000-0003-2218-8182; Peng, Hong/0000-0001-5522-072X			Banik NL, 1997, BRAIN RES, V748, P205, DOI 10.1016/S0006-8993(96)01302-9; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hahn SM, 1998, INT J RADIAT ONCOL, V42, P839, DOI 10.1016/S0360-3016(98)00317-4; Hahn SM, 2000, FREE RADICAL BIO MED, V28, P953, DOI 10.1016/S0891-5849(00)00176-3; HAHN SM, 1992, CANCER RES, V52, P1750; Hall E D, 2001, J Spinal Cord Med, V24, P142; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hu GH, 2003, J NEUROSURG, V98, P393, DOI 10.3171/jns.2003.98.2.0393; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kato N, 2003, BRAIN RES, V979, P188, DOI 10.1016/S0006-8993(03)02918-4; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Leker RR, 2002, EXP NEUROL, V176, P355, DOI 10.1006/exnr.2002.7910; Liu XZ, 1997, J NEUROSCI, V17, P5395; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Park Youn-Kwan, 1998, Journal of Korean Medical Science, V13, P638; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; RATAN RR, 1994, J NEUROSCI, V14, P4385; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schultke E, 2003, J NEUROTRAUM, V20, P583, DOI 10.1089/089771503767168500; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu H, 2001, AM J PHYSIOL-HEART C, V281, pH975; Zeman RJ, 2001, EXP NEUROL, V172, P228, DOI 10.1006/exnr.2001.7803; Zeman RJ, 1999, EXP NEUROL, V159, P267, DOI 10.1006/exnr.1999.7146; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	39	37	40	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2004	21	10					1405	1414		10.1089/neu.2004.21.1405			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	867BT	WOS:000224817800005	15672631				2021-06-18	
J	Rancan, M; Bye, N; Otto, VI; Trentz, O; Kossmann, T; Frentzel, S; Morganti-Kossmann, MC				Rancan, M; Bye, N; Otto, VI; Trentz, O; Kossmann, T; Frentzel, S; Morganti-Kossmann, MC			The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; chemokines; cell adhesion molecules; neuroinflammation; blood-brain barrier	BARRIER DYSFUNCTION; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; MICE DEFICIENT; AXONAL INJURY; TNF-ALPHA; EXPRESSION; RECEPTOR; CX(3)CR1; CSF	The potential role of the chemokine Fractalkine (CX(3)CL1) in the pathophysiology of traumatic brain injury (TBI) was investigated in patients with head trauma and in mice after experimental cortical contusion. In control individuals, soluble (s)Fractalkine was present at low concentrations in cerebrospinal fluid (CSF) (12.6 to 57.3 pg/mL) but at much higher levels in serum (21,288 to 74,548 pg/mL). Elevation of sFractalkine in CSF of TBI patients was observed during the whole study period (means: 29.92 to 535.33 pg/mL), whereas serum levels remained within normal ranges (means: 3,100 to 59,159 pg/mL). Based on these differences, a possible passage of sFractalkine from blood to CSF was supported by the strong correlation between blood-brain barrier dysfunction (according to the CSF-/serum-albumin quotient) and sFractalkine concentrations in CSF (R = 0.706; P < 0.01). In the brain of mice subjected to closed head injury, neither Fractalkine protein nor mRNA were found to be augmented; however, Fractalkine receptor (CX(3)CR1) mRNA steadily increased peaking at 1 week postinjury (P < 0.05, one-way analysis of variance). This possibly implies the receptor to be the key factor determining the action of constitutively expressed Fractalkine. Altogether, these data suggest that the Fractalkine-CX3CRI protein system may be involved in the inflammatory response to TBI, particularly for the accumulation of leukocytes in the injured parenchyma.	Monash Univ, Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3004, Australia; Swiss Fed Inst Technol, Inst Pharmaceut Chem, Dept Chem & Appl Biosci, Zurich, Switzerland; Univ Zurich Hosp, Div Trauma Surg, Dept Surg, Zurich, Switzerland; Novartis Pharma AG, NIBR, Basel, Switzerland	Rancan, M (corresponding author), Monash Univ, Alfred Hosp, Dept Trauma Surg, Commercial Rd, Melbourne, Vic 3004, Australia.	RancanMario@hotmail.com		Morganti-Kossmann, Cristina/0000-0002-0807-2063			ANTHONY DC, 2001, PROGR BRAIN RES, P507; Balabanian K, 2002, AM J RESP CRIT CARE, V165, P1419, DOI 10.1164/rccm.2106007; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Cook DN, 2001, MOL CELL BIOL, V21, P3159, DOI 10.1128/MCB.21.9.3159-3165.2001; Fischer FR, 2000, J NEUROIMMUNOL, V110, P195, DOI 10.1016/S0165-5728(00)00351-9; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hughes PM, 2002, GLIA, V37, P314, DOI 10.1002/glia.10037; JENNETT B, 1976, LANCET, V1, P1031; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kastenbauer S, 2003, J NEUROIMMUNOL, V137, P210, DOI 10.1016/S0165-5728(03)00085-7; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; STOCKER R, 1995, INTEGRATED APPROACH, P196; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zujovic V, 2001, J NEUROIMMUNOL, V115, P135, DOI 10.1016/S0165-5728(01)00259-4	37	37	37	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2004	24	10					1110	1118		10.1097/01.WCB.0000133470.91843.72			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	859YP	WOS:000224304600005	15529011	Bronze			2021-06-18	
J	Nybo, T; Sainio, M; Muller, K				Nybo, T; Sainio, M; Muller, K			Stability of vocational outcome in adulthood after moderate to severe preschool brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						childhood brain injury; mid-life vocational outcome; stability of vocational status	HEAD-INJURY; TERM; CHILDREN; CHILDHOOD; TESTS; AGE	We studied how moderate to severe childhood traumatic brain injury (TBI) affects vocational outcome with time. This is the second follow-up of patients who were injured as preschoolers in traffic accidents. In the first follow-up the mean age was 23 years and in the present study the average age of the 27-patient cohort was 40 years. Twenty-two patients were assessed clinically by a neuropsychologist, neurologist and a social worker. Five patients, although not able or willing to participate in the clinical study, were contacted by telephone and interviewed on their Vocational outcome. Compared to the first follow-up, 20/27 patients in total had no change in their vocational status. Nine out of the 27 patients were working full-time, two had subsidized jobs and 16 were not working. Twenty-four of 27 patients were independent in daily living. In the neuropsychological tests of executive functions, preserved flexibility associated with full-time work status. In conclusion, (1)/(3) of the patients were still employed full-time over 30 years after the TBI. This suggests that favorable vocational Outcome, reached by young adulthood, is maintained at least until middle age.	Finnish Inst Occupat Hlth, Sect Clin Neurosci, Helsinki 00250, Finland	Nybo, T (corresponding author), Finnish Inst Occupat Hlth, Sect Clin Neurosci, Topeliuksenkatu 41AA, Helsinki 00250, Finland.	taina.nybo@occuphealth.fi					Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Heaton R. K, 1981, WISCONSIN CARD SORTI; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Nybo T, 1999, BRAIN INJURY, V13, P759; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Verger K, 2000, BRAIN INJURY, V14, P495; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; 1999, CAMBRIDGE NEUROPSYCH; 1944, MANUAL DIRECTION SCO; 2003, FINLAND FIGURES 2003	22	37	37	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2004	10	5					719	723		10.1017/S1355617704105109			5	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	848XZ	WOS:000223502700008	15327719				2021-06-18	
J	Curry, DJ; Wright, DA; Lee, RC; Kang, UJ; Frim, DM				Curry, DJ; Wright, DA; Lee, RC; Kang, UJ; Frim, DM			Surfactant poloxamer 188-related decreases in inflammation and tissue damage after experimental brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						surfactant; poloxamer; traumatic brain injury; chemotaxis; membrane fluidity; cytokine; pediatric neurosurgery	NEUTROPHIL ACTIVATION; EXCITOTOXIC LESIONS; CYTOKINE PRODUCTION; RHEOTHRX INJECTION; BLOCK POLYMER; MEMBRANE; CELLS; INTERLEUKIN-1; AGGREGATION; FIBROBLASTS	Object. The surfactant, poloxamer 188 (P-188), has been found to protect against tissue injury in various experimental models. Its protective mechanism may involve the effects of the surfactant against oxidative stress and inflammation. The authors investigated the role of P-188 in the reduction of tissue injury and macrophage response in a model of excitotoxic brain injury in the rat striatum. Methods. Fifteen Sprague-Dawley rats underwent stereotactic injection of 120 nmol of quinolinic acid into the striatum and received intracisternal injection of vehicle or P-188 (40 mg/kg) at 10 minutes and 4 hours postinjury. Rats were killed after 1 week, and the histological score was determined based on the degree of overall tissue injury (Grades 1-4) at the lesion site. The number of macrophages within the lesioned striatum was compared with that found within the striatum on the nonoperated contralateral side. The scores related to tissue damage and the macrophage ratios of each group were then compared using t-tests. Striatal injection of the toxin produced a lesion characterized by necrosis and inflammation surrounding the injection site in all six control animals. In rats in which intracisternal P-188 was administered, significantly less tissue injury was demonstrated (mean score 2.45 +/- 0.74) than in controls (mean score 3.14 +/- 0.75) (p = 0.045). The rats that received intracisternal surfactant also had significantly less macrophage infiltrate (mean ratio 1.06 +/- 0.18) than control animals (mean ratio 2.00 +/- 0.48) (p = 0.004). Conclusions. The surfactant P-188 reduces tissue loss and macrophage infiltrate after excitotoxic brain injury in the rat. Possible mechanisms of this effect may include direct surfactant modulation of inflammatory cell membrane fluidity.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA	Frim, DM (corresponding author), Univ Chicago, Childrens Hosp, Sect Pediat Neurosurg, MC-40661klkl,5841 S Maryland Ave, Chicago, IL 60637 USA.	dfrim@peds.bsd.uchicago.edu	Kang, Un/AAV-2858-2020; Wright, David/K-7898-2012	Kang, Un/0000-0002-5970-6839; Wright, David/0000-0002-2785-0254			AdamsGraves P, 1997, BLOOD, V90, P2041, DOI 10.1182/blood.V90.5.2041; ARMSTRONG JK, 1995, THROMB RES, V79, P437, DOI 10.1016/0049-3848(95)00134-D; BAJAJ AK, 1989, CIRCULATION, V79, P645, DOI 10.1161/01.CIR.79.3.645; Bastiaanse EML, 1997, CARDIOVASC RES, V33, P272, DOI 10.1016/S0008-6363(96)00193-9; Batrakova E, 1999, PHARM RES-DORDR, V16, P1373, DOI 10.1023/A:1018942823676; Bier M, 1999, BIOELECTROMAGNETICS, V20, P194, DOI 10.1002/(SICI)1521-186X(1999)20:3<194::AID-BEM6>3.0.CO;2-0; Clarke MSF, 1999, LEARN MEMORY, V6, P634, DOI 10.1101/lm.6.6.634; COLBASSANI HJ, 1989, STROKE, V20, P1241, DOI 10.1161/01.STR.20.9.1241; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAHLGREN C, 1980, CELL BIOPHYS, V2, P253, DOI 10.1007/BF02790453; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1993, NEUROREPORT, V4, P655, DOI 10.1097/00001756-199306000-00013; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; GIULIAN D, 1989, J NEUROSCI, V9, P4416; HUNTER R, 1981, J IMMUNOL, V127, P1244; Jackson JK, 2000, BIOMATERIALS, V21, P1483, DOI 10.1016/S0142-9612(00)00034-X; Jagannath C, 1999, ANTIMICROB AGENTS CH, V43, P2898, DOI 10.1128/AAC.43.12.2898; Jewell RC, 1997, J PHARM SCI, V86, P808, DOI 10.1021/js960491e; KNIZE DM, 1969, SURG GYNECOL OBSTETR, V129, P1019; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; MAY LE, 1958, J AM GERIATR SOC, V6, P814, DOI 10.1111/j.1532-5415.1958.tb00788.x; MCINTOSH TK, 1999, SECONDARY BRAIN INJU; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; MEZROW CK, 1992, J THORAC CARDIOV SUR, V103, P1143; MIYANCHI Y, 1966, CIRCULATION S, V33, P171; Moghimi SM, 1996, J NATL CANCER I, V88, P766, DOI 10.1093/jnci/88.11.766; Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167-7799(00)01485-2; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OWEN E, 1978, J CELL SCI, V32, P363; Parnaud G, 2001, BRIT J CANCER, V84, P90, DOI 10.1054/bjoc.2000.1540; PATON B, 1968, USE NONIONIC DETERGE; PERSKIN MH, 1992, MECH AGEING DEV, V64, P303, DOI 10.1016/0047-6374(92)90086-S; PINKERTON PH, 1978, J CLIN PATHOL, V31, P300, DOI 10.1136/jcp.31.4.300; RODEHEAVER GT, 1980, ANN EMERG MED, V9, P572, DOI 10.1016/S0196-0644(80)80228-9; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scholer N, 2000, J MICROENCAPSUL, V17, P639; SPIKA S, 1996, CLIN IMMUNOL IMMUNOP, V79, P224; Tan J, 1999, J BIOMED MATER RES, V46, P465, DOI 10.1002/(SICI)1097-4636(19990915)46:4<465::AID-JBM4>3.0.CO;2-N; Toth K, 1997, CLIN HEMORHEOL MICRO, V17, P117; UHLER TA, 1994, NEUROSURGERY, V34, P122; WADDELL W, 1957, METABOLISM, V9, P572; WANG M, 2000, JOINT SECT PED NEURO, P48; WEATHERL.RC, 1969, SURGERY, V66, P208; WELLS R, 1968, CIRCULATION       S2, V37, P168; WOLACH B, 1992, J LEUKOCYTE BIOL, V51, P324; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	50	37	38	2	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	1		S			91	96		10.3171/ped.2004.101.2.0091			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	843QS	WOS:000223100100015	16206978				2021-06-18	
J	Aimaretti, G; Ambrosio, MR; Benvenga, S; Borretta, G; De Marinis, L; De Menis, E; Di Somma, C; Faustini-Fustini, M; Grottoli, S; Gasco, V; Gasperi, M; Logoluso, F; Scaroni, C; Giordano, G; Ghigo, E				Aimaretti, G; Ambrosio, MR; Benvenga, S; Borretta, G; De Marinis, L; De Menis, E; Di Somma, C; Faustini-Fustini, M; Grottoli, S; Gasco, V; Gasperi, M; Logoluso, F; Scaroni, C; Giordano, G; Ghigo, E			Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI)	GROWTH HORMONE & IGF RESEARCH			English	Article; Proceedings Paper	35th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism	APR 04-05, 2003	Prague, CZECH REPUBLIC	Pfizer Inc		growth hormone deficiency; adulthood; diagnosis; traumatic brain injury; subarachnoid haemorrhage	PLUS-ARGININE; YOUNG-ADULTS; DIAGNOSIS	In adults, hypopituitarism and growth hormone deficiency (GHD) should be suspected and diagnosed within an appropriate clinical context. It has been demonstrated that all patients with primary hypothalamic-pituitary diseases before and after any medical intervention (defined as neurosurgery, radiotherapy and medical therapy) are at obvious risk - more than just at high risk for hypopituitarism (greater than 80%, had severe GHD). The same obvious risk applies to patients diagnosed as having congenital or acquired GHD in childhood (between 30% and 50% of patients with severe GHD after retesting). Taking into account the fragility of the infundibular hypothalamic structure, patients with other common pathological conditions of the central nervous system (CNS), such as traumatic brain injury (TBI), subarachnoid haemorrhage (SAH) or primary brain tumours (BT) with related medical intervention could be at risk for developing hypopituitarism, including GHD. GHD is the first and most common sign of pituitary impairment. Despite the risk of pituitary dysfunction and the results of some studies that these risks are greater than previously believed, neuroendocrine evaluations are still not routinely included as part of the clinical management plan for patients with TBI and SAH. Preliminary results of a multicenter study performed under the auspices of the Italian Society of Endocrinology underscore the high risk of hypopituitarism and GHD under these clinical conditions. Thus, careful screening of pituitary function should always be performed in patients following TBI and SAH. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab Dis, I-10126 Turin, Italy	Ghigo, E (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab Dis, Cso Dogliotti 14, I-10126 Turin, Italy.	ezio.ghigo@unito.it	Scaroni, Carla/G-3853-2017; Faustini-Fustini, Marco/AAU-7933-2020; Di Somma, Carolina/K-7772-2016	Scaroni, Carla/0000-0001-9396-3815; Di Somma, Carolina/0000-0002-5724-1951; ambrosio, maria rosaria/0000-0002-7911-9770			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; Aimaretti G, 2001, Pituitary, V4, P129, DOI 10.1023/A:1015306705154; Aimaretti G, 2001, J Pediatr Endocrinol Metab, V14 Suppl 5, P1233; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Aimaretti G, 2003, CLIN ENDOCRINOL, V59, P56, DOI 10.1046/j.1365-2265.2003.01794.x; Aimaretti G, 2000, J CLIN ENDOCR METAB, V85, P3693, DOI 10.1210/jc.85.10.3693; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Ceballos R, 1966, Ala J Med Sci, V3, P185; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Cornelia G, 2003, GROWTH HORM IGF RES, V13, P104, DOI 10.1016/S1096-6374(03)00010-8; DANIEL PM, 1959, LANCET, V2, P927; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; EDWARDS OM, 1986, MEDICINE, V65, P281; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lamberts SWJ, 1998, LANCET, V352, P127; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; 2001, J CLIN ENDOCRINOL ME, V83, P379	25	37	37	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1096-6374	1532-2238		GROWTH HORM IGF RES	Growth Horm. IGF Res.	JUN	2004	14			A			S114	S117		10.1016/j.ghir.2004.03.025			4	Cell Biology; Endocrinology & Metabolism	Cell Biology; Endocrinology & Metabolism	827CS	WOS:000221876700026	15135791				2021-06-18	
J	Dawson, DR; Levine, B; Schwartz, ML; Stuss, DT				Dawson, DR; Levine, B; Schwartz, ML; Stuss, DT			Acute predictors of real-world outcomes following traumatic brain injury: a prospective study	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC AMNESIA; COMMUNITY INTEGRATION; RECOVERY; EMPLOYMENT; RETURN; DISABILITY; SEVERITY; COMA	Primary objective: To determine whether the recovery of acute attention and memory improves the prediction of real-world outcomes over that provided by standard demographic and injury-severity measures. Research design: Participants were recruited consecutively at the time of injury and followed prospectively at 1 (time 1, or T1) and 4 years (time 2, or T2). Methods and procedures: Measures of attention and memory and the Galveston Orientation and Amnesia Test (GOAT) were administered to 94 participants daily from the time of injury until the criterion was met. Sixty-three per cent returned at T1 and 53% returned at T2. Outcomes were psychosocial distress, return to work and/or school, and quality of life. Main outcomes and results: Recovery of attention, memory and orientation did not significantly improve prediction of outcomes at T1, but did so at T2. At T2, recovery of free recall of three words over 24 h was a more sensitive predictor of psychosocial distress and return to productivity than the GOAT. Conclusions: Free recall of three words may be a useful acute clinical test to enhance prediction of long-term outcomes.	Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Surg Neurosurg, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada	Dawson, DR (corresponding author), Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Dawson, Deirdre R/I-8882-2014; Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Dawson, Deirdre R/0000-0001-7517-6121; Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X			BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brown M, 1999, MT SINAI J MED, V66, P160; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Kelsey JL, 1986, METHODS OBSERVATIONA; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, UNPUB TEST AUDITORY; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; MOORE AD, 1994, BRAIN INJURY, V7, P193; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; OCONNER C, 2001, THESIS U TORONTO TOR; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wechsler D., 1987, WECHSLER MEMORY SCAL; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	45	37	38	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2004	18	3					221	238		10.1080/02699050310001617406			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900001	14726283				2021-06-18	
J	Alban, JP; Hopson, MM; Ly, V; Whyte, J				Alban, JP; Hopson, MM; Ly, V; Whyte, J			Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; methylphenidate; vital signs; adverse effects	DOUBLE-BLIND; PLACEBO; ADOLESCENTS	Objective: To study methylphenidate's adverse effects and impact on vital signs within the adult traumatic brain injury population. Design: Thirty-five adults with traumatic brain injury enrolled in a double-blind, placebo-controlled, 6-wk crossover study of methylphenidate, given in a dose of 0.3 mg/kg/dose, twice a day. Vital signs were taken by trained clinicians and research assistants. Participants filled out weekly questionnaires pertaining to the adverse effects. Results: Poor appetite was the only adverse effect related to methylphenidate. Other adverse effects commonly associated with methylphenidate, such as insomnia, rapid heart rate, and anxiety, were not found to be significantly related to the medication. The average rise in mean arterial pressure on methylphenidate was 2.5 mm. Methylphenidate showed a stronger impact on pulse, with an average increase of 7 beats/min. Baseline vital signs did not predict the degree of increase on methylphenidate. Conclusion: Methylphenidate appears to be safe for the adult population with traumatic brain injury. However, because a few individuals experienced significant changes in vital signs and adverse effects, all patients should be monitored.	Thomas Jefferson Univ, Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19141 USA	Whyte, J (corresponding author), Thomas Jefferson Univ, Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor Rd,Korman Bldg,Suite 213, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			BARNHART E, 1991, PHYS DESK REFERENCE, P865; Burke DT, 2003, AM J PHYS MED REHAB, V82, P493, DOI 10.1097/00002060-200307000-00001; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Efron D, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e6; Glenn MB, 1998, J HEAD TRAUMA REHAB, V13, P87, DOI 10.1097/00001199-199810000-00010; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Jansen IHM, 2001, J AM GERIATR SOC, V49, P474, DOI 10.1046/j.1532-5415.2001.49092.x; JOHNSON ML, 1992, AM J PHYS MED REHAB, V71, P239, DOI 10.1097/00002060-199208000-00008; KLORMAN R, 1987, J AM ACAD CHILD PSY, V26, P363, DOI 10.1097/00004583-198705000-00015; LINGAM VR, 1988, J CLIN PSYCHIAT, V49, P151; LOWE TL, 1982, JAMA-J AM MED ASSOC, V247, P1729, DOI 10.1001/jama.247.12.1729; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; ROSENBERG PB, 1991, J CLIN PSYCHIAT, V52, P263; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; VARLEY CK, 1983, J AM ACAD CHILD PSY, V22, P351, DOI 10.1016/S0002-7138(09)60671-3; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	18	37	37	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	2004	83	2					131	137		10.1097/01.phm.0000112308.68586.1d			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	767AP	WOS:000188416600007	14758299				2021-06-18	
J	Evans, RW				Evans, RW			Post-traumatic headaches	NEUROLOGIC CLINICS			English	Article							MINOR HEAD-INJURY; BRAIN-INJURY; MILD; MIGRAINE; EPIDEMIOLOGY; CONCUSSION; RECOVERY; TRAUMA	Post-traumatic headaches are one of the most common and controversial secondary headache types. After mild head injury, up to 50% of people develop a post concussion syndrome, which has been controversial for over 135 years. Headache is estimated as present in 30% to 90% of patients after mild head injury. Most headaches are of the tension type, although migraines can increase in frequency or occur acutely or chronically de novo. The treatments are the same as for the primary headaches. Approximately 20% of patients have persistent post-traumatic headaches for more than 1 year, which may not resolve despite the settlement of any pending litigation.	Univ Texas, Houston Med Sch, Pk Plaza Hosp, Dept Neurol, Houston, TX 77004 USA	Evans, RW (corresponding author), Univ Texas, Houston Med Sch, Pk Plaza Hosp, Dept Neurol, 1200 Binz 1370, Houston, TX 77004 USA.	rwevans@pol.net					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andrikopoulos J, 2003, HEADACHE, V43, P553; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BENOIT BG, 1982, CAN J NEUROL SCI, V9, P321, DOI 10.1017/S0317167100044140; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Denker P., 1944, NY STATE J MED, V44, P379; Edna T H, 1987, J Oslo City Hosp, V37, P41; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Erichsen JE, 1867, RAILWAY OTHER INJURI; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; EVANS RW, 2000, PROGNOSIS NEUROLOGIC, P366; EVANS RW, 2004, MEDLINK NEUROLOGY; EVANS RW, 2000, HDB HEADACHE, P117; Fukutake T, 2000, NEUROLOGY, V54, P264, DOI 10.1212/WNL.54.1.264; Gee JR, 2003, HEADACHE, V43, P276, DOI 10.1046/j.1526-4610.2003.03053.x; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GRAHAM DI, 1996, NEUROLOGY TRAUMA, P53; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Headache Classification Subcommittee of the International headache Society, 2004, CEPHALALGIA S1, V24, P59; Jennett B, 1990, HDB CLIN NEUROLOGY, V13, P1; Jensen TS, 2000, HEADACHES, P781; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lay CL, 1999, HEADACHE, V39, P275, DOI 10.1046/j.1526-4610.1999.3904275.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Limmroth V, 1991, AM J EPIDEMIOL, V134, P1111; Loder E, 2002, CLIN J PAIN, V18, pS169, DOI 10.1097/00002508-200211001-00009; LORD SM, 1994, J NEUROL NEUROSUR PS, V57, P1187, DOI 10.1136/jnnp.57.10.1187; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILO R, 1987, ACTA NEUROCHIR, V84, P13, DOI 10.1007/BF01456345; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; Rigler I, 1879, UEBER VERLETZUNGEN E; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; Russell MB, 1996, EUR J NEUROL, V3, P424, DOI 10.1111/j.1468-1331.1996.tb00243.x; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Soriani S, 2000, ARCH PEDIAT ADOL MED, V154, P90; SYMONDS C, 1962, LANCET, V1, P1; TRIMBLE M, 1981, POSTTRAUMTIC NEUROSI; VILMING ST, 2000, LOW CEREBROSPINAL FL, P831; WEINSTOCK A, 1995, NEUROLOGY, V45, pA347; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; WRIGHTSON P, 1989, MILD HEAD INJURY, P245	54	37	38	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2004	22	1					237	+		10.1016/S0733-8619(03)00097-5			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	779DZ	WOS:000189281300014	15062537				2021-06-18	
J	von Holst, H; Cassidy, JD				von Holst, H; Cassidy, JD			Mandate of the who collaborating centre task force on mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; epidemiology; diagnosis; treatment; prognosis		In collaboration with outside experts, the WHO Collaborating Centre for Neurotrauma at the Karolinska Institute, Stockholm, Sweden, has assembled a task force to undertake a best-evidence synthesis of the literature on mild traumatic brain injury. The task force has addressed the epidemiology, diagnosis, prognosis, treatment and economic costs of mild traumatic brain injury in order to make recommendations to reduce the medical as well as the social consequences of mild traumatic brain injury.	Karolinska Hosp, Dept Neurosurg, WHO, Collaborating Ctr Neurotrauma Task Force MTBI, SE-17176 Stockholm, Sweden; Royal Inst Technol, Ctr Technol Hlth, Stockholm, Sweden; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden	von Holst, H (corresponding author), Karolinska Hosp, Dept Neurosurg, WHO, Collaborating Ctr Neurotrauma Task Force MTBI, SE-17176 Stockholm, Sweden.	hans.vonholst@ks.se					Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Levin HS, 1989, MILD HEAD INJURY; Slavin R. E., 1986, EDUC RES, V15, P5, DOI [10.3102/0013189X015009005, DOI 10.3102/0013189X015009005]; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; SPITZER WO, 1995, SPINE, V20, P2372; SPITZER WO, 1995, SPINE, V20, pS1; SPITZER WO, 1987, SPINE, V12, pS1; TEASDALE G, 1974, LANCET, V2, P81; *WHO, WHAT IS WHO COLL CTR	10	37	38	0	2	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			8	10		10.1080/16501960410023633			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	800QR	WOS:000220043300003	15083866	DOAJ Gold			2021-06-18	
J	Wiese, H; Stude, P; Nebel, K; Osenberg, D; Volzke, V; Ischebeck, W; Stolke, D; Diener, HC; Keidel, M				Wiese, H; Stude, P; Nebel, K; Osenberg, D; Volzke, V; Ischebeck, W; Stolke, D; Diener, HC; Keidel, M			Impaired movement-related potentials in acute frontal traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						traumatic brain injury; frontal lobe; EEG; Bereitschaftspotential; movement related potential; supplementary motor area	SUPPLEMENTARY MOTOR AREA; HUMAN CEREBRAL-CORTEX; HIGH-RESOLUTION EEG; FUNCTIONAL REORGANIZATION; POSTSTROKE HEMIPARESIS; MAGNETIC STIMULATION; UNILATERAL MOVEMENTS; PREMOTOR CORTEX; RHESUS-MONKEY; STROKE	Objective: Focal brain lesions due to traumatic brain injury (TBI) do not only lead to functional deficits in the lesion area, but also disturb the structurally intact neuronal network connected to the lesion site. Therefore we hypothesized dysfunctions of the cortical motor network after frontal TBI. The movement related potential (MRP) is an EEG component related to voluntary movement consisting of the Bereitschaftspotential (BP), the negative slope (NS), and the motor potential (MP). The aim of our study was to demonstrate alterations in the movement related cortical network in the acute stage after TBI by comparing our patients' MRPs to those of a healthy control group. Methods: EEGs of 22 patients with magnetic resonance imaging defined contusions of the prefrontal cortex were recorded within 8 weeks after TBI. We further recruited a healthy control group. The paradigm consisted of self-paced abductions of the right index finger. Results: Compared to healthy controls, the BP in the patient group was significantly reduced and its onset delayed. Moreover, an enhanced contribution of the postrolandic hemisphere ipsilateral to the movement and a reduced contribution of the left frontal cortex, ipsilateral to the lesion in the majority of the patients, were observed during motor execution (MP). Conclusions: Anatomical connections between the prefrontal cortex and the supplementary motor area (SMA) are known to exist. We suggest that prefrontal lesions lead to reduced neuronal input into the SMA. This deficit in the preparatory motor network may cause the reduced BPs in our patients. Moreover, an increased need for attentional resources might explain the enhanced motor potentials during movement execution. In conclusion, we demonstrated altered MRPs in the acute stage after frontal TBI, which are a consequence of disturbed neuronal networks involved in the preparation and execution of voluntary movements. (C) 2003 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Univ Essen Gesamthsch, Dept Neurol, D-45122 Essen, Germany; Klin Holthausen, Hattingen, Germany; Univ Essen Gesamthsch, Dept Neurosurg, D-45122 Essen, Germany; Dist Hosp Bayreuth, Dept Neurol, Bayreuth, Germany; Dist Hosp Bayreuth, Dept Neurorehabil, Bayreuth, Germany	Wiese, H (corresponding author), Univ Essen Gesamthsch, Dept Neurol, Hufelandstr 55, D-45122 Essen, Germany.	holger.wiese@uni-essen.de	Wiese, Holger/M-5281-2014; Diener, Hans-Christoph/AAF-7275-2019	Wiese, Holger/0000-0003-4928-0771; 			BARBAS H, 1987, J COMP NEUROL, V256, P211, DOI 10.1002/cne.902560203; BATES JF, 1993, J COMP NEUROL, V336, P211, DOI 10.1002/cne.903360205; Cao Y, 1998, STROKE, V29, P112, DOI 10.1161/01.STR.29.1.112; Caramia MD, 1996, NEUROREPORT, V7, P1756, DOI 10.1097/00001756-199607290-00012; Caramia MD, 2000, CLIN NEUROPHYSIOL, V111, P1990, DOI 10.1016/S1388-2457(00)00430-2; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cui RQ, 1999, NEUROIMAGE, V9, P124, DOI 10.1006/nimg.1998.0388; CUNNINGTON R, 1995, BRAIN, V118, P935, DOI 10.1093/brain/118.4.935; Cunnington R, 2002, NEUROIMAGE, V15, P373, DOI 10.1006/nimg.2001.0976; DEECKE L, 1969, EXP BRAIN RES, V7, P158; DEECKE L, 1987, J NEUROL NEUROSUR PS, V50, P1430, DOI 10.1136/jnnp.50.11.1430; Green JB, 1999, STROKE, V30, P2659, DOI 10.1161/01.STR.30.12.2659; IKEDA A, 1995, ELECTROEN CLIN NEURO, V95, P323, DOI 10.1016/0013-4694(95)00086-E; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; JASON GW, 1986, NEUROPSYCHOLOGIA, V24, P181, DOI 10.1016/0028-3932(86)90051-5; JURGENS U, 1984, BRAIN RES, V300, P63, DOI 10.1016/0006-8993(84)91341-6; KEIDEL M, 1983, NATURWISSENSCHAFTEN, V70, P180, DOI 10.1007/BF01047555; KELLER I, 1990, ELECTROEN CLIN NEURO, V76, P351, DOI 10.1016/0013-4694(90)90036-J; Knosche T, 1996, ELECTROEN CLIN NEURO, V99, P183, DOI 10.1016/0013-4694(96)95648-5; KOLB B, 1981, NEUROPSYCHOLOGIA, V19, P491, DOI 10.1016/0028-3932(81)90016-6; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; Lee KM, 1999, NEUROIMAGE, V9, P117, DOI 10.1006/nimg.1998.0393; LEONARD G, 1988, NEUROPSYCHOLOGIA, V26, P79, DOI 10.1016/0028-3932(88)90032-2; LIBET B, 1982, ELECTROEN CLIN NEURO, V54, P322, DOI 10.1016/0013-4694(82)90181-X; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; LUPPINO G, 1993, J COMP NEUROL, V338, P114, DOI 10.1002/cne.903380109; MCADAM DW, 1971, ELECTROEN CLIN NEURO, V30, P511, DOI 10.1016/0013-4694(71)90148-9; MCADAM DW, 1969, ELECTROEN CLIN NEURO, V27, P73, DOI 10.1016/0013-4694(69)90111-4; NATIV A, 1994, ARCH PHYS MED REHAB, V75, P1322; NATIV A, 1991, PHYS THER, V71, P48, DOI 10.1093/ptj/71.1.48; NESHIGE R, 1988, BRAIN, V111, P719; Netz J, 1997, BRAIN, V120, P1579, DOI 10.1093/brain/120.9.1579; Praamstra P, 1996, ELECTROEN CLIN NEURO, V98, P468, DOI 10.1016/0013-4694(96)95643-6; Richer F, 1999, NEUROPSYCHOLOGIA, V37, P1427, DOI 10.1016/S0028-3932(99)00029-9; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; Seitz RJ, 1998, ARCH NEUROL-CHICAGO, V55, P1081, DOI 10.1001/archneur.55.8.1081; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; SINGH J, 1990, BRAIN RES, V531, P45, DOI 10.1016/0006-8993(90)90756-2; TEASDALE G, 1974, LANCET, V2, P81; Turton A, 1996, ELECTROMYOGR MOTOR C, V101, P316, DOI 10.1016/0924-980X(96)95560-5; Urbano A, 1996, NEUROREPORT, V8, P203, DOI 10.1097/00001756-199612200-00041; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Zimmermann P., 1994, TESTBATTERIE AUFMERK	46	37	37	0	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2004	115	2					289	298		10.1016/S1388-2457(03)00348-1			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	774KL	WOS:000188978600004	14744568				2021-06-18	
J	Wang, YT; Kent, RD; Duffy, JR; Thomas, JE; Weismer, G				Wang, YT; Kent, RD; Duffy, JR; Thomas, JE; Weismer, G			Alternating motion rate as an index of speech motor disorder in traumatic brain injury	CLINICAL LINGUISTICS & PHONETICS			English	Article						speech motor disorder; traumatic brain injury; alternating motion rate	CLOSED-HEAD-INJURY; VOICE ONSET TIME; DYSARTHRIC SPEAKERS; ELECTROMAGNETIC ARTICULOGRAPHY; KINEMATIC ANALYSIS; VERBAL IMPAIRMENT; SPEAKING RATE; FEATURES; CHILDREN	The task of syllable alternating motion rate (AMR) (also called diadochokinesis) is suitable for examining speech disorders of varying degrees of severity and in individuals with varying levels of linguistic and cognitive ability. However, very limited information on this task has been published for subjects with traumatic brain injury (TBI). This study is a quantitative and qualitative acoustic analysis of AMR in seven subjects with TBI. The primary goal was to use acoustic analyses to assess speech motor control disturbances for the group as a whole and for individual patients. Quantitative analyses included measures of syllable rate, syllable and intersyllable gap durations, energy maxima, and voice onset time (VOT). Qualitative analyses included classification of features evident in spectrograms and waveforms to provide a more detailed description. The TBI group had (1) a slowed syllable rate due mostly to lengthened syllables and, to a lesser degree, lengthened intersyllable gaps, (2) highly correlated syllable rates between AMR and conversation, (3) temporal and energy maxima irregularities within repetition sequences, (4) normal median VOT values but with large variation, and (5) a number of speech production abnormalities revealed by qualitative analysis, including explosive speech quality, breathy voice quality, phonatory instability, multiple or missing stop bursts, continuous voicing, and spirantization. The relationships between these findings and TBI speakers' neurological status and dysarthria types are also discussed. It was concluded that acoustic analyses of the AMR task provides specific information on motor speech limitations in individuals with TBI.	Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Kent, RD (corresponding author), Univ Wisconsin, Waisman Ctr, Rm 435,1500 Highland Ave, Madison, WI 53705 USA.	kent@waisman.wisc.edu	Kent, Raymond D/AAI-1928-2020		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC00319] Funding Source: Medline		ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; Auzou P, 2000, CLIN LINGUIST PHONET, V14, P131; BLUMBERGER J, 1995, BRAIN INJURY, V9, P797, DOI 10.3109/02699059509008235; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; Darley F., 1975, MOTOR SPEECH DISORDE; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; DAVIS K, 1995, J CHILD LANG, V22, P275, DOI 10.1017/S030500090000979X; Duffy J. R., 2020, MOTOR SPEECH DISORDE; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Goozee JV, 1999, J MED SPEECH-LANG PA, V7, P209; Goozee JV, 2000, BRAIN INJURY, V14, P153, DOI 10.1080/026990500120817; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; Kent R, 1998, J MED SPEECH-LANG PA, V6, P165; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; Kent RD, 1999, J MED SPEECH-LANG PA, V7, P83; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; Kent RD, 1997, FOLIA PHONIATR LOGO, V49, P63, DOI 10.1159/000266440; KENT RD, 1980, J PHONETICS, V8, P157, DOI 10.1016/S0095-4470(19)31460-3; KENT RD, 1982, BRAIN LANG, V15, P259, DOI 10.1016/0093-934X(82)90060-8; Kent RD, 2002, ACOUSTIC ANAL SPEECH; KREUL EJ, 1972, J SPEECH HEAR RES, V15, P72, DOI 10.1044/jshr.1501.72; Kuehn D. P., 1976, J PHONETICS, V4, P303; LEFKOWITZ D, 1994, J MED SPEECH-LANG PA, V2, P1; McHenry M, 2000, LARYNGOSCOPE, V110, P1157, DOI 10.1097/00005537-200007000-00017; MCHENRY MA, 1994, J SPEECH HEAR RES, V37, P1271, DOI 10.1044/jshr.3706.1271; McHenry MA, 1998, ARCH PHYS MED REHAB, V79, P545, DOI 10.1016/S0003-9993(98)90071-5; McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; McHenry MA, 2001, BRAIN INJURY, V15, P741, DOI 10.1080/02699050117120; McHenry MA, 1996, DISORDERS MOTOR SPEE, P229; MILENKOVIC P, 2000, TIME FREQUENCY ANAL; Nishio M, 2001, CLIN LINGUIST PHONET, V15, P309; Ozsancak C, 2001, FOLIA PHONIATR LOGO, V53, P48, DOI 10.1159/000052653; PORTNOY RA, 1982, J SPEECH HEAR DISORD, V47, P324, DOI 10.1044/jshd.4703.324; PTACEK PH, 1966, J SPEECH HEAR RES, V9, P353, DOI 10.1044/jshr.0903.353; RIETVELD ACM, 1987, J PHONETICS, V15, P273, DOI 10.1016/S0095-4470(19)30571-6; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; WEISMER G, 1997, HDB PHONETIC SCI, P191; Westbury JR, 1993, ANN B RES I LOGOPEDI, P13; WILSON J T L, 1990, Brain Injury, V4, P349; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZIEGLER W, 1988, BRIT J DISORD COMMUN, V23, P215	48	37	39	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9206	1464-5076		CLIN LINGUIST PHONET	Clin. Linguist. Phon.	JAN-FEB	2004	18	1					57	84		10.1080/02699200310001596160			28	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	773JA	WOS:000188894800004	15053268				2021-06-18	
J	Mussack, T; Dvorak, J; Graf-Baumann, T; Jochum, M				Mussack, T; Dvorak, J; Graf-Baumann, T; Jochum, M			Serum S-100B protein levels in young amateur soccer players after controlled heading and normal exercise	EUROPEAN JOURNAL OF MEDICAL RESEARCH			English	Article						heading; minor head injury; S-100B; soccer; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PATIENT-MANAGEMENT; DAMAGE; FOOTBALL; MARKER; TOMOGRAPHY; HISTORY; PHASE; LEAD	Background: Repeated impacts by heading might lead to significant head injuries in soccer players comparable to those of patients with accidental minor traumatic brain injury (TBI). The neuroprotein S-100B released into the circulation is suggested to be a reliable marker indicating brain damage. The objective was to evaluate the neuroprotein S-100B serum levels in young amateur soccer players early after controlled heading compared to early measurements after normal exercise as well as in other patients after minor TBI. Material and Methods: Sixty-one male amateur soccer players (median age 15.3 years) performed controlled heading aimed at the forehead for 55 minutes. Data were compared to 58 male amateur soccer players (15.9 years) performing 61 minutes of normal exercise training without head contact and 81 young male patients early after TBI who underwent computed tomography (CCT) for detection of intracranial lesions. First venous blood samples were drawn before the training sessions, second and third samples 60 and 360 minutes after heading or 64 and 355 minutes after exercise, respectively, 65 and 366 minutes after TBI. Results: Median S-100B serum levels of the heading group only slightly increased from 0.15 ng/ml to 0.18 ng/ml 60 minutes after end of training. Within 360 minutes S-100B values decreased again to 0.15 ng/ml reaching the initial values. S-100B serum values of the exercise group showed a similar transient increase exhibiting significant lower levels before exercise (0.10 ng/ml) as well as 64 minutes (0.11 ng/ml) and 355 minutes after exercise (0.09 ng/ml) compared to the heading group. According to age stratification in the heading group, starting median S-100B levels were significantly higher in subjects with 12-13 years (0.22 ng/ml) and 14-15 years (0.17 ng/ml) compared to those with 16-17 years of age (0.06 ng/ml). None of the subcollectives did reach median S-100B levels of the CCT+ group (n = 20) at admission (0.62 ng/ml) or 366 minutes later (0.32 ng/ml), which were significantly elevated compared to those of the CCT- group (n = 61) at admission (0.10 ng/ml) or 370 minutes later (0.08 ng/ml). Conclusions: Controlled repetitive heading in young amateur soccer players leads to a transient increase between 60 to 360 min after training, but does not appear to evoke a longer lasting S-100B release into serum indicating cellular brain damage. After heading S-100B levels are significantly elevated compared to normal exercise. Although soccer players with 12-13 years and 14-15 years revealed significantly higher S-100B values than with 16-17 years of age, the transient increase is independent of the age-related starting values. However, since brain damage due to abrupt heading a ball of high speed or accidental trauma during regular soccer games cannot be excluded, S-100B measurements in soccer players are initiated during video-controlled soccer games.	Univ Munich, Dept Surg, Klinikum Innenstadt, D-80336 Munich, Germany; FIFA, Med Assessment & Res Ctr, Zurich, Switzerland; Univ Munich, Klinikum Innenstadt, Dept Clin Chem & Clin Biochem, D-8000 Munich, Germany	Mussack, T (corresponding author), Univ Munich, Dept Surg, Klinikum Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	mussack@ch-i.med.uni-muenchen.de					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Baethmann A, 1999, ACT NEUR S, V73, P93; Baethmann A, 1998, ACT NEUR S, V71, P107; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bruce D A, 1982, Clin Sports Med, V1, P495; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Gennarelli TA, 1993, BIOMECHANICS IMPACT, P411; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hammon JW, 2000, J THORAC CARDIOV SUR, V119, P130, DOI 10.1016/S0022-5223(00)70227-3; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mussack T, 2000, ACT NEUR S, V76, P393; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reilly T., 1976, J HUMAN MOVEMENT STU, V2, P87; Roaas A, 1979, Br J Sports Med, V13, P3; Ross J, 2000, HAEMOPHILIA, V6, P41; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	40	37	37	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0949-2321	2047-783X		EUR J MED RES	Eur. J. Med. Res.	OCT 22	2003	8	10					457	464					8	Medicine, Research & Experimental	Research & Experimental Medicine	736FN	WOS:000186160900004	14594652				2021-06-18	
J	Santos, JB; Schauwecker, PE				Santos, JB; Schauwecker, PE			Protection provided by cyclosporin A against excitotoxic neuronal death is genotype dependent	EPILEPSIA			English	Article						seizures; mouse strain; kainate; mitochondria; excitotoxicity; resistance	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL-ARTERY OCCLUSION; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; KAINIC ACID; IN-VITRO; IMMUNOSUPPRESSANTS CYCLOSPORINE	Purpose: Previous studies have shown that the immunosuppressant cyclosporin A (CsA), a specific blocker of the mitochondrial permeability transition (MPT) pore, can dramatically ameliorate the selective neuronal necrosis resulting from ischemia-reperfusion, traumatic brain injury, and N-methyl-D-aspartate (NMDA)-evoked neurotoxicity. The purpose of this study was to determine whether two different immunosuppressants, CsA and FK-506, could ameliorate the neuronal damage observed after kainate-induced seizures in strains that are differentially susceptible to excitotoxin-induced cell death. Methods: Excitotoxin-resistant (C57BL/6) or -susceptible (FVB/N) mice were administered kainate alone (30 mg/kg), CsA alone (5, 10, or 20 mg/kg), or one of the immunosuppressants (CsA, 5 mg/kg or 10 mg/kg; FK-506, 0.5 mg/kg) followed by kainate. After drug administration, mice were monitored continuously for the onset and extent of seizure activity. After a survival of 7 days, animals were assessed for hippocampal damage. Results: Whereas CsA alone induced no epileptogenic effects and both immunosuppressants were without effect on the induction of kainate-induced seizures, administration of CsA to excitotoxin-susceptible mice (FVB/N) virtually eliminated neuronal cell death. In contrast, induction of neuronal cell death was evident when CsA was administered to excitotoxin-resistant mice (C57BL/6). Administration of FK-506, another commonly used immunosuppressant, which lacks an effect on the MPT, had no effect on modification of susceptibility to kainate-induced cell death in either strain. Conclusions: As our data show differential protection of hippocampal neurons against excitotoxic cell death by pretreatment with CsA, these results suggest that strain-dependent differences in mitochondrial integrity and function may exist.	Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, Los Angeles, CA 90089 USA	Schauwecker, PE (corresponding author), Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, BMT 401,1333 San Pabio St, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038696] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38696-01] Funding Source: Medline		ADAMS DH, 1987, LANCET, V1, P949; Bernardi P, 1998, BBA-BIOENERGETICS, V1365, P200, DOI 10.1016/S0005-2728(98)00069-3; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Buckman JF, 2001, J NEUROSCI, V21, P5054, DOI 10.1523/JNEUROSCI.21-14-05054.2001; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Butcher SP, 1997, J NEUROSCI, V17, P6939; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROMPTON M, 1988, BIOCHEM J, V255, P357; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; FRAKLIN KBJ, 1997, MOUSE BRAIN STEREOTA; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LIPTON SA, 1994, BRAIN RES, V547, P344; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Matsuura K, 1996, BRAIN RES, V733, P101, DOI 10.1016/0006-8993(96)00686-5; Mattson Mark P., 1996, V71, P1; Moriwaki A, 1998, NEUROSCIENCE, V86, P855, DOI 10.1016/S0306-4522(98)00071-2; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NADLER JV, 1980, BRAIN RES, V191, P387, DOI 10.1016/0006-8993(80)91289-5; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; NADLER JV, 1980, BRAIN RES, V195, P47; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; OKONKWO DO, 1999, ARCH BIOCHEM BIOPHYS, V311, P219; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OLNEY JW, 1986, ADV EXPT MED BIOL, P632; PACKER MA, 1995, EUR J BIOCHEM, V234, P231, DOI 10.1111/j.1432-1033.1995.231_c.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RACUSEN LC, 1990, LIFE SCI, V46, P1021, DOI 10.1016/0024-3205(90)90026-N; ROTHMAN SM, 1992, ANN NY ACAD SCI, V648, P133; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHINDER AF, 1996, J NEUROSCI, V16, P6126; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHWEIZER M, 1993, BIOCHEM PHARMACOL, V45, P641, DOI 10.1016/0006-2952(93)90138-M; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; Serkova N, 1999, J PHARMACOL EXP THER, V289, P800; Shuttleworth CWR, 2001, J NEUROSCI, V21, P4225, DOI 10.1523/JNEUROSCI.21-12-04225.2001; Sidman R. L., 1971, ATLAS MOUSE BRAIN SP; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611; WANG GJ, 1994, J NEUROPHYSIOL, V72, P2563; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Wong M, 2000, EPILEPSIA, V41, P271, DOI 10.1111/j.1528-1157.2000.tb00155.x; Wszolek ZK, 1997, SEIZURE, V6, P31, DOI 10.1016/S1059-1311(97)80050-7; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3	67	37	38	0	1	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0013-9580			EPILEPSIA	Epilepsia	AUG	2003	44	8					995	1002		10.1046/j.1528-1157.2003.66302.x			8	Clinical Neurology	Neurosciences & Neurology	708VG	WOS:000184590000002	12887430	Bronze			2021-06-18	
J	Canning, CG; Shepherd, RB; Carr, JH; Alison, JA; Wade, L; White, A				Canning, CG; Shepherd, RB; Carr, JH; Alison, JA; Wade, L; White, A			A randomized controlled trial of the effects of intensive sit-to-stand training after recent traumatic brain injury on sit-to-stand performance	CLINICAL REHABILITATION			English	Article							STROKE PATIENTS; EXERCISE; REHABILITATION; PROGRAM	Objective: To examine the effectiveness of intensive practice of sit-to-stand on motor performance, exercise capacity and exercise efficiency in traumatic brain-injured patients during early inpatient rehabilitation. Design: Single-blind randomized controlled pilot study. Setting: Brain injury rehabilitation unit. Subjects: Twenty-four subjects who had recently sustained a severe traumatic brain injury (TBI) were randomized into an experimental (n = 13) and a control (n = 11) group. Interventions: In addition to their usual rehabilitation programme, subjects in the experimental group participated in four weeks of intensive training of sit-to-stand and step-up exercises with the aim of improving performance of sit-to-stand. The control group did no additional sit-to-stand or step-up training. Main outcome measures: Total number of sit-to-stands in 3 min as a measure of motor performance; peak oxygen consumption during a maximal 3-min sit-to-stand test (VO(2)peak) as a measure of exercise capacity; oxygen consumption during a 3-min equivalent workload sit-to-stand test (VO(2)equiv) as a measure of exercise efficiency. Pre- and post-training measurements were made. Results: The exercise programme resulted in a 62% improvement in motor performance (number of repetitions of sit-to-stand in 3 min) for the experimental group compared with the control group's 18% improvement (p < 0.05). There was no significant difference between groups for changes in exercise capacity or efficiency. In the experimental group, the increase in VO(2)peak from pre-test to post-test correlated with the increase in sit-to-stand repetitions (p < 0.05). Conclusions: Intensive task-specific training is recommended as an important component of rehabilitation early following severe traumatic brain injury.	Univ Sydney, Fac Hlth Sci, Sch Physiotherapy, Lidcombe, NSW 1825, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW, Australia	Canning, CG (corresponding author), Univ Sydney, Fac Hlth Sci, Sch Physiotherapy, POB 170, Lidcombe, NSW 1825, Australia.		Alison, Jennifer/B-6250-2012				Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Berger R. A., 1988, P 34 ANN M ORTH RES; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; Convertino VA, 1997, MED SCI SPORT EXER, V29, P187, DOI 10.1097/00005768-199702000-00004; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Jackson D, 2001, CLIN REHABIL, V15, P535, DOI 10.1191/026921501680425252; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Macko RF, 1997, STROKE, V28, P326, DOI 10.1161/01.STR.28.2.326; NEISTADT ME, 1994, AM J OCCUP THER, V48, P877, DOI 10.5014/ajot.48.10.877; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; Saltin B, 1968, CIRCULATION       S7, V38, pVII1, DOI DOI 10.1161/01; Wolman RL, 1994, CLIN REHABIL, V8, P253	15	37	43	0	14	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	JUL	2003	17	4					355	362		10.1191/0269215503cr620oa			8	Rehabilitation	Rehabilitation	678RY	WOS:000182881300002	12785242				2021-06-18	
J	Knudsen, SK; Oen, EO				Knudsen, SK; Oen, EO			Blast-induced neurotrauma in whales	NEUROSCIENCE RESEARCH			English	Article						blast injury; brain; penthrite; explosives; traumatic brain injury; minke whale; Balaenoptera acutorostrata; Cetacea	TRAUMATIC BRAIN-INJURY; ADULT-RAT BRAIN; PRESSURE WAVE INJURIES; DIFFUSE AXONAL INJURY; LASTING IMPULSE NOISE; NON-PENETRATIVE BLAST; SUBDURAL-HEMATOMA; NERVOUS-SYSTEM; MINKE WHALES; EXPOSURE	A majority of investigations on primary blast injuries have focused on gas-containing organs, while the likelihood of blast-induced neurotrauma remains underrated. In Norway minke whales (Balaenoptera acutorostrata) are hunted using small fishing boats rigged with harpoon guns, which fire harpoons tipped with a grenade containing a charge of 30-g penthrite. The grenade detonates 60-70 cm inside the animal. The present study was undertaken to characterize the neuropathological changes caused by the penthrite blast and evaluate its role in the loss of consciousness and death in hunted whales. The study included 37 minke whales that were examined shipboard. The brains were later subjected to gross and light microscopy examination. The results showed that intra-body detonation of the grenade in near vicinity of the brain resulted in trauma similar to severe traumatic brain injury associated with a direct blow to the head. Detonation in more distant areas of the body resulted in injuries resembling acceleration-induced diffuse traumatic brain injury. The authors conclude that even if several vital organs were fatally injured in most whales, the neurotrauma induced by the blast-generated pressure waves were the primary cause for the immediate or very rapid loss of consciousness and death. (C) 2003 Elsevier Science Ireland Ltd. and the Japan Neuroscience Society. All rights reserved.	Norwegian Sch Vet Sci, Dept Arctic Vet Med, NO-9292 Tromso, Norway	Knudsen, SK (corresponding author), Norwegian Sch Vet Sci, Dept Arctic Vet Med, NO-9292 Tromso, Norway.						Abbott WD, 1943, J AMER MED ASSOC, V121, P739, DOI 10.1001/jama.1943.02840100025007; AITA J A, 1946, Bull U S Army Med Dep, V6, P411; Ascroft PB, 1943, LANCET, V1, P234; BAYTOS JF, 1980, LASL EXPLOSIVE PROPE, P130; Berlin R, 1976, Acta Chir Scand Suppl, V459, P1; BOSTROM K, 1992, ACTA NEUROCHIR SUPP, V55, pS25; BOSTROM K, 1986, ACTA NEUROCHIR SUPP, V36, pS51; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; CERNAK I, 1996, J TRAUMA, V40, pS418; CLEMEDSON C. J., 1954, MILITARY SURGEON, V114, P424; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; CROOKS DA, 1991, VIRCHOWS ARCH A, V418, P479, DOI 10.1007/BF01606496; CULLING CF, 1985, CELLULAR PATHOLOGY T, P160; DEGIROLANI U, 1994, ROBBINS PATHOLOGICAL, P1305; DEMANN D, 1990, INT J NEUROSCI, V54, P101, DOI 10.3109/00207459008986624; DENNYBROWN D, 1943, AM NEURAL ASS, V68, P98; Dobratz B. M., 1981, LLNL EXPLOSIVE HDB P; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; ESIRI MM, 1996, OPPENHEIMERS DIAGNOS, P7; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; Fulton J. F., 1942, NEW ENGL J MED, V226, P1; Guy R J, 2000, J R Nav Med Serv, V86, P27; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; HAUG T, 1998, SJOPATTEDYR OM HVAL, P1; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; JACOBS GB, 1968, MIL MED, V133, P132; JONSGARD A, 1992, PUBLICATION KOMMANDO, V27, P25; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Knudsen SK, 2002, J NEUROSCI METH, V120, P35, DOI 10.1016/S0165-0270(02)00182-6; Krohn PL, 1942, LANCET, V1, P252; Li B, 2001, Chin J Traumatol, V4, P97; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McIntosh TK, 1996, LAB INVEST, V74, P315; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mott F. W., 1917, J ROY ARMY MED CORPS, V29, P662; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Mott FW, 1916, LANCET, V1, P545; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; MYERS CS, 1940, SHELL SHOCK FRANCE 1, P1; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; OEN EO, 1995, ACTA VET SCAND, V36, P111; OEN EO, 1983, NORD VET MED, V35, P314; OEN EO, 1995, ACTA VET SCAND, V36, P103; OEN EO, 2002, IWC54WK7AWI6; OEN EO, 1999, IWC51WK10; OEN EO, 1995, KILLING METHODS MINK; OEN EO, 1995, ACTA VET SCAND, V36, P152; OEN EO, 1999, IWC51WK11; Phillips Y., 1990, TXB MILITARY MED 1, V5, P221; PHILLIPS YY, 1986, ANN EMERG MED, V15, P1446, DOI 10.1016/S0196-0644(86)80940-4; POLLOCK LJ, 1943, ILLINOIS M J, V83, P165; ROGERS L, 1945, MED J AUSTRALIA, V2, P209; Rosen Leif, 1992, Tidsskrift for den Norske Laegeforening, V112, P1590; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; SHARPNACK DD, 1990, TXB MILITARY MED 1, V5, P271; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stewart OW, 1941, LANCET, V1, P172; STUHMILLER JH, 1990, TXB MILITARY MED 1, V5, P241; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; SUNESON A, 1989, J TRAUMA, V29, P10, DOI 10.1097/00005373-198901000-00003; SUNESON A, 1988, J TRAUMA, V28, P197; Sylvia FR, 2001, MIL MED, V166, P918; Tomita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P213; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VLVERTON JT, 1996, J TRAUMA, V40, pS111; WOOD H, 1946, U S Nav Med Bull, V46, P51; Zhao WG, 1999, NEUROL MED-CHIR, V39, P735, DOI 10.2176/nmc.39.735; 1996, IWC484	81	37	42	0	11	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0168-0102			NEUROSCI RES	Neurosci. Res.	JUL	2003	46	3					377	386		10.1016/S0168-0102(03)00101-9			10	Neurosciences	Neurosciences & Neurology	694QR	WOS:000183785900013	12804799				2021-06-18	
J	Libby, AM; Sills, MR; Thurston, MK; Orton, HD				Libby, AM; Sills, MR; Thurston, MK; Orton, HD			Costs of childhood physical abuse: Comparing inflicted and unintentional traumatic brain injuries	PEDIATRICS			English	Article						child abuse; craniocerebral trauma; traumatic brain injury; direct service costs; health care costs; health expenditures; head injuries; hospital costs; length of stay; severity of illness; trauma; nervous system	NURSE HOME VISITATION; HEAD-INJURY; RANDOMIZED TRIAL; STRESS-DISORDER; MALTREATMENT; CHILDREN; INFANTS; NEGLECT; POLICY	Objectives. To estimate the effect of early childhood abuse (ie, inflicted injury) on medical costs of head trauma. Methods. Abstracts of patient records were drawn from the annual 1993-2000 Colorado state-mandated hospital discharge database maintained by the Colorado Hospital Association. The 2 dependent variables were total charges (TC) and length of stay. Our key independent variable was the nature of injury, ie, inflicted or unintentional; other independent variables were age, severity level, death, and trauma designation of the hospital. Comparisons of variables between patients with inflicted and unintentional head trauma were performed using Student's t tests or chi(2) statistics. Ordinary least squares regression was used to estimate the marginal and total effects of inflicted injury on TC and LOS. Results. Of the 1097 head trauma patients <3 years old, 814 had unintentional and 283 had inflicted head trauma. Head trauma was defined using the Centers for Disease Control definition of traumatic brain injury. Patients with inflicted injuries were younger and had a higher average severity level and overall mortality rate than did patients with unintentional head trauma. The regression models showed that, controlling for age and severity, patients with inflicted head trauma stayed in the hospital 52% longer (2 days), and had a mean total bill 89% higher ($4232 more) than did patients with unintentional head trauma. Conclusions. The findings from multivariate models of TC and length of stay corroborate the simpler univariate findings of earlier studies. By focusing on the impact of those cases of child abuse that lead to a specific, severe clinical entity (traumatic brain injury), we isolated a significant economic impact of abuse on health care expenditures for injury.	Univ Colorado, Hlth Sci Ctr, Dept Emergency Med, Denver, CO USA; Childrens Hosp, Denver, CO 80218 USA; Brigham Young Univ, Dept Econ, Provo, UT 84602 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA	Libby, AM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Box 6508,Mail Stop F800, Aurora, CO 80045 USA.		Libby, Anne M/B-6984-2013; Libby, Anne M./K-3476-2015	Libby, Anne M/0000-0002-4564-9407; Sills, Marion/0000-0003-1322-0822			Berkowitz Carol D., 1995, Emergency Medicine Clinics of North America, V13, P321; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; De Bellis MD, 2001, CHILD ABUSE NEGLECT, V25, P923, DOI 10.1016/S0145-2134(01)00247-2; Deb S, 1999, AM J PSYCHIAT, V156, P374; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Famularo R, 1996, CHILD ABUSE NEGLECT, V20, P1245, DOI 10.1016/S0145-2134(96)00119-6; FAMULARO R, 1994, ARCH PEDIAT ADOL MED, V148, P1032, DOI 10.1001/archpedi.1994.02170100030007; Finkelhor D, 1998, JAMA-J AM MED ASSOC, V280, P1864, DOI 10.1001/jama.280.21.1864; Forjuoh SN, 2000, CHILD ABUSE NEGLECT, V24, P1019, DOI 10.1016/S0145-2134(00)00163-0; FREEMAN JL, 1995, MED CARE, V33, P806, DOI 10.1097/00005650-199508000-00006; Gedeit R, 2001, Pediatr Rev, V22, P118, DOI 10.1542/pir.22-4-118; Irazuzta JE, 1997, CHILD ABUSE NEGLECT, V21, P751, DOI 10.1016/S0145-2134(97)00036-7; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JOHNSON CF, 2000, NELSONS TXB PEDIAT, P113; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Krugman RD, 1997, PEDIATRICS, V100, P890, DOI 10.1542/peds.100.5.890; Macfie J, 2001, DEV PSYCHOPATHOL, V13, P233, DOI 10.1017/S0954579401002036; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; *NAT PED TRAUM REG, 1996, CHILDR AD DIS DUE TR, P3; NORUSIS MJ, 1999, SPSS 9 0 WINDOWS USE; OLDS D, 1995, PEDIATRICS, V95, P365; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Osberg JS, 1997, BRAIN INJURY, V11, P11; PECLET MH, 1990, J PEDIATR SURG, V25, P85, DOI 10.1016/S0022-3468(05)80169-1; PEREZ CM, 1994, CHILD ABUSE NEGLECT, V18, P617, DOI 10.1016/0145-2134(94)90012-4; *PREV CHILD AB AM, 2001, TOT EST COST CHILD A; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rubin D, 2001, CURR OPIN PEDIATR, V13, P388, DOI 10.1097/00008480-200110000-00002; Runge J W, 1993, Emerg Med Clin North Am, V11, P241; Rutledge R, 1998, J TRAUMA, V45, P791, DOI 10.1097/00005373-199810000-00032; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; SUMMERS CL, 1992, ARCH DIS CHILD, V67, P905, DOI 10.1136/adc.67.7.905; Theodore AD, 1999, PEDIATRICS, V104, P168; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 2001, CHILD MALT 1999; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015	43	37	38	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2003	112	1					58	65		10.1542/peds.112.1.58			8	Pediatrics	Pediatrics	696WR	WOS:000183911000025	12837868				2021-06-18	
J	Konrad, K; Gauggel, S; Schurek, J				Konrad, K; Gauggel, S; Schurek, J			Catecholamine functioning in children with traumatic brain injuries and children with attention-deficit/hyperactivity disorder	COGNITIVE BRAIN RESEARCH			English	Article						attention-deficit/hyperactivity disorder; traumatic brain injury; urinary catecholamines; eyeblink rate	DEFICIT-HYPERACTIVITY DISORDER; CORTICAL COGNITIVE FUNCTION; INHIBITORY CONTROL; HEAD-INJURY; ADHD; EPINEPHRINE; MECHANISMS	Recent studies suggest that children with attention-deficit/hyperactivity disorder (ADHD) and children with traumatic brain injuries (TBI) show changes in similar neuronal networks, including the dopaminergic (DA) and norepinephrinergic (NA) systems. Therefore, indirect measures of catecholamine activity were assessed. Twenty-six children with TBI, 31 children with ADHD, and 26 normal controls, 8 to 12 years of age, were investigated with a 90-min cognitive test battery. Before and after the tests, urine samples were collected to measure catecholamine activity in response to cognitive stress. Spontaneous eyeblinking as an indirect measure of DA activity was counted. Children with TBI and ADHD excreted significantly more normetanephrine in resting situations and less epinephrine (EPI) after cognitive stress, and showed a decreased blink rate compared to normal controls. Children with TBI also showed a higher excretion of metanephrine in the resting situation in comparison to children with ADHD and controls. Whereas children with ADHD showed a higher tonic activity of the NA system and a less adaptive EPI excretion in response to cognitive stress, children with TBI seem to be additionally impaired in their tonic EPI excretion. Our study provides further support for similar but also different neurobiochemical characteristics in both groups. (C) 2003 Elsevier Science B.V. All rights reserved.	Rhein Westfal TH Aachen, Dept Child & Adolescent Psychiat, D-52074 Aachen, Germany; Univ Technol Chemnitz, Dept Psychol, Chemnitz, Germany; Univ Marburg, Dept Clin Chem, Marburg, Germany	Konrad, K (corresponding author), Rhein Westfal TH Aachen, Dept Child & Adolescent Psychiat, Neuenhofer Weg 21, D-52074 Aachen, Germany.	kerstin.konrad@kjp.rwth-anchen.de	Konrad, Kerstin/H-7747-2013	Konrad, Kerstin/0000-0001-9039-2615; Gauggel, Siegfried/0000-0002-2742-4917			Anderson GM, 2000, J AM ACAD CHILD PSY, V39, P635, DOI 10.1097/00004583-200005000-00018; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; Arnsten AFT, 1996, ARCH GEN PSYCHIAT, V53, P448; Caplan R, 1996, BIOL PSYCHIAT, V39, P1032, DOI 10.1016/0006-3223(95)00315-0; Cyr M, 1998, DRUGS, V56, P215, DOI 10.2165/00003495-199856020-00005; DAUGHERTY TK, 1993, J GENET PSYCHOL, V154, P177, DOI 10.1080/00221325.1993.9914731; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Dopfner M., 1998, DIAGNOSTIK SYSTEM PS; ELIA J, 1990, CLIN PHARMACOL THER, V48, P57, DOI 10.1038/clpt.1990.118; ELWOOD SW, 1986, J HUM STRESS, V12, P154, DOI 10.1080/0097840X.1986.9936782; GLOWINSKI J, 1984, CIBA F SYMP, V107, P150; Halperin JM, 1997, J AM ACAD CHILD PSY, V36, P1688, DOI 10.1097/00004583-199712000-00017; Hanna GL, 1996, BIOL PSYCHIAT, V40, P553, DOI 10.1016/0006-3223(96)00103-5; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; KARSON CN, 1983, BRAIN, V106, P643, DOI 10.1093/brain/106.3.643; KHAN AU, 1981, AM J PSYCHIAT, V138, P108; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; MAAS JW, 1983, MHPG BASIC MECHANISM, P33; Pliszka SR, 1996, J AM ACAD CHILD PSY, V35, P264, DOI 10.1097/00004583-199603000-00006; PLISZKA SR, 1994, J AM ACAD CHILD PSY, V33, P1165, DOI 10.1097/00004583-199410000-00012; PYCOCK CJ, 1980, NATURE, V286, P74, DOI 10.1038/286074a0; RANDOLPH C, 1992, BRAIN INJURY, V12, P383; Roozendaal B, 1996, P NATL ACAD SCI USA, V93, P1429, DOI 10.1073/pnas.93.4.1429; SCHACHAR R, 1989, UNPUB PARENT INTERVI; Solanto MV, 2000, NEUROSCI BIOBEHAV R, V24, P27, DOI 10.1016/S0149-7634(99)00061-5; Swanson JM, 1998, MOL PSYCHIATR, V3, P38, DOI 10.1038/sj.mp.4000354; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TUCHMAN M, 1985, PEDIATRICS, V75, P324; UNNEWEHR S, 1995, DIAGNOSTISCHES INTER; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Williams SM, 1998, CEREB CORTEX, V8, P321, DOI 10.1093/cercor/8.4.321; ZAMETKIN AJ, 1979, ANN NEUROL, V5, P453, DOI 10.1002/ana.410050509	35	37	37	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0926-6410			COGNITIVE BRAIN RES	Cognit. Brain Res.	MAY	2003	16	3					425	433		10.1016/S0926-6410(03)00057-0			9	Computer Science, Artificial Intelligence; Neurosciences; Neuroimaging	Computer Science; Neurosciences & Neurology	677MW	WOS:000182813000011	12706222				2021-06-18	
J	Zimmermann, C; Haberl, RL				Zimmermann, C; Haberl, RL			L-arginine improves diminished cerebral CO2 reactivity in patients	STROKE			English	Article						arginine; risk; vasomotor reactivity	TRANSCRANIAL DOPPLER SONOGRAPHY; CORTICAL IMPACT INJURY; NITRIC-OXIDE; CEREBROVASCULAR REACTIVITY; CARDIOVASCULAR-DISEASE; VASOMOTOR REACTIVITY; BLOOD-FLOW; ATHEROSCLEROSIS; ENDOTHELIUM; RELAXATION	Background and Purpose-There is experimental evidence that L-arginine restores diminished CO, reactivity after mild traumatic brain injury in rats. This effect is believed to be mediated by L-arginine-derived nitric oxide, which is a permissive substrate for CO2 reactivity. To clarify whether these findings can be transferred to the clinical situation and have beneficial effects in patients, we studied the effects Of L-arginine on CO2 reactivity of the cerebral vessels in patients with impaired vasomotor reactivity (VMR) and compared them with patients with normal VMR. Methods-Twenty-two patients with cardiovascular risk factors and VMR <50% with no extracranial or intracranial stenoses were examined by bilateral transcranial Doppler sonography of the right and left middle cerebral arteries and compared with 20 age- and risk-matched patients with normal VMR (>50%). VMR was tested by 1-minute hyperventilation, followed by a 3-minute inhalation of 5% CO2. Examinations were performed before and after infusion of 30 g L-arginine over 30 minutes. The 22 patients with reduced VMR (<50%) were compared with 20 patients with normal VMR (>50%). Results-Initial mean VMR of the 42 patients was 50+/-12%. There was no difference between the right- and the left-side VMR. In the 22 patients with reduced VMR in the first examination (42+/-8%), VMR increased significantly after infusion Of L-arginine (52+/-14%, P=0.005). In contrast, values did not change after infusion Of L-arginine in the 20 patients with normal VMR (59+/-8% before versus 59+/-13% after L-arginine). There was a negative correlation of initial CO2 vasoreactivity and the percentage of VMR increase after infusion Of L-arginine. Conclusions-Our data support the hypothesis that in humans L-arginine is able to improve impaired CO2 reactivity of the cerebral vessels. This effect can be found in patients at cardiovascular risk with impaired VMR and might have therapeutic implications in the future.	Krankenhaus Munchen Harlaching, Dept Neurol, D-81545 Munich, Germany	Zimmermann, C (corresponding author), Krankenhaus Munchen Harlaching, Dept Neurol, Sanatoriumspl 2, D-81545 Munich, Germany.						BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386; Cannon RO, 1998, CLIN CHEM, V44, P1809; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; Cupini LM, 2001, ARCH NEUROL-CHICAGO, V58, P577, DOI 10.1001/archneur.58.4.577; Didion SP, 2001, STROKE, V32, P761, DOI 10.1161/01.STR.32.3.761; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; Giraldez RR, 1997, J BIOL CHEM, V272, P21420, DOI 10.1074/jbc.272.34.21420; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Golding EM, 2000, J CEREBR BLOOD F MET, V20, P820, DOI 10.1097/00004647-200005000-00008; Iadecola C, 1996, AM J PHYSIOL-REG I, V271, pR990; LADECOLA C, 1992, P NATL ACAD SCI USA, V89, P3913; Maccario M, 1997, J ENDOCRINOL INVEST, V20, P488, DOI 10.1007/BF03348006; MADDEN JA, 1993, PHARMACOL THERAPEUT, V59, P229, DOI 10.1016/0163-7258(93)90045-F; Micieli G, 1997, J NEUROL SCI, V150, P71, DOI 10.1016/S0022-510X(97)05380-X; Pfefferkorn T, 2001, STROKE, V32, P17, DOI 10.1161/01.STR.32.1.17; Reutens DC, 1997, J CEREBR BLOOD F MET, V17, P309, DOI 10.1097/00004647-199703000-00008; RINGELSTEIN EB, 1988, STROKE, V19, P963, DOI 10.1161/01.STR.19.8.963; SANDOR P, 1994, J CEREBR BLOOD F MET, V14, P49, DOI 10.1038/jcbfm.1994.8; Sterzer P, 2001, STROKE, V32, P2817, DOI 10.1161/hs1201.099663; TAYSTMAN RJ, 1997, PRIMER CEREBROVASCUL, P55; Terborg C, 2000, STROKE, V31, P924, DOI 10.1161/01.STR.31.4.924; TRUELSEN T, 1994, STROKE, V25, P802, DOI 10.1161/01.STR.25.4.802; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; WIDDER B, 1995, DOPPLER DUPLEXSONOGR, P296	24	37	39	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAR	2003	34	3					643	647		10.1161/01.STR.0000056526.35630.47			5	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	653ZJ	WOS:000181466700017	12624285	Bronze			2021-06-18	
J	Hart, T; Millis, S; Novack, T; Englander, J; Fidler-Sheppard, R; Bell, KR				Hart, T; Millis, S; Novack, T; Englander, J; Fidler-Sheppard, R; Bell, KR			The relationship between neuropsychologic function and level of caregiver supervision at 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cognition; outcomes research; rehabilitation	PRACTICAL SCALE; RATING-SCALE; OUTCOMES; TESTS; INDIVIDUALS; INTEGRATION; PREDICTION; DISABILITY; VALIDITY; ABILITY	Objectives: To evaluate distribution of levels of caregiver supervision at 1 year after traumatic brain injury, and to determine neuropsychologic predictors of supervision level. Design: Prospective longitudinal design, concurrent measurement of neuropsychologic function and supervision level. Setting: Seventeen Traumatic Brain Injury Model Systems centers. Participants: A total of 563 adults tested at 1 year postinjury; and a subgroup of 452 studied for neuropsychologic function in the absence of impairment in mobility or basic self-care, as assessed by high FIM(TM) instrument motor scores. Interventions: Not applicable. Main Outcome Measure: Supervision level measured by scores on Supervision Rating Scale (SRS). Results: Two thirds (69%) of the sample was rated as independent of supervision. Participants without significant dysfunction on motor FIM were grouped into supervision groups differing in intensity of time commitment from caregiver (independent, moderate supervision, heavy supervision). In univariate analyses, groups differed on demographic variables (education, race, productivity prior to injury), duration of altered consciousness, and all but 1 neuropsychologic measure. A binomial regression model (complementary log-log model) revealed that supervision at 1 year was predicted by education and scores on the Trail Making Test Part B and digits backward. Conclusions: Findings confirm the importance of preinjury status and measures of working memory and cognitive flexibility in predicting functional independence after TBI. The SRS appears prone to ceiling effects in persons followed prospectively after moderate to severe TBI.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Alabama, Spain Rehabil Ctr, Birmingham, AL USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Bell, Kathleen/0000-0002-0928-2046			BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cahn-Weiner DA, 2000, CLIN NEUROPSYCHOL, V14, P187, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT187; Carlson MC, 1999, J GERONTOL B-PSYCHOL, V54, pS262, DOI 10.1093/geronb/54B.5.S262; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall P, 1998, THEOR COMP FLUID DYN, V10, P1; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P133; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Neese LE, 2000, BRAIN INJURY, V14, P719; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; SANDER A, 1999, REHABILITATION ADULT, P199; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A M, 1998, Rehabil Nurs, V23, P252; *STAT CORP, 2001, STAT STAT SOFTW; Tabachnick B., 2001, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	42	37	39	0	17	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					221	230		10.1053/apmr.2003.50023			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700011	12601653				2021-06-18	
J	Gibbons, H; Sato, TA; Dragunow, M				Gibbons, H; Sato, TA; Dragunow, M			Hypothermia suppresses inducible nitric oxide synthase and stimulates cyclooxygenase-2 in lipopolysaccharide stimulated BV-2 cells	MOLECULAR BRAIN RESEARCH			English	Article						hypothermia; inducible nitric oxide synthase; pro-inflammatory cytokines; cyclooxygenase-2; nuclear factor-kappa B	KAPPA-B KINASE; TRANSIENT CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; POSTISCHEMIC HYPOTHERMIA; MILD HYPOTHERMIA; MICROGLIAL ACTIVATION; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; CYTOKINE PRODUCTION	Hypothermia is neuroprotective, possibly through suppression of microglial activation. We investigated the effects of hypothermia on lipopolysaccharide (LPS) stimulated BV-2 cells. At 37degreesC, LPS elicited strong increases in inducible nitric oxide synthase (iNOS), nitric oxide (NO), cyclooxygenase-2 (COX-2), tumour necrosis factor-alpha. (TNF-alpha), and interleukin-6 (IL-6), accompanied by translocation of nuclear factor-kappaB (NF-kappaB) to the nucleus. Hypothermia (33degreesC) caused complete suppression of iNOS and NO, a partial reduction of IL-6 but did not prevent TNF-alpha production or NF-kappaB translocation. In contrast, LPS induced cyclooxygenase-2 (COX-2) to higher levels under hypothermic conditions. These results show that hypothermia selectively suppresses iNOS in microglia, (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Auckland, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland 1, New Zealand; Univ Auckland, Liggins Inst, Fac Med & Hlth Sci, Auckland 1, New Zealand	Dragunow, M (corresponding author), Univ Auckland, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland 1, New Zealand.						Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Ehrlich LC, 1998, NEUROREPORT, V9, P1723, DOI 10.1097/00001756-199806010-00010; Elmquist JK, 1997, J COMP NEUROL, V381, P119, DOI 10.1002/(SICI)1096-9861(19970505)381:2<119::AID-CNE1>3.0.CO;2-6; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; Jeohn GH, 2000, MOL BRAIN RES, V79, P18, DOI 10.1016/S0169-328X(00)00081-4; Jiang CY, 1998, NATURE, V391, P82; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kataoka K, 1998, NEUROSCI RES, V32, P103, DOI 10.1016/S0168-0102(98)00076-5; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Ko HK, 2001, BRAIN RES, V894, P297, DOI 10.1016/S0006-8993(00)03188-7; Kumar K, 1997, NEUROREPORT, V8, P947, DOI 10.1097/00001756-199703030-00026; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Langford D, 2001, BRAIN PATHOL, V11, P306; Luhm J, 1998, EUR J BIOCHEM, V256, P325, DOI 10.1046/j.1432-1327.1998.2560325.x; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Mirzoeva S, 1999, BRAIN RES, V844, P126, DOI 10.1016/S0006-8993(99)01911-3; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Nakajima Y, 1997, BRAIN RES, V765, P113, DOI 10.1016/S0006-8993(97)00522-2; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Trautman MS, 1996, PLACENTA, V17, P239, DOI 10.1016/S0143-4004(96)90044-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Walton M, 1998, J NEUROSCI RES, V53, P330, DOI 10.1002/(SICI)1097-4547(19980801)53:3<330::AID-JNR7>3.0.CO;2-B; Walton M, 1998, MOL BRAIN RES, V61, P11, DOI 10.1016/S0169-328X(98)00169-7; Walton MR, 2000, J NEUROIMMUNOL, V104, P109, DOI 10.1016/S0165-5728(99)00262-3; Williams K, 1996, NEUROCHEM INT, V29, P55, DOI 10.1016/0197-0186(95)00138-7	57	37	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JAN 31	2003	110	1					63	75	PII S0169-328X(02)00585-5	10.1016/S0169-328X(02)00585-5			13	Neurosciences	Neurosciences & Neurology	703WX	WOS:000184306100008	12573534				2021-06-18	
J	Oehmichen, M; Walter, T; Meissner, C; Friedrich, HJ				Oehmichen, M; Walter, T; Meissner, C; Friedrich, HJ			Time course of cortical hemorrhages after closed traumatic brain injury: Statistical analysis of posttraumatic histomorphological alterations	JOURNAL OF NEUROTRAUMA			English	Article						cortical hemorrhage; histomorphological criteria; statistical evaluation; time course; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; SPINAL-CORD-INJURY; HEAD-INJURY; NEURONAL DEGENERATION; AXONAL INJURY; ADULT-RAT; CONTUSIONS; ACCUMULATION; ASTROCYTES; EXPRESSION	We examined 305 autopsied brains for histomorphological alterations to determine the time course of reactions in cortical hemorrhages following traumatic closed brain injury. Eighteen morphological criteria were considered: red blood cells (RBCs), polymorphonuclear leukocytes (PMNs), macrophages (Ms), RBC-containing Ms, hemosiderin, hematoidin, lipid-containing Ms, fibroblasts, endothelial cells, collagenous fibres, gemistocytic astrocytes, fibrillary gliosis, hemosiderin-containing astrocytes, neuronal damage, neuronophagy, axonal swelling (beta-amyloid precursor protein: beta-APP), axonal bulbs (van Gieson stairi), and mineralisation of neurons. The interval between the time of brain injury and death ranged from 1 min to 58 years. Following routine staining and immunohistochemical staining of microglia (CD68), astrocytes (GFAP) and injured axons (beta-APP), paraffin sections were examined by light microscopy for the presence of the selected histomorphological features. For each cytomorphological phenomenon, the time at which it could be demonstrated for the first time and for the last time (observation period) was determined. The relative frequency of each criterion was established for each observation period. The limits of confidence for the respective relative frequencies were estimated with a reliability of 95% according to Clopper and Pearson. An apparent correlation was found between the frequency of a given histomorphological phenomenon and the length of the posttraumatic interval. To check for accuracy of prediction, half of the cases (group 1; n = 153) were used to develop a multistage evaluation model; half (group 2; n = 152) were used to evaluate the validity of the data of group 1. Applying this model, 117 of the 152 control group cases (76.97%) could be correctly classified and further 26 cases (17.11%) being assigned to an interval close to the correct interval. Thus, this model allows classification of the correct posttraumatic interval or an interval close to the correct posttraumatic interval in about 95% of cases. We developed a software program that allows the estimation of survival time of TBI based on the relative frequency of the 18 morphological features. Applying this software will help to estimate the posttraumatic interval of cortical hemorrhages following TBI of unknown survival time (till.walter@t-online.de).	Med Univ Lubeck, Inst Legal Med, D-23562 Lubeck, Germany; Univ Kiel, Inst Legal Med, Kiel, Germany; Med Univ Lubeck, Inst Med Biometry & Stat, D-23538 Lubeck, Germany	Oehmichen, M (corresponding author), Med Univ Lubeck, Inst Legal Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.	oehmich@rmed.mu-luebeck.de					ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Adams RD, 1968, INTRO NEUROPATHOLOGY; Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; Baldwin SA, 1998, J NEUROTRAUM, V15, P1015, DOI 10.1089/neu.1998.15.1015; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BAZZAZ AA, 1995, NEUROPATHOL APPL NEU, V21, P447; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cizkova D, 2000, CELL MOL NEUROBIOL, V20, P367, DOI 10.1023/A:1007018327133; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; COLMANT GW, 1963, ZEREBRALE HYPOXIE; COOPER CJ, 1934, BIOMETRIKA, V26, P404; COURVILLE CB, 1964, FORENSIC NEUROPATHOL; EISENMENGER W, 1977, THESIS MUNCHEN; ENG LF, 1983, PROG NEUROPATH, V5, P19; Engel S, 1996, ACT NEUR S, V66, P87; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; HALBHUBER KJ, 1995, WOUND HEALING PROCES, P203; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOWARTH F., 1955, ACTA ANAT, V25, P112; JACOB H, 1961, Dtsch Z Gesamte Gerichtl Med, V51, P352, DOI 10.1007/BF00575848; KENNADY JC, 1967, PAC MED SURG, V75, P163; Kimelberg HK, 1997, RES LEG MED, V17, P295; Kleinbaum D. G., 1998, LOGISTIC REGRESSION; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KORNYEY S, 1955, HISTOPATHOLOGIE KLIN; Krauland W, 1973, Beitr Gerichtl Med, V30, P226; LAIHO K, 1995, WOUND HEALING PROCES, P229; Lassmann H, 1997, RES LEG MED, V17, P253; LEDER LD, 1964, KLIN WOCHENSCHR, V42, P553, DOI 10.1007/BF01486688; LOBERG EM, 1992, ACTA NEUROPATHOL, V84, P234; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Meyermann R, 1997, RES LEG MED, V17, P261; MOSSAKOWSKI M J, 1972, Neuropatologia Polska, V10, P317; Muller G, 1930, Z GESAMTE NEUROL PSY, V124, P1, DOI 10.1007/BF02865091; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; Oehmichen M, 1997, RES LEG MED, V17, P203; Oehmichen M, 1981, Beitr Gerichtl Med, V39, P57; OEHMICHEN M, 1986, FORENSIC SCI INT, V30, P281, DOI 10.1016/0379-0738(86)90136-2; OEHMICHEN M, 1990, WUNDHEILUNG; OEHMICHEN M, 1995, WOUND HEALING PROCES, P15; OEHMICHEN M, 1978, MONONUCLEAR PHAGOCYT; PETERS G, 1955, HDB SPEZIELLEN PATHO, V13, P363; Povlishock John T., 1995, P504; Povlishock JT, 1997, RES LEG MED, V17, P175; RUBINSTEIN LJ, 1962, J NEUROPATH EXP NEUR, V21, P116, DOI 10.1097/00005072-196201000-00010; RYAN GA, 1994, J TRAUMA, V36, P469; SACHS L, 1994, STAT STAT METHODEN I; SAMPEDRO MN, 1998, SCIENCE, V240, P1784; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHRODER R, 1998, CHRONOMORPHOLOGIE ZE; SELLIER K, 1963, HEFTE UNFALLHEILKUND, V76; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Soares HD, 1995, J NEUROSCI, V15, P8223; Spielmeyer W., 1922, HISTOPATHOLOGIE NERV; STRASSMANN G, 1949, ARCH PATHOL, V47, P205; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Van Gieson J., 1889, NEW YORK MED J, V50, P57	60	37	39	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2003	20	1					87	103		10.1089/08977150360517218			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	641BB	WOS:000180723200008	12614591				2021-06-18	
J	Peru, A; Beltramello, A; Moro, V; Sattibaldi, L; Berlucchi, G				Peru, A; Beltramello, A; Moro, V; Sattibaldi, L; Berlucchi, G			Temporary and permanent signs of interhemispheric disconnection after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						CUD; corpus callosum; head trauma	SIMPLE REACTION-TIMES; CORPUS-CALLOSUM; HEMISPHERIC DISCONNECTION; AXONAL INJURY; LIGHT DETECTION; TOPOGRAPHY; COMMUNICATION; CALLOSOTOMY; RESPONSES; SPLENIUM	The corpus callosum is frequently damaged by closed head traumas, and the resulting deficits of interhemispheric communication may vary according to the specific position of the lesion within the corpus callosum. This paper describes a single case who suffered a severe traumatic brain injury resulting in a lesion of the posterior body of the corpus callosum. Among the classical symptoms of interhemispheric disconnection, left hand anomia, left upper limb ideomotor dyspraxia, left visual field dyslexia and dysnomia, and left ear suppression in a dichotic listening task were observed shortly after the injury but recovered completely or almost completely with the passage of time. The only symptom of interhemispheric disconnection which was found to persist more than 4 years after the injury was an abnormal prolongation of the crossed-uncrossed difference in a simple visuomotor reaction time task. This prolongation was comparable with that observed in subjects with complete callosal lesions or agenesis. The results suggest that the posterior body of the corpus callosum may be an obligatory interhemispheric communication channel for mediating fast visuo-motor responses. The transient nature of other symptoms of interhemispheric disconnection suggests a relatively wide dispersion of fibers with different functions through the callosal body, such that parts of them can survive a restricted lesion and allow functional recovery of hemispheric interactions. An assessment of the evolution in time of symptoms of interhemispheric disconnection following restricted callosal lesions may reveal fine and coarse features of the anatomo-functional topography of the corpus callosum. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Verona, Sez Fisiol Umana, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy; Osped Maggiore Borgo Trento, Dipartimento Neuroradiol, Verona, Italy; Osped Sacrp Cuore, Serv Rieducaz & Riabilitaz Funz, Negrar, Italy	Berlucchi, G (corresponding author), Univ Verona, Sez Fisiol Umana, Dipartimento Sci Neurol & Vis, Strada Grazie 8, I-37134 Verona, Italy.	giovanni.berlucchi@univr.it	Moro, Valentina/K-6464-2016; Moro, Valentina/AAM-2224-2021	Moro, Valentina/0000-0002-7119-7264; Moro, Valentina/0000-0002-7119-7264; peru, andrea/0000-0002-8032-0551			AGLIOTI S, 1993, EXP BRAIN RES, V95, P151; ALEXANDER MP, 1988, NEUROLOGY, V38, P802, DOI 10.1212/WNL.38.5.802; BASHORE TR, 1981, PSYCHOL BULL, V89, P352, DOI 10.1037/0033-2909.89.2.352; BEREK K, 1994, J NEUROL SCI, V123, P2, DOI 10.1016/0022-510X(94)90195-3; BERLUCCHI G, 1995, NEUROPSYCHOLOGIA, V33, P923, DOI 10.1016/0028-3932(95)00031-W; Berlucchi G, 1997, NEUROPSYCHOLOGIA, V35, P941, DOI 10.1016/S0028-3932(97)00022-5; BERLUCCHI G, 1999, HDB CLIN EXPT NEUROP, P635; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bogen J.E., 1993, CLIN NEUROPSYCHOLOGY, P337; BOLDRINI P, 1992, CORTEX, V28, P135, DOI 10.1016/S0010-9452(13)80172-4; BRIGGS G G, 1975, Cortex, V11, P230; BRION S, 1975, TROUBLES TRANSFERT I; CECCALDI M, 1994, REV NEUROL-FRANCE, V150, P229; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHELAZZI L, 1988, VISION RES, V28, P95, DOI 10.1016/0042-6989(88)90011-9; CLARKE JM, 1989, BRAIN, V112, P849, DOI 10.1093/brain/112.4.849; CLARKE S, 1995, EXP BRAIN RES, V104, P534, DOI 10.1007/BF00231988; Corballis MC, 2002, NEUROPSYCHOLOGIA, V40, P423, DOI 10.1016/S0028-3932(01)00097-5; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; Deloche Gerard, 1993, Brain Injury, V7, P363, DOI 10.3109/02699059309034963; Funnell MG, 2000, ARCH NEUROL-CHICAGO, V57, P185, DOI 10.1001/archneur.57.2.185; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; GESCHWIND DH, 1995, NEUROLOGY, V45, P802, DOI 10.1212/WNL.45.4.802; GESCHWIND N, 1985, EPILEPSY CORPUS CALL, P349; GORDON HW, 1971, BRAIN, V94, P327, DOI 10.1093/brain/94.2.327; Habib M, 1998, NEUROCHIRURGIE, V44, P102; Iacoboni M, 2000, NEUROPSYCHOLOGIA, V38, P535, DOI 10.1016/S0028-3932(99)00121-9; IACOBONI M, 1994, NEUROREPORT, V5, P2521; Ihori N, 2000, EUR NEUROL, V44, P65, DOI 10.1159/000008199; Intriligator J, 2000, NEUROREPORT, V11, P2639, DOI 10.1097/00001756-200008210-00007; KAGA K, 1990, Brain Topography, V3, P175, DOI 10.1007/BF01128874; KAZUI S, 1993, ANN NEUROL, V33, P401, DOI 10.1002/ana.410330413; Lakmache Y, 1998, P NATL ACAD SCI USA, V95, P9042, DOI 10.1073/pnas.95.15.9042; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Levander MB, 1998, BRAIN INJURY, V12, P165, DOI 10.1080/026990598122791; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MARZI CA, 1991, NEUROPSYCHOLOGIA, V29, P1163, DOI 10.1016/0028-3932(91)90031-3; MATSUNAMI K, 1994, NEUROSCI RES, V20, P137, DOI 10.1016/0168-0102(94)90031-0; MILNER AD, 1985, NEUROPSYCHOLOGIA, V23, P323, DOI 10.1016/0028-3932(85)90019-3; MILNER B, 1968, SCIENCE, V161, P184, DOI 10.1126/science.161.3837.184; Moses P, 2000, CEREB CORTEX, V10, P1200, DOI 10.1093/cercor/10.12.1200; Pandya D. N., 1986, 2 HEMISPHERES ONE BR, P47; Pollmann S, 2002, NEUROPSYCHOLOGY, V16, P56, DOI 10.1037//0894-4105.16.1.56; Polster T, 2001, J NEUROL NEUROSUR PS, V70, P459, DOI 10.1136/jnnp.70.4.459; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SCHOTT B, 1969, REV NEUROL, V20, P359; Sparks R., 1968, CORTEX, V4, P3, DOI DOI 10.1016/S0010-9452(68)80009-7; Sperry R. W., 1969, HDB CLINICAL NEUROLO, V4, P273, DOI DOI 10.1023/B:HUMP.0000036333.34541.54; SPRINGER SP, 1975, NEUROPSYCHOLOGIA, V13, P341, DOI 10.1016/0028-3932(75)90011-1; SUGISHITA M, 1995, BRAIN, V118, P417, DOI 10.1093/brain/118.2.417; TASSINARI G, 1994, BEHAV BRAIN RES, V64, P141, DOI 10.1016/0166-4328(94)90126-0; Tokutomi T, 1997, ACT NEUR S, V70, P80; Tomaiuolo F, 2001, NEUROREPORT, V12, P1469, DOI 10.1097/00001756-200105250-00035; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; VUILLEUMIER P, 1995, NEUROCHIRURGIE, V41, P98; Yamadori A, 1988, Behav Neurol, V1, P11, DOI 10.3233/BEN-1988-1103	58	37	40	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2003	41	5					634	643	PII S0028-3932(02)00203-8	10.1016/S0028-3932(02)00203-8			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	654FQ	WOS:000181483900012	12559156				2021-06-18	
J	Willinger, R; Baumgartner, D				Willinger, R; Baumgartner, D			Numerical and physical modelling of the human head under impact - towards new injury criteria	INTERNATIONAL JOURNAL OF VEHICLE DESIGN			English	Article						accident reconstruction; brain; dummy head; finite element method; injury criteria		This paper presents original physical and numerical human head models followed by their modal and temporal validation against human head vibration analysis in vivo and cadaver impact tests. The human head FE model developed by ULP presents two particularities: one at the brain-skull interface level where fluid-structure interaction is taken into account, the other at the skull modelling level by integrating the bone fracture simulation. Validation shows that the model correlated well with a number of experimental cadaver tests and predicted intracranial pressure accurately. However, for long duration impacts the model reaches its limits. The skull stiffness and fracture force were very accurately predicted when compared with values from the literature. In a second step a new dummy head prototype named Bimass is presented. It has been constructed using a Hybrid III headform and comprises two masses: a skull and a mass to represent the brain attached to the skull with a damped spring system. The novel feature of this device is that it can simulate the brain-skull relative displacement at a frequency close to 150 Hz as recorded under vibration analysis in vivo. Helmet damage from thirteen motorcycle accidents was replicated in drop tests conducted in collaboration with Transport Research Laboratory (UK). Simulation of these accidents using both FE model and Bimass dummy head led to the first tentative proposals for tolerance limits and injury criteria relative to specific injury mechanisms.	Univ Strasbourg, CNRS 7507, Inst Fluid & Solid Mech, F-67000 Strasbourg, France	Willinger, R (corresponding author), Univ Strasbourg, CNRS 7507, Inst Fluid & Solid Mech, 2 Rue Boussingault, F-67000 Strasbourg, France.	willi@imfs.u-strasbg.fr					ALBSHARAT AS, 1999, P ASME SUMM M BIG SK; BRINN J, 1970, P 14 STAPP CAR CRASH; CHINN BP, 1999, P IRCOBI C, P53; FERNER H, 1985, EDITION MED INT PARI; Harris C. M., 1988, SHOCK VIBRATION HDB; HODGSON VR, 1967, P 11 STAPP CAR CRASH, P79; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; Kang HS, 1997, P 41 STAPP CAR CRASH, P329; KENNER VH, 1973, J BIOMECH, V6, P1, DOI 10.1016/0021-9290(73)90032-8; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; LOWENHIELM P, 1973, IRCOBI LYON, P423; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J. A., 1999, P INT RESEAR C BIOME, P17; PIEKARSKI K, 1970, J APPL PHYS, V41, P215, DOI 10.1063/1.1658323; RUAN JS, 1993, P 37 STAPP CAR CRASH, P69; STALNAKER RL, 1971, J BIOMECH, V4, P127, DOI 10.1016/0021-9290(71)90023-6; Trosseille X., 1992, P 36 STAPP CAR CRASH, DOI 10.4271/922527; TSAIWU, 1971, J COMPOSITE MAT; VIANO DC, 1988, P 32 STAPP CAR CRASH, P1; Williams T. G., 1995, J CONSUMER MARKETING, V12, P4, DOI DOI 10.1108/07363769510147218; Willinger R, 2000, J SOUND VIB, V235, P611, DOI 10.1006/jsvi.1999.2931; Willinger R, 1999, CR ACAD SCI II B, V327, P125, DOI 10.1016/S1287-4620(99)80021-0; WILLINGER R, 1992, ACCIDENT ANAL PREV, V26, P767; WILLINGER R, 2000, 327 COST; WILLINGER R, 1990, INT C BIOM IMP, P203; Willinger R, 2000, P INT RES COUNC BIOK, V28, P209; WOODWARD AS, 1901, CATALOGUE FOSSIL FIS, V4, P1; YOGONANDAN N, 1994, P HEAD INJ 94 S WASH; ZHOU C, 1996, AGARD	31	37	39	0	15	INDERSCIENCE ENTERPRISES LTD	GENEVA	WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 856, CH-1215 GENEVA, SWITZERLAND	0143-3369	1741-5314		INT J VEHICLE DES	Int. J. Veh. Des.		2003	32	1-2					94	115		10.1504/IJVD.2003.003239			22	Engineering, Mechanical; Transportation Science & Technology	Engineering; Transportation	691PK	WOS:000183614500008					2021-06-18	
J	Marciano, PG; Eberwine, JH; Ragupathi, R; Saatman, KE; Meaney, DF; McIntosh, TK				Marciano, PG; Eberwine, JH; Ragupathi, R; Saatman, KE; Meaney, DF; McIntosh, TK			Expression profiling following traumatic brain injury: A review	NEUROCHEMICAL RESEARCH			English	Article						traumatic brain injury; microarray; immediate early genes; cytokines; neurotrophic factors; gene expression	NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; HEAT-SHOCK-PROTEIN; FOS MESSENGER-RNA; C-FOS; GENE-EXPRESSION; CELL-DEATH; RAT-BRAIN; NEUROTROPHIC FACTOR; DIFFERENTIAL EXPRESSION	Traumatic brain injury (TBI) elicits a complex sequence of putative autodestructive and neuroprotective cellular cascades. It is hypothesized that the genomic responses of cells in the injured brain serve as the basis for these cascades. Traditional methods for analyzing differential gene expression following brain trauma demonstrate that immediate early genes, cytokines, transcription factors, and neurotrophic factors can all participate in the brain's active and directed response to injury, and may do so concurrently. It is this complexity and multiplicity of interrelated molecular mechanisms that has demanded new methods for comprehensive and parallel evaluation of putative as well as novel gene targets. Recent advances in DNA microarray technology have enabled the simultaneous evaluation of thousands of genes and the subsequent generation of massive amounts of biological data relevant to CNS injury. This emerging technology can serve to further current knowledge regarding recognized molecular cascades as well as to identify novel molecular mechanisms that occur throughout the post-traumatic period. The elucidation of the complex alterations in gene expression underlying the pathological sequelae following TBI is of central importance in the design of future therapeutic agents.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Eberwine, James/B-2247-2010	Meaney, David/0000-0002-0954-4122			ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENVENISTE EN, 1992, CHEM IMMUNOL, V52, P106; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; D'MELLO SR, 1991, J NEUROCHEM, V57, P1570, DOI 10.1111/j.1471-4159.1991.tb06353.x; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; Eberwine J, 1996, BIOTECHNIQUES, V20, P584; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GIULIAN D, 1995, J NEUROSCI, V15, P7712; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; HANSEN JN, 1974, NUCLEIC ACIDS RES, V1, P787, DOI 10.1093/nar/1.6.787; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lobenhofer EK, 2001, ENVIRON HEALTH PERSP, V109, P881, DOI 10.2307/3454988; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Noordewier MO, 2001, TRENDS BIOTECHNOL, V19, P412, DOI 10.1016/S0167-7799(01)01735-8; NORRIS JG, 1994, J IMMUNOL, V152, P841; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; O'Dell DM, 1998, BIOTECHNIQUES, V25, P566, DOI 10.2144/98254bm04; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Oyesiku NM, 1996, J COMP NEUROL, V364, P68, DOI 10.1002/(SICI)1096-9861(19960101)364:1<68::AID-CNE6>3.0.CO;2-Q; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Porchet N, 2000, METH MOL B, V125, P305; Prediger EA, 2000, METH MOL B, V160, P495; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; RUZDIJIC S, 1993, BRAIN RES, V601, P230, DOI 10.1016/0006-8993(93)91715-5; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SCHIAFFONATI L, 1990, J CELL PHYSIOL, V143, P79, DOI 10.1002/jcp.1041430110; SHARP FR, 1994, NEUROTOXICOLOGY, V15, P51; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THERY C, 1993, NEUROSCI LETT, V150, P195, DOI 10.1016/0304-3940(93)90534-R; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMAS WE, 1992, BRAIN RES REV, V17, P61; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YOUNG B, 1992, J NEUROTRAUM, V9, pS375	91	37	42	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	OCT	2002	27	10					1147	1155		10.1023/A:1020973308941			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	611VE	WOS:000179037800018	12462413				2021-06-18	
J	Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH				Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH			Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury	BRAIN RESEARCH			English	Article						brain microdialysis; glucose; glutamate; traumatic brain injury	TRAUMATIC BRAIN INJURY; HUMAN HEAD-INJURY; GLUTAMATE RELEASE; RAT; BW619C89; DAMAGE; ANTAGONISTS; LAMOTRIGINE; ASPARTATE; MECHANISM	Increases in brain interstitial excitatory amino acid (EAA(1)) concentrations after ischemia are ameliorated by use-dependent Na+ channel antagonists and by supplementing interstitial glucose, but the regulation of EAA(1) after traumatic brain injury (TBI) is unknown. We studied the regulation of EAA(1), after TBI using the controlled cortical impact model in rats. To monitor changes in EAA(1), microdialysis probes were placed in the cortex adjacent to the contusion and in the ipsilateral hippocampus. Significant increases in dialysate EAA, after TBI were found compared to levels measured in sham controls. Treatment with the use-dependent Na+ channel antagonist 619C89 (30 mg/kg i.v.) did not significantly decrease dialysate glutamate compared to vehicle controls in hippocampus (10.4 +/- 2.4 vs. 11.9 +/- 1.6 muM), but there was significant decrease in dialysate glutamate in cortex after 619C89 treatment (19.3 +/- 3 vs. 12.6 +/- 1.1 muM, P<0.05). Addition of 30 mM glucose to the dialysate, a treatment that decreases EAA(1) after ischemia, had no significant effect upon dialysate glutamate after TBI in cortex (20.0 +/- 4.9 vs. 11.7 +/- 3.4 mu M) or in hippocampus (10.9 +/- 2.0 vs. 8.9 +/- 2.4 mu M). These results suggest that neither increased release of EAAs due to Na+ channel-mediated depolarization nor failure of glutamate reuptake due to glucose deprivation can explain the majority of the increase in EAA(1) following TBI. Published by Elsevier Science B.V.	Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; Vernalis Ltd, Wokingham, England; Vet Affairs Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Graham, SH (corresponding author), Univ Pittsburgh, Dept Neurol, 526 S BST, Pittsburgh, PA 15213 USA.	sgra@pitt.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015; Palmer, Alan/AAP-8650-2020	Kochanek, Patrick M/0000-0002-2627-913X; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318] Funding Source: Medline		Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHOI DW, 1987, J NEUROSCI, V7, P357; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; EDWARDS MD, 1994, ANESTHESIOLOGY, V81, pA857; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SWANSON RA, 1992, NEUROSCI LETT, V147, P143, DOI 10.1016/0304-3940(92)90580-Z; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P1; SWANSON RA, 1994, BRAIN RES, V664, P94, DOI 10.1016/0006-8993(94)91958-5; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zauner A, 1996, ACT NEUR S, V67, P40	27	37	45	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 5	2002	943	1					15	22	PII S0006-8993(02)02471-X	10.1016/S0006-8993(02)02471-X			8	Neurosciences	Neurosciences & Neurology	576TK	WOS:000177021000003	12088834				2021-06-18	
J	Kaegi, S; Schwab, ME; Dietz, V; Fouad, K				Kaegi, S; Schwab, ME; Dietz, V; Fouad, K			Electromyographic activity associated with spontaneous functional recovery after spinal cord injury in rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						animal model; locomotion; rehabilitation; spinal cord injury	CENTRAL PATTERN GENERATOR; PARAPLEGIC PATIENTS; LOCOMOTOR RECOVERY; WEIGHT SUPPORT; LESIONS; CATS; REGENERATION; MUSCLE; AXONS; DEGENERATION	This investigation was designed to study the spontaneous functional recovery of adult rats with incomplete spinal cord injury (SCI) at thoracic level during a time course of 2 weeks. Daily testing sessions included open field locomotor examination and electromyographic (EMG) recordings from a knee extensor (vastus lateralis, VL) and an ankle flexor muscle (tibialis anterior, TA) in the hindlimbs of treadmill walking rats. The BBB score (a locomotor score named after Basso et al. , 1995, J. Neurotrauma , 12 , 1-21) and various measures from EMG recordings were analysed (i.e. step cycle duration, rhythmicity of limb movements, flexor and extensor burst duration, EMG amplitude, root-mean-square, activity overlap between flexor and extensor muscles and hindlimb coupling). Directly after SCI, a marked drop in locomotor ability occurred in all rats with subsequent partial recovery over 14 days. The recovery was most pronounced during the first week. Significant changes were noted in the recovery of almost all analysed EMG measures. Within the 14 days of recovery, many of these measures approached control levels. Persistent abnormalities included a prolonged flexor burst and increased activity overlap between flexor and extensor muscles. Activity overlap between flexor and extensor muscles might be directly caused by altered descending input or by maladaptation of central pattern generating networks and/or sensory feedback.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Univ Hosp Balgrist, ParaCare, CH-8008 Zurich, Switzerland	Fouad, K (corresponding author), Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada.		Schwab, Martin E/B-6818-2016	Fouad, Karim/0000-0003-3654-7852			BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BASSO DM, 1994, RESTOR NEUROL NEUROS, V7, P95, DOI 10.3233/RNN-1994-7205; Brustein E, 1998, J NEUROPHYSIOL, V80, P1245; CAZALETS JR, 1995, J NEUROSCI, V15, P4943; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; de Leon RD, 1999, J NEUROPHYSIOL, V82, P359; DIETZ V, 1995, ANN NEUROL, V37, P574, DOI 10.1002/ana.410370506; DIETZ V, 1981, BRAIN, V104, P431, DOI 10.1093/brain/104.3.431; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; Dietz V, 1998, SPINAL CORD, V36, P380, DOI 10.1038/sj.sc.3100590; EDGERTON RV, 1983, SPINAL CORD RECONSTR, P435; Edgerton V R, 1997, Adv Neurol, V72, P233; EIDELBERG E, 1981, EXP BRAIN RES, V42, P81; Fagerstedt P, 2000, EXP BRAIN RES, V134, P147, DOI 10.1007/s002210000455; Fouad K, 1997, NEUROSCI LETT, V236, P9, DOI 10.1016/S0304-3940(97)00756-8; Fouad K, 2001, CURR BIOL, V11, P1766, DOI 10.1016/S0960-9822(01)00535-8; FUNG J, 1989, ELECTROEN CLIN NEURO, V73, P233, DOI 10.1016/0013-4694(89)90124-7; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Giszter SF, 1998, J NEUROPHYSIOL, V80, P3021; GOLDBERGER ME, 1977, BRAIN RES, V123, P59, DOI 10.1016/0006-8993(77)90643-6; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Gorska T, 1996, ACTA NEUROBIOL EXP, V56, P177; GRILLNER S, 1978, BRAIN RES, V146, P269, DOI 10.1016/0006-8993(78)90973-3; GRILLNER S, 1985, ANNU REV NEUROSCI, V8, P233, DOI 10.1146/annurev.ne.08.030185.001313; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; Grillner S, 1998, BRAIN RES REV, V26, P184, DOI 10.1016/S0165-0173(98)00002-2; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797; HELGREN ME, 1993, EXP NEUROL, V123, P17, DOI 10.1006/exnr.1993.1137; Hiersemenzel LP, 2000, NEUROLOGY, V54, P1574, DOI 10.1212/WNL.54.8.1574; Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734; Holaday J W, 1983, Adv Shock Res, V10, P95; Jiang W, 1996, J NEUROPHYSIOL, V76, P849; Kiehn O, 1996, J NEUROPHYSIOL, V75, P1472; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Loy DN, 2002, J NEUROSCI, V22, P315, DOI 10.1523/JNEUROSCI.22-01-00315.2002; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; MORI S, 1992, BRAIN DEV S, V14, P109; NOGA BR, 1991, J NEUROSCI, V11, P1691; Pearson KG, 2001, J PHYSIOL-LONDON, V533, P75, DOI 10.1111/j.1469-7793.2001.0075b.x; PEARSON KG, 1993, ANNU REV NEUROSCI, V16, P265, DOI 10.1146/annurev.ne.16.030193.001405; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; Rossignol S, 1999, PROG BRAIN RES, V123, P349, DOI 10.1016/S0079-6123(08)62870-8; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schwab ME, 1996, PHYSIOL REV, V76, P319; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; Whishaw IQ, 1998, BEHAV BRAIN RES, V93, P167, DOI 10.1016/S0166-4328(97)00152-6	52	37	37	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JUL	2002	16	2					249	258		10.1046/j.1460-9568.2002.02076.x			10	Neurosciences	Neurosciences & Neurology	582RB	WOS:000177364000008	12169107				2021-06-18	
J	Thomale, UW; Kroppenstedt, SN; Beyer, TF; Schaser, KD; Unterberg, AW; Stover, JF				Thomale, UW; Kroppenstedt, SN; Beyer, TF; Schaser, KD; Unterberg, AW; Stover, JF			Temporal profile of cortical perfusion and microcirculation after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; contusion; intravital microscopy; laser doppler flowmetry; orthogonal polarization spectral imaging; secondary injury; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL HEAD-INJURY; LASER-DOPPLER FLOWMETRY; NITRIC-OXIDE; CEREBROSPINAL-FLUID; CONTUSION VOLUME; L-ARGININE; GLUTAMATE; NECROSIS	Impaired cerebral perfusion contributes to evolving posttraumatic tissue damage. Spontaneous reversibility of reduced perfusion within the first days after injury could make a persisting impact on secondary tissue damage less likely and needs to be considered for possible therapeutic approaches. The present study was designed to characterize the temporal profile and impact of trauma severity on cortical perfusion and microcirculation during the first 48 h after controlled cortical impact injury (CCI). In 10 rats, pericontusional cortical perfusion and microcirculation using laser Doppler flowmetry (LDF) and orthogonal polarization spectral (OPS) imaging were assessed before, and at 4, 24, and 48 h after CCI. Influence of trauma severity was studied by varying the penetration depth of the impactor rod (0.5 vs. 1 mm), thereby inducing a less and a more severe contusion. Mean arterial blood pressure (MABP), arterial blood gases, and blood glucose were monitored. With unchanged MABP and paCO(2), cortical perfusion and microcirculation were significantly impaired during the first 48 h following CCI. Hypoperfusion observed at 4 h related to vasoconstriction and microcirculatory stasis preceded a long-lasting phase of hyperperfusion at 24 and 48 h reflected by vasodilation and increased flow velocity in arterioles and venules. Hyperperfusion was mostly pronounced in rats with a less severe contusion. Following CCI, trauma severity markedly influences changes in pericontusional cortical perfusion and microcirculation. Overall, pericontusional cortical hypoperfusion observed within the early phase preceded a long lasting phase of hyperperfusion up to 48 h after CCI.	Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany; Humboldt Univ, Virchow Med Ctr, Charite, Dept Trauma & Reconstruct Surg, D-13353 Berlin, Germany; Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA	Thomale, UW (corresponding author), Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	uthomale@charite.de					Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BAEZ S, 1977, MICROCIRCULATION, P23; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Fabricius M, 1997, J CEREBR BLOOD F MET, V17, P1326, DOI 10.1097/00004647-199712000-00008; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; Groner W, 1999, NAT MED, V5, P1209; Harris AG, 2000, J VASC RES, V37, P469, DOI 10.1159/000054079; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; Klyscz T, 1997, BIOMED TECH, V42, P168, DOI 10.1515/bmte.1997.42.6.168; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Maeda T, 1997, ACT NEUR S, V70, P102; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stover JF, 2000, J NEUROTRAUM, V17, P1171, DOI 10.1089/neu.2000.17.1171; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; THOMALE UW, J NEUROSCI METHODS, V108, P85; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZWEIFACH BW, 1974, CIRC RES, V34, P843, DOI 10.1161/01.RES.34.6.841	48	37	37	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2002	19	4					403	413		10.1089/08977150252932361			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	542XP	WOS:000175071200002	11990347	Green Accepted			2021-06-18	
J	Wallis, G; Chatziastros, A; Bulthoff, H				Wallis, G; Chatziastros, A; Bulthoff, H			An unexpected role for visual feedback in vehicle steering control	CURRENT BIOLOGY			English	Article							INJURIES; MODELS; DRIVER	Some motor tasks can be completed, quite literally, with our eyes shut. Most people can touch their nose without looking or reach for an object after only a brief glance at its location. This distinction leads to one of the defining questions of movement control: is information gleaned prior to starting the movement sufficient to complete the task (open loop), or is feedback about the progress of the movement required (closed loop)? One task that has commanded considerable interest in the literature over the years is that of steering a vehicle, in particular lane-correction and lane-changing tasks. Recent work has suggested that this type of task can proceed in a fundamentally open loop manner [1, 2], with feedback mainly serving to correct minor, accumulating errors. This paper reevaluates the conclusions of these studies by conducting a new set of experiments in a driving simulator. We demonstrate that, in fact, drivers rely on regular visual feedback, even during the well-practiced steering task of lane changing. Without feedback, drivers fail to initiate the return phase of the maneuver, resulting in systematic errors in final heading. The results provide new insight into the control of vehicle heading, suggesting that drivers employ a simple policy of "turn and see," with only limited understanding of the relationship between steering angle and vehicle heading.	Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; Univ Queensland, Sch Human Movement Studies, Percept & Motor Syst Lab, Brisbane, Qld 4072, Australia	Wallis, G (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.	gwallis@hms.uq.edu.au	Bulthoff, Heinrich H/J-6579-2012; Wallis, Guy/G-2342-2011; Bulthoff, Heinrich/AAC-8818-2019	Bulthoff, Heinrich H/0000-0003-2568-0607; Wallis, Guy/0000-0003-1601-1540; 			BOER E, 1998, P 1998 IEEE INT C IN, V1, P291; DONGES E, 1978, HUM FACTORS, V20, P691, DOI 10.1177/001872087802000607; Dorf R. C., 1995, MODERN CONTROL SYSTE; Duma SM, 1996, J TRAUMA, V41, P114, DOI 10.1097/00005373-199607000-00018; GODTHELP J, 1985, ERGONOMICS, V28, P1419, DOI 10.1080/00140138508963268; HARRIS CS, 1965, PSYCHOL REV, V72, P419, DOI 10.1037/h0022616; Hess R. A., 1990, IEEE Control Systems Magazine, V10, P3, DOI 10.1109/37.60415; Hildreth EC, 2000, J EXP PSYCHOL HUMAN, V26, P1106, DOI 10.1037//0096-1523.26.3.1106; Land MF, 2001, CURR BIOL, V11, P1215, DOI 10.1016/S0960-9822(01)00351-7; MCRUER D, 1969, ERGONOMICS, V12, P599, DOI 10.1080/00140136908931082; MCRUER DT, 1977, HUM FACTORS, V19, P381, DOI 10.1177/001872087701900406; *NATL HIGHW TRAFF, 1999, AIR BAG SAF FACT SHE; *NATL HIGHW TRAFF, 1999, AIR BAG VID PAG; Parkin S, 1995, ACCIDENT ANAL PREV, V27, P777, DOI 10.1016/0001-4575(95)00035-6; REID LD, 1981, ERGONOMICS, V24, P447, DOI 10.1080/00140138108924867; Salvucci DD, 2001, INT J HUM-COMPUT ST, V55, P85, DOI 10.1006/ijhc.2001.0472; Segui-Gomez M, 1998, NEW ENGL J MED, V339, P132, DOI 10.1056/NEJM199807093390219; THOMAS P, 1995, ACCIDENT ANAL PREV, V27, P561, DOI 10.1016/0001-4575(94)00085-Z	18	37	37	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	FEB 19	2002	12	4					295	299	PII S0960-9822(02)00685-1	10.1016/S0960-9822(02)00685-1			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	523RL	WOS:000173969100018	11864569				2021-06-18	
J	Ding, YC; Yao, B; Zhou, YD; Park, H; McAllister, JP; Diaz, FG				Ding, YC; Yao, B; Zhou, YD; Park, H; McAllister, JP; Diaz, FG			Prereperfusion flushing of ischemic territory: a therapeutic study in which histological and behavioral assessments were used to measure ischemia-reperfusion injury in rats with stroke	JOURNAL OF NEUROSURGERY			English	Article						cerebral ischemia; infarction; neurological deficit; reperfusion damage; microcirculation; motor response; rat	CEREBRAL-ARTERY OCCLUSION; TRANSIENT FOCAL ISCHEMIA; POSTISCHEMIC HYPOTHERMIA; FOREBRAIN ISCHEMIA; FREE-RADICALS; NEOCORTICAL INFARCTION; MOLECULAR MECHANISMS; GERBIL HIPPOCAMPUS; ALCOHOL EXPOSURE; NEURONAL INJURY	Object. In ischemic stroke, the ischemic crisis activates a cascade of traumatic events that are potentiated by reperfusion and eventually lead to neuronal degeneration. The primary aim of this study was to investigate a procedure that could minimize this damage by interfering with the interactions between reestablished blood flow and ischemically damaged tissue, as well as by improving regional microcirculation. Methods. Using a novel hollow filament, the authors flushed the ischemic territory with heparinized saline before vascular reperfusion after occlusion of the middle cerebral artery (MCA). The results demonstrate a statistically significant (p < 0.001) reduction in infarct volume (75%; from 45.3 +/- 3.6% to 11.4 +/- 1.7%, determined with Nissl staining) in rats in which a 2-hour MCA occlusion was followed by a 48-hour reperfusion. Infarction and neuronal degeneration were confirmed using silver staining, which revealed a significantly larger infarct (36.3%, p < 0.05) than that detected with Nissl staining. The long-term neuroprotection of the prereperfusion flushing was also evaluated. This was determined by a series of motor behavior tasks (foot placing parallel bar traversing, rope and ladder climbing) performed up to 28 days after reperfusion. Motor deficits were found to be significantly ameliorated in animals that underwent the flushing procedure (p < 0.001). In addition, neurological outcome was also improved significantly (p < 0.001) in the same animals. Conclusions. These results indicate that interaction between reperfusion and the metabolically and biochemically compromised tissue could be interrupted by the prereperfusion flushing procedure, which could lead to a reduction in brain injury from stroke. Mechanical reopening of the cerebral occlusion with local flushing and isolated reperfusion of the regionally injured brain might offer new treatment options for patients with stroke.	Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Ding, YC (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, Lande Med Res Bldg,Room 48,550 E Canfield, Detroit, MI 48201 USA.		McAllister, James P./N-9657-2019				ADAMS JH, 1997, NEUROSURG CLIN N AM, V8, P207; Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BECK J, 2000, RESTOR NEUROL NEUROS, V16, P162; Becker KJ, 1998, CURR OPIN NEUROL, V11, P45, DOI 10.1097/00019052-199802000-00008; Bivin W.S., 1979, LABORATORY RAT, VI, P73; BULKLEY GB, 1987, J VASC SURG, V5, P512, DOI 10.1067/mva.1987.avs0050512b; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; CHEN H, 1992, J NEUROL SCI, V107, P191, DOI 10.1016/0022-510X(92)90288-V; CHIANG J, 1968, AM J PATHOL, V52, P455; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; CLARK RK, 1994, BRAIN RES BULL, V35, P387, DOI 10.1016/0361-9230(94)90119-8; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DIETRICH WD, 1984, J NEUROPATH EXP NEUR, V43, P72, DOI 10.1097/00005072-198401000-00006; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DOUGHERTY JH, 1907, NEUROLOGY, V27, P382; Emerich DF, 1999, STROKE THERAPY, P195; Fischer M, 1996, INTENS CARE MED, V22, P1214; GARCIA JH, 1994, AM J PATHOL, V144, P188; GINSBERG MD, 1990, CEREBROVAS BRAIN MET, V2, P58; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Goodlett CR, 1996, PHARMACOL BIOCHEM BE, V55, P531, DOI 10.1016/S0091-3057(96)00248-1; HABERL RL, 1994, THROMB RES, V74, pS13, DOI 10.1016/S0049-3848(10)80003-9; Hall ED, 1999, STROKE THERAPY, P245; HALLENBECK JM, 1990, ARCH NEUROL-CHICAGO, V47, P1245, DOI 10.1001/archneur.1990.00530110107027; HARA A, 1995, NEUROL RES, V17, P461, DOI 10.1080/01616412.1995.11740364; Hossmann KA, 1997, SHOCK, V8, P95, DOI 10.1097/00024382-199708000-00004; Huang J, 1999, NEUROSURGERY, V45, P328, DOI 10.1097/00006123-199908000-00027; HUNTER AJ, 1995, TRENDS PHARMACOL SCI, V16, P123, DOI 10.1016/S0165-6147(00)88999-3; IWAI T, 1993, LIFE SCI, V52, P1031, DOI 10.1016/0024-3205(93)90195-9; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; Jones TA, 1999, J NEUROSCI, V19, P10153; Kato H, 1999, CELL MOL NEUROBIOL, V19, P93, DOI 10.1023/A:1006920725663; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KIESSLING M, 1994, BRAIN PATHOL, V4, P21; Klintsova AY, 1998, BRAIN RES, V800, P48, DOI 10.1016/S0006-8993(98)00495-8; KOIZUMI J, 1985, P 10 M JAP STROK SOC, P4; KORTHUIS RJ, 1985, CIRC RES, V57, P599, DOI 10.1161/01.RES.57.4.599; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MELCER T, 1995, NEUROTOXICOL TERATOL, V17, P103, DOI 10.1016/0892-0362(94)00058-L; MEYER LS, 1990, ALCOHOL CLIN EXP RES, V14, P23, DOI 10.1111/j.1530-0277.1990.tb00440.x; Mohr J.P., 1986, STROKE PATHOPHYSIOLO, P377; MULLER TB, 1994, INT J MICROCIRC, V14, P289, DOI 10.1159/000178843; OLSSON Y, 1971, ACTA NEUROPATHOL, V17, P68, DOI 10.1007/BF00684742; OVERGAARD K, 1994, CEREBROVAS BRAIN MET, V6, P257; PHILLIS JW, 1997, PRIMER CEREBROVASCUL, P261; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; SAITO I, 1987, STROKE, V18, P863, DOI 10.1161/01.STR.18.5.863; Samama MM, 1997, THROMB HAEMOSTASIS, V78, P173; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1993, PROG BRAIN RES, V96, P1; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Watson BD, 1998, CELL MOL NEUROBIOL, V18, P581, DOI 10.1023/A:1020209616428; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P617, DOI 10.1038/jcbfm.1991.112; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; WOOD JH, 1985, STROKE, V16, P765, DOI 10.1161/01.STR.16.5.765; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	75	37	41	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2002	96	2					310	319		10.3171/jns.2002.96.2.0310			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	517BU	WOS:000173591900016	11838805				2021-06-18	
J	Donaldson, J; Shi, R; Borgens, R				Donaldson, J; Shi, R; Borgens, R			Polyethylene glycol rapidly in damaged sciatic restores physiological functions nerves of guinea pigs	NEUROSURGERY			English	Article						axon sealing; axotomy; nerve injury; neurotrauma; peripheral nerve; polyethylene glycol	SPINAL-CORD INJURY; MEMBRANE-FUSION; RECOVERY; NEURONS; REPAIR; DOGS	OBJECTIVE: We have studied the ability of the hydrophilic polymer polyethylene glycol (PEG) to anatomically and physiologically reconnect damaged axons of the adult guinea pig spinal cord. Here we have extended this approach to test whether completely severed guinea pig sciatic nerves in isolation could be fused and whether PEG was able to repair severe standardized crush injuries to sciatic nerves in vivo. METHODS: The fusion test was performed with isolated sciatic nerves maintained in a double-sucrose gap recording chamber. For in vivo experiments, the sciatic nerve was surgically exposed in the hind leg of deeply anesthetized adult guinea pigs and was crushed proximal to its insertion in the gastrocnemius muscle. PEG was injected just beneath the epineurium with a 29-gauge needle, allowed to remain in the damaged axon region for 2 minutes, and removed. Sham-treated guinea pigs received an injection of water or Krebs' solution. Three indices of recovery were simultaneously monitored in response to electrical stimulation of the proximal nerve, i.e., 1) recovery of compound muscle action potentials (in millivolts), 2) contraction force of the muscle (in dynes), and 3) displacement of the muscle (in millimeters). RESULTS: When isolated sciatic nerves were severed within the double-sucrose gap chamber, compound action potential propagation through the transection plane was eliminated. After abutment of the two segments and 2-minute PEG application to this site, variable compound action potential recovery was measured in all four cases. The crush injuries to the sciatic nerve in vivo eliminated the three functional responses to sciatic nerve stimulation in all animals. Within the first 30 minutes after treatment, only 1 of 12 control animals exhibited spontaneous recovery in any of these measures, compared with six of eight PEG-treated animals. By 45 minutes, two more sham-treated animals and one more PEG-treated animal had recovered at least one functional response. This difference in proportions between PEG-treated and sham-treated animals was statistically significant (P less than or equal to 0.02). CONCLUSION: We conclude that these preliminary data suggest that PEG application may be a way to interfere with the steady dissolution of peripheral nerve fibers after mechanical damage and to even functionally fuse or reconnect severed proximal and distal segments.	Purdue Univ, Ctr Paralysis Res, Sch Vet Med, Inst Appl Neurol, W Lafayette, IN 47907 USA; Indiana Univ, Sch Med, Div Neurosurg, Wishard Mem Hosp, Indianapolis, IN USA	Borgens, R (corresponding author), Purdue Univ, Ctr Paralysis Res, Sch Vet Med, Inst Appl Neurol, 1244 VCPR, W Lafayette, IN 47907 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 39288-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER		Bisby Mark A., 1995, P553; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; CARAFOLI E, 1985, SCI AM, V253, P70, DOI 10.1038/scientificamerican1185-70; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; Lucas JH, 1997, NEUROSCIENTIST, V3, P89; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Rosenberg LJ, 1996, BRAIN RES, V734, P349; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	26	37	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2002	50	1					147	156		10.1097/00006123-200201000-00023			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	506AC	WOS:000172946900034	11844245				2021-06-18	
J	Harter, L; Keel, M; Hentze, H; Leist, M; Ertel, W				Harter, L; Keel, M; Hentze, H; Leist, M; Ertel, W			Caspase-3 activity is present in cerebrospinal fluid from patients with traumatic brain injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						apoptosis; neurons; trauma; brain; DEVD-afc; zVAD	DEATH	Loss of neurons after traumatic brain injury (TBI) might involve dysregulated. apoptosis. Activation of caspase-3 is one hallmark of apoptosis. Therefore, caspase-3 activity (cleavage of DEVD-afc) was measured in cerebrospinal fluid (CSF) samples (n = 113) from 27 patients with TBI at day I t0 14 after trauma. Caspase-3 activity was detected in 31 (27.4%) CSF samples with-highest values (> 5.5 41 muM/min) seen at day 2-5 after trauma. No caspase-3 activity was found in serum from patients or CSF from controls. The presence of activated caspase-3 in CSF suggests ongoing apoptotic processes during traumatic brain injury. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland; Inst Mol & Cell Biol, Singapore 117609, Singapore; H Lundbeck & Co AS, DK-2500 Valby, Denmark	Harter, L (corresponding author), Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland.		Leist, Marcel/D-2133-2010	Leist, Marcel/0000-0002-3778-8693			Clark RSB, 1999, FASEB J, V13, P813; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1998, Results Probl Cell Differ, V24, P105; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; RINK A, 1995, AM J PATHOL, V147, P1575; STOCKER R, 1995, UPD INT CAR, V22, P196; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615	9	37	39	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	DEC 3	2001	121	1-2					76	78		10.1016/S0165-5728(01)00409-X			3	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	508NJ	WOS:000173095100010	11730942				2021-06-18	
J	Aoki, M; Tamatani, M; Taniguchi, M; Yamaguchi, A; Bando, Y; Kasai, K; Miyoshi, Y; Nakamura, Y; Vitek, MP; Tohyama, M; Tanaka, H; Sugimoto, H				Aoki, M; Tamatani, M; Taniguchi, M; Yamaguchi, A; Bando, Y; Kasai, K; Miyoshi, Y; Nakamura, Y; Vitek, MP; Tohyama, M; Tanaka, H; Sugimoto, H			Hypothermic treatment restores glucose regulated protein 78 (GRP78) expression in ischemic brain	MOLECULAR BRAIN RESEARCH			English	Article						hypothermia; GRP78; neuroprotection; hippocampal neuron	FOCAL CEREBRAL-ISCHEMIA; GERBIL HIPPOCAMPUS; MILD HYPOTHERMIA; TRANSIENT ISCHEMIA; OXIDATIVE STRESS; NEURONAL DEATH; MESSENGER-RNA; RAT-BRAIN; APOPTOSIS; TEMPERATURE	Mild hypothermia is a well-known method of reducing brain damage caused by traumatic, hypoxic, and ischemic injury. To elucidate the neuroprotective mechanism induced by hypothermic treatment, we compared gene expression profiles in the hippocampus of gerbils rendered ischemic for 15 min and then reperfused for 3 h under conditions of normothermia (37 +/-0.5 degreesC) or hypothermic treatment (34 +/-0.5 degreesC). Using the differential display method, we observed significantly reduced expression of the 78 kDa glucose regulated protein (GRP78), in ischemic gerbil hippocampus that underwent normothermic reperfusion, but normal GRP78 expression in animals that underwent hypothermic reperfusion. In situ hybridization and Northern blot analysis showed GRP78 mRNA expression was reduced in the CAI region of the hippocampus under normothermic conditions, but was not reduced under hypothermic conditions. Western blot analysis also showed the levels of immunoreactive GRP78 protein decreased in neurons of the hippocampal CA-1 region under normothermia, but not under hypothermic treatments. Furthermore, adenovirus-mediated overexpression of GRP78 protects rat hippocampal neurons from cell death and inhibits the rise in intracellular calcium concentration normally induced by hydrogen peroxide. These results suggest that reduction in GRP78 expression contributes to cell damage in the ischemic brain and that hypothermia-mediated restoration of GRP78 expression is one mechanism that enhances neuronal survival. (C) 2001 Published by Elsevier Science B.V.	Osaka Univ, Grad Sch Med, Dept Traumatol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Clin Genet, Suita, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	Tanaka, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Vitek, Michael/0000-0001-8140-8048			BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; CHOI DW, 1993, RES P ARNMD, V71, P23; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; HIGASHI T, 1994, BRAIN RES, V650, P239, DOI 10.1016/0006-8993(94)91787-6; KATO H, 1994, BRAIN RES, V634, P235, DOI 10.1016/0006-8993(94)91926-7; KAWAGOE J, 1993, BRAIN RES, V621, P121, DOI 10.1016/0006-8993(93)90306-8; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Liang P, 1997, J CELL SCI, V110, P1431; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Mattson MP, 1996, ADV NEUROL, V71, P1; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002	32	37	41	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	NOV 1	2001	95	1-2					117	128		10.1016/S0169-328X(01)00255-8			12	Neurosciences	Neurosciences & Neurology	494RH	WOS:000172299300013	11687283				2021-06-18	
J	Fisher, J; Mizrahi, T; Schori, H; Yoles, E; Levkovitch-Verbin, H; Haggiag, S; Revel, M; Schwartz, M				Fisher, J; Mizrahi, T; Schori, H; Yoles, E; Levkovitch-Verbin, H; Haggiag, S; Revel, M; Schwartz, M			Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility	JOURNAL OF NEUROIMMUNOLOGY			English	Article						neuroprotection IL-6 deficiency; axonal injury; optic nerved; glutamate toxicity; inflammation	CENTRAL-NERVOUS-SYSTEM; AUTOIMMUNE T-CELLS; MYELIN BASIC-PROTEIN; SPINAL-CORD INJURY; BRAIN INJURY; MICROGLIAL ACTIVATION; CYTOKINE PRODUCTION; TRANSGENIC MICE; OPTIC-NERVE; INTERLEUKIN-6	Axonal injury initiates a process of neuronal degeneration, with resulting death of neuronal cell bodies. We show here that in C57BL/6J mice, previously shown to have a limited ability to manifest a post-traumatic protective immunity, the rate of neuronal survival is increased if IL-6 is deficient during the first 24 hours after optic nerve injury. Immunocytochemical staining preformed 7 days after the injury revealed an increased number of activated microglia in the IL-6-deficient mice compared to the wild-type mice. In addition, IL-6-deficient mice showed an increased resistance to glutamate toxicity. These findings suggest that the presence of IL-6 during the early post-traumatic phase, at least in mice that are susceptible to autoimmune disease development, has a negative effect on neuronal survival. This further substantiates the contention that whether immune-derived factors are beneficial or harmful for nerve recovery after injury depends on the phenotype of the immune cells and the timing and nature of their dialog with the damaged neural tissue. (C) 2001 Elsevier Science B.V. All rights reserved.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Haggiag, Shalom/AAL-8385-2021	Fisher, Jasmin/0000-0003-4477-9047; Haggiag, Shalom/0000-0002-5569-4121			BARRES BA, 1993, DEVELOPMENT, V118, P283; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BENNUN A, 1983, J IMMUNOL, V130, P1205; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Fiske BK, 2000, NEUROSCIENCE, V96, P807, DOI 10.1016/S0306-4522(99)00601-6; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Jensen MB, 2000, J NEUROSCI, V20, P3612; KAHN MA, 1994, GLIA, V12, P87, DOI 10.1002/glia.440120202; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; LEE SC, 1993, J IMMUNOL, V150, P2659; LIU DX, 1994, J NEUROCHEM, V62, P37; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; Penkowa M, 1999, GLIA, V25, P343; Schwartz M, 2000, IMMUNOL TODAY, V21, P265, DOI 10.1016/S0167-5699(00)01633-9; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Schwartz M, 1996, J GLAUCOMA, V5, P427; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Sugiura S, 2000, EUR J NEUROSCI, V12, P457, DOI 10.1046/j.1460-9568.2000.00922.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001	42	37	43	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	SEP 3	2001	119	1					1	9		10.1016/S0165-5728(01)00342-3			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	471VW	WOS:000170950200001	11525794				2021-06-18	
J	Feinstein, A; Ouchterlony, D; Somerville, J; Jardine, A				Feinstein, A; Ouchterlony, D; Somerville, J; Jardine, A			The effects of litigation on symptom expression: a prospective study following mild traumatic brain injury	MEDICINE SCIENCE AND THE LAW			English	Article							MINOR HEAD-INJURY; QUESTIONNAIRE; RECOVERY; SCALE	Objective: To prospectively assess the association between litigation and neurobehavioural symptoms following mild Traumatic Brain Injury (TBI). Design: a prospective study with the inception cohort assessed on average 42.2(17.2) days after injury. Setting: an outpatient clinic within a large general hospital. Patients: a consecutive sample of 100 clinic attenders with mild TBI. Outcome measures: A cognitive screen (Mini-Mental State Examination (MMSE), Galveston Orientation and Amnesia Test (GOAT), a measure of psychological distress (the 28 item General Health Questionnaire (GHQ)) and two head injury outcome measures, the Glasgow Outcome Scale (GOS) and the Rivermead Head Injury Follow-up Questionnaire (RHFUQ). Results: Demographic characteristics, TBI severity ratings and premorbid risk factors for poor outcome did not differ between litigants (27.8 per cent of the sample) and non-litigants. However, litigants were significantly more anxious (p <0.0001), depressed (p <0.01), had greater social dysfunction (p <0.0001) and had poorer outcome on the GOS (p <0.002) and RHFUQ (p <0.002). There were no cognitive differences between the groups. Conclusions: the data demonstrate an association between litigation and increased psychological distress at the outset of the litigation process. While association is not synonymous with causality, the absence of demographic, premorbid and TBI related differences between litigants and non-litigants suggests that the pursuit of compensation may influence the subjective expression of symptoms following mild traumatic brain injury.	Sunnybrook Hosp, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada	Feinstein, A (corresponding author), Sunnybrook Hosp, Room FG38,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Jardine, Alan/L-5770-2019				Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Cartlidge N E, 1981, HEAD INJURY; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; KAY DWK, 1971, LANCET, V2, P1052; Kay Thomas E., 1992, Archives of Physical Medicine and Rehabilitation, V73, P955; KELLY R, 1981, J ROY SOC MED, V74, P275; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P160; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V	21	37	38	0	1	CHILTERN PUBLISHING	BEACONSFIELD	34 AYLESBURY END, BEACONSFIELD, BUCKS, ENGLAND HP9 1LW	0025-8024			MED SCI LAW	Med. Sci. Law	APR	2001	41	2					116	121		10.1177/002580240104100206			6	Law; Medicine, Legal; Pathology	Government & Law; Legal Medicine; Pathology	431EA	WOS:000168617800006	11368391				2021-06-18	
J	Mazzini, L; Zaccala, M; Gareri, F; Giordano, A; Angelino, E				Mazzini, L; Zaccala, M; Gareri, F; Giordano, A; Angelino, E			Long-latency auditory-evoked potentials in severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						auditory; brain injuries; evoked potentials; rehabilitation	EVENT-RELATED POTENTIALS; HEAD-INJURY; ODDBALL PARADIGM; RATING-SCALE; COMA; STIMULI; P300; COMPONENTS; RESPONSES; EMERGENCE	Objective: To detect the effects of different deviant stimuli on long-latency auditory-evoked potentials (LLAEPs) in patients with severe impairment of consciousness from traumatic brain injury (TBI) and to define their prognostic value for late functional outcome. Design: Correlational study on a prospective cohort. Setting: Brain injury rehabilitation center, Patients: Eleven volunteers and 21 consecutively sampled patients with severe TBI referred to the inpatient intensive rehabilitation unit of primary care in a university-based system. Main Outcome Measures: The LLAEPs recorded with different paradigms; and the Glasgow Outcome Scale (GOS), Disability Rating Scale (DRS), FIM(TM) instrument, and Neurobehavioural Rating Scale (NBHRS). Results: N100-P150 complex showed high reliability. Patients with good outcomes showed N100 and P150 mean latencies similar to those of unimpaired patients and shorter than patients with unfavorable outcomes. When the deviant stimulus was the patient's name, N100 latency showed high correlations with DRS (p <.007), FIM (p <.01), and NBHRS (p <.009). P250 and P300 showed a low percentage of occurrence with passive paradigms in both patients and controls. Their scores were inversely correlated to the Glasgow Coma Scale (p <.03) and the Innsbruck Coma Scale (p <.003), but no significant correlations were found with functional and behavioral outcomes. Patients with COS score 1-2 1 year posttrauma had significantly longer latency and lower amplitude of N100 and P150 than those with GOS score 4-5. Conclusions: LLAEPs can be recorded in patients with severe impairment of consciousness by means of passive paradigms, The use of a stimulus that is relevant for the patient can enhance the accuracy of the test and its relationship with functional outcome.	IRCCS, Fdn Salvatore Maugeri, Ctr Med Veruno, Dept Neurol Rehabil,Med Ctr Rehabil, I-28010 Veruno, NO, Italy; IRCCS, Fdn Salvatore Maugeri, Bioengn Serv, Med Ctr Rehabil, I-28010 Veruno, NO, Italy; IRCCS, Fdn Salvatore Maugeri, Psychol Serv, Med Ctr Rehabil, I-28010 Veruno, NO, Italy	Mazzini, L (corresponding author), IRCCS, Fdn Salvatore Maugeri, Ctr Med Veruno, Dept Neurol Rehabil,Med Ctr Rehabil, I-28010 Veruno, NO, Italy.	lmazzini@fsm.it	Mazzini, Letizia/AAA-2262-2021; Giordano, Andrea/E-8442-2019	Giordano, Andrea/0000-0002-6051-0067			Altman D. G., 1990, PRACTICAL STAT MED R; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BARNES MP, 1991, CURR OPIN NEUROL NEU, V4, P12; BASTUJI H, 1995, J CLIN NEUROPHYSIOL, V12, P155, DOI 10.1097/00004691-199503000-00006; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Boutros N, 1997, PSYCHIAT RES, V69, P183, DOI 10.1016/S0165-1781(96)02919-8; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; DOEBRICH HM, 1986, SURG NEUROL, V26, P112; FARWELL LA, 1991, PSYCHOPHYSIOLOGY, V28, P531, DOI 10.1111/j.1469-8986.1991.tb01990.x; FRUHSTOR.H, 1969, ELECTROEN CLIN NEURO, V27, P346, DOI 10.1016/0013-4694(69)91443-6; GARCIALARREA L, 1992, NEUROPSYCHOLOGIA, V30, P723, DOI 10.1016/0028-3932(92)90042-K; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; HEGERL U, 1993, BIOL PSYCHIAT, V33, P173, DOI 10.1016/0006-3223(93)90137-3; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KEVANISHVILI ZS, 1979, ELECTROEN CLIN NEURO, V47, P280, DOI 10.1016/0013-4694(79)90280-3; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, TRAUMATIC BRAIN INJU, V2, P53; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Nordby H, 1996, NEUROREPORT, V7, P1082, DOI 10.1097/00001756-199604100-00026; PFEFFERBAUM A, 1990, ELECTROEN CLIN NEURO, V76, P6, DOI 10.1016/0013-4694(90)90052-L; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; POLICH J, 1989, ELECTROEN CLIN NEURO, V74, P312, DOI 10.1016/0168-5597(89)90061-0; POLICH J, 1987, ELECTROENCEPHALOGR C, V63, P311; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROTH WT, 1973, PSYCHOPHYSIOLOGY, V10, P125, DOI 10.1111/j.1469-8986.1973.tb01097.x; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; Starr A, 1988, HDB ELECTROENCEPHALO, P97; TEASDALE G, 1974, LANCET, V2, P81; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; WOODS DL, 1980, SCIENCE, V207, P655, DOI 10.1126/science.7352278; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O	42	37	42	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2001	82	1					57	65		10.1053/apmr.2001.18076			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	389WY	WOS:000166262700010	11239287				2021-06-18	
J	Ricker, JH; Muller, RA; Zafonte, RD; Black, KM; Millis, SR; Chugani, H				Ricker, JH; Muller, RA; Zafonte, RD; Black, KM; Millis, SR; Chugani, H			Verbal recall and recognition following traumatic brain injury: A [O-15]-water positron emission tomography study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CROSSED CEREBELLAR DIASCHISIS; CLOSED HEAD-INJURY; FUNCTIONAL NEUROANATOMY; LEARNING TEST; GLUCOSE-METABOLISM; PREFRONTAL CORTEX; EPISODIC MEMORY; PET IMAGES; SHORT-TERM; PERFORMANCE	Although several studies exist which have examined static functional neuroimaging following traumatic brain injury (TBI), controlled cognitive activation studies of episodic memory in this population have not been published. The present investigation studied verbal recall using [O-15]-water positron emission tomography (PET) in 5 individuals who sustained severe TBI (M GCS = 6.8; M years post-injury = 3.18), and 4 non-injured control participants. Statistical image analysis demonstrated changes in frontoparietal regional cerebral blood flow (rCBF) in both groups, but there were interesting differences between groups and across conditions. Frontal lobe rCBF changes in TBI patients were reduced during free recall but enhanced during recognition, when compared to controls. Changes in cerebellar rCBF were observed in the control group during free recall, but not in the TBI sample. In both groups, bifrontal rCBF increases were noted on recognition tasks. The present findings provide evidence of alterations in specific substrates involved in verbal recall following brain injury.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ Calif San Diego, Dept Cognit Sci, San Diego, CA 92103 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Kessler Med Rehabil Res & Educ Corp, Dept Res, W Orange, NJ USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI USA	Ricker, JH (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jricker@kmrrec.org		Ricker, Joseph/0000-0003-3415-991X			Alavi A, 1997, J NUCL MED, V38, P1717; ANDREASEN NC, 1995, P NATL ACAD SCI USA, V92, P5111, DOI 10.1073/pnas.92.11.5111; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BARON JC, 1995, REV NEUROL, V151, P511; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P254, DOI 10.1162/jocn.1997.9.2.254; Catalan MJ, 1998, BRAIN, V121, P253, DOI 10.1093/brain/121.2.253; CHERTKOW H, 1994, FUNCTIONAL ACTIVATIO; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELUCA J, IN PRESS ARCH PHYSIC; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; Fiez JA, 1996, J NEUROSCI, V16, P808; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; KAPUR S, 1995, NEUROREPORT, V6, P1880, DOI 10.1097/00001756-199510020-00014; Keenan PA, 1996, CLIN NEUROPSYCHOL, V10, P455, DOI 10.1080/13854049608406706; KERTESZ A, LOCALIZATION NEUROIM, P151; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; METTER EJ, 1987, NEUROLOGY, V37, P1599, DOI 10.1212/WNL.37.10.1599; Millis Scott R., 1993, Brain Injury, V7, P53, DOI 10.3109/02699059309008156; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; MINOSHIMA S, 1993, INT CONGR SER, V1030, P409; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Mottaghy FM, 1999, EXP BRAIN RES, V128, P332, DOI 10.1007/s002210050853; Nolde SF, 1998, NEUROREPORT, V9, P3509, DOI 10.1097/00001756-199810260-00032; PANTANO P, 1986, BRAIN, V109, P677, DOI 10.1093/brain/109.4.677; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; Roland P. E., 1993, BRAIN ACTIVATION; ROSENTHAL M, 2000, HDB REHABILITATION P, pCH26; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schmahmann JD, 1997, INT REV NEUROBIOL, V41, P31, DOI 10.1016/S0074-7742(08)60346-3; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; Talairach J., 1988, COPLANAR STEREOTAXIC; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Woodard JL, 1998, NEUROPSYCHOLOGY, V12, P491, DOI 10.1037/0894-4105.12.4.491; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZAFONTE RD, 1996, MED REHABILITATION T, P251	54	37	37	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	2					196	206		10.1076/jcen.23.2.196.1204			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	412QZ	WOS:000167567000006	11309673				2021-06-18	
J	Schiefermeier, M; Kollegger, H; Madl, C; Schwarz, C; Holzer, M; Kofler, J; Sterz, F				Schiefermeier, M; Kollegger, H; Madl, C; Schwarz, C; Holzer, M; Kofler, J; Sterz, F			Apolipoprotein E polymorphism - Survival and neurological outcome after cardiopulmonary resuscitation	STROKE			English	Article						apolipoproteins E; heart arrest; polymorphism; resuscitation; stroke outcome	HOSPITAL CARDIAC-ARREST; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BRAIN INJURY; HEAD-INJURY; ALLELE; ASSOCIATION; PROTEIN; PLASMA; APOE	Background and Purpose-The apolipoprotein E 3/3 (apoE 3/3) genotype is associated with a reduced risk of developing Alzheimer's disease and with a favorable neurological outcome after traumatic head injury. In vitro studies suggest that the most common genotype, apoE 3/3, may be involved in neuroprotective and neuroregenerative mechanisms. The aim of this study was to determine whether the apoE 3/3 genotype has an impact on survival and neurological outcome after cardiopulmonary resuscitation. Methods-Eighty patients with cardiac arrest were investigated prospectively for their apoE genotype. Epidemiological data were assessed according to recommended guidelines. Patients were divided into 2 groups, ie, with the apoE 3/3 genotype present or absent, and tested for differences in survival and neurological outcome. Further statistical analysis with respect to survival and neurological outcome was performed by using a stepwise logistic regression analysis. Results-Patients with the apoE 3/3 genotype had a significantly higher survival rate (64% versus 33%, P=0.007) and more often a favorable neurological outcome (55% versus 27%, P=0.013) compared with patients with other apoE genotypes. The apoE 3/3 genotype was shown to be a substantial predictive factor for a favorable neurological outcome (odds ratio 3.2) and was, apart from other essential factors, predictive for survival (odds ratio 4.4) after cardiopulmonary resuscitation. Conclusions-These data give evidence that patients with the apoE 3/3 genotype have a better chance of recovery after cardiopulmonary resuscitation than do patients with apoE genotypes other than 3/3.	Univ Vienna, Dept Clin Neurol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 4, Div Intens Care Med, A-1090 Vienna, Austria; Univ Vienna, Dept Emergency Med, A-1090 Vienna, Austria	Schiefermeier, M (corresponding author), Univ Vienna, Dept Clin Neurol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Kofler, Julia/AAJ-8032-2021				ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Behringer W, 1998, ANN INTERN MED, V129, P450, DOI 10.7326/0003-4819-129-6-199809150-00004; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Greenberg SM, 1997, ANN NEUROL, V41, P701, DOI 10.1002/ana.410410604; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; MADI C, 2000, CRIT CARE MED, V28, P721; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mullner M, 1997, INTENS CARE MED, V23, P1138, DOI 10.1007/s001340050470; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Perers E, 1999, RESUSCITATION, V40, P133, DOI 10.1016/S0300-9572(99)00022-2; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Schiefermeier M, 2000, BRAIN, V123, P585, DOI 10.1093/brain/123.3.585; Schmidt R, 1997, STROKE, V28, P951, DOI 10.1161/01.STR.28.5.951; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; SIEST G, 1995, CLIN CHEM, V41, P1068; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; van Walraven C, 1999, ARCH INTERN MED, V159, P129, DOI 10.1001/archinte.159.2.129; Wass CT, 1996, MAYO CLIN PROC, V71, P801; WelshBohmer KA, 1997, ANN NEUROL, V42, P319, DOI 10.1002/ana.410420308; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Weston CFM, 1997, RESUSCITATION, V34, P27, DOI 10.1016/S0300-9572(96)01031-3; Yamauchi K, 1999, CLIN CHEM, V45, P497; ZHANG MY, 1994, METABOLISM, V43, P1523, DOI 10.1016/0026-0495(94)90011-6	32	37	39	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2000	31	9					2068	2073		10.1161/01.STR.31.9.2068			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	351YT	WOS:000089188300006	10978031	Bronze			2021-06-18	
J	McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B				McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B			Changes in spiritual beliefs after traumatic disability	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						disability; spirituality; life change events; rehabilitation	HEALTH; NEEDS; SURVIVORS; CANCER; PEOPLE; SELF	Objectives: To discover the effect of sudden-onset disability on spirituality, specifically, to investigate changes following the onset of disability in spiritual concepts and to outline a theoretical framework consisting of relationships with the self, others, the world, and a supreme power. Study Design: The study used a cross-sectional, qualitative approach to understand changes in spirituality from the perspective of the disabled person. Intensive semistructured interviews were conducted with 16 participants, each of whom had either a spinal cord injury or brain injury, within the 2-year period after discharge from rehabilitation. Changes in spiritual concepts were explored in relation to 3 types of relationships (intrapersonal, interpersonal, and transpersonal) and 5 themes (awareness, closeness, trust, purpose, and vulnerability). Results: Specific changes in spirituality described by sample members were: greater awareness of the self; a change in their view of their own independence; a sense of purpose in life that was not present before the onset of the disability; greater awareness of their own mortality and vulnerability; a new understanding of trust, especially when depending on others; loss of some significant relationships; greater appreciation and closeness with others and the world; and greater understanding of other disadvantaged groups. Conclusions: The interviews portrayed a significant ability to conceptualize issues in a spiritual context in the 2-year period after discharge from rehabilitation. Further, the changes reported suggest a positive effect of spirituality in the adjustment period following onset.	Queens Univ, Sch Rehabil Therapy, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Philosophy, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Theol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Rehabil Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Chaplaincy, Kingston, ON K7L 3N6, Canada; Reg Community Brain Injury Serv, Kingston, ON, Canada	McColl, MA (corresponding author), Queens Univ, Sch Rehabil Therapy, Kingston, ON K7L 3N6, Canada.						ANDERSON JM, 1993, ARCH PHYS MED REHAB, V74, P574, DOI 10.1016/0003-9993(93)90154-3; Berggren-Thomas P, 1995, J Gerontol Nurs, V21, P5; Bowers C C, 1987, Rehabil Nurs, V12, P90; CARSON V, 1988, J PSYCHOL THEOL, V16, P159; CONDELUCI A, 1991, INTERDEPENDENCE ROUT; DiMatteo M. R., 1981, SOCIAL NETWORKS SOCI, P117; Elsdon R, 1995, Prof Nurse, V10, P641; Erikson EH., 1963, CHILDHOOD SOC, V2nd Edn.; FINE SB, 1991, AM J OCCUP THER, V45, P493, DOI 10.5014/ajot.45.6.493; Fitzgerald J, 1997, DISABIL REHABIL, V19, P407, DOI 10.3109/09638289709166565; Fowler J.W., 1981, STAGES FAITH; FOWLER JW, 1985, LIFE MAPS, P94; Frankl VE., 1984, MANS SEARCH MEANING; FRAZEE C, 1999, INTRO DISABILITY HAN, P59; HALSTEAD MT, 1994, CANCER NURS, V17, P94; Herth K A, 1989, Oncol Nurs Forum, V16, P67; Horsburgh M, 1997, DISABIL REHABIL, V19, P398, DOI 10.3109/09638289709166564; JOHNSON SC, 1991, J RELIG HEALTH, V30, P21, DOI 10.1007/BF00986676; Lindsey E, 1996, J ADV NURS, V24, P465, DOI 10.1046/j.1365-2648.1996.02135.x; MCCOLL MA, 1994, PARAPLEGIA, V32, P261, DOI 10.1038/sc.1994.46; MCCOLL MA, 1995, PHYSIOTHERAPY OLDER; MCCOLL MA, IN PRESS DISABIL REH; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; REED PG, 1992, RES NURS HEALTH, V15, P349, DOI 10.1002/nur.4770150505; Robinson A, 1994, Holist Nurs Pract, V8, P1; ROSS L, 1995, INT J NURS STUD, V32, P457, DOI 10.1016/0020-7489(95)00007-K; Schmidt K. H., 1988, STUDIA CELTICA JAPON, V1, P1; Schuetz B, 1995, Aust Fam Physician, V24, P775; Selway D, 1998, DISABIL SOC, V13, P429, DOI 10.1080/09687599826722; SMITH DW, 1995, NURS SCI QUART, V8, P133, DOI 10.1177/089431849500800309; SOEKEN KL, 1987, NURS CLIN N AM, V22, P603; Walter T, 1997, PALLIATIVE MED, V11, P21, DOI 10.1177/026921639701100103; Watkins E, 1997, J SUBST ABUSE TREAT, V14, P581, DOI 10.1016/S0740-5472(97)00138-4; Young C, 1993, Geriatr Nurs, V14, P298, DOI 10.1016/S0197-4572(06)80054-6; Young E W, 1984, J Am Coll Health, V32, P273	35	37	37	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2000	81	6					817	823		10.1053/apmr.2000.5567			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	320EN	WOS:000087389000023	10857530				2021-06-18	
J	Chapman, EH; Weintraub, RJ; Milburn, MA; Pirozzi, TO; Woo, E				Chapman, EH; Weintraub, RJ; Milburn, MA; Pirozzi, TO; Woo, E			Homeopathic treatment of mild traumatic brain injury: A randomized, double-blind, placebo-controlled clinical trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MINOR HEAD-INJURY; UNITED-STATES; MEDICINE; METAANALYSIS	Bachground: Mild traumatic brain injury (MTBI) affects 750,000 persons in the United States annually Five to fifteen percent have persistent dysfunction and disability. No effective, standard pharmacological treatment exists specifically for this problem. We designed a pilot research project to study the clinical effectiveness of homeopathic medicine in the treatment of persistent MTBI. Method: A randomized, double-blind, placebo-controlled trial of GO patients, with a four-month follow-up (N = 50), was conducted at Spaulding Rehabilitation Hospital (SRH). Patients with persistent MTBI (mean 2.93 years since injury, SD 3.1) were randomly assigned to receive a homeopathic medicine or placebo. The primary outcome measure was the subject-rated SRH-MBTI Functional Assessment, composed of three subtests: a Difficulty with Situations Scale (DSS), a Symptom Rating Scale (SRS), and a Participation in Daily Activities Scale (PDAS). The SRH Cognitive-Linguistic Test Battery was used as the secondary measure. Results: Analysis of covariance demonstrated that the homeopathic treatment was the only significant or near-significant predictor of improvement on DSS subtests (P = .009; 95% CI -.895 to -.15), SRS (P = .058; 95% CI -.548 to .01) and the Ten Most Common Symptoms of MTBI (P = .027; 35% CI -.766 to -.048). These results indicate a significant improvement from the homeopathic treatment versus the control and translate into clinically significant outcomes. Conclusions: This study suggests that homeopathy may have a role in treating persistent,MTBI. Our findings require large-scale, independent replication.	Harvard Univ, Sch Med, Boston, MA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA; Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA	Chapman, EH (corresponding author), 91 Cornell St, Newton, MA 02462 USA.						ALVES W, 1993, J HEAT TRAUMA REHABI, V8, P13; BOISSEL JP, 1996, REPORT HOMEOPATHIC M; BONAVIDA B, 1997, P 1 INT S PHYS CHEM, P4; CHAPMAN E, 1992, J AM I HOMEOPATHY, V83, P74; CHIPKIN P, 1990, P 1990 PROF CAS C SE, P87; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Committee on Mild Traumatic Brain Injury American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DANTES F, 1996, P 51 C LMHI, P335; Davidson J R, 1997, Altern Ther Health Med, V3, P46; DIEM K, 1970, DOCUMENTA GEIGY SCI, P31; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1996, ARCH INTERN MED, V156, P2162, DOI 10.1001/archinte.156.19.2162; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall DM, 1974, PSYCHOL EFFECTS CONS; HAHNEMANN S, 1996, ORGONON MED ART, P171; HAYES R, 1948, HOMEOPATHIC RECORDER, V64, P152; *HOM PHARM CONV US, 1995, HOM PHARM CONV US HP; HORN LJ, 1992, REHABILITATION POSTC; JACOBS J, 1994, PEDIATRICS, V93, P719; JONAS W, 1996, HEALING HOMEOPATHY, P9; KAY T, 1988, MINOR HEAD INJURY IN; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kayne SB, 1997, HOMEOPATHIC PHARM, P366; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KRAUS JF, 1989, MILD HEAD INJURY, P245; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LINDE K, 1994, HUM EXP TOXICOL, V13, P481, DOI 10.1177/096032719401300706; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Lo SY, 1996, MOD PHYS LETT B, V10, P921, DOI 10.1142/S0217984996001048; Lo SY, 1996, MOD PHYS LETT B, V10, P909, DOI 10.1142/S0217984996001036; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; POSTHUMA A, 1988, COGNIT REHABIL, V3, P22; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; RILEY D, 1994, J AM I HOOMEOPATHY, V84, P144; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; SHERR JY, 1994, DYNAMIC METHODOLOGY; SINITSYN AP, 1997, P 1 INT S PHYS CHEM, P6; *SPSS INC, 1997, SPSS ADV STAT 7 5; Turkey J. W., 1977, EXPLORATORY DATA ANA; TURNER RJ, 1983, RES COMMUNITY MENTAL, V3, P67; *US FDA, 1998, COMP POL GUID; VITHOULKAS G, 1980, SCI HOMEOPATHY; WARKENTIN DK, 1992, MACREPERTORY 3 4; WOODCOCK RW, 1990, WOODCOCKJOHNSON PSYC; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; ZASLER N, 1993, J HEAD TRAUMA REHAB, V8, P48	55	37	37	0	11	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					521	542		10.1097/00001199-199912000-00002			22	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300001	10671699				2021-06-18	
J	Sherer, M; Bergloff, P; High, W; Nick, TG				Sherer, M; Bergloff, P; High, W; Nick, TG			Contribution of functional ratings to prediction of longterm employment outcome after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; WORK; COMMUNITY; RETURN; SCALE	The present study investigated the contribution of functional ratings to prediction of employment outcome after traumatic brain injury (TBI). Previous studies have suggested that functional ratings obtained at a significant time post-injury can supplement neurologic, pre-injury, neuropsychologic, and other post-injury variables in predicting long-term employment outcome. Functional ratings studied were patients' needs for physical, cognitive, and behavioural supervision. This investigation also addressed the issue of predicting long-term outcome for the select group of TBI patients who receive post-acute brain injury rehabilitation. Subjects were 76 patients with TBI. The mean age (25th, 50th, and 75th percentiles) was 32 (22, 28, 39) years and mean premorbid education level was 13 (12, 12, 14) years. Predictors studied were severity of injury, premorbid education level, pre-injury substance use. and needs for physical, cognitive and behavioural supervision at discharge from postacute rehabilitation. Supervision needs ratings were obtained an average of 9.6 (4.2, 5.9, 11.2) months post-injury. Productivity status was assessed an average of 22.5 (12.6, 20.7, 30.5) months post-injury and 12.9 (4.9, 12.4, 16.6) months post-discharge from treatment. Spearman correlation coefficients revealed that premorbid educational level, pre-injury substance use, and needs for physical and behavioural supervision were related to long-term functional outcome (p < 0.05). However, multiple logistic regression analysis revealed that only level of pre-injury substance use was predictive of long-term productivity outcome once adjusted for the effects of the other predictors. Patients with no history of pre-injury substance use were more than eight times as likely to be employed at follow-up as those with a history of pre-injury substance abuse (p < 0.01).	Mississippi Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Baylor Coll Med, Houston, TX 77030 USA; Inst Rehabil & Res, Houston, TX USA	Sherer, M (corresponding author), Mississippi Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BONTKE CF, 1991, NEUROSURG CLIN N AM, V2, P1; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V7, P296; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; HAGEN C, 1979, INTERVENTION STRATEG; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET          0301, P489; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PONFORD JL, 1995, BRAIN INJURY, V9, P11; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SHERER M, CANCER, V80, P250; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	26	37	37	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1999	13	12					973	981					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600003	10628502				2021-06-18	
J	Mackay, LE; Morgan, AS; Bernstein, BA				Mackay, LE; Morgan, AS; Bernstein, BA			Factors affecting oral feeding with severe traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aspiration; brain injury; dysphagia	HEAD-INJURY; DYSPHAGIA; ADULTS	Safe and adequate nutrition, vital to the recovery from a traumatic brain injury; can be severely compromised by the presence of dysphagia. This study identified injury severity and swallowing factors that were associated with impaired oral intake in patients with severe brain injury, An admitting Glasgow Coma Scale (GSC) 3-5; a Rancho Los Amigos Scale of Cognitive Functioning OVA) Level II; a computed tomography (CT) scan exhibiting, midline shift, brainstem involvement, or brain pathology requiring emergent operative procedures; or ventilation time greater than or equal to 15 days identified patients at highest risk for abnormal swallowing, aspiration, and delay in initiation of oral feeding and achievement of total oral feeding. When combined in multivariate models, RLA Level, CT scan, ventilation time and aspiration emerged as significant independent predictors of impaired oral intake.	St Francis Hosp & Med Ctr, Med Surg Program, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Otolaryngol Sect, Farmington, CT USA; St Francis Hosp & Med Ctr, Trauma Serv, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Dept Surg, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Dept Pediat, Hartford, CT 06105 USA	Mackay, LE (corresponding author), St Francis Hosp & Med Ctr, Med Surg Program, MS 20904,114 Woodland St, Hartford, CT 06105 USA.						Aviv JE, 1997, AM J MED, V103, p74S, DOI 10.1016/S0002-9343(97)00327-6; Caruso Anthony J., 1997, Seminars in Speech and Language, V18, P181; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; COOPER KR, 1989, TXB HEAD INJURY, P255; Dejaeger E, 1996, AGING-CLIN EXP RES, V8, P130, DOI 10.1007/BF03339567; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Hagen C, 1981, TOP LANG DIS, V1, P73; Jaradeh Safwan, 1994, Dysphagia, V9, P218, DOI 10.1007/BF00301913; KASHIMA HK, 1989, GERIATRIC OTORHINOLA, P122; Kosta JC, 1998, GERIATR NURS, V19, P195, DOI 10.1016/S0197-4572(98)90154-9; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Logemann J, 1983, EVALUATION TREATMENT, P132; Logemann J. A., 1983, EVALUATION TREATMENT; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; LOGEMANN JA, 1986, MANUAL VIDEOFLUOROGR; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; MACKAY LE, 1997, MAXIMIZING BRAIN INJ; MACKAY LE, 1997, MAXIMIZING BRAIN INJ, P444; MORGUN A, 1997, MODERN SOIL MICROBIO, P331; Paterson WG, 1996, CAN FAM PHYSICIAN, V42, P925; PEPE J, 1997, MAXIMIZING BRAIN INJ, P396; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; Plant RL, 1998, OTOLARYNG CLIN N AM, V31, P477, DOI 10.1016/S0030-6665(05)70065-7; Shaker Reza, 1994, Dysphagia, V9, P221, DOI 10.1007/BF00301914; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; TEASDALE G, 1974, LANCET, V2, P81; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; YOUNG B, 1992, J NEUROTRAUM, V9, pS375	28	37	40	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					435	447		10.1097/00001199-199910000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600004	10653939				2021-06-18	
J	Sanders, MJ; Dietrich, WD; Green, EJ				Sanders, MJ; Dietrich, WD; Green, EJ			Cognitive function following traumatic brain injury: Effects of injury severity and recovery period in a parasagittal fluid-percussive injury model	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; fluid percussion; Morris water maze; recovery; severity	MORRIS WATER MAZE; CLOSED HEAD-INJURY; SPATIAL NAVIGATION; RATS; MEMORY; LESIONS; DEFICITS; IMPAIRMENT; DAMAGE; HYPOTHERMIA	Previous work in this laboratory has demonstrated that rats show substantial deficits on the cued and hidden versions of the Morris water maze, as well as an apparent time-dependent recovery over a period of months, following moderate parasagittal fluid-percussion (FP) injury. However, the longitudinal nature of those studies precluded definitive statements regarding recovery because of the possible confound of practice-dependent improvements in performance. The present experiments were undertaken to address this issue and to investigate more closely the relationship between impact severity and posttraumatic learning/memory deficits, which have not been examined thoroughly in this model, Separate groups of rats were subjected to mild (1.1 to 1.4 atm), moderate (1.8 to 2.1 atm), or severe (2.2 to 2.7 atm) FP injury (or sham surgery) and tested on several water maze tasks at either 5 days or 8 weeks after injury, Moderately and severely injured animals showed impairment in acquisition of the hidden platform task at both time points, Cued platform task performance was impaired significantly in severely injured animals 8 weeks after insult. Mildly injured animals exhibited no significant deficits on either task at either time point. The results indicate that deficits on the hidden platform task are more robust than those on the cued platform task, and that performance on both tasks is dependent on injury severity. They also indicate that the learning/memory deficits in this model are relatively enduring, suggesting that the model is a reasonable one for assessing potential treatment regimens.	Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA; Univ Miami, Program Neurosci, Coral Gables, FL 33124 USA	Green, EJ (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL036588] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL36588] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [3029] Funding Source: Medline		Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Cain DP, 1996, REV NEUROSCIENCE, V7, P215; DEBRUIN JPC, 1994, BRAIN RES, V652, P323, DOI 10.1016/0006-8993(94)90243-7; DEKKER AJ, 1994, NEUROSCIENCE, V60, P299, DOI 10.1016/0306-4522(94)90244-5; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; SANDERS MJ, 1998, J NEUROTRAUM, V15, P894; Savage LM, 1997, BEHAV BRAIN RES, V82, P133, DOI 10.1016/S0166-4328(97)80983-7; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6	31	37	39	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					915	925		10.1089/neu.1999.16.915			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900006	10547100				2021-06-18	
J	Lin, J; Hou, SM				Lin, J; Hou, SM			Antegrade locked nailing for humeral shaft fractures	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							DIAPHYSEAL FRACTURES; EXPERIENCE; FIXATION	Treatment results of antegrade locked nailing of acute humeral shaft fractures, including union rate and recovery of shoulder function, have been inconsistent. This led the current authors to hypothesize that implant design and surgical techniques might account for this inconsistency. In the current study, 47 fractures (38 acute; nine pathologic) in 47 patients achieved union with the techniques of closed nailing, short to long segment nailing, and fracture compression, Satisfactory recovery of shoulder function occurred because of minimal surgical trauma, prevention of impingement by the nail or locking screws, and prevention of axillary nerve injury or comminution of the humeral head, Forty-seven patients with 38 acute fractures and nine pathologic fractures were treated with humeral locked nails. Mean followup time was 21.4 months. With a single operation, all 38 acute fractures proceeded to eventual union; the average time to union was 7.8 weeks. Thirty-five patients had excellent or satisfactory recovery of shoulder function. Complications included slipout of the proximal screw, nail breakage, fragment displacement, and transient postoperative radial nerve palsy. All nine patients with pathologic fractures had substantial pain relief and increased arm function after surgery. The current study shows the reliability of antegrade locked nailing for proximal and middle third fractures of the humeral shaft.	Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei 100, Taiwan	Lin, J (corresponding author), Natl Taiwan Univ Hosp, Dept Orthoped Surg, 7 Chung Shan S Rd, Taipei 100, Taiwan.						BALFOUR GW, 1982, J BONE JOINT SURG AM, V64, P11, DOI 10.2106/00004623-198264010-00002; BELL MJ, 1985, J BONE JOINT SURG BR, V67, P293; Brumback RJ, 1996, CLIN ORTHOP RELAT R, P292; Crates J, 1998, CLIN ORTHOP RELAT R, P40; Dabezies E J, 1992, J Orthop Trauma, V6, P10; ESTERHAI JL, 1986, CLIN ORTHOP RELAT R, P228; FOSTER RJ, 1985, J BONE JOINT SURG AM, V67A, P857, DOI 10.2106/00004623-198567060-00005; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HEIM D, 1993, J TRAUMA, V35, P226, DOI 10.1097/00005373-199308000-00009; Hems TEJ, 1996, INJURY, V27, P485, DOI 10.1016/0020-1383(96)00056-3; HUNTER SG, 1982, CLIN ORTHOP RELAT R, P192; IKPEME JO, 1994, INJURY, V25, P447, DOI 10.1016/0020-1383(94)90271-2; INGMAN AM, 1994, J BONE JOINT SURG BR, V76B, P23; Klenerman L, 1966, J Bone Joint Surg Br, V48, P105; KRETTEK C, 1995, CLIN ORTHOP RELAT R, P34; Lin J, 1997, CLIN ORTHOP RELAT R, P147; Lin J, 1998, CLIN ORTHOP RELAT R, P203; Lin J, 1998, J TRAUMA, V44, P859, DOI 10.1097/00005373-199805000-00019; Lin J, 1998, J TRAUMA, V45, P1051, DOI 10.1097/00005373-199812000-00013; McKee MD, 1996, J ORTHOP TRAUMA, V10, P500, DOI 10.1097/00005131-199610000-00009; Modabber MR, 1998, CLIN ORTHOP RELAT R, P93; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1077, DOI 10.2106/00004623-197052060-00001; Redmond BJ, 1996, J BONE JOINT SURG AM, V78A, P891, DOI 10.2106/00004623-199606000-00012; Remiger AR, 1997, J ORTHOP TRAUMA, V11, P308, DOI 10.1097/00005131-199705000-00016; RIEMER BL, 1991, ORTHOPEDICS, V14, P239; RIEMER BL, 1994, ORTHOPEDICS, V17, P19; RIEMER BL, 1992, ORTHOPEDICS, V15, P697; RIEMER BL, 1993, ORTHOPEDICS, V16, P1219; RIEMER BL, 1996, SCI PRACTICE INTRAME, P241; ROBINSON CM, 1992, J BONE JOINT SURG BR, V74, P558; RODRIGUEZMERCHAN EC, 1995, J ORTHOP TRAUMA, V9, P194, DOI 10.1097/00005131-199506000-00003; Rommens PM, 1998, CLIN ORTHOP RELAT R, P26; ROMMENS PM, 1995, J BONE JOINT SURG BR, V77B, P84; SARMIENTO A, 1977, J BONE JOINT SURG AM, V59, P596, DOI 10.2106/00004623-197759050-00004; SCHOPFER A, 1994, J ORTHOP TRAUMA, V8, P414, DOI 10.1097/00005131-199410000-00008; SWIONTKOWSKI MF, 1990, SURG SHOULDER, P208; Tome JL, 1998, CLIN ORTHOP RELAT R, P51; ZAGORSKI JB, 1988, J BONE JOINT SURG AM, V70A, P607, DOI 10.2106/00004623-198870040-00018; ZIMMERMAN MC, 1994, J ORTHOP TRAUMA, V8, P233, DOI 10.1097/00005131-199406000-00009	39	37	43	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1999		365					201	210					10	Orthopedics; Surgery	Orthopedics; Surgery	225PR	WOS:000081970400025	10627704				2021-06-18	
J	Groswasser, Z; Melamed, S; Agranov, E; Keren, O				Groswasser, Z; Melamed, S; Agranov, E; Keren, O			Return to work as an integrative outcome measure following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							PROLONGED POSTTRAUMATIC UNAWARENESS; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; COMMUNITY INTEGRATION; SUPPORTED EMPLOYMENT; REHABILITATION; PREDICTION; CONSCIOUSNESS; SERVICES; PROGRAM	In recent years we have witnessed the growing recognition of the centrality of work involvement in the successful rehabilitation of brain injured patients. Evidence from studies conducted at Loewenstein Rehabilitation Hospital (LRH) and from other studies, points to a strong and consistent positive association between employment and social integration, leisure activities, enhanced self-esteem, and perceived quality of life. Patients surviving severe traumatic brain injury (TBI) often suffer from residual impairments in motor control, communication skills, cognition, and social behaviour. These distinctly hamper their capability to return to work and to continue working for an extended period of time. Comprehensive and integrated rehabilitation programmes, such as those employed in LRH, were proven to be effective in returning patients to stable employment. This was demonstrated in the results of our recent follow-up study of 334 severe TBI patients, which indicated that 55.7% were gainfully employed 8-13 years post-discharge from LRH.	Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, Raanana, Israel; Natl Inst Occupat & Environm Hlth, Dept Occupat Hlth Psychol, Raanana, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel		zeevgros@ccsg.tau.ac.il					Ashley MJ, 1997, BRAIN INJURY, V11, P677; BENYISHAY Y, 1987, J HEAD TRAUMATIC REH, V1, P90; BOWLING A, 1997, MEASURING HLTH REV Q, P6; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CORKIN C, 1984, ARCH NEUROL-CHICAGO, V41, P957; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FABIANO RJ, 1995, J APPL REHABILITATIO, V26, P17; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; GROSWASSER Z, 1996, THESIS HEBRES U JERU; Hillier SL, 1997, BRAIN INJURY, V11, P661; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; JOHNSON R, 1987, INT DISABILITY STUDI, V9, P44; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; Klove H, 1972, Scand J Rehabil Med, V4, P55; KRAVETZ S, 1985, REHABIL PSYCHOL, V30, P195, DOI 10.1037//0090-5550.30.4.195; KRAVETZ S, 1973, THESIS U WISCONSIN; Kreutzer J S, 1991, Int Disabil Stud, V13, P162; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Marme M., 1993, J APPL REHABILITATIO, V24, P19; Maslow A., 1954, MOTIVATION PERSONALI; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SHIN DC, 1978, SOC INDIC RES, V5, P475, DOI 10.1007/BF00352944; STANBROOK M, 1990, BRAIN INJURY, V4, P183; STERN JM, 1985, SCAND J REHABIL MED, P53; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; Wilson B, 1994, BRAIN INJURY NEUROPS, P85; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	59	37	37	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-OCT	1999	9	3-4					493	504		10.1080/096020199389545			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	242GV	WOS:000082932900022					2021-06-18	
J	Hicks, RR; Boggs, A; Leider, D; Kraemer, P; Brown, R; Scheff, SW; Seroogy, KB				Hicks, RR; Boggs, A; Leider, D; Kraemer, P; Brown, R; Scheff, SW; Seroogy, KB			Effects of exercise following lateral fluid percussion brain injury in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain-derived neurotrophic factor; cognition; traumatic brain injury	NEUROTROPHIN-3 MESSENGER-RNAS; LONG-TERM POTENTIATION; DOPAMINERGIC-NEURONS; INCREASED EXPRESSION; CEREBRAL INFARCTION; FOREBRAIN ISCHEMIA; PHYSICAL-ACTIVITY; DYNAMIC EXERCISE; BLOOD-FLOW; HIPPOCAMPUS	Previous studies have suggested that brain-derived neurotrophic factor (BDNF) is involved in memory and learning, and may be neuroprotective following various brain insults. Exercise has been found to increase BDNF mRNA levels in various brain regions, including specific subpopulations of hippocampal neurons. In the present study, we were interested in whether following traumatic brain injury, exercise could increase BDNF mRNA expression, attenuate neuropathology, and improve cognitive and neuromotor performance. We subjected adult male Sprague-Dawley rats to a fluid percussion brain injury, followed by either 18 days of treadmill exercise or handling. Spatial memory was evaluated in a Morris Water Maze (MWM) and motor function was evaluated with a battery of neuromotor tests. Neuropathology was evaluated by measuring the cortical lesion volume and the extent of neuronal loss in the hippocampus, Expression of BDNF mRNA in the hippocampus was assessed with in situ hybridization and densitometry. Hybridization signal for BDNF mRNA was significantly increased bilaterally in the exercise group in hippocampal regions CA1 and CA3 (p < 0.05), but not in the granule cell layer of the dentate gyrus, No significant differences were observed between the groups in neuropathology, spatial memory, or motor performance. This study suggests that after traumatic brain injury, exercise elevates BDNF mRNA in specific regions of the hippocampus.	Univ Kentucky, Dept Phys Therapy, Lexington, KY 40536 USA; Univ Kentucky, Dept Psychol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hicks, RR (corresponding author), Univ Kentucky, Dept Phys Therapy, CAHP Bldg,Rm 213, Lexington, KY 40536 USA.						Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEBRUIN LA, 1990, AM J PHYSIOL, V259, pR773; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Dishman RK, 1997, MED SCI SPORT EXER, V29, P63, DOI 10.1097/00005768-199701000-00010; Dragunow M, 1997, MOL BRAIN RES, V46, P274, DOI 10.1016/S0169-328X(97)00021-1; Dustman R. E., 1994, Journal of Aging and Physical Activity, V2, P143; ETNIER JL, 1995, SPORTS MED, V19, P81, DOI 10.2165/00007256-199519020-00001; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; GALL CM, 1992, MOL CELL NEUROSCI, V3, P56, DOI 10.1016/1044-7431(92)90009-Q; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; JORGENSEN LG, 1992, J APPL PHYSIOL, V73, P1825; JURASKA JM, 1989, BRAIN RES, V479, P115, DOI 10.1016/0006-8993(89)91341-3; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KRAEMER PJ, 1995, PSYCHOBIOLOGY, V23, P144; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LINDSAY RM, 1993, NEUROTROPHIC FACTORS, P257; MARKGRAF CG, 1994, STROKE, V25, P153, DOI 10.1161/01.STR.25.1.153; Marty S, 1997, TRENDS NEUROSCI, V20, P198, DOI 10.1016/S0166-2236(96)01026-0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOHAMMED AH, 1993, BEHAV BRAIN RES, V57, P183, DOI 10.1016/0166-4328(93)90134-C; Montkowski A, 1997, NEUROREPORT, V8, P779, DOI 10.1097/00001756-199702100-00040; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rocamora N, 1996, J NEUROSCI, V16, P4411; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Seroogy K., 1997, NEUROCHEMISTRY PRACT, P121; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Somani SM, 1996, BIOCHEM MOL BIOL INT, V38, P587; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; THOMAS SN, 1989, J APPL PHYSIOL, V67, P744; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; Ueyama T, 1997, NEUROSCI RES, V28, P103, DOI 10.1016/S0168-0102(97)00030-8; WhiteWelkley JE, 1996, J APPL PHYSIOL, V80, P931; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	51	37	38	0	5	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	MAY	1998	12	1					41	47					7	Neurosciences	Neurosciences & Neurology	150NT	WOS:000077671800004					2021-06-18	
J	Raskin, SA; Mateer, CA; Tweeten, R				Raskin, SA; Mateer, CA; Tweeten, R			Neuropsychological assessment of individuals with mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; SYMPTOMS; DISEASE; MEMORY	The cognitive sequelae of mild traumatic brain injury (MTBI) remain to be clearly delineated. Although the majority of studies have demonstrated deficits on tests of complex attention and working memory, the appropriate clinical tools to be used in an evaluation are still not clearly known. In this study 148 subjects who met the criteria for MTBI were assessed with a comprehensive neuropsychological battery, including a measure of personality. Subjects performed significantly worse than normative data on tests of time dependent attention, and on tests of verbal memory. Cognitive performance was found to be related to demographic variables of gender and age, but not to education, educational status, length of loss of consciousness, or length of time post injury. No emotional or personality variable was related to performance on cognitive neuropsychological measures.	Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; Trinity Coll, Neurosci Program, Hartford, CT 06106 USA; Univ Victoria, Dept Psychol, Victoria, BC, Canada; Good Samaritan Neuropsychol Serv, Puyallup, WA USA	Raskin, SA (corresponding author), Trinity Coll, Dept Psychol, Hartford, CT 06106 USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BOHNEN N, 1992, NEUROSURGERY, V30, P692; CICERONE K, 1993, AM C REH MED DENV CO; CROSSON B, 1988, J CLIN EXPT NEUROPSY, V10, P769; DAHLSTROM WG, 1975, MMPI HDB, V1; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Grimsley G., 1971, EMPLOYEE APTITUDE SU; GRONWALL D, 1974, LANCET, V2, P1452; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HOLLINGSHEAD AB, 1977, 4 FACTOR INDEX SOCIA; JASTAJK J, 1965, WIDE RANGE ACHIEVEME; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kramer JH, 1989, NEUROPSYCHOLOGY, V3, P111, DOI 10.1037//0894-4105.3.2.111; KRAUS J, 1988, BRAIN INJURY, V3, P177; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; MASSMAN PJ, 1990, J CLIN EXP NEUROPSYC, V12, P729, DOI 10.1080/01688639008401015; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NORUSIS MJ, 1988, SPSS PC PLUS MANUAL; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; Ruff R., 1989, MILD HEAD INJURY, P152; SIMON E, 1994, J CLIN EXP NEUROPSYC, V16, P414, DOI 10.1080/01688639408402652; Smith A., 1973, SYMBOL DIGIT MODALIT; SOHLBERG M, 1989, ATTENTION PROCESS TE; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler, 1981, WAIS R MANUAL; WECHSLER D, 1984, WMS R MANUAL; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950	38	37	37	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	1998	12	1					21	30		10.1076/clin.12.1.21.1724			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	ZE592	WOS:000072810000003					2021-06-18	
J	Narotam, PK; Rodell, TC; Nadvi, SS; Bhoola, KD; Troha, JM; Parbhoosingh, R; van Dellen, JR				Narotam, PK; Rodell, TC; Nadvi, SS; Bhoola, KD; Troha, JM; Parbhoosingh, R; van Dellen, JR			Traumatic brain contusions: A clinical role for the kinin antagonist CP-0127	ACTA NEUROCHIRURGICA			English	Article						brain injury; brain contusion; kinin-kallikrein system; bradykinin receptor antagonist	CEREBRAL ARTERIOLAR DILATION; BRADYKININ ANTAGONIST; KALLIKREIN; EDEMA; INJURY; SYSTEM; MEDIATOR; ANGIOTENSIN; INHIBITION; RECEPTORS	Focal cerebral contusions can be dynamic and expansive, leading to delayed neurological deterioration. Due to the high mortality associated with such cerebral contusions, our standard practice had evolved into evacuating contusions in patients who had a deterioration in level of consciousness, lesions > 30 cc and CT suggestion of raised ICP. Experimental brain edema studies have implicated kinins in causing 2 degrees brain swelling. CP-0127 (Bradycor (TM)), a specific bradykinin antagonist, has been found to reduce cerebral edema in a cold lesion model in rats. In a randomized, single blind pilot study, a 7 day infusion of CP-0127 (3.0 mu g/kg/min) was compared to placebo in patients with focal cerebral contusions presenting within 24-96 hours of closed head injury with an initial GCS 9-14. The ICP, GCS, and vital signs were monitored hourly. The total lesion burden (TLB) was measured on serial CT scans. There were no differences in age, baseline GCS, TLB, initial ICP, or laboratory findings between the two groups (n = 20). The mean (+/- s.d) rise in peak ICP from baseline was greater in the placebo group than with CP-0127 (21.9 +/- 4.7 vs 9.5 +/- 2.0, P = 0.018). In addition, the mean reduction in GCS in the placebo group was significantly greater than in the CP-0127 group (4 +/- 1.0 vs 0.6 +/- 0.4, P = 0.002). Significantly raised ICP and clinically significant neurological deterioration occurred in 7/9 patients on placebo (77%) and only in 1 patient (9%; n = 11) on CP-0127, mandating surgery (P = 0.005). There were no adverse drug reactions, significant changes in vital signs or variations in the laboratory values. The cerebral perfusion pressure was adequately maintained in all patients irrespective of therapy. These preliminary results with CP-0127 provide supporting evidence that the kinin-kallikrein system could be involved in cerebral edema. In this study, treatment with CP-0127 appeared to alter the natural history of traumatic brain contusions by preventing the 2 degrees brain swelling. In addition, CP-0127 obviated the need for surgery in the majority of treated patients. CP-0127 could act on the cerebral vasculature to limit dys-autoregulation and brain swelling or on the blood brain barrier to reduce cerebral edema.	Univ Manitoba, Hlth Sci Ctr, Neurosurg Sect, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; OXIS Int Inc, Portland, OR USA; Univ KwaZulu Natal, Dept Neurosurg, ZA-4001 Durban, South Africa; Wentworth Provincial Hosp, Durban, South Africa; Univ KwaZulu Natal, Dept Expt & Clin Pharmacol, ZA-4001 Durban, South Africa; Cortech Inc, Denver, CO USA; MRC S Africa, Cape Town, South Africa	Narotam, PK (corresponding author), Z3020,409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.		Parboosing, Raveen/T-1933-2019	Parboosing, Raveen/0000-0002-5476-1011			AUER LM, 1979, ACTA NEUROCHIR, V49, P207, DOI 10.1007/BF01808960; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHERONIS JC, 1992, J MED CHEM, V35, P1563, DOI 10.1021/jm00087a010; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHU CS, 1994, J BIOMECH, V27, P187, DOI 10.1016/0021-9290(94)90208-9; CZERNICKI Z, 1979, ACTA NEUROCHIR, V50, P311, DOI 10.1007/BF01808530; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; ELLIS EF, 1990, NEW TRENDS LIPID MED, V4, P129; Fein AM, 1997, JAMA-J AM MED ASSOC, V277, P482, DOI 10.1001/jama.277.6.482; FIGUEROA C D, 1990, Human Psychopharmacology, V5, P183, DOI 10.1002/hup.470050303; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; GENDELL HM, 1985, MINN MED, V68, P556; GREENBAUM LM, 1968, FED PROC, V27, P90; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; HORI S, 1968, JPN J PHYSIOL, V18, P772; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KARIYA K, 1982, BIOCHEM BIOPH RES CO, V107, P1461, DOI 10.1016/S0006-291X(82)80163-0; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MULLERESTERL W, 1986, J NEUROSURG, V64, P269; NAROTAM PK, 1993, BRIT J NEUROSURG, V7, P281, DOI 10.3109/02688699309023810; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; REILLY PL, 1975, LANCET, V2, P375; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SNYMAN C, 1994, BRAZ J MED BIOL RES, V27, P1877; STEWART JM, 1989, ADV EXP MED BIOL, V274, P81; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; VAVREK RJ, 1989, ADV EXP MED BIOL, V274, P395; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WHALLEY ET, 1983, PFLUG ARCH EUR J PHY, V398, P175, DOI 10.1007/BF00581069; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V324, P296, DOI 10.1007/BF00502627; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x	46	37	38	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1998	140	8					793	803		10.1007/s007010050181			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	123UY	WOS:000076144700019	9810446				2021-06-18	
J	Williams, WH; Williams, JMG; Ghadiali, EJ				Williams, WH; Williams, JMG; Ghadiali, EJ			Autobiographical memory in traumatic brain injury: Neuropsychological and mood predictors of recall	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; CLOSED-HEAD INJURY; DEPRESSION; AMNESIA; ANXIETY; SCALE	Survivors of traumatic brain injury are often impaired in their recall of specific events. Depressed, suicidal, and post-traumatically stressed patients also tend to be over-general in autobiographical recall. In this study we examined the extent to which neurological damage and disturbed mood converge to lead to problems in autobiographical recall for survivors of traumatic brain injury. Eighteen participants completed measures of depression and anxiety (HAD), tests of general memory and immediate recall (Rivermead), and of current and premorbid verbal IQ (SCOLP). In addition they completed a 20 cue word autobiographical memory test and made causal attributions for their trauma events. Correlational analyses revealed that difficulty in autobiographical recall was related to reduced immediate recall ability and mood disturbance. Remedial implications are discussed.	Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely CB6 1DN, Cambs, England; Univ Cambridge, Cambridge CB2 1TN, England; Univ Wales, Bangor, Gwynedd, Wales; Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England				williams, huw/0000-0003-0670-2620			ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; BADDELEY A, 1992, NATO ADV SCI INST SE, V65, P13; Baddeley A.D., 1986, AUTOBIOGRAPHICAL MEM, P225; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BENEDICT RHB, 1992, J HEAD TRAUMA REHAB, V7, P84; Bond M. R., 1990, REHABILITATION ADULT, P179; BREWIN CR, 1988, BRIT J CLIN PSYCHOL, V27, P1, DOI 10.1111/j.2044-8260.1988.tb00748.x; BREWIN CR, 1984, J SOC CLIN PSYCHOL, V2, P156, DOI DOI 10.1521/JSCP.1984.2.2.156; Brooks N, 1989, Brain Inj, V3, P325, DOI 10.3109/02699058909004556; BROOKS N, 1990, REHABILITATION ADULT, P163; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BULMAN RJ, 1977, J PERS SOC PSYCHOL, V35, P351, DOI 10.1037/0022-3514.35.5.351; CIMINO CR, 1991, BRAIN COGNITION, V6, P23; CLARK DM, 1982, J ABNORM PSYCHOL, V91, P87, DOI 10.1037/0021-843X.91.2.87; EVANS J, 1992, PSYCHOL MED, V22, P399, DOI 10.1017/S0033291700030348; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; JENNETT B, 1990, REHABILITATION ADULT, P3; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MACKINNON DF, 1989, PSYCHOBIOLOGY, V17, P247, DOI 10.1007/BF03337776; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCNALLY RJ, 1994, COGNITION EMOTION, V8, P351, DOI 10.1080/02699939408408946; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Rabbitt P. A., 1988, PRACTICAL ASPECTS ME, P175; RUSSELL D, 1982, J PERS SOC PSYCHOL, V42, P1137, DOI 10.1037//0022-3514.42.6.1137; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STAMBROOK M, 1989, CANADIAN J REHABILIT, V3, P87; STARKSTEIN SE, 1990, ARCH GEN PSYCHIAT, V47, P246, DOI 10.1001/archpsyc.1990.01810150046008; Wechsler D, 1981, WECHSLER MEMORY SCAL; Williams JH, 1994, CONDITION BASED MAIN, P1; WILLIAMS JMG, 1986, J ABNORM PSYCHOL, V95, P144, DOI 10.1037/0021-843X.95.2.144; WILLIAMS JMG, 1988, PSYCHOL MED, V18, P689, DOI 10.1017/S0033291700008370; WILLIAMS JMG, 1992, NATO ADV SCI INST SE, V65, P391; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; ZAHN BS, 1989, PSYCHIAT FORUM   WIN, P6; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZOLAMORGAN S, 1983, NEUROPSYCHOLOGIA, V21, P487, DOI 10.1016/0028-3932(83)90005-2	41	37	37	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	1998	8	1					43	60		10.1080/713755551			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	YW987	WOS:000071994900004					2021-06-18	
J	Queen, SA; Chen, MJ; Feeney, DM				Queen, SA; Chen, MJ; Feeney, DM			d-amphetamine attenuates decreased cerebral glucose utilization after unilateral sensorimotor cortex contusion in rats	BRAIN RESEARCH			English	Article						amphetamine; cerebral glucose utilization; cortical contusion; traumatic brain injury; remote functional depression	CONCUSSIVE BRAIN INJURY; EXCITATORY AMINO-ACIDS; BLOOD-FLOW; NEOCORTICAL ABLATIONS; 2-DEOXYGLUCOSE UPTAKE; CORTICAL ASTROCYTES; MOTOR RECOVERY; FOCAL ISCHEMIA; BASAL GANGLIA; CONSCIOUS RAT	Unilateral contusion injury to the sensorimotor cortex causes, among other symptoms, a transient contralateral hindlimb hemiparesis in rats. A single i.p. 2 mg/kg dose of d-amphetamine (d-AMPH) 24 h after injury accelerates spontaneous recovery from this particular deficit. The mechanism(s) of spontaneous and d-AMPH enhanced recovery are unknown but alleviation of a neuronal depression has been proposed. This quantitative CMRglu study a as designed to determine effects of cortical contusion injury and d-AMPH on CMRglu in cortical and subcortical structures. At 2 days after injury, CMRglu was significantly reduced compared to sham-operated controls only in structures ipsilateral to contusion. Affected structures included the caudate putamen, medial geniculate nucleus, lateral geniculate nucleus and the parietal cortex immediately posterior to injury. By 6 days post-contusion the hypometabolism partially reversed in all structures. A single low dose of d-AMPH significantly alleviated the post-traumatic CMRglu reduction at 2 days after injury. Importantly, while this alleviation was nut significant for any single structure, the main effect of treatment was highly significant. d-AMPH increased CMRglu at 2 days post-injury by 18-33% compared to contused/saline-treated rats. These results suggest that alleviation of neuronal metabolic depression may contribute to spontaneous and d-AMPH enhanced recovery. (C) 1997 Elsevier Science B.V.	Univ Montana, Phys Therapy Program, Dept Phys Therapy, Sch Pharm & Allied Hlth Sci, Missoula, MT 59812 USA; Utah State Univ, Dept Psychol, Logan, UT 84322 USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Queen, SA (corresponding author), Univ Montana, Phys Therapy Program, Dept Phys Therapy, Sch Pharm & Allied Hlth Sci, McGill Hall,Room 026, Missoula, MT 59812 USA.						BECK T, 1995, STROKE, V26, P1107, DOI 10.1161/01.STR.26.6.1107; BECK T, 1990, J CEREBR BLOOD F MET, V10, P542, DOI 10.1038/jcbfm.1990.96; BECK T, 1987, AM J PHYSIOL, V252, pH504; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; COOPER RM, 1984, EXP NEUROL, V83, P134, DOI 10.1016/0014-4886(84)90052-9; COOPER RM, 1984, EXP NEUROL, V86, P261, DOI 10.1016/0014-4886(84)90185-7; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DAUTH GW, 1985, ANN NEUROL, V17, P431, DOI 10.1002/ana.410170503; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P195, DOI 10.1038/jcbfm.1986.32; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1990, STROKE, V21, P147; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FENEY DM, IN PRESS CEREBROVASC, V1; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GILMAN S, 1987, ANN NEUROL, V22, P370, DOI 10.1002/ana.410220314; HEISS WD, 1990, J CEREBR BLOOD F MET, V10, P127, DOI 10.1038/jcbfm.1990.16; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HOSOKAWA S, 1985, BRAIN RES, V343, P8, DOI 10.1016/0006-8993(85)91152-7; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1996, NEUROTRAUMA, P1459; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KLEIN AE, 1993, SOC NEUR ABSTR, V19, P1878; KOGURE K, 1979, STROKE, V10, P179, DOI 10.1161/01.STR.10.2.179; KROBERT K A, 1990, Society for Neuroscience Abstracts, V16, P43; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; Kuczenski R, 1983, STIMULANTS NEUROCHEM, P31; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MIES G, 1990, J CEREBR BLOOD F MET, V10, P638, DOI 10.1038/jcbfm.1990.116; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P100, DOI 10.1038/jcbfm.1988.13; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; ORZI F, 1983, J CEREBR BLOOD F MET, V3, P154, DOI 10.1038/jcbfm.1983.22; Panigrahy A., 1995, Society for Neuroscience Abstracts, V21, P2119; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PELLEGRINO LJ, 1986, STEREOTAXIC ATLAS RA; PORRINO LJ, 1984, BRAIN RES, V307, P311, DOI 10.1016/0006-8993(84)90485-2; Queen SA, 1996, BRAIN RES, V724, P246, DOI 10.1016/0006-8993(96)00308-3; RISCHKE R, 1991, J CEREBR BLOOD F MET, V11, P106, DOI 10.1038/jcbfm.1991.12; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHIBUYA M, 1987, J NEURAL TRANSM, V68, P271, DOI 10.1007/BF02098503; SHIMOYAMA I, 1988, ANN NEUROL, V24, P718, DOI 10.1002/ana.410240605; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SORG O, 1991, BRAIN RES, V563, P227, DOI 10.1016/0006-8993(91)91538-C; Von Monakow C, 1969, BRAIN BEHAVIOR, P27; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WECHSLER LR, 1979, J NEUROCHEM, V32, P15, DOI 10.1111/j.1471-4159.1979.tb04504.x; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAO H, 1995, J CEREBR BLOOD F MET, V15, P398, DOI 10.1038/jcbfm.1995.50; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU NC, 1993, P NATL ACAD SCI USA, V90, P4042, DOI 10.1073/pnas.90.9.4042	75	37	37	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 28	1997	777	1-2					42	50		10.1016/S0006-8993(97)00717-8			9	Neurosciences	Neurosciences & Neurology	YM565	WOS:000071077500005	9449411				2021-06-18	
J	McGann, W; Werven, G; Douglas, MM				McGann, W; Werven, G; Douglas, MM			Social competence and head injury: A practical approach	BRAIN INJURY			English	Article								Social competence assessment and training has long focused on specific skills within the clinical setting. In addition, emphasis has been placed on identifying deficits relative to an arbitrary, often idiosyncratic metric. In this article, we discuss the importance of the principles that underlie communication and which are reflected in the range of behaviours described as 'social competence'. We review methods we have found productive in the training of these principles with persons who have suffered traumatic brain injuries.	MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	McGann, W (corresponding author), SW WASHINGTON MED CTR,400 NE MOTHER JOSEPH PL,VANCOUVER,WA 98664, USA.						Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; MCGANN W, 1995, BRAIN INJURY, V9, P93, DOI 10.3109/02699059509004575; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123	5	37	38	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					621	628		10.1080/026990597123179			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600001	9376830				2021-06-18	
J	Cicerone, KD				Cicerone, KD			Clinical sensitivity of four measures of attention to mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD INJURY; SUSTAINED ATTENTION; CONCUSSION; DEFICITS	The percentage of mild traumatic brain-injury patients receiving impaired scores was determined for four neuropsychological measures of attention: Digit Span, Trail Making Test, Paced Auditory Serial Addition test (PASAT), and an auditory Continuous Performance Test of Attention (CPTA). Sensitivity was also determined based on overall criteria for multiple measures. Significant variability among the attention measures was apparent, with patients more likely to demonstrate impaired performance on the PASAT and CPTA. This appeared due to the interaction of demands upon information processing speed and capacity in response to externally paced stimuli. The results are relevant to concerns regarding the clinical interpretation of neuropsychological measures of attention.		Cicerone, KD (corresponding author), JFK JOHNSON REHABIL INST,2048 OAK TREE RD,EDISON,NJ 08820, USA.						Baribeau J., 1989, J NEUROL REHABIL, V3, P71; DEARY IJ, 1994, BIOL PSYCHOL, V38, P1, DOI 10.1016/0301-0511(94)90046-9; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; GRONWALL D, 1975, LANCET, V2, P995; Heaton R.K., 1991, COMPREHENSIVE NORMS; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PICANO JJ, 1992, ARCH CLIN NEUROPSYCH, V7, P271, DOI 10.1016/0887-6177(92)90168-M; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1992, NEUROPSYCHOLOGY CONS, P9; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SCHMIDT S, 1994, J AM SOC NEPHROL, V5, P383; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; VANZOMERAN AH, 1994, CLIN NEUROPSYCHOLOGY; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wolfson D., 1993, HALSTEAD REITAN NEUR	23	37	37	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	1997	11	3					266	272		10.1080/13854049708400455			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	XL666	WOS:A1997XL66600005					2021-06-18	
J	Bombardier, CH; Ehde, D; Kilmer, J				Bombardier, CH; Ehde, D; Kilmer, J			Readiness to change alcohol drinking habits after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; CHANGE QUESTIONNAIRE; SUBSTANCE-ABUSE; ISSUES	Objective: To describe how motivated are persons with recent traumatic brain injury (TBI) to change their alcohol drinking habits and what factors affect their motivation. Design: Survey. Setting: Acute inpatient rehabilitation program. Patients: Subjects were 50 patients with recent TBI during inpatient rehabilitation. Main Outcome Measures: Readiness to Change (RTC) questionnaire, Michigan Alcoholism Screening Test (MAST), and alcohol use questions. Results: Subjects were 36 years old; 86% were men. Eightfour percent fell in the contemplation or action phases. Comparisons with a separate medical patient sample suggested that TBI may be associated with greater contemplation of change and greater readiness to take action to change alcohol use. Multivariate analyses indicated that within the TBI sample a positive history of alcoholism, alcohol involved in the accident, and higher daily consumption were associated with greater readiness to change (especially contemplation scores). Conclusions: Soon after TBI, drinkers frequently contemplate changing their alcohol use. This situation may represent an underutilized window of opportunity to reduce postinjury alcohol use and abuse. Motivational interviewing techniques seem well suited to facilitate change during this period. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195	Bombardier, CH (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT REHABIL MED,325 9TH AVE,BOX 359740,SEATTLE,WA 98104, USA.		Ehde, Dawn/K-1883-2016	Ehde, Dawn/0000-0002-9555-2347	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U48/CCU009654, R49/CCR002570] Funding Source: Medline		BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DONOVAN D, 1995, RES SOC ALC STEAMB S; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EVANS RW, 1992, NEUROL CLIN, V10, P815; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; HEATHER N, 1993, 19 U NEW S WAL NAT D; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; Jacobson GR, 1989, HDB ALCOHOLISM TREAT, P17; Jones G.A., 1992, NEUROREHABILITATION, V2, P27; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Miller WR, 1991, MOTIVATIONAL INTERVI; *NAT HEAD INJ FDN, 1988, SUBST AB TASK FORC W; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Selzer M. L., 1971, AM J PSYCHIAT, V127, P89; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020	27	37	37	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1997	78	6					592	596		10.1016/S0003-9993(97)90424-X			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	XD759	WOS:A1997XD75900005	9196466				2021-06-18	
J	Ho, MR; Bennett, TL				Ho, MR; Bennett, TL			Efficacy of neuropsychological rehabilitation for mild-moderate traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							COGNITIVE REHABILITATION; ISSUES	The growing literature on cognitive rehabilitation is increasingly demanding more evaluation related to the validity of such therapy. The current research addresses same of the criticisms of previous previous efficacy studies and provides support for the effectiveness of cognitive rehabilitation according to a specific treatment protocol employed at an outpatient rehabilitation program. Stringent subject selection criterion were utilized to maximize the validity of the statistical comparisons of selected pre- and post- rehabilitation neuropsychological test scores and cognitive level of functioning. Results supported improvement in performance on selected neuropsychological rest scores and cognitive functioning following cognitive rehabilitation. Limited validating evidence for behavioral indicators of level of cognitive functioning were obtained through correlations of behavioral ratings to their corresponding neuropsychological test scores. Results suggest that traditional measures of efficacy of cognitive rehabilitation may be insensitive to the cognitive sequalae of mild head injury due, in part, to compensatory strategies invoked by the subjects. (C) 1997 National Academy of Neuropsychology.	COLORADO STATE UNIV, FT COLLINS, CO 80524 USA; BRAIN INJURY RECOVERY PROGRAM, FT COLLINS, CO 80524 USA							ACIMOVIC ML, 1991, M COL HEAD INJ FDN B; BENNETT TL, 1992, J HEAD INJURY, V3, P21; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BERROL S, 1990, ARCH NEUROL-CHICAGO, V47, P219, DOI 10.1001/archneur.1990.00530020127025; DICKER BG, 1989, J HEAD TRAUMA REHAB, V4, P73; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; GORDON WA, 1989, J HEAD TRAUMA REHAB, V4, P76; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MAZMANINAN PE, 1991, COGNITIVE REHABILITA; PARSONS OA, 1978, J CONSULT CLIN PSYCH, V46, P608, DOI 10.1037/0022-006X.46.4.608; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; REYNOLDS CR, 1988, EXCEPT CHILDREN, V54, P324; REYNOLDS CR, 1981, SCH PSYCHOL REV, V10, P343; ROJAS DC, 1995, ARCH CLIN NEUROPSYCH, V10, P101, DOI 10.1016/0887-6177(94)E0038-Q; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SYMONDS C, 1962, LANCET, V1, P1; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; Wolfson D., 1993, HALSTEAD REITAN NEUR	23	37	38	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1997	12	1					1	11					11	Psychology, Clinical; Psychology	Psychology	WQ271	WOS:A1997WQ27100001	14588430				2021-06-18	
J	Lu, YC; Liu, SL; Gong, QZ; Hamm, RJ; Lyeth, BG				Lu, YC; Liu, SL; Gong, QZ; Hamm, RJ; Lyeth, BG			Inhibition of nitric oxide synthase potentiates hypertension and increases mortality in traumatically brain-injured rats	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						L-NAME; mortality; morbidity; blood pressure; fluid percussion; traumatic brain injury; rat	FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; BLOOD-FLOW; L-ARGININE; NEUROTRANSMITTER RELEASE; RELAXING FACTOR; MODEL; ACTIVATION; IMPAIRMENT; RECEPTORS	We examined the effects of N-omega-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase (NOS), on mortality, morbidity, and cardiovascular parameters following traumatic brain injury (TBI) in the rat. Rats were anesthetized with 2% isoflurane prior to moderate (2.0 atmosphere), central fluid percussion TBI. Temporalis muscle temperature was maintained at 37 +/- 0.5 degrees C. L-NAME (10 mg/kg iv) was administered once at either 5 min before, 5 min after, or 15 min after TBI. Sensorimotor deficits and spatial learning/memory deficits were assessed after injury. Separate groups of rats were monitored for cardiovascular parameters. Preinjury administration of L-NAME significantly increased mortality from 13 (vehicle) to 70% (associated with pulmonary edema), whereas postinjury, L-NAME had no effect on mortality (14 and 25%). L-NAME administered at 5 or 15 min after injury had no significant effect on motor performance or cognitive performance deficits associated with TBI. L-NAME in uninjured rats increased arterial blood pressure by 25 mmHg within 2 min. L-NAME injected 5 min before TBI greatly prolonged the hypertensive episode associated with TBI (1 min in vehicle vs 60 min in L-NAME). L-NAME injected 5 min after TBI caused a sustained 35 mmHg increase in blood pressure. These findings suggest that acute inhibition of NOS has detrimental consequences on mortality that may be owing to its cardiovascular effects.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298				Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ASHWAL S, 1993, J NEUROSURG ANESTH, V5, P241; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BUCHANAN JE, 1993, BRAIN RES, V610, P248, DOI 10.1016/0006-8993(93)91408-K; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; BULLOCK R, 1994, INTRACRANIAL PRESSUR, V9, P238; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DIRNAGL U, 1993, NEUROSCI LETT, V149, P43, DOI 10.1016/0304-3940(93)90343-J; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELKARIB AO, 1993, CLIN EXP HYPERTENS, V15, P819, DOI 10.3109/10641969309041644; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FELDMAN PL, 1993, CHEM ENG NEWS, V12, P26; GARDINER SM, 1990, HYPERTENSION, V15, P486, DOI 10.1161/01.HYP.15.5.486; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERBERG LJ, 1995, PSYCHOPHARMACOLOGY, V119, P115, DOI 10.1007/BF02246062; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P884; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAGGIO R, 1995, BRAIN RES, V679, P184, DOI 10.1016/0006-8993(95)00217-E; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOLLACE V, 1992, NEUROSCI LETT, V137, P87, DOI 10.1016/0304-3940(92)90305-Q; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NISHIKAWA T, 1994, STROKE, V25, P877, DOI 10.1161/01.STR.25.4.877; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; QUAST MJ, 1995, BRAIN RES, V677, P204, DOI 10.1016/0006-8993(95)00134-C; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; TANAKA K, 1993, NEUROREPORT, V4, P267, DOI 10.1097/00001756-199303000-00010; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; WEISSMAN BA, 1992, NEUROSCI LETT, V146, P139, DOI 10.1016/0304-3940(92)90062-C; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZORUMSKI CF, 1993, BIOCHEM PHARMACOL, V46, P777, DOI 10.1016/0006-2952(93)90484-E	44	37	37	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	JAN-FEB	1997	30	1-2					125	137		10.1007/BF02815154			13	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	WK182	WOS:A1997WK18200009	9138424				2021-06-18	
J	Cruz, J				Cruz, J			Relationship between early patterns of cerebral extraction of oxygen and outcome from severe acute traumatic brain swelling: Cerebral ischermia or cerebral viability?	CRITICAL CARE MEDICINE			English	Article						head injury; coma; intracranial pressure; oxyhemoglobin; hemodynamics; neurologic emergencies; patient outcome assessment; Glasgow Outcome Scale; brain swelling; cerebral extraction of oxygen	ACUTE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; METABOLIC-RATE; CONSUMPTION; ISCHEMIA	Objective: To evaluate outcome from severe acute traumatic diffuse brain swelling, in relation to early patterns of global cerebral extraction of oxygen. Design: Prospective, interventional study. Setting: Neuroscience intensive care unit of a university hospital. Patients: Adults (n = 205) with acute, essentially isolated brain trauma (predominantly diffuse brain swelling), undergoing routine early monitoring of cerebral extraction of oxygen and intracranial pressure, along with other monitoring modalities. Interventions: Routine neuroemergency procedures. Measurements and Main Results: Cerebral extraction of oxygen (arteriojugular oxyhemoglobin saturation difference) was measured in each patient, early in the acute phase (2 to 8 hrs postinjury), Outcome at 6 months postinjury was significantly better in patients with initially increased cerebral extraction of oxygen (>42%) than in those patients with normal (24% to 42%) or decreased (<24%) values, In contrast, no significant differences were found among these three groups with respect to age, initial Glasgow Coma Scale score, intracranial pressure, cerebral perfusion pressure, Pace,, total hemoglobin content, and time from injury when the initial measurements were performed. Conclusions: Initially increased cerebral extraction of oxygen appears to indicate global cerebral viability rather than cerebral ischemia in patients with acute traumatic diffuse brain swelling.		Cruz, J (corresponding author), MED COLL PENN & HAHNEMANN UNIV,DEPT NEUROSURG,BROAD & VINE ST,MAIL STOP 455,PHILADELPHIA,PA 19102, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR303687] Funding Source: Medline		BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CRUZ J, 1992, J TRAUMA, V33, P304, DOI 10.1097/00005373-199208000-00022; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Cruz J., 1995, Journal of Neurotrauma, V12, P444; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81	24	37	38	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	JUN	1996	24	6					953	956		10.1097/00003246-199606000-00013			4	Critical Care Medicine	General & Internal Medicine	UQ807	WOS:A1996UQ80700013	8681597				2021-06-18	
J	Raskin, SA; Sohlberg, MM				Raskin, SA; Sohlberg, MM			The efficacy of prospective memory training in two adults with brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	23rd Annual Meeting of the International-Neuropsychological-Society	FEB 08-11, 1995	SEATTLE, WA	Int Neuropsychol Soc			RECOVERY; DOMAIN	Objective: Investigation of prospective memory training in traumatic brain injury (TBI). Design: Within-subject A-B-A-B study with before-after trial assessment on criterion standard neuropsychological measures and two types of generalization probes. Setting: Subjects received outpatient assessment and training in a private clinic. Patients: Two individuals with TBI were selected from 30 consecutive referrals to an outpatient clinic. Subject selection criteria included age of 20 to 55 years; acquired brain injury greater than 1 year; ability to tell time; no previous participation in cognitive rehabilitation; no previous neurologic or psychiatric disorder, substance abuse history, or learning disability; significant other available to take generalization data. Intervention: Subjects received separate blocks of two types of memory intervention; prospective memory training and retrospective memory drill. Prospective memory training consisted of repetitive administration of assigned actions to be completed at future specified times. Retrospective memory intervention required the subjects to recall their prior actions. Main Outcome Measures: Four outcome measures were used: (1) performance on the prospective memory screening test, (2) performance on criterion standard neuropsychological measures, (3) and 4) probes of everyday prospective memory. Results: Results were consistent across both subjects and suggested their ability to complete designated tasks at target times improved in both the training and community environments as a function of the prospective memory training. One subject improved from a I-minute prospective memory span to 5 minutes and the other from 2 minutes to 10 minutes. Conclusions: Preliminary data suggest that prospective memory training can improve an individual's prospective memory span and that this training generalizes to daily life.	HOSP GOOD SAMARITAN,CTR CONTINUING REHABIL,PUYALLUP,WA; UNIV OREGON,DEPT COMMUN DISORDERS & SCI,EUGENE,OR 97403	Raskin, SA (corresponding author), TRINITY COLL,DEPT PSYCHOL,HARTFORD,CT 06106, USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BUTTERS MA, 1993, J CLIN EXP NEUROPSYC, V15, P219, DOI 10.1080/01688639308402559; DAVIS HP, 1994, COLORADO NEUROPSYCHO; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; FRANZEN M, NEUROPSYCHOL REV, V2, P29; Furst C., 1986, COGNITIVE REHABILITA, V4, P24; Fuster JM., 1980, PREFRONTAL CORTEX; GAGNE RM, 1962, J EXP PSYCHOL, V63, P12, DOI 10.1037/h0048703; GLISKY EL, 1988, J LEARN DISABIL-US, V21, P333, DOI 10.1177/002221948802100604; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HARRIS JE, 1982, HUM LEARN, V1, P123; HARRIS JE, 1983, EVERYDAY MEMORY ACTI; KORIAT A, 1990, MEM COGNITION, V18, P568, DOI 10.3758/BF03197099; KRESNER R, 1989, EXP BRAIN RES, V74, P163; KVAVILASHVILI L, 1992, APPL COGNITIVE PSYCH, V6, P507, DOI 10.1002/acp.2350060605; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Levy R. L., 1984, EVERYDAY MEMORY ACTI; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MATEER CA, 1988, ATTENTION PROCESS TR; Meacham J. A., 1982, J APPL DEV PSYCHOL, V3, P121, DOI DOI 10.1016/0193-3973(82)90023-5; OLTON D, 1991, MEMORY ORG LOCUS CHA; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIMAMURA AP, 1988, J EXP PSYCHOL LEARN, V14, P763, DOI 10.1037/0278-7393.14.4.763; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1989, PROSPECTIVE MEMORY S; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; WEST RL, 1984, M AM PSYCH ASS TOR C; WILKENS A, 1988, PRACTICAL ASPECTS ME, P1; Wilson B.A, 1987, REHABILITATION MEMOR; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; WINOGRAD E, 1988, PRACTICAL ASPECTS ME, P1	41	37	38	0	11	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					32	51		10.1097/00001199-199606000-00007			20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400007					2021-06-18	
J	Porter, M; OBrien, M				Porter, M; OBrien, M			Incidence and severity of injuries resulting from amateur boxing in Ireland	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						injury incidence; amateur boxing; competition; training; cerebral injuries		Objective: To determine the incidence, pattern, and severity of injuries resulting from participation in amateur boxing. Design: A prospective 5-month survey of injuries which occurred during competitive amateur boxing and training. Setting: Amateur boxing competitions held in Dublin between November 1992 and March 1993, and the six largest amateur boxing clubs in Dublin. Participants: All the competitors in the tournaments and the >16 year old members of the boxing clubs. Interventions: Participation in competitive amateur bouts and/or boxing training. Main outcome measures: Incidence, pattern, and severity of injuries sustained in competition and training. Results: The incidence of injuries in competition was 0.92 injuries per man-hour of play (or 0.7 injuries per boxer per year), while the incidence in training was 0.69 injuries per boxer per year. Cerebral injuries were reported only in competition, most of these being mild concussion. Hand, wrist and facial injuries were related to direct impact and occurred more frequently in competition than training, while injuries to other body parts were predominantly chronic and training-associated. Shoulder and knee injuries were the most debilitating injuries seen. Conclusions: The yearly risk of injury resulting from participation in amateur boxing is relatively low when compared with other sports, Cerebral injuries, which occur almost exclusively in competition, are predominantly mild concussions.	TRINITY COLL DUBLIN,DEPT ANAT,DUBLIN,IRELAND	Porter, M (corresponding author), AUSTRALIAN INST SPORT,DEPT SPORTS MED,POB 176,BELCONNEN,ACT 2616,AUSTRALIA.						ENZENAUER RW, 1980, JAMA-J AM MED ASSOC, V261, P1463; ESTWANIK J, 1984, PHYSICIAN SPORTSMED, V12, P23; JORDAN B, 1990, PHYSICIAN SPORTSMED, V8, P81; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; SCHMIDTOLSEN S, 1990, AM J SPORT MED, V18, P98, DOI 10.1177/036354659001800117; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; WATSON AWA, 1993, INCIDENCE NATURE SPO; WELCH MJ, 1986, PHYSICIAN SPORTSMED, V14, P81, DOI 10.1080/00913847.1986.11709169; WELCH MJ, 1982, PHYSICIAN SPORTSMED, V10, P43	9	37	39	0	7	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	APR	1996	6	2					97	101		10.1097/00042752-199604000-00006			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	UC180	WOS:A1996UC18000006	8673583				2021-06-18	
J	SchmitterEdgecombe, M				SchmitterEdgecombe, M			Effects of divided attention on implicit and explicit memory performance following severe closed head injury	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	International-Neuropsychological-Society Meeting	JAN, 1995	SEATTLE, WA	Int Neuropsychol Soc			UNCONSCIOUS INFLUENCES; HUNTINGTONS-DISEASE; RECOGNITION MEMORY; INTENTIONAL USES; INFORMATION; ALZHEIMERS; ACTIVATION; RETRIEVAL; RETENTION; AMNESIA	This study investigated the relation between attentional limitations and memory impairments in patients with dosed head injuries (CHI). Twenty-seven CHI participants (> 1 year postinjury) and 27 matched controls rated their liking of target words under conditions of full and divided attention. Participants then completed an implicit test of tachistoscopic identification (TI) and an explicit test of recognition for the target words. As expected, the results revealed impaired explicit memory but preserved perceptually driven implicit memory performance following a CHI. Contrary to what was hypothesized, a reduction in attention available at encoding did not disproportionately impair the recognition performance of the CHI patients. Finally, unlike controls, the CHI participants' priming scores on the TI task were significantly affected by dividing attention at encoding. However, this finding interacted with CHI participants' perceptual processing rates, suggesting that nonmemory cognitive factors may influence measured performances on implicit memory tests.	MEMPHIS UNIV, MEMPHIS, TN 38152 USA	SchmitterEdgecombe, M (corresponding author), WASHINGTON STATE UNIV, DEPT PSYCHOL, PULLMAN, WA 99164 USA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANDERSON CM, 1974, J VERB LEARN VERB BE, V13, P107, DOI 10.1016/S0022-5371(74)80035-6; AURENBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BUCKNER RL, 1995, J NEUROSCI, V15, P12; CATTELL RB, 1973, HDB INDIVIDUAL GROUP; CERMAK LS, 1992, BRAIN COGNITION, V20, P367, DOI 10.1016/0278-2626(92)90027-J; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DYWAN J, 1993, BRAIN COGNITION, V21, P20, DOI 10.1006/brcg.1993.1002; EICH E, 1984, MEM COGNITION, V12, P105, DOI 10.3758/BF03198423; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; FAHY JF, 1995, J INT NEUROPSYCH SOC, V1, P183; GARDINER JM, 1990, MEM COGNITION, V18, P579, DOI 10.3758/BF03197100; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GREENE RL, 1986, Q J EXP PSYCHOL-A, V38, P663, DOI 10.1080/14640748608401619; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HAMANN SB, 1995, NEUROPSYCHOLOGY, V9, P3, DOI 10.1037/0894-4105.9.1.3; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Heaton R. K, 1981, WISCONSIN CARD SORTI; HEINDEL WC, 1990, BRAIN COGNITION, V13, P282, DOI 10.1016/0278-2626(90)90053-Q; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; HORTON DL, 1993, J MEM LANG, V32, P39, DOI 10.1006/jmla.1993.1003; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1989, J EXP PSYCHOL GEN, V118, P115, DOI 10.1037/0096-3445.118.2.115; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; JENNINGS JM, 1993, PSYCHOL AGING, V8, P283, DOI 10.1037/0882-7974.8.2.283; JERNIGAN TL, 1993, NEUROPSYCHOLOGY, V7, P14, DOI DOI 10.1037/0894-4105.7.1.14; Kaplan E., 1987, MANUAL CALIFORNIA VE; KELLEY CM, 1993, J MEM LANG, V32, P1, DOI 10.1006/jmla.1993.1001; Kucera H, 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1988, SCAND J REHABIL MED, P33; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MADDEN DJ, 1986, EXP AGING RES, V12, P71; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; PARKIN AJ, 1990, MEM COGNITION, V18, P507, DOI 10.3758/BF03198483; PARKIN AJ, 1990, EUROPEAN J COGNITIVE, V2, P71, DOI DOI 10.1080/09541449008406198; RANDOLPH C, 1993, J CLIN EXP NEUROPSYC, V15, P853, DOI 10.1080/01688639308402603; RANDOLPH C, 1991, J CLIN EXP NEUROPSYC, V13, P479, DOI 10.1080/01688639108401065; REINITZ MT, 1994, J EXP PSYCHOL LEARN, V20, P161, DOI 10.1037/0278-7393.20.1.161; RICHARDSONKLAVEHN A, 1988, ANNU REV PSYCHOL, V39, P475, DOI 10.1146/annurev.ps.39.020188.002355; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; ROEDIGER HL, 1989, VARIETIES MEMORY CON; ROGERS WA, 1994, PSYCHOL AGING, V9, P398, DOI 10.1037/0882-7974.9.3.398; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SCHACTER DL, 1990, DEV NEURAL BASES HIG, V608, P543; SCHMITTEREDGECO.M, 1995, 15 ANN M NAT AC NEUR; SCHMITTEREDGECO.M, IN PRESS J INT NEURO; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SMITH ER, 1988, J EXP SOC PSYCHOL, V24, P490, DOI 10.1016/0022-1031(88)90048-0; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; SQUIRE LR, 1992, J EXP PSYCHOL LEARN, V18, P106, DOI 10.1037/0278-7393.18.1.106; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SRINIVAS K, 1990, J MEM LANG, V29, P389, DOI 10.1016/0749-596X(90)90063-6; STANOVICH KE, 1979, MEM COGNITION, V7, P77, DOI 10.3758/BF03197588; Toth J. P., 1992, NEUROPSYCHOLOGY MEMO, P46; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	65	37	38	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	1996	10	2					155	167					13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	UD704	WOS:A1996UD70400002					2021-06-18	
J	Hornstein, A; Lennihan, L; Seliger, G; Lichtman, S; Schroeder, K				Hornstein, A; Lennihan, L; Seliger, G; Lichtman, S; Schroeder, K			Amphetamine in recovery from brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY	A chart review of dextroamphetamine treatment in 27 traumatic brain injury patients during rehabilitation therapy suggests that amphetamine treatment enhanced the recovery and functional status of 15 patients.	HELEN HAYES HOSP,DEPT NEUROL,W HAVERSTRAW,NY 10993; HELEN HAYES HOSP,DEPT INTERNAL MED,W HAVERSTRAW,NY 10993; COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY	Hornstein, A (corresponding author), HELEN HAYES HOSP,DEPT PSYCHIAT,ROUTE 9W,W HAVERSTRAW,NY 10993, USA.						*AM HEART ASS, 1988, 1989 STROK FACTS; BARRETT K, 1991, J NEUROL NEUROSUR PS, V54, P718, DOI 10.1136/jnnp.54.8.718; COOPER JR, 1986, BIOCH BASIS NEUROPHA, P293; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FLEET WS, 1987, NEUROLOGY, V37, P1765, DOI 10.1212/WNL.37.11.1765; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Kraus Jess F., 1994, P3; MALING HM, 1946, J NEUROPHYSIOL, V9, P379; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; Robinson Robert G., 1994, P219; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Starkstein S. E., 1993, DEPRESSION NEUROLOGI, P28; URANOVA NA, 1989, J HIRNFORSCH, V30, P45	15	37	39	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1996	10	2					145	148		10.1080/026990596124647			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UB726	WOS:A1996UB72600009	8696315				2021-06-18	
J	Spain, DA; DeWeese, C; Reynolds, MA; Richardson, JD				Spain, DA; DeWeese, C; Reynolds, MA; Richardson, JD			Transpyloric passage of feeding tubes in patients with head injuries does not decrease complications	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							GASTROSTOMY; SAFETY	Early enteral nutrition is reported to improve outcome of patients with severe closed head injuries (CHI). The efficacy and safety of nasoenteric tube (NET) feeds, however, has been questioned; the risk of aspiration is the major concern. Our purpose was to determine the rate of transpyloric migration, the efficacy of adjunctive measures to promote passage, and the effect on pulmonary complications. Seventy-four consecutive patients with moderate to severe CHI received enteral nutrition. Glasgow Coma Scale (GSC) score was 5.2 on admission and 6.9 at 48 hours, NETs were placed an average of 5.6 days after admission; an average of three abdominal films per patient mere used to assess tube position, No patients had endoscopic NET placement during this period. Ten patients required fluoroscopic placement after failure to pass spontaneously by 5 days, Overall, transpyloric passage was achieved in 32 patients (43%), whereas 42 (57%) remained intragastric, There were no differences between the postpyloric and intragastric groups in days to full feeding (5 vs. 7 days), ventilator days (11.9 vs, 12.5), intensive care unit length of stay (15.5 vs, 15.1), or incidence of pneumonia (81 vs, 69%) or aspiration (6 vs 7%), Sixty-two patients (83%) were transferred to extended care facilities and 50 (68%) were still receiving NET feedings, Spontaneous transpyloric passage of NET occurred in less than one-half of patients with severe CHI. The routine use of adjunctive measures to promote transpyloric passage was not particularly successful, had no obvious benefit, and therefore may not he necessary.		Spain, DA (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT SURG,LOUISVILLE,KY 40292, USA.						BORZOTTA AP, 1994, J TRAUMA, V36, P158; BORZOTTA AP, 1993, SURG FORUM, V42, P29; DAMELIO LF, 1994, AM SURGEON, V60, P180; FAY DE, 1991, AM J GASTROENTEROL, V86, P1604; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; GRANT JP, 1983, JPEN-PARENTER ENTER, V7, P299, DOI 10.1177/0148607183007003299; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; KIVER KF, 1984, JPEN-PARENTER ENTER, V8, P95; MARIAN M, 1993, SURG GYNECOL OBSTET, V176, P475; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; RAPP RP, 1983, J NEUROSURG, V58, P401; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; STARK SP, 1991, AM SURGEON, V57, P203; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; Ugo P J, 1992, Nutr Clin Pract, V7, P284, DOI 10.1177/0115426592007006284; VANE DW, 1982, J PEDIATR SURG, V17, P960, DOI 10.1016/S0022-3468(82)80475-2	17	37	37	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1995	39	6					1100	1102		10.1097/00005373-199512000-00015			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	TL905	WOS:A1995TL90500015	7500401				2021-06-18	
J	WADE, S; DROTAR, D; TAYLOR, HG; STANCIN, T				WADE, S; DROTAR, D; TAYLOR, HG; STANCIN, T			ASSESSING THE EFFECTS OF TRAUMATIC BRAIN INJURY ON FAMILY FUNCTIONING - CONCEPTUAL AND METHODOLOGICAL ISSUES	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						TRAUMATIC BRAIN INJURY; FAMILY ADAPTATION; FAMILY ASSESSMENT; SOCIAL RESOURCES; STRESSORS	CLOSED HEAD-INJURY; CHRONICALLY ILL; RISK-FACTORS; CHILDREN; SEQUELAE; ADAPTATION; STRESS	Reviewed empirical literature published since 1975 on the effects of pediatric traumatic brain injury (TBI) on the family. Few systematic, hypothesis-driven investigations of the impact of TBI on family functioning have been conducted. However, existing findings indicate that severe TBI can adversely affect families and individual family members. Certain factors, such as poor preinjury functioning and parental psychological disorder, appear To place families at greater risk for long-term disruption. Issues associated with the conceptualization of the impact of TBI on various aspects of family functioning are discussed and methodological considerations are outlined. Special attention is given to novel strategies for studying these complex, multifaceted issues. Finally, a framework is proposed for examining the processes of family adaptation after pediatric TBI to guide future research directions.	CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; RAINBOW BABIES & CHILDRENS HOSP,CLEVELAND,OH 44106; METROHLTH MED CTR,CLEVELAND,OH 44109			Stancin, Terry/L-7993-2019		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		BIJUR PE, 1990, PEDIATRICS, V86, P337; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Boss P, 1992, J FAMILY PSYCHOL, V6, P113, DOI DOI 10.1037/0893-3200.6.2.113; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carlson C.I., 1989, FAMILY ASSESSMENT GU; COLE DA, 1989, J COUNS PSYCHOL, V36, P456, DOI 10.1037/0022-0167.36.4.456; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Gottman J. M., 1993, J FAM PSYCHOL, V7, P57, DOI DOI 10.1037/0893-3200.7.1.57; GOTTMAN JM, 1992, J PERS SOC PSYCHOL, V63, P221, DOI 10.1037/0022-3514.63.2.221; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Hobfoll S.E., 1992, J FAM PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; HU XH, 1993, CAN MED ASSOC J, V149, P421; KAZAK AE, 1989, J CONSULT CLIN PSYCH, V57, P25, DOI 10.1037/0022-006X.57.1.25; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; LEZAK M, 1987, J CLIN EXPT NEUROPSY, V10, P111; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; McCubbin H. I., 1982, FAMILY STRESS COPING, P26; NAKAYAMA DK, 1990, J TRAUMA, V30, P1390, DOI 10.1097/00005373-199011000-00012; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Ransom D., 1990, FAMILY VARIABLES CON, P48; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; ROLLAND JS, 1987, FAM PROCESS, V26, P203, DOI 10.1111/j.1545-5300.1987.00203.x; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; TAYLOR HG, 1992, CLIN NEUROPSYCHOL, V6, P259; TAYLRO HG, IN PRESS TRAUMATIC H; THOMPSON RJ, 1993, J PEDIATR PSYCHOL, V18, P549, DOI 10.1093/jpepsy/18.5.549; WAALAND P, 1991, NEUROPSYCHOL REHABIL, V1, P19; WALLANDER JL, 1989, J PEDIATR PSYCHOL, V14, P157, DOI 10.1093/jpepsy/14.2.157	35	37	39	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	DEC	1995	20	6					737	752		10.1093/jpepsy/20.6.737			16	Psychology, Developmental	Psychology	TK236	WOS:A1995TK23600004	8558375				2021-06-18	
J	BIEGON, A; JOSEPH, AB				BIEGON, A; JOSEPH, AB			DEVELOPMENT OF HU-211 AS A NEUROPROTECTANT FOR ISCHEMIC BRAIN-DAMAGE	NEUROLOGICAL RESEARCH			English	Article; Proceedings Paper	Cambridge-Healthtech-Institute Meeting on New Strategies to Prevent Neural Damage from Ischemic Stroke	OCT 27-28, 1994	BOSTON, MA	Cambridge Healthtech Inst		NMDA ANTAGONISTS; ANTIOXIDANTS; STROKE; HEAD INJURY	RAT MODEL; RECEPTOR; INJURY; OCCLUSION	HU-211 (Dexanabinol), a putative neuroprotective agent, was evaluated in a number of animal models including closed head injury, optic nerve crush, global ischemia and focal ischemia. In these models, a single injection of HU-211 given after the insult confers long term functional improvement and significant increase in neuronal survival. Neuroprotective doses of HU-211 were found to be safe in a 14 day toxicological study in two species. In terms of mechanism, the compound behaves as a noncompetitive NMDA antagonist in vitro and in vivo. It blocks NMDA stimulated calcium influx in primary neuronal culture, and head injury related calcium influx in rats. In addition, HU-211 is a potent scavenger of peroxy and hydroxy radicals in vitro and it protects cultured neurons from toxicity of radical generators. Thus, Dexanabinol holds a unique position among putative neuroprotective agents since it combines NMDA blocking activity and free radical scavenging properties in one molecule. These observations support the development of HU-211 as a novel, multiple-action treatment approach for brain damage associated with stroke, cardiac arrest and trauma.		BIEGON, A (corresponding author), PHARMOS LTD, RES & DEV, IL-76326 REHOVOT, ISRAEL.						BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; ESHHAR N, 1994, J NEUROCHEM, V63, pS79; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; HOWLETT AC, 1990, NEUROPHARMACOLOGY, V29, P161, DOI 10.1016/0028-3908(90)90056-W; IZUMI Y, 1993, EXP NEUROL, V121, P14, DOI 10.1006/exnr.1993.1067; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MELDRUM B, 1987, NEUROTOXINS THEIR PH, P33; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; NADLER V, 1994, AM SOC NEUR ABST, V20, P194; NADLER V, 1993, NEUROSCI LETT, V159, P1; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; VERED M, 1994, ACTA NEUROCHIR, P335; VOLPE BT, 1984, STROKE, V15, P267	26	37	39	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	AUG	1995	17	4					275	280		10.1080/01616412.1995.11740326			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	RP369	WOS:A1995RP36900006	7477742				2021-06-18	
J	FLANAGAN, S; MCDONALD, S; TOGHER, L				FLANAGAN, S; MCDONALD, S; TOGHER, L			EVALUATING SOCIAL SKILLS FOLLOWING TRAUMATIC BRAIN INJURY - THE BRISS AS A CLINICAL TOOL	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; BEHAVIORAL-ASSESSMENT; COMPETENCE; RECOVERY	Deficits in social behaviour are a major obstacle to the reintegration into the community of traumatically brain-injured (TBI) individuals. Recognition of the importance of social skill remediation has highlighted the need for a suitable assessment tool. The TBI population presents particular requirements with respect to the special nature of deficits which commonly occur as a result of frontal lobe impairment. The Behaviorally Referenced Rating System of Intermediate Social Skills (the BRISS) has been shown to have good psychometric properties with a TBI population. It also provides a measure of particular social skills associated with frontal lobe functioning. This study examines the ability of the verbal scales of the BRISS to identify social skill deficits at the individual client level and to detect significant changes in skills following an intervention programme involving five chronic TBI males. In the case of one client, who demonstrated significant clinical improvement in social behaviour, the BRISS was found to identify specific areas of apparent change. The difficulty of using the BRISS as a sole measure of social skills is discussed in the light of relatively large pre-intervention within-subject variability which was found with respect to some behaviours.	UNIV NEW S WALES,SCH PSYCHOL,KENSINGTON,NSW 2033,AUSTRALIA; LIDCOMBE HOSP,DEPT SPEECH PATHOL,LIDCOMBE,NSW,AUSTRALIA			McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748			ARKOWITZ H, 1975, BEHAV THER, V6, P3, DOI 10.1016/S0005-7894(75)80056-6; Boake C, 1991, COGNITIVE REHABILITA; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BORKOVEC TD, 1974, BEHAV THER, V5, P503, DOI 10.1016/S0005-7894(74)80040-7; BOWERS S, 1973, PSYCHOL REV, V80, P306; BRAUNLINGMCMORR.D, 1986, J REHABIL, V52, P39; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CROSSON B, CLIN NEUROPSYCHOLOGI, V1, P335; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EKEHAMMAR B, 1974, PSYCHOL BULL, V81, P1026, DOI 10.1037/h0037457; ENDLER NS, 1976, PSYCHOL BULL, V89, P956; FARRELL AD, 1985, BEHAV ASSESS, V7, P155; FOWLER RS, 1972, AM J NURS, V76, P2056; GLASGOW RE, 1975, BEHAV THER, V6, P488, DOI 10.1016/S0005-7894(75)80005-0; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KAZDIN AE, 1992, METHODOLOGICAL ISSUE; Kinsella G, 1989, Int Disabil Stud, V11, P9; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; Milton S. B., 1986, CLIN NEUROPSYCHOLOGY, P223, DOI [10.1007/978-1-4613-2291-7_11, DOI 10.1007/978-1-4613-2291-7_11]; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; Prutting C., 1983, PRAGMATIC ASSESSMENT, P29; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHAVELSON RJ, 1991, GENERALISABILITY THE; SIEGEL S, 1988, NONPARAMETRIC STATIS; TROWER P, 1980, J CONSULT CLIN PSYCH, V48, P327, DOI 10.1037/0022-006X.48.3.327; TWENTYMAN CT, 1975, J CONSULT CLIN PSYCH, V43, P384, DOI 10.1037/h0076743; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Walsh K. W., 1985, UNDERSTANDING BRAIN; WOLF MM, 1978, J APPL BEHAV ANAL, V11, P203, DOI 10.1901/jaba.1978.11-203	38	37	37	0	7	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					321	338		10.3109/02699059509005773			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000001	7640679				2021-06-18	
J	HIGH, WM; BOAKE, C; LEHMKUHL, LD				HIGH, WM; BOAKE, C; LEHMKUHL, LD			CRITICAL ANALYSIS OF STUDIES EVALUATING THE EFFECTIVENESS OF REHABILITATION AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						EFFECTIVENESS OF REHABILITATION; TRAUMATIC BRAIN INJURY; OUTCOME STUDIES; EXPERIMENTAL DESIGN	CLOSED-HEAD-INJURY; INPATIENT REHABILITATION; STROKE REHABILITATION; PRACTICAL SCALE; RECOVERY; COMA; MILD; ORIENTATION	This article critiques recent studies of the effectiveness of inpatient and outpatient rehabilitation after traumatic brain injury with respect to how well they have controlled for the nature and severity of initial brain injury, time since injury, and preinjury characteristics of the subjects. These variables potentially confound the results of studies attempting to determine whether rehabilitation after traumatic brain injury results in improved outcomes and whether it is cost effective. To advance this field of research, investigators must be more uniform and explicit in the characterization of their subjects with respect to severity of injury and preinjury characteristics and more uniform in their selection of functional outcome measures, and they must use control groups of patients who receive few services or alternative treatments.	INST REHABIL & RES,BRAIN INJURY RES CTR,HOUSTON,TX; INST REHABIL & RES,DEPT NEUROPSYCHOL,HOUSTON,TX	HIGH, WM (corresponding author), BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030, USA.						ADAMS KM, 1985, J CLIN EXP NEUROPSYC, V7, P445, DOI 10.1080/01688638508401276; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BLACK P, 1975, CIBA F S, V34; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BOAKE C, 1993, ARCH PHYS MED REHAB, V74, P669; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DEPEDROCUESTA J, 1992, ACTA NEUROL SCAND, V86, P433; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Ebrahim S., 1990, CLIN EPIDEMIOLOGY ST; EVANS SH, 1968, PSYCHOL BULL, V69, P225, DOI 10.1037/h0025666; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Granger C. V., 1984, FUNCTIONAL ASSESSMEN; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HAFFEY WJ, 1989, PHYSICAL MED REHABIL; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; JENNETT B, 1975, LANCET, V1, P480; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LORD FM, 1969, PSYCHOL BULL, V72, P336, DOI 10.1037/h0028108; LORD FM, 1967, PSYCHOL BULL, V68, P304, DOI 10.1037/h0025105; MACKAY LE, 1992, ARCH PHYS MED REHAB, V72, P635; MAXWELL S, 1975, PSYCHOL BULL, V82, P187, DOI 10.1037/h0076378; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUSK HA, 1969, LATE EFFECTS HEAD IN; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TEASDALE G, 1974, LANCET, V2, P81; Timmons M, 1987, J HEAD TRAUMA REHAB, V2, P64; TOBIS JS, 1982, SCAND J REHABIL MED, V14, P83; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHITENECK CG, 1992, NEUROREHABIL, V2, P31; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winer BJ., 1971, STAT PRINCIPLES EXPT; YU J, 1976, ARCH PHYS MED REHAB, V57, P38	62	37	37	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1995	10	1					14	26		10.1097/00001199-199502000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QF163	WOS:A1995QF16300003					2021-06-18	
J	RAMUNDO, ML; MCKNIGHT, T; KEMPF, J; SATKOWIAK, L				RAMUNDO, ML; MCKNIGHT, T; KEMPF, J; SATKOWIAK, L			CLINICAL PREDICTORS OF COMPUTED TOMOGRAPHIC ABNORMALITIES FOLLOWING PEDIATRIC TRAUMATIC BRAIN INJURY	PEDIATRIC EMERGENCY CARE			English	Article						HEAD TRAUMA; COMPUTED TOMOGRAPHY; GLASGOW COMA SCALE		Children commonly seek attention in emergency departments following head injury. Head computed tomography (CT) is often used to decide subsequent disposition. Clinical criteria predicting CT abnormalities would allow effective and timely treatment and minimize unnecessary procedures depleting overburdened medical resources. We prospectively compared presenting clinical features with subsequent emergent head CT in 300 children less than 19 years old over a nine-month period. The disposition of patients following imaging was also recorded. Only suspected abuse was more than 50% positively predictive in children below age two and those above age two. Two signs were more than 67% positively predictive in both age groups: focal motor deficit and pupillary asymmetry. Patients with abnormal CTs were the only children to undergo emergent neurosurgery (30%) and were nearly five times as likely to be intensively monitored. Children with normal CTs were nearly five times as likely to be observed in a routine department or at home. We conclude that no single clinical feature can predict with certainty an abnormality on immediate head CT. However, children suspected of being abused, and those with focal motor deficits or pupillary asymmetry, should be imaged. Finally, emergent CT when judiciously ordered likely reduces unforeseen morbidity and minimizes costly intensive care observation.		RAMUNDO, ML (corresponding author), CHILDRENS HOSP MED CTR AKRON,DEPT EMERGENCY MED & TRAUMA SERV,AKRON,OH 44308, USA.							0	37	37	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	1995	11	1					1	4		10.1097/00006565-199502000-00001			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	QH189	WOS:A1995QH18900001	7739953				2021-06-18	
J	LEBRET, F; RUEL, P; ROSIER, H; GOARIN, JP; RIOU, B; VIARS, P				LEBRET, F; RUEL, P; ROSIER, H; GOARIN, JP; RIOU, B; VIARS, P			DIAGNOSIS OF TRAUMATIC MEDIASTINAL HEMATOMA WITH TRANSESOPHAGEAL ECHOCARDIOGRAPHY	CHEST			English	Article							BLUNT THORACIC TRAUMA; AORTIC TRANSECTION; CHEST TRAUMA; RUPTURE; INJURY; CT	In patients with blunt chest trauma, early diagnosis of mediastinal hematoma is important, because it could be associated with thoracic vessel injury. Mediastinal hematoma is generally evoked because of a widened mediastinum on chest radiograph, but radiologic diagnosis may lead to excessive angiography being performed. Transesophageal echocardiography (TEE) provides accurate views of the mediastinum and can be rapidly performed at the bedside. Thus, we conducted a prospective study to define TEE signs of mediastinal hematoma. TEE was performed in 22 thoracic trauma patients (trauma group) and in 20 brain-dead patients without thoracic trauma (control group). The positive diagnosis of mediastinal hematoma was made using thoracic surgery or computed tomographic scan. The specificity of TEE was 75 percent and sensitivity was 100 percent. In the trauma group, there was only one false positive but angiography discovered a traumatic aneurysm of the proximal right subclavian artery. No false negative was noted. We described three different TEE signs of mediastinal hematoma: (1) an increased distance between the probe and the aortic wall; (2) a double contour of the aortic wall; and (3) visualization of the ultrasound signal between the aortic wall and the visceral pleura. The distance between the esophageal probe and the aortic wall was the most accurate sign because it could be easily obtained; the threshold value for this distance was 3 mm. TEE appears to be an accurate method to diagnose traumatic mediastinal hematoma.	GRP HOSP PITIE SALPETRIERE,DIV RADIOL,PARIS,FRANCE; GRP HOSP PITIE SALPETRIERE,DEPT ANESTHESIOL,F-75634 PARIS,FRANCE							AYELLA RJ, 1977, J TRAUMA, V7, P199; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BROOKS SW, 1992, J TRAUMA, V32, P761, DOI 10.1097/00005373-199206000-00015; BROOKS SW, 1991, J TRAUMA, V31, P841, DOI 10.1097/00005373-199106000-00016; BURNEY RE, 1984, CHEST, V85, P605, DOI 10.1378/chest.85.5.605; GALVIN IF, 1991, ANN THORAC SURG, V51, P310, DOI 10.1016/0003-4975(91)90811-4; GOARIN JP, 1993, CHEST, V103, P618, DOI 10.1378/chest.103.2.618; HEIBERG E, 1983, AM J ROENTGENOL, V140, P1119, DOI 10.2214/ajr.140.6.1119; MILLER FB, 1989, SURGERY, V106, P596; MIRVIS SE, 1987, RADIOLOGY, V163, P487, DOI 10.1148/radiology.163.2.3562831; OVERFORS CO, 1978, RADIOL CLIN N AM, V16, P407; RICHARDSON P, 1991, AM J ROENTGENOL, V156, P273, DOI 10.2214/ajr.156.2.1898798; SANDOR F, 1967, THORAX, V22, P43, DOI 10.1136/thx.22.1.43; SHAPIRO MJ, 1991, J TRAUMA, V31, P835, DOI 10.1097/00005373-199106000-00015; STURM JT, 1979, SURGERY, V85, P365; WILSON RF, 1972, ARCH SURG-CHICAGO, V104, P551; WOODRING JH, 1984, RADIOLOGY, V151, P15, DOI 10.1148/radiology.151.1.6701306	17	37	38	0	1	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348	0012-3692			CHEST	Chest	FEB	1994	105	2					373	376		10.1378/chest.105.2.373			4	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	MX262	WOS:A1994MX26200016	8306731				2021-06-18	
J	WILSON, JTL; TEASDALE, GM; HADLEY, DM; WIEDMANN, KD; LANG, D				WILSON, JTL; TEASDALE, GM; HADLEY, DM; WIEDMANN, KD; LANG, D			POSTTRAUMATIC AMNESIA - STILL A VALUABLE YARDSTICK	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							BLUNT HEAD-INJURY; PRACTICAL SCALE; EARLY INDEXES; SEVERITY; SEQUELAE	Records of coma and post-traumatic amnesia (PTA) were collected for a group of 38 patients with closed head injury. The results confirmed earlier studies indicating that patients may have short or negligible coma but report prolonged PTA. Comparison of eight patients with prolonged PTA (>7 days) and short coma (<6 hours) with the rest of the group on MRI in the acute stage showed that these patients had significantly more extensive hemispheric damage. In the group as a whole both coma and PTA were related to the number of areas in central brain structures in which lesions were detected, but only PTA was significantly related to the number of hemispheric areas in which lesions were found. It is concluded that although both coma and PTA are related to brain damage they reflect disparate patterns of lesions. Assessment of PTA can thus provide additional information concerning severity of injury.	UNIV GLASGOW,INST NEUROL SCI,DEPT NEUROSURG,GLASGOW,SCOTLAND; UNIV GLASGOW,INST NEUROL SCI,DEPT NEURORADIOL,GLASGOW,SCOTLAND	WILSON, JTL (corresponding author), UNIV STIRLING,DEPT PSYCHOL,STIRLING FK9 4LA,SCOTLAND.		Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HADLEY DM, 1988, CLIN RADIOL, V39, P131; JENKINS A, 1986, LANCET, V2, P445; Levin H. S., 1984, NEUROPSYCHOLOGY MEMO; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mayes A., 1988, HUMAN ORGANIC MEMORY; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHORES A, 1990, AUST NZ J PSYCHIAT, V24, P133, DOI 10.3109/00048679009062895; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1984, HDB CLIN NEUROLOGY, V1, P185; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135; 1961, LANCET, V2, P1445	18	37	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1994	57	2					198	201		10.1136/jnnp.57.2.198			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	NB044	WOS:A1994NB04400014	8126505	Green Published, Bronze			2021-06-18	
J	LUBUSKO, AA; MOORE, AD; STAMBROOK, M; GILL, DD				LUBUSKO, AA; MOORE, AD; STAMBROOK, M; GILL, DD			COGNITIVE BELIEFS FOLLOWING SEVERE TRAUMATIC BRAIN INJURY - ASSOCIATION WITH POSTINJURY EMPLOYMENT STATUS	BRAIN INJURY			English	Article							SCHOOL-LEAVERS; CONTROL SCALE; HEAD-INJURY; UNEMPLOYMENT; LOCUS; DEPRESSION; HEALTH; STRESS; LIFE; MEN	In this exploratory study, the cognitive beliefs of 19 severely traumatically brain-injured (TBI) patients were assessed to determine their association with post-injury employment status (that is, full-time, part-time or unemployed). Cognitive measures included the Multidimensional Health Locus of Control (MHLC) scale, the Revised Internal-External Scale (RIES) and the Beck Hopelessness Scale (BHS). Patients who did not return to their pre-injury level of employment (n = 10) were found to have lower MHLC Internal, higher RIES Powerful Others locus of control beliefs, and higher BHS scores as compared with a group of patients who returned to their pre-injury employment status (n = 9). In addition, longer lengths of post-traumatic amnesia, longer hospital stays and lower-prestige occupations post-injury were associated with poorer employment status. No differences were present between the groups in age, years of education, Glasgow Coma Scale on admission, length of coma, months post-injury, or pre-injury occupation. These results suggest that cognitive beliefs are a potential target for further research in TBI outcome.	UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT PSYCHOL,NEUROPSYCHOL RES UNIT,820 SHERBROOK ST,WINNIPEG R3A 1M3,MB,CANADA; UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT PSYCHIAT,NEUROPSYCHOL RES UNIT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT MED,NEUROPSYCHOL RES UNIT,WINNIPEG R3T 2N2,MANITOBA,CANADA; SOC MANITABANS & DISABILIT,WINNIPEG,MB,CANADA							ALLOY LB, 1988, BRIT J CLIN PSYCHOL, V27, P5, DOI 10.1111/j.2044-8260.1988.tb00749.x; Beck A. T., 1967, DEPRESSION CLIN EXPT; BLISHEN BR, 1967, CAN REV SOCIOL ANTHR, V4, P41; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; FEATHER NT, 1983, J ABNORM PSYCHOL, V92, P185, DOI 10.1037/0021-843X.92.2.185; FRANK RG, 1987, J CONSULT CLIN PSYCH, V55, P727; FURNHAM A, 1984, INT J MENT HEALTH, V13, P51, DOI 10.1080/00207411.1984.11448966; GRIMM BH, 1986, HDB CLIN NEUROPSYCHO, V2, P495; HOLDER EE, 1988, J CLIN PSYCHOL, V44, P753, DOI 10.1002/1097-4679(198809)44:5<753::AID-JCLP2270440514>3.0.CO;2-A; KEEFE T, 1984, SOC WORK, V29, P264, DOI 10.1093/sw/29.3.264; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRAUSE N, 1986, J GERONTOL, V41, P617, DOI 10.1093/geronj/41.5.617; LAYTON C, 1987, PERS INDIV DIFFER, V8, P149, DOI 10.1016/0191-8869(87)90025-0; LEFCOURT H, 1981, RES LOCUS CONTROL CO, V1, P1; LEVENSON H, 1974, J PERS ASSESS, V38, P377, DOI 10.1080/00223891.1974.10119988; MELVILLE DI, 1985, PSYCHOL MED, V15, P789, DOI 10.1017/S0033291700005018; MILLER WR, 1975, J ABNORM PSYCHOL, V84, P228, DOI 10.1037/h0076720; NAGENSON T, 1974, SCANDINAVIAN J REHAB, V6, P5; Nagy VT, 1983, J SOC CLIN PSYCHOL, V1, P58; NELSON DW, 1983, AM J COMMUN PSYCHOL, V11, P705, DOI 10.1007/BF00896604; OLAFSSON O, 1986, SOC SCI MED, V22, P1105, DOI 10.1016/0277-9536(86)90177-2; PARRY G, 1988, BRIT J CLIN PSYCHOL, V27, P23, DOI 10.1111/j.2044-8260.1988.tb00750.x; PHARES EJ, 1955, THESIS OHIO STATE U; PLATT SD, 1987, BRIT J PSYCHIAT, V151, P27, DOI 10.1192/bjp.151.1.27; Seligman M., 1975, HELPLESSNESS; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STAMBROOK M, 1988, CANADIAN J REHABI S4, V1, P74; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; STRICKLAND BR, 1978, J CONSULT CLIN PSYCH, V46, P1192, DOI 10.1037/0022-006X.46.6.1192; TAYLOR SE, 1982, PERS SOC PSYCHOL B, V8, P549, DOI 10.1177/0146167282083024; TIGGEMANN M, 1984, J OCCUP PSYCHOL, V57, P33, DOI 10.1111/j.2044-8325.1984.tb00145.x; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WALLSTON KA, 1978, HLTH ED MONOGRAPHS, V6; WINEFIELD HR, 1982, J PERS ASSESS, V46, P614, DOI 10.1207/s15327752jpa4606_10	35	37	37	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1994	8	1					65	70		10.3109/02699059409150959			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MQ291	WOS:A1994MQ29100007	8124318				2021-06-18	
J	MCINTOSH, TK; FERNYAK, S; HAYES, RL; FADEN, AI				MCINTOSH, TK; FERNYAK, S; HAYES, RL; FADEN, AI			BENEFICIAL EFFECT OF THE NONSELECTIVE OPIATE ANTAGONIST NALOXONE HYDROCHLORIDE AND THE THYROTROPIN-RELEASING-HORMONE (TRH) ANALOG YM-14673 ON LONG-TERM NEUROBEHAVIORAL OUTCOME FOLLOWING EXPERIMENTAL BRAIN INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							SPINAL-CORD INJURY; CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; TRAUMATIC BRAIN; ENDOGENOUS OPIOIDS; INTRATHECAL INJECTION; DYNORPHIN; MECHANISM; RECEPTORS	Neurobehavioral dysfunction following traumatic brain injury results, in part, from delayed biochemical changes initiated by the traumatic insult. Endogenous opioid peptides have been implicated as one type of neurochemical factor involved in the delayed pathological sequelae of central nervous system (CNS) injury, including brain trauma. Both opiate antagonists and thyrotropin-releasing hormone (TRH) and its analogs, which antagonize the physiologic effects of endogenous opioids, have been shown to improve cardiovascular, cerebrovascular, metabolic, and neurologic status following both traumatic and ischemic CNS injury. The present study evaluated the ability of the opiate antagonist naloxone hydrochloride to improve posttraumatic neurologic motor function following experimental fluid-percussion brain injury in the rat, and compared the therapeutic effectiveness of naloxone to the long-acting, centrally active TRH analog YM-14673. Thirty minutes following fluid-percussion brain injury of moderate severity, animals received an intravenous bolus of either naloxone (2.0 mg/kg with constant infusion of 1.7 mg/kg/h, rt = 8), YM-14673 (1.0 mg/kg, n = 8), or saline (n = 8). Although naloxone caused a modest and nonsignificant increase in mean arterial blood pressure (MAP), YM-14673 significantly increased MAP within 5 min of administration (p < 0.05), an effect that continued up to 4 h postinjury. Postinjury administration of both naloxone and YM-14673 caused a significant improvement in neurobehavioral outcome which persisted up to 4 weeks postinjury. These results suggest that endogenous opioid peptides may	UNIV PENN,SCH MED,DEPT BIOENGN,PHILADELPHIA,PA 19104; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX; GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007	MCINTOSH, TK (corresponding author), UNIV PENN,SCH MED,DEPT NEUROSURG,105 HAYDEN,240 S 33RD ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS26818] Funding Source: Medline		ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; ANDREWS B, 1989, J PHARMACOL EXP THER, V247, P1248; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BAKSHI R, 1990, J NEUROSCI, V10, P3793; BASKIN DS, 1981, LANCET, V2, P272; BERRY SC, 1984, BRIT J PHARMACOL, V83, P179, DOI 10.1111/j.1476-5381.1984.tb10133.x; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; CHOI DW, 1988, EUR J PHARMACOL, V155, P27, DOI 10.1016/0014-2999(88)90399-8; DERRICK BE, 1991, BRAIN RES BULL, V27, P219, DOI 10.1016/0361-9230(91)90071-Q; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1992, AM J PHYSIOL, V263, pR909; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1992, J NEUROSCI, V12, P425; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1984, LIFE SCI, V22, P1537; FADEN AI, 1982, NEUROLOGY, V322, P1083; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; HALL ED, 1986, PROCESSES RECOVERY N, P63; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLADAY JW, 1980, BRAIN RES, V189, P295, DOI 10.1016/0006-8993(80)90032-3; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; HUDSON CJ, 1991, BRAIN RES, V564, P261, DOI 10.1016/0006-8993(91)91462-A; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; LEVIN HS, 1991, J NEUROTRAUM, V9, pS359; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1158; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOISES HC, 1985, EUR J PHARMACOL, V108, P85, DOI 10.1016/0014-2999(85)90286-9; PARSONS CG, 1986, NEUROPHARMACOLOGY, V25, P217, DOI 10.1016/0028-3908(86)90045-6; PHILLIS JW, 1985, NEUROSURGERY, V17, P596, DOI 10.1227/00006123-198510000-00010; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; STEWART P, 1989, LIFE SCI, V44, P1504; STOKES BT, 1984, BRAIN RES, V290, P187, DOI 10.1016/0006-8993(84)90753-4; TURNER DM, 1984, NEUROSURGERY, V14, P688, DOI 10.1227/00006123-198406000-00008; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZABRAMSKI JM, 1984, STROKE, V15, P621, DOI 10.1161/01.STR.15.4.621; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	57	37	38	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1993	10	4					373	384		10.1089/neu.1993.10.373			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	MQ818	WOS:A1993MQ81800002	8145261				2021-06-18	
J	VILKKI, J				VILKKI, J			COGNITIVE FLEXIBILITY AND MENTAL PROGRAMMING AFTER CLOSED HEAD-INJURIES AND ANTERIOR OR POSTERIOR CEREBRAL EXCISIONS	NEUROPSYCHOLOGIA			English	Article							FRONTAL-LOBE LESIONS; COMPUTERIZED-TOMOGRAPHY; DEFICITS; DAMAGE	Cognitive inflexibility and deficient mental programming are specifically related to frontal lobe lesions. The aim was to demonstrate that closed head injury (CHI) patients with brain lesions verified by computed tomography have such cognitive deficits, and are inferior in these respects to patients with posterior cerebral excisions mainly for tumours. This hypothesis was confirmed using a Category Identification and Sorting test as well as a measure of mental programming in a Spatial Learning task. Furthermore, CHI patients who had non-frontal parenchymal lesions were inferior by these measures to patients with posterior excisions. This result suggests that diffuse axonal lesion in CHI causes the deficits similar to those following frontal lobe excision.		VILKKI, J (corresponding author), UNIV CENT HOSP HELSINKI,DEPT NEUROSURG,TOPELIUKSENKATU 5,SF-00260 HELSINKI,FINLAND.						ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Fuster JM., 1980, PREFRONTAL CORTEX; Goldberg E., 1987, FRONTAL LOBES REVISI, P159; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Grafman J., 1987, NEUROBEHAVIORAL RECO, P43; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; KARNATH HO, 1991, NEUROPSYCHOLOGIA, V29, P271, DOI 10.1016/0028-3932(91)90042-7; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Milner B, 1964, FRONTAL GRANULAR COR, P313; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1984, CLOSED HEAD INJURY P, P4; Teuber H. L., 1964, FRONTAL GRANULAR COR, P410; TEUBER H-L, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P615; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P971, DOI 10.1016/0028-3932(89)90072-9; VILKKI J, 1992, IN PRESS J CLIN EXP, V14; Wechsler D., 2008, WECHSLER ADULT INTEL; WILSON JTL, 1991, BRAIN INJURY, V4, P349	33	37	37	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	SEP	1992	30	9					807	814		10.1016/0028-3932(92)90084-Y			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	JP951	WOS:A1992JP95100005	1407495				2021-06-18	
J	DISCALA, C; GRANT, CC; BROOKE, MM; GANS, BM				DISCALA, C; GRANT, CC; BROOKE, MM; GANS, BM			FUNCTIONAL OUTCOME IN CHILDREN WITH TRAUMATIC BRAIN INJURY - AGREEMENT BETWEEN CLINICAL JUDGMENT AND THE FUNCTIONAL INDEPENDENCE MEASURE	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						DISABILITY; PEDIATRICS, HEAD INJURY, TRAUMA		As improvements in the delivery of trauma care have increased survival from injury, it has become essential to assess the resulting morbidity to plan for medical and psychosocial services, particularly for children whose needs may be wide and long term. This paper focuses on the assessment of disability of 598 children, age 8 to 19 yr, hospitalized for traumatic brain injury with or without injury to other body regions, exclusive of spinal cord injury. The disability was measured at discharge from acute care in nine areas of functional activities and a recovery time assigned by a clinician. For the study, children were divided into three groups: those whose recovery was expected in <7 months (Group A: n = 463), in 7 to 24 months (Group B: n = 66) and in >2 yr (Group C: n = 69). The clinician's expectation of recovery time significantly (P < 0.01) reflected the injury severity as measured by the Glasgow Coma Scale and the injury Severity Score. By the Glasgow Coma Scale, 16.4% were comatose on admission in Group A, 51.5% in Group B and 58% in Group C. The injury Severity Score was significantly different with 25.5% severely injured in Group A, 68.2% in Group B and 84% in Group C. At discharge, 15% in Group A had four or more areas of impairments, 61% in Group B and 84% in Group C. The Functional independence Measure confirmed the clinician's assessment of compromise with significantly (P < 0.01) different average values of 110, 80 and 58 for Groups A, B and C, respectively.	REHABIL INST MICHIGAN,DETROIT,MI; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48201	DISCALA, C (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,DEPT REHABIL MED,RES & TRAINING CTR REHABIL & CHILDHOOD TRAUMA,BOSTON,MA 02111, USA.						BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EMHOFF TA, 1991, J TRAUMA, V9, P1227; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Keith R A, 1987, Adv Clin Rehabil, V1, P6; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1989, J PEDIATR SURG, V24, P156, DOI 10.1016/S0022-3468(89)80237-4; WESSON DE, 1989, J TRAUMA, V5, P589; 1990, AM J DIS CHILD, V144, P627	11	37	37	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	1992	71	3					145	148		10.1097/00002060-199206000-00004			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HY972	WOS:A1992HY97200004	1385712				2021-06-18	
J	MESSENHEIMER, JA; ROBERTSON, KR; WILKINS, JW; KALKOWSKI, JC; HALL, CD				MESSENHEIMER, JA; ROBERTSON, KR; WILKINS, JW; KALKOWSKI, JC; HALL, CD			EVENT-RELATED POTENTIALS IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PROSPECTIVE-STUDY	ARCHIVES OF NEUROLOGY			English	Article							AIDS DEMENTIA COMPLEX; HUNTINGTONS-DISEASE; P300; LATENCY; SCALP	P3 event-related evoked potentials (ERP) were recorded from 47 human immunodeficiency virus (HIV)-positive subjects examined twice and 29 HIV-positive subjects examined three times at 6-month intervals. The P3 latency significantly increased over time for asymptomatic subjects and subjects with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. N2 latency was prolonged relative to control values in both HIV-positive groups but did not increase with time. The P3 latency correlated with neuropsychologic measures of motor control and speed of mental processing. Confounding factors (active or previous substance abuse, developmental disabilities, and history of closed head injury or epilepsy) did not significantly affect ERP latencies. Endogenous ERP components are frequently abnormal in HIV-positive subjects and the P3 latency progressively increases over time. Continued follow-up is required to determine the clinical utility of ERP studies in the HIV-positive population.		MESSENHEIMER, JA (corresponding author), UNIV N CAROLINA, SCH MED, DEPT NEUROL, CTR AIDS NEUROL, 7025 BURNETT WOMACK BLDG, CHAPEL HILL, NC 27599 USA.				NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS026680] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00046] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 PO1 NS26680-01] Funding Source: Medline		BALL SS, 1989, J GERONTOL, V44, pM195, DOI 10.1093/geronj/44.6.M195; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GOODIN DS, 1990, ANN NEUROL, V27, P414, DOI 10.1002/ana.410270409; GOODIN DS, 1986, BRAIN, V109, P1103, DOI 10.1093/brain/109.6.1103; GRANT I, 1990, J CONSULT CLIN PSYCH, V58, P22, DOI 10.1037/0022-006X.58.1.22; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; HALGREN E, 1986, EVOKED POTENTIAL, P269; HANSCH EC, 1982, ANN NEUROL, V11, P599, DOI 10.1002/ana.410110608; HO DD, 1989, ANN INTERN MED, V111, P400, DOI 10.7326/0003-4819-111-5-400; HOMBERG V, 1986, ELECTROEN CLIN NEURO, V63, P552, DOI 10.1016/0013-4694(86)90143-4; JOHNSON R, 1988, BRAIN, V111, P1517, DOI 10.1093/brain/111.6.1517; KARNISKI W, 1989, ELECTROEN CLIN NEURO, V72, P373, DOI 10.1016/0013-4694(89)90043-6; MCARTHUR JC, 1989, ANN NEUROL, V26, P601, DOI 10.1002/ana.410260504; McCarthy G, 1987, Electroencephalogr Clin Neurophysiol Suppl, V39, P331; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NEWTON MR, 1989, BRAIN, V112, P1637, DOI 10.1093/brain/112.6.1637; OLLO C, 1991, NEUROLOGY, V41, P209, DOI 10.1212/WNL.41.2_Part_1.209; PERRAULT N, 1984, ELECTROEN CLIN NEURO, V59, P261, DOI 10.1016/0168-5597(84)90044-3; POLICH J, 1990, ELECTROEN CLIN NEURO, V77, P179, DOI 10.1016/0168-5597(90)90036-D; ROSENBERG C, 1985, ARCH NEUROL-CHICAGO, V42, P984, DOI 10.1001/archneur.1985.04060090066016; SKLARE DA, 1984, ELECTROEN CLIN NEURO, V59, P420, DOI 10.1016/0168-5597(84)90043-1; Syndulko K, 1982, CLIN APPLICATIONS EV, P279; WILKINS JW, 1990, J ACQ IMMUN DEF SYND, V3, P938; WOOD CC, 1982, ANN NY ACAD SCI, V388, P139, DOI 10.1111/j.1749-6632.1982.tb50789.x	25	37	38	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	APR	1992	49	4					396	400		10.1001/archneur.1992.00530280086027			5	Clinical Neurology	Neurosciences & Neurology	HM463	WOS:A1992HM46300020	1558522				2021-06-18	
J	LEVIN, HS				LEVIN, HS			NEUROBEHAVIORAL RECOVERY	JOURNAL OF NEUROTRAUMA			English	Article							CLOSED-HEAD-INJURY; BEHAVIORAL SEQUELAE; PRACTICAL SCALE; BRAIN-LESIONS; AMNESIA TEST; MEMORY; CONSCIOUSNESS; PERFORMANCE; MILD; ORIENTATION	This review discusses recent programs in early and late neurobehavioral recovery from closed head injury (CHI). The research on early recovery has encompassed the relationship of localized brain lesions to the duration of impaired consciousness and features of posttraumatic amnesia. Of the research on late neurobehavioral outcome of CHI, studies emanating from the Traumatic Coma Data Bank are reviewed in detail, including analysis of acute neurologic indices in relation to recovery of memory, information processing speed, and other cognitive measures. Recent studies concerning the neurobehavioral outcome of CHI in children are discussed as are investigations of behavioral disturbance, psychosocial outcome, and family variables. The review concludes with an assessment of recent studies concerning the efficacy of rehabilitation directed toward the cognitive sequelae of CHI and preliminary trials to evaluate the potential use of psychoactive drugs in the postacute management of head injured patients.		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D-73,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS032339] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 3-2339, NS-21889] Funding Source: Medline		ALBERT ML, 1976, ARCH NEUROL-CHICAGO, V33, P453, DOI 10.1001/archneur.1976.00500060059013; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; ALEXANDER MP, 1988, NEUROLOGY, V38, P802, DOI 10.1212/WNL.38.5.802; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BECKER DP, 1985, CENTRAL NERVOUS SYST; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Butters N, 1980, ALCOHOLIC KORSAKOFFS; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; HUPPERT FA, 1979, CORTEX, V15, P385, DOI 10.1016/S0010-9452(79)80065-9; JENNETT B, 1975, LANCET, V1, P480; Kinsella G, 1989, Int Disabil Stud, V11, P9; LEDOUX JE, 1977, ANN NEUROL, V2, P417, DOI 10.1002/ana.410020513; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1989, LANCET, V2, P1001; LUDLOW CL, 1987, ANN NEUROL, V22, P60, DOI 10.1002/ana.410220114; MENTIS M, 1987, J SPEECH HEAR RES, V30, P89; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SANO K, 1983, J NEUROSURG, V58, P223, DOI 10.3171/jns.1983.58.2.0223; SERAFETINIDES EA, 1965, BRAIN, V88, P107, DOI 10.1093/brain/88.1.107; SHUM DH, J CLIN EXP NEUROPSYC, V12, P247; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; WEINGARTNER H, 1983, SCIENCE, V221, P380, DOI 10.1126/science.6867715; WHETSELL LA, 1989, J TRAUMA, V29, P1158, DOI 10.1097/00005373-198908000-00015; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	59	37	37	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S359	S373					15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600036	1588627				2021-06-18	
J	COSTANTINO, PD; RUSSELL, E; REISCH, D; BREIT, RA; HART, C				COSTANTINO, PD; RUSSELL, E; REISCH, D; BREIT, RA; HART, C			RUPTURED PETROUS CAROTID ANEURYSM PRESENTING WITH OTORRHAGIA AND EPISTAXIS	AMERICAN JOURNAL OF OTOLOGY			English	Article							DETACHABLE BALLOON; SKULL BASE; ARTERY; MANAGEMENT; RESECTION; SURGERY	Aneurysm formation and rupture within the petrous internal carotid artery (ICA) is an extremely rare occurrence with approximately 10 such cases in the literature. Etiologies of petrous ICA aneurysms include atherosclerosis, closed head trauma, iatrogenic injury during mastoid surgery, chronic middle ear infections, and congenital causes. Therapeutic options include carotid artery ligation, aneurysm resection with or without reconstruction, and radiographically controlled vessel occlusion. The case of a patient who presented with otorrhagia, epistaxis, and transient focal neurologic signs due to a ruptured petrous ICA aneurysm is presented. The incidence, etiology, and anatomy of these aneurysms is reviewed, and the various tests for determining adequacy of collateral cerebral blood flow are described. Factors that affect the selection of surgical versus radiologic control of these lesions are also discussed.	NORTHWESTERN UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT RADIOL,DIV NEURORADIOL,CHICAGO,IL 60611; UNIV ALABAMA,CTR MED,DEPT SURG,BIRMINGHAM,AL 35294							ANDERSON RD, 1972, RADIOLOGY, V102, P639, DOI 10.1148/102.3.639; BARRETT JH, 1960, ARCHIV OTOLARYNGOL, V72, P366; BARROW DL, 1982, J NEUROSURG, V56, P396, DOI 10.3171/jns.1982.56.3.0396; BUSBY DR, 1968, ARCH OTOLARYNGOL, V87, P295; CHANDY MJ, 1986, J LARYNGOL OTOL, V103, P425; Chiappetta F, 1982, J Neurosurg Sci, V26, P205; DEBRUN G, 1978, J NEUROSURG, V49, P635, DOI 10.3171/jns.1978.49.5.0635; DEVRIES EJ, 1988, LARYNGOSCOPE, V98, P960; FISCH U, 1984, OTOLARYNG CLIN N AM, V17, P513; FISCH U, 1982, NEUROLOGICAL SURGERY, P269; GLASSOCK ME, 1983, LARYNGOSCOPE, V93, P1445; GUNTHER R, 1981, FORTSCHR RONTEGENSTR, V135, P532; HIRANANDANI L H, 1962, J Laryngol Otol, V76, P703, DOI 10.1017/S0022215100059922; HOLTZMAN N, 1979, J NEUROSURG, V51, P258; KELLY JJ, 1979, ARCH SURG-CHICAGO, V114, P1361; KOPANIKY D, 1981, SURG NEUROL, V15, P141, DOI 10.1016/0090-3019(81)90034-3; LEONETTI JP, 1990, OTOLARYNG HEAD NECK, V102, P3, DOI 10.1177/019459989010200102; MILLER JD, 1977, J NEUROL NEUROSUR PS, V40, P64, DOI 10.1136/jnnp.40.1.64; MOORE O, 1955, CANCER, V8, P712, DOI 10.1002/1097-0142(1955)8:4<712::AID-CNCR2820080414>3.0.CO;2-L; Morantz R A, 1976, Surg Neurol, V6, P313; Myerson MC, 1934, ARCHIV OTOLARYNGOL, V20, P195; PECKER J, 1960, PRESSE MED, V68, P1023; PIERINI E A, 1954, Prensa Med Argent, V41, P945; SEFTEL DM, 1959, ARCHIV OTOLARYNGOL, V70, P52; SEKHAR LN, 1986, NEUROSURGERY, V19, P967, DOI 10.1227/00006123-198612000-00012; SEKHAR LN, 1987, TUMORS CRANIAL BASE, P641; SPETZLER RF, 1985, NEUROSURGERY, V16, P111, DOI 10.1227/00006123-198501000-00026; STALLINGS JO, 1969, ARCH OTOLARYNGOL, V90, P65; TRANMER BI, 1985, NEUROSURGERY, V6, P381; WILLINSKY R, 1987, NEURORADIOLOGY, V29, P570, DOI 10.1007/BF00350444	30	37	38	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0192-9763			AM J OTOL	Am. J. Otol.	SEP	1991	12	5					378	383					6	Otorhinolaryngology	Otorhinolaryngology	GD873	WOS:A1991GD87300013	1789309				2021-06-18	
J	MONTANE, I; EISMONT, FJ; GREEN, BA				MONTANE, I; EISMONT, FJ; GREEN, BA			TRAUMATIC OCCIPITOATLANTAL DISLOCATION	SPINE			English	Article								Four patients with traumatic occipitoatlantal dislocation are presented. The dislocations were the result of rapid deceleration motor vehicle accidents. The mechanism of injury was by hyperextension-rotation combined with a distraction force. Three patients sustained multiple injuries. Neurologic findings were variable. One patient with complete cord transection and closed head trauma died 4 days after the injury. In the three surviving patients, the occipitoatlantal dislocation was not diagnosed by the initial examiner. Prompt recognition and stabilization are essential to avoid further neurologic injury. Care must be taken not to increase the dislocation. A halo applied before operation facilitates reduction and allows posterior occipitoatlantal fusion to be performed under optimum conditions.	UNIV MIAMI,SCH MED,DEPT ORTHOPAED & REHABIL,MIAMI,FL 33152								0	37	38	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0362-2436			SPINE	SPINE	FEB	1991	16	2					112	116		10.1097/00007632-199102000-00002			5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	EX676	WOS:A1991EX67600002	2011763				2021-06-18	
J	BAYLESS, JD; VARNEY, NR; ROBERTS, RJ				BAYLESS, JD; VARNEY, NR; ROBERTS, RJ			TINKER TOY TEST-PERFORMANCE AND VOCATIONAL OUTCOME IN PATIENTS WITH CLOSED-HEAD INJURIES	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									VET ADM MED CTR,PSYCHOL SERV 116-B,IOWA CITY,IA 52240; UNIV IOWA,IOWA CITY,IA 52240							BENTON AL, 1983, TEST 3 DIMENSIONAL C; HARLOW J, 1868, MASSACHUSETTS MED SO, V2, P329; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445	3	37	37	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1989	11	6					913	917		10.1080/01688638908400944			5	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CC215	WOS:A1989CC21500010	2592530				2021-06-18	
J	Denny-Brown, D; Russell, WR				Denny-Brown, D; Russell, WR			Experimental cerebral concussion	JOURNAL OF PHYSIOLOGY-LONDON			English	Article																DURET H, 1920, TRAUMATISMES CRANIOC, V2; KOCHER T, 1901, HIRNERSCHUTTERUNG 2, V3; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; POLIS A, 1894, REV CHIR, V14, P645; Polis A, 1894, REV CHIR, V14, P273	5	37	37	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	DEC	1940	99	1					153	153		10.1113/jphysiol.1940.sp003887			1	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	V40IS	WOS:000202726600015	16995229	Green Published			2021-06-18	
J	Dolce, G; Quintieri, M; Leto, E; Milano, M; Pileggi, A; Lagani, V; Pignolo, L				Dolce, Giuliano; Quintieri, Maria; Leto, Elio; Milano, Michele; Pileggi, Antonio; Lagani, Vincenzo; Pignolo, Loris			Dysautonomia and Clinical Outcome in Vegetative State	JOURNAL OF NEUROTRAUMA			English	Article						dysautonomia; outcome; vegetative state		A dramatic disorder tentatively attributed to diencephalic-hypothalamic damage or dysfunction, dysautonomia, affects recovery from brain injury. Its incidence, correlation with etiology, and relevance as a predictor of outcome were retrospectively surveyed in 333 patients in vegetative state (VS) for more than 2 weeks at admission. Outcome was assessed according to the Glasgow Outcome Scale. Data were treated statistically by multi-variate analyses. Dysautonomia occurred in 26.1% of patients, with greater incidence among post-traumatic (31.9%) than non-traumatic (15.8%) patients. Outcome was worse among non-traumatic than post-traumatic patients irrespective of dysautonomia, and worst among non-traumatic patients with dysautonomia. Dysautonomia proved common among patients in VS (with incidence depending on etiology and age) and influenced the patients' outcome through mechanisms still to be defined, but conceivably mediated by diencephalic-hypothalamic unbalance.	[Dolce, Giuliano; Quintieri, Maria; Leto, Elio; Milano, Michele; Pileggi, Antonio] St Anna Inst, Crotone, Italy; [Lagani, Vincenzo; Pignolo, Loris] Univ Calabria, Dept Elect Informat & Systemist, Cosenza, Italy	Dolce, G (corresponding author), S Anna Inst, Via Siris 11, I-88900 Crotone, Italy.	giulianodolce@libero.it					ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2005, BRAIN INJURY, V19, P545, DOI 10.1080/02699050400025075; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Dolce G., 2002; Enna SJ, 2006, ADV PHARMACOL, V54, P1, DOI 10.1016/S1054-3589(06)54001-3; Gloeckner G.W., 2001, SPSS WINDOWS INTRO U; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; Jennett B., 2002, VEGETATIVE STATE MED; Kang YM, 2004, INT J NEUROSCI, V114, P299, DOI 10.1080/00207450490264115; Laureys S, 2000, LANCET, V355, P1825, DOI 10.1016/S0140-6736(05)73084-1; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; O'Brien Brian P, 2006, Crit Care Resusc, V8, P200; Ong J, 2005, CNS DRUG REV, V11, P317; Shiel A, 2004, BRIT J NEUROSURG, V18, P5, DOI 10.1080/02688690410001660625; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Young GB, 2004, J CLIN NEUROPHYSIOL, V21, P379; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076	23	36	40	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2021	38	10					1441	1444		10.1089/neu.2008.0536			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RZ6DB	WOS:000648685300009	18771395				2021-06-18	
J	Wallace, EJ; Mathias, JL; Ward, L				Wallace, Erica J.; Mathias, Jane L.; Ward, Lynn			Diffusion tensor imaging changes following mild, moderate and severe adult traumatic brain injury: a meta-analysis	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Diffusion tensor imaging; Adults; Outcomes; Neuroimaging; Meta-analysis	WHITE-MATTER INTEGRITY; AXONAL INJURY; CORPUS-CALLOSUM; OUTCOME PREDICTION; SERIAL CHANGES; CONSCIOUSNESS; METRICS; DTI; ABNORMALITIES; INFLAMMATION	Diffusion tensor imaging quantifies the asymmetry (fractional anisotropy; FA) and amount of water diffusion (mean diffusivity/apparent diffusion coefficient; MD/ADC) and has been used to assess white matter damage following traumatic brain injury (TBI). In healthy brains, diffusion is constrained by the organization of axons, resulting in high FA and low MD/ADC. Following a TBI, diffusion may be altered; however the exact nature of these changes has yet to be determined. A meta-analysis was therefore conducted to determine the location and extent of changes in DTI following adult TBI. The data from 44 studies that compared the FA and/or MD/ADC data from TBI and Control participants in different regions of interest (ROIs) were analyzed. The impact of injury severity, post-injury interval (acute: 1 week, subacute: 1 week-3 months, chronic: > 3 months), scanner details and acquisition parameters were investigated in subgroup analyses, with the findings indicating that mild TBI should be examined separately to that of moderate to severe injuries. Lower FA values were found in 88% of brain regions following mild TBI and 92% following moderate-severe TBI, compared to Controls. MD/ADC was higher in 95% and 100% of brain regions following mild and moderate-severe TBI, respectively. Moderate to severe TBI resulted in larger changes in FA and MD/ADC than mild TBI. Overall, changes to FA and MD/ADC were widespread, reflecting more symmetric and a higher amount of diffusion, indicative of white matter damage.	[Wallace, Erica J.; Mathias, Jane L.; Ward, Lynn] Univ Adelaide, Sch Psychol, Fac Med Hlth Sci, Adelaide, SA, Australia	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Fac Med Hlth Sci, Adelaide, SA, Australia.	jane.mathias@adelaide.edu.au					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bandak F A, 2015, Handb Clin Neurol, V127, P89, DOI 10.1016/B978-0-444-52892-6.00006-4; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Borenstein M., 2009, SUBGROUP ANAL INTRO, P149; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Boyles AL, 2011, EPIDEMIOLOGY, V22, P746, DOI 10.1097/EDE.0b013e318225ba48; Brandstack N, 2011, CLIN NEURORADIOL, V21, P75, DOI 10.1007/s00062-011-0058-5; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Chang MC, 2010, NEUROREHABILITATION, V26, P339, DOI 10.3233/NRE-2010-0571; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cristofori Irene, 2015, Handb Clin Neurol, V128, P579, DOI 10.1016/B978-0-444-63521-1.00037-6; D'souza Maria M, 2015, Indian J Radiol Imaging, V25, P404, DOI 10.4103/0971-3026.169445; Dean PJA, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.292; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Douglas David B, 2015, Top Magn Reson Imaging, V24, P241, DOI 10.1097/RMR.0000000000000062; Ellis PD, 2010, ESSENTIAL GUIDE TO EFFECT SIZES: STATISTICAL POWER, META-ANALYSIS AND THE INTERPRETATION OF RESEARCH RESULTS, P1; Fitsiori A, 2011, BRIT J RADIOL, V84, P5, DOI 10.1259/bjr/21946513; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Haberg AK, 2015, J NEUROSCI RES, V93, P1109, DOI 10.1002/jnr.23534; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Hedges L.V., 1985, STAT METHODS META AN; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hong JH, 2012, J HEAD TRAUMA REHAB, V27, P172, DOI 10.1097/HTR.0b013e318217192d; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Huisman T A G M, 2010, Cancer Imaging, V10 Spec no A, pS163, DOI 10.1102/1470-7330.2010.9023; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Imperati D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023437; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jang SH, 2013, NEUROSCI LETT, V543, P47, DOI 10.1016/j.neulet.2013.02.058; Johnson SB, 2009, J ADOLESCENT HEALTH, V45, P216, DOI 10.1016/j.jadohealth.2009.05.016; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kim JH, 2015, J HEAD TRAUMA REHAB, V30, pE40, DOI 10.1097/HTR.0000000000000121; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lee HD, 2015, BRAIN INJURY, V29, P1219, DOI 10.3109/02699052.2015.1045028; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipsey M.W., 2001, PRACTICAL META ANAL; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Madden DJ, 2012, BBA-MOL BASIS DIS, V1822, P386, DOI 10.1016/j.bbadis.2011.08.003; Maruta J, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00035; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Mueller BA, 2015, NEUROPSYCHOL REV, V25, P250, DOI 10.1007/s11065-015-9291-z; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Orwin R. G., 1983, J EDUC STAT, V8, P157, DOI [10.3102/10769986008002157., DOI 10.2307/1164923]; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Palmer HS, 2010, J NEUROTRAUM, V27, P853, DOI 10.1089/neu.2009.1225; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Pinto PS, 2012, J NEUROIMAGING, V22, pe1, DOI 10.1111/j.1552-6569.2011.00688.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Rosenthal JA, 1996, J SOC SERV RES, V21, P37, DOI 10.1300/J079v21n04_02; Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1, DOI 10.1002/0470870168; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Scott G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0445-y; Seo JP, 2012, NEUROREHABILITATION, V30, P323, DOI 10.3233/NRE-2012-0762; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Strauss Sara, 2015, Top Magn Reson Imaging, V24, P353, DOI 10.1097/RMR.0000000000000071; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Ubukata S, 2016, J NEUROPSYCH CLIN N, V28, P97, DOI 10.1176/appi.neuropsych.15070159; Uchino A, 2006, EUR RADIOL, V16, P905, DOI 10.1007/s00330-005-0037-9; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Wilde EA, 2016, J NEUROTRAUM, V33, P2000, DOI 10.1089/neu.2015.4212; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yao S, 2015, J NEUROL SCI, V356, P168, DOI 10.1016/j.jns.2015.06.044; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu YN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/548392	99	36	37	2	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	DEC	2018	12	6					1607	1621		10.1007/s11682-018-9823-2			15	Neuroimaging	Neurosciences & Neurology	HF3AD	WOS:000454107000007	29383621				2021-06-18	
J	Broglio, SP; Kontos, AP; Levin, H; Schneider, K; Wilde, EA; Cantu, RC; Feddermann-Demont, N; Fuller, GW; Gagnon, I; Gioia, GA; Giza, C; Griesbach, GS; Leddy, JJ; Lipton, ML; Mayer, AR; McAllister, TW; McCrea, M; McKenzie, LB; Putukian, M; Signoretti, S; Suskauer, SJ; Tamburro, R; Turner, M; Yeates, KO; Zemek, R; Ala'i, S; Esterlitz, J; Gay, K; Bellgowan, PSF; Joseph, K				Broglio, Steven P.; Kontos, Anthony P.; Levin, Harvey; Schneider, Kathryn; Wilde, Elisabeth A.; Cantu, Robert C.; Feddermann-Demont, Nina; Fuller, Gordon W.; Gagnon, Isabelle; Gioia, Gerard A.; Giza, Christopher; Griesbach, Grace S.; Leddy, John J.; Lipton, Michael L.; Mayer, Andrew R.; McAllister, Thomas W.; McCrea, Michael; McKenzie, Lara B.; Putukian, Margot; Signoretti, Stefano; Suskauer, Stacy J.; Tamburro, Robert; Turner, Michael; Yeates, Keith O.; Zemek, Roger; Ala'i, Sherita; Esterlitz, Joy; Gay, Katelyn; Bellgowan, Patrick S. F.; Joseph, Kristen		Sport-Related Concussion CDE	National Institute of Neurological Disorders and Stroke and Department of Defense Sport-Related Concussion Common Data Elements Version 1.0 Recommendations	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; clinical outcomes; clinical research; common data elements; data sets; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PSYCHOLOGICAL HEALTH; OUTCOME MEASURES; WORKING GROUP; DEMOGRAPHICS; BIOSPECIMENS	Through a partnership with the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, and Department of Defense, the development of Sport-Related Concussion (SRC) Common Data Elements (CDEs) was initiated. The aim of this collaboration was to increase the efficiency and effectiveness of clinical research studies and clinical treatment outcomes, increase data quality, facilitate data sharing across studies, reduce study start-up time, more effectively aggregate information into metadata results, and educate new clinical investigators. The SRC CDE Working Group consisted of 32 worldwide experts in concussion from varied fields of related expertise divided into three Subgroups: Acute (<72h post-concussion), Subacute (3 days-3 months post-concussion) and Persistent/Chronic (>3 months post-concussion). To develop CDEs, the Subgroups reviewed various domains, then selected from, refined, and added to existing CDEs, case report forms and field-tested data elements from national registries and funded research studies. Recommendations were posted to the NINDS CDE Website for Public Review from February 2017 to April 2017. Following an internal Working Group review of recommendations, along with consideration of comments received from the Public Review period, the first iteration (Version 1.0) of the NINDS SRC CDEs was completed in June 2017. The recommendations include Core and Supplemental-Highly Recommended CDEs for cognitive data elements and symptom checklists, as well as other outcomes and end-points (e.g., vestibular, oculomotor, balance, anxiety, depression), and sample case report forms (e.g., injury reporting, demographics, concussion history) for domains typically included in clinical research studies. The NINDS SRC CDEs and supporting documents are publicly available on the NINDS CDE website www.commondataelements.ninds.nih.gov. Widespread use of CDEs by researchers and clinicians will facilitate consistent SRC clinical research and trial design, data sharing, and metadata retrospective analysis.	[Broglio, Steven P.] Univ Michigan, Ann Arbor, MI 48109 USA; [Kontos, Anthony P.] Univ Pittsburgh, Pittsburgh, PA USA; [Levin, Harvey; Wilde, Elisabeth A.] Baylor Coll Med, Houston, TX 77030 USA; [Levin, Harvey; Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Schneider, Kathryn; Yeates, Keith O.] Univ Calgary, Calgary, AB, Canada; [Wilde, Elisabeth A.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Cantu, Robert C.] Emerson Hosp, Concuss Ctr, Concord, MA USA; [Feddermann-Demont, Nina] Univ Zurich, Swiss Concuss Ctr, Zurich, Switzerland; [Fuller, Gordon W.] Univ Sheffield, Sheffield, S Yorkshire, England; [Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Hlth Ctr, Montreal, PQ, Canada; [Gioia, Gerard A.] Childrens Natl Hlth Syst, Washington, DC USA; [Giza, Christopher] Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Steve Tisch BrainSPORT Program, Los Angeles, CA USA; [Griesbach, Grace S.] Ctr Neuro Skills, Encino, CA USA; [Leddy, John J.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA; [Lipton, Michael L.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Lipton, Michael L.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Mayer, Andrew R.] Univ New Mexico, Mind Res Network, Albuquerque, NM 87131 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [McCrea, Michael] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [McKenzie, Lara B.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Signoretti, Stefano] San Camillo Forlanini Hosp, Rome, Italy; [Suskauer, Stacy J.; Tamburro, Robert] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD USA; [Tamburro, Robert] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA; [Turner, Michael] Int Concuss & Head Injury Res Fdn, London, England; [Zemek, Roger] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada; [Ala'i, Sherita; Esterlitz, Joy; Gay, Katelyn; Joseph, Kristen] Emmes Corp, Rockville, MD USA; [Bellgowan, Patrick S. F.] NINDS, Bethesda, MD USA	Broglio, SP (corresponding author), Univ Michigan, NeuroTrauma Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Yeates, Keith/AAJ-4223-2020; Signoretti, stefano/AAL-5631-2020	Signoretti, stefano/0000-0002-8086-1622; McKenzie, Lara/0000-0003-2889-0001; Yeates, Keith/0000-0001-7680-2892; Schneider, Kathryn/0000-0002-5951-5899; Fuller, Gordon Ward/0000-0001-8532-3500	U.S Army Medical Research and Materiel Command's Combat Casualty Care Research Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HHSN271201700064C, HHSN271201200034C]	The funding source for this project is the U.S Army Medical Research and Materiel Command's Combat Casualty Care Research Program and NIH contracts HHSN271201700064C and HHSN271201200034C. The views expressed here are those of the authors and do not represent those of the National Institutes of Health (NIH), the National Institute of Neurological Disorders and Stroke (NINDS) or the U.S. government. The development of the NINDS SRC CDEs was made possible thanks to the great investment of time and effort of Working Group members and the members of the NINDS CDE Project team participating from 2016 to present. In addition, we are grateful for the input provided during the public review period.	Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; National Institute of Neurological Disorders and Stroke, TRAUM BRAIN INJ COMM; National Institute of Neurological Disorders and Stroke, SPORTS REL CONC COMM; National Institute of Neurological Disorders and Stroke, 2017, GLOSSARYNINDS COMM D; National Institute of Neurological Disorders and Stroke, NINDS COMM DAT EL; National Institutes of Health U. S . Army Medical Research and Materiel Commang Combat Casualty Care Research Program National Institutes of Health Center for Information Technology National Institute of Neurological Disorders and Stroke, 2017, FED INT TRAUM BRAIN; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	24	36	36	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2018	35	23					2776	2783		10.1089/neu.2018.5643		JUL 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HB1WO	WOS:000439648200001	29717643	Green Accepted, Green Published			2021-06-18	
J	Russo, MV; Latour, LL; McGavern, DB				Russo, Matthew V.; Latour, Lawrence L.; McGavern, Dorian B.			Distinct myeloid cell subsets promote meningeal remodeling and vascular repair after mild traumatic brain injury	NATURE IMMUNOLOGY			English	Article							BARRIER DISRUPTION; MACROPHAGE SUBSETS; MONOCYTE SUBSETS; SPINAL-CORD; IN-VIVO; TISSUE; CNS; NEUROPROTECTION; FIBRIN; MICE	Mild traumatic brain injury (mTBI) can cause meningeal vascular injury and cell death that spreads into the brain parenchyma and triggers local inflammation and recruitment of peripheral immune cells. The factors that dictate meningeal recovery after mTBI are unknown at present. Here we demonstrated that most patients who had experienced mTBI resolved meningeal vascular damage within 2-3 weeks, although injury persisted for months in a subset of patients. To understand the recovery process, we studied a mouse model of mTBI and found extensive meningeal remodeling that was temporally reliant on infiltrating myeloid cells with divergent functions. Inflammatory myelomonocytic cells scavenged dead cells in the lesion core, whereas wound-healing macrophages proliferated along the lesion perimeter and promoted angiogenesis through the clearance of fibrin and production of the matrix metalloproteinase MMP-2. Notably, a secondary injury experienced during the acute inflammatory phase aborted this repair program and enhanced inflammation, but a secondary injury experienced during the wound-healing phase did not. Our findings demonstrate that meningeal vasculature can undergo regeneration after mTBI that is dependent on distinct myeloid cell subsets.	[Russo, Matthew V.; McGavern, Dorian B.] NINDS, Viral Immunol & Intravital Imaging Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Russo, Matthew V.] Johns Hopkins Univ, Grad Partnership Program, Baltimore, MD USA; [Latour, Lawrence L.] NINDS, Acute Cerebrovasc Diagnost Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	McGavern, DB (corresponding author), NINDS, Viral Immunol & Intravital Imaging Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	mcgavernd@mail.nih.gov	Latour, Larry/AAH-5663-2021	Latour, Larry/0000-0001-6160-5263	US National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Center for Neuroscience and Regenerative Medicine (CNRM) at the Uniformed Services University of the Health Sciences; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003120, ZIANS003112] Funding Source: NIH RePORTER	Supported by the US National Institutes of Health (NIH), the National Institute of Neurological Disorders and Stroke (NINDS) and the Center for Neuroscience and Regenerative Medicine (CNRM) at the Uniformed Services University of the Health Sciences, a collaborative effort among NIH, the Department of Defense, and Walter Reed National Military Medical Center to develop innovative approaches for brain injury diagnosis and recovery.	Adams RA, 2004, MOL INTERV, V4, P163; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cho CH, 2007, CIRC RES, V100, pE47, DOI 10.1161/01.RES.0000259564.92792.93; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dal-Secco D, 2015, J EXP MED, V212, P447, DOI 10.1084/jem.20141539; Davalos D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2230; Elkington Paul T., 2009, V531, P253, DOI 10.1007/978-1-59745-396-7_16; Engelhardt B, 2017, NAT IMMUNOL, V18, P123, DOI 10.1038/ni.3666; Faust N, 2000, BLOOD, V96, P719; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Gruenbaum SE, 2016, CNS DRUGS, V30, P791, DOI 10.1007/s40263-016-0355-2; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Ho KM, 2014, J NEUROSURG, V121, P674, DOI 10.3171/2014.6.JNS132838; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hubbard NE, 2005, CELL IMMUNOL, V234, P102, DOI 10.1016/j.cellimm.2005.06.001; Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim JV, 2009, NATURE, V457, P191, DOI 10.1038/nature07591; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Landsman L, 2007, J IMMUNOL, V178, P2000, DOI 10.4049/jimmunol.178.4.2000; Laurens N, 2006, J THROMB HAEMOST, V4, P932, DOI 10.1111/j.1538-7836.2006.01861.x; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Manglani M, 2018, CURR PROTOC IMMUNOL, V120, P2421; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Minutti CM, 2017, SEMIN CELL DEV BIOL, V61, P3, DOI 10.1016/j.semcdb.2016.08.006; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Motley MP, 2016, BLOOD, V127, P1085, DOI 10.1182/blood-2015-05-644260; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Olingy CE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00477-1; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Schledzewski K, 2006, J PATHOL, V209, P67, DOI 10.1002/path.1942; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Vannella KM, 2017, ANNU REV PHYSIOL, V79, P593, DOI 10.1146/annurev-physiol-022516-034356; Weavers H, 2016, CURR BIOL, V26, P1975, DOI 10.1016/j.cub.2016.06.012; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127	58	36	36	2	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1529-2908	1529-2916		NAT IMMUNOL	Nat. Immunol.	MAY	2018	19	5					442	+		10.1038/s41590-018-0086-2			13	Immunology	Immunology	GD5QT	WOS:000430562400008	29662169	Green Accepted			2021-06-18	
J	Schaffert, J; Lobue, C; White, CL; Chiang, HS; Didehbani, N; Lacritz, L; Rossetti, H; Dieppa, M; Hart, J; Cullum, CM				Schaffert, Jeff; Lobue, Christian; White, Charles L., III; Chiang, Hsueh-Sheng; Didehbani, Nyaz; Lacritz, Laura; Rossetti, Heidi; Dieppa, Marisara; Hart, John, Jr.; Cullum, C. Munro			Traumatic Brain Injury History Is Associated With an Earlier Age of Dementia Onset in Autopsy-Confirmed Alzheimer's Disease	NEUROPSYCHOLOGY			English	Article						National Alzheimer's Coordinating Center (NACC); traumatic brain injury (TBI); Alzheimer's disease (AD); age of onset; autopsy	MILD COGNITIVE IMPAIRMENT; SEVERE HEAD-INJURY; DIAGNOSTIC-CRITERIA; CLINICAL-DIAGNOSIS; NATIONAL INSTITUTE; INCREASED RISK; OF-ONSET; PATHOLOGY; RECOMMENDATIONS; DEGENERATION	Objective: To evaluate whether a history of traumatic brain injury (TBI) with reported loss of consciousness (LOC) is a risk factor for earlier onset of Alzheimer's disease (AD) in an autopsy-confirmed sample. Method: Data from 2,133 participants with autopsy-confirmed AD (i.e., at least Braak neurofibrillary tangle stages III to VI and CERAD neuritic plaque score moderate to frequent) were obtained from the National Alzheimer's Coordinating Center (NACC). Participants were categorized by presence/absence of self-reported remote (i.e., > 1 year prior to their first Alzheimer's Disease Center visit) history of TBI with LOC (TBI+ vs. TBI-). Analyses of Covariance (ANCOVA) controlling for sex, education, and race compared groups on clinician-estimated age of symptom onset and age of diagnosis. Results: Average age of onset was 2.34 years earlier (p = .01) for the TBI+ group (n = 194) versus the TBI+ group (n = 1900). Dementia was diagnosed on average 2.83 years earlier (p = .002) in the TBI+ group (n = 197) versus the TBI+ group (n = 1936). Using more stringent neuropathological criteria (i.e., Braak stages V-VI and CERAD frequent), both age of AD onset and diagnosis were 3.6 years earlier in the TBI+ group (both p's < .001). Conclusions: History of TBI with reported LOC appears to be a risk factor for earlier AD onset. This is the first study to use autopsy-confirmed cases, supporting previous investigations that used clinical criteria for the diagnosis of AD. Further investigation as to possible underlying mechanisms of association is needed.	[Schaffert, Jeff; Lobue, Christian; Didehbani, Nyaz; Lacritz, Laura; Rossetti, Heidi] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [White, Charles L., III] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Chiang, Hsueh-Sheng; Hart, John, Jr.] Univ Texas Dallas, Sch Behav & Brain Sci, Richardson, TX 75083 USA; [Chiang, Hsueh-Sheng; Dieppa, Marisara] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hart, John, Jr.; Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA	Cullum, CM (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	munro.cullum@utsouthwestern.edu	White, Charles L/AAJ-1858-2021; Cullum, C. Munro/AAC-2496-2019	White, Charles L/0000-0002-3870-2804; Cullum, C. Munro/0000-0001-9706-5465; Chiang, Hsueh-Sheng/0000-0003-2211-6007; Didehbani, Nyaz/0000-0001-6121-5759; Dieppa, Marisara/0000-0002-4532-0601; Schaffert, Jeffrey/0000-0002-8842-980X	University of Texas Southwestern Alzheimer's disease Center (NIH/NIA) [P3012300-19]; Texas Alzheimer's Research and Care Consortium (TARCC); NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574];  [P50 AG005138];  [P30 AG008051];  [P30 AG013854];  [P30 AG008017];  [P30 AG010161];  [P50 AG047366];  [P30 AG010129];  [P50 AG016573];  [P50 AG005131];  [P50 AG023501];  [P30 AG035982];  [P30 AG028383];  [P30 AG053760];  [P30 AG010124];  [P50 AG005133];  [P50 AG005142];  [P30 AG012300];  [P30 AG049638];  [P50 AG005136];  [P50 AG033514];  [P50 AG005681];  [P50 AG047270]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG025688, P30AG008017, P50AG005134, P30AG010129, P30AG049638, P30AG013846, U01AG016976, P30AG028383, P30AG019610, P30AG010124, P50AG016574, P50AG005146, P50AG005136, P30AG053760, P30AG010161, P50AG005142, P50AG023501, P30AG010133, P30AG013854, P50AG005681, P50AG033514, P50AG016573, P30AG008051, P50AG047366, P50AG005131, P30AG012300, P50AG047266, P50AG008702, P50AG005138, P30AG035982, P50AG047270, P50AG005133] Funding Source: NIH RePORTER	This work was supported in part by the University of Texas Southwestern Alzheimer's disease Center (NIH/NIA grant P3012300-19) and the Texas Alzheimer's Research and Care Consortium (TARCC). The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded ADCs: P30 AG019610 (PI Eric Reiman), P30 AG013846 (PI Neil Kowall), P50 AG008702 (PI Scott Small), P50 AG025688 (PI Allan Levey), P50 AG047266 (PI Todd Golde), P30 AG010133 (PI Andrew Saykin), P50 AG005146 (PI Marilyn Albert), P50 AG005134 (PI Bradley Hyman), P50 AG016574 (PI Ronald Petersen), P50 AG005138 (PI Mary Sano), P30 AG008051 (PI Thomas Wisniewski), P30 AG013854 (PI M. Marsel Mesulam), P30 AG008017 (PI Jeffrey Kaye), P30 AG010161 (PI David Bennett), P50 AG047366 (PI Victor Henderson), P30 AG010129 (PI Charles DeCarli), P50 AG016573 (PI Frank LaFerla), P50 AG005131 (PI James Brewer), P50 AG023501 (PI Bruce Miller), P30 AG035982 (PI Russell Swerdlow), P30 AG028383 (PI Linda Van Eldik), P30 AG053760 (PI Henry Paulson), P30 AG010124 (PI John Trojanowski), P50 AG005133 (PI Oscar Lopez), P50 AG005142 (PI Helena Chui), P30 AG012300 (PI Roger Rosenberg), P30 AG049638 (PI Suzanne Craft), P50 AG005136 (PI Thomas Grabowski), P50 AG033514 (PI Sanjay Asthana), P50 AG005681 (PI John Morris), P50 AG047270 (PI Stephen Strittmatter).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Bigler Erin D, 2015, Handb Clin Neurol, V128, P691, DOI 10.1016/B978-0-444-63521-1.00043-1; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Deutsch MB, 2015, DEMENT GERIATR COGN, V39, P143, DOI 10.1159/000369787; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Li W, 2016, J NEUROL, V263, P1280, DOI 10.1007/s00415-016-8093-4; LoBue C., J NEUROPSYCHIATRY CL; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Serrano-Pozo A, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006189; Silbert LC, 2012, NEUROLOGY, V79, P741, DOI 10.1212/WNL.0b013e3182661f2b; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Sundman MH., 2014, J ALZHEIMERS DIS PAR, V4, P137; Tomaiuolo F, 2012, BRAIN RES BULL, V87, P373, DOI 10.1016/j.brainresbull.2012.01.008; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633	41	36	38	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2018	32	4					410	416		10.1037/neu0000423			7	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	GH1GU	WOS:000433151900004	29389151	Bronze, Green Accepted			2021-06-18	
J	Anderson, EN; Gochenaur, L; Singh, A; Grant, R; Patel, K; Watkins, S; Wu, JY; Pandey, UB				Anderson, Eric N.; Gochenaur, Lauren; Singh, Aditi; Grant, Rogan; Patel, Krishani; Watkins, Simon; Wu, Jane Y.; Pandey, Udai Bhan			Traumatic injury induces stress granule formation and enhances motor dysfunctions in ALS/FTD models	HUMAN MOLECULAR GENETICS			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; RNA-BINDING PROTEINS; FRONTOTEMPORAL LOBAR DEGENERATION; BRAIN-INJURY; HEAD-INJURY; DROSOPHILA MODEL; AXONAL INJURY; CYTOPLASMIC MISLOCALIZATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE	Traumatic brain injury (TBI) has been predicted to be a predisposing factor for amyotrophic lateral sclerosis (ALS) and other neurological disorders. Despite the importance of TBI in ALS progression, the underlying cellular and molecular mechanisms are still an enigma. Here, we examined the contribution of TBI as an extrinsic factor and investigated whether TBI influences the susceptibility of developing neurodegenerative symptoms. To evaluate the effects of TBI in vivo, we applied mild to severe trauma to Drosophila and found that TBI leads to the induction of stress granules (SGs) in the brain. The degree of SGs induction directly correlates with the level of trauma. Furthermore, we observed that the level of mortality is directly proportional to the number of traumatic hits. Interestingly, trauma-induced SGs are ubiquitin, p62 and TDP-43 positive, and persistently remain over time suggesting that SGs might be aggregates and exert toxicity in our fly models. Intriguingly, TBI on animals expressing ALS-linked genes increased mortality and locomotion dysfunction suggesting that mild trauma might aggravate neurodegenerative symptoms associated with ALS. Furthermore, we found elevated levels of high molecular weight ubiquitinated proteins and p62 in animals expressing ALS-causing genes with TBI, suggesting that TBI may lead to the defects in protein degradation pathways. Finally, we observed that genetic and pharmacological induction of autophagy enhanced the clearance of SGs and promoted survival of flies in vivo. Together, our study demonstrates that trauma can induce SG formation in vivo and might enhance neurodegenerative phenotypes in the fly models of ALS.	[Anderson, Eric N.; Singh, Aditi; Grant, Rogan; Patel, Krishani; Pandey, Udai Bhan] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Div Child Neurol,Dept Pediat, Pittsburgh, PA 15224 USA; [Gochenaur, Lauren; Pandey, Udai Bhan] Univ Pittsburgh, Dept Neurosci, Dietrich Sch Arts & Sci, Pittsburgh, PA 15260 USA; [Watkins, Simon] Univ Pittsburgh, Med Ctr, Ctr Biol Imaging, Pittsburgh, PA 15261 USA; [Watkins, Simon] Univ Pittsburgh, Med Ctr, Dept Cell Biol, Pittsburgh, PA 15261 USA; [Wu, Jane Y.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Pandey, Udai Bhan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA; [Pandey, Udai Bhan] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA	Pandey, UB (corresponding author), Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Div Child Neurol,Dept Pediat, Pittsburgh, PA 15224 USA.; Pandey, UB (corresponding author), Univ Pittsburgh, Dept Neurosci, Dietrich Sch Arts & Sci, Pittsburgh, PA 15260 USA.; Pandey, UB (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.; Pandey, UB (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.	udai@pitt.edu		Grant, Rogan/0000-0003-0655-0882; watkins, simon/0000-0003-4092-1552	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS081303, NS094921, NS100055, NS101661, NS098379]; Muscular Dystrophy Association (MDA)Muscular Dystrophy Association; Robert Packard Center for ALS at Johns Hopkins; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS094921, R21NS101661, R01NS081303, R21NS098379, R21NS100055] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health R01 (NS081303), R21 grants (NS094921, NS100055, NS101661 and NS098379), Muscular Dystrophy Association (MDA) and the Robert Packard Center for ALS at Johns Hopkins to UBP.	Al-Chalabi A, 2012, ACTA NEUROPATHOL, V124, P339, DOI 10.1007/s00401-012-1022-4; Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Armon C, 2012, AMYOTROPH LATERAL SC, V13, P351, DOI 10.3109/17482968.2012.660954; Arnold ES, 2013, P NATL ACAD SCI USA, V110, pE736, DOI 10.1073/pnas.1222809110; Ash PEA, 2014, BRAIN RES, V1584, P52, DOI 10.1016/j.brainres.2014.05.052; Aulas A, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00423, 10.3389/fncel.2015.00423]; Ayala YM, 2008, J CELL SCI, V121, P3778, DOI 10.1242/jcs.038950; Barmada SJ, 2010, J NEUROSCI, V30, P639, DOI 10.1523/JNEUROSCI.4988-09.2010; Baron DM, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-30; Bartlett BJ, 2011, AUTOPHAGY, V7, P572, DOI 10.4161/auto.7.6.14943; Bellou V, 2016, PARKINSONISM RELAT D, V23, P1, DOI 10.1016/j.parkreldis.2015.12.008; Belly A, 2005, NEUROSCI LETT, V379, P152, DOI 10.1016/j.neulet.2004.12.071; Bosco DA, 2010, HUM MOL GENET, V19, P4160, DOI 10.1093/hmg/ddq335; Bose JK, 2008, J BIOL CHEM, V283, P28852, DOI 10.1074/jbc.M805376200; Bozzoni V, 2016, FUNCT NEUROL, V31, P7, DOI 10.11138/fneur/2016.31.1.007; Buchan JR, 2013, CELL, V153, P1461, DOI 10.1016/j.cell.2013.05.037; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Byrne S, 2011, J NEUROL NEUROSUR PS, V82, P623, DOI 10.1136/jnnp.2010.224501; Cannon JR, 2011, TOXICOL SCI, V124, P225, DOI 10.1093/toxsci/kfr239; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen Pan, 2016, F1000Res, V5, DOI 10.12688/f1000research.7431.1; Chen YB, 2011, PROTEIN CELL, V2, P477, DOI 10.1007/s13238-011-1065-7; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Coffman CJ, 2005, NEUROEPIDEMIOLOGY, V24, P141, DOI 10.1159/000083297; Colombrita C, 2009, J NEUROCHEM, V111, P1051, DOI 10.1111/j.1471-4159.2009.06383.x; Corrado L, 2010, J MED GENET, V47, P190, DOI 10.1136/jmg.2009.071027; Crowther DC, 2005, NEUROSCIENCE, V132, P123, DOI 10.1016/j.neuroscience.2004.12.025; Daigle JG, 2013, HUM MOL GENET, V22, P1193, DOI 10.1093/hmg/dds526; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; DeVorkin Lindsay, 2014, Cold Spring Harb Protoc, V2014, P959, DOI 10.1101/pdb.prot080333; Dewey CM, 2012, BRAIN RES, V1462, P16, DOI 10.1016/j.brainres.2012.02.032; Dewey CM, 2011, MOL CELL BIOL, V31, P1098, DOI 10.1128/MCB.01279-10; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Fang F, 2009, ENVIRON HEALTH PERSP, V117, P1387, DOI 10.1289/ehp.0900580; Feddermann-Demont N, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.630; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Ginsberg SD, 1998, ACTA NEUROPATHOL, V96, P487, DOI 10.1007/s004010050923; Godena VK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017808; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Gros-Louis F, 2006, BBA-MOL BASIS DIS, V1762, P956, DOI 10.1016/j.bbadis.2006.01.004; Haley RW, 2003, NEUROLOGY, V61, P750, DOI 10.1212/WNL.61.6.750; Hand CK, 2002, MUSCLE NERVE, V25, P135; Hasegawa M, 2017, PHARMACOL THERAPEUT, V172, P22, DOI 10.1016/j.pharmthera.2016.11.010; Horner RD, 2003, NEUROLOGY, V61, P742, DOI 10.1212/01.WNL.0000069922.32557.CA; Horner RD, 2008, NEUROEPIDEMIOLOGY, V31, P28, DOI 10.1159/000136648; Hyman AA, 2014, ANNU REV CELL DEV BI, V30, P39, DOI 10.1146/annurev-cellbio-100913-013325; Ingre C, 2015, CLIN EPIDEMIOL, V7, P181, DOI 10.2147/CLEP.S37505; Ito D, 2011, NEUROLOGY, V77, P1636, DOI 10.1212/WNL.0b013e3182343365; Johnson FO, 2011, J PHARMACOL EXP THER, V338, P518, DOI 10.1124/jpet.110.174466; Johnson FO, 2009, NEUROTOXICOLOGY, V30, P761, DOI 10.1016/j.neuro.2009.07.010; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Kabashi E, 2010, HUM MOL GENET, V19, P671, DOI 10.1093/hmg/ddp534; Kabuta T, 2006, J BIOL CHEM, V281, P30524, DOI 10.1074/jbc.M603337200; Kasarskis EJ, 2009, AMYOTROPH LATERAL SC, V10, P35, DOI 10.1080/17482960802351029; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Keller BA, 2012, ACTA NEUROPATHOL, V124, P733, DOI 10.1007/s00401-012-1035-z; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; King A, 2013, ACTA NEUROPATHOL, V125, P303, DOI 10.1007/s00401-012-1050-0; Kunst CB, 2004, AM J HUM GENET, V75, P933, DOI 10.1086/426001; KURLAND LT, 1992, J NEUROL SCI, V113, P133, DOI 10.1016/0022-510X(92)90241-C; Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Kwee LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032768; Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066; Kwon S, 2007, GENE DEV, V21, P3381, DOI 10.1101/gad.461107; Lagier-Tourenne C, 2010, HUM MOL GENET, V19, pR46, DOI 10.1093/hmg/ddq137; Lanson NA, 2012, BRAIN RES, V1462, P44, DOI 10.1016/j.brainres.2012.01.039; Lanson NA, 2011, HUM MOL GENET, V20, P2510, DOI 10.1093/hmg/ddr150; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; LEIGH PN, 1988, NEUROSCI LETT, V93, P197, DOI 10.1016/0304-3940(88)90081-X; Li YR, 2013, J CELL BIOL, V201, P361, DOI 10.1083/jcb.201302044; Liang C, 2010, CELL DEATH DIFFER, V17, P1807, DOI 10.1038/cdd.2010.115; Liu-Yesucevitz L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013250; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Matsuoka T, 2011, NEUROPATHOLOGY, V31, P71, DOI 10.1111/j.1440-1789.2010.01129.x; Matus S, 2014, NEUROBIOL AGING, V35, P2832, DOI 10.1016/j.neurobiolaging.2014.08.019; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mazroui R, 2007, MOL BIOL CELL, V18, P2603, DOI 10.1091/mbc.E06-12-1079; McKee AC, 2017, JAMA-J AM MED ASSOC, V318, P2353, DOI 10.1001/jama.2017.16687; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Meisl G, 2016, SCI REP-UK, V6, DOI 10.1038/srep18728; Mo C, 2015, NEUROSCI BIOBEHAV R, V52, P178, DOI 10.1016/j.neubiorev.2015.03.003; Molliex A, 2015, CELL, V163, P123, DOI 10.1016/j.cell.2015.09.015; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nezis IP, 2008, J CELL BIOL, V180, P1065, DOI 10.1083/jcb.200711108; Nichols C. D., 2012, J VIS EXP IN PRESS; Nomura T, 2014, J BIOL CHEM, V289, P1192, DOI 10.1074/jbc.M113.516492; Osterwalder T, 2001, P NATL ACAD SCI USA, V98, P12596, DOI 10.1073/pnas.221303298; Pazman C, 2000, DEVELOPMENT, V127, P1715; Polymenidou M, 2012, BRAIN RES, V1462, P3, DOI 10.1016/j.brainres.2012.02.059; Protter DSW, 2016, TRENDS CELL BIOL, V26, P668, DOI 10.1016/j.tcb.2016.05.004; Pupillo E, 2012, EUR J NEUROL, V19, P1509, DOI 10.1111/j.1468-1331.2012.03723.x; Qiu HY, 2014, J CLIN INVEST, V124, P981, DOI 10.1172/JCI72723; Ramaswami M, 2013, CELL, V154, P727, DOI 10.1016/j.cell.2013.07.038; Renton AE, 2014, NAT NEUROSCI, V17, P17, DOI 10.1038/nn.3584; Riggs JE, 1996, ARCH NEUROL-CHICAGO, V53, P225, DOI 10.1001/archneur.1996.00550030031019; Riggs JE, 2001, MIL MED, V166, P731; RIGGS JE, 1985, ARCH NEUROL-CHICAGO, V42, P205, DOI 10.1001/archneur.1985.04060030015004; RIGGS JE, 1995, CLIN NEUROPHARMACOL, V18, P273, DOI 10.1097/00002826-199506000-00008; Riggs JE, 2003, MIL MED, V168, P143; Ryu HH, 2014, NEUROBIOL AGING, V35, P2822, DOI 10.1016/j.neurobiolaging.2014.07.026; Saini A, 2014, LANGMUIR, V30, P3845, DOI 10.1021/la404710w; Saini A, 2011, CHEMBIOCHEM, V12, P2495, DOI 10.1002/cbic.201100427; Salminen A, 2012, PROG NEUROBIOL, V96, P87, DOI 10.1016/j.pneurobio.2011.11.005; Sama RRK, 2013, J CELL PHYSIOL, V228, P2222, DOI 10.1002/jcp.24395; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Sarov M, 2016, ELIFE, V5, DOI 10.7554/eLife.12068; Scaramuzzino C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061576; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Smethurst P, 2016, NEUROBIOL DIS, V96, P236, DOI 10.1016/j.nbd.2016.08.007; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Terni B, 2007, ACTA NEUROPATHOL, V113, P403, DOI 10.1007/s00401-006-0192-3; Thomsen GM, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0059-14.2015; Vanacore N, 2006, PARKINSONISM RELAT D, V12, P327, DOI 10.1016/j.parkreldis.2005.11.007; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942; Vanderweyde T, 2013, GERONTOLOGY, V59, P524, DOI 10.1159/000354170; Villar-Pique A, 2016, P NATL ACAD SCI USA, V113, pE6506, DOI 10.1073/pnas.1606791113; Volkening K, 2009, BRAIN RES, V1305, P168, DOI 10.1016/j.brainres.2009.09.105; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang XJ, 2010, NEUROSCI LETT, V469, P112, DOI 10.1016/j.neulet.2009.11.055; Wiesner D, 2018, EXP NEUROL, V299, P15, DOI 10.1016/j.expneurol.2017.09.011; Williams K. L., 2012, NEUROBIOL AGING, V33, pe3; Winton MJ, 2008, J BIOL CHEM, V283, P13302, DOI 10.1074/jbc.M800342200; Wolozin B, 2014, DISCOV MED, V17, P47; Xu ZH, 2013, P NATL ACAD SCI USA, V110, P7778, DOI 10.1073/pnas.1219643110	132	36	36	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	APR 15	2018	27	8					1366	1381		10.1093/hmg/ddy047			16	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	GC0TM	WOS:000429490700005	29432563	Bronze, Green Published			2021-06-18	
J	Lee, SW; Gajavelli, S; Spurlock, MS; Andreoni, C; Vaccari, JPD; Bullock, MR; Keane, RW; Dietrich, WD				Lee, Stephanie W.; Gajavelli, Shyam; Spurlock, Markus S.; Andreoni, Cody; Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Keane, Robert W.; Dietrich, W. Dalton			Microglial Inflammasome Activation in Penetrating Ballistic-Like Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						inflammasome; microglia; penetrating ballistic-like brain injury; penetrating traumatic brain injury	INNATE IMMUNE-RESPONSE; NLRP3 INFLAMMASOME; CELL-DEATH; LOADING CONTROL; TOTAL PROTEIN; CEREBROSPINAL-FLUID; GUNSHOT WOUNDS; UNITED-STATES; GASDERMIN D; BETA-ACTIN	Penetrating traumatic brain injury (PTBI) is a significant cause of death and disability in the United States. Inflammasomes are one of the key regulators of the interleukin (IL)-1 beta mediated inflammatory responses after traumatic brain injury. However, the contribution of inflammasome signaling after PTBI has not been determined. In this study, adult male Sprague-Dawley rats were subjected to sham procedures or penetrating ballistic-like brain injury (PBBI) and sacrificed at various time-points. Tissues were assessed by immunoblot analysis for expression of IL-1 beta, IL-18, and components of the inflammasome: apoptosis-associated speck-like protein containing a caspase-activation and recruitment domain (ASC), caspase-1, X-linked inhibitor of apoptosis protein (XIAP), nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3), and gasdermin-D (GSDMD). Specific cell types expressing inflammasome proteins also were evaluated immunohistochemically and assessed quantitatively. After PBBI, expression of IL-1 beta, IL-18, caspase-1, ASC, XIAP, and NLRP3 peaked around 48 h. Brain protein lysates from PTBI animals showed pyroptosome formation evidenced by ASC laddering, and also contained increased expression of GSDMD at 48 h after injury. ASC-positive immunoreactive neurons within the perilesional cortex were observed at 24 h. At 48 h, ASC expression was concentrated in morphologically activated cortical microglia. This expression of ASC in activated microglia persisted until 12 weeks following PBBI. This is the first report of inflammasome activation after PBBI. Our results demonstrate cell-specific patterns of inflammasome activation and pyroptosis predominantly in microglia, suggesting a sustained pro-inflammatory state following PBBI, thus offering a therapeutic target for this type of brain injury.	[Lee, Stephanie W.; Gajavelli, Shyam; Spurlock, Markus S.; Andreoni, Cody; Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Keane, Robert W.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@med.miami.edu	Gajavelli, Shyam/AAI-1374-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	Gajavelli, Shyam/0000-0002-5947-6973; de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; 	NIH NINDS awardsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS089443, RO1 NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS089443] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD023579] Funding Source: NIH RePORTER	NIH NINDS awards R01 NS089443 and RO1 NS042133. The authors wish to thank Deborah Shear and Walter Reed Army Research Institute for providing the PBBI apparatus; Melissa Carballosa-Gautam and Pantelis Tsoulfas for confocal microscopy training, and Karla N. Rivera and Michael Kaplan for immunohistochemistry and immunoblotting support for this study.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Beaman V, 2000, ANN EMERG MED, V35, P258, DOI 10.1016/S0196-0644(00)70077-1; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bruns J., 2003, EPILEPSIA, V44, pS2; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Cartagena CM, 2013, NEUROMOL MED, V15, P504, DOI 10.1007/s12017-013-8236-z; Cartagena CM, 2013, J MOL NEUROSCI, V49, P301, DOI 10.1007/s12031-012-9828-z; Chen W, 2015, ELECTROPHORESIS, V36, P2046, DOI 10.1002/elps.201500138; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davis A E, 2000, Crit Care Nurs Q, V23, P1; de Lanerolle NC, 2015, SEMIN NEUROL, V35, P12, DOI 10.1055/s-0035-1544240; de Rivero Vaccari J.P., 2015, J NEUROCHEM, V136, pS39; Djukic M, 2006, BRAIN, V129, P2394, DOI 10.1093/brain/awl206; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Du L, 2017, MOL NEUROBIOL, V54, P7567, DOI 10.1007/s12035-016-0245-0; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Gajavelli S, 2015, J CEREBR BLOOD F MET, V35, P773, DOI 10.1038/jcbfm.2014.243; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Gilda JE, 2015, METHODS MOL BIOL, V1295, P381, DOI 10.1007/978-1-4939-2550-6_27; Gilda JE, 2013, ANAL BIOCHEM, V440, P186, DOI 10.1016/j.ab.2013.05.027; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanisch UK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00065; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Hellwig S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00071; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Ji KA, 2007, GLIA, V55, P1577, DOI 10.1002/glia.20571; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; Kabba J. A., 2017, CELL MOL NEUROBIOL, P1; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Khan MB, 2014, WORLD NEUROSURG, V82, P14, DOI 10.1016/j.wneu.2013.01.026; Lin David J, 2012, Surg Neurol Int, V3, P98, DOI 10.4103/2152-7806.100187; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Oehmichen Manfred, 2009, Leg Med (Tokyo), V11 Suppl 1, pS50, DOI 10.1016/j.legalmed.2009.01.113; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Pruitt BA, 2001, J TRAUMA, V51, pS1, DOI 10.1097/00005373-200108001-00001; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Sarkar S, 2017, NPJ PARKINSON DIS, V3, DOI 10.1038/s41531-017-0032-2; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Taabazuing CY, 2017, CELL CHEM BIOL, V24, P507, DOI 10.1016/j.chembiol.2017.03.009; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Thacker JS, 2016, ANAL BIOCHEM, V496, P76, DOI 10.1016/j.ab.2015.11.022; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Venegas C, 2017, NATURE, V552, P355, DOI 10.1038/nature25158; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang S.J., 2017, CELL MOL NEUROBIOL, V265, P22; Yao CP, 2008, BRAIN INJURY, V22, P723, DOI 10.1080/02699050802304706; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3	81	36	38	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1681	1693		10.1089/neu.2017.5530		APR 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000428879200001	29439605	Green Published			2021-06-18	
J	Braun, M; Khan, ZT; Khan, MB; Kumar, M; Ward, A; Achyut, BR; Arbab, AS; Hess, DC; Hoda, MN; Baban, B; Dhandapani, KM; Vaibhav, K				Braun, Molly; Khan, Zenab T.; Khan, Mohammad B.; Kumar, Manish; Ward, Ayobami; Achyut, Bhagelu R.; Arbab, Ali S.; Hess, David C.; Hoda, Md. Nasrul; Baban, Babak; Dhandapani, Krishnan M.; Vaibhav, Kumar			Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Cannabinoid receptor 2; Macrophage; Controlled cortical impact; Inflammation; Marijuana	IN-VITRO MODEL; CB2 RECEPTOR; CEREBRAL EDEMA; CANNABIDIOL; INFLAMMATION; CELL; AGONIST; MODERATE; MICE; NEUROPROTECTION	Inflammation is an important mediator of secondary neurological injury after traumatic brain injury (TBI). Endocannabinoids, endogenously produced arachidonate based lipids, have recently emerged as powerful anti-inflammatory compounds, yet the molecular and cellular mechanisms underlying these effects are poorly defined. Endocannabinoids are physiological ligands for two known cannabinoid receptors, CB1R and CB2R. In the present study, we hypothesized that selective activation of CB2R attenuates neuroinflammation and reduces neurovascular injury after TBI. Using a murine controlled cortical impact (CCI) model of TBI, we observed a dramatic upregulation of CB2R within infiltrating myeloid cells beginning at 72 h. Administration of the selective CB2R agonist, GP1a (1-5 mg/kg), attenuated pro-inflammatory M1 macrophage polarization, increased anti-inflammatory M2 polarization, reduced edema development, enhanced cerebral blood flow, and improved neurobehavioral outcomes after TBI. In contrast, the CB2R antagonist, AM630, worsened outcomes. Taken together, our findings support the development of selective CB2R agonists as a therapeutic strategy to improve TBI outcomes while avoiding the psychoactive effects of CB1R activation. Published by Elsevier Inc.	[Braun, Molly; Khan, Zenab T.; Ward, Ayobami; Dhandapani, Krishnan M.; Vaibhav, Kumar] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA; [Khan, Zenab T.] Augusta Univ, Ctr Nursing Res, Augusta, GA USA; [Khan, Mohammad B.; Hess, David C.; Hoda, Md. Nasrul; Baban, Babak] Augusta Univ, Med Coll Georgia, Dept Neurol, Augusta, GA USA; [Kumar, Manish] EMBL, Monterotondo, Italy; [Baban, Babak] Augusta Univ, Dent Coll Georgia, Dept Oral Biol, Augusta, GA USA; [Achyut, Bhagelu R.; Arbab, Ali S.] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA; [Hoda, Md. Nasrul; Vaibhav, Kumar] Augusta Univ, Coll Allied Hlth Sci, Dept Med Lab Imaging & Radiol Sci, Augusta, GA USA; [Baban, Babak] Augusta Univ, Med Coll Georgia, Dept Surg, Augusta, GA USA	Vaibhav, K (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.	kvaibhav@augusta.edu	Arbab, Ali/AAS-1933-2020; Kumar, Manish/AAC-2278-2019; Vaibhav, Kumar/H-4120-2019	Kumar, Manish/0000-0002-0855-3406; Vaibhav, Kumar/0000-0002-4206-3830; Dhandapani, Krishnan/0000-0001-7044-1117	Augusta University Research Institute [PSRP00095]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R03HD094606, R01NS065172, R21NS075774, R03NS084228]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD094606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS084228, R01NS065172, R21NS075774] Funding Source: NIH RePORTER	Financial support for this project was provided by a Grant from the Augusta University Research Institute (PSRP00095) and by Grants from the National Institutes of Health (R03HD094606, R01NS065172, R21NS075774 and R03NS084228).	Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Allen S, 2016, SUBST USE MISUSE, V51, P1577, DOI 10.1080/10826084.2016.1188955; Anday JK, 2005, PHARMACOL RES, V52, P463, DOI 10.1016/j.phrs.2005.07.005; Ashton CH, 2011, ACTA PSYCHIAT SCAND, V124, P250, DOI 10.1111/j.1600-0447.2011.01687.x; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Baban B, 2005, INT IMMUNOL, V17, P909, DOI 10.1093/intimm/dxh271; Baban B, 2013, EXP MOL PATHOL, V95, P288, DOI 10.1016/j.yexmp.2013.09.002; Bahi A, 2014, PHYSIOL BEHAV, V135, P119, DOI 10.1016/j.physbeh.2014.06.003; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Braun M, 2017, J IMMUNOL, V198, P3615, DOI 10.4049/jimmunol.1601948; Bravo-Ferrer I, 2017, STROKE, V48, P204, DOI 10.1161/STROKEAHA.116.014793; Buch SJ, 2013, AM J PATHOL, V183, P1375, DOI 10.1016/j.ajpath.2013.08.003; Campos AC, 2012, PHILOS T R SOC B, V367, P3364, DOI 10.1098/rstb.2011.0389; Castillo A, 2010, NEUROBIOL DIS, V37, P434, DOI 10.1016/j.nbd.2009.10.023; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00209; Chen H, 2016, CLIN EXP PHARMACOL P, V43, P1107, DOI 10.1111/1440-1681.12650; Chuchawankul S, 2004, INT IMMUNOPHARMACOL, V4, P265, DOI 10.1016/j.intimp.2003.12.011; Conti S, 2002, BRIT J PHARMACOL, V135, P181, DOI 10.1038/sj.bjp.0704466; Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Schier ARD, 2014, CNS NEUROL DISORD-DR, V13, P953, DOI 10.2174/1871527313666140612114838; Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648; Donat CK, 2014, ACTA NEUROBIOL EXP, V74, P197; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hind WH, 2016, BRIT J PHARMACOL, V173, P815, DOI 10.1111/bph.13368; Hou JM, 2017, J NEUROTRAUM, V34, P2456, DOI 10.1089/neu.2016.4851; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Ignatowska-Jankowska BM, 2013, PSYCHOPHARMACOLOGY, V229, P591, DOI 10.1007/s00213-013-3117-6; Jin X, 2012, J SOFTWARE, V7, P6, DOI DOI 10.1371/J0URNAL.P0NE.0041892; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Khan MB, 2015, TRANSL STROKE RES, V6, P69, DOI 10.1007/s12975-014-0374-6; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kishimoto S, 2005, J BIOCHEM, V137, P217, DOI 10.1093/jb/mvi021; Kozela E, 2013, J NEUROIMMUNE PHARM, V8, P1265, DOI 10.1007/s11481-013-9493-1; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; Massa F, 2006, J Endocrinol Invest, V29, P47; McKallip RJ, 2002, J PHARMACOL EXP THER, V302, P451, DOI 10.1124/jpet.102.033506; McKallip RJ, 2002, BLOOD, V100, P627, DOI 10.1182/blood-2002-01-0098; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nilsson O, 2006, EUR J PHARMACOL, V547, P165, DOI 10.1016/j.ejphar.2006.07.016; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; Peterson TC, 2015, BEHAV BRAIN RES, V294, P254, DOI 10.1016/j.bbr.2015.08.007; Plomgaard AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173440; Pottker B., 2017, BRAIN STRUCT FUNCT; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Rom S, 2013, AM J PATHOL, V183, P1548, DOI 10.1016/j.ajpath.2013.07.033; Pazos MR, 2013, NEUROPHARMACOLOGY, V71, P282, DOI 10.1016/j.neuropharm.2013.03.027; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Salehi A., 2017, J CEREB BLOOD FLOW M; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Sharma MD, 2010, IMMUNITY, V33, P942, DOI 10.1016/j.immuni.2010.11.022; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Steffens S, 2012, BRIT J PHARMACOL, V167, P313, DOI 10.1111/j.1476-5381.2012.02042.x; Su E., 2016, TRANSLATIONAL RES TR; Syed YY, 2014, DRUGS, V74, P563, DOI 10.1007/s40265-014-0197-5; Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006; Tomar S, 2015, J PHARMACOL EXP THER, V353, P369, DOI 10.1124/jpet.114.220368; Valenzano KJ, 2005, NEUROPHARMACOLOGY, V48, P658, DOI 10.1016/j.neuropharm.2004.12.008; Vos B.C., 2017, CLIN J SPORT MED; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang Melvyn Weibin, 2015, J Addict, V2015, P707596, DOI 10.1155/2015/707596; Ziring D, 2006, IMMUNOGENETICS, V58, P714, DOI 10.1007/s00251-006-0138-x	81	36	37	1	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	FEB	2018	68						224	237		10.1016/j.bbi.2017.10.021			14	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	FU7YL	WOS:000424068600021	29079445	Green Accepted, Bronze			2021-06-18	
J	Wu, LC; Kuo, C; Loza, J; Kurt, M; Laksari, K; Yanez, LZ; Senif, D; Anderson, SC; Miller, LE; Urban, JE; Stitzel, JD; Camarillo, DB				Wu, Lyndia C.; Kuo, Calvin; Loza, Jesus; Kurt, Mehmet; Laksari, Kaveh; Yanez, Livia Z.; Senif, Daniel; Anderson, Scott C.; Miller, Logan E.; Urban, Jillian E.; Stitzel, Joel D.; Camarillo, David B.			Detection of American Football Head Impacts Using Biomechanical Features and Support Vector Machine Classification	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; ICE HOCKEY; EXPOSURE; PLAYERS; CONCUSSION; SENSORS; SYSTEM; KINEMATICS; MOUTHGUARD	Accumulation of head impacts may contribute to acute and long-term brain trauma. Wearable sensors can measure impact exposure, yet current sensors do not have validated impact detection methods for accurate exposure monitoring. Here we demonstrate a head impact detection method that can be implemented on a wearable sensor for detecting field football head impacts. Our method incorporates a support vector machine classifier that uses biomechanical features from the time domain and frequency domain, as well as model predictions of head-neck motions. The classifier was trained and validated using instrumented mouthguard data from collegiate football games and practices, with ground truth data labels established from video review. We found that low frequency power spectral density and wavelet transform features (10 similar to 30 Hz) were the best performing features. From forward feature selection, fewer than ten features optimized classifier performance, achieving 87.2% sensitivity and 93.2% precision in cross-validation on the collegiate dataset (n = 387), and over 90% sensitivity and precision on an independent youth dataset (n = 32). Accurate head impact detection is essential for studying and monitoring head impact exposure on the field, and the approach in the current paper may help to improve impact detection performance on wearable sensors.	[Wu, Lyndia C.; Kuo, Calvin; Loza, Jesus; Yanez, Livia Z.; Senif, Daniel; Anderson, Scott C.; Camarillo, David B.] Stanford Univ, Stanford, CA 94305 USA; [Kurt, Mehmet] Stevens Inst Technol, Hoboken, NJ 07030 USA; [Laksari, Kaveh] Univ Arizona, Tucson, AZ USA; [Miller, Logan E.; Urban, Jillian E.; Stitzel, Joel D.] Wake Forest Univ, Winston Salem, NC 27109 USA	Wu, LC (corresponding author), Stanford Univ, Stanford, CA 94305 USA.	lyndiacw@stanford.edu	Kuo, Calvin/AAH-1933-2019; Wu, Lyndia/AAQ-1106-2020; Stitzel, Joel/B-4045-2012	Kuo, Calvin/0000-0001-8401-9136; Wu, Lyndia/0000-0002-8236-032X; Stitzel, Joel/0000-0001-9762-3033; Miller, Logan/0000-0002-6348-7536	Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center	The authors would like to thank Stanford Athletics, Coach Shaw and the Football Team for their support in this research. We would also like to thank Camarillo Lab interns and Wake Forest University interns who aided in device fabrication, data collection, and video analysis. We would like to express special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center, as well as Mireille Kelley and the iTAKL study for providing support.	Abramowitz Milton, 1965, HDB MATH FUNCTIONS F; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Altun K, 2010, PATTERN RECOGN, V43, P3605, DOI 10.1016/j.patcog.2010.04.019; [Anonymous], 2015, US SOCC ANN REC REC; Bao L, 2004, LECT NOTES COMPUT SC, V3001, P1, DOI 10.1007/978-3-540-24646-6_1; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, P 2016 NAT ATHL TRAI; Cortes N, 2017, AM J SPORT MED, V45, P2379, DOI 10.1177/0363546517706703; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Doukas Charalampos, 2008, 2008 Second International Conference on Pervasive Computing Technologies for Healthcare (PervasiveHealth), P103, DOI 10.1109/PCTHEALTH.2008.4571042; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gissane C., 2014, AM J SPORT MED; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haran F. J., 2012, INT J SPORTS MED, V24; Hernandez F., 2014, ANN BIOMED ENG; Huang J, 2005, IEEE T KNOWL DATA EN, V17, P299, DOI 10.1109/TKDE.2005.50; Kuo C., 2017, BIORXIV; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Lustrek . M., 2008, INFORMATICA, V33, P205; Mannini A, 2010, SENSORS-BASEL, V10, P1154, DOI 10.3390/s100201154; Mantyjarvi J., 2001, P IEEE INT C SYST MA, V2, P2, DOI DOI 10.1109/ICSMC.2001.973004.(2001); Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mez J., 2016, JAMA NEUROL, P4; Motiwale S, 2016, 2016 3RD IEEE EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS, P204, DOI 10.1109/BHI.2016.7455870; Musicant D.R, 2003, P FLAIRS C, P356; Najafi B, 2003, IEEE T BIO-MED ENG, V50, P711, DOI 10.1109/TBME.2003.812189; Nevins D, 2016, PROCEDIA ENGINEER, V147, P186, DOI 10.1016/j.proeng.2016.06.211; Nyan MN, 2008, J BIOMECH, V41, P3475, DOI 10.1016/j.jbiomech.2008.08.009; Preece SJ, 2009, PHYSIOL MEAS, V30, pR1, DOI 10.1088/0967-3334/30/4/R01; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Reynolds BB, 2016, AM J SPORT MED, V44, P2947, DOI 10.1177/0363546516648442; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Sae S., 1995, ELECT INSTRUMENTAT 1, V552, P25; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Vasavada AN, 1998, SPINE, V23, P412, DOI 10.1097/00007632-199802150-00002; Vasavada AN, 2008, J BIOMECH, V41, P114, DOI 10.1016/j.jbiomech.2007.07.007; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wu L.C., 2015, ANN BIOMED ENG; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153; Wu WM, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.2208	44	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	DEC 21	2017	7								855	10.1038/s41598-017-17864-3			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FX2OU	WOS:000425901700001	29321637	DOAJ Gold, Green Published			2021-06-18	
J	Kim, D; Doyle, EK; Wisnowski, JL; Kim, JH; Haldar, JP				Kim, Daeun; Doyle, Eamon K.; Wisnowski, Jessica L.; Kim, Joong Hee; Haldar, Justin P.			Diffusion-relaxation correlation spectroscopic imaging: A multidimensional approach for probing microstructure	MAGNETIC RESONANCE IN MEDICINE			English	Article						diffusion; relaxation; compartment modeling; correlation spectroscopy; constrained reconstruction	INVERSE LAPLACE TRANSFORM; 2D MRI RELAXOMETRY; MULTICOMPONENT T-1; MYELIN WATER; BRAIN; NMR; DISTRIBUTIONS; TIME; QUANTIFICATION; FRAMEWORK	PurposeTo propose and evaluate a novel multidimensional approach for imaging subvoxel tissue compartments called Diffusion-Relaxation Correlation Spectroscopic Imaging. Theory and MethodsMultiexponential modeling of MR diffusion or relaxation data is commonly used to infer the many different microscopic tissue compartments that contribute signal to macroscopic MR imaging voxels. However, multiexponential estimation is known to be difficult and ill-posed. Observing that this ill-posedness is theoretically reduced in higher dimensions, diffusion-relaxation correlation spectroscopic imaging uses a novel multidimensional imaging experiment that jointly encodes diffusion and relaxation information, and then uses a novel constrained reconstruction technique to generate a multidimensional diffusion-relaxation correlation spectrum for every voxel. The peaks of the multidimensional spectrum are expected to correspond to the distinct tissue microenvironments that are present within each macroscopic imaging voxel. ResultsUsing numerical simulations, experiment data from a custom-built phantom, and experiment data from a mouse model of traumatic spinal cord injury, diffusion-relaxation correlation spectroscopic imaging is demonstrated to provide substantially better multicompartment resolving power compared to conventional diffusion- and relaxation-based methods. ConclusionThe diffusion-relaxation correlation spectroscopic imaging approach provides powerful new capabilities for resolving the different components of multicompartment tissue models, and can be leveraged to significantly expand the insights provided by MRI in studies of tissue microstructure. Magn Reson Med 78:2236-2249, 2017. (c) 2017 International Society for Magnetic Resonance in Medicine.	[Kim, Daeun; Haldar, Justin P.] Univ Southern Calif, Dept Elect Engn, Los Angeles, CA USA; [Doyle, Eamon K.; Haldar, Justin P.] Univ Southern Calif, Dept Biomed Engn, Los Angeles, CA USA; [Doyle, Eamon K.] Childrens Hosp Angeles, Dept Cardiol, Los Angeles, CA USA; [Wisnowski, Jessica L.] Childrens Hosp Angeles, Dept Radiol, Los Angeles, CA USA; [Kim, Joong Hee] Washington Univ, Dept Neurol & Radiol, St Louis, MO USA	Kim, D (corresponding author), Univ Southern Calif, Univ Pk Campus,3710 McClintock Ave,RTH 317, Los Angeles, CA 90036 USA.	daeunk@usc.edu	Haldar, Justin P/B-4983-2008	Haldar, Justin P/0000-0002-1838-0211; Kim, Daeun/0000-0002-9887-5598; Doyle, Eamon/0000-0002-8652-6518	NSFNational Science Foundation (NSF) [CCF-1350563]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21-EB022951, R01-NS089212, R01-DK097115]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB022951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK097115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089212] Funding Source: NIH RePORTER; Direct For Computer & Info Scie & EnginrNational Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE) [1350563] Funding Source: National Science Foundation	Grant sponsor: NSF award; Grant number: CCF-1350563; Grant sponsor: NIH; Grant numbers: R21-EB022951, R01-NS089212 and R01-DK097115.	Acton F. S., 1990, NUMERICAL METHODS WO; Afonso MV, 2011, IEEE T IMAGE PROCESS, V20, P681, DOI 10.1109/TIP.2010.2076294; Ahola S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9363; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Assaf Y, 2008, MAGN RESON MED, V59, P1347, DOI 10.1002/mrm.21577; Bai RL, 2015, J MAGN RESON, V255, P88, DOI 10.1016/j.jmr.2015.04.002; Benjamini D, 2016, J MAGN RESON, V271, P40, DOI 10.1016/j.jmr.2016.08.004; Brunsing RL, 2017, J MAGN RESON IMAGING, V45, P323, DOI 10.1002/jmri.25419; Callaghan PT, 2003, MAGN RESON IMAGING, V21, P243, DOI 10.1016/S0730-725X(03)00131-0; Celik H, 2013, J MAGN RESON, V236, P134, DOI 10.1016/j.jmr.2013.07.008; Cloninger A, 2014, SIAM J IMAGING SCI, V7, P1775, DOI 10.1137/130932168; De Santis S, 2016, NEUROIMAGE, V141, P133, DOI 10.1016/j.neuroimage.2016.07.037; De Santis S, 2016, MAGN RESON MED, V75, P372, DOI 10.1002/mrm.25644; De-Baron, 1795, J ECOLE POLYTECHNIQU, V1, P24; Deoni Sean C L, 2010, Top Magn Reson Imaging, V21, P101, DOI 10.1097/RMR.0b013e31821e56d8; Deoni SCL, 2008, MAGN RESON MED, V60, P1372, DOI 10.1002/mrm.21704; Does MD, 1998, MAGN RESON IMAGING, V16, P1033, DOI 10.1016/S0730-725X(98)00139-8; Does MD, 2002, MAGNET RESON MED, V47, P274, DOI 10.1002/mrm.10060; Edelstein WA, 2010, J AM COLL RADIOL, V7, P650, DOI 10.1016/j.jacr.2010.05.002; ENGLISH AE, 1991, MAGNET RESON MED, V22, P425, DOI 10.1002/mrm.1910220250; Epstein CL, 2008, SIAM REV, V50, P504, DOI 10.1137/060657273; Fenrich FRE, 2001, NMR BIOMED, V14, P133, DOI 10.1002/nbm.685; Freed DE, 2010, CR PHYS, V11, P181, DOI 10.1016/j.crhy.2010.06.016; Galvosas P, 2010, CR PHYS, V11, P172, DOI 10.1016/j.crhy.2010.06.014; Gatidis S, 2014, MAGN RESON MED, V72, P459, DOI 10.1002/mrm.24944; Hafftka A, 2015, 2015 INT C SAMPL THE; Hamilton J, 2016, P 24 ANN M ISMRM SIN; Hurlimann MD, 2002, J MAGN RESON, V157, P31, DOI 10.1006/jmre.2002.2567; Hwang D, 2009, J MAGN RESON IMAGING, V30, P203, DOI 10.1002/jmri.21783; Istratov AA, 1999, REV SCI INSTRUM, V70, P1233, DOI 10.1063/1.1149581; Jelescu IO, 2016, NMR BIOMED, V29, P33, DOI 10.1002/nbm.3450; Jones DK., 2011, DIFFUSION MRI THEORY; Kaden E, 2016, NEUROIMAGE, V139, P346, DOI 10.1016/j.neuroimage.2016.06.002; Kim D, 2016, P 24 ANN M ISMRM SIN; Kim JH, 2009, J NEUROTRAUM, V26, P1395, DOI [10.1089/neu.2008.0728, 10.1089/neu.2008-0728]; Kumar D, 2012, MAGN RESON MED, V68, P1536, DOI 10.1002/mrm.24170; Lamanna R, 2005, CONCEPT MAGN RESON A, V26A, P78, DOI 10.1002/cmr.a.20036; Lanczos C., 1956, APPL ANAL; Le Bihan D, 2012, NEUROIMAGE, V61, P324, DOI 10.1016/j.neuroimage.2011.11.006; LEE JH, 1993, J AM CHEM SOC, V115, P7761, DOI 10.1021/ja00070a022; Lin YG, 2014, IEEE T MED IMAGING, V33, P173, DOI 10.1109/TMI.2013.2283229; MacKay A, 2006, MAGN RESON IMAGING, V24, P515, DOI 10.1016/j.mri.2005.12.037; MACKAY A, 1994, MAGNET RESON MED, V31, P673, DOI 10.1002/mrm.1910310614; McGivney DF, 2016, P 24 ANN M ISMRM SIN; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Mitchell J, 2012, PROG NUCL MAG RES SP, V62, P34, DOI 10.1016/j.pnmrs.2011.07.002; Mulkern RV, 2009, MAGN RESON IMAGING, V27, P1151, DOI 10.1016/j.mri.2009.05.003; Mulkern RV, 1999, NMR BIOMED, V12, P51, DOI 10.1002/(SICI)1099-1492(199902)12:1<51::AID-NBM546>3.0.CO;2-E; Mulkern RV, 2016, J MAGN RESON IMAG; Niendorf T, 1996, MAGN RESON MED, V36, P847, DOI 10.1002/mrm.1910360607; PEEMOELLER H, 1981, J MAGN RESON, V45, P193, DOI 10.1016/0022-2364(81)90116-5; PROVENCHER SW, 1979, J BIOCHEM BIOPH METH, V1, P313, DOI 10.1016/0165-022X(79)90021-6; Scherrer B., 2015, MAGNETIC RESONANCE M, V76, P963; Sodickson DK, 2015, MED IMAGING 2015 BIO; Song YQ, 2002, J MAGN RESON, V154, P261, DOI 10.1006/jmre.2001.2474; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tu TW, 2010, J NEUROTRAUM, V27, P253, DOI 10.1089/neu.2009.1026; Varadarajan D, 2015, IEEE T MED IMAGING, V34, P2191, DOI 10.1109/TMI.2015.2427157; Venkataramanan L, 2002, IEEE T SIGNAL PROCES, V50, P1017, DOI 10.1109/78.995059; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Whittall KP, 1997, MAGNET RESON MED, V37, P34, DOI 10.1002/mrm.1910370107; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072	62	36	36	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	DEC	2017	78	6					2236	2249		10.1002/mrm.26629			14	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	FM4FE	WOS:000414967400017	28317261	Green Accepted, Bronze			2021-06-18	
J	Chhor, V; Moretti, R; Le Charpentier, T; Sigaut, S; Lebon, S; Schwendimann, L; Ore, MV; Zuiani, C; Milan, V; Josserand, J; Vontell, R; Pansiot, J; Degos, V; Ikonomidou, C; Titomanlio, L; Hagberg, H; Gressens, P; Fleiss, B				Chhor, Vibol; Moretti, Raffaella; Le Charpentier, Tifenn; Sigaut, Stephanie; Lebon, Sophie; Schwendimann, Leslie; Ore, Marie-Virginie; Zuiani, Chiara; Milan, Valentina; Josserand, Julien; Vontell, Regina; Pansiot, Julien; Degos, Vincent; Ikonomidou, Chrysanthy; Titomanlio, Luigi; Hagberg, Henrik; Gressens, Pierre; Fleiss, Bobbi			Role of microglia in a mouse model of paediatric traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Phenotype; Cytokine; Chemokine; Apoptosis; Neuron; Immature; Cerebral; Macrophage; Inflammation; Minocycline	WHITE-MATTER INJURY; CELL-DEATH; MICROGLIA/MACROPHAGE ACTIVATION; CEREBRAL-ISCHEMIA; RAT-BRAIN; MINOCYCLINE; EXPRESSION; PROTECTS; AGE; NEUROPROTECTION	The cognitive and behavioural deficits caused by traumatic brain injury (TBI) to the immature brain are more severe and persistent than TBI in the mature brain. Understanding this developmental sensitivity is critical as children under four years of age sustain TBI more frequently than any other age group. Microglia (MG), resident immune cells of the brain that mediate neuroinflammation, are activated following TBI in the immature brain. However, the type and temporal profile of this activation and the consequences of altering it are still largely unknown. In a mouse model of closed head weight drop paediatric brain trauma, we characterized i) the temporal course of total cortical neuroinflammation and the phenotype of ex vivo isolated CD11B-positive microglia/macrophage (MG/M Phi) using a battery of 32 markers, and ii) neuropathological outcome 1 and 5 days post-injury. We also assessed the effects of targeting MG/M Phi activation directly, using minocycline a prototypical microglial activation antagonist, on these processes and outcome. TBI induced a moderate increase in both pro- and anti-inflammatory cytokines/chemokines in the ipsilateral hemisphere. Isolated cortical MG/M Phi expressed increased levels of markers of endogenous reparatory/regenerative and immunomodulatory phenotypes compared with shams. Blocking MG/M Phi activation with minocycline at the time of injury and 1 and 2 days post-injury had only transient protective effects, reducing ventricular dilatation and cell death 1 day post-injury but having no effect on injury severity at 5 days. This study demonstrates that, unlike in adults, the role of MG/M Phi in injury mechanisms following TBI in the immature brain may not be negative. An improved understanding of MG/M Phi function in paediatric TBI could support translational efforts to design therapeutic interventions. (C) 2016 The Author(s). Published by Elsevier Inc.	[Chhor, Vibol; Moretti, Raffaella; Le Charpentier, Tifenn; Sigaut, Stephanie; Lebon, Sophie; Schwendimann, Leslie; Ore, Marie-Virginie; Zuiani, Chiara; Milan, Valentina; Josserand, Julien; Pansiot, Julien; Degos, Vincent; Titomanlio, Luigi; Gressens, Pierre; Fleiss, Bobbi] Unversite Paris Diderot, PROTECT, INSERM, Sorbonne Paris Cite, Paris, France; [Chhor, Vibol; Moretti, Raffaella; Le Charpentier, Tifenn; Sigaut, Stephanie; Lebon, Sophie; Schwendimann, Leslie; Ore, Marie-Virginie; Zuiani, Chiara; Milan, Valentina; Josserand, Julien; Pansiot, Julien; Degos, Vincent; Titomanlio, Luigi; Gressens, Pierre; Fleiss, Bobbi] PremUP, Paris, France; [Chhor, Vibol] Georges Pompidou European Hosp, Dept Anesthesia & Intens Care, Paris, France; [Moretti, Raffaella] Univ Udine, Udine, Italy; [Vontell, Regina; Hagberg, Henrik; Gressens, Pierre; Fleiss, Bobbi] Kings Coll London, St Thomas Hosp, Dept Perinatal Imaging & Hlth, Dept Div Imaging Sci & Biomed Engn, London SE1 7EH, England; [Hagberg, Henrik] Hop La Pitie Salpetriere, Dept Anesthesia & Intens Care, F-75013 Paris, France; [Ikonomidou, Chrysanthy] Univ Wisconsin, Dept Neurol, Madison, WI USA; [Degos, Vincent] Gothenburg Univ, Sahlgrenska Acad E Hosp, Dept Clin Sci, S-41685 Gothenburg, Sweden; [Zuiani, Chiara] Univ Trieste, Trieste, Italy	Fleiss, B (corresponding author), Inserm U1141, Hop Robert Debre, 48 Blvd Serurier, F-75019 Paris, France.	Bobbi.Fleiss@inserm.fr	gressens, pierre/M-7557-2017; Fleiss, Bobbi/F-9899-2011	gressens, pierre/0000-0002-0909-4221; Fleiss, Bobbi/0000-0001-7828-673X; Sigaut, Stephanie/0000-0002-4888-7769; Hagberg, Henrik/0000-0003-3962-1448	InsermInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; Universite Paris Diderot; Universite Sorbonne-Paris-Cite; Investissement d'AvenirFrench National Research Agency (ANR) [ANR-11-INBS-0011]; ERA-NET Neuron (Micromet); DHU PROTECT; PremUP; Fondation de FranceFondation de France; Fondation pour la Recherche sur le Cerveau; Fondation des Gueules Cassees; Institut Servier; Roger de Spoelberch Foundation; Grace de Monaco Foundation; Leducq FoundationLeducq Foundation; Cerebral Palsy Alliance Research Foundation Australia; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [VR 2015-02493]; Hjarnfonden (Brain Foundation) [2015-0004]; Swedish Governmental [ALFGBG-426401]; Wellcome TrustWellcome TrustEuropean Commission [WSCR P32674]; Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London and King's College Hospital NHS Foundation Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802853] Funding Source: researchfish; Action Medical Research [2485] Funding Source: researchfish	This study was supported by grants from Inserm, Universite Paris Diderot, Universite Sorbonne-Paris-Cite, Investissement d'Avenir (ANR-11-INBS-0011, NeurATRIS), ERA-NET Neuron (Micromet), DHU PROTECT, PremUP, Fondation de France, Fondation pour la Recherche sur le Cerveau, Fondation des Gueules Cassees, Institut Servier, Roger de Spoelberch Foundation, Grace de Monaco Foundation, Leducq Foundation, Cerebral Palsy Alliance Research Foundation Australia, The Swedish Medical Research Council (VR 2015-02493), Hjarnfonden (Brain Foundation 2015-0004), Swedish Governmental Grant to Researchers at University Hospitals (ALFGBG-426401), and the Wellcome Trust (WSCR P32674). In addition, the authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The supporting bodies played no role in any aspect of study design, analysis, interpretation or decision to publish these data.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Bennet L., 2013, CLIN EXP PHARM PHYSL; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Z, 2006, NEUROSCIENCE, V137, P425, DOI 10.1016/j.neuroscience.2005.09.023; Carlsson Y, 2011, ANN NEUROL, V70, P781, DOI 10.1002/ana.22431; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Copland IB, 2004, AM J RESP CRIT CARE, V169, P739, DOI 10.1164/rccm.200310-1417OC; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Faustino JV, 2011, J NEUROSCI, V31, P12992, DOI 10.1523/JNEUROSCI.2102-11.2011; Fernandez-Gomez FJ, 2005, NEUROBIOL DIS, V20, P384, DOI 10.1016/j.nbd.2005.03.019; Fleiss B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-70; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Gonzalez JC, 2007, EUR J NEUROSCI, V26, P2481, DOI 10.1111/j.1460-9568.2007.05873.x; Grabert K, 2016, NAT NEUROSCI, V19, P504, DOI 10.1038/nn.4222; Griffin R, 2006, J NEUROCHEM, V99, P1263, DOI 10.1111/j.1471-4159.2006.04165.x; Hagberg H, 2012, ANN NEUROL, V71, P444, DOI 10.1002/ana.22620; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Hart AD, 2012, BRAIN BEHAV IMMUN, V26, P754, DOI 10.1016/j.bbi.2011.11.006; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Husson I, 2005, CEREB CORTEX, V15, P250, DOI 10.1093/cercor/bhh127; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Kaindl AM, 2007, PROTEOM CLIN APPL, V1, P640, DOI 10.1002/prca.200600696; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kernt M, 2010, CLIN OPHTHALMOL, V4, P591; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Koistinaho M, 2005, J CEREBR BLOOD F MET, V25, P460, DOI 10.1038/sj.jcbfm.9600040; Kumar A., 2015, J NEUROTRAUMA; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lechpammer M, 2008, NEUROPATH APPL NEURO, V34, P379, DOI 10.1111/j.1365-2990.2007.00925.x; Li ZL, 2014, BRAIN BEHAV IMMUN, V38, P237, DOI 10.1016/j.bbi.2014.02.008; Lingwood BE, 2008, J NEUROSCI METH, V171, P140, DOI 10.1016/j.jneumeth.2008.02.011; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Moretti R., 2016, J NEUROSCI RES; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nijboer CH, 2010, BRAIN BEHAV IMMUN, V24, P420, DOI 10.1016/j.bbi.2009.11.009; Pinto PS, 2012, J NEUROIMAGING, V22, pe1, DOI 10.1111/j.1552-6569.2011.00688.x; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Schang AL, 2014, BRAIN BEHAV IMMUN, V37, P95, DOI 10.1016/j.bbi.2013.11.005; Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4; Schultz C, 2004, CLIN EXP IMMUNOL, V135, P130, DOI 10.1111/j.1365-2249.2004.02313.x; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Sriram K, 2006, J NEUROCHEM, V96, P706, DOI 10.1111/j.1471-4159.2005.03566.x; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35; Wang G., 2013, J CEREB BLOOD FLOW M; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yang YR, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0245-4; Yoon SY, 2012, NEUROSCIENCE, V221, P214, DOI 10.1016/j.neuroscience.2012.06.024; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	87	36	37	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JUL	2017	63				SI		197	209		10.1016/j.bbi.2016.11.001			13	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	EW0ZG	WOS:000402219100019	27818218	Other Gold, Green Published			2021-06-18	
J	Sen, T; Gupta, R; Kaiser, H; Sen, N				Sen, Tanusree; Gupta, Rajaneesh; Kaiser, Helen; Sen, Nilkantha			Activation of PERK Elicits Memory Impairment through Inactivation of CREB and Downregulation of PSD95 After Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						CREB; GSK3B; PERK; PSD95; TBI	UNFOLDED PROTEIN RESPONSE; HIPPOCAMPAL SYNAPTIC PLASTICITY; ENDOPLASMIC-RETICULUM STRESS; GLYCOGEN-SYNTHASE KINASE-3; TRANSLATIONAL CONTROL; ALZHEIMERS-DISEASE; EIF2-ALPHA KINASES; CELL-SURVIVAL; MOUSE MODEL; ER STRESS	The PKR-like ER kinase (PERK), a transmembrane protein, resides in the endoplasmic reticulum (ER). Its activation serves as a key sensor of ER stress, which has been implicated in traumatic brain injury (TBI). The loss of memory is one of the most common symptoms after TBI, but the precise role of PERK activation in memory impairment after TBI has not been well elucidated. Here, we have shown that blocking the activation of PERK using GSK2656157 prevents the loss of dendritic spines and rescues memory deficits after TBI. To elucidate the molecular mechanism, we found that activated PERK phosphorylates CAMP response element binding protein (CREB) and PSD95 directly at the S129 and T19 residues, respectively. Phosphorylation of CREB protein prevents its interaction with a coactivator, CREB-binding protein, and subsequently reduces the BDNF level after TBI. Conversely, phosphorylation of PSD95 leads to its downregulation in pericontusional cortex after TBI in male mice. Treatment with either GSK2656157 or overexpression of a kinase-dead mutant of PERK (PERK-K618A) rescues BDNF and PSD95 levels in the pericontusional cortex by reducing phosphorylation of CREB and PSD95 proteins after TBI. Similarly, administration of either GSK2656157 or overexpression of PERK-K618A in primary neurons rescues the loss of dendritic outgrowth and number of synapses after treatment with a PERK activator, tunicamycin. Therefore, our study suggests that inhibition of PERK phosphorylation could be a potential therapeutic target to restore memory deficits after TBI.	[Sen, Tanusree; Sen, Nilkantha] Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,A504, Pittsburgh, PA 15213 USA; [Gupta, Rajaneesh; Kaiser, Helen] Augusta Univ, Dept Neurosci & Regenerat Med, Augusta, GA 30907 USA	Sen, N (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,A504, Pittsburgh, PA 15213 USA.	senn@pitt.edu	Sen, Nilkantha/AAW-9788-2020; Gupta, Rajaneesh/AAD-5893-2019	Gupta, Rajaneesh/0000-0003-0212-6478	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NS094516, RO1EY025622]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY025622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094516] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grants RO1NS094516 and RO1EY025622 to N.S. and R.G.). We thank Dr. Alexis Stranahan from Augusta University for Dil staining to study synaptic morphology.	Andres RH, 2011, STROKE, V42, P2923, DOI 10.1161/STROKEAHA.110.606368; Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109; Banhegyi G, 2007, ANN NY ACAD SCI, V1113, P58, DOI 10.1196/annals.1391.007; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Beique JC, 2003, J PHYSIOL-LONDON, V546, P859, DOI 10.1113/jphysiol.2002.031369; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011; Cheng DM, 2006, MOL CELL PROTEOMICS, V5, P1158, DOI 10.1074/mcp.D500009-MCP200; Chi XX, 2007, J NEUROPHYSIOL, V98, P2683, DOI 10.1152/jn.00437.2007; Costa-Mattioli M, 2005, NATURE, V436, P1166, DOI 10.1038/nature03897; Costa-Mattioli M, 2007, CELL, V129, P195, DOI 10.1016/j.cell.2007.01.050; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Di Giovanni S, 2005, J BIOL CHEM, V280, P2084, DOI 10.1074/jbc.M411975200; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; El-Hussein AE, 2000, SCIENCE, V290, P1364; Erion JR, 2014, J NEUROSCI, V34, P2618, DOI 10.1523/JNEUROSCI.4200-13.2014; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Halliday M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.49; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Herold S, 2011, MOL CELL NEUROSCI, V46, P79, DOI 10.1016/j.mcn.2010.08.008; Jouvert P, 2004, J NEUROSCI, V24, P10716, DOI 10.1523/JNEUROSCI.1398-04.2004; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Krishnamoorthy J, 2014, CELL CYCLE, V13, P801, DOI 10.4161/cc.27726; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Liu Z, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.183; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Ma T, 2013, NAT NEUROSCI, V16, P1299, DOI 10.1038/nn.3486; Marciniak SJ, 2006, J CELL BIOL, V172, P201, DOI 10.1083/jcb.200508099; Mir S, 2014, MOL CELL, V56, P786, DOI 10.1016/j.molcel.2014.10.019; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Nelson CD, 2013, J NEUROSCI, V33, P12122, DOI 10.1523/JNEUROSCI.0131-13.2013; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Ohno M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00022; Park K, 2013, FUTUR NEUROL, V8, P555, DOI 10.2217/FNL.13.35; Pereira C, 2013, ISRN CELL BIOL, V2013, DOI [10.1155/2013/256404, DOI 10.1155/2013/256404]; Radford H, 2015, ACTA NEUROPATHOL, V130, P633, DOI 10.1007/s00401-015-1487-z; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900; Schaffer DJ, 2010, BRAIN RES, V1362, P32, DOI 10.1016/j.brainres.2010.09.041; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; Sen N, 2012, MOL CELL, V45, P13, DOI 10.1016/j.molcel.2011.10.021; Sen N, 2011, P NATL ACAD SCI USA, V108, P20178, DOI 10.1073/pnas.1117820108; Sen N, 2009, NEURON, V63, P81, DOI 10.1016/j.neuron.2009.05.024; Sen T, 2016, NEUROPHARMACOLOGY, V107, P79, DOI 10.1016/j.neuropharm.2016.03.009; Stranahan AM, 2007, HIPPOCAMPUS, V17, P1017, DOI 10.1002/hipo.20348; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Trinh MA, 2012, CELL REP, V1, P676, DOI 10.1016/j.celrep.2012.04.010; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Uchida M, 2006, J CELL SCI, V119, P3067, DOI 10.1242/jcs.03043; Uchida S, 2010, J NEUROSCI, V30, P15007, DOI 10.1523/JNEUROSCI.1436-10.2010; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764; Wu K, 2004, BRAIN RES, V1008, P284, DOI 10.1016/j.brainres.2004.02.051; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002	69	36	37	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 14	2017	37	24					5900	5911		10.1523/JNEUROSCI.2343-16.2017			12	Neurosciences	Neurosciences & Neurology	EX4VC	WOS:000403232000011	28522733	Green Published, Bronze			2021-06-18	
J	Robinson, S; Berglass, JB; Denson, JL; Berkner, J; Anstine, CV; Winer, JL; Maxwell, JR; Qiu, JH; Yang, YR; Sillerud, LO; Meehan, WP; Mannix, R; Jantzie, LL				Robinson, Shenandoah; Berglass, Jacqueline B.; Denson, Jesse L.; Berkner, Justin; Anstine, Christopher V.; Winer, Jesse L.; Maxwell, Jessie R.; Qiu, Jianhua; Yang, Yirong; Sillerud, Laurel O.; Meehan, William P., III; Mannix, Rebekah; Jantzie, Lauren L.			Microstructural and Microglial Changes After Repetitive Mild Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						DTI; microhemorrhage; inflammation; SWI; axial diffusion; RRID:AB_2314667; RRID:AB_323909; RRID:AB_2144905	TUMOR-NECROSIS-FACTOR; DIFFUSE AXONAL INJURY; WHITE-MATTER; CEREBRAL MICROBLEEDS; MOUSE MODEL; SPINAL-CORD; TENSOR; RECEPTOR; TRACTOGRAPHY; VALIDATION	Traumatic brain injury (TBI) is a major public health issue, with recently increased awareness of the potential long-term sequelae of repetitive injury. Although TBI is common, objective diagnostic tools with sound neurobiological predictors of outcome are lacking. Indeed, such tools could help to identify those at risk for more severe outcomes after repetitive injury and improve understanding of biological underpinnings to provide important mechanistic insights. We tested the hypothesis that acute and subacute pathological injury, including the microgliosis that results from repeated mild closed head injury (rmCHI), is reflected in susceptibility-weighted magnetic resonance imaging and diffusion-tensor imaging microstructural abnormalities. Using a combination of high-resolution magnetic resonance imaging, stereology, and quantitative PCR, we studied the pathophysiology of male mice that sustained seven consecutive mild traumatic brain injuries over 9 days in acute (24 hr) and subacute (1 week) time periods. rmCHI induced focal cortical microhemorrhages and impaired axial diffusivity at 1 week postinjury. These microstructural abnormalities were associated with a significant increase in microglia. Notably, microgliosis was accompanied by a change in inflammatory microenvironment defined by robust spatiotemporal alterations in tumor necrosis factor-a receptor mRNA. Together these data contribute novel insight into the fundamental biological processes associated with repeated mild brain injury concomitant with subacute imaging abnormalities in a clinically relevant animal model of repeated mild TBI. These findings suggest new diagnostic techniques that can be used as biomarkers to guide the use of future protective or reparative interventions. (C) 2016 Wiley Periodicals, Inc.	[Robinson, Shenandoah; Winer, Jesse L.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurosurg, Kirby Ctr Neurobiol, Boston, MA USA; [Robinson, Shenandoah; Winer, Jesse L.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Kirby Ctr Neurobiol, Boston, MA USA; [Robinson, Shenandoah] Johns Hopkins Univ, Pediat Neurosurg, Baltimore, MD USA; [Berglass, Jacqueline B.; Berkner, Justin; Qiu, Jianhua; Meehan, William P., III; Mannix, Rebekah] Harvard Med Sch, Boston Childrens Hosp, Dept Emergency Med, Boston, MA USA; [Anstine, Christopher V.; Maxwell, Jessie R.; Jantzie, Lauren L.] Univ New Mexico, Dept Pediat, Albuquerque, NM 87131 USA; [Anstine, Christopher V.; Maxwell, Jessie R.; Jantzie, Lauren L.] Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; [Yang, Yirong; Sillerud, Laurel O.; Meehan, William P., III] Univ New Mexico, Dept Neurol, BRaIN, Albuquerque, NM 87131 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA	Jantzie, LL (corresponding author), Dept Pediat, MSC10 5590,1 Univ New Mexico, Albuquerque, NM 87131 USA.	ljantzie@salud.unm.edu	Maxwell, Jessie R./N-1890-2019; Mannix, Rebekah/AAD-8702-2020	Maxwell, Jessie R./0000-0001-8990-7239; 	Centers for Biomedical Research Excellence [Jantzie/CoBRE P30GM103400]; National Hockey League Alumni Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103400] Funding Source: NIH RePORTER	Contract grant sponsor: Centers for Biomedical Research Excellence; Contract grant number: Jantzie/CoBRE P30GM103400/Pi:Liu; Contract grant sponsor: National Hockey League Alumni Association	Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Bruce ED, 2015, MOL CELL NEUROSCI, V66, P103, DOI 10.1016/j.mcn.2015.03.017; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Erickson MA, 2011, BRAIN BEHAV IMMUN, V25, P1637, DOI 10.1016/j.bbi.2011.06.006; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fox RJ, 2008, ARCH NEUROL-CHICAGO, V65, P1179, DOI 10.1001/archneur.65.9.1179; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Jantzie LL, 2014, MOL CELL NEUROSCI, V61, P152, DOI 10.1016/j.mcn.2014.06.009; Jantzie LL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-131; Kallakuri S, 2015, J CLIN IMAG SCI, V5, DOI 10.4103/2156-7514.166354; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu SF, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3552; Liu S, 2014, J HISTOCHEM CYTOCHEM, V62, P767, DOI 10.1369/0022155414546692; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mori Y, 2014, INT IMMUNOL, V26, P93, DOI 10.1093/intimm/dxt044; Mouton, 2014, NEUROSTEREOLOGY UNBI; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Mukherjee P, 2001, RADIOLOGY, V221, P349, DOI 10.1148/radiol.2212001702; Naude PJW, 2014, BEHAV BRAIN RES, V258, P43, DOI 10.1016/j.bbr.2013.10.006; Naude PJW, 2011, FEBS J, V278, P888, DOI 10.1111/j.1742-4658.2011.08017.x; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Owen JP, 2013, NEUROIMAGE-CLIN, V2, P844, DOI 10.1016/j.nicl.2013.06.009; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Robinson S, 2016, J NEUROSURG-PEDIATR, V17, P739, DOI 10.3171/2015.10.PEDS15554; Toth A, 2016, NEUROSCI LETT, V617, P207, DOI 10.1016/j.neulet.2016.02.028; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229	49	36	36	0	36	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2017	95	4					1025	1035		10.1002/jnr.23848			11	Neurosciences	Neurosciences & Neurology	EJ8DP	WOS:000393455500008	27452502	Green Accepted			2021-06-18	
J	Howell, DR; Beasley, M; Vopat, L; Meehan, WP				Howell, David R.; Beasley, Michael; Vopat, Lisa; Meehan, William P., III			The Effect of Prior Concussion History on Dual-Task Gait following a Concussion	JOURNAL OF NEUROTRAUMA			English	Article						concussion; dual-task; gait; locomotion; mild traumatic brain injury	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; BALANCE CONTROL; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; MUSCULOSKELETAL INJURY; HIGH-SCHOOL; LONG-TERM; ADOLESCENTS; MANAGEMENT	Sustaining repeated concussions has been associated with worse outcomes after additional injuries. This effect has been identified using symptom inventories and neurocognitive tests; however, few investigations have examined how a prior concussion history affects gait soon after a subsequent concussion. We examined the gait characteristics of athletes with no documented concussion history (n = 31), athletes recovering from their first lifetime concussion (n = 15), and athletes recovering from their second or greater lifetime concussion (n = 22). All participants completed a single-task and dual-task gait examination, a medical history questionnaire, and a postconcussion symptom scale. Multivariate analyses of covariance (MANCOVA) models were used to evaluate mean gait differences among groups, and Spearman's q analyses were used to assess correlations between the number of lifetime concussions and gait characteristics. Patients reporting to the clinic with their second or greater lifetime concussion demonstrated smaller stride lengths than healthy control participants during dual-task walking (p = 0.01; d = 0.70). A moderate but insignificant correlation was detected between dual-task gait speed and the number of prior concussions (q = 0.41, p = 0.07). These results indicate that a cumulative effect of concussions across the lifetime may contribute to worsening dual-task dynamic motor function after concussion.	[Howell, David R.; Vopat, Lisa; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.; Beasley, Michael; Vopat, Lisa; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Boston, MA USA; [Howell, David R.; Beasley, Michael; Vopat, Lisa; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Beasley, Michael; Vopat, Lisa; Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA	Howell, DR (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu			National Hockey League Alumni Association through Corey C. Griffin Pro-Am Tournament	This study was funded by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley T. A., 2015, J SPORT HLTH SCI; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12253; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Mancini M, 2016, GAIT POSTURE, V43, P125, DOI 10.1016/j.gaitpost.2015.08.015; Mancini Martina, 2011, J Bioeng Biomed Sci, VSuppl 1, P007; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2012, GAIT POSTURE, V36, P471, DOI 10.1016/j.gaitpost.2012.04.010; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meagher J, 2015, WORLD J PSYCHIATR, V5, P305, DOI 10.5498/wjp.v5.i3.305; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Wright JM, 2014, WILD ENVIRON MED, V25, P319, DOI 10.1016/j.wem.2014.01.004; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zhu WM, 2012, J SPORT HEALTH SCI, V1, P9, DOI 10.1016/j.jshs.2012.02.002; Zuckerman SL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15593	52	36	36	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					838	844		10.1089/neu.2016.4609			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200010	27541061				2021-06-18	
J	Meng, QY; Zhuang, YM; Ying, Z; Agrawal, R; Yang, X; Gomez-Pinilla, F				Meng, Qingying; Zhuang, Yumei; Ying, Zhe; Agrawal, Rahul; Yang, Xia; Gomez-Pinilla, Fernando			Traumatic Brain Injury Induces Genome-Wide Transcriptomic, Methylomic, and Network Perturbations in Brain and Blood Predicting Neurological Disorders	EBIOMEDICINE			English	Article						Traumatic brain injury; Cognition; Hippocampus; Leukocytes; Gene networks; Transcriptome; DNA methylome	GENE-EXPRESSION; ALZHEIMERS-DISEASE; FLUID BIOMARKERS; COMMON VARIANTS; CAUSAL GENES; IDENTIFICATION; ASSOCIATION; REVEALS; EPIGENETICS; HIPPOCAMPAL	The complexity of the traumatic brain injury (TBI) pathology, particularly concussive injury, is a serious obstacle for diagnosis, treatment, and long-term prognosis. Here we utilize modern systems biology in a rodent model of concussive injury to gain a thorough view of the impact of TBI on fundamental aspects of gene regulation, which have the potential to drive or alter the course of the TBI pathology. TBI perturbed epigenomic programming, transcriptional activities (expression level and alternative splicing), and the organization of genes in networks centered around genes such as Anax2, Ogn, and Fmod. Transcriptomic signatures in the hippocampus are involved in neuronal signaling, metabolism, inflammation, and blood function, and they overlap with those in leukocytes from peripheral blood. The homology between genomic signatures from blood and brain elicited by TBI provides proof of concept information for development of biomarkers of TBI based on composite genomic patterns. By intersecting with human genome-wide association studies, many TBI signature genes and network regulators identified in our rodent model were causally associated with brain disorders with relevant link to TBI. The overall results show that concussive brain injury reprograms genes which could lead to predisposition to neurological and psychiatric disorders, and that genomic information from peripheral leukocytes has the potential to predict TBI pathogenesis in the brain. (C) 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Meng, Qingying; Zhuang, Yumei; Ying, Zhe; Agrawal, Rahul; Yang, Xia; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Yang, X; Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA.	xyang123@ucla.edu; fgomezpi@ucla.edu		Agrawal, Rahul/0000-0001-8128-3724	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DK104363, R01NS050465]; American Heart AssociationAmerican Heart Association [13SDG17290032]; Leducq FoundationLeducq Foundation; Hellman Fellows Award; UCLA Faculty Research Grant; UCLA CTSI [UL1TR000124]; Letten Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK104363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465] Funding Source: NIH RePORTER	XY is supported by NIH grant R01DK104363, American Heart Association Scientist Development Grant 13SDG17290032, Leducq Foundation, Hellman Fellows Award, UCLA Faculty Research Grant, and UCLA CTSI Grant UL1TR000124. FGP is supported by NIH grants R01NS050465, R01DK104363, and The Letten Foundation. None of the funding sources had any role in the design and conduct of the study, the collection, analysis, or interpretation of the data, or the preparation, review, or approval of the manuscript.	Agrawal R, 2012, J PHYSIOL-LONDON, V590, P2485, DOI 10.1113/jphysiol.2012.230078; Barnes P, 2012, HIPPOCAMPUS, V22, P149, DOI 10.1002/hipo.20879; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bosch DGM, 2016, EUR J HUM GENET, V24, P660, DOI 10.1038/ejhg.2015.186; Chen PY, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-203; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Cichon S, 2009, MOL PSYCHIATR, V14, P10, DOI 10.1038/mp.2008.126; Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789; Derry JMJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014319; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758; Furberg H, 2010, NAT GENET, V42, P441, DOI 10.1038/ng.571; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Heinzen EL, 2010, J ALZHEIMERS DIS, V19, P69, DOI 10.3233/JAD-2010-1212; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Huan TX, 2013, ARTERIOSCL THROM VAS, V33, P1427, DOI 10.1161/ATVBAHA.112.300112; Jakovcevski M, 2012, NAT MED, V18, P1194, DOI 10.1038/nm.2828; Jung S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-58; Kasarskis A, 2011, PHARMACOGENOMICS, V12, P1695, DOI [10.2217/pgs.11.115, 10.2217/PGS.11.115]; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lardenoije R, 2015, PROG NEUROBIOL, V131, P21, DOI 10.1016/j.pneurobio.2015.05.002; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Lipponen A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31570; Lupton MK, 2016, NEUROBIOL AGING, V40, P68, DOI 10.1016/j.neurobiolaging.2015.12.023; MADIGAN D, 1995, INT STAT REV, V63, P215, DOI 10.2307/1403615; Makinen VP, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004502; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Masliah E, 2013, EPIGENETICS-US, V8, P1030, DOI 10.4161/epi.25865; Max JE, 2014, PSYCHIAT CLIN N AM, V37, P125, DOI 10.1016/j.psc.2013.11.003; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Meng QY, 2016, EBIOMEDICINE, V7, P157, DOI 10.1016/j.ebiom.2016.04.008; Millstein J, 2011, SLEEP, V34, P1469, DOI 10.5665/sleep.1378; Mukasa A, 2010, P NATL ACAD SCI USA, V107, P2616, DOI 10.1073/pnas.0914356107; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Narayanan M, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145304; Pearl J., 1988, PROBABILISTIC REASON; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rezai-Zadeh K, 2009, EXPERT REV NEUROTHER, V9, P1623, DOI 10.1586/ERN.09.118; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Samal BB, 2015, J MOL NEUROSCI, V57, P282, DOI 10.1007/s12031-015-0626-2; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Schadt EE, 2009, NAT REV DRUG DISCOV, V8, P286, DOI 10.1038/nrd2826; Seshadri S, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S15; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Stankiewicz AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142195; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Surendran P, 2016, NAT GENET, V48, P1151, DOI 10.1038/ng.3654; Szyf M, 2016, TRANSL BEHAV MED, V6, P55, DOI 10.1007/s13142-016-0387-7; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132; Tu ZD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003107; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wang HQ, 2011, BIOINFORMATICS, V27, P225, DOI 10.1093/bioinformatics/btq650; Wang IM, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.24; Wang XS, 2014, STROKE, V45, P619, DOI 10.1161/STROKEAHA.113.003823; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Yamaki T, 1996, J NUCL MED, V37, P1166; Yang X, 2012, CURR DRUG METAB, V13, P952, DOI 10.2174/138920012802138633; Yang X, 2010, GENOME RES, V20, P1020, DOI 10.1101/gr.103341.109; Yang X, 2009, NAT GENET, V41, P415, DOI 10.1038/ng.325; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhai HY, 2011, J NEUROSCI, V31, P14346, DOI 10.1523/JNEUROSCI.3299-11.2011; Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030; Zhu J, 2004, CYTOGENET GENOME RES, V105, P363, DOI 10.1159/000078209; Zhu J, 2008, NAT GENET, V40, P854, DOI 10.1038/ng.167; Zhu J, 2007, PLOS COMPUT BIOL, V3, P692, DOI 10.1371/journal.pcbi.0030069	73	36	36	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2352-3964			EBIOMEDICINE	EBioMedicine	FEB	2017	16						184	194		10.1016/j.ebiom.2017.01.046			11	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	EM4DB	WOS:000395262400031	28174132	DOAJ Gold, Green Published			2021-06-18	
J	Moore, RD; Lepine, J; Ellemberg, D				Moore, R. Davis; Lepine, Julien; Ellemberg, Dave			The independent influence of concussive and sub-concussive impacts on soccer players' neurophysiological and neuropsychological function	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Sub-concussion; Concussion; Neurophysiology; ERPs; Neuropsychology	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; DEFAULT MODE NETWORK; HEAD IMPACTS; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; COGNITIVE CONTROL; SPORT HELD; FEMALE	Accumulating research demonstrates that repetitive sub-concussive impacts can alter the structure, function and connectivity of the brain. However, the functional significance of these alterations as well as the independent contribution of concussive and sub-concussive impacts to neurophysiological and neuropsychological health are unclear. Accordingly, we compared the neurophysiological and neuropsychological function of contact athletes with (concussion group) and without (sub-concussion group) a history of concussion, to non-contact athletes. We evaluated event-related brain potentials (ERPs) elicited during an oddball task and performance on a targeted battery of neuropsychological tasks. Athletes in the sub-concussion and concussion groups exhibited similar amplitude reductions in the ERP indices of attentional resource allocation (P3b) and attentional orienting (P3a) relative to non-contact athletes. However, only athletes in the concussion group exhibited reduced amplitude in the ERP index of perceptual attention (N1). Athletes in the sub-concussion and concussion groups also exhibited deficits in memory recall relative to non-contact athletes, but athletes in the concussion group also exhibited significantly more recall errors than athletes in the sub-concussion group. Additionally, only athletes in the concussion group exhibited response delays during the oddball task. The current findings suggest that sub concussive impacts are associated with alterations in the neurophysiological and neuropsychological indices of essential cognitive functions, albeit to a lesser degree than the combination of sub-concussive and concussive impacts. (C) 2016 Elsevier B.V. All rights reserved.	[Moore, R. Davis] Univ South Carolina, Arnold Sch Publ Hlth, 921 Assembly St, Columbia, SC 29201 USA; [Lepine, Julien; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, 100 Boul Edouard Montpetit, Montreal, PQ H3T 1J4, Canada	Moore, RD (corresponding author), Univ South Carolina, Arnold Sch Publ Hlth, 921 Assembly St, Columbia, SC 29201 USA.	moorerd3@mailbox.sc.edu; julien.lepine@umontreal.ca; dave.ellemberg@umontreal.ca			CIHRCanadian Institutes of Health Research (CIHR) [R0017986] Funding Source: Medline		Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Buckner RL, 2012, NEUROIMAGE, V62, P1137, DOI 10.1016/j.neuroimage.2011.10.035; Castelli D. M., 2012, DEV COGNITIVE NEU S1, V2, P590; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Culbertson W.C., 2001, TOWER LONDON DX TOLD; Culbertson WC, 1998, ASSESSMENT, V5, P215, DOI 10.1177/107319119800500302; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; HILLYARD SA, 1984, PERCEPT PSYCHOPHYS, V36, P185, DOI 10.3758/BF03202679; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Koerte L. N., 2015, J NEUROTRAUMA; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Luck S.J., 2005, EVENT RELATED POTENT; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moore R. D., 2015, BIOL PSYCHOL; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Munte TF, 2000, HDB NEUROPSYCHOLOGY, P139; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Nieuwenhuis S, 2005, PSYCHOL BULL, V131, P510, DOI 10.1037/0033-2909.131.4.510; Oostenveld R, 2001, CLIN NEUROPHYSIOL, V112, P713, DOI 10.1016/S1388-2457(00)00527-7; Polich J., 2003, THEORETICAL OVERVIEW; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Smith A., 1982, PSYCHOL SERVICES; Stephens R., 2010, J NEUROPSYCHIATRY CL; Straume-Naesheim TM, 2009, NEUROSURGERY, V64, P719, DOI 10.1227/01.NEU.0000340681.12949.6D; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	65	36	36	1	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	FEB	2017	112						22	30		10.1016/j.ijpsycho.2016.11.011			9	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	EJ5GK	WOS:000393245600003	27867100				2021-06-18	
J	Reis, PA; Alexandre, PCB; D'Avila, JC; Siqueira, LD; Antunes, B; Estato, V; Tibirica, EV; Verdonk, F; Sharshar, T; Chretien, F; Castro-Faria-Neto, HC; Bozza, FA				Reis, Patricia A.; Alexandre, Pedro C. B.; D'Avila, Joana C.; Siqueira, Luciana D.; Antunes, Barbara; Estato, Vanessa; Tibirica, Eduardo V.; Verdonk, Franck; Sharshar, Tarek; Chretien, Fabrice; Castro-Faria-Neto, Hugo C.; Bozza, Fernando A.			Statins prevent cognitive impairment after sepsis by reverting neuroinflammation, and microcirculatory/endothelial dysfunction	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Statin; Cognition; Sepsis; Neuroinflammation; Endothelium	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL DYSFUNCTION; ROSUVASTATIN; MORTALITY; THERAPY; DISEASE; MODEL; RATS	Acute brain dysfunction is a frequent condition in sepsis patients and is associated with increased mortality and long-term neurocognitive consequences. Impaired memory and executive function are common findings in sepsis survivors. Although neuroinflammation and blood-brain barrier dysfunction have been associated with acute brain dysfunction and its consequences, no specific treatments are available that prevent cognitive impairment after sepsis. Experimental sepsis was induced in Swiss Webster mice by intraperitoneal injection of cecal material (5 mg/kg, 500 mu L). Control groups (n = 5/group each experiment) received 500 mu L of saline. Support therapy recover (saline 0.9%, 1 mL and imipenem 30 mg/kg) were applied (6, 24 and 48 h post injection, n = 5-10/group, each experiment), together or not with additive orally treatment with statins (atorvastatin/simvastatin 20 mg/kg b.w.). Survival rate was monitored at 6, 24 and 48 h. In a setting of experiments, animals were euthanized at 6 and 24 h after induction for biochemical, immunohistochemistry and intravital analysis. Statins did not prevented mortality in septic mice, however survivors presented lower clinical score. At another setting of experiments, after 15 days, mice survivors from fecal supernatant peritoneal sepsis presented cognitive dysfunction for contextual hippocampal and aversive amygdala-dependent memories, which was prevented by atorvastatin/simvastatin treatment. Systemic and brain tissue levels of proinflammatory cytokines/chemokines and activation of microglial were lower in septic mice treated with statins. Brain lipid peroxidation and myeloperoxidase levels were also reduced by statins treatment. Intravital examination of the brain vessels of septic animals revealed decreased functional capillary density and increased rolling and adhesion of leukocytes, and blood flow impairment, which were reversed by treatment with statins. In addition, treatment with statins restored the cholinergic vasodilator response due to sepsis. Taken together, these data demonstrated that statins reverse microvascular dysfunction and reduce neuroinflammation during sepsis, preventing the development of long-term cognitive decline. (C) 2016 Elsevier Inc. All rights reserved.	[Reis, Patricia A.; Alexandre, Pedro C. B.; D'Avila, Joana C.; Siqueira, Luciana D.; Castro-Faria-Neto, Hugo C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, Rio De Janeiro, Brazil; [Antunes, Barbara; Estato, Vanessa; Tibirica, Eduardo V.] Fiocruz MS, Inst Oswaldo Cruz, Lab Cardiovasc Invest, Rio De Janeiro, Brazil; [Verdonk, Franck; Sharshar, Tarek; Chretien, Fabrice] Inst Pasteur, Dept Histopathol & Anim Models, Paris, France; [Bozza, Fernando A.] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil; [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil; [Castro-Faria-Neto, Hugo C.] Univ Estacio Sa, Fac Med, Rio De Janeiro, Brazil	Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FiOCRUZ, Evandro Chagas Natl Inst Infect Dis, Lab Crit Care, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.	fernando.bozza@ipec.fiocruz.br	Estato, Vanessa/AAJ-9060-2020; d'Avila, Joana/L-8970-2013; Chretien, fabrice B/D-4035-2018; Bozza, Fernando A/A-2618-2013; Verdonk, Franck/AAG-8997-2021	d'Avila, Joana/0000-0002-2045-0813; Chretien, fabrice B/0000-0002-2794-1383; Bozza, Fernando A/0000-0003-4878-0256; Verdonk, Franck/0000-0001-7061-5594	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), BrasilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), BrasilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), BrasilFundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Institute Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (INBEB), Brasil; Fundacao Oswaldo Cruz, Brasil and Institute Pasteur, France	This work was supported by grants from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brasil, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brasil, Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brasil, Institute Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (INBEB), Brasil, Fundacao Oswaldo Cruz, Brasil and Institute Pasteur, France. HCCFN is a fellow on the program Pesquisa Produtividade from Universidade Estacio de Sa.	Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1; Bozza FA, 2010, J CEREBR BLOOD F MET, V30, P440, DOI 10.1038/jcbfm.2009.215; Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003; Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Hernandes MS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-36; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Jukema JW, 2012, J AM COLL CARDIOL, V60, P875, DOI 10.1016/j.jacc.2012.07.007; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kwok JMF, 2013, VASC PHARMACOL, V58, P21, DOI 10.1016/j.vph.2012.10.003; Lim SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081218; Londono D, 2011, J IMMUNOL, V186, P7176, DOI 10.4049/jimmunol.1100060; Merx MW, 2005, CIRCULATION, V112, P117, DOI 10.1161/CIRCULATIONAHA.104.502195; Moraes CA, 2014, MOL NEUROBIOL; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Needham DM, 2016, LANCET RESP MED, V4, P203, DOI 10.1016/S2213-2600(16)00005-9; Pesic S, 2002, PHARMACOLOGY, V64, P182, DOI 10.1159/000056169; Quevedo J, 1999, LEARN MEMORY, V6, P600, DOI 10.1101/lm.6.6.600; Reis PA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003099; Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963; Tralhao AFR, 2014, POSTGRAD MED, V126, DOI 10.3810/pgm.2014.11.2832; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Rosengarten B, 2007, CEREBROVASC DIS, V23, P140, DOI 10.1159/000097051; Sabino B, 2008, J CARDIOVASC PHARM, V51, P402, DOI 10.1097/FJC.0b013e3181673bc5; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Sharshar T, 2016, LANCET RESP MED, V4, P169, DOI 10.1016/S2213-2600(16)00028-X; Srivastava K, 2012, CELL MOL NEUROBIOL, V32, P319, DOI 10.1007/s10571-011-9777-z; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Winters BD, 2010, CRIT CARE MED, V38, P1276, DOI 10.1097/CCM.0b013e3181d8cc1d; Yasuda H, 2006, KIDNEY INT, V69, P1535, DOI 10.1038/sj.ki.5000300; Yende S, 2016, CRIT CARE MED, V44, P1461, DOI 10.1097/CCM.0000000000001658	37	36	38	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	FEB	2017	60						293	303		10.1016/j.bbi.2016.11.006			11	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	EH6UA	WOS:000391908200030	27833044				2021-06-18	
J	Fang, Q; Guo, SX; Zhou, HL; Han, R; Wu, P; Han, CM				Fang, Quan; Guo, Songxue; Zhou, Hanlei; Han, Rui; Wu, Pan; Han, Chunmao			Astaxanthin protects against early burn-wound progression in rats by attenuating oxidative stress-induced inflammation and mitochondria-related apoptosis	SCIENTIFIC REPORTS			English	Article							SUBARACHNOID HEMORRHAGE; BRAIN-INJURY; NECROSIS; INVOLVEMENT; AUTOPHAGY; CYTOKINES; TISSUE; CELLS; ZONE; MICE	Burn-wound progression can occur in the initial or peri-burn area after a deep burn injury. The stasis zone has a higher risk of deterioration mediated by multiple factors but is also considered salvageable. Astaxanthin (ATX), which is extracted from some marine organisms, is a natural compound with a strong antioxidant effect that has been reported to attenuate organ injuries caused by traumatic injuries. Hence, we investigated the potential effects of ATX on preventing early burn-wound progression. A classic "comb" burn rat model was established in this study for histological and biological assessments, which revealed that ATX, particularly higher doses, alleviated histological deterioration in the stasis zone. Additionally, we observed dose-dependent improvements in oxidative stress and the release of inflammatory mediators after ATX treatment. Furthermore, ATX dose-dependently attenuated burn-induced apoptosis in the wound areas, and this effect was accompanied by increases in Akt and Bad phosphorylation and a downregulation of cytochrome C and caspase expression. In addition, the administration of Ly 294002 further verified the effect of ATX. In summary, we demonstrated that ATX protected against early burn-wound progression in a rat deep-burn model. This protection might be mediated by the attenuation of oxidative stress-induced inflammation and mitochondria-related apoptosis.	[Fang, Quan; Guo, Songxue; Zhou, Hanlei; Wu, Pan; Han, Chunmao] Zhejiang Univ, Affiliated Hosp 2, Dept Burns, Coll Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China; [Fang, Quan] Zhejiang Univ, Affiliated Hosp 2, Binjiang Branch, Dept Plast Surg,Coll Med, 1511 Jianghong Rd, Hangzhou 310000, Zhejiang, Peoples R China; [Han, Rui] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Dermatol, 3 East Qingchun Rd, Hangzhou 310020, Zhejiang, Peoples R China	Han, CM (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Burns, Coll Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	Hanchunmao1@163.com			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81301375, 81401591, 81671909]; Zhejiang Provincial National Natural Science Foundation of China [LQ13H150001]	This work was supported by the following grants: National Natural Science Foundation of China (NSFC) Grants 81301375, 81401591 and 81671909 and Zhejiang Provincial National Natural Science Foundation of China Grant LQ13H150001. We especially appreciate the support from Miss Andrea Moscoso in improving our language presentation.	Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Arturson G, 1996, BURNS, V22, P255, DOI 10.1016/0305-4179(95)00153-0; Cao JG, 2014, ANIM SCI J, V85, P150, DOI 10.1111/asj.12103; Cao W, 2011, BASIC RES CARDIOL, V106, P1207, DOI 10.1007/s00395-011-0199-3; Chalah A, 2008, ADV EXP MED BIOL, V615, P25, DOI 10.1007/978-1-4020-6554-5_3; Chen Jui-Tung, 2016, J Clin Med Res, V8, P701, DOI 10.14740/jocmr2672w; Choi HD, 2011, BRIT J NUTR, V105, P220, DOI 10.1017/S0007114510003454; Curek GD, 2010, TOXICOLOGY, V267, P147, DOI 10.1016/j.tox.2009.11.003; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960; Eski M, 2012, BURNS, V38, P283, DOI 10.1016/j.burns.2011.08.008; Fassett RG, 2012, MOLECULES, V17, P2030, DOI 10.3390/molecules17022030; Gross A, 2016, BBA-BIOENERGETICS, V1857, P1243, DOI 10.1016/j.bbabio.2016.01.017; Guo SX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124897; Guo SX, 2015, MAR DRUGS, V13, P2105, DOI 10.3390/md13042105; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; JACKSON DM, 1953, BRIT J SURG, V40, P588, DOI 10.1002/bjs.18004016413; Johnson R. M., 2003, ADV SKIN WOUND CARE, V16, P178; JOHNSON RM, 2003, ADV SKIN WOUND CARE, V16, P188; Kidd P, 2011, ALTERN MED REV, V16, P355; Kishimoto Y, 2016, MAR DRUGS, V14, DOI 10.3390/md14020035; Knabl JS, 1999, BURNS, V25, P715, DOI 10.1016/S0305-4179(99)00086-8; Kopani M, 2006, CLIN CHIM ACTA, V364, P61, DOI 10.1016/j.cca.2005.05.016; Latha B, 2001, BURNS, V27, P309, DOI 10.1016/S0305-4179(00)00127-3; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Liu XB, 2009, BRAIN RES, V1254, P18, DOI 10.1016/j.brainres.2008.11.076; Ndiaye MA, 2014, ANTIOXID REDOX SIGN, V20, P2982, DOI 10.1089/ars.2013.5645; Park JS, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-18; Salibian AA, 2016, BURNS, V42, P1025, DOI 10.1016/j.burns.2015.11.007; Schmauss D, 2015, J BURN CARE RES, V36, pE176, DOI 10.1097/BCR.0000000000000131; Schwacha MG, 2010, J SURG RES, V158, P112, DOI 10.1016/j.jss.2008.07.034; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Shupp JW, 2010, J BURN CARE RES, V31, P849, DOI 10.1097/BCR.0b013e3181f93571; Singer AJ, 2008, ACAD EMERG MED, V15, P549, DOI 10.1111/j.1553-2712.2008.00115.x; Singer AJ, 2007, ACAD EMERG MED, V14, P1125, DOI 10.1111/j.1553-2712.2007.tb02330.x; Singh V, 2007, ANN PLAS SURG, V59, P109, DOI 10.1097/01.sap.0000252065.90759.e6; SLATER TF, 1984, BIOCHEM J, V222, P1; Speranza L, 2012, MAR DRUGS, V10, P890, DOI 10.3390/md10040890; Sun LT, 2012, WOUND REPAIR REGEN, V20, P563, DOI 10.1111/j.1524-475X.2012.00813.x; Tan JQ, 2013, BURNS, V39, P1551, DOI 10.1016/j.burns.2013.04.018; Wu HJ, 2015, MAR DRUGS, V13, P5750, DOI 10.3390/md13095750; Xiao MJ, 2014, ACAD EMERG MED, V21, P383, DOI 10.1111/acem.12352; Yasui Y, 2011, CHEM-BIOL INTERACT, V193, P79, DOI 10.1016/j.cbi.2011.05.006; Ye QY, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-156; Yeh PT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146438; Yuan X, 2014, EXP THER MED, V8, P973, DOI 10.3892/etm.2014.1820; Zhang XS, 2015, BRAIN RES, V1624, P113, DOI 10.1016/j.brainres.2015.07.020; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291	48	36	43	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 27	2017	7								41440	10.1038/srep41440			13	Multidisciplinary Sciences	Science & Technology - Other Topics	EJ4BZ	WOS:000393162200001	28128352	DOAJ Gold, Green Published			2021-06-18	
J	DeKosky, ST; Asken, BM				DeKosky, Steven T.; Asken, Breton M.			Injury cascades in TBI-related neurodegeneration	BRAIN INJURY			English	Article						Traumatic brain injury; TBI; Concussion; Neurodegeneration; Chronic traumatic encephalopathy; CTE; Repetitive brain trauma; Dementia	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEINS; HIGH-SCHOOL FOOTBALL; ALZHEIMERS-DISEASE; HEAD-INJURY; BETA ACCUMULATION; RISK-FACTOR; ENCEPHALOPATHY; DEMENTIA; HUMANS	Traumatic brain injury (TBI) is a widely recognized risk factor for neurodegenerative disease. The purpose Of this review is to provide an update on the state Of the science related to injury cascades in TBI-related neurodegeneration.;Acute and chronic pathological outcomes of TBI are,similar to those seen in several neurodegenerative conditions, suggesting common linking pathways. Initial research described severe TBI patients with post-mortem identification of abnormal proteins, such as amyloid deposits. History of mild TBI (mTBI) is less consistently associated with heightened risk of neurodegenerative outcomes, but specific populations with complicated medical histories and comorbidities may be more susceptible. Our understanding of a pathological signature associated with repetitive nnTBI and/or sobclincial brain trauma advanced significantly over the past decade, and is now commonly referred to as chronic traumatic encephalopathy. We discuss hypotheses linking TBI to neurodegenerative disease, and the importance of considering factors like injury severity, timing of injury (early life versus older age), injury frequency, and repetitive subclinical brain trauma when extrapolating results from current literature to certain populations. We describe the challenges to obtaining the data necessary for accurate epidemiological research and determination of true risk magnitude, and note the importance of developing treatment-based approaches to risk mitigation.	[DeKosky, Steven T.] Univ Florida, McKnight Brain Inst, Dept Neurol, Gainesville, FL USA; [DeKosky, Steven T.] Univ Florida, McKnight Brain Inst, Dept Neurosci, Gainesville, FL USA; [Asken, Breton M.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Clin & Hlth Psychol, Neuropsychol, Gainesville, FL USA	DeKosky, ST (corresponding author), McKnight Brain Inst, Dept Neurol & Neurosci, POB 100236, Gainesville, FL 32610 USA.	DeKosky@UFL.edu		DeKosky, Steven/0000-0003-3743-2758; Asken, Breton/0000-0001-8419-142X	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG047266]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG047266] Funding Source: NIH RePORTER	This work was supported by NIA AG047266 (STDeK). Dr DeKosky reports consulting for Acumen, Inc., Amgen, Biogen, Cognition Therapeutics, Lilly Pharmaceuticals and Novartis Pharmaceuticals.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dickstein D, 2016, NEUROLOGY, V86; Figueiredo-Pereira ME, 2015, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00104; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gandy S, 2014, F1000RESEARCH, P3229; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Koga S, 2016, J NEUROPATH EXP NEUR, V75, P963, DOI 10.1093/jnen/nlw073; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mielke MM, 2014, NEUROLOGY, V82, P70, DOI 10.1212/01.wnl.0000438229.56094.54; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	64	36	36	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1177	1182		10.1080/02699052.2017.1312528			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600003	28981345	Green Accepted, Other Gold			2021-06-18	
J	Fellows, RP; Dahmen, J; Cook, D; Schmitter-Edgecombe, M				Fellows, Robert P.; Dahmen, Jessamyn; Cook, Diane; Schmitter-Edgecombe, Maureen			Multicomponent analysis of a digital Trail Making Test	CLINICAL NEUROPSYCHOLOGIST			English	Article						Trail Making Test; executive functions; speed; medication management; inhibition	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; CONSTRUCT-VALIDITY; MEDICATION MANAGEMENT; OLDER-ADULTS; PART-B; ABILITIES; TASK; PERFORMANCE; RELIABILITY	Objective: The purpose of the current study was to use a newly developed digital tablet-based variant of the TMT to isolate component cognitive processes underlying TMT performance. Method: Similar to the paper-based trail making test, this digital variant consists of two conditions, Part A and Part B. However, this digital version automatically collects additional data to create component subtest scores to isolate cognitive abilities. Specifically, in addition to the total time to completion and number of errors, the digital Trail Making Test (dTMT) records several unique components including the number of pauses, pause duration, lifts, lift duration, time inside each circle, and time between circles. Participants were community-dwelling older adults who completed a neuropsychological evaluation including measures of processing speed, inhibitory control, visual working memory/sequencing, and set-switching. The abilities underlying TMT performance were assessed through regression analyses of component scores from the dTMT with traditional neuropsychological measures. Results: Results revealed significant correlations between paper and digital variants of Part A (r(s)=.541, p<.001) and paper and digital versions of Part B (r(s)=.799, p<.001). Regression analyses with traditional neuropsychological measures revealed that Part A components were best predicted by speeded processing, while inhibitory control and visual/spatial sequencing were predictors of specific components of Part B. Exploratory analyses revealed that specific dTMT-B components were associated with a performance-based medication management task. Conclusions: Taken together, these results elucidate specific cognitive abilities underlying TMT performance, as well as the utility of isolating digital components.	[Fellows, Robert P.; Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA; [Dahmen, Jessamyn; Cook, Diane] Washington State Univ, Sch Elect Engn & Comp Sci, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			NIH: National Institute of Biomedical Imaging and Bioengineering (NBIB) Smart Environment Technologies for Health Assessment and Assistance [R01 EB009675]; National Science FoundationNational Science Foundation (NSF) [DGE-0900781]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R25AG046114] Funding Source: NIH RePORTER	This work was supported by the NIH: National Institute of Biomedical Imaging and Bioengineering (NBIB) Smart Environment Technologies for Health Assessment and Assistance [grant number R01 EB009675] and the National Science Foundation [grant number DGE-0900781].	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Army Individual Test Battery, 1944, MAN DIR SCOR; Bell-McGinty S, 2002, INT J GERIATR PSYCH, V17, P828, DOI 10.1002/gps.646; BRANDT J, 2003, TELEPHONE INTERVIEW; Cahn-Weiner Deborah A, 2002, Appl Neuropsychol, V9, P187, DOI 10.1207/S15324826AN0903_8; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Dahmen J., 2016, ANAL DIGITAL V UNPUB; Delis DC, 2001, DELISKAPLAN EXECUTIV; Fellows RP, 2015, J CLIN EXP NEUROPSYC, V37, P1013, DOI 10.1080/13803395.2015.1050360; Fellows RP, 2014, J CLIN EXP NEUROPSYC, V36, P806, DOI 10.1080/13803395.2014.943696; Franzen MD, 1996, CLIN NEUROPSYCHOL, V10, P125, DOI 10.1080/13854049608406672; GAUDINO EA, 1995, J CLIN EXP NEUROPSYC, V17, P529, DOI 10.1080/01688639508405143; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Langenecker SA, 2007, J CLIN EXP NEUROPSYC, V29, P842, DOI 10.1080/13803390601147611; Manning KJ, 2012, CLIN NEUROPSYCHOL, V26, P45, DOI 10.1080/13854046.2011.639312; Mcalister C, 2016, ARCH CLIN NEUROPSYCH, V31, P123, DOI 10.1093/arclin/acv089; ODONNELL JP, 1994, J CLIN PSYCHOL, V50, P596, DOI 10.1002/1097-4679(199407)50:4<596::AID-JCLP2270500416>3.0.CO;2-S; Patterson TL, 2002, J CLIN PSYCHOPHARM, V22, P11, DOI 10.1097/00004714-200202000-00003; Poreh A., 2012, ARCH ASSESSMENT PSYC, V2, P57; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Royall DR, 1998, J NEUROL NEUROSUR PS, V64, P588, DOI 10.1136/jnnp.64.5.588; SALTHOUSE TA, 1995, NEUROPSYCHOLOGY, V9, P518, DOI 10.1037/0894-4105.9.4.518; Salthouse TA, 2000, NEUROPSYCHOLOGY, V14, P102, DOI 10.1037/0894-4105.14.1.102; Salthouse TA, 2011, INTELLIGENCE, V39, P222, DOI 10.1016/j.intell.2011.03.001; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Smith A., 1991, SYMBOL DIGIT MODALIT; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suchy Y, 2010, J INT NEUROPSYCH SOC, V16, P26, DOI 10.1017/S1355617709990804; Wechsler D, 1997, WMS 3 ADM SCORING MA; Wechsler D., 2001, WECHSLER TEST ADULT; Williams JM, 1991, MEMORY ASSESSMENT SC; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zakzanis KK, 2005, NEUROPSYCHOLOGIA, V43, P1878, DOI 10.1016/j.neuropsychologia.2005.03.013	39	36	39	3	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					154	167		10.1080/13854046.2016.1238510			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300009	27690752	Green Accepted			2021-06-18	
J	Gao, YY; Zhuang, Z; Gao, ST; Li, X; Zhang, ZH; Ye, ZN; Li, LW; Tang, C; Zhou, ML; Han, X; Li, J				Gao, Yongyue; Zhuang, Zong; Gao, Shanting; Li, Xiang; Zhang, Zihuan; Ye, Zhennan; Li, Liwen; Tang, Chao; Zhou, Mengliang; Han, Xiao; Li, Jie			Tetrahydrocurcumin reduces oxidative stress-induced apoptosis via the mitochondrial apoptotic pathway by modulating autophagy in rats after traumatic brain injury	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Traumatic brain injury; tetrahydrocurcumin; oxidative stress; autophagy; mitochondrial apoptosis pathway	CEREBRAL-ISCHEMIA; MEDIATED AUTOPHAGY; RAPAMYCIN PROTECTS; HYPOXIA-ISCHEMIA; CELL-DEATH; IN-VITRO; DAMAGE; MICE; NEUROPROTECTION; INHIBITION	Tetrahydrocurcumin (THC) has been identified as a multi-functional neuroprotective agent in numerous neurological disorders. Oxidative stress as a result of injury may induce neuronal apoptosis after traumatic brain injury (TBI). Treatment with THC may improve neurological function following TBI by attenuating oxidative stress and apoptosis and by enhancing autophagy. The purpose of this study was to investigate the mechanism of neuroprotection by THC against oxidative stress-induced neuronal apoptosis after TBI. We hypothesized that neuroprotection by THC may involve modulation of autophagy and the mitochondria apoptotic pathway. We used western blot analysis to evaluate the effect of THC on proteins involved in mitochondrial autophagy and apoptosis after TBI. The terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay and immunofluorescence staining were used to confirm the role of THC in apoptosis and autophagy, respectively. THC-induced neuroprotection was assessed by neurological severity scoring (NSS) and by measuring the brain water content. We demonstrated that treatment with THC increased expression of autophagy-associated proteins LC3-II and Beclin-1 at 24 h post-TBI. Treatment with THC also reduced expression of malondialdehyde (MDA) and increased glutathione peroxidase (GPx) activity. Further, treatment with THC attenuated apoptosis by modulating mitochondrial apoptosis and reducing oxidative stress. Treatment with 3-methyladenine (3-MA) mitigated autophagy activation and reversed the inhibitory effect of THC on the translocation of Bax to the mitochondrial membrane. Moreover, treatment with THC improved neurological function and reduced the brain water content in rats after TBI. We concluded that the neuroprotective effects of THC are mediated by enhancing autophagy activation and by attenuation of oxidative stress and apoptosis after TBI, probably by modulating the mitochondrial apoptotic pathway. We suggest that THC may be an effective therapeutic agent to treat TBI.	[Gao, Yongyue; Zhuang, Zong; Li, Xiang; Ye, Zhennan; Li, Liwen; Tang, Chao; Zhou, Mengliang; Li, Jie] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China; [Gao, Shanting] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China; [Han, Xiao] Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Dept Biochem & Mol Biol, Nanjing 210002, Jiangsu, Peoples R China; [Zhang, Zihuan] Zhongdu Hosp, Dept Neurosurg, Bengbu 233015, Anhui, Peoples R China	Li, J (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njLi-jiepro@126.com		Zhou, Meng-liang/0000-0002-1165-5489	Jinling Hospital of Nanjing, School of Medicine, Nanjing University [2010 M023]; Major Innovative Project of Medical Science and Technology of Nanjing Military Command [14ZX16]; Project of Nanjing Science and Technology Development [201605078]; National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81400980]	This work was supported by grants from Jinling Hospital of Nanjing, School of Medicine, Nanjing University (No. 2010 M023) and the Major Innovative Project of Medical Science and Technology of Nanjing Military Command (No. 14ZX16) and the Project of Nanjing Science and Technology Development (No. 201605078) and the National Natural Science Foundation, China (No. 81400980).	Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Balduini W, 2009, AUTOPHAGY, V5, P221, DOI 10.4161/auto.5.2.7363; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Chen J, 2015, AM J TRANSL RES, V7, P1510; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cheng KK, 2013, AAPS J, V15, P324, DOI 10.1208/s12248-012-9444-4; Clark RS, 2014, AUTOPHAGY, V4, P88; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Grivennikova VG, 2010, BBA-BIOENERGETICS, V1797, P939, DOI 10.1016/j.bbabio.2010.02.013; Hagberg H, 2014, LANCET NEUROL, V13, P217, DOI 10.1016/S1474-4422(13)70261-8; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Liu F, 2016, NEUROPEPTIDES, V58, P1, DOI 10.1016/j.npep.2016.03.004; Ma J, 2016, AM J TRANSL RES, V8, P1895; Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377; Mishra S, 2011, NEUROREPORT, V22, P23, DOI 10.1097/WNR.0b013e328341e141; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Song KI, 2015, PLANTA MED, V81, P286, DOI 10.1055/s-0035-1545696; Tyagi N, 2012, J MOL NEUROSCI, V47, P128, DOI 10.1007/s12031-011-9695-z; Ulbrich F, 2016, J NEUROCHEM, V138, P859, DOI 10.1111/jnc.13662; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhang QC, 2016, AM J TRANSL RES, V8, P1197; Zhen YL, 2016, AM J TRANSL RES, V8, P911	36	36	39	1	11	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2017	9	3					887	899					13	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	ER7XK	WOS:000399028800005	28386319				2021-06-18	
S	Johnson, VE; Stewart, W; Arena, JD; Smith, DH		Beart, P; Robinson, M; Rattray, M; Maragakis, NJ		Johnson, Victoria E.; Stewart, William; Arena, John D.; Smith, Douglas H.			Traumatic Brain Injury as a Trigger of Neurodegeneration	NEURODEGENERATIVE DISEASES: PATHOLOGY, MECHANISMS, AND POTENTIAL THERAPEUTIC TARGETS	Advances in Neurobiology		English	Article; Book Chapter						Traumatic brain injury (TBI); Chronic traumatic encephalopathy (CTE); Tau; Amyloid beta; Diffuse axonal injury (DAI)	AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; CAVUM SEPTI PELLUCIDI; FRONTOTEMPORAL LOBAR DEGENERATION; PROFESSIONAL FOOTBALL PLAYERS; LONG-TERM ACCUMULATION; NONMISSILE HEAD-INJURY; ALZHEIMERS-DISEASE; DEMENTIA-PUGILISTICA	Although millions of individuals suffer a traumatic brain injury (TBI) worldwide each year, it is only recently that TBI has been recognized as a major public health problem. Beyond the acute clinical manifestations, there is growing recognition that a single severe TBI (sTBI) or repeated mild TBIs (rTBI) can also induce insidious neurodegenerative processes, which may be associated with early dementia, in particular chronic traumatic encephalopathy (CTE). Identified at autopsy examination in individuals with histories of exposure to sTBI or rTBI, CTE is recognized as a complex pathology featuring both macroscopic and microscopic abnormalities. These include cavum septum pellucidum, brain atrophy and ventricular dilation, together with pathologies in tau, TDP-43, and amyloid-beta. However, the establishment and characterization of CTE as a distinct disease entity is in its infancy. Moreover, the relative "dose" of TBI, such as the frequency and severity of injury, associated with risk of CTE remains unknown. As such, there is a clear and pressing need to improve the recognition and diagnosis of CTE and to identify mechanistic links between TBI and chronic neurodegeneration.	[Johnson, Victoria E.; Arena, John D.; Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stewart, William] Univ Penn, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland	Smith, DH (corresponding author), Univ Penn, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Stewart, William/0000-0003-2199-2582; Arena, John/0000-0002-4322-4472			ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALLSOP D, 1990, AM J PATHOL, V136, P255; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; Areza-Fegyveres R, 2007, ARQ NEURO-PSIQUIAT, V65, P830, DOI 10.1590/S0004-282X2007000500019; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Brettschneider J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039216; Brettschneider J, 2012, ACTA NEUROPATHOL, V123, P395, DOI 10.1007/s00401-011-0932-x; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CDC, 1999, TRAUM BRAIN INJ US R; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; Constantinidis J, 1967, Schweiz Arch Neurol Neurochir Psychiatr, V100, P117; Control CfD, 2016, PERC DISTR TBI REL E; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Farbota KD, 2012, J INT NEUROPSYCH SOC, V18, P1; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferguson FR, 1965, 8 INT C NEUR VIENN, V1; FERINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39, DOI 10.1159/000110750; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Geser F, 2009, J NEUROL, V256, P1205, DOI 10.1007/s00415-009-5069-7; Geser F, 2009, ARCH NEUROL-CHICAGO, V66, P180, DOI 10.1001/archneurol.2008.558; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Huber A., 1993, J NEUROTRAUMA S1, V10, pS180; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; MACPHERSON P, 1988, NEURORADIOLOGY, V30, P506, DOI 10.1007/BF00339691; MANN DMA, 1983, CLIN NEUROPATHOL, V2, P1; Marshall L F, 2000, Clin Neurosurg, V46, P105; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET, V2, P795; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NEUBUERGER KT, 1959, ARCH NEURO PSYCHIATR, V81, P403, DOI 10.1001/archneurpsyc.1959.02340160001001; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sato T, 2009, NEUROSCIENCE, V164, P1565, DOI 10.1016/j.neuroscience.2009.09.050; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SCHWIDDE JT, 1952, AMA ARCH NEUROL PSY, V67, P625, DOI 10.1001/archneurpsyc.1952.02320170043006; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Siman R, 2015, J NEUROTRAUMA; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SPILLANE J D, 1962, Br Med J, V2, P1205; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	154	36	36	1	7	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	2190-5215		978-3-319-57193-5; 978-3-319-57191-1	ADV NEUROBIOL	Adv. Neurobiol.		2017	15						383	400		10.1007/978-3-319-57193-5_15	10.1007/978-3-319-57193-5		18	Biology; Neurosciences	Life Sciences & Biomedicine - Other Topics; Neurosciences & Neurology	BL2HH	WOS:000448960500016	28674990				2021-06-18	
J	Storey, EP; Master, SR; Lockyer, JE; Podolak, OE; Grady, MF; Master, CL				Storey, Eileen P.; Master, Stephen R.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.; Master, Christina L.			Near Point of Convergence after Concussion in Children	OPTOMETRY AND VISION SCIENCE			English	Article						concussion; mild traumatic brain injury; near point of convergence; Brock string; pencil pushups; vision therapy	SPORT-RELATED CONCUSSION; VISUAL FUNCTION; HIGH-SCHOOL; RECOVERY; NEARPOINT	Purpose. To determine the incidence of abnormal near point of convergence (NPC) after acute concussion in pediatric patients and to describe the clinical course of such patients. Methods. A retrospective cohort study of 275 pediatric patients 5 to 18 years of age presenting to a tertiary care children's hospital subspecialty concussion program with a new concussion between July 1, 2014 and June 30, 2015 was conducted. Results. Sixty-seven out of 275 pediatric patients presenting to a subspecialty concussion referral program were found to have abnormal NPC on physical examination as measured by an accommodative rule. Twenty-six (46%) patients recovered with standard clinical care over a median time frame of 4.5 weeks (range 1-18), including a brief period of cognitive and physical rest followed by gradual return to school and physical activities without any formal interventions. An additional 23 (41%) patients recovered a median of 11 weeks post-injury after referral for formal vestibular therapy, including interventions for abnormal convergence, such as Brock string and pencil pushups. Seven (13%) patients with persistent abnormal NPC and concomitant symptoms that necessitated referral for formal office-based vision therapy with developmental optometry recovered a median of 23 weeks post-injury and a median of 16 weeks after referral to vision therapy. Conclusions. Assessment for NPC is a diagnostic entity that warrants consideration in children with concussion. Concussion questionnaires may not be sensitive to detect vision symptoms in children, making an accurate assessment for convergence important in the evaluation of concussion. Some children with abnormal NPC will recover without any formal intervention after concussion; however, a subset of patients with persistent abnormal NPC after concussion may benefit from interventions including vestibular and/or vision therapy.	[Storey, Eileen P.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Div Orthoped Surg, Philadelphia, PA 19104 USA; [Master, Stephen R.] Weill Cornell Med Sch, New York, NY USA; [Grady, Matthew F.; Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Master, CL (corresponding author), Childrens Hosp Philadelphia, Div Orthoped, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270			Baker JG, 2014, INT J CLIN PRACT, V68, P1286, DOI 10.1111/ijcp.12517; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pardini D, 2004, BRIT J SPORT MED, V38, P654; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Zuckerman SL, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417735.94052.d6	26	36	36	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					96	100		10.1097/OPX.0000000000000910			5	Ophthalmology	Ophthalmology	EM5ZZ	WOS:000395393900013	27391530				2021-06-18	
J	Hinzman, JM; Wilson, JA; Mazzeo, AT; Bullock, MR; Hartings, JA				Hinzman, Jason M.; Wilson, J. Adam; Mazzeo, Anna Teresa; Bullock, M. Ross; Hartings, Jed A.			Excitotoxicity and Metabolic Crisis Are Associated with Spreading Depolarizations in Severe Traumatic Brain Injury Patients	JOURNAL OF NEUROTRAUMA			English	Article						electrocorticography; multi-modal monitoring; spreading depression	HUMAN CEREBRAL-CORTEX; HUMAN HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; AMINO-ACID RELEASE; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; GLUTAMATE RELEASE; BLOOD-FLOW; PERIINFARCT DEPOLARIZATIONS; ONLINE MICRODIALYSIS	Cerebral microdialysis has enabled the clinical characterization of excitotoxicity (glutamate > 10 mu M) and non-ischemic metabolic crisis (lactate/pyruvate ratio [LPR] > 40) as important components of secondary damage in severe traumatic brain injury (TBI). Spreading depolarizations (SD) are pathological waves that occur in many patients in the days following TBI and, in animal models, cause elevations in extracellular glutamate, increased anaerobic metabolism, and energy substrate depletion. Here, we examined the association of SD with changes in cerebral neurochemistry by placing a microdialysis probe alongside a subdural electrode strip in peri-lesional cortex of 16 TBI patients requiring neurosurgery. In 107 h (median; range: 76-117 h) of monitoring, 135 SDs were recorded in six patients. Glutamate (50 mu mol/L) and lactate (3.7 mmol/L) were significantly elevated on day 0 in patients with SD compared with subsequent days and with patients without SD, whereas pyruvate was decreased in the latter group on days 0 and 1 (two-way analysis of variance [ANOVA], p values < 0.05). In patients with SD, both glutamate and LPR increased in a dose-dependent manner with the number of SDs in the microdialysis sampling period (0, 1, >= 2 SD) [glutamate: 2.1 -> 7.0 -> 52.3 mu mol/L; LPR: 27.8 -> 29.9 -> 45.0, p values < 0.05]. In these patients, there was a 10% probability of SD occurring when glutamate and LPR were in normal ranges, but a 60% probability when both variables were abnormal (> 10 mu mol/L and > 40 mu mol/L, respectively). Taken together with previous studies, these preliminary clinical results suggest SDs are a key pathophysiological process of secondary brain injury associated with non-ischemic glutamate excitotoxicity and severe metabolic crisis in severe TBI patients.	[Hinzman, Jason M.; Wilson, J. Adam; Hartings, Jed A.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; [Hartings, Jed A.] Univ Cincinnati, Inst Neurosci, Neurotrauma Ctr, Cincinnati, OH USA; [Mazzeo, Anna Teresa; Bullock, M. Ross] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA USA; [Mazzeo, Anna Teresa] Univ Turin, Dept Anesthesia & Intens Care, Turin, Italy; [Bullock, M. Ross] Univ Miami, Dept Neurosurg, Miami, FL USA; [Hartings, Jed A.] Mayfield Clin, Cincinnati, OH USA	Hinzman, JM (corresponding author), Univ Cincinnati, 231 Albert Sabin Way,ML0517, Cincinnati, OH 45267 USA.	jmhinz2@gmail.com		Mazzeo, Anna Teresa/0000-0002-8454-7243; Hartings, Jed/0000-0001-8583-3471			Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Bahar S, 2000, J NEUROPHYSIOL, V84, P311; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cruz NF, 1999, J CEREBR BLOOD F MET, V19, P380, DOI 10.1097/00004647-199904000-00004; De Fazio M, 2011, NEUROCRIT CARE, V14, P91, DOI 10.1007/s12028-010-9494-3; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; GARTHWAITE G, 1992, EUR J NEUROSCI, V4, P353, DOI 10.1111/j.1460-9568.1992.tb00882.x; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2008, NEUROL RES, V30, P876, DOI 10.1179/174313208X309739; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2014, J NEUROSURG, V120, P434, DOI 10.3171/2013.9.JNS13581; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2012, LANCET NEUROL, V11, P389, DOI 10.1016/S1474-4422(12)70085-6; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Iijima T, 1998, NEUROSCI RES, V32, P201, DOI 10.1016/S0168-0102(98)00090-X; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Krajewski KL, 2011, ACTA NEUROCHIR SUPPL, V110, P125, DOI 10.1007/978-3-7091-0353-1_22; Landolt H, 1998, J CLIN NEUROSCI, V5, P193, DOI 10.1016/S0967-5868(98)90037-6; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; McGinn Melissa J., 2016, NEUROSURG CLIN N AM, V27, P397; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Somjen GG., 2004, IONS BRAIN NORMAL FU; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2005, CRIT CARE MED, V33, P2147, DOI 10.1097/01.CCM.0000179029.95415.51; TAYLOR DL, 1994, J NEUROCHEM, V62, P2368; Timofeev I, 2008, ACTA NEUROCHIR SUPPL, V102, P99, DOI 10.1007/978-3-211-85578-2_20; Timofeev I, 2013, J CEREBR BLOOD F MET, V33, P422, DOI 10.1038/jcbfm.2012.186; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; VANHARREVELD A, 1959, J NEUROCHEM, V3, P300; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5; Zauner A, 1996, ACT NEUR S, V67, P40; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113	70	36	36	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1775	+		10.1089/neu.2015.4226			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100006	26586606	Green Published			2021-06-18	
J	Miller, LE; Urban, JE; Stitzel, JD				Miller, Logan E.; Urban, Jillian E.; Stitzel, Joel D.			Development and validation of an atlas-based finite element brain model	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Brain atlas; Head injury; Validation; Optimization; Finite element model; CORA	MAXIMUM PRINCIPAL STRAIN; VISCOELASTIC PROPERTIES; PROBABILISTIC ATLAS; HEAD; INJURY; BIOMECHANICS; METHODOLOGY; RESPONSES; IMPACTS; SPORTS	Traumatic brain injury is a leading cause of disability and injury-related death. To enhance our ability to prevent such injuries, brain response can be studied using validated finite element (FE) models. In the current study, a high-resolution, anatomically accurate FE model was developed from the International Consortium for Brain Mapping brain atlas. Due to wide variation in published brain material parameters, optimal brain properties were identified using a technique called Latin hypercube sampling, which optimized material properties against three experimental cadaver tests to achieve ideal biomechanics. Additionally, falx pretension and thickness were varied in a lateral impact variation. The atlas-based brain model (ABM) was subjected to the boundary conditions from three high-rate experimental cadaver tests with different material parameter combinations. Local displacements, determined experimentally using neutral density targets, were compared to displacements predicted by the ABM at the same locations. Error between the observed and predicted displacements was quantified using CORrelation and Analysis (CORA), an objective signal rating method that evaluates the correlation of two curves. An average CORA score was computed for each variation and maximized to identify the optimal combination of parameters. The strongest relationships between CORA and material parameters were observed for the shear parameters. Using properties obtained through the described multiobjective optimization, the ABM was validated in three impact configurations and shows good agreement with experimental data. The final model developed in this study consists of optimized brain material properties and was validated in three cadaver impacts against local brain displacement data.	[Miller, Logan E.; Urban, Jillian E.; Stitzel, Joel D.] Wake Forest Ctr Injury Biomech, 575 Patterson Ave,Suite 120, Winston Salem, NC 27101 USA	Miller, LE (corresponding author), Wake Forest Ctr Injury Biomech, 575 Patterson Ave,Suite 120, Winston Salem, NC 27101 USA.	logmille@wakehealth.edu	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033; Miller, Logan/0000-0002-6348-7536	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS082453]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082453] Funding Source: NIH RePORTER	Funding for this project is provided by the National Institutes of Health (R01 NS082453). All simulations were run on the DEAC Cluster at Wake Forest University. The authors would like to thank the ANSIR Lab for providing the ICBM label maps and Elizabeth Lillie for her work on the MATLAB code to produce the ABM from the label maps.	Abel J, 1978, SAE TECHNICAL PAPERS; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chan HS, 1974, SAE TECHNICAL PAPER; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gehre C, 2009, 21 ESV C JUN 15 18 2; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Golman A., 2013, P 41 INT WORKSH; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Good CD, 2001, NEUROIMAGE, V14, P685, DOI 10.1006/nimg.2001.0857; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W, 2007, THESIS; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Jirousek O, 2005, SOLID MECH APPL, V124, P459; Kangarlou K, 2013, SWITZ RES PARK J, V102, P1571; KENNER VH, 1972, INT J MECH SCI, V14, P557, DOI 10.1016/0020-7403(72)90056-2; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; King AI, 2003, P IRCOBI C LISB; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Lauret C, 2009, MED ENG PHYS, V31, P392, DOI 10.1016/j.medengphy.2008.05.004; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Matsumae M, 1996, J NEUROSURG, V84, P982, DOI 10.3171/jns.1996.84.6.0982; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; MAZZIOTTA JC, 1995, NEUROIMAGE, V2, P89, DOI 10.1006/nimg.1995.1012; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meaney DF, 1993, ASME CRASHWORTHINESS, V25, P169; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; Pinnoji PK, 2010, INT J IMPACT ENG, V37, P274, DOI 10.1016/j.ijimpeng.2009.05.013; Post A, 2014, COMPUT METHOD BIOMEC, V17, P1785, DOI 10.1080/10255842.2013.766724; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Stalnaker RL, 1977, VALIDATION STUDIES H; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tinard V, 2012, MATER DESIGN, V37, P79, DOI 10.1016/j.matdes.2011.12.005; Urban Jillian E, 2012, Biomed Sci Instrum, V48, P447; Vavalle NA, 2013, TRAFFIC INJ PREV, V14, pS87, DOI 10.1080/15389588.2013.802777; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Yu H, 2004, INT J CRASHWORTHINES, V9, P175, DOI 10.1533/ijcr.2004.0276; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	55	36	37	2	11	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	OCT	2016	15	5					1201	1214		10.1007/s10237-015-0754-1			14	Biophysics; Engineering, Biomedical	Biophysics; Engineering	DW4KM	WOS:000383611800014	26762217	Green Accepted			2021-06-18	
J	Nwachuku, EL; Puccio, AM; Adeboye, A; Chang, YF; Kim, J; Okonkwo, DO				Nwachuku, Enyinna L.; Puccio, Ava M.; Adeboye, Adeolu; Chang, Yue-Fang; Kim, Jinho; Okonkwo, David O.			Time course of cerebrospinal fluid inflammatory biomarkers and relationship to 6-month neurologic outcome in adult severe traumatic brain injury	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Traumatic brain injury; Biomarkers; Inflammatory cytokines; Therapeutic targets; Neurological outcome	INTERLEUKIN-6; CYTOKINES	Objective: Activation of the inflammatory cascade is a known pathophysiologic process in severe traumatic brain injury (TBI) with yet non-standardized scientific data regarding relationship to outcome. The understanding of the time course of expression of cerebrospinal fluid (CSF) biomarker levels following severe TBI is an important step toward using these biomarkers to measure injury severity and/or early response to therapeutic interventions. The objective of the current study is to report the time course and values of a battery of CSF inflammatory biomarkers following severe TBI in our reasonably sized patient cohort. Patients and methods: Our patient cohort consists of 32 consented patients, who met the study's inclusion criteria for data collection from 2000 to 2010. The time course and values of a battery of CSF biomarkers (IL-1 beta, IL-6, TNF-alpha, IFN-gamma, IL-12p70, IL-10, and IL-8) following severe TBI in this patient cohort was characterized. Additionally, the correlation of biomarker concentration with 6-month neurological outcome was assessed. Serial CSF sampling through an external ventricular drain was performed over the first five days following injury. Concentration of a panel of inflammatory biomarkers (IL-1 beta, IL-6, TNF-alpha, IFN-gamma, IL-12p70, IL-10, and IL-8) were evaluated using Meso Scale Discovery's Multi-Array technology. Glasgow Outcome Scale (GOS) score at six months following injury was dichotomized into poor outcome (GOS 1-3) and favorable outcome (GOS 4-5). Statistical analyses were performed using Kruskal-Wallis test and linear regression analysis. Results: The result shows that CSF concentrations of inflammatory biomarkers had a significant association with 6-month neurological outcome (p-values <= 0.05 for each marker), with the favorable outcome group having lower concentrations of these biomarkers on average, in comparison to the poor neurologic outcome group over the first five days after TBI. All inflammatory biomarkers decreased to normal levels by post-trauma day 5, except for IL-6 and IL-8. Upregulation and increased expression of key inflammatory markers following severe TBI were significant predictors of worse 6-month neurologic outcome. Additionally, post-trauma day 5 concentrations of IL-6 and IL-8 remained elevated over normal CSF values. Conclusion: The study shows that inflammatory biomarkers in CSF are potential biomarkers of injury severity and progression and/or recovery; they could prove beneficial in the future assessment of injury severity and response to therapy after severe TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Nwachuku, Enyinna L.; Puccio, Ava M.; Chang, Yue-Fang; Kim, Jinho; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA; [Adeboye, Adeolu] Quinnipiac Univ, Frank H Netter MD Sch Med, 300 Bassett Rd,MNH-211K, N Haven, CT 06473 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	Nwachukuel@upmc.edu; puccam@upmc.edu; Adeolu.adeboye@quinnipiac.edu; Changy@upmc.edu; Jinhokim@pitt.edu; Okonkwodo@upmc.edu			NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [2R25MH054318]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS030318]	This work was supported by an NIMH training grant (2R25MH054318) and NINDS (P01 NS030318). Authors have no conflict of interest to disclose.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Alexander GM, 2005, PAIN, V116, P213, DOI 10.1016/j.pain.2005.04.013; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Brisby H, 2002, EUR SPINE J, V11, P62, DOI 10.1007/s005860100306; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lindqvist D, 2009, BIOL PSYCHIAT, V66, P287, DOI 10.1016/j.biopsych.2009.01.030; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	20	36	36	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	OCT	2016	149						1	5		10.1016/j.clineuro.2016.06.009			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DW7JH	WOS:000383826500001	27450760				2021-06-18	
J	Reid, AY; Bragin, A; Giza, CC; Staba, RJ; Engel, J				Reid, Aylin Y.; Bragin, Anatol; Giza, Christopher C.; Staba, Richard J.; Engel, Jerome, Jr.			The progression of electrophysiologic abnormalities during epileptogenesis after experimental traumatic brain injury	EPILEPSIA			English	Article						Lateral fluid percussion injury; Seizure; Electroencephalography; Posttraumatic epilepsy; Biomarker	FLUID PERCUSSION INJURY; SPIKE-WAVE DISCHARGES; SPRAGUE-DAWLEY RATS; POSTTRAUMATIC EPILEPSY; ANIMAL-MODELS; SEIZURE; HIPPOCAMPAL; SEVERITY	Objective: Posttraumatic epilepsy (PTE) accounts for 20% of acquired epilepsies. Experimental models are important for studying epileptogenesis. We previously reported that repetitive high-frequency oscillations with spikes (rHFOSs) occur early after lateral fluid percussion injury (FPI) and may be a biomarker for PTE. The objective of this study was to use multiple electrodes in rat hippocampal and neocortical regions to describe the long-term electroencephalographic and behavioral evolution of rHFOSs and epileptic seizures after traumatic brain injury (TBI). Methods: Adult male rats underwent mild, moderate, or severe FPI or sham injury followed by video-electroencephalography (EEG) recordings with a combination of 16 neocortical and hippocampal electrodes at an early, intermediate, or late time-point after injury, up to 52 weeks. Recordings were analyzed for the presence of rHFOSs and seizures. Results: Analysis was done on 28 rats with FPI and 7 shams. Perilesional rHFOSs were recorded in significantly more rats after severe (70.3%) than mild (20%) injury or shams (14.3%). Frequency of occurrence was significantly highest in the early (10.8/h) versus late group (3.2/h). Late focal seizures originating from the same electrodes were recorded in significantly more rats in the late (87.5%) versus early period (22.2%), occurring almost exclusively in injured rats. Seizure duration increased significantly over time, averaging 19 s at the beginning of the early period and 27 s at the end of the late period. Seizure frequency also increased significantly over time, from 4.4 per week in the early group to 26.4 per week in the late group. Rarely, rats displayed early seizures or generalized seizures. Significance: FPI results in early rHFOSs and later spontaneous focal seizures arising from peri-lesional neocortex, supporting its use as a model for PTE. Epilepsy severity increased over time and was related to injury severity. The association between early rHFOSs and later focal seizures suggests that rHFOSs may be a potential noninvasive biomarker of PTE.	[Reid, Aylin Y.; Bragin, Anatol; Staba, Richard J.; Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Dept Neurosurg & Pediat Neurol, Los Angeles, CA USA; [Giza, Christopher C.; Engel, Jerome, Jr.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp UCLA, Los Angeles, CA USA; [Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA USA; [Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA	Reid, AY (corresponding author), Univ Hlth Network, Div Neurol, 399 Bathurst St,Off 5W-438, Toronto, ON M5G 1P7, Canada.	aylin.reid@utoronto.ca	Staba, Richard/AAN-3149-2021	Reid, Aylin Yasmin/0000-0001-6855-9669	Alberta Innovates-Health Solutions; UCLA BIRC [NS05489, NS027544, NS057420]; Child Neurology Foundation/Winokur Family Foundation; Today's and Tomorrow's Children Fund; Thrasher Research Foundation; Citizens United for Research in Epilepsy;  [NS065877];  [NS071048];  [NS033310];  [NS080181]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033310, R01NS071048, P20NS080181, R01NS027544, R01NS065877, R37NS033310, K02NS057420] Funding Source: NIH RePORTER	The authors would like to thank Mr. Joyel Almajano and Ms. Yan Cai for their technical support. AYR was supported by a Clinical Fellowship award from Alberta Innovates-Health Solutions. AB was supported by NS065877. CCG was supported by UCLA BIRC, NS05489, NS027544, NS057420, Child Neurology Foundation/Winokur Family Foundation, Today's and Tomorrow's Children Fund, and the Thrasher Research Foundation. RJS was supported by NS071048 and Citizens United for Research in Epilepsy. JE was supported by NS033310 and NS080181.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V110, P421; Bolkadze T, 2012, J NEUROTRAUM, V20, P789; Bragin A, 2016, EPILEPSIA, V57, P735, DOI 10.1111/epi.13359; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Eastman CL, 2015, EXP NEUROL, V264, P150, DOI 10.1016/j.expneurol.2014.12.010; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Langer M, 2011, NEUROPHARMACOLOGY, V61, P1033, DOI 10.1016/j.neuropharm.2011.06.015; LERNERNATOLI M, 1984, EXP NEUROL, V83, P1, DOI 10.1016/0014-4886(84)90040-2; Loscher W, 2015, EPILEPSY BEHAV, V52, P78, DOI 10.1016/j.yebeh.2015.08.037; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Prins ML, 2006, BRAIN RES DEV BRAIN, V95, P272; Rakhade SN, 2011, EPILEPSIA, V52, P753, DOI 10.1111/j.1528-1167.2011.02992.x; Rodgers KM, 2015, J NEUROSCI, V35, P9194, DOI 10.1523/JNEUROSCI.0919-15.2015; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	28	36	36	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	OCT	2016	57	10					1558	1567		10.1111/epi.13486			10	Clinical Neurology	Neurosciences & Neurology	EB8QV	WOS:000387656800005	27495360	Green Accepted			2021-06-18	
J	Baez, E; Echeverria, V; Cabezas, R; Avila-Rodriguez, M; Garcia-Segura, LM; Barreto, GE				Baez, Eliana; Echeverria, Valentina; Cabezas, Ricardo; Avila-Rodriguez, Marco; Miguel Garcia-Segura, Luis; Barreto, George E.			Protection by Neuroglobin expression in Brain Pathologies	FRONTIERS IN NEUROLOGY			English	Article						astrocytes; neuroglobin; mitochondria; neuroprotection; brain injury	OXYGEN-GLUCOSE DEPRIVATION; MOUSE CORTICAL-NEURONS; OXIDATIVE STRESS; PARKINSONS-DISEASE; MITOCHONDRIAL-FUNCTION; CEREBRAL MALARIA; UP-REGULATION; NITRIC-OXIDE; IN-VIVO; ASTROCYTE MITOCHONDRIA	Astrocytes play an important role in physiological, metabolic, and structural functions, and when impaired, they can be involved in various pathologies including Alzheimer, focal ischemic stroke, and traumatic brain injury. These disorders involve an imbalance in the blood flow and nutrients such as glucose and lactate, leading to biochemical and molecular changes that cause neuronal damage, which is followed by loss of cognitive and motor functions. Previous studies have shown that astrocytes are more resilient than neurons during brain insults as a consequence of their more effective antioxidant systems, transporters, and enzymes, which made them less susceptible to excitotoxicity. In addition, astrocytes synthesize and release different protective molecules for neurons, including neuroglobin, a member of the globin family of proteins. After brain injury, neuroglobin expression is induced in astrocytes. Since neuroglobin promotes neuronal survival, its increased expression in astrocytes after brain injury may represent an endogenous neuroprotective mechanism. Here, we review the role of neuroglobin in the central nervous system, its relationship with different pathologies, and the role of different factors that regulate its expression in astrocytes.	[Baez, Eliana; Cabezas, Ricardo; Avila-Rodriguez, Marco; Barreto, George E.] Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, Colombia; [Echeverria, Valentina] Univ San Sebastian, Fac Ciencias Salud, Concepcion, Chile; [Miguel Garcia-Segura, Luis] CSIC, Inst Cajal, Madrid, Spain; [Barreto, George E.] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile	Barreto, GE (corresponding author), Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, Colombia.; Garcia-Segura, LM (corresponding author), CSIC, Inst Cajal, Madrid, Spain.; Barreto, GE (corresponding author), Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile.	lmgs@cajal.csic.es; gsampaio@javeriana.edu.co	Garcia-Segura, Luis M/U-3711-2017; Barreto, George E./B-5747-2014; Barreto, George E./AAD-7420-2020; Valentina Echeverria Moran, BCh/E-7765-2013	Garcia-Segura, Luis M/0000-0002-2450-2916; Barreto, George E./0000-0002-6644-1971; Barreto, George E./0000-0002-6644-1971; Valentina Echeverria Moran, BCh/0000-0003-2393-5418; Avila-Rodriguez, Marco/0000-0003-4612-3236	Pontificia Universidad Javeriana	GB's work is supported by Pontificia Universidad Javeriana.	Acaz-Fonseca E, 2016, PROG NEUROBIOL, V144, P5, DOI 10.1016/j.pneurobio.2016.06.002; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Posada-Duque RA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00231; Antao ST, 2010, ANTIOXID REDOX SIGN, V13, P769, DOI 10.1089/ars.2009.2977; Rodriguez MA, 2014, J STEROID BIOCHEM, V144, P294, DOI 10.1016/j.jsbmb.2014.07.009; Avila-Rodriguez M, 2016, MOL CELL ENDOCRINOL, V433, P35, DOI 10.1016/j.mce.2016.05.024; Avivi A, 2010, P NATL ACAD SCI USA, V107, P21570, DOI 10.1073/pnas.1015379107; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Barreto GE, 2012, INT J NEUROSCI, V122, P223, DOI 10.3109/00207454.2011.648292; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bree AJ, 2009, AM J PHYSIOL-ENDOC M, V297, pE194, DOI 10.1152/ajpendo.91041.2008; Brittain T, 2010, IUBMB LIFE, V62, P878, DOI 10.1002/iub.405; Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burmester T, 2009, J EXP BIOL, V212, P1423, DOI 10.1242/jeb.000729; Cabezas R, 2016, MED CHEM, V12, P204, DOI 10.2174/1573406411666151019120444; Cabezas R, 2015, NEUROTOX RES, V27, P355, DOI 10.1007/s12640-014-9509-5; Cabezas R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00211; Cabezas R, 2012, NEUROSCI RES, V74, P80, DOI 10.1016/j.neures.2012.07.008; Jurado-Coronel JC, 2016, CURR PHARM DESIGN, V22, P1305, DOI 10.2174/138161282210160304112133; Cantinieaux D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069515; Carmody RN, 2009, J HUM EVOL, V57, P379, DOI 10.1016/j.jhevol.2009.02.011; Chen XM, 2015, NEUROSCI LETT, V606, P194, DOI 10.1016/j.neulet.2015.09.002; Chen XQ, 2005, GLIA, V50, P182, DOI 10.1002/glia.20147; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; De Marinis E, 2013, J NEUROENDOCRINOL, V25, P260, DOI 10.1111/jne.12007; De Marinis E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.30; De Marinis E, 2010, NEUROSIGNALS, V18, P223, DOI 10.1159/000323906; Dellavalle B, 2010, GLIA, V58, P1220, DOI 10.1002/glia.21002; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/BSE0470115, 10.1042/bse0470115]; Dugan LL, 2004, J BIOENERG BIOMEMBR, V36, P317, DOI 10.1023/B:JOBB.0000041761.61554.44; Duong TTH, 2009, J NEUROCHEM, V108, P1143, DOI 10.1111/j.1471-4159.2008.05846.x; Fago A, 2004, J BIOL CHEM, V279, P44417, DOI 10.1074/jbc.M407126200; Fago A, 2006, J INORG BIOCHEM, V100, P1339, DOI 10.1016/j.jinorgbio.2006.03.009; Fuchs C, 2006, CYTOGENET GENOME RES, V112, P296, DOI 10.1159/000089884; Gotting M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12284; Gorr TA, 2011, ACTA PHYSIOL, V202, P563, DOI 10.1111/j.1748-1716.2010.02205.x; Gouix E, 2014, PHARMACOL RES, V87, P8, DOI 10.1016/j.phrs.2014.06.002; Greenamyre JT, 2003, PARKINSONISM RELAT D, V9, pS59, DOI 10.1016/S1353-8020(03)00023-3; Greenberg DA, 2008, CURR OPIN PHARMACOL, V8, P20, DOI 10.1016/j.coph.2007.09.003; Guglielmotto M, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00147; Guo Y, 2015, BRAIN RES, V1600, P1, DOI 10.1016/j.brainres.2014.12.046; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hu Y, 2015, INT J MOL SCI, V16, P24895, DOI 10.3390/ijms161024895; Hundahl CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034462; Hundahl CA, 2010, BRAIN RES, V1331, P58, DOI 10.1016/j.brainres.2010.03.056; Iglesias J, 2017, MOL NEUROBIOL, V54, P2518, DOI 10.1007/s12035-016-9833-2; Jayaraman T, 2011, J BIOL CHEM, V286, P42679, DOI 10.1074/jbc.M111.271973; Jin KL, 2012, NEUROSCI LETT, V519, P47, DOI 10.1016/j.neulet.2012.05.018; Jin KL, 2011, PHARMACOLOGY, V87, P81, DOI 10.1159/000322998; Jin KL, 2010, STROKE, V41, P557, DOI 10.1161/STROKEAHA.109.567149; Jing L, 2015, INT J BIOL SCI, V11, P59, DOI 10.7150/ijbs.10174; Khan AA, 2008, FASEB J, V22, P1737, DOI 10.1096/fj.07-100784; Kubik LL, 2015, TOXICOL SCI, V144, P7, DOI 10.1093/toxsci/kfu254; Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x; Lechauve C, 2013, BBA-PROTEINS PROTEOM, V1834, P1772, DOI 10.1016/j.bbapap.2013.04.014; Lechauve C, 2009, J MOL BIOL, V388, P968, DOI 10.1016/j.jmb.2009.03.047; LeDoux SP, 2007, NEUROSCIENCE, V145, P1249, DOI 10.1016/j.neuroscience.2006.10.002; Lee MC, 2010, NEURON, V66, P859, DOI 10.1016/j.neuron.2010.05.015; Lee VY, 2002, J BIOL CHEM, V277, P16067, DOI 10.1074/jbc.M111177200; Li Y, 2016, J MOL NEUROSCI, V58, P28, DOI 10.1007/s12031-015-0645-z; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Lin Y, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-110; Liu JX, 2009, J NEUROSCI RES, V87, P164, DOI 10.1002/jnr.21826; Liu N, 2013, NEUROSCI LETT, V534, P333, DOI 10.1016/j.neulet.2012.11.025; Liu ZF, 2015, INT J CLIN EXP MED, V8, P5351; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magistretti P.J., 2002, NEUROPSYCHOPHARMACOL; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Medina-Ceja L, 2007, REV NEUROLOGIA, V45, P341, DOI 10.33588/rn.4506.2005647; Meir JU, 2009, J EXP BIOL, V212, P3330, DOI 10.1242/jeb.033761; Mohideen SS, 2013, J OCCUP HEALTH, V55, P29, DOI 10.1539/joh.12-0118-OA; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Ohsumi A, 2010, J NEUROTRAUM, V27, P1255, DOI 10.1089/neu.2009.1234; Oliveira K, 2015, METAB BRAIN DIS, V30, P1401, DOI 10.1007/s11011-015-9718-5; Patel VP, 2011, INT J CLIN EXP PATHO, V4, P215; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Picotti P, 2009, FEBS J, V276, P7027, DOI 10.1111/j.1742-4658.2009.07416.x; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Purushothuman S, 2015, BRAIN RES, V1601, P52, DOI 10.1016/j.brainres.2015.01.003; Qin HJ, 2012, BRAIN TUMOR PATHOL, V29, P10, DOI 10.1007/s10014-011-0066-9; Qiu Xin Yao, 2014, Biomol Concepts, V5, P195, DOI 10.1515/bmc-2014-0011; Quijano María Cristina, 2012, Rev. Cienc. Salud, V10, P21; Raida Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076565; Raida Zindy, 2012, Exp Transl Stroke Med, V4, P15, DOI 10.1186/2040-7378-4-15; Rappold PM, 2010, NEUROTHERAPEUTICS, V7, P413, DOI 10.1016/j.nurt.2010.07.001; Raychaudhuri S, 2008, BIOPHYS J, V95, P3559, DOI 10.1529/biophysj.108.135483; Raychaudhuri S, 2010, APOPTOSIS, V15, P401, DOI 10.1007/s10495-009-0436-5; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Reuss S, 2016, MOL NEUROBIOL, V53, P1461, DOI 10.1007/s12035-014-9082-1; Schneuer M, 2012, NEUROSCIENCE, V223, P35, DOI 10.1016/j.neuroscience.2012.07.052; Shang AJ, 2015, MOL MED REP, V12, P1693, DOI 10.3892/mmr.2015.3593; Sharlin DS, 2010, J NEUROENDOCRINOL, V22, P153, DOI 10.1111/j.1365-2826.2009.01947.x; Shelby M, 2004, REPROD TOXICOL, V18, P303, DOI 10.1016/j.reprotox.2003.10.013; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Simon R, 2013, NEUROSCI LETT, V549, P1, DOI 10.1016/j.neulet.2013.05.016; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020420; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song X, 2014, INT J CLIN EXP PATHO, V7, P2163; Steele ML, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.09.018; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Taylor JM, 2014, NEUROSCI LETT, V577, P125, DOI 10.1016/j.neulet.2014.03.012; Tiso M, 2011, J BIOL CHEM, V286, P18277, DOI 10.1074/jbc.M110.159541; Toro-Urrego N, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00152; Torrente D, 2014, HUM EXP TOXICOL, V33, P673, DOI 10.1177/0960327113509659; Van Leuven W, 2013, BBA-PROTEINS PROTEOM, V1834, P1764, DOI 10.1016/j.bbapap.2013.04.015; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Wang TH, 2015, CLIN TOXICOL, V53, P823, DOI 10.3109/15563650.2015.1064939; Watanabe S, 2012, J BIOL CHEM, V287, P30128, DOI 10.1074/jbc.M112.373381; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011; Woo SK, 2012, J CEREBR BLOOD F MET, V32, P525, DOI 10.1038/jcbfm.2011.159; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yu Z, 2012, NEUROSCIENCE, V218, P235, DOI 10.1016/j.neuroscience.2012.05.054; Yu Z, 2009, NEUROSCIENCE, V162, P396, DOI 10.1016/j.neuroscience.2009.04.055; Yu ZL, 2014, NEUROSCIENCE, V270, P158, DOI 10.1016/j.neuroscience.2014.04.013; Yu ZY, 2013, NEUROBIOL DIS, V56, P95, DOI 10.1016/j.nbd.2013.04.015; Yu ZY, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/756989; Yu ZY, 2012, INT J MOL SCI, V13, P6995, DOI 10.3390/ijms13066995; Yu ZY, 2009, NEUROL RES, V31, P122, DOI 10.1179/174313209X389866; Yue X, 2014, NEUROSCIENCE, V258, P385, DOI 10.1016/j.neuroscience.2013.11.038; Zhao J, 2011, SEMIN CELL DEV BIOL, V22, P705, DOI 10.1016/j.semcdb.2011.09.012; Zhao S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-67; Zhong ZX, 2013, TOXICOLOGY, V306, P16, DOI 10.1016/j.tox.2013.01.022; Zhou D, 2008, EUR J PEDIATR, V167, P1169, DOI 10.1007/s00431-007-0653-2; Zou J, 2010, NEUROCHEM INT, V56, P577, DOI 10.1016/j.neuint.2009.12.021	138	36	36	0	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	SEP 12	2016	7								146	10.3389/fneur.2016.00146			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DV6AT	WOS:000383013600002	27672379	DOAJ Gold, Green Published			2021-06-18	
J	Bouzat, P; Almeras, L; Manhes, P; Sanders, L; Levrat, A; David, JS; Cinotti, R; Chabanne, R; Gloaguen, A; Bobbia, X; Thoret, S; Oujamaa, L; Bosson, JL; Payen, JF				Bouzat, Pierre; Almeras, Luc; Manhes, Pauline; Sanders, Laurence; Levrat, Albrice; David, Jean-Stephane; Cinotti, Raphael; Chabanne, Russel; Gloaguen, Aurelie; Bobbia, Xavier; Thoret, Sophie; Oujamaa, Lydia; Bosson, Jean-Luc; Payen, Jean-Francois		TBI-TCD Study Investigators	Transcranial Doppler to Predict Neurologic Outcome after Mild to Moderate Traumatic Brain Injury	ANESTHESIOLOGY			English	Article							HEAD-INJURY; INTRACRANIAL-PRESSURE; PULSATILITY INDEX; FLOW-VELOCITY; BLOOD-FLOW; DETERIORATION	Background: To assess the performance of transcranial Doppler (TCD) in predicting neurologic worsening after mild to moderate traumatic brain injury. Methods: The authors conducted a prospective observational study across 17 sites. TCD was performed upon admission in 356 patients (Glasgow Coma Score [GCS], 9 to 15) with mild lesions on cerebral computed tomography scan. Normal TCD was defined as a pulsatility index of less than 1.25 and diastolic blood flow velocity higher than 25 cm/s in the two middle cerebral arteries. The primary endpoint was secondary neurologic deterioration on day 7. Results: Twenty patients (6%) developed secondary neurologic deterioration within the first posttraumatic week. TCD thresholds had 80% sensitivity (95% CI, 56 to 94%) and 79% specificity (95% CI, 74 to 83%) to predict neurologic worsening. The negative predictive values and positive predictive values of TCD were 98% (95% CI, 96 to 100%) and 18% (95% CI, 11 to 28%), respectively. In patients with minor traumatic brain injury (GCS, 14 to 15), the sensitivity and specificity of TCD were 91% (95% CI, 59 to 100%) and 80% (95% CI, 75 to 85%), respectively. The area under the receiver operating characteristic curve of a multivariate predictive model including age and GCS was significantly improved with the adjunction of TCD. Patients with abnormal TCD on admission (n = 86 patients) showed a more altered score for the disability rating scale on day 28 compared to those with normal TCD (n = 257 patients). Conclusions: TCD measurements upon admission may provide additional information about neurologic outcome after mild to moderate traumatic brain injury. This technique could be useful for in-hospital triage in this context.	[Bouzat, Pierre; Almeras, Luc; Manhes, Pauline; Oujamaa, Lydia; Payen, Jean-Francois] CHU Grenoble Alpes, Pole Anesthesie Reanimat, Grenoble, France; [Bouzat, Pierre; Payen, Jean-Francois] INSERM, Grenoble, France; [Bouzat, Pierre; Payen, Jean-Francois] Univ Grenoble Alpes, Grenoble Inst Neurosci, Grenoble, France; [Manhes, Pauline; Thoret, Sophie; Bosson, Jean-Luc] CHU Grenoble, Ctr Invest Clin, Grenoble, France; [Sanders, Laurence] CHU Grenoble, Serv Accueil Urgences Chirurg, Grenoble, France; [Levrat, Albrice] Ctr Hosp Annecy Genevois, Serv Reanimat, Annecy, France; [David, Jean-Stephane] Hosp Civils Lyon, Dept Anesthesie Reanimat, Lyon, France; [Cinotti, Raphael] CHU Nantes, Dept Anesthesie Reanimat, Nantes, France; [Chabanne, Russel] CHU Clermont Ferrand, Dept Anesthesie Reanimat, Clermont Ferrand, France; [Gloaguen, Aurelie] CHU Dijon, Dept Med Urgence SAMU SMUR, Dijon, France; [Bobbia, Xavier] CHU Nimes, Dept Anesthesie Reanimat Urgences, Nimes, France	Bouzat, P (corresponding author), CHU Grenoble, Pole Anesthesie Reanimat, BP 217, F-38000 Grenoble, France.	pbouzat@chu-grenoble.fr	David, Jean Stephane/H-9399-2019; Payen, Jean-Francois/L-6667-2014; Bouzat, Pierre/AAC-4105-2019; Bouzat, Pierre/L-6881-2014; bosson, jean-luc/AAP-5163-2020; Chabanne, Russell/AAI-2180-2019	David, Jean Stephane/0000-0001-6274-7044; Bouzat, Pierre/0000-0003-4667-6738; bosson, jean-luc/0000-0003-0967-6026; 	Programme hospitalier de recherche Clinique interregional, Interregion Sud-est, France	Support was provided solely from institutional sources (Programme hospitalier de recherche Clinique interregional 2010, Interregion Sud-est, France).	AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Ahmad M, 2013, INTENS CARE MED, V39, P1150, DOI 10.1007/s00134-013-2885-0; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P153, DOI 10.1097/MCC.0000000000000071; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Bouzat P, 2011, NEUROSURGERY, V68, P1603, DOI 10.1227/NEU.0b013e31820cd43e; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Czosnyka M, 1996, J NEUROSURG, V84, P79, DOI 10.3171/jns.1996.84.1.0079; Davis DP, 2007, J TRAUMA, V62, P277, DOI 10.1097/TA.0b013e31802ef4a3; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Keller T, 2009, NEW ENGL J MED, V361, P868, DOI 10.1056/NEJMoa0903515; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Owaidah T, 2014, THROMB J, V12, DOI 10.1186/s12959-014-0028-7; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42	24	36	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2016	125	2					346	354		10.1097/ALN.0000000000001165			9	Anesthesiology	Anesthesiology	DY3VC	WOS:000385022200014	27224640				2021-06-18	
J	Multani, N; Goswami, R; Khodadadi, M; Ebraheem, A; Davis, KD; Tator, CH; Wennberg, R; Mikulis, DJ; Ezerins, L; Tartaglia, MC				Multani, Namita; Goswami, Ruma; Khodadadi, Mozhgan; Ebraheem, Ahmed; Davis, Karen D.; Tator, Charles H.; Wennberg, Richard; Mikulis, David J.; Ezerins, Leo; Tartaglia, Maria Carmela			The association between white-matter tract abnormalities, and neuropsychiatric and cognitive symptoms in retired professional football players with multiple concussions	JOURNAL OF NEUROLOGY			English	Article						Sport-related concussion; Repetitive mild traumatic brain injury; Diffusion tensor imaging; Superior longitudinal fasciculus; Visuospatial function	CHRONIC TRAUMATIC ENCEPHALOPATHY; BRAIN-INJURY; MEMORY COMPLAINTS; AXONAL INJURY; HEAD-INJURY; DIFFUSION; MRI; IMPAIRMENT; SPORTS; TRACTOGRAPHY	Retired professional athletes, who have suffered repetitive concussions, report symptoms of depression, anxiety, and memory impairment over time. Moreover, recent imaging data suggest chronic white-matter tract deterioration in sport-related concussion. The aim of this study is to evaluate the impact of repetitive concussions in retired professional football players on white-matter tracts, and relate these changes to neuropsychological function. All subjects (18 retired professional football players and 17 healthy controls) underwent imaging, neuropsychological assessment, and reported on concussion-related symptoms. Whole brain tract-based spatial statistics analysis revealed increased axial diffusivity in the right hemisphere of retired players in the (1) superior longitudinal fasciculus (SLF), (2) corticospinal tract, and (3) anterior thalamic radiations, suggesting chronic axonal degeneration in these tracts. Moreover, retired players report significantly higher neuropsychiatric and cognitive symptoms than healthy controls, and worsening of these symptoms since their last concussion. Loss of integrity in the right SLF significantly correlated with participants' visual learning ability. In sum, these results suggest that repetitive concussions in retired professional football players are associated with focal white-matter tract abnormalities that could explain some of the neuropsychiatric symptoms and cognitive deficits experienced by these retired athletes.	[Multani, Namita; Goswami, Ruma; Khodadadi, Mozhgan; Ebraheem, Ahmed; Davis, Karen D.; Tator, Charles H.; Wennberg, Richard; Mikulis, David J.; Ezerins, Leo; Tartaglia, Maria Carmela] Toronto Western Hosp, Tanz Ctr Res Neurodegenerat Dis, Memory Clin, Canadian Sports Concuss Project, 399 Bathurst St,West Wing 5-449, Toronto, ON M5T 2S8, Canada; [Multani, Namita; Tartaglia, Maria Carmela] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, 60 Leonard Ave, Toronto, ON M5T 2S8, Canada; [Goswami, Ruma; Davis, Karen D.; Tator, Charles H.; Mikulis, David J.] Univ Hlth Network, Div Brain Imaging & Behav Syst Neurosci, Toronto Western Hosp, Toronto Western Res Inst, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Davis, Karen D.; Tator, Charles H.; Mikulis, David J.] Univ Toronto, Inst Med Sci, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada; [Davis, Karen D.; Tator, Charles H.] Univ Toronto, Dept Surg, 149 Coll St, Toronto, ON M5T 1P5, Canada; [Tator, Charles H.] Univ Hlth Network, Toronto Western Hosp, Div Neurosurg, Krembil Neurosci Ctr, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Multani, Namita; Wennberg, Richard; Tartaglia, Maria Carmela] Univ Hlth Network, Toronto Western Hosp, Div Neurol, Krembil Neurosci Ctr, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Mikulis, David J.] Univ Hlth Network, Toronto Western Hosp, Dept Med Imaging, 399 Bathurst St, Toronto, ON M5T 2S8, Canada	Tartaglia, MC (corresponding author), Toronto Western Hosp, Tanz Ctr Res Neurodegenerat Dis, Memory Clin, Canadian Sports Concuss Project, 399 Bathurst St,West Wing 5-449, Toronto, ON M5T 2S8, Canada.; Tartaglia, MC (corresponding author), Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, 60 Leonard Ave, Toronto, ON M5T 2S8, Canada.; Tartaglia, MC (corresponding author), Univ Hlth Network, Toronto Western Hosp, Div Neurol, Krembil Neurosci Ctr, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.	carmela.tartaglia@uhn.ca	Mikulis, David J/H-5167-2019	Mikulis, David/0000-0003-3956-0892	PSI Foundation; Canadian Sports Concussion Project, Krembil Neuroscience Centre, Toronto Western Hospital (Toronto General & Western Hospital Foundation)	PSI Foundation and the Canadian Sports Concussion Project, Krembil Neuroscience Centre, Toronto Western Hospital (Toronto General & Western Hospital Foundation).	Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bendlin BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037720; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chechlacz M, 2015, J NEUROSCI, V35, P10647, DOI 10.1523/JNEUROSCI.0210-15.2015; Ciccarelli O, 2008, LANCET NEUROL, V7, P715, DOI 10.1016/S1474-4422(08)70163-7; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hoeft F, 2007, J NEUROSCI, V27, P11960, DOI 10.1523/JNEUROSCI.3591-07.2007; Holdnack H, 2001, WECHSLER TEST ADULT; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jessen F, 2014, ALZHEIMERS DEMENT, V10, P76, DOI 10.1016/j.jalz.2012.09.017; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kryscio RJ, 2014, NEUROLOGY, V83, P1359, DOI 10.1212/WNL.0000000000000856; Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186; Mamah D, 2010, PSYCHIAT RES-NEUROIM, V183, P144, DOI 10.1016/j.pscychresns.2010.04.013; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Mitchell AJ, 2014, ACTA PSYCHIAT SCAND, V130, P439, DOI 10.1111/acps.12336; Mori S., 2005, MRI ATLAS HUMAN WHIT; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Reisberg B, 2010, ALZHEIMERS DEMENT, V6, P11, DOI 10.1016/j.jalz.2009.10.002; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Thiebaut de Schotten M, 2011, NAT NEUROSCI, V14, P1245, DOI 10.1038/nn.2905; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; van der Flier WM, 2004, J NEUROL, V251, P671, DOI 10.1007/s00415-004-0390-7; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	57	36	37	0	36	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	JUL	2016	263	7					1332	1341		10.1007/s00415-016-8141-0			10	Clinical Neurology	Neurosciences & Neurology	DQ4PH	WOS:000379185300010	27142715				2021-06-18	
J	Cardim, D; Robba, C; Donnelly, J; Bohdanowicz, M; Schmidt, B; Damian, M; Varsos, GV; Liu, XY; Cabeleira, M; Frigieri, G; Cabella, B; Smielewski, P; Mascarenhas, S; Czosnyka, M				Cardim, Danilo; Robba, Chiara; Donnelly, Joseph; Bohdanowicz, Michal; Schmidt, Bernhard; Damian, Maxwell; Varsos, Georgios V.; Liu, Xiuyun; Cabeleira, Manuel; Frigieri, Gustavo; Cabella, Brenno; Smielewski, Peter; Mascarenhas, Sergio; Czosnyka, Marek			Prospective Study on Noninvasive Assessment of Intracranial Pressure in Traumatic Brain-Injured Patients: Comparison of Four Methods	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; noninvasive ICP monitoring; transcranial Doppler	CEREBRAL PERFUSION-PRESSURE; TRANSCRANIAL DOPPLER SONOGRAPHY; CRITICAL CLOSING PRESSURE; PULSATILITY INDEX; CLINICAL-EXPERIENCE; BLOOD-FLOW; ICP; ULTRASONOGRAPHY; PREDICTION; DYNAMICS	Elevation of intracranial pressure (ICP) may occur in many diseases, and therefore the ability to measure it noninvasively would be useful. Flow velocity signals from transcranial Doppler (TCD) have been used to estimate ICP; however, the relative accuracy of these methods is unclear. This study aimed to compare four previously described TCD-based methods with directly measured ICP in a prospective cohort of traumatic brain-injured patients. Noninvasive ICP (nICP) was obtained using the following methods: 1) a mathematical "black-box" model based on interaction between TCD and arterial blood pressure (nICP_BB); 2) based on diastolic flow velocity (nICP_FVd); 3) based on critical closing pressure (nICP_CrCP); and 4) based on TCD-derived pulsatility index (nICP_PI). In time domain, for recordings including spontaneous changes in ICP greater than 7 mm Hg, nICP_PI showed the best correlation with measured ICP (R = 0.61). Considering every TCD recording as an independent event, nICP_BB generally showed to be the best estimator of measured ICP (R = 0.39; p < 0.05; 95% confidence interval [CI] = 9.94 mm Hg; area under the curve [AUC] = 0.66; p < 0.05). For nICP_FVd, although it presented similar correlation coefficient to nICP_BB and marginally better AUC (0.70; p < 0.05), it demonstrated a greater 95% CI for prediction of ICP (14.62 mm Hg). nICP_CrCP presented a moderate correlation coefficient (R = 0.35; p < 0.05) and similar 95% CI to nICP_BB (9.19 mm Hg), but failed to distinguish between normal and raised ICP (AUC = 0.64; p > 0.05). nICP_PI was not related to measured ICP using any of the above statistical indicators. We also introduced a new estimator (nICP_Av) based on the average of three methods (nICP_BB, nICP_FVd, and nICP_CrCP), which overall presented improved statistical indicators (R = 0.47; p < 0.05; 95% CI = 9.17 mm Hg; AUC = 0.73; p < 0.05). nICP_PI appeared to reflect changes in ICP in time most accurately. nICP_BB was the best estimator for ICP "as a number." nICP_Av demonstrated to improve the accuracy of measured ICP estimation.	[Cardim, Danilo; Donnelly, Joseph; Varsos, Georgios V.; Liu, Xiuyun; Cabeleira, Manuel; Cabella, Brenno; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Robba, Chiara] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; [Bohdanowicz, Michal; Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Schmidt, Bernhard] Univ Hosp Chemnitz, Dept Neurol, Chemnitz, Germany; [Damian, Maxwell] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Neurol, Cambridge, England; [Frigieri, Gustavo; Mascarenhas, Sergio] Univ Sao Paulo, Phys Inst Sao Carlos, Sao Carlos, SP, Brazil	Cardim, D (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	dac69@cam.ac.uk	Robba, Chiara/AAS-7421-2020; Donnelly, Joseph/N-6803-2019; Liu, Xiuyun/V-4427-2017; Cardim, Danilo Augusto/B-8447-2012; Donnelly, Joseph/E-9235-2018; Cabella, Brenno C.T./G-6169-2012	Donnelly, Joseph/0000-0002-6502-8069; Liu, Xiuyun/0000-0001-9540-4865; Cardim, Danilo Augusto/0000-0002-9261-1321; Donnelly, Joseph/0000-0002-6502-8069; Cabella, Brenno C.T./0000-0003-2214-645X; Smielewski, Peter/0000-0001-5096-3938; czosnyka, marek/0000-0003-2446-8006	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390] Funding Source: Medline		Alperin NJ, 2000, RADIOLOGY, V217, P877, DOI 10.1148/radiology.217.3.r00dc42877; Asil T, 2003, J ULTRAS MED, V22, P1049, DOI 10.7863/jum.2003.22.10.1049; Bartusis L, 2012, ELEKTRON ELEKTROTECH, V122, P45, DOI 10.5755/j01.eee.122.6.1194; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Budohoski Karol P, 2012, Acta Neurochir Suppl, V114, P121, DOI 10.1007/978-3-7091-0956-4_22; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; CZOSNYKA M, 1994, ULTRASOUND MED BIOL, V20, P391, DOI 10.1016/0301-5629(94)90008-6; Czosnyka M, 1996, J NEUROSURG, V84, P79, DOI 10.3171/jns.1996.84.1.0079; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; DAHL A, 1992, STROKE, V23, P15, DOI 10.1161/01.STR.23.1.15; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; Eide PK, 2010, J NEUROSURG, V113, P1317, DOI 10.3171/2010.7.JNS10483; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Frank AM, 2000, ZBL NEUROCHIR, V61, P177, DOI 10.1055/s-2000-15597; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; HANLO PW, 1995, ULTRASOUND MED BIOL, V21, P613, DOI 10.1016/0301-5629(94)00147-6; Hosmer D, 1989, APPL LOGISTIC REGRES; Jones HA, 2009, NURS CRIT CARE, V14, P303, DOI 10.1111/j.1478-5153.2009.00352.x; Kashif FM, 2008, COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2, P369, DOI 10.1109/CIC.2008.4749055; Kashif FM, 2012, SCI TRANSL MED, V129, P44; KASUGA Y, 1987, J NEUROSURG, V66, P907, DOI 10.3171/jns.1987.66.6.0907; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Marmarelis P. Z., 1978, ANAL PHYSL SYSTEM; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Michaeli D, 2002, J NEUROSURG, V96, P1132, DOI 10.3171/jns.2002.96.6.1132; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; NICHOL J, 1951, AM J PHYSIOL, V164, P330; Popovic Djordje, 2009, Recent Patents on Biomedical Engineering, V2, P165, DOI 10.2174/1874764710902030165; Prunet B, 2012, AM J EMERG MED, V30, P936, DOI 10.1016/j.ajem.2011.05.005; Puppo Corina, 2012, Acta Neurochir Suppl, V114, P283, DOI 10.1007/978-3-7091-0956-4_55; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; Ragauskas A, 2003, MED ENG PHYS, V25, P667, DOI 10.1016/S1350-4533(03)00082-1; REID A, 1989, J NEUROL NEUROSUR PS, V52, P610, DOI 10.1136/jnnp.52.5.610; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Schmidt B, 1997, STROKE, V28, P2465, DOI 10.1161/01.STR.28.12.2465; Schmidt B, 2000, J NEUROSURG, V92, P793, DOI 10.3171/jns.2000.92.5.0793; Schmidt Bernhard, 2002, Eur J Ultrasound, V16, P37, DOI 10.1016/S0929-8266(02)00044-7; Shimbles S, 2005, PHYSIOL MEAS, V26, P1085, DOI 10.1088/0967-3334/26/6/017; Steinbach GC, 2005, AVIAT SPACE ENVIR MD, V76, P85; Ueno T, 1998, ACT NEUR S, V71, P66; Varsos GV, 2015, J NEUROSURG, V123, P638, DOI 10.3171/2014.10.JNS14613; Varsos GV, 2013, J CEREBR BLOOD F MET, V33, P235, DOI 10.1038/jcbfm.2012.161; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Wakerley B, 2014, J NEUROIMAGING, V24, P302, DOI 10.1111/j.1552-6569.2012.00745.x; Wakerley BR, 2015, J NEUROIMAGING, V25, P111, DOI 10.1111/jon.12100; Zhao YL, 2005, ACTA NEUROCHIR SUPPL, V95, P351	49	36	38	6	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					792	802		10.1089/neu.2015.4134			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900010	26414916	Green Published			2021-06-18	
J	Janova, H; Bottcher, C; Holtman, IR; Regen, T; van Rossum, D; Gotz, A; Ernst, AS; Fritsche, C; Gertig, U; Saiepour, N; Gronke, K; Wrzos, C; Ribes, S; Rolfes, S; Weinstein, J; Ehrenreich, H; Pukrop, T; Kopatz, J; Stadelmann, C; Salinas-Riester, G; Weber, MS; Prinz, M; Bruck, W; Eggen, BJL; Boddeke, HWGM; Priller, J; Hanisch, UK				Janova, Hana; Boettcher, Chotima; Holtman, Inge R.; Regen, Tommy; van Rossum, Denise; Goetz, Alexander; Ernst, Anne-Sophie; Fritsche, Christin; Gertig, Ulla; Saiepour, Nasrin; Gronke, Konrad; Wrzos, Claudia; Ribes, Sandra; Rolfes, Simone; Weinstein, Jonathan; Ehrenreich, Hannelore; Pukrop, Tobias; Kopatz, Jens; Stadelmann, Christine; Salinas-Riester, Gabriela; Weber, Martin S.; Prinz, Marco; Brueck, Wolfgang; Eggen, Bart J. L.; Boddeke, Hendrikus W. G. M.; Priller, Josef; Hanisch, Uwe-Karsten			CD14 is a key organizer of microglial responses to CNS infection and injury	GLIA			English	Article						chemokines; cytokines; inflammation; monocytes; neutrophils; Toll-like receptor; damage	RECEPTOR 4; I INTERFERON; BRAIN; CELLS; LPS; INFLAMMATION; ACTIVATION; LIPOPOLYSACCHARIDE; RECRUITMENT; MACROPHAGES	Microglia, innate immune cells of the CNS, sense infection and damage through overlapping receptor sets. Toll-like receptor (TLR) 4 recognizes bacterial lipopolysaccharide (LPS) and multiple injury-associated factors. We show that its co-receptor CD14 serves three non-redundant functions in microglia. First, it confers an up to 100-fold higher LPS sensitivity compared to peripheral macrophages to enable efficient proinflammatory cytokine induction. Second, CD14 prevents excessive responses to massive LPS challenges via an interferon -mediated feedback. Third, CD14 is mandatory for microglial reactions to tissue damage-associated signals. In mice, these functions are essential for balanced CNS responses to bacterial infection, traumatic and ischemic injuries, since CD14 deficiency causes either hypo- or hyperinflammation, insufficient or exaggerated immune cell recruitment or worsened stroke outcomes. While CD14 orchestrates functions of TLR4 and related immune receptors, it is itself regulated by TLR and non-TLR systems to thereby fine-tune microglial damage-sensing capacity upon infectious and non-infectious CNS challenges.	[Janova, Hana; Regen, Tommy; van Rossum, Denise; Goetz, Alexander; Ernst, Anne-Sophie; Fritsche, Christin; Gertig, Ulla; Saiepour, Nasrin; Gronke, Konrad; Wrzos, Claudia; Ribes, Sandra; Stadelmann, Christine; Weber, Martin S.; Brueck, Wolfgang; Hanisch, Uwe-Karsten] Univ Gottingen, Inst Neuropathol, Robert Koch Str 40, D-37075 Gottingen, Germany; [Boettcher, Chotima; Rolfes, Simone; Priller, Josef] Charite, Dept Neuropsychiat, D-10117 Berlin, Germany; [Holtman, Inge R.; Rolfes, Simone; Priller, Josef] Charite, Lab Mol Psychiat, D-10117 Berlin, Germany; [Holtman, Inge R.; Eggen, Bart J. L.; Boddeke, Hendrikus W. G. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Sect Med Physiol, NL-9713 AW Groningen, Netherlands; [Regen, Tommy] Johannes Gutenberg Univ Mainz, Inst Mol Med, D-55131 Mainz, Germany; [van Rossum, Denise] Sartorius Stedim Biotech GmbH, D-37079 Gottingen, Germany; [Weinstein, Jonathan] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Ehrenreich, Hannelore] Max Planck Inst Expt Med, Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany; [Pukrop, Tobias] Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; [Kopatz, Jens] Univ Bonn, Dept Neural Regenerat, Inst Reconstruct Neurobiol, D-53127 Bonn, Germany; [Salinas-Riester, Gabriela] Univ Gottingen, Transcriptome Anal Lab, D-37077 Gottingen, Germany; [Prinz, Marco] Univ Freiburg, Inst Neuropathol, D-79106 Freiburg, Germany; [Prinz, Marco] Univ Freiburg, BIOSS Ctr Biol Signaling, D-79106 Freiburg, Germany; [Hanisch, Uwe-Karsten] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04103 Leipzig, Germany	Janova, H (corresponding author), Univ Gottingen, Inst Neuropathol, Robert Koch Str 40, D-37075 Gottingen, Germany.	janova.hana@seznam.cz	Holtman, Inge R./AAE-8655-2020	Holtman, Inge R./0000-0001-9752-4756; Stadelmann, Christine/0000-0003-1766-5458; Weinstein, Jonathan/0000-0001-6080-9758; Priller, Josef/0000-0001-7596-0979; Ehrenreich, Hannelore/0000-0001-8371-5711; Ernst, Anne-Sophie/0000-0003-1483-5781; Regen, Tommy/0000-0002-7275-3330	German Research Council (DFG)German Research Foundation (DFG) [SFB/TRR43, FOR1336]; NeuroCure; DZNEHelmholtz Association; BIH; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076620, K02NS065008] Funding Source: NIH RePORTER	German Research Council (DFG, SFB/TRR43, UKH, JP, WB; FOR1336, JP, MP, UKH; NeuroCure, DZNE, and BIH, JP.	Asea A, 2000, NAT MED, V6, P435; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Cauwels A, 1999, J IMMUNOL, V162, P4762; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; Esen N, 2014, GLIA, V62, P1452, DOI 10.1002/glia.22692; Gangloff SC, 2005, J IMMUNOL, V175, P3940, DOI 10.4049/jimmunol.175.6.3940; Garin A, 2010, IMMUNITY, V33, P84, DOI 10.1016/j.immuni.2010.07.005; Gay NJ, 2014, NAT REV IMMUNOL, V14, P546, DOI 10.1038/nri3713; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim S, 2013, MOL MED, V19, P88, DOI 10.2119/molmed.2012.00306; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Pagano M, 2011, FRONT BIOSCI-LANDMRK, V16, P698, DOI 10.2741/3713; Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011; Regen T, 2011, BRAIN BEHAV IMMUN, V25, P957, DOI 10.1016/j.bbi.2010.10.009; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sahay B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000687; Scheffel J, 2012, GLIA, V60, P1930, DOI 10.1002/glia.22409; Scheibe F, 2012, J CEREBR BLOOD F MET, V32, P1578, DOI 10.1038/jcbfm.2012.55; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Trotta T, 2014, J NEUROIMMUNOL, V268, P1, DOI 10.1016/j.jneuroim.2014.01.014; van Rossum D, 2008, GLIA, V56, P271, DOI 10.1002/glia.20611; Wang C, 2009, NAT IMMUNOL, V10, P744, DOI 10.1038/ni.1742; Zanoni I, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00032; Zanoni I, 2011, CELL, V147, P868, DOI 10.1016/j.cell.2011.09.051; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118	35	36	36	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2016	64	4					635	649		10.1002/glia.22955			15	Neurosciences	Neurosciences & Neurology	DD8CX	WOS:000370153300012	26683584				2021-06-18	
J	Nakae, R; Takayama, Y; Kuwamoto, K; Naoe, Y; Sato, H; Yokota, H				Nakae, Ryuta; Takayama, Yasuhiro; Kuwamoto, Kentaro; Naoe, Yasutaka; Sato, Hidetaka; Yokota, Hiroyuki			Time Course of Coagulation and Fibrinolytic Parameters in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						coagulopathy; D-dimer; fibrinolysis; prognosis; traumatic brain injury	SEVERE HEAD-INJURY; ACTIVATED FACTOR-VII; HEMOSTATIC ABNORMALITIES; INTRACRANIAL HEMORRHAGE; D-DIMER; COAGULOPATHY; PROGRESSION; TALK; COMA; DETERIORATE	Traumatic brain injury (TBI) has long been associated with coagulopathy; however, the time course of coagulation/fibrinolytic parameters in the acute phase of TBI remains unclear. The purpose of the study was to analyze the time course of coagulation/fibrinolytic parameters in the acute phase of TBI and to elucidate parameter relationships to prognosis. We retrospectively evaluated 234 patients with severe isolated TBI with initial blood samples obtained no more than 1 h after injury. Platelet count, prothrombin time, activated partial thromboplastin time (aPTT), plasma levels of fibrinogen, and D-dimer were measured on arrival in the emergency department and 3, 6, and 12 h after injury. Multivariate logistic regression analysis was performed to identify risk factors for poor prognosis at each time point. From hospital admission to 12 h after injury, an elevated D-dimer level was a significant negative prognostic indicator (admission: p < 0.0001; 3 h after injury: p = 0.0005; 6 h after injury: p = 0.005; 12 h after injury: p = 0.0009). An upward trend of aPTT on admission and 3 h after injury was also a significant negative prognostic indicator (admission: p = 0.0011; 3 h after injury: p = 0.013). On multivariate logistic regression analysis, which included all initial variables, independent risk factors for poor prognosis included older age (p = 0.0005), low Glasgow Coma Scale score (p < 0.0001), high Abbreviated Injury Score (p = 0.015), aPTT >30.2 sec (p = 0.019), and elevated D-dimer level (p = 0.0005). We concluded that D-dimer is the best coagulation/fibrinolytic parameter to monitor for prediction of outcome.	[Nakae, Ryuta; Naoe, Yasutaka] Kawaguchi Municipal Med Ctr, Emergency & Crit Care Ctr, 180 Nishiaraijuku, Kawaguchi, Saitama 3330833, Japan; [Takayama, Yasuhiro; Kuwamoto, Kentaro; Sato, Hidetaka; Yokota, Hiroyuki] Nippon Med Sch, Dept Emergency & Crit Care Med, 1-1-5 Sendagi, Tokyo 113, Japan	Nakae, R (corresponding author), Kawaguchi Municipal Med Ctr, Emergency & Crit Care Ctr, 180 Nishiaraijuku, Kawaguchi, Saitama 3330833, Japan.	nakae@nms.ac.jp		Nakae, Ryuta/0000-0003-1820-2463			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; [Anonymous], 1998, ABBR INJ SCAL AIS 19; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; ClinicalTrials. gov, PREH TRAN AC US TRAU; CRASH 2 trial collaborators, 2011, BMJ-BRIT MED J, V343, pd3795; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Goldschlager T, 2007, J CLIN NEUROSCI, V14, P618, DOI 10.1016/j.jocn.2006.02.018; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JAMJOOM A, 1992, Acta Neurochirurgica, V115, P86, DOI 10.1007/BF01406363; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; KARIO K, 1991, THROMB RES, V62, P501, DOI 10.1016/0049-3848(91)90023-P; KARIO K, 1993, ATHEROSCLEROSIS, V103, P131, DOI 10.1016/0021-9150(93)90256-T; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; MacCallum PK, 2000, THROMB HAEMOSTASIS, V83, P421; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; May AK, 1997, AM SURGEON, V63, P233; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; PHONPRASERT C, 1980, J TRAUMA, V20, P679, DOI 10.1097/00005373-198008000-00008; Ratanalert S, 2002, J CLIN NEUROSCI, V9, P640, DOI 10.1054/jocn.2002.1085; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Shigemori M, 2012, NEUROL MED-CHIR, V52, P1; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Sun YR, 2011, BRIT J NEUROSURG, V25, P363, DOI 10.3109/02688697.2011.552650; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; WINTER JP, 1989, ANN EMERG MED, V18, P553, DOI 10.1016/S0196-0644(89)80842-X; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	60	36	36	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2016	33	7					688	695		10.1089/neu.2015.4039			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DI6QK	WOS:000373624700008	26414158				2021-06-18	
J	Shura, RD; Miskey, HM; Rowland, JA; Yoash-Gantz, RE; Denning, JH				Shura, Robert D.; Miskey, Holly M.; Rowland, Jared A.; Yoash-Gantz, Ruth E.; Denning, John H.			Embedded Performance Validity Measures with Postdeployment Veterans: Cross-Validation and Efficiency with Multiple Measures	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						multiple measures; veteran; neuropsychological assessment; Word Memory Test; performance validity	TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; COMPLEX FIGURE TEST; TEST FAILURE; MALINGERING DETECTION; EVALUATION CONTEXT; LIKELIHOOD RATIOS; INADEQUATE EFFORT; SUSPECT EFFORT; RESPONSE BIAS	Embedded validity measures support comprehensive assessment of performance validity. The purpose of this study was to evaluate the accuracy of individual embedded measures and to reduce them to the most efficient combination. The sample included 212 postdeployment veterans (average age=35 years, average education=14 years). Thirty embedded measures were initially identified as predictors of Green's Word Memory Test (WMT) and were derived from the California Verbal Learning Test-Second Edition (CVLT-II), Conners' Continuous Performance Test-Second Edition (CPT-II), Trail Making Test, Stroop, Wisconsin Card Sorting Test-64, the Wechsler Adult Intelligence Scale-Third Edition Letter-Number Sequencing, Rey Complex Figure Test (RCFT), Brief Visuospatial Memory Test-Revised, and the Finger Tapping Test. Eight nonoverlapping measures with the highest area-under-the-curve (AUC) values were retained for entry into a logistic regression analysis. Embedded measure accuracy was also compared to cutoffs found in the existing literature. Twenty-one percent of the sample failed the WMT. Previously developed cutoffs for individual measures showed poor sensitivity (SN) in the current sample except for the CPT-II (Total Errors, SN=.41). The CVLT-II (Trials 1-5 Total) showed the best overall accuracy (AUC=.80). After redundant measures were statistically eliminated, the model included the RCFT (Recognition True Positives), CPT-II (Total Errors), and CVLT-II (Trials 1-5 Total) and increased overall accuracy compared with the CVLT-II alone (AUC=.87). The combination of just 3 measures from the CPT-II, CVLT-II, and RCFT was the most accurate/efficient in predicting WMT performance.	[Shura, Robert D.; Miskey, Holly M.; Rowland, Jared A.; Yoash-Gantz, Ruth E.] WG Bill Hefner Vet Affairs Med Ctr, Mid Atlantic Mental Illness Res Educ & Clin Ctr, Salisbury, Wilts, England; [Shura, Robert D.; Miskey, Holly M.; Rowland, Jared A.; Yoash-Gantz, Ruth E.] WG Bill Hefner Vet Affairs Med Ctr, Mental Hlth & Behav Sci Serv Line, Salisbury, Wilts, England; [Shura, Robert D.; Miskey, Holly M.; Yoash-Gantz, Ruth E.] Wake Forest Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Psychiat & Behav Sci, Dept Anat & Neurobiol, Winston Salem, NC USA; [Denning, John H.] Alvin C York Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Murfreesboro, TN USA; [Denning, John H.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Shura, RD (corresponding author), Hefner VAMC, 11M-2 MH BS,1601 Brenner Ave, Salisbury, NC 28144 USA.	robert.shura2@va.gov	Shura, Robert D/J-6749-2019; Rowland, Jared A./AAN-3030-2021	Rowland, Jared A./0000-0002-3655-3411; Miskey, Holly/0000-0002-5139-4586; Shura, Robert/0000-0002-9505-0080	W. G. "Bill" Hefner Veterans Affairs Medical Center; Mid-Atlantic Mental Illness Research Education and Clinical Center; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and TreatmentUS Department of Veterans Affairs	This work was supported by the This research was supported by resources of the W. G. "Bill" Hefner Veterans Affairs Medical Center, the Mid-Atlantic Mental Illness Research Education and Clinical Center, and the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment..	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Benedict R., 1997, BRIEF VISUOSPATIAL M; Berry D., 2008, CLIN ASSESSMENT MALI, P237; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carone DA, 2014, CLIN NEUROPSYCHOL, V28, P146, DOI 10.1080/13854046.2013.861019; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Conners C, 2004, CONNERS CONTINUOUS P; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Dedert EA, 2009, J PSYCHIATR RES, V43, P830, DOI 10.1016/j.jpsychires.2009.01.004; Delis DC, 2000, CALIFORNIA VERBAL LE; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; First MB., 1997, STRUCTURED CLIN INTE; Gfeller JD, 2013, BEHAV SCI LAW, V31, P833, DOI 10.1002/bsl.2084; Golden CJ, 2002, STROOP COLOR WORD TE; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Green P., 2005, GREENS WORD MEMORY T; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2001, CLIN NEUROPSYCHOL, V15, P228, DOI 10.1076/clin.15.2.228.1901; Heaton R. K, 1981, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Lu P. H., 2007, ASSESSMENT FEIGNED C, P128; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Merten T, 2013, PSYCHOL INJ LAW, V6, P122, DOI 10.1007/s12207-013-9155-x; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers JE, 2014, ARCH CLIN NEUROPSYCH, V29, P224, DOI 10.1093/arclin/acu001; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Pearson, 2009, ADV CLIN SOL WAIS 4; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reitan RM., 1985, HALSTEAD REITAN NEUR; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001	57	36	36	1	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 3	2016	23	2					94	104		10.1080/23279095.2015.1014556			11	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	DE4TK	WOS:000370623000003	26375185				2021-06-18	
J	Hanlon, LA; Huh, JW; Raghupathi, R				Hanlon, Lauren A.; Huh, Jimmy W.; Raghupathi, Ramesh			Minocycline Transiently Reduces Microglia/Macrophage Activation but Exacerbates Cognitive Deficits Following Repetitive Traumatic Brain Injury in the Neonatal Rat	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Abusive head trauma; Cognition; Inflammation; Microglia; Neurodegeneration; Pediatric	WHITE-MATTER INJURY; NONACCIDENTAL HEAD-INJURY; HYPOXIC-ISCHEMIC INJURY; LONG-TERM POTENTIATION; CYTOCHROME-C RELEASE; MICROGLIAL ACTIVATION; AXONAL INJURY; IMMATURE RAT; INTRACEREBRAL-HEMORRHAGE; RODENT MODEL	Elevated microglial/macrophage-associated biomarkers in the cerebrospinal fluid of infant victims of abusive head trauma (AHT) suggest that these cells play a role in the pathophysiology of the injury. In a model of AHT in 11-day-old rats, 3 impacts (24 hours apart) resulted in spatial learning and memory deficits and increased brain microglial/macrophage reactivity, traumatic axonal injury, neuronal degeneration, and cortical and white-matter atrophy. The antibiotic minocycline has been effective in decreasing injury-induced microglial/macrophage activation while simultaneously attenuating cellular and functional deficits in models of neonatal hypoxic ischemia, but the potential for this compound to rescue deficits after impact-based trauma to the immature brain remains unexplored. Acute minocycline administration in this model of AHT decreased microglial/macrophage reactivity in the corpus callosum of brain-injured animals at 3 days postinjury, but this effect was lost by 7 days postinjury. Additionally, minocycline treatment had no effect on traumatic axonal injury, neurodegeneration, tissue atrophy, or spatial learning deficits. Interestingly, minocycline-treated animals demonstrated exacerbated injury-induced spatial memory deficits. These results contrast with previous findings in other models of brain injury and suggest that minocycline is ineffective in reducing microglial/macrophage activation and ameliorating injury-induced deficits following repetitive neonatal traumatic brain injury.	[Hanlon, Lauren A.; Raghupathi, Ramesh] Drexel Univ, Coll Med, Program Neurosci, Philadelphia, PA 19129 USA; [Huh, Jimmy W.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Ramesh.raghupathi@drexelmed.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD069163]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD069163] Funding Source: NIH RePORTER	This study was supported by NIH grant HD069163.	Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Andes D, 2002, INT J ANTIMICROB AG, V19, P261, DOI 10.1016/S0924-8579(02)00022-5; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Bishop Naomi B, 2006, Curr Probl Pediatr Adolesc Health Care, V36, P318, DOI 10.1016/j.cppeds.2006.05.004; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Buller KM, 2009, J NEUROSCI RES, V87, P599, DOI 10.1002/jnr.21890; Burke NN, 2014, BRAIN BEHAV IMMUN, V42, P147, DOI 10.1016/j.bbi.2014.06.015; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Z, 2006, NEUROSCIENCE, V137, P425, DOI 10.1016/j.neuroscience.2005.09.023; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Cowell RM, 2002, STROKE, V33, P795, DOI 10.1161/hs0302.103740; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; del Rey A, 2013, BRAIN BEHAV IMMUN, V33, P15, DOI 10.1016/j.bbi.2013.05.011; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Faustino JV, 2011, J NEUROSCI, V31, P12992, DOI 10.1523/JNEUROSCI.2102-11.2011; Ferrazzano P, 2013, CNS NEUROL DISORD-DR, V12, P338, DOI 10.2174/1871527311312030007; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Finnie JW, 2012, J CLIN NEUROSCI, V19, P1159, DOI 10.1016/j.jocn.2011.12.019; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Harker KT, 2002, J NEUROSCI, V22, P1155, DOI 10.1523/JNEUROSCI.22-03-01155.2002; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Ivacko JA, 1996, PEDIATR RES, V39, P39, DOI 10.1203/00006450-199601000-00006; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Lechpammer M, 2008, NEUROPATH APPL NEURO, V34, P379, DOI 10.1111/j.1365-2990.2007.00925.x; Leonardo CC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-34; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matschke J, 2009, PEDIATRICS, V124, P1587, DOI 10.1542/peds.2008-3734; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; MCRAE A, 1995, DEV BRAIN RES, V84, P245, DOI 10.1016/0165-3806(94)00177-2; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; Neumann H, 2007, J NEUROIMMUNOL, V184, P92, DOI 10.1016/j.jneuroim.2006.11.032; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Parks SE, 2012, PEDIAT ABUSIVE HEAD; PETERS A, 1976, J NEUROCYTOL, V5, P63, DOI 10.1007/BF01176183; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Pont-Lezica L, 2011, J NEUROCHEM, V119, P901, DOI 10.1111/j.1471-4159.2011.07504.x; Potts Mathew B, 2006, NeuroRx, V3, P143; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Trofimov AN, 2014, NEUROSCI BEHAV PHYSL, V44, P359, DOI DOI 10.1007/S11055-014-9918-1; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; van Groen T, 2002, BEHAV BRAIN RES, V136, P329, DOI 10.1016/S0166-4328(02)00199-7; Vann SD, 2003, BEHAV BRAIN RES, V140, P107, DOI 10.1016/S0166-4328(02)00274-7; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Wixey JA, 2011, NEUROSCIENCE, V182, P184, DOI 10.1016/j.neuroscience.2011.03.033; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	89	36	37	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2016	75	3					214	226		10.1093/jnen/nlv021			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DL7CF	WOS:000375796500002	26825312	Green Published, Bronze			2021-06-18	
J	Warne, J; Pryce, G; Hill, JM; Shi, X; Lenneras, F; Puentes, F; Kip, M; Hilditch, L; Walker, P; Simone, MI; Chan, AWE; Towers, GJ; Coker, AR; Duchen, MR; Szabadkai, G; Baker, D; Selwood, DL				Warne, Justin; Pryce, Gareth; Hill, Julia M.; Shi, Xiao; Lenneras, Felicia; Puentes, Fabiola; Kip, Maarten; Hilditch, Laura; Walker, Paul; Simone, Michela I.; Chan, A. W. Edith; Towers, Greg J.; Coker, Alun R.; Duchen, Michael R.; Szabadkai, Gyorgy; Baker, David; Selwood, David L.			Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; HUMAN CYCLOPHILIN-D; CYCLOSPORINE-A; AXONAL DEGENERATION; ATP SYNTHASE; TRIPHENYLPHOSPHONIUM CATIONS; LENTIVIRAL VECTOR; P-GLYCOPROTEIN	The mitochondrial permeability transition pore is a recognized drug target for neurodegenerative conditions such as multiple sclerosis and for ischemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, PPIF), is a positive regulator of the pore, and genetic down-regulation or knock-out improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off-target effects, immunosuppression, and toxicity. We therefore designed and synthesized a new mitochondrially targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine. X-ray analysis was used to validate the design concept, and biological evaluation revealed selective cellular inhibition of CypD and the permeability transition pore with reduced cellular toxicity compared with cyclosporine. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis, JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for in vivo use.	[Warne, Justin; Pryce, Gareth; Shi, Xiao; Kip, Maarten; Simone, Michela I.; Chan, A. W. Edith; Coker, Alun R.; Selwood, David L.] UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England; [Pryce, Gareth; Lenneras, Felicia; Puentes, Fabiola; Baker, David] Queen Mary Univ London, Barts & London Sch Med & Dent, Neuroimmunol Unit, Blizard Inst, 4 Newark St, London E1 2AT, England; [Hill, Julia M.; Duchen, Michael R.; Szabadkai, Gyorgy] UCL, Dept Cell & Dev Biol, Mortimer St, London WC1E 6BT, England; [Hilditch, Laura; Towers, Greg J.] UCL, Med Res Council, Ctr Med Mol Biol, Div Infect & Immun, Mortimer St, London WC1E 6BT, England; [Walker, Paul] Cyprotex Discovery Ltd, 100 Barbirolli Sq, Manchester M2 3AB, Lancs, England; [Szabadkai, Gyorgy] Univ Padua, Dept Biomed Sci, I-35122 Padua, Italy; [Simone, Michela I.] Univ Newcastle, Sch Environm & Life Sci, Discipline Chem, Callaghan, NSW 2308, Australia	Selwood, DL (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.; Baker, D (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Neuroimmunol Unit, Blizard Inst, 4 Newark St, London E1 2AT, England.	david.baker@qmul.ac.uk; d.selwood@ucl.ac.uk	duchen, michael/A-2116-2009; Simone, Michela/AAS-7878-2020; Simone, Michela I./A-6887-2011	duchen, michael/0000-0003-2548-4294; Simone, Michela/0000-0002-1339-8236; Simone, Michela I./0000-0002-1339-8236; Szabadkai, Gyorgy/0000-0002-3006-3577; Coker, Alun/0000-0001-7385-0143; Walker, Paul/0000-0002-7840-9709; Selwood, David/0000-0002-6817-5064; Towers, Gregory/0000-0002-7707-0264	FastForward; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society; Wellcome TrustWellcome TrustEuropean Commission [090940]; Medical Research Council, a Medical Research Council Confidence in Concept AwardUK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research University College London Hospitals Biomedical Research Centre; Eisai UK Ltd.Eisai Co Ltd; British Heart FoundationBritish Heart Foundation; Telethon ItalyFondazione Telethon; Italian Association for Cancer Research (AIRC)Fondazione AIRC per la ricerca sul cancro; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0801172] Funding Source: researchfish; Wellcome TrustWellcome TrustEuropean Commission [108183/Z/15/Z] Funding Source: researchfish	This work was supported by FastForward, National Multiple Sclerosis Society, Wellcome Trust Senior Fellowship 090940 (to G. J. T.), the Medical Research Council, a Medical Research Council Confidence in Concept Award (to G. J. T. and D. S.), and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Three authors (G. S., D. B., and D. L. S.) are inventors on a patent filed by the university. Through the university revenue sharing scheme, inventors may, should the invention be commercialized and in the fullness of time, receive some financial benefit.; Supported by a studentship from Eisai UK Ltd.; Supported by the British Heart Foundation, Wellcome Trust, Telethon Italy, and the Italian Association for Cancer Research (AIRC).	Al-Izki S, 2014, BRAIN, V137, P92, DOI 10.1093/brain/awt324; Al-Izki S, 2012, MULT SCLER RELAT DIS, V1, P29, DOI 10.1016/j.msard.2011.09.001; Alavian KN, 2014, P NATL ACAD SCI USA, V111, P10580, DOI 10.1073/pnas.1401591111; ALLEN SJ, 1993, CELL IMMUNOL, V146, P335, DOI 10.1006/cimm.1993.1031; AMOR S, 1994, J IMMUNOL, V153, P4349; Astin R, 2013, SCI REP-UK, V3, DOI 10.1038/srep02467; Bainbridge JWB, 2001, GENE THER, V8, P1665, DOI 10.1038/sj.gt.3301574; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Baker D, 2011, MULT SCLER J, V17, P647, DOI 10.1177/1352458511398885; Barbarino JM, 2013, PHARMACOGENET GENOM, V23, P563, DOI 10.1097/FPC.0b013e328364db84; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Bart J, 2000, CANCER TREAT REV, V26, P449, DOI 10.1053/ctrv.2000.0194; Basso E, 2008, J BIOL CHEM, V283, P26307, DOI 10.1074/jbc.C800132200; Bonora M, 2013, CELL CYCLE, V12, P674, DOI 10.4161/cc.23599; Campbell GR, 2014, MULT SCLER J, V20, P1806, DOI 10.1177/1352458514544537; Chinopoulos C, 2011, FEBS J, V278, P1112, DOI 10.1111/j.1742-4658.2011.08026.x; Chung NS, 2004, ADV DRUG DELIVER REV, V56, P1315, DOI 10.1016/j.addr.2003.12.003; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Davis TL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000439; Du H, 2011, NEUROBIOL AGING, V32, P398, DOI 10.1016/j.neurobiolaging.2009.03.003; Dube H, 2012, BIOCHEM J, V441, P901, DOI 10.1042/BJ20111301; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Gaali S, 2010, ACS MED CHEM LETT, V1, P536, DOI 10.1021/ml1001272; Gallay PA, 2013, DRUG DES DEV THER, V7, P105, DOI 10.2147/DDDT.S30946; Gane EJ, 2010, LIVER INT, V30, P1019, DOI 10.1111/j.1478-3231.2010.02250.x; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Giorgio V, 2009, J BIOL CHEM, V284, P33982, DOI 10.1074/jbc.M109.020115; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Guo L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054914; Halestrap AP, 2015, J MOL CELL CARDIOL, V78, P129, DOI 10.1016/j.yjmcc.2014.08.018; Hampton DW, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-84; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Hazelton JL, 2009, J NEUROSCI RES, V87, P1250, DOI 10.1002/jnr.21921; Hecking M, 2008, TRANSPL INT, V21, P223, DOI 10.1111/j.1432-2277.2007.00563.x; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hoye AT, 2008, ACCOUNTS CHEM RES, V41, P87, DOI 10.1021/ar700135m; Jackson SJ, 2009, J NEUROPATH EXP NEUR, V68, P616, DOI 10.1097/NEN.0b013e3181a41d23; Jackson SJ, 2005, NEUROSCIENCE, V134, P261, DOI 10.1016/j.neuroscience.2005.02.045; Kageyama T, 2013, J NEUROL, V260, P627, DOI 10.1007/s00415-012-6692-2; Kajitani K, 2008, PROTEINS, V70, P1635, DOI 10.1002/prot.21855; Kapoor R, 2003, ANN NEUROL, V53, P174, DOI 10.1002/ana.10443; KAPPOS L, 1988, ANN NEUROL, V23, P56, DOI 10.1002/ana.410230110; Kato M, 2009, CARDIOVASC RES, V83, P335, DOI 10.1093/cvr/cvp094; Kutzelnigg A, 2014, HAND CLINIC, V122, P15, DOI 10.1016/B978-0-444-52001-2.00002-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemasters JJ, 2007, METHOD CELL BIOL, V80, P283, DOI 10.1016/S0091-679X(06)80014-2; Leo S, 2008, ANN NY ACAD SCI, V1147, P264, DOI 10.1196/annals.1427.019; Lim SY, 2011, J CELL MOL MED, V15, P2443, DOI 10.1111/j.1582-4934.2010.01235.x; Liu YY, 2006, ANAL BIOCHEM, V356, P100, DOI 10.1016/j.ab.2006.04.040; Macarron R, 2011, FUTURE MED CHEM, V3, P505, DOI [10.4155/FMC.11.19, 10.4155/fmc.11.19]; Mahad D, 2008, BRAIN, V131, P1722, DOI 10.1093/brain/awn105; MAKLER MT, 1990, Patent No. 4946849; Malouitre S, 2010, BIOCHEM J, V425, P137, DOI 10.1042/BJ20090332; Marta M, 2012, CNS NEUROL DISORD-DR, V11, P610, DOI 10.2174/187152712801661301; Martin LJ, 2014, NEUROBIOL AGING, V35, P1132, DOI 10.1016/j.neurobiolaging.2013.11.008; Martin LJ, 2009, EXP NEUROL, V218, P333, DOI 10.1016/j.expneurol.2009.02.015; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McEwan WA, 2009, J VIROL, V83, P8270, DOI 10.1128/JVI.00670-09; Millard M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013131; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nikolovska-Coleska Z, 2004, ANAL BIOCHEM, V332, P261, DOI 10.1016/j.ab.2004.05.055; Ohno N, 2014, P NATL ACAD SCI USA, V111, P9953, DOI 10.1073/pnas.1401155111; ONEILL JK, 1992, J NEUROIMMUNOL, V38, P53, DOI 10.1016/0165-5728(92)90090-8; Porteous CM, 2013, BBA-GEN SUBJECTS, V1830, P3458, DOI 10.1016/j.bbagen.2013.02.005; Pryce G, 2005, J NEUROIMMUNOL, V165, P41, DOI 10.1016/j.jneuroim.2005.04.009; Pryce G, 2014, FASEB J, V28, P117, DOI 10.1096/fj.13-239442; Quintanilla RA, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-45; Raftopoulos R, 2015, MULT SCLER J, V21, P273; Rasaiyaah J, 2013, NATURE, V503, P402, DOI 10.1038/nature12769; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Reddy PH, 2012, BBA-MOL BASIS DIS, V1822, P639, DOI 10.1016/j.bbadis.2011.10.011; Reily C, 2013, REDOX BIOL, V1, P86, DOI 10.1016/j.redox.2012.11.009; Rodrigues JR, 2007, EXP PARASITOL, V115, P19, DOI 10.1016/j.exppara.2006.05.002; Ross MF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P222, DOI 10.1007/s10541-005-0104-5; Savino C, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/719407; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; Schlatter D, 2005, ACTA CRYSTALLOGR D, V61, P513, DOI 10.1107/S0907444905003070; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Sharma Pradeep, 2005, Farmaco (Lausanne), V60, P870, DOI 10.1016/j.farmac.2005.08.006; Smulik JA, 2002, ORG LETT, V4, P2051, DOI 10.1021/ol0258987; Starr R, 1996, J NEUROSCI RES, V44, P328; Su K, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00169; Su KG, 2012, EUR J NEUROSCI, V35, P562, DOI 10.1111/j.1460-9568.2011.07972.x; Templeton I, 2014, METHODS MOL BIOL, V1113, P471, DOI 10.1007/978-1-62703-758-7_22; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; Valasani KR, 2014, ACTA CRYSTALLOGR F, V70, P717, DOI 10.1107/S2053230X14009480; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; Wu N, 2015, EUR REV MED PHARMACO, V19, P446; Ylinen LMJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001062; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	99	36	39	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	2016	291	9					4356	4373		10.1074/jbc.M115.700385			18	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DF8JT	WOS:000371604600009	26679998	Green Published, Other Gold			2021-06-18	
J	Kota, DJ; Prabhakara, KS; van Brummen, AJ; Bedi, S; Xue, HS; DiCarlo, B; Cox, CS; Olson, SD				Kota, Daniel J.; Prabhakara, Karthik S.; van Brummen, Alexandra J.; Bedi, Supinder; Xue, Hasen; DiCarlo, Bryan; Cox, Charles S., Jr.; Olson, Scott D.			Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Traumatic brain injury; Propranolol; Mesenchymal stromal cell; beta-Blocker	CENTRAL-NERVOUS-SYSTEM; ACTIVATED MICROGLIAL/MACROPHAGE RESPONSE; ANTIINFLAMMATORY PROTEIN TSG-6; BETA-BLOCKER EXPOSURE; NEURAL STEM-CELLS; BONE-MARROW; HEAD-INJURY; IN-VIVO; INFLAMMATORY RESPONSE; SYMPATHETIC HYPERACTIVITY	More than 6.5 million patients are burdened by the physical, cognitive, and psychosocial deficits associated with traumatic brain injury (TBI) in the U.S. Despite extensive efforts to develop neuroprotective therapies for this devastating disorder, there have been no successful outcomes in human clinical trials to date. Retrospective studies have shown that beta-adrenergic receptor blockers, specifically propranolol, significantly decrease mortality of TBI through mechanisms not yet fully elucidated but are thought to counterbalance a hyperadrenergic state resulting from a TBI. Conversely, cellular therapies have been shown to improve long-term behavior following TBI, likely by reducing inflammation. Given the nonredundancy in their therapeutic mechanisms, we hypothesized that a combination of acute propranolol followed by mesenchymal stem cells (MSCs) isolated from human bone marrow would have additive effects in treating a rodent model of TBI. We have found that the treatments are well-tolerated individually and in combination with no adverse events. MSCs decrease BBB permeability at 96 hours after injury, inhibit a significant accumulation of activated microglia/ macrophage in the thalamic region of the brain both short and long term, and enhance neurogenesis short term. Propranolol decreases edema and reduces the number of fully activated microglia at 7 days and the number of semiactivated microglia at 120 days. Combinatory treatment improved cognitive and memory functions 120 days following TBI. Therefore, the results here suggest a new, efficacious sequential treatment for TBI may be achieved using the beta-blocker propranolol followed by MSC treatment.	[Kota, Daniel J.; Prabhakara, Karthik S.; van Brummen, Alexandra J.; Bedi, Supinder; Xue, Hasen; DiCarlo, Bryan; Cox, Charles S., Jr.; Olson, Scott D.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-233, Houston, TX 77030 USA	Olson, SD (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-233, Houston, TX 77030 USA.	Scott.D.Olson@uth.tmc.edu		Olson, Scott/0000-0001-8032-3755	Institute for Rehabilitation and Research (TIRR) Foundation Mission Connect Award [13-110]; Clare A. Glassell Family Pediatric Stem Cell Research Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER	This study was performed with funding support from The Institute for Rehabilitation and Research (TIRR) Foundation Mission Connect Award 13-110 and the generous support of the Clare A. Glassell Family Pediatric Stem Cell Research Fund.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081585; Bai LH, 2007, NEUROCHEM RES, V32, P353, DOI 10.1007/s11064-006-9212-x; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bauer G, 2008, MOL THER, V16, P1308, DOI 10.1038/mt.2008.93; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Calzarossa C, 2013, NEUROSCIENCE, V234, P158, DOI 10.1016/j.neuroscience.2012.12.038; Chen M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0284-x; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Darlington PJ, 2011, EXPERT REV NEUROTHER, V11, P1295, DOI [10.1586/ERN.11.113, 10.1586/ern.11.113]; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Ker K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006686.pub2; Kotova PD, 2014, BBA-MOL CELL RES, V1843, P1899, DOI 10.1016/j.bbamcr.2014.05.002; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee H, 2013, HUM GENE THER, V24, P655, DOI 10.1089/hum.2013.001; Lee JM, 2012, INT IMMUNOPHARMACOL, V13, P219, DOI 10.1016/j.intimp.2012.03.024; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Ley EJ, 2012, J TRAUMA ACUTE CARE, V73, P33, DOI 10.1097/TA.0b013e31825a769b; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Liu Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-135; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; McIntosh TK, 1996, LAB INVEST, V74, P315; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nakano N, 2010, NEUROSCI LETT, V483, P57, DOI 10.1016/j.neulet.2010.07.062; Nicholas RS, 2001, EUR J NEUROSCI, V13, P959, DOI 10.1046/j.0953-816x.2001.01470.x; Ooi YY, 2010, INT IMMUNOPHARMACOL, V10, P1532, DOI 10.1016/j.intimp.2010.09.001; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Ribeiro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt336; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Teixeira FG, 2013, CELL MOL LIFE SCI, V70, P3871, DOI 10.1007/s00018-013-1290-8; Tran TY, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E8; Trouche E, 2010, STEM CELLS DEV, V19, P1571, DOI 10.1089/scd.2009.0353; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walton NM, 2006, GLIA, V54, P815, DOI 10.1002/glia.20419; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yoo KH, 2009, CELL IMMUNOL, V259, P150, DOI 10.1016/j.cellimm.2009.06.010; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	83	36	38	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	JAN	2016	5	1					33	44		10.5966/sctm.2015-0065			12	Cell & Tissue Engineering	Cell Biology	DB8FJ	WOS:000368752300010	26586775	DOAJ Gold, Green Published			2021-06-18	
J	Li, W; Wang, T; Xiao, SF				Li, Wei; Wang, Tao; Xiao, Shifu			Type 2 diabetes mellitus might be a risk factor for mild cognitive impairment progressing to Alzheimer's disease	NEUROPSYCHIATRIC DISEASE AND TREATMENT			English	Article						T2DM; AD; MCI; risk factor	MENTAL-STATE-EXAMINATION; FOLLOW-UP; DEMENTIA; INDIVIDUALS; INSULIN; COHORT; DECLINE; BETA; AGE	Background: Mild cognitive impairment (MCI) is the prodromal stage of Alzheimer's disease (AD), so identification of the related risk factors can be helpful. Although the association between type 2 diabetes mellitus (T2DM) and these modest changes in cognition is well established, whether T2DM will promote the transformation of MCI into AD is not a unified conclusion. Objective: This study aims to explore the relationship between T2DM and MCI in the elderly population living in the community in Shanghai, People's Republic of China. Methods: A total of 197 participants were included in the study. They were screened for T2DM, hyperlipidemia, traumatic brain injury, and family history of dementia. The Mini-Mental State Examination and the Montreal Cognitive Assessment were used to assess cognitive function. The diagnosis of AD was made according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, whereas the diagnosis of MCI was made according to Petersen's criteria. Then, we investigated the relation between T2DM and MCI. Results: A total of 82 (41.6%) participants had no cognitive impairment, 82 (41.6%) participants had MCI, and 33 (16.8%) participants had AD. Multivariate logistic regression models demonstrated that T2DM was a risk factor for AD (odds ratio = 49.723, 95% CI = 21.173-111.987). Conclusion: T2DM might be a risk factor for MCI progressing into AD.	[Li, Wei; Wang, Tao; Xiao, Shifu] Shanghai Jiao Tong Univ, Sch Med, Alzheimers Dis & Related Disorders Ctr, 600 South Wanping Rd, Shanghai 200030, Peoples R China; [Li, Wei; Wang, Tao; Xiao, Shifu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Dept Geriatr Psychiat, Shanghai, Peoples R China	Xiao, SF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Alzheimers Dis & Related Disorders Ctr, 600 South Wanping Rd, Shanghai 200030, Peoples R China.	xiaoshifu@msn.com			China Ministry of Science and TechnologyMinistry of Science and Technology, China [2009BAI77B03]	This work was supported by a grant from the China Ministry of Science and Technology (2009BAI77B03).	Abbatecola AM, 2010, DIABETES CARE, V33, P1706, DOI 10.2337/dc09-2030; Almeida OP, 1999, ARQ NEURO-PSIQUIAT, V57, P421, DOI 10.1590/S0004-282X1999000300013; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; Ates MP, 2016, NEUROSCIENCE, V325, P124, DOI 10.1016/j.neuroscience.2016.03.051; Awad N, 2004, J CLIN EXP NEUROPSYC, V26, P1044, DOI 10.1080/13803390490514875; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Bruehl H, 2009, BRAIN RES, V1280, P186, DOI 10.1016/j.brainres.2009.05.032; Freude S, 2005, DIABETES, V54, P3343, DOI 10.2337/diabetes.54.12.3343; Hassing LB, 2004, J INT NEUROPSYCH SOC, V10, P599, DOI 10.1017/S1355617704104165; Hsu CC, 2011, J ALZHEIMERS DIS, V24, P485, DOI 10.3233/JAD-2011-101524; Huang CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087095; Knight EM, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0282-y; Kopf D, 2009, J ALZHEIMERS DIS, V16, P677, DOI 10.3233/JAD-2009-1011; Koran M. E. I., 2016, BRAIN IMAGING BEHAV; Korolev IO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0138866; Kulstad JJ, 2006, NEUROLOGY, V66, P1506, DOI 10.1212/01.wnl.0000216274.58185.09; Leibson C L, 1997, Ann N Y Acad Sci, V826, P422, DOI 10.1111/j.1749-6632.1997.tb48496.x; Leibson CL, 1997, AM J EPIDEMIOL, V145, P301; Liu Y, 2011, J PATHOL, V225, P54, DOI 10.1002/path.2912; Ma F, 2015, J ALZHEIMERS DIS, V43, P1441, DOI 10.3233/JAD-141566; Mitchell AJ, 2009, ACTA PSYCHIAT SCAND, V119, P252, DOI 10.1111/j.1600-0447.2008.01326.x; Mittal K, DIABETES METAB SYNDR; Ng TP, 2016, JAMA NEUROL, V73, P456, DOI 10.1001/jamaneurol.2015.4899; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Piccinin AM, 2013, J GERONTOL B-PSYCHOL, V68, P374, DOI 10.1093/geronb/gbs077; Ren RJ., 2015, MOL NEUROBIOL; Sarlus H, 2015, J ALZHEIMERS DIS, V48, P495, DOI 10.3233/JAD-143147; Sebastiao I, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00110; Sims-Robinson C, 2010, NAT REV NEUROL, V6, P551, DOI 10.1038/nrneurol.2010.130; Tiffin-Richards FE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106700; Trzepacz PT, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0103-3; Xu WL, 2004, NEUROLOGY, V63, P1181, DOI 10.1212/01.WNL.0000140291.86406.D1	35	36	36	1	12	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1178-2021			NEUROPSYCH DIS TREAT	Neuropsychiatr. Dis. Treat.		2016	12						2489	2495		10.2147/NDT.S111298			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	DX6JV	WOS:000384490800001	27729793	DOAJ Gold, Green Published			2021-06-18	
J	Lobue, C; Denney, D; Hynan, LS; Rossetti, HC; Lacritz, LH; Hart, J; Womack, KB; Woon, FL; Cullum, CM				LoBue, Christian; Denney, David; Hynan, Linda S.; Rossetti, Heidi C.; Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.; Woon, Fu L.; Cullum, C. Munro			Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Age of onset; mild cognitive impairment; risk factors; traumatic brain injury	HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC SYMPTOMS; DEMENTIA; DEPRESSION; PREVALENCE; PATHOLOGY; ONSET	This study examined whether history of traumatic brain injury (TBI) is associated with increased risk and earlier onset of mild cognitive impairment (MCI). Subjects with MCI (n = 3,187) and normal cognition (n = 3,244) were obtained from the National Alzheimer's Coordinating Center database. TBI was categorized based on lifetime reported TBI with loss of consciousness (LOC) without chronic deficit. Logistic regression was used to examine TBI history as a predictor of MCI, adjusted for demographics, apolipoprotein E-epsilon 4 (ApoE4), a composite vascular risk score, and history of psychiatric factors. ANCOVA was used to examine whether age at MCI diagnosis and estimated age of onset differed between those with (TBI+) and without (TBI-) a history of TBI. TBI history was a significant predictor (p < 0.01) and associated with increased odds of MCI diagnosis in unadjusted (OR = 1.25; 95% CI = 1.05-1.49) and adjusted models, accounting for age, education, ApoE4, and a composite vascular score (OR = 1.32; 95% CI = 1.10-1.58). This association, however, was largely attenuated (OR = 1.14; 95% CI = 0.94-1.37; p = 0.18) after adjustment for reported history of depression. MCI was diagnosed a mean of 2.3 years earlier (p < 0.001) in the TBI+ group, and although TBI+ subjects had an estimated mean of decline 1.7 years earlier, clinician-estimated age of onset failed to differ (p = 0.13) when gender and psychiatric factors were controlled. This is the first report of a possible role for TBI as a risk factor in MCI, but its association may be related to other factors such as gender and depression and requires further investigation.	[LoBue, Christian; Denney, David; Hynan, Linda S.; Rossetti, Heidi C.; Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.; Woon, Fu L.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Hynan, Linda S.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75230 USA	Lobue, C (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75208 USA.	christian.lobue@utsouthwestern.edu	Hynan, Linda S/P-6473-2016; Cullum, C. Munro/AAC-2496-2019; Womack, Kyle/O-5422-2018	Cullum, C. Munro/0000-0001-9706-5465; Womack, Kyle/0000-0002-6060-9075; Hynan, Linda/0000-0002-4642-7769	NIH/NIA Alzheimer's Disease Center Grant [P3012300-19]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P30 AG010129];  [P50 AG016573];  [P50 AG016570];  [P50 AG005131];  [P50AG023501];  [P30 AG035982];  [P30AG028383];  [P30 AG010124];  [P50 AG005136];  [P50 AG033514];  [P50 AG005681];  [U01 AG032984]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, P50AG025688, P30AG013854, U01AG016976, P01AG003991, P50AG005136, P50AG016573, P50AG005142, P30AG019610, P30AG010161, P30AG035982, P50AG005133, P50AG008702, P50AG005138, U01AG032984, P50AG005146, P30AG010129, P30AG008051, P50AG005681, P30AG012300, P30AG010133, P30AG008017, P30AG028383, P50AG016574, P50AG005134, P30AG013846, P50AG033514, P50AG023501, P50AG005131, P50AG016570] Funding Source: NIH RePORTER	Funding for this study was provided in part by the NIH/NIA P3012300-19 Alzheimer's Disease Center Grant. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30AG028383 (PI LindaVan Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD). The Alzheimer's Disease Genetic Consortium (ADGC) is funded by NIA Grant U01 AG032984.	Abisambra JF, 2014, J ALZHEIMERS DIS, V40, P495, DOI 10.3233/JAD-131019; Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Byers AL, 2011, NAT REV NEUROL, V7, P323, DOI 10.1038/nrneurol.2011.60; DeRight J, 2015, ANN BEHAV MED, V49, P344, DOI 10.1007/s12160-014-9681-0; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Faul M, 2010, TRAUMATIC BRAIN INJU, V2, P1; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Geda YE, 2008, ARCH GEN PSYCHIAT, V65, P1193, DOI 10.1001/archpsyc.65.10.1193; Gilbert M, 2014, INT PSYCHOGERIATR, V26, P1593, DOI 10.1017/S1041610214000842; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Luchsinger JA, 2005, NEUROLOGY, V65, P545, DOI 10.1212/01.wnl.0000172914.08967.dc; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Mielke MM, 2014, NEUROLOGY, V82, P70, DOI 10.1212/01.wnl.0000438229.56094.54; Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Tabachnick B., 2001, USING MULTIVARIATE S; US National Institutes of Health, 1998, NIH CONSENSUS STATE, P26	39	36	37	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	51	3					727	736		10.3233/JAD-150895			10	Neurosciences	Neurosciences & Neurology	DJ5IL	WOS:000374240200009	26890760	Green Accepted			2021-06-18	
J	Pugh, MJ; Finley, EP; Wang, CP; Copeland, LA; Jaramillo, CA; Swan, AA; Elnitsky, CA; Leykum, LK; Mortensen, EM; Eapen, BA; Noel, PH; Pugh, JA				Pugh, Mary Jo; Finley, Erin P.; Wang, Chen-Pin; Copeland, Laurel A.; Jaramillo, Carlos A.; Swan, Alicia A.; Elnitsky, Christine A.; Leykum, Luci K.; Mortensen, Eric M.; Eapen, Blessen A.; Noel, Polly H.; Pugh, Jacqueline A.		TRACC Res Team	A retrospective cohort study of comorbidity trajectories associated with traumatic brain injury in veterans of the Iraq and Afghanistan wars	BRAIN INJURY			English	Article						Comorbidity; Trajectories; Iraq and Afghanistan wars; veteran; healthcare; brain injury	POLYTRAUMA-CLINICAL-TRIAD; SUBSTANCE USE DISORDERS; MENTAL-HEALTH; GENDER-DIFFERENCES; COMBAT DEPLOYMENT; OEF/OIF VETERANS; ALCOHOL-USE; CARE; PREVALENCE; SYMPTOMS	Objectives: To identify and validate trajectories of comorbidity associated with traumatic brain injury in male and female Iraq and Afghanistan war Veterans (IAV).Methods: Derivation and validation cohorts were compiled of IAV who entered the Department of Veterans Affairs (VA) care and received 3 years of VA care between 2002-2011. Chronic disease and comorbidities associated with deployment including TBI were identified using diagnosis codes. A latent class analysis (LCA) of longitudinal comorbidity data was used to identify trajectories of comorbidity.Results: LCA revealed five trajectories that were similar for women and men: (1) Healthy, (2) Chronic Disease, (3) Mental Health, (4) Pain and (5) Polytrauma Clinical Triad (PCT: pain, mental health and TBI). Two additional classes found in men were 6) Minor Chronic and 7) PCT with chronic disease. Among these gender-stratified trajectories, it was found that women were more likely to experience headache (Pain trajectory) and depression (Mental Health trajectory), while men were more likely to experience lower back pain (Pain trajectory) and substance use disorder (Mental Health trajectory). The probability of TBI was highest in the PCT-related trajectories, with significantly lower probabilities in other trajectories.Conclusions: It was found that TBI was most common in PCT-related trajectories, indicating that TBI is commonly comorbid with pain and mental health conditions for both men and women. The relatively young age of this cohort raises important questions regarding how disease burden, including the possibility of neurodegenerative sequelae, will accrue alongside normal age-related decline in individuals with TBI. Additional big data' methods and a longer observation period may allow the development of predictive models to identify individuals with TBI that are at-risk for adverse outcomes.	[Pugh, Mary Jo; Finley, Erin P.; Jaramillo, Carlos A.; Swan, Alicia A.; Leykum, Luci K.; Eapen, Blessen A.; Noel, Polly H.; Pugh, Jacqueline A.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA; [Pugh, Mary Jo; Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Finley, Erin P.; Swan, Alicia A.; Leykum, Luci K.; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, Dept Med, San Antonio, TX 78229 USA; [Copeland, Laurel A.] Cent Texas Vet Hlth Baylor Scott & White, Ctr Appl Hlth Res, Temple, TX USA; [Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Dept Med, Bryan, TX USA; [Elnitsky, Christine A.; TRACC Res Team] Univ N Carolina, Sch Nursing, Coll Hlth & Human Serv, Charlotte, NC USA; [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Div Gen Internal Med, Dallas, TX USA; [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr Dallas, Div Gen Internal Med, Dallas, TX USA; [Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA	Pugh, MJ (corresponding author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	pughm@uthscsa.edu	Copeland, Laurel A/C-3763-2017; Swan, Alicia A/O-3536-2018; Pugh, Mary Jo/K-5336-2019; Mortensen, Eric/AAF-2713-2020; Pugh, Jacqueline/I-6199-2013	Copeland, Laurel A/0000-0002-9478-0209; Swan, Alicia A/0000-0003-2412-0499; Pugh, Mary Jo/0000-0003-4196-7763; Pugh, Jacqueline/0000-0003-4933-141X; Noel, Polly/0000-0002-1519-7489; Finley, Erin/0000-0003-4497-7721; Mortensen, Eric/0000-0002-3880-5563	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; South Texas Veterans Healthcare System/Audie L. Murphy Division; Edith Nourse Rogers VA Memorial Hospital; VA Research and Development	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). The funding agency had no role in data collection, analysis or manuscript development. The authors acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the Edith Nourse Rogers VA Memorial Hospital. We also acknowledge assistance with manuscript preparation by Natalie Rohde, Margaret Wells, Barbara Elizondo and Kathleen Franklin. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Drs. Pugh, Finley, Copeland, Jaramillo, Leykum, Mortensen, Eapen and Pugh are VA employees; this study was funded by VA Research and Development.	Abrams TE, 2013, PSYCHIAT SERV, V64, P142, DOI 10.1176/appi.ps.201200217; Bandeen-Roche K, 1997, J AM STAT ASSOC, V92, P1375, DOI 10.2307/2965407; Bean-Mayberry B, 2010, VA EVIDENCE BASED SY; Besterman-Dahan K, 2012, J HEALTH CARE CHAPL, V18, P151, DOI 10.1080/08854726.2012.723538; Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295; Carle A, 2015, CLIN ENDOCRINOL, V83, P717, DOI 10.1111/cen.12787; Chapman PL, 2012, MIL MED, V177, P270, DOI 10.7205/MILMED-D-11-00305; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cornell JE, 2009, APP MULTIVARIATE RES, V12, P163; Cutler JA, 2008, HYPERTENSION, V52, P818, DOI 10.1161/HYPERTENSIONAHA.108.113357; Defense Manpower Data Center, 2012, CONT TRACK SYST PROF; Elnitsky CA, 2013, MIL MED, V178, P775, DOI 10.7205/MILMED-D-13-00012; Falvo MJ, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1124; Fryar Cheryl D, 2012, NCHS Data Brief, P1; Haskell SG, 2012, CLIN J PAIN, V28, P163, DOI 10.1097/AJP.0b013e318223d951; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Janak J.C., 2015, TRAUMATIC BRAIN INJU, P6, DOI [10.2217/fmeb2013.13.296, DOI 10.2217/FMEB2013.13.296]; Kelsall HL, 2015, EPIDEMIOL REV, V37, P38, DOI 10.1093/epirev/mxu014; Kitahara CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034979; Kline A, 2010, AM J PUBLIC HEALTH, V100, P276, DOI 10.2105/AJPH.2009.162925; Krishnan LL, 2005, DEMENT GERIATR COGN, V20, P245, DOI 10.1159/000087345; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Maguen S, 2012, MIL MED, V177, P797, DOI 10.7205/MILMED-D-11-00412; McAndrew LM, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-73; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; National Center for PTSD, 2010, REP VA CONS C PRACT; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Olives C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060308; Patten E., 2011, WOMEN US MILITARY GR; Pietrzak E, 2012, J MIL VETERANS HEALT, V20, P24; Poblador-Plou B, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-84; Prados-Torres A, 2014, J CLIN EPIDEMIOL, V67, P254, DOI 10.1016/j.jclinepi.2013.09.021; Pugh MJ, 2015, EPILEPSIA, V56, P321, DOI 10.1111/epi.12873; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; PUGH MJV, 2015, THE JOURNAL OF HEAD, V30, P29; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Seal KH, 2011, DRUG ALCOHOL DEPEN, V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; Shepperd S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000086; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Street AE, 2013, J GEN INTERN MED, V28, pS556, DOI 10.1007/s11606-013-2333-4; Thomsen CJ, 2011, J PSYCHIATR RES, V45, P1321, DOI 10.1016/j.jpsychires.2011.04.003; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; US Department of Health and Human Services, 2010, MULT CHRON COND STRA; Vanderpump MPJ, 2011, BRIT MED BULL, V99, P39, DOI 10.1093/bmb/ldr030; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1; Vogt D, 2013, MILITARY PSYCHOL DES, P148; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432	53	36	36	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	12					1481	1490		10.1080/02699052.2016.1219055			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ED1IO	WOS:000388599100010	27834535				2021-06-18	
J	Barker-Collo, S; Jones, K; Theadom, A; Starkey, N; Dowell, A; McPherson, K; Ameratunga, S; Dudley, M; Te Ao, B; Feigin, V				Barker-Collo, Suzanne; Jones, Kelly; Theadom, Alice; Starkey, Nicola; Dowell, Anthony; McPherson, Kathryn; Ameratunga, Shanthi; Dudley, Margaret; Te Ao, Braden; Feigin, Valery		BIONIC Res Grp	Neuropsychological outcome and its correlates in the first year after adult mild traumatic brain injury: A population- based New Zealand study	BRAIN INJURY			English	Article							DEPRESSION FOLLOWING MILD; CONCUSSION SYMPTOMS QUESTIONNAIRE; COGNITIVE FAILURES QUESTIONNAIRE; HEAD-INJURY; CONSTRUCT-VALIDITY; HOSPITAL ANXIETY; CULTURAL-BIAS; SCALE; RELIABILITY; DEFICITS		[Barker-Collo, Suzanne] Univ Auckland, Fac Sci, Sch Psychol, Auckland 1141, New Zealand; [Jones, Kelly; Theadom, Alice; Te Ao, Braden; Feigin, Valery] Auckland Univ Technol, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Starkey, Nicola] Univ Waikato, Fac Arts & Social Sci, Sch Psychol, Hamilton, New Zealand; [Dowell, Anthony] Univ Otago, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand; [McPherson, Kathryn] Auckland Univ Technol, Hlth & Rehabil Res Inst, Person Ctr Res Ctr, Auckland, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Auckland 1141, New Zealand; [Dudley, Margaret] Auckland Univ Technol, Sch Publ Hlth & Psychosocial Studies, Auckland, New Zealand	Barker-Collo, S (corresponding author), Univ Auckland, Sch Psychol, Clin Training Programme, Tamaki Campus,Private Bag 92019, Auckland 1141, New Zealand.	s.barker-collo@auckland.ac.nz	Feigin, Valery/AAF-2313-2019; Starkey, Nicola/AAJ-3795-2020; Jones, Kelly/I-5199-2019	Starkey, Nicola/0000-0002-4370-8186; McPherson, Kathryn/0000-0003-1240-8882; Ameratunga, Shanthi/0000-0001-8042-2251; McPherson, Kath/0000-0003-0487-8497; Feigin, Valery L./0000-0002-6372-1740; Te Ao, Braden/0000-0002-1050-200X; Theadom, Alice/0000-0003-0351-6216	New Zealand Health Research CouncilHealth Research Council of New Zealand	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This study was funded by the New Zealand Health Research Council.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arciniegas, 2000, Curr Treat Options Neurol, V2, P169; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arfanakisa K, 2003, AM J NEURORADIOL, V23, P792; Barker-Collo S, 2002, CLIN NEUROPSYCHOL, V16, P290, DOI 10.1076/clin.16.3.290.13856; Barker-Collo SL, 2001, APHASIOLOGY, V15, P85, DOI 10.1080/02687040042000124; Barker-Collo S, 2008, NEW ZEAL J PSYCHOL, V37, P53; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blouin JSM, 2012, INT ENCY REHABILITAT; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Emerson E, 2012, TIZARD LEARN DISABIL, V17, P139, DOI 10.1108/13595471211240988; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Finkelstein E, 2006, INCIDENCE EC BURDEN; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GRIGSBY J, 1992, PERCEPT MOTOR SKILL, V74, P883, DOI 10.2466/PMS.74.3.883-892; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri CT, 2004, AM NEUR ASS ANN M BA; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Heilman K.M., 2003, CLIN NEUROPSYCHOLOGY; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hibbird MR, 1998, AM J PSYCHIAT, V156, P374; Horowitz SH, 2014, STATE LEARNING DISAB; Johnson LG, 2008, MEDSCAPE J MED, V10, P327; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KAYE K, 1990, J AM GERIATR SOC, V38, P1304, DOI 10.1111/j.1532-5415.1990.tb03452.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Michopoulos Ioannis, 2008, Ann Gen Psychiatry, V7, P4, DOI 10.1186/1744-859X-7-4; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ogden J. A., 2003, BRAIN IMPAIR, V4, P122, DOI [10.1375/brim.4.2.122.27026, DOI 10.1375/BRIM.4.2.122.27026]; Ogden JA, 1997, NEW ZEAL J PSYCHOL, V26, P2; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2013, EUR J NEUROL, V20, P1135, DOI 10.1111/ene.12099; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wallace JC, 2004, PERS INDIV DIFFER, V37, P307, DOI 10.1016/j.paid.2003.09.005; Willemsen-van Son A, 2009, J REHABILITATION MED, V41, P521; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	64	36	36	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC 6	2015	29	13-14					1604	1616		10.3109/02699052.2015.1075143			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CY8LL	WOS:000366659800011	26382561				2021-06-18	
J	Figueiro, MG; Hunter, CM; Higgins, PA; Hornick, TR; Jones, GE; Plitnick, B; Brons, J; Rea, MS				Figueiro, Mariana G.; Hunter, Claudia M.; Higgins, Patricia A.; Hornick, Thomas R.; Jones, Geoffrey E.; Plitnick, Barbara; Brons, Jennifer; Rea, Mark S.			Tailored lighting intervention for persons with dementia and caregivers living at home	SLEEP HEALTH			English	Article						Alzheimer's disease; ADRD; dementia; Sleep; Light therapy; Short-wavelength light; Circadian rhythms; Depression	ALZHEIMERS-DISEASE; BRIGHT LIGHT; REST-ACTIVITY; SLEEP QUALITY; RHYTHM DISTURBANCES; ACTION SPECTRUM; THERAPY; EXPOSURES; PATTERNS	Objectives: Light therapy has shown promise as a nonpharmacological treatment to help regulate abnormal sleep-wake patterns and associated behavioral issues prevalent among individuals diagnosed with Alzheimer disease and related dementia (ADRD). The present study investigated the effectiveness of a lighting intervention designed to increase circadian stimulation during the day using light sources that have high short-wavelength content and high light output. Methods: Thirty-five persons with ADRD and 34 caregivers completed the 11-week study. During week 1, subjective questionnaires were administered to the study participants. During week 2, baseline data were collected using Daysimeters and actigraphs. Researchers installed the lighting during week 3, followed by 4 weeks of the tailored lighting intervention. During the last week of the lighting intervention, Daysimeter, actigraph, and questionnaire data were again collected. Three weeks after the lighting intervention was removed, a third data collection (post-intervention assessment) was performed. Results: The lighting intervention significantly increased circadian entrainment, as measured by phasor magnitude, and sleep efficiency, as measured by actigraphy data, and significantly reduced symptoms of depression in the participants with ADRD. The caregivers also exhibited an increase in circadian entrainment during the lighting intervention; a seasonal effect of greater sleep efficiency and longer sleep duration was also found for caregivers. Conclusions: Ambient lighting interventions designed to increase daytime circadian stimulation can be used to increase sleep efficiency in persons with ADRD and their caregivers and may also be effective for other populations such as healthy older adults with sleep problems, adolescents, and veterans with traumatic brain injury. (C) 2015 National Sleep Foundation. Published by Elsevier Inc. All rights reserved.	[Figueiro, Mariana G.; Hunter, Claudia M.; Jones, Geoffrey E.; Plitnick, Barbara; Brons, Jennifer; Rea, Mark S.] Rensselaer Polytech Inst, Lighting Res Ctr, 21 Union St, Troy, NY 12180 USA; [Higgins, Patricia A.] Case Western Reserve Univ, Sch Nursing, Cleveland, OH 44106 USA; [Higgins, Patricia A.; Hornick, Thomas R.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Hornick, Thomas R.] Louis Stokes Cleveland Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Cleveland, OH USA	Figueiro, MG (corresponding author), Rensselaer Polytech Inst, Lighting Res Ctr, 21 Union St, Troy, NY 12180 USA.	figuem@rpi.edu		Jones, Geoffrey/0000-0003-2453-4376; Rea, Mark/0000-0001-8458-9876	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034157]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034157] Funding Source: NIH RePORTER	The study was funded by the National Institute on Aging (grant no. R01AG034157). GE Lighting donated the lamps and ballasts used in the study. The authors would like to acknowledge Ashritha Epur of Case Western Reserve University and the Louis Stokes Cleveland Veterans Affairs Medical Center. Sharon Lesage, Erin Ryan, Brittany Wood, Rebekah Mullaney, and Dennis Guyon of the Lighting Research Center are also acknowledged for their technical and editorial assistance.	Alzheimer's Association, 2015, ESS DIAGN WORK; Ancoli-Israel S., 1989, B CLIN NEUROSCI, V54, P127; Ancoli-Israel Sonia, 2003, Behav Sleep Med, V1, P22, DOI 10.1207/S15402010BSM0101_4; Benedict C, 2015, ALZHEIMERS DEMENT, V11, P1090, DOI 10.1016/j.jalz.2014.08.104; BLIWISE DL, 1993, SLEEP, V16, P40, DOI 10.1093/sleep/16.1.40; BLIWISE DL, 1995, J GERONTOL A-BIOL, V50, pM303, DOI 10.1093/gerona/50A.6.M303; Brainard GC, 2001, J NEUROSCI, V21, P6405; Buchanan DT, 2014, J CLIN SLEEP MED, V10, P1003, DOI 10.5664/jcsm.4038; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Colenda CC, 1997, ALZ DIS ASSOC DIS, V11, P175, DOI 10.1097/00002093-199709000-00011; Figueiro MG, 2013, LIGHTING RES TECHNOL, V45, P421, DOI 10.1177/1477153512450453; Figueiro MG, 2014, CLIN INTERV AGING, V9, P1527, DOI 10.2147/CIA.S68557; Figueiro MG, 2012, J ALZHEIMERS DIS, V31, P711, DOI 10.3233/JAD-2012-120484; Forbes D, 2014, COCHRANE DB SYST REV, V2; Gasio PF, 2003, EXP GERONTOL, V38, P207, DOI 10.1016/S0531-5565(02)00164-X; Hanford N, 2013, J ALZHEIMERS DIS, V33, P913, DOI 10.3233/JAD-2012-121645; Higgins PA, 2010, AM J ALZHEIMERS DIS, V25, P353, DOI 10.1177/1533317510363467; HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804; Ju YES, 2013, JAMA NEUROL, V70, P587, DOI 10.1001/jamaneurol.2013.2334; KATZ B, 1989, ANN NEUROL, V26, P221, DOI 10.1002/ana.410260207; Kouros CD, 2015, J SLEEP RES, V24, P24, DOI 10.1111/jsr.12226; Koyama E, 1999, PSYCHIAT CLIN NEUROS, V53, P227, DOI 10.1046/j.1440-1819.1999.00483.x; Lucey BP, 2014, NEUROBIOL AGING, V35, pS29, DOI 10.1016/j.neurobiolaging.2014.03.035; Lyketsos CG, 1999, INT J GERIATR PSYCH, V14, P520, DOI 10.1002/(SICI)1099-1166(199907)14:7<520::AID-GPS983>3.3.CO;2-D; Mishima K, 1998, CHRONOBIOL INT, V15, P647, DOI 10.3109/07420529808993200; MOORE RY, 1992, PROG BRAIN RES, V93, P101; Neumann PJ, 2000, J AM GERIATR SOC, V48, P1646, DOI 10.1111/j.1532-5415.2000.tb03877.x; Ownby RL, 2001, AM J GERIAT PSYCHIAT, V9, P217, DOI 10.1176/appi.ajgp.9.3.217; PRINZ PN, 1982, J AM GERIATR SOC, V30, P86, DOI 10.1111/j.1532-5415.1982.tb01279.x; Rea Mark S, 2010, J Circadian Rhythms, V8, P2, DOI 10.1186/1740-3391-8-2; Rea Mark S, 2008, J Circadian Rhythms, V6, P7, DOI 10.1186/1740-3391-6-7; Riemersma-van Der Lek RF, 2008, JAMA-J AM MED ASSOC, V299, P2642, DOI 10.1001/jama.299.22.2642; SATLIN A, 1991, NEUROPSYCHOPHARMACOL, V5, P115; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Sloane PD, 2015, LIGHTING RES TECHNOL, V47, P161, DOI 10.1177/1477153513517255; Sloane PD, 2007, J AM GERIATR SOC, V55, P1524, DOI 10.1111/j.1532-5415.2007.01358.x; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; Thapan K, 2001, J PHYSIOL-LONDON, V535, P261, DOI 10.1111/j.1469-7793.2001.t01-1-00261.x; Tonetti L, 2015, SLEEP MED, V16, P936, DOI 10.1016/j.sleep.2015.03.026; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; Wirth MD, 2015, ANN EPIDEMIOL, V25, P773, DOI 10.1016/j.annepidem.2015.05.001; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yamadera H, 2000, PSYCHIAT CLIN NEUROS, V54, P352, DOI 10.1046/j.1440-1819.2000.00711.x	43	36	37	1	10	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	2352-7218	2352-7226		SLEEP HEALTH	Sleep Health	DEC	2015	1	4					322	330		10.1016/j.sleh.2015.09.003			9	Clinical Neurology	Neurosciences & Neurology	VD5ZF	WOS:000437200600017	27066526	Green Accepted			2021-06-18	
J	Karumbaiah, L; Enam, SF; Brown, AC; Saxena, T; Betancur, MI; Barker, TH; Bellamkonda, RV				Karumbaiah, Lohitash; Enam, Syed Faaiz; Brown, Ashley C.; Saxena, Tarun; Betancur, Martha I.; Barker, Thomas H.; Bellamkonda, Ravi V.			Chondroitin Sulfate Glycosaminoglycan Hydrogels Create Endogenous Niches for Neural Stem Cells	BIOCONJUGATE CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; BINDING GROWTH-FACTORS; SPINAL-CORD; EXTRACELLULAR-MATRIX; HYALURONIC-ACID; HYBRID CHAINS; SELF-RENEWAL; MOLECULAR-INTERACTIONS; PROGENITOR CELLS; SYSTEM	Neural stem cells (NSCs) possess great potential for neural tissue repair after traumatic injuries to the central nervous system (CNS). However, poor survival and self-renewal of NSCs after injury severely limits its therapeutic potential. Sulfated chondroitin sulfate glycosaminoglycans (CS-GAGs) linked to CS proteoglycans (CSPGs) in the brain extracellular matrix (ECM) have the ability to bind and potentiate trophic factor efficacy, and promote NSC self-renewal in vivo. In this study, we investigated the potential of CS-GAG hydrogels composed of monosulfated CS-4 (CS-A), CS-6 (CS-C), and disulfated CS-4,6 (CS-E) CS-GAGs as NSC carriers, and their ability to create endogenous niches by enriching specific trophic factors to support NSC self-renewal. We demonstrate that CS-GAG hydrogel scaffolds showed minimal swelling and degradation over a period of 15 days in vitro, absorbing only 6.5 +/- 0.019% of their initial weight, and showing no significant loss of mass during this period. Trophic factors FGF-2, BDNF, and IL10 bound with high affinity to CS-GAGs, and were significantly (p <0.05) enriched in CS-GAG hydrogels when compared to unsulfated hyaluronic acid (HA) hydrogels. Dissociated rat subventricular zone (SVZ) NSCs when encapsulated in CS-GAG hydrogels demonstrated similar to 88.5 +/- 6.1% cell viability in vitro. Finally, rat neurospheres in CS-GAG hydrogels conditioned with the mitogen FGF-2 demonstrated significantly (p < 0.05) higher self-renewal when compared to neurospheres cultured in unconditioned hydrogels. Taken together, these findings demonstrate the ability of CS-GAG based hydrogels to regulate NSC self-renewal, and facilitate growth factor enrichment locally.	[Enam, Syed Faaiz; Saxena, Tarun; Barker, Thomas H.; Bellamkonda, Ravi V.] Emory Univ, Sch Med, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Karumbaiah, Lohitash; Betancur, Martha I.] Univ Georgia, Regenerat Biosci Ctr, Athens, GA 30602 USA; [Brown, Ashley C.] N Carolina State Univ, UNC Chapel Hill, Joint Dept Biomed Engn, Raleigh, NC 27695 USA	Bellamkonda, RV (corresponding author), Emory Univ, Sch Med, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	ravi@gatech.edu		Enam, Syed Faaiz/0000-0002-5320-6809; Karumbaiah, Lohitash/0000-0001-7969-417X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 079739]; Georgia Institute of Technology/Emory University Regenerative Engineering and Medicine Center; University of Georgia Athletic Association; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR00454]; National Institutes of Health (NIH/NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 P41 RR018502-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR018502] Funding Source: NIH RePORTER	This research was supported in part by NIH R01 079739 (RVB), seed grant funding from the Georgia Institute of Technology/Emory University Regenerative Engineering and Medicine Center and The University of Georgia Athletic Association awarded to RVB and LK. This work is also supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR00454. The National Institutes of Health (NIH/NCRR)-funded grant entitled 'Integrated Technology Resource for Biomedical Glycomics' (grant no. 1 P41 RR018502-01) to the Complex Carbohydrate Research Center, The University of Georgia. We would also like to acknowledge Ms. Meghan Logun for technical assistance with SEM imaging, and Dr. Johannes Leisen for technical assistance with NMR.	Akita K, 2008, STEM CELLS, V26, P798, DOI 10.1634/stemcells.2007-0448; Austin JW, 2012, BIOMATERIALS, V33, P4555, DOI 10.1016/j.biomaterials.2012.03.022; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004; Banerjee A, 2009, BIOMATERIALS, V30, P4695, DOI 10.1016/j.biomaterials.2009.05.050; BERTOLOTTO A, 1990, J NEUROL SCI, V100, P113, DOI 10.1016/0022-510X(90)90021-E; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131; Cai SS, 2005, BIOMATERIALS, V26, P6054, DOI 10.1016/j.biomaterials.2005.03.012; Cave JW, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00016; Conovaloff A, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056003; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; DAMON DH, 1988, J CELL PHYSIOL, V135, P293, DOI 10.1002/jcp.1041350217; Deepa SS, 2006, J BIOL CHEM, V281, P17789, DOI 10.1074/jbc.M600544200; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Donaghue IE, 2014, J CONTROL RELEASE, V190, P219, DOI 10.1016/j.jconrel.2014.05.040; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; Emerling DE, 1996, NEURON, V17, P1089, DOI 10.1016/S0896-6273(00)80242-1; Erceg S, 2009, STEM CELLS, V27, P78, DOI 10.1634/stemcells.2008-0543; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; Gerecht S, 2007, P NATL ACAD SCI USA, V104, P11298, DOI 10.1073/pnas.0703723104; Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; Gray JA, 1999, PHILOS T R SOC B, V354, P1407, DOI 10.1098/rstb.1999.0488; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Ida M, 2006, J BIOL CHEM, V281, P5982, DOI 10.1074/jbc.M507130200; Jedrzejas MJ, 2005, PROTEINS, V61, P227, DOI 10.1002/prot.20592; Jeon O, 2009, BIOMATERIALS, V30, P2724, DOI 10.1016/j.biomaterials.2009.01.034; Johnson PJ, 2009, BIOTECHNOL BIOENG, V104, P1207, DOI 10.1002/bit.22476; Joss L, 1998, ANAL BIOCHEM, V261, P203, DOI 10.1006/abio.1998.2744; Karumbaiah L, 2014, CURR MED CHEM, V21, P4257, DOI 10.2174/0929867321666140815124447; Karumbaiah L, 2011, GLIA, V59, P981, DOI 10.1002/glia.21170; Kazanis I, 2011, DEV NEUROBIOL, V71, P1006, DOI 10.1002/dneu.20970; KIANG WL, 1981, J BIOL CHEM, V256, P529; Kim BG, 2007, CELL TRANSPLANT, V16, P355, DOI 10.3727/000000007783464885; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; LAMBERG SI, 1974, J INVEST DERMATOL, V63, P433, DOI 10.1111/1523-1747.ep12680346; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Lawrence R, 2008, NAT METHODS, V5, P291, DOI 10.1038/nmeth0408-291; Li Q, 2004, J BIOMED MATER RES A, V68A, P28, DOI 10.1002/jbm.a.20007; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602; Manzi A, 2001, Curr Protoc Mol Biol, VChapter 17, DOI 10.1002/0471142727.mb1709s32; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MARGOLIS RU, 1967, BIOCHIM BIOPHYS ACTA, V141, P91, DOI 10.1016/0304-4165(67)90248-6; Marshall Gregory P. II, 2008, V438, P135, DOI 10.1007/978-1-59745-133-8_12; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Matsui T, 2012, STEM CELLS, V30, P1109, DOI 10.1002/stem.1091; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Mitsunaga C, 2006, J BIOL CHEM, V281, P18942, DOI 10.1074/jbc.M510870200; Mizumoto S, 2013, GLYCOCONJUGATE J, V30, P619, DOI 10.1007/s10719-012-9463-5; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Oohira A, 2001, SEIKAGAKU, V73, P471; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Park D, 2010, STEM CELLS, V28, P2162, DOI 10.1002/stem.541; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; Saxena T, 2012, J NEUROTRAUM, V29, P1747, DOI 10.1089/neu.2011.1818; Saxena T, 2009, J BIOMED MATER RES A, V90A, P1206, DOI 10.1002/jbm.a.32178; Schwartz NB, 2004, GLYCOCONJUGATE J, V21, P329, DOI 10.1023/B:GLYC.0000046278.34016.36; Seidlits SK, 2010, BIOMATERIALS, V31, P3930, DOI 10.1016/j.biomaterials.2010.01.125; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Sirko S, 2007, DEVELOPMENT, V134, P2727, DOI 10.1242/dev.02871; Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309; Strehin I, 2010, BIOMATERIALS, V31, P2788, DOI 10.1016/j.biomaterials.2009.12.033; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2007, CURR OPIN STRUC BIOL, V17, P536, DOI 10.1016/j.sbi.2007.08.015; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Valmikinathan CM, 2012, SOFT MATTER, V8, P1964, DOI 10.1039/c1sm06629c; Varghese S, 2008, MATRIX BIOL, V27, P12, DOI 10.1016/j.matbio.2007.07.002; Vermonden T, 2008, BIOMACROMOLECULES, V9, P919, DOI 10.1021/bm7013075; Wang SC, 2007, INT J PHARM, V329, P103, DOI 10.1016/j.ijpharm.2006.08.041; Williams CG, 2005, BIOMATERIALS, V26, P1211, DOI 10.1016/j.biomaterials.2004.04.024; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zhong J, 2010, NEUROREHAB NEURAL RE, V24, P636, DOI 10.1177/1545968310361958	98	36	37	4	46	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1043-1802			BIOCONJUGATE CHEM	Bioconjugate Chem.	DEC	2015	26	12					2336	2349		10.1021/acs.bioconjchem.5b00397			14	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic	Biochemistry & Molecular Biology; Chemistry	CZ1PI	WOS:000366877400007	26440046				2021-06-18	
J	Failla, MD; Myrga, JM; Ricker, JH; Dixon, CE; Conley, YP; Wagner, AK				Failla, Michelle D.; Myrga, John M.; Ricker, Joseph H.; Dixon, C. Edward; Conley, Yvette P.; Wagner, Amy K.			Posttraumatic Brain Injury Cognitive Performance Is Moderated by Variation Within ANKK1 and DRD2 Genes	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						ANKK1; cognitive deficits; DRD2; dopamine; genetic variation; Rehabilomics; traumatic brain injury	DOPAMINE-RECEPTOR GENE; TRANSPORTER EXPRESSION; ATTENTION DEFICITS; KINASE GENE; A1 ALLELE; REHABILITATION; POLYMORPHISMS; ASSOCIATION; GENOTYPE; MEMORY	Objective: As dopamine neurotransmission impacts cognition, we hypothesized that variants in the linked dopamine D2 receptor (DRD2) and ankyrin repeat and kinase domain (ANKK1) genes might account for some individual variability in cognitive recovery following traumatic brain injury (TBI). Participants: Prospective cohort of 108 survivors of severe TBI, recruited consecutively from a level 1 trauma center. Design: We examined relationships between DRD2 genetic variation and functional recovery at 6 and 12 months post-TBI. Main Measures: Cognitive performance was evaluated using 8 neuropsychological tests targeting different cognitive domains. An overall cognitive composite was developed using normative data. We also assessed functional cognition, depression status, and global outcome. Subjects were genotyped for 6 DRD2 tagging single-nucleotide polymorphisms and Taq1A within ANKK1. Results: ANKK1 Taq1A heterozygotes performed better than homozygotes across several cognitive domains at both time points postinjury. When adjusting for age, Glasgow Coma Scale score, and education, the Taq1A (ANKK1) and rs6279 (DRD2) variants were associated with overall composite scores at 6 months post-TBI (P =. 0453 and P=. 0452, respectively). At 12months, only Taq1A remained a significant genetic predictor of cognition (P =.0128). Following multiple-comparisons correction, there were no significant associations between examined genetic variants and functional cognition, depression status, and global outcome. Conclusion: These data suggest that genetic variation within DRD2 influences cognitive recovery post-TBI. Understanding genetic influences on dopaminergic systems post-TBI may impact current treatment paradigms.	[Failla, Michelle D.; Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Myrga, John M.; Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Dev, Sch Nursing, Pittsburgh, PA 15213 USA; [Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Ricker, Joseph H.] NYU, Sch Med, Dept Rehabil Med, New York, NY USA; [Dixon, C. Edward] Pittsburgh VA Healthcare Syst, Pittsburgh, PA USA	Wagner, AK (corresponding author), Univ Pittsburgh, Phys Med & Rehabil, Sch Med, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067; Ricker, Joseph/0000-0003-3415-991X	DODUnited States Department of Defense [W81XWH-071-0701]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162, R01NR013342]; NIDRR [H133A120087]; NIH University of Pittsburgh Clinical and Translational Science Institute [UL1TR000005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342] Funding Source: NIH RePORTER	This research was supported by DOD W81XWH-071-0701, NIH R01 HD048162, NIDRR H133A120087, NIH R01NR013342, and NIH UL1TR000005 University of Pittsburgh Clinical and Translational Science Institute.	Aalto S, 2005, J NEUROSCI, V25, P2471, DOI 10.1523/JNEUROSCI.2097-04.2005; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Braver TS, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P713; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Comings DE, 2000, MOL GENET METAB, V71, P19, DOI 10.1006/mgme.2000.3015; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Cools R, 2011, BIOL PSYCHIAT, V69, pE113, DOI 10.1016/j.biopsych.2011.03.028; Dawson JD, 2010, J AM GERIATR SOC, V58, P1090, DOI 10.1111/j.1532-5415.2010.02872.x; Delis DC, 2000, CALIFORNIA VERBAL LE; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Dunlop BW, 2007, ARCH GEN PSYCHIAT, V64, P327, DOI 10.1001/archpsyc.64.3.327; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fleming J, 1999, BRAIN INJURY, V13, P417; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; GOLDMAN D, 1993, ALCOHOL CLIN EXP RES, V17, P199, DOI 10.1111/j.1530-0277.1993.tb00749.x; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Injury Prevention and Control, INJ PREV CONTR TRAUM; JENNETT B, 1975, LANCET, V1, P480; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Laakso A, 2005, PHARMACOGENET GENOM, V15, P387, DOI 10.1097/01213011-200506000-00003; Laine TPJ, 2001, ALCOHOL ALCOHOLISM, V36, P262, DOI 10.1093/alcalc/36.3.262; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; Lee FJS, 2007, EMBO J, V26, P2127, DOI 10.1038/sj.emboj.7601656; Leon-Carrion J, 2013, BRAIN INJURY, V27, P1119, DOI 10.3109/02699052.2013.804204; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mi HY, 2011, PHARMACOGENET GENOM, V21, P350, DOI 10.1097/FPC.0b013e32833ee605; Monakhov M, 2008, SCHIZOPHR RES, V100, P302, DOI 10.1016/j.schres.2008.01.007; Munafo MR, 2007, MOL PSYCHIATR, V12, P454, DOI 10.1038/sj.mp.4001938; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Ponce G, 2009, NEUROTOX RES, V16, P50, DOI 10.1007/s12640-009-9046-9; Reitan RM., 1985, HALSTEAD REITAN NEUR; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Susman M, 2002, J TRAUMA, V53, p[219, 223]; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; van Veelen NMJ, 2010, SCHIZOPHR RES, V120, P191, DOI 10.1016/j.schres.2010.04.011; Voisey J, 2009, DEPRESS ANXIETY, V26, P28, DOI 10.1002/da.20517; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2012, BRAIN INJURY, V26, P1658, DOI 10.3109/02699052.2012.700089; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Willmott C, 2014, J NEUROTRAUM, V31, P1507, DOI 10.1089/neu.2013.3308; Willmott C, 2013, BRAIN INJURY, V27, P1281, DOI 10.3109/02699052.2013.809553; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zhang Y, 2007, P NATL ACAD SCI USA, V104, P20552, DOI 10.1073/pnas.0707106104	73	36	36	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					E54	E66		10.1097/HTR.0000000000000118			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300007	25931179	Green Accepted			2021-06-18	
J	Kim, JH; Ahn, SH; Cho, YW; Kim, SH; Jang, SH				Kim, Jin Hyun; Ahn, Sang Ho; Cho, Yoon Woo; Kim, Seong Ho; Jang, Sung Ho			The Relation Between Injury of the Spinothalamocortical Tract and Central Pain in Chronic Patients With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						central pain; diffusion tensor imaging; spinothalamocortical tract; traumatic brain injury	CENTRAL POSTSTROKE PAIN; SPINAL-CORD-INJURY; DIFFUSION TENSOR TRACTOGRAPHY; THALAMO-CORTICAL PATHWAY; NEUROPATHIC PAIN; CORTICORETICULAR PATHWAY; SENSORY ABNORMALITIES; MECHANISMS; MANAGEMENT; PATHOPHYSIOLOGY	Objectives: Little is known about the pathogenetic etiology of central pain in patients with traumatic brain injury (TBI). We investigated the relation between injury of the spinothalamocortical tract (STT) and chronic central pain in patients with mild TBI. Design: Retrospective survey. Participants: We recruited 40 consecutive chronic patients with mild TBI and 21 normal control subjects: 8 patients were excluded by the inclusion criteria and the remaining 32 patients were finally recruited. The patients were classified according to 2 groups based on the presence of central pain: the pain group (22 patients) and the nonpain group (10 patients). Methods: Diffusion tensor tractography for the STT was performed using the Functional Magnetic Resonance Imaging of the Brain Software Library. Values of fractional anisotropy (FA), mean diffusivity (MD), and tract volume of each STT were measured. Results: Lower FA value and tract volume were observed in the pain group than in the nonpain group and the control group (P <.05). By contrast, higher MD value was observed in the pain group than in the nonpain group and the control group (P <.05). However, no significant differences in all diffusion tensor imaging parameters were observed between the nonpain group and the control group (P >.05). Conclusions: Decreased FA and tract volume and increased MD of the STTs in the pain group appeared to indicate injury of the STT. As a result, we found that injury of the STT is related to the occurrence of central pain in patients with mild TBI. We believe that injury of the STT is a pathogenetic etiology of central pain following mild TBI.	[Kim, Jin Hyun; Ahn, Sang Ho; Cho, Yoon Woo; Jang, Sung Ho] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea; [Kim, Seong Ho] Yeungnam Univ, Coll Med, Dept Neurosurg, Taegu 705717, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2012R1A1A4A01001873]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A4A01001873).	Alexander AL, 2006, NEUROIMAG CLIN N AM, V16, P299, DOI 10.1016/j.nic.2006.02.006; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Barad M., 2009, CONTINUUM MINNEAP MI, V15, P30, DOI 10.1212/01.con.0000348853.20265.b7; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Deppe M, 2013, NEUROIMAGE-CLIN, V2, P258, DOI 10.1016/j.nicl.2013.01.008; Devulder J, 2002, ACTA NEUROL BELG, V102, P97; Ducreux D, 2006, BRAIN, V129, P963, DOI 10.1093/brain/awl016; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; Fillard P, 2011, NEUROIMAGE, V56, P220, DOI 10.1016/j.neuroimage.2011.01.032; Flaherty S A, 1996, AANA J, V64, P133; Goto T, 2008, PAIN, V140, P509, DOI 10.1016/j.pain.2008.10.009; Gustin SM, 2010, CEREB CORTEX, V20, P1409, DOI 10.1093/cercor/bhp205; Haines D.E., 2002, FUNDAMENTAL NEUROSCI; Hong JH, 2011, AM J NEURORADIOL, V32, P1358, DOI 10.3174/ajnr.A2497; Hong JH, 2012, EUR NEUROL, V67, P12, DOI 10.1159/000333012; Hong JH, 2010, EUR NEUROL, V64, P163, DOI 10.1159/000319040; Hong JH, 2010, NEUROSCI LETT, V468, P102, DOI 10.1016/j.neulet.2009.10.075; Jang SH, 2015, J REHABIL MED, V47, P133, DOI 10.2340/16501977-1896; Jang SH, 2013, STROKE, V44, P1099, DOI 10.1161/STROKEAHA.111.000269; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Merskey H, 1994, CLASSIFICATION CHRON; Miller M D, 1993, Fam Pract Res J, V13, P15; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neil JJ, 2008, J MAGN RESON IMAGING, V27, P1, DOI 10.1002/jmri.21087; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Pagani E, 2008, NEUROIMAGE, V41, P657, DOI 10.1016/j.neuroimage.2008.03.021; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Seghier ML, 2005, J PAIN, V6, P208, DOI 10.1016/j.jpain.2004.11.004; Seo JP, 2014, J REHABIL MED, V46, P374, DOI 10.2340/16501977-1783; Seo JP, 2013, BRAIN INJURY, V27, P749, DOI 10.3109/02699052.2013.771794; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tenovuo O, 2007, PAIN, V131, P241, DOI 10.1016/j.pain.2007.07.003; VESTERGAARD K, 1995, PAIN, V61, P177, DOI 10.1016/0304-3959(94)00140-A; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; Wasner G, 2008, BRAIN, V131, P2387, DOI 10.1093/brain/awn169; Wechsler D., 1981, WAIS R MANUAL WECHSL; Williams JM, 1991, MAS MEMORY ASSESSMEN; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yoon EJ, 2013, BRAIN RES, V1540, P64, DOI 10.1016/j.brainres.2013.10.007	51	36	36	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					E40	E46		10.1097/HTR.0000000000000121			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300005	25699625				2021-06-18	
J	Manskow, US; Sigurdardottir, S; Roe, C; Andelic, N; Skandsen, T; Damsgard, E; Elmstahl, S; Anke, A				Manskow, Unn Sollid; Sigurdardottir, Solrun; Roe, Cecilie; Andelic, Nada; Skandsen, Toril; Damsgard, Elin; Elmstahl, Solve; Anke, Audny			Factors Affecting Caregiver Burden 1 Year After Severe Traumatic Brain Injury: A Prospective Nationwide Multicenter Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregiver burden; GOS-E; social network; traumatic brain injury	QUALITY-OF-LIFE; SOCIAL SUPPORT; PSYCHOSOCIAL INTERVENTION; FAMILY CAREGIVERS; DEMENTIA; SCALE; PREDICTORS; APPRAISAL; RELATIVES; DISTRESS	Objectives: To assess burden in the caregivers of patients with severe traumatic brain injury (TBI) 1 year postinjury, related to caregiver's demographic data and social network, patient's demographic data, injury severity, and functional status. Design: Prospective national multicenter study. Self-report from caregivers, patient data collected from the national cohort on patients with severe TBI. Participants: 92 caregivers. Main outcome measure: The Caregiver Burden Scale (CBS). Results: Total caregiver burden was reported high in 16% of caregivers and moderate in 34%. The mean total burden index was 2.12, indicating a moderate burden. Caregivers reported highest scores on the General strain index, followed by the Disappointment index. Poor social network, feeling loneliness, and caring for patients with severe disability were significant predictors of higher burden in univariate analyses (P <.01). Multiple linear regression analyses showed that experiencing loneliness and caring for a patient with more severe disability were independent predictors for higher caregiver burden for all CBS indices. Marital status (married) and low frequency of meeting friends were significant results in some indices. Conclusions: Lack of a social network, feeling loneliness, and patient's functional status are predictors of caregiver burden. General strain, disappointment, and isolation were identified as areas in which caregiver burden is high.	[Manskow, Unn Sollid; Anke, Audny] Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9017 Tromso, Norway; [Manskow, Unn Sollid; Damsgard, Elin] Univ Tromso, Fac Hlth Sci, Dept Hlth & Care Sci, N-9001 Tromso, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Roe, Cecilie; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol, Fac Med, Dept Neurosci, N-7034 Trondheim, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Elmstahl, Solve] Lund Univ, Dept Hlth Sci, Div Geriatr Med, S-22100 Lund, Sweden; [Anke, Audny] Univ Tromso, Dept Clin Med, Fac Hlth Sci, N-9001 Tromso, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, N-0316 Oslo, Norway	Manskow, US (corresponding author), Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9017 Tromso, Norway.	unn.manskow@gmail.com		Anke, Audny/0000-0002-2491-2560; Andelic, Nada/0000-0002-3719-4406	North Norwegian Health Authorities [8744/SFP1108-13]	This study was conducted with grants from the North Norwegian Health Authorities (grant number 8744/SFP1108-13). The authors report no conflicts of interest.	Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andren S, 2008, J CLIN NURS, V17, P790, DOI 10.1111/j.1365-2702.2007.02066.x; Andren S, 2008, SCAND J CARING SCI, V22, P98, DOI 10.1111/j.1471-6712.2007.00498.x; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Annerstedt L, 2000, SCAND J PUBLIC HEALT, V28, P23, DOI 10.1080/713797382; Arango-Lasprilla JC, 2010, NEUROREHABILITATION, V27, P83, DOI 10.3233/NRE-2010-0583; Association for the Advancement of Automotive Medicine, ABBR INJ SCAL AIS 20; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARRERA M, 1986, AM J COMMUN PSYCHOL, V14, P413, DOI 10.1007/BF00922627; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Dahlrup B, 2011, CLIN INTERV AGING, V6, P9, DOI 10.2147/CIA.S14237; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; GEORGE LK, 1989, BRIT J PSYCHIAT, V154, P478, DOI 10.1192/bjp.154.4.478; Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; Hagen C., 1972, LEVELS COGNITIVE FUN; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lefebvre H, 2012, BRAIN INJURY, V26, P1084, DOI 10.3109/02699052.2012.666364; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Norup A, 2012, BRAIN INJURY, V26, P1192, DOI 10.3109/02699052.2012.672790; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu CY, 2011, GEN HOSP PSYCHIAT, V33, P37, DOI 10.1016/j.genhosppsych.2010.10.006	44	36	36	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					411	423		10.1097/HTR.0000000000000085			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300013	25119652				2021-06-18	
J	Rose, NS; Rendell, PG; Hering, A; Kliegel, M; Bidelman, GM; Craik, FIM				Rose, Nathan S.; Rendell, Peter G.; Hering, Alexandra; Kliegel, Matthias; Bidelman, Gavin M.; Craik, Fergus I. M.			Cognitive and neural plasticity in older adults' prospective memory following training with the Virtual Week computer game	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						prospective memory; cognitive training; ERPs (event-related potentials); aging; activities of daily living (ADL); Virtual Week	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; IMPLEMENTATION INTENTIONS; INSTRUMENTAL ACTIVITIES; NEUROLOGICAL DISORDERS; IMPROVING MEMORY; AGE-DIFFERENCES; CUE FOCALITY; REHABILITATION	Prospective memory (PM) - the ability to remember and successfully execute our intentions and planned activities - is critical for functional independence and declines with age, yet few studies have attempted to train PM in older adults. We developed a PM training program using the Virtual Week computer game. Trained participants played the game in 12, 1-h sessions over 1 month. Measures of neuropsychological functions, lab-based PM, event-related potentials (ERPs) during performance on a lab-based PM task, instrumental activities of daily living, and real-world PM were assessed before and after training. Performance was compared to both no-contact and active (music training) control groups. PM on the Virtual Week game dramatically improved following training relative to controls, suggesting PM plasticity is preserved in older adults. Relative to control participants, training did not produce reliable transfer to laboratory-based tasks, but was associated with a reduction of an ERP component (sustained negativity over occipito-parietal cortex) associated with processing PM cues, indicative of more automatic PM retrieval. Most importantly, training produced far transfer to real-world outcomes including improvements in performance on real world PM and activities of daily living. Real-world gains were not observed in either control group. Our findings demonstrate that short-term training with the Virtual Week game produces cognitive and neural plasticity that may result in real-world benefits to supporting functional independence in older adulthood.	[Rose, Nathan S.; Bidelman, Gavin M.; Craik, Fergus I. M.] Rotman Res Inst, Toronto, ON, Canada; [Rose, Nathan S.; Rendell, Peter G.] Australian Catholic Univ, Sch Psychol, Melbourne, Vic, Australia; [Rose, Nathan S.; Rendell, Peter G.] Univ Geneva, Fac Psychol & Sci Educ, Geneva, Switzerland; [Bidelman, Gavin M.] Univ Memphis, Inst Intelligent Syst, Memphis, TN 38152 USA; [Bidelman, Gavin M.] Univ Memphis, Sch Commun Sci & Disorders, Memphis, TN 38152 USA	Rose, NS (corresponding author), Rotman Res Inst, Toronto, ON, Canada.	nathan.rose@acu.edu.au	Hering, Alexandra/AAL-5929-2020; Rendell, Peter/E-7539-2010; Bidelman, Gavin M/D-9998-2016	Hering, Alexandra/0000-0002-7952-9032; Rendell, Peter/0000-0002-4829-4322; Bidelman, Gavin M/0000-0002-1821-3261; Rose, Nathan/0000-0002-7619-4441; Kliegel, Matthias/0000-0002-2001-2522	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Baycrest's Centre for Brain Fitness; Australian Research CouncilAustralian Research Council; Roland Ernst foundation; Centre for Brain Fitness; Suzanna Penningroth	This research was supported in part by grants from the Natural Sciences and Engineering Research Council of Canada, Baycrest's Centre for Brain Fitness, the Australian Research Council, and the Roland Ernst foundation. We thank Sylvain Moreno for supporting the music training program for the active control group which was sponsored by the Centre for Brain Fitness, Suzanna Penningroth for providing data regarding everyday prospective memory tasks that were incorporated into the Virtual Week training program, Trevor Daniels for assistance with programming the Virtual Week training game, and Karen Lau, Brittany Murphy, and Virtual Week for their tireless efforts with data collection.	Bidelman GM, 2015, J NEUROSCI, V35, P1240, DOI 10.1523/JNEUROSCI.3292-14.2015; Bisiacchi PS, 2008, AGING CLIN EXP RES, V20, P569; Brom SS, 2014, PSYCHOL AGING, V29, P744, DOI 10.1037/a0037181; Brom SS, 2014, EUR J AGEING, V11, P89, DOI 10.1007/s10433-013-0288-2; Cona G, 2015, NEUROSCI BIOBEHAV R, V52, P21, DOI 10.1016/j.neubiorev.2015.02.007; Cona G, 2014, CEREB CORTEX, V24, P2630, DOI 10.1093/cercor/bht116; Craik FIM, 2006, MEM COGNITION, V34, P1236, DOI 10.3758/BF03193268; Craik FIM, 2012, J APPL RES MEM COGN, V1, P51, DOI 10.1016/j.jarmac.2011.12.001; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; CROVITZ HF, 1984, B PSYCHONOMIC SOC, V22, P413; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DESMOND DW, 1994, INT J GERIATR PSYCH, V9, P803, DOI 10.1002/gps.930091006; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fish J, 2010, NEUROPSYCHOL REHABIL, V20, P161, DOI 10.1080/09602010903126029; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gollwitzer PM, 1999, AM PSYCHOL, V54, P493, DOI 10.1037//0003-066X.54.7.493; Gross AL, 2012, AGING MENT HEALTH, V16, P722, DOI 10.1080/13607863.2012.667783; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Hering A, 2014, PSYCHOL RES-PSYCH FO, V78, P892, DOI 10.1007/s00426-014-0566-4; Ihle A, 2013, PSYCHOL AGING, V28, P714, DOI 10.1037/a0033653; Kinsella GJ, 2009, J NEUROL NEUROSUR PS, V80, P730, DOI 10.1136/jnnp.2008.148346; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kliegel M, 2003, INT J PSYCHOL, V38, P207, DOI 10.1080/00207590344000132; Kliegel M, 2008, PSYCHOL AGING, V23, P203, DOI 10.1037/0882-7974.23.1.203; Kliegel M, 2012, J APPL RES MEM COGN, V1, P58, DOI 10.1016/j.jarmac.2012.01.002; Lee JH, 2016, BRIT J CLIN PSYCHOL, V55, P154, DOI 10.1111/bjc.12084; Leitz JR, 2009, PSYCHOPHARMACOLOGY, V205, P379, DOI 10.1007/s00213-009-1546-z; Liu LL, 2004, PSYCHOL AGING, V19, P318, DOI 10.1037/0882-7974.19.2.318; Lopez-Calderon J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00213; McDaniel MA, 2014, PSYCHOL AGING, V29, P717, DOI 10.1037/a0037363; McDaniel MA, 2012, J APPL RES MEM COGN, V1, P45, DOI 10.1016/j.jarmac.2011.11.002; McFarland CP, 2011, AGING NEUROPSYCHOL C, V18, P633, DOI 10.1080/13825585.2011.613449; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Moreno S, 2011, PSYCHOL SCI, V22, P1425, DOI 10.1177/0956797611416999; Morrison AB, 2011, PSYCHON B REV, V18, P46, DOI 10.3758/s13423-010-0034-0; Owsley C, 2002, GERONTOLOGY, V48, P254, DOI 10.1159/000058360; Penningroth SL, 2013, EUR J AGEING, V10, P211, DOI 10.1007/s10433-013-0265-9; Phillips L. H., 2008, PROSPECTIVE MEMORY C; Piras F, 2011, EUR J PHYS REHAB MED, V47, P149; Radford K, 2012, J INT NEUROPSYCH SOC, V18, P738, DOI 10.1017/S1355617712000379; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Raven J, 1996, MANUAL RAVENS PROGR; Reichman WE., 2010, AGING HLTH, V6, P565, DOI [DOI 10.2217/AHE.10.54, 10.2217/ahe.10.54]; Rendell PG, 2007, J INT NEUROPSYCH SOC, V13, P410, DOI 10.1017/S1355617707070579; Rendell PG, 2011, COGNITION EMOTION, V25, P916, DOI 10.1080/02699931.2010.508610; Rendell PG, 2000, APPL COGNITIVE PSYCH, V14, pS43, DOI 10.1002/acp.770; Rose NS, 2015, CAN J EXP PSYCHOL, V69, P252, DOI 10.1037/cep0000054; Rose NS, 2010, PSYCHOL AGING, V25, P595, DOI 10.1037/a0019771; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; Shipstead Z, 2012, PSYCHOL BULL, V138, P628, DOI 10.1037/a0027473; Shum D, 2011, J REHABIL MED, V43, P216, DOI 10.2340/16501977-0647; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; Tucker-Drob EM, 2011, NEUROPSYCHOLOGY, V25, P368, DOI 10.1037/a0022348; VERHAEGHEN P, 1992, PSYCHOL AGING, V7, P242, DOI 10.1037/0882-7974.7.2.242; Wallstrom GL, 2004, INT J PSYCHOPHYSIOL, V53, P105, DOI 10.1016/j.ijpsycho.2004.03.007; Wechsler D., 1997, WAIS 3 ADM SCORING M; West R, 2005, PSYCHOPHYSIOLOGY, V42, P698, DOI 10.1111/j.1469-8986.2005.00361.x; West R, 2011, NEUROPSYCHOLOGIA, V49, P2233, DOI 10.1016/j.neuropsychologia.2010.12.028; Woods SP, 2012, J INT NEUROPSYCH SOC, V18, P134, DOI 10.1017/S1355617711001263; Zachary R., 1986, SHIPLEY I LIVING SCA	64	36	38	0	59	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 28	2015	9									10.3389/fnhum.2015.00592			13	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CY5ZS	WOS:000366487300002	26578936	DOAJ Gold, Green Published			2021-06-18	
J	Guilfoyle, MR; Carpenter, KLH; Helmy, A; Pickard, JD; Menon, DK; Hutchinson, PJA				Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Helmy, Adel; Pickard, John D.; Menon, David K.; Hutchinson, Peter J. A.			Matrix Metalloproteinase Expression in Contusional Traumatic Brain Injury: A Paired Microdialysis Study	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; extracellular matrix; microdialysis	THERAPEUTIC HYPOTHERMIA; CEREBROSPINAL-FLUID; FOCAL ISCHEMIA; MATRIX-METALLOPROTEINASE-9; INHIBITION; DOXYCYCLINE; STROKE; EDEMA; BLOOD; RATS	Matrix metalloproteinases (MMPs) are extracellular enzymes that have been implicated in the pathophysiology of blood-brain barrier (BBB) breakdown, contusion expansion, and vasogenic edema after traumatic brain injury (TBI). Specifically, in focal injury models, increased MMP-9 expression has been observed in pericontusional brain, and MMP-9 inhibitors reduce brain swelling and final lesion volume. The aim of this study was to examine whether there is a similarly localized increase of MMP concentrations in patients with contusional TBI. Paired microdialysis catheters were inserted into 12 patients with contusional TBI (with or without associated mass lesion) targeting pericontusional and radiologically normal brain defined on admission computed tomography scan. Microdialysate was pooled every 8h and analyzed for MMP-1, -2, -7, -9, and -10 using a multiplex immunoassay. Concentrations of MMP-1, -2, and -10 were similar at both monitoring sites and did not show discernible temporal trends. Overall, there was a gradual increase in MMP-7 concentrations in both normal and injured brain over the monitoring period, although this was not consistent in every patient. MMP-9 concentrations were elevated in pericontusional, compared to normal, brain, with the maximal difference at the earliest monitoring times (i.e., <24h postinjury). Repeated-measures analysis of variance showed that MMP-9 concentrations were significantly higher in pericontusional brain (p=0.03) and within the first 72h of injury, compared with later in the monitoring period (p=0.04). No significant differences were found for the other MMPs assayed. MMP-9 concentrations are increased in pericontusional brain early post-TBI and may represent a potential therapeutic target to reduce hemorrhagic progression and vasogenic edema.	[Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Helmy, Adel; Pickard, John D.; Hutchinson, Peter J. A.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Menon, David K.] Univ Cambridge, Dept Med, Div Anesthesia, Cambridge CB2 0QQ, England	Guilfoyle, MR (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	mrg48@cam.ac.uk	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Hutchinson, Peter/0000-0002-2796-1835; Carpenter, Keri/0000-0001-8236-7727	National Institute for Health Research (NIHR) Academic Clinical FellowshipNational Institute for Health Research (NIHR); Royal College of Surgeons/Philip King Research Fellowship; Beverley and Raymond Sackler Fellowship; joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship; NIHR Biomedical Research Center, Cambridge; Traumatic Brain Injury NIHR Health Technology Cooperative; NIHR Senior Investigator Award; Cambridge NIHR BRCNational Institute for Health Research (NIHR); NIHR Research Professorship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	M.R.G. was supported by a National Institute for Health Research (NIHR) Academic Clinical Fellowship, a Royal College of Surgeons/Philip King Research Fellowship, and a Beverley and Raymond Sackler Fellowship. A.H. was supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship. K.L.H.C. is supported by the NIHR Biomedical Research Center, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). J.D.P. is supported by the Traumatic Brain Injury NIHR Health Technology Cooperative. D.K.M. is supported by an NIHR Senior Investigator Award. P.J.A.H. is supported by the Cambridge NIHR BRC and an NIHR Research Professorship.	Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Avolio C, 2003, J NEUROIMMUNOL, V136, P46, DOI 10.1016/S0165-5728(03)00006-7; Chen F, 2009, HEPATOLOGY, V50, P1914, DOI 10.1002/hep.23203; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; JENNETT B, 1975, LANCET, V1, P480; Jiang XF, 2001, NEUROSCI LETT, V305, P41, DOI 10.1016/S0304-3940(01)01800-6; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lindeman JHN, 2009, CIRCULATION, V119, P2209, DOI 10.1161/CIRCULATIONAHA.108.806505; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Preshaw PM, 2004, J CLIN PERIODONTOL, V31, P697, DOI 10.1111/j.1600-051X.2004.00558.x; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; Sparano JA, 2004, J CLIN ONCOL, V22, P4683, DOI 10.1200/JCO.2004.08.054; TEASDALE G, 1974, LANCET, V2, P81; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vandooren J, 2013, CRIT REV BIOCHEM MOL, V48, P222, DOI 10.3109/10409238.2013.770819; Vilalta A, 2008, ACTA NEUROCHIR SUPPL, V102, P415, DOI 10.1007/978-3-211-85578-2_81; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zheng KB, 2013, NEUROL INDIA, V61, P606, DOI 10.4103/0028-3886.125258	32	36	37	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2015	32	20					1553	1559		10.1089/neu.2014.3764			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CS6VH	WOS:000362220500002	25858502	Bronze, Green Published			2021-06-18	
J	Bharath, RD; Munivenkatappa, A; Gohel, S; Panda, R; Saini, J; Rajeswaran, J; Shukla, D; Bhagavatula, ID; Biswal, BB				Bharath, Rose D.; Munivenkatappa, Ashok; Gohel, Suril; Panda, Rajanikant; Saini, Jitender; Rajeswaran, Jamuna; Shukla, Dhaval; Bhagavatula, Indira D.; Biswal, Bharat B.			Recovery of resting brain connectivity ensuing mild traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						mild traumatic brain injury; resting state functional connectivity; longitudinal study; time varying changes; brain plasticity; hyper connectivity	DIFFUSE AXONAL INJURY; HEAD-INJURY; FUNCTIONAL CONNECTIVITY; COGNITIVE IMPAIRMENT; WORKING-MEMORY; NETWORK; STATE; DEFICITS; TASK; FMRI	Brains reveal amplified plasticity as they recover from an injury. We aimed to define time dependent plasticity changes in patients recovering from mild traumatic brain injury (mTBI). Twenty-five subjects with mild head injury were longitudinally evaluated within 36 h, 3 and 6 months using resting state functional connectivity (RSFC). Region of interest (ROI) based connectivity differences over time within the patient group and in comparison with a healthy control group were analyzed at p < 0.005. We found 33 distinct ROI pairs that revealed significant changes in their connectivity strength with time. Within 3 months, the majority of the ROI pairs had decreased connectivity in mTBI population, which increased and became comparable to healthy controls at 6 months. Within this diffuse decreased connectivity in the first 3 months, there were also few regions with increased connections. This hyper connectivity involved the salience network and default mode network within 36 h, and lingual, inferior frontal and fronto-parietal networks at 3 months. Our findings in a fairly homogenous group of patients with mTBI evaluated during the 6 month window of recovery defines time varying brain connectivity changes as the brain recovers from an injury. A majority of these changes were seen in the frontal and parietal lobes between 3 and 6 months after injury. Hyper connectivity of several networks supported normal recovery in the first 6 months and it remains to be seen in future studies whether this can predict an early and efficient recovery of brain function.	[Bharath, Rose D.; Panda, Rajanikant] Natl Inst Mental Hlth & Neurosci, Adv Brain Imaging Facil, Cognit Neurosci Ctr, Bangalore 560029, Karnataka, India; [Bharath, Rose D.; Panda, Rajanikant; Saini, Jitender] Natl Inst Mental Hlth & Neurosci, Dept Neuroimaging & Intervent Radiol, Bangalore 560029, Karnataka, India; [Munivenkatappa, Ashok] Natl Inst Mental Hlth & Neurosci, Dept Clin Neurosci, Bangalore 560029, Karnataka, India; [Gohel, Suril; Biswal, Bharat B.] Univ Hts, New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ USA; [Rajeswaran, Jamuna] Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Neuropsychol Unit, Bangalore 560029, Karnataka, India; [Biswal, Bharat B.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India	Bhagavatula, ID (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Hosur Rd, Bangalore 560029, Karnataka, India.	bidevidr@gmaii.com		Panda, Rajanikant/0000-0002-0960-4340; Bharath, Rose Dawn/0000-0002-7464-4250	Department of Science and Technology, IndiaDepartment of Science & Technology (India) [SR/CSI/44/2008(5)]; National Institute of Aging, a part of National Institute of Health, US (NIH) [R01AG032088]	This research work was funded by the Department of Science and Technology, India under the cognitive science initiative, Ref: SR/CSI/44/2008(5). BB and SG are supported by funding from National Institute of Aging, a part of National Institute of Health, US (NIH) [grant number R01AG032088 (BB)]. We thank all the patients who participated in the study for their time and patience especially during the follow up visits. We also acknowledge the staff and radiographers from the Department of Neuroimaging and Interventional Radiology for their technical support during data collection especially during odd hours.	Beason-Held LL, 2009, BRAIN IMAGING BEHAV, V3, P123, DOI 10.1007/s11682-008-9054-z; Bharath RD, 2015, AM J NEURORADIOL, V36, P1890, DOI 10.3174/ajnr.A4373; Bharath RD, 2015, EUR J NEUROL, V22, P796, DOI 10.1111/ene.12653; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Comeau WL, 2010, BEHAV BRAIN RES, V214, P91, DOI 10.1016/j.bbr.2010.04.033; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Giza CC, 2001, J ATHL TRAINING, V36, P228; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kolb B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00377; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Munivenkatappa A, 2014, J NEUROSURG SCI; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rao S.L., 2004, NIMHANS NEUROPSYCHOL; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Shanmukhi S, 2003, NEUROL INDIA, V51, P518; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stamelou M, 2012, BRAIN, V135, P1668, DOI 10.1093/brain/awr224; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Taylor PA, 2013, BRAIN CONNECT, V3, P523, DOI 10.1089/brain.2013.0154; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	43	36	36	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	SEP 22	2015	9								513	10.3389/fnhum.2015.00513			13	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CT2RJ	WOS:000362650900002	26441610	DOAJ Gold, Green Published			2021-06-18	
J	Liu, ZH; Yip, PK; Adams, L; Davies, M; Lee, JW; Michael, GJ; Priestley, JV; Michael-Titus, AT				Liu, Zhuo-Hao; Yip, Ping K.; Adams, Louise; Davies, Meirion; Lee, Jae Won; Michael, Gregory J.; Priestley, John V.; Michael-Titus, Adina T.			A Single Bolus of Docosahexaenoic Acid Promotes Neuroplastic Changes in the Innervation of Spinal Cord Interneurons and Motor Neurons and Improves Functional Recovery after Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article						docosahexaenoic acid; neuroplasticity; omega-3 polyunsaturated fatty acids; spinal cord injury	TRAUMATIC BRAIN-INJURY; POLYUNSATURATED FATTY-ACIDS; ADULT-RAT; CORTICOSPINAL TRACT; SYNAPTIC PLASTICITY; PTEN/MTOR PATHWAY; PTEN INHIBITION; NERVOUS-SYSTEM; IN-VITRO; EXPRESSION	Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid that is essential in brain development and has structural and signaling roles. Acute DHA administration is neuroprotective and promotes functional recovery in animal models of adult spinal cord injury (SCI). However, the mechanisms underlying this recovery have not been fully characterized. Here we investigated the effects of an acute intravenous bolus of DHA delivered after SCI and characterized DHA-induced neuroplasticity within the adult injured spinal cord. We found robust sprouting of uninjured corticospinal and serotonergic fibers in a rat cervical hemisection SCI model. A mouse pyramidotomy model was used to confirm that this robust sprouting was not species or injury model specific. Furthermore, we demonstrated that corticospinal fibers sprouting to the denervated side of the cord following pyramidotomy contact V2a interneurons. We also demonstrated increased serotonin fibers and synaptophysin in direct contact with motor neurons. DHA also increased synaptophysin in rat cortical cell cultures. A reduction in phosphatase and tensin homolog (PTEN) has been shown to be involved in axonal regeneration and synaptic plasticity. We showed that DHA significantly upregulates miR-21 and downregulates PTEN in corticospinal neurons. Downregulation of PTEN and upregulation of phosphorylated AKT by DHA were also seen in primary cortical neuron cultures and were accompanied by increased neurite outgrowth. In summary, acute DHA induces anatomical and synaptic plasticity in adult injured spinal cord. This study shows that DHA has therapeutic potential in cervical SCI and provides evidence that DHA could exert its beneficial effects in SCI via enhancement of neuroplasticity.	[Liu, Zhuo-Hao; Yip, Ping K.; Adams, Louise; Davies, Meirion; Lee, Jae Won; Michael, Gregory J.; Priestley, John V.; Michael-Titus, Adina T.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England; [Liu, Zhuo-Hao] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp, Dept Neurosurg, Linkou 33305, Taiwan	Michael-Titus, AT (corresponding author), Barts & London Queen Marys Sch Med & Dent, Blizard Inst, Ctr Neurosci & Trauma, 4 Newark St, London E1 2AT, England.	a.t.michael-titus@qmul.ac.uk	Liu, Zhuo-Hao/C-6758-2011	Liu, Zhuo-Hao/0000-0003-4079-8697	Chang Gung Memorial Hospital, TaiwanChang Gung Memorial Hospital [CMRPG3A1051-1054]; CMDRP; Barts and the London Charity; Nathalie Rose Barr PhD Studentship ISRT	This work was supported by Chang Gung Memorial Hospital, Taiwan CMRPG3A1051-1054 to Z.-H.L., CMDRP and Barts and the London Charity to P.K.Y. and A.T.M.-T., and the Nathalie Rose Barr PhD Studentship ISRT to L.A. and J.V.P. We thank Prof. F.J. Alvarez for advice on locomotor interneuron markers and Dr. L.-F. Wong for advice on qRT-PCR.	Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Al-Mosawie A, 2007, EUR J NEUROSCI, V26, P3003, DOI 10.1111/j.1460-9568.2007.05907.x; Averill S, 2004, NEUROSCIENCE, V123, P419, DOI 10.1016/j.neuroscience.2003.09.031; Azim E, 2014, NATURE, V508, P357, DOI 10.1038/nature13021; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Cafferty WBJ, 2008, J NEUROSCI, V28, P11998, DOI 10.1523/JNEUROSCI.3877-08.2008; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Cao Y, 2008, NEUROREHAB NEURAL RE, V22, P262, DOI 10.1177/1545968307308550; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; Ciranna L, 2006, CURR NEUROPHARMACOL, V4, P101, DOI 10.2174/157015906776359540; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Ding J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080429; Dougherty KJ, 2010, ANN NY ACAD SCI, V1198, P85, DOI 10.1111/j.1749-6632.2010.05502.x; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Edgerton VR, 2004, ANNU REV NEUROSCI, V27, P145, DOI 10.1146/annurev.neuro.27.070203.144308; Figueroa JD, 2013, J NEUROTRAUM, V30, P853, DOI 10.1089/neu.2012.2718; Fouad K, 2012, EXP NEUROL, V235, P91, DOI 10.1016/j.expneurol.2011.02.009; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gulino R, 2007, NEUROSCI RES, V57, P148, DOI 10.1016/j.neures.2006.10.001; Hains BC, 2002, EXP NEUROL, V175, P347, DOI 10.1006/exnr.2002.7892; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; Hawthorne AL, 2011, J NEUROSCI, V31, P5605, DOI 10.1523/JNEUROSCI.6663-10.2011; Hu JZ, 2013, J NEUROTRAUM, V30, P1349, DOI 10.1089/neu.2012.2748; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Ichiyama RM, 2008, J NEUROSCI, V28, P7370, DOI 10.1523/JNEUROSCI.1881-08.2008; Jordan LM, 2008, BRAIN RES REV, V57, P183, DOI 10.1016/j.brainresrev.2007.07.019; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Kansal S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084627; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Lee SK, 2001, NAT NEUROSCI, V4, P1183, DOI 10.1038/nn750; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Liu G, 2012, EXP NEUROL, V233, P447, DOI 10.1016/j.expneurol.2011.11.018; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Lopez-Dolado E, 2013, J NEUROTRAUM, V30, P191, DOI 10.1089/neu.2012.2530; Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880; Macias M, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-144; Mandal CC, 2012, CARCINOGENESIS, V33, P1897, DOI 10.1093/carcin/bgs198; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Morin C, 2013, RECENT PAT ANTI-CANC, V8, P319, DOI 10.2174/1574891X113089990032; NACIMIENTO W, 1995, ACTA NEUROPATHOL, V90, P552; Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00053; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-6; Puskas LG, 2003, P NATL ACAD SCI USA, V100, P1580, DOI 10.1073/pnas.0337683100; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Ramer LM, 2004, J NEUROSCI, V24, P10796, DOI 10.1523/JNEUROSCI.3337-04.2004; Robson LG, 2010, NEUROBIOL AGING, V31, P678, DOI 10.1016/j.neurobiolaging.2008.05.027; Russell KL, 2013, PROSTAG LEUKOTR ESS, V89, P97, DOI 10.1016/j.plefa.2013.05.004; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sandhir R, 2014, NEUROCHEM INT, V78, P117, DOI 10.1016/j.neuint.2014.09.009; Saruhashi Y, 2009, ARCH ORTHOP TRAUM SU, V129, P1279, DOI 10.1007/s00402-008-0754-z; Solfrizzi V, 2006, NEUROBIOL AGING, V27, P1694, DOI 10.1016/j.neurobiolaging.2005.09.026; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Tetzlaff W, 2009, NAT NEUROSCI, V12, P1077, DOI 10.1038/nn0909-1077; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Venna VR, 2009, PSYCHONEUROENDOCRINO, V34, P199, DOI 10.1016/j.psyneuen.2008.08.025; Wang D, 2011, SPINAL CORD, V49, P486, DOI 10.1038/sc.2010.124; Ward RE, 2010, J NEUROTRAUM, V27, P1769, DOI 10.1089/neu.2010.1348; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wurtman RJ, 2006, BRAIN RES, V1088, P83, DOI 10.1016/j.brainres.2006.03.019; Yip PK, 2006, HUM MOL GENET, V15, P3107, DOI 10.1093/hmg/ddl251; Yip PK, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000399; Zhao J, 2013, NEUROSCIENCE, V238, P242, DOI 10.1016/j.neuroscience.2013.02.046	78	36	38	0	15	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 16	2015	35	37					12733	12752		10.1523/JNEUROSCI.0605-15.2015			20	Neurosciences	Neurosciences & Neurology	CU6RC	WOS:000363659500013	26377463	Green Published, Bronze			2021-06-18	
J	Baker, JG; Leddy, JJ; Darling, SR; Rieger, BP; Mashtare, TL; Sharma, T; Willer, BS				Baker, John G.; Leddy, John J.; Darling, Scott R.; Rieger, Brian P.; Mashtare, Terry L.; Sharma, Tania; Willer, Barry S.			Factors Associated With Problems for Adolescents Returning to the Classroom After Sport-Related Concussion	CLINICAL PEDIATRICS			English	Article						return to learn; sport-related concussion; school problems; symptoms; computer testing; recovery time	SYMPTOMS; RELIABILITY; MANAGEMENT; RECOVERY; ZURICH; PLAY	The primary objective of this study was to determine factors in the clinic setting associated with concussion-related problems in the school setting. A total of 91 student athletes, 13 to 19 years old, completed the SCAT2 and computerized testing during their initial visit to the clinic. During a follow-up telephone interview, one-third reported problems with return to school. The presence of problems reported in school was associated with severity of concussion as represented by recovery time and the overall number of symptoms at the first clinic visit. Gender, age, and previous concussions were not associated with school problems. Athletes with computerized test scores below the ninth percentile were more likely to report school problems. The current study offers some descriptive information for clinicians and ideas for future research related to adolescent athletes with concussion and problems with return to the classroom.	[Baker, John G.; Leddy, John J.; Darling, Scott R.; Mashtare, Terry L.; Sharma, Tania; Willer, Barry S.] SUNY Buffalo, Buffalo, NY 14214 USA; [Rieger, Brian P.] SUNY Upstate Med Univ, Phys Med & Rehabil, Syracuse, NY 13210 USA	Baker, JG (corresponding author), SUNY Buffalo, UBMD Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	jgbaker@buffalo.edu			Robert Rich Family Foundation; Program for Understanding Childhood Concussion and Stroke; Buffalo Bills Team Physician Fund; Buffalo Sabres Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Robert Rich Family Foundation, Program for Understanding Childhood Concussion and Stroke, Buffalo Bills (Ralph Wilson) Team Physician Fund, and the Buffalo Sabres Foundation.	Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2009, BRIT J SPORT MED S1, V43, pi85; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Piland SG, 2003, J ATHL TRAINING, V38, P104; Pontifex MB, 2012, RES Q EXERCISE SPORT, V83, P553; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008	18	36	36	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	SEP	2015	54	10					961	968		10.1177/0009922815588820			8	Pediatrics	Pediatrics	CP6PF	WOS:000360009000005	26084537				2021-06-18	
J	Bigler, ED				Bigler, Erin D.			Neuroimaging as a biomarker in symptom validity and performance validity testing	BRAIN IMAGING AND BEHAVIOR			English	Article						Symptom validity testing; Performance validity testing; Effort; Neuroimaging; Cognitive neuroscience of effort	TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; WHITE-MATTER INJURY; CONVERSION DISORDER; MULTIPLE-SCLEROSIS; COGNITIVE EFFORT; RESPONSE BIAS; PSYCHOLOGICAL-ASSESSMENT; PSYCHOSOCIAL RISK; ILLNESS BEHAVIOR	How neuropsychological assessment findings are deemed valid has been a topic of numerous articles but few have addressed any role that neuroimaging studies could provide. Within military and various clinical samples of individuals undergoing neuropsychological evaluations, high levels of failure on measures of symptom validity testing (SVT) and/or performance validity testing (PVT) have been reported. Where 'failure' is defined as a below cut-score performance on some pre-determined set-point on a SVT/PVT measure, are such failures always indicative of invalid test findings or are there other explanations, especially based on informative neuroimaging findings? This review starts with the premise that even though the SVT/PVT task is designed to be simple and easy to perform, it nonetheless requires intact frontoparietal attention, working memory and task engagement (motivation) networks. If there is damage or pathology within any aspect of these networks as demonstrated by neuroimaging findings, the patient may perform below the cut-point as a result of the underlying damage or pathophysiology. The argument is made that neuroimaging findings should be considered as to where SVT/PVT cut-points are established and there should be much greater flexibility in SVT/PVT measures based on other personal, demographic and neuroimaging information. Several case studies are used to demonstrate these points.	Brigham Young Univ, Dept Psychol & Neurosci Ctr, Provo, UT 84602 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol & Neurosci Ctr, 1001 Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu					Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Arnsten AFT, 2012, NEURON, V76, P223, DOI 10.1016/j.neuron.2012.08.038; Arnsten AFT, 2012, J AM ACAD CHILD PSY, V51, P356, DOI 10.1016/j.jaac.2012.01.008; Aronoff Gerald M, 2007, Pain Pract, V7, P178, DOI 10.1111/j.1533-2500.2007.00126.x; Astafiev SV, 2015, J NEUROTRAUM, V32, P1254, DOI 10.1089/neu.2014.3547; Aybek S, 2014, JAMA PSYCHIAT, V71, P52, DOI 10.1001/jamapsychiatry.2013.2842; Bass C, 2007, J ROY SOC MED, V100, P81, DOI 10.1258/jrsm.100.2.81; Bass C, 2014, LANCET, V383, P1422, DOI 10.1016/S0140-6736(13)62186-8; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; BENDEFELDT F, 1976, ARCH GEN PSYCHIAT, V33, P1250; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bigler E. D., 2015, USE SYMPTOM VALIDITY; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2014, NEUROLOGY, V83, P1226, DOI 10.1212/WNL.0000000000000848; Bigler ED, 2014, NEUROLOGY, V82, P1641, DOI 10.1212/WNL.0000000000000395; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Binder LM, 2014, CLIN NEUROPSYCHOL, V28, P1366, DOI 10.1080/13854046.2014.978383; Bol Y, 2010, CLIN REHABIL, V24, P854, DOI 10.1177/0269215510367540; Bracht T, 2015, J AFFECT DISORDERS, V170, P143, DOI 10.1016/j.jad.2014.08.031; Brancu M, 2014, PSYCHIAT RES, V217, P86, DOI 10.1016/j.psychres.2014.02.025; Braver TS, 2014, COGN AFFECT BEHAV NE, V14, P443, DOI 10.3758/s13415-014-0300-0; Browndyke JN, 2008, BRAIN INJURY, V22, P481, DOI 10.1080/02699050802084894; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Chew LJ, 2013, DEV NEUROSCI-BASEL, V35, P102, DOI 10.1159/000346157; Clark A. L., 2015, WHITE MATTE IN PRESS; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Clery-Melin ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023178; Cooper DB, 2014, J REHABIL RES DEV, V51, P1023, DOI [10.1682/JRRD.2013.05.0104, 10.1682/JRRD.2013.05.0140]; Costanzo ME, 2014, NEUROSCI LETT, V577, P11, DOI 10.1016/j.neulet.2014.05.054; Dahm J, 2015, INJURY, V46, P142, DOI 10.1016/j.injury.2014.07.012; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; DeRight J, 2015, CLIN NEUROPSYCHOL, V29, P101, DOI 10.1080/13854046.2014.989267; Dobryakova E, 2013, J INT NEUROPSYCH SOC, V19, P849, DOI 10.1017/S1355617713000684; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Engelmann JB, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.004.2009; Engstrom M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00140; Esposito F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094222; Farah MJ, 2014, NAT REV NEUROSCI, V15, P123, DOI 10.1038/nrn3665; Ferrari R, 2001, MED HYPOTHESES, V57, P68, DOI 10.1054/mehy.2000.1167; Fervaha G, 2013, NEUROSCI BIOBEHAV R, V37, P2649, DOI 10.1016/j.neubiorev.2013.09.001; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick R.I., 2003, J FORENSIC NEUROPSYC, V2, P1, DOI [DOI 10.1300/J151v02n03_01, 10.1300/J151v02n03_01, DOI 10.1300/J151V02N03_01]; Freedman D., 2015, USE NORMATIVE DATA M; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Gil R, 2010, REV NEUROL-FRANCE, V166, P699, DOI 10.1016/j.neurol.2010.01.002; Gombos VA, 2006, GENET SOC GEN PSYCH, V132, P197, DOI 10.3200/MONO.132.3.197-214; Gondi V, 2010, RADIOTHER ONCOL, V97, P370, DOI 10.1016/j.radonc.2010.09.013; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Groenewold NA, 2015, COGN AFFECT BEHAV NE, V15, P69, DOI 10.3758/s13415-014-0316-5; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Hammar A, 2003, J INT NEUROPSYCH SOC, V9, P954, DOI 10.1017/S1355617703960152; Hammar A, 2012, PSYCHIAT RES, V198, P420, DOI 10.1016/j.psychres.2011.11.020; Hampson NE, 2014, APPL NEUROPSYCH-ADUL, V21, P183, DOI 10.1080/09084282.2013.787425; Harrington ME, 2012, PROG NEUROBIOL, V99, P93, DOI 10.1016/j.pneurobio.2012.07.004; HARTLAGE S, 1993, PSYCHOL BULL, V113, P247, DOI 10.1037/0033-2909.113.2.247; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Herman AB, 2013, J NEUROSCI, V33, P5439, DOI 10.1523/JNEUROSCI.1472-12.2013; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Hoover S, 2014, INT J PSYCHOPHYSIOL, V91, P139, DOI 10.1016/j.ijpsycho.2013.12.009; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Hughes DM, 2015, SOC COGN AFFECT NEUR, V10, P1015, DOI 10.1093/scan/nsu149; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Induruwa I, 2012, J NEUROL SCI, V323, P9, DOI 10.1016/j.jns.2012.08.007; Jak AJ, 2015, J CLIN EXP NEUROPSYC, V37, P379, DOI 10.1080/13803395.2015.1020769; Jobes DA, 2013, PSYCHIATRY, V76, P126, DOI 10.1521/psyc.2013.76.2.126; Johnstone T, 2007, J NEUROSCI, V27, P8877, DOI 10.1523/JNEUROSCI.2063-07.2007; Kamat R, 2014, J CLIN EXP NEUROPSYC, V36, P854, DOI 10.1080/13803395.2014.950636; Kanaan R, 2009, BRAIN, V132, P2889, DOI 10.1093/brain/awp060; Kawa L, 2015, J NEUROTRAUM, V32, P1190, DOI 10.1089/neu.2014.3669; KIMBLE GA, 1950, J EXP PSYCHOL, V40, P248, DOI 10.1037/h0056256; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; Kwan O, 2002, MED HYPOTHESES, V59, P129, DOI 10.1016/S0306-9877(02)00119-6; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P325, DOI 10.1080/13803395.2015.1013021; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larsen JD, 2010, BRAIN INJURY, V24, P89, DOI 10.3109/02699050903508218; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lester K, 2007, J BEHAV MED, V30, P177, DOI 10.1007/s10865-007-9095-6; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Liu XH, 2014, ACTA NEUROPSYCHIATR, V26, P195, DOI 10.1017/neu.2013.47; Lloyd DM, 2014, PSYCHOSOM MED, V76, P413, DOI 10.1097/PSY.0000000000000076; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Lui YW, 2014, NEUROLOGY, V83, P1235, DOI 10.1212/WNL.0000000000000834; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; Matthews G, 2015, HUM FACTORS, V57, P125, DOI 10.1177/0018720814539505; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; Nave KA, 2014, JAMA PSYCHIAT, V71, P582, DOI 10.1001/jamapsychiatry.2014.189; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Nicholson TR, 2014, J NEUROL NEUROSUR PS, V85, P227, DOI 10.1136/jnnp-2013-305012; Nicholson TRJ, 2011, J NEUROL NEUROSUR PS, V82, P1267, DOI 10.1136/jnnp.2008.171306; Nihonmatsu-Kikuchi N, 2013, J ALZHEIMERS DIS, V37, P611, DOI 10.3233/JAD-130752; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; O'Neil EB, 2015, J COGNITIVE NEUROSCI, V27, P1708, DOI 10.1162/jocn_a_00816; Ota M, 2015, PSYCHIAT CLIN NEUROS, V69, P360, DOI 10.1111/pcn.12255; Passarotti AM, 2012, BRAIN CONNECT, V2, P320, DOI 10.1089/brain.2012.0089; Patti F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120754; Pedersen H, 2014, ARCH CLIN NEUROPSYCH, V29; Perez DL, 2012, J NEUROPSYCH CLIN N, V24, P141, DOI 10.1176/appi.neuropsych.11050110; Pessoa L, 2010, FRONT NEUROSCI-SWITZ, V4, DOI [10.3389/fnins.2010.00017, 10.3389/fnhum.2010.00172]; Ploetz DM, 2016, CHILD NEUROPSYCHOL, V22, P133, DOI 10.1080/09297049.2014.986446; Pogoda TK, 2016, J HEAD TRAUMA REHAB, V31, P191, DOI 10.1097/HTR.0000000000000092; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Rey A, 1964, LEXAMEN CLIN PSYCHOL; Rey A., 1958, LEXAMEN CLINIQUE PSY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Robinson MJF, 2014, J NEUROSCI, V34, P16567, DOI 10.1523/JNEUROSCI.2013-14.2014; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2012, J NEUROPSYCH CLIN N, V24, pE33, DOI 10.1176/appi.neuropsych.11020044; Salamone JD, 2007, PSYCHOPHARMACOLOGY, V191, P389, DOI 10.1007/s00213-006-0623-9; Sarter M, 2006, BRAIN RES REV, V51, P145, DOI 10.1016/j.brainresrev.2005.11.002; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Sela I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046527; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Silvia PJ, 2014, MOTIV EMOTION, V38, P779, DOI 10.1007/s11031-014-9443-0; Skerrett TN, 2006, J PSYCHOSOM RES, V61, P587, DOI 10.1016/j.jpsychores.2006.04.018; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Starkstein SE, 2014, PSYCHIAT CLIN N AM, V37, P103, DOI 10.1016/j.psc.2013.10.002; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Storbeck J, 2015, COGNITION EMOTION, V29, P95, DOI 10.1080/02699931.2014.904222; Suchotzki K, 2015, HUM BRAIN MAPP, V36, P427, DOI 10.1002/hbm.22637; Suchy Y, 2012, CLIN NEUROPSYCHOL, V26, P1296, DOI 10.1080/13854046.2012.722230; Sweet JJ, 2013, BEHAV SCI LAW, V31, P756, DOI 10.1002/bsl.2088; Takarada Y, 2014, NEUROSCI RES, V89, P54, DOI 10.1016/j.neures.2014.09.005; Tanner JJ, 2015, CLIN NEUROPSYCHOL, V29, P272, DOI 10.1080/13854046.2015.1008047; Thomas P, 1999, EUR ARCH PSY CLIN N, V249, P79, DOI 10.1007/s004060050070; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; U. S. Armed Forces, 1998, MSMR, V20, P20; U. S. Armed Forces, 1998, MSMR, V20, P23; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; van Hooft EAJ, 2012, J APPL PSYCHOL, V97, P301, DOI 10.1037/a0025711; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wieser GL, 2013, GLIA, V61, P869, DOI 10.1002/glia.22480; Willis PF, 2011, MIL MED, V176, P1426, DOI 10.7205/MILMED-D-11-00168; Yang XH, 2014, PSYCHIAT RES, V220, P874, DOI 10.1016/j.psychres.2014.08.056; Yang Z, 2014, NEUROIMAGE, V99, P80, DOI 10.1016/j.neuroimage.2014.05.034; Young G, 2014, PSYCHOL INJ LAW, V7, P206, DOI 10.1007/s12207-014-9202-2; Zeineh MM, 2015, RADIOLOGY, V274, P517, DOI 10.1148/radiol.14141079; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zorrilla EP, 2013, NEUROSCI BIOBEHAV R, V37, P1932, DOI 10.1016/j.neubiorev.2012.11.019	156	36	36	1	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					421	444		10.1007/s11682-015-9409-1			24	Neuroimaging	Neurosciences & Neurology	CR8LQ	WOS:000361604300005	26100657				2021-06-18	
J	Gabbatore, I; Sacco, K; Angeleri, R; Zettin, M; Bara, BG; Bosco, FM				Gabbatore, Ilaria; Sacco, Katiuscia; Angeleri, Romina; Zettin, Marina; Bara, Bruno G.; Bosco, Francesca M.			Cognitive Pragmatic Treatment: A Rehabilitative Program for Traumatic Brain Injury Individuals	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive; communication; pragmatics; training; traumatic brain injury	CLOSED-HEAD-INJURY; COMMUNICATION PARTNERS; NARRATIVE LANGUAGE; ADULTS; IMPAIRMENTS; SKILLS; MIND; COMPREHENSION; RECOGNITION; DISCOURSE	Objective: To verify the efficacy of Cognitive Pragmatic Treatment (CPT), a new rehabilitation training program for improving communicative-pragmatic abilities. Design: The CPT program consists of 24 group sessions, concerned with improving several communication modalities, theory of mind (ToM), and cognitive components that can affect pragmatic performance, such as awareness and executive functions. Participants: A sample of 15 adults with severe traumatic brain injury. Main Measures: Improvements were evaluated before and after training, using the equivalent forms of the Assessment Battery for Communication (ABaCo), a tool for evaluating comprehension and production of a wide range of pragmatic phenomena. A neuropsychological and ToM assessment was also conducted. Results: The patients' performance improved after training, in terms of both comprehension and production, in all the communication modalities assessed by the ABaCo, that is, linguistic, extralinguistic, paralinguistic, and social appropriateness abilities. The follow-up showed that the improvement of patients persists after 3 months from the end of the training. Conclusions: The results suggest that the CPT program is efficacious in improving communicative-pragmatic abilities in individuals with TBI, and that improvements at this level are still detectable even in chronic patients years after the injury.	[Gabbatore, Ilaria; Sacco, Katiuscia; Angeleri, Romina; Bara, Bruno G.; Bosco, Francesca M.] Univ & Polytech Turin, Ctr Cognit Sci, Dept Psychol, Via Po 14, I-10123 Turin, Italy; [Sacco, Katiuscia] Koelliker Hosp, Brain Imaging Grp, Turin, Italy; [Bara, Bruno G.; Bosco, Francesca M.] Neurosci Inst Turin, Turin, Italy; [Zettin, Marina] Ctr Puzzle, Turin, Italy; [Angeleri, Romina] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Bosco, FM (corresponding author), Univ & Polytech Turin, Ctr Cognit Sci, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	francesca.bosco@unito.it	bosco, francesca marina/B-6746-2013; Gabbatore, Ilaria/AAC-1925-2019	bosco, francesca marina/0000-0001-6101-8587; Gabbatore, Ilaria/0000-0002-9724-8066	Cassa di Risparmio di Torino, CRT, Vivomeglio Project	This research has been supported by Cassa di Risparmio di Torino, CRT, Vivomeglio Project.	Altman D, 1991, PRACTICAL STAT MED R; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; ATEN JL, 1982, J SPEECH HEAR DISORD, V47, P93, DOI 10.1044/jshd.4701.93; Bara B. G., 1998, COGNITION CONTEXT, P317; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara BG., 2010, COGNITIVE PRAGMATICS; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bosco FM, 2004, J PRAGMATICS, V36, P467, DOI 10.1016/S0378-2166(03)00055-9; Bosco FM., 2010, PRAGMATICS ENCY, P391; Bosco FM, INT J HLTH IN PRESS; Bosco FM, 2006, J PRAGMATICS, V38, P1398, DOI 10.1016/j.pragma.2005.06.011; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P290, DOI 10.1016/j.jcomdis.2012.03.002; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Brownell H, 2013, J HEAD TRAUMA REHAB, V28, P446, DOI 10.1097/HTR.0b013e31825b5e85; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cattelani R., 2006, NEUROPSICOLOGIA SIND; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Cummings L., 2014, PRAGMATIC DISORDERS; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dollaghan CA, 2004, J COMMUN DISORD, V37, P391, DOI 10.1016/j.jcomdis.2004.04.002; Driscoll DM, 2011, J NEUROTRAUM, V28, P319, DOI 10.1089/neu.2010.1523; Ehrlich JS., 1985, COGNITIVE REHABILITA, V3, P32; Elman RJ, 1999, J SPEECH LANG HEAR R, V42, P411, DOI 10.1044/jslhr.4202.411; Evans K, 2011, BRAIN INJURY, V25, P767, DOI 10.3109/02699052.2011.576307; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Galetto V, 2013, J NEUROLINGUIST, V26, P649, DOI 10.1016/j.jneuroling.2013.05.004; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gaudreau G, 2013, NEUROPSYCHOLOGY, V27, P702, DOI 10.1037/a0034655; Gindri Gigiane, 2014, Dement. neuropsychol., V8, P58, DOI 10.1590/S1980-57642014DN81000009; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Holland AL, 1991, J NEUROLINGUISTICS, V6, P197, DOI DOI 10.1016/0911-6044(91)90007-6; Huber W, 1996, AACHENER APHASIE TES; Joanette Y., 1990, DISCOURSE ABILITY BR; Johnson JE, 2012, BRAIN INJURY, V26, P1118, DOI 10.3109/02699052.2012.666370; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; MARSHALL RC, 1999, INTRO GROUP TREATMEN; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1999, COMMUNICATION DISORD; McDonald S, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Raven JC, 1947, COLOURED PROGR MAT S; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Sacco K, 2008, J COGN SCI, V9, P111; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spinnler H., 1987, ITALIAN J NEUROLOGIC, V6, P20; Struchen M.A., 2005, REHABILITATION TRAUM, P88; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Tirassa M, 2008, EMERG COMMUN-STUD NE, V10, P81; Togher L, 2013, J REHABIL MED, V45, P637, DOI 10.2340/16501977-1173; Togher L, 2012, DISABIL REHABIL, V34, P1562, DOI 10.3109/09638288.2012.656788; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI DOI 10.1375/BRIM.7.3.246; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	78	36	36	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					E14	E28		10.1097/HTR.0000000000000087			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400003	25310292				2021-06-18	
J	Salvador, E; Burek, M; Forster, C				Salvador, Ellaine; Burek, Malgorzata; Foerster, CarolaY.			Stretch and/or oxygen glucose deprivation (OGD) in an in vitro traumatic brain injury (TBI) model induces calcium alteration and inflammatory cascade	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blood brain barrier; cEND; astrocytes; traumatic brain injury; cell stretch; oxygen-glucose deprivation; calcium level	NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; ENDOTHELIAL-CELLS; RECEPTOR ANTAGONIST; BARRIER PROPERTIES; TIGHT JUNCTIONS; NERVOUS-SYSTEM; EXPRESSION; INTERLEUKIN-1; INHIBITION	The blood-brain barrier (BBB), made up of endothelial cells of capillaries in the brain, maintains the microenvironment of the central nervous system. During ischemia and traumatic brain injury (TBI), cellular disruption leading to mechanical insult results to the BBB being compromised. Oxygen glucose deprivation (OGD) is the most commonly used in vitro model for ischemia. On the other hand, stretch injury is currently being used to model TBI in vitro. In this paper, the two methods are used alone or in combination, to assess their effects on cerebrovascular endothelial cells cEND in the presence or absence of astrocytic factors. Applying severe stretch and/or OGD to cEND cells in our experiments resulted to cell swelling and distortion. Damage to the cells induced release of lactate dehydrogenase enzyme (LDH) and nitric oxide (NO) into the cell culture medium. In addition, mRNA expression of inflammatory markers interleukin (I L)-6, IL-1 alpha chemokine (C-C motif) ligand 2 (CCL2) and tumor necrosis factor (TNF)-alpha also increased. These events could lead to the opening of calcium ion channels resulting to excitotoxicity. This could be demonstrated by increased calcium level in OGD-subjected cEND cells incubated with astrocyte-conditioned medium. Furthermore, reduction of cell membrane integrity decreased tight junction proteins claudin-5 and occludin expression. In addition, permeability of the endothelial cell monolayer increased. Also, since cell damage requires an increased uptake of glucose, expression of glucose transporter glut1 was found to increase at the mRNA level after OGD. Overall, the effects of OGD on cEND cells appear to be more prominent than that of stretch with regards to TJ proteins, NO, glutl expression, and calcium level. Astrocytes potentiate these effects on calcium level in cEND cells. Combining both methods to model TBI in vitro shows a promising improvement to currently available models.	[Salvador, Ellaine; Burek, Malgorzata; Foerster, CarolaY.] Univ Wurzburg, Zentrum Operat Med, Klin & Poliklin Anesthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany	Forster, C (corresponding author), Univ Wurzburg, Zentrum Operat Med, Klin & Poliklin Anesthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	foerster_c@ukw.de	Burek, Malgorzata/AAF-3283-2021	Burek, Malgorzata/0000-0001-6148-2195	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German Research Foundation (DFG) [FO 315/4-]; European Union Seventh Framework Programme (FP7) [HEALTH-F2-2009-241778]	We thank Dr. Winfried Neuhaus of the Department of Pharmaceutical Chemistry, University of Vienna for the helpful discussions. This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under grant number FO 315/4- and the European Union Seventh Framework Programme (FP7/2007-2013) under Grant agreement No. HEALTH-F2-2009-241778 (to CF and MB).	Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; Atlee JL, 2007, COMPLICATIONS ANESTH; Audus K.L., 1991, TARGETED DRUG DELIVE, P43, DOI [10. 1007/978-3-642-75862-1_3, DOI 10.1007/978-3-642-75862-1_3]; AUDUS KL, 1990, PHARM RES-DORDR, V7, P435, DOI 10.1023/A:1015800312910; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berrout J, 2012, BRAIN RES, V1436, P1, DOI 10.1016/j.brainres.2011.11.044; Blecharz KG, 2014, BIOL CELL, V106, DOI 10.1111/boc.201300083; Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4; Brockmann K, 2009, BRAIN DEV-JPN, V31, P545, DOI 10.1016/j.braindev.2009.02.008; Burek M., 2013, J STEROIDS HORMONAL, V5, P1, DOI [10.4172/2157-7536.1000128, DOI 10.4172/2157-7536.1000128]; Burek M, 2012, JOVE-J VIS EXP, DOI 10.3791/4022; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Ceruti S, 2011, NEUROCHEM INT, V59, P259, DOI 10.1016/j.neuint.2011.05.013; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cheung J. Y., 1986, NEW ENGL J MED, V314, P314; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; DINARELLO CA, 1991, BLOOD, V77, P1627; Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Espinoza-Rojo Monica, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P317; FARACI FM, 1994, STROKE, V25, P1679, DOI 10.1161/01.STR.25.8.1679; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Forster C, 2008, HISTOCHEM CELL BIOL, V130, P55, DOI 10.1007/s00418-008-0424-9; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; Forstermann U, 1998, FASEB J, V12, P773; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gidday JM, 1999, J NEUROTRAUM, V16, P27, DOI 10.1089/neu.1999.16.27; Gray H., 2011, ANN QUEENSTOWN UPDAT, P51; Guo XL, 2005, BIOCHEM GENET, V43, P175, DOI 10.1007/s10528-005-1510-5; Haslam G, 2000, CYTOTECHNOLOGY, V32, P63, DOI 10.1023/A:1008121125755; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Jowers CT, 2013, J NEUROSCI METH, V218, P1, DOI 10.1016/j.jneumeth.2013.04.020; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Munaron L, 2000, J CELL PHYSIOL, V185, P454, DOI 10.1002/1097-4652(200012)185:3<454::AID-JCP17>3.0.CO;2-A; Neuhaus W, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00352; Neuhaus W, 2012, NEUROSCI LETT, V506, P44, DOI 10.1016/j.neulet.2011.10.045; Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Salvador E, 2013, JOVE-J VIS EXP, DOI 10.3791/50928; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Silwedel C, 2006, J NEUROIMMUNOL, V179, P37, DOI 10.1016/j.jneuroim.2006.06.019; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Vandamme W, 2004, J NEUROCHEM, V88, P411, DOI 10.1046/j.1471-4159.2003.02163.x; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolterbeek HT, 2005, ASSAY DRUG DEV TECHN, V3, P675, DOI 10.1089/adt.2005.3.675; Yu AS, 2010, AM J PHYSIOL-CELL PH, V299, pC1277, DOI 10.1152/ajpcell.00296.2010; Yu CH, 2011, J VET SCI, V12, P299, DOI 10.4142/jvs.2011.12.3.299	65	36	36	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	AUG 21	2015	9								323	10.3389/fncel.2015.00323			14	Neurosciences	Neurosciences & Neurology	CP8WS	WOS:000360176300001	26347611	DOAJ Gold, Green Published			2021-06-18	
J	Nelson, LD; Pfaller, AY; Rein, LE; McCrea, MA				Nelson, Lindsay D.; Pfaller, Adam Y.; Rein, Lisa E.; McCrea, Michael A.			Rates and Predictors of Invalid Baseline Test Performance in High School and Collegiate Athletes for 3 Computerized Neurocognitive Tests: ANAM, Axon Sports, and ImPACT	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						baseline testing; computerized testing; neurocognitive testing; validity; concussion; mild traumatic brain injury; ImPACT; ANAM; Axon Sports	TEST-RETEST RELIABILITY; FALSE DISCOVERY RATE; CONCUSSION ASSESSMENT; BIOPSYCHOSOCIAL CHARACTERISTICS; COGNITIVE IMPAIRMENT; NORMATIVE DATA; BRAIN-INJURY; SENSITIVITY; SCORES; PREVALENCE	Background: Preseason baseline testing using computerized neurocognitive tests (CNTs) is increasingly performed on athletes. Adequate effort is critical to establish valid estimates of ability, but many users do not evaluate performance validity, and the conditions that affect validity are not well understood across the available CNTs. Purpose: To examine the rates and predictors of invalid baseline performance for 3 popular CNTs: Automated Neuropsychological Assessment Metrics (ANAM), Axon Sports, and Immediate Post-Concussion and Cognitive Testing (ImPACT). Study Design: Controlled laboratory study. Methods: High school and collegiate athletes (N = 2063) completed 2 of 3 CNTs each during preseason evaluations. All possible pairings were present across the sample, and the order of administration was randomized. Examiners provided 1-on-1, scripted pretest instructions, emphasizing the importance of good effort. Profile validity was determined by the manufacturers' standard criteria. Results: The overall percentage of tests flagged as of questionable validity was lowest for ImPACT (2.7%) and higher for ANAM and Axon (10.7% and 11.3%, respectively). The majority of invalid baseline profiles were flagged as such because of failure on only 1 validity criterion. Several athlete and testing factors (eg, attention deficit hyperactivity disorder [ADHD], estimated general intellectual ability, administration order) predicted validity status for 1 or more CNTs. Considering only first CNT administrations and participants without ADHD and/or a learning disability (n = 1835) brought the rates of invalid baseline performances to 2.1%, 8.8%, and 7.0% for ImPACT, ANAM, and Axon, respectively. Invalid profiles on the Medical Symptom Validity Test (MSVT) were rare (1.8% of participants) and demonstrated poor correspondence to CNT validity outcomes. Conclusion: The validity criteria for these CNTs may not identify the same causes of invalidity or be equally sensitive to effort. The validity indicators may not be equally appropriate for some athletes (eg, those with neurodevelopmental disorders). Clinical Relevance: The data suggest that athletes do not put forth widespread low effort or that some validity criteria are more sensitive to invalid performance than others. It is important for examiners to be aware of the conditions that maximize the quality of baseline assessments and to understand what sources of invalid performance are captured by the validity criteria that they obtain.	[Nelson, Lindsay D.; Pfaller, Adam Y.; Rein, Lisa E.; McCrea, Michael A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute grant [1UL1-RR031973 (-01)]; National Center for Advancing Translational Sciences (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: This work was supported by the US Army Medical Research and Materiel Command under award number W81XWH-12-1-0004. This publication was also supported by the Clinical and Translational Science Institute grant 1UL1-RR031973 (-01) and by the National Center for Advancing Translational Sciences (National Institutes of Health) grant 8UL1TR000055.	[Anonymous], 2003, GREENS MED SYMPTOM V; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; ImPACT Applications Inc, TECHN MAN ONL IMPACT; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Moriarity JM, 2012, BRIT J SPORT MED, V46, P1011, DOI 10.1136/bjsports-2011-090893; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Rahman-Filipiak AAM, 2013, NEUROPSYCHOL REV, V23, P314, DOI 10.1007/s11065-013-9241-6; Roebuck-Spencer TM, 2013, ARCH CLIN NEUROPSYCH, V28, P700, DOI 10.1093/arclin/act055; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2014, J ATHL TRAINING, V49, P659, DOI 10.4085/1062-6050-49.3.37; Schatz P, 2014, ARCH CLIN NEUROPSYCH, V29, P625, DOI 10.1093/arclin/acu041; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Solomon GS, 2013, ARCH CLIN NEUROPSYCH, V28, P9, DOI 10.1093/arclin/acs108; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Szabo AJ, 2013, J ATHL TRAINING, V48, P851, DOI 10.4085/1062-6050-48.6.20; Wechsler D., 2001, WECHSLER TEST ADULT; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	44	36	36	1	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2015	43	8					2018	2026		10.1177/0363546515587714			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CO1DF	WOS:000358892400030	26059178	Green Accepted			2021-06-18	
J	Ponsford, J; Schonberger, M; Rajaratnam, SMW				Ponsford, Jennie; Schoenberger, Michael; Rajaratnam, Shantha M. W.			A Model of Fatigue Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							PSYCHIATRIC-DISORDERS; SLEEP; DEPRESSION; SCALE; DISTURBANCES; NEUROENDOCRINE; ASSOCIATION; PREVALENCE; ANXIETY	Objective: Fatigue is one of the most frequent sequelae of traumatic brain injury (TBI), although its causes are poorly understood. This study investigated the interrelationships between fatigue and sleepiness, vigilance performance, depression, and anxiety, using a structural equation modeling approach. Methods: Seventy-two participants with moderate to severe TBI (78% males) were recruited a median of 305 days postinjury. They completed the Fatigue Severity Scale, a vigilance task, the Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. A model of the interrelationships between the study variables was developed, tested, and modified with path analysis. Results: The modified model had a good overall fit (chi(2)(2) = 1.3, P = .54; comparative fit index = 1.0; root-mean square error of approximation = 0.0; standardized root-mean square residual = 0.02). Most paths in this model were significant (P < .05). Fatigue predicted anxiety, depression, and daytime sleepiness. Depression predicted daytime sleepiness and poor vigilance, whereas anxiety tended to predict reduced daytime sleepiness. Conclusions: This model confirms the complexity of fatigue experience. It supports the hypothesis that fatigue after TBI is a cause, not a consequence, of anxiety, depression, and daytime sleepiness, which, in turn (especially depression), may exacerbate fatigue by affecting cognitive functioning. These findings suggest that to alleviate fatigue, it is important to address each of these factors. However, the findings need to be confirmed with a longitudinal research design.	[Ponsford, Jennie; Schoenberger, Michael; Rajaratnam, Shantha M. W.] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol & Psychotherapy, D-79106 Freiburg, Germany	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334002]; Monash UniversityMonash University; Vanda Pharmaceuticals; Takeda Pharmaceuticals North AmericaTakeda Pharmaceutical Company Ltd; Philips Lighting; Philips Respironics; Cephalon; ResMed Foundation	This work was supported by the National Health and Medical Research Council (project ID 334002) and Monash University. The authors acknowledge the contributions of Monique Roper to data collection for this study and Carlo Ziino for design of the vigilance task.; Jennie Ponsford has received royalties from Psychology Press and Guilford Press for textbooks on traumatic brain injury, has received an honorarium, travel, and accommodation support to present a lecture on fatigue and sleep disturbance at the TBI Interagency Conference in Washington, District of Columbia, May 2011. Michael Schonberger reports no conflicts of interest. Shantha Rajaratnam has served as a consultant through his institution to Vanda Pharmaceuticals, Philips Respironics, EdanSafe, The Australian Workers' Union, and National Transport Commission and has through his institution received research grants and/or unrestricted educational grants from Vanda Pharmaceuticals, Takeda Pharmaceuticals North America, Philips Lighting, Philips Respironics, Cephalon, and ResMed Foundation and reimbursements for conference travel expenses from Vanda Pharmaceuticals. His institution has received equipment donations or other support from Optalert, Compumedics, and Tyco Healthcare. He has also served as an expert witness and/or consultant to shift work organizations.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arnett PA, 2002, CLIN NEUROPSYCHOL, V16, P341, DOI 10.1076/clin.16.3.341.13852; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jansson M, 2006, PSYCHOL HEALTH, V21, P383, DOI 10.1080/14768320500129015; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lazarus R.S., 1984, STRESS APPRAISAL COP; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Parasuraman R, 1998, ATTENTIVE BRAIN, P221; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Parkes JD, 1998, J SLEEP RES, V7, P41, DOI 10.1046/j.1365-2869.1998.00093.x; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Strober LB, 2005, ARCH CLIN NEUROPSYCH, V20, P631, DOI 10.1016/j.acn.2005.04.002; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	41	36	36	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					277	282		10.1097/HTR.0000000000000049			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CM8JA	WOS:000357944700006	24721811				2021-06-18	
J	Joyce, AS; Labella, CR; Carl, RL; Lai, JS; Zelko, FA				Joyce, Aisha S.; Labella, Cynthia R.; Carl, Rebecca L.; Lai, Jin-Shei; Zelko, Frank A.			The Postconcussion Symptom Scale: Utility of a Three-Factor Structure	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; MILD TRAUMATIC BRAIN INJURY; PEDIATRIC; ATHLETE; SPORTS	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; PREDICTORS; RECOVERY; VALIDITY; IMPACT	Purpose: This study aimed to determine the factor structure of a 19-item Postconcussion Symptom Scale and to examine associations between factor scores and sex, previous history of concussion, and length of time since injury. Methods: This is a retrospective medical record review of pediatric patients with concussion seen in a sports medicine clinic from April 2008 to September 2012. We performed an exploratory factor analysis (EFA) followed by a confirmatory factor analysis (CFA). ANOVA and regression analysis were used to examine associations between factor scores and sex, previous history of concussion, mood disorder, anxiety disorder or attention-deficit disorder, and length of time since injury. Results: EFA supported a three-factor solution for postconcussive symptoms employing 18 of the original 19 scale items. Factor 1 consisted of eight cognition-related items, factor 2 consisted of six somatic-related items, and factor 3 consisted of four emotional-related items. CFA results confirmed the unidimensionality of factors 1 (neurocognitive), 2 (somatic) and 3 (emotional), with factor 3 being considered borderline. Females and patients with anxiety disorders had significantly worse (higher) scores on all three factors. Patients seen >14 d after the concussive injury had worse (higher) factor 3 (emotional) scores than those seen <14 d after the injury. There was no significant difference in postconcussive symptom factor structures between those with and without a previous history of concussion. Conclusions: Our investigation demonstrates a consistent symptom 3-factor structure of the Postconcussion Symptom Scale in pediatric patients with concussions. Females and patients with anxiety disorders had higher scores than males for all three factors. Patients seen >14 d after concussive injury had higher scores for emotional symptoms, suggesting that prolonged concussion symptoms may affect emotional health.	[Joyce, Aisha S.; Labella, Cynthia R.; Carl, Rebecca L.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Orthopaed Surg & Sports Med, Chicago, IL 60611 USA; [Joyce, Aisha S.; Labella, Cynthia R.; Carl, Rebecca L.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Lai, Jin-Shei] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Zelko, Frank A.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Child & Adolescent Psychiat, Chicago, IL 60611 USA; [Zelko, Frank A.] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA	Joyce, AS (corresponding author), 601 Childrens Lane, Norfolk, VA 23507 USA.	aishasophia@gmail.com	Meijer, Anna/K-5118-2016				CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cook KF, 2009, QUAL LIFE RES, V18, P447, DOI 10.1007/s11136-009-9464-4; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	18	36	36	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2015	47	6					1119	1123		10.1249/MSS.0000000000000534			5	Sport Sciences	Sport Sciences	CI4TC	WOS:000354745500003	25268538				2021-06-18	
J	Peterson, BL; Won, S; Geddes, RI; Sayeed, I; Stein, DG				Peterson, Bethany L.; Won, Soonmi; Geddes, Rastafa I.; Sayeed, Iqbal; Stein, Donald G.			Sex-related differences in effects of progesterone following neonatal hypoxic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Cell proliferation; CNS repair; Development; Microglia; Neuroplasticity; Sex difference	CORTICAL PLASTICITY; GENDER-DIFFERENCES; PREFRONTAL CORTEX; ISCHEMIC INJURY; IMMATURE BRAIN; NEWBORN RATS; NEUROPROTECTION; EXPRESSION; RECOVERY; BEHAVIOR	There is no satisfactory therapeutic intervention for neonatal hypoxic ischemic (HI) encephalopathy. Progesterone is known to be effective in treating traumatic brain injury in adult animals but its effects in neonatal brains have not been reported. Brain injuries were induced by a unilateral common carotid artery ligation plus hypoxia exposure. Progesterone was administered immediately after hypoxia and daily for 5 days at 8 mg/kg, followed by a tapered dose for two days. At six weeks post-injury, lesion size and inflammatory factors were evaluated. Progesterone-treated, HI-injured male animals, but not females, showed significant long-term tissue protection compared to vehicle, suggesting an important sex difference in neuroprotection. Progesterone-treated, HI-injured male rats had fewer activated microglia in the cortex and hippocampus compared to controls. The rats were tested for neurological reflexes, motor asymmetry, and cognitive performance at multiple time points. The injured animals exhibited few detectable motor deficits, suggesting a high level of age- and injury-related neuroplasticity. There were substantial sex differences on several behavioral tests, indicating that immature males and females should be analyzed separately. Progesterone-treated animals showed modest beneficial effects in both sexes compared to vehicle-treated injured animals. Sham animals given progesterone did not behave differently from vehicle-treated sham animals on any measures. (C) 2015 Elsevier B.V. All rights reserved.	[Peterson, Bethany L.; Won, Soonmi; Geddes, Rastafa I.; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020	Geddes, Rastafa/0000-0002-7313-761X	Besins Critical Care; Marcus Foundation; Allen and Company	We thank the Emory Institute for Drug Development for providing the progesterone serum assays used in this experiment. This research was partially supported by an unrestricted gift from Besins Critical Care; the majority of funding was donated by the Marcus Foundation and Allen and Company.	Balduini W, 2000, BRAIN RES, V859, P318, DOI 10.1016/S0006-8993(00)01997-1; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; BARTH TM, 1990, J NEUROSCI, V10, P3449; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; Doverhag C, 2010, NEUROBIOL DIS, V38, P36, DOI 10.1016/j.nbd.2009.12.024; Fan XY, 2010, CURR NEUROPHARMACOL, V8, P324, DOI 10.2174/157015910793358150; Geddes RI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087252; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Goldman PS, 1972, PLASTICITY RECOVERY, P149; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grobin AC, 2003, J NEUROSCI, V23, P1832; Guillet R, 2012, PEDIATR RES, V71, P205, DOI 10.1038/pr.2011.30; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Halliwell C, 2009, DEV NEUROREHABIL, V12, P269, DOI 10.3109/17518420903087715; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1333, DOI 10.1097/01.WCB.0000141559.17620.36; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1317, DOI 10.1097/01.WCB.0000141558.40491.75; Hill CA, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/867531; Hoeger H, 2000, LIFE SCI, V66, P947, DOI 10.1016/S0024-3205(99)00678-5; HUTTENLOCHER PR, 1989, DEV BRAIN RES, V47, P59, DOI 10.1016/0165-3806(89)90108-9; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Kaore SN, 2012, J PHARM PHARMACOL, V64, P1040, DOI 10.1111/j.2042-7158.2012.01464.x; KARTJETILLOTSON G, 1985, BRAIN RES, V332, P103, DOI 10.1016/0006-8993(85)90393-2; Kaur C, 2013, J NEUROIMMUNE PHARM, V8, P66, DOI 10.1007/s11481-012-9347-2; Kellogg CK, 1999, DEV BRAIN RES, V115, P17, DOI 10.1016/S0165-3806(99)00041-3; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kolb B, 2013, PROG BRAIN RES, V207, P35, DOI 10.1016/B978-0-444-63327-9.00005-9; Kolb B, 2011, DEV MED CHILD NEUROL, V53, P4, DOI 10.1111/j.1469-8749.2011.04054.x; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Lenz KM, 2013, J NEUROSCI, V33, P2761, DOI 10.1523/JNEUROSCI.1268-12.2013; Li HF, 2011, J CEREBR BLOOD F MET, V31, P2106, DOI 10.1038/jcbfm.2011.75; Liu YQ, 2002, PEDIATR RES, V51, P25, DOI 10.1203/00006450-200201000-00007; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; Luoma JI, 2012, J STEROID BIOCHEM, V131, P30, DOI 10.1016/j.jsbmb.2011.11.002; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Nakajima W, 2000, J NEUROSCI, V20, P7994; Nemati F, 2012, BEHAV BRAIN RES, V229, P168, DOI 10.1016/j.bbr.2012.01.002; Nudi ET, 2014, J NEUROTRAUMA; Ong J, 2005, PEDIATR RES, V58, P600, DOI 10.1203/01.PDR.0000179381.86809.02; Qiu L, 2007, J CEREBR BLOOD F MET, V27, P785, DOI 10.1038/sj.jcbfm.9600385; Reglodi D, 2003, BEHAV BRAIN RES, V140, P131, DOI 10.1016/S0166-4328(02)00289-9; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Rogers E, 2006, J HEAD TRAUMA REHAB, V21, P279, DOI 10.1097/00001199-200605000-00008; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sabir H, 2012, STROKE, V43, P3364, DOI 10.1161/STROKEAHA.112.674481; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shankaran S, 2012, ARCH DIS CHILD-FETAL, V97, pF398, DOI 10.1136/archdischild-2011-301524; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith AL, 2014, EXP NEUROL, V254, P54, DOI 10.1016/j.expneurol.2014.01.003; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Ten VS, 2003, BEHAV BRAIN RES, V145, P209, DOI 10.1016/S0166-4328(03)00146-3; Thornton C, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/506320; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Wagner CK, 2008, ENDOCRINOLOGY, V149, P2743, DOI 10.1210/en.2008-0049; Wang XY, 2009, J IMMUNOL, V183, P7471, DOI 10.4049/jimmunol.0900762; Wang XY, 2014, INT J NEUROSCI, V124, P42, DOI 10.3109/00207454.2013.817407; Whitaker-Azmitia PM, 2014, MED HYPOTHESES, V82, P313, DOI 10.1016/j.mehy.2013.12.018; Wong R, 2013, J CEREBR BLOOD F MET, V33, P1362, DOI 10.1038/jcbfm.2013.120; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2014, ACAD EMERG MED, V21, P1414, DOI 10.1111/acem.12532; Xu Chun-Yang, 2010, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V26, P370; Zhu CL, 2009, J CEREBR BLOOD F MET, V29, P342, DOI 10.1038/jcbfm.2008.124	68	36	38	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 1	2015	286						152	165		10.1016/j.bbr.2015.03.005			14	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CG8XS	WOS:000353599600023	25746450				2021-06-18	
J	Yaffe, K; Nettiksimmons, J; Yesavage, J; Byers, A				Yaffe, Kristine; Nettiksimmons, Jasmine; Yesavage, Jerome; Byers, Amy			Sleep Quality and Risk of Dementia Among Older Male Veterans	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article						Sleep; dementia; veterans	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DAYTIME SLEEPINESS; BEHAVIOR DISORDER; LEWY BODIES; MEMORY; DEPRIVATION; DISTURBANCE; IMPAIRMENT; SYMPTOMS	Objective: To determine whether a diagnosis of sleep disturbance is associated with dementia in older veterans. Methods: For this retrospective cohort study, we obtained medical record data from the Department of Veterans Affairs National Patient Care Database for 200,000 randomly selected veterans aged 55 years and older. Prevalent cases of dementia from the baseline period (2000-2003) were excluded, leaving an analytic sample of 179,738 male veterans. Follow-up took place from 2004 to 2011. The primary outcome was all-cause dementia, ascertained using International Classification of Disease, Ninth Revision codes. Sleep disturbance, the primary predictor, was also ascertained using these codes. Results: After adjusting for potential confounders, those with sleep disturbance had a 27% increased risk of dementia (hazard ratio: 1.27; 95% confidence interval: 1.20-1.34). Conclusion: Sleep disturbance was associated with increased risk of dementia among a large cohort of older, primarily male veterans.	[Yaffe, Kristine; Nettiksimmons, Jasmine; Byers, Amy] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA; [Yaffe, Kristine; Byers, Amy] San Francisco Veteran Affairs Med Ctr, San Francisco, CA 94121 USA; [Yesavage, Jerome] Stanford Univ, Sch Med, Dept Psychiat Sci, Palo Alto, CA 94304 USA; [Yesavage, Jerome] Stanford Univ, Sch Med, Dept Behav Sci, Palo Alto, CA 94304 USA; [Yesavage, Jerome] Palo Alto Veteran Affairs Med Ctr, Palo Alto, CA USA	Yaffe, K (corresponding author), San Francisco Veteran Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA.	Kristine.yaffe@ucsf.edu			Sierra Pacific VISN Mental Illness Research, Education, and Clinical Centers; Department of DefenseUnited States Department of Defense [W81XWH-11-2-0189]	This study was supported by The Sierra Pacific VISN Mental Illness Research, Education, and Clinical Centers and by a Department of Defense grant (W81XWH-11-2-0189), which was administered by the Northern California Institute for Research and Education.	Ballard C, 2013, DRUG AGING, V30, P603, DOI 10.1007/s40266-013-0092-x; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Blackwell T, 2006, J GERONTOL A-BIOL, V61, P405, DOI 10.1093/gerona/61.4.405; Bliwise Donald L, 2004, Clin Cornerstone, V6 Suppl 1A, pS16, DOI 10.1016/S1098-3597(04)90014-2; Bliwise DL, 2011, DEMENT GERIATR COGN, V31, P239, DOI 10.1159/000326238; Boeve BF, 2013, LANCET NEUROL, V12, P469, DOI 10.1016/S1474-4422(13)70054-1; Canchola AJ, 2003, COX REGRESSION USING; Chen PL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049113; Claassen DO, 2010, NEUROLOGY, V75, P494, DOI 10.1212/WNL.0b013e3181ec7fac; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Elwood PC, 2011, J EPIDEMIOL COMMUN H, V65, P820, DOI 10.1136/jech.2009.100503; Faestel PM, 2013, J CLIN SLEEP MED, V9, P577, DOI 10.5664/jcsm.2754; Foley D, 2004, J PSYCHOSOM RES, V56, P497, DOI 10.1016/j.jpsychores.2004.02.010; Foley D, 2001, J AM GERIATR SOC, V49, P1628, DOI 10.1046/j.1532-5415.2001.t01-1-49271.x; Havekes R, 2012, CELL SIGNAL, V24, P1251, DOI 10.1016/j.cellsig.2012.02.010; Hiestand DM, 2006, CHEST, V130, P780, DOI 10.1378/chest.130.3.780; Iranzo A, 2013, LANCET NEUROL, V12, P443, DOI 10.1016/S1474-4422(13)70056-5; Katz IR, 2012, AM J GERIAT PSYCHIAT, V20, P195, DOI 10.1097/JGP.0b013e3182435f00; Kinoshita LM, 2012, SLEEP BREATH, V16, P1201, DOI 10.1007/s11325-011-0632-8; Knutson KL, 2010, BEST PRACT RES CL EN, V24, P731, DOI 10.1016/j.beem.2010.07.001; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; Ooms S, 2014, JAMA NEUROL, V71, P971, DOI 10.1001/jamaneurol.2014.1173; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Terzaghi M, 2013, MOVEMENT DISORD, V28, P1416, DOI 10.1002/mds.25523; VITIELLO MV, 1991, CAN J PSYCHOL, V45, P221, DOI 10.1037/h0084283; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xu L, 2011, SLEEP, V34, P575, DOI 10.1093/sleep/34.5.575; Yaffe K, 2011, JAMA-J AM MED ASSOC, V306, P613, DOI 10.1001/jama.2011.1115; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61	30	36	36	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1064-7481	1545-7214		AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	JUN	2015	23	6					651	654		10.1016/j.jagp.2015.02.008			4	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	CH9EF	WOS:000354338100013	25794635				2021-06-18	
J	Robertson, CL; Saraswati, M				Robertson, Courtney L.; Saraswati, Manda			Progesterone protects mitochondrial function in a rat model of pediatric traumatic brain injury	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article						Mitochondrial bioenergetics; Glutathione; Neuroprotection; Pediatric brain injury; Trauma	CORTICAL CONTUSION INJURY; IMMATURE RATS; CELL-DEATH; HYPOXIA-ISCHEMIA; N-ACETYLCYSTEINE; OXIDATIVE STRESS; FEMALE RATS; CNS TRAUMA; DYSFUNCTION; RECOVERY	Progesterone has been studied extensively in preclinical models of adult traumatic brain injury (TBI), and has advanced to clinical trials in adults with TBI. However, there are very few preclinical studies in pediatric TBI models investigating progesterone for neuroprotection. Immature male and female rats (postnatal day, PND 17-21) underwent controlled cortical impact (CCI) to the left parietal cortex. Rats received either progesterone (10 mg/kg) at 1 h (i.p.) and 6 h (s.c.) after TBI or vehicle (22.5 % cyclohexdrin), and were compared to na < ve, age-matched littermates. At 24 h after CCI, brain mitochondria were isolated from the ipsilateral hemisphere. Active (State 3) and resting (State 4) mitochondrial respiration were measured, and mitochondrial respiratory control ratio (RCR, State 3/State 4) was determined. Total mitochonidral glutathione content was measured. A separate group of rats were studied for histology, and received progesterone or vehicle every 24 h (s.c.) for 7 days. In male rats, TBI reduced mitochondrial RCR, and progesterone preserved mitochondrial RCR. This improvement of RCR was predominantly through significant decreases in State 4 respiratory rates. In female rats, post-injury treatment with progesterone did not significantly improve mitochondrial RCR. Normal (uninjured) male rats had lower mitochondrial glutathione content than normal female rats. After TBI, progesterone prevented loss of mitochondrial glutathione in male rats only. Tissue loss was reduced in progesterone treated female rats at 7d after CCI. Future studies will be directed at correlation with neurologic outcome testing. These preclinical studies could provide information for planning future clinical trials of progesterone treatment in children with TBI.	[Robertson, Courtney L.; Saraswati, Manda] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Bloomberg Childrens Ctr, Baltimore, MD 21287 USA; [Robertson, Courtney L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA	Robertson, CL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Bloomberg Childrens Ctr, 1800 Orleans St,Room 6321, Baltimore, MD 21287 USA.	crober48@jhmi.edu					Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Baykara B, 2013, BIOTECH HISTOCHEM, V88, P250, DOI 10.3109/10520295.2013.769630; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Gilland E, 1998, J CEREBR BLOOD F MET, V18, P297, DOI 10.1097/00004647-199803000-00008; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOLTZMAN D, 1975, J NEUROCHEM, V24, P1011, DOI 10.1111/j.1471-4159.1975.tb03670.x; HOLTZMAN D, 1973, BIOL NEONATE, V22, P230; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Konkle ATM, 2011, ENDOCRINOLOGY, V152, P223, DOI 10.1210/en.2010-0607; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Manole MD, 2011, CURR PHARM DESIGN, V17, P3854; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Ozacmak VH, 2009, PHYSIOL RES, V58, P909, DOI 10.33549/physiolres.931647; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P43, DOI 10.1016/S0165-3806(00)00111-5; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Shimamura K, 1995, J REPROD FERTIL, V105, P253, DOI 10.1530/jrf.0.1050253; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Uysal N, 2013, TURK NEUROSURG, V23, P129, DOI 10.5137/1019-5149.JTN.5582-11.1; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wallin C, 2000, DEV BRAIN RES, V125, P51, DOI 10.1016/S0165-3806(00)00112-7; Walson KH, 2011, CRIT CARE MED, V39, P335, DOI 10.1097/CCM.0b013e3181ffda0e; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	63	36	36	0	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	APR	2015	47	1-2					43	51		10.1007/s10863-014-9585-5			9	Biophysics; Cell Biology	Biophysics; Cell Biology	CB3UO	WOS:000349554700004	25348484				2021-06-18	
J	Yuan, HJ; Myers, SJ; Wells, G; Nicholson, KL; Swanger, SA; Lyuboslavsky, P; Tahirovic, YA; Menaldino, DS; Ganesh, T; Wilson, LJ; Liotta, DC; Snyder, JP; Traynelis, SF				Yuan, Hongjie; Myers, Scott J.; Wells, Gordon; Nicholson, Katherine L.; Swanger, Sharon A.; Lyuboslavsky, Polina; Tahirovic, Yesim A.; Menaldino, David S.; Ganesh, Thota; Wilson, Lawrence J.; Liotta, Dennis C.; Snyder, James P.; Traynelis, Stephen F.			Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects	NEURON			English	Article							RANDOMIZED CONTROLLED-TRIAL; D-ASPARTATE ANTAGONIST; ACUTE ISCHEMIC STROKE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; AMINO-TERMINAL DOMAIN; CLINICAL-TRIALS; NR2B SUBUNIT; INTRACELLULAR PH; EXTRACELLULAR PH	Stroke remains a significant problem despite decades of work on neuroprotective strategies. NMDA receptor ( NMDAR) antagonists are neuroprotective in preclinical models, but have been clinically unsuccessful, in part due to side effects. Here we describe a prototypical GluN2B-selective antagonist with an IC50 value that is 10-fold more potent at acidic pH 6.9 associated with ischemic tissue compared to pH 7.6, a value close to the pH in healthy brain tissue. This should maximize neuroprotection in ischemic tissue while minimizing on-target side effects associated with NMDAR blockade in noninjured brain regions. We have determined the mechanism underlying pH-dependent inhibition and demonstrate the utility of this approach in vivo. We also identify dicarboxylate dimers as a novel proton sensor in proteins. These results provide insight into the molecular basis of pH-dependent neuroprotective NMDAR block, which could be beneficial in a wide range of neurological insults associated with tissue acidification.	[Yuan, Hongjie; Myers, Scott J.; Swanger, Sharon A.; Lyuboslavsky, Polina; Ganesh, Thota; Traynelis, Stephen F.] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; [Wells, Gordon; Tahirovic, Yesim A.; Menaldino, David S.; Wilson, Lawrence J.; Liotta, Dennis C.; Snyder, James P.] Emory Univ, Dept Chem, Atlanta, GA 30322 USA; [Nicholson, Katherine L.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Nicholson, Katherine L.] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA 23298 USA	Traynelis, SF (corresponding author), Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA.	strayne@emory.edu		Swanger, Sharon/0000-0003-0615-6244	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS036654]; ATDC; EmTech Bio; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036604, R01NS036654, R37NS036654, R01NS065371] Funding Source: NIH RePORTER	This work was supported by NINDS (NS036654 ST), by ATDC (ST), EmTech Bio (RD). We thank Hiro Furukawa for critical comments on the manuscript, and Phuong Le, Jing Zhang, and Anel Tankovic for excellent technical assistance. We thank Ray Dingledine (NS36604) for early contributions and discussion. Several of the authors (Y.A.T., J.P.S., S.J.M., S.F.T., L.J.W., and D.C.L.) are coinventors of patented and patent-pending technology related to glutamate receptors, have an equity position (J.P.S., D.C.L., and S.F.T.), are board members (D.C.L.), paid consultants (S.F.T.), current employees (S.J.M.), or former employees (P.L.,Y.A.T., and L.J.W.) for a company (NeurOp Inc) that has licensed this technology.	Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Balster R L, 1988, Psychopharmacol Ser, V4, P122; Banke TG, 2005, J NEUROSCI, V25, P42, DOI 10.1523/JNEUROSCI.3154-04.2005; BENVENISTE M, 1992, MOL PHARMACOL, V42, P679; Bertorelli R, 1998, NEUROSCI LETT, V246, P41, DOI 10.1016/S0304-3940(98)00221-3; Blagrove M, 2009, PSYCHOPHARMACOLOGY, V203, P109, DOI 10.1007/s00213-008-1377-3; Bombarda E, 2010, J PHYS CHEM B, V114, P1994, DOI 10.1021/jp908926w; Burger PB, 2012, MOL PHARMACOL, V82, P344, DOI 10.1124/mol.112.078568; Chang YQ, 2014, SCIENCE, V344, P1131, DOI 10.1126/science.1252043; Chaperon F, 2003, BEHAV PHARMACOL, V14, P477, DOI 10.1097/01.fbp.0000091471.79060.ed; CHOI DW, 1988, J NEUROSCI, V8, P185; Dawson DA, 2001, BRAIN RES, V892, P344, DOI 10.1016/S0006-8993(00)03269-8; De Vry J, 2003, BEHAV PHARMACOL, V14, P229, DOI 10.1097/00008877-200305000-00007; Diener HC, 2002, J NEUROL, V249, P561, DOI 10.1007/s004150200065; ELLREN K, 1989, NEUROSCIENCE, V32, P371, DOI 10.1016/0306-4522(89)90085-7; Farin A, 2004, ACT NEUR S, V89, P101; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Hamill CE, 2009, EXP NEUROL, V217, P136, DOI 10.1016/j.expneurol.2009.01.023; Hansen KB, 2014, NEURON, V81, P1084, DOI 10.1016/j.neuron.2014.01.035; Harris TK, 2002, IUBMB LIFE, V53, P85, DOI 10.1080/15216540211468; HATFIELD RH, 1992, EUR J PHARMACOL, V216, P1, DOI 10.1016/0014-2999(92)90201-E; Hatton CJ, 2005, NEURON, V46, P261, DOI 10.1016/j.neuron.2005.03.005; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; KAPLAN J, 1987, RESUSCITATION, V15, P149, DOI 10.1016/0300-9572(87)90012-8; Karakas E, 2014, SCIENCE, V344, P992, DOI 10.1126/science.1251915; Karakas E, 2011, NATURE, V475, P249, DOI 10.1038/nature10180; Karakas E, 2009, EMBO J, V28, P3910, DOI 10.1038/emboj.2009.338; KATSURA K, 1992, EUR J NEUROSCI, V4, P166, DOI 10.1111/j.1460-9568.1992.tb00863.x; Katsura K., 1998, P563; Kidwell CS, 2001, STROKE, V32, P1349, DOI 10.1161/01.STR.32.6.1349; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Low CM, 2003, MOL PHARMACOL, V63, P1212, DOI 10.1124/mol.63.6.1212; Macrae CF, 2006, J APPL CRYSTALLOGR, V39, P453, DOI 10.1107/S0021 88980600731X; MATSUMOTO T, 1990, STROKE, V21, P1192, DOI 10.1161/01.STR.21.8.1192; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Mosley CA, 2009, BIOORGAN MED CHEM, V17, P6463, DOI 10.1016/j.bmc.2009.05.085; Mott DD, 1998, NAT NEUROSCI, V1, P659, DOI 10.1038/3661; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581; Nicholson KL, 2007, BEHAV PHARMACOL, V18, P731, DOI 10.1097/FBP.0b013e3282f14ed6; Nutt JG, 2008, MOVEMENT DISORD, V23, P1860, DOI 10.1002/mds.22169; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z; Pahk AJ, 1997, NEUROSCI LETT, V225, P29, DOI 10.1016/S0304-3940(97)00176-6; Preskorn SH, 2008, J CLIN PSYCHOPHARM, V28, P631, DOI 10.1097/JCP.0b013e31818a6cea; Ritschel T, 2009, CHEMBIOCHEM, V10, P716, DOI 10.1002/cbic.200800782; Rowland LM, 2005, AVIAT SPACE ENVIR MD, V76, pC52; Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P1719, DOI 10.1001/jama.285.13.1719; Saver JL, 2013, STROKE, V44, P270, DOI 10.1161/STROKEAHA.112.671354; Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c; Shipman ST, 2007, PHYS CHEM CHEM PHYS, V9, P4572, DOI 10.1039/b704900e; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; Sussman F, 2013, CURR PHARM DESIGN, V19, P4257, DOI 10.2174/1381612811319230009; Tahirovic YA, 2008, J MED CHEM, V51, P5506, DOI 10.1021/jm8002153; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; Tzeli D, 2011, J AM CHEM SOC, V133, P16977, DOI 10.1021/ja206555d; Vance KM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1295; Vasileiou C, 2009, PROTEINS, V76, P281, DOI 10.1002/prot.22334; Wang HC, 2014, NEUROCRIT CARE, V20, P119, DOI 10.1007/s12028-013-9944-9; Wroge CM, 2012, J NEUROSCI, V32, P6732, DOI 10.1523/JNEUROSCI.6371-11.2012; Xiao F, 2004, RESUSCITATION, V61, P209, DOI 10.1016/j.resuscitation.2003.12.022; Yang Y, 2003, J NEUROSURG, V98, P397, DOI 10.3171/jns.2003.98.2.0397; Young D., 2001, COMPUTATIONAL CHEM, P330; Yuan HJ, 2009, J NEUROSCI, V29, P12045, DOI 10.1523/JNEUROSCI.1365-09.2009; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428	71	36	37	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAR 18	2015	85	6					1305	1318		10.1016/j.neuron.2015.02.008			14	Neurosciences	Neurosciences & Neurology	CD8BA	WOS:000351319000016	25728572	Green Accepted, Bronze			2021-06-18	
J	Cuthbert, JP; Harrison-Felix, C; Corrigan, JD; Kreider, S; Bell, JM; Coronado, VG; Whiteneck, GG				Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Corrigan, John D.; Kreider, Scott; Bell, Jeneita M.; Coronado, Victor G.; Whiteneck, Gale G.			Epidemiology of Adults Receiving Acute Inpatient Rehabilitation for a Primary Diagnosis of Traumatic Brain Injury in the United States	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; outcomes; prevalence; rehabilitation; traumatic brain injury	SYSTEMS NATIONAL DATABASE; PRACTICAL SCALE; REPRESENTATIVENESS; ORIENTATION; COMA	Objective: To estimate the overall and by age-group characteristics at admission and discharge from rehabilitation between 2001 and 2010 of all late-teens and adults undergoing inpatient rehabilitation for a primary diagnosis of traumatic brain injury (TBI) in the United States. Design: Secondary data analysis. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 years and older receiving inpatient rehabilitation for a primary diagnosis of TBI between 2001 and 2010. Main Outcome Measures: Functional independence, level of disability, and living situation. Results: The incidence of TBI by age group found the largest proportion of cases to be aged 80 years and older, with a gradual decline in incidence in the age group of 30 years, at which point there was a slight increase. Injuries resulted predominantly from falls (49.8%) and motor vehicle crashes (40.8%); however, injuries to the youngest individuals were largely from motor vehicle crashes with decreasing rates as age increased, while injuries due to falls rose as age increased, with the oldest age groups most likely to incur a TBI. Preinjury alcohol misuse and substance use were found to occur in 22.9% and 12.2% of the total population, respectively; however, age distributions demonstrated high preinjury use among individuals younger than 50 years (eg, 46.4% and 30.6% for those aged 20 and 29 years, respectively) with decreasing misuse as age increased. Of the total population, 49.2% were retired, 31.1% employed, 14.1% not working, and 5.6% students. Trends by age showed that younger individuals were more likely to be students or employed (eg, 14.5% and 62.0% for those aged 20 and 29 years, respectively), with employment status peaking for those aged 30 to 39 years, and declining to 3.2% for the oldest age group (80 years and older). The trend of person(s) living alone between pre- and postrehabilitation showed the least amount of change for those aged 16 to 19 years with steadily increasing changes as age increased. Similar trends were seen for residence changes pre- and postrehabilitation, with the youngest most likely to return to living at a private residence, and a gradual decrease in return to living at a private residence as age increased. FIM instrument ("FIM") Motor and Cognitive subscale scores demonstrated that younger individuals had lower scores at admission to rehabilitation and higher scores at rehabilitation discharge. Conclusion: This study provides population estimates for all patients 16 years of age and older receiving inpatient rehabilitation for a primary diagnosis of TBI in the United States between 2001 and 2010. A recent trend shows the aging of the inpatient TBI rehabilitation population. Many characteristics important to rehabilitation outcomes are influenced by age, with older individuals trending toward being female, having less severe TBIs, incurring TBIs as a result of falls, but showing less improvement during rehabilitation, greater resulting disability, and more changes in their living situation postrehabilitation. These findings are of particular interest, as the oldest age groups considered in these analyses did not include the baby boom population.	[Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Kreider, Scott; Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Bell, Jeneita M.; Coronado, Victor G.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Cuthbert, JP (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	JCuthbert@craighospital.org			US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (NIDRR); NIDRR [H133A110006]; Traumatic Brain Injury Model System Centers grant from NIDRR [H133A070029]; NIDRR	This research was supported by an intra-agency agreement between the US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC) and the US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (NIDRR) with supplemental funding to the NIDRR-funded Traumatic Brain Injury Model Systems National Data and Statistical Center (grant no. H133A110006). It was also supported by a Traumatic Brain Injury Model System Centers grant from NIDRR to Ohio State University (grant no. H133A070029). This article does not reflect the official policy or opinions of the CDC or the US Department of Health and Human Services and does not constitute an endorsement of the individuals or their programs-by CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated. The TBI Model Systems National Database is supported by NIDRR and created and maintained by the TBI Model Systems Centers Program. However, these contents do not necessarily reflect the opinions or views of the TBI Model Systems Centers, NIDRR or the US Department of Education.	American Medical Rehabilitation Providers Association, EREHABDATA 2012; [Anonymous], 1997, GUID UN DAT SET MED; Centers for Disease Control and Preve-ntion, 2011, NAT HOSP DISCH SURV; Centers for Disease Control and Prevention, AUD INS COMM BOOM 19; Coronado V. G., 2012, BRAIN INJURY MED, P45; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan J, 2006, BRAIN INJURY MED PRI, P1105; Corrigan JD, TECHNICAL REPORT PRO; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cruise CM, 2006, CLIN GERIATR MED, V22, P257, DOI 10.1016/j.cger.2005.12.015; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Department of Veterans Affairs and Department of Defense, CLIN PRACT GUID MAN; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Graham J. W., 2003, RES METHODS PSYCHOL; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kalton G., 2003, J OFF STAT, V19, P81; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Medicare Program, 2005, INP REH FAC PROS 412; National Data and Statistical Center, TRAUM BRAIN INJ MOD; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; Uniform Data System, 2012, UN DAT SYST MED REH; *US DEP HHS, 2004, INT CLASS DIS 9 REV	28	36	36	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2015	30	2					122	135		10.1097/HTR.0000000000000012			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CF1MG	WOS:000352309300015	24495917				2021-06-18	
J	Nathan, DE; Oakes, TR; Yeh, PH; French, LM; Harper, JF; Liu, W; Wolfowitz, RD; Wang, B; Graner, JL; Riedy, G				Nathan, Dominic E.; Oakes, Terrence R.; Yeh, Ping Hong; French, Louis M.; Harper, Jamie F.; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan; Graner, John L.; Riedy, Gerard			Exploring Variations in Functional Connectivity of the Resting State Default Mode Network in Mild Traumatic Brain Injury	BRAIN CONNECTIVITY			English	Article						default mode network; dual-regression ICA; exploratory biomarkers of mild TBI; goodness-of-fit measure; neuropsychological assessments of mTBI; resting state fMRI	POSTTRAUMATIC-STRESS-DISORDER; CINGULATE CORTEX; CHRONIC PAIN; ACTIVATION; VETERANS; DEPRESSION; DIAGNOSIS; MILITARY; MEMORY; FMRI	A definitive diagnosis of mild traumatic brain injury (mTBI) is difficult due to the absence of biomarkers in standard clinical imaging. The brain is a complex network of interconnected neurons and subtle changes can modulate key networks of cognitive function. The resting state default mode network (DMN) has been shown to be sensitive to changes induced by pathology. This study seeks to determine whether quantitative measures of the DMN are sensitive in distinguishing mTBI subjects. Resting state functional magnetic resonance imaging data were obtained for healthy (n = 12) and mTBI subjects (n = 15). DMN maps were computed using dual-regression Independent Component Analysis (ICA). A goodness-of-fit (GOF) index was calculated to assess the degree of spatial specificity and sensitivity between healthy controls and mTBI subjects. DMN regions and neuropsychological assessments were examined to identify potential relationships. The resting state DMN maps indicate an increase in spatial coactivity in mTBI subjects within key regions of the DMN. Significant coactivity within the cerebellum and supplementary motor areas of mTBI subjects were also observed. This has not been previously reported in seed-based resting state network analysis. The GOF suggested the presence of high variability within the mTBI subject group, with poor sensitivity and specificity. The neuropsychological data showed correlations between areas of coactivity within the resting state network in the brain with a number of measures of emotion and cognitive functioning. The poor performance of the GOF highlights the key challenge associated with mTBI injury: the high variability in injury mechanisms and subsequent recovery. However, the quantification of the DMN using dual-regression ICA has potential to distinguish mTBI from healthy subjects, and provide information on the relationship of aspects of cognitive and emotional functioning with their potential neural correlates.	[Nathan, Dominic E.; Yeh, Ping Hong; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan] Henry Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Nathan, Dominic E.; Yeh, Ping Hong; Harper, Jamie F.; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan; Riedy, Gerard] Natl Capital Neuroimaging Consortium, Bethesda, MD USA; [Nathan, Dominic E.; Wolfowitz, Rachel D.; Riedy, Gerard] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Nathan, Dominic E.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Nathan, Dominic E.; Oakes, Terrence R.; Yeh, Ping Hong; Harper, Jamie F.; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan; Graner, John L.; Riedy, Gerard] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Dept Neuroimaging, Bethesda, MD USA; [French, Louis M.; Riedy, Gerard] Ctr Neurosci & Regenerat Med, Rockville, MD USA	Riedy, G (corresponding author), Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Natl Capital NeuroImaging Consortium, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	gerard.p.riedy.civ@mail.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense [300606-07.01-60855]; Congressional Directed Medical Research Programs [W81XWH-08-2-0165]	We are grateful to Cara Olson, PhD, Research Assistant Professor and Biostatistics Consultant at the Uniformed Services University of the Health Sciences for assistance with the statistics, Jacob Hershorin, MS, psychometrist at the National Intrepid Center of Excellence, Walter Reed National Military Medical Center for assistance with analysis of the clinical assessment data, and Anthony Panettiere, MD, Neurologist at the National Intrepid Center of Excellence, Walter Reed National Military Medical Center. The views expressed in this article are solely those of the authors and do not reflect official policy of the United States Department of Defense, United States Military, or the United States Government. This research was supported by Center for Neuroscience and Regenerative Medicine (CNRM), (G.R., Henry M. Jackson Foundation Award Number: 300606-07.01-60855) and the Congressional Directed Medical Research Programs (G.R., CDMRP Award Number: W81XWH-08-2-0165).	Baliki MN, 2008, J NEUROSCI, V28, P1398, DOI 10.1523/JNEUROSCI.4123-07.2008; Beckmann C.F., 2009, 15 ANN M ORG HUM BRA; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chikazoe J, 2007, J COGNITIVE NEUROSCI, V19, P69, DOI 10.1162/jocn.2007.19.1.69; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Diedrichsen J, 2009, NEUROIMAGE, V46, P39, DOI 10.1016/j.neuroimage.2009.01.045; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Franklin TR, 2011, DRUG ALCOHOL DEPEN, V117, P176, DOI 10.1016/j.drugalcdep.2011.01.015; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Gerberding JL, 2003, REP C MILD TRAUM BRA; Grabner G, 2006, LECT NOTES COMPUT SC, V4191, P58; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hyvarinen A, 2001, INDEPENDENT COMPONENT ANALYSIS: PRINCIPLES AND PRACTICE, P71; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Koch W, 2012, NEUROBIOL AGING, V33, P466, DOI 10.1016/j.neurobiolaging.2010.04.013; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lane RD, 1998, J COGNITIVE NEUROSCI, V10, P525, DOI 10.1162/089892998562924; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Liang M, 2006, NEUROREPORT, V17, P209, DOI 10.1097/01.wnr.0000198434.06518.b8; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Marx E, 2004, NEUROIMAGE, V21, P1818, DOI 10.1016/j.neuroimage.2003.12.026; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mazoyer B, 2001, BRAIN RES BULL, V54, P287, DOI 10.1016/S0361-9230(00)00437-8; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrella JR, 2011, NEUROLOGY, V76, P511, DOI 10.1212/WNL.0b013e31820af94e; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rapoport M, 2000, J NEUROPSYCH CLIN N, V12, P193, DOI 10.1176/appi.neuropsych.12.2.193; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P421, DOI 10.1097/HTR.0b013e3181c13439; Seminowicz DA, 2007, J NEUROPHYSIOL, V97, P3651, DOI 10.1152/jn.01210.2006; Sheline YI, 2009, P NATL ACAD SCI USA, V106, P1942, DOI 10.1073/pnas.0812686106; Silver JM, 2005, TXB TRAUMATIC BRAIN; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Snell RS, 2009, CLIN NEUROANATOMY; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Uddin LQ, 2008, J NEUROSCI METH, V169, P249, DOI 10.1016/j.jneumeth.2007.11.031; van de Ven VG, 2004, HUM BRAIN MAPP, V22, P165, DOI 10.1002/hbm.20022; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vlassenko A, 2004, J NEUROPSYCH CLIN N, V16, P360, DOI 10.1176/appi.neuropsych.16.3.360; Whitfield-Gabrieli S, 2009, P NATL ACAD SCI USA, V106, P1279, DOI 10.1073/pnas.0809141106; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yan CG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005743; Zoroya G., 2009, 360000 VETERANS MAY; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	64	36	38	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2158-0014	2158-0022		BRAIN CONNECT	Brain Connect.	MAR	2015	5	2					102	114		10.1089/brain.2014.0273			13	Neurosciences	Neurosciences & Neurology	VG7FN	WOS:000448192300004	25222050				2021-06-18	
J	Manoel, ALD; Neto, AC; Veigas, PV; Rizoli, S				de Oliveira Manoel, Airton Leonardo; Capone Neto, Antonio; Veigas, Precilla V.; Rizoli, Sandro			Traumatic Brain Injury Associated Coagulopathy	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Abbreviated injury scale score; Trauma-coagulopathy; DIC	SEVERE HEAD-INJURY; BASE DEFICIT; INTRAVASCULAR COAGULATION; PROGRESSIVE HEMORRHAGE; THROMBOCYTOPENIA; HYPOPERFUSION; RISK	The presence of coagulopathy is common after severe trauma. The aim of this study was to identify whether isolated severe traumatic brain injury (TBI) is an independent risk factor for coagulopathy. Prospective observational cohort of adult patients admitted to a Level I Trauma Center within 6 h of injury. Patients were categorized according to the abbreviated injury scale (AIS): Group 1-isolated severe TBI (AIS head a parts per thousand yen 3 + AIS non-head < 3); Group 2-severe multisystem trauma associated with severe TBI (AIS head a parts per thousand yen 3 + AIS non-head a parts per thousand yen 3); Group 3-severe multisystem trauma without TBI (AIS head < 3 + AIS non-head a parts per thousand yen 3). Primary outcome was the development of coagulopathy. Secondary outcome was in-hospital mortality. Three hundred and forty five patients were included (Group 1 = 48 patients, Group 2 = 137, and Group 3 = 160). Group 1 patients had the lowest incidence of coagulopathy and disseminated intravascular coagulopathy, and in general presented with better coagulation profile measured by either classic coagulation tests, thromboelastography or clotting factors. Isolated severe TBI was not an independent risk factor for the development of coagulopathy (OR 1.06; 0.35-3.22 CI, p = 0.92), however, isolated severe TBI patients who developed coagulopathy had higher mortality rates than isolated severe TBI patients without coagulopathy (66 vs. 16.6 %, p < 0.05). The presence of coagulopathy (OR 5.61; 2.65-11.86 CI, p < 0.0001) and isolated severe TBI (OR 11.51; 3.9-34.2 CI, p < 0.0001) were independent risk factors for in-hospital mortality. Isolated severe TBI is not an independent risk factor for the development of coagulopathy. However, severe TBI patients who develop coagulopathy have extremely high mortality rates.	[de Oliveira Manoel, Airton Leonardo; Rizoli, Sandro] Univ Toronto, St Michaels Hosp, Trauma & Neurosurg Intens Care Unit, Toronto, ON M4N 3M5, Canada; [de Oliveira Manoel, Airton Leonardo] Univ Toronto, St Michaels Hosp, Dept Med Imaging, Toronto, ON M4N 3M5, Canada; [Capone Neto, Antonio] Hosp Israelita Albert Einstein, Adult Intens Care Unit, Sao Paulo, Brazil; [Veigas, Precilla V.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Rizoli, Sandro] Univ Toronto, St Michaels Hosp, Endowed Chair Trauma Res, Toronto, ON M4N 3M5, Canada	Manoel, ALD (corresponding author), Univ Toronto, St Michaels Hosp, Trauma & Neurosurg Intens Care Unit, 30 Bond St Donnelly Wing,Room 3-074B, Toronto, ON M4N 3M5, Canada.	airtonleo.manoel@gmail.com	de Oliveira Manoel, Airton Leonardo/C-4724-2018	de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013	Canadian Institute of Health Research/NovoNordiskNovo NordiskCanadian Institutes of Health Research (CIHR); NovoNordiskNovo Nordisk	S.B.R. received a salary award from the Canadian Institute of Health Research/NovoNordisk, honoraria and speaking fees from NovoNordisk.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; DAVIS JW, 1991, SURG GYNECOL OBSTET, V173, P473; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Frith D, 2010, SURG-J R COLL SURG E, V8, P159, DOI 10.1016/j.surge.2009.10.022; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schrieber M, 2007, J TRAUMA, V63, P1261; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1	33	36	37	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2015	22	1					34	44		10.1007/s12028-014-0026-4			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CA3FH	WOS:000348791300006	25052157				2021-06-18	
J	Duranteau, J; Asehnoune, K; Pierre, S; Ozier, Y; Leone, M; Lefrant, JY				Duranteau, Jacques; Asehnoune, Karim; Pierre, Sebastien; Ozier, Yves; Leone, Marc; Lefrant, Jean-Yves		Grp Travail Soc Francaise Anesthes; SRLF; SFMU; GEHT	Recommendations on the resuscitation of haemorrhagic shock	ANESTHESIE & REANIMATION			French	Article							TRAUMATIC BRAIN-INJURY; FLUID RESUSCITATION; HYPOTENSIVE RESUSCITATION; TRANSFUSION REQUIREMENTS; VOLUME RESUSCITATION; HYDROXYETHYL STARCH; INTRAVENOUS FLUID; LACTATE CLEARANCE; VASCULAR ACCESS; BLOOD LACTATE		[Duranteau, Jacques] Univ Paris Sud XI, Hop Paris, Hop Univ Paris Sud, Serv Anesthesie Reanimat, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France; [Asehnoune, Karim] CHU Nantes, Hotel Dieu, Serv Anesthesie Reanimat Chirurgicale, F-44035 Nantes, France	Duranteau, J (corresponding author), Univ Paris Sud XI, Hop Paris, Hop Univ Paris Sud, Serv Anesthesie Reanimat, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	jacques.duranteau@bct.aphp.fr	Leone, Marc/P-4835-2016	Leone, Marc/0000-0002-3097-758X			Agence nationale de securite du medicament et des produits de sante Haute autorite de Sante, 2012, TRANSF PLASM THER PR; Arnold RC, 2009, SHOCK, V32, P35, DOI 10.1097/SHK.0b013e3181971d47; Bayer O, 2013, CRIT CARE MED, V41, P2532, DOI 10.1097/CCM.0b013e3182978fb6; Bayer O, 2012, CRIT CARE MED, V40, P2543, DOI 10.1097/CCM.0b013e318258fee7; Bayer O, 2011, CRIT CARE MED, V39, P1335, DOI 10.1097/CCM.0b013e318212096a; Bhangu A, 2013, INJURY, V44, P1693, DOI 10.1016/j.injury.2012.07.193; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Bolliger D, 2009, BRIT J ANAESTH, V102, P793, DOI 10.1093/bja/aep098; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; Davenport RA, 2010, BRIT J SURG, V97, P109, DOI 10.1002/bjs.6806; De Backer D, 2010, NEW ENGL J MED, V362, P779, DOI 10.1056/NEJMoa0907118; Downey DM, 2009, AM SURGEON, V75, P1100; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Fenger-Eriksen C, 2010, TRANSFUSION, V50, P2571, DOI 10.1111/j.1537-2995.2010.02752.x; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; FRITZ H, 1965, ACTA MED SCAND, V178, P403; Fuller G, 2014, INJURY, V45, P612, DOI 10.1016/j.injury.2013.09.008; Grottke O, 2010, CRIT CARE, V14, DOI 10.1186/cc8960; GUEUGNIAUD PY, 1987, LANCET, V2, P573; Hampton DA, 2013, J TRAUMA ACUTE CARE, V75, pS9, DOI 10.1097/TA.0b013e318290cd52; Hartog CS, 2011, ANESTH ANALG, V112, P156, DOI 10.1213/ANE.0b013e3181eaff91; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Haute Autorite de Sante, 2008, PRIS CHARG SURD ANT; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hess JR, 2009, TRANSFUSION, V49, P34, DOI 10.1111/j.1537-2995.2008.01944.x; Johansson PI, 2007, TRANSFUSION, V47, P593, DOI 10.1111/j.1537-2995.2007.01160.x; Leidel BA, 2012, RESUSCITATION, V83, P40, DOI 10.1016/j.resuscitation.2011.08.017; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MANIKIS P, 1995, AM J EMERG MED, V13, P619, DOI 10.1016/0735-6757(95)90043-8; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Meier J, 2007, CRIT CARE MED, V35, P1484, DOI 10.1097/01.CCM.0000265740.62130.1C; Moganasundram S, 2010, ANESTH ANALG, V110, P995, DOI 10.1213/ANE.0b013e3181cd6d20; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Perel P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub6; Pernod G, 2013, ANN FR ANESTH, V32, P691, DOI 10.1016/j.annfar.2013.04.016; Plurad DS, 2011, J TRAUMA, V71, P565, DOI 10.1097/TA.0b013e3182213d52; Reades R, 2011, ANN EMERG MED, V58, P509, DOI 10.1016/j.annemergmed.2011.07.020; Regnier MA, 2012, ANESTHESIOLOGY, V117, P1276, DOI 10.1097/ALN.0b013e318273349d; Ricard JD, 2013, CRIT CARE MED, V41, P2108, DOI 10.1097/CCM.0b013e31828a42c5; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Rourke C, 2012, J THROMB HAEMOST, V10, P1342, DOI 10.1111/j.1538-7836.2012.04752.x; Sammour T, 2009, INJURY, V40, P104, DOI 10.1016/j.injury.2008.07.032; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Thomas-Rueddel DO, 2012, INTENS CARE MED, V38, P1134, DOI 10.1007/s00134-012-2560-x; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Vogt KN, 2012, TRANSFUSION MED, V22, P156, DOI 10.1111/j.1365-3148.2012.01150.x; Yeguiayan JM, 2011, CRIT CARE, V15, DOI 10.1186/cc9982; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	56	36	36	0	0	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	2352-5800	2352-5819		ANESTH REANIM	Anesth. Reanim.	FEB	2015	1	1					62	74		10.1016/j.anrea.2014.12.007			13	Anesthesiology	Anesthesiology	V3Q7P	WOS:000218501200013					2021-06-18	
J	Wang, L; Wang, XN; Su, H; Han, ZY; Yu, HJ; Wang, D; Jiang, RC; Liu, ZL; Zhang, JN				Wang, Liang; Wang, Xiaonan; Su, Hua; Han, Zhenying; Yu, Huijie; Wang, Dong; Jiang, Rongcai; Liu, Zhenlin; Zhang, Jianning			Recombinant Human Erythropoietin Improves the Neurofunctional Recovery of Rats Following Traumatic Brain Injury via an Increase in Circulating Endothelial Progenitor Cells	TRANSLATIONAL STROKE RESEARCH			English	Article						Traumatic brain injury; Erythropoietin; Endothelial progenitor cells; Angiogenesis	ISCHEMIA-REPERFUSION INJURY; FUNCTIONAL OUTCOMES; CEREBRAL-ISCHEMIA; NEOVASCULARIZATION; MICE; TRANSPLANTATION; PROTECTS; ANGIOGENESIS; MYOCARDIUM; STROKE	Previous studies show that circulating endothelial progenitor cells (EPCs) promote angiogenesis, which is a process associated with improved recovery in animal models of traumatic brain injury (TBI), and that recombinant human erythropoietin (rhEPO) plays a protective role following stroke. Thus, it was hypothesized that rhEPO would enhance recovery following brain injury in a rat model of TBI via an increase in the mobilization of EPCs and, subsequently, in angiogenesis. Flow cytometry assays using CD34- and CD133-specific antibodies were utilized to identify alterations in EPC levels, CD31 and CD34 antibody-stained brain tissue sections were used to quantify angiogenesis, and the Morris water maze (MWM) test and the modified Neurological Severity Score (mNSS) test were used to evaluate behavioral recovery. Compared with saline treatment, treatment with rhEPO significantly increased the number of circulating EPCs on days 1, 4, 7, and 14 (P < 0.05), improved spatial learning ability on days 24 and 25 (P < 0.05), and enhanced memory recovery on day 26 (P < 0.05). Moreover, rhEPO treatment decreased mNSS assessment scores on days 14, 21, and 25 (P < 0.05). There was a strong correlation between levels of circulating EPCs and CD34- and CD31-positive cells within the injured boundary zone (CD34(+) r = 0.910, P < 0.01; CD31(+) r = 0.894, P < 0.01) and the ipsilateral hippocampus (CD34(+) r = 0.841, P < 0.01; CD31(+) r = 0.835, P < 0.01). The present data demonstrate that rhEPO treatment improved functional outcomes in rats following TBI via an increase in the mobilization of EPCs and in subsequent angiogenesis.	[Wang, Liang; Liu, Zhenlin] Tianjin 5th Ctr Hosp, Dept Neurosurg, Tianjin 300450, Peoples R China; [Wang, Xiaonan] Nankai Hosp, Dept Neurosurg, Tianjin 300102, Peoples R China; [Su, Hua] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Cerebrovasc Res Ctr, San Francisco, CA 94110 USA; [Han, Zhenying; Yu, Huijie; Wang, Dong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China	Liu, ZL (corresponding author), Tianjin 5th Ctr Hosp, Dept Neurosurg, 41 Zhejiang Rd, Tianjin 300450, Peoples R China.	wjzhenlin817@sina.com; jianningzhang@hotmail.com			Emerging Project Committee of Science and Technology of Tanggu District of Tianjin, China [2012XQ15-07]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100920, 81200907]; Tianjin Research Program of Application Foundation and Advanced Technology [12JCQNJC6800]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL122774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027713] Funding Source: NIH RePORTER	We thank Li Liu, Weiyun Cui, Fanglian Chen, and Lei Zhang for their excellent technical support. The authors thank Voltaire Gungab for the editorial assistance. This work was supported by grants from the Emerging Project Committee of Science and Technology of Tanggu District of Tianjin (2012XQ15-07), China; the National Natural Science Foundation of China (grants 81100920 and 81200907); and Tianjin Research Program of Application Foundation and Advanced Technology (grants12JCQNJC6800).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bahlmann FH, 2004, BLOOD, V103, P921, DOI 10.1182/blood-2003-04-1284; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Clarkson AN, 2007, BRAIN RES, V1171, P111, DOI 10.1016/j.brainres.2007.06.100; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gehling UM, 2000, BLOOD, V95, P3106; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; Grisar JC, 2011, BIOMARK MED, V5, P731, DOI [10.2217/BMM.11.92, 10.2217/bmm.11.92]; Hirata A, 2006, J AM COLL CARDIOL, V48, P176, DOI 10.1016/j.jacc.2006.04.008; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2001, CIRCULATION, V103, P634; Ladhoff J, 2010, CARDIOVASC RES, V88, P121, DOI 10.1093/cvr/cvq109; Li B, 2006, FASEB J, V20, P1495, DOI 10.1096/fj.05-5137fje; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Lipsic E, 2004, J CARDIOVASC PHARM, V44, P473, DOI 10.1097/01.fjc.0000140209.04675.c3; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Maeng YS, 2009, BLOOD, V113, P233, DOI 10.1182/blood-2008-06-162891; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Ozisik PA, 2007, SURG NEUROL, V68, P547, DOI 10.1016/j.surneu.2007.01.030; Park KJ, 2014, J CEREBR BLOOD F MET, V34, P357, DOI 10.1038/jcbfm.2013.216; Potts Mathew B, 2006, NeuroRx, V3, P143; Resch T, 2012, STEM CELL REV REP, V8, P926, DOI 10.1007/s12015-011-9332-9; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Satoh K, 2006, CIRCULATION, V113, P1442, DOI 10.1161/CIRCULATIONAHA.105.583732; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tei K, 2008, STEM CELLS, V26, P819, DOI 10.1634/stemcells.2007-0671; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Wang L, 2004, NEUROREPORT, V15, P1225, DOI 10.1097/01.wnr.0000127636.15181.c1; Westenbrink BD, 2007, EUR HEART J, V28, P2018, DOI 10.1093/eurheartj/ehm177; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yip HK, 2011, CRIT CARE, V15, DOI 10.1186/cc10002; Yuan Q, 2012, INJURY, V43, P2094, DOI 10.1016/j.injury.2012.03.028; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	47	36	39	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	FEB	2015	6	1					50	59		10.1007/s12975-014-0362-x			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AZ3IT	WOS:000348121500007	25085436	Green Accepted			2021-06-18	
J	Juengst, SB; Graham, KM; Pulantara, IW; McCue, M; Whyte, EM; Dicianno, BE; Parmanto, B; Arenth, PM; Skidmore, ERD; Wagner, AK				Juengst, Shannon B.; Graham, Kristin M.; Pulantara, I. Wayan; McCue, Michael; Whyte, Ellen M.; Dicianno, Brad E.; Parmanto, Bambang; Arenth, Patricia M.; Skidmore, Elizabeth R. D.; Wagner, Amy K.			Pilot feasibility of an mHealth system for conducting ecological momentary assessment of mood-related symptoms following traumatic brain injury	BRAIN INJURY			English	Article						Depression; mental health assessments; rehabilomics; telehealth tools; traumatic brain injury	NEGATIVE AFFECT; DEPRESSION; VALIDITY; ANXIETY; REHABILITATION; SMARTPHONE; PREDICTORS; DISORDER; ADULTS; RATES	Objective: This study assessed pilot feasibility and validity of a mobile health (mHealth) system for tracking mood-related symptoms after traumatic brain injury (TBI). Design: A prospective, repeated measures design was used to assess compliance with daily ecological momentary assessments (EMA) conducted via a smartphone application over an 8-week period. Methods: An mHealth system was developed specifically for individuals with TBI and utilized previously validated tools for depressive and anxiety symptoms (Patient Health Questionnaire-9, Generalized Anxiety Disorder-7). Feasibility was assessed in 20 community-dwelling adults with TBI via an assessment of compliance, satisfaction and usability of the smartphone applications. The authors also developed and implemented a clinical patient safety management mechanism for those endorsing suicidality. Results: Participants correctly completed 73.4% of all scheduled assessments, demonstrating good compliance. Daily assessments took <2 minutes to complete. Participants reported high satisfaction with smartphone applications (6.3 of 7) and found them easy to use (6.2 of 7). Comparison of assessments obtained via telephone-based interview and EMA demonstrated high correlations (r = 0.81-0.97), supporting the validity of conducting these assessments via smartphone application in this population. Conclusions: EMA conducted via smartphone demonstrates initial feasibility among adults with TBI and presents numerous opportunities for long-term monitoring of mood-related symptoms in real-world settings.	[Juengst, Shannon B.; Whyte, Ellen M.; Dicianno, Brad E.; Arenth, Patricia M.; Skidmore, Elizabeth R. D.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Graham, Kristin M.; McCue, Michael; Dicianno, Brad E.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15213 USA; [Pulantara, I. Wayan; Parmanto, Bambang] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Hlth Informat Management, Pittsburgh, PA 15213 USA; [Whyte, Ellen M.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Psychiat, Pittsburgh, PA 15213 USA; [Skidmore, Elizabeth R. D.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Sch Med, Phys Med & Rehabil, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Dicanno, Brad/AAC-5918-2019; Juengst, Shannon B/AAC-5891-2019	Dicanno, Brad/0000-0003-0738-0192; Juengst, Shannon/0000-0003-4709-545X; Pulantara, I Wayan/0000-0002-6532-3666	National Institute on Disability & Rehabilitation Research (NIDRR) [H133A120087]	The authors report no conflicts of interest. The National Institute on Disability & Rehabilitation Research (NIDRR) supported this work, under the grant 'Rehabilomics: Revolutionizing 21st Century TBI Care and Research, H133A120087'.	[Anonymous], 2010, TBI US REP TRAUM BRA; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ben-Zeev D, 2013, PSYCHIATR REHABIL J, V36, P289, DOI 10.1037/prj0000019; Boman IL, 2007, DISABIL REHABIL-ASSI, V2, P23, DOI 10.1080/17483100600856213; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Choi SW, 2014, PSYCHOL ASSESSMENT, V26, P513, DOI 10.1037/a0035768; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Culley C, 2010, NEUROPSYCHOL REHABIL, V20, P103, DOI 10.1080/09602010902906926; DAVIS FD, 1993, INT J MAN MACH STUD, V38, P475, DOI 10.1006/imms.1993.1022; De Joode EA, 2013, NEUROPSYCHOL REHABIL, V23, P133, DOI 10.1080/09602011.2012.726632; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donker T, 2013, J MED INTERNET RES, V15, P541; Dunbar MS, 2010, NICOTINE TOB RES, V12, P226, DOI 10.1093/ntr/ntp198; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Garcia C, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.2576; Garcia-Palacios A, 2014, EUR J PAIN, V18, P862, DOI 10.1002/j.1532-2149.2013.00425.x; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hoofien D, 2001, BRAIN INJURY, V15, P189; Husky M, 2014, PSYCHIAT RES, V220, P564, DOI 10.1016/j.psychres.2014.08.019; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Juengst SB, 2014, BRAIN BEHAV IMMUN, V41, P134, DOI 10.1016/j.bbi.2014.05.020; Juengst SB, 2015, J HEAD TRAUMA REHAB, V30, P207, DOI 10.1097/HTR.0000000000000031; Kim J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074979; Kirk GD, 2013, AIDS RES TREAT, V2013, DOI 10.1155/2013/594671; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lella A, 2014, COMSCORE REPORTS APR; LEWIS JR, 1995, INT J HUM-COMPUT INT, V7, P57, DOI 10.1080/10447319509526110; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Obeid JS, 2013, J BIOMED INFORM, V46, P259, DOI 10.1016/j.jbi.2012.10.006; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Runyan JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071325; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Smyth J. M., 2003, J HAPPINESS STUD, V4, P35, DOI [10.1023/A:1023657221954, DOI 10.1023/A:1023657221954]; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Strong CAH, 2011, J INT NEUROPSYCH SOC, V17, P230, DOI 10.1017/S1355617710001451; TEASDALE G, 1974, LANCET, V2, P81; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; Walz LC, 2014, J ANXIETY DISORD, V28, P925, DOI 10.1016/j.janxdis.2014.09.022; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WATSON D, 1995, J ABNORM PSYCHOL, V104, P15, DOI 10.1037/0021-843X.104.1.15; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	53	36	36	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	11					1351	1361		10.3109/02699052.2015.1045031			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CR4MF	WOS:000361306100010	26287756				2021-06-18	
J	Dardiotis, E; Paterakis, K; Tsivgoulis, G; Tsintou, M; Hadjigeorgiou, GF; Dardioti, M; Grigoriadis, S; Simeonidou, C; Komnos, A; Kapsalaki, E; Fountas, K; Hadjigeorgiou, GM				Dardiotis, Efthimios; Paterakis, Konstantinos; Tsivgoulis, Georgios; Tsintou, Magdalini; Hadjigeorgiou, Georgios F.; Dardioti, Maria; Grigoriadis, Savas; Simeonidou, Constantina; Komnos, Apostolos; Kapsalaki, Eftychia; Fountas, Kostas; Hadjigeorgiou, Georgios M.			AQP4 Tag Single Nucleotide Polymorphisms in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						polymorphism; traumatic brain injury; tag SNPs; genetics; AQP4	GENETIC ASSOCIATION; AQUAPORIN-4 GENE; NERVOUS-SYSTEM; KNOCKOUT MICE; HEAD-INJURY; EDEMA; POPULATION; EVENTS	Accumulating evidence suggests that the extent of brain injury and the clinical outcome after traumatic brain injury (TBI) are modulated, to some degree, by genetic variants. Aquaporin-4 (AQP4) is the predominant water channel in the central nervous system and plays a critical role in controlling the water content of brain cells and the development of brain edema after TBI. We sought to investigate the influence of the AQP4 gene region on patient outcome after TBI by genotyping tag single nucleotide polymorphisms (SNPs) along AQP4 gene. A total of 363 patients with TBI (19.6% female) were prospectively evaluated. Data including the Glasgow Coma Scale (GCS) scores at admission, the presence of intracranial hemorrhage, and the 6-month Glasgow Outcome Scale (GOS) scores were collected. Seven tag SNPs across the AQP4 gene were identified based on the HapMap data. Using logistic regression analyses, SNPs and haplotypes were tested for associations with 6-month GOS after adjusting for age, GCS score, and sex. Significant associations with TBI outcome were detected for rs3763043 (OR [95% confidence interval (CI)]: 5.15 [1.60-16.5], p=0.006, for recessive model), rs3875089 (OR [95% CI]: 0.18 [0.07-0.50] p=0.0009, for allele difference model), and a common haplotype of AQP4 tag SNPs (OR [95% CI]: 2.94, [1.34-6.36], p=0.0065). AQP4 tag SNPs were not found to influence the initial severity of TBI or the presence of intracranial hemorrhages. In conclusion, the present study provides evidence for possible involvement of genetic variations in AQP4 gene in the functional outcome of patients with TBI.	[Dardiotis, Efthimios; Tsintou, Magdalini; Dardioti, Maria; Hadjigeorgiou, Georgios M.] Univ Thessaly, Univ Hosp Larissa, Neurogenet Lab, Dept Neurol, Larisa 41100, Greece; [Paterakis, Konstantinos; Hadjigeorgiou, Georgios F.; Fountas, Kostas] Univ Thessaly, Univ Hosp Larissa, Dept Neurosurg, Larisa 41100, Greece; [Tsivgoulis, Georgios] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Neurol 2, GR-11527 Athens, Greece; [Tsivgoulis, Georgios] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic; [Grigoriadis, Savas] Aristotle Univ Thessaloniki, Hippokrat Univ Hosp, Dept Neurosurg 2, GR-54006 Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Dept Physiol, GR-54006 Thessaloniki, Greece; [Komnos, Apostolos] Gen Hosp Larissa, Intens Care Unit, Larisa, Greece; [Kapsalaki, Eftychia] Univ Thessaly, Sch Med, Dept Radiol, Larisa 41100, Greece	Hadjigeorgiou, GM (corresponding author), Univ Thessaly, Univ Hosp Larissa, Neurogenet Lab, Dept Neurol,Biopolis, Mezourlo Hill, Larisa 41100, Greece.	gmhadji@med.uth.gr	Paterakis, Konstantinos/AAH-4554-2019; Tsivgoulis, Georgios/AAD-7467-2019; Tsivgoulis, Georgios/AAD-5360-2020	Tsivgoulis, Georgios/0000-0002-0640-3797; Dardiotis, Efthimios/0000-0003-2957-641X	European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Research Committee of the University of Thessaly, Greece [2845]	Georgios Tsivgoulis has been supported by the European Regional Development Fund - Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123); The study was supported in part by a research grant of the Research Committee of the University of Thessaly, Greece (Code: 2845).	Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Ban M, 2007, J NEUROL, V254, P398, DOI 10.1007/s00415-006-0392-8; Bird TD, 2001, NEUROLOGY, V57, P1153, DOI 10.1212/WNL.57.7.1153; Carter KW, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-557; Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60; Dardiotis E, 2006, SURG NEUROL, V66, P334, DOI 10.1016/j.surneu.2006.05.042; Dardiotis E, 2012, CURR OPIN PSYCHIATR, V25, P231, DOI 10.1097/YCO.0b013e3283523c0e; Dardiotis E, 2011, PHARMACOGENET GENOM, V21, P136, DOI 10.1097/FPC.0b013e328343ab15; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554; Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Kerty E, 2013, ACTA OPHTHALMOL, V91, P88, DOI 10.1111/j.1755-3768.2011.02231.x; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kleffner I, 2008, STROKE, V39, P1333, DOI 10.1161/STROKEAHA.107.500785; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li W, 2012, CNS NEUROSCI THER, V18, P558, DOI 10.1111/j.1755-5949.2012.00322.x; Li ZQ, 2009, CELL RES, V19, P519, DOI 10.1038/cr.2009.33; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Mai WH, 2013, J NEUROIMMUNOL, V255, P75, DOI 10.1016/j.jneuroim.2012.10.004; Opdal SH, 2010, PEDIATR RES, V68, P48, DOI [10.1203/PDR.0b013e3181df4e7c, 10.1203/00006450-201011001-00091]; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Park TJ, 2014, GENE, V536, P302, DOI 10.1016/j.gene.2013.12.007; Robertson CS, 2011, J NEUROTRAUM, V28, P727, DOI 10.1089/neu.2010.1476; Romeiro RR, 2007, NEUROSCI LETT, V426, P133, DOI 10.1016/j.neulet.2007.09.004; Rubino E, 2009, J HEADACHE PAIN, V10, P111, DOI 10.1007/s10194-009-0100-z; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb	43	36	37	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1920	1926		10.1089/neu.2014.3347			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500004	24999750	Green Published			2021-06-18	
J	Nekludov, M; Mobarrez, F; Gryth, D; Bellander, BM; Wallen, H				Nekludov, Michael; Mobarrez, Fariborz; Gryth, Dan; Bellander, Bo-Michael; Wallen, Hakan			Formation of Microparticles in the Injured Brain of Patients with Severe Isolated Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						microparticles; traumatic brain injury; cerebrovenous; coagulopathy; neurosurgical ICU	PLATELET-DERIVED MICROPARTICLES; TISSUE FACTOR; INFLAMMATORY RESPONSE; CEREBROSPINAL-FLUID; COAGULATION; BLOOD; ACTIVATION; MICROVESICLES; COAGULOPATHY; HEMOSTASIS	The potential pathophysiological role of circulating microparticles (MPs) has been recognized in various conditions, such as cardiovascular and thrombotic diseases. Traumatic brain injury (TBI) has a complex pathophysiology that involves coagulopathy and inflammation. We investigated endothelial-, platelet-, and leukocyte-derived microparticles (EMPs, PMPs, and LMPs, respectively) in 16 patients with severe isolated TBI. Arterial and cerebrovenous samples were taken repeatedly, during 1-72 h after injury. Subpopulations of MPs, exposing tissue factor (TF) and P-selectin, were also studied. MP counts in cerebrovenous samples, irrespective of cellular origin, were higher in TBI cases, compared to healthy controls (peak levels of EMPs were approximately 7 times higher, PMPs 1.4 times higher, and LMPs 2 times higher, respectively; p<0.001 for all). MP counts declined sharply from high levels shortly after the trauma toward slightly elevated levels 72 h later. EMPs and PMPs exposing TF, as well as PMPs exposing P-selectin, showed a transcranial gradient with higher concentration in cerebrovenous, compared to arterial, samples. In contrast, LMPs exposing TF were higher in arterial samples, suggesting accumulation of LMPs in the brain. We conclude that the pattern of circulating MPs is altered after TBI. PMPs exposing P-selectin and EMPs exposing TF seem to be generated in the injured brain, whereas LMPs exposing TF are accumulated. The pathophysiological significance of these changes in MP pattern in TBI should be further investigated. Including MPs exposing brain-specific antigens in the assessment of brain injury would give further information of origin and likely give additional information of the size of the injury, given that the MP phenotypes investigated in the present study are not brain-specific markers.	[Nekludov, Michael; Gryth, Dan] Karolinska Inst, Karolinska Univ Hosp, Dept Physiol & Pharmacol, Sect Anesthesiol, Stockholm, Sweden; [Mobarrez, Fariborz; Wallen, Hakan] Karolinska Inst, Danderyds Hosp, Dept Clin Sci, Div Cardiovasc Med, Stockholm, Sweden; [Bellander, Bo-Michael] Karolinska Inst, Karolinska Univ Hosp, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden	Nekludov, M (corresponding author), Karolinska Univ Hosp Solna, Dept Anesthesiol, SE-17176 Stockholm, Sweden.	michael.nekludov@karolinska.se	Mobarrez, Fariborz/AAK-8929-2020	Mobarrez, Fariborz/0000-0002-7106-6248; Nekludov, Michael/0000-0001-9916-7086	Carnegie Foundation; Capio Foundation; Karolinska Institute fundKarolinska Institutet [245]	The authors thank Dr. Margareta Blomback for being such a powerful source of energy for our team. The authors thank the nursing personnel at NICU for all the assistance and everlasting helpfulness during the study. The authors thank the medical statistics expert, Eva Hagel, Karolinska Institute, for professionally performed analyses of our data. The authors also thank the Carnegie Foundation, the Capio Foundation, and Karolinska Institute fund 245 for financial support.	Biro E, 2003, J THROMB HAEMOST, V1, P2561, DOI 10.1046/j.1538-7836.2003.00456.x; Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521; Dasgupta SK, 2006, TRANSL RES, V148, P19, DOI 10.1016/j.lab.2006.03.006; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jy W, 2007, THROMB RES, V121, P319, DOI 10.1016/j.thromres.2007.04.014; Key NS, 2010, SEMIN THROMB HEMOST, V36, P865, DOI 10.1055/s-0030-1267040; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Langer F, 2013, BLOOD, V121, P2324, DOI 10.1182/blood-2012-10-460493; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Mause SF, 2010, CIRCULATION, V122, P495, DOI 10.1161/CIRCULATIONAHA.109.909473; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Mobarrez F, 2013, SCHIZOPHR RES, V143, P192, DOI 10.1016/j.schres.2012.10.030; Mobarrez F, 2010, THROMB RES, V125, pE110, DOI 10.1016/j.thromres.2009.10.006; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Owens AP, 2011, CIRC RES, V108, P1284, DOI 10.1161/CIRCRESAHA.110.233056; Sanborn MR, 2012, J NEUROSURG, V117, P579, DOI 10.3171/2012.6.JNS111163; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; Skeppholm M, 2012, THROMB HAEMOSTASIS, V107, P1122, DOI 10.1160/TH11-11-0779; Soop A, 2013, SCAND J IMMUNOL, V78, P205, DOI 10.1111/sji.12076; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Tilley RE, 2008, THROMB RES, V122, P604, DOI 10.1016/j.thromres.2007.12.023; Van der Zee PM, 2006, CLIN CHEM, V52, P657, DOI 10.1373/clinchem.2005.057414; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014; Vikerfors A, 2012, LUPUS, V21, P802, DOI 10.1177/0961203312437809; Zachau Anne C, 2012, J Med Case Rep, V6, P274, DOI 10.1186/1752-1947-6-274; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348	33	36	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1927	1933		10.1089/neu.2013.3168			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500005	24956150				2021-06-18	
J	Vergales, BD; Zanelli, SA; Matsumoto, JA; Goodkin, HP; Lake, DE; Moorman, JR; Fairchild, KD				Vergales, Brooke D.; Zanelli, Santina A.; Matsumoto, Julie A.; Goodkin, Howard P.; Lake, Douglas E.; Moorman, J. Randall; Fairchild, Karen D.			Depressed Heart Rate Variability is Associated with Abnormal EEG, MRI, and Death in Neonates with Hypoxic Ischemic Encephalopathy	AMERICAN JOURNAL OF PERINATOLOGY			English	Article						hypoxic ischemic encephalopathy; heart rate variability; neonate; asphyxia; electroen-cephalogram	TRAUMATIC BRAIN-INJURY; SEPSIS-LIKE ILLNESS; THERAPEUTIC HYPOTHERMIA; PREMATURE-INFANTS; CARDIAC-ARREST; FETAL SHEEP; CHILDREN; ASPHYXIA; PHYSIOMARKERS; MORTALITY	Objective Asphyxia can lead to autonomic nervous system dysfunction, including depressed heart rate variability (HRV). We tested the hypothesis that low HRV is associated with adverse short-term outcomes of abnormalities on electroencephalogram (EEG) and brain magnetic resonance imaging (MRI) and death in neonates with hypoxic ischemic encephalopathy (HIE). Study Design Neonates undergoing hypothermia therapy for HIE underwent monitoring of HRV. HRV in the first day after birth and after hypothermia and rewarming (days 4-7) were analyzed in relation to death and severity of abnormal findings on EEG and MRI. Results A total of 37 neonates had data available in the first 24 hour after birth and 67 had data days 2 to 7. Depressed HRV was significantly associated with adverse outcomes of death or moderate-to-severe abnormalities on EEG or MRI. In the first 24 hours, the odds ratio (OR) of one or more adverse outcomes for every 10-millisecond decrease in HRV was 3.19 (95% CI, 1.3-7.8; p = 0.01). HRV improved over time but low HRV remained significantly associated with adverse outcomes days 4 to 7 (OR, 2.72; CI, 1.32-5.61; p < 0.01). Conclusions Monitoring HRV, which is reflected in the heart rate characteristic index, may provide useful adjunct information on the severity of brain injury in infants with HIE.	[Vergales, Brooke D.; Zanelli, Santina A.; Fairchild, Karen D.] Univ Virginia, Dept Pediat, Div Neonatol, Charlottesville, VA USA; [Matsumoto, Julie A.] Univ Virginia, Dept Radiol & Med Imaging, Div Neuroradiol, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia, Dept Neurol, Div Pediat Neurol, Charlottesville, VA USA; [Lake, Douglas E.; Moorman, J. Randall] Univ Virginia, Dept Med, Div Cardiovasc Med, Charlottesville, VA USA; [Lake, Douglas E.] Univ Virginia, Dept Stat, Charlottesville, VA USA	Fairchild, KD (corresponding author), Univ Virginia Hlth Syst, Dept Pediat, Div Neonatol, POB 800386, Charlottesville, VA 22908 USA.	kdf2n@virginia.edu	Moorman, J Randall/ABG-9946-2020	Goodkin, Howard/0000-0003-0528-4949	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [051609]; NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [064640]; University of Virginia Children's Hospital	This work was supported by the following funding sources: NICHD 051609 (KDF), NIGMS 064640 (JRM), and the University of Virginia Children's Hospital.	Addison K, 2009, J PERINATOL, V29, P750, DOI 10.1038/jp.2009.81; Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Aliefendioglu D, 2012, INDIAN J PEDIATR, V79, P1468, DOI 10.1007/s12098-012-0703-2; [Anonymous], 2006, J CLIN NEUROPHYSIOL, V23, P92; Barkovich AJ, 2006, AM J NEURORADIOL, V27, P533; Beuchee A, 2009, NEONATOLOGY, V96, P109, DOI 10.1159/000208792; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Burnsed J, 2011, J CLIN NEUROPHYSIOL, V28, P10, DOI 10.1097/WNP.0b013e318205134b; Cao HQ, 2004, ANN BIOMED ENG, V32, P233, DOI 10.1023/B:ABME.0000012743.81754.0b; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Fairchild K, 2010, J PERINATOL, V30, P324, DOI 10.1038/jp.2009.168; Fairchild KD, 2013, CURR OPIN PEDIATR, V25, P172, DOI 10.1097/MOP.0b013e32835e8fe6; Fairchild KD, 2010, CLIN PERINATOL, V37, P581, DOI 10.1016/j.clp.2010.06.002; Fairchild KD, 2009, AM J PHYSIOL-REG I, V297, pR1019, DOI 10.1152/ajpregu.00132.2009; Fleisher LA, 1996, CLIN SCI, V90, P97, DOI 10.1042/cs0900097; Flower AA, 2010, EXP BIOL MED, V235, P531, DOI 10.1258/ebm.2010.009336; FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290; Frasch MG, 2009, REPROD SCI, V16, P509, DOI 10.1177/1933719108327597; George S, 2004, AM J PHYSIOL-REG I, V287, pR925, DOI 10.1152/ajpregu.00263.2004; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Gonzalez FF, 2009, CLIN PERINATOL, V36, P859, DOI 10.1016/j.clp.2009.07.013; Griffin MP, 2007, PEDIATR RES, V61, P222, DOI 10.1203/01.pdr.0000252438.65759.af; Griffin MP, 2005, PEDIATRICS, V115, P937, DOI 10.1542/peds.2004-1393; Griffin MP, 2005, PEDIATRICS, V116, P1070, DOI 10.1542/peds.2004-2461; Griffin MP, 2004, PEDIATR RES, V55, P782, DOI 10.1203/01.PDR.0000119366.21770.9E; Griffin MP, 2003, PEDIATR RES, V53, P920, DOI 10.1203/01.PDR.0000064904.05313.D2; Griffin MP, 2001, PEDIATRICS, V107, P97, DOI 10.1542/peds.107.1.97; GRIFFIN MP, 1994, J CARDIOVASC ELECTR, V5, P112, DOI 10.1111/j.1540-8167.1994.tb01151.x; Haensel A, 2008, PSYCHONEUROENDOCRINO, V33, P1305, DOI 10.1016/j.psyneuen.2008.08.007; Hallioglu O, 2008, EPILEPSY RES, V79, P49, DOI 10.1016/j.eplepsyres.2007.12.020; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kovatchev BP, 2003, PEDIATR RES, V54, P892, DOI 10.1203/01.PDR.0000088074.97781.4F; Kox M, 2012, J NEUROTRAUM, V29, P747, DOI 10.1089/neu.2011.2035; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Lasky RE, 2009, NEONATOLOGY, V96, P93, DOI 10.1159/000205385; LOWENSOHN RI, 1977, LANCET, V1, P626; Massaro AN, 2012, J PEDIATR-US, V161, P434, DOI 10.1016/j.jpeds.2012.02.047; Mercuri E, 2000, PEDIATRICS, V106, P235, DOI 10.1542/peds.106.2.235; Moorman JR, 2011, J PEDIATR-US, V159, P900, DOI 10.1016/j.jpeds.2011.06.044; Moorman JR, 2006, IEEE T BIO-MED ENG, V53, P126, DOI 10.1109/TBME.2005.859810; Norman GJ, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00131; Pin TW, 2009, EUR J PAEDIATR NEURO, V13, P224, DOI 10.1016/j.ejpn.2008.05.001; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Richman JS, 2004, METHOD ENZYMOL, V384, P172; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shellhaas RA, 2008, J PEDIATR-US, V153, P369, DOI 10.1016/j.jpeds.2008.03.004; Tiainen M, 2009, CRIT CARE MED, V37, P403, DOI 10.1097/CCM.0b013e31819572c4; Westgate JA, 1999, BRIT J OBSTET GYNAEC, V106, P664, DOI 10.1111/j.1471-0528.1999.tb08365.x; Zanelli S, 2008, J PERINATOL, V28, P171, DOI 10.1038/sj.jp.7211896	52	36	37	0	11	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0735-1631	1098-8785		AM J PERINAT	Am. J. Perinatol.	NOV	2014	31	10					855	861		10.1055/s-0033-1361937			7	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	AP3FS	WOS:000341961600005	24347263				2021-06-18	
J	McGuine, TA; Hetzel, S; McCrea, M; Brooks, MA				McGuine, Timothy A.; Hetzel, Scott; McCrea, Michael; Brooks, M. Alison			Protective Equipment and Player Characteristics Associated With the Incidence of Sport-Related Concussion in High School Football Players A Multifactorial Prospective Study	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						football helmet; concussion; high school	STATES HIGH-SCHOOL; IMPACT PERFORMANCE; RISK-FACTORS; EPIDEMIOLOGY; COLLEGIATE; SYMPTOMS; INJURIES; HELMETS	Background: The incidence of sport-related concussion (SRC) in high school football is well documented. However, limited prospective data are available regarding how player characteristics and protective equipment affect the incidence of SRC. Purpose: To determine whether the type of protective equipment (helmet and mouth guard) and player characteristics affect the incidence of SRC in high school football players. Design: Cohort study; Level of evidence, 2. Methods: Certified athletic trainers (ATs) at each high school recorded the type of helmet worn (brand, model, purchase year, and recondition status) by each player as well as information regarding players' demographics, type of mouth guard used, and history of SRC. The ATs also recorded the incidence and days lost from participation for each SRC. Incidence of SRC was compared for various helmets, type of mouth guard, history of SRC, and player demographics. Results: A total of 2081 players (grades 9-12) enrolled during the 2012 and/or 2013 football seasons (2287 player-seasons) and participated in 134,437 football (practice or competition) exposures. Of these players, 206 (9%) sustained a total of 211 SRCs (1.56/1000 exposures). There was no difference in the incidence of SRC (number of helmets, % SRC [95% CI]) for players wearing Riddell (1171, 9.1% [7.6%-11.0%]), Schutt (680, 8.7% [6.7%-11.1%]), or Xenith (436, 9.2% [6.7%-12.4%]) helmets. Helmet age and recondition status did not affect the incidence of SRC. The rate of SRC (hazard ratio [HR]) was higher in players who wore a custom mouth guard (HR = 1.69 [95% CI, 1.20-2.37], P < .001) than in players who wore a generic mouth guard. The rate of SRC was also higher (HR = 1.96 [95% CI, 1.40-2.73], P < .001) in players who had sustained an SRC within the previous 12 months (15.1% of the 259 players [95% CI, 11.0%-20.1%]) than in players without a previous SRC (8.2% of the 2028 players [95% CI, 7.1%-9.5%]). Conclusion: Incidence of SRC was similar regardless of the helmet brand (manufacturer) worn by high school football players. Players who had sustained an SRC within the previous 12 months were more likely to sustain an SRC than were players without a history of SRC. Sports medicine providers who work with high school football players need to realize that factors other than the type of protective equipment worn affect the risk of SRC in high school players.	[McGuine, Timothy A.; Hetzel, Scott; McCrea, Michael; Brooks, M. Alison] Univ Wisconsin, Madison, WI 53711 USA	McGuine, TA (corresponding author), Univ Wisconsin, Hlth Sports Med Ctr, 621 Sci Dr, Madison, WI 53711 USA.	tmcguine@uwhealth.org			University of Wisconsin Department of Orthopedics and Rehabilitation; UW Sports Medicine Classic Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055894] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: Funding for this study was provided by the University of Wisconsin Department of Orthopedics and Rehabilitation and UW Sports Medicine Classic Fund.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Comstock D, 2012, EPIDEMIOLOGY PREVENT; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Demorest RA, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P177, DOI 10.1007/978-0-387-89545-1_13; Desmarteau D, 2006, CURR SPORT MED REP, V5, P268; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kelly JP, 1997, NEUROLOGY, V48, P581; Knowles S, 2012, EPIDEMIOLOGY, V20, P302; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Nation AD, 2011, CLIN PEDIATR, V50, P200, DOI 10.1177/0009922810388511; National Federation of State High School Associations, 2012, HIGH SCH ATHL PART S; Olson DE, 2011, CURR SPORT MED REP, V10, P290, DOI 10.1249/JSR.0b013e31822d4029; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Singh GD, 2009, DENT TRAUMATOL, V25, P515, DOI 10.1111/j.1600-9657.2009.00808.x; Takeda T, 2005, DENT TRAUMATOL, V21, P134, DOI 10.1111/j.1600-9657.2005.00320.x; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Wisconsin Interscholastioc Athletic Association, WIAA CONC POL	36	36	36	0	50	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2014	42	10					2470	2478		10.1177/0363546514541926			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AQ4XQ	WOS:000342805000026	25060072	Green Accepted			2021-06-18	
J	Minei, JP; Fabian, TC; Guffey, DM; Newgard, CD; Bulger, EM; Brasel, KJ; Sperry, JL; MacDonald, RD				Minei, Joseph P.; Fabian, Timothy C.; Guffey, Danielle M.; Newgard, Craig D.; Bulger, Eileen M.; Brasel, Karen J.; Sperry, Jason L.; MacDonald, Russell D.		Resuscitation Outcome Consortium I	Increased Trauma Center Volume Is Associated With Improved Survival After Severe Injury Results of a Resuscitation Outcomes Consortium Study	ANNALS OF SURGERY			English	Article						trauma center designation level; trauma center outcomes; trauma center survival; trauma center volume; trauma systems	STANDARD OPERATING PROCEDURES; SCALE COLLABORATIVE PROJECT; ORIENTED RESEARCH CORE; CLINICAL CARE; HOST RESPONSE; DATA-BANK; LEVEL-I; HYPERTONIC RESUSCITATION; CENTER DESIGNATION; PATIENT	Objective: To investigate the relationship between trauma center volume and outcome. Background: The Resuscitation Outcomes Consortium is a network of 11 centers and 60 hospitals conducting emergency care research. For many procedures, high-volume centers demonstrate superior outcomes versus low-volume centers. This remains controversial for trauma center outcomes. Methods: This study was a secondary analysis of prospectively collected data from the Resuscitation Outcomes Consortium multicenter out-of-hospital Hypertonic Saline Trial in patients with Glasgow Coma Scale score of 8 or less (traumatic brain injury) or systolic blood pressure of 90 or less and pulse of 110 or more (shock). Regression analyses evaluated associations between trauma volume and the following outcomes: 24-hour mortality, 28-day mortality, ventilator-free days, Multiple Organ Dysfunction Scale incidence, worst Multiple Organ Dysfunction Scale score, and poor 6-month Glasgow Outcome Scale-Extended score. Results: A total of 2070 patients were evaluated: 1251 in the traumatic brain injury cohort and 819 in the shock cohort. Overall, 24-hour and 28-day mortality was 16% and 25%, respectively. For every increase of 500 trauma center admissions, there was a 7% decreased odds of 24-hour and 28-day mortality for all patients. As trauma center volume increased, nonorgan dysfunction complications increased, ventilator-free days increased, and worst Multiple Organ Dysfunction Scale score decreased. The associations with higher trauma center volume were similar for the traumatic brain injury cohort, including better neurologic outcomes at 6 months, but not for the shock cohort. Conclusions: Increased trauma center volume was associated with increased survival, more ventilator-free days, and less severe organ failure. Trauma system planning and implementation should avoid unnecessary duplication of services.	[Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Fabian, Timothy C.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; [Guffey, Danielle M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Newgard, Craig D.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Brasel, Karen J.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Sperry, Jason L.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [MacDonald, Russell D.] Univ Toronto, Dept Med, Toronto, ON, Canada; [MacDonald, Russell D.] Ornge Transport Med, Mississauga, ON, Canada	Minei, JP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn Trauma Crit Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joseph.minei@utsouthwestern.edu		Guffey, Danielle/0000-0003-3721-614X	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077866, HL077867, HL077871, HL077872, HL077873, HL077881, HL077885, HL077887, HL077908]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077866, U01HL077872, U01HL077908, U01HL077885, U01HL077871, U01HL077863, U01HL077887, U01HL077867, U01HL077873, U01HL077881] Funding Source: NIH RePORTER	The Resuscitation Outcomes Consortium is supported by a series of cooperative agreements to 9 regional clinical centers and 1 Data Coordinating Center (5U01 HL077863-University of Washington Data Coordinating Center; HL077866-Medical College of Wisconsin; HL077867-University of Washington; HL077871-University of Pittsburgh; HL077872-St. Michael's Hospital; HL077873-Oregon Health and Science University; HL077881-University of Alabama at Birmingham; HL077885-Ottawa Hospital Research Institute; HL077887-University of Texas Southwestern Medical Center, Dallas; HL077908-University of California San Diego) from the National Heart, Lung and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research & Material Command, The Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defense Research and Development Canada and the Heart, Stroke Foundation of Canada, and the American Heart Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung and Blood Institute or the National Institutes of Health. The authors declare no conflicts of interest.	American College of Surgeons, 2006, RES OPT CAR INJ PAT; Arbabi S, 2005, J TRAUMA, V59, P815, DOI 10.1097/01.ta.0000188390.80199.37; Bennett KM, 2011, J SURG RES, V167, P19, DOI 10.1016/j.jss.2010.05.020; Bochicchio GV, 2008, SURG INFECT, V9, P415, DOI 10.1089/sur.2006.069; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Bukur M, 2012, AM SURGEON, V78, P36; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Claridge JA, 2000, J TRAUMA, V48, P8, DOI 10.1097/00005373-200001000-00003; Clement RC, 2013, J NEUROSURG, V118, P687, DOI 10.3171/2012.10.JNS12682; Cole E, 2014, J TRAUMA ACUTE CARE, V76, P730, DOI 10.1097/TA.0b013e31829fdbd7; Cole E, 2013, J TRAUMA ACUTE CARE, V74, P51, DOI 10.1097/TA.0b013e3182788b0f; Croce MA, 2005, J TRAUMA, V59, P19, DOI 10.1097/01.TA.0000171459.21450.DC; Cudnik MT, 2009, J TRAUMA, V66, P1321, DOI 10.1097/TA.0b013e3181929e2b; Cuschieri J, 2012, ANN SURG, V255, P993, DOI 10.1097/SLA.0b013e31824f1ebc; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Freeman Jenny, 2006, J Health Serv Res Policy, V11, P101, DOI 10.1258/135581906776318857; Glance LG, 2004, J TRAUMA, V56, P682, DOI 10.1097/01.TA.0000053469.92142.40; Harbrecht BG, 2007, J TRAUMA, V63, P703, DOI 10.1097/TA.0b013e31811eadea; Kardooni S, 2008, J TRAUMA, V64, P273, DOI 10.1097/TA.0b013e31816335ae; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Marx WH, 2011, J TRAUMA, V71, P339, DOI 10.1097/TA.0b013e3182214055; Matsushima K, 2014, JAMA SURG, V149, P319, DOI 10.1001/jamasurg.2013.4834; Minei JP, 2012, CRIT CARE MED, V40, P1129, DOI 10.1097/CCM.0b013e3182376e9f; Minei JP, 2010, ANN SURG, V252, P149, DOI 10.1097/SLA.0b013e3181df0401; Nathens AB, 2005, J TRAUMA, V59, P764, DOI 10.1097/01.ta.0000177759.17704.35; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; Pandya SR, 2011, J TRAUMA, V70, P1326, DOI 10.1097/TA.0b013e31820e327c; Pasquali SK, 2013, ANN THORAC SURG, V95, P197, DOI 10.1016/j.athoracsur.2012.08.074; Richardson JD, 1998, J TRAUMA, V44, P266, DOI 10.1097/00005373-199802000-00004; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Sava J, 2003, J TRAUMA, V54, P829, DOI 10.1097/01.TA.0000063002.12062.21; Simon R, 2009, J TRAUMA, V67, P645, DOI 10.1097/TA.0b013e31818cae0c; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tepas JJ, 2013, J TRAUMA ACUTE CARE, V74, P143, DOI 10.1097/TA.0b013e3182788b5a; West MA, 2006, J TRAUMA, V61, P436, DOI 10.1097/01.ta.0000232517.83039.c4; Yaghoubian A, 2008, AM SURGEON, V74, P930	40	36	36	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	SEP	2014	260	3					456	465		10.1097/SLA.0000000000000873			10	Surgery	Surgery	AO2SJ	WOS:000341175600006	25115421	Green Accepted			2021-06-18	
J	Corbo, V; Salat, DH; Amick, MM; Leritz, EC; Milberg, WP; McGlinchey, RE				Corbo, Vincent; Salat, David H.; Amick, Melissa M.; Leritz, Elizabeth C.; Milberg, William P.; McGlinchey, Regina E.			Reduced cortical thickness in veterans exposed to early life trauma	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Posttraumatic stress disorder (PTSD); Trauma; Posterior cingulate; Amygdala; Cortical thickness	POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; CORTICOTROPIN-RELEASING-FACTOR; SMALLER HIPPOCAMPAL VOLUME; ANTERIOR CINGULATE CORTEX; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; PREFRONTAL CORTEX; LONG-TERM; BRAIN	Studies have shown that early life trauma may influence neural development and increase the risk of developing psychological disorders in adulthood. We used magnetic resonance imaging to examine the impact of early life trauma on the relationship between current posttraumatic stress disorder (PTSD) symptoms and cortical thickness/subcortical volumes in a sample of deployed personnel from Operation Enduring Freedom/Operation Iraqi Freedom. A group of 108 service members enrolled in the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) were divided into those with interpersonal early life trauma (EL-Trauma+) and Control (without interpersonal early life trauma) groups based on the Traumatic Life Events Questionnaire. PTSD symptoms were assessed using the Clinician-Administered PTSD Scale. Cortical thickness and subcortical volumes were analyzed using the FreeSurfer image analysis package. Thickness of the paracentral and posterior cingulate regions was positively associated with PTSD severity in the EL-Trauma+ group and negatively in the Control group. In the EL-Trauma+ group, both the right amygdala and the left hippocampus were positively associated with PTSD severity. This study illustrates a possible influence of early life trauma on the vulnerability of specific brain regions to stress. Changes in neural morphometry may provide information about the emergence and maintenance of symptoms in individuals with PTSD. Published by Elsevier Ireland Ltd.	[Corbo, Vincent; Salat, David H.; Amick, Melissa M.; Leritz, Elizabeth C.; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Geriatr Res Educ & Clin Ctr, Jamaica Plain, MA USA; [Corbo, Vincent; Amick, Melissa M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Corbo, Vincent; Salat, David H.] VA Boston Healthcare, Neuroimaging Res Vet NeRVe Ctr, Jamaica Plain, MA USA; [Salat, David H.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA; [Leritz, Elizabeth C.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA	Corbo, V (corresponding author), Boston Univ, VA Boston Healthcare, Boston, MA 02215 USA.	vincent.corbo@mail.mcgill.ca	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS062148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR010827] Funding Source: NIH RePORTER	This research was support by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C).	American Psychiatric Association, 2004, DIAGN STAT MAN MENT, VFOURTH; Andersen SL, 2008, J NEUROPSYCH CLIN N, V20, P292, DOI 10.1176/appi.neuropsych.20.3.292; Beckmann M, 2009, J NEUROSCI, V29, P1175, DOI 10.1523/JNEUROSCI.3328-08.2009; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 2001, J CLIN PSYCHIAT, V62, P16; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Buss C, 2007, J NEUROSCI, V27, P2592, DOI 10.1523/JNEUROSCI.3252-06.2007; Carpenter LL, 2004, NEUROPSYCHOPHARMACOL, V29, P777, DOI 10.1038/sj.npp.1300375; Carrion VG, 2007, PEDIATRICS, V119, P509, DOI 10.1542/peds.2006-2028; Chen YC, 2004, P NATL ACAD SCI USA, V101, P15782, DOI 10.1073/pnas.0403975101; Cohen RA, 2006, BIOL PSYCHIAT, V59, P975, DOI 10.1016/j.biopsych.2005.12.016; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dannlowski U, 2012, BIOL PSYCHIAT, V71, P286, DOI 10.1016/j.biopsych.2011.10.021; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Dickie EW, 2013, PSYCHOL MED, V43, P645, DOI 10.1017/S0033291712001328; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fortier C.B., 2013, J HEAD TRAUMA REHAB, V66, P1373; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Geuze E, 2008, NEUROIMAGE, V41, P675, DOI 10.1016/j.neuroimage.2008.03.007; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hartley CA, 2011, CEREB CORTEX, V21, P1954, DOI 10.1093/cercor/bhq253; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Heim C, 2002, DEPRESS ANXIETY, V15, P117, DOI 10.1002/da.10015; Heim CM, 2013, AM J PSYCHIAT, V170, P616, DOI 10.1176/appi.ajp.2013.12070950; Hellstrom IC, 2012, PHILOS T R SOC B, V367, P2495, DOI 10.1098/rstb.2012.0223; Jarnum H, 2011, ACTA PSYCHIAT SCAND, V124, P435, DOI 10.1111/j.1600-0447.2011.01766.x; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kitayama N, 2006, J AFFECT DISORDERS, V90, P171, DOI 10.1016/j.jad.2005.11.006; Koenig LB, 2009, J STUD ALCOHOL DRUGS, V70, P296, DOI 10.15288/jsad.2009.70.296; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Kuo JR, 2012, ARCH GEN PSYCHIAT, V69, P1080, DOI 10.1001/archgenpsychiatry.2012.73; Landre L, 2010, PSYCHIAT RES-NEUROIM, V183, P181, DOI 10.1016/j.pscychresns.2010.01.015; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Leritz EC, 2011, NEUROIMAGE, V54, P2659, DOI 10.1016/j.neuroimage.2010.10.050; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039025; Lupien SJ, 2011, P NATL ACAD SCI USA, V108, P14324, DOI 10.1073/pnas.1105371108; Milad MR, 2005, P NATL ACAD SCI USA, V102, P10706, DOI 10.1073/pnas.0502441102; Nichols TE, 2012, NEUROIMAGE, V62, P811, DOI 10.1016/j.neuroimage.2012.04.014; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Pitman RK, 2001, J CLIN PSYCHIAT, V62, P47; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Rimol LM, 2010, BIOL PSYCHIAT, V68, P41, DOI 10.1016/j.biopsych.2010.03.036; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Tottenham N, 2010, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.068.2009; van der Kolk BA, 2003, CHILD ADOL PSYCH CL, V12, P293, DOI 10.1016/S1056-4993(03)00003-8; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Vogt BA, 2003, EUR J NEUROSCI, V18, P3134, DOI 10.1111/j.1460-9568.2003.03034.x; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Vyas A, 2002, J NEUROSCI, V22, P6810; Wignall EL, 2004, BIOL PSYCHIAT, V56, P832, DOI 10.1016/j.biopsych.2004.09.015; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Woon FL, 2008, HIPPOCAMPUS, V18, P729, DOI 10.1002/hipo.20437; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Zhang TY, 2006, BIOL PSYCHOL, V73, P72, DOI 10.1016/j.biopsycho.2006.01.009	68	36	36	0	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	AUG 30	2014	223	2					53	60		10.1016/j.pscychresns.2014.04.013			8	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	AM6ZK	WOS:000340014300001	24862391	Green Accepted			2021-06-18	
J	Ojo, JO; Greenberg, MB; Leary, P; Mouzon, B; Bachmeier, C; Mullan, M; Diamond, DM; Crawford, F				Ojo, Joseph O.; Greenberg, M. Banks; Leary, Paige; Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Diamond, David M.; Crawford, Fiona			Neurobehavioral, neuropathological and biochemical profiles in a novel mouse model of co-morbid post-traumatic stress disorder and mild traumatic brain injury	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						post-traumatic stress disorder; mild traumatic brain injury; mouse models; anxiety and social behavior; cognitive function; plasma and brain biomarkers	URINARY CORTISOL EXCRETION; PLASMA-CORTISOL; DEXAMETHASONE-SUPPRESSION; CEREBROSPINAL-FLUID; EMOTIONAL MEMORIES; ANIMAL-MODEL; DYSFUNCTION; DEPRESSION; INCREASE; DEFICITS	Co-morbid mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) has become the signature disorder for returning combat veterans. The clinical heterogeneity and overlapping symptomatology of mTBI and PTSD underscore the need to develop a preclinical model that will enable the characterization of unique and overlapping features and allow discrimination between both disorders. This study details the development and implementation of a novel experimental paradigm for PTSD and combined PTSD-mTBI. The PTSD paradigm involved exposure to a danger-related predator odor under repeated restraint over a 21 day period and a physical trauma (inescapable footshock). We administered this paradigm alone, or in combination with a previously established mTBI model. We report outcomes of behavioral, pathological and biochemical profiles at an acute timepoint. PTSD animals demonstrated recall of traumatic memories, anxiety and an impaired social behavior. In both mTBI and combination groups there was a pattern of disinhibitory like behavior. mTBI abrogated both contextual fear and impairments in social behavior seen in PTSD animals. No major impairment in spatial memory was observed in any group. Examination of neuroendocrine and neuroimmune responses in plasma revealed a trend toward increase in corticosterone in PTSD and combination groups, and an apparent increase in Th1 and Th17 proinflammatory cytokine(s) in the PTSD only and mTBI only groups respectively. In the brain there were no gross neuropathological changes in any groups. We observed that mTBI on a background of repeated trauma exposure resulted in an augmentation of axonal injury and inflammatory markers, neurofilament L and ICAM-1 respectively. Our observations thus far suggest that this novel stress-trauma-related paradigm may be a useful model for investigating further the overlapping and distinct spatio-temporal and behavioral/biochemical relationship between mTBI and PTSD experienced by combat veterans.	[Ojo, Joseph O.; Greenberg, M. Banks; Leary, Paige; Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA; [Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Diamond, David M.; Crawford, Fiona] James A Haley Vet Hosp, Res & Dev Serv, Tampa, FL 33612 USA; [Mouzon, Benoit; Bachmeier, Corbin; Mullan, Michael; Crawford, Fiona] Open Univ, Dept Life Sci, Milton Keynes MK7 6AA, Bucks, England; [Diamond, David M.] Univ S Florida, Dept Psychol, Dept Mol Pharmacol & Physiol, Ctr Preclin & Clin Res PTSD, Tampa, FL 33620 USA	Ojo, JO (corresponding author), Roskamp Inst, 2040 Whitfield Avenue, Sarasota, FL 34243 USA.	bojo@roskampinstitute.net			Roskamp Foundation	We would like to thank Ariel Gonzalez for his help in performing some of the biochemical experiments involved in this study. This study was supported by the Roskamp Foundation.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Baker DG, 2001, NEUROIMMUNOMODULAT, V9, P209, DOI 10.1159/000049028; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bluthe RM, 1999, PSYCHONEUROENDOCRINO, V24, P301, DOI 10.1016/S0306-4530(98)00077-8; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Bremner JD, 2003, PSYCHONEUROENDOCRINO, V28, P733, DOI 10.1016/S0306-4530(02)00067-7; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cain DP, 1997, BEHAV BRAIN RES, V84, P179, DOI 10.1016/S0166-4328(96)00149-0; Cain DP, 1997, CURR OPIN NEUROBIOL, V7, P235, DOI 10.1016/S0959-4388(97)80012-8; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Daskalakis NP, 2013, PSYCHONEUROENDOCRINO, V38, P1895, DOI 10.1016/j.psyneuen.2013.06.006; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Diamond David M., 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/60803; Diamond DM, 1999, HIPPOCAMPUS, V9, P542, DOI 10.1002/(SICI)1098-1063(1999)9:5<542::AID-HIPO8>3.0.CO;2-N; Diamond DM, 2005, HIPPOCAMPUS, V15, P1006, DOI 10.1002/hipo.20107; Diamond DM, 2004, HIPPOCAMPUS, V14, P281, DOI 10.1002/hipo.10186; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dranovsky A, 2006, BIOL PSYCHIAT, V59, P1136, DOI 10.1016/j.biopsych.2006.03.082; Duval F, 2004, ANN NY ACAD SCI, V1032, P273, DOI 10.1196/annals.1314.036; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Goenjian AK, 1996, AM J PSYCHIAT, V153, P929; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; GRONWALL D, 1974, LANCET, V2, P605; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Joels M, 2006, TRENDS COGN SCI, V10, P152, DOI 10.1016/j.tics.2006.02.002; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KANT GJ, 1987, PHYSIOL BEHAV, V40, P775, DOI 10.1016/0031-9384(87)90282-4; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Maes M, 1998, ACTA PSYCHIAT SCAND, V98, P328, DOI 10.1111/j.1600-0447.1998.tb10092.x; MASON JW, 1986, J NERV MENT DIS, V174, P145, DOI 10.1097/00005053-198603000-00003; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; MCFALL ME, 1992, BIOL PSYCHIAT, V31, P1050, DOI 10.1016/0006-3223(92)90097-J; Mesquita AR, 2008, J PSYCHIATR RES, V43, P89, DOI 10.1016/j.jpsychires.2008.02.004; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Norrholm SD, 2011, BIOL PSYCHIAT, V69, P556, DOI 10.1016/j.biopsych.2010.09.013; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ojo B, 2011, EXP NEUROL, V232, P318, DOI 10.1016/j.expneurol.2011.09.025; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Park CR, 2008, LEARN MEMORY, V15, P271, DOI 10.1101/lm.721108; PITMAN RK, 1990, BIOL PSYCHIAT, V27, P245, DOI 10.1016/0006-3223(90)90654-K; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAND CW, 1946, ARCH NEURO PSYCHIATR, V55, P79, DOI 10.1001/archneurpsyc.1946.02300130003001; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rohleder N, 2004, BIOL PSYCHIAT, V55, P745, DOI 10.1016/j.biopsych.2003.11.018; Sandi Carmen, 2007, Neural Plasticity, V2007, DOI 10.1055/2007/78970; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seedat S, 2003, PSYCHONEUROENDOCRINO, V28, P796, DOI 10.1016/S0306-4530(02)00086-0; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Spivak B, 1997, BIOL PSYCHIAT, V42, P345, DOI 10.1016/S0006-3223(96)00375-7; Stein MB, 1997, BIOL PSYCHIAT, V42, P680, DOI 10.1016/S0006-3223(96)00489-1; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; VANDERKOLK BA, 1995, J TRAUMA STRESS, V8, P505, DOI 10.1002/jts.2490080402; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; YEHUDA R, 1995, AM J PSYCHIAT, V152, P982; YEHUDA R, 1995, ARCH GEN PSYCHIAT, V52, P583; Young EA, 2004, ARCH GEN PSYCHIAT, V61, P394, DOI 10.1001/archpsyc.61.4.394; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zoladz PR, 2012, PSYCHONEUROENDOCRINO, V37, P1531, DOI 10.1016/j.psyneuen.2012.02.007; Zoladz PR, 2008, STRESS, V11, P259, DOI 10.1080/10253890701768613; Zoladz PR, 2013, NEUROSCI BIOBEHAV R, V37, P860, DOI 10.1016/j.neubiorev.2013.03.024	81	36	36	0	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	JUN 23	2014	8								213	10.3389/fnbeh.2014.00213			23	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AK1RS	WOS:000338194100001	25002839	DOAJ Gold, Green Published			2021-06-18	
J	Greene, NH; Kernic, MA; Vavilala, MS; Rivara, FP				Greene, Nathaniel. H.; Kernic, Mary A.; Vavilala, Monica S.; Rivara, Frederick P.			Variation in Pediatric Traumatic Brain Injury Outcomes in the United States	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference of the American-Society-of-Anesthesiologists	OCT 16, 2013	San Francisco, CA	Amer Soc Anesthesiologists		Healthcare disparities; Patient outcome assessment; Rehabilitation; Traumatic brain injury	FUNCTIONAL OUTCOMES; INSURANCE STATUS; CHILDREN; ADMISSION; REGISTRY; CARE	Objective: To ascertain the degree of variation, by state of hospitalization, in outcomes associated with traumatic brain injury (TBI) in a pediatric population. Design: A retrospective cohort study of pediatric patients admitted to a hospital with a TBI. Setting: Hospitals from states in the United States that voluntarily participate in the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project. Participants: Pediatric (age <= 19y) patients hospitalized for TBI (N = 71,476) in the United States during 2001, 2004, 2007, and 2010. Interventions: None. Main Outcome Measures: Primary outcome was proportion of patients discharged to rehabilitation after an acute care hospitalization among alive discharges. The secondary outcome was inpatient mortality. Results: The relative risk of discharge to inpatient rehabilitation varied by as much as 3-fold among the states, and the relative risk of inpatient mortality varied by as much as nearly 2-fold. In the United States, approximately 1981 patients could be discharged to inpatient rehabilitation care if the observed variation in outcomes was eliminated. Conclusions: There was significant variation between states in both rehabilitation discharge and inpatient mortality after adjusting for variables known to affect each outcome. Future efforts should be focused on identifying the cause of this state-to-state variation, its relationship to patient outcome, and standardizing treatment across the United States. (C) 2014 by the American Congress of Rehabilitation Medicine	[Greene, Nathaniel. H.; Vavilala, Monica S.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Greene, Nathaniel. H.; Kernic, Mary A.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Kernic, Mary A.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA	Greene, NH (corresponding author), Duke Univ Hosp, DUMC Box 3094, Durham, NC 27710 USA.	nathaniel.greene@duke.edu	Greene, Nathaniel/J-3450-2014	Greene, Nathaniel/0000-0003-0230-0499	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS072308] Funding Source: Medline		Clark DE OT, 2010, ICDPIC STATA MODULE; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cummings P, 2009, ARCH PEDIAT ADOL MED, V163, P438, DOI 10.1001/archpediatrics.2009.31; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hamlat CA, 2012, ANN SURG, V255, P165, DOI 10.1097/SLA.0b013e31823840ca; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Rice-Townsend S, 2013, J PEDIATR SURG, V48, P104, DOI 10.1016/j.jpedsurg.2012.10.025; Scales CD, 2011, J UROLOGY, V186, P146, DOI 10.1016/j.juro.2011.03.018; Sears JM, 2014, INJURY, V45, P16, DOI 10.1016/j.injury.2012.12.024; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Stallion A, 2007, J TRAUMA, V62, P1262; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	16	36	36	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2014	95	6					1148	1155		10.1016/j.apmr.2014.02.020			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AI3OY	WOS:000336773000020	24631594	Green Accepted			2021-06-18	
J	Hetherington, HP; Hamid, H; Kulas, J; Ling, G; Bandak, F; de Lanerolle, NC; Pan, JW				Hetherington, Hoby P.; Hamid, Hamada; Kulas, Joseph; Ling, Geoffrey; Bandak, Faris; de Lanerolle, Nihal C.; Pan, Jullie W.			MRSI of the Medial Temporal Lobe at 7 T in Explosive Blast Mild Traumatic Brain Injury	MAGNETIC RESONANCE IN MEDICINE			English	Article						mild traumatic brain injury; MRSI; hippocampus; 7 T	WORD MEMORY TEST; SYMPTOM VALIDITY TEST; ENDURING FREEDOM; WAR VETERANS; IRAQ; TBI; SPECTROSCOPY; CONCUSSION; EXPOSURE; SOLDIERS	Purpose: Up to 19% of veterans returning from the wars in Iraq and Afghanistan have a history of mild traumatic brain injury with 70% associated with blast exposure. Tragically, 20-50% of this group reports persistent symptoms, including memory loss. Unfortunately, routine clinical imaging is typically normal, making diagnosis and clinical management difficult. The goal of this work was to develop methods to acquire hippocampal MRSI at 7 T and evaluate their sensitivity to detect injury in veterans with mild traumatic brain injury. Methods: At 7 T, hippocampal MRSI measurements are limited by: (1) poor B-0 homogeneity; (2) insufficient B-1(+) strength and homogeneity; and (3) chemical shift dispersion artifacts. To overcofme these limitations we: (1) used third degree B-0 shimming; (2) an inductively decoupled transceiver array with radiofrequency shimming; and (3) a volume localized single slice sequence using radiofrequency shimming-based outer volume suppression. Results: In 20 controls and 25 veterans with mild traumatic brain injury due to blast exposure with memory impairment, hippocampal N-acetyl aspartate to choline (P < 0.001) and N-acetyl aspartate to creatine (P < 0.001) were decreased in comparison to control subjects. Conclusion: With the appropriate methods robust spectroscopic imaging of the hippocampus can be carried out at 7 T. MRSI at 7 T can detect hippocampal injury in veterans with mild traumatic brain injury. (c) 2013 Wiley Periodicals, Inc.	[Hetherington, Hoby P.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA; [Hetherington, Hoby P.; de Lanerolle, Nihal C.; Pan, Jullie W.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA; [Hamid, Hamada] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Hamid, Hamada] West Haven Vet Adm Med Ctr, Dept Neurol, West Haven, CT USA; [Kulas, Joseph] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Kulas, Joseph] West Haven Vet Adm Med Ctr, Dept Psychol, West Haven, CT USA; [Ling, Geoffrey; Bandak, Faris] Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; [Bandak, Faris] Integrated Serv Grp Inc, Potomac, MD USA; [Pan, Jullie W.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA	Hetherington, HP (corresponding author), Univ Pittsburgh, Dept Radiol, B820 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.	hetheringtonh@upmc.edu	Altalib, Hamada/B-9656-2018	Altalib, Hamada/0000-0001-7154-1400	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EB009871, R01EB011639, R01NS081772]; DARPA/SPAWARUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-08-C-2005]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009871, R01EB011639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [F32ES027306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090417, R01NS081772] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant numbers: R01EB009871, R01EB011639, R01NS081772, and DARPA/SPAWAR N66001-08-C-2005.	Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Avdievich NI, 2009, MAGN RESON MED, V62, P17, DOI 10.1002/mrm.21970; Avdievich NI, 2011, APPL MAGN RESON, V41, P483, DOI 10.1007/s00723-011-0280-y; Avdievich NI, 2009, J MAGN RESON IMAGING, V29, P461, DOI 10.1002/jmri.21660; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cavus I, 2008, EPILEPSIA, V49, P1358, DOI 10.1111/j.1528-1167.2008.01603.x; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick RI, 2009, J HEAD TRAUMA REHAB, V24, P105, DOI 10.1097/HTR.0b013e31819b1210; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hetherington HP, 2007, NEUROLOGY, V69, P2256, DOI 10.1212/01.wnl.0000286945.21270.6d; Hetherington HP, 2006, MAGN RESON MED, V56, P26, DOI 10.1002/mrm.20941; Hetherington HP, 2010, MAGN RESON MED, V63, P9, DOI 10.1002/mrm.22182; Hetherington HP, 1996, MAGNET RESON MED, V36, P21, DOI 10.1002/mrm.1910360106; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Miyasaka N, 2006, J MAGN RESON IMAGING, V24, P908, DOI 10.1002/jmri.20709; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pan JW, 2012, MAGN RESON MED, V68, P1007, DOI 10.1002/mrm.24122; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Tanelian T., 2008, INVISIBLE WOUNDS WAR; Tanielian T, 2009, ASSESSING COMBAT EXP; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vaughan JT, 2001, MAGN RESON MED, V46, P24, DOI 10.1002/mrm.1156; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	43	36	36	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	APR	2014	71	4					1358	1367		10.1002/mrm.24814			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AD2CL	WOS:000333040500002	23918077	Green Accepted			2021-06-18	
J	Kim, SY; Shim, MS; Kim, KY; Weinreb, RN; Wheeler, LA; Ju, WK				Kim, S. Y.; Shim, M. S.; Kim, K-Y; Weinreb, R. N.; Wheeler, L. A.; Ju, W-K			Inhibition of cyclophilin D by cyclosporin A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury	CELL DEATH & DISEASE			English	Article						cyclosporin A; retinal ischemia; retinal ganglion cell; cyclophilin D; mitochondrial DNA; mitochondrial transcription factor A	PERMEABILITY TRANSITION PORE; TRAUMATIC BRAIN-INJURY; ADENINE-NUCLEOTIDE TRANSLOCASE; RAT RETINA; TRANSCRIPTION FACTOR; TRANSIENT ISCHEMIA; REPERFUSION INJURY; CEREBRAL-ISCHEMIA; NEURONAL DEATH; INFARCT SIZE	Cyclosporin A (CsA) inhibits the opening of the mitochondrial permeability transition pore (MPTP) by interacting with cyclophilin D (CypD) and ameliorates neuronal cell death in the central nervous system against ischemic injury. However, the molecular mechanisms underlying CypD/MPTP opening-mediated cell death in ischemic retinal injury induced by acute intraocular pressure (IOP) elevation remain unknown. We observed the first direct evidence that acute IOP elevation significantly upregulated CypD protein expression in ischemic retina at 12 h. However, CsA prevented the upregulation of CypD protein expression and promoted retinal ganglion cell (RGC) survival against ischemic injury. Moreover, CsA blocked apoptotic cell death by decreasing cleaved caspase-3 protein expression in ischemic retina. Of interest, although the expression level of Bcl-xL protein did not show a significant change in ischemic retina treated with vehicle or CsA at 12 h, ischemic damage induced the reduction of Bcl-xL immunoreactivity in RGCs. More importantly, CsA preserved Bcl-xL immunoreactivity in RGCs of ischemic retina. In parallel, acute IOP elevation significantly increased phosphorylated Bad (pBad) at Ser112 protein expression in ischemic retina at 12 h. However, CsA significantly preserved pBad protein expression in ischemic retina. Finally, acute IOP elevation significantly increased mitochondrial transcription factor A (Tfam) protein expression in ischemic retina at 12 h. However, CsA significantly preserved Tfam protein expression in ischemic retina. Studies on mitochondrial DNA (mtDNA) content in ischemic retina showed that there were no statistically significant differences in mtDNA content among control and ischemic groups treated with vehicle or CsA. Therefore, these results provide evidence that the activation of CypD-mediated MPTP opening is associated with the apoptotic pathway and the mitochondrial alteration in RGC death of ischemic retinal injury. On the basis of these observations, our findings suggest that CsA-mediated CypD inhibition may provide a promising therapeutic potential for protecting RGCs against ischemic injury-mediated mitochondrial dysfunction.	[Kim, S. Y.; Shim, M. S.; Weinreb, R. N.; Ju, W-K] Univ Calif San Diego, Lab Opt Nerve Biol, Dept Ophthalmol, Hamilton Glaucoma Ctr, La Jolla, CA 92037 USA; [Kim, K-Y] Univ Calif San Diego, Ctr Res Biol Syst, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92037 USA; [Kim, K-Y] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92037 USA; [Wheeler, L. A.] Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA USA	Ju, WK (corresponding author), Univ Calif San Diego, Lab Opt Nerve Biol, Dept Ophthalmol, Hamilton Glaucoma Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.	danielju@glaucoma.ucsd.edu		Kim, Sang Yeop/0000-0002-5781-9039	Allergan Inc.AbbVieAllergan; National Institute Health [EY018658, P30EY022589]; Research to Prevent Blindness (New York, NY, USA)Research to Prevent Blindness (RPB); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY022589, R01EY018658] Funding Source: NIH RePORTER	This work was supported, in part, by funding provided by an Allergan Inc. (WKJ), the National Institute Health Grants EY018658 (WKJ) and P30EY022589 (Vision Research Core Grant) and an unrestricted grant from Research to Prevent Blindness (New York, NY, USA).	ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Chen H, 2001, STROKE, V32, P2382, DOI 10.1161/hs1001.097099; Chtistophe M, 2006, CURR PHARM DESIGN, V12, P739; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Cui Q, 2007, NEUROSCIENCE, V146, P986, DOI 10.1016/j.neuroscience.2007.02.034; Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Friberg H, 1998, J NEUROSCI, V18, P5151; Gouriou Y, 2011, BIOCHIMIE, V93, P2060, DOI 10.1016/j.biochi.2011.08.001; Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a; Hokari M, 2010, NEUROPATHOLOGY, V30, P401, DOI 10.1111/j.1440-1789.2009.01086.x; Javadov S, 2007, CELL PHYSIOL BIOCHEM, V20, P1, DOI 10.1159/000103747; Javadov S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00076; Ju WK, 2000, J NEUROPATH EXP NEUR, V59, P241, DOI 10.1093/jnen/59.3.241; Ju WK, 2000, NEUROSCI LETT, V283, P133, DOI 10.1016/S0304-3940(00)00931-9; Ju WK, 2011, METHODS MOL BIOL, V740, P149, DOI 10.1007/978-1-61779-108-6_16; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Lai RK, 2002, VISUAL NEUROSCI, V19, P175, DOI 10.1017/S0952523802191152; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lee D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047098; Leger PL, 2011, EXP NEUROL, V230, P58, DOI 10.1016/j.expneurol.2010.06.009; Levin LA, 1997, INVEST OPHTH VIS SCI, V38, P2545; Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046498; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Malouitre S, 2010, BIOCHEM J, V425, P137, DOI 10.1042/BJ20090332; Martin LJ, 2011, TOXICOL PATHOL, V39, P220, DOI 10.1177/0192623310389475; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Ngo HB, 2011, NAT STRUCT MOL BIOL, V18, P1290, DOI 10.1038/nsmb.2159; Nucci C, 2007, INT REV NEUROBIOL, V82, P397, DOI 10.1016/S0074-7742(07)82022-8; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Park SW, 2011, INVEST OPHTH VIS SCI, V52, P2837, DOI 10.1167/iovs.09-5010; Piao Y, 2012, BBA-GEN SUBJECTS, V1820, P577, DOI 10.1016/j.bbagen.2011.08.007; Rao VK, 2014, BBA-MOL BASIS DIS, V1842, P1267, DOI 10.1016/j.bbadis.2013.09.003; Russo R, 2008, PROG BRAIN RES, V173, P575, DOI 10.1016/S0079-6123(08)01139-4; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino Hiroyuki, 2013, Acta Neurochir Suppl, V118, P311, DOI 10.1007/978-3-7091-1434-6_61; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vander Heiden MG, 1999, MOL CELL, V3, P159; Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Wurm A, 2011, PROG RETIN EYE RES, V30, P324, DOI 10.1016/j.preteyeres.2011.06.001; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Yuen CM, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-141	60	36	37	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAR	2014	5								e1105	10.1038/cddis.2014.80			11	Cell Biology	Cell Biology	AE1TW	WOS:000333754100009	24603333	DOAJ Gold, Green Published			2021-06-18	
J	Kjeldgaard, D; Forchhammer, H; Teasdale, T; Jensen, RH				Kjeldgaard, Dorte; Forchhammer, Hysse; Teasdale, Tom; Jensen, Rigmor H.			Chronic post-traumatic headache after mild head injury: A descriptive study	CEPHALALGIA			English	Article						Chronic post-traumatic headache; brain concussion; Quality of Life; SF-36; Rivermead Post Concussion Symptoms Questionnaire; Harvard Trauma Questionnaire	POST-CONCUSSION SYMPTOMS; TRAUMATIC BRAIN-INJURY; STRESS-DISORDER; CHRONIC PAIN; QUESTIONNAIRE; POPULATION; PREVALENCE; INSTRUMENT; DISABILITY; MIGRAINE	Background The aetiology behind chronic post-traumatic headache (CPTH) after mild head injury is unclear and management is complicated. In order to optimize treatment strategies we aimed to characterize a CPTH population. Methods Ninety patients with CPTH and 45 patients with chronic primary headaches were enrolled from the Danish Headache Center. All patients were interviewed about demographic and headache data. They completed the Harvard Trauma Questionnaire (HTQ), Rivermead Post Concussion Symptoms Questionnaire, SF-36 and a headache diary. Results The CPTH group experienced more cognitive (p<0.001) and somatic symptoms (p=0.048) and rated their self-perceived health as more affected in terms of physical function (p=0.036), physical role function (p=0.012) and social function (p=0.012) than the control group. Surprisingly, 31% of the CPTH group had a score equal to or above the cut-off score for having post-traumatic stress disorder (PTSD) according to the HTQ. In terms of demographics and headache, the groups were comparable except the CPTH group were more often without affiliation to the labour market (p<0.001). Conclusions The loss of work capacity and high levels of disability for the CPTH patients suggests directions for further research into what important factors are embedded in the patients' PTSD symptoms and might explain their prolonged illness.	[Kjeldgaard, Dorte; Jensen, Rigmor H.] Univ Copenhagen, Danish Headache Ctr, DK-2600 Glostrup, Denmark; [Forchhammer, Hysse] Univ Copenhagen, Dept Neurol, DK-2600 Glostrup, Denmark; [Teasdale, Tom] Univ Copenhagen, Dept Psychol, DK-2600 Glostrup, Denmark	Jensen, RH (corresponding author), Univ Copenhagen, Glostrup Hosp, Danish Headache Ctr, Nrd Ringvej 69, DK-2600 Glostrup, Denmark.	rigmor.jensen@regionh.dk			LundbeckLundbeck Corporation [R67-A6507]; Helsefonden [2099B033]	The research received grants from Lundbeck (R67-A6507) and Helsefonden (2099B033).	Aaseth K, 2008, CEPHALALGIA, V28, P705, DOI 10.1111/j.1468-2982.2008.01577.x; American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN; Andersen TE, 2012, SCAND J PAIN, V3, P39, DOI 10.1016/j.sjpain.2011.10.001; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P991, DOI 10.1016/S0895-4356(98)00091-2; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; Ifergane G, 2009, EUR J INTERN MED, V20, P182, DOI 10.1016/j.ejim.2008.05.001; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jensen R, 2011, CEPHALALGIA, V31, P1549, DOI 10.1177/0333102411424212; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lanteri-Minet M, 2011, CEPHALALGIA, V31, P837, DOI 10.1177/0333102411398400; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Linde M, 2012, EUR J NEUROL, V19, P703, DOI 10.1111/j.1468-1331.2011.03612.x; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Marcus DA, 2003, HEADACHE, V43, P117, DOI 10.1046/j.1526-4610.2003.03028.x; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RUSSELL MB, 1992, CEPHALALGIA, V12, P369, DOI 10.1111/j.1468-2982.1992.00369.x; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Vargas BB, 2012, CURR OPIN NEUROL, V25, P284, DOI 10.1097/WCO.0b013e3283535bf5; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; Ware JE, 2001, QUAL LIFE RES, V10, P405, DOI 10.1023/A:1012588218728; Zasler ND, 2011, J HEAD TRAUMA REHAB, V26, P397, DOI 10.1097/HTR.0b013e31822721f8; Zeeberg P, 2005, CEPHALALGIA, V25, P1159, DOI 10.1111/j.1468-2982.2005.00980.x	34	36	36	0	23	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	MAR	2014	34	3					191	200		10.1177/0333102413505236			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	303OS	WOS:000330684500005	24045573				2021-06-18	
J	Barbey, AK; Colom, R; Paul, E; Forbes, C; Krueger, F; Goldman, D; Grafman, J				Barbey, Aron K.; Colom, Roberto; Paul, Erick; Forbes, Chad; Krueger, Frank; Goldman, David; Grafman, Jordan			Preservation of General Intelligence following Traumatic Brain Injury: Contributions of the Met66 Brain-Derived Neurotrophic Factor	PLOS ONE			English	Article							BDNF VAL66MET POLYMORPHISM; ACTIVITY-DEPENDENT SECRETION; FAMILY-BASED ASSOCIATION; CARD SORTING TEST; ALZHEIMERS-DISEASE; NEURONAL DEVELOPMENT; RECEPTOR SORTILIN; BIPOLAR DISORDER; EPISODIC MEMORY; WORKING-MEMORY	Brain-derived neurotrophic factor (BDNF) promotes survival and synaptic plasticity in the human brain. The Val66Met polymorphism of the BDNF gene interferes with intracellular trafficking, packaging, and regulated secretion of this neurotrophin. The human prefrontal cortex (PFC) shows lifelong neuroplastic adaption implicating the Val66Met BDNF polymorphism in the recovery of higher-order executive functions after traumatic brain injury (TBI). In this study, we examined the effect of this BDNF polymorphism on the preservation of general intelligence following TBI. We genotyped a sample of male Vietnam combat veterans (n = 156) consisting of a frontal lobe lesion group with focal penetrating head injuries for the Val66Met BDNF polymorphism. Val/Met did not differ from Val/Val genotypes in general cognitive ability before TBI. However, we found substantial average differences between these groups in general intelligence (approximate to half a standard deviation or 8 IQ points), verbal comprehension (6 IQ points), perceptual organization (6 IQ points), working memory (8 IQ points), and processing speed (8 IQ points) after TBI. These results support the conclusion that Val/Met genotypes preserve general cognitive functioning, whereas Val/Val genotypes are largely susceptible to TBI.	[Barbey, Aron K.; Paul, Erick] Univ Illinois, Decis Neurosci Lab, Urbana, IL 61801 USA; [Barbey, Aron K.; Paul, Erick] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Barbey, Aron K.] Univ Illinois, Dept Internal Med, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Dept Psychol, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Neurosci Program, Champaign, IL 61820 USA; [Colom, Roberto] Univ Autonoma Madrid, Fdn CIEN, Fdn Reina Sofia, Madrid, Spain; [Forbes, Chad] Univ Delaware, Dept Psychol, Delaware, MD USA; [Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA USA; [Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA; [Grafman, Jordan] Rehabil Inst Chicago, Traumat Brain Injury Res Lab, Chicago, IL 60611 USA	Barbey, AK (corresponding author), Univ Illinois, Decis Neurosci Lab, Urbana, IL 61801 USA.	barbey@illinois.edu; jgrafman@ric.edu	Colom, Roberto/F-8779-2010; Majid, Salma/AAT-2616-2020; Goldman, David/F-9772-2010; Barbey, Aron/L-7312-2015	Colom, Roberto/0000-0001-5865-163X; Majid, Salma/0000-0002-1724-5405; Goldman, David/0000-0002-1724-5405; Barbey, Aron/0000-0002-6092-0912	U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]; Ministerio de Ciencia e Innovacion [Ministry of Science and Innovation, Spain] [PSI2010-20364]; Universidad Autonoma de Madrid [CEMU-2012-004]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	This work was supported by funding from the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the United States Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study, grant number DAMD17-01-1-0675). R. Colom was supported by grant PSI2010-20364 from Ministerio de Ciencia e Innovacion [Ministry of Science and Innovation, Spain] and and CEMU-2012-004 [Universidad Autonoma de Madrid]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Shawi R, 2008, EUR J NEUROSCI, V27, P2103, DOI 10.1111/j.1460-9568.2008.06152.x; Arbuckle J.L., 2006, AMOS VERSION 7 0 COM; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Barbey AK, 2012, CORTEX; Barbey AK, 2011, CEREB CORTEX, V21, P789, DOI 10.1093/cercor/bhq153; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Beste C, 2010, NEUROSCIENCE, V166, P178, DOI 10.1016/j.neuroscience.2009.12.022; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Dempster E, 2005, AM J MED GENET B, V134B, P73, DOI 10.1002/ajmg.b.30150; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Frustaci A, 2008, NEUROPSYCHOBIOLOGY, V58, P163, DOI 10.1159/000182892; Gratacos M, 2007, BIOL PSYCHIAT, V61, P911, DOI 10.1016/j.biopsych.2006.08.025; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Ho BC, 2007, AM J PSYCHIAT, V164, P1890, DOI 10.1176/appi.ajp.2007.05111903; Ho BC, 2006, ARCH GEN PSYCHIAT, V63, P731, DOI 10.1001/archpsyc.63.7.731; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662; Koenigs M, 2009, J NEUROSCI, V29, P14980, DOI 10.1523/JNEUROSCI.3706-09.2009; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Kunugi H, 2001, MOL PSYCHIATR, V6, P83, DOI 10.1038/sj.mp.4000792; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; Montag C, 2009, PSYCHOL MED, V39, P1831, DOI 10.1017/S0033291709005509; Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Oroszi G, 2006, ANN RHEUM DIS, V65, P1330, DOI 10.1136/ard.2006.051623; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Riemenschneider M, 2002, MOL PSYCHIATR, V7, P782, DOI 10.1038/sj.mp.4001073; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rybakowski JK, 2003, BIPOLAR DISORD, V5, P468, DOI 10.1046/j.1399-5618.2003.00071.x; Rybakowski JK, 2006, MOL PSYCHIATR, V11, P122, DOI 10.1038/sj.mp.4001765; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Tan YL, 2005, SCHIZOPHR RES, V77, P355, DOI 10.1016/j.schres.2005.03.012; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Ventriglia M, 2002, MOL PSYCHIATR, V7, P136, DOI 10.1038/sj.mp.4000952; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Wechsler D, 1997, WAIS 3 ADM SCORING M; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Zivadinov R, 2007, HUM MOL GENET, V16, P2659, DOI 10.1093/hmg/ddm189	59	36	36	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2014	9	2							e88733	10.1371/journal.pone.0088733			8	Multidisciplinary Sciences	Science & Technology - Other Topics	AC3BC	WOS:000332389000017	24586380	DOAJ Gold, Green Published			2021-06-18	
J	Wong, J; Mellor, D				Wong, Jessica; Mellor, David			Intimate partner violence and women's health and wellbeing: Impacts, risk factors and responses	CONTEMPORARY NURSE			English	Article						intimate partner violence; physical health; mental health; nursing responses	POSTTRAUMATIC-STRESS-DISORDER; DOMESTIC VIOLENCE; MENTAL-HEALTH; GASTROINTESTINAL DISORDERS; ABUSIVE RELATIONSHIP; PHYSICAL ABUSE; SEXUAL-ABUSE; CHRONIC PAIN; PREVALENCE; CONSEQUENCES	Women have approximately a one in four chance of experiencing intimate partner violence (IPV). Those who do are at increased risk of developing physical and mental health problems including traumatic brain injury, chronic pain, gastrointestinal disorders, depression, post-traumatic stress disorder, and substance-related disorders. Nurses, in whatever situation they work, are therefore highly likely to encounter women who are victims of IPV. This paper explores the prevalence of physical and mental health issues for women with an experience of IPV. Factors that influence a woman's experience of IPV such as culture, remaining in an abusive relationship, and childhood sexual abuse as a risk factor of IPV are also examined. Recommended responses for women with an experience of IPV are discussed.	[Wong, Jessica; Mellor, David] Deakin Univ, Sch Psychol, Melbourne, Vic, Australia	Wong, J (corresponding author), Deakin Univ, Sch Psychol, Melbourne, Vic, Australia.			Mellor, David/0000-0001-5007-5906			Alexander RW, 1998, ARTHRIT CARE RES, V11, P102, DOI 10.1002/art.1790110206; Arndt N., 1982, DISS ABSTR INT B, V42, p3405B; Bostock J, 2009, J COMMUNITY APPL SOC, V19, P95, DOI 10.1002/casp.985; Brown S., 1991, COUNSELING VICTIMS V; Campbell J, 2002, ARCH INTERN MED, V162, P1157, DOI 10.1001/archinte.162.10.1157; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Campbell JC, 1997, PSYCHIAT CLIN N AM, V20, P353, DOI 10.1016/S0193-953X(05)70317-8; CAMPBELL R, 1995, PSYCHOL WOMEN QUART, V19, P237, DOI 10.1111/j.1471-6402.1995.tb00290.x; Cascardi M, 1999, J FAM VIOLENCE, V14, P227, DOI 10.1023/A:1022827915757; Coker AL, 2002, AM J PREV MED, V23, P260, DOI 10.1016/S0749-3797(02)00514-7; Coker AL, 2002, J WOMEN HEALTH GEN-B, V11, P465, DOI 10.1089/15246090260137644; Corrigan J. D., 2003, AM J OBSTET GYNECOL, V188, P184; Curry MA, 1998, OBSTET GYNECOL, V92, P530, DOI 10.1016/S0029-7844(98)00258-0; Daigneault I, 2009, CHILD ABUSE NEGLECT, V33, P638, DOI 10.1016/j.chiabu.2009.04.003; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; Desai H D, 2000, J Am Pharm Assoc (Wash), V40, P525; Dienemann J, 2000, Issues Ment Health Nurs, V21, P499; DiLillo D, 2001, J INTERPERS VIOLENCE, V16, P116, DOI 10.1177/088626001016002002; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; Ellsberg M, 2008, LANCET, V371, P1165, DOI 10.1016/S0140-6736(08)60522-X; Gazmararian JA, 1996, JAMA-J AM MED ASSOC, V275, P1915, DOI 10.1001/jama.275.24.1915; Gleason W J, 1993, Violence Vict, V8, P53; Golding JM, 1999, J FAM VIOLENCE, V14, P99, DOI 10.1023/A:1022079418229; Grisso JA, 1999, NEW ENGL J MED, V341, P1899, DOI 10.1056/NEJM199912163412506; HABER JD, 1985, ADV PAIN RES THER, V9, P889; Harrykissoon SD, 2002, ARCH PEDIAT ADOL MED, V156, P325, DOI 10.1001/archpedi.156.4.325; Hartik L. M., 1978, DISS ABSTR INT B, V40, p893B; Hathaway JE, 2000, AM J PREV MED, V19, P302, DOI 10.1016/S0749-3797(00)00236-1; Hegarty K, 2000, MED J AUSTRALIA, V173, P363, DOI 10.5694/j.1326-5377.2000.tb125688.x; Hegarty KL, 2002, AUST NZ J PUBL HEAL, V26, P437, DOI 10.1111/j.1467-842X.2002.tb00344.x; Humphreys C, 2003, BRIT J SOC WORK, V33, P209, DOI 10.1093/bjsw/33.2.209; Huth-Bocks Alissa C, 2002, Violence Vict, V17, P169, DOI 10.1891/vivi.17.2.169.33647; Janssen PA, 2003, AM J OBSTET GYNECOL, V188, P1341, DOI 10.1067/mob.2003.274; KALMUSS DS, 1982, J MARRIAGE FAM, V44, P277, DOI 10.2307/351538; Kim J, 2008, J INTERPERS VIOLENCE, V23, P1465, DOI 10.1177/0886260508314307; Krug E.G., 2002, WORLD REPORT VIOLENC; Lown EA, 2001, PSYCHOSOM MED, V63, P352, DOI 10.1097/00006842-200105000-00004; McNutt LA, 2002, AM J PREV MED, V22, P84, DOI 10.1016/S0749-3797(01)00407-X; Mehrotra M., 1999, VIOLENCE AGAINST WOM, V5, P619, DOI [10.1177/10778019922181400, DOI 10.1177/10778019922181400]; Mouzos J., 2005, HOMICIDE AUSTR 2003; PARKER B, 1993, NURS RES, V42, P173; Perona M, 2005, CLIN GASTROENTEROL H, V3, P436, DOI 10.1016/S1542-3565(04)00776-1; Phillips KE, 2006, J FAM VIOLENCE, V21, P259, DOI 10.1007/s10896-006-9023-5; Plichta SB, 2004, J INTERPERS VIOLENCE, V19, P1296, DOI 10.1177/0886260504269685; Raj Anita, 2002, J Am Med Womens Assoc (1972), V57, P111; RAND MR, 1997, VIOLENCE RELATED INJ; Rhodes NR, 1998, AGGRESS VIOLENT BEH, V3, P391, DOI 10.1016/S1359-1789(97)00025-6; Roberts G, 2006, INTIMATE PARTNER ABU; Roberts GL, 1998, WOMEN HEALTH, V28, P117; Romito P, 2001, VIOLENCE AGAINST WOM, V7, P1429, DOI 10.1177/10778010122183937; RUSBULT CE, 1995, PERS SOC PSYCHOL B, V21, P558, DOI 10.1177/0146167295216002; SASSETTI MR, 1993, PRIMARY CARE, V20, P289; STRUBE MJ, 1988, PSYCHOL BULL, V104, P236, DOI 10.1037/0033-2909.104.2.236; Varvaro F F, 1993, Orthop Nurs, V12, P37, DOI 10.1097/00006416-199301000-00009; Vos T, 2006, B WORLD HEALTH ORGAN, V84, P739, DOI 10.2471/BLT.06.030411; Walker L., 1978, VICTIMOLOGY, V2, P525, DOI DOI 10.1521/JSCP.23.4.445.40311; Walker L.E.A., 1979, BATTERED WOMAN; WARSHAW C, 1996, IMPROVING HLTH CARE; Weinbaum Z, 2001, AM J PREV MED, V21, P313, DOI 10.1016/S0749-3797(01)00363-4; West D, 2004, INTERNATIONAL PERSPECTIVES ON FAMILY VIOLENCE AND ABUSE: A COGNITIVE ECOLOGICAL APPROACH, P361; Woods S J, 2000, Issues Ment Health Nurs, V21, P309, DOI 10.1080/016128400248112; Woods SJ, 2005, J INTERPERS VIOLENCE, V20, P394, DOI 10.1177/0886260504267882; Wuest J, 2008, J PAIN, V9, P1049, DOI 10.1016/j.jpain.2008.06.009; Yoshihama M, 1994, Violence Vict, V9, P63; Yoshihma M, 2010, CHILD YOUTH SERV REV, V32, P28, DOI 10.1016/j.childyouth.2009.06.013	65	36	37	0	35	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1037-6178	1839-3535		CONTEMP NURSE	Contemp. Nurse.	FEB	2014	46	2					170	179		10.5172/conu.2014.46.2.170			10	Nursing	Nursing	AX9PO	WOS:000347234500005	24787250				2021-06-18	
J	Tartaglia, MC; Hazrati, LN; Davis, KD; Green, REA; Wennberg, R; Mikulis, D; Ezerins, LJ; Keightley, M; Tator, C				Tartaglia, Maria Carmela; Hazrati, Lili-Naz; Davis, Karen D.; Green, Robin E. A.; Wennberg, Richard; Mikulis, David; Ezerins, Leo J.; Keightley, Michelle; Tator, Charles			Chronic traumatic encephalopathy and other neurodegenerative	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						concussions; chronic traumatic encephalopathy; neurodegenerative disease; Alzheimer's disease; frontotempora I lobar degeneration; tau	FOOTBALL-LEAGUE PLAYER; BRAIN-INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; CEREBROSPINAL-FLUID; UNMYELINATED AXONS; PARKINSON DISEASE; CORPUS-CALLOSUM; FRONTAL LOBES; DEMENTIA	"Chronic traumatic encephalopathy" (CTE) is described as a slowly progressive neurodegenerative disease believed to result from multiple concussions. Traditionally, concussions were considered benign events and although most people recover fully, about 10% develop a post-concussive syndrome with persisting neurological, cognitive and neuropsychiatric symptoms. CTE was once thought to be unique to boxers, but it has now been observed in many different athletes having suffered multiple concussions as well as in military personal after repeated blast injuries. Much remains unknown about the development of CTE but its pathological substrate is usually tau, similar to that seen in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). The aim of this "perspective" is to compare and contrast clinical and pathological CTE with the other neurodegenerative proteinopathies and highlight that there is an urgent need for understanding the relationship between concussion and the development of CTE as it may provide a window into the development of a proteinopathy and thus new avenues for treatment.	[Tartaglia, Maria Carmela; Wennberg, Richard] Toronto Hosp, Univ Hlth Network, Krembil Neurosci Ctr, Div Neurol, Toronto, ON M5T 2S8, Canada; [Tartaglia, Maria Carmela; Hazrati, Lili-Naz] Toronto Hosp, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5T 2S8, Canada; [Tartaglia, Maria Carmela; Hazrati, Lili-Naz; Davis, Karen D.; Green, Robin E. A.; Wennberg, Richard; Mikulis, David; Ezerins, Leo J.; Keightley, Michelle; Tator, Charles] Canadian Sports Concussion Project, Toronto, ON, Canada; [Hazrati, Lili-Naz] Toronto Hosp, Dept Lab Med & Pathol, Toronto, ON M5T 2S8, Canada; [Davis, Karen D.] Toronto Hosp, Univ Hlth Network, Dept Neurosurg, Toronto, ON M5T 2S8, Canada; [Davis, Karen D.] Univ Hlth Network, Toronto Western Res Inst, Div Brain Imaging & Behav Syst Neurosci, Toronto, ON, Canada; [Davis, Karen D.] Toronto Hosp, Dept Surg, Toronto, ON M5T 2S8, Canada; [Davis, Karen D.] Toronto Hosp, Inst Med Sci, Toronto, ON M5T 2S8, Canada; [Green, Robin E. A.; Keightley, Michelle] Toronto Rehabil Inst, Toronto, ON, Canada; [Mikulis, David] Toronto Hosp, Joint Dept Med Imaging, Toronto Western Hosp, Div Neuroradiol, Toronto, ON M5T 2S8, Canada; [Ezerins, Leo J.] Canadian Football League Alumni Assoc, Toronto, ON, Canada; [Keightley, Michelle] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Keightley, Michelle] Toronto Hosp, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5T 2S8, Canada; [Keightley, Michelle] Toronto Hosp, Grad Dept Rehabil Sci, Toronto, ON M5T 2S8, Canada; [Keightley, Michelle] Toronto Hosp, Dept Psychol, Toronto, ON M5T 2S8, Canada; [Keightley, Michelle; Tator, Charles] Toronto Hosp, Krembil Neurosci Ctr, Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada	Tartaglia, MC (corresponding author), Toronto Hosp, Tanz Ctr Res Neurodegenerat Dis, Toronto Western Hosp, Memory Clin, West Wing 5-449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	carmela.tartaglia@uhn.on.ca	hazrati, lili-naz/AAE-7785-2020; Mikulis, David J/H-5167-2019	hazrati, lili-naz/0000-0003-2715-1485; Green, Robin/0000-0001-9451-3963; Mikulis, David/0000-0003-3956-0892			Adnan A, 2013, BRAIN INJURY, V27, P1415, DOI 10.3109/02699052.2013.823659; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Braak H, 1997, Int Psychogeriatr, V9 Suppl 1, P257, DOI 10.1017/S1041610297004973; Braak H., 1997, INT PSYCHOGERIATR S, V9, P269, DOI DOI 10.1017/S1041610297004973; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; BRUN A, 1993, DEMENTIA, V4, P126, DOI 10.1159/000107311; Brunden KR, 2010, EXP NEUROL, V223, P304, DOI 10.1016/j.expneurol.2009.08.031; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Green Robin, 2010, Neuropsychol Rehabil, V20, P471, DOI 10.1080/09602011003693298; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hu WT, 2010, NEUROLOGY, V75, P2079, DOI 10.1212/WNL.0b013e318200d78d; Hu WT, 2013, NEUROLOGY, V81, P1945, DOI 10.1212/01.wnl.0000436625.63650.27; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Lomen-Hoerth C, 2003, NEUROLOGY, V60, P1094, DOI 10.1212/01.WNL.0000055861.95202.8D; Loosemore M, 2007, BMJ-BRIT MED J, V335, P809, DOI 10.1136/bmj.39342.690220.55; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parnetti L, 2013, NAT REV NEUROL, V9, P131, DOI 10.1038/nrneurol.2013.10; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Rosen HJ, 2005, BRAIN, V128, P2612, DOI 10.1093/brain/awh628; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Schapira AHV, 2013, CURR OPIN NEUROL, V26, P395, DOI 10.1097/WCO.0b013e3283633741; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sperling Reisa, 2013, Continuum (Minneap Minn), V19, P325, DOI 10.1212/01.CON.0000429181.60095.99; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Whitwell JL, 2012, NAT REV NEUROL, V8, P131, DOI 10.1038/nrneurol.2012.7; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wortzel H. S., 2013, BEHAV SCI LAW, DOI [10.1002/bsl.2079, DOI 10.1002/BSL.2079.[]; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	65	36	36	0	27	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JAN 31	2014	8								30	10.3389/fnhum.2014.00030			6	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	302WY	WOS:000330637000001	24550810	DOAJ Gold, Green Published			2021-06-18	
J	Kiechle, K; Bazarian, JJ; Merchant-Borna, K; Stoecklein, V; Rozen, E; Blyth, B; Huang, JH; Dayawansa, S; Kanz, K; Biberthaler, P				Kiechle, Karin; Bazarian, Jeffrey J.; Merchant-Borna, Kian; Stoecklein, Veit; Rozen, Eric; Blyth, Brian; Huang, Jason H.; Dayawansa, Samantha; Kanz, Karl; Biberthaler, Peter			Subject-Specific Increases in Serum S-100B Distinguish Sports-Related Concussion from Sports-Related Exertion	PLOS ONE			English	Article							NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; HIGH-SCHOOL; BIOCHEMICAL MARKERS; COMPUTED-TOMOGRAPHY; S100 PROTEINS; ELITE PLAYERS; DAMAGE S-100B; EPIDEMIOLOGY	Background: The on-field diagnosis of sports-related concussion (SRC) is complicated by the lack of an accurate and objective marker of brain injury. Purpose: To compare subject-specific changes in the astroglial protein, S100B, before and after SRC among collegiate and semi-professional contact sport athletes, and compare these changes to differences in S100B before and after non-contact exertion. Study Design: Longitudinal cohort study. Methods: From 2009-2011, we performed a prospective study of athletes from Munich, Germany, and Rochester, New York, USA. Serum S100B was measured in all SRC athletes at pre-season baseline, within 3 hours of injury, and at days 2, 3 and 7 post-SRC. Among a subset of athletes, S100B was measured after non-contact exertion but before injury. All samples were collected identically and analyzed using an automated electrochemiluminescent assay to quantify serum S100B levels. Results: Forty-six athletes (30 Munich, 16 Rochester) underwent baseline testing. Thirty underwent additional post-exertion S100B testing. Twenty-two athletes (16 Rochester, 6 Munich) sustained a SRC, and 17 had S100B testing within 3 hours post-injury. The mean 3-hour post-SRC S100B was significantly higher than pre-season baseline (0.099+/-0.008 mu g/L vs. 0.058+/-0.006 mu g/L, p = 0.0002). Mean post-exertion S100B was not significantly different than the preseason baseline. S100B levels at post-injury days 2, 3 and 7 were significantly lower than the 3-hour level, and not different than baseline. Both the absolute change and proportional increase in S100B 3-hour post-injury were accurate discriminators of SRC from non-contact exertion without SRC (AUC 0.772 and 0.904, respectively). A 3-hour post-concussion S100B >0.122 mu g/L and a proportional S100B increase of >45.9% over baseline were both 96.7% specific for SRC. Conclusions: Relative and absolute increases in serum S100B can accurately distinguish SRC from sports-related exertion, and may be a useful adjunct to the diagnosis of SRC.	[Kiechle, Karin; Kanz, Karl] Univ Munich, Dept Trauma Surg, Klinikum Univ Munchen, Munich, Germany; [Bazarian, Jeffrey J.; Merchant-Borna, Kian; Blyth, Brian] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Stoecklein, Veit] Univ Munich, Dept Neurosurg, Klinikum Univ Munchen, Munich, Germany; [Rozen, Eric] Univ Rochester, Dept Athlet & Recreat, Rochester, NY USA; [Huang, Jason H.; Dayawansa, Samantha] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Biberthaler, Peter] Tech Univ Munich, Dept Trauma Surg, D-80290 Munich, Germany	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24HD064754]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health grant K24HD064754. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Ben Abdesselam O, 2003, CLIN CHEM, V49, P836, DOI 10.1373/49.5.836; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bonham VL, 2010, NEW ENGL J MED, V363, P997, DOI 10.1056/NEJMp1007639; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FierceBiomarkers, 2012, A STARS I MICR SFC F; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pham N, 2010, PLOS ONE, V5, DOI DOI 10.1371/ANN0TATI0N/BDCB41F2-A320-4401-A6AB-86E71738597E].PL0S; Prevention CCfDC, 2007, MMWR-MORBID MORTAL W, V56, P733; Rickels E, 2011, UNFALLCHIRURG, V114, P417, DOI 10.1007/s00113-010-1872-y; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Tang W., 2012, APPL CATEGORICAL COU; Towend W, 2006, J NEUROTRAUM, V23, P149; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	29	36	37	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e84977	10.1371/journal.pone.0084977			7	Multidisciplinary Sciences	Science & Technology - Other Topics	291WL	WOS:000329862500199	24416325	DOAJ Gold, Green Published			2021-06-18	
J	Corrigan, F; Thornton, E; Roisman, LC; Leonard, AV; Vink, R; Blumbergs, PC; van den Heuvel, C; Cappai, R				Corrigan, Frances; Thornton, Emma; Roisman, Laila C.; Leonard, Anna V.; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna; Cappai, Roberto			The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96-110	JOURNAL OF NEUROCHEMISTRY			English	Article							NEURITE OUTGROWTH; GROWTH-FACTOR; ALZHEIMERS-DISEASE; FAMILY-MEMBERS; MICE; DOMAIN; FGF; SULFATE; APP; IMPACT	We have previously shown that following traumatic brain injury (TBI) the presence of the amyloid precursor protein (APP) may be neuroprotective. APP knockout mice have increased neuronal death and worse cognitive and motor outcomes following TBI, which is rescued by treatment with exogenous sAPP alpha (the secreted ectodomain of APP generated by alpha-secretase cleavage). Two neuroprotective regions were identified in sAPP alpha, the N and C-terminal domains D1 and D6a/E2 respectively. As both D1 and D6a/E2 contain heparin binding activity it was hypothesized that this is responsible for the neuroprotective activity. In this study, we focused on the heparin binding site, encompassed by residues 96-110 in D1, which has previously been shown to have neurotrophic properties. We found that treatment with APP96-110 rescued motor and cognitive deficits in APP-/- mice following focal TBI. APP96-110 also provided neuroprotection in Sprague-Dawley rats following diffuse TBI. Treatment with APP96-110 significantly improved functional outcome as well as preserve histological cellular morphology in APP-/- mice following focal controlled cortical impact injury. Furthermore, following administration of APP96-110 in rats after diffuse impact acceleration TBI, motor and cognitive outcomes were significantly improved and axonal injury reduced. These data define the heparin binding site in the D1 domain of sAPP alpha, represented by the sequence APP96-110, as the neuroprotective site to confer neuroprotection following TBI.	[Corrigan, Frances; Thornton, Emma; Leonard, Anna V.; Vink, Robert; van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA, Australia; [Roisman, Laila C.; Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Roisman, Laila C.; Cappai, Roberto] Univ Melbourne, Mol Sci & BioTechnol Inst Bio21, Melbourne, Vic 3010, Australia; [Blumbergs, Peter C.] Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia	Cappai, R (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	r.cappai@unimelb.edu.au	Vink, Robert/J-7351-2012; Roisman, Laila C./P-9129-2019; AM, Robert Vink/S-5616-2019; Cappai, Roberto/B-3347-2010	Vink, Robert/0000-0002-4885-0667; Roisman, Laila C./0000-0001-8455-9327; AM, Robert Vink/0000-0002-4885-0667; Cappai, Roberto/0000-0002-9505-8496; Corrigan, Frances/0000-0001-6150-8893; , Corinna/0000-0003-0664-8935	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	This study was funded in part by a grant from the National Health and Medical Research Council of Australia. We thank Prof. Hui Zheng for providing the APP knockout mice and Dr Mark Habgood (University of Melbourne), Dr Jenna Zeibell and Jim Manavis for expert technical assistance. We thank Dr Chi Pham (The University of Melbourne) for purifying the D1 domain. RC is a National Health and Medical Research Council Senior Research Fellow. No authors have a conflict of interest to declare.	Anliker B, 2006, NEURODEGENER DIS, V3, P239, DOI 10.1159/000095262; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Ford-Perriss M, 2002, GLYCOBIOLOGY, V12, P721, DOI 10.1093/glycob/cwf072; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Gakhar-Koppole N, 2008, EUR J NEUROSCI, V28, P871, DOI 10.1111/j.1460-9568.2008.06398.x; Gallagher J, 2007, DEV CELL, V13, P166, DOI 10.1016/j.devcel.2007.07.015; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; GREENBERG SM, 1995, NEUROBIOL AGING, V16, P403, DOI 10.1016/0197-4580(94)00172-W; Heber S, 2000, J NEUROSCI, V20, P7951; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Itoh N, 2007, BIOL PHARM BULL, V30, P1819, DOI 10.1248/bpb.30.1819; Kaden D, 2008, J BIOL CHEM, V283, P7271, DOI 10.1074/jbc.M708046200; Koopmans G, 2003, PHYSIOL BEHAV, V79, P683, DOI 10.1016/S0031-9384(03)00171-9; Kwak YD, 2006, BIOCHEM BIOPH RES CO, V344, P431, DOI 10.1016/j.bbrc.2006.03.054; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin XH, 1999, DEVELOPMENT, V126, P3715; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morimoto T, 1998, J NEUROSCI, V18, P9386; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Paxinos G, 2007, MOUSE BRAIN STEREOTA; Raman R, 2005, CHEM BIOL, V12, P267, DOI 10.1016/j.chembiol.2004.11.020; Rapraeger AC, 2002, METHOD CELL BIOL, V69, P83, DOI 10.1016/S0091-679X(02)69009-0; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SMALL DH, 1994, J NEUROSCI, V14, P2117; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Song HH, 2005, J BIOL CHEM, V280, P2116, DOI 10.1074/jbc.M410090200; Spillman D., 1994, CURR OPIN STRUC BIOL, V4, P667; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Young-Pearse TL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-15	43	36	36	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2014	128	1					196	204		10.1111/jnc.12391			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AA3FQ	WOS:000330978700011	23919582	Bronze, Green Published			2021-06-18	
J	Frith, M; Togher, L; Ferguson, A; Levick, W; Docking, K				Frith, Matthew; Togher, Leanne; Ferguson, Alison; Levick, Wayne; Docking, Kimberley			Assessment practices of speech-language pathologists for cognitive communication disorders following traumatic brain injury in adults: An international survey	BRAIN INJURY			English	Article						Assessment; cognitive; language; survey	CLINICAL NEUROPSYCHOLOGISTS; DISCOURSE; APHASIA; MANAGEMENT; DEFICITS; SCALE; MTBI	Primary objective: This study's objective was to examine the current assessment practices of SLPs working with adults with acquired cognitive communication impairments following a TBI. Methods and procedures: Two hundred and sixty-five SLPs from the UK, the US, Canada, Australia and New Zealand responded to the online survey stating the areas of communication frequently assessed and the assessment tools they use. Main outcomes and results: SLPs reported that they routinely assessed functional communication (78.8%), whereas domains such as discourse were routinely assessed by less than half of the group (44.3%). Clinicians used aphasia and cognitive communication/high level language tools and tools assessing functional performance, discourse, pragmatic skills or informal assessments were used by less than 10% of the group. The country and setting of service delivery influenced choice of assessment tools used in clinical practice. Conclusions: These findings have implications for training of SLPs in a more diverse range of assessment tools for this clinical group. The findings raise questions regarding the statistical validity and reliability of assessments currently used in clinical practice. It highlights the need for further research into how SLPs can be supported in translating current evidence about the use of assessment tools into clinical practice.	[Frith, Matthew] Hunter New England Local Hlth Dist, Kaleidoscope Children Young People & Families, Sydney, NSW, Australia; [Frith, Matthew; Togher, Leanne; Docking, Kimberley] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Frith, Matthew; Togher, Leanne; Docking, Kimberley] NHMRC Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia; [Ferguson, Alison] Univ Newcastle, Sch Humanities & Social Sci, Newcastle, NSW 2300, Australia; [Levick, Wayne] Univ Newcastle, Sch Psychol, Newcastle, NSW 2300, Australia	Frith, M (corresponding author), Kaleidoscope, HNE LHD POB 2563 Dangar, Dangar, NSW 2309, Australia.	matthew.frith@hnehealth.nsw.gov.au	Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			Adamovich B. B., 1992, SCALES COGNITIVE ABI; American Speech-Language-Hearing Association, 2003, EV TREAT COMM COGN D; Bernicot J, 2001, INT J LANG COMM DIS, V36, P245; Blais Jean-Guy, 2011, J Appl Meas, V12, P370; Blyth T, 2012, BRAIN INJURY, V26, P234, DOI 10.3109/02699052.2012.654587; Bowers L, 2005, WORLD TEST; Christie J., 1986, MOUNT WILGA HIGH LEV; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; College of Audiologists and Speech-Language Pathologists of On- tario, 2002, PREF PRACT GUID COGN; Douglas J, 2000, TROBE COMMUNICATION; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; Ellmo W, 1995, MEASURE COGNITIVE LI; Ellmo W, 1997, J NEW JERSEY SPEECH, V6, P17; Frank EM, 1996, J MED SPEECH-LANG PA, V4, P81; Frank EM, 1997, J MED SPEECH-LANG PA, V5, P97; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; Helm-Estabrooks N., 2001, COGNITIVE LINGUISTIC; Hofmans J, 2009, QUAL QUANT, V43, P703, DOI 10.1007/s11135-007-9154-7; Holland A, 1999, COMMUNICATION ACTIVI; Howard D, 2004, COMPREHENSIVE APHASI; Howell D., 1995, FUNDAMENTAL STAT BEH; Hughes J, 2007, CAN J SPEECH-LANG PA, V31, P134; Isaki E, 2000, BRAIN INJURY, V14, P441; Kaplan E., 2001, Boston naming test; Katz RC, 2000, INT J LANG COMM DIS, V35, P303; Kay J, 1992, PSCHOLINGUISTIC ASSE; Kertesz A., 2006, W APHASIA BATTERY RE; King KA, 2006, BRAIN INJURY, V20, P725, DOI 10.1080/02699050600743824; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; Lee JW, 2002, RES NURS HEALTH, V25, P295, DOI 10.1002/nur.10041; MacDonald S., 2003, FUNCTIONAL ASSESSMEN; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S., 2002, AWARENESS SOCIAL INF; McGrane SA, 2000, BRAIN INJURY, V14, P975; Morgan AT, 2011, J EVAL CLIN PRACT, V17, P275, DOI 10.1111/j.1365-2753.2010.01436.x; Parkin A E, 2001, Aust J Rural Health, V9, P297, DOI 10.1046/j.1038-5282.2001.00383.x; Parrish C., 2009, SIG 2 PERSPECTIVES N, V19, P47, DOI DOI 10.1044/NNS1D19.2.47; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Randolph C., 2001, REPEATABLE BATTERY A; Ross-Swain D., 1996, ROSS INFORM PROCESSI; Royal College of Speech and Language Therapists, 2005, RCSLT CLIN GUID; Secord, 1989, TEST LANGUAGE COMPET; Shiel A, 2000, WESSEX HEADN INJURY; Simmons-Mackie N, 2005, J COMMUN DISORD, V38, P1, DOI 10.1016/j.jcomdis.2004.03.007; Steel J, 2013, BRAIN INJURY, V27, P819, DOI 10.3109/02699052.2013.775492; Togher L, 2001, J COMMUN DISORD, V34, P131, DOI 10.1016/S0021-9924(00)00045-9; Turkstra KM., 2005, SEMINARS SPEECH LANG, V26, P213; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Uniform Data System for Medical Rehabilitation, 1996, FUNCT INF MEAS FIM; Verna A, 2009, INT J SPEECH-LANG PA, V11, P191, DOI 10.1080/17549500902726059; Vogel AP, 2010, J EVAL CLIN PRACT, V16, P1183, DOI 10.1111/j.1365-2753.2009.01291.x; Wertheimer JC, 2008, J HEAD TRAUMA REHAB, V23, P273, DOI 10.1097/01.HTR.0000336840.76209.a1; Wilson FC, 2007, DISABIL REHABIL, V29, P1751, DOI 10.1080/09638280601118432; Wong MN, 2010, APHASIOLOGY, V24, P1155, DOI 10.1080/02687030903168212; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV	58	36	37	2	53	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	13-14					1657	1666		10.3109/02699052.2014.947619			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT1LY	WOS:000344696600004	25158134				2021-06-18	
J	Joseph, B; Aziz, H; Zangbar, B; Kulvatunyou, N; Pandit, V; O'Keeffe, T; Tang, A; Wynne, J; Friese, RS; Rhee, P				Joseph, Bellal; Aziz, Hassan; Zangbar, Bardiya; Kulvatunyou, Narong; Pandit, Viraj; O'Keeffe, Terence; Tang, Andrew; Wynne, Julie; Friese, Randall S.; Rhee, Peter			Acquired coagulopathy of traumatic brain injury defined by routine laboratory tests: Which laboratory values matter?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; coagulopathy and platelet count; progression of intracranial hemorrhage; neurosurgical intervention; mortality	PROTHROMBIN COMPLEX CONCENTRATE; HEAD TRAUMA; INTRACRANIAL HEMORRHAGE; PROGRESSIVE HEMORRHAGE; PROGNOSTIC VALUE; THROMBOCYTOPENIA; PREDICTORS; CHILDREN; IMPACT	BACKGROUND: Coagulopathy is a major determinant of disability and death in patients with traumatic intracranial hemorrhage. However, the correlation between coagulopathy defined by routine coagulation tests and clinical outcomes in traumatic brain injury (TBI) is not well defined. The aim of our study was to determine the effect of coagulopathy diagnosed by routine laboratory tests on outcomes in TBI patients. METHODS: We performed a retrospective cohort analysis of all isolated TBI patients exclusive of prehospital antiplatelet and anticoagulants with coagulation tests, namely, international normalized ratio (INR), platelet count, and partial thromboplastin time at admission. We defined coagulopathy by an INR of 1.5 or greater, partial thromboplastin time of 35 or greater, or platelet count of 100 x 10(3)/mu L or less. Outcome measures were progression on repeat head computed tomography (RHCT), need for neurosurgical intervention, and mortality. RESULTS: A total of 591 patients were enrolled, with a mean (SD) age of 47.4 (26.5) years and 67% being male. Of the patients, 13.3% were coagulopathic at admission. Platelet count of 100 x 10(3)/mu L or less was an independent predictor of progression on RHCT (odd ratio [OR], 4; 95% confidence interval [CI], 1.7-10), need for neurosurgical intervention (OR, 3.6; 95% CI, 1.2-6.1), and mortality (OR, 2.6; 95% CI, 1.1-4.8). INR was an independent predictor of progression on RHCT (OR, 2; 95% CI, 1.1-4.3). CONCLUSION: Routine bedside coagulation parameters at admission play an important role in predicting outcomes in blunt TBI. Platelet count is the strongest predictor for progression of initial insult on RHCT, need for neurosurgical intervention, and mortality. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Aziz, Hassan; Zangbar, Bardiya; Kulvatunyou, Narong; Pandit, Viraj; O'Keeffe, Terence; Tang, Andrew; Wynne, Julie; Friese, Randall S.; Rhee, Peter] Univ Arizona, Coll Med, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Zangbar, Bardiya/K-7147-2014	Zangbar, Bardiya/0000-0003-1215-1693			Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Dzik WH, 2007, TRANSFUSION MED, V17, P367, DOI 10.1111/j.1365-3148.2007.00795.x; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Fries D, 2006, BRIT J ANAESTH, V97, P460, DOI 10.1093/bja/ael191; Joseph B, 2014, J SURG RES, V186, P287, DOI 10.1016/j.jss.2013.08.009; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vanderschueren S, 2000, CRIT CARE MED, V28, P1871, DOI 10.1097/00003246-200006000-00031; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Wu C, 2012, J TRAUMA ACUTE CARE, V73, P1247, DOI 10.1097/TA.0b013e318265d24e	24	36	42	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					121	125		10.1097/TA.0b013e3182a9cc95			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200024	24368366				2021-06-18	
J	Kelso, ML; Gendelman, HE				Kelso, Matthew L.; Gendelman, Howard E.			Bridge Between Neuroimmunity and Traumatic Brain Injury	CURRENT PHARMACEUTICAL DESIGN			English	Article						Traumatic brain injury; neuroimmunity; mononuclear phagocytes; astrocytes; neurodegeneration; inflammation	REGULATORY T-CELLS; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; CENTRAL-NERVOUS-SYSTEM; COLONY-STIMULATING FACTOR; NICOTINIC ACETYLCHOLINE-RECEPTOR; GLUTAMATE TRANSPORTER PROTEINS; EXPERIMENTAL MYASTHENIA-GRAVIS; AMYOTROPHIC-LATERAL-SCLEROSIS; FOCAL CEREBRAL-ISCHEMIA	The pathophysiology of degenerative, infectious, inflammatory and traumatic diseases of the central nervous system includes a significant immune component. As to the latter, damage to the cerebral vasculature and neural cell bodies, caused by traumatic brain injury (TBI) activates innate immunity with concomitant infiltration of immunocytes into the damaged nervous system. This leads to pro-inflammatory cytokine and prostaglandin production and lost synaptic integrity and more generalized neurotoxicity. Engagement of adaptive immune responses follows including the production of antibodies and lymphocyte proliferation. These affect the tempo of disease along with tissue repair and as such provide a number of potential targets for pharmacological treatments for TBI. However, despite a large body of research, no such treatment intervention is currently available. In this review we will discuss the immune response initiated following brain injuries, drawing on knowledge gained from a broad array of experimental and clinical studies. Our discussion seeks to address potential therapeutic targets and propose ways in which the immune system can be controlled to promote neuroprotection.	[Kelso, Matthew L.] Univ Nebraska Med Ctr, Dept Pharm Practice, Coll Pharm, Omaha, NE 68198 USA; [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Coll Med, Omaha, NE 68198 USA	Kelso, ML (corresponding author), Univ Nebraska Med Ctr, Dept Pharm Practice, Coll Pharm, Omaha, NE 68198 USA.	mkelso@unmc.edu			Carol Swarts Neuroscience Research Laboratory; Frances and Louie Blumkin Foundation; Department of DefenseUnited States Department of Defense [W81XWH11-1-0700]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P20 GM103480, P01 NS43985]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P01MH064570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034239, R01NS036126, P01NS031492, P01NS043985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG043540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA028555] Funding Source: NIH RePORTER	The authors would like to acknowledge Mrs. Robin Taylor for her assistance with the figures and Dr. JoEllyn McMillan for her editorial comments. This work was supported by the Carol Swarts Neuroscience Research Laboratory, the Frances and Louie Blumkin Foundation, Department of Defense Grant W81XWH11-1-0700, and National Institutes of Health grants P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P20 GM103480 and P01 NS43985.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Banerjee R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002740; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Berry JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061177; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Brynskikh AM, NANOMEDICINE LOND, V5, P379; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Chen C, 2005, J NEUROPHYSIOL, V93, P929, DOI 10.1152/jn.00696.2004; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Choi SH, 2010, PHARMACOGENOMICS J, V10, P448, DOI 10.1038/tpj.2009.68; Choi Y, 2007, NEUROPSYCHOPHARMACOL, V32, P2393, DOI 10.1038/sj.npp.1301377; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cosentino M, 2013, J NEUROIMMUNE PHARM, V8, P1, DOI 10.1007/s11481-013-9440-1; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Simone R, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-4; DeFelipe J, 2002, J NEUROCYTOL, V31, P299, DOI 10.1023/A:1024130211265; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fagan SC, 2010, STROKE, V41, P2283, DOI 10.1161/STROKEAHA.110.582601; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Ferretti MT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-62; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Ghorpade A, 2008, NEUROIMMUNE PHARM, P89; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Girgis H, 2013, BRAIN RES, V1491, P78, DOI 10.1016/j.brainres.2012.10.049; Gong N, 2011, J NEUROIMMUNOL, V230, P33, DOI 10.1016/j.jneuroim.2010.08.014; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356494; Hercus TR, 2012, GROWTH FACTORS, V30, P63, DOI 10.3109/08977194.2011.649919; Hickey RW, 2007, PEDIAT RES; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hu WH, 2003, GLIA, V44, P13, DOI 10.1002/glia.10268; Huang Y.L., 2008, NEUROIMMUNE PHARMACO, V15, P183; Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kaindl AM, 2012, ANN NEUROL, V72, P536, DOI 10.1002/ana.23626; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Khatibi NH, 2011, ACTA NEUROCHIR SUPPL, V111, P277, DOI 10.1007/978-3-7091-0693-8_46; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Klyachko NL, 2012, NANOMED-NANOTECHNOL, V8, P119, DOI 10.1016/j.nano.2011.05.010; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kong T, 2009, J NEUROSURG, V111, P155, DOI 10.3171/2008.12.JNS08172; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kox M, 2008, NEUROLOGY, V70, P480, DOI 10.1212/01.wnl.0000279479.69502.3e; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Liu JU, 2009, J IMMUNOL, V182, P3855, DOI 10.4049/jimmunol.0803330; Liu YW, 2006, NAT MED, V12, P518, DOI 10.1038/nm1402; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Lu DC, 2011, J NEUROTRAUMA; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matyszak MK, 1996, NEUROSCIENCE, V74, P599, DOI 10.1016/0306-4522(96)00160-1; Meissner A, 2003, BLOOD, V102, P2724, DOI 10.1182/blood-2003-01-0007; Menalled LB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009793; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Montiel T, 2005, NEUROSCIENCE, V133, P667, DOI 10.1016/j.neuroscience.2004.11.020; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Mosley RL, 2006, CLIN NEUROSCI RES, V6, P261, DOI 10.1016/j.cnr.2006.09.006; Mrakovcic-Sutic I, 2010, SCAND J IMMUNOL, V72, P57, DOI 10.1111/j.1365-3083.2010.02407.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nishihara T, 2011, EXP NEUROL, V229, P507, DOI 10.1016/j.expneurol.2011.04.006; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Olivecrona M, 2012, BRAIN INJURY, V26, P67, DOI 10.3109/02699052.2011.635351; Olivecrona M, 2009, J NEUROTRAUM, V26, P1251, DOI [10.1089/neu.2008.0605, 10.1089/neu.2008-0605]; Ouyang YB, 2007, J NEUROSCI, V27, P4253, DOI 10.1523/JNEUROSCI.0211-07.2007; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reynolds AD, 2007, J LEUKOCYTE BIOL, V82, P1083, DOI 10.1189/jlb.0507296; Reynolds AD, 2010, J IMMUNOL, V184, P2261, DOI 10.4049/jimmunol.0901852; Ridwan S, 2012, J NEURAL TRANSM, V119, P1389, DOI 10.1007/s00702-012-0794-y; Rosenbaugh EG, 2010, BIOMATERIALS, V31, P5218, DOI 10.1016/j.biomaterials.2010.03.026; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Rumbaugh JA, 2007, J NEUROVIROL, V13, P168, DOI 10.1080/13550280601178218; Schabitz WR, 2008, J CEREBR BLOOD F MET, V28, P29, DOI 10.1038/sj.jcbfm.9600496; Schwab JM, 2002, J NEUROSURG, V96, P892, DOI 10.3171/jns.2002.96.5.0892; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Schwarz H, 2010, MOVEMENT DISORD, V25, P2219, DOI 10.1002/mds.23236; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Sheng JR, 2008, CLIN IMMUNOL, V128, P172, DOI 10.1016/j.clim.2008.03.509; Sheng JR, 2011, J NEUROIMMUNOL, V240, P65, DOI 10.1016/j.jneuroim.2011.10.010; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Soares HD, 1995, J NEUROSCI, V15, P8223; Srivastava MVP, 2012, NEUROL INDIA, V60, P23, DOI 10.4103/0028-3886.93584; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; Trajkovic V, 2004, GLIA, V47, P168, DOI 10.1002/glia.20046; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yi JH, 2007, BRAIN RES, V1154, P200, DOI 10.1016/j.brainres.2007.04.011; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhao Y, J NANOMED NONOTECHNO, pS4; Zou T, 2011, TRANSFUSION, V51, p160S, DOI 10.1111/j.1537-2995.2011.03379.x; NEUROSURGERY	182	36	37	0	11	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2014	20	26					4284	4298					15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AK6AA	WOS:000338508000014	24025052				2021-06-18	
J	Kamper, JE; Pop, V; Fukuda, AM; Ajao, DO; Hartman, RE; Badaut, J				Kamper, Joel E.; Pop, Viorela; Fukuda, Andrew M.; Ajao, David O.; Hartman, Richard E.; Badaut, Jerome			Juvenile traumatic brain injury evolves into a chronic brain disorder: Behavioral and histological changes over 6 months	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Pediatric; Behavior; Neurodegeneration; MRI	CONTROLLED CORTICAL IMPACT; EXPERIMENTAL-MODELS; IMMATURE RAT; NEUROBEHAVIORAL OUTCOMES; CHILDREN; MOTOR; MAZE; PHENOTYPE; ADULTHOOD	Traumatic brain injury (TBI) refers to physical trauma to the brain that can lead to motor and cognitive dysfunctions. TBI is particularly serious in infants and young children, often leading to long-term functional impairments. Although clinical research is useful for quantifying and observing the effects of these injuries, few studies have empirically assessed the long-term effects of juvenile TBI (jTBI) on behavior and histology. After a controlled cortical impact delivered to postnatal 17 day old rats, functional abilities were measured after 3, 5, and 6 months using open field (activity levels), zero maze (anxiety-like behaviors), rotarod (sensorimotor abilities, coordination, and balance), and water maze (spatial learning and memory, swim speed, turn bias). Sensorimotor function was impaired for up to 6 months in jTBI animals, which showed no improvement from repeated test exposure. Although spatial learning was not impaired, spatial memory deficits were observed in jTBI animals starting at 3 months after injury. Magnetic resonance imaging and histological data revealed that the effects of jTBI were evolving for up to 6 months post-injury, with reduced cortical thickness, decreased corpus callosum area and CA1 neuronal cell death in jTBI animals distant to the impact site. These findings suggest that this model of jTBI produces long-term impairments comparable to those reported clinically. Although some deficits were stable over time, the variable nature of other deficits (e.g., memory) as well as changing properties of the lesion itself, suggest that the effects of a single jTBI produce a chronic brain disorder with long-term complications. (C) 2013 Elsevier Inc. All rights reserved.	[Kamper, Joel E.; Hartman, Richard E.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA; [Fukuda, Andrew M.; Ajao, David O.; Badaut, Jerome] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92350 USA; [Pop, Viorela; Badaut, Jerome] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA	Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat Pharmacol & Physiol, Coleman Pavil,Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.		Kamper, Joel/V-2450-2019	Kamper, Joel/0000-0001-5098-5176; Fukuda, Andrew/0000-0002-7927-6602	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD061946]; Swiss Science FoundationSwiss National Science Foundation (SNSF) [FN 31003A-122166]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	The authors thank Dr. Andre Obenaus, Ms. Jacqueline Coats, Mr. Sonny Kim, and Mr. Kamal Ambadipudi for technical help in collecting MRI data. This work was supported in part by the NIH R01HD061946 (to JB) and the Swiss Science Foundation (FN 31003A-122166, to JB).	Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Fernandez-Teruel A, 2002, PHARMACOL BIOCHEM BE, V73, P233, DOI 10.1016/S0091-3057(02)00787-6; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; Giza CC, 2006, INDIAN J NEUROTRAUM, V3, P19; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; GRANACHER RP, 2003, NEUROPSYCHIATRIC PSY; Hall CS, 1932, U CALIFORNIA PUBLICA, V6, P1; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hartman RE, 2011, TRANSL STROKE RES, V2, P433, DOI 10.1007/s12975-011-0132-y; JONES BJ, 1968, N-S ARCH PHARMAKOL, V259, P211, DOI 10.1007/BF00537801; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kramer ME, 2008, J INT NEUROPSYCH SOC, V14, P424, DOI 10.1017/S1355617708080545; Lekic T, 2011, EXP NEUROL, V227, P96, DOI 10.1016/j.expneurol.2010.09.017; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024	36	36	38	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2013	250						8	19		10.1016/j.expneurol.2013.09.016			12	Neurosciences	Neurosciences & Neurology	270FZ	WOS:000328305600002	24076005	Green Accepted			2021-06-18	
J	Neselius, S; Zetterberg, H; Blennow, K; Marcusson, J; Brisby, H				Neselius, Sanna; Zetterberg, Henrik; Blennow, Kaj; Marcusson, Jan; Brisby, Helena			Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; FLUID APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; AXONAL INJURY; CONCUSSION; RISK; BIOMARKER; SPORTS	Introduction: Diagnosis of mild TBI is hampered by the lack of imaging or biochemical measurements for identifying or quantifying mild TBI in a clinical setting. We have previously shown increased biomarker levels of protein reflecting axonal (neurofilament light protein and tau) and glial (GFAP and S-100B) damage in cerebrospinal fluid (CSF) after a boxing bout. The aims of this study were to find other biomarkers of mild TBI, which may help clinicians diagnose and monitor mild TBI, and to calculate the role of APOE epsilon 4 allele genotype which has been associated with poor outcome after TBI. Materials and Methods: Thirty amateur boxers with a minimum of 45 bouts and 25 non-boxing matched controls were included in a prospective cohort study. CSF and blood were collected at one occasion between 1 and 6 days after a bout, and after a rest period for at least 14 days (follow up). The controls were tested once. CSF levels of neurofilament heavy (pNFH), amyloid precursor proteins (sAPP alpha and sAPP beta), ApoE and ApoA1 were analyzed. In blood, plasma levels of A beta 42 and ApoE genotype were analyzed. Results: CSF levels of pNFH were significantly increased between 1 and 6 days after boxing as compared with controls (p<0.001). The concentrations decreased at follow up but were still significantly increased compared to controls (p = 0.018). CSF pNFH concentrations correlated with NFL (r = 0.57 after bout and 0.64 at follow up, p<0.001). No significant change was found in the other biomarkers, as compared to controls. Boxers carrying the APOE epsilon 4 allele had similar biomarker concentrations as non-carriers. Conclusions: pNFH, even without unconsciousness or concussion symptoms. Possession of the APOE epsilon 4 allele was not found to influence biomarker levels after acute TBI.	[Neselius, Sanna; Brisby, Helena] Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden; [Neselius, Sanna; Brisby, Helena] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Dept Psychiat & Neurochem, Clin Neurochem Lab, S-41345 Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden; [Marcusson, Jan] Linkoping Univ Hosp, Geriatr Sect, S-58185 Linkoping, Sweden; [Marcusson, Jan] Linkoping Univ, Inst Clin & Expt Med, Linkoping, Sweden	Neselius, S (corresponding author), Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden.	sanna.neselius@vgregion.se			Marianne and Marcus Wallenberg Foundation, SWEDEN; ALF Grants, County Council of Vastra Gotaland, SWEDEN; Sahlgrenska University Hospital, Gothenburg, SWEDEN; Gothenburg Medical Society, SWEDEN; ALF Grants, County Council of Ostergotland, SWEDEN; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This study has been funded by the Marianne and Marcus Wallenberg Foundation, SWEDEN; ALF Grants, County Council of Vastra Gotaland, SWEDEN; Sahlgrenska University Hospital, Gothenburg, SWEDEN; Gothenburg Medical Society, SWEDEN; ALF Grants, County Council of Ostergotland, SWEDEN and The Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Bramley H, 2012, CLIN PEDIATR, V51, P283, DOI 10.1177/0009922811422434; Constantinescu R, 2009, PARKINSONISM RELAT D, V15, P205, DOI 10.1016/j.parkreldis.2008.05.001; De Strooper B, 2000, J CELL SCI, V113, P1857; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; Ganesalingam J, 2013, AMYOTROPH LAT SCL FR, V14, P146, DOI 10.3109/21678421.2012.729596; Graham DI, 1996, ACT NEUR S, V66, P96; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kuhle J, 2011, NEUROLOGY, V76, P1206, DOI 10.1212/WNL.0b013e31821432ff; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Olivecrona Z, 2012, ACTA NEUROCHIR, V154, P675, DOI 10.1007/s00701-012-1292-6; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Piccini A, 2005, J BIOL CHEM, V280, P34186, DOI 10.1074/jbc.M501694200; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Puchades M, 2003, MOL BRAIN RES, V118, P140, DOI 10.1016/j.molbrainres.2003.08.005; Roses AD, 1996, CURR OPIN NEUROL, V9, P265, DOI 10.1097/00019052-199608000-00004; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Tegner Y, 1991, Br J Sports Med, V25, P87; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Xie YY, 2003, J NEUROSCI RES, V73, P557, DOI 10.1002/jnr.10667; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zetterberg H, 2008, ARCH NEUROL-CHICAGO, V65, P1102, DOI 10.1001/archneur.65.8.1102; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	35	36	36	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e81249	10.1371/journal.pone.0081249			5	Multidisciplinary Sciences	Science & Technology - Other Topics	255RX	WOS:000327258600111	24260563	DOAJ Gold, Green Published			2021-06-18	
J	Waters, RJ; Murray, GD; Teasdale, GM; Stewart, J; Day, I; Lee, RJ; Nicoll, JAR				Waters, Ryan J.; Murray, Gordon D.; Teasdale, Graham M.; Stewart, Janice; Day, Ian; Lee, Robert J.; Nicoll, James A. R.			Cytokine Gene Polymorphisms and Outcome after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; genetics; head injury; inflammation; traumatic brain injury	TUMOR-NECROSIS-FACTOR; ALPHA PROMOTER POLYMORPHISM; IN-SITU DETECTION; HEAD-INJURY; TNF-ALPHA; ASSOCIATION; INTERLEUKIN-1-BETA; DAMAGE; INFLAMMATION; INHIBITION	Clinical outcome after traumatic brain injury (TBI) is variable and cannot easily be predicted. There is increasing evidence to suggest that there may be genetic influences on outcome. Cytokines play an important role in mediating the inflammatory response provoked within the central nervous system after TBI. This study was designed to identify associations between cytokine gene polymorphisms and clinical outcome 6 months after head injury. A prospectively identified cohort of patients (n=1096, age range 0-93 years, mean age 37) was used. Clinical outcome at 6 months was assessed using the Glasgow Outcome Scale. In an initial screen of 11 cytokine gene single nucleotide polymorphisms (SNPs) previously associated with disease susceptibility or outcome (TNFA -238 and -308, IL6 -174, -572 and -597, IL1A -889, IL1B -31, -511 and +3953, and TGFB -509 and -800), TNFA -308 was identified as having a likely association. The TNFA -308 SNP was further evaluated, and a significant association was identified, with 39% of allele 2 carriers having an unfavorable outcome compared with 31% of non-carriers (adjusted odds ratio 1.67, confidence interval 1.19-2.35, p=0.003). These findings are consistent with experimental and clinical data suggesting that neuroinflammation has an impact on clinical outcome after TBI and that tumor necrosis factor alpha plays an important role in this process.	[Waters, Ryan J.] Univ Hosp Southampton NHS Fdn Trust, Wessex Neurol Ctr, Southampton, Hants, England; [Murray, Gordon D.; Lee, Robert J.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Teasdale, Graham M.; Stewart, Janice] Univ Glasgow, Inst Neurol Sci, So Gen Hosp, Glasgow, Lanark, Scotland; [Day, Ian] Sch Social & Community Med, Bristol Genet Epidemiol Labs, Bristol, Avon, England; [Nicoll, James A. R.] Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England	Nicoll, JAR (corresponding author), Southampton Gen Hosp, Mailpoint 813, Southampton SO16 6YD, Hants, England.	J.Nicoll@soton.ac.uk	; Nicoll, James/I-9253-2017	Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9601296N]; APOE genotyping; Fausto Iannotti Scholarship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish	This work was supported by the Medical Research Council (grant number G9601296N) which funded establishment of the Head Injury Prospective Cohort (1996-1999) and APOE genotyping; and a Fausto Iannotti Scholarship (Mr Bob Barber) that funded Ryan Waters.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Culpan D, 2003, NEUROSCI LETT, V350, P61, DOI 10.1016/S0304-3940(03)00854-1; Dean FB, 2001, GENOME RES, V11, P1095, DOI 10.1101/gr.180501; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Harcos P, 2006, CYTOKINE, V33, P100, DOI 10.1016/j.cyto.2005.12.006; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; JENNETT B, 1975, LANCET, V1, P480; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; Lio D, 2006, MECH AGEING DEV, V127, P567, DOI 10.1016/j.mad.2006.01.015; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637, DOI 10.1016/0016-5085(94)90696-3; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Ruuls SR, 1999, AM J HUM GENET, V65, P294, DOI 10.1086/302517; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Tanriverdi T, 2006, SURG NEUROL, V65, P7, DOI 10.1016/j.surneu.2005.05.024; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Um JY, 2003, MOL BRAIN RES, V115, P50, DOI 10.1016/S0169-328X(03)00179-7; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229	59	36	36	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1710	1716		10.1089/neu.2012.2792			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000003	23768161	Green Published			2021-06-18	
J	Goodman, MD; Makley, AT; Campion, EM; Friend, LAW; Lentsch, AB; Pritts, TA				Goodman, Michael D.; Makley, Amy T.; Campion, Eric M.; Friend, Lou Ann W.; Lentsch, Alex B.; Pritts, Timothy A.			Preinjury alcohol exposure attenuates the neuroinflammatory response to traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Alcohol; Inflammation; Neuroinflammation	NEURON-SPECIFIC ENOLASE; ETHANOL; MODEL; MORTALITY; INTOXICATION; MODERATE; FLUID; BINGE; RATS; MICE	Background: Traumatic brain injury (TBI) initiates a neuroinflammatory response that increases the risk of TBI-related mortality. Acute alcohol intoxication at the time of TBI is associated with improved survival. Ethanol is recognized as a systemic immunomodulator that may also impart neuroprotection. The effects of alcohol on TBI-induced neuroinflammation, however, are unknown. We hypothesized that ethanol treatment prior to TBI may provide neuroprotection by diminishing the neuroinflammatory response to injury. Materials and methods: Mice underwent gavage with ethanol (EtOH) or water (H2O) prior to TBI. Animals were subjected to blunt TBI or sham injury (Sham). Posttraumatic rapid righting reflex (RRR) and apnea times were assessed. Cerebral and serum samples were analyzed by ELISA for inflammatory cytokine levels. Serum neuron-specific enolase (NSE), a biomarker of injury severity, was also measured. Results: Neurologic recovery from TBI was more rapid in H2O-treated mice compared with EtOH-treated mice. However, EtOH/TBI mice had a 4-fold increase in RRR time compared with EtOH/Sham, whereas H2O/TBI mice had a 15-fold increase in RRR time compared with H2O/Sham. Ethanol intoxication at the time of TBI significantly increased posttraumatic apnea time. Preinjury EtOH treatment was associated with reduced levels of proinflammatory cytokines IL-6, KC, MCP-1, and MIP-1 alpha post TBI. NSE was significantly increased post injury in the H2O/TBI group compared with H2O/Sham but was not significantly reduced by EtOH pretreatment. Conclusions: Alcohol treatment prior to TBI reduces the local neuroinflammatory response to injury. The decreased neurologic and inflammatory impact of TBI in acutely intoxicated patients may be responsible for improved clinical outcomes. (C) 2013 Elsevier Inc. All rights reserved.	[Goodman, Michael D.; Makley, Amy T.; Campion, Eric M.; Friend, Lou Ann W.; Lentsch, Alex B.; Pritts, Timothy A.] Univ Cincinnati, Dept Surg, Coll Med, Inst Mil Med, Cincinnati, OH 45267 USA	Goodman, MD (corresponding author), Univ Cincinnati, Dept Surg, Mail Locat 0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	md-goodman@hotmail.com		Pritts, Timothy/0000-0003-2495-3255	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM08478]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478] Funding Source: NIH RePORTER	This work was supported in part by awards from NIH training grant T32 GM08478.	[Anonymous], 2001, TRAUM BRAIN INJ US R, V2004; Carson EJ, 1996, ALCOHOL CLIN EXP RES, V20, P132, DOI 10.1111/j.1530-0277.1996.tb01055.x; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Livy DJ, 2003, ALCOHOL, V29, P165, DOI 10.1016/S0741-8329(03)00025-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Szabo G, 2009, ALCOHOL CLIN EXP RES, V33, P220, DOI 10.1111/j.1530-0277.2008.00842.x; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	31	36	38	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2013	184	2					1053	1058		10.1016/j.jss.2013.04.058			6	Surgery	Surgery	215XE	WOS:000324243500055	23721933	Green Accepted			2021-06-18	
J	Vlajkovic, SM; Lin, SCY; Wong, ACY; Wackrow, B; Thorne, PR				Vlajkovic, Srdjan M.; Lin, Shelly Ching-yu; Wong, Ann Chi Yan; Wackrow, Brad; Thorne, Peter R.			Noise-induced changes in expression levels of NADPH oxidases in the cochlea	HEARING RESEARCH			English	Article							INDUCED HEARING-LOSS; NOX FAMILY; CISPLATIN; ROLES; BRAIN; RAT; SUPEROXIDE; GENERATION; INHIBITORS; MUTATIONS	NADPH oxidases are enzymes that transport electrons across the plasma membrane and generate superoxide radical from molecular oxygen. The current study investigated the expression and distribution of NOX/DUOX members of the NADPH oxidase family (NOX1-5 and DUOX1-2) in the rat cochlea and their regulation in response to noise. Wistar rats (8-10 weeks) were exposed for 24 h to band noise (8-12 kHz) at moderate (100 dB) or traumatic (110 dB) sound pressure levels (SPL). Animals exposed to ambient noise (45-55 dB SPL) served as controls. Immunohistochemistly demonstrated predominant expression of all NOX/DUOX isoforms in the sensory and supporting cells of the organ of Corti, with very limited immunoexpression in the lateral wall tissues and spiral ganglion neurons. Noise exposure induced up-regulation of NOX1 and DUOX2 in the cochlea, whereas NOX3 was down-regulated. A significant reduction in the intensity of NOX3 immunolabeling was observed in the inner sulcus region of the cochlea after exposure to noise. Post-exposure inhibition of NADPH oxidases by Diphenyleneiodonium (DPI), a broadly selective NADPH oxidase inhibitor, mitigated noise-induced hearing loss. Conclusion: Noise-induced up-regulation of NOX1 and DUOX2 could be linked to cochlear injury. In contrast, down-regulation of NOX3 may represent an endogenous protective mechanism to reduce oxidative stress in the noise-exposed cochlea. Inhibition of NADPH oxidases is potentially a novel pathway for therapeutic management of noise-induced hearing loss. (C) 2013 Elsevier B.V. All rights reserved.	[Vlajkovic, Srdjan M.; Lin, Shelly Ching-yu; Wackrow, Brad; Thorne, Peter R.] Univ Auckland, Dept Physiol, Fac Med & Hlth Sci, Auckland 1142, New Zealand; [Thorne, Peter R.] Univ Auckland, Discipline Audiol, Fac Med & Hlth Sci, Auckland 1142, New Zealand; [Wong, Ann Chi Yan] Univ New S Wales, Sch Med Sci, Translat Neurosci Facil, Sydney, NSW, Australia	Vlajkovic, SM (corresponding author), Univ Auckland, Dept Physiol, Fac Med & Hlth Sci, Private Bag 92019, Auckland 1142, New Zealand.	s.vlajkovic@auckland.ac.nz		Wong, Ann CY/0000-0001-7011-0369; Thorne, Peter/0000-0003-0214-0210; Vlajkovic, Srdjan/0000-0001-8548-6844	University of Auckland Faculty Research Development Fund	This study was supported by the University of Auckland Faculty Research Development Fund.	Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70; Banfi B, 2004, J BIOL CHEM, V279, P46065, DOI 10.1074/jbc.M403046200; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cross R.A., 1986, BIOCHEM J, V237, P111; Forman HJ, 2010, BIOCHEMISTRY-US, V49, P835, DOI 10.1021/bi9020378; HAMERNIK RP, 1984, HEARING RES, V16, P143, DOI 10.1016/0378-5955(84)90004-2; Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kawahara T, 2005, J BIOL CHEM, V280, P31859, DOI 10.1074/jbc.M501882200; Kim HJ, 2010, J NEUROSCI, V30, P3933, DOI 10.1523/JNEUROSCI.6054-09.2010; Kim JA, 2011, EXPERT OPIN THER PAT, V21, P1147, DOI 10.1517/13543776.2011.584870; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Le Prell CG, 2007, HEARING RES, V226, P22, DOI 10.1016/j.heares.2006.10.006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mukherjea D, 2006, NEUROSCIENCE, V139, P733, DOI 10.1016/j.neuroscience.2005.12.044; Mukherjea D, 2010, ANTIOXID REDOX SIGN, V13, P589, DOI 10.1089/ars.2010.3110; Nakano Y, 2007, BIOCHEM J, V403, P97, DOI 10.1042/BJ20060819; Oishi N, 2011, EXPERT OPIN EMERG DR, V16, P235, DOI 10.1517/14728214.2011.552427; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Rybak LP, 2012, CELL MOL LIFE SCI, V69, P2429, DOI 10.1007/s00018-012-1016-3; Schramm A, 2012, VASC PHARMACOL, V56, P216, DOI 10.1016/j.vph.2012.02.012; Thorne PR, 2008, NEW ZEAL MED J, V121, P33; Ueno N, 2005, J BIOL CHEM, V280, P23328, DOI 10.1074/jbc.M414548200; Wangemann P, 2002, HEARING RES, V165, P1, DOI 10.1016/S0378-5955(02)00279-4; Wong ACY, 2012, HISTOCHEM CELL BIOL, V137, P599, DOI 10.1007/s00418-012-0922-7; Wong ACY, 2010, HEARING RES, V260, P81, DOI 10.1016/j.heares.2009.12.004; Yamashita D, 2005, NEUROSCIENCE, V134, P633, DOI 10.1016/j.neuroscience.2005.04.015; Yamashita D, 2004, BRAIN RES, V1019, P201, DOI 10.1016/j.brainres.2004.05.104	31	36	36	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5955			HEARING RES	Hear. Res.	OCT	2013	304						145	152		10.1016/j.heares.2013.07.012			8	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	225PM	WOS:000324974800015	23899412				2021-06-18	
J	McGurk, SR; Mueser, KT; Cicerone, KD; Silverstein, SM; Myers, R; Bell, MD; Covell, NH; Drake, RE; Medalia, A; Bellack, AS; Essock, SM				McGurk, Susan R.; Mueser, Kim T.; Cicerone, Keith D.; Silverstein, Steven M.; Myers, Robert; Bell, Morris D.; Covell, Nancy H.; Drake, Robert E.; Medalia, Alice; Bellack, Alan S.; Essock, Susan M.			Mental Health System Funding of Cognitive Enhancement Interventions for Schizophrenia: Summary and Update of the New York Office of Mental Health Expert Panel and Stakeholder Meeting	PSYCHIATRIC REHABILITATION JOURNAL			English	Article						cognitive remediation; cognitive rehabilitation; severe mental illness; psychiatric rehabilitation; traumatic brain injury		Topic: A growing research literature indicates that cognitive enhancement (CE) interventions for people with schizophrenia can improve cognitive functioning and may benefit psychosocial functioning (e.g., competitive employment, quality of social relationships). Debate continues regarding the strength of evidence for CE and related policy implications, such as the appropriateness of funding CE services. Purpose: This paper summarizes and updates a meeting of experts and stakeholders convened in 2008 by the New York Office of Mental Health to review evidence on the impact of CE for people with schizophrenia and other serious mental illnesses, and addresses whether the evidence base for CE interventions is sufficient to warrant funding. Sources Used: Specific recommendations based on the extant literature are provided regarding the structure and components of CE programs that should be present in order to improve cognitive and psychosocial outcomes and therefore merit consideration of funding. Conclusions and Implications for Practice: These recommendations may serve as a starting point in developing standards for CE programs. Establishing evidence-based practice standards for implementing CE interventions for people with serious mental illnesses may facilitate dissemination of programs that have the greatest potential for improving individuals' functional outcomes while minimizing incremental costs associated with providing CE services. Important open questions include how the performance of CE programs should be monitored and which individuals might be expected to benefit from CE as evidenced by improved functioning in their everyday lives.	[McGurk, Susan R.; Mueser, Kim T.] Boston Univ, Ctr Psychiat Rehabil, Dept Occupat Therapy Psychol & Psychiat, Boston, MA 02215 USA; [Covell, Nancy H.] New York State Psychiat Inst & Hosp, Dept Mental Hlth Serv & Policy Res, New York, NY 10032 USA; [Cicerone, Keith D.] Univ Med & Dent, Robert Wood Johnson Med Sch Med, JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA; [Myers, Robert] Dartmouth Med Sch, Dartmouth Psychiat Res Ctr, Dept Psychiat & Community & Family Med, Dartmouth, NS, Canada; [Silverstein, Steven M.] Rutgers Univ Behav HealthCare, UMDNJ Univ Behav HealthCare, Violence Inst NJ, Div Schizophrenia Res, Piscataway, NJ USA; [Medalia, Alice] Columbia Univ, Ctr Med, Dept Psychiat, New York, NY USA; [Bellack, Alan S.] Univ Maryland, Sch Med, Bethesda, MD USA; [Bell, Morris D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; [Essock, Susan M.] Columbia Univ, Dept Psychiat, New York, NY USA; [Essock, Susan M.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA	McGurk, SR (corresponding author), Boston Univ, Ctr Psychiat Rehabil, 940 Commonwealth Ave West, Boston, MA 02215 USA.	mcgurk@bu.edu	Drake, Robert/AAS-3310-2020				Addington J, 2008, SCHIZOPHR RES, V99, P176, DOI 10.1016/j.schres.2007.07.004; Allen DN, 2007, SCHIZOPHR RES, V93, P325, DOI 10.1016/j.schres.2007.02.008; Bell M, 2003, ACTA PSYCHIAT SCAND, V108, P101, DOI 10.1034/j.1600-0447.2003.00090.x; Bell M, 2001, ARCH GEN PSYCHIAT, V58, P763, DOI 10.1001/archpsyc.58.8.763; Bell M, 2009, SCHIZOPHRENIA BULL, V35, P738, DOI 10.1093/schbul/sbm169; Bell MD, 2008, SCHIZOPHR RES, V105, P18, DOI 10.1016/j.schres.2008.06.026; Bell MD, 2005, J REHABIL RES DEV, V42, P829, DOI 10.1682/JRRD.2005.03.0061; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BRACY O, 1995, COGREHAB SOFTWARE; Brenner HD, 1994, INTEGRATED PSYCHOL T; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cognitive Remediation Expert Working Group, 2012, CREW M SCHIZ INT RES; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Dickinson D, 2010, AM J PSYCHIAT, V167, P170, DOI 10.1176/appi.ajp.2009.09020264; Dixon LB, 2010, SCHIZOPHRENIA BULL, V36, P48, DOI 10.1093/schbul/sbp115; Drake RE., 2012, IPS SUPPORTED EMPLOY, DOI [10.1093/acprof:oso/9780199734016.001.0001, DOI 10.1093/ACPROF:OSO/9780199734016.001.0001]; Eack SM, 2009, PSYCHIAT SERV, V60, P1468, DOI 10.1176/appi.ps.60.11.1468; Fett AKJ, 2011, NEUROSCI BIOBEHAV R, V35, P573, DOI 10.1016/j.neubiorev.2010.07.001; Fisher M, 2013, ANNU REV CLIN PSYCHO, V9, P435, DOI 10.1146/annurev-clinpsy-032511-143134; Fisher M, 2009, AM J PSYCHIAT, V166, P805, DOI 10.1176/appi.ajp.2009.08050757; Fiszdon JM, 2006, SCHIZOPHR RES, V87, P261, DOI 10.1016/j.schres.2006.04.011; Green MF, 2004, SCHIZOPHR RES, V72, P1, DOI 10.1016/j.schres.2004.09.006; Green MF, 1996, AM J PSYCHIAT, V153, P321; Greig TC, 2007, SCHIZOPHR RES, V96, P156, DOI 10.1016/j.schres.2007.07.003; HEATON R, 1994, ARCH GEN PSYCHIAT, V51, P469; HEINRICHS DW, 1984, SCHIZOPHRENIA BULL, V10, P388, DOI 10.1093/schbul/10.3.388; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; Hoe M, 2012, PSYCHOL MED, V42, P2287, DOI 10.1017/S0033291712000578; Hogarty GE, 2004, ARCH GEN PSYCHIAT, V61, P866, DOI 10.1001/archpsyc.61.9.866; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; KESSLER RC, 1995, AM J PSYCHIAT, V152, P1026; Kidd SA, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/715176; Killackey E, 2008, BRIT J PSYCHIAT, V193, P114, DOI 10.1192/bjp.bp.107.043109; Krabbendam L, 2003, PSYCHOPHARMACOLOGY, V169, P376, DOI 10.1007/s00213-002-1326-5; Kurtz MM, 2008, J CONSULT CLIN PSYCH, V76, P491, DOI 10.1037/0022-006X.76.3.491; Kurtz MM, 2007, SCHIZOPHR RES, V89, P251, DOI 10.1016/j.schres.2006.09.001; Kurtz MM, 2012, SCHIZOPHRENIA BULL, V38, P1092, DOI 10.1093/schbul/sbr036; Kurtz MM, 2011, CLIN PSYCHOL REV, V31, P663, DOI 10.1016/j.cpr.2011.02.008; Kurtz MM, 2005, SCHIZOPHR RES, V74, P15, DOI 10.1016/j.schres.2004.07.005; Kurtz MM, 2001, NEUROPSYCHOL REV, V11, P197, DOI 10.1023/A:1012953108158; Liberman RP, 2007, J MENTAL HLTH, V16, P595, DOI DOI 10.1080/09638230701494902; Lindenmayer JP, 2008, PSYCHIAT SERV, V59, P241, DOI 10.1176/appi.ps.59.3.241; Lindenmayer JP, 2013, SCHIZOPHRENIA BULL, V39, P507, DOI 10.1093/schbul/sbs120; MacCabe JH, 2013, JAMA PSYCHIAT, V70, P261, DOI 10.1001/2013.jamapsychiatry.43; McGurk SR, 2005, SCHIZOPHRENIA BULL, V31, P898, DOI 10.1093/schbul/sbi037; McGurk SR, 2004, SCHIZOPHR RES, V70, P147, DOI 10.1016/j.schres.2004.01.009; McGurk SR, 2003, PSYCHIAT SERV, V54, P1129, DOI 10.1176/appi.ps.54.8.1129; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; McGurk SR, 2007, AM J PSYCHIAT, V164, P437, DOI 10.1176/appi.ajp.164.3.437; McGurk SR, 2006, PSYCHIAT SERV, V57, P1421, DOI 10.1176/appi.ps.57.10.1421; McGurk SR, 2008, AM J PSYCHIATR REHAB, V11, P90, DOI 10.1080/15487760701853136; McGurk SR, 2009, SCHIZOPHRENIA BULL, V35, P319, DOI 10.1093/schbul/sbn182; Medalia A, 2005, SCHIZOPHRENIA BULL, V31, P942, DOI 10.1093/schbul/sbi045; Medalia A., 2009, COGNITIVE REMEDIATIO; Medalia A, 2011, SCHIZOPHRENIA BULL, V37, pS122, DOI 10.1093/schbul/sbr063; Medalia A, 2009, NEUROPSYCHOL REV, V19, P353, DOI 10.1007/s11065-009-9097-y; Mueser K. T., 1993, BEHAV THERAPIST, V16, P218; Mueser KT, 2012, PSYCHIATR REHABIL J, V35, P417, DOI 10.1037/h0094573; MUESER KT, 1991, PSYCHIAT RES, V37, P281, DOI 10.1016/0165-1781(91)90064-V; Mueser KT, 2001, SCHIZOPHRENIA BULL, V27, P281, DOI 10.1093/oxfordjournals.schbul.a006874; Nuechterlein KH, 2008, PSYCHIATR REHABIL J, V31, P340, DOI 10.2975/31.4.2008.340.349; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Patterson TL, 2001, SCHIZOPHR RES, V48, P351, DOI 10.1016/S0920-9964(00)00109-2; Penn DL, 1997, PSYCHOL BULL, V121, P114, DOI 10.1037/0033-2909.121.1.114; Pilling S, 2002, PSYCHOL MED, V32, P783, DOI 10.1017/S0033291702005640; Pitschel-Walz G, 2001, SCHIZOPHRENIA BULL, V27, P73, DOI 10.1093/oxfordjournals.schbul.a006861; Ritsner M, 2005, QUAL LIFE RES, V14, P1693, DOI 10.1007/s11136-005-2816-9; Roberts DL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/742106; Sartory G, 2005, SCHIZOPHR RES, V75, P219, DOI 10.1016/j.schres.2004.10.004; Sergi MJ, 2007, SCHIZOPHR RES, V90, P316, DOI 10.1016/j.schres.2006.09.028; Silverstein SM, 1998, PSYCHIAT QUART, V69, P95, DOI 10.1023/A:1024758402191; Silverstein SM, 2005, PSYCHOL MED, V35, P829, DOI 10.1017/S0033291704003356; Silverstein SM, 1998, PSYCHIAT QUART, V69, P169, DOI 10.1023/A:1022197109569; SILVERSTEIN SM, 1994, CONTINUUM, V1, P251; Silverstein SM, 2009, SCHIZOPHRENIA BULL, V35, P222, DOI 10.1093/schbul/sbm150; Bell MS, 2007, NY TIMES BK REV, P6; Smith TE, 1999, AM J PSYCHIAT, V156, P1817; Spaulding WD, 1999, SCHIZOPHRENIA BULL, V25, P275, DOI 10.1093/oxfordjournals.schbul.a033378; Spaulding WD, 1999, SCHIZOPHRENIA BULL, V25, P657, DOI 10.1093/oxfordjournals.schbul.a033409; Statucka M, 2013, PSYCHIAT RES, V206, P125, DOI 10.1016/j.psychres.2012.12.005; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vauth R, 2005, SCHIZOPHRENIA BULL, V31, P55, DOI 10.1093/schbul/sbi013; Velligan DI, 2008, SCHIZOPHR RES, V102, P312, DOI 10.1016/j.schres.2008.02.005; Wykes T, 1999, SCHIZOPHRENIA BULL, V25, P291, DOI 10.1093/oxfordjournals.schbul.a033379; Wykes T, 2005, COGNITIVE REMEDIATIO; Wykes T, 2008, SCHIZOPHRENIA BULL, V34, P523, DOI 10.1093/schbul/sbm114; Wykes T, 2011, SCHIZOPHRENIA BULL, V37, pS80, DOI 10.1093/schbul/sbr064; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855; Wykes T, 2009, SCHIZOPHR RES, V113, P252, DOI 10.1016/j.schres.2009.05.025; Zammit S, 2004, ARCH GEN PSYCHIAT, V61, P354, DOI 10.1001/archpsyc.61.4.354	94	36	39	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1095-158X	1559-3126		PSYCHIATR REHABIL J	Psychiatr. Rehabil. J.	SEP	2013	36	3					133	145		10.1037/prj0000020			13	Psychiatry; Rehabilitation	Psychiatry; Rehabilitation	V36SU	WOS:000209231800002	24059629				2021-06-18	
J	DeMuro, JP; Simmons, S; Jax, J; Gianelli, SM				DeMuro, Jonas P.; Simmons, Susan; Jax, Judy; Gianelli, Scott M.			Application of the shock index to the prediction of need for hemostasis intervention	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							MASSIVE TRANSFUSION; HEART-RATE; TRAUMA; UTILITY; RESUSCITATION; PATIENT	Introduction: The traditional method to identify hemorrhage after trauma has been vital signs-based. More recent attempts have used mathematical prediction models, but these are limited by the need for additional data including a Focused Assessment with Sonography for Trauma exam, or an arterial blood gas. Shock Index (SI) is the mathematical relationship of the heart rate divided by the systolic blood pressure; the cutoff of >0.9 has been associated with bleeding. Methods: A total of 4292 trauma patients were identified in database over an 11 year period. Inclusion criteria included age >16 years and initial presentation to our trauma center. Patients were excluded for incomplete data, traumatic brain injury, or transfer leaving 4277 patients for analysis. Patients were further subdivided by age, and by mechanism of injury (blunt versus penetrating). Finally, patients were divided into bleeding versus nonbleeding, and the SI formula was applied to their initial hospital vital signs. Results: Across our dataset, using the standard SI cutoff of >0.9 as the threshold for bleeding, the sensitivity is 54.5%, with a specificity of 93.6%. In the geriatric subanalysis, there was no difference for sensitivity between the age groups, but SI is more specific in the older patients. There was no difference in sensitivity using SI in blunt versus penetrating. Lowering the SI to >= 0.8 increases the sensitivity to 76.1%, with a specificity of 87.4%. Conclusion: SI, at a lowered threshold of >= 0.8, can be used to identify trauma patients that will require intervention for hemostasis. (C) 2013 Elsevier Inc. All rights reserved.	[DeMuro, Jonas P.; Simmons, Susan; Jax, Judy] Winthrop Univ Hosp, Div Trauma & Crit Care, Dept Surg, Mineola, NY 11501 USA; [Gianelli, Scott M.] SUNY Stony Brook, Sch Marine & Atmospher Sci, Suffolk, NY USA	DeMuro, JP (corresponding author), Winthrop Univ Hosp, Div Trauma & Crit Care, Dept Surg, Mineola, NY 11501 USA.	jdemuro@winthrop.org					Cannon CM, 2009, J TRAUMA, V67, P1426, DOI 10.1097/TA.0b013e3181bbf728; Chico-Fernandez M, 2011, MED INTENSIVA, V35, P546, DOI 10.1016/j.medin.2011.06.010; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; Gaarder C, 2009, J TRAUMA, V67, P323, DOI 10.1097/TA.0b013e3181a4ed27; Heffernan DS, 2010, J TRAUMA, V69, P813, DOI 10.1097/TA.0b013e3181f41af8; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; Pasquier P, 2012, AM J SURG, V204, P812, DOI 10.1016/j.amjsurg.2011.10.022; Rady MY, 1996, AM J EMERG MED, V14, P218, DOI 10.1016/S0735-6757(96)90136-9; RODEHEFFER RJ, 1984, CIRCULATION, V69, P203, DOI 10.1161/01.CIR.69.2.203; Tisherman SA, 2004, J TRAUMA, V57, P898, DOI 10.1097/01.TA.0000133577.25793.E5; Vandromme MJ, 2011, J TRAUMA, V70, P384, DOI 10.1097/TA.0b013e3182095a0a; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf; Yussof Shah Jahan Mohd, 2012, Med J Malaysia, V67, P406; Zarzaur BL, 2010, J TRAUMA, V68, P1134, DOI 10.1097/TA.0b013e3181d87488	16	36	38	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	AUG	2013	31	8					1260	1263		10.1016/j.ajem.2013.05.027			4	Emergency Medicine	Emergency Medicine	201SN	WOS:000323163400021	23806728				2021-06-18	
J	Bracchi-Ricard, V; Lambertsen, KL; Ricard, J; Nathanson, L; Karmally, S; Johnstone, J; Ellman, DG; Frydel, B; McTigue, DM; Bethea, JR				Bracchi-Ricard, Valerie; Lambertsen, Kate L.; Ricard, Jerome; Nathanson, Lubov; Karmally, Shaffiat; Johnstone, Joshua; Ellman, Ditte G.; Frydel, Beata; McTigue, Dana M.; Bethea, John R.			Inhibition of astroglial NF-kappaB enhances oligodendrogenesis following spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article						NF-kappaB; Spinal cord injury; Astrocyte; Oligodendrocyte; Microglia; CXCR4; TNFR2; Toll-like receptor	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CEREBRAL-ARTERY OCCLUSION; CHEMOKINE RECEPTOR CXCR4; IN-SITU HYBRIDIZATION; TRANSGENIC INHIBITION; FUNCTIONAL RECOVERY; EXPRESSION; INFLAMMATION; REMYELINATION	Background: Astrocytes are taking the center stage in neurotrauma and neurological diseases as they appear to play a dominant role in the inflammatory processes associated with these conditions. Previously, we reported that inhibiting NF-kappa B activation in astrocytes, using a transgenic mouse model (GFAP-I kappa B alpha-dn mice), results in improved functional recovery, increased white matter preservation and axonal sparing following spinal cord injury (SCI). In the present study, we sought to determine whether this improvement, due to inhibiting NF-kappa B activation in astrocytes, could be the result of enhanced oligodendrogenesis in our transgenic mice. Methods: To assess oligodendrogenesis in GFAP-I kappa B alpha-dn compared to wild-type (WT) littermate mice following SCI, we used bromodeoxyuridine labeling along with cell-specific immuno-histochemistry, confocal microscopy and quantitative cell counts. To further gain insight into the underlying molecular mechanisms leading to increased white matter, we performed a microarray analysis in naive and 3 days, 3 and 6 weeks following SCI in GFAP-I kappa B alpha-dn and WT littermate mice. Results: Inhibition of astroglial NF-kappa B in GFAP-I kappa B alpha-dn mice resulted in enhanced oligodendrogenesis 6 weeks following SCI and was associated with increased levels of myelin proteolipid protein compared to spinal cord injured WT mice. The microarray data showed a large number of differentially expressed genes involved in inflammatory and immune response between WT and transgenic mice. We did not find any difference in the number of microglia/leukocytes infiltrating the spinal cord but did find differences in their level of expression of toll-like receptor 4. We also found increased expression of the chemokine receptor CXCR4 on oligodendrocyte progenitor cells and mature oligodendrocytes in the transgenic mice. Finally TNF receptor 2 levels were significantly higher in the transgenic mice compared to WT following injury. Conclusions: These studies suggest that one of the beneficial roles of blocking NF-kappa B in astrocytes is to promote oligodendrogenesis through alteration of the inflammatory environment.	[Bracchi-Ricard, Valerie; Lambertsen, Kate L.; Ricard, Jerome; Karmally, Shaffiat; Johnstone, Joshua; Frydel, Beata; Bethea, John R.] Univ Miami, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Lambertsen, Kate L.; Ellman, Ditte G.] Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, DK-5000 Odense C, Denmark; [Nathanson, Lubov] Univ Miami, Miller Sch Med, Dept Mol & Cellular Med, Miami, FL 33136 USA; [McTigue, Dana M.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Dept Neurosci, Columbus, OH 43210 USA	Bethea, JR (corresponding author), Univ Miami, Miami Project Cure Paralysis, Miami, FL 33136 USA.	JBethea@miami.edu	Lambertsen, Kate L./I-8676-2014	Lambertsen, Kate L./0000-0001-9276-4902; Ricard, Jerome/0000-0002-9019-4165; Nathanson, Lubov/0000-0003-1038-9083	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS051709-06]; Danish MRCDanish Medical Research Council; Carlsberg FoundationCarlsberg Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051709] Funding Source: NIH RePORTER	This work was supported by NIH grants NS051709-06 (JRB) and The Danish MRC and the Carlsberg Foundation (KLL). The authors acknowledge the technical assistance provided by technicians Karen Rich, Inge Holst Nielsen, Dorte Lyholmer and Louise Lykkemark.	Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Banisadr G, 2011, NEUROBIOL DIS, V44, P19, DOI 10.1016/j.nbd.2011.05.019; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; Brambilla R, 2009, J IMMUNOL, V182, P2628, DOI 10.4049/jimmunol.0802954; Carbajal KS, 2011, GLIA, V59, P1813, DOI 10.1002/glia.21225; Chew LJ, 2011, J NEUROSCI, V31, P13921, DOI 10.1523/JNEUROSCI.3343-11.2011; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Clausen BH, 2005, NEUROSCIENCE, V132, P879, DOI 10.1016/j.neuroscience.2005.01.031; Cruz-Orengo L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-170; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Dziembowska M, 2005, GLIA, V50, P258, DOI 10.1002/glia.20170; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Foote AK, 2005, BRAIN, V128, P528, DOI 10.1093/brain/awh417; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Glezer I, 2006, FASEB J, V20, P750, DOI 10.1096/fj.05-5234fje; Gottle P, 2010, ANN NEUROL, V68, P915, DOI 10.1002/ana.22214; Han YL, 2001, BRAIN RES, V888, P1, DOI 10.1016/S0006-8993(00)02924-3; Hayashi H, 2008, BIOCHEM BIOPH RES CO, V367, P584, DOI 10.1016/j.bbrc.2007.12.183; Khorooshi R, 2008, J IMMUNOL, V181, P7284, DOI 10.4049/jimmunol.181.10.7284; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kostianovsky AM, 2008, J IMMUNOL, V181, P5425, DOI 10.4049/jimmunol.181.8.5425; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Kremer D, 2011, ANN NEUROL, V69, P602, DOI 10.1002/ana.22415; Lambertsen KL, 2007, NEUROSCIENCE, V144, P934, DOI 10.1016/j.neuroscience.2006.10.046; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lambertsen KL, 2002, J CEREBR BLOOD F MET, V22, P785, DOI 10.1097/00004647-200207000-00004; Lambertsen KL, 2001, BRAIN RES PROTOC, V7, P175, DOI 10.1016/S1385-299X(01)00062-9; Li MZ, 2011, GLIA, V59, P108, DOI 10.1002/glia.21080; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Moore CS, 2011, J NEUROSCI, V31, P6247, DOI 10.1523/JNEUROSCI.5474-10.2011; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; Nash B, 2011, J NEUROSCI, V31, P13028, DOI 10.1523/JNEUROSCI.1449-11.2011; Nielsen HH, 2011, AM J PATHOL, V179, P2028, DOI 10.1016/j.ajpath.2011.06.006; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Opatz J, 2009, MOL CELL NEUROSCI, V40, P293, DOI 10.1016/j.mcn.2008.11.002; Patel JR, 2012, ACTA NEUROPATHOL, V124, P847, DOI 10.1007/s00401-012-1034-0; Patel JR, 2010, P NATL ACAD SCI USA, V107, P11062, DOI 10.1073/pnas.1006301107; Petty JM, 2007, J IMMUNOL, V178, P8148, DOI 10.4049/jimmunol.178.12.8148; Schonberg DL, 2007, J NEUROPATH EXP NEUR, V66, P1124, DOI 10.1097/nen.0b013e31815c2530; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P1, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Sohn J, 2006, J NEUROSCI, V26, P9722, DOI 10.1523/JNEUROSCI.1716-06.2006; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002; Wang LH, 2009, ONCOL REP, V22, P1333, DOI 10.3892/or_00000572; Wang YP, 2011, J NEUROSCI, V31, P6053, DOI 10.1523/JNEUROSCI.5524-09.2011; West MJ, 1996, J COMP NEUROL, V370, P11; Wu JF, 2010, GLIA, V58, P410, DOI 10.1002/glia.20932; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475	63	36	40	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUL 23	2013	10								92	10.1186/1742-2094-10-92			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	201VO	WOS:000323171300001	23880092	DOAJ Gold, Green Published			2021-06-18	
J	Levi, Y; Rassovsky, Y; Agranov, E; Sela-Kaufman, M; Vakil, E				Levi, Yifat; Rassovsky, Yuri; Agranov, Eugenia; Sela-Kaufman, Michal; Vakil, Eli			Cognitive Reserve Components as Expressed in Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Reserve; CR; TBI; Structural equation modeling; Head injury; Rehabilitation	CONSTRUCT-VALIDITY; EDUCATION; RISK; MEMORY; INTELLIGENCE; PREDICTION; SEVERITY; DEMENTIA; LIFETIME; MODERATE	Traumatic brain injury (TBI) is the most common cause of brain damage, resulting in long-term disability. The "reserve" construct has been proposed to account for the reported mismatch between brain damage and its clinical expression. Although numerous studies have used various measures thought to reflect this construct, few studies have examined its underlying structure in clinical populations, and no studies have systematically studied this construct in TBI. In the present study, structural equation modeling technique was used to evaluate several models hypothesized to represent cognitive reserve (CR) in TBI. A broad range of data typically reported in the literature as representing CR was collected from 89 individuals who sustained moderate-to-severe TBI. Analyses revealed a best fitting model that consisted of three separate factors representing premorbid intelligence, socioeconomic status and leisure activity, with distinct pattern of associations among the three factors. Findings provide empirical support for the notion of a multi-factorial CR and suggest a coherent framework for further investigation.	[Levi, Yifat; Rassovsky, Yuri; Vakil, Eli] Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel; [Rassovsky, Yuri; Vakil, Eli] Bar Ilan Univ, Leslie & Susan Gonda Goldschmied Multidisciplinar, IL-52900 Ramat Gan, Israel; [Rassovsky, Yuri] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Agranov, Eugenia] Sheba Med Ctr, Ramat Gan, Israel; [Agranov, Eugenia] Tel Aviv Univ, Fac Med, IL-69978 Tel Aviv, Israel; [Sela-Kaufman, Michal] Acad Coll Tel Aviv Yaffo, Dept Behav Sci, Tel Aviv, Israel	Vakil, E (corresponding author), Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel.	vakile@mail.biu.ac.il		Rassovsky, Yuri/0000-0002-6362-9944			BENTLER PM, 1996, EQS STRUCTURAL EQUAT; BICKEL H, 1994, PSYCHOL MED, V24, P179, DOI 10.1017/S0033291700026945; Bigler E. D, 2006, COGNITIVE RESERVE TH; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Brosch I., 2000, MEGAMOT, V40, P185; CAPRON C, 1989, NATURE, V340, P552, DOI 10.1038/340552a0; Central Bureau of Statistics, 2012, OCC INC ACC NAT INS; Dik MG, 2003, J CLIN EXP NEUROPSYC, V25, P643, DOI 10.1076/jcen.25.5.643.14583; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI 10.1111/j.1467-8624.1994.tb00752.x; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; HAUSER RM, 1986, J LABOR ECON, V4, pS83, DOI 10.1086/298122; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HOLMAN TB, 1984, J LEISURE RES, V16, P277; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jamshidian M, 1999, J EDUC BEHAV STAT, V24, P21, DOI 10.2307/1165260; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kraus JF, 1993, HEAD INJURY, P1; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; KURTZKE JF, 1984, ANN NEUROL, V16, P265, DOI 10.1002/ana.410160302; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Legendre SA, 2003, J NEUROPSYCH CLIN N, V15, P333, DOI 10.1176/jnp.15.3.333; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Manly JJ, 2005, J GERIATR PSYCH NEUR, V18, P213, DOI 10.1177/0891988705281868; Mortimer JA, 2003, J CLIN EXP NEUROPSYC, V25, P671, DOI 10.1076/jcen.25.5.671.14584; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Murrey GJ, 2004, REHABIL PSYCHOL, V49, P259, DOI 10.1037/0090-5550.49.3.259; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Roe A., 1956, PSYCHOL OCCUPATIONS; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; Ropacki SA, 2007, ARCH CLIN NEUROPSYCH, V22, P73, DOI 10.1016/j.acn.2006.11.001; RUSSELL EW, 1980, PERCEPT MOTOR SKILL, V51, P121, DOI 10.2466/pms.1980.51.1.121; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Satz P, 2011, J CLIN EXP NEUROPSYC, V33, P121, DOI 10.1080/13803395.2010.493151; Scarmeas N, 2003, ARCH NEUROL-CHICAGO, V60, P359, DOI 10.1001/archneur.60.3.359; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Schmand B, 1997, PSYCHOL MED, V27, P1337, DOI 10.1017/S0033291797005461; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Siedlecki KL, 2009, J INT NEUROPSYCH SOC, V15, P558, DOI 10.1017/S1355617709090857; SNOWDON DA, 1989, AM J EPIDEMIOL, V130, P999, DOI 10.1093/oxfordjournals.aje.a115433; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, P112, DOI 10.1097/01.wad.0000213815.20177.19; Sumowski JF, 2009, J INT NEUROPSYCH SOC, V15, P606, DOI 10.1017/S1355617709090912; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Valenzuela MJ, 2007, PSYCHOL MED, V37, P1015, DOI 10.1017/S003329170600938X; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742	59	36	36	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2013	19	6					664	671		10.1017/S1355617713000192			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	170QY	WOS:000320869700005	23575273				2021-06-18	
J	Veenith, TV; Carter, E; Grossac, J; Newcombe, VFJ; Outtrim, JG; Lupson, V; Williams, GB; Menon, DK; Coles, JP				Veenith, Tonny V.; Carter, Eleanor; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne G.; Lupson, Victoria; Williams, Guy B.; Menon, David K.; Coles, Jonathan P.			Inter Subject Variability and Reproducibility of Diffusion Tensor Imaging within and between Different Imaging Sessions	PLOS ONE			English	Article							PRINCIPAL EIGENVECTOR MEASUREMENTS; TRAUMATIC BRAIN-INJURY; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; TRACTOGRAPHY; MR; DEGENERATION; MULTICENTER; SCANNER	The aim of these studies was to provide reference data on intersubject variability and reproducibility of diffusion tensor imaging. Healthy volunteers underwent imaging on two occasions using the same 3T Siemens Verio magnetic resonance scanner. At each session two identical diffusion tensor sequences were obtained along with standard structural imaging. Fractional anisotropy, apparent diffusion coefficient, axial and radial diffusivity maps were created and regions of interest applied in normalised space. The baseline data from all 26 volunteers were used to calculate the intersubject variability, while within session and between session reproducibility were calculated from all the available data. The reproducibility of measurements were used to calculate the overall and within session 95% prediction interval for zero change. The within and between session reproducibility data were lower than the values for intersubject variability, and were different across the brain. The regional mean (range) coefficient of variation figures for within session reproducibility were 2.1 (0.9-5.5%), 1.2 (0.4-3.9%), 1.2 (0.4-3.8%) and 1.8 (0.4-4.3%) for fractional anisotropy, apparent diffusion coefficient, axial and radial diffusivity, and were lower than between session reproducibility measurements (2.4 (1.1-5.9%), 1.9 (0.7-5.7%), 1.7 (0.7-4.7%) and 2.4 (0.9-5.8%); p < 0.001). The calculated overall and within session 95% prediction intervals for zero change were similar. This study provides additional reference data concerning intersubject variability and reproducibility of diffusion tensor imaging conducted within the same imaging session and different imaging sessions. These data can be utilised in interventional studies to quantify change within a single imaging session, or to assess the significance of change in longitudinal studies of brain injury and disease.	[Veenith, Tonny V.; Carter, Eleanor; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne G.; Menon, David K.; Coles, Jonathan P.] Univ Cambridge, Div Anaesthesia, Cambridge, Cambs, England; [Lupson, Victoria; Williams, Guy B.] Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, Cambs, England	Coles, JP (corresponding author), Univ Cambridge, Div Anaesthesia, Cambridge, Cambs, England.	jpc44@wbic.cam.ac.uk	Veenith, Tonny/AAI-3067-2020	Veenith, Tonny/0000-0002-4125-8804; Newcombe, Virginia/0000-0001-6044-9035; Outtrim, Joanne/0000-0001-8118-6430	National Institute of Academic Anaesthesia and Raymond Beverly Sackler studentship; NIHRNational Institute for Health Research (NIHR); Wellcome trustWellcome TrustEuropean Commission; Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701532, G0001354B, G1000183B, G9439390, G0001354, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007, NF-SI-0512-10090] Funding Source: researchfish	Dr. TV Veenith was supported by clinical research training fellowship from the National Institute of Academic Anaesthesia and Raymond Beverly Sackler studentship. VFJN is supported by an NIHR academic clinical fellowship. JPC was supported by Wellcome trust project grant. DKM is supported by an NIHR Senior Investigator Award. This work was supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects (G9439390 ID 65883)), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the Technology Platform funding provided by the UK Department of Health. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Alves GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052859; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bisdas S, 2008, AM J NEURORADIOL, V29, P1128, DOI 10.3174/ajnr.A1044; Bozzali M, 2002, J NEUROL NEUROSUR PS, V72, P742, DOI 10.1136/jnnp.72.6.742; Brander A, 2010, ACTA RADIOL, V51, P800, DOI 10.3109/02841851.2010.495351; Cassol E, 2004, MULT SCLER J, V10, P188, DOI 10.1191/1352458504ms997oa; Cercignani M, 2003, AM J NEURORADIOL, V24, P638; Ciccarelli O, 2003, NEUROIMAGE, V19, P1545, DOI 10.1016/S1053-8119(03)00190-3; Ciccarelli O, 2003, NEUROIMAGE, V18, P348, DOI 10.1016/S1053-8119(02)00042-3; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Danielian LE, 2010, NEUROIMAGE, V49, P1572, DOI 10.1016/j.neuroimage.2009.08.062; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; FRISTON KJ, 1995, CLIN NEUROSCI, V3, P89; Hannoun S, 2012, AM J NEURORADIOL, V33, P1363, DOI 10.3174/ajnr.A2983; Heiervang E, 2006, NEUROIMAGE, V33, P867, DOI 10.1016/j.neuroimage.2006.07.037; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Thierry AGM, 2006, EUR RADIOL, V16, P1651, DOI 10.1007/s00330-006-0175-8; Huppertz HJ, 2010, NEUROIMAGE, V49, P2216, DOI 10.1016/j.neuroimage.2009.10.066; Jansen JFA, 2007, INVEST RADIOL, V42, P327, DOI 10.1097/01.rli.0000262757.10271.e5; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; Lemkaddem A, 2012, NEUROIMAGE, V62, P87, DOI 10.1016/j.neuroimage.2012.04.045; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Pfefferbaum A, 2003, J MAGN RESON IMAGING, V18, P427, DOI 10.1002/jmri.10377; Senda J, 2012, J NEUROL SCI, V319, P105, DOI 10.1016/j.jns.2012.04.019; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stamatakis EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014496; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Takao H, 2012, HUM BRAIN MAPP, V33, P466, DOI 10.1002/hbm.21225; Takao H, 2011, HUM BRAIN MAPP, V32, P1762, DOI 10.1002/hbm.21145; Takao H, 2011, NEUROIMAGE, V54, P1053, DOI 10.1016/j.neuroimage.2010.09.023; Teipel SJ, 2011, PSYCHIAT RES-NEUROIM, V194, P363, DOI [10.1016/j.pscychresns2011.05.012, 10.1016/j.pscychresns.2011.05.012]; Vollmar C, 2010, NEUROIMAGE, V51, P1384, DOI 10.1016/j.neuroimage.2010.03.046; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zhu T, 2011, NEUROIMAGE, V56, P1398, DOI 10.1016/j.neuroimage.2011.02.010	43	36	36	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e65941	10.1371/journal.pone.0065941			12	Multidisciplinary Sciences	Science & Technology - Other Topics	174IH	WOS:000321148400008	23840380	DOAJ Gold, Green Published			2021-06-18	
J	Borczuk, P; Penn, J; Peak, D; Chang, YC				Borczuk, Pierre; Penn, Joshua; Peak, David; Chang, Yuchiao			Patients with traumatic subarachnoid hemorrhage are at low risk for deterioration or neurosurgical intervention	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Mild head trauma; subarachnoid hemorrhage; neurosurgical consultation	MINOR HEAD-INJURY; BRAIN-INJURY; COMPUTED-TOMOGRAPHY; UTILITY; CONSULTATION; MANAGEMENT; RULE	BACKGROUND: Current standard of care for patients with traumatic intracranial hemorrhage (TIH) includes neurosurgical consultation and/or transfer to a trauma center with neurosurgical backup. We hypothesize that a set of low-risk criteria can be applied to such patients to identify those who may not require neurosurgical evaluation. METHODS: This is a cross-sectional study of consecutive emergency department patients in 2009 and 2010 with TIH on computerized tomographic scan owing to blunt head trauma. Patients presented to an urban academic Level I trauma center (volume, 92,000) were older than 15 years and had a Glasgow Coma Scale (GCS) score of 13 or greater. Charts were abstracted using a standardized data form by two emergency physicians. Our principal outcome was deterioration represented by a composite of neurosurgical intervention, clinical deterioration, or worsening computerized tomographic scan result. RESULTS: During the study period, 404 patients were seen with TIH and met our inclusion criteria, and 48 of those patients (11.8%) deteriorated. Patients with isolated subarachnoid hemorrhage, were less likely to deteriorate (odds ratio [OR], 0.08; 95% confidence interval [CI], 0.011-0.58). Characteristics associated with deterioration were subdural hematomas (OR, 2.63; 95% CI, 1.198-5.81) or presenting GCS of less than 15 (OR, 2.12; 95% CI, 1.01-4.43). The use of anticoagulant medications or antiplatelet agents were not associated with deterioration for warfarin, aspirin, or clopidogrel; however bleeding diatheses were corrected with vitamin K, fresh frozen plasma, and platelets as necessary. CONCLUSION: Patients with isolated traumatic subarachnoid hemorrhage are at low risk for deterioration. These individuals may not need neurosurgical consultation or transfer to a trauma center where neurosurgical backup is available. Those patients with subdural hematoma or a GCS of less than 15 have a higher risk of deterioration and require neurosurgical evaluation. (Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Borczuk, Pierre; Peak, David] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Chang, Yuchiao] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Borczuk, Pierre; Penn, Joshua; Peak, David] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA; [Penn, Joshua] Winchester Hosp, Dept Emergency Med, Boston, MA USA	Borczuk, P (corresponding author), Massachusetts Gen Hosp, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA.	pborczuk@partners.org					Ashkenazi I, 2007, EMERG MED J, V24, P550, DOI 10.1136/emj.2006.044461; Barker DE, 2006, AM SURGEON, V72, P1166; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Huynh T, 2006, AM SURGEON, V72, P1162; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Trzeciak S, 2003, EMERG MED J, V20, P402, DOI 10.1136/emj.20.5.402; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	19	36	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2013	74	6					1504	1509		10.1097/TA.0b013e31829215cf			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AB4DO	WOS:000331739800018	23694879				2021-06-18	
J	Monti, MM; Pickard, JD; Owen, AM				Monti, Martin M.; Pickard, John D.; Owen, Adrian M.			Visual cognition in disorders of consciousness: From V1 to top-down attention	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; minimally conscious state; consciousness; cognition; fMRI; vision	PERSISTENT VEGETATIVE STATE; HUMAN EXTRASTRIATE CORTEX; EVENT-RELATED FMRI; BEHAVIORAL-ASSESSMENT; MEDICAL ASPECTS; BRAIN ACTIVITY; AWARENESS; ROBUST; AREAS; OPTIMIZATION	What is it like to be at the lower boundaries of consciousness? Disorders of consciousness such as coma, the vegetative state, and the minimally conscious state are among the most mysterious and least understood conditions of the human brain. Particularly complicated is the assessment of residual cognitive functioning and awareness for diagnostic, rehabilitative, legal, and ethical purposes. In this article, we present a novel functional magnetic resonance imaging exploration of visual cognition in a patient with a severe disorder of consciousness. This battery of tests, first developed in healthy volunteers, assesses increasingly complex transformations of visual information along a known caudal to rostral gradient from occipital to temporal cortex. In the first five levels, the battery assesses (passive) processing of light, color, motion, coherent shapes, and object categories (i.e., faces, houses). At the final level, the battery assesses the ability to voluntarily deploy visual attention in order to focus on one of two competing stimuli. In the patient, this approach revealed appropriate brain activations, undistinguishable from those seen in healthy and aware volunteers. In addition, the ability of the patient to focus one of two competing stimuli, and switch between them on command, also suggests that he retained the ability to access, to some degree, his own visual representations. Hum Brain Mapp, 2013. (c) 2012 Wiley Periodicals, Inc.	[Monti, Martin M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Monti, Martin M.; Owen, Adrian M.] MRC, Cognit & Brain Sci Unit, Cambridge, England; [Pickard, John D.] Univ Cambridge, Acad Neurosurg Unit, Cambridge CB2 1TN, England; [Owen, Adrian M.] Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada	Monti, MM (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	monti@psych.ucla.edu	Owen, Adrian M/B-4997-2015; Williams, Jackie/B-3495-2015	Monti, Martin M/0000-0001-5511-3780	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [U.1055.01.002.00007.01, U.1055.01.002.00001.01]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [ICT Programme Project FP7-247919]; James S. McDonnell Foundation Scholar Award; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: researchfish	Contract grant sponsor: Medical Research Council; Contract grant numbers: U.1055.01.002.00007.01 and U.1055.01.002.00001.01; Contract grant sponsor: European Commission; Contract grant number: ICT Programme Project FP7-247919; Contract grant sponsor: James S. McDonnell Foundation Scholar Award.	Bekinschtein TA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00005; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Beauchamp MS, 1999, CEREB CORTEX, V9, P257, DOI 10.1093/cercor/9.3.257; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Bekinschtein TA, 2008, J NEUROL NEUROSUR PS, V79, P826, DOI 10.1136/jnnp.2007.132738; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2009, PROG BRAIN RES, V177, P231, DOI 10.1016/S0079-6123(09)17716-6; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Faugeras F, 2011, NEUROLOGY, V77, P264, DOI 10.1212/WNL.0b013e3182217ee8; Fins JJ, 2008, AM J BIOETHICS, V8, P3, DOI 10.1080/15265160802318113; Giacino JT, 2009, PROG BRAIN RES, V177, P33, DOI 10.1016/S0079-6123(09)17704-X; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giesbrecht B, 2004, CEREB CORTEX, V14, P521, DOI 10.1093/cercor/bhh014; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Hadjikhani N, 1998, NAT NEUROSCI, V1, P235, DOI 10.1038/681; Hampshire A, 2006, CEREB CORTEX, V16, P1679, DOI 10.1093/cercor/bhj116; Henson R, 2005, Q J EXP PSYCHOL-A, V58, P193, DOI 10.1080/02724980443000502; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; JENNETT B, 1972, LANCET, V1, P734; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kircher T, 2009, HUM BRAIN MAPP, V30, P4116, DOI 10.1002/hbm.20833; Kourtzi Z, 2000, J NEUROSCI, V20, P3310, DOI 10.1523/JNEUROSCI.20-09-03310.2000; Lamme VAF, 2010, COGN NEUROSCI-UK, V1, P204, DOI 10.1080/17588921003731586; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; McKeefry DJ, 1997, BRAIN, V120, P2229, DOI 10.1093/brain/120.12.2229; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Monti MM, 2010, J PSYCHOPHYSIOL, V24, P76, DOI 10.1027/0269-8803/a000016; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Monti MM, 2009, PROG BRAIN RES, V177, P249, DOI 10.1016/S0079-6123(09)17717-8; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Monti MM, 2009, ANN NY ACAD SCI, V1157, P81, DOI 10.1111/j.1749-6632.2008.04121.x; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Posner J., 2007, PLUM POSNERS DIAGNOS, V4; PUCE A, 1995, J NEUROPHYSIOL, V74, P1192; Qin PM, 2010, HUM BRAIN MAPP, V31, P1993, DOI 10.1002/hbm.20989; Qin PM, 2008, NEUROSCI LETT, V448, P24, DOI 10.1016/j.neulet.2008.10.029; Reinholz J, 2005, COGNITIVE BRAIN RES, V24, P702, DOI 10.1016/j.cogbrainres.2005.04.009; Rissman J, 2003, J COGNITIVE NEUROSCI, V15, P1160, DOI 10.1162/089892903322598120; Ropper AH, 2010, NEW ENGL J MED, V362, P648, DOI 10.1056/NEJMe0909667; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tong F, 1998, NEURON, V21, P753, DOI 10.1016/S0896-6273(00)80592-9; Tootell RBH, 1998, TRENDS COGN SCI, V2, P174, DOI 10.1016/S1364-6613(98)01171-1; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127	61	36	36	0	45	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2013	34	6					1245	1253		10.1002/hbm.21507			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	129QA	WOS:000317855400001	22287214	Green Published			2021-06-18	
J	Ishihara, Y; Kawami, T; Ishida, A; Yamazaki, T				Ishihara, Yasuhiro; Kawami, Tomohito; Ishida, Atsuhiko; Yamazaki, Takeshi			Allopregnanolone-mediated protective effects of progesterone on tributyltin-induced neuronal injury in rat hippocampal slices	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Neuroprotection; Progesterone; Allopregnanolone; Tributyltin; Hippocampal slices; GABA(A) receptor	OXYGEN-GLUCOSE DEPRIVATION; TRAUMATIC BRAIN-INJURY; ACUTE EXPOSURE; CELL-DEATH; SIGNAL-TRANSDUCTION; GABA(A) RECEPTOR; NEUROSTEROIDS; CULTURES; SYNAPTOGENESIS; EXCITOTOXICITY	Increasing evidence shows that progesterone, a neuroactive steroid, has protective actions in central nervous system, but there is little evidence to show the protective mechanism of progesterone on neurotoxicity induced by environmental chemicals. In this study, we examined the effects of progesterone on neuronal injury induced by tributyltin (TBT) in rat hippocampal slices. Treatment with progesterone dose-dependently suppressed hippocampal neuronal injury induced by TBT. The neuroprotective action of progesterone was completely canceled with pretreatment by finasteride, a 5 alpha-reductase inhibitor, but it was not affected by mifepristone, a progesterone receptor antagonist, or by SU-10603, a cytochrome P450 17 alpha. inhibitor. The content of allopregnanolone in the slices was significantly increased by treatment with progesterone, and this increment was greatly suppressed with a pretreatment of finasteride. Treatment with allopregnanolone attenuated neuronal injury induced by TBT in a dose-dependent manner. The neuroprotective effects not only of progesterone but also of allopregnanolone were canceled by bicuculline, a potent gamma-aminobutyric acid A (GABA(A)) receptor antagonist. Pretreatment with muscimol, a GABA(A) receptor agonist, attenuated hippocampal neuronal injury elicited by TBT. Taken together, allopregnanolone converted from progesterone in hippocampal slices could protect neurons from TBT-induced neurotoxicity due to a GABA(A) receptor-dependent mechanism. One of the physiological roles of neuroactive steroids might be neuroprotection from environmental chemicals. (C) 2012 Elsevier Ltd. All rights reserved.	[Ishihara, Yasuhiro; Kawami, Tomohito; Ishida, Atsuhiko; Yamazaki, Takeshi] Hiroshima Univ, Lab Mol Brain Sci, Grad Sch Integrated Arts & Sci, Higashihiroshima 724, Japan	Yamazaki, T (corresponding author), Hiroshima Univ, Lab Mol Brain Sci, Grad Sch Integrated Arts & Sci, 1-7-1 Kagamiyama, Hiroshima 7398521, Japan.	takey@hiroshima-u.ac.jp	Ishihara, Yasuhiro/U-6511-2017	Ishihara, Yasuhiro/0000-0001-9751-7660	Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22310041] Funding Source: KAKEN	We thank Dr. Eiji Munetsuna, Fujita Health University for technical contributions to the hippocampal slice cultures. This work was supported by Grants-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Ardeshiri A, 2006, EUR J NEUROSCI, V24, P2567, DOI 10.1111/j.1460-9568.2006.05142.x; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Casalbore P, 2010, J CELL PHYSIOL, V224, P710, DOI 10.1002/jcp.22170; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; EMA M, 1991, DRUG CHEM TOXICOL, V14, P161, DOI 10.3109/01480549109017874; EMA M, 1991, NEUROTOXICOL TERATOL, V13, P489, DOI 10.1016/0892-0362(91)90054-Z; Gasior M, 1999, TRENDS PHARMACOL SCI, V20, P107, DOI 10.1016/S0165-6147(99)01318-8; Higashi T, 2007, J CHROMATOGR B, V848, P188, DOI 10.1016/j.jchromb.2006.10.036; Ishihara Y, 2012, NEUROCHEM INT, V60, P782, DOI 10.1016/j.neuint.2012.03.004; Kawato S, 2003, ADV BIOPHYS, V37, P1, DOI 10.1016/S0065-227X(03)80002-3; Koczyk D, 1996, ACTA NEUROBIOL EXP, V56, P237; Le Goascogne C, 2000, GLIA, V29, P14, DOI 10.1002/(SICI)1098-1136(20000101)29:1<14::AID-GLIA2>3.3.CO;2-E; Lee BY, 2005, NEUROSCI RES, V52, P347, DOI 10.1016/j.neures.2005.04.008; Munetsuna E, 2009, ENDOCRINOLOGY, V150, P4260, DOI 10.1210/en.2008-1644; Nakatsu Y, 2006, TOXICOL SCI, V89, P235, DOI 10.1093/toxsci/kfj007; OCALLAGHAN JP, 1988, J PHARMACOL EXP THER, V246, P394; Radley E, 2012, NEUROSCI LETT, V506, P131, DOI 10.1016/j.neulet.2011.10.065; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Romer W, 1997, STEROIDS, V62, P688, DOI 10.1016/S0039-128X(97)00068-8; Sakamoto H, 2001, J NEUROSCI, V21, P6221; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Shibuya K, 2003, BBA-GEN SUBJECTS, V1619, P301, DOI 10.1016/S0304-4165(02)00489-0; Tsuda T, 1995, J AOAC INT, V78, P941; Whalen MM, 1999, ENVIRON RES, V81, P108, DOI 10.1006/enrs.1999.3968	28	36	38	1	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	MAY	2013	135						1	6		10.1016/j.jsbmb.2012.12.013			6	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	117AL	WOS:000316924400001	23280249				2021-06-18	
J	LaFrance, WC; DeLuca, M; Machan, JT; Fava, JL				LaFrance, W. Curt, Jr.; DeLuca, Marie; Machan, Jason T.; Fava, Joseph L.			Traumatic brain injury and psychogenic nonepileptic seizures yield worse outcomes	EPILEPSIA			English	Article						Traumatic brain injury; Nonepileptic seizures; Risk; Depression; Comorbidity	QUALITY-OF-LIFE; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; RECOMMENDATIONS; SEQUELAE; EPILEPSY	Purpose: To investigate the relationship between traumatic brain injury (TBI) and psychogenic nonepileptic seizures (PNES). We hypothesized that PNES with TBI would be associated with more psychiatric comorbidities and disability than PNES without TBI. Methods: In this cross-sectional study comparing patients with PNES with TBI to patients with PNES without TBI, medical records from 255 consecutive patients with electroencephalography (EEG)-confirmed PNES were reviewed to assess variables including demographic, head injury, neurologic, psychiatry, social variables, and quality of life and symptoms scales. Parametric, analysis of covariance (ANCOVA), and logistic regression analyses were performed, to compare psychiatric and function variables between the two study groups while controlling for age and sex. Key Findings: Of the 92 patients with PNES who fulfilled inclusion/exclusion criteria, 41 (44.6%) had a history of TBI. Of the 41 patients with TBI, 30 (73%) met criteria for mild TBI (mTBI). Patients with TBI had more mood disorder diagnoses, were more likely to receive disability, and had lower global functioning than non-TBI patients with PNES, after adjusting for age and sex. Patients with TBI and PNES had significantly increased odds for having major depression, behavioral impulsivity, posttraumatic stress disorder diagnosis, and a trauma/abuse history. Significance: TBI is a significant risk factor in patients with PNES, being associated with increased psychiatric diagnostic comorbidity, symptoms severity, poorer functioning, and increased disability. This study reveals the importance of identifying and addressing the impact of TBI in patients with seizure disorders. Addressing the sequelae of TBI in PNES may be a target to improve functioning.	[LaFrance, W. Curt, Jr.] Rhode Isl Hosp, Dept Neurol, Providence, RI 02903 USA; [LaFrance, W. Curt, Jr.] Rhode Isl Hosp, Dept Psychiat, Providence, RI 02903 USA; [LaFrance, W. Curt, Jr.; DeLuca, Marie] Brown Univ, Dept Neurol, Providence, RI 02912 USA; [LaFrance, W. Curt, Jr.] Brown Univ, Dept Psychiat, Providence, RI 02912 USA; [Machan, Jason T.] Rhode Isl Hosp, Dept Biostat, Providence, RI 02903 USA; [Machan, Jason T.] Brown Univ, Dept Med Orthopaed, Providence, RI 02912 USA; [Fava, Joseph L.] Miriam Hosp, Ctr Behav Med, Providence, RI 02906 USA; [Fava, Joseph L.] Miriam Hosp, Ctr Preventat Med, Providence, RI 02906 USA	LaFrance, WC (corresponding author), Rhode Isl Hosp, 593 Eddy St, Providence, RI 02903 USA.	william_lafrance_jr@brown.edu	Machan, Jason T/D-3897-2013; LaFrance, W Curt/AAN-6707-2021	Machan, Jason T/0000-0003-2048-4914; LaFrance, W Curt/0000-0002-4901-3852; Fava, Joseph/0000-0001-7129-7903	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5K23 NS45902]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS045902] Funding Source: NIH RePORTER	This study was funded in part by the NINDS 5K23 NS45902 (PI: LaFrance). Portions of this manuscript were presented in a poster at the 2010 American Academy of Neurology Annual meeting.	ALPER K, 1993, NEUROLOGY, V43, P1950, DOI 10.1212/WNL.43.10.1950; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bowman ES, 1996, AM J PSYCHIAT, V153, P57; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Duncan R, 2008, NEUROLOGY, V71, P1000, DOI 10.1212/01.wnl.0000326593.50863.21; Dworetzky BA, 2005, EPILEPSIA, V46, P1418, DOI 10.1111/j.1528-1167.2005.13004.x; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; Ettinger AB, 1999, EPILEPSIA, V40, P1292, DOI 10.1111/j.1528-1157.1999.tb00860.x; Gilliam FG, 2006, LANCET NEUROL, V5, P399, DOI 10.1016/S1474-4422(06)70415-X; Goldstein LH, 2010, NEUROLOGY, V74, P1986, DOI 10.1212/WNL.0b013e3181e39658; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Krawetz P, 2001, J NERV MENT DIS, V189, P38, DOI 10.1097/00005053-200101000-00007; LaFrance WC, 2010, NEUROLOGY, V75, P1166, DOI 10.1212/WNL.0b013e3181f4d5a9; LaFrance WC, 2009, NEUROLOGY, V73, P366, DOI 10.1212/WNL.0b013e3181b04c83; LaFrance WC, 2009, EPILEPSY BEHAV, V14, P591, DOI 10.1016/j.yebeh.2009.02.016; LaFrance WC, 2006, NEUROLOGY, V66, P1620, DOI 10.1212/01.wnl.0000224953.94807.be; LaFrance WC, 2002, EPILEPSY BEHAV, V3, pS19, DOI 10.1016/S1525-5069(02)00505-4; Mokleby K, 2002, EPILEPSIA, V43, P193, DOI 10.1046/j.1528-1157.2002.20901.x; National Center for Prevention and Control, 2003, C MILD TRAUM BRAIN I; Nicholl J, 2009, SEMIN NEUROL, V29, P247, DOI 10.1055/s-0029-1223878; Pakalnis A, 2000, J CHILD NEUROL, V15, P78, DOI 10.1177/088307380001500202; Reuber M, 2002, EPILEPSY BEHAV, V3, P249, DOI 10.1016/S1525-5050(02)00004-5; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Salinsky M, 2011, NEUROLOGY, V77, P945, DOI 10.1212/WNL.0b013e31822cfc46; Szaflarski JP, 2003, EPILEPSIA, V44, P236, DOI 10.1046/j.1528-1157.2003.35302.x; Task Force on DSM-IVTR, 2000, DIAGN STAT MAN MENT; Testa SM, 2007, EPILEPSIA, V48, P973, DOI 10.1111/j.1528-1167.2006.00965.x; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267; Vickrey BG, 1993, QUALITY LIFE EPILEPS; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa	38	36	36	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	APR	2013	54	4					718	725		10.1111/epi.12053			8	Clinical Neurology	Neurosciences & Neurology	117PL	WOS:000316965500021	23281644	Bronze			2021-06-18	
J	Valiyaveettil, M; Alamneh, YA; Miller, SA; Hammamieh, R; Arun, P; Wang, Y; Wei, YL; Oguntayo, S; Long, JB; Nambiar, MP				Valiyaveettil, Manojkumar; Alamneh, Yonas A.; Miller, Stacey-Ann; Hammamieh, Rasha; Arun, Peethambaran; Wang, Ying; Wei, Yanling; Oguntayo, Samuel; Long, Joseph B.; Nambiar, Madhusoodana P.			Modulation of cholinergic pathways and inflammatory mediators in blast-induced traumatic brain injury	CHEMICO-BIOLOGICAL INTERACTIONS			English	Article; Proceedings Paper	International Meeting on Cholinesterases	JUN 04-09, 2012	Kazan, RUSSIA			Repeated blast exposure; Cholinergic pathway; Inflammation; Acetylcholinisterase; Micro RNA; Traumatic brain injury	ANTIINFLAMMATORY PATHWAY; ACETYLCHOLINESTERASE ACTIVITY; LUNG TRAUMA; STRESS; MODEL; BLOOD; MICRORNAS; EXPOSURE; MOUSE; RATS	Cholinergic activity has been recognized as a major regulatory component of stress responses after traumatic brain injury (TB!). Centrally acting acetylcholinesterase (AChE) inhibitors are also being considered as potential therapeutic candidates against TBI mediated cognitive impairments. We have evaluated the expression of molecules involved in cholinergic and inflammatory pathways in various regions of brain after repeated blast exposures in mice. Isoflurane anesthetized C57BL/6J mice were restrained and placed in a prone position transverse to the direction of the shockwaves and exposed to three 20.6 psi blast overpressures with 1-30 min intervals. Brains were collected at the 6 h time point after the last blast exposure and subjected to cDNA microarray and microRNA analysis. cDNA microarray analysis showed significant changes in the expression of cholinergic (muscarinic and nicotinic) and gammaaminobutyric acid and glutamate receptors in the midbrain region along with significant changes in multiple genes involved in inflammatory pathways in various regions of the brain. MicroRNA analysis of cerebellum revealed differential expression of miR-132 and 183, which are linked to cholinergic anti-inflammatory signaling, after blast exposure. Changes in the expression of myeloperoxidase in the cerebellum were confirmed by Western blotting. These results indicate that early pathologic progression of blast TBI involves dysregulation of cholinergic and inflammatory pathways related genes. Acute changes in molecules involved in the modulation of cholinergic and inflammatory pathways after blast TBI can cause long-term central and peripheral pathophysiological changes. (C) 2012 Published by Elsevier Ireland Ltd.	[Valiyaveettil, Manojkumar; Alamneh, Yonas A.; Arun, Peethambaran; Wang, Ying; Wei, Yanling; Oguntayo, Samuel; Long, Joseph B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Miller, Stacey-Ann; Hammamieh, Rasha] USA, Ctr Environm Hlth Res, Med Res & Mat Command, Ft Detrick, MD 21702 USA	Valiyaveettil, M (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA.	m.valiyaveettil@amedd.army.mil; madhu-soodana.nambiar@amedd.army.mil					AUGUSTINSSON KB, 1978, CLIN CHIM ACTA, V89, P239, DOI 10.1016/0009-8981(78)90322-4; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Czura CJ, 2003, J ENDOTOXIN RES, V9, P409, DOI 10.1179/096805103225002755; Dalle Lucca Jurandir J, 2012, J Neurol Sci, V318, P146, DOI 10.1016/j.jns.2012.02.002; DONOVAN DA, 1994, J WILDLIFE DIS, V30, P234, DOI 10.7589/0090-3558-30.2.234; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fujiki M, 2008, J CLIN NEUROSCI, V15, P791, DOI 10.1016/j.jocn.2007.07.002; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gorbunov NV, 2006, EXP MOL PATHOL, V80, P11, DOI 10.1016/j.yexmp.2005.06.007; Gorbunov NV, 2005, INT J IMMUNOPATH PH, V18, P547, DOI 10.1177/039463200501800315; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Martinez N, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-44; Meerson A, 2010, J MOL NEUROSCI, V40, P47, DOI 10.1007/s12031-009-9252-1; Meshorer E, 2005, MOL PSYCHIATR, V10, P985, DOI 10.1038/sj.mp.4001735; Meshorer E, 2006, TRENDS NEUROSCI, V29, P216, DOI 10.1016/j.tins.2006.02.005; Pavlov VA, 2006, BIOCHEM SOC T, V34, P1037, DOI 10.1042/BST0341037; Pavlov VA, 2005, BRAIN BEHAV IMMUN, V19, P493, DOI 10.1016/j.bbi.2005.03.015; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Ropper A, 2011, NEW ENGL J MED, V364, P2156, DOI 10.1056/NEJMe1102187; Shaked I, 2009, IMMUNITY, V31, P965, DOI 10.1016/j.immuni.2009.09.019; Soreq H, 2011, TRENDS MOL MED, V17, P548, DOI 10.1016/j.molmed.2011.06.009; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Valiyaveettil M, 2012, NEUROSCI LETT, V506, P141, DOI 10.1016/j.neulet.2011.10.067; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990	31	36	39	0	20	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0009-2797	1872-7786		CHEM-BIOL INTERACT	Chem.-Biol. Interact.	MAR 25	2013	203	1			SI		371	375		10.1016/j.cbi.2012.10.022			5	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	134HU	WOS:000318201800074	23159883				2021-06-18	
J	Hendrix, S; Kramer, P; Pehl, D; Warnke, K; Boato, F; Nelissen, S; Lemmens, E; Pejler, G; Metz, M; Siebenhaar, F; Maurer, M				Hendrix, Sven; Kramer, Peter; Pehl, Debora; Warnke, Katharina; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi; Pejler, Gunnar; Metz, Martin; Siebenhaar, Frank; Maurer, Marcus			Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4	FASEB JOURNAL			English	Article						entorhinal cortex lesion; mMCP-4; protease; T cells	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; CEREBRAL-ISCHEMIA; EARLY RESPONDERS; MICE; ACTIVATION; PROTEASES; BIOLOGY; MOUSE	Mast cells (MCs) are found abundantly in the brain and the meninges and play a complex role in neuroinflammatory diseases, such as stroke and multiple sclerosis. Here, we show that MC-deficient Kit(W)/Kit(W-v) mice display increased neurodegeneration in the lesion area after brain trauma. Furthermore, MC-deficient mice display significantly more brain inflammation, namely an increased presence of macrophages/microglia, as well as dramatically increased T-cell infiltration at days 4 and 14 after injury, combined with increased astrogliosis at day 14 following injury. The number of proliferating Ki67(+) macrophages/microglia and astrocytes around the lesion area is more than doubled in these MC-deficient mice. In parallel, MC-deficient Kit(W-sh/W-sh) mice display increased presence of macrophages/microglia at day 4, and persistent astrogliosis at day 4 and 14 after brain trauma. Further analysis of mice deficient in one of the most relevant MC proteases, i.e., mouse mast cell protease 4 (mMCP-4), revealed that astrogliosis and T-cell infiltration are significantly increased in mMCP-4-knockout mice. Finally, treatment with an inhibitor of mMCP-4 significantly increased macrophage/microglia numbers and astrogliosis. These data suggest that MCs exert protective functions after trauma, at least in part via mMCP-4, by suppressing exacerbated inflammation via their proteases.-Hendrix, S., Kramer, P., Pehl, D., Warnke, K., Boato, F., Nelissen, S., Lemmens, E., Pejler, G., Metz, M., Siebenhaar, F., Maurer, M. Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4. FASEB J. 27, 920-929 (2013). www.fasebj.org	[Hendrix, Sven; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi] Hasselt Univ, Dept Morphol, Diepenbeek, Belgium; [Hendrix, Sven; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi] Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium; [Kramer, Peter; Pehl, Debora; Warnke, Katharina] Charite, Ctr Anat Cell Biol & Neurobiol, D-13353 Berlin, Germany; [Metz, Martin; Siebenhaar, Frank; Maurer, Marcus] Charite, Dept Dermatol, D-13353 Berlin, Germany; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden	Hendrix, S (corresponding author), Dept Morphol, Agoralaan Gebouw D, BE-3590 Diepenbeek, Belgium.	sven.hendrix@uhasselt.be	Metz, Martin/B-8799-2009; Metz, Martin/M-5237-2013; Hendrix, Sven/F-4059-2010	Metz, Martin/0000-0002-4070-9976; Metz, Martin/0000-0002-4070-9976; Hendrix, Sven/0000-0003-2344-7369; Kramer, Peter/0000-0003-4780-5271; Lemmens, Evi/0000-0001-6044-5659; Siebenhaar, Frank/0000-0003-4532-1644; Maurer, Marcus/0000-0002-4121-481X; Boato, Francesco/0000-0001-9741-8021	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SPP1394]; Fonds Wetenschappelijk Onderzoek-VlaanderenFWO [G.0834.11N, G.0389.12]	The authors are indebted to Doreen Ludecke and Julia Konig for their engaged and skillful technical assistance, to Nathalie Geurts for performing the FACS analyses and to Dearbhaile Dooley for editing the text. P.K. was a member of GRK1258. This study was supported in part by grants from Deutsche Forschungsgemeinschaft (SPP1394) and from Fonds Wetenschappelijk Onderzoek-Vlaanderen (G.0834.11N, G.0389.12) to S.H. The authors declare no conflicts of interests.	Bennett JL, 2009, J IMMUNOL, V182, P5507, DOI 10.4049/jimmunol.0801485; Berghmans N, 2011, J INTERF CYTOK RES, V31, P575, DOI 10.1089/jir.2010.0137; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Brown MA, 2002, MOL IMMUNOL, V38, P1373, DOI 10.1016/S0161-5890(02)00091-3; Caughey GH, 2011, ADV EXP MED BIOL, V716, P212, DOI 10.1007/978-1-4419-9533-9_12; Del Turco D, 2003, HIPPOCAMPUS, V13, P685, DOI 10.1002/hipo.10118; DROPP JJ, 1972, ANAT REC, V174, P227, DOI 10.1002/ar.1091740207; Dumitru CA, 2012, CANCER IMMUNOL IMMUN, V61, P1155, DOI 10.1007/s00262-012-1294-5; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hendrix S, 2006, NEUROSCI LETT, V392, P174, DOI 10.1016/j.neulet.2005.09.029; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x; Jin YX, 2009, STROKE, V40, P3107, DOI 10.1161/STROKEAHA.109.549691; Kwidzinski E, 2003, J NEURAL TRANSM-SUPP, P29, DOI 10.1007/978-3-7091-0643-3_2; Li HM, 2011, J IMMUNOL, V187, P274, DOI 10.4049/jimmunol.1003603; Lindsberg PJ, 2010, J CEREBR BLOOD F MET, V30, P689, DOI 10.1038/jcbfm.2009.282; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; Manni L, 1998, INT J DEV NEUROSCI, V16, P1, DOI 10.1016/S0736-5748(98)00003-3; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Piconese S, 2011, LAB INVEST, V91, P627, DOI 10.1038/labinvest.2011.3; Robbie-Ryan M, 2003, J IMMUNOL, V170, P1630, DOI 10.4049/jimmunol.170.4.1630; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Skaper SD, 2001, J NEUROCHEM, V76, P47, DOI 10.1046/j.1471-4159.2001.00008.x; Skaper SD, 1996, J NEUROCHEM, V66, P1157; Strbian D, 2007, J CEREBR BLOOD F MET, V27, P795, DOI 10.1038/sj.jcbfm.9600387; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Strbian D, 2009, ANN MED, V41, P438, DOI 10.1080/07853890902887303; Taiwo OB, 2005, PAIN, V114, P131, DOI 10.1016/j.pain.2004.12.002; Tanzola MB, 2003, J IMMUNOL, V171, P4385, DOI 10.4049/jimmunol.171.8.4385; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Waskow C, 2004, BLOOD, V104, P1688, DOI 10.1182/blood-2004-04-1247; Zappulla JP, 2002, J NEUROIMMUNOL, V131, P5, DOI 10.1016/S0165-5728(02)00250-3; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	38	36	38	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					920	929		10.1096/fj.12-204800			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	WOS:000315585200008	23193170				2021-06-18	
J	Franceschini, M; Rampello, A; Agosti, M; Massucci, M; Bovolenta, F; Sale, P				Franceschini, Marco; Rampello, Anais; Agosti, Maurizio; Massucci, Maurizio; Bovolenta, Federica; Sale, Patrizio			Walking Performance: Correlation between Energy Cost of Walking and Walking Participation. New Statistical Approach Concerning Outcome Measurement	PLOS ONE			English	Article							COMMUNITY AMBULATION; STROKE PATIENTS; LEVEL WALKING; OLDER-ADULTS; GAIT; REHABILITATION; POPULATION; PARAMETERS; MOBILITY; INJURY	Walking ability, though important for quality of life and participation in social and economic activities, can be adversely affected by neurological disorders, such as Spinal Cord Injury, Stroke, Multiple Sclerosis or Traumatic Brain Injury. The aim of this study is to evaluate if the energy cost of walking (CW), in a mixed group of chronic patients with neurological diseases almost 6 months after discharge from rehabilitation wards, can predict the walking performance and any walking restriction on community activities, as indicated by Walking Handicap Scale categories (WHS). One hundred and seven subjects were included in the study, 31 suffering from Stroke, 26 from Spinal Cord Injury and 50 from Multiple Sclerosis. The multivariable binary logistical regression analysis has produced a statistical model with good characteristics of fit and good predictability. This model generated a cut-off value of. 40, which enabled us to classify correctly the cases with a percentage of 85.0%. Our research reveal that, in our subjects, CW is the only predictor of the walking performance of in the community, to be compared with the score of WHS. We have been also identifying a cut-off value of CW cost, which makes a distinction between those who can walk in the community and those who cannot do it. In particular, these values could be used to predict the ability to walk in the community when discharged from the rehabilitation units, and to adjust the rehabilitative treatment to improve the performance.	[Franceschini, Marco; Sale, Patrizio] IRCCS San Raffale, Dept NeuroRehabilitat, Rome, Italy; [Rampello, Anais; Agosti, Maurizio] Univ Hosp, Dept Rehabil, Parma, Italy; [Massucci, Maurizio] Hosp Passignano, Rehabil Unit, Perugia, Italy; [Bovolenta, Federica] Med Rehabil NOCSAE Hosp AUSL Modena, Modena, Italy	Sale, P (corresponding author), IRCCS San Raffale, Dept NeuroRehabilitat, Rome, Italy.	patrizio.sale@gmail.com	Sale, Patrizio/J-3276-2019; Sale, Patrizio/K-8757-2016	Sale, Patrizio/0000-0002-4850-3673; Sale, Patrizio/0000-0002-4850-3673; Franceschini, Marco/0000-0002-2131-1583; Agosti, Maurizio/0000-0003-2365-3488			BAMBER D, 1975, J MATH PSYCHOL, V12, P387, DOI 10.1016/0022-2496(75)90001-2; Barbeau H, 2001, CURR OPIN NEUROL, V14, P735, DOI 10.1097/00019052-200112000-00009; Bernardi M, 1999, J ELECTROMYOGR KINES, V9, P149, DOI 10.1016/S1050-6411(98)00046-7; Blessey R L, 1976, Phys Ther, V56, P1019; Bregman DJJ, 2010, PROSTHET ORTHOT INT, V34, P293, DOI 10.3109/03093646.2010.495969; Corrigan R, 2008, DISABIL REHABIL, V30, P1079, DOI 10.1080/09638280701623158; Cunha IT, 2002, AM J PHYS MED REHAB, V81, P848, DOI 10.1097/00002060-200211000-00008; Delextrat A, 2011, HUM MOVEMENT SCI, V30, P115, DOI 10.1016/j.humov.2010.10.004; Duffy CM, 1997, DEV MED CHILD NEUROL, V39, P234; Eriksson JS, 2012, EUR J APPL PHYSIOL, V112, P345, DOI 10.1007/s00421-011-1985-1; Finlayson ML, 2010, PHYS MED REH CLIN N, V21, P357, DOI 10.1016/j.pmr.2009.12.003; Franceschini M, 2003, CLIN REHABIL, V17, P368, DOI 10.1191/0269215503cr622oa; Ijzerman MJ, 2002, ARCH PHYS MED REHAB, V83, P1777, DOI 10.1053/apmr.2002.35655; Kelly JO, 2003, ARCH PHYS MED REHAB, V84, P1780, DOI 10.1016/S0003-9993(03)00376-9; Lapointe R, 2001, SPINAL CORD, V39, P327, DOI 10.1038/sj.sc.3101167; Lord SE, 2004, ARCH PHYS MED REHAB, V85, P234, DOI 10.1016/j.apmr.2003.05.002; Maclean N, 2000, SOC SCI MED, V50, P495; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; Mudge S, 2009, ARCH PHYS MED REHAB, V90, P296, DOI 10.1016/j.apmr.2008.07.025; Pang MYC, 2007, PHYS THER, V87, P282, DOI 10.2522/ptj.20060142; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Peyrot N, 2009, J APPL PHYSIOL, V106, P1763, DOI 10.1152/japplphysiol.91240.2008; Rosdahl H, 2010, EUR J APPL PHYSIOL, V109, P159, DOI 10.1007/s00421-009-1326-9; SCHAFER H, 1989, STAT MED, V8, P1381, DOI 10.1002/sim.4780081110; Shumway-Cook A, 2002, PHYS THER, V82, P670, DOI 10.1093/ptj/82.7.670; Snook EM, 2009, NEUROREHAB NEURAL RE, V23, P108, DOI 10.1177/1545968308320641; van de Port IG, 2008, J REHABIL MED, V40, P23, DOI 10.2340/16501977-0114; van Hedel HJA, 2010, RESTOR NEUROL NEUROS, V28, P123, DOI 10.3233/RNN-2010-0508; WATERS R L, 1983, Journal of Orthopaedic Research, V1, P73, DOI 10.1002/jor.1100010110; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P756; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; World Health Organization/Regional Office for Europe. Vienna Declaration on Nutrition and Noncommunicable Diseases in the Context of Health, 2013, WHO EUR MIN C NUTR N, P5, DOI [DOI 10.1136/BMJ.F4417, 10.1136/bmj.f4417]; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zamparo P., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P348; Zamparo P, 1998, SCAND J MED SCI SPOR, V8, P222; ZWEIG MH, 1993, CLIN CHEM, V39, P561	37	36	36	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e56669	10.1371/journal.pone.0056669			8	Multidisciplinary Sciences	Science & Technology - Other Topics	098DA	WOS:000315524900030	23468871	DOAJ Gold, Green Published			2021-06-18	
J	Cruse, D; Thibaut, A; Demertzi, A; Nantes, JC; Bruno, MA; Gosseries, O; Vanhaudenhuyse, A; Bekinschtein, TA; Owen, AM; Laureys, S				Cruse, Damian; Thibaut, Aurore; Demertzi, Athena; Nantes, Julia C.; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bekinschtein, Tristan A.; Owen, Adrian M.; Laureys, Steven			Actigraphy assessments of circadian sleep-wake cycles in the Vegetative and Minimally Conscious States	BMC MEDICINE			English	Article						Vegetative State; Minimally Conscious State; circadian rhythms; sleep; actigraphy	BRAIN; NEUROPATHOLOGY; RHYTHMS; VARIABILITY; DISORDERS; AWARENESS; INJURY; LIGHT	Background: The Vegetative and Minimally Conscious States (VS; MCS) are characterized by absent or highly disordered signs of awareness alongside preserved sleep-wake cycles. According to international diagnostic guidelines, sleep-wake cycles are assessed by means of observations of variable periods of eye-opening and eye-closure. However, there is little empirical evidence for true circadian sleep-wake cycling in these patients, and there have been no large-scale investigations of the validity of this diagnostic criterion. Methods: We measured the circadian sleep-wake rhythms of 55 VS and MCS patients by means of wrist actigraphy, an indirect method that is highly correlated with polysomnographic estimates of sleeping/waking. Results: Contrary to the diagnostic guidelines, a significant proportion of patients did not exhibit statistically reliable sleep-wake cycles. The circadian rhythms of VS patients were significantly more impaired than those of MCS patients, as were the circadian rhythms of patients with non-traumatic injuries relative to those with traumatic injuries. The reliability of the circadian rhythms were significantly predicted by the patients' levels of visual and motor functioning, consistent with the putative biological generators of these rhythms. Conclusions: The high variability across diagnoses and etiologies highlights the need for improved guidelines for the assessment of sleep-wake cycles in VS and MCS, and advocates the use of actigraphy as an inexpensive and non-invasive alternative.	[Cruse, Damian; Nantes, Julia C.; Owen, Adrian M.] Univ Western Ontario, Brain & Mind Inst, London, ON N6A 3K7, Canada; [Thibaut, Aurore; Demertzi, Athena; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Hosp, Dept Neurol, Coma Sci Grp, B-4000 Sart Tilman Par Liege, Belgium; [Thibaut, Aurore; Demertzi, Athena; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Hosp, Cyclotron Res Ctr, B-4000 Sart Tilman Par Liege, Belgium; [Thibaut, Aurore; Demertzi, Athena; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Liege, B-4000 Sart Tilman Par Liege, Belgium; [Bekinschtein, Tristan A.] MRC, Cognit & Brain Sci Unit, Cambridge CB2 7EF, England	Cruse, D (corresponding author), Univ Western Ontario, Brain & Mind Inst, 1151 Richmond St, London, ON N6A 3K7, Canada.	dcruse@uwo.ca	Owen, Adrian M/B-4997-2015; Vanhaudenhuyse, Audrey/AAP-2455-2020; Demertzi, Athena/I-1251-2019; Thibaut, Aurore/U-8101-2019; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020; Williams, Jackie/B-3495-2015	Demertzi, Athena/0000-0001-8021-3759; Laureys, Steven/0000-0002-3096-3807; Gosseries, Olivia/0000-0001-9011-7496; Bekinschtein, Tristan/0000-0001-5501-8628	European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Fonds de la Recherche ScientifiqueFonds de la Recherche Scientifique - FNRS; Mind Science Foundation; Belgian French-Speaking Community Concerted Research Action; University Hospital of Liege; University of LiegeUniversity of Liege; Wellcome TrustWellcome TrustEuropean Commission; Canada Excellence Research Chair Programme (CERC); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	This research was supported by generous funding from the European Commission, Fonds de la Recherche Scientifique, the Mind Science Foundation, the Belgian French-Speaking Community Concerted Research Action, University Hospital of Liege, University of Liege, the Wellcome Trust, the Canada Excellence Research Chair Programme (CERC), and the Canadian Institutes of Health Research (CIHR).	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adams JH, 1992, GREENFIELDS NEUROPAT; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Ancoli-Israel S, 2002, J AM GERIATR SOC, V50, P282, DOI 10.1046/j.1532-5415.2002.50060.x; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bekinschtein TA, 2009, BRAIN INJURY, V23, P915, DOI 10.1080/02699050903283197; Bekinschtein T, 2009, PROG BRAIN RES, V177, P171, DOI 10.1016/S0079-6123(09)17712-9; Berger AM, 2008, J PAIN SYMPTOM MANAG, V36, P191, DOI 10.1016/j.jpainsymman.2007.10.008; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; BROWN A, 1990, PROG CLIN BIOL RES, V341, P77; CAMPBELL SS, 1988, PHYSIOL BEHAV, V42, P141, DOI 10.1016/0031-9384(88)90289-2; Candelieri A, 2011, J NEUROTRAUM, V28, P2013, DOI 10.1089/neu.2011.1885; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; de Souza L, 2003, SLEEP, V26, P81, DOI 10.1093/sleep/26.1.81; De Weer AS, 2011, EUR J NEUROL, V18, P1432, DOI 10.1111/j.1468-1331.2011.03477.x; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Fukudome Y, 1996, AM J PHYSIOL-REG I, V270, pR1109; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Guan J, 2011, J INT MED RES, V39, P2281, DOI 10.1177/147323001103900625; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; Jean-Louis G, 2000, PHYSIOL BEHAV, V68, P347, DOI 10.1016/S0031-9384(99)00186-9; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Landsness E, 2011, BRAIN, V134, P2222, DOI 10.1093/brain/awr152; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Oksenberg A, 2000, SLEEP, V23, P953; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pattoneri Paolo, 2005, J Clin Hypertens (Greenwich), V7, P734, DOI 10.1111/j.1524-6175.2005.04780.x; Refinetti R, 2006, CIRCADIAN PHYSL; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Shochat T, 2000, J SLEEP RES, V9, P373, DOI 10.1046/j.1365-2869.2000.00221.x; Spivak E, 2007, SPINAL CORD, V45, P765, DOI 10.1038/sj.sc.3102040; Veasey SC, 2004, SLEEP, V27, P194, DOI 10.1093/sleep/27.2.194	44	36	37	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	JAN 24	2013	11								18	10.1186/1741-7015-11-18			11	Medicine, General & Internal	General & Internal Medicine	137HJ	WOS:000318426000001	23347467	DOAJ Gold, Green Published			2021-06-18	
S	Beauchamp, MH; Anderson, V		Dulac, O; Lassonde, M; Sarnat, HB		Beauchamp, M. H.; Anderson, V.			Cognitive and psychopathological sequelae of pediatric traumatic brain injury	PEDIATRIC NEUROLOGY, PT II	Handbook of Clinical Neurology		English	Article; Book Chapter							EXECUTIVE FUNCTIONS; PERSONALITY-CHANGE; SKILLS; CHILDREN; PREDICTORS; ADOLESCENTS; OUTCOMES; MIND; DISORDER		[Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, M. H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Anderson, V.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, V.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, V.] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia	Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Ayr LK, 2005, J INT NEUROPSYCH SOC, V11, P249, DOI 10.1017/S1355617705050307; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Kenny DT, 2007, COMTEMPORARY ISSUES, V107, P1; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Morgan AT, 2010, CHILD CARE HLTH DEV, V36, P44, DOI 10.1111/j.1365-2214.2009.00961.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nybo T, 2005, ACTA NEUROL SCAND, V112, P338, DOI 10.1111/j.1600-0404.2005.00489.x; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; RUTTER M, 1983, DEV NEUROPSYCHIATRY; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; TEASDALE G, 1974, LANCET, V2, P81; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Verger K, 2000, BRAIN INJURY, V14, P495; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535	39	36	36	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0072-9752		978-0-444-62699-8; 978-0-444-52910-7	HAND CLINIC			2013	112						913	920					8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	BA6KI	WOS:000337167400015	23622301				2021-06-18	
J	Cheong, CU; Chang, CP; Chao, CM; Cheng, BC; Yang, CZ; Chio, CC				Cheong, Chong-Un; Chang, Ching-Ping; Chao, Chien-Ming; Cheng, Bor-Chih; Yang, Chung-Zhing; Chio, Chung-Ching			Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-alpha Contents and by Stimulating Newly Formed Neurogenesis	MEDIATORS OF INFLAMMATION			English	Article							NECROSIS-FACTOR-ALPHA; ADULT-RAT; HIPPOCAMPAL NEUROGENESIS; NEURONAL DIFFERENTIATION; CELL-PROLIFERATION; DENTATE GYRUS; EXPRESSION; DOUBLECORTIN; INFLAMMATION; CONTRIBUTES	It remains unclear whether etanercept penetrates directly into the contused brain and improves the outcomes of TBI by attenuating brain contents of TNF-alpha and/or stimulating newly formed neurogenesis. Rats that sustained TBI are immediately treated with etanercept. Acute neurological and motor injury is assessed in all rats the day prior to and 7 days after surgery. The numbers of the colocalizations of 5-bromodeoxyuridine and doublecortin specific markers in the contused brain injury that occurred during TBI were counted by immunofluorescence staining. Enzyme immunoassay for quantitative determination of TNF-alpha or etanercept in brain tissues is also performed. Seven days after systemic administration of etanercept, levels of etanercept can be detected in the contused brain tissues. In addition, neurological and motor deficits, cerebral contusion, and increased brain TNF-alpha contents caused by TBI can be attenuated by etanercept therapy. Furthermore, the increased numbers of the colocalizations of 5-bromodeoxyuridine and doublecortin specific markers in the contused brain tissues caused by TBI can be potentiated by etanercept therapy. These findings indicate that systemically administered etanercept may penetrate directly into the contused brain tissues and may improve outcomes of TBI by reducing brain contents of TNF-alpha and by stimulating newly formed neurogenesis.	[Cheong, Chong-Un; Chao, Chien-Ming] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan; [Chang, Ching-Ping; Cheng, Bor-Chih] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Chao, Chien-Ming; Cheng, Bor-Chih; Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Yang, Chung-Zhing] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei 110, Taiwan	Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan.	ccchio.ns@gmail.com	Bilfinger, Thomas V./J-6392-2019		National Science CouncilMinistry of Science and Technology, Taiwan [NSC90-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, NSC101-2314-B-218-001-MY3]; Department of Health, the Center of Excellence for Clinical Trial and Research in Neuroscience of the Republic of China [DOH99-TD-B-111-003]	This work was supported in part by the National Science Council (Grant nos. NSC90-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, and NSC101-2314-B-218-001-MY3) and the Department of Health, the Center of Excellence for Clinical Trial and Research in Neuroscience of the Republic of China (Grant no. DOH99-TD-B-111-003).	Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Campbell S, 2007, T I MET FINISH, V85, P6, DOI 10.1179/imf.2007.85.1.6; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Jiang Y, 2008, NEUROBIOL DIS, V32, P125, DOI 10.1016/j.nbd.2008.06.017; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Liu YP, 2005, BRAIN RES, V1054, P152, DOI 10.1016/j.brainres.2005.06.085; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Parent JM, 1997, J NEUROSCI, V17, P3727; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Wang Y, 1997, J NEUROSCI, V17, P4341; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	39	36	40	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2013	2013								620837	10.1155/2013/620837			9	Cell Biology; Immunology	Cell Biology; Immunology	141PJ	WOS:000318736800001	23710117	DOAJ Gold, Green Published			2021-06-18	
J	Hours, M; Chossegros, L; Charnay, P; Tardy, H; Nhac-Vu, HT; Boisson, D; Luaute, J; Laumon, B				Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Boisson, Dominique; Luaute, Jacques; Laumon, Bernard			Outcomes one year after a road accident: Results from the ESPARR cohort	ACCIDENT ANALYSIS AND PREVENTION			English	Article						ESPARR; France; Cohort study; One year follow-up; Road accident; Outcome	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; FOLLOW-UP; TRAFFIC ACCIDENTS; MAJOR TRAUMA; PSYCHOLOGICAL TRAUMA; SOCIAL-CONSEQUENCES; IMPROVES ACCURACY; SEVERITY SCORE	Objective: Reducing the rates of death, trauma and sequelae associated with road accidents is the prime goal of road safety authorities, and success requires having data on victims' outcomes in the long term. The present study examined the outcome of adult road accident victims one year after their accident. Design: A follow-up study. Methods: The cohort comprised 886 injured road-accident victims, aged >= 16 years, and living in the Rhone administrative Departement, France (taken from the ESPARR Cohort). Data were collected on victim characteristics at the time of crash, and self-reported outcomes one year later. The population of respondents at the one-year questionnaire follow-up was divided into two categories according to injury severity, as mild-to-moderate (M.AIS <3) or severe (M.AIS 3+). Qualitative variables were compared between these 2 groups using Chi(2) or Fisher exact tests. Results: At one year post-accident, 45% of the mild-to-moderate injury group versus only 20% of severely injured subjects reported full recovery of health (p <0.001). 20% of the cohort, as a whole, reported permanent pain. More than half of the severely injured subjects reported that the accident had had an impact on the everyday life of their family; this was twice as many as in the mild-to-moderate injury group (55% vs. 22%). Most of the severely injured reported impact on leisure, projects and emotional life: 20% reported relational difficulties in the couple, 16% reported impaired sexual life, and the rate of separation was significantly higher than in the mild-to-moderate injury group (5% vs. 1%; p <0.001). Mean time off work was significantly longer in the severe injury group: 245 +/- 158 days vs. 75 +/- 104 days (p <0.001); and 32% of the severe injury group (p <0.001) who had stopped work had not returned at 1 year, compared to 5% of the mild-to-moderate injury group. Conclusions: One year after a road accident, the consequences for victims remain significant. In terms of physical impact, pain frequently persists, impairing daily life for many. There is an elevated rate of chronic PTSD (post-traumatic stress disorder) and a non-negligible impact on affective and occupational life. (C) 2012 Elsevier Ltd. All rights reserved.	[Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Boisson, Dominique; Luaute, Jacques; Laumon, Bernard] Univ Lyon, F-69622 Lyon, France; [Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Laumon, Bernard] IFSTTAR, UMRESTTE, F-69675 Bron, France; [Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Laumon, Bernard] Univ Lyon 1, UMRESTTE, F-69373 Lyon, France; [Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Laumon, Bernard] Henry Gabrielle Hosp, Hosp Civils Lyon, Rehabil & Phys Med Unit, F-69230 St Genis Laval, France	Hours, M (corresponding author), IFSTTAR, UMRESTTE, 25 Ave Francois Mitterrand, F-69675 Bron, France.	martine.hours@ifsttar.fr; laetitia.chossegros@ifsttar.fr; pierrette.charnay@ifsttar.fr; helene.tardy@ifsttar.fr; vu.hoang-thy-nhac@ifsttar.fr; dominique.boisson@chu-lyon.fr; jacques.luaute@chu-lyon.fr; bernard.laumon@ifsttar.fr	TARDY, HELENE/AAE-6287-2019; Luaute, jacques/H-4618-2017	TARDY, HELENE/0000-0001-8351-9825; Luaute, jacques/0000-0002-6387-9572			*AAAM, 1990, ABBR INJ SCAL 1990 R, P74; Amoros E, 2006, ACCIDENT ANAL PREV, V38, P627, DOI 10.1016/j.aap.2005.11.006; ANDERSSON AL, 1994, SCAND J SOC MED, V22, P299, DOI 10.1177/140349489402200409; Andersson AL, 1997, INJURY, V28, P539, DOI 10.1016/S0020-1383(97)00083-1; Association for the Advancement of Automotive Medicine (AAAM), 1994, INJ IMP SCAL, P66; BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Calmels P., 1996, Annales de Readaptation et de Medecine Physique, V39, P241; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Chossegros L, 2011, ACCIDENT ANAL PREV, V43, P471, DOI 10.1016/j.aap.2010.10.004; Currens JAB, 2000, INJURY, V31, P99, DOI 10.1016/S0020-1383(99)00246-6; De Mey-Guillard C, 2005, ENCEPHALE, V31, P76; DiGallo A, 1996, BRIT J PSYCHIAT, V169, P405, DOI 10.1192/bjp.169.4.405; Edwards P, 2007, J CLIN EPIDEMIOL, V60, P417, DOI 10.1016/j.jclinepi.2006.06.021; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; EVANS RW, 1992, NEUROL CLIN, V10, P815; Frommberger UH, 1998, EUR ARCH PSY CLIN N, V248, P316, DOI 10.1007/s004060050057; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; Jeavons S, 2000, J TRAUMA STRESS, V13, P359, DOI 10.1023/A:1007797904536; Jeavons S, 2000, BEHAV RES THER, V38, P499, DOI 10.1016/S0005-7967(99)00073-X; Laumon B, 1997, 41 ANN P ASS ADV AUT, P127; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Mayou R, 2003, INJURY, V34, P197, DOI 10.1016/S0020-1383(02)00285-1; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; McClure RJ, 1996, ACCIDENT ANAL PREV, V28, P443, DOI 10.1016/0001-4575(96)00012-7; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Schluter PJ, 2006, ANZ J SURG, V76, P886, DOI 10.1111/j.1445-2197.2006.03900.x; Soderstrom CA, 1997, J TRAUMA, V43, P925; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; van der Sluis CK, 1998, INJURY, V29, P277, DOI 10.1016/S0020-1383(97)00198-8; van der Sluis CK, 1998, INJURY, V29, P281, DOI 10.1016/S0020-1383(97)00199-X; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; Ventureyra VAG, 2002, PSYCHOTHER PSYCHOSOM, V71, P47, DOI 10.1159/000049343; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Wise EK, 2010, ARCH PHYS MED REHAB, V91, P1357, DOI 10.1016/j.apmr.2010.06.009; Yang Z, 2010, INJURY, V41, P226, DOI 10.1016/j.injury.2009.10.019; Yao SN, 2003, ENCEPHALE, V29, P232	45	36	36	0	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JAN	2013	50						92	102		10.1016/j.aap.2012.03.037			11	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	079SD	WOS:000314191600012	23200444				2021-06-18	
J	Khabour, OF; Alzoubi, KH; Alomari, MA; Alzubi, MA				Khabour, Omar F.; Alzoubi, Karem H.; Alomari, Mahmoud A.; Alzubi, Mohammad A.			Changes in spatial memory and BDNF expression to simultaneous dietary restriction and forced exercise	BRAIN RESEARCH BULLETIN			English	Article						Every other day fasting; Exercise; Memory; BDNF; Hippocampus	TRAUMATIC BRAIN-INJURY; HIGH-FAT DIET; CALORIC RESTRICTION; TREADMILL EXERCISE; NEUROTROPHIC FACTOR; VOLUNTARY EXERCISE; PHYSICAL-EXERCISE; FOOD RESTRICTION; OXIDATIVE STRESS; COGNITIVE FUNCTION	Previous literature suggests that learning and memory formation can be influenced by diet and exercise. In the current study, we investigated the combined effects of forced swimming exercise (FSE) and every other day fasting (EODF) on spatial memory formation and on the levels of brain-derived neurotrophic factor (BDNF) in the hippocampus of Wistar male rats. The radial arm water maze (RAWM) paradigm was used to assess changes in learning and memory formation, whereas ELISA assay was used to measure BDNF protein levels. The FSE and/or EODF were simultaneously instituted for 6 weeks. Results show that FSE improved learning, short-term as well as long-term memory formation, and significantly increased BDNF protein in the hippocampus (p < 0.05). However, EODF had no effect on either spatial learning and memory formation or the levels of hippocamapal BDNF protein (p > 0.05). In addition, EODF did not modulate beneficial effect of swimming exercise on cognitive function (p > 0.05). Thus exercise enhanced, while EODF did not affect spatial learning and memory formation. (C) 2012 Elsevier Inc. All rights reserved.	[Khabour, Omar F.] Jordan Univ Sci & Technol, Dept Med Lab Sci, Irbid 22110, Jordan; [Alzoubi, Karem H.; Alzubi, Mohammad A.] Jordan Univ Sci & Technol, Dept Clin Pharm, Irbid 22110, Jordan; [Alomari, Mahmoud A.] Jordan Univ Sci & Technol, Dept Rehabil Sci, Irbid 22110, Jordan	Khabour, OF (corresponding author), Jordan Univ Sci & Technol, Fac Appl Med Sci, Dept Med Lab Sci, Irbid 22110, Jordan.	khabour@just.edu.jo	Alomari, Mahmoud A/K-3263-2014; Alzoubi, Karem/E-6285-2014	Alomari, Mahmoud A/0000-0003-3605-5946; Alzoubi, Karem/0000-0002-2808-5099	Jordan University of Science and Technology	This work has been supported from the Deanship of Research in Jordan University of Science and Technology.	Adams JM, 2008, HYPERTENSION, V52, P932, DOI 10.1161/HYPERTENSIONAHA.108.118935; Alzoubi KH, 2009, BEHAV BRAIN RES, V204, P117, DOI 10.1016/j.bbr.2009.05.025; Alzoubi KH, 2012, BEHAV BRAIN RES, V226, P205, DOI 10.1016/j.bbr.2011.09.017; Anderson RM, 2010, TRENDS ENDOCRIN MET, V21, P134, DOI 10.1016/j.tem.2009.11.005; Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Ang ET, 2006, BRAIN RES, V1113, P186, DOI 10.1016/j.brainres.2006.07.023; Arida RM, 2011, AM J PHYS MED REHAB, V90, P452, DOI 10.1097/PHM.0b013e3182063a9c; Azab M, 2009, J TOXICOL ENV HEAL A, V72, P295, DOI 10.1080/15287390802526357; Bekinschtein P, 2011, SEMIN CELL DEV BIOL, V22, P536, DOI 10.1016/j.semcdb.2011.07.002; Cechetti F, 2012, NEUROBIOL LEARN MEM, V97, P90, DOI 10.1016/j.nlm.2011.09.008; Chen Lin, 2006, Neurosci Bull, V22, P1; Collins A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004330; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Depp CA, 2010, AM J PREV MED, V39, P173, DOI 10.1016/j.amepre.2010.03.020; Diamond DM, 1999, HIPPOCAMPUS, V9, P542, DOI 10.1002/(SICI)1098-1063(1999)9:5<542::AID-HIPO8>3.0.CO;2-N; Drumond LE, 2012, BRAIN RES BULL, V88, P385, DOI 10.1016/j.brainresbull.2012.04.005; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Duman RS, 2005, NEUROBIOL AGING, V26, pS88, DOI 10.1016/j.neurobiolaging.2005.08.018; Erickson KI, 2012, NEUROSCIENTIST, V18, P82, DOI 10.1177/1073858410397054; Fontana L, 2010, AGE, V32, P97, DOI 10.1007/s11357-009-9118-z; Fuentes T, 2012, EUR J APPL PHYSIOL, V112, P1917, DOI 10.1007/s00421-011-2164-0; Geng AL, 2007, ARCH ANIM NUTR, V61, P50, DOI 10.1080/17450390601117041; Gold SM, 2003, J NEUROIMMUNOL, V138, P99, DOI 10.1016/S0165-5728(03)00121-8; Greene WC, 2004, NAT MED, V10, P778, DOI 10.1038/nm0804-778; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Hansalik M, 2006, EXP GERONTOL, V41, P169, DOI 10.1016/j.exger.2005.11.002; Heydari AR, 2007, NUCLEIC ACIDS RES, V35, P7485, DOI 10.1093/nar/gkm860; Hoffman Martin D, 2007, Curr Pain Headache Rep, V11, P93; Hu M, 2012, ACTA HAEMATOL-BASEL, V127, P156, DOI 10.1159/000335620; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Jee YS, 2008, NEUROSCI LETT, V443, P188, DOI 10.1016/j.neulet.2008.07.078; Johnson NA, 2006, EXP PHYSIOL, V91, P693, DOI 10.1113/expphysiol.2006.033399; Kennard JA, 2012, PHYSIOL BEHAV, V106, P423, DOI 10.1016/j.physbeh.2012.02.023; Khabour OF, 2010, HIPPOCAMPUS, V20, P637, DOI 10.1002/hipo.20657; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Lojovich JM, 2010, J HEAD TRAUMA REHAB, V25, P184, DOI 10.1097/HTR.0b013e3181dc78cd; Lumini JA, 2008, SPORTS MED, V38, P735, DOI 10.2165/00007256-200838090-00003; Ma Qiang, 2008, Neurosci Bull, V24, P265, DOI 10.1007/s12264-008-0402-1; Mager DE, 2006, FASEB J, V20, P631, DOI 10.1096/fj.05-5263com; Martin LB, 2007, AM J PHYSIOL-REG I, V292, pR316, DOI 10.1152/ajpregu.00386.2006; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; MEANS LW, 1993, PHYSIOL BEHAV, V54, P503, DOI 10.1016/0031-9384(93)90243-9; Mello PB, 2008, AN ACAD BRAS CIENC, V80, P301, DOI 10.1590/S0001-37652008000200008; Mello PB, 2009, NEUROBIOL LEARN MEM, V92, P364, DOI 10.1016/j.nlm.2009.04.004; Molteni R, 2004, P NATL ACAD SCI USA, V101, P8473, DOI 10.1073/pnas.0401443101; Morgan T. E., 2007, V35, P83; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Ni H, 2011, BIOL TRACE ELEM RES, V142, P704, DOI 10.1007/s12011-010-8793-z; Nichol KE, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-13; Pan Y, 2011, NEUROSCIENCE, V197, P330, DOI 10.1016/j.neuroscience.2011.08.065; Saadipour K, 2009, Pak J Biol Sci, V12, P1206; Sim YJ, 2005, PHYSIOL BEHAV, V84, P733, DOI 10.1016/j.physbeh.2005.02.019; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Thompson D, 2012, PHYSIOL REV, V92, P157, DOI 10.1152/physrev.00012.2011; Toscano-Silva M, 2010, PHYSIOL BEHAV, V101, P302, DOI 10.1016/j.physbeh.2010.05.012; Tseng CN, 2011, J NURS RES, V19, P119, DOI 10.1097/JNR.0b013e3182198837; Varady K.A., 2008, NUTRITION; Vollert C, 2011, BEHAV BRAIN RES, V224, P233, DOI 10.1016/j.bbr.2011.05.010; Weiner RB, 2012, PROG CARDIOVASC DIS, V54, P380, DOI 10.1016/j.pcad.2012.01.006; Wu AG, 2003, NEUROSCI LETT, V339, P166, DOI 10.1016/S0304-3940(03)00008-9; Yanai S, 2004, NEUROBIOL AGING, V25, P325, DOI 10.1016/S0197-4580(03)00115-5; Zagaar M, 2012, NEUROBIOL DIS, V45, P1153, DOI 10.1016/j.nbd.2011.12.039	63	36	37	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JAN	2013	90						19	24		10.1016/j.brainresbull.2012.08.005			6	Neurosciences	Neurosciences & Neurology	083ES	WOS:000314446100003	23000024				2021-06-18	
J	Li, SX; Sun, Y; Shan, D; Feng, B; Xing, JJ; Duan, YJ; Dai, JP; Lei, H; Zhou, YW				Li, Shangxun; Sun, Yan; Shan, Dai; Feng, Bin; Xing, Jingjun; Duan, Yijie; Dai, Jiapei; Lei, Hao; Zhou, Yiwu			Temporal profiles of axonal injury following impact acceleration traumatic brain injury in rats-a comparative study with diffusion tensor imaging and morphological analysis	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Traumatic brain injury; Traumatic axonal injury; Diffusion tensor imaging; Biomarker; beta-Amyloid precursor protein; Neurofilament	INTRAAXONAL NEUROFILAMENT COMPACTION; AMYLOID PRECURSOR PROTEIN; EARLY-DIAGNOSIS; SPINAL-CORD; MOUSE MODEL; DAMAGE; ACCUMULATION; TRANSPORT; RECOVERY; MILD	Traumatic axonal injury (TAI) plays a major role in the development of neurological impairments after traumatic brain injury (TBI), but it is commonly difficult to evaluate it precisely and early with conventional histological biomarkers, especially when the patients experience short-term survival after TBI. Diffusion tensor imaging (DTI) has shown some promise in detecting TAI, but longitudinal studies on the compromised white matter with DTI at early time points (a parts per thousand currency sign72 h) following impact acceleration TBI are still absent. In the present study, rats were subjected to the Marmarou model and imaged with DTI at 3, 12, 24, and 72 h (n = 5 each) post-injury. Using a region-of-interest-based approach, the regions of interest including the corpus callosum, bilateral external capsule, internal capsule, and pyramidal tract were studied. Two DTI parameters, fraction anisotropy and axial diffusivity, were significantly reduced from 3 to 72 h in each region after trauma, corresponding to the gradient of axonal damage demonstrated by immunohistochemical staining of beta-amyloid precursor protein and neurofilament light chain. Remarkably, DTI changes predicted the approximate time in the acute phase following TBI. These results indicate that the temporal profiles of diffusion parameters in DTI may be able to provide a tool for early diagnosis of TAI following impact acceleration TBI.	[Li, Shangxun; Xing, Jingjun; Duan, Yijie; Zhou, Yiwu] Huazhong Univ Sci & Technol, Tongji Med Coll, Fac Forens Med, Wuhan 430030, Peoples R China; [Sun, Yan; Feng, Bin; Dai, Jiapei] S Cent Univ Nationlities, Wuhan Inst Neurosci & Neuroengn, Wuhan 430074, Peoples R China; [Shan, Dai; Lei, Hao] Chinese Acad Sci, State Key Lab Magnet Resonance & Atom & Mol Phys, Wuhan Ctr Magnet Resonance, Wuhan Inst Phys & Math, Wuhan 430071, Peoples R China	Zhou, YW (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Fac Forens Med, Wuhan 430030, Peoples R China.	jdai@mail.scuec.edu.cn; leihao@wipm.ac.cn; yiwuhedi@sina.com	Lei, Hao/A-7004-2008; , 雷皓/H-8147-2019	Lei, Hao/0000-0003-3412-1241; , 雷皓/0000-0003-3412-1241; Dai, Jiapei/0000-0002-1474-5754	Scientific Research Foundation for the Returned Overseas Chinese Scholars from State Education MinistryScientific Research Foundation for the Returned Overseas Chinese Scholars; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30870674, 20921004, 31070961]; Research Foundation for the Key Laboratory of Neuroscience and Neuroengineering from South Central University for Nationalities [XJS09001]	This work was supported by the Scientific Research Foundation for the Returned Overseas Chinese Scholars from State Education Ministry and the National Natural Science Foundation of China (Grant Nos. 30870674, 20921004, and 31070961) and partly by the Research Foundation for the Key Laboratory of Neuroscience and Neuroengineering from South Central University for Nationalities (XJS09001).	ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Hayashi Takahito, 2009, Leg Med (Tokyo), V11 Suppl 1, pS171, DOI 10.1016/j.legalmed.2009.01.076; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Ogata Mamoru, 2007, Legal Medicine, V9, P105, DOI 10.1016/j.legalmed.2006.11.013; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Wang HC, 2010, J CLIN NEUROSCI, V17, P157, DOI 10.1016/j.jocn.2009.07.099; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	46	36	37	2	24	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	JAN	2013	127	1					159	167		10.1007/s00414-012-0712-8			9	Medicine, Legal	Legal Medicine	065QR	WOS:000313164100023	22573358				2021-06-18	
J	Mukherjee, S; Zeitouni, S; Cavarsan, CF; Shapiro, LA				Mukherjee, Sanjib; Zeitouni, Suzanne; Cavarsan, Clarissa Fantin; Shapiro, Lee A.			Increased seizure susceptibility in mice 30 days after fluid percussion injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; post-traumatic epilepsy; pentylenetetrazole; mouse models	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC EPILEPSY; COGNITIVE DYSFUNCTION; PENTYLENETETRAZOLE; MICROGLIA; IMPACT; MODEL; RATS; TBI	Traumatic brain injury (TBI) has been reported to increase seizure susceptibility and also contribute to the development of epilepsy. However, the mechanistic basis of the development of increased seizure susceptibility and epilepsy is not clear. Though there is substantial work done using rats, data are lacking regarding the use of mice in the fluid percussion injury (FPI) model. It is unclear if mice, like rats, will experience increased seizure susceptibility following FPI. The availability of a mouse model of increased seizure susceptibility after FPI would provide a basis for the use of genetically modified mice to study mechanism(s) of the development of post-traumatic epilepsy. Therefore, this study was designed to test the hypothesis that, mice subjected to a FPI develop increased seizure susceptibility to a subconvulsive dose of the chemoconvulsant, pentylenetetrazole (PTZ). Three groups of mice were used: FPI, sham, and naive controls. On day 30 after FPI, mice from the three groups were injected with PTZ. The results showed that FPI mice exhibited an increased severity, frequency, and duration of seizures in response to PTZ injection compared with the sham and naive control groups. Histopathological assessment was used to characterize the injury at 1, 3, 7, and 30 days after FPI. The results show that mice subjected to the FPI had a pronounced lesion and glial response that was centered at the FPI focus and peaked at 3 days. By 30 days, only minimal evidence of a lesion is observed, although there is evidence of a chronic glial response. These data are the first to demonstrate an early increase in seizure susceptibility following FPI in mice. Therefore, future studies can incorporate transgenic mice into this model to further elucidate mechanisms of TB I-induced increases in seizure susceptibility.	[Mukherjee, Sanjib; Cavarsan, Clarissa Fantin; Shapiro, Lee A.] Scott & White Hosp, Dept Surg, Temple, TX USA; [Mukherjee, Sanjib; Zeitouni, Suzanne; Cavarsan, Clarissa Fantin; Shapiro, Lee A.] Cent Texas Vet Hlth Care Syst, Temple, TX USA; [Zeitouni, Suzanne; Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX USA; Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Temple, TX USA	Shapiro, LA (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Bldg 205,1901 South 1st St, Temple, TX 76504 USA.	lshapiro@medicine.tamhsc.edu	Cavarsan, Clarissa F./J-9221-2013	Cavarsan, Clarissa F./0000-0002-6687-2130	Scott and White Hospital (RGP) [90347]; Central Texas Veterans Health Care System, Temple, TX, USA	We are also grateful for the funding support from Scott and White Hospital (RGP#90347). This material is the result of work supported with resources, including a SHEEP grant and the use of facilities at the Central Texas Veterans Health Care System, Temple, TX, USA. We are also grateful to Megan Ruch for her technical support. We would like to thank Drs. Richard Robertson and Pier Di Patre for their meaningful comments regarding the histology data.	Silva LFA, 2011, J NEUROL SCI, V308, P35, DOI 10.1016/j.jns.2011.06.030; Arisi GM, 2011, AGING DIS, V2, P294; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Galic MA, 2012, FRONT NEUROENDOCRIN, V33, P116, DOI 10.1016/j.yfrne.2011.12.002; Jain S, 2011, N-S ARCH PHARMACOL, V383, P385, DOI 10.1007/s00210-011-0606-1; Junque C, 1999, REV NEUROLOGIA, V28, P423, DOI 10.33588/rn.2804.98420; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kramer K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041476; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Pitkanen A., 2012, JASPERS BASIC MECH E, P331; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Shapiro LA, 2005, NEUROSCIENCE, V136, P823, DOI 10.1016/j.neuroscience.2005.03.059; Shapiro LA, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01491.x; Shapiro LA, 2009, BRAIN RES, V1266, P29, DOI 10.1016/j.brainres.2009.02.031; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Wilhelm EA, 2012, LIFE SCI, V90, P666, DOI 10.1016/j.lfs.2012.03.005; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	30	36	36	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								28	10.3389/fneur.2013.00028			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QT	WOS:000209629000028	23519723	DOAJ Gold, Green Published			2021-06-18	
J	Tepas, JJ; Pracht, EE; Orban, BL; Flint, LM				Tepas, Joseph J., III; Pracht, Etienne E.; Orban, Barbara L.; Flint, Lewis M.			High-volume trauma centers have better outcomes treating traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	PROMMTT Symposium held at the 71st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 12-15, 2012	HI	Amer Assoc Surg Trauma		Brain injury; clinical outcome; clinical case volume; performance assessment		BACKGROUND: Survival and discharge status from severe traumatic brain injury (TBI) patients treated during the past 11 years in seven state-designated Level I trauma centers was analyzed to test for a relationship between patient volume and outcome. METHODS: Data for patients age 16 years to 64 years were aggregated by quarter for years 2000 to 2010. TBI patients were identified using DRG International Classification of Diseases-9th Rev.-Clinical Modification codes: 800 to 804 and 850.1 to 854. Severity was defined using the International Classification Injury Severity Score (ICISS) less than 0.85 (risk of death >15%). Using a random effects model controlling for sex, race, ethnicity, and insurance status, TBI volume was analyzed against quarterly inpatient mortality and functional recovery, defined as discharge to home or rehabilitation versus transfer to skilled nursing facilities. Hospitals were categorized into quarterly TBI volume quintiles, using the top quintile (highest-volume center) as control. To account for overall injury severity influence, ICISS was further categorized as less than 20%, 20% to 40%, and 40% to 60%. RESULTS: Two high-volume hospitals consistently treated more TBI patients (>40 patients per quarter). Four treated less than 40 patients per quarter, and one transitioned to high-volume midway through the study period. After controlling for severity, demographics, and insurance status, highest-volume centers demonstrated a 9% lower mortality risk (p < 0.001). Lower-volume hospitals discharged a significantly larger proportion of TBI patients to skilled nursing facilities and fewer patients to home or rehabilitation facilities (p < 0.01). CONCLUSION: High volume (>40 patients per quarter) is associated with improved severe TBI patient survival and, probably, improved quality of life. Efforts to identify best practices and implement educational interventions to improve compliance with best-practice standards will benefit patients with severe traumatic brain injury. (J Trauma Acute Care Surg. 2013;74: 143-148. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Tepas, Joseph J., III] Univ Florida, Coll Med Jacksonville, Dept Surg, Jacksonville, FL 32209 USA; [Pracht, Etienne E.; Orban, Barbara L.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA; [Flint, Lewis M.] Amer Coll Surg, Div Educ, Chicago, IL USA	Tepas, JJ (corresponding author), Univ Florida, Coll Med Jacksonville, Dept Surg, 653 W 8th St, Jacksonville, FL 32209 USA.	jjt@jax.ufl.edu					American College of Surgeons, 2007, RES OPT CAR INJ PAT; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Donabedian A, 2000, B WORLD HEALTH ORGAN, V78, P857; Donabedian A, 2001, Health Aff (Millwood), V20, P137; Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; Fantus RJ, 2006, J TRAUMA, V61, P266; Glance LG, 2011, ARCH SURG-CHICAGO, V146, P1170, DOI 10.1001/archsurg.2011.247; LaPar DJ, ANN SURG; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Massarweh NN, 2011, J AM COLL SURGEONS, V212; Nathens A B, 2001, Adv Surg, V35, P61; Papa L, 2006, J TRAUMA, V61, P261, DOI 10.1097/01.ta.0000221789.53864.ba; Pracht EE, 2007, MED CARE RES REV, V64, P83, DOI 10.1177/1077558706296241; Reinke Thomas, 2010, Manag Care, V19, P7; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089	15	36	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2013	74	1					143	147		10.1097/TA.0b013e3182788b5a			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	071VI	WOS:000313623300034	23271089				2021-06-18	
J	Turner-Stokes, L; Siegert, RJ				Turner-Stokes, Lynne; Siegert, Richard J.			A comprehensive psychometric evaluation of the UK FIM plus FAM	DISABILITY AND REHABILITATION			English	Article						Extended activities of daily living; factor analysis; Mokken analysis; neurological rehabilitation; psychometrics; UK FIM plus FAM	FUNCTIONAL ASSESSMENT MEASURE; TRAUMATIC BRAIN-INJURY; INTERRATER RELIABILITY; INDEPENDENCE MEASURE; SCALE ANALYSIS; REHABILITATION; PERFORMANCE; DISABILITY; FIM+FAM; UTILITY	Purpose: To evaluate the psychometric properties of the UK FIM + FAM. Methods: (a) A systematic literature review integrating the evidence for psychometric qualities of both the original and UK versions, and (b) exploratory and confirmatory factor analysis of admission/discharge data from an inpatient general neuro-rehabilitation cohort using parametric and non-parametric techniques. A prospective cohort of 459 patients with a male: female ratio of 57: 43 and mean age of 44.5 (SD 14.3) years participated in this study. Results: Seven published articles together demonstrated acceptable utility, concurrent validity, inter-rater reliability and responsiveness of the UK FIM + FAM. Factor analysis demonstrated that all items loaded high (40.58) on the first principal component and distinct motor and cognitive factors emerged after rotation. A four-factor solution also demonstrated four distinct, interpretable dimensions (Physical, Psychosocial, Communication and Extended Activities of Everyday Living (EADL)). Mokken analysis of the second data set confirmed these dimensions. Cronbach's alpha s were 0.97 and 0.96 for the motor and cognitive domains and 0.90-0.97 for the subscales. Analysis of responsiveness demonstrated "large" effect sizes (0.86-1.29). Conclusions: The UK FIM + FAM, including the newer EADL module, is a valid, reliable scale of functional independence. It has high internal consistency in two domains and four subscales and is responsive to changes occurring in a general inpatient neuro-rehabilitation population.	[Turner-Stokes, Lynne; Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Sch Med, London SE5 9PJ, England; [Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, London, England; [Siegert, Richard J.] Auckland Univ Technol, Sch Publ Hlth & Psychosocial Studies, Auckland, New Zealand; [Siegert, Richard J.] Auckland Univ Technol, Sch Rehabil & Occupat Studies, Auckland, New Zealand	Turner-Stokes, L (corresponding author), Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, Bessemer Rd,Denmark Hill, London SE5 9PJ, England.	lynne.turner-stokes@dial.pipex.com	Siegert, Richard J./K-2030-2019; Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462; Siegert, Richard/0000-0002-3074-0929	National Institute for Health Research in England (NIHR)National Institute for Health Research (NIHR) [RP-PG-0407-10185]; Dunhill Medical TrustDunhill Medical Trust; Luff Foundation; National Institute for Health ResearchNational Institute for Health Research (NIHR) [RP-PG-0407-10185] Funding Source: researchfish	Outcome measurement is a specific research interest of our centre. The UK FIM + FAM were both developed through this department, but is disseminated free of charge to trained users. Neither of the authors has any personal financial interests in the work undertaken or the findings reported. This manuscript presents independent research commissioned by the National Institute for Health Research in England (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0407-10185). The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Financial support for the preparation of this manuscript was also provided by the Dunhill Medical Trust and the Luff Foundation.	Alcott D, 1997, DISABIL REHABIL, V19, P355, DOI 10.3109/09638289709166551; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Hobart JC, 2001, NEUROLOGY, V57, P639, DOI 10.1212/WNL.57.4.639; Jorge LL, 2011, INT J REHABIL RES, V34, P89, DOI 10.1097/MRR.0b013e32833ba55f; Law J, 2009, DISABIL REHABIL, V31, P825, DOI 10.1080/09638280802355049; Linn R T, 1999, J Outcome Meas, V3, P339; LOEVINGER J, 1948, PSYCHOL BULL, V45, P507, DOI 10.1037/h0055827; McPherson K, 1997, NEUROPSYCHOL REHABIL, V7, P241, DOI 10.1080/713755530; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; McPherson KM, 1997, INT J REHABIL RES, V20, P1, DOI 10.1097/00004356-199703000-00001; MOKKEN RJ, 1982, APPL PSYCH MEAS, V6, P417, DOI 10.1177/014662168200600404; Molenaar I.W., 2000, MSP5 WINDOWS PROGRAM; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pett M., 2003, MAKING SENSE FACTOR; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Seel RT, 2007, J HEAD TRAUMA REHAB, V22, P267, DOI 10.1097/01.HTR.0000290971.56130.c8; Siegert RJ, 2010, J REHABIL MED, V42, P936, DOI 10.2340/16501977-0602; Sijtsma K., 2002, MEASUREMENT METHODS, V5; Tabachnick B., 2001, USING MULTIVARIATE S; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Tesio L, 1998, J Outcome Meas, V2, P79; Thompson B., 2004, EXPLORATORY CONFIRMA; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 2012, DISABIL REHABIL, V34, P1871, DOI 10.3109/09638288.2012.670033; Turner-Stokes L, 2012, CLIN REHABIL, V26, P264, DOI 10.1177/0269215511417467; Turner-Stokes L, 2009, J REHABIL MED, V41, P528, DOI 10.2340/16501977-0383; van Schuur WH, 2003, POLIT ANAL, V11, P139, DOI 10.1093/pan/mpg002; Vogele B, 2009, NEUROLOGIE REHABILIT, V15, P308; Wilson FC, 2009, NEUROREHABILITATION, V24, P377, DOI 10.3233/NRE-2009-0492	39	36	37	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2013	35	22					1885	1895		10.3109/09638288.2013.766271			11	Rehabilitation	Rehabilitation	230PW	WOS:000325355400005	23384240	Green Published, Bronze			2021-06-18	
J	Li, HY; Huang, JB; Du, WL; Jia, CX; Yao, HL; Wang, YZ				Li, Hongyu; Huang, Junbo; Du, Wanlu; Jia, Caixia; Yao, Hailan; Wang, Yizheng			TRPC6 inhibited NMDA receptor activities and protected neurons from ischemic excitotoxicity	JOURNAL OF NEUROCHEMISTRY			English	Article						excitotoxicity; focal ischemia; neuroprotection; transgenic mice; TRPC6	TRAUMATIC BRAIN-INJURY; TYROSINE PHOSPHORYLATION; GLUCOSE DEPRIVATION; CORTICAL CULTURES; CEREBRAL-ISCHEMIA; CHANNELS; MECHANISMS; CALCIUM; STROKE; RATS	Excitotoxicity induced by NMDA receptor-mediated intracellular Ca2+ ([Ca2+]i) overload is a major cause of delayed neuronal death in cerebral ischemia. Transient receptor potential canonical (TRPC) 6 protects neurons from ischemic brain damage. However, the mechanisms by which TRPC6 protects neurons are largely unknown. Here, we reported that TRPC6 suppressed the [Ca2+]i elevation induced by NMDA and protected neurons from excitotoxicity. Over-expressing or down-regulating TRPC6 suppressed or aggravated Ca2+ overload under excitotoxicity, respectively. TRPC6 protected cultured neurons from damage caused by NMDA toxicity or oxygen glucose deprivation (OGD). Moreover, the infarct volume in TRPC6 transgenic (Tg) mice was smaller than that in wild-type (WT) littermates. The TRPC6 Tg mice had better behavior performance and lower mortality than their WT littermates. Thus, TRPC6 inhibited NMDA receptor-triggered neurotoxicity and protected neurons from ischemic brain damage. Increase in TRPC6 activity could be a potential strategy for stroke prevention and therapy.	[Li, Hongyu; Huang, Junbo; Du, Wanlu; Jia, Caixia; Yao, Hailan; Wang, Yizheng] Chinese Acad Sci, Lab Neural Signal Transduct, Inst Neurosci, SIBS,State Key Lab Neurosci, Shanghai 200031, Peoples R China; [Li, Hongyu; Huang, Junbo] Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China	Wang, YZ (corresponding author), Chinese Acad Sci, Lab Neural Signal Transduct, Inst Neurosci, SIBS,State Key Lab Neurosci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	yzwang@ion.ac.cn		Du, Wanlu/0000-0003-2612-7846	NNSF of ChinaNational Natural Science Foundation of China (NSFC) [81130081]	This work was supported by a grant (81130081) from NNSF of China. We thank Q. Hu and ZJ. Fan for technical assistance. The authors have no conflict of interest to declare.	Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Du WL, 2010, J CLIN INVEST, V120, P3480, DOI 10.1172/JCI43165; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Jia YC, 2007, NAT NEUROSCI, V10, P559, DOI 10.1038/nn1870; Jiang M, 2006, NAT PROTOC, V1, P695, DOI 10.1038/nprot.2006.86; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Lei ZG, 2006, NEUROSCI LETT, V407, P224, DOI 10.1016/j.neulet.2006.06.019; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Liu Y, 2003, BRAIN RES, V972, P142, DOI 10.1016/S0006-8993(03)02519-8; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Pei L, 2000, ACTA PHARMACOL SIN, V21, P695; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Riccio A, 2009, CELL, V137, P761, DOI 10.1016/j.cell.2009.03.039; Sattler R, 1998, J NEUROCHEM, V71, P2349; Smith Paul F, 2003, Curr Opin Investig Drugs, V4, P826; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tai YL, 2008, J CELL SCI, V121, P2301, DOI 10.1242/jcs.026906; Tao YM, 2006, MOL CELL BIOL, V26, P1038, DOI 10.1128/MCB.26.3.1038-1050.2006; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Zhou J, 2008, NAT NEUROSCI, V11, P741, DOI 10.1038/nn.2127; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	36	36	40	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	DEC	2012	123	6					1010	1018		10.1111/jnc.12045			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	051WK	WOS:000312158500012	23043486				2021-06-18	
J	Su, E; Bell, MJ; Kochanek, PM; Wisniewski, SR; Bayir, H; Clark, RSB; Adelson, PD; Tyler-Kabara, EC; Janesko-Feldman, KL; Berger, RP				Su, E.; Bell, M. J.; Kochanek, P. M.; Wisniewski, S. R.; Bayir, H.; Clark, R. S. B.; Adelson, P. D.; Tyler-Kabara, E. C.; Janesko-Feldman, K. L.; Berger, R. P.			Increased CSF Concentrations of Myelin Basic Protein After TBI in Infants and Children: Absence of Significant Effect of Therapeutic Hypothermia	NEUROCRITICAL CARE			English	Article						Axonal injury; Pediatrics; Secondary injury	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; AXONAL INJURY; CEREBROSPINAL-FLUID; WHITE-MATTER; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; GENDER; MATURATION	Background The objectives of this study were to determine effects of severe traumatic brain injury (TBI) on cerebrospinal fluid (CSF) concentrations of myelin basic protein (MBP) and to assess relationships between clinical variables and CSF MBP concentrations. Methods We measured serial CSF MBP concentrations in children enrolled in a randomized controlled trial evaluating therapeutic hypothermia (TH) after severe pediatric TBI. Control CSF was obtained from children evaluated, but found not to be having CNS infection. Generalized estimating equation models and Wilcoxon Rank-Sum test were used for comparisons of MBP concentrations. Results There were 27 TBI cases and 57 controls. Overall mean (+/- SEM) TBI case MBP concentrations for 5 days after injury were markedly greater than controls (50.49 +/- A 6.97 vs. 0.11 +/- A 0.01 ng/ml, p < 0.01). Mean MBP concentrations were lower in TBI patients < 1 year versus > 1 year (9.18 +/- A 1.67 vs. 60.22 +/- A 8.26 ng/ml, p = 0.03), as well as in cases with abusive head trauma (AHT) versus non-abusive TBI (14.46 +/- A 3.15 vs. 61.17 +/- A 8.65 ng/ml, p = 0.03). TH did not affect MBP concentrations. Conclusions Mean CSF MBP increases markedly after severe pediatric TBI, but is not affected by TH. Infancy and AHT are associated with low MBP concentrations, suggesting that age-dependent myelination influences MBP concentrations after injury. Given the magnitude of MBP increases, axonal injury likely represents an important therapeutic target in pediatric TBI.	[Su, E.; Bell, M. J.; Kochanek, P. M.; Bayir, H.; Clark, R. S. B.; Janesko-Feldman, K. L.; Berger, R. P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, M. J.; Adelson, P. D.; Tyler-Kabara, E. C.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Bell, M. J.; Kochanek, P. M.; Bayir, H.; Clark, R. S. B.; Berger, R. P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Wisniewski, S. R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Adelson, P. D.] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Adelson, P. D.] Univ Arizona, Coll Med, Phoenix, AZ USA	Su, E (corresponding author), Johns Hopkins Univ Hosp, Div Pediat Anesthesia & Crit Care Med, Charlotte R Bloomberg Childrens Ctr, 1800 Orleans St, Baltimore, MD 21287 USA.	esu4@jhmi.edu	Su, Erik/AAG-9374-2019; Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015; Tyler-Kabara, Elizabeth/H-4930-2013	Su, Erik/0000-0002-1054-308X; Kochanek, Patrick M/0000-0002-2627-913X; Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Wisniewski, Stephen/0000-0002-3877-9860	 [T32HD040686];  [RO1 NS 38448-01];  [NS30318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R01NS038448, P50NS030318, P01NS030318] Funding Source: NIH RePORTER	This investigation was supported by Grant Nos.: T32HD040686 (ES, PMK), RO1 NS 38448-01(PDA), and NS30318 (PMK).	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gao W, 2009, AM J NEURORADIOL, V30, P290, DOI 10.3174/ajnr.A1363; GARCIAALIX A, 1994, PEDIATRICS, V93, P234; LEVIN SD, 1985, DEV MED CHILD NEUROL, V27, P807; Li H, 2009, J NEUROTRAUM, V26, P1905, DOI 10.1089/neu.2008-0828; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; MUKHERJEE A, 1985, CLIN BIOCHEM, V18, P304, DOI 10.1016/S0009-9120(85)80037-0; NOSEWORTHY TW, 1985, CRIT CARE MED, V13, P743, DOI 10.1097/00003246-198509000-00010; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; THOMAS D G T, 1978, Lancet, V1, P113; VANENGELEN BGM, 1992, CLIN CHEM, V38, P813	28	36	39	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	DEC	2012	17	3					401	407		10.1007/s12028-012-9767-0			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	050QP	WOS:000312069400014	22890910	Green Accepted			2021-06-18	
J	Ryan, CG; Thompson, RE; Temkin, NR; Crane, PK; Ellenbogen, RG; Elmore, JG				Ryan, Christina G.; Thompson, Rachel E.; Temkin, Nancy R.; Crane, Paul K.; Ellenbogen, Richard G.; Elmore, Joann G.			Acute traumatic subdural hematoma: Current mortality and functional outcomes in adult patients at a Level I trauma center	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Acute subdural hematoma; traumatic brain injury; subdural hematoma; mortality	INJURY; SCORE	BACKGROUND: Existing data on outcomes following subdural hematoma have provided limited information on medical complications and functional outcomes. Mortality rates previously reported range from 22% to 66%. METHODS: This is a retrospective cohort study of prospectively collected data from a trauma registry in Washington State from 2005 through 2008. Patients were categorized by surgical evacuation status with the hypothesis that those undergoing evacuation represented a more severe injury. RESULTS: The 1,427 patients included in the study had a mean age of 58 years, and most of them were male (63%). Glasgow Coma Scale (GCS) score on presentation was greater than 12 in 58%; the average Injury Severity Score (ISS) was 27.5. Mean length of stay was 9.6 days (range, 1-110), with 40% spending 2 or more days in the intensive care unit. Twenty-eight percent experienced medical complications. At discharge, 94% had GCS score of 13 or greater. Independence with expression, feeding, and locomotion at discharge was noted for 92%, 81%, and 43%, respectively. Inpatient mortality was 16% and did not differ significantly between the evacuated group (15%) and the nonevacuated group (17%). CONCLUSION: This large cohort of patients with acute traumatic subdural hematoma demonstrated a lower mortality rate than those of previous reports, including among patients requiring surgical evacuation (J Trauma Acute Care Surg. 2012;73: 1348-1352). (J Trauma Acute Care Surg. 2012;73:1348-1354. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Ryan, Christina G.; Thompson, Rachel E.; Crane, Paul K.; Elmore, Joann G.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Ryan, Christina G.; Thompson, Rachel E.; Temkin, Nancy R.; Ellenbogen, Richard G.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Elmore, Joann G.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA	Ryan, CG (corresponding author), Univ Washington, Harborview Med Ctr, Hosp Med, 325 9th Ave,Box 359780, Seattle, WA 98104 USA.	cgilmore@uw.edu	Crane, Paul K/C-8623-2014	Crane, Paul/0000-0003-4278-7465	National Cancer Institute at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [2 KO5 CA104699-06]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K05CA104699] Funding Source: NIH RePORTER	This work was supported by the National Cancer Institute at the National Institutes of Health (2 KO5 CA104699-06 to J.G.E.).	Abe M, 2003, SURG NEUROL, V59, P464, DOI 10.1016/S0090-3019(03)00078-8; [Anonymous], 2006, ICD 9 CM INT CLASS D; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Dent DL, 1995, J TRAUMA, V39, P42; Depreitere B, 2003, ACTA NEUROCHIR, V145, P541, DOI 10.1007/s00701-003-0020-7; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; JENNETT B, 1976, LANCET, V1, P1031; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; No authors listed. Rating the severity of tissue damage, 1971, JAMA-J AM MED ASSOC, V215, P277; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Tallon JM, 2008, CAN J SURG, V51, P339; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014	14	36	37	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73	5					1348	1353		10.1097/TA.0b013e31826fcb30			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	043VF	WOS:000311577100056	23117390	Green Accepted			2021-06-18	
J	Taylor, C; Jan, S; Curtis, K; Tzannes, A; Li, Q; Palmer, C; Dickson, C; Myburgh, J				Taylor, Colman; Jan, Stephen; Curtis, Kate; Tzannes, Alex; Li, Qiang; Palmer, Cameron; Dickson, Cara; Myburgh, John			The cost-effectiveness of physician staffed Helicopter Emergency Medical Service (HEMS) transport to a major trauma centre in NSW, Australia	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Helicopter Emergency Medical Services; Primary scene response; Cost-effectiveness; Health economics; Trauma care; Trauma system	WILLINGNESS-TO-PAY; INJURED PATIENTS; BRAIN-INJURY; EMS; MORTALITY; IMPACT; CARE	Background and context: Helicopter Emergency Medical Services (HEMS) are highly resource-intensive facilities that are well established as part of trauma systems in many high-income countries. We evaluated the cost-effectiveness of a physician-staffed HEMS intervention in combination with treatment at a major trauma centre versus ground ambulance or indirect transport (via a referral hospital) in New South Wales (NSW), Australia. Methods: Cost and effectiveness estimates were derived from a cohort of trauma patients arriving at St George Hospital in NSW, Australia during an 11-year period. Adjusted estimates of in-hospital mortality were derived using logistic regression and adjusted hospital costs were estimated through a general linear model incorporating a gamma distribution and log link. These estimates along with other assumptions were incorporated into a Markov model with an annual cycle length to estimate a cost per life saved and a cost per life-year saved at one year and over a patient's lifetime respectively in three patient groups (all patients; patients with serious injury [Injury Severity Score > 12]; patients with traumatic brain injury [TBI]). Results: Results showed HEMS to be more costly but more effective at reducing in-hospital mortality leading to a cost per life saved of $1,566,379, $533,781 and $519,787 in all patients, patients with serious injury and patients with TBI respectively. When modelled over a patient's lifetime, the improved mortality associated with HEMS led to a cost per life year saved of $96,524, $50,035 and $49,159 in the three patient groups respectively. Sensitivity analyses revealed a higher probability of HEMS being cost-effective in patients with serious injury and TBI. Conclusion: Our investigation confirms a HEMS intervention is associated with improved mortality in trauma patients, especially in patients with serious injury and TBI. The improved benefit of HEMS in patients with serious injury and TBI leads to improved estimated cost-effectiveness. (C) 2012 Elsevier Ltd. All rights reserved.	[Taylor, Colman; Jan, Stephen; Curtis, Kate; Li, Qiang; Myburgh, John] George Inst Global Hlth, Sydney, NSW, Australia; [Taylor, Colman] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Curtis, Kate] Univ Sydney, Sydney Nursing Sch, Sydney, NSW 2006, Australia; [Curtis, Kate; Tzannes, Alex; Dickson, Cara; Myburgh, John] St George Hosp, Sydney, NSW, Australia; [Tzannes, Alex] Ambulance Serv NSW, Sydney, NSW, Australia; [Myburgh, John] Univ NSW, Fac Med, Sydney, NSW, Australia; [Palmer, Cameron] Royal Childrens Hosp Melbourne, Trauma Serv, Melbourne, Vic, Australia; [Palmer, Cameron] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Taylor, C (corresponding author), POB M201,Missenden Rd, Camperdown, NSW 2050, Australia.	ctaylor@georgeinstitute.org.au	black, deborah/C-2829-2017; Jan, Stephen/AAG-3333-2021	black, deborah/0000-0001-9174-1565; Jan, Stephen/0000-0003-2839-1405	NSW Department of Health	Co-authors Curtis, Tzannes, Dickson and Myburgh and all paid employees of the NSW Department of Health, which funds Helicopter Emergency Medical Services. The primary author (C. Taylor) has a paid part-time position with Novartis Pharmaceuticals.	Access Economics, 2007, HLTH NAT VAL STAT LI; Ambulance Service of New South Wales, 2008, PROT T1 PREH MAN MAJ; [Anonymous], 2009, EC COST SPINAL CORD, P1; Australian Bureau of Statistics, 2011, ABS LIF TABL; Australian Bureau of Statistics, 2011, CONS PRIC IND AUSTR; Australian Government Department of Health and Aging, 2008, GUID PREP SUBM PHARM; Australian Institute of Health and Welfare, 2010, HLTH WELF EXP SER; Bledsoe BE, 2006, J TRAUMA, V60, P1257, DOI 10.1097/01.ta.0000196489.19928.c0; Botker MA, 2009, SCANDINAVIAN J TRAUM, V5, P17; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Galvagno SM, 2012, JAMA-J AM MED ASSOC, V307, P8; Garner Alan A, 2004, Emerg Med Australas, V16, P318, DOI 10.1111/j.1742-6723.2004.00636.x; Gearhart PA, 1997, ANN EMERG MED, V30, P500, DOI 10.1016/S0196-0644(97)70010-6; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hensher DA, 2009, TRANSPORT RES A-POL, V43, P692, DOI 10.1016/j.tra.2009.06.001; Independent Pricing and Regulatory Tribunal of New South Wales, 2005, REV FIN ASP AMB SERV; Lerner EB, 2006, ANN EMERG MED, V47, P515, DOI 10.1016/j.annemergmed.2006.01.012; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Meltzer D, 1997, J HEALTH ECON, V16, P33, DOI 10.1016/S0167-6296(96)00507-3; NSW Health, 2010, NSW COSTS CAR STAND; NSW Health, 2011, SEL SPEC STAT SERV P; NSW Health Department, 2006, NSW PROGR PROD DAT C; Olsen JA, 1998, SOC SCI MED, V46, P1, DOI 10.1016/S0277-9536(97)00129-9; Palmer CS, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-29; Rinburg AN, 2009, BRIT J SURG, V96, P1365, DOI 10.1002/bjs.6720; Ringburg Akkie N, 2009, Air Med J, V28, P298, DOI 10.1016/j.amj.2009.03.007; Ringburg A, 2009, PREHOSP EMERG CARE, V13, P37, DOI 10.1080/10903120802472004; Ringburg AN, 2009, PREHOSP EMERG CARE, V13, P2009; Shepherd MV, 2008, EMERG MED AUSTRALAS, V20, P494, DOI 10.1111/j.1742-6723.2008.01135.x; Taylor CB, 2011, INJURY, V42, P1088, DOI 10.1016/j.injury.2011.02.013; Taylor CB, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2009.09.030; Thomas Stephen H, 2002, Prehosp Emerg Care, V6, P242, DOI 10.1080/10903120290938634; Thomas SH, 2007, PREHOSP EMERG CARE, V11, P477, DOI 10.1080/10903120701537097; Thomas Stephen H, 2003, Curr Opin Anaesthesiol, V16, P153, DOI 10.1097/00001503-200304000-00008; Thomas Stephen H, 2004, Prehosp Emerg Care, V8, P322; Thomas Stephen H, 2002, Prehosp Emerg Care, V6, P359, DOI 10.1080/10903120290938508	41	36	38	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	NOV	2012	43	11					1843	1849		10.1016/j.injury.2012.07.184			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014VR	WOS:000309404300012	22898559				2021-06-18	
J	Angeleri, R; Bosco, FM; Gabbatore, I; Bara, BG; Sacco, K				Angeleri, Romina; Bosco, Francesca M.; Gabbatore, Ilaria; Bara, Bruno G.; Sacco, Katiuscia			Assessment battery for communication (ABaCo): normative data	BEHAVIOR RESEARCH METHODS			English	Article						Normative data; Communication; Assessment; Pragmatics	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; NEUROPRAGMATICS; IMPAIRMENT; ABILITY	The Assessment Battery for Communication (ABaCo) was introduced to evaluate pragmatic abilities in patients with cerebral lesions. The battery is organized into five evaluation scales focusing on separate components of pragmatic competence. In the present study, we present normative data for individuals 15-75 years of age (N = 300). The sample was stratified by age, sex, and years of education, according to Italian National Institute of Statistics indications in order to be representative of the general national population. Since performance on the ABaCo decreases with age and lower years of education, the norms were stratified for both age and education. The ABaCo is a valuable tool in clinical practice; the normative data provided here will enable clinicians to determine different kinds and specific levels of communicative impairments more precisely.	[Angeleri, Romina; Bosco, Francesca M.; Gabbatore, Ilaria; Bara, Bruno G.; Sacco, Katiuscia] Univ Turin, Ctr Cognit Sci, Dept Psychol, I-10123 Turin, Italy; [Bosco, Francesca M.; Bara, Bruno G.; Sacco, Katiuscia] Neurosci Inst Turin, Turin, Italy; [Sacco, Katiuscia] Koelliker Hosp, CCS fMRI Neuroradiol, Turin, Italy	Angeleri, R (corresponding author), Univ Turin, Ctr Cognit Sci, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	romina.angeleri@unito.it	Sacco, Katiuscia/J-2133-2012; bosco, francesca marina/B-6746-2013; Gabbatore, Ilaria/AAC-1925-2019	Sacco, Katiuscia/0000-0002-9660-5236; bosco, francesca marina/0000-0001-6101-8587; Gabbatore, Ilaria/0000-0002-9724-8066			Adams C, 2002, J CHILD PSYCHOL PSYC, V43, P973, DOI 10.1111/1469-7610.00226; Altman D, 1991, PRACTICAL STAT MED R; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG., 2010, COGNITIVE PRAGMATICS; BATES E, 1976, LANGUAGE CONTEXT STU; Benton E, 1996, INT J REHABIL RES, V19, P47, DOI 10.1097/00004356-199603000-00005; Bishop DVM, 1998, J CHILD PSYCHOL PSYC, V39, P879, DOI 10.1111/1469-7610.00388; Bryan KL., 1995, RIGHT HEMISPHERE LAN; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Cutica I, 2006, BRAIN LANG, V98, P12, DOI 10.1016/j.bandl.2006.01.001; Dardier V, 2011, J COMMUN DISORD, V44, P359, DOI 10.1016/j.jcomdis.2011.02.001; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Ehrlich JS., 1985, COGNITIVE REHABILITA, V3, P32; Ferre P, 2011, REHABIL RES PRACT, V2011, DOI 10.1155/2011/131820; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; GARDNER H, 1986, RIGHT HEMISPHERE COM; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Kempson R.M., 1975, PRESUPPOSITION DELIM; Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; Mitrushina M., 2005, HDB NORMATIVE DATA N; Penn C, 1985, S Afr J Commun Disord, V32, P18; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123; Sacco K, 2008, J COGN SCI, V9, P111; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Zanini S, 2005, NEUROL SCI, V26, P13, DOI 10.1007/s10072-005-0377-x; Zanini S., 2003, BATTERIA LINGUAGGIO	31	36	36	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1554-351X	1554-3528		BEHAV RES METHODS	Behav. Res. Methods	SEP	2012	44	3			SI		845	861		10.3758/s13428-011-0174-9			17	Psychology, Mathematical; Psychology, Experimental	Psychology	084WQ	WOS:000314571200017	22180102	Bronze			2021-06-18	
J	Neumann, D; Zupan, B; Babbage, DR; Radnovich, AJ; Tomita, M; Hammond, F; Willer, B				Neumann, Dawn; Zupan, Barbra; Babbage, Duncan R.; Radnovich, Alexander J.; Tomita, Machiko; Hammond, Flora; Willer, Barry			Affect Recognition, Empathy, and Dysosmia After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the North-American-Brain-Injury-Society	SEP 17, 2011	New Orleans, LA	N Amer Brain Injury Soc		Affect; Brain injuries; Empathy; Olfaction disorders; Rehabilitation	SMELL IDENTIFICATION TEST; FACIAL AFFECT RECOGNITION; VENTROMEDIAL PREFRONTAL CORTEX; OLFACTORY DYSFUNCTION; HEAD-INJURY; NONVERBAL-COMMUNICATION; EMOTION RECOGNITION; INDIVIDUAL-DIFFERENCES; ALZHEIMERS-DISEASE; DECODING ACCURACY	Objective: To investigate if olfaction is associated with affect recognition and empathy deficits after traumatic brain injury (TBI). Prior research has shown that TBI often leads to loss of smell. We hypothesized a relationship with emotion perception, because the neural substrates of the olfactory system overlap with the ventral circuitry of the orbital frontal cortex, which play a critical role in affective responses, such as empathy. Design: Comparative study investigating differences between participants with TBI who had impaired olfaction (dysosmia) with those with normal olfaction (normosmia). Setting: Postacute rehabilitation facilities in the United States, Canada, and New Zealand. Participants: Participants (N= 106) in the current study were a convenience sample of adults with moderate to severe TBI who were tested for olfactory function as part of a larger, related study on affect recognition. On average, participants were 11.5 years postinjury. Interventions: Not applicable. Main Outcome Measures: Olfaction (Brief Smell Identification Test), facial affect recognition (Diagnostic Assessment of Nonverbal Affect 2-Adult Faces [DANVA2-AF]), vocal affect recognition (Diagnostic Assessment of Nonverbal Affect 2-Adult Paralanguage [DANVA2-AP]), emotional inference (Emotional Inference from Stories Test [EIST]), and empathy (Interpersonal Reactivity Index [IRI]). Results: Fifty-six percent of participants were dysosrnic and only 36% of these participants were aware of their deficit. Participants with dysosmia performed significantly poorer on the DANVA2-AF (P=.003), DANVA2-AP (P=.007), EIST (P=.016), and IRI (P=.013). Medium effect sizes were found for all measures. Dysosmia had a sensitivity value of 86.4% for detecting facial affect recognition impairments and 67.8% for vocal affect recognition impairments. Conclusions: This study shows that olfactory deficits may be indicative of affect recognition impairments and reduced empathy. Early knowledge of affect recognition and empathy deficits would be valuable so that treatment could be implemented predischarge.	[Neumann, Dawn; Hammond, Flora] Dept Phys Med & Rehabil, Charlotte, NC USA; [Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Babbage, Duncan R.] Massey Univ, Sch Psychol, Wellington, New Zealand; [Radnovich, Alexander J.] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Tomita, Machiko] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Rehabil Sci, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Sch Med, Dept Psychiat, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Sch Med, Dept Rehabil Med, Buffalo, NY 14260 USA	Neumann, D (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	dmneuman@iupui.edu		Babbage, Duncan/0000-0002-9259-9246; Barbra, Zupan/0000-0002-4603-333X			Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; Anderson AK, 2000, NEUROPSYCHOLOGY, V14, P526, DOI 10.1037/0894-4105.14.4.526; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Baum KM, 1998, J NONVERBAL BEHAV, V22, P89, DOI 10.1023/A:1022954014365; Brookshire RH, 1993, DISCOURSE COMPREHENS; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Carton JS, 1999, J NONVERBAL BEHAV, V23, P91, DOI 10.1023/A:1021339410262; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Costanzo R, 2003, NEUROL DIS THER, V57, P629; COSTANZO RM, 1987, ANN NY ACAD SCI, V510, P242; Cox CL, 2011, SOC COGN AFFECT NEUR; Critchley H, 2000, HUM BRAIN MAPP, V9, P93, DOI 10.1002/(SICI)1097-0193(200002)9:2<93::AID-HBM4>3.0.CO;2-Z; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; Davis MH, 1980, JSAS CATALOG SELECTE, V10; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Doty RL, 2006, INT ARCH OCC ENV HEA, V79, P268, DOI 10.1007/s00420-005-0055-6; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DOTY RL, 1995, NEURODEGENERATION, V4, P93, DOI 10.1006/neur.1995.0011; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; Fan Y, 2011, NEUROSCI BIOBEHAV R, V35, P903, DOI 10.1016/j.neubiorev.2010.10.009; Goudsmit N, 2003, PSYCHIAT RES, V120, P155, DOI 10.1016/S0165-1781(03)00194-X; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Heywood PG, 1990, 14 ANN C REH BRAIN I; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Kjelvik G, 2007, INT J GERIATR PSYCH, V22, P1020, DOI 10.1002/gps.1783; Kohler CG, 2007, J NEUROPSYCH CLIN N, V19, P128, DOI 10.1176/appi.neuropsych.19.2.128; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McIntosh G C, 1997, Appl Neuropsychol, V4, P62, DOI 10.1207/s15324826an0401_8; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; NORDIN S, 1995, J GERONTOL B-PSYCHOL, V50, pP187, DOI 10.1093/geronb/50B.4.P187; NOWICKI S, 1988, J SOC PSYCHOL, V128, P363, DOI 10.1080/00224545.1988.9713753; Nowicki S, 1998, GENET SOC GEN PSYCH, V124, P39; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; NOWICKI S, 1989, J GENET PSYCHOL, V150, P39, DOI 10.1080/00221325.1989.9914572; Nowicki S, 1997, J GENET PSYCHOL, V158, P357, DOI 10.1080/00221329709596674; Phillips ML, 1998, P ROY SOC B-BIOL SCI, V265, P1809, DOI 10.1098/rspb.1998.0506; Phillips ML, 2003, BRIT J PSYCHIAT, V182, P190, DOI 10.1192/bjp.182.3.190; Pope K, 2007, NEUROSCI LETT, V422, P13, DOI 10.1016/j.neulet.2007.05.041; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Radnovich AJ, 2009, DISS ABSTR INT B; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; RIGGIO RE, 1989, PERS INDIV DIFFER, V10, P93, DOI 10.1016/0191-8869(89)90184-0; Rosip JC, 2004, J NONVERBAL BEHAV, V28, P267, DOI 10.1007/s10919-004-4159-6; Seubert J, 2010, NEUROIMAGE, V53, P746, DOI 10.1016/j.neuroimage.2010.07.012; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; Spinella M, 2002, INT J NEUROSCI, V112, P605, DOI 10.1080/00207450290025680; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012; Zupan B., 2009, DEP APPL LING RES DA	72	36	38	2	25	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1414	1420		10.1016/j.apmr.2012.03.009			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700019	22446155				2021-06-18	
J	Warren, KM; Reeves, TM; Phillips, LL				Warren, Kelly M.; Reeves, Thomas M.; Phillips, Linda L.			MT5-MMP, ADAM-10, and N-Cadherin Act in Concert To Facilitate Synapse Reorganization after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						a distintegrin and metalloproteinase-10 (ADAM-10); brain injury; membrane type 5-matrix metalloproteinase (MT5-MMP); N-cadherin; synaptic plasticity	LONG-TERM POTENTIATION; AMYLOID PRECURSOR PROTEIN; MATRIX-METALLOPROTEINASE EXPRESSION; AMPA RECEPTOR TRAFFICKING; COMBINED FLUID PERCUSSION; CULTURED RAT ASTROCYTES; OLFACTORY NERVE INJURY; GFAP MESSENGER-RNA; DENTATE-GYRUS; CEREBRAL-ISCHEMIA	Matrix metalloproteinases (MMPs) influence synaptic recovery following traumatic brain injury (TBI). Membrane type 5-matrix metalloproteinase (MT5-MMP) and a distintegrin and metalloproteinase-10 (ADAM-10) are membrane-bound MMPs that cleave N-cadherin, a protein critical to synapse stabilization. This study examined protein and mRNA expression of MT5-MMP, ADAM-10, and N-cadherin after TBI, contrasting adaptive and maladaptive synaptogenesis. The effect of MMP inhibition on MT5-MMP, ADAM-10, and N-cadherin was assessed during maladaptive plasticity and correlated with synaptic function. Rats were subjected to adaptive unilateral entorhinal cortical lesion (UEC) or maladaptive fluid percussion TBI + bilateral entorhinal cortical lesion (TBI + BEC). Hippocampal MT5-MMP and ADAM-10 protein was significantly elevated 2 and 7 days post-injury. At 15 days after UEC, each MMP returned to control level, while TBI + BEC ADAM-10 remained elevated. At 2 and 7 days, N-cadherin protein was below control. By the 15-day synapse stabilization phase, UEC N-cadherin rose above control, a shift not seen for TBI + BEC. At 7 days, increased TBI + BEC ADAM-10 transcript correlated with protein elevation. UEC ADAM-10 mRNA did not change, and no differences in MT5-MMP or N-cadherin mRNA were detected. Confocal imaging showed MT5-MMP, ADAM-10, and N-cadherin localization within reactive astrocytes. MMP inhibition attenuated ADAM-10 protein 15 days after TBI + BEC and increased N-cadherin. This inhibition partially restored long-term potentiation induction, but did not affect paired-pulse facilitation. Our results confirm time-and injury-dependent expression of MT5-MMP, ADAM-10, and N-cadherin during reactive synaptogenesis. Persistent ADAM-10 expression was correlated with attenuated N-cadherin level and reduced functional recovery. MMP inhibition shifted ADAM-10 and N-cadherin toward adaptive expression and improved synaptic function.	[Warren, Kelly M.; Reeves, Thomas M.; Phillips, Linda L.] Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Phillips, LL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	llphilli@vcu.edu			NIH/NINDS Center Core Grant [NS047463]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS057758, NS056247, NS044372]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056247, R01NS057758, R56NS044372, R01NS044372, P30NS047463] Funding Source: NIH RePORTER	The authors wish to thank Lesley K. Harris, Raiford T. Black, and Nancy N. Lee for their excellent technical assistance. Quantitative RT-PCR was conducted through the VCU Molecular Diagnostics Laboratory, Department of Pathology, in collaboration with Dr. Cathy I. Dumur and Tana L. Blevins. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, which is funded in part by NIH/NINDS Center Core Grant NS047463. These studies were supported by NIH/NINDS grants NS057758, NS056247, and NS044372.	Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Bandyopadhyay S, 2006, J NEUROSCI RES, V84, P106, DOI 10.1002/jnr.20864; Bernstein HG, 2003, J NEUROCYTOL, V32, P153, DOI 10.1023/B:NEUR.0000005600.61844.a6; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Bozdagi O, 2004, MOL CELL NEUROSCI, V27, P509, DOI 10.1016/j.mcn.2004.08.008; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Cao R, 2006, NEUROSCI LETT, V401, P136, DOI 10.1016/j.neulet.2006.03.005; CHANG HS, 1989, BRAIN RES, V505, P220, DOI 10.1016/0006-8993(89)91446-7; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Conant K, 2005, MATRIX METALLOPROTEINASES IN THE CENTRAL NERVOUS SYSTEM, P1, DOI 10.1142/9781860947179; Conant K, 2010, NEUROSCIENCE, V166, P508, DOI 10.1016/j.neuroscience.2009.12.061; Costanzo RM, 2008, NEUROREPORT, V19, P327, DOI 10.1097/WNR.0b013e3282f50c7b; Costanzo RM, 2006, NEUROREPORT, V17, P1787, DOI 10.1097/WNR.0b013e32800fef87; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dong JH, 2004, GLIA, V47, P102, DOI 10.1002/glia.10355; Dumur CI, 2009, LARYNGOSCOPE, V119, P91, DOI 10.1002/lary.20005; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Ferraro GB, 2011, J BIOL CHEM, V286, P31418, DOI 10.1074/jbc.M111.249169; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; Harris JL, 2011, HIPPOCAMPUS, V21, P81, DOI 10.1002/hipo.20725; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hayashita-Kinoh H, 2001, CELL GROWTH DIFFER, V12, P573; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Huntley GW, 2012, HIPPOCAMPUS, V22, P17, DOI 10.1002/hipo.20859; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Jangouk P, 2009, GLIA, V57, P1765, DOI 10.1002/glia.20889; Jaworski DM, 2000, BRAIN RES, V860, P174, DOI 10.1016/S0006-8993(00)02035-7; KAMPHUIS W, 1992, NEUROSCI LETT, V141, P101, DOI 10.1016/0304-3940(92)90344-7; KEPPEL G, 1991, DESIGN ANAL RESEARCH; Kieseier BC, 2003, GLIA, V42, P398, DOI 10.1002/glia.10226; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Komori K, 2004, FEBS LETT, V557, P125, DOI 10.1016/S0014-5793(03)01458-3; Lathia JD, 2008, J NEUROCHEM, V107, P1471, DOI 10.1111/j.1471-4159.2008.05715.x; LEUNG LS, 1994, BRAIN RES, V650, P75; LEVINE G, 1991, GUIDE SPSS ANAL VARI; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Llano E, 1999, CANCER RES, V59, P2570; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LOMO T, 1971, EXP BRAIN RES, V12, P46; Maarouf CL, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-20; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; Maretzky T, 2008, J INVEST DERMATOL, V128, P1737, DOI 10.1038/sj.jid.5701242; Marrs GS, 2009, MOL CELL NEUROSCI, V40, P390, DOI 10.1016/j.mcn.2008.12.007; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; Mayer J, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-52; McCusker Catherine D, 2009, Commun Integr Biol, V2, P155; Meighan PC, 2007, J NEUROCHEM, V102, P2085, DOI 10.1111/j.1471-4159.2007.04682.x; Monea S, 2006, J NEUROSCI, V26, P2300, DOI 10.1523/JNEUROSCI.3521-05.2006; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Mysore SP, 2007, FRONT CELL NEUROSCI, V1, DOI 10.3389/neuro.03.001.2007; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Nuriya M, 2006, J NEUROCHEM, V97, P652, DOI 10.1111/j.1471-4159.2006.03740.x; Okonkwo David O., 2003, P263; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ortiz RM, 2005, MOL BRAIN RES, V137, P272, DOI 10.1016/j.molbrainres.2005.03.008; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Plumb J, 2005, J NEUROIMMUNOL, V164, P1, DOI 10.1016/j.jneuroim.2005.02.021; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Reeves TM, 2003, J NEUROSCI, V23, P10182; REEVES TM, 1986, EXP BRAIN RES, V65, P167; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 2001, STROKE, V32, P1162, DOI 10.1161/01.STR.32.5.1162; Sbai O, 2010, GLIA, V58, P344, DOI 10.1002/glia.20927; Schlomann U, 2000, J NEUROSCI, V20, P7964; SCHULTZ GS, 1992, INVEST OPHTH VIS SCI, V33, P3325; Sekine-Aizawa Y, 2001, EUR J NEUROSCI, V13, P935, DOI 10.1046/j.0953-816x.2001.01462.x; Shan WS, 2002, J NEUROSCI RES, V69, P292, DOI 10.1002/jnr.10305; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Takeichi M, 2005, TRENDS CELL BIOL, V15, P216, DOI 10.1016/j.tcb.2005.02.002; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Toft-Hansen H, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-24; Tousseyn T, 2009, J BIOL CHEM, V284, P11738, DOI 10.1074/jbc.M805894200; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang WY, 2005, NEUROSCIENCE, V134, P1167, DOI 10.1016/j.neuroscience.2005.04.064; Wang X, 1999, FEBS LETT, V462, P261, DOI 10.1016/S0014-5793(99)01534-3; Wang XB, 2008, P NATL ACAD SCI USA, V105, P19520, DOI 10.1073/pnas.0807248105; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wells GMA, 1996, GLIA, V18, P332, DOI 10.1002/(SICI)1098-1136(199612)18:4<332::AID-GLIA7>3.3.CO;2-4; Wojtowicz T, 2010, HIPPOCAMPUS, V20, P917, DOI 10.1002/hipo.20787; Yang P, 2006, PROG NEUROBIOL, V79, P73, DOI 10.1016/j.pneurobio.2006.05.001; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zalewska T, 2003, BRAIN RES, V977, P62, DOI 10.1016/S0006-8993(03)02742-2; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	114	36	37	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1922	1940		10.1089/neu.2012.2383			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400396	22489706	Green Published			2021-06-18	
J	Ravin, R; Blank, PS; Steinkamp, A; Rappaport, SM; Ravin, N; Bezrukov, L; Guerrero-Cazares, H; Quinones-Hinojosa, A; Bezrukov, SM; Zimmerberg, J				Ravin, Rea; Blank, Paul S.; Steinkamp, Alex; Rappaport, Shay M.; Ravin, Nitay; Bezrukov, Ludmila; Guerrero-Cazares, Hugo; Quinones-Hinojosa, Alfredo; Bezrukov, Sergey M.; Zimmerberg, Joshua			Shear Forces during Blast, Not Abrupt Changes in Pressure Alone, Generate Calcium Activity in Human Brain Cells	PLOS ONE			English	Article							IN-VITRO; INJURY; MODEL; MECHANISMS; WAVE; RESPONSES	Blast-Induced Traumatic Brain Injury (bTBI) describes a spectrum of injuries caused by an explosive force that results in changes in brain function. The mechanism responsible for primary bTBI following a blast shockwave remains unknown. We have developed a pneumatic device that delivers shockwaves, similar to those known to induce bTBI, within a chamber optimal for fluorescence microscopy. Abrupt changes in pressure can be created with and without the presence of shear forces at the surface of cells. In primary cultures of human central nervous system cells, the cellular calcium response to shockwaves alone was negligible. Even when the applied pressure reached 15 atm, there was no damage or excitation, unless concomitant shear forces, peaking between 0.3 to 0.7 Pa, were present at the cell surface. The probability of cellular injury in response to a shockwave was low and cell survival was unaffected 20 hours after shockwave exposure.	[Ravin, Rea; Blank, Paul S.; Steinkamp, Alex; Rappaport, Shay M.; Ravin, Nitay; Bezrukov, Ludmila; Bezrukov, Sergey M.; Zimmerberg, Joshua] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Phys Biol, NIH, Bethesda, MD USA; [Blank, Paul S.; Rappaport, Shay M.; Bezrukov, Sergey M.; Zimmerberg, Joshua] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Guerrero-Cazares, Hugo; Quinones-Hinojosa, Alfredo] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA	Ravin, R (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Phys Biol, NIH, Bethesda, MD USA.	zimmerbj@mail.nih.gov	Blank, Paul/Q-9673-2019	Guerrero-Cazares, Hugo/0000-0003-1307-719X	Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [ZIAHD001409, ZIAHD000072] Funding Source: NIH RePORTER	Support for this work included funding from Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM) and the Intramural Program of the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arun P, 2011, NEUROREPORT, V22, P379, DOI 10.1097/WNR.0b013e328346b138; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; BRODE HL, 1959, PHYS FLUIDS, V2, P217, DOI 10.1063/1.1705911; Center DaVBI, 2011, DEP DEF NUMB TRAUM B; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howard D, 1997, ULTRASOUND MED BIOL, V23, P1107, DOI 10.1016/S0301-5629(97)00081-1; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; LaPlaca Michelle C, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2384; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Shin HS, 2009, J NANOSCI NANOTECHNO, V9, P7330, DOI 10.1166/jnn.2009.1769; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; WHITTAKER VP, 1993, J NEUROCYTOL, V22, P735, DOI 10.1007/BF01181319; Zhang JY, 2009, STAPP CAR CRASH JO, V53, P215	27	36	36	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e39421	10.1371/journal.pone.0039421			8	Multidisciplinary Sciences	Science & Technology - Other Topics	967FO	WOS:000305892100049	22768078	DOAJ Gold, Green Published			2021-06-18	
J	Hu, ZH; Yu, DN; Almeida-Suhett, C; Tu, K; Marini, AM; Eiden, L; Braga, MF; Zhu, J; Li, Z				Hu, Zhonghua; Yu, Danni; Almeida-Suhett, Camila; Tu, Kang; Marini, Ann M.; Eiden, Lee; Braga, Maria F.; Zhu, Jun; Li, Zheng			Expression of miRNAs and Their Cooperative Regulation of the Pathophysiology in Traumatic Brain Injury	PLOS ONE			English	Article							GENE-EXPRESSION; MICRORNA; IMPACT; RAT; NEUROPROTECTION; MECHANISMS; GENOME; MEMORY	Traumatic brain injury (TBI) is a leading cause of injury-related death and disability worldwide. Effective treatment for TBI is limited and many TBI patients suffer from neuropsychiatric sequelae. The molecular and cellular mechanisms underlying the neuronal damage and impairment of mental abilities following TBI are largely unknown. Here we used the next generation sequencing platform to delineate miRNA transcriptome changes in the hippocampus at 24 hours and 7 days following TBI in the rat controlled cortical impact injury (CCI) model, and developed a bioinformatic analysis to identify cellular activities that are regulated by miRNAs differentially expressed in the CCI brains. The results of our study indicate that distinct sets of miRNAs are regulated at different post-traumatic times, and suggest that multiple miRNA species cooperatively regulate cellular pathways for the pathological changes and management of brain injury. The distinctive miRNAs expression profiles at different post-CCI times may be used as molecular signatures to assess TBI progression. In addition to known pathophysiological changes, our study identifies many other cellular pathways that are subjected to modification by differentially expressed miRNAs in TBI brains. These pathways can potentially be targeted for development of novel TBI treatment.	[Hu, Zhonghua; Li, Zheng] NIMH, Unit Synapse Dev & Plast, NIH, Bethesda, MD 20892 USA; [Eiden, Lee] NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA; [Tu, Kang; Zhu, Jun] NHLBI, Genet & Dev Biol Ctr, NIH, Bethesda, MD 20892 USA; [Yu, Danni] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA; [Almeida-Suhett, Camila; Braga, Maria F.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Marini, Ann M.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Neurol, Bethesda, MD 20814 USA	Hu, ZH (corresponding author), NIMH, Unit Synapse Dev & Plast, NIH, Bethesda, MD 20892 USA.	lizheng2@mail.nih.gov	Hu, Zhonghua/J-1169-2016; Li, Zheng/I-8016-2014; Hu, Zhonghua/F-9493-2014; Almeida-Suhett, Camila/I-8045-2016	Hu, Zhonghua/0000-0002-0117-7081; Li, Zheng/0000-0002-2978-2531; Eiden, Lee/0000-0001-7524-944X; Almeida-Suhett, Camila/0000-0002-7588-9487	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZICHL006058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002386, ZIAMH002882] Funding Source: NIH RePORTER	Support for this work includes funding from the Intramural Research Program of the NIMH and Department of Defense in the Center for Neuroscience and Regenerative Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barr TL, 2011, BIOL RES NURS, V13, P140, DOI 10.1177/1099800410385671; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fenelon K, 2011, P NATL ACAD SCI USA, V108, P4447, DOI 10.1073/pnas.1101219108; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Konopka W, 2010, J NEUROSCI, V30, P14835, DOI 10.1523/JNEUROSCI.3030-10.2010; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Ling KH, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-176; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shao NY, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-409; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P1, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Twigger SN, 2008, NAT GENET, V40, P523, DOI 10.1038/ng0508-523; Wu H, 2010, MOL CELL, V38, P67, DOI 10.1016/j.molcel.2010.02.021	35	36	38	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39357	10.1371/journal.pone.0039357			11	Multidisciplinary Sciences	Science & Technology - Other Topics	964XV	WOS:000305730900050	22761770	DOAJ Gold, Green Published			2021-06-18	
J	Biersteker, HAR; Andriessen, TMJC; Horn, J; Franschman, G; van der Naalt, J; Hoedemaekers, CWE; Lingsma, HF; Haitsma, I; Vos, PE				Biersteker, Heleen A. R.; Andriessen, Teuntje M. J. C.; Horn, Janneke; Franschman, Gaby; van der Naalt, Joukje; Hoedemaekers, Cornelia W. E.; Lingsma, Hester F.; Haitsma, Iain; Vos, Pieter E.			Factors influencing intracranial pressure monitoring guideline compliance and outcome after severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						computed tomography; Glasgow Outcome Scale; guideline adherence; intracranial pressure; multivariate analysis; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; COMPUTERIZED-TOMOGRAPHY; PROSPECTIVE MULTICENTER; EUROPEAN BRAIN; INTENSIVE-CARE; MANAGEMENT; MODERATE; CLASSIFICATION; COMPLICATIONS	Objective: To determine adherence to Brain Trauma Foundation guidelines for intracranial pressure monitoring after severe traumatic brain injury, to investigate if characteristics of patients treated according to guidelines (ICP+) differ from those who were not (ICP-), and whether guideline compliance is related to 6-month outcome. Design: Observational multicenter study. Patients: Consecutive severe traumatic brain injury patients (>= 16 yrs, n = 265) meeting criteria for intracranial pressure monitoring. Measurements and Main Results: Data on demographics, injury severity, computed tomography findings, and patient management were registered. The Glasgow Outcome Scale Extended was dichotomized into death (Glasgow Outcome Scale Extended = 1) and unfavorable outcome (Glasgow Outcome Scale Extended 1-4). Guideline compliance was 46%. Differences between the monitored and nonmonitored patients included a younger age (median 44 vs. 53 yrs), more abnormal pupillary reactions (52% vs. 32%), and more intracranial pathology (subarachnoid hemorrhage 62% vs. 44%; intraparenchymal lesions 65% vs. 46%) in the ICP+ group. Patients with a total intracranial lesion volume of similar to 150 mL and a midline shift of similar to 12 mm were most likely to receive an intracranial pressure monitor and probabilities decreased with smaller and larger lesions and shifts. Furthermore, compliance was low in patients with no (Traumatic Coma Databank score I -10%) visible intracranial pathology. Differences in case-mix resulted in higher a priori probabilities of dying (median 0.51 vs. 0.35, p < .001) and unfavorable outcome (median 0.79 vs. 0.63, p < .001) in the ICP+ group. After correction for baseline and clinical characteristics with a propensity score, intracranial pressure monitoring guideline compliance was not associated with mortality (odds ratio 0.93, 95% confidence interval 0.47-1.85, p = .83) nor with unfavorable outcome (odds ratio 1.81, 95% confidence interval 0.88-3.73, p = .11). Conclusions: Guideline noncompliance was most prominent in patients with minor or very large computed tomography abnormalities. Intracranial pressure monitoring was not associated with 6-month outcome, but multiple baseline differences between monitored and nonmonitored patients underline the complex nature of examining the effect of intracranial pressure monitoring in observational studies. (Crit Care Med 2012; 40:1914-1922)	[Biersteker, Heleen A. R.; Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Hoedemaekers, Cornelia W. E.] Radboud Univ Nijmegen, Dept Intens Care Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [Franschman, Gaby] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands; [van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Lingsma, Hester F.] Ctr Med Decis Making, Dept Publ Hlth, Erasmus Med Ctr, Rotterdam, Netherlands; [Haitsma, Iain] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Vos, PE (corresponding author), Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015		Dutch Brain Foundation [Hersenstichting - HSN-07-01]	The POCON study is funded by the Dutch Brain Foundation (Hersenstichting - HSN-07-01).	Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 2009, J CLIN NEUROSCI, V16, P236, DOI 10.1016/j.jocn.2008.02.008; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bremmer R, 2010, NEUROCRIT CARE, V12, P362, DOI 10.1007/s12028-009-9329-2; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Buret H, 2008, J TRAUMA, V65, P499, DOI 10.1097/TA.0b013e318180208e; Chesnut RM, 2008, J TRAUMA, V65, P500, DOI 10.1097/TA.0b013e31818020b3; Chesnut RM, 2006, CRIT CARE MED, V34, P2262, DOI 10.1097/01.CCM.0000229885.76483.F7; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Grande PO, 2009, J TRAUMA, V67, P415, DOI 10.1097/TA.0b013e3181aa236e; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Huizenga JE, 2002, ACAD EMERG MED, V9, P806, DOI 10.1197/aemj.9.8.806; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Lane PL, 2000, CAN J SURG, V43, P442; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rincon Fred, 2006, Curr Neurol Neurosci Rep, V6, P507, DOI 10.1007/s11910-006-0053-4; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Salim A, 2008, AM SURGEON, V74, P1088; Servadei F, 2000, NEUROSURGERY, V46, P70; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stevens RD, 2005, CRIT CARE MED, V33, P2415, DOI 10.1097/01.CCM.0000182993.63691.E1; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; Stover JF, 2006, CRIT CARE MED, V34, P1582, DOI 10.1097/01.CCM.0000216697.37348.FC; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	54	36	36	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1914	1922		10.1097/CCM.0b013e3182474bde			9	Critical Care Medicine	General & Internal Medicine	946EZ	WOS:000304335600030	22488001				2021-06-18	
J	Wilde, EA; McCauley, SR; Barnes, A; Wu, TC; Chu, ZL; Hunter, JV; Bigler, ED				Wilde, Elisabeth A.; McCauley, Stephen R.; Barnes, Amanda; Wu, Trevor C.; Chu, Zili; Hunter, Jill V.; Bigler, Erin D.			Serial measurement of memory and diffusion tensor imaging changes within the first week following uncomplicated mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Diffusion tensor imaging; Concussion; Mild traumatic brain injury; Semi-acute; Serial measurement; Memory	VERBAL WORKING-MEMORY; WHITE-MATTER INJURY; DSM-IV CRITERIA; POSTCONCUSSIONAL DISORDER; AXONAL INJURY; PRACTICAL SCALE; RISK-FACTORS; HEAD-INJURY; CONCUSSION; RECOVERY	Patients (n = 8) with uncomplicated mild traumatic brain injury (mTBI) underwent serial assessments (4) with diffusion tensor imaging (DTI) and neuropsychological testing within the first 8 days post-injury. Using a multi-case study design, we examined changes in brain parenchyma (via DTI-derived fractional anisotropy [FA], apparent diffusion coefficient [ADC], axial diffusivity [AD] and radial diffusivity [RD] in the left cingulum bundle) and in memory performance (via Hopkins Verbal Learning Test-Revised). Qualitative inspection of the results indicated that memory performance was transiently affected in most participants over the course of the week, with performance most negatively impacted on the second assessment (days 3-4 or 97-144 h post-injury), and then returning to within normal limits by 8 days post-injury. Alternatively, FA and other DTI metrics showed a more complex pattern, with the trajectory of some participants changing more prominently than others. For example, FA transiently increased in some participants over the study period, but the pattern was heterogeneous. Memory performance appeared to mirror changes in FA in certain cases, supporting a pathophysiological basis to memory impairment following mTBI. However, the pattern and the degree of symmetry between FA and memory performance was complex and did not always correspond. Serial imaging over the semi-acute recovery period may be important in reconciling conflicting findings in mTBI utilizing memory and/or DTI. Serial use of imaging modalities including DTI may aid understanding of underlying pathophysiological changes in the semi-acute post-injury period. Should a consistent pattern emerge that allows identification of patients at-risk for acute and/or persistent symptoms, such knowledge could guide development of therapeutic targets in mTBI and in understanding the most effective administration time window for these agents.	[Wilde, Elisabeth A.; McCauley, Stephen R.; Barnes, Amanda; Wu, Trevor C.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Barnes, Amanda; Wu, Trevor C.] Univ Texas Houston, Sch Med, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Wu, Trevor C.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA	Wilde, EA (corresponding author), Baylor Coll Med, Phys Med & Rehabil Alliance, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu; mccauley@bcm.edu; afbarnes@bcm.edu; ctwu@bcm.edu; zchu@bcm.tmc.edu; jvhunter@texaschildrens.org; erinb@cortex.byu.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R03NS069943-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS069943] Funding Source: NIH RePORTER	This project was supported by grant number 1R03NS069943-01 from the National Institute of Neurological Disorders and Stroke. Portions of this study were presented at the 29th annual meeting of the National Neurotrauma Symposium, Ft. Lauderdale, Florida, June, 2011.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kaneda M, 2008, NEUROSCI LETT, V436, P57, DOI 10.1016/j.neulet.2008.02.069; Ker K, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a865; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; TEASDALE G, 1974, LANCET, V2, P81; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	58	36	36	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557			BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		319	328		10.1007/s11682-012-9174-3			10	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900011	22684768				2021-06-18	
J	Loncarevic-Vasiljkovic, N; Pesic, V; Todorovic, S; Popic, J; Smiljanic, K; Milanovic, D; Ruzdijic, S; Kanazir, S				Loncarevic-Vasiljkovic, Natasa; Pesic, Vesna; Todorovic, Smilja; Popic, Jelena; Smiljanic, Kosara; Milanovic, Desanka; Ruzdijic, Sabera; Kanazir, Selma			Caloric Restriction Suppresses Microglial Activation and Prevents Neuroapoptosis Following Cortical Injury in Rats	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; FOOD RESTRICTION; DIETARY RESTRICTION; DAMAGE; AGE; NEURODEGENERATION; MECHANISMS; APOPTOSIS; CYTOKINES; CASPASES	Traumatic brain injury (TBI) is a widespread cause of death and a major source of adult disability. Subsequent pathological events occurring in the brain after TBI, referred to as secondary injury, continue to damage surrounding tissue resulting in substantial neuronal loss. One of the hallmarks of the secondary injury process is microglial activation resulting in increased cytokine production. Notwithstanding that recent studies demonstrated that caloric restriction (CR) lasting several months prior to an acute TBI exhibits neuroprotective properties, understanding how exactly CR influences secondary injury is still unclear. The goal of the present study was to examine whether CR (50% of daily food intake for 3 months) alleviates the effects of secondary injury on neuronal loss following cortical stab injury (CSI). To this end, we examined the effects of CR on the microglial activation, tumor necrosis factor-alpha (TNF-alpha) and caspase-3 expression in the ipsilateral (injured) cortex of the adult rats during the recovery period (from 2 to 28 days) after injury. Our results demonstrate that CR prior to CSI suppresses microglial activation, induction of TNF-alpha and caspase-3, as well as neurodegeneration following injury. These results indicate that CR strongly attenuates the effects of secondary injury, thus suggesting that CR may increase the successful outcome following TBI.	[Loncarevic-Vasiljkovic, Natasa; Pesic, Vesna; Todorovic, Smilja; Popic, Jelena; Smiljanic, Kosara; Milanovic, Desanka; Ruzdijic, Sabera; Kanazir, Selma] Univ Belgrade, Dept Neurobiol, Inst Biol Res, Belgrade, Serbia	Loncarevic-Vasiljkovic, N (corresponding author), Univ Belgrade, Dept Neurobiol, Inst Biol Res, Belgrade, Serbia.	selkan@ibiss.bg.ac.rs	Kanazir, Selma/E-5495-2015	Kanazir, Selma/0000-0002-7229-5296; Todorovic, Smilja/0000-0001-7155-4914; Smiljanic, Kosara/0000-0002-6790-5491; Popic, Jelena/0000-0002-0959-3856; Pesic, Vesna/0000-0002-1415-5834; Loncarevic-Vasiljkovic, Natasa/0000-0002-8350-1390	Ministry of Education and Science, Republic of Serbia [ON173056]	This work is funded by the Ministry of Education and Science, Republic of Serbia (grant No ON173056). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arumugam TV, 2010, ANN NEUROL, V67, P41, DOI 10.1002/ana.21798; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chiba T, 2010, BIOCHEM BIOPH RES CO, V399, P98, DOI 10.1016/j.bbrc.2010.07.048; Chopek JW, 2010, MECH AGEING DEV, V131, P650, DOI 10.1016/j.mad.2010.09.001; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hiona A, 2004, ANN NY ACAD SCI, V1019, P96, DOI 10.1196/annals.1297.018; Jeong MA, 2011, J NEUROTRAUM, V28, P479, DOI 10.1089/neu.2010.1609; Kraft AD, 2009, NEUROTOXICOLOGY, V30, P785, DOI 10.1016/j.neuro.2009.07.001; Lee LW, 2003, NEUROMOL MED, V4, P179, DOI 10.1385/NMM:4:3:179; Loncarevic-Vasiljkovic N, 2009, EXP NEUROL, V220, P198, DOI 10.1016/j.expneurol.2009.08.024; Madinier A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008101; Manzanero Silvia, 2011, Exp Transl Stroke Med, V3, P8, DOI 10.1186/2040-7378-3-8; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Pekovic S, 2006, NEUROBIOLOGICAL STUDIES - FROM GENES TO BEHAVIOUR 2006, P143; Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reed JL, 2010, APPL PHYSIOL NUTR ME, V35, P573, DOI 10.1139/H10-046; Roberge MC, 2008, BEHAV BRAIN RES, V187, P123, DOI 10.1016/j.bbr.2007.09.002; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Sharma S, 2005, BRAIN RES BULL, V67, P482, DOI 10.1016/j.brainresbull.2005.07.015; Sharma S, 2008, NEUROCHEM RES, V33, P1178, DOI 10.1007/s11064-007-9503-x; Sola E, 2009, OBES SURG, V19, P571, DOI 10.1007/s11695-008-9772-8; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Tuttolomondo A, 2009, CURR TOP MED CHEM, V9, P1240, DOI 10.2174/156802609789869619; Veenith T, 2009, WORLD J EMERG SURG, V2, P4; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	39	36	36	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2012	7	5							e37215	10.1371/journal.pone.0037215			9	Multidisciplinary Sciences	Science & Technology - Other Topics	959TM	WOS:000305336300079	22615943	DOAJ Gold, Green Published			2021-06-18	
J	Theeler, BJ; Flynn, FG; Erickson, JC				Theeler, Brett J.; Flynn, Frederick G.; Erickson, Jay C.			Chronic Daily Headache in U.S. Soldiers After Concussion	HEADACHE			English	Article						mild traumatic brain injury; concussion; posttraumatic headache; military	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; PREVALENCE; VETERANS; MIGRAINE; RISK; IRAQ	Objective.-To determine the prevalence and characteristics of, and factors associated with, chronic daily headache (CDH) in U.S. soldiers after a deployment-related concussion. Methods.-A cross-sectional, questionnaire-based study was conducted with a cohort of 978 U.S. soldiers who screened positive for a deployment-related concussion upon returning from Iraq or Afghanistan. All soldiers underwent a clinical evaluation at the Madigan Traumatic Brain Injury Program that included a history, physical examination, 13-item self-administered headache questionnaire, and a battery of cognitive and psychological assessments. Soldiers with CDH, defined as headaches occurring on 15 or more days per month for the previous 3 months, were compared to soldiers with episodic headaches occurring less than 15 days per month. Results.-One hundred ninety-six of 978 soldiers (20%) with a history of deployment-related concussion met criteria for CDH and 761 (78%) had episodic headache. Soldiers with CDH had a median of 27 headache days per month, and 46/196 (23%) reported headaches occurring every day. One hundred seven out of 196 (55%) soldiers with CDH had onset of headaches within 1 week of head trauma and thereby met the time criterion for posttraumatic headache (PTHA) compared to 253/761 (33%) soldiers with episodic headache. Ninety-seven out of 196 (49%) soldiers with CDH used abortive medications to treat headache on 15 or more days per month for the previous 3 months. One hundred thirty out of 196 (66%) soldiers with CDH had headaches meeting criteria for migraine compared to 49% of soldiers with episodic headache. The number of concussions, blast exposures, and concussions with loss of consciousness was not significantly different between soldiers with and without CDH. Cognitive performance was also similar for soldiers with and without CDH. Soldiers with CDH had significantly higher average scores on the posttraumatic stress disorder (PTSD) checklist compared to soldiers with episodic headaches. Forty-one percent of soldiers with CDH screened positive for PTSD compared to only 18% of soldiers with episodic headache. Conclusions.-The prevalence of CDH in returning U.S. soldiers after a deployment-related concussion is 20%, or 4- to 5-fold higher than that seen in the general U.S. population.CDH following a concussion usually resembles chronic migraine and is associated with onset of headaches within the first week after concussion. The mechanism and number of concussions are not specifically associated with CDH as compared to episodic headache. In contrast, PTSD symptoms are strongly associated with CDH, suggesting that traumatic stress may be an important mediator of headache chronification. These findings justify future studies examining strategies to prevent and treat CDH in military service members following a concussive injury.	[Theeler, Brett J.] 187th Med Battal, AMEDD Student Detachment, Ft Sam Houston, TX 78234 USA; [Erickson, Jay C.] USA, Med Corps, Madigan Army Med Ctr, Dept Med,Neurol Serv, Austin, TX USA; [Flynn, Frederick G.] Madigan Traumat Brain Injury Program, Ft Lewis, WA USA	Theeler, BJ (corresponding author), 187th Med Battal, AMEDD Student Detachment, Ft Sam Houston, TX 78234 USA.	btheeler@hotmail.com					*ARM FORC HLTH SUR, 2009, MED SURVEILLANCE MON, V16, P2; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; de Leeuw R, 2005, HEADACHE, V45, P1365, DOI 10.1111/j.1526-4610.2005.00269.x; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton RB, 2011, HEADACHE, V51, P77, DOI 10.1111/j.1526-4610.2011.01954.x; Mathew NT, 2009, HEADACHE, V49, P1466, DOI 10.1111/j.1526-4610.2009.01566.x; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Ruff RL, 2010, F1000 MED REP, V2, P1; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Scher AI, 2008, HEADACHE, V48, P16, DOI 10.1111/j.1526-4610.2007.00970.x; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	24	36	36	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAY	2012	52	5					732	738		10.1111/j.1526-4610.2012.02112.x			7	Clinical Neurology	Neurosciences & Neurology	936NA	WOS:000303595900004	22404747				2021-06-18	
J	Hua, F; Reiss, JI; Tang, HL; Wang, J; Fowler, X; Sayeed, I; Stein, DG				Hua, Fang; Reiss, Jenny I.; Tang, Huiling; Wang, Jun; Fowler, Xavier; Sayeed, Iqbal; Stein, Donald G.			Progesterone and low-dose vitamin D hormone treatment enhances sparing of memory following traumatic brain injury	HORMONES AND BEHAVIOR			English	Article						Traumatic brain injury; Combination treatments; Functional repair; Progesterone; Vitamin D3 hormone	MORRIS WATER MAZE; SPATIAL WORKING-MEMORY; NERVOUS-SYSTEM; HIPPOCAMPAL-NEURONS; CEREBRAL-ISCHEMIA; CAUDATE-PUTAMEN; D TOXICITY; MALE RATS; IN-VIVO; EXPRESSION	Progesterone (PROG) has been shown to protect the brain from traumatic injury and is now in Phase III clinical trials. Our work shows that PROG's beneficial effects can be reduced in vitamin D hormone (VDH)deficient subjects. VDH can modulate neuronal apoptosis, trophic factors, inflammation, oxidative stress, excitotoxicity, and myelin and axon repair. We investigated whether VDH combined with PROG could improve behavioral outcomes more than PROG alone in VDH-sufficient rats given bilateral contusions of the medial frontal cortex. PROG and different doses of VDH (1 mu g/kg, VDH1; 2.5 mu g/kg, VDH2; 5 mu g/kg, VDH3) were injected intraperitoneally 1 h post-injury. Eight additional doses of PROG were given subcutaneously over 8 days with tapering over the last 2 days. Neurobehavioral tests, necrotic cavity, neuronal death and activation of astrocytes were evaluated 21 days post-injury. We found that PROG and PROG +VDH preserve spatial memory processing. VDH1 + PROG improved performance in acquisition more effectively than PROG alone, indicating that the low VDH dose is optimal for combination therapy. There were no significant differences in necrotic cavity size among the groups. The density of positive staining for reactive astrocytes (glial fibrillary acidic protein (GFAP)) increased and the cell bodies and processes of GFAP-positive cells were enlarged in the PROG + VDH1 group. Our data indicate that the combination of PROG and VDH is more effective than PROG alone in preserving spatial and reference memory, and that PROG plus low-dose VDH can activate GFAP reactions up to 21 days after injury. This effect may be one of the mechanisms underlying PROG's neuroprotective effects in combination with VDH. (C) 2012 Elsevier Inc. All rights reserved.	[Hua, Fang; Reiss, Jenny I.; Tang, Huiling; Wang, Jun; Fowler, Xavier; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	fhua2@emory.edu; jreiss44@gmail.com; htang9@emory.edu; jwang26@emory.edu; xfowler@emory.edu; isayeed@emory.edu; dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS048451, 1R01HD061971]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER	This work was supported by NIH 5R01NS048451 and 1R01HD061971 to DGS. A portion of this research was supported by a gift from BHR Pharma, AHA National Program SDG 0830481N to FH, and AHA 11SDG5430002 to IS. The authors thank Dr. Xiaobo Ma for his contribution to the evaluation of the necrotic cavity.	Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Baldi E, 2005, NEUROSCI LETT, V378, P176, DOI 10.1016/j.neulet.2004.12.029; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Buell JS, 2008, MOL ASPECTS MED, V29, P415, DOI 10.1016/j.mam.2008.05.001; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012925; Chatterjee M, 2001, MUTAT RES-FUND MOL M, V475, P69, DOI 10.1016/S0027-5107(01)00080-X; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; De Keyser J, 2008, J NEUROL SCI, V267, P3, DOI 10.1016/j.jns.2007.08.044; Devan BD, 1999, BEHAV BRAIN RES, V100, P5, DOI 10.1016/S0166-4328(98)00107-7; DEVIRAGH PA, 1989, P NATL ACAD SCI USA, V86, P3887; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; Ferretti V, 2007, BEHAV BRAIN RES, V179, P43, DOI 10.1016/j.bbr.2007.01.009; Frielingsdorf H, 2006, BEHAV BRAIN RES, V168, P37, DOI 10.1016/j.bbr.2005.10.008; Gangisetty O, 2010, NEUROSCIENCE, V170, P865, DOI 10.1016/j.neuroscience.2010.07.037; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gunn BG, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00131; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jones G, 2008, AM J CLIN NUTR, V88, p582S; Kajta M, 2009, NEUROCHEM INT, V55, P265, DOI 10.1016/j.neuint.2009.03.010; Lin AMY, 2005, ANN NY ACAD SCI, V1053, P319, DOI 10.1196/annals.1344.028; Losem-Heinrichs E, 2005, ARCH BIOCHEM BIOPHYS, V439, P70, DOI 10.1016/j.abb.2005.04.021; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; PAULSON PE, 1994, BEHAV NEUROSCI, V108, P624, DOI 10.1037/0735-7044.108.3.624; Prior H, 1997, BEHAV BRAIN RES, V87, P183, DOI 10.1016/S0166-4328(97)02282-1; Stein DG, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P2223; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Stein DG, 2011, PM&R, V3, pS100, DOI 10.1016/j.pmrj.2011.03.010; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Thacher TD, 2011, MAYO CLIN PROC, V86, P50, DOI 10.4065/mcp.2010.0567; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang JP, 2010, BEHAV BRAIN RES, V209, P119, DOI 10.1016/j.bbr.2010.01.026; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zhang R, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-65	54	36	38	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0018-506X			HORM BEHAV	Horm. Behav.	APR	2012	61	4					642	651		10.1016/j.yhbeh.2012.02.017			10	Behavioral Sciences; Endocrinology & Metabolism	Behavioral Sciences; Endocrinology & Metabolism	925LW	WOS:000302763700024	22570859	Green Accepted			2021-06-18	
J	Kang, EK; Kim, DY; Paik, NJ				Kang, Eun-Kyoung; Kim, Dae-Yul; Paik, Nam-Jong			TRANSCRANIAL DIRECT CURRENT STIMULATION OF THE LEFT PREFRONTAL CORTEX IMPROVES ATTENTION IN PATIENTS WITH TRAUMATIC BRAIN INJURY: A PILOT STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; attention; cognition; transcranial direct current stimulation	WORKING-MEMORY; COGNITIVE REHABILITATION; ASSISTIVE-TECHNOLOGY; DC STIMULATION; POLARIZATION; DEPRESSION; DISORDER; CHILDREN; SYSTEM	Objective: To determine whether a single session of anodal transcranial direct current stimulation to the left dorsolateral prefrontal cortex improves attention in patients with traumatic brain injury. Design: Double-blinded, cross-over design. Patients: Nine patients with attention deficit after traumatic brain injury. Methods: Patients underwent a computerized contrast reaction time task before and after the administration of real transcranial direct current stimulation (2 mA for 20 min) or sham transcranial direct current stimulation (2 mA for 1 min) to the left dorsolateral prefrontal cortex in a double-blind, crossover manner. Results: Immediately post-stimulation, the transcranial direct current stimulation group showed a tendency of shortened reaction time relative to baseline (87.3 +/- 7.8%), whereas the sham stimulation group (122.4 +/- 715.5%) did not (p = 0.056). However, this difference was not significant 3 or 24 h after stimulation (p > 0.05). The numbers of correct responses were not changed at any time after stimulation. Conclusion: Anodal transcranial direct current stimulation applied to the left dorsolateral prefrontal cortex improves attention compared with sham stimulation in patients with traumatic brain injury, which suggests a potential role for this intervention in improving attention during cognitive training after traumatic brain injury. A further prospective randomized trial is required to confirm the benefits conferred by transcranial direct current stimulation in this patient population.	[Kang, Eun-Kyoung; Paik, Nam-Jong] Seoul Natl Univ, Bundang Hosp, Dept Rehabil Med, Songnam, South Korea; [Kim, Dae-Yul] Univ Ulsan, Coll Med, Dept Rehabil Med, Asan Med Ctr, Seoul, South Korea; [Paik, Nam-Jong] Seoul Natl Univ, Coll Med, Dept Rehabil Med, Seoul, South Korea	Paik, NJ (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Rehabil Med, Coll Med, 166 Gumi Ro, Songnam 463707, Gyeonggi Do, South Korea.	njpaik@snu.ac.kr	Paik, Nam-Jong/D-5798-2012	Paik, Nam-Jong/0000-0002-5193-8678	Ministry for Health, Welfare & Family Affairs, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A101901]; Handok and Daewoong Pharmaceuticals Co., Ltd; SK Chemicals Ltd.	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (Grant number: A101901), and by research funds from Handok and Daewoong Pharmaceuticals Co., Ltd and SK Chemicals Ltd.	Ashman TA, 2006, MT SINAI J MED, V73, P999; Baddeley A. D., 1986, WORKING MEMORY; Boggio PS, 2007, J AFFECT DISORDERS, V101, P91, DOI 10.1016/j.jad.2006.10.026; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; CHELUNE GJ, 1986, CHILD PSYCHIAT HUM D, V16, P221, DOI 10.1007/BF00706479; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Elmer S, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-29; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2006, DEPRESS ANXIETY, V23, P482, DOI 10.1002/da.20201; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Kang EK, 2009, RESTOR NEUROL NEUROS, V27, P645, DOI 10.3233/RNN-2009-0514; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lopresti EF, 2008, IEEE ENG MED BIOL, V27, P29, DOI 10.1109/EMB.2007.907396; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Neligan A, 2009, J PEDIATR-US, V155, P449, DOI 10.1016/j.jpeds.2009.06.056; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2004, CLIN NEUROPHYSIOL, V115, P2419, DOI 10.1016/j.clinph.2004.05.001; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Priori A, 2009, BRAIN STIMUL, V2, P241, DOI 10.1016/j.brs.2009.02.004; Rango M, 2008, MAGN RESON MED, V60, P782, DOI 10.1002/mrm.21709; SHUE KL, 1992, BRAIN COGNITION, V20, P104, DOI 10.1016/0278-2626(92)90064-S; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Wassermann EM, 2005, TRENDS COGN SCI, V9, P503, DOI 10.1016/j.tics.2005.09.001; Zencius AH, 1998, BRAIN INJURY, V12, P53, DOI 10.1080/026990598122854; Zomeren A. H., 1994, CLIN NEUROPSYCHOLOGY; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	37	36	38	0	19	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	APR	2012	44	4					346	350		10.2340/16501977-0947			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	939WS	WOS:000303850800008	22434324	DOAJ Gold			2021-06-18	
J	Stein, DM; Lindell, AL; Murdock, KR; Kufera, JA; Menaker, J; Bochicchio, GV; Aarabi, B; Scalea, TM				Stein, Deborah M.; Lindell, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Bochicchio, Grant V.; Aarabi, Bizhan; Scalea, Thomas M.			Use of Serum Biomarkers To Predict Cerebral Hypoxia after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; clinical management of CNS injury; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; INTRACTABLE INTRACRANIAL HYPERTENSION; MULITPLE COMPARTMENT SYNDROME; FIBRILLARY ACIDIC PROTEIN; GLASGOW OUTCOME SCALE; CARDIAC-ARREST; CEREBROSPINAL-FLUID; TISSUE OXYGEN; DECOMPRESSIVE CRANIECTOMY	The management of severe traumatic brain injury (TBI) focuses on prevention and treatment of secondary insults such as cerebral hypoxia (CH). There are a number of biomarkers that are thought to play a part in secondary injury following severe TBI. This study evaluates the association between S100 beta, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP), detected in the serum of severe TBI patients and CH as measured by brain tissue oxygen partial pressure (Pbo(2)). Patients with severe TBI were prospectively enrolled. Pressure times time (PTD; mm Hg*h), measuring the depth and duration of CH, was calculated for 12-h periods for episodes of moderate (Pbo(2) < 20 mm Hg) and severe (Pbo(2) < 15 mm Hg) CH, and compared to serum levels of S100 beta, NSE, and GFAP drawn prior to periods of monitoring. An adjusted mixed model analysis was applied as was receiver operating characteristic (ROC) curve analysis. Of 76 patients enrolled, 24 had Pbo(2) monitoring. One hundred and thirty serum samples were matched with 12-h periods of monitoring. Significant associations were found in adjusted analyses between increasing serum levels of S100 beta (coefficient = 0.57, 0.56; p < 0.001), NSE (coefficient = 0.48, 0.52; p < 0.001), and GFAP (coefficient = 0.29, 0.30; p = 0.003 and 0.002), and increasing PTD of moderate (Pbo(2) < 20mm Hg) and severe (Pbo(2) < 15 mm Hg) CH. AUCs for the prediction of moderate and severe CH were 0.62 and 0.66 for S100 beta, 0.55 and 0.71 for NSE, and 0.50 and 0.62 for GFAP, respectively. Specificities were between 76% and 90% for S100 beta and NSE. S100 beta, NSE, and GFAP demonstrate promise as candidate serum markers of impending CH. The fact that these biomarker elevations occur prior to the onset of clinical manifestations suggests that we may be able to predict imminent events following TBI. Given the morbidity of CH, early intervention and prevention may have a significant impact on outcomes and help guide decisions about the timing of interventions.	[Stein, Deborah M.] Univ Maryland, Med Ctr, Div Crit Care,Sch Med, R Adams Cowley Shock Trauma Ctr,Program Trauma, Baltimore, MD 21201 USA; [Stein, Deborah M.; Lindell, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Bochicchio, Grant V.; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Med Ctr, Div Crit Care,Sch Med, R Adams Cowley Shock Trauma Ctr,Program Trauma, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963	 [W81XWH-07-2-0118]	This study was supported by W81XWH-07-2-0118. The authors would like to thank Dr. Hegang Chen for his statistical assistance with this study.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Astudillo R, 1996, EUR J CARDIO-THORAC, V10; Bardt TF, 1998, ACT NEUR S, V71, P153; Basile AM, 2001, EUR NEUROL, V45, P151, DOI 10.1159/000052114; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bridges E, 2010, AACN ADV CRIT CARE, V21, P260, DOI 10.1097/NCI.0b013e3181e67385; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; CUNNINGHAM RT, 1991, EUR J CLIN INVEST, V21, P497, DOI 10.1111/j.1365-2362.1991.tb01401.x; DAUBERSCHMIDT R, 1991, MOL CHEM NEUROPATHOL, V14, P237, DOI 10.1007/BF03159939; Dings J, 1998, NEUROL RES, V20, pS71; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Gracias VH, 2007, J TRAUMA, V62, P656; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; KENNEDY CS, 2004, CLIN PEDIAT EMERG ME, V5, P224; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; KRAUS JF, 1996, NEUROTRAUMA, P13; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Reisinger J, 2007, EUR HEART J, V28, P52, DOI 10.1093/eurheartj/ehl316; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Scalea TM, 2007, J TRAUMA, V62, P647, DOI 10.1097/TA.0b013e31802ee542; SELLMAN M, 1992, SCAND J THORAC CARD, V26, P39, DOI 10.3109/14017439209099051; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stroick M, 2006, CURR MED CHEM, V13, P3053, DOI 10.2174/092986706778521751; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	69	36	37	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1140	1149		10.1089/neu.2011.2149			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100014	22360297				2021-06-18	
J	Baker, TA; Romero, J; Bach, HH; Strom, JA; Gamelli, RL; Majetschak, M				Baker, Todd A.; Romero, Jacqueline; Bach, Harold H.; Strom, Joel A.; Gamelli, Richard L.; Majetschak, Matthias			Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage	CRITICAL CARE MEDICINE			English	Article						biomarker; inflammation; injury severity; mortality; resuscitation; shock	NECROSIS-FACTOR-ALPHA; MULTIPLE ORGAN FAILURE; INFLAMMATORY GENE-TRANSCRIPTION; SEVERELY INJURED PATIENTS; TRAUMATIC BRAIN-INJURY; SEVERE BLUNT TRAUMA; HLA-DR EXPRESSION; EXOGENOUS UBIQUITIN; RESPONSE SYNDROME; IMMUNE-RESPONSE	Objective: To define systemic release kinetics of a panel of cytokines and heat shock proteins in porcine polytrauma/hemorrhage models and to evaluate whether they could be useful as early trauma biomarkers. Design: Prospective observational study. Setting: Research laboratory. Subjects: Twenty-one Yorkshire pigs. Interventions: None. Measurements and Main Results: Pigs underwent polytrauma (femur fractures/lung contusion, P), hemorrhage (mean arterial pressure 25-30 mm Hg, H), polytrauma plus hemorrhage (P/H), or sham procedure (S). Plasma was obtained at baseline, in 5- to 15-min intervals during a 60-min shock period without intervention, and in 60- to 120-min intervals during fluid resuscitation for up to 300 min. Plasma was assayed for interleukin-10, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-12/interleukin-23p40, interleukin-13, interleukin-17, interleukin-18, interferon gamma, transforming growth factor-beta, tumor necrosis factor-alpha, heat shock protein 40, heat shock protein 70, and heat shock protein 90 by enzyme-linked immunosorbent assay. All animals after S, P, and H survived (n = 5/group). Three of six animals after P/H died. Interleukin-10 increased during shock after P and this increase was attenuated after H. Tumor necrosis factor-alpha increased during the shock period after P, H, and also after S. P/H abolished the systemic interleukin-10 and tumor necrosis factor-alpha release and resulted in 20% to 30% increased levels of interleukin-6 during shock. As fluid resuscitation was initiated, tumor necrosis factor-alpha and interleukin-10 levels decreased after P, H, and P/H; heat shock protein 70 increased after P; and interleukin-6 levels remained elevated after P/H and also increased after P and S. Conclusions: Differential regulation of the systemic cytokine release after polytrauma and/or hemorrhage, in combination with the effects of resuscitation, can explain the variability and inconsistent association of systemic cytokine/heat shock protein levels with clinical variables in trauma patients. Insults of major severity (P/H) partially suppress the systemic inflammatory response. The plasma concentrations of the measured cytokines/heat shock proteins do not reflect injury severity or physiological changes in porcine trauma models and are unlikely to be able to serve as useful trauma biomarkers in patients. (Crit Care Med 2012; 40: 876-885)	[Baker, Todd A.; Romero, Jacqueline; Bach, Harold H.; Gamelli, Richard L.; Majetschak, Matthias] Loyola Univ Chicago, Stritch Sch Med, Burn & Shock Trauma Inst, Dept Surg, Maywood, IL 60153 USA; [Majetschak, Matthias] Loyola Univ Chicago, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Maywood, IL USA; [Strom, Joel A.] Univ Florida, Coll Med Jacksonville, Div Cardiol, Jacksonville, FL USA	Majetschak, M (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Burn & Shock Trauma Inst, Dept Surg, Maywood, IL 60153 USA.	mmajetschak@lumc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM008750]; U.S. Department of the Army [W81XWH-05-1-0585]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008750] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health T32 GM008750 and the U.S. Department of the Army under Award Number W81XWH-05-1-0585. The U.S. Army Medical Research Acquisition Activity, (Fort Detrick, MD) is the awarding and administering acquisition office. Information contained in this article does not necessarily reflect the position or the policy of the government, and no official endorsement is inferred.	ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Adib-Conquy M, 2007, FEBS LETT, V581, P3723, DOI 10.1016/j.febslet.2007.03.074; Angele MK, 2008, CRIT CARE, V12, DOI 10.1186/cc6919; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Block EFJ, 2004, J TRAUMA, V56, P999; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; Cerovic O, 2003, INTENS CARE MED, V29, P1300, DOI 10.1007/s00134-003-1753-8; CINAT M, 1995, J TRAUMA, V39, P112, DOI 10.1097/00005373-199507000-00015; De AK, 2000, J IMMUNOL, V165, P3951, DOI 10.4049/jimmunol.165.7.3951; Ditschkowski M, 1999, ANN SURG, V229, P246, DOI 10.1097/00000658-199902000-00013; Ditschkowski M, 1999, EUR J SURG, V165, P1129, DOI 10.1080/110241599750007630; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2838, DOI 10.1097/CCM.0b013e318186f6b3; Earle SA, 2005, SURGERY, V138, P431, DOI 10.1016/j.surg.2005.06.026; Ertel W, 1998, UNFALLCHIRURG, V101, P520, DOI 10.1007/s001130050304; Flohe S, 2004, INTENS CARE MED, V30, P96, DOI 10.1007/s00134-003-2041-3; Flohe SB, 2008, INNATE IMMUN-LONDON, V14, P333, DOI 10.1177/1753425908100016; Frangen TM, 2008, SHOCK, V29, P462, DOI 10.1097/SHK.0b013e3181598a9d; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; GRYGLEWSKI A, 1985, ARCH IMMUNOL THER EX, V33, P489; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Jastrow KM, 2009, J AM COLL SURGEONS, V209, P320, DOI 10.1016/j.jamcollsurg.2009.05.002; Kamada H, 2000, CANCER RES, V60, P6416; KAMPSCHMIDT RF, 1980, P SOC EXP BIOL MED, V164, P537; Kawasaki T, 2009, AM J PHYSIOL-CELL PH, V296, pC124, DOI 10.1152/ajpcell.00447.2008; Keel M, 1996, J TRAUMA, V41, P430, DOI 10.1097/00005373-199609000-00008; Liener UC, 2002, SHOCK, V17, P169, DOI 10.1097/00024382-200203000-00002; Liu Jing-Qu, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P70; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Majetschak M, 2000, UNFALLCHIRURG, V103, P903, DOI 10.1007/s001130050639; Majetschak M, 1999, ANN SURG, V230, P207, DOI 10.1097/00000658-199908000-00011; Majetschak M, 1997, J TRAUMA, V43, P880, DOI 10.1097/00005373-199712000-00002; Majetschak M, 1999, CRIT CARE MED, V27, P313, DOI 10.1097/00003246-199902000-00037; Majetschak M, 2000, CRIT CARE MED, V28, P1847, DOI 10.1097/00003246-200006000-00027; Majetschak M, 2005, CLIN DIAGN LAB IMMUN, V12, P296, DOI 10.1128/CDLI.12.2.296-303.2005; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; MANIKIS P, 1995, AM J EMERG MED, V13, P619, DOI 10.1016/0735-6757(95)90043-8; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; Moomey CB, 1999, CRIT CARE MED, V27, P154, DOI 10.1097/00003246-199901000-00044; Namas R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008406; Pespeni M, 2005, J SURG RES, V126, P41, DOI 10.1016/j.jss.2005.01.012; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Proctor KG, 2008, AM J PHYSIOL-REG I, V294, pR1822, DOI 10.1152/ajpregu.90301.2008; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Roetman B, 2008, J INTERF CYTOK RES, V28, P741, DOI 10.1089/jir.2008.0029; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Schmitz D, 2010, INFLAMM RES, V59, P141, DOI 10.1007/s00011-009-0081-z; Spielmann S, 2001, ACTA ANAESTH SCAND, V45, P364, DOI 10.1034/j.1399-6576.2001.045003364.x; SVOBODA P, 1994, J TRAUMA, V36, P336, DOI 10.1097/00005373-199403000-00009; Watters JM, 2006, J TRAUMA, V61, P300, DOI 10.1097/01.ta.0000224211.36154.44; Wheeler Derek S, 2005, Pediatr Crit Care Med, V6, P308, DOI 10.1097/01.PCC.0000161075.97355.2E; Yadav K, 2009, RESUSCITATION, V80, P83, DOI 10.1016/j.resuscitation.2008.09.012; Ziegler TR, 2005, INTENS CARE MED, V31, P1079, DOI 10.1007/s00134-005-2690-5	57	36	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2012	40	3					876	885		10.1097/CCM.0b013e318232e314			10	Critical Care Medicine	General & Internal Medicine	895YO	WOS:000300532800023	21983369	Green Accepted			2021-06-18	
J	Clausen, F; Marklund, N; Lewen, A; Enblad, P; Basu, S; Hillered, L				Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Enblad, Per; Basu, Samar; Hillered, Lars			Interstitial F-2-Isoprostane 8-Iso-PGF(2 alpha) As a Biomarker of Oxidative Stress after Severe Human Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; microdialysis; oxidative stress; traumatic brain injury	CEREBRAL MICRODIALYSIS; LIPID-PEROXIDATION; HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; CEREBROSPINAL-FLUID; SYSTEM X(C)(-); FREE-RADICALS; GLYCEROL; DAMAGE; RATS	Oxidative stress is a major contributor to the secondary injury process after experimental traumatic brain injury (TBI). The importance of oxidative stress in the pathobiology of human TBI is largely unknown. The F-2-isoprostane 8-iso-prostaglandin F-2 alpha (8-iso-PGF(2 alpha)), synthesized in vivo through non-enzymatic free radical catalyzed peroxidation of arachidonic acid, is a widely used biomarker of oxidative stress in multiple disease states, including TBI and cerebral ischemia/reperfusion. Our hypothesis is that harvesting of biomarkers directly in the injured brain by cerebral microdialysis (MD) is advantageous because of its high spatial and temporal resolution compared to blood or cerebrospinal fluid sampling. The aim of this study was to test the feasibility of measuring 8-iso-PGF(2 alpha) in MD, ventricular cerebrospinal fluid (vCSF), and plasma samples collected from patients with severe TBI, and to compare the MD signals with MD-glycerol, implicated as a biomarker of oxidative stress, as well as MD-glutamate, a biomarker of excitotoxicity. Six patients (4 men, 2 women) were included in the study, three of whom had a focal/mixed TBI, and three a diffuse axonal injury (DAI). Following the bedside analysis of routine MD biomarkers (glucose, lactate: pyruvate ratio, glycerol, and glutamate), two 12-hMD samples per day were used to analyze 8-iso-PGF(2 alpha) from 24 h up to 8 days post-injury. The interstitial levels of 8-iso-PGF(2 alpha) were markedly higher than the levels obtained from plasma and vCSF (p < 0.05), supporting our hypothesis. The MD-8-iso-PGF(2 alpha) levels correlated strongly (p < 0.05) with MD-glycerol and MD-glutamate, which are widely used biomarkers of membrane phospholipid degradation/oxidative stress and excitotoxicity, respectively. This study demonstrates the feasibility of analyzing 8-iso-PGF(2 alpha) in MD samples from the human brain. Our results support a close relationship between oxidative stress and excitotoxicity following human TBI. MD-8-iso-PGF(2 alpha) in combination with MD-glycerol may be useful biomarkers of oxidative stress in the neurointensive care setting.	[Clausen, Fredrik] Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden; [Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Enblad, Per; Hillered, Lars] Uppsala Univ, Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; [Basu, Samar] Uppsala Univ, Univ Uppsala Hosp, Dept Publ Hlth & Caring Sci Oxidat Stress & Infla, S-75185 Uppsala, Sweden; [Basu, Samar] Univ Auvergne, Fac Pharm, Lab Biochim Biol Mol & Nutr, Clermont Ferrand, France	Clausen, F (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	Fredrik.clausen@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Hillered, Lars/0000-0002-2808-9292; Marklund, Niklas/0000-0002-9797-5626; Clausen, Fredrik/0000-0003-3592-4417	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Foundation; Uppsala University Hospital; Selander Foundation; Ahlen Foundation	This study was supported by the Swedish Research Council, the Swedish Brain Foundation, Uppsala University Hospital, the Selander Foundation, and the Ahlen Foundation.	AWAD JA, 1993, J BIOL CHEM, V268, P4161; Bachi A, 1997, BRIT J PHARMACOL, V121, P1770, DOI 10.1038/sj.bjp.0701321; Basu S, 1998, PROSTAG LEUKOTR ESS, V58, P319, DOI 10.1016/S0952-3278(98)90042-4; Basu S, 2000, FEBS LETT, V470, P1, DOI 10.1016/S0014-5793(00)01279-5; Basu S, 2008, ANTIOXID REDOX SIGN, V10, P1405, DOI 10.1089/ars.2007.1956; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2008, CRIT CARE, V12, DOI 10.1186/cc6779; Belton O, 2000, CIRCULATION, V102, P840; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; FREEMAN BA, 1982, LAB INVEST, V47, P412; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Idris AH, 2005, CRIT CARE MED, V33, P2043, DOI 10.1097/01.CCM.0000174104.50799.BD; JACOBSON I, 1985, J NEUROSCI METH, V15, P263, DOI 10.1016/0165-0270(85)90107-4; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; Nguyen NHT, 2007, J NEUROCHEM, V101, P1694, DOI 10.1111/j.1471-4159.2006.04433.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Qin S, 2006, J NEUROSCI, V26, P3345, DOI 10.1523/JNEUROSCI.5186-05.2006; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Sato H, 2002, J NEUROSCI, V22, P8028; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Servadei F, 2000, NEUROSURGERY, V46, P70; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Sjogren P, 2005, ARTERIOSCL THROM VAS, V25, P2580, DOI 10.1161/01.ATV.0000190675.08857.3d; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; STALHAMMAR D, 1988, ACTA NEUROCHIR, V90, P73, DOI 10.1007/BF01560558; Sumbria RK, 2011, NEUROCHEM RES, V36, P109, DOI 10.1007/s11064-010-0276-2; TEASDALE G, 1974, LANCET, V2, P81; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wiklund L, 2005, ANN NY ACAD SCI, V1053, P205, DOI 10.1196/annals.1344.019; ZALBA, 2007, CEREBROVASC DIS, V24, P24	61	36	38	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					766	775		10.1089/neu.2011.1754			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900007	21639729				2021-06-18	
J	Bansal, V; Ryu, SY; Lopez, N; Allexan, S; Krzyzaniak, M; Eliceiri, B; Baird, A; Coimbra, R				Bansal, Vishal; Ryu, Seok Yong; Lopez, Nicole; Allexan, Sarah; Krzyzaniak, Michael; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul			Vagal Stimulation Modulates Inflammation through a Ghrelin Mediated Mechanism in Traumatic Brain Injury	INFLAMMATION			English	Article						traumatic brain injury; inflammation; vagus nerve; ghrelin; neuroenteric axis	INTESTINAL DYSFUNCTION; ORGAN DYSFUNCTION; NERVOUS-SYSTEM; RELEASE; ACETYLCHOLINE; CYTOKINES; PEPTIDE; SEPSIS; LEPTIN; TNF	Traumatic brain injury (TBI) releases a cascade of inflammatory cytokines. Vagal nerve stimulation (VNS) and ghrelin have known anti-inflammatory effects; furthermore, ghrelin release is stimulated by acetylcholine. We hypothesized VNS decreases post-TBI inflammation through a ghrelin-mediated mechanism. TBI was created in five groups of mice: sham, TBI, TBI/ghrelin, TBI/VNS, and TBI/VNS/ghrelin receptor antagonist (GRa). Serum and tissue ghrelin, and serum TNF-alpha were measured. Ghrelin increased following VNS 2 h post-TBI compared to sham or TBI. At 6 h, TBI and TBI/VNS/GRa had increased TNF-alpha compared to sham while TBI/VNS and TBI/ghrelin had TNF-alpha level comparable to sham. The highest ghrelin was measured in stomach where TBI decreased ghrelin in contrast to an increase by VNS. In conclusion, VNS increased serum ghrelin and decreased TNF-alpha following TBI. This was abrogated with GRa. Our data suggests that ghrelin plays an important role in the anti-inflammatory effects of VNS following TBI.	[Bansal, Vishal; Ryu, Seok Yong; Lopez, Nicole; Allexan, Sarah; Krzyzaniak, Michael; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Ryu, Seok Yong] Inje Univ, Dept Emergency Med, Sanggye Paik Hosp, Seoul, South Korea	Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Eliceiri, Brian/0000-0003-1811-1916; Baird, Andrew/0000-0003-0027-9905; Lopez, Nicole/0000-0002-4807-7360	Inje Research and Scholarship Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER	This research was supported in part by the 2009 Inje Research and Scholarship Foundation.	Acampa M, 2008, NEUROSCI LETT, V432, P69, DOI 10.1016/j.neulet.2007.12.030; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; German J, 2009, ENDOCRINOLOGY, V150, P4502, DOI 10.1210/en.2009-0445; Hosoda H, 2008, REGUL PEPTIDES, V146, P12, DOI 10.1016/j.regpep.2007.07.005; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kemp CD, 2008, AM SURGEON, V74, P866; Koch A, 2010, CRIT CARE, V14, DOI 10.1186/cc9029; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; La Cava A, 2004, J MOL MED, V82, P4, DOI 10.1007/s00109-003-0492-1; Li Y, 2007, CURR MED CHEM, V14, P2554, DOI 10.2174/092986707782023334; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Parrish WR, 2008, MOL MED, V14, P567, DOI 10.2119/2008-00079.Parrish; Qiu WC, 2008, WORLD J GASTROENTERO, V14, P2572, DOI 10.3748/wjg.14.2572; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Shrestha YB, 2009, PEPTIDES, V30, P1187, DOI 10.1016/j.peptides.2009.02.001; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vaughan T, 2010, MOL IMMUNOL, V47, P2515, DOI 10.1016/j.molimm.2010.06.006; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; Waseern T, 2008, SURGERY, V143, P334, DOI 10.1016/j.surg.2007.09.039; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Wu RQ, 2009, CRIT CARE MED, V37, P2421, DOI 10.1097/CCM.0b013e3181a557a2; Zhang WZ, 2004, J PHYSIOL-LONDON, V559, P729, DOI 10.1113/jphysiol.2004.064121; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	31	36	41	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	FEB	2012	35	1					214	220		10.1007/s10753-011-9307-7			7	Cell Biology; Immunology	Cell Biology; Immunology	896FM	WOS:000300550900025	21360048	Green Published, Other Gold			2021-06-18	
J	Bregy, A; Nixon, R; Lotocki, G; Alonso, OF; Atkins, CM; Tsoulfas, P; Bramlett, HM; Dietrich, WD				Bregy, Amade; Nixon, Ryan; Lotocki, George; Alonso, Ofelia F.; Atkins, Coleen M.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton			Posttraumatic hypothermia increases doublecortin expressing neurons in the dentate gyrus after traumatic brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						Dentate gyrus; Doublecortin; Fluid-percussion; Hypothermia; Neurogenesis; Traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN; CONTROLLED CORTICAL IMPACT; TRANSIENT GLOBAL-ISCHEMIA; NEURAL PROGENITOR CELLS; FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; HIPPOCAMPAL NEUROGENESIS; SUBVENTRICULAR ZONE; ENHANCED NEUROGENESIS; ADULT RATS	Previous studies have demonstrated that moderate hypothermia reduces histopathological damage and improves behavioral outcome after experimental traumatic brain injury (TBI). Further investigations have clarified the mechanisms underlying the beneficial effects of hypothermia by showing that cooling reduces multiple cell injury cascades. The purpose of this study was to determine whether hypothermia could also enhance endogenous reparative processes following TBI such as neurogenesis and the replacement of lost neurons. Male Sprague-Dawley rats underwent moderate fluid-percussion brain injury and then were randomized into normothermia (37 degrees C) or hypothermia (33 degrees C) treatment. Animals received injections of 5-bromo-2'-deoxyuridine (BrdU) to detect mitotic cells after brain injury. After 3 or 7 days, animals were perfusion-fixed and processed for immunocytochemistry and confocal analysis. Sections were stained for markers selective for cell proliferation (BrdU), neuroblasts and immature neurons (doublecortin), and mature neurons (NeuN) and then analyzed using non-biased stereology to quantify neurogenesis in the dentate gyrus (DG). At 7 days after TBI, both normothermic and hypothermic TBI animals demonstrated a significant increase in the number of BrdU-immunoreactive cells in the DG as compared to sham-operated controls. At 7 days post-injury, hypothermia animals had a greater number of BrdU (ipsilateral cortex) and doublecortin (ipsilateral and contralateral cortex) immunoreactive cells in the DG as compared to normothermia animals. Because adult neurogenesis following injury may be associated with enhanced functional recovery, these data demonstrate that therapeutic hypothermia sustains the increase in neurogenesis induced by TBI and this may be one of the mechanisms by which hypothermia promotes reparative strategies in the injured nervous system. (C) 2011 Elsevier Inc. All rights reserved.	[Bregy, Amade; Nixon, Ryan; Lotocki, George; Alonso, Ofelia F.; Atkins, Coleen M.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Dept Neurol Surg, Neurotrauma Res Ctr, Miami Project Cure Paralysis,Miller Sch Med, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, Leonard M Miller Sch Med, 1095 NW 14th Terrace,Suite 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493; Tsoulfas, Pantelis/0000-0003-1974-6366; Nixon, Ryan/0000-0002-5759-4415	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, NS42133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER	The authors wish to thank Jeremy Lytle for editorial support. This study was supported by the National Institutes of Health grants NS030291 and NS42133.	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Atkins C.M., 2010, EUR J NEUROSCI, V28, P35; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Back SA, 2002, J NEUROSCI, V22, P455, DOI 10.1523/JNEUROSCI.22-02-00455.2002; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bonde S, 2006, EUR J NEUROSCI, V23, P965, DOI 10.1111/j.1460-9568.2006.04635.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Covolan L, 2000, HIPPOCAMPUS, V10, P169, DOI 10.1002/(SICI)1098-1063(2000)10:2<169::AID-HIPO6>3.3.CO;2-N; DASH PK, 1995, J NEUROSCI, V15, P2030; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Felling RJ, 2003, J NEUROSCI RES, V73, P277, DOI 10.1002/jnr.10670; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Jessberger S, 2007, J NEUROSCI, V27, P9400, DOI 10.1523/JNEUROSCI.2002-07.2007; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kalluri HSG, 2007, EUR J NEUROSCI, V25, P1041, DOI 10.1111/j.1460-9568.2007.05336.x; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kitamura T, 2009, CELL, V139, P814, DOI 10.1016/j.cell.2009.10.020; Koch JD, 2008, J CEREBR BLOOD F MET, V28, P1294, DOI 10.1038/jcbfm.2008.15; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Lasarzik I, 2009, ANESTH ANALG, V109, P1632, DOI 10.1213/ANE.0b013e3181bab451; Lau BWM, 2009, NEUROREPORT, V20, P371, DOI 10.1097/WNR.0b013e328324edcd; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu YP, 2005, BRAIN RES, V1054, P152, DOI 10.1016/j.brainres.2005.06.085; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Moreno-Lopez B, 2004, J NEUROSCI, V24, P85, DOI 10.1523/JNEUROSCI.1574-03.2004; Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010; Packer MA, 2003, P NATL ACAD SCI USA, V100, P9566, DOI 10.1073/pnas.1633579100; Parent JM, 1997, J NEUROSCI, V17, P3727; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pedersen MO, 2009, HISTOL HISTOPATHOL, V24, P573, DOI 10.14670/HH-24.573; Peng H, 2008, GLIA, V56, P903, DOI 10.1002/glia.20665; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Potts MB, 2009, J NEUROSCI RES, V87, P1848, DOI 10.1002/jnr.21996; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rossi C, 2006, EUR J NEUROSCI, V24, P1850, DOI 10.1111/j.1460-9568.2006.05059.x; Russo-Neustadt AA, 2004, NEUROPSYCHOPHARMACOL, V29, P2189, DOI 10.1038/sj.npp.1300514; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Scott BW, 2000, EXP NEUROL, V165, P231, DOI 10.1006/exnr.2000.7458; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Silasi G, 2011, J CEREBR BLOOD F MET, V31, P1725, DOI 10.1038/jcbfm.2011.25; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Verwer RWH, 2007, BRAIN, V130, P3321, DOI 10.1093/brain/awm264; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	117	36	37	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2012	233	2			SI		821	828		10.1016/j.expneurol.2011.12.008			8	Neurosciences	Neurosciences & Neurology	890CV	WOS:000300123600031	22197046	Green Accepted			2021-06-18	
J	Oron, A; Oron, U; Streeter, J; De Taboada, L; Alexandrovich, A; Trembovler, V; Shohami, E				Oron, Amir; Oron, Uri; Streeter, Jackson; De Taboada, Luis; Alexandrovich, Alexander; Trembovler, Victoria; Shohami, Esther			Near Infrared Transcranial Laser Therapy Applied at Various Modes to Mice following Traumatic Brain Injury Significantly Reduces Long-Term Neurological Deficits	JOURNAL OF NEUROTRAUMA			English	Article						low-level laser therapy; magnetic resonance imaging; mice; motor function; pulsed laser; traumatic brain injury	CLOSED-HEAD INJURY; MYOCARDIAL-INFARCTION; EMBOLIC STROKES; LIGHT THERAPY; IRRADIATION; SAFETY; RATS; MECHANISMS; PROTEIN; MOTOR	Near-infrared transcranial laser therapy (TLT) has been found to modulate various biological processes including traumatic brain injury (TBI). Following TBI in mice, in this study we assessed the possibility of various near-infrared TLT modes (pulsed versus continuous) in producing a beneficial effect on the long-term neurobehavioral outcome and brain lesions of these mice. TBI was induced by a weight-drop device, and neurobehavioral function was assessed from 1 h to 56 days post-trauma using the Neurological Severity Score (NSS). The extent of recovery is expressed as the difference in NSS (dNSS), the difference between the initial score and that at any other later time point. An 808-nm Ga-Al-As diode laser was employed transcranially 4, 6, or 8h post-trauma to illuminate the entire cortex of the brain. Mice were divided into several groups of 6-8 mice: one control group that received a sham treatment and experimental groups that received either TLT continuous wave (CW) or pulsed wave (PW) mode transcranially. MRI was taken prior to sacrifice at 56 days post-injury. From 5-28 days post-TBI, the NSS of the laser-treated mice were significantly lower (p<0.05) than those of the non-laser-treated control mice. The percentage of surviving mice that demonstrated full recovery at 56 days post-CHI (NSS=0, as in intact mice) was the highest (63%) in the group that had received TLT in the PW mode at 100 Hz. In addition, magnetic resonance imaging (MRI) analysis demonstrated significantly smaller infarct lesion volumes in laser-treated mice compared to controls. Our data suggest that non-invasive TLT of mice post-TBI provides a significant long-term functional neurological benefit, and that the pulsed laser mode at 100 Hz is the preferred mode for such treatment.	[Oron, Amir] Kaplan Med Ctr, Dept Hand Surg, Rehovot, Israel; [Oron, Uri; Streeter, Jackson; De Taboada, Luis] PhotoThera Inc, Carlsbad, CA USA; [Alexandrovich, Alexander; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Oron, U (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Zool, IL-69978 Tel Aviv, Israel.	oronu@post.tau.ac.il		De Taboada, Luis/0000-0002-0153-6419			Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Avni D, 2005, PHOTOMED LASER SURG, V23, P273, DOI 10.1089/pho.2005.23.273; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Karu T, 2007, 10 LECT BASIC SCI LA; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; McFaddaen L., 2011, J NEUROTRAUM, V28, P2821; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Oron U, 2001, CIRCULATION, V103, P296; Oron U, 2006, PHOTOMED LASER SURG, V24, P111, DOI 10.1089/pho.2006.24.111; Shefer G, 2002, J CELL SCI, V115, P1461; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; WINSON J, 1972, BEHAV BIOL, V7, P479, DOI 10.1016/S0091-6773(72)80210-4; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Yaakobi T, 2001, J APPL PHYSIOL, V90, P2411; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	33	36	37	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					401	407		10.1089/neu.2011.2062			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300019	22040267				2021-06-18	
J	Batchelor, JS; Grayson, A				Batchelor, John S.; Grayson, Alan			A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antiplatelet medication-associated intracramal haemorrhage	BMJ OPEN			English	Article							INTRACEREBRAL HEMORRHAGE; BRAIN-INJURY; HEAD-INJURY; EMERGENCY REVERSAL; ELDERLY-PATIENTS; ASPIRIN; THERAPY; AGENTS; MILD; RISK	Objectives: The aim of this study was to evaluate by meta-analysis the current level of evidence in order to establish the impact of a platelet transfusion on survival in patients on pre-injury antiplatelet agents who sustain an intracranial haemorrhage (either spontaneous or traumatic). Design: This was a meta-analysis; the MEDLINE Database was searched using the PubMed interface and the Ovid interface. CINAHL and EM BASE Databases were also searched. The search was performed to identify randomised controlled trials (RCT)'s case-controlled studies or nested case-controlled studies. Comparing the outcome (death or survival) of patients with intracranial haemorrhage (ICH) and pre-injury antiplatelet agents who received a platelet transfusion against a similar cohort of patients who did not receive a platelet transfusion. Results: 499 citations were obtained from the PubMed search. 31 full articles were reviewed from 34 abstracts. 6 studies were found suitable for the meta-analysis. No randomised controlled studies were identified. 2 of the six studies were in patients with spontaneous ICH. The remaining four studies were in patients with traumatic intracranial haemorrhage. Significant heterogeneity was present between the studies, I-2=58.276. The random effects model was therefore the preferred model, this produced a pooled OR for survival of 0.773 (95% Cl 0.414 to 1.442). Conclusions: The results of this meta-analysis has shown, based upon six small studies, that there was no clear benefit in terms of survival in the administration of a platelet transfusion to patients with antiplatelet-associated ICH. Further work is required in order to establish any potential benefit in the administration of a platelet transfusion in patients with spontaneous or traumatic intracranial haemorrhage who were on pre-injury antiplatelet agents.	[Batchelor, John S.; Grayson, Alan] Manchester Royal Infirm, Dept Emergency Med, Manchester M13 9WL, Lancs, England	Batchelor, JS (corresponding author), Manchester Royal Infirm, Dept Emergency Med, Oxford Rd, Manchester M13 9WL, Lancs, England.	johnbatchelor@msn.com					Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Beshay JE, 2010, J NEUROSURG, V112, P307, DOI 10.3171/2009.7.JNS0982; Campbell PG, 2010, WORLD NEUROSURG, V74, P279, DOI 10.1016/j.wneu.2010.05.030; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; de Gans K, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-19; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Fabbri A, 2010, J NEUROL NEUROSUR PS, V81, P1275, DOI 10.1136/jnnp.2009.197467; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Sansing LH, 2009, NEUROLOGY, V72, P1397, DOI 10.1212/01.wnl.0000342709.31341.88; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e	20	36	36	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2012	2	2							e000588	10.1136/bmjopen-2011-000588			7	Medicine, General & Internal	General & Internal Medicine	091IF	WOS:000315042100030	22492383	DOAJ Gold, Green Published			2021-06-18	
B	Green, P; Flaro, L; Brockhaus, R; Montijo, J		Reynolds, CR; Horton, AM		Green, Paul; Flaro, Lloyd; Brockhaus, Robbi; Montijo, Jorge			Performance on the WMT, MSVT, and NV-MSVT in Children with Developmental Disabilities and in Adults with Mild Traumatic Brain Injury	DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION			English	Article; Book Chapter							WORD MEMORY TEST; SYMPTOM VALIDITY TESTS; MALINGERED NEUROCOGNITIVE DYSFUNCTION; EXTERNAL INCENTIVES; EXAGGERATION; VALIDATION; SEVERITY; FAILURE; DAMAGE		[Brockhaus, Robbi] Alexianer Krankenhaus, Krefeld, Germany		paulgreen@shaw.ca					Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Doane BM, 2009, LAW HUMAN BEHAV, V33, P329, DOI 10.1007/s10979-008-9157-5; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P., 2005, MANUAL WORD MEMORY T; Green P., 2008, MANUAL NONVERBAL MED; Green P., 2009, 1 EUR C SYMPT VAL TE; Green P., 2004, MANUAL MED SYMPTOM V; GREEN P, 1996, MANUAL WORD MEMORY T; Green P., 1995, MANUAL ORAL WORD MEM; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry M., 2009, J CLIN EXPT NEUROPSY, V8, P1; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh TN, 1996, TEST MEMORY MALINGER	35	36	36	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES			978-1-4614-0441-5				2012							201	219		10.1007/978-1-4614-0442-2_6	10.1007/978-1-4614-0442-2		19	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	BAD69	WOS:000303852000006					2021-06-18	
J	Svoboda, E; Richards, B; Leach, L; Mertens, V				Svoboda, Eva; Richards, Brian; Leach, Larry; Mertens, Valerie			PDA and smartphone use by individuals with moderate-to-severe memory impairment: Application of a theory-driven training programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Cognitive rehabilitation; Memory intervention; Technology; PDA; Smartphone; Amnesia	TRAUMATIC BRAIN-INJURY; PAGING SYSTEM; COGNITIVE REHABILITATION; AID; AMNESIA	We describe a structured, theory-driven training programme for individuals with moderate-to-severe memory impairment in the use of emerging commercial technology. We demonstrate its application to 10 individuals with memory impairment from a variety of aetiologies. A within-subject, ABAB multi-case experimental design was used to evaluate the impact of personal digital assistant or smartphone use on day-to-day memory functioning at baseline, immediately post-intervention, at return to baseline, and at short-term follow-up (range = 3-8 months). An errorless fading-of-cues protocol enabled all participants to acquire the skill set necessary to operate their PDA or smartphone independently. All 10 individuals showed robust improvement in day-to-day functioning post-intervention as quantified across a number of ecologically valid questionnaire and task-based measures. This was further corroborated by family members with whom six of the participants resided. These findings demonstrate that individuals with moderate-to-severe memory impairment can acquire the skills necessary to independently, flexibly and broadly apply commercial technology to support their everyday memory functioning. Moreover the findings confirm that the gap between individuals with memory impairment and potent emerging technology can be closed by the application of a systematic theory-driven training programme.	[Svoboda, Eva; Richards, Brian; Leach, Larry; Mertens, Valerie] Baycrest Neuropsychol & Cognit Hlth Program, Toronto, ON, Canada	Svoboda, E (corresponding author), Baycrest Ctr Geriatr Care, Neuropsychol & Cognit Hlth Program, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	esvoboda@baycrest.org					Bauer RM, 2008, TXB CLIN NEUROPSYCHO, P729; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen J., 1977, STAT POWER ANAL BEHA, P1; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; Cullen C. N., 1976, NURS TIMES, V72, P45; DePompei R, 2008, NEUROREHABILITATION, V23, P487; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gentry T., 2008, AM J OCCUPATIONAL TH, V62, P8, DOI DOI 10.5014/AJOT.62.1.18; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Liberty K., 1980, METHODS INSTRUCTION; MARKOWITSCH HJ, 2000, OXFORD HDB MEMORY, P465; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; RICHARDS B, 1990, J CLIN EXPT NEUROPSY, V12, P395; Roth R.M., 2005, BEHAV RATING INVENTO; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOHLBERG MM, 2001, COGNITIVE REHABILITA, P194; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; Svoboda E, 2006, NEUROPSYCHOLOGIA, V44, P2189, DOI 10.1016/j.neuropsychologia.2006.05.023; Svoboda E, 2010, NEUROPSYCHOL REHABIL, V20, P562, DOI 10.1080/09602011003669918; Svoboda E, 2009, J INT NEUROPSYCH SOC, V15, P629, DOI 10.1017/S1355617709090791; Troyer A. K., 2002, J GERONTOL B-PSYCHOL, V57B, P19, DOI [10.1093/geronb/57.1.P19, DOI 10.1093/GERONB/57.1.P19]; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WALSH BF, 1979, AM J MENT DEF, V83, P473; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	42	36	36	1	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	3					408	427		10.1080/09602011.2011.652498			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	936BV	WOS:000303566800005	22292945				2021-06-18	
J	White, MD; Mulvey, P; Fox, AM; Choate, D				White, Michael D.; Mulvey, Philip; Fox, Andrew M.; Choate, David			A Hero's Welcome? Exploring the Prevalence and Problems of Military Veterans in the Arrestee Population	JUSTICE QUARTERLY			English	Article						veterans and crime; military and crime; combat-related problems and crime	POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; SUBSTANCE-ABUSE; WAR-ZONE; IRAQ; PTSD; ILL; VIOLENCE	The potential for veterans to end up in the criminal justice system as a result of physical and psychological problems that may be combat-related has generated much interest, illustrated most recently by the development of specialized veterans' courts. However, little is known about how often veterans are arrested and incarcerated, the nature of their problems, or the extent to which their military service has contributed to their criminality. Using interview data from 2,102 arrestees booked in Maricopa County (AZ) during 2009, this paper examines the problems and prior experiences of arrested military veterans and compares veteran and non-veteran arrestees along a range of measures. Results indicate that veterans comprise 6.3% of the arrestee population, and that more than 50% of veterans report suffering from at least one combat-related problem including physical injury, post-traumatic stress disorder (PTSD), other mental health problems, and substance abuse. Multivariate analysis indicates that veteran arrestees differ from non-veterans on a number of key measures, most notably more frequent arrests for violent offenses and greater use of crack cocaine and opiates. The paper concludes with a discussion of implications for the potential link between military service and criminality as well as for criminal justice policy and practice.	[White, Michael D.; Mulvey, Philip; Fox, Andrew M.] Arizona State Univ, Sch Criminol & Criminal Justice, Phoenix, AZ 85004 USA; [Mulvey, Philip] Arizona State Univ, Ctr Appl Behav Hlth Policy, Phoenix, AZ 85004 USA; [Fox, Andrew M.; Choate, David] Arizona State Univ, Ctr Violence Prevent & Community Safety, Phoenix, AZ 85004 USA	White, MD (corresponding author), Arizona State Univ, Sch Criminol & Criminal Justice, 411 N Cent Ave, Phoenix, AZ 85004 USA.	mdwhite1@asu.edu		Fox, Andrew/0000-0001-5919-1735			ABRAMSON MF, 1972, HOSP COMMUNITY PSYCH, V23, P101; Alemagno S. A., 2004, CHARACTERISTICS ARRE; ARCHER D, 1976, AM SOCIOL REV, V41, P937, DOI 10.2307/2094796; Associated Press, 2004, ASSOCIATED PRESS; Beckham JC, 1998, J TRAUMA STRESS, V11, P777, DOI 10.1023/A:1024453618638; Belenko S., 2001, RES DRUG COURTS CRIT; Bennett J. V., 1954, FED PROBAT, V18, P40; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; Bremner JD, 1996, AM J PSYCHIAT, V153, P369; Byrne C A, 1996, Violence Vict, V11, P213; Cunningham M., 2007, VITAL MISSION ENDING; Daly R., 2006, PSYCHIAT NEWS, V41, P8; DARROW C, 1922, CRIME ITS CAUSES TRE; Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Ditton P.P., 1999, MENTAL HLTH TREATMEN; Dupont R, 2000, J AM ACAD PSYCHIATRY, V28, P338; Erickson SK, 2008, PSYCHIAT SERV, V59, P178, DOI 10.1176/ps.2008.59.2.178; Fontana A, 2005, J NERV MENT DIS, V193, P203, DOI 10.1097/01.nmd.0000154835.92962.e5; Freeman TW, 2001, J NERV MENT DIS, V189, P317, DOI 10.1097/00005053-200105000-00008; Gearan A., 2010, ARIZONA REPUBLI 0630, P1; Goldkamp JS, 2001, J DRUG ISSUES, V31, P27, DOI 10.1177/002204260103100104; GREEN BL, 1990, AM J PSYCHIAT, V147, P729; Greenburg DL, 2007, J GEN INTERN MED, V22, P888, DOI 10.1007/s11606-007-0172-x; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Hendin H, 1984, Psychohist Rev, V12, P25; Higgins S. Anthony, 1991, LAW PSYCHOL REV, V15, P259; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; JORDAN BK, 1992, J CONSULT CLIN PSYCH, V60, P916, DOI 10.1037/0022-006X.60.6.916; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; KARDINER A, 1941, PSYCHOSOMATIC MED MO, V2; Katz CM, 1997, J CRIM JUST, V25, P31, DOI 10.1016/S0047-2352(96)00049-9; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Lamb HR, 1998, PSYCHIATR SERV, V49, P483, DOI 10.1176/ps.49.4.483; LASKO NB, 1994, COMPR PSYCHIAT, V35, P373, DOI 10.1016/0010-440X(94)90278-X; Lewis L., 2008, NATL PUBLIC RAD 0404; Maricopa County Arizona, 2010, MARICOPA COUNTY JUST; MCFALL ME, 1991, J NERV MENT DIS, V179, P33, DOI 10.1097/00005053-199101000-00007; McGuire J, 2003, PSYCHIAT SERV, V54, P201, DOI 10.1176/appi.ps.54.2.201; Menzies R., 2006, CRIMINOLOGY, V25, P429; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mumola C. J., 2000, VETERANS PRISONS JAI; National Council on Disability, 2009, INV WOUNDS SERV SERV; National Survey on Drug Use and Health, 2005, SUBST US DEP TREATM; Noonan M. E., 2007, VETERANS STATE FEDER; O'Bryant J., 2007, US FORCES IRAQ; O'Bryant J., 2008, US FORCES AFGHANISTA; O'Hanlon M. E., 2008, IRAQ INDEX TRACKING; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pizarro J, 2006, ARCH GEN PSYCHIAT, V63, P193, DOI 10.1001/archpsyc.63.2.193; Riccardi N., 2009, LOS ANGELES TIM 1003; Saxon AJ, 2001, PSYCHIATR SERV, V52, P959, DOI 10.1176/appi.ps.52.7.959; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; SHAW DM, 1987, COMPR PSYCHIAT, V28, P403, DOI 10.1016/0010-440X(87)90057-5; Sherman MD, 2006, J MARITAL FAM THER, V32, P479, DOI 10.1111/j.1752-0606.2006.tb01622.x; SPEED N, 1989, J NERV MENT DIS, V177, P147, DOI 10.1097/00005053-198903000-00004; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Steadman H.J., 1997, PROVIDING SERVICES J; Teller JLS, 2006, PSYCHIAT SERV, V57, P232, DOI 10.1176/appi.ps.57.2.232; TEPLIN LA, 1983, PSYCHOL BULL, V94, P54, DOI 10.1037/0033-2909.94.1.54; TEPLIN LA, 1992, INT J LAW PSYCHIAT, V15, P139, DOI 10.1016/0160-2527(92)90010-X; TEPLIN LA, 1994, AM J PUBLIC HEALTH, V84, P290, DOI 10.2105/AJPH.84.2.290; TEPLIN LA, 1984, AM PSYCHOL, V39, P794, DOI 10.1037/0003-066X.39.7.794; TEPLIN LA, 1985, AM J PSYCHIAT, V142, P593; Troops risk undetected brain injury, 2006, US TODAY         MAY; True W. R., 1988, AM J EPIDEMIOL, V177, P154; Visher CA, 1991, COMP URINALYSIS TECH; White M. D., 2009, ARIZONA ARRESTEE REP; White M. D., 2010, ARIZONA ARRESTEE REP; Willbach H, 1948, J CRIM LAW CRIM, V38, P501, DOI 10.2307/1138926; Wilson D. B., 2006, J EXP CRIMINOL, V2, P459; YAGER T, 1984, ARCH GEN PSYCHIAT, V41, P327	74	36	36	0	21	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0741-8825	1745-9109		JUSTICE Q	Justice Q.		2012	29	2					258	286		10.1080/07418825.2011.560890			29	Criminology & Penology	Criminology & Penology	920LS	WOS:000302406600004					2021-06-18	
J	Ho, KM; Honeybul, S; Lind, CRP; Gillett, GR; Litton, E				Ho, Kwok M.; Honeybul, Stephen; Lind, Christopher R. P.; Gillett, Grant R.; Litton, Edward			Cost-Effectiveness of Decompressive Craniectomy as a Lifesaving Rescue Procedure for Patients With Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Expenditure; Resources; Cost-benefit; Outcome	PRIORITIES; COHORT	Background: Decompressive craniectomy has been traditionally used as a lifesaving rescue procedure for patients with refractory intracranial hypertension after severe traumatic brain injury (TBI), but its cost-effectiveness remains uncertain. Methods: Using data on length of stay in hospital, rehabilitation facility, procedural costs, and Glasgow Outcome Scale (GOS) up to 18 months after surgery, the average total hospital costs per life-year and quality-adjusted life-year (QALY) were calculated for patients who had decompressive craniectomy for TBI between 2004 and 2010 in Western Australia. The Corticosteroid Randomisation After Significant Head Injury prediction model was used to quantify the severity of TBI. Results: Of the 168 patients who had 18-month follow-up data available after the procedure, 70 (42%) achieved a good outcome (GOS-5), 27 (16%) had moderate disability (GOS-4), 34 (20%) had severe disability (GOS-3), 5 (3%) were in vegetative state (GOS-2), and 32 (19%) died (GOS-1). The hospital costs increased with the severity of TBI and peaked when the predicted risk of an unfavorable outcome was about 80%. The average cost per life-year gained (US$671,000 per life-year) and QALY (US$682,000 per QALY) increased substantially and became much more than the usual acceptable cost-effective limit (US$100,000 per QALY) when the predicted risk of an unfavorable outcome was >80%. Changing different underlying assumptions of the analysis did not change the results significantly. Conclusions: Severity of TBI had an important effect on cost-effectiveness of decompressive craniectomy. As a lifesaving procedure, decompressive craniectomy was not cost-effective for patients with extremely severe TBI.	[Ho, Kwok M.; Litton, Edward] Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6000, Australia; [Lind, Christopher R. P.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Gillett, Grant R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand; [Gillett, Grant R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand	Ho, KM (corresponding author), Royal Perth Hosp, Dept Intens Care Med, Wellington St, Perth, WA 6000, Australia.	kwok.ho@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Lind, Christopher/K-3629-2012; litton, edward/C-5384-2017	Ho, Kwok M./0000-0002-6705-6004; Lind, Christopher/0000-0001-9991-1725; litton, edward/0000-0002-5125-6829	Department of Intensive Care Medicine at Royal Perth Hospital	Supported by the Department of Intensive Care Medicine at Royal Perth Hospital.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AIHW, 2006, AUSTR HOSP STAT 2004; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Alexander GC, 2004, ARCH INTERN MED, V164, P593, DOI 10.1001/archinte.164.6.593; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; BOCHNER F, 1994, BRIT MED J, V308, P901, DOI 10.1136/bmj.308.6933.901; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Braithwaite RS, 2008, MED CARE, V46, P349, DOI 10.1097/MLR.0b013e31815c31a7; Cookson R, 2000, J MED ETHICS, V26, P323, DOI 10.1136/jme.26.5.323; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Daniels N, 2009, HEALTH AFFAIR, V28, pW909, DOI 10.1377/hlthaff.28.5.w909; Fuchs VR, 2010, NEW ENGL J MED, V363, P704, DOI 10.1056/NEJMp0906597; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Ho KM, 2011, BRIT J ANAESTH, V106, P528, DOI 10.1093/bja/aeq417; Ho KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003226; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Malmivaara K, 2011, EUR J NEUROL, V18, P656, DOI 10.1111/j.1468-1331.2010.03294.x; Owens DK, 2011, ANN INTERN MED, V154, P174, DOI 10.7326/0003-4819-154-3-201102010-00007; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rechner IJ, 2005, ANAESTH INTENS CARE, V33, P477, DOI 10.1177/0310057X0503300409; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39	25	36	36	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1637	1644		10.1097/TA.0b013e31823a08f1			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	869RT	WOS:000298616400035	22182872				2021-06-18	
J	Sun, YH; Dai, MC; Wang, YT; Wang, WJ; Sun, QF; Yang, GY; Bian, LG				Sun, Yuhao; Dai, Minchao; Wang, Yongting; Wang, Wenjing; Sun, Qingfang; Yang, Guo-Yuan; Bian, Liuguan			Neuroprotection and Sensorimotor Functional Improvement by Curcumin after Intracerebral Hemorrhage in Mice	JOURNAL OF NEUROTRAUMA			English	Article							BLOOD-BRAIN-BARRIER; TIGHT JUNCTION PROTEINS; CEREBRAL-ISCHEMIA; FOCAL ISCHEMIA; CLINICAL-TRIAL; CELL-CULTURE; RAT-BRAIN; MATRIX; INHIBITION; MODEL	Previous studies revealed that curcumin is neuroprotective in diseases of the central nervous system such as cerebral ischemia and traumatic brain injury. However, the effect of curcumin on intracerebral hemorrhage remains unclear. We, therefore, investigated the pre-clinical effect of curcumin treatment on neurological outcomes following intracerebral hemorrhage, using a mouse model. Intracerebral hemorrhage was induced by autologous blood injection into the right basal ganglia. Curcumin (150 mg/kg) was administered 15 min after intracerebral hemorrhage. Grid walk and neurological scores were evaluated at 1, 3, 7, and 14 days post-injury. Mice were killed at 24 h or 28 days following injury, for histological examination. Evans Blue and water content in the ipsilateral and contralateral hemispheres were measured to evaluate the extent of blood-brain barrier disruption and brain edema. Zonula occludens-1 was detected by immunostaining. In situ zymography was used to measure the localization and focal enzymatic activity of matrix metalloproteinase. Our results demonstrated that curcumin reduced brain edema, measured by alleviated water content and Evans Blue leakage at 24 h (p < 0.05). Lateral ventricle measurements indicated that curcumin reduced brain tissue loss in the ipsilateral hemisphere (p < 0.05). The same dose of curcumin also significantly attenuated neurological deficits at 1 and 3 days of intracerebral hemorrhage (p < 0.05). Immunostaining showed that tight junction continuity around the hematoma was better sustained in curcumin-treated mice than in vehicle-treated mice. At 24 h, the number of matrix metalloproteinase-positive cells was significantly reduced by curcumin (p < 0.05). Our study suggests that curcumin ameliorates intracerebral hemorrhage damage by preventing matrix metalloproteinase-mediated blood-brain barrier damage and brain edema, which might provide therapeutic potential for intracerebral hemorrhage.	[Sun, Yuhao; Dai, Minchao; Wang, Wenjing; Sun, Qingfang; Yang, Guo-Yuan; Bian, Liuguan] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Ruijin Hosp, Shanghai 200025, Peoples R China; [Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Med, Dept Neurol, Ruijin Hosp, Shanghai 200025, Peoples R China; [Wang, Yongting; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Med, Neurosci & Neuroengn Res Ctr, Med Res Inst X, Shanghai 200025, Peoples R China	Bian, LG (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Ruijin Hosp, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.	bian6612@yahoo.com.cn	Wang, Yongting/C-2916-2014		Shanghai Committee of Science and TechnologyShanghai Science & Technology Committee [09JC1409700, 10JC1410700, 10411954200, 09140902400, 10JC1408100]	This research was supported by Shanghai Committee of Science and Technology grants 09JC1409700, 10JC1410700, 10411954200 (L. G. B., Q. F. S.), 09140902400, 10JC1408100 (G.Y.Y., Y.T.W.). We thank the collaborative support of the Med-X research Institute (http//med-x.sjtu.edu.cn) and Ms. Karena Shen for assistance with manuscript preparation.	Abilleira S, 2003, J NEUROSURG, V99, P65, DOI 10.3171/jns.2003.99.1.0065; Asahi M, 2001, J NEUROSCI, V21, P7724; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Baum L, 2008, J CLIN PSYCHOPHARM, V28, P110, DOI 10.1097/jcp.0b013e318160862c; Belayev L, 2003, STROKE, V34, P2221, DOI 10.1161/01.STR.0000088061.06656.1E; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Dohare P, 2008, BEHAV BRAIN RES, V193, P289, DOI 10.1016/j.bbr.2008.06.012; Ghoneim AI, 2002, PHARMACOL RES, V46, P273, DOI 10.1016/S1043-6618(02)00123-8; Grossetete M, 2008, J CEREBR BLOOD F MET, V28, P752, DOI 10.1038/sj.jcbfm.9600572; Jiang J, 2007, EUR J PHARMACOL, V561, P54, DOI 10.1016/j.ejphar.2006.12.028; Kim SY, 2005, BIOCHEM BIOPH RES CO, V337, P510, DOI 10.1016/j.bbrc.2005.09.079; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Lapchak PA, 2011, EXPERT OPIN INV DRUG, V20, P13, DOI 10.1517/13543784.2011.542410; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Rathore P, 2008, NEUROCHEM RES, V33, P1672, DOI 10.1007/s11064-007-9515-6; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROSENBERG GA, 1993, NEUROSCI LETT, V160, P117, DOI 10.1016/0304-3940(93)90927-D; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Wachtel M, 1999, J CELL SCI, V112, P4347; Wang HH, 2009, GLIA, V57, P24, DOI 10.1002/glia.20732; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang MS, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-57; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu CY, 2008, J NEUROCHEM, V105, P1499, DOI 10.1111/j.1471-4159.2008.05318.x; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xue MZ, 2006, J NEUROSCI, V26, P10281, DOI 10.1523/JNEUROSCI.2806-06.2006; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167; Zhao J, 2010, NEUROCHEM RES, V35, P374, DOI 10.1007/s11064-009-0065-y	35	36	39	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2011	28	12					2513	2521		10.1089/neu.2011.1958			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	865DS	WOS:000298291600011	21770745	Green Published			2021-06-18	
J	Kalanithi, P; Schubert, RD; Lad, SP; Harris, OA; Boakye, M				Kalanithi, Paul; Schubert, Ryan D.; Lad, Shivanand P.; Harris, Odette A.; Boakye, Maxwell			Hospital costs, incidence, and inhospital mortality rates of traumatic subdural hematoma in the United States Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic subdural hematoma; incidence; cost; traumatic brain injury; National Inpatient Sample; mortality	STROKE RISK-FACTORS; PROGNOSTIC-FACTORS; COMATOSE PATIENTS; CRANIOTOMY; CRITERIA	Object. This study provides the first US national data regarding frequency, cost, and mortality rate of traumatic subdural hematoma (SDH), and identifies demographic factors affecting morbidity and death in patients with traumatic SDH undergoing surgical drainage. Methods. A retrospective analysis was conducted by querying the Nationwide Inpatient Sample, the largest all-payer database of nonfederal community hospitals. All cases of traumatic SDH were identified using ICD-9 codes. The study consisted of 2 parts: 1) trends data, which were abstracted from the years 1993-2006, and 2) univariate analysis and multivariate logistic regression of demographic variables on inhospital complications and deaths for the years 1993-2002. Results. Admissions for traumatic SDH increased 154% from 17,328 in 1993 to 43,996 in 2006. Inhospital deaths decreased from 16.4% to 11.6% for traumatic SDH. Average costs increased 67% to $47,315 per admission. For the multivariate regression analysis, between 1993 and 2002, 67,864 patients with traumatic SDH underwent operative treatment. The inhospital mortality rate was 14.9% for traumatic SDH drainage, with an 18% inhospital complication rate. Factors affecting inhospital deaths included presence of coma (OR = 2.45) and more than 2 comorbidities (OR = 1.60). Increased age did not worsen the inhospital mortality rate. Conclusions. Nationally, frequency and cost of traumatic SDH cases are increasing rapidly. (DOI: 10.3171/2011.6.JNS101989)	[Kalanithi, Paul; Lad, Shivanand P.; Harris, Odette A.; Boakye, Maxwell] Stanford Univ Hosp & Clin, Dept Neurosurg, Palo Alto, CA USA; [Kalanithi, Paul; Lad, Shivanand P.; Harris, Odette A.; Boakye, Maxwell] VA Palo Alto Hlth Care Syst, Outcomes Res Ctr, Palo Alto, CA USA; [Schubert, Ryan D.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Kalanithi, P (corresponding author), Stanford Univ, Dept Neurosurg, Med Ctr, Lane Bldg,300 Pasteur Dr, Palo Alto, CA 94305 USA.	paul.kalanithi@gmail.com	Kalanithi, Paul/B-1074-2012	Schubert, Ryan/0000-0002-3132-5831			Abe M, 2003, SURG NEUROL, V59, P464, DOI 10.1016/S0090-3019(03)00078-8; [Anonymous], 2011, OV NAT INP SAMPL NIS; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Cruz J, 2001, NEUROSURGERY, V49, P864; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Holloway RG, 2010, NEW ENGL J MED, V362, P1757, DOI 10.1056/NEJMp0907808; Kalanithi P, 2010, AANS NEUROSURGEON, V19, P28; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Marion DW, 2006, NEUROSURGERY, V58, P655; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; ROSENORN J, 1978, J NEUROSURG, V48, P345, DOI 10.3171/jns.1978.48.3.0345; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; U.S. Bureau of Lab. Stat, CONS PRIC IND ALL UR; van den Brink WA, 1999, ACTA NEUROCHIR, V141, P509, DOI 10.1007/s007010050332; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	31	36	36	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2011	115	5					1013	1018		10.3171/2011.6.JNS101989			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	839OR	WOS:000296377800026	21819196				2021-06-18	
J	O'Kane, JW; Levy, MR; Pietila, KE; Caine, DJ; Schiff, MA				O'Kane, John W.; Levy, Marni R.; Pietila, Kristin E.; Caine, Dennis J.; Schiff, Melissa A.			Survey of Injuries in Seattle Area Levels 4 to 10 Female Club Gymnasts	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						gymnastics; youth; injury; concussion; risk factors	EPIDEMIOLOGY; ELITE	Objective: To evaluate incidence, distribution, and contributing factors of injury in club gymnastics. Design: Cross-sectional survey. Setting: Five randomly selected gymnastics clubs near Seattle, WA. Participants: Ninety-six club gymnasts from competitive levels 4 to 10. Interventions: The participants completed a questionnaire regarding demographics, injuries and contributing factors, and exposure time in the last competitive season. Main Outcome Measures: Acute and overuse injury incidence rates stratified by practice and competition, age categories, and level using relative risks and 95% confidence intervals (CIs). Chi-square testing was used to compare demographic-specific and gymnastic-specific variables between injured and uninjured. Multivariate regression modeling was used to assess independent risk factors for risk of acute and overuse injuries. Results: Acute injury rate was 1.3 per 1000 hours and in univariate, but not multivariate analysis, it was 3.6-fold greater (95% CI, 1.6-9.1) among 10 to 12 year olds and 3.1-fold greater (95% Cl, 1.3-8.0) among 13 to 17 year olds compared with 7 to 9 year olds. The most common acutely injured body parts were foot (21.0%), ankle (19.3%), knee (14.0%), and wrist (8.8%). The majority of injuries occurred in practice, but the meet injury rate was higher. Most injuries occurred on floor exercise (32.1%), beam (20.7%), and bars (17.0). Injury was most common during landing. The overuse injury rate was 1.8 per 1000 hours. During their gymnastics careers, concussions occurred in 30.2% and stress fractures affecting mostly low back and foot occurred in 16.7% of the gymnasts. Conclusions: Gymnasts are at similar risk of acute and overuse injuries, and acute injury rates were greater among older gymnasts. However, this predictor did not remain significant in multivariate analysis. Concussions and stress fractures are common. Gymnastics injury prevention studies should focus on older gymnasts, concussion education, and landing after a skill.	[O'Kane, John W.] UW Sports Med Clin, Bank Amer Arena, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Levy, Marni R.; Schiff, Melissa A.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Pietila, Kristin E.; Schiff, Melissa A.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Caine, Dennis J.] Univ N Dakota, Dept Phys Educ Exercise Sci & Wellness, Grand Forks, ND 58201 USA	O'Kane, JW (corresponding author), UW Sports Med Clin, Bank Amer Arena, Dept Orthopaed & Sports Med, 3950 Montlake Blvd,Room 148,Box 354060, Seattle, WA 98195 USA.	jokane@u.washington.edu					BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; Bak K., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P148; CAINE D, 1989, AM J SPORT MED, V17, P811, DOI 10.1177/036354658901700616; Caine D, 2005, MED SPORT SCI, V48, P18, DOI 10.1159/000084282; Caine D, 2003, PHYS THER SPORT, V4, P10, DOI 10.1016/S1466-853X(02)00070-6; Caine DJ, 2006, BRIT J SPORT MED, V40, P91; DIXON M, 1993, MED SCI SPORT EXER, V25, P1322; Harringe ML, 2007, SCAND J MED SCI SPOR, V17, P115, DOI 10.1111/j.1600-0838.2006.00546.x; Kolt GS, 1999, BRIT J SPORT MED, V33, P312, DOI 10.1136/bjsm.33.5.312; Kolt GS, 2004, PERCEPT MOTOR SKILL, V99, P195, DOI 10.2466/PMS.99.5.195-207; LINDNER KJ, 1990, CAN J SPORT SCI, V15, P254; LINDNER KJ, 1993, J HUM MOVEMENT STUD, V25, P69; Marshall SW, 2007, J ATHL TRAINING, V42, P234; Martens R., 1990, COMPETITIVE ANXIETY; Singh S, 2008, PEDIATRICS, V121, pE954, DOI 10.1542/peds.2007-0767; US Centers for Disease Control and Prevention, CDC GROWTH CHARTS US	16	36	38	2	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2011	21	6					486	492		10.1097/JSM.0b013e31822e89a8			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	849PK	WOS:000297137400004	21959798				2021-06-18	
J	Ley, EJ; Clond, MA; Singer, MB; Shouhed, D; Salim, A				Ley, Eric J.; Clond, Morgan A.; Singer, Matt B.; Shouhed, Daniel; Salim, Ali			IL6 Deficiency Affects Function After Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; controlled cortical impact; behavioral testing; cytokine; heat shock protein; IL6; HSP70; HSP 72; IL1 beta	INTERLEUKIN-1 RECEPTOR ANTAGONIST; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; MICE; IL-6; CYTOKINE; IMPACT; CORRELATE; SEVERITY; KNOCKOUT	Objective. Interleukin-6 (IL6) is a major inflammatory mediator and one of the first cytokines produced after traumatic brain injury (TBI). This study evaluates early behavioral changes and acute inflammation after TBI in IL6 knock-out mice using electromagnetic controlled cortical impact. Methods. IL6 knock-out (KO) and C57BL/6 (WT) male mice were subjected to TBI or sham injury (n = 6 mice per group) using electromagnetic controlled cortical impact. Behavioral deficits were tested by standard performance tests. Brain IL1 beta expression was measured by ELISA and HSP70 expression was measured by Western blot. Results. After TBI, KO showed reduced performance on the neuroscreen compared with wild type (KO 3.2 +/- 0.7 versus WT 4.7 +/- 0.2 points, P = 0.007), less exploratory activity in the open field test (KO 1090.2 +/- 1799.2 versus WT 5636.8 +/- 1291.8 regions explored per hour, P = 0.003) less rearing behavior in the open field test (KO 36.4 +/- 79.2 versus WT 346.5 +/- 18.5 rearing per hour, P = 0.0006), reduced travel on the rotarod (KO 3.5 +/- 4.0 versus WT 13.0 +/- 4.0 cm, P = 0.0109), and reduced time balanced on the rotarod (KO 15.0 +/- 11.5 versus WT 36.2 +/- 5.9 s, P = 0.0109). After TBI, IL6 knock-out mice had significantly elevated IL1 beta (KO 58.16 +/- 17.54 versus WT 14.98 +/- 8.33 pg/mL, P = 0.003 and nonsignificantly increased HSP70 levels (KO 0.93 +/- 0.96 versus WT 0.68 +/- 0.97, P = 0.77). Conclusion. IL6 deficiency after TBI is associated with poor behavior performance, and appears to affect expression of IL1 beta and, possibly, HSP70. (C) 2011 Elsevier Inc. All rights reserved.	[Ley, Eric J.; Clond, Morgan A.; Singer, Matt B.; Shouhed, Daniel; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Clond, Morgan/0000-0002-3036-4193	American Association for the Surgery of Trauma Research and Education Foundation	The authors acknowledge support in part for this study by a grant from the American Association for the Surgery of Trauma Research and Education Foundation.	Beere HM, 2000, NAT CELL BIOL, V2, P469; Bracken MB, 2005, NEUROSURGERY, V57, P1300, DOI 10.1227/01.NEU.0000187320.71967.59; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Howell JM, 2006, PROTEOMICS, V6, P2050, DOI 10.1002/pmic.200500517; Juttler E, 2002, NEUROSCIENTIST, V8, P268, DOI 10.1177/1073858402008003012; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mannick JA, 2002, J AM COLL SURGEONS, V194, P104, DOI 10.1016/S1072-7515(01)01123-1; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Reyes TM, 1999, BRAIN RES, V851, P215, DOI 10.1016/S0006-8993(99)02189-7; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	28	36	36	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	OCT	2011	170	2					253	256		10.1016/j.jss.2011.03.006			4	Surgery	Surgery	823NH	WOS:000295128600024	21529825				2021-06-18	
J	Roscigno, CI; Swanson, KM				Roscigno, Cecelia I.; Swanson, Kristen M.			Parents' Experiences Following Children's Moderate to Severe Traumatic Brain Injury: A Clash of Cultures	QUALITATIVE HEALTH RESEARCH			English	Article						brain injury; children, disability; culture / cultural competence; disability / disabled persons; lived experience; parenting; phenomenology; trauma	SCHOOL; MODEL; PERSPECTIVES; PREDICTORS; RECOVERY; SYSTEM; NEEDS; WORK; CARE; TBI	Little is understood about parents' experiences following children's moderate to severe traumatic brain injury (TBI). Using descriptive phenomenology, we explored common experiences of parents whose children were diagnosed with moderate to severe TBI. Parents from across the United States (N = 42, from 37 families) participated in two semistructured interviews (similar to 90 minutes in length and 12 to 15 months apart) in the first 5 years following children's TBI. First interviews were in person. Second interviews, done in person or by phone, facilitated updating parents' experiences and garnering their critique of the descriptive model. Parent themes were (a) grateful to still have my child, (b) grieving for the child I knew, (c) running on nerves, and (d) grappling to get what my child and family need. Parents reported cultural barriers because of others' misunderstandings. More qualitative inquiry is needed to understand how the knowledge, attitudes, beliefs, and culture-based expectations of others influence parents' interactions and the family's adjustment and well-being.	[Roscigno, Cecelia I.] Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, Chicago, IL 60612 USA; [Swanson, Kristen M.] Univ N Carolina, Sch Nursing, Chapel Hill, NC USA	Roscigno, CI (corresponding author), Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, 845 S Damen Ave,MC 802, Chicago, IL 60612 USA.	roscigno@uic.edu			NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007091, F31NR009599] Funding Source: NIH RePORTER; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [1 F31 NR009599-02, T32 NR007091, F31 NR009599] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [6 T73 MC 00041-11-03);] Funding Source: Medline		Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Benn KM, 2004, BRAIN INJURY, V18, P239, DOI 10.1080/02699050310001617343; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; Bradbury-Jones Caroline, 2010, Nurse Res, V17, P25; BRONFENBRENNER U, 1977, AM PSYCHOL, V32, P513, DOI 10.1037/0003-066x.32.7.513; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Chisholm J, 2001, Axone, V23, P12; Clark Alex, 2008, Clin Child Psychol Psychiatry, V13, P565, DOI 10.1177/1359104508090607; Colaizzi PF., 1978, EXISTENTIAL PHENOMEN, P48; Committee on Quality of Health Care in America Institute of Medicine, 2001, CROSS QUAL CHASM NEW; Conway J., 2006, PARTNERING PATIENTS; Crothers IR, 2007, BRAIN INJURY, V21, P47, DOI 10.1080/02699050601149054; Duff Diane, 2006, Axone, V27, P9; Eker C, 2000, BRAIN INJURY, V14, P605; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gearing RE, 2004, QUAL HEALTH RES, V14, P1429, DOI 10.1177/1049732304270394; Gfroerer SD, 2008, BRAIN INJURY, V22, P649, DOI 10.1080/02699050802227162; Glang A, 2008, NEUROREHABILITATION, V23, P477; GUBA EG, 1989, 4 GENERATION EVALUAT, P228; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Husserl E., 1982, IDEAS PERTAINING PUR; Husserl E, 1965, PHENOMENOLOGY CRISIS; Jumisko E, 2007, DISABIL REHABIL, V29, P1535, DOI 10.1080/09638280601055816; Kao Hsueh-Fen S, 2004, J Neurosci Nurs, V36, P73; Kirschner PA, 2006, EDUC PSYCHOL-US, V41, P75, DOI 10.1207/s15326985ep4102_1; Knafl K., 2003, J FAM NURS, V9, P232, DOI [DOI 10.1177/1074840703255435, 10.1177/1074840703255435]; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Patterson J. M., 1983, STRESS FAMILY, VII, P21; Philipsen G, 2005, LEA COMMUN SER, P355; Philipsen Gerry, 1997, DEV COMMUNICATION TH, P119; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Reder EAK, 2009, ARCH PEDIAT ADOL MED, V163, P653, DOI 10.1001/archpediatrics.2009.87; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Ryan-Nicholls Kimberley D, 2009, Nurse Res, V16, P70; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Smith J E, 2000, Care Manag J, V2, P27; Smith Michele S, 2002, Rehabil Nurs, V27, P209; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; TEASDALE G, 1974, LANCET, V2, P81; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Wongvatunyu S, 2005, J NURS SCHOLARSHIP, V37, P48, DOI 10.1111/j.1547-5069.2005.00015.x	56	36	36	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323	1552-7557		QUAL HEALTH RES	Qual. Health Res.	OCT	2011	21	10			SI		1413	1426		10.1177/1049732311410988			14	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	817HI	WOS:000294662200009	21613654	Green Accepted			2021-06-18	
J	Braun, M; Tupper, D; Kaufmann, P; McCrea, M; Postal, K; Westerveld, M; Wills, K; Deer, T				Braun, Michelle; Tupper, David; Kaufmann, Paul; McCrea, Michael; Postal, Karen; Westerveld, Michael; Wills, Karen; Deer, Teresa			Neuropsychological Assessment: A Valuable Tool in the Diagnosis and Management of Neurological, Neurodevelopmental, Medical, and Psychiatric Disorders	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						neuropsychological assessment; diagnosis; neurological disorders; neurodevelopmental disorders; clinical management	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; OLDER-ADULTS; PSYCHOLOGICAL-ASSESSMENT; NEUROCOGNITIVE OUTCOMES; ECOLOGICAL VALIDITY; FUNCTIONAL OUTCOMES; FINANCIAL CAPACITY; AMERICAN-ACADEMY	For both children and adults with neurological, neurodevelopmental, medical, or psychiatric disorders, neuropsychological assessment can be a valuable tool in determining diagnosis, prognosis, and functional abilities as well as informing clinical management. This review summarizes the contributions of neuropsychological assessment to clinical care across diagnostic categories, with the goal of helping clinicians determine its utility for individual patients.	[Braun, Michelle] Wheaton Franciscan Healthcare, Dept Neurol & Neurosurg, Racine, WI 53405 USA; [McCrea, Michael] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Deer, Teresa] Neuropsychol Consultants, Kenosha, WI USA; [Tupper, David] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Wills, Karen] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA; [Kaufmann, Paul] Univ Nebraska, Dept Hlth & Human Serv, Lincoln, NE USA; [Postal, Karen] Neuropsychol Consultants, Andover, MA USA; [Westerveld, Michael] Florida Hosp, Orlando, FL USA	Braun, M (corresponding author), Wheaton Franciscan Healthcare, Dept Neurol & Neurosurg, 3805B Spring St,Ste 320, Racine, WI 53405 USA.	michelle.braun@wfhc.org	Postal, Karen/AAA-3184-2020				Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Alosco ML, 2011, J CARDIOVASC NURS; Amato MP, 2008, NEUROLOGY, V71, P632, DOI 10.1212/01.wnl.0000324621.58447.00; American Academy of Clinical Neuropsychology, 2010, AACN RESP AMA PCPI D; [Anonymous], 1996, Neurology, V47, P592; Antony SP, 2010, NEUROPSYCHOL TRENDS, P37, DOI 10.7358/neur-2010-007-anto; Areza-Fegyveres Renata, 2010, Dement. neuropsychol., V4, P14, DOI 10.1590/S1980-57642010DN40100003; Attix DK, 2009, CLIN NEUROPSYCHOL, V23, P21, DOI 10.1080/13854040801945078; Baars MAE, 2009, DEMENT GERIATR COGN, V27, P173, DOI 10.1159/000200465; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Balthazar MLF, 2010, J INT NEUROPSYCH SOC, V16, P205, DOI 10.1017/S1355617709990956; Barker-Collo S, 2010, NEUROLOGY, V75, P1608, DOI 10.1212/WNL.0b013e3181fb44c8; Barker-Collo S, 2006, NEUROPSYCHOL REV, V16, P53, DOI 10.1007/s11065-006-9007-5; Bearden CE, 2010, CURR PSYCHIAT REP, V12, P499, DOI 10.1007/s11920-010-0151-5; Benedict RHB, 2007, J NEUROL, V254, P22, DOI 10.1007/s00415-007-2007-4; Bercaw EL, 2011, CLIN NEUROPSYCHOL, V25, P72, DOI 10.1080/13854046.2010.532813; Bronstein JM, 2011, ARCH NEUROL-CHICAGO, V68, P165, DOI 10.1001/archneurol.2010.260; Chan AS, 2004, NEUROPSYCHOLOGY, V18, P700, DOI 10.1037/0894-4105.18.4.700; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Clusmann H, 2008, SEMIN ULTRASOUND CT, V29, P60, DOI 10.1053/j.sult.2007.11.004; Cohen RA, 2010, NEUROPSYCHOLOGY CARD; Cosentino S, 2011, INT J ALZHEIMERS DIS; CULLUM CM, 1993, J CLIN EXP NEUROPSYC, V15, P321, DOI 10.1080/01688639308402566; Cummings J, 2010, J ALZHEIMERS DIS, V21, P843, DOI 10.3233/JAD-2010-100078; Damholdt MF, 2012, ACTA NEUROL SCAND, V125, P311, DOI 10.1111/j.1600-0404.2011.01561.x; de Jager CA, 2009, AGE AGEING, V38, P455, DOI 10.1093/ageing/afp068; Depp CA, 2008, J CLIN PSYCHOPHARM, V28, P225, DOI 10.1097/JCP.0b013e318166dfed; Devos H, 2011, NEUROLOGY, V76, P747, DOI 10.1212/WNL.0b013e31820d6300; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Diller L, 1992, NEUROPSYCHOLOGY, V6, P357; Duinkerke Anja, 2004, Cogn Behav Neurol, V17, P179, DOI 10.1097/01.wnn.0000124916.16017.6a; Eack S. M., 2010, PSYCHOL MED, P1; Edwards Christopher L, 2007, Neuropsychiatr Dis Treat, V3, P705; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Elamin M, 2011, NEUROLOGY, V76, P1263, DOI 10.1212/WNL.0b013e318214359f; Farias ST, 2003, ARCH CLIN NEUROPSYCH, V18, P655, DOI 10.1016/S0887-6177(02)00159-2; Fasano A, 2010, BRAIN, V133, P2664, DOI 10.1093/brain/awq221; Feigin VL, 2008, INT J STROKE, V3, P33, DOI 10.1111/j.1747-4949.2008.00177.x; Ferman TJ, 2006, CLIN NEUROPSYCHOL, V20, P623, DOI 10.1080/13854040500376831; Fletcher JM, 1999, PEDIATR CLIN N AM, V46, P885, DOI 10.1016/S0031-3955(05)70161-9; Frazier TW, 2004, NEUROPSYCHOLOGY, V18, P543, DOI 10.1037/0894-4105.18.3.543; Gasquoine PG, 2011, J CLIN EXP NEUROPSYC, V33, P486, DOI 10.1080/13803395.2010.536759; Gavett BE, 2010, J INT NEUROPSYCH SOC, V16, P651, DOI 10.1017/S1355617710000421; Gavett BE, 2009, J INT NEUROPSYCH SOC, V15, P121, DOI 10.1017/S1355617708090176; Gelb SR, 2010, NEUROPSYCHOLOGY, V24, P514, DOI 10.1037/a0018670; Geroldi C, 2008, ALZ DIS ASSOC DIS, V22, P309, DOI 10.1097/WAD.0b013e3181871a47; Gilman S, 2005, EXP NEUROL, V191, pS95, DOI 10.1016/j.expneurol.2004.06.017; Godefroy O, 2009, EUR NEUROL, V61, P223, DOI 10.1159/000197107; Gold JI, 2008, PEDIATR HEMAT ONCOL, V25, P409, DOI 10.1080/08880010802107497; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Gorman AA, 2009, NEUROPSYCHOL REV, V19, P186, DOI 10.1007/s11065-009-9095-0; Gottesman RF, 2010, LANCET NEUROL, V9, P895, DOI 10.1016/S1474-4422(10)70164-2; Graydon FJX, 2001, EPILEPSY BEHAV, V2, P140, DOI 10.1006/ebeh.2001.0163; Gure TR, 2010, J GERONTOL A-BIOL, V65, P434, DOI 10.1093/gerona/glp197; Gustaw-Rothenberg K, 2008, DEMENT GERIATR COGN, V26, P165, DOI 10.1159/000150443; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hanna-Pladdy B, 2010, INT J NEUROSCI, V120, P538, DOI 10.3109/00207454.2010.496539; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Helmstaedter C, 2004, EPILEPSY BEHAV, V5, pS45, DOI 10.1016/j.yebeh.2003.11.006; Henry TR, 2011, EPILEPSY BEHAV, V20, P194, DOI 10.1016/j.yebeh.2010.12.008; Hentschel F, 2005, INT J GERIATR PSYCH, V20, P645, DOI 10.1002/gps.1333; Hermann B, 2007, J INT NEUROPSYCH SOC, V13, P12, DOI 10.1017/S135561770707004X; Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872; Herrmann N, 2011, EXPERT OPIN PHARMACO, V12, P787, DOI 10.1517/14656566.2011.558006; Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47; Hoth KF, 2008, COGN BEHAV NEUROL, V21, P65, DOI 10.1097/WNN.0b013e3181799dc8; Humphrey L, 2003, CLIN NEUROPSYCHOLOGY; Jak AJ, 2009, J INT NEUROPSYCH SOC, V15, P890, DOI 10.1017/S1355617709090638; Jak AJ, 2009, AM J GERIAT PSYCHIAT, V17, P368, DOI 10.1097/JGP.0b013e31819431d5; Jerskey BA, 2009, J INT NEUROPSYCH SOC, V15, P137, DOI 10.1017/S1355617708090073; Jones B L, 2000, Semin Clin Neuropsychiatry, V5, P157, DOI 10.1053/scnp.2000.6726; Kalirao P, 2011, AM J KIDNEY DIS, V57, P612, DOI 10.1053/j.ajkd.2010.11.026; Kalmar JH, 2008, NEUROPSYCHOLOGY, V22, P442, DOI 10.1037/0894-4105.22.4.442; Kaufmann PM, 2009, CLIN NEUROPSYCHOL, V23, P1130, DOI 10.1080/13854040903107809; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kim SH, 2010, DEMENT GERIATR COGN, V29, P213, DOI 10.1159/000278422; Knopman DS, 2009, ALZHEIMERS DEMENT, V5, P207, DOI 10.1016/j.jalz.2009.01.027; Kozora E, 2004, ARTHRIT RHEUM-ARTHR, V51, P810, DOI 10.1002/art.20692; Di Legge Silvia, 2010, Dement. neuropsychol., V4, P4, DOI 10.1590/S1980-57642010DN40100002; Leung AWS, 2010, NEUROREHABILITATION, V27, P351, DOI 10.3233/NRE-2010-0619; Libon DJ, 2007, NEUROLOGY, V68, P369, DOI 10.1212/01.wnl.0000252820.81313.9b; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Long CJ., 1996, ECOLOGICAL VALIDITY; Loring DW, 2007, NEUROPSYCHOL REV, V17, P413, DOI 10.1007/s11065-007-9043-9; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; Mackin RS, 2009, J INT NEUROPSYCH SOC, V15, P793, DOI 10.1017/S1355617709990300; Marcotte T., 2010, NEUROPSYCHOLOGY EVER; Martin R, 2001, EPILEPSIA, V42, P764, DOI 10.1046/j.1528-1157.2001.33300.x; Martino DJ, 2011, J NERV MENT DIS, V199, P459, DOI 10.1097/NMD.0b013e3182214190; Masson JD, 2010, J INTELL DISABIL RES, V54, P457, DOI 10.1111/j.1365-2788.2010.01280.x; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McLennan SN, 2010, J CARDIOVASC NURS, V25, P390, DOI 10.1097/JCN.0b013e3181dae445; Mendez MF, 2007, AM J GERIAT PSYCHIAT, V15, P84, DOI 10.1097/01.JGP.0000231744.69631.33; Messier C, 2010, J CLIN EXP NEUROPSYC, V32, P809, DOI 10.1080/13803390903540323; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Meyers CA, 2006, J CLIN ONCOL, V24, P1305, DOI 10.1200/JCO.2005.04.6086; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Morgan JE, 2008, TXB CLIN NEUROPSYCHO; Morris DM, 2006, NEUROREHABILITATION, V21, P131; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Muslimovic D, 2005, NEUROLOGY, V65, P1239, DOI 10.1212/01.wnl.0000180516.69442.95; Naskar S, 2010, BRAIN RES REV, V65, P1, DOI 10.1016/j.brainresrev.2010.04.010; Nordlund A, 2007, NEUROPSYCHOLOGY, V21, P706, DOI 10.1037/0894-4105.21.6.706; Novack TA, 2010, HDB REHABILITATION P; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963; Oda H, 2009, PSYCHOGERIATRICS, V9, P85, DOI 10.1111/j.1479-8301.2009.00283.x; Okun MS, 2007, CLIN NEUROPSYCHOL, V21, P162, DOI 10.1080/13825580601025940; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Pfiffner LJ, 2006, J ABNORM CHILD PSYCH, V34, P725, DOI 10.1007/s10802-006-9060-9; Posner J, 2007, ACAD PSYCHIATR, V31, P479, DOI 10.1176/appi.ap.31.6.479; Quiske A, 2007, EPILEPSY BEHAV, V10, P328, DOI 10.1016/j.yebeh.2006.12.009; Randolph C, 2009, LIVER INT, V29, P629, DOI 10.1111/j.1478-3231.2009.02009.x; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Razani J, 2011, J GERIATR PSYCH NEUR, V24, P23, DOI 10.1177/0891988710390812; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ris MD, 2007, J INT NEUROPSYCH SOC, V13, P50, DOI 10.1017/S1355617707070087; Robottom BJ, 2009, INT REV NEUROBIOL, V84, P229, DOI 10.1016/S0074-7742(09)00412-7; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; ROURKE BP, 1994, FRAMES REFERENCE ASS; Sabsevitz DS, 2001, EPILEPSIA, V42, P1408, DOI 10.1046/j.1528-1157.2001.38500.x; Sachdev PS, 2006, DEMENT GERIATR COGN, V21, P300, DOI 10.1159/000091438; Salmon DP, 2009, ANNU REV PSYCHOL, V60, P257, DOI 10.1146/annurev.psych.57.102904.190024; Sauer AM, 2009, J ANESTH, V23, P256, DOI 10.1007/s00540-009-0744-5; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Schatz David Beck, 2006, J Atten Disord, V10, P141, DOI 10.1177/1087054706286698; Scott JC, 2011, NEUROPSYCHOLOGY, V25, P511, DOI 10.1037/a0022491; Shrivastava A, 2011, J PSYCHIATR PRACT, V17, P194, DOI 10.1097/01.pra.0000398412.67115.5c; Sirven JI, 2000, NEUROLOGY, V54, P2166, DOI 10.1212/WNL.54.11.2166; Smith G. E., 2008, TXB CLIN NEUROPSYCHO; Spaan PEJ, 2010, BEHAV NEUROL, V23, P203, DOI [10.3233/BEN-2010-0295, 10.1155/2010/946315]; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Stephan BCM, 2010, NAT REV NEUROL, V6, P318, DOI 10.1038/nrneurol.2010.54; Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940; Tabert MH, 2006, ARCH GEN PSYCHIAT, V63, P916, DOI 10.1001/archpsyc.63.8.916; Talacchi A, 2011, J NEURO-ONCOL, V103, P541, DOI 10.1007/s11060-010-0417-0; Temple RO, 2006, ARCH CLIN NEUROPSYCH, V21, P371, DOI 10.1016/j.acn.2006.05.002; Tierney MC, 2005, NEUROLOGY, V64, P1853, DOI 10.1212/01.WNL.0000163773.21794.0B; Toniolo Silvia, 2011, G Ital Med Lav Ergon, V33, pA29; Towgood K, 2004, J INT NEUROPSYCH SOC, V10, P114; Trepanier LL, 2000, BRAIN COGNITION, V42, P324, DOI 10.1006/brcg.1999.1108; Triebel KL, 2009, NEUROLOGY, V73, P928, DOI 10.1212/WNL.0b013e3181b87971; Visser PJ, 2009, LANCET NEUROL, V8, P619, DOI 10.1016/S1474-4422(09)70139-5; von Rhein M, 2011, J PEDIATR-US, V158, P984, DOI 10.1016/j.jpeds.2010.11.040; Wagle J, 2011, DEMENT GERIATR COGN, V31, P379, DOI 10.1159/000328970; Wahlin TBR, 2007, NEUROPSYCHOLOGY, V21, P31, DOI 10.1037/0894-4105.21.1.31; Waldstein SR, 2010, HANDBOOK OF MEDICAL NEUROPSYCHOLOGY: APPLICATIONS OF COGNITIVE NEUROSCIENCE, P69, DOI 10.1007/978-1-4419-1364-7_5; Waldstein SR, 2010, J ALZHEIMERS DIS, V20, P833, DOI 10.3233/JAD-2010-091591; Weimer DL, 2009, ALZHEIMERS DEMENT, V5, P215, DOI 10.1016/j.jalz.2009.01.028; Weinberg DG, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS1150; Wilson BA, 1999, APPL PREV PSYCHOL, V2, P209; Wright SL, 2007, J GERIATR PSYCH NEUR, V20, P189, DOI 10.1177/0891988707308801; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Ylikoski R, 2000, ARCH GERONTOL GERIAT, V30, P115, DOI 10.1016/S0167-4943(00)00045-5; Zihl J, 2010, APPL NEUROPSYCHOL, V17, P44, DOI 10.1080/09084280903526133	159	36	36	0	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1543-3633	1543-3641		COGN BEHAV NEUROL	Cogn. Behav. Neurol.	SEP	2011	24	3					107	114		10.1097/WNN.0b013e3182351289			8	Behavioral Sciences; Clinical Neurology	Behavioral Sciences; Neurosciences & Neurology	823YB	WOS:000295162800001	21945982				2021-06-18	
J	Kirkham, FJ; Haywood, P; Kashyape, P; Borbone, J; Lording, A; Pryde, K; Cox, M; Keslake, J; Smith, M; Cuthbertson, L; Murugan, V; Mackie, S; Thomas, NH; Whitney, A; Forrest, KM; Parker, A; Forsyth, R; Kipps, CM				Kirkham, F. J.; Haywood, P.; Kashyape, P.; Borbone, J.; Lording, A.; Pryde, K.; Cox, M.; Keslake, J.; Smith, M.; Cuthbertson, L.; Murugan, V.; Mackie, S.; Thomas, N. H.; Whitney, A.; Forrest, K. M.; Parker, A.; Forsyth, R.; Kipps, C. M.			Movement disorder emergencies in childhood	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article; Proceedings Paper	9th European-Pediatric-Neurology-Society Congress	MAY 11-14, 2011	Cavtat, CROATIA	European Pediat Neurol Soc		Chorea; Dystonia; Status dystonicus; Paroxysmal Autonomic Instability with Dystonia; Sandifer syndrome; Myoclonus; Opsoclonus; Tremor; Parkinsonism; Drugs; Neuroleptic malignant syndrome; Metabolic; Infection; Sydenham's chorea; Systemic lupus erythematosus; Cardiopulmonary bypass; Wilson's disease; Organic aciduria; Biotin; Creatine	OPSOCLONUS-MYOCLONUS SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACUTE NECROTIZING ENCEPHALOPATHY; NEUROLEPTIC MALIGNANT SYNDROME; TRAUMATIC BRAIN-INJURY; PAROXYSMAL AUTONOMIC INSTABILITY; CONGENITAL HEART-DISEASE; CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; SYDENHAMS-CHOREA	The literature on paediatric acute-onset movement disorders is scattered. In a prospective cohort of 52 children (21 male; age range 2mo-15y), the commonest were chorea, dystonia, tremor, myoclonus, and Parkinsonism in descending order of frequency. In this series of mainly previously well children with cryptogenic acute movement disorders, three groups were recognised: (1) Psychogenic disorders (n = 12), typically >10 years of age, more likely to be female and to have tremor and myoclonus (2) Inflammatory or autoimmune disorders (n = 22), including N-methyl-D-aspartate receptor encephalitis, opsoclonus-myoclonus, Sydenham chorea, systemic lupus erythematosus, acute necrotizing encephalopathy (which may be autosomal dominant), and other encephalitides and (3) Non-inflammatory disorders (n = 18), including drug-induced movement disorder, post-pump chorea, metabolic, e.g. glutaric aciduria, and vascular disease, e.g. moyamoya. Other important noninflammatory movement disorders, typically seen in symptomatic children with underlying aetiologies such as trauma, severe cerebral palsy, epileptic encephalopathy, Down syndrome and Rett syndrome, include dystonic posturing secondary to gastro-oesophageal reflux (Sandifer syndrome) and Paroxysmal Autonomic Instability with Dystonia (PAID) or autonomic 'storming'. Status dystonicus may present in children with known extrapyramidal disorders, such as cerebral palsy or during changes in management e.g. introduction or withdrawal of neuroleptic drugs or failure of intrathecal baclofen infusion; the main risk in terms of mortality is renal failure from rhabdomyolysis. Although the evidence base is weak, as many of the inflammatory/autoimmune conditions are treatable with steroids, immunoglobulin, plasmapheresis, or cyclophosphamide, it is important to make an early diagnosis where possible. Outcome in survivors is variable. Using illustrative case histories, this review draws attention to the practical difficulties in diagnosis and management of this important group of patients. (C) 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[Kirkham, F. J.] UCL Inst Child Hlth, London, England; [Kirkham, F. J.; Haywood, P.; Kashyape, P.; Borbone, J.; Lording, A.; Pryde, K.; Cox, M.; Keslake, J.; Smith, M.; Cuthbertson, L.; Murugan, V.; Mackie, S.; Thomas, N. H.; Whitney, A.; Forrest, K. M.; Kipps, C. M.] Southampton Univ Hosp NHS Trust, Southampton, Hants, England; [Kirkham, F. J.] Univ Southampton, Southampton SO9 5NH, Hants, England; [Haywood, P.; Smith, M.] Community Child Hlth, Southampton, Hants, England; [Parker, A.] Addenbrookes Hosp, Cambridge, England; [Forsyth, R.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Kirkham, FJ (corresponding author), UCL Inst Child Hlth, London, England.	fk@soton.ac.uk	Forsyth, Rob J/I-9226-2012; Kipps, Christopher/AAB-1053-2020; Kirkham, Fenella/C-2442-2009; Forsyth, Rob/H-9193-2019	Forsyth, Rob J/0000-0002-5657-4180; Kipps, Christopher/0000-0002-5205-9712; Kirkham, Fenella/0000-0002-2443-7958; Forsyth, Rob/0000-0002-5657-4180; kashyape, pawan/0000-0001-7164-7256			Acampa M, 2008, NEUROSCI LETT, V432, P69, DOI 10.1016/j.neulet.2007.12.030; Agrawal S, 2010, ARCH DIS CHILD, V95, P312, DOI 10.1136/adc.2009.164889; Ashtekar CS, 2003, DEV MED CHILD NEUROL, V45, P634, DOI 10.1017/S0012162203001154; Avcin T, 2008, ARTHRIT RHEUM-ARTHR, V59, P206, DOI 10.1002/art.23334; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Baik JS, 2010, MOVEMENT DISORD, V25, P1482, DOI 10.1002/mds.23130; Barash J, 2005, PEDIATR NEUROL, V32, P205, DOI 10.1016/j.pediatrneurol.2004.09.012; Beleza P, 2008, EUR J PAEDIATR NEURO, V12, P505, DOI 10.1016/j.ejpn.2007.11.005; Bell J, 2008, PEDIATR BLOOD CANCER, V50, P370, DOI 10.1002/pbc.20899; Ben-Pazi H, 2003, J PEDIATR-US, V143, P267, DOI 10.1067/S0022-3476(03)00366-4; Benseler SM, 2007, LUPUS, V16, P564, DOI 10.1177/0961203307078971; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BORBONE J, 2009, EUR J PAED NEUROL S1, V13, pS20; Borghi E, 2005, J MED VIROL, V75, P427, DOI 10.1002/jmv.20285; BRUYN GW, 1984, EUR NEUROL, V23, P278, DOI 10.1159/000115743; Burke MJ, 2008, PEDIATR BLOOD CANCER, V50, P679, DOI 10.1002/pbc.21009; Cardoso F, 2000, EUR J NEUROL, V7, P467, DOI 10.1046/j.1468-1331.2000.00100.x; Catsman-Berrevoets CE, 2009, PEDIATR BLOOD CANCER, V53, P1048, DOI 10.1002/pbc.22226; Choi IS, 1999, EUR NEUROL, V42, P141, DOI 10.1159/000008088; Corapcioglu F, 2008, PEDIATR HEMAT ONCOL, V25, P756, DOI 10.1080/08880010802341690; CURLESS RG, 1994, J PEDIATR-US, V124, P737, DOI 10.1016/S0022-3476(05)81365-4; Dale RC, 2005, DEV MED CHILD NEUROL, V47, P785, DOI 10.1017/S0012162205001647; Dale RC, 2004, ARCH DIS CHILD, V89, P604, DOI 10.1136/adc.2003.031856; Dale RC, 2004, BRAIN, V127, P21, DOI 10.1093/brain/awh008; Dale RC, 2001, ANN NEUROL, V50, P588, DOI 10.1002/ana.1250; Dale RC, 2007, MOVEMENT DISORD, V22, P2281, DOI 10.1002/mds.21664; Dale RC, 2010, DEV MED CHILD NEUROL, V52, P739, DOI 10.1111/j.1469-8749.2009.03598.x; Dale RC, 2009, ANN NEUROL, V66, P704, DOI 10.1002/ana.21807; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Deconinck N, 2006, PEDIATR NEUROL, V34, P312, DOI 10.1016/j.pediatrneurol.2005.08.034; DELEON S, 1990, ANN THORAC SURG, V50, P714, DOI 10.1016/0003-4975(90)90668-V; Demiroren K, 2007, J CHILD NEUROL, V22, P550, DOI 10.1177/0883073807302614; Dimova PS, 2006, MOVEMENT DISORD, V21, P564, DOI 10.1002/mds.20742; du Plessis AJ, 2002, PEDIATR NEUROL, V27, P9, DOI 10.1016/S0887-8994(02)00382-X; EDWARDS PD, 1975, J NEUROL NEUROSUR PS, V38, P729, DOI 10.1136/jnnp.38.8.729; Ertekin V, 2010, PEDIATR NEUROL, V42, P441, DOI 10.1016/j.pediatrneurol.2010.02.009; Ertle F, 2008, PEDIATR BLOOD CANCER, V50, P683, DOI 10.1002/pbc.21107; Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756; FREILINGER M, 2011, EUR J PAEDIAT NEU S1, V15, pS18; Frucht S, 2000, MOVEMENT DISORD, V15, P1; Gable MS, 2009, EUR J CLIN MICROBIOL, V28, P1421, DOI 10.1007/s10096-009-0799-0; Gamboa E T, 1973, Trans Am Neurol Assoc, V98, P177; Garvey MA, 2005, J CHILD NEUROL, V20, P424, DOI 10.1177/08830738050200050601; GASCON GG, 1994, BRAIN DEV-JPN, V16, P94, DOI 10.1016/0387-7604(94)90102-3; Ghosh J B, 2005, Indian J Pediatr, V72, P85, DOI 10.1007/BF02760591; Gika AD, 2010, MOVEMENT DISORD, V25, P385, DOI 10.1002/mds.22926; Gika AD, 2010, DEV MED CHILD NEUROL, V52, P99, DOI 10.1111/j.1469-8749.2009.03405.x; Gouider-Khouja N, 2010, EUR J PAEDIATR NEURO, V14, P304, DOI 10.1016/j.ejpn.2009.11.005; Green C, 2002, PEDIATR NEUROL, V26, P318, DOI 10.1016/S0887-8994(01)00396-4; GROOTHUIS JR, 1977, AM J DIS CHILD, V131, P1131, DOI 10.1001/archpedi.1977.02120230077014; Guerrini R, 2007, NEUROLOGY, V69, P427, DOI 10.1212/01.wnl.0000266594.16202.c1; Guideri F, 2005, PEDIATR CARDIOL, V26, P574, DOI 10.1007/s00246-005-0784-z; Gupta A, 2009, CURR OPIN NEUROL, V22, P430, DOI 10.1097/WCO.0b013e32832dc169; HAYWOOD P, 2009, EUR J PAED NEUROL S1, V13, pS33; HAYWOOD P, 2009, EUR J PAED NEUROL S1, V13, pS32; Holden KR, 1998, J PEDIATR-US, V132, P162, DOI 10.1016/S0022-3476(98)70505-0; Huber BM, 2010, EUR J PEDIATR, V169, P441, DOI 10.1007/s00431-009-1048-3; HUNTLEY DT, 1993, DEV MED CHILD NEUROL, V35, P631; Jech R, 2009, MOVEMENT DISORD, V24, P2291, DOI 10.1002/mds.22764; Kabakus N, 2006, PEDIATR INT, V48, P622, DOI 10.1111/j.1442-200X.2006.02280.x; Khan MR, 2011, JCPSP-J COLL PHYSICI, V21, P119, DOI 02.2011/JCPSP.119120; Kiechl-Kohlendorfer U, 1999, NEUROPEDIATRICS, V30, P96, DOI 10.1055/s-2007-973468; Kim JH, 2004, KOREAN J RADIOL, V5, P171, DOI 10.3348/kjr.2004.5.3.171; KIM JS, 1995, MOVEMENT DISORD, V10, P510, DOI 10.1002/mds.870100419; KIM KH, 2009, KOREAN J PEDIAT, V2010, P616; Kipps CM, 2005, MOVEMENT DISORD, V20, P322, DOI 10.1002/mds.20325; Klein A, 2007, EUR J PEDIATR, V166, P359, DOI 10.1007/s00431-006-0247-4; KOMATSU H, 1992, BRAIN DEV-JPN, V14, P400, DOI 10.1016/S0387-7604(12)80348-2; Kotagal P, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e46; Krug P, 2010, EUR J PAEDIATR NEURO, V14, P400, DOI 10.1016/j.ejpn.2009.12.005; Kurian MA, 2011, DEV MED CHILD NEUROL, V53, P394, DOI 10.1111/j.1469-8749.2011.03955.x; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; Levin DA, 2005, PEDIATR CARDIOL, V26, P34, DOI 10.1007/s00246-004-0669-6; Lo SE, 2005, NEUROCRIT CARE, V3, P139, DOI 10.1385/NCC:3:2:139; Long SS, 2005, ADV EXP MED BIOL, V568, P1; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Manji H, 1998, BRAIN, V121, P243, DOI 10.1093/brain/121.2.243; Mariotti P, 2007, MOVEMENT DISORD, V22, P963, DOI 10.1002/mds.21471; Mariotti P, 2010, LANCET, V376, P388, DOI 10.1016/S0140-6736(10)60711-8; McCarthy JE, 2009, PARKINSONISM RELAT D, V15, P792, DOI 10.1016/j.parkreldis.2009.04.002; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; MEDLOCK MD, 1993, ANN NEUROL, V34, P820, DOI 10.1002/ana.410340611; MILLER G, 1995, ARCH PEDIAT ADOL MED, V149, P764, DOI 10.1001/archpedi.1995.02170200054008; Neuhut R, 2009, J CHILD ADOL PSYCHOP, V19, P415, DOI 10.1089/cap.2008.0130; OKANO S, 1992, PEDIATR NEUROL, V8, P72, DOI 10.1016/0887-8994(92)90058-7; Olfat M, 2004, CLIN RHEUMATOL, V23, P395, DOI 10.1007/s10067-004-0898-3; Oosterveer DM, 2010, PEDIATR NEUROL, V43, P1, DOI 10.1016/j.pediatrneurol.2009.11.015; Paliwal VK, 2010, J NEURAL TRANSM, V117, P613, DOI 10.1007/s00702-010-0366-y; Pandey P, 2010, J NEUROSURG-PEDIATR, V6, P559, DOI 10.3171/2010.9.PEDS10192; Pang KK, 2010, EUR J PAEDIATR NEURO, V14, P156, DOI 10.1016/j.ejpn.2009.03.002; Parodi S, 2009, NEUROPEDIATRICS, V40, P103; Paviour DC, 2004, MOVEMENT DISORD, V19, P123, DOI 10.1002/mds.10644; Paz JA, 2006, PEDIATR NEUROL, V34, P264, DOI 10.1016/j.pediatrneurol.2005.08.028; Piekutowska-Abramczuk D, 2009, CLIN GENET, V76, P195, DOI 10.1111/j.1399-0004.2009.01195.x; Poloni C, 2010, DEV MED CHILD NEUROL, V52, pe78, DOI 10.1111/j.1469-8749.2009.03542.x; POWELL FC, 1994, STROKE, V25, P117, DOI 10.1161/01.STR.25.1.117; Pradhan S, 1999, NEUROLOGY, V53, P1781, DOI 10.1212/WNL.53.8.1781; Pranzatelli MR, 2010, J PEDIAT HEMATOL ONC, V32, pE167, DOI 10.1097/MPH.0b013e3181cf0726; Pranzatelli MR, 2009, J CHILD NEUROL, V24, P316, DOI 10.1177/0883073808324217; PRANZATELLI MR, 1994, PEDIATR NEUROL, V10, P131, DOI 10.1016/0887-8994(94)90045-0; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Prockop LD, 2005, J NEUROIMAGING, V15, P144, DOI 10.1177/1051228404273819; PRONICKA E, 1984, J INHERIT METAB DIS, V7, P113; Pronicka E, 2001, J INHERIT METAB DIS, V24, P707, DOI 10.1023/A:1012937204315; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; RAMANAN PV, 2009, J INDIAN MED ASSOC, V107, P253; ROBINSON RO, 1988, ARCH DIS CHILD, V63, P1466, DOI 10.1136/adc.63.12.1466; Rostasy K, 2006, NEUROPEDIATRICS, V37, P291, DOI 10.1055/s-2006-955931; Rothenberg AB, 2009, PEDIATR RADIOL, V39, P723, DOI 10.1007/s00247-009-1282-x; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; Schwingenschuh P, 2008, MOVEMENT DISORD, V23, P1882, DOI 10.1002/mds.22280; SEBIRE G, 1992, J PEDIATR-US, V121, P845, DOI 10.1016/S0022-3476(05)80326-9; Sibbitt WL, 2002, J RHEUMATOL, V29, P1536; Silva RR, 1999, J AM ACAD CHILD PSY, V38, P187, DOI 10.1097/00004583-199902000-00018; Singer HS, 1997, MOVEMENT DISORD, V12, P588, DOI 10.1002/mds.870120417; Smith Steven M, 2010, Paediatr Drugs, V12, P285, DOI 10.2165/11532530-000000000-00000; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; STEINLIN MI, 1995, PEDIATR NEUROL, V13, P191, DOI 10.1016/0887-8994(95)00110-2; Teive HAG, 2005, ARQ NEURO-PSIQUIAT, V63, P26, DOI 10.1590/S0004-282X2005000100005; Teixeira AL, 2005, PARKINSONISM RELAT D, V11, P327, DOI 10.1016/j.parkreldis.2005.02.007; Uc Ergun Y, 2003, Semin Pediatr Neurol, V10, P62; van Toorn R, 2005, EUR J PAEDIATR NEURO, V9, P423, DOI 10.1016/j.ejpn.2005.06.007; VAN TR, 2004, EUR J PAEDIATR NEURO, V8, P211; Wait SD, 2009, J NEUROSURG-PEDIATR, V4, P217, DOI 10.3171/2009.4.PEDS08444; Walker Kathleen G, 2010, Ther Adv Neurol Disord, V3, P301, DOI 10.1177/1756285610382063; Walker KG, 2005, DEV MED CHILD NEUROL, V47, P771, DOI 10.1017/S0012162205001611; WALLACH S, 1994, AM J MED, V97, P494, DOI 10.1016/0002-9343(94)90336-0; Wasserman JK, 2010, MOVEMENT DISORD, V25, P1754, DOI 10.1002/mds.23161; WICAL BS, 1990, PEDIATR NEUROL, V6, P202; Wilken B, 2008, EUR J PAEDIATR NEURO, V12, P51, DOI 10.1016/j.ejpn.2007.05.005; WONG PC, 1992, CIRCULATION, V86, P118; Zomorrodi A, 2006, PEDIATRICS, V117, pE675, DOI 10.1542/peds.2005-1573	137	36	36	1	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	SEP	2011	15	5					390	404		10.1016/j.ejpn.2011.04.005			15	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	830LN	WOS:000295658600002	21835657				2021-06-18	
J	Kopelman, TR; Berardoni, NE; O'Neill, PJ; Hedayati, P; Vail, SJ; Pieri, PG; Feiz-Erfan, I; Pressman, MA				Kopelman, Tammy R.; Berardoni, Nicole E.; O'Neill, Patrick J.; Hedayati, Poya; Vail, Sydney J.; Pieri, Paola G.; Feiz-Erfan, Iman; Pressman, Melissa A.			Risk Factors for Blunt Cerebrovascular Injury in Children: Do They Mimic Those Seen in Adults?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Pediatric; Trauma; Blunt cerebrovascular injury; Risk factors	CAROTID-ARTERY INJURIES; SEAT-BELT; TRAUMA; DIAGNOSIS; OUTCOMES	Background: Eastern Association for the Surgery of Trauma guideline for the evaluation of blunt cerebrovascular injury (BCVI) states that pediatric trauma patients should be evaluated using the same criteria as the adult population. The purpose of our study was to determine whether adult criteria translate to the pediatric population. Methods: Retrospective evaluation was performed at a Level I trauma center of blunt pediatric trauma patients (age <15 years) presenting over a 5-year period. Data obtained included patient demographics, presence of adult risk factors for BCVI (Glasgow coma scale <= 8, skull base fracture, cervical spine fracture, complex facial fractures, and soft tissue injury to the neck), presence of signs/symptoms of BCVI, method of evaluation, treatment, and outcome. Results: A total of 1,209 pediatric trauma patients were admitted during the study period. While 128 patients met criteria on retrospective review for evaluation based on Eastern Association for the Surgery of Trauma criteria, only 52 patients (42%) received subsequent radiographic evaluation. In all, 14 carotid artery or vertebral artery injuries were identified in 11 patients (all admissions, 0.9% incidence; all screened, 21% incidence). Adult risk factors were present in 91% of patients diagnosed with an injury. Major thoracic injury was found in 67% of patients with carotid artery injuries. Cervical spine fracture was found in 100% of patients with vertebral artery injuries. Stroke occurred in four patients (36%). Stroke rate after admission for untreated patients was 38% (3/8) versus 0.0% in those treated (0/2). Mortality was 27% because of concomitant severe traumatic brain injury. Conclusion: Risk factors for BCVI in the pediatric trauma patient appear to mimic those of the adult patient.	[Kopelman, Tammy R.; O'Neill, Patrick J.; Vail, Sydney J.; Pieri, Paola G.; Feiz-Erfan, Iman; Pressman, Melissa A.] Maricopa Cty Gen Hosp, Dept Surg, Phoenix, AZ 85008 USA; [Berardoni, Nicole E.; Hedayati, Poya] Maricopa Cty Gen Hosp, Dept Radiol, Phoenix, AZ 85008 USA	Kopelman, TR (corresponding author), Maricopa Cty Gen Hosp, Dept Surg, Phoenix, AZ 85008 USA.	tammy_kopelman@dmgaz.org					Berne JD, 2001, J AM COLL SURGEONS, V192, P314, DOI 10.1016/S1072-7515(01)00772-4; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; Chamoun RB, 2008, J NEUROS-PEDIATR, V2, P101, DOI 10.3171/PED/2008/2/8/101; Cothren C. Clay, 2005, Clinics, V60, P489, DOI 10.1590/S1807-59322005000600011; Cuff RF, 2005, J TRAUMA, V58, P620, DOI 10.1097/01.TA.0000078884.59598.CF; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FABIAN TC, 1990, J TRAUMA, V30, P953, DOI 10.1097/00005373-199008000-00003; Kerwin AJ, 2001, J TRAUMA, V51, P308, DOI 10.1097/00005373-200108000-00013; Levack MM, 2009, J PEDIATR SURG, V44, pE29, DOI 10.1016/j.jpedsurg.2009.05.026; Lew SM, 1999, PEDIATR NEUROSURG, V30, P239, DOI 10.1159/000028804; McConnell EJ, 1997, J TRAUMA, V43, P150, DOI 10.1097/00005373-199707000-00038; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Parikh AA, 1997, J AM COLL SURGEONS, V185, P80, DOI 10.1016/S1072-7515(01)00886-9; Riches KJ, 2002, AM J FOREN MED PATH, V23, P45, DOI 10.1097/00000433-200203000-00009; Rozycki GS, 2002, J TRAUMA, V52, P618, DOI 10.1097/00005373-200204000-00002; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; 2006, MMWR MORB MORTAL WKL, V55, P624	22	36	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2011	71	3					559	564		10.1097/TA.0b013e318226eadd			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	818MX	WOS:000294756900012	21908994				2021-06-18	
J	Caeyenberghs, K; Leemans, A; Geurts, M; Linden, CV; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Geurts, Monique; Linden, Catharine Vander; Smits-Engelsman, Bouwien C. M.; Sunaert, Stefan; Swinnen, Stephan P.			Correlations Between White Matter Integrity and Motor Function in Traumatic Brain Injury Patients	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						diffuse axonal injury; traumatic brain injury rehabilitation; fractional anisotropy; motor skills; pediatric brain injury	MOVEMENT ASSESSMENT BATTERY; DIFFUSION-TENSOR MRI; CORPUS-CALLOSUM; AXONAL INJURY; HEAD-INJURY; BEHAVIOR RELATIONSHIPS; CEREBELLAR ATROPHY; MUTUAL INFORMATION; CHILDREN; MILD	Background. Deterioration of motor function is one of several clinical manifestations following traumatic brain injury (TBI) in children and adolescents. Objective. To investigate the relationship between white matter (WM) integrity using diffusion tensor imaging (DTI) and motor functioning in young TBI patients. Methods. A group with moderate to severe TBI (n = 24) and a control group (n = 17) were scanned using DTI along with standard anatomical scans. Using ExploreDTI software, WM regions/tracts that carry efferent output (motor) from the brain were evaluated, as well as the corpus callosum, brainstem, internal capsule, and subcortical WM structures. Motor function was assessed using the Movement Assessment Battery for Children (M-ABC), consisting of manual dexterity, ball skills, and static and dynamic balance items. Results. TBI patients were less successful on the M-ABC than the controls and showed lower WM fractional anisotropy (FA) in the corpus callosum, anterior corona radiata, corticospinal tract, and cerebellum. Decreased FA was associated with lower motor performance in the TBI group but not in the control group. Conclusion. This study provides evidence for a structural alteration of motor pathways and regions in children and adolescents with TBI that are correlated with motor functioning. Further studies may be able to identify therapeutic targets and monitor the effects of new interventions.	[Caeyenberghs, Karen] Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, B-3001 Heverlee, Belgium; [Leemans, Alexander] Cardiff Univ, Cardiff, S Glam, Wales; [Leemans, Alexander] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Linden, Catharine Vander] Ghent Univ Hosp, B-9000 Ghent, Belgium; [Smits-Engelsman, Bouwien C. M.] Univ Professionals, Breda, Netherlands	Caeyenberghs, K (corresponding author), Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Tervuursevest 101, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@faber.kuleuven.be	Sunaert, Stefan/E-8031-2011; Leemans, Alexander/A-1784-2011	Sunaert, Stefan/0000-0002-1177-4680; Leemans, Alexander/0000-0002-9306-6126; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation-Flanders (FWO)FWO [7.0004.05, G.0482.010]	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: Support for this study was provided through a grant from the Research Programme of the Research Foundation-Flanders (FWO) (Levenslijn # 7.0004.05 and G.0482.010). Karen Caeyenberghs is funded by a postdoctoral fellowship of the Research Foundation-Flanders (FWO).	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Arfanakis K, 2002, MAGNET RESON MED, V47, P354, DOI 10.1002/mrm.10046; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bleyenheuft Y, 2007, PEDIATRICS, V120, pE1502, DOI 10.1542/peds.2007-0394; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Croce RV, 2001, PERCEPT MOTOR SKILL, V93, P275, DOI 10.2466/pms.2001.93.1.275; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Foulder-Hughes L., 2003, BRIT J OCCUPATIONAL, V66, P9; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Greenwood R, 2002, J NEUROL NEUROSUR PS, V73, pI8; HAZRATI LN, 1992, BRAIN RES, V585, P267, DOI 10.1016/0006-8993(92)91216-2; Henderson S. E., 1992, MOVEMENT ASSESSMENT; Hsu JL, 2010, NEUROIMAGE, V49, P32, DOI 10.1016/j.neuroimage.2009.08.031; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Klein S, 2010, IEEE T MED IMAGING, V29, P196, DOI 10.1109/TMI.2009.2035616; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; LeBihan D, 1995, NMR BIOMED, V8, P375; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Leemans A, 2005, LECT NOTES COMPUT SC, V3708, P523; Leemans A., 2009, 17 ANN M INT SOC MAG; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Sage CA, 2009, HUM BRAIN MAPP, V30, P3657, DOI 10.1002/hbm.20794; Schaechter JD, 2009, HUM BRAIN MAPP, V30, P3461, DOI 10.1002/hbm.20770; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Smits-Engelsman BCM, 1998, HUM MOVEMENT SCI, V17, P699, DOI 10.1016/S0167-9457(98)00019-0; Smits-Engelsman BCM, 2008, PHYS THER, V88, P286, DOI 10.2522/ptj.20070068; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Sterr A, 2010, NEUROREHAB NEURAL RE, V24, P413, DOI 10.1177/1545968309348310; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; van Hartingsveldt Margo J, 2005, Occup Ther Int, V12, P1, DOI 10.1002/oti.11; Van Hecke W, 2008, NEUROIMAGE, V43, P69, DOI 10.1016/j.neuroimage.2008.07.006; Van Hecke W, 2007, IEEE T MED IMAGING, V26, P1598, DOI 10.1109/TMI.2007.906786; Van Hecke W, 2010, J MAGN RESON IMAGING, V31, P1492, DOI 10.1002/jmri.22198; Van Hecke W, 2009, NEUROIMAGE, V46, P692, DOI 10.1016/j.neuroimage.2009.02.032; Van Waelvelde H, 2007, CLIN REHABIL, V21, P465, DOI 10.1177/0269215507074052; Verhoeven JS, 2010, HUM BRAIN MAPP, V31, P470, DOI 10.1002/hbm.20880; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	66	36	37	0	31	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL-AUG	2011	25	6					492	502		10.1177/1545968310394870			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	774KL	WOS:000291384200001	21427274				2021-06-18	
J	Li, N; Zhao, WG; Zhang, WF				Li, Ning; Zhao, Wei-Guo; Zhang, Wei-Feng			Acute Kidney Injury in Patients with Severe Traumatic Brain Injury: Implementation of the Acute Kidney Injury Network Stage System	NEUROCRITICAL CARE			English	Article						Acute kidney injury; Renal dysfunction; Traumatic brain injury; Outcome; Acute kidney injury network (AKIN)	ORGAN DYSFUNCTION; RENAL DYSFUNCTION; FLUID THERAPY; HEAD-INJURY; OUTCOMES; FAILURE; COMPLICATIONS; SCORE	Background There is limited information on the incidence and effect of acute kidney injury (AKI) in patients with severe traumatic brain injury (TBI), although AKI may affect outcome. Recently, acute kidney injury network (AKIN) classification has been widely accepted as a consensus definition for AKI. The aim of this study is to estimate the frequency and level of severity of AKI in patients with severe TBI by using AKIN criteria and to study whether AKI affects outcome. Methods The authors retrospectively identified a total of 136 patients with severe TBI admitted to the neurosurgical center during a 3-year period ending May 2010. Demographic data, severity of TBI, serum creatinine, urine output, outcome at 6 month, and death were collected. Renal function was assessed by using AKIN criteria. Results Thirty-one patients (23%) were classified as having AKI by using AKIN criteria during their hospitalization. Of them, 21 patients (68%) were stratified as stage 1, 7 patients (22%) as stage 2, and 3 patients (10%) as stage 3. Patients who developed AKI were older, had lower Glasgow coma scale at admission, and had higher level of admission serum creatinine and blood urea nitrogen. Patients with AKI had higher mortality and worse outcome when compared with patients with normal renal function. Furthermore, patients with mild renal dysfunction (stage 1 AKI) are also found having increased mortality and worse long-term outcome, compared with patients without renal dysfunction. Conclusion It is demonstrated using the newly defined AKIN criteria for renal dysfunction that AKI is a relatively common feature in patients with severe TBI, and even seemingly insignificant decrease in renal function may be associated with worse outcome. This study highlights the importance of close surveillance of renal function and stresses the value of renal hygiene in the severe TBI population.	[Li, Ning; Zhao, Wei-Guo; Zhang, Wei-Feng] Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Shanghai 200025, Peoples R China	Zhao, WG (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Shanghai 200025, Peoples R China.	lining930@yahoo.com; rjneurosurgery@yahoo.com.cn; zhangwf198@163.com					Ali T, 2007, J AM SOC NEPHROL, V18, P1292, DOI 10.1681/ASN.2006070756; Barrantes F, 2008, CRIT CARE MED, V36, P1397, DOI 10.1097/CCM.0b013e318168fbe0; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Chen YC, 2009, SHOCK, V31, P139, DOI 10.1097/SHK.0b013e31817d419e; Coca SG, 2007, AM J KIDNEY DIS, V50, P712, DOI 10.1053/j.ajkd.2007.07.018; Costantini TW, 2009, J TRAUMA, V67, P283, DOI 10.1097/TA.0b013e3181a51a51; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Levy MM, 2005, CRIT CARE MED, V33, P2194, DOI 10.1097/01.CCM.0000182798.39709.84; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Molitoris BA, 2007, NAT CLIN PRACT NEPHR, V3, P439, DOI 10.1038/ncpneph0551; Moore EM, 2010, RENAL FAILURE, V32, P1060, DOI 10.3109/0886022X.2010.510234; Nijboer WN, 2010, CRIT CARE MED, V38, P1155, DOI 10.1097/CCM.0b013e3181cf6e78; Ponte B, 2008, NEPHROL DIAL TRANSPL, V23, P3859, DOI 10.1093/ndt/gfn398; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wahlstrom MR, 2009, ACTA ANAESTH SCAND, V53, P18, DOI 10.1111/j.1399-6576.2008.01798.x; Zacharia BE, 2009, STROKE, V40, P2375, DOI 10.1161/STROKEAHA.108.545210; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007	22	36	37	1	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2011	14	3					377	381		10.1007/s12028-011-9511-1			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	759FT	WOS:000290226800008	21298359				2021-06-18	
J	Baldwin, K; Hosalkar, HS; Donegan, DJ; Rendon, N; Ramsey, M; Keenan, MAE				Baldwin, Keith; Hosalkar, Harish S.; Donegan, Derek J.; Rendon, Norma; Ramsey, Matthew; Keenan, Mary Ann E.			Surgical Resection of Heterotopic Bone About the Elbow: An Institutional Experience With Traumatic and Neurologic Etiologies	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						Heterotopic ossification; brain injury; trauma; elbow	OSSIFICATION	Purpose We evaluated the outcomes of patients with elbow heterotopic ossification (HO) who underwent surgical intervention. Our goal was to elucidate differences in outcome of surgical treatment between those patients with traumatic brain injury, direct elbow trauma, or combined etiologies. In addition, we used regression analysis to adjust for confounding factors (such as age, gender, preoperative range of motion [ROM], location of HO, chronicity of HO [ie, time from HO formation to surgery], and whether motor control was spastic or normal) on the relationship between surgical outcome and etiology. Methods We reviewed 60 patients (64 elbows) surgically treated for heterotopic ossification. A total of 42 patients had trauma as the primary etiology, 15 had traumatic brain injury, and 7 had combined etiologies. All had pain or functional limitations at presentation. All patients had surgical resection of their HO. Functional and ROM outcomes were recorded. Results Mean preoperative arc of motion for the entire cohort was 57 degrees (range, 0 degrees to 15 degrees). Mean postoperative arc for the entire cohort was 106 degrees (range, 0 degrees to 145 degrees) at a mean follow-up of 44 months (range, 21-72 mo), demonstrating a significant gain. Average gain, in arc of motion was 49 degrees (range, 10 degrees to 140 degrees). Gains in motion were not significantly different in any individual etiologic group. A total of 6% of cases were complicated by infection, 13% of cases had recurrence of HO, and 11% of cases required repeat surgery for infection or recurrence. Preoperative ROM was an important independent predictor of final range achieved and gain in ROM after surgical intervention. Recurrence rates were higher in patients with neurologic involvement. Postoperative stiffness was related to preoperative stiffness, delay of surgery longer than 12 months, and anterior location of the HO. Conclusions Surgical excision of heterotopic bone about the elbow results in significant gains in ROM regardless of etiology. The likelihood of recurrence is higher in patients with central nervous system injuries than in patients with purely localized trauma. (J Hand Surg 2011;36A: 798-803. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.)	Univ Penn, Dept Orthopaed Surg, Sch Med, Philadelphia, PA 19104 USA; Thomas Jefferson Univ Hosp, Dept Orthopaed Surg, Rothman Inst, Sch Med, Philadelphia, PA 19107 USA; Rady Childrens Hosp, San Diego, CA USA	Keenan, MAE (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	maryann.keenan@uphs.upenn.edu	Keenan, Mary Ann/ABB-1551-2020				FIGGIE MP, 1989, J BONE JOINT SURG AM, V71A, P513, DOI 10.2106/00004623-198971040-00006; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P38; HASTINGS H, 1994, HAND CLIN, V10, P417; Heirweg S, 2003, Acta Orthop Belg, V69, P18; JUPITER J, 2006, STIFF ELBOW, P9; Jupiter JB, 1998, J BONE JOINT SURG AM, V80A, P248, DOI 10.2106/00004623-199802000-00012; Jupiter Jesse B, 2003, Instr Course Lect, V52, P93; Lazarus MD, 1999, NEUROREHABILITATION, V12, P145; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; ORZEL JA, 1985, J NUCL MED, V26, P125; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; STANLEY D, 1998, SURG ELBOW, P228; Thompson H C 3rd, 1967, Clin Orthop Relat Res, V50, P129; Viola RW, 1999, J HAND SURG-AM, V24A, P370; Viola RW, 2000, CLIN ORTHOP RELAT R, P65	16	36	39	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	MAY	2011	36A	5					798	803		10.1016/j.jhsa.2011.01.015			6	Orthopedics; Surgery	Orthopedics; Surgery	758SC	WOS:000290185700005	21458925				2021-06-18	
J	Dalla Libera, AL; Regner, A; De Paoli, J; Centenaro, L; Martins, TT; Simon, D				Dalla Libera, Andre Luiz; Regner, Andrea; De Paoli, Juliana; Centenaro, Leonara; Martins, Tatiane Tolazzi; Simon, Daniel			IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury	BRAIN INJURY			English	Article						Interleukin-6; traumatic brain injury; genetic polymorphism; neuroinflammation	HEAD-INJURY; MAJOR TRAUMA; INTERLEUKIN-6; DISEASE; EXPRESSION; HAPLOTYPES; GENOTYPE; HUMANS; GENDER; GENE	Objective: The aim of this study was to test whether a functional polymorphism (-174C/G) located in the promoter region of the interleukin-6 (IL-6) gene is associated with primary short-term outcome (death or Intensive Care Unit discharge) in patients with severe traumatic brain injury (TBI). Methods: The study group consisted of 77 male patients who suffered severe TBI. The -174C/G IL-6 polymorphism was analysed by polymerase chain reaction (PCR) followed by restriction digestion. Results: Severe TBI was associated with a 44% mortality rate. The GG genotype was significantly more frequent in the survivor group than in non-surviving patients (67% vs 41%; p = 0.038); similarly, the IL-6 -174G allele was more frequent in the survivor group than in non-surviving patients (81% vs 65%; p = 0.031). Conclusion: The findings indicate that genetic variation regarding inflammatory response has significant impact on the short-term outcome for patients after acute severe TBI.	[Dalla Libera, Andre Luiz; Regner, Andrea; Simon, Daniel] Univ Luterana Brasil ULBRA, Programa Posgrad Genit & Toxicol Aplicada, Canoas, Brazil; [Regner, Andrea; De Paoli, Juliana; Simon, Daniel] Univ Luterana Brasil, Programa Posgrad Diagnost Genet & Mol, Canoas, Brazil; [Regner, Andrea; Centenaro, Leonara; Martins, Tatiane Tolazzi] Univ Luterana Brasil, Curso Med, Canoas, Brazil	Simon, D (corresponding author), Univ Luterana Brasil, PPG Diagnost Genet & Mol, Av Farroupilha 8001,Predio 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	daniel.simon@ulbra.br	Simon, Daniel/A-9087-2011; Regner, Andrea/M-2596-2014	Simon, Daniel/0000-0003-1122-8468; Regner, Andrea/0000-0002-6657-7991	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [484391/2007-0, 568691/2008-3]	The authors report no conflicts of interest. The present study received financial support from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; research grants 484391/2007-0 and 568691/2008-3).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Harding DR, 2004, PEDIATRICS, V114, P941, DOI 10.1542/peds.2003-0494-F; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; KRAUS JF, 1996, NEUROTRAUMA, P13; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McDaniel DO, 2007, J TRAUMA, V63, P147, DOI 10.1097/TA.0b013e31806bf0ab; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Noe E, 2010, BRAIN INJURY, V24, P886, DOI 10.3109/02699051003724952; Opdal SH, 2007, HUM IMMUNOL, V68, P541, DOI 10.1016/j.humimm.2007.02.008; Rivera-Chavez FA, 2003, SHOCK, V20, P218, DOI 10.1097/00024382-200309000-00004; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sperry JL, 2008, J TRAUMA, V64, P572, DOI 10.1097/TA.0b013e3181650fdf; Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200; Thorns V, 2002, J NEUROIMMUNOL, V127, P22, DOI 10.1016/S0165-5728(02)00072-3; Tsukamoto K, 1998, J HUM GENET, V43, P71, DOI 10.1007/s100380050042; Vasilescu A, 2003, GENES IMMUN, V4, P441, DOI 10.1038/sj.gene.6363983; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Wilson M, 2007, BRIT J ANAESTH, V99, P43, DOI 10.1093/bja/aem142; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	33	36	36	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2011	25	4					365	369		10.3109/02699052.2011.556107			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600005	21314275				2021-06-18	
J	Ahn, SK; Jeon, SY; Kim, JP; Park, JJ; Hur, DG; Kim, DW; Woo, SH; Kwon, OJ; Kim, JY				Ahn, Seong-Ki; Jeon, Sea-Yuong; Kim, Jin-Pyeong; Park, Jung Je; Hur, Dong Gu; Kim, Dae-Woo; Woo, Seung-Hoon; Kwon, Oh-Jin; Kim, Jin-Yong			Clinical Characteristics and Treatment of Benign Paroxysmal Positional Vertigo After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Benign paroxysmal positional vertigo; Therapy	MANAGEMENT; DIAGNOSIS; DIZZINESS; MANEUVER; BPPV	Background: Traumatic brain injury (TBI) has been reported to be a common cause of benign paroxysmal positional vertigo (BPPV). However, only a few studies have investigated BPPV after TBI. The aim of this study was to identify the clinical characteristics of BPPV after TBI and to determine whether there are clinical differences between BPPV after TBI and idiopathic BPPV. Methods: The authors reviewed the medical records of 192 consecutive patients with positional vertigo after head injury during the period 2003 to 2009 and investigated 112 patients with idiopathic BPPV treated over the same period. The clinical characteristics of BPPV after TBI and the clinical differences between the traumatic BPPV and idiopathic BPPV groups were investigated. Results: A total of 32 patients with BPPV after TBI fulfilled the inclusion criteria. Twenty-four patients in the traumatic BPPV group had posterior semicircular canal-BPPV and 11 patients lateral semicircular canal-BPPV. A total of 58 repositioning maneuver sessions were performed in these 32 patients. Members of the traumatic BPPV group required more treatment sessions than members of the idiopathic group (p < 0.05), but no tendency to recur was observed in the traumatic group (p > 0.05). Recurrence rates in the traumatic and idiopathic BPPV groups were 15.6% and 18.8%, respectively (p > 0.05). Conclusions: It is likely that BPPV after TBI is more difficult to treat than idiopathic BPPV, but no tendency to recur was observed in patients who developed BPPV after TBI compared with idiopathic BPPV. Further prospective clinical meta-analytic studies are needed to investigate the outcome of BPPV after TBI.	[Ahn, Seong-Ki; Jeon, Sea-Yuong; Kim, Jin-Pyeong; Park, Jung Je; Hur, Dong Gu; Kim, Dae-Woo; Woo, Seung-Hoon; Kwon, Oh-Jin; Kim, Jin-Yong] Gyeongsang Natl Univ, Sch Med, Dept Otolaryngol, Jinju 660702, South Korea	Ahn, SK (corresponding author), Gyeongsang Natl Univ, Sch Med, Dept Otolaryngol, Jinju 660702, South Korea.	skahn@gnu.ac.kr					BALOH RW, 1993, NEUROLOGY, V43, P2542, DOI 10.1212/WNL.43.12.2542; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Casani AP, 2002, LARYNGOSCOPE, V112, P172, DOI 10.1097/00005537-200201000-00030; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Escher A, 2007, EUR ARCH OTO-RHINO-L, V264, P1239, DOI 10.1007/s00405-007-0337-6; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Fung K, 1996, J OTOLARYNGOL, V25, P243; Gordon CR, 2004, ARCH NEUROL-CHICAGO, V61, P1590, DOI 10.1001/archneur.61.10.1590; Hilton M, 2002, CLIN OTOLARYNGOL, V27, P440, DOI 10.1046/j.1365-2273.2002.00613.x; Hughes CA, 1997, LARYNGOSCOPE, V107, P607, DOI 10.1097/00005537-199705000-00010; KATSARKAS A, 1978, J OTOLARYNGOL, V7, P320; Katsarkas A, 1999, ACTA OTO-LARYNGOL, V119, P745, DOI 10.1080/00016489950180360; Lempert T, 1996, LARYNGOSCOPE, V106, P476, DOI 10.1097/00005537-199604000-00015; LONGRIDGE NS, 1978, J OTOLARYNGOL, V7, P395; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; Motin M, 2005, BRAIN INJURY, V19, P693, DOI 10.1080/02699050400013600; Nunez RA, 2000, OTOLARYNG HEAD NECK, V122, P647, DOI 10.1067/mhn.2000.105185; Nuti D, 1998, ACTA OTO-LARYNGOL, V118, P455, DOI 10.1080/00016489850154559; Parnes LS, 2003, CAN MED ASSOC J, V169, P681; Vannucchi P, 1997, J VESTIBUL RES-EQUIL, V7, P1; White JA, 2005, OTOLARYNG HEAD NECK, V133, P278, DOI 10.1016/j.otohns.2005.03.080; 2001, J ORAL MAXILLOFAC SU, V59, P106	25	36	37	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2011	70	2					442	446		10.1097/TA.0b013e3181d0c3d9			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	719FV	WOS:000287187700041	20489667				2021-06-18	
J	Terrio, HP; Nelson, LA; Betthauser, LM; Harwood, JE; Brenner, LA				Terrio, Heidi P.; Nelson, Lonnie A.; Betthauser, Lisa M.; Harwood, Jeri E.; Brenner, Lisa A.			Postdeployment Traumatic Brain Injury Screening Questions: Sensitivity, Specificity, and Predictive Values in Returning Soldiers	REHABILITATION PSYCHOLOGY			English	Article						concussion; military; postdeployment; screening; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; IRAQ; IDENTIFICATION; RELIABILITY; AFGHANISTAN; DEPRESSION; DEPLOYMENT; VALIDITY; TBI	Objective: To evaluate the sensitivity, specificity, and predictive values of Post-Deployment Health Assessment traumatic brain injury (TBI) screening questions employed by the Department of Defense (DOD). Participants: Complete data was obtained from 3,072 soldiers upon return from a 15-month deployment to Iraq. Method: Comparisons were made between responses to the DOD four-item screener and a brief structured clinical interview for likely deployment-related TBI history. The interview process was facilitated using responses to the Warrior Administered Retrospective Casualty Assessment Tool (WARCAT). Results: The sensitivity and specificity of the DOD screening tool (positive response to all four items) in comparison to the clinician-confirmed diagnosis was 60% and 96%, respectively. The sensitivity increased to 80%, with a slight decrease in specificity to 93%, for positive TBI screening when affirmative responses to questions 1 and 2 only were included. Conclusions: Affirmative responses to questions 1 and 2 of the DOD TBI screening tool demonstrated higher sensitivity for clinician-diagnosed deployment-related TBI. These two items perform better than positive responses to all four questions; the criteria presently being used for documentation and referral of a deployment-related TBI. These findings support further exploration of TBI screening and assessment procedures.	[Terrio, Heidi P.] Evans Army Community Hosp, Def & Vet Brain Injury Ctr, Dept Deployment Hlth, Ft Carson, CO USA; [Betthauser, Lisa M.] Univ Colorado Denver, Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA; [Harwood, Jeri E.] Univ Colorado Denver, Dept Pediat, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Psychiat, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Neurol, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Phys Med & Rehabil, Sch Med, Denver, CO USA	Terrio, HP (corresponding author), USA, Western Reg Med Command, Bldg 2006,Liggett Ave,Room 317,Mail Stop 109,Box, Jblm, WA 98433 USA.	heidi.terrio@amedd.army.mil	Brenner, Lisa A./AAG-2442-2019				American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; *DEP DEF, 2009, 649002E DEP DEF; Department of Defense, 2006, 649003 DEP DEF; Deployment Health Clinical Center, 2010, POSTD HLTH ASS PDHA; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; *EV ARM COMM HOSP, 2010, SOLD READ PROC INJ E; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; *IBM, SPSS VERS 15 0 COMP; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; OLSONMADDEN J, 2010, ASSESSMENT DIA UNPUB; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; *SPSS, PASW VERS 18 0 COMP; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Wright KM, 2008, MIL MED, V173, P411, DOI 10.7205/MILMED.173.5.411	32	36	36	0	2	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2011	56	1					26	31		10.1037/a0022685			6	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	735LZ	WOS:000288417400003	21401283				2021-06-18	
J	Goodman, MD; Makley, AT; Huber, NL; Clarke, CN; Friend, LAW; Schuster, RM; Bailey, SR; Barnes, SL; Dorlac, WC; Johannigman, JA; Lentsch, AB; Pritts, TA				Goodman, Michael D.; Makley, Amy T.; Huber, Nathan L.; Clarke, Callisia N.; Friend, Lou Ann W.; Schuster, Rebecca M.; Bailey, Stephanie R.; Barnes, Stephen L.; Dorlac, Warren C.; Johannigman, Jay A.; Lentsch, Alex B.; Pritts, Timothy A.			Hypobaric Hypoxia Exacerbates the Neuroinflammatory Response to Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; inflammation; neuroinflammation; aeromedical evacuation; hypobaric; hypoxia	NEURON-SPECIFIC ENOLASE; GROWTH-FACTOR PRODUCTION; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; SERUM INTERLEUKIN-6; PLASMA; CHILDREN; ALTITUDE; MODEL; ASSOCIATION	Objective. To determine the inflammatory effects of time-dependent exposure to the hypobaric environment of simulated aeromedical evacuation following traumatic brain injury (TBI). Methods. Mice were subjected to a blunt TBI or sham injury. Righting reflex response (RRR) time was assessed as an indicator of neurologic recovery. Three or 24 h (Early and Delayed groups, respectively) after TBI, mice were exposed to hypobaric flight conditions (Fly) or ground-level control (No Fly) for 5 h. Arterial blood gas samples were obtained from all groups during simulated flight. Serum and cortical brain samples were analyzed for inflammatory cytokines after flight. Neuron specific enolase (NSE) was measured as a serum biomarker of TBI severity. Results. TBI resulted in prolonged RRR time compared with sham injury. After TBI alone, serum levels of interleukin-6 (IL-6) and keratinocyte-derived chemokine (KC) were increased by 6 h post-injury. Simulated flight significantly reduced arterial oxygen saturation levels in the Fly group. Post-injury altitude exposure increased cerebral levels of IL-6 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), as well as serum NSE in the Early but not Delayed Flight group compared to ground-level controls. Conclusions. The hypobaric environment of aeromedical evacuation results in significant hypoxia. Early, but not delayed, exposure to a hypobaric environment following TBI increases the neuroinflammatory response to injury and the severity of secondary brain injury. Optimization of the post-injury time to fly using serum cytokine and biomarker levels may reduce the potential secondary cerebral injury induced by aeromedical evacuation. (C) 2011 Elsevier Inc. All rights reserved.	[Goodman, Michael D.; Makley, Amy T.; Huber, Nathan L.; Clarke, Callisia N.; Friend, Lou Ann W.; Schuster, Rebecca M.; Bailey, Stephanie R.; Dorlac, Warren C.; Johannigman, Jay A.; Lentsch, Alex B.; Pritts, Timothy A.] Univ Cincinnati, Coll Med, Dept Surg, Inst Mil Med, Cincinnati, OH 45267 USA; [Barnes, Stephen L.] Univ Missouri, Sch Med, Div Acute Care Surg, Columbia, MO USA	Goodman, MD (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, Inst Mil Med, Mail Locat 0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	goodmamd@uc.edu		Pritts, Timothy/0000-0003-2495-3255; Barnes, Stephen/0000-0001-6186-1435	United States Air Force/Henry Jackson Foundation [FA8650-05-2-6518]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478] Funding Source: NIH RePORTER	This work is supported by the United States Air Force/Henry Jackson Foundation award FA8650-05-2-6518. This work does not reflect the views of the United States Air Force or Department of Defense.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bendz B, 2000, LANCET, V356, P1657, DOI 10.1016/S0140-6736(00)03165-2; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; COTTRELL JJ, 1995, AVIAT SPACE ENVIR MD, V66, P126; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hartmann G, 2000, CYTOKINE, V12, P246, DOI 10.1006/cyto.1999.0533; Johannigman JA, 2008, CRIT CARE MED, V36, pS377, DOI 10.1097/CCM.0b013e31817e31e1; Johannigman JA, 2007, J TRAUMA, V62, pS35, DOI 10.1097/TA.0b013e31806540f3; Klausen T, 1997, EUR J APPL PHYSIOL, V76, P480, DOI 10.1007/s004210050278; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mazzeo RS, 2005, EXERC IMMUNOL REV, V11, P6; MERIC E, 2008, J EMERG MED; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Zhu Tao, 2004, Chin J Traumatol, V7, P32	37	36	39	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	JAN	2011	165	1					30	37		10.1016/j.jss.2010.05.055			8	Surgery	Surgery	692ET	WOS:000285136000013	20850781	Green Accepted			2021-06-18	
J	Hasiloglu, ZI; Albayram, S; Selcuk, H; Ceyhan, E; Delil, S; Arkan, B; Baskoy, L				Hasiloglu, Z. I.; Albayram, S.; Selcuk, H.; Ceyhan, E.; Delil, S.; Arkan, B.; Baskoy, L.			Cerebral Microhemorrhages Detected by Susceptibility-Weighted Imaging in Amateur Boxers	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; PROFESSIONAL BOXERS; HEAD-INJURY; DAMAGE; CHILDREN; LESIONS; MRI	BACKGROUND AND PURPOSE: SWI is a new technique for evaluating diffuse axonal injury associated with punctate hemorrhages. The aim of our study was to determine the prevalence of cerebral microhemorrhages in amateur boxers compared with nonboxers by using SWI and to evaluate the sensitivity of SWI compared with T2 FSE and T2*GE sequences. MATERIALS AND METHODS: We performed cranial MR imaging with a 1.5T scanner in 21 amateur boxers and 21 control subjects. The study protocol included conventional MR images, T2 FSE, T2*GE, and SWI sequences. The proportions of boxers and controls having CSP, DPVS, cerebral atrophy, cerebellar atrophy, ventricular dilation. PSWMD, and microhemorrhages were computed and were compared by using the chi(2) test of proportions. The relationship between microhemorrhages and boxing-related covariates was assessed by using the Wilcoxon rank sum test. The association between the categories was tested by using the Fisher exact test. RESULTS: Using SWI, microhemorrhages were found in 2 (9.52%) of 21 boxers. The microhemorrhages were not visible on T2 FSE or T2*GE images. The proportion of subjects with microhemorrhages did not differ significantly between the boxers and control subjects (chi(2) = 0.525, df = 1, P = .4688). The prevalence of CSP and DPVS was significantly higher in the boxers than in the control subjects. CONCLUSIONS: More microhemorrhages were detected in amateur boxers than in controls, but this difference was not statistically significant.	[Hasiloglu, Z. I.; Albayram, S.] Istanbul Univ, Cerrahpasa Med Sch, Div Neuroradiol, Dept Radiol, TR-34300 Kmp Istanbul, Turkey; [Delil, S.] Istanbul Univ, Cerrahpasa Med Sch, Dept Neurol, TR-34300 Kmp Istanbul, Turkey; [Selcuk, H.] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Radiol, Istanbul, Turkey; [Ceyhan, E.] Koc Univ, Dept Math, Istanbul, Turkey	Albayram, S (corresponding author), Istanbul Univ, Cerrahpasa Med Sch, Div Neuroradiol, Dept Radiol, TR-34300 Kmp Istanbul, Turkey.	salbayram@hotmail.com	Delil, Memet Sakir/AAP-9301-2021; Baskoy, Lutfullah/AAY-3245-2020; Selcuk, Hakan/AAL-2052-2020	Selcuk, Hakan/0000-0001-5606-4423			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; CORSELLIS JAN, 1989, BMJ-BRIT MED J, P105; Hahnel S, 2008, AM J NEURORADIOL, V29, P388, DOI 10.3174/ajnr.A0799; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Loosemore M, 2007, BMJ-BRIT MED J, V335, P809, DOI 10.1136/bmj.39342.690220.55; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	20	36	41	0	10	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2011	32	1					99	102		10.3174/ajnr.A2250			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	717BC	WOS:000287016200017	20966064	Green Published, Other Gold			2021-06-18	
B	Iverson, GL; Lange, RT		Schoenberg, MR; Scott, JG		Iverson, Grant L.; Lange, Rael T.			Mild Traumatic Brain Injury	LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH			English	Article; Book Chapter							MINOR HEAD-INJURY; SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; POSTTRAUMATIC-STRESS-DISORDER; TERM BENZODIAZEPINE USE; OPERATION DESERT-STORM; VOLUNTARY EXERCISE; POSTCONCUSSION-SYNDROME; PROFESSIONAL FOOTBALL; NEUROTROPHIC FACTOR	Mild traumatic brain injuries (MTBI) are heterogeneous. This injury falls on a broad spectrum, from very mild neurometabolic changes in the brain with rapid recovery to permanent problems due to structural brain damage. It is incorrect to assume that MTBIs cannot cause permanent brain damage and it is incorrect to assume that MTBIs typically cause permanent brain damage. This is a highly individualized injury most people recover relatively quickly and fully. However, some people have long-term problems. These long-term problems can be caused or maintained by multiple factors. Brain damage, although possible, is probably not the root cause of long-term problems in most patients. Instead, a diverse set of pre-existing and co-occurring conditions and factors likely cause and/or maintain symptoms and problems in most patients (e.g., personality characteristics; preexisting health and mental health problems; co-morbid chronic pain, depression, anxiety disorders; social psychological factors; and litigation). It is important to carefully consider a multitude of factors that can cause or maintain symptom reporting long after an MTBI before concluding that a person is likely to have permanent damage to the function of his or her brain.	[Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.; Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Coquitlam, BC, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada	Iverson, GL (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.	giverson@interchange.ubc.ca; rlange@dvbic.org					Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Barker MJ, 2004, ARCH CLIN NEUROPSYCH, V19, P437, DOI 10.1016/S0887-6177(03)00096-9; Barker MJ, 2004, CNS DRUGS, V18, P37, DOI 10.2165/00023210-200418010-00004; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carey ME, 1998, MIL MED, V163, P581; CAREY ME, 1982, ACTA CHIR SCAND, P351; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Drazen JM, 2005, NEW ENGL J MED, V352, P2121, DOI 10.1056/NEJMe048332; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Frazier TW, 2004, NEUROPSYCHOLOGY, V18, P543, DOI 10.1037/0894-4105.18.3.543; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Grant I, 2003, J INT NEUROPSYCH SOC, V9, P679, DOI 10.1017/S1355617703950016; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Jovanovski D, 2005, J CLIN EXP NEUROPSYC, V27, P189, DOI 10.1080/13803390490515694; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; KRAUS JF, 2005, TXB TRAUMATIC BRAIN, P3; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; LAHMEYER HW, 1987, J PSYCHIAT RES, V21, P1, DOI 10.1016/0022-3956(87)90004-5; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Paniak C, 2000, BRAIN INJURY, V14, P219; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Peleg K, 2006, J AM COLL SURGEONS, V202, P643, DOI 10.1016/j.jamcollsurg.2005.12.019; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; Pietropaolo S, 2008, BEHAV BRAIN RES, V192, P42, DOI 10.1016/j.bbr.2008.03.014; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sosin DM, 1996, BRAIN INJURY, V10, P47; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; UZZELL BP, 1987, SURG NEUROL, V27, P419, DOI 10.1016/0090-3019(87)90247-3; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	125	36	36	0	7	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES			978-0-387-70703-7				2011							697	719		10.1007/978-0-387-76978-3_22	10.1007/978-0-387-76978-3		23	Clinical Neurology; Neurosciences; Psychology	Neurosciences & Neurology; Psychology	BTF43	WOS:000286799800022					2021-06-18	
J	Levin, HS; Wilde, EA; Hanten, G; Li, XQ; Chu, ZD; Vasquez, AC; Cook, L; Yallampalli, R; Hunter, JV				Levin, Harvey S.; Wilde, Elisabeth A.; Hanten, Gerri; Li, Xiaoqi; Chu, Zili David; Vasquez, Ana C.; Cook, Lori; Yallampalli, Ragini; Hunter, Jill V.			Mental State Attributions and Diffusion Tensor Imaging After Traumatic Brain Injury in Children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							LONG-TERM OUTCOMES; WORKING-MEMORY; SOCIAL BRAIN; HEAD-INJURY; MIND; ADOLESCENTS; PERCEPTION; SKILLS	We studied social cognition in 49 children 3 months after moderate to severe traumatic brain injury (TBI) and in 39 children with orthopedic injury (OI). Children underwent diffusion tensor imaging (DTI) and a mental attribution task showing two triangles. Mental state attributions increased when one triangle reacted to intentions of the other, but less so in the TBI than the OI group. DTI identified injury to white matter microstructure in the TBI group, but the relation of DTI to mental attributions did not differ between groups. Moderate to severe TBI produces white matter disconnections that may affect social cognitive networks.	[Levin, Harvey S.; Wilde, Elisabeth A.; Hanten, Gerri; Li, Xiaoqi; Vasquez, Ana C.; Yallampalli, Ragini] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Chu, Zili David; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Cook, Lori] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA; [Chu, Zili David; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889-26A1, R01 NS021889-25, R01 NS021889, R01 NS021889-27] Funding Source: Medline		Abell F, 2000, COGNITIVE DEV, V15, P1, DOI 10.1016/S0885-2014(00)00014-9; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; De Lange FP, 2008, CURR BIOL, V18, P454, DOI 10.1016/j.cub.2008.02.057; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gobbini MI, 2007, J COGNITIVE NEUROSCI, V19, P1803, DOI 10.1162/jocn.2007.19.11.1803; Hanten G, 2009, TOP LANG DISORD, V29, P236, DOI 10.1097/TLD.0b013e3181b531f0; Heider F, 1944, AM J PSYCHOL, V57, P243, DOI 10.2307/1416950; HOOGENRAAD F, 2002, MULTICENTER EVALUATI; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lombardo MV, 2010, J COGNITIVE NEUROSCI, V22, P1623, DOI 10.1162/jocn.2009.21287; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pelphrey KA, 2008, ANN NY ACAD SCI, V1145, P283, DOI 10.1196/annals.1416.007; REYNOLDS CR, 1998, BEHAV ASSESSMENT SYS; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Sparrow S., 1984, VINELAND ADAPTIVE BE; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; Woodcock R. W., 2001, WOODCOCKJOHNSON TEST; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535	40	36	36	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2011	36	3					273	287	PII 935838800	10.1080/87565641.2010.549885			15	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	746LB	WOS:000289247200001	21462007	Green Accepted			2021-06-18	
J	Mozeiko, J; Le, K; Coelho, C; Krueger, F; Grafman, J				Mozeiko, Jennifer; Le, Karen; Coelho, Carl; Krueger, Frank; Grafman, Jordan			The relationship of story grammar and executive function following TBI	APHASIOLOGY			English	Article; Proceedings Paper	40th Clinical Aphasiology Conference (CAC)	MAY 23-27, 2010	Isle of Palms, SC			Traumatic brain injury; penetrating head injury; Discourse analysis; narrative discourse; Story grammar; Executive function	TRAUMATIC BRAIN-INJURY; DEFICITS; ADULTS	Background: Story grammar is a super-structural measure of discourse performance that has shown to be sensitive to the deficits seen following traumatic brain injury (TBI). Narrative organisation and identification of logical relationships between events and characters are key components of story grammar. Reports of significant correlations for measures of story grammar and scores from various tests of executive functioning for individuals with TBI are thought to reflect executive control of cognitive and linguistic organisational processes. Aims: The purpose of the present study was to re-examine the relationship between story grammar and executive functions (EF) in a large group of participants with severe TBI secondary to diverse penetrating head wounds. It was hypothesised that participants with TBI would have significantly lower story grammar scores than a comparison group without TBI, and that story grammar performance of the group with TBI would be significantly correlated with their EF scores. Methods Procedures: A total of 167 participants with TBI and a comparison group of 46 adults without TBI were asked to retell a 16-frame story. Transcripts of each story retelling were broken into T-units and were analysed for story grammar. Outcomes Results: Results of MANOVA showed significant effect of group on the discourse measures. Univariate tests showed significant differences between the group with TBI and the comparison group for each of the story grammar measures. Story grammar measures were significantly correlated with executive function (EF) scores. Conclusions: Results indicated that the participants with TBI demonstrated significantly poorer performance on measures of story grammar abilities, lending support to earlier reports of story grammar impairments resulting from closed head injury (CHI). The present study also found significant correlations for measures of story grammar and the Sorting Test. Cognitive skills such as mental flexibility, required for successful performance on this card sorting task are likely the same as those required for episode generation. These findings have clinical implications for the management of cognitive-communication disorders in individuals with TBI. First, story grammar warrants inclusion in analyses of discourse. Second, discourse deficits following brain injury do not resolve spontaneously and persist as social barriers.	[Mozeiko, Jennifer; Le, Karen; Coelho, Carl] Univ Connecticut, Dept Commun Disorders, Storrs, CT USA; [Krueger, Frank; Grafman, Jordan] NINDS, Cognit Neurosci Sect, Bethesda, MD 20892 USA	Grafman, J (corresponding author), Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jgrafman@kesslerfoundation.org		Grafman, Jordan H./0000-0001-8645-4457			Barrett J., 1998, OLD MCDONALD HAD APA; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); COELHO CA, 1998, ANAL DISCOURSE COMMU, P115; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Delis DC, 2001, DELISKAPLAN EXECUTIV; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dunbar K, 1995, ANN NY ACAD SCI, V769, P289, DOI 10.1111/j.1749-6632.1995.tb38146.x; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Grafman J, 1999, LANCET, V354, P1921, DOI 10.1016/S0140-6736(99)90438-5; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Gupta R, 2009, NEUROPSYCHOLOGIA, V47, P1686, DOI 10.1016/j.neuropsychologia.2009.02.007; Hunt K. W, 1965, 3 NCTE; Kaplan E., 1983, BOSTON NAMING TEST; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Latzman RD, 2010, ASSESSMENT, V17, P172, DOI 10.1177/1073191109356254; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, P611; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; PLAG JA, 1967, PERS PSYCHOL, V20, P323, DOI 10.1111/j.1744-6570.1967.tb01527.x; Robbins TW, 1997, METHODOLOGY FRONTAL, V10, P215; Stein N. L., 1979, ADV DISCOURSE PROCES, V2, P53; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; U. S. Department of Defense, 1984, TEST MAN ARM SERV VO; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745; Zasler N. D., 2007, BRAIN INJURY MED PRI, P779	28	36	36	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2011	25	6-7					826	835	PII 934165989	10.1080/02687038.2010.543983			10	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	775XO	WOS:000291497000014					2021-06-18	
J	Shear, DA; Tate, CC; Tate, MC; Archer, DR; LaPlaca, MC; Stein, DG; Dunbar, GL				Shear, Deborah A.; Tate, Ciara C.; Tate, Matthew C.; Archer, David R.; LaPlaca, Michelle C.; Stein, Donald G.; Dunbar, Gary L.			Stem cell survival and functional outcome after traumatic brain injury is dependent on transplant timing and location	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Neural stem cells; traumatic brain injury; motor recovery; spatial learning and memory; stem cell survival and migration; CNS repair	CHONDROITIN SULFATE PROTEOGLYCAN; SPINAL-CORD-INJURY; NG2-POSITIVE CELLS; NG2; RECOVERY; DEFICITS; MODEL; MOTOR; RAT	Purpose: Recent work indicates that transplanted neural stem cells (NSCs) can survive, migrate to the injury site, and facilitate recovery from traumatic brain injury (TBI). The present study manipulated timing and location of NSC transplants following controlled cortical impact injury (CCI) in mice to determine optimal transplant conditions. Methods: In Experiment 1 (timing), NSCs (E14.5 mouse) were injected into the host striatum, ipsilateral to the injury, at 2, 7, or 14 days. In Experiment 2 (location), NSCs or vehicle were injected into the mouse striatum (7 days post-CCI) either ipsilateral or contralateral to the injury and cognitive and motor abilities were assessed from weeks 1-8 post-transplant. Histological measures of NSC survival, migration, and differentiation were taken at 6 and 8 weeks post-transplant. Results: The results demonstrate that: (1) 2-7 days post-injury is the optimal time-range for delivering NSCs; (2) time of transplantation does not affect short-term phenotypic differentiation; (3) transplant location affects survival, migration, phenotype, and functional efficacy; and (4) NSC-mediated functional recovery is not contingent upon NSC migration or phenotypic differentiation. Conclusions: These findings provide further support for the idea that mechanisms other than the replacement of damaged neurons or glia, such as NSC-induced increases in protective neurotrophic factors, may be responsible for the functional recovery observed in this model of TBI.	[Shear, Deborah A.; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Tate, Ciara C.; LaPlaca, Michelle C.] Emory Univ, Dept Biomed Engn, Georgia Inst Technol, Atlanta, GA 30322 USA; [Tate, Matthew C.] Emory Univ, Sch Med, Atlanta, GA USA; [Archer, David R.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Stein, Donald G.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; [Shear, Deborah A.; Dunbar, Gary L.] Field Neurosci Inst, Saginaw, MI USA; [Shear, Deborah A.; Dunbar, Gary L.] Cent Michigan Univ, Dept Psychol, Neurosci Program, Mt Pleasant, MI 48859 USA	Shear, DA (corresponding author), Walter Reed Army Inst Res, MRMC UWI C, Bldng 503-2 W14, Silver Spring, MD 20910 USA.	Deborah.Shear@AMEDD.ARMY.MIL	Stein, Donald/AAJ-5139-2020; Shear, Deborah/B-3607-2011		John G. Kulhavi Professorship	This work was supported by a generous research gift from Field Neurosciences Institute, Saginaw MI (to DGS) and a John G. Kulhavi Professorship (to GLD).	Chittajallu R, 2004, J PHYSIOL-LONDON, V561, P109, DOI 10.1113/jphysiol.2004.074252; Dey ND, 2010, BEHAV BRAIN RES, V214, P193, DOI 10.1016/j.bbr.2010.05.023; Dunbar Gary L, 2006, Behav Cogn Neurosci Rev, V5, P63, DOI 10.1177/1534582306289367; Horner PJ, 2002, J NEUROCYTOL, V31, P469, DOI 10.1023/A:1025739630398; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Levine JM, 1996, PERSPECT DEV NEUROBI, V3, P245; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Nakahira E, 2006, DEV BIOL, V291, P123, DOI 10.1016/j.ydbio.2005.12.010; Polito A, 2005, J ANAT, V207, P707, DOI 10.1111/j.1469-7580.2005.00454.x; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Rossignol J, 2011, BEHAV BRAIN RES, V217, P369, DOI 10.1016/j.bbr.2010.11.006; Shear DA, 2000, NEUROREPORT, V11, P1833, DOI 10.1097/00001756-200006260-00007; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; STEIN DG, 1995, BRAIN REPAIR; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Trotter J, 2005, J NEUROL SCI, V233, P37, DOI 10.1016/j.jns.2005.03.024; Wu D, 2005, J NEUROCYTOL, V34, P459, DOI 10.1007/s11068-006-8998-4	23	36	45	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2011	29	4					215	225		10.3233/RNN-2011-0593			11	Neurosciences	Neurosciences & Neurology	814VR	WOS:000294485800001	21697596				2021-06-18	
J	Stock, SE; Davies, DK; Wehmeyer, ML; Lachapelle, Y				Stock, Steven E.; Davies, Daniel K.; Wehmeyer, Michael L.; Lachapelle, Yves			Emerging new practices in technology to support independent community access for people with intellectual and cognitive disabilities	NEUROREHABILITATION			English	Article						Intellectual and cognitive disabilities; technology; community access	PARTICIPATION; ADULTS	The concept of community access is a multidimensional term, which may involve issues related to physical access, knowledge and information, power and control, relationships and communications, advocacy, participation and quality of life [21]. This paper discusses historical and emerging practices and interventions related to physical access to community and community based information for individuals with cognitive disabilities such as intellectual disability, autism or traumatic brain injury. While much societal attention has been paid to features of independent community access for populations such as individuals with hearing, vision or physical disabilities, less attention has focused on independent community access for people with intellectual and other significant cognitive disabilities. Attitudes and actions by families and professional service communities are often mixed for some individuals in this population. The somewhat limited research base in these areas is explored, including a case study review and results from several promising feasibility studies. The paper concludes with comments concerning future prospects and recommendations for improving independent community access for persons with significant cognitive disabilities.	[Stock, Steven E.; Davies, Daniel K.] AbleLink Technol Inc, Colorado Springs, CO USA; [Wehmeyer, Michael L.] Univ Kansas, Lawrence, KS 66045 USA; [Lachapelle, Yves] Univ Quebec, Trois Rivieres, PQ GA9 5H7, Canada	Stock, SE (corresponding author), 618 N Nevada Ave, Colorado Springs, CO 80903 USA.	steve@ablelinktech.com					AGRAN M, 1994, SKILLS INDEPENDENT L, P221; BOURLAND E, 1996, NICHCY TRANSITION SU, V9; DAVIES DK, 2008, WAYFINDER COGN UNPUB; DAVIES DK, 2010, INTELLECTUA IN PRESS; DAVIES DK, 2009, DEV EVALUATION UNPUB; Demers L., 2002, TECHNOL DISABIL, V14, P101, DOI DOI 10.3233/TAD-2002-14304; *DIR, COMM TRANSP SHOPM; Foo P, 2005, J EXP PSYCHOL LEARN, V31, P195, DOI 10.1037/0278-7393.31.2.195; GLAUSIER SR, 2000, CATALYST, V34, P11; GOLD MW, 1972, ADAPTIVE BEHAV PHILO; HALPERN A S, 1986, Australia and New Zealand Journal of Developmental Disabilities, V12, P147; *HUMANWARE, HUMANWARE PROD; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; KUGEL RB, 1969, PRESIDENTS COMMITTEE; LEE M, 1990, PARENTS ALLIANCE EMP; Mechling L, 2010, EDUC TRAIN AUTISM DE, V45, P230; Bryen DN, 2007, INTELLECT DEV DISAB, V45, P1, DOI 10.1352/1934-9556(2007)45[1:CPUBAW]2.0.CO;2; NIHIRA L, 1975, AM J MENT DEF, V79, P538; Nind M, 2009, DISABIL SOC, V24, P273, DOI 10.1080/09687590902789446; PORTAL ADA, ADA TRANSPORTATION S; REARDON MJ, 1993, GETTING BOARD REV TR; Stankiewicz BJ, 2007, J EXP PSYCHOL HUMAN, V33, P378, DOI 10.1037/0096-1523.33.2.378; SULLIVAN J, MOBILITY FOR ALL COM; Temple VA, 2009, INT J REHABIL RES, V32, P89, DOI 10.1097/MRR.0b013e328307f5a0; Verdonschot MML, 2009, J INTELL DISABIL RES, V53, P303, DOI 10.1111/j.1365-2788.2008.01144.x; Verdonschot MML, 2009, J INTELL DISABIL RES, V53, P54, DOI 10.1111/j.1365-2788.2008.01128.x; WEHMEYER ML, 2001, SELF DETERMINATION S	27	36	37	0	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2011	28	3					261	269		10.3233/NRE-2011-0654			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	783MF	WOS:000292086600009	21558631	Green Published			2021-06-18	
J	Wali, B; Sayeed, I; Stein, DG				Wali, Bushra; Sayeed, Iqbal; Stein, Donald G.			Improved behavioral outcomes after progesterone administration in aged male rats with traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Aging; male rats; progesterone; recovery of function; traumatic brain injury	MORRIS WATER MAZE; INFLAMMATORY RESPONSE; CORTICAL CONTUSION; COGNITIVE RECOVERY; NERVOUS-SYSTEM; ISCHEMIC BRAIN; CNS INJURY; EDEMA; ALLOPREGNANOLONE; NEUROSTEROIDS	Twenty-month-old male Fischer 344 rats with bilateral contusions of the frontal cortex (n = 8/group) or sham operations received 16 mg/kg of progesterone or vehicle at 1 and 6 h post-injury, then once every 24 h for the next seven days, with tapering of the dose over the final two treatments. The rats' behavioral recovery was then evaluated on tests of locomotor activity and Morris water maze learning. All rats were sacrificed 21 days post-TBI and brains were perfused and cryoprotected for necrotic cavity measurements. The injury produced significant impairments in activity and spatial learning compared to sham controls. The progesterone-treated rats had better functional outcomes than vehicle-treated rats with similar cortical injuries. The neurosteroid treatment did not affect the size of the necrotic cavity.	[Stein, Donald G.] Emory Univ, Brain Res Lab, Dept Emergency Med, Sch Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Emergency Med, Sch Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 5R01NS048451-04S2]; BHR	We acknowledge Leslie McCann for her help in manuscript preparation. This work was supported by NIH/NINDS grants 1R01 5R01NS048451-04S2 to DGS. Dr. Donald Stein is entitled to royalty from products of BHR Pharma, Ltd. related to the research described in this presentation, and may receive research funding from BHR, which is developing products related to this research. In addition, the author serves as consultant to BHR and receives compensation for these services. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies.	BAGIELLA E, 2010, J HEAD TRAUMA REHABI; Bitran D, 1996, PSYCHOPHARMACOLOGY, V125, P65, DOI 10.1007/BF02247394; BITRAN D, 1993, PHARMACOL BIOCHEM BE, V45, P423, DOI 10.1016/0091-3057(93)90260-Z; BITRAN D, 1995, J NEUROENDOCRINOL, V7, P171, DOI 10.1111/j.1365-2826.1995.tb00744.x; BIXO M, 1990, PSYCHONEUROENDOCRINO, V15, P159, DOI 10.1016/0306-4530(90)90025-5; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US E; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; PAXINOS G, 1986, RAT BRAIN STEREOTAXI, pR8; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Singh M, 2008, FRONT BIOSCI-LANDMRK, V13, P1083, DOI 10.2741/2746; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; STUSS DT, 1999, COGNITIVE NEUROREHAB; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; You JM, 2009, CAN J PHYSIOL PHARM, V87, P440, DOI [10.1139/y09-027, 10.1139/Y09-027]; Zinder O, 1999, ACTA PHYSIOL SCAND, V167, P181; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	60	36	37	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2011	29	1					61	71		10.3233/RNN-2011-0579			11	Neurosciences	Neurosciences & Neurology	722ZZ	WOS:000287476200006	21335669				2021-06-18	
J	Allen, DN; Leany, BD; Thaler, NS; Cross, C; Sutton, GP; Mayfield, J				Allen, Daniel N.; Leany, Brian D.; Thaler, Nicholas S.; Cross, Chad; Sutton, Griffin P.; Mayfield, Joan			Memory and Attention Profiles in Pediatric Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Attention; Childhood brain insult; Head injury; Traumatic brain; Injury; Learning and Memory	INDEX SCORE PATTERNS; VERBAL-LEARNING TEST; III STANDARDIZATION SAMPLE; TEST-CHILDRENS VERSION; CLOSED-HEAD-INJURY; WISC-III; CLUSTER SUBTYPES; NEUROCOGNITIVE OUTCOMES; BEHAVIOR PROBLEMS; SHORT-TERM	Traumatic brain injury (TBI) causes heterogeneous patterns of neurocognitive deficits. In an attempt to identify homogenous subgroups within this heterogeneity, cluster analysis was used to examine memory and attention abilities as measured by the Test of Memory and Learning (TOMAL) in 300 children, 150 with TBI and 150 matched nonbrain injured controls (standardization sample [SS]). Significant differences were present between the TBI and the SS groups on all TOMAL subscale and index scores, with the TBI groups performing approximately 1.3 SD below the SS. Factor analysis of the TOMAL indicated six factors that assessed various aspects of verbal and nonverbal learning and memory, as well as attention/concentration. Cluster analyses of TOMAL factor scores indicated that a four-cluster solution was optimal for the SS group, and a five-cluster solution for the TBI group. For the TBI clusters, differences were present for clinical, achievement, neurocognitive, and behavioral variables, providing some support for the validity of the cluster solution. These findings suggest that TBI results in unique patterns of neurocognitive impairment that are not accounted for by individual differences in test performance commonly observed in normal populations. Additionally, neurocognitive profiles identified using cluster analysis may prove useful for identifying homogeneous subgroups of children with TBI that are differentiated by a number of important clinical, cognitive, and behavioral variables associated with treatment and outcomes.	[Allen, Daniel N.] Univ Nevada, Dept Psychol, Neuropsychol Res Program, Las Vegas, NV 89154 USA; [Cross, Chad] Univ Nevada, Epidemiol & Biostat Unit, Dept Environm & Occupat Hlth, Las Vegas, NV 89154 USA; [Mayfield, Joan] Our Childrens House Baylor, Dallas, TX USA	Allen, DN (corresponding author), Univ Nevada, Dept Psychol, Neuropsychol Res Program, 4505 Maryland Pkwy, Las Vegas, NV 89154 USA.	daniel.allen@unlv.edu		Allen, Daniel/0000-0003-4868-2242			Aldenderfer M.S., 1984, CLUSTER ANAL; Alexander AI, 2005, ARCH CLIN NEUROPSYCH, V20, P587, DOI 10.1016/j.acn.2004.12.005; Allen DN, 2007, NEUROPSYCHOLOGY, V21, P713, DOI 10.1037/0894-4105.21.6.713; Allen DN, 2010, PSYCHOL ASSESSMENT, V22, P57, DOI 10.1037/a0016056; Allen DN, 2000, J NERV MENT DIS, V188, P381, DOI 10.1097/00005053-200006000-00010; Allen DN, 2003, J INT NEUROPSYCH SOC, V9, P56, DOI 10.1017/S135561770391006X; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Beery K., 2004, BEERYBUKTENICA DEV T; Carrow-Woolfolk E., 1996, ORAL WRITTEN LANGUAG; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Conners C., 2000, CONNERS CONTINUOUS P; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P249, DOI 10.1080/13854049708400453; Crosson B., 1990, CLIN NEUROPSYCHOL, V4, P253, DOI 10.1080/13854049008401908; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Demery JA, 2002, J CLIN EXP NEUROPSYC, V24, P818, DOI 10.1076/jcen.24.6.818.8400; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 2001, ASSESSMENT, V8, P193, DOI 10.1177/107319110100800207; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 1999, DEV NEUROPSYCHOL, V16, P163, DOI 10.1207/S15326942DN1602_2; Donders J, 2008, J CLIN EXP NEUROPSYC, V30, P741, DOI 10.1080/13803390701689595; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Duval J, 2008, J CHILD NEUROL, V23, P663, DOI 10.1177/0883073808314161; Everitt B., 2001, CLUSTER ANAL; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Gil AM, 2003, J SCHOOL PSYCHOL, V41, P337, DOI 10.1016/S0022-4405(03)00085-2; Goldstein G, 1998, J INT NEUROPSYCH SOC, V4, P353, DOI 10.1017/S1355617798003531; Goldstein G, 2008, NEUROPSYCHOLOGY, V22, P301, DOI 10.1037/0894-4105.22.3.301; Goldstein G, 2010, BRAIN INJURY, V24, P625, DOI 10.3109/02699051003670882; Gross D, 2004, RES NURS HEALTH, V27, P413, DOI 10.1002/nur.20040; Hair J., 1992, MULTIVARIATE DATA AN; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lee S. W., 1994, BEHAV DISORDERS, V19, P87; LOEBER R, 1990, J CLIN CHILD PSYCHOL, V19, P136, DOI 10.1207/s15374424jccp1902_5; MALEC JF, 1993, CLIN NEUROPSYCHOL, V7, P48, DOI DOI 10.1080/13854049308401887; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; McAuley C, 2000, BRIT J SOC WORK, V30, P91, DOI 10.1093/bjsw/30.1.91; MCCONAUGHY SH, 1992, J AM ACAD CHILD PSY, V31, P932, DOI 10.1097/00004583-199209000-00023; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1981, Journal of Clinical Neuropsychology, V3, P79, DOI 10.1080/01688638108403115; Mottram L, 2006, DEV NEUROPSYCHOL, V30, P865, DOI 10.1207/s15326942dn3003_6; Murji S, 2003, J INT NEUROPSYCH SOC, V9, P1, DOI 10.1017/S1355617703910010; Naglieri JA, 2005, ARCH CLIN NEUROPSYCH, V20, P385, DOI 10.1016/j.acn.2004.09.008; Palmer BW, 1997, NEUROPSYCHOLOGY, V11, P437, DOI 10.1037/0894-4105.11.3.437; Randazzo KV, 2003, J AM ACAD CHILD PSY, V42, P1343, DOI 10.1097/01.chi.0000085753.71002.da; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reynolds C. R., 2007, TEST MEMORY LEARNING; Reynolds C.R., 1994, TEST MEMORY LEARNING; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; REYNOLDS CR, 1994, ARCH CLIN NEUROPSYCH, V9, P553, DOI 10.1016/0887-6177(94)90042-6; Reynolds CR, 1996, ARCH CLIN NEUROPSYCH, V11, P29, DOI 10.1016/0887-6177(95)00027-5; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Stolberg PC, 2009, ARCH CLIN NEUROPSYCH, V24, P476; Taylor HG., 2006, EXCEPTIONALITY, V14, P141, DOI [10.1207/s15327035ex1403_3, DOI 10.1207/S15327035EX1403_3, DOI 10.1207/S15327035EX1403_]; TEASDALE G, 1974, LANCET, V2, P81; Thaler NS, 2010, CLIN NEUROPSYCHOL, V24, P246, DOI 10.1080/13854040903277305; THALER NS, 2010, AM COLL PROF NEUR AN; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; TIFFIN J, 1948, PURDUE PEGBOARD TEST; van der Heijden P, 2003, ASSESSMENT, V10, P115, DOI 10.1177/1073191103010002001; Verger K, 2001, BRAIN INJURY, V15, P211; Wexler BE, 2009, AM J PSYCHIAT, V166, P189, DOI 10.1176/appi.ajp.2008.08020258; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; WOODCOCK RW, 1989, WOODCOCKJOHNSON PSYC; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Young S, 2005, BRIT J CLIN PSYCHOL, V44, P47, DOI 10.1348/014466504X197769	80	36	37	0	33	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2010	25	7					618	633		10.1093/arclin/acq051			16	Psychology, Clinical; Psychology	Psychology	673KK	WOS:000283658500004	20667890	Bronze			2021-06-18	
J	Lustenberger, T; Talving, P; Barmparas, G; Schnuriger, B; Lam, L; Inaba, K; Demetriades, D				Lustenberger, Thomas; Talving, Peep; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Inaba, Kenji; Demetriades, Demetrios			Skateboard-Related Injuries: Not to be Taken Lightly. A National Trauma Databank Analysis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Skateboard injuries; Head injuries; Extremity fractures; Outcomes; Prevention		Background: With the increasing popularity of skateboarding, trauma centers are experiencing increased number of skateboard injuries. The incidence and type of injuries and the effect of age on these variables are poorly described in the literature. Methods: Data from National Trauma Databank during a 5-year period was used for this study. Injury Severity Score (ISS), injured body area, specific injuries, and outcomes were calculated according to age groups (younger than 10 years, 10-16 years, and older than 16 years). Results: During the study period, there were 2,270 admissions due to skateboard-related injuries (0.1% of all trauma admissions). There were 187 patients (8%) younger than 10 years, 1,314 patients (58%) 10 years to 16 years, and 769 patients (34%) older than 16 years. The overall mortality was 1.1% and ranged from 0% in the age group younger than 10 years to 0.3% in the group 10 years to 16 years and 2.6% in the group older than 16 years (p < 0.001). The incidence of severe trauma (Injury Severity Score >= 16) in the three age groups was 5.4%, 13.5%, and 23.7%, respectively (p < 0.001). The incidence of traumatic brain injury in the three age groups was 24.1%, 32.6%, and 45.5%, respectively (p < 0.001). The younger age group (younger than 10 years) was significantly more likely to suffer femur fractures and less likely to suffer tibia fractures than the older age groups. Helmets and use of a skateboard park were significant factors protecting against head injury. Conclusion: Skateboard-related injuries are associated with a high incidence of traumatic brain injury and long bone fractures. Age plays an important role in the anatomic distribution of injuries, injury severity, and outcomes. Our findings demonstrate that helmet utilization and designated skateboard areas significantly reduce the incidence of serious head injuries.	[Lustenberger, Thomas; Talving, Peep; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Inaba, Kenji; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA 90033 USA	Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles Cty Gen Hosp LAC USC,Dept Surg, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	INABA, KENJI/AAC-8532-2020; Barmparas, Galinos/L-6530-2019; Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Bull MJ, 2002, PEDIATRICS, V109, P542; CASS DT, 1990, MED J AUSTRALIA, V153, P140, DOI 10.5694/j.1326-5377.1990.tb136832.x; Forsman L, 2001, BRIT J SPORT MED, V35, P325, DOI 10.1136/bjsm.35.5.325; KRUSE P, 1990, Ugeskrift for Laeger, V152, P681; Kyle SB, 2002, J TRAUMA, V53, P686, DOI 10.1097/00005373-200210000-00011; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; Rethnam Ulfin, 2008, BMC Res Notes, V1, P59, DOI 10.1186/1756-0500-1-59; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; SCHMID A, 1993, UNFALLCHIRURG, V96, P641; Skateboard injuries, 1995, PEDIATRICS, V95, P611; Zalavras C, 2005, AM J SPORT MED, V33, P568, DOI 10.1177/0363546504269256	11	36	36	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2010	69	4					924	927		10.1097/TA.0b013e3181b9a05a			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	664KP	WOS:000282959100052	20065875				2021-06-18	
J	Hakan, T; Toklu, HZ; Biber, N; Ozevren, H; Solakoglu, S; Demirturk, P; Aker, FV				Hakan, Tayfun; Toklu, Hale Z.; Biber, Necat; Ozevren, Huseyin; Solakoglu, Seyhun; Demirturk, Pelin; Aker, Fugen V.			Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability	NEUROLOGICAL RESEARCH			English	Article						Antioxidant; blood-brain barrier; brain injury; closed head trauma; edema; meloxicam	OXIDATIVE STRESS; HEAD-INJURY; RAT; CYCLOOXYGENASE-2; MODEL; INFLAMMATION; NEUROPROTECTION; METABOLISM; MODULATION; RELEASE	Objective: The overproduction of reactive oxygen species and resultant damage to cellular proteins or lipids of cell membranes and DNA by free radicals are the underlying mechanisms of many neuropathologies. Cyclooxygenase-2 (COX-2) inhibitors have been suggested to be neuroprotective by reducing prostanoid and free radical synthesis, or by directing arachidonic acid metabolism through alternate pathways. This study investigated the putative neuroprotective effect of the COX-2 inhibitor, meloxicam, in a rat model of diffuse brain injury. Methods: Sprague-Dawley rats were subjected to traumatic brain injury with a weight-drop device using 300 g 21 m weight-height impact. The groups were: control, meloxicam (2 mg/kg, i.p.), trauma and trauma z meloxicam (2 mg/kg, i.p.). Forty-eight hours after the injury, neurological examination scores were measured, the animals were decapitated and brain tissues were taken. Brain edema and blood-brain barrier (BBB) permeability were evaluated by wet-dry weight method and Evans blue (EB) extravasation respectively. In brain tissues, malonedialdehyde, glutathione, myeloperoxidase and Na/K-ATPase levels were measured. Results: The neurological examination scores mildly increased in trauma groups 48 hours after the induction of trauma. Meloxicam treatment improved the altered neurological status. The trauma caused a significant increase in brain water content that was partially reversed by meloxicam. Meloxicam also reduced the EB extravasation indicating the preservation of the BBB integrity. Meloxicam treatment also significantly reduced the increase in malondialdehyde and myeloperoxidase levels glutathione content of the brains that had been significantly increased after trauma. Conclusion: Meloxicam exerts neuroprotective effect by preserving BBB permeability and by reducing brain edema (probably by its anti-inflammatory properties) in the diffuse brain injury model.	[Hakan, Tayfun; Biber, Necat; Ozevren, Huseyin] Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, TR-34668 Istanbul, Turkey; [Toklu, Hale Z.] Marmara Univ, Sch Pharm, Dept Pharmacol, Istanbul, Turkey; [Solakoglu, Seyhun] Istanbul Univ, Istanbul Sch Med, Dept Histol & Embryol, Istanbul, Turkey; [Demirturk, Pelin; Aker, Fugen V.] Haydarpasa Numune Teaching & Res Hosp, Dept Pathol, Istanbul, Turkey	Hakan, T (corresponding author), Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, TR-34668 Istanbul, Turkey.	tayfunhakan@yahoo.com	Toklu, Hale/AAR-2330-2020; Ozevren, Huseyin/AAC-1236-2021; Hakan, Tayfun/P-8626-2015; Hakan, Tayfun/O-9979-2019; solakoglu, seyhun/AAA-4412-2021; solakoglu, seyhun/AAE-5691-2020	Toklu, Hale/0000-0002-9797-3591; Ozevren, Huseyin/0000-0002-5437-4003; Hakan, Tayfun/0000-0003-1444-7076; Hakan, Tayfun/0000-0003-1444-7076; solakoglu, seyhun/0000-0002-1389-9639; 			Agha AM, 1999, PHARMACOL RES, V40, P385, DOI 10.1006/phrs.1999.0522; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arafa HMM, 2007, EUR J PHARMACOL, V564, P181, DOI 10.1016/j.ejphar.2007.02.065; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; Beuge J. A., 1972, METHOD ENZYMOL, V52, P302; BEUTLER E, 1963, J LAB CLIN MED, V61, P888; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Dobrota D, 1999, CELL MOL NEUROBIOL, V19, P141, DOI 10.1023/A:1006909927287; Engelhardt G, 1996, BIOCHEM PHARMACOL, V51, P29, DOI 10.1016/0006-2952(95)02110-8; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Jun-Qing Y, 2006, EUR J PHARMACOL, V547, P52, DOI 10.1016/j.ejphar.2006.07.031; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Ogino K, 1997, PHARMACOLOGY, V55, P44, DOI 10.1159/000139511; READING HW, 1980, Q J EXP PHYSIOL CMS, V65, P105, DOI 10.1113/expphysiol.1980.sp002495; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Tegeder I, 2000, J PHARMACOL EXP THER, V292, P1161; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479	37	36	36	1	16	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	2010	32	6					629	635		10.1179/016164109X12464612122731			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	613SS	WOS:000279001300010	19660237				2021-06-18	
J	Rousseaux, M; Verigneaux, C; Kozlowski, O				Rousseaux, M.; Verigneaux, C.; Kozlowski, O.			An analysis of communication in conversation after severe traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						behaviour; non-verbal communication; traumatic brain injury; verbal communication	CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; SOCIAL COMMUNICATION; PERCEPTION DEFICITS; EMOTION PERCEPTION; DYSARTHRIA; NEUROPRAGMATICS; RECOGNITION; LISTENER; ABILITY	Background and objective: Communication disorders have been reported following severe traumatic brain injury. However, we have little information about patient behaviour during dyadic interaction. Here, we analyzed conversation at the rehabilitation and chronic phase post traumatic brain injury (TBI), to define the main mechanisms of verbal and non-verbal communication disorders and relationship with other cognitive difficulties. Methods: Sixteen patients were evaluated at the rehabilitation phase (2-12 months) and 18 at the chronic phase (after 2 years) following severe TBI. They were compared with equivalent groups of matching (gender, age, education level) control subjects. We used the Lille Communication Test, which comprises three parts: participation to communication (greeting, attention, engagement), verbal communication (verbal comprehension, speech outflow, intelligibility, word production, syntax, verbal pragmatics, verbal feedback) and non-verbal communication (understanding gestures, affective expressivity, producing gestures, pragmatics, non-verbal feedback). We also investigated executive functions (Stroop test, trail-making test, categorical evocation), language (Montreal-Toulouse protocol) and behaviour (Neurobehavioural Rating Scale). Verbal communication disorders were relatively equivalent at the rehabilitation and chronic phases. Results: Patients were impaired (P < 0.01) in their participation to communication, especially in greeting behaviour. Verbal communication was mostly affected by difficulties in producing fluent and intelligible language and using pragmatics (responding to open questions, presenting new information and introducing new themes, organizing discourse and adapting to interlocutor knowledge). Non-verbal communication was impaired by difficulties in using pragmatics (mostly adapted prosody). Participation and verbal communication correlated with the executive functions, language and behavioural assessment. Conclusions: Disorders of social communication justify systematic assessment in patients with TBI.	[Rousseaux, M.; Verigneaux, C.; Kozlowski, O.] CHRU, Hop Swynghedauw, Serv Reeduc Neurol, F-59037 Lille, France; [Rousseaux, M.; Verigneaux, C.] Univ Lille 2, Inst Orthophonie, Lille, France	Rousseaux, M (corresponding author), CHRU, Hop Swynghedauw, Serv Reeduc Neurol, F-59037 Lille, France.	marc.rousseaux@chru-lille.fr			AllerganAbbVieAllergan; IPSENIpsen; MERZ	Dr Marc Rousseaux received honoraria for lecturing and serving in the scientific advisory board from Allergan, IPSEN and MERZ.	Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Aubert S., 2004, Annales de Readaptation et de Medecine Physique, V47, P135, DOI 10.1016/j.annrmp.2004.02.001; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Borgaro SR, 2004, BRAIN INJURY, V18, P33, DOI 10.1080/0269905031000110562; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Cools C, 1998, INT J REHABIL RES, V21, P323, DOI 10.1097/00004356-199809000-00007; D'Innocenzo J, 2006, CLIN LINGUIST PHONET, V20, P659, DOI 10.1080/02699200500224272; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Davis G.A., 1981, LANGUAGE INTERVENTIO, P169; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Drummond SS, 2004, BRAIN INJURY, V18, P41, DOI 10.1080/0269905031000149461; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Guo YE, 2008, BRAIN INJURY, V22, P83, DOI 10.1080/02699050701824150; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P369, DOI 10.1080/026990598122502; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Nespoulous J.-L., 1992, PROTOCOLE MONTREAL T; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Rousseaux M, 2001, TLC TEST LILLOIS COM; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Wenke RJ, 2008, BRAIN INJURY, V22, P339, DOI 10.1080/02699050801960987	32	36	37	0	20	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1351-5101			EUR J NEUROL	Eur. J. Neurol.	JUL	2010	17	7					922	929		10.1111/j.1468-1331.2009.02945.x			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	613YQ	WOS:000279021700007	20100227				2021-06-18	
J	Arnold, JD; Dart, BW; Barker, DE; Maxwell, RA; Burkholder, HC; Mejia, VA; Smith, PW; Longley, JM				Arnold, Joshua D.; Dart, Benjamin W.; Barker, Donald E.; Maxwell, Robert A.; Burkholder, Hans C.; Mejia, Vicente A.; Smith, Philip W.; Longley, Joy M.			Unfractionated Heparin Three Times a Day versus Enoxaparin in the Prevention of Deep Vein Thrombosis in Trauma Patients	AMERICAN SURGEON			English	Article; Proceedings Paper	Southeastern Surgical Congress 2010	FEB 20-23, 2010	Savannah, GA				MOLECULAR-WEIGHT HEPARIN; FATAL PULMONARY-EMBOLISM; LOW-DOSE HEPARIN; VENOUS THROMBOEMBOLISM; POSTTHROMBOTIC SYNDROME; MULTICENTER TRIAL; SURGICAL-PATIENTS; RISK; ANTICOAGULANT; MANAGEMENT	Venous thromboembolic disease is a significant source of morbidity and mortality in hospitalized trauma patients. Multiple drugs and dosing regimens have been suggested for pharmacoprophylaxis. In this study, we compared efficacy, complications, and cost of unfractionated heparin administered subcutaneously three times a day with standard-dosed enoxaparin for prophylaxis of deep venous thrombosis (DVT) in adult trauma patients over 1 year. Patients admitted for greater than 72 hours who received pharmacoprophylaxis as part of a comprehensive DVT protocol were included. A change was made in the protocol from enoxaparin (30 mg twice a day or 40 mg per day) to heparin (5000 U three times a day) at midyear. Surveillance lower extremity venous ultrasound was performed according to established institutional guidelines. Data, including demographics, associated injuries, complications, and cost, were collected and analyzed. Four hundred seventy-six patients met inclusion criteria. Two hundred thirty-seven (49.8%) patients received enoxaparin and 239 (50.2%) received heparin. Proximal lower extremity DVTs were detected in 16 (6.75%) patients in the enoxaparin group and 17 (7.11%) in the heparin group (P = 0.999). Risk factors for DVT in these patients included spinal cord injury (P = 0.001) and closed head injury (P = 0.031). There was no difference between the incidence of pulmonary emboli and bleeding. There was an estimated yearly pharmacy cost savings of $135,606. In trauma patients, subcutaneous heparin dosed three times a day may be as effective as standard-dosed enoxaparin for prophylaxis of venous thromboembolism without increased complications. Heparin three times a day for venous thromboembolism prophylaxis was associated with significant pharmaceutical cost savings.	[Arnold, Joshua D.; Dart, Benjamin W.; Barker, Donald E.; Maxwell, Robert A.; Burkholder, Hans C.; Mejia, Vicente A.; Smith, Philip W.; Longley, Joy M.] Univ Tennessee, Coll Med, Dept Surg, Chattanooga, TN USA	Arnold, JD (corresponding author), 979 E 3rd St,Suite B401, Chattanooga, TN 37403 USA.	arnoljd5@hotmail.com					Anderson, 2005, BLOOD, V106, P910; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; Bara L, 1988, Acta Chir Scand Suppl, V543, P65; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; BJORNSSON TD, 1982, CLIN PHARMACOL THER, V31, P104, DOI 10.1038/clpt.1982.16; BRADBROOK ID, 1987, BRIT J CLIN PHARMACO, V23, P667, DOI 10.1111/j.1365-2125.1987.tb03100.x; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Cushman M, 2004, AM J MED, V117, P19, DOI 10.1016/j.amjmed.2004.01.018; DEITELZWEIG S, 2009, J THROMB THROMB 1001; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Haas S, 2005, THROMB HAEMOSTASIS, V94, P814, DOI 10.1160/TH02-10-0189; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, SEMIN THROMB HEMOST, V16, P12; Heit JA, 2000, ARCH INTERN MED, V160, P761, DOI 10.1001/archinte.160.6.761; HIRSH J, 1976, CIRCULATION, V53, P691, DOI 10.1161/01.CIR.53.4.691; Hirsh J, 2008, CHEST, V133, p141S, DOI 10.1378/chest.08-0689; Johanson NA, 2009, J BONE JOINT SURG AM, V91A, P1756, DOI 10.2106/JBJS.I.00511; JOHNSON EA, 1976, CARBOHYD RES, V51, P119, DOI 10.1016/S0008-6215(00)84041-0; *JOINT COMM CTR ME, SPEC MAN NAT HOSP IM; Kahn SR, 2002, BLOOD REV, V16, P155, DOI 10.1016/S0268-960X(02)00008-5; Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189; Lechler E, 1996, HAEMOSTASIS, V26, P49; MacDougall DA, 2006, AM J HEALTH-SYST PH, V63, pS5, DOI 10.2146/ajhp060388; Merli G, 2003, J TRAUMA, V54, P1116, DOI 10.1097/01.TA.0000066385.10596.71; OLSSON P, 1963, ACTA MED SCAND, V173, P619; Passman MA, 2010, AM J SURG, V199, pS21, DOI 10.1016/j.amjsurg.2009.10.005; Prandoni P, 2009, BRIT J HAEMATOL, V145, P286, DOI 10.1111/j.1365-2141.2009.07601.x; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Spinal Cord Injury Thromboprophylaxis Investigators, 2003, J TRAUMA, V54, P1125; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Velmahos GC, 2006, AM SURGEON, V72, P757; Wakefield TW, 2008, CURR PROB SURG, V45, P844, DOI 10.1067/j.cpsurg.2008.08.002; WOLF H, 1991, SEMIN THROMB HEMOST, V17, P343, DOI 10.1055/s-2007-1002632	38	36	39	1	8	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JUN	2010	76	6					563	570					8	Surgery	Surgery	602YG	WOS:000278174400002	20583509				2021-06-18	
J	Lakshmanan, R; Loo, JA; Drake, T; Leblanc, J; Ytterberg, AJ; McArthur, DL; Etchepare, M; Vespa, PM				Lakshmanan, R.; Loo, J. A.; Drake, T.; Leblanc, J.; Ytterberg, A. J.; McArthur, D. L.; Etchepare, M.; Vespa, P. M.			Metabolic Crisis After Traumatic Brain Injury is Associated with a Novel Microdialysis Proteome	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Microdialysis; Proteomics; Metabolic crisis; Biomarkers	BIOMARKERS; PROTEINS; PRESSURE; DAMAGE; SERUM; TAU	To examine if the metabolic distress after traumatic brain injury (TBI) is associated with a unique proteome. Patients with severe TBI prospectively underwent cerebral microdialysis for the initial 96 h after injury. Hourly sampling of metabolism was performed and patients were categorized as having normal or abnormal metabolism as evidenced by the lactate/pyruvate ratio (LPR) threshold of 40. The microdialysate was frozen for proteomic batch processing retrospectively. We employed two different routes of proteomic techniques utilizing mass spectrometry (MS) and categorized as diagnostic and biomarker identification approaches. The diagnostic approach was aimed at finding a signature of MS peaks which can differentiate these two groups. We did this by enriching for intact peptides followed by MALDI-MS analysis. For the biomarker identification approach, we applied classical bottom-up (trypsin digestion followed by LC-MS/MS) proteomic methodologies. Five patients were studied, 3 of whom had abnormal metabolism and 2 who had normal metabolism. By comparison, the abnormal group had higher LPR (1609 +/- A 3691 vs. 15.5 +/- A 6.8, P < 0.001), higher glutamate (157 +/- A 84 vs. 1.8 +/- A 1.4 mu M, P < 0.001), and lower glucose (0.27 +/- A 0.35 vs. 1.8 +/- A 1.1 mmol/l, P < 0.001). The abnormal group demonstrated 13 unique proteins as compared with the normal group in the microdialysate. These proteins consisted of cytoarchitectural proteins, as well as blood breakdown proteins, and a few mitochondrial proteins. A unique as yet to be characterized peptide was found at m/z (mass/charge) 4733.5, which may represent a novel biomarker of metabolic distress. Metabolic distress after TBI is associated with a differential proteome that indicates cellular destruction during the acute phase of illness. This suggests that metabolic distress has immediate cellular consequences after TBI.	[McArthur, D. L.; Etchepare, M.; Vespa, P. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg & Neurol, Ronald Reagan UCLA Med Ctr, Los Angeles, CA 90095 USA; [Drake, T.; Leblanc, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Lakshmanan, R.; Loo, J. A.; Ytterberg, A. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Vespa, PM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg & Neurol, Ronald Reagan UCLA Med Ctr, 757 Westwood Blvd,RR 6236A, Los Angeles, CA 90095 USA.	PVespa@mednet.ucla.edu	McArthur, David/E-6442-2013; Ytterberg, Anders/E-1773-2016	McArthur, David/0000-0003-3385-1314; Ytterberg, Anders/0000-0002-1485-2314	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS058489] Funding Source: Medline		Afinowi R, 2009, J NEUROSCI METH, V181, P95, DOI 10.1016/j.jneumeth.2009.02.021; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Larsen MR, 2001, PROTEOMICS, V1, P223; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Maurer Martin H, 2003, Proteome Sci, V1, P7, DOI 10.1186/1477-5956-1-7; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Yang XY, 2009, BRAIN INJURY, V23, P830, DOI 10.1080/02699050903196670; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zuberovic A, 2009, ELECTROPHORESIS, V30, P1836, DOI 10.1002/elps.200800714	22	36	37	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2010	12	3					324	336		10.1007/s12028-010-9342-5			13	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	590RJ	WOS:000277244700003	20225002	Green Accepted			2021-06-18	
J	Mao, HJ; Jin, X; Zhang, LY; Yang, KH; Igarashi, T; Noble-Haeusslein, LJ; King, AI				Mao, Haojie; Jin, Xin; Zhang, Liying; Yang, King H.; Igarashi, Takuji; Noble-Haeusslein, Linda J.; King, Albert I.			Finite Element Analysis of Controlled Cortical Impact-Induced Cell Loss	JOURNAL OF NEUROTRAUMA			English	Article						brain biomechanics; controlled cortical impact; finite element models; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; CONTUSION INJURY; HIPPOCAMPAL-NEURONS; RAT; VULNERABILITY; DEFORMATION; STRAIN; MODEL	The controlled cortical impact (CCI) model has been extensively used to study region-specific patterns of neuronal injury and cell death after a focal traumatic brain injury. Although external parameters such as impact velocity and depth of penetration have been defined in this injury model, little is known about the intracranial mechanical responses within cortical and subcortical brain regions where neuronal loss is prevalent. At present, one of the best methods to determine the internal responses of the brain is finite element (FE) modeling. A previously developed and biomechanically validated detailed three-dimensional FE rat brain model, consisting of 255,700 hexahedral elements and representing all essential anatomical features of a rat brain, was used to study intracranial responses in a series of CCI experiments in which injury severity ranged from mild to severe. A linear relationship was found between the percentage of the neuronal loss observed in vivo and the FE model-predicted maximum principal strain (R-2=0.602). Interestingly, the FE model also predicted some risk of injury in the cerebellum, located remote from the point of impact, with a 25% neuronal loss for the "severe'' impact condition. More research is needed to examine other regions that do not have histological data for comparison with FE model predictions before this injury mechanism and the associated injury threshold can be fully established.	[Mao, Haojie; Jin, Xin; Zhang, Liying; Yang, King H.; King, Albert I.] Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Igarashi, Takuji] Narita Red Cross Hosp, Dept Neurosurg, Chiba, Japan	Yang, KH (corresponding author), Wayne State Univ, Ctr Bioengn, 818 W Hancock, Detroit, MI 48201 USA.	king.yang@wayne.edu	Jin, Xin/J-6476-2015; Lang, Steven/AAE-8102-2021; Mao, Haojie/Q-7514-2018	Lang, Steven/0000-0003-1669-9146; Mao, Haojie/0000-0002-7563-9234	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS046389, NS050159]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS065937, R01NS050159, R01NS046389] Funding Source: NIH RePORTER	This study was supported in part by grants NS046389 and NS050159 from the National Institute of Neurological Disorders and Stroke.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arbogast K., 1997, P 41 STAPP CAR CRASH; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Conti AC, 1998, J NEUROSCI, V18, P5663; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; King AI, 2003, IRCOBI C LISB PORT; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pena A, 2005, ACT NEUR S, V95, P333; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHREIBER DI, 1997, STAPP CAR CRASH C WA; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Toth Z, 1997, J NEUROSCI, V17, P8106; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; ZHOU C, 1994, 942214 SAE	35	36	36	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					877	888		10.1089/neu.2008.0616			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400010	20199194	Green Published			2021-06-18	
J	Thomas, BW; Mejia, VA; Maxwell, RA; Dart, BW; Smith, PW; Gallagher, MR; Claar, SC; Greer, SH; Barker, DE				Thomas, Bradley W.; Mejia, Vicente A.; Maxwell, Robert A.; Dart, Benjamin W.; Smith, Philip W.; Gallagher, Michael R.; Claar, Sean C.; Greer, Stephen H.; Barker, Donald E.			Scheduled Repeat CT Scanning for Traumatic Brain Injury Remains Important in Assessing Head Injury Progression	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	121st Annual Meeting of the Southern-Surgical-Association	DEC, 2009	Hot Springs, VA	SE Surg Assoc			SERIAL COMPUTED-TOMOGRAPHY; HEMORRHAGE; MANAGEMENT; HEMATOMAS; UTILITY; CLASSIFICATION; DIAGNOSIS; CHILDREN; MODERATE; SCANS	BACKGROUND: Scheduled repeat brain CT (SRBCT) is used to monitor progression of traumatic brain injury (TBI). Previous studies have suggested that routine SRBCT can be replaced by an unscheduled repeat brain CT after deterioration on serial neurological examination. In this study, we evaluated if SRBCT has a role in the management of TBI. STUDY DESIGN: Retrospective observational study of 1,019 consecutive adult patients admitted to a Level I trauma center with CT evidence of TBI on initial brain CT (IBCT). All patients with intracranial pathology on IBCT were scheduled for SRBCT and underwent sequential neurological physical examinations. Interventions (surgical or medical) after IBCT SRBCT, or neurological change were recorded. RESULTS: One thousand nineteen patients with IBCT evidence of TBI were identified from the trauma registry during a 50-month study period beginning in November 2001. Eighty-six (8.9%) of these patients went directly for craniotomy. After exclusions, 887 patients were analyzed. A total of 692 (78%) patients had a no worse first SRBCT and neurologic changes requiring intervention later developed in 11 (1.6%) of these patients. One hundred ninety-five (22%) patients had a worse first SRBCT, with 14 (7.2%) requiring immediate intervention. Seven (3.6%) worse first SRBCT patients had a subsequent SRBCT that worsened, leading to an intervention. A neurologic change that precipitated an intervention developed subsequently in an additional 19 (9.7%) patients with a worse first SRBCT. Chi-square analysis demonstrated that a first SRBCT that was worse was more likely to result in an intervention than if the first SRBCT was no worse. CONCLUSIONS: A worse SRBCT is more likely to result in neurologic intervention. SRBCT remains useful in assessing patients with TBI. (J Am Coll Surg 2010;210:824-832. (C) 2010 by the American College of Surgeons)	[Thomas, Bradley W.; Mejia, Vicente A.; Maxwell, Robert A.; Dart, Benjamin W.; Smith, Philip W.; Gallagher, Michael R.; Claar, Sean C.; Greer, Stephen H.; Barker, Donald E.] Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, Chattanooga, TN 37401 USA	Thomas, BW (corresponding author), Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, 979 E 3rd St,Suite 401, Chattanooga, TN 37401 USA.	bradley.w.thomas@gmail.com					Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; Camins M B, 1996, Bull Am Coll Surg, V81, P16; Camins MB, 1996, B AM COLL SURG, V81, P47; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Cooper P R, 1992, Neurosurg Clin N Am, V3, P659; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; HUNEIDI AHS, 1992, ANN ROY COLL SURG, V74, P345; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LUND E, 1982, NEURORADIOLOGY, V22, P181, DOI 10.1007/BF00341246; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MENDELOW AD, 1979, BRIT MED J, V2, P134, DOI 10.1136/bmj.2.6182.134-a; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; PARK H, 2009, BR J NEUROSURG  0804, P1; Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Shackford SR, 2004, J TRAUMA, V56, P480; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sinson G, 2001, J TRAUMA, V51, P875; Stearley H E, 1998, Am J Crit Care, V7, P282; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; TEASDALE G, 1974, LANCET, V2, P81; Vano E, 1998, BRIT J RADIOL, V71, P728, DOI 10.1259/bjr.71.847.9771383; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; 2006, MMWR MORB MORTAL WKL, V55, P201	48	36	41	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	MAY	2010	210	5					824	830		10.1016/j.jamcollsurg.2009.12.039			7	Surgery	Surgery	594HZ	WOS:000277528700058	20421059				2021-06-18	
J	Babikian, T; Marion, SD; Copeland, S; Alger, JR; O'Neill, J; Cazalis, F; Mink, R; Giza, CC; Vu, JA; Hilleary, SM; Kernan, CL; Newman, N; Asarnow, RF				Babikian, Talin; Marion, Sarah DeBoard; Copeland, Sarah; Alger, Jeffry R.; O'Neill, Joseph; Cazalis, Fabienne; Mink, Richard; Giza, Christopher C.; Vu, Jennifer A.; Hilleary, Suzanne M.; Kernan, Claudia L.; Newman, Nina; Asarnow, Robert F.			Metabolic Levels in the Corpus Callosum and Their Structural and Behavioral Correlates after Moderate to Severe Pediatric TBI	JOURNAL OF NEUROTRAUMA			English	Article						corpus callosum; diffusion tensor imaging; evoked potentials; magnetic resonance spectroscopy; pediatric traumatic brain injury	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; DIFFUSE AXONAL INJURY; PROTON MR SPECTROSCOPY; HEAD TRAUMA; CHILDREN; FEATURES	Diffuse axonal injury (DAI) secondary to traumatic brain injury (TBI) contributes to long-term functional morbidity. The corpus callosum (CC) is particularly vulnerable to this type of injury. Magnetic resonance spectroscopy (MRS) was used to characterize the metabolic status of two CC regions of interest (ROIs) (anterior and posterior), and their structural (diffusion tensor imaging; DTI) and neurobehavioral (neurocognitive functioning, bimanual coordination, and interhemispheric transfer time [IHTT]) correlates. Two groups of moderate/severe TBI patients (ages 12-18 years) were studied: post-acute (5 months post-injury; n - 10), and chronic (14.7 months post-injury; n 8), in addition to 10 age-matched healthy controls. Creatine (energy metabolism) did not differ between groups across both ROIs and time points. In the TBI group, choline (membrane degeneration/in-inflammation) was elevated for both ROIs at the post-acute but not chronic period. N-acetyl aspartate (NAA) (neuronal/axonal integrity) was reduced initially for both ROIs, with partial normalization at the chronic time point. Posterior, not anterior, NAA was positively correlated with DTI fractional anisotropy (FA) (r = 0.88), and most domains of neurocognition (r range 0.22-0.65), and negatively correlated with IHTT (r = -0.89). Inverse corerlations were noted between creatine and posterior FA (r = -0.76), neurocognition (r range -0.22 to -0.71), and IHTT (r = 0.76). Multimodal studies at distinct time points in specific brain structures are necessary to delineate the course of the degenerative and reparative processes following TBI, which allows for preliminary hypotheses about the nature and course of the neural mechanisms of subsequent functional morbidity. This will help guide the future development of targeted therapeutic agents.	[Babikian, Talin] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Copeland, Sarah; Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Alger, Jeffry R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Alger, Jeffry R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA; [Mink, Richard; Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Marion, Sarah DeBoard; Hilleary, Suzanne M.] Fuller Grad Sch Psychol, Dept Psychol, Pasadena, CA USA; [Mink, Richard] Harbor UCLA, Los Angeles Biomed Res Inst, Los Angeles, CA USA; [Vu, Jennifer A.] Univ Calif Los Angeles, Grad Sch Educ & Informat Studies, Los Angeles, CA 90095 USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Grad Sch, Dept Psychol, Los Angeles, CA 90095 USA	Babikian, T (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Room C8-746, Los Angeles, CA 90095 USA.	tbabikian@mednet.ucla.edu			National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS053169, NS27544, NS057420]; UCLA Brain Injury Research Center (BIRC); Della Martin Foundation; Winokur Family Foundation/Child Neurology Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS057420, R01NS027544, F32NS053169] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (F32NS053169, NS27544, and NS057420), the UCLA Brain Injury Research Center (BIRC), the Della Martin Foundation, and the Winokur Family Foundation/Child Neurology Foundation.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brown WS, 1999, NEUROPSYCHOLOGIA, V37, P1165, DOI 10.1016/S0028-3932(99)00011-1; BROWN WS, 1991, BIMANUAL COORD UNPUB; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cohen M.J., 1997, CHILDRENS MEMORY SCA; COPELAND S, 2008, UC NEUR C CARM CA; Delis D, 1994, CALIFORNIA VERBAL LE; Delis DC, 2000, CALIFORNIA VERBAL LE; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.0.CO;2-6; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hoon AH, 2000, J DEV BEHAV PEDIATR, V21, P291, DOI 10.1097/00004703-200008000-00007; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; JEEVES MA, 1988, NEUROPSYCHOLOGIA, V26, P833, DOI 10.1016/0028-3932(88)90053-X; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MARION SD, 2008, UC NEUR C CARM CA; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; O'Neill J, 2006, ISMRM WORKSH QUANT S; Parry L, 2004, CHILD NEUROPSYCHOL, V10, P248, DOI 10.1080/09297040490909279; PREILOWSKI BF, 1972, NEUROPSYCHOLOGIA, V10, P267, DOI 10.1016/0028-3932(72)90018-8; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUGG MD, 1985, J NEUROL NEUROSUR PS, V48, P367, DOI 10.1136/jnnp.48.4.367; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; Tasker RC, 2006, EMERG MED J, V23, P519, DOI 10.1136/emj.2005.028779; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 1977, WECHSLER MEMORY SCAL, VThird; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	46	36	39	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					473	481		10.1089/neu.2009.1058			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100002	19925210	Green Published			2021-06-18	
J	Garden, N; Sullivan, KA; Lange, RT				Garden, Natalie; Sullivan, Karen A.; Lange, Rael T.			The Relationship Between Personality Characteristics and Postconcussion Symptoms in a Nonclinical Sample	NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; postconcussion syndrome; personality; MMCI-III; BC-PSI	TRAUMATIC BRAIN-INJURY; CLINICAL MULTIAXIAL INVENTORY; POST-CONCUSSION SYNDROME; EMOTIONAL RISK-FACTORS; COMPLAINT BASE RATES; MILD HEAD-INJURY; MCMI-III; MISERABLE MINORITY; CHRONIC PAIN; DEPRESSION	Postconcussion symptoms are relatively common in the acute recovery period following mild traumatic brain injury. However, for a small subset of patients, self reported postconcussion symptoms continue long after injury. Many factors have been proposed to account for the presence of persistent postconcussion symptoms. The influence of personality traits has been proposed as one explanation, The purpose of this study was to examine the relation between postconcussion-like symptom reporting and personality traits in a sample of 96 healthy participants. Participants completed the British Columbia Postconcussion Symptom Inventory and the Millon Clinical Multiaxial Inventory III (MCMI-III). There was a strong positive relation between the majority of MCMI-III scales and postconcussion-like symptom reporting. Approximately half of the sample met the International Classification of Diseases-10 Criterion C symptoms for Postconcussional Syndrome. Compared with those participants who did not meet this criterion, the PCS group had significant elevations on the negativistic, depression, major depression, dysthymia, anxiety, dependent, sadistic, somatic, and borderline scales of the MCMI-Ill. These findings support the hypothesis that personality traits can play a contributing role in self reported postconcussion symptoms.	[Garden, Natalie; Sullivan, Karen A.] Queensland Univ Technol, Sch Psychol & Counselling, Clin Neuropsychol Res Grp, Kelvin Grove 4059, Australia; [Sullivan, Karen A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove 4059, Australia; [Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada	Sullivan, KA (corresponding author), Queensland Univ Technol, Sch Psychol & Counselling, Clin Neuropsychol Res Grp, Victoria Pk Rd, Kelvin Grove 4059, Australia.	karen.sullivan@qut.edu.au			School of Psychology and Counselling, Queensland University of Technology	The Human Research Ethics Committee of Queensland University of Technology (Approval No. 0700000965) approved all research documented in this report. Funding for this project was provided by the School of Psychology and Counselling, Queensland University of Technology. We acknowledge the generous assistance of Patricia Obst, statistics consultant, Queensland University of Technology.	Aluja A, 2007, INT J CLIN HLTH PSYC, V7, P307; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Blood L, 2008, J FORENSIC PSYCHOL P, V8, P24, DOI 10.1080/15228930801947286; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Craig RJ, 1997, SUBST USE MISUSE, V32, P1385, DOI 10.3109/10826089709039384; CRAIG RJ, 1992, J SUBST ABUSE TREAT, V9, P249, DOI 10.1016/0740-5472(92)90068-Y; Craig RJ, 2005, NEW DIRECTIONS INTER; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GARDEN NA, APPL NEUROP IN PRESS; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gondolf EW, 1999, J FAM VIOLENCE, V14, P1, DOI 10.1023/A:1022843324943; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; HAGGARD R, 2008, J PAIN, V9, P67; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; HOLLIMAN NB, 1989, J CLIN PSYCHOL, V45, P373, DOI 10.1002/1097-4679(198905)45:3<373::AID-JCLP2270450305>3.0.CO;2-R; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; King AR, 1998, J PERS ASSESS, V71, P253, DOI 10.1207/s15327752jpa7102_12; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Lannoo E, 1997, J PSYCHOSOM RES, V43, P505, DOI 10.1016/S0022-3999(97)00152-9; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Manchikanti Laxmaiah, 2002, Pain Physician, V5, P40; McCann J. T., 2001, J FORENSIC PSYCHOL P, V1, P27, DOI DOI 10.1300/J158V01N02_02; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Millon T., 2006, MILLON CLIN MULTIAXI; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; REPKO GP, 1985, J CLIN PSYCHOL, V43, P478; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruocco AC, 2007, BRAIN INJURY, V21, P1233, DOI 10.1080/02699050701716919; Ruocco AC, 2007, J NEUROPSYCH CLIN N, V19, P27, DOI 10.1176/appi.neuropsych.19.1.27; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Rush BK, 2004, REHABIL PSYCHOL, V49, P275, DOI 10.1037/0090-5550.49.4.275; Ruttan LA, 2003, J CLIN EXP NEUROPSYC, V25, P407, DOI 10.1076/jcen.25.3.407.13812; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; TUOKKO H, 1991, Brain Injury, V5, P287, DOI 10.3109/02699059109008098; VANEM P, 2007, SCAND J PSYCHOL, V49, P83; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WATSON DC, 1995, PERS INDIV DIFFER, V19, P817, DOI 10.1016/S0191-8869(95)00130-1; WIERZBICKI M, 1993, J CLIN PSYCHOL, V49, P204, DOI 10.1002/1097-4679(199303)49:2<204::AID-JCLP2270490211>3.0.CO;2-W; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 INT STAT CLAS	74	36	36	0	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2010	24	2					168	175		10.1037/a0017431			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	567XV	WOS:000275483100005	20230111				2021-06-18	
J	McLeod, TCV; Gioia, GA				McLeod, Tamara C. Valovich; Gioia, Gerard A.			Cognitive Rest: The Often Neglected Aspect of Concussion Management	ATHLETIC THERAPY TODAY			English	Article							METAANALYSIS		[McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ USA; [McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Dept Interdisciplinary Hlth Sci, Interdisciplinary Res Lab, Mesa, AZ USA; [Gioia, Gerard A.] Childrens Natl Med Ctr, Div Pediat Neuropsychol, Rockville, MD USA; [McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Dept Interdisciplinary Hlth Sci, CORE AT Practice Based Res Network, Mesa, AZ USA	McLeod, TCV (corresponding author), AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ USA.		McLeod, Tamara/AAU-9435-2020				Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; *CDCP, HEADS UP BRAIN INJ Y; Giza CC, 2001, J ATHL TRAINING, V36, P228; LOGAN K, 2009, ATHLETIC TRAINING SP, V1, P251; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214	8	36	36	0	5	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1078-7895			ATHLET THER TODAY	Athlet. Ther. Today	MAR	2010	15	2					1	3		10.1123/att.15.2.1			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	576CS	WOS:000276122200001					2021-06-18	
J	Di Pietro, V; Amin, D; Pernagallo, S; Lazzarino, G; Tavazzi, B; Vagnozzi, R; Pringle, A; Belli, A				Di Pietro, Valentina; Amin, Daven; Pernagallo, Salvatore; Lazzarino, Giuseppe; Tavazzi, Barbara; Vagnozzi, Roberto; Pringle, Ashley; Belli, Antonio			Transcriptomics of Traumatic Brain Injury: Gene Expression and Molecular Pathways of Different Grades of Insult in a Rat Organotypic Hippocampal Culture Model	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; gene expression; IL-1; diffuse axonal injury; transcriptomics	TEMPORAL WINDOW; HEAD-INJURY; VULNERABILITY; INFLAMMATION; MICRODIALYSIS; INTERLEUKIN-1; CONCUSSIONS; MANAGEMENT; INHIBITORS; SEIZURE	Traumatic brain injury (TBI) is the one of the most common forms of head trauma, and it remains a leading cause of death and disability. It is known that the initial mechanical axonal injury triggers a complex cascade of neuroinflammatory and metabolic events, the understanding of which is essential for clinical, translational, and pharmacological research. These can occur even in mild TBI, and are associated with several post-concussion manifestations, including transiently heightened vulnerability to a second insult. Recent studies have challenged the tenet that ischemia is the ultimate modality of tissue damage following TBI, as metabolic dysfunction can develop in the presence of normal perfusion and before intracranial hypertension. In order to elucidate the cellular and molecular changes occurring in TBI as a direct result of neuronal injury and in the absence of ischemic damage, we performed a microarray analysis of expressed genes and molecular interaction pathways for different levels of severity of trauma using an in-vitro model. A stretch injury, equivalent to human diffuse axonal injury, was delivered to rat organotypic hippocampal slice cultures, and mRNA levels following a 10% (mild) and 50% (severe) stretch were compared with controls at 24 h. More genes were differentially expressed following 10% stretch than 50% stretch, indicating the early activation of complex cellular mechanisms. The data revealed remarkable differential gene expression following mTBI, even in the absence of cell damage. Pathway analysis revealed that molecular interactions in both levels of injury were similar, with IL-1 beta playing a central role. Additional pathways of neurodegeneration involving RhoA (ras homolog gene family, member A) were found in 50% stretch.	[Di Pietro, Valentina; Amin, Daven; Pringle, Ashley; Belli, Antonio] Univ Southampton, Sch Med, Div Clin Neurosci, Southampton SO16 6YD, Hants, England; [Pernagallo, Salvatore] Univ Edinburgh, Sch Chem, Edinburgh, Midlothian, Scotland; [Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Catania, Italy; [Tavazzi, Barbara] Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy	Belli, A (corresponding author), Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, S Acad Block MP806, Southampton SO16 6YD, Hants, England.	a.belli@soton.ac.uk	TAVAZZI, BARBARA/AAB-9830-2019; Pernagallo, Salvatore/B-4739-2009; Belli, Antonio/I-3799-2015; Pernagallo, Salvatore/K-3003-2017; Pernagallo, Salvatore/P-3224-2019; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; Pernagallo, Salvatore/0000-0002-0259-9008; Pernagallo, Salvatore/0000-0002-0259-9008; lazzarino, giuseppe/0000-0002-5917-7279; Pringle, Ashley/0000-0003-2421-4380	Italian Ministry of University and Scientific ResearchMinistry of Education, Universities and Research (MIUR) [2007JBHZ5F-COFIN]	We wish to thank the Wessex Neurological Centre Trust for funding this study and for their continuing support for our research. We also wish to thank the Italian Ministry of University and Scientific Research for funding Dr. Tavazzi's work (research grant PRIN 2007JBHZ5F-COFIN 2007). We are also grateful to Prof. Mark Bradley of the School of Chemistry, University of Edinburgh, for his support.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Berry M, 1982, Bibl Anat, P1; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Domeniconi M, 2005, J NEUROL SCI, V233, P43, DOI 10.1016/j.jns.2005.03.023; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; FAN L, 1995, MOL BRAIN RES, V30, P125; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Jay G W, 1996, J Insur Med, V27, P262; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kerrien S, 2007, NUCLEIC ACIDS RES, V35, pD561, DOI 10.1093/nar/gkl958; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Roopra A, 2001, Mol Interv, V1, P219; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Saavedra A, 2007, NEUROBIOL DIS, V25, P92, DOI 10.1016/j.nbd.2006.08.019; SAUGSTAD JA, 2007, SOC NEUR ABSTR, V116, P111; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; TEASDALE G, 1974, LANCET, V2, P81; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	37	36	36	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					349	359		10.1089/neu.2009.1095			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800008	19903084				2021-06-18	
J	de Guise, E; Lepage, JF; Tinawi, S; LeBlanc, J; Dagher, J; Lamoureux, J; Feyz, M				de Guise, Elaine; Lepage, Jean-Francois; Tinawi, Simon; LeBlanc, Joanne; Dagher, Jehane; Lamoureux, Julie; Feyz, Mitra			Comprehensive Clinical Picture of Patients with Complicated vs Uncomplicated Mild Traumatic Brain Injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Neuropsychology; Neurology; Rivermead Post-Concussive Questionnaire; Early rehabilitation setting; Imaging	SEVERE HEAD-INJURY; RECOVERY; DEPRESSION; CONCUSSION; DISABILITY; VARIABLES; SEVERITY	To compare the acute clinical profile of patients with uncomplicated vs complicated mild TBI (MTBI), socio-demographic and medical history variables were gathered for 176 patients diagnosed with MTBI and with (complicated, N = 45) or without (uncomplicated, N = 131) positive findings on cerebral imaging. Neurological examination, neuropsychological assessment and self-evaluation of post-concussive symptoms were done at 2 weeks post trauma. Patients with complicated MTBI were more likely to show auditory and vestibular system dysfunction. Surprisingly, the uncomplicated group reported more severe post-concussive symptoms than patients with positive CT scans. The groups showed no other difference in neurological, psychological, or cognitive outcome. A complete neurological examination should be done acutely in patients with MTBI to determine more specific follow-up required.	[de Guise, Elaine; LeBlanc, Joanne; Feyz, Mitra] McGill Univ, Traumat Brain Injury Program, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; [de Guise, Elaine] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada; [Lepage, Jean-Francois] Univ Montreal, Montreal, PQ, Canada; [Tinawi, Simon; Dagher, Jehane] McGill Univ, Dept Rehabil Med, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; [Lamoureux, Julie] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada	de Guise, E (corresponding author), McGill Univ, Traumat Brain Injury Program, Ctr Hlth, Montreal Gen Hosp Site,Room D13-124 1650 Cedar Av, Montreal, PQ H3G 1A4, Canada.	elaine.deguise@muhc.mcgill.ca		Lamoureux, Julie/0000-0002-4986-2504			ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; BECK AT, 1962, AM J PSYCHIAT, V119, P351, DOI 10.1176/ajp.119.4.351; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Corrigan J., 2005, PROBLEMATIC SUBSTANC; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; DUCKWORTH JL, 2010, CURRENT OPINION CRIT, V10, P1097; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Hawkins ML, 2003, AM SURGEON, V69, P497; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hooper, 1983, HOOPER VISUAL ORG TE; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KING N, 1995, J NEUROL, V242, P1432; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; LORNE S, 2003, CANADIAN ASS MED J, V30, P169; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCCREA MA, 2008, MILD TRAUMATIC BRAIN, P13; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Spreen O., 1991, COMPENDIUM NEUROPSYC; THIJS C, 1989, BRIT MED J, V298, P255, DOI 10.1136/bmj.298.6668.255; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Wechsler D., 1997, WAIS 3 MANUAL; Wechsler D., 1997, WMS 3 MANUAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	44	36	36	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	7					1113	1130	PII 925983925	10.1080/13854046.2010.506199			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	659UM	WOS:000282592400002	20730678				2021-06-18	
S	French, LM		Barchas, JD; Difede, J		French, Louis M.			Military traumatic brain injury: an examination of important differences	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	military TBI; mild TBI; blast injury; war trauma	POSTTRAUMATIC-STRESS-DISORDER; SERVICE MEMBERS; MENTAL-HEALTH; IRAQI FREEDOM; COMBAT DUTY; BLAST; US; REHABILITATION; POLYTRAUMA; AFGHANISTAN	Traumatic brain injury, especially mild traumatic brain injury, is a common consequence of modern warfare. In the current conflicts in Iraq and Afghanistan, much attention has been devoted to blast as a "new" mechanism of brain injury. While the evidence for primary blast effects upon the central nervous system is limited and controversial, there are a number of aspects of blast-induced brain injury that may be different. These include high rates of sensory impairment, pain issues, and polytrauma. In addition, the emotional context in which the injury occurred must also be considered in understanding the clinical presentation of these patients. Successful treatment of these individuals must use a multidisciplinary approach focused on the varied conditions that occur in those injured.	[French, Louis M.] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA; [French, Louis M.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [French, Louis M.] Natl Naval Med Ctr, Washington, DC USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	French, LM (corresponding author), Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, MATC Bldg 2A,Room 203,6900 Georgia Ave NW, Washington, DC 20307 USA.	louis.french@us.army.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368; CAREY ME, 1982, ACTA CHIR SCAND, P351; CARROLL LJ, 2004, J REHABIL MED, V84, pS84; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; FRENCH LM, 2008, J SPEC OPER MED, V8, P77; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Helfer TM, 2010, AM J PREV MED, V38, pS71, DOI 10.1016/j.amepre.2009.10.025; Hilber D, 2010, AM J PREV MED, V38, pS78, DOI 10.1016/j.amepre.2009.10.015; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Lanska DJ, 2009, ANN NEUROL, V66, P444, DOI 10.1002/ana.21822; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lieberman HR, 2005, AVIAT SPACE ENVIR MD, V76, pC7; Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014; Luria Alexandr Romanovich, 2004, MAN SHATTERED WORLD; Luria AR., 1976, WORKING BRAIN INTRO; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Martin E.M, 2008, J TRAUMA NURS, V15, P100; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; McDonald I, 2007, BRAIN, V130, P288, DOI 10.1093/brain/awl335; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Messinger SD, 2009, DISABIL REHABIL, V31, P2130, DOI [10.3109/09638280902943223a, 10.3109/09638280902943223]; Mott FW, 1916, LANCET, V1, P545; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Packard RC, 2008, CURR PAIN HEADACHE R, V12, P67, DOI 10.1007/s11916-008-0013-6; Pasquina PF, 2008, J REHABIL RES DEV, V45, P953, DOI 10.1682/JRRD.2007.10.0163; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Polusny MA, 2009, MIL MED, V174, P353, DOI 10.7205/MILMED-D-01-1608; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; SEMMES J, 1954, AM J PSYCHOL, V67, P220, DOI 10.2307/1418625; Shafi S, 2005, J TRAUMA, V59, P830, DOI 10.1097/01.ta.0000188147.36232.c0; Stansbury LG, 2008, J ORTHOP TRAUMA, V22, P43, DOI 10.1097/BOT.0b013e31815b35aa; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; WARDEN DL, 2005, TXB TRAUMATIC BRAIN, P231; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	70	36	36	0	8	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						38	45		10.1111/j.1749-6632.2010.05696.x			8	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000006	20955324				2021-06-18	
J	Graham, JE; Radice-Neumann, DM; Reistetter, TA; Hammond, FM; Dijkers, M; Granger, CV				Graham, James E.; Radice-Neumann, Dawn M.; Reistetter, Timothy A.; Hammond, Flora M.; Dijkers, Marcel; Granger, Carl V.			Influence of Sex and Age on Inpatient Rehabilitation Outcomes Among Older Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Aged; Brain injuries; Rehabilitation	ETHNIC-DIFFERENCES; IMPACT; EPIDEMIOLOGY; GENDER; SYSTEM	Graham JE, Radice-Neumann DM, Reistetter TA, Hammond FM, Dijkers M, Granger CV. Influence of sex and age on inpatient rehabilitation outcomes among older adults with traumatic brain injury. Arch Phys Med Rehabil 2010;91:43-50. Objective: To assess the influence of sex and age on inpatient rehabilitation outcomes in a large national sample of older adults with traumatic brain injury (TBI). Design: Prospective case series. Setting: Eight hundred forty-eight inpatient rehabilitation facilities that subscribe to the Uniform Data System for Medical Rehabilitation. Participants: Patients (n=18,413) age 65 years and older admitted for inpatient rehabilitation after TBI from 2005 through 2007. Interventions: None. Main Outcome Measures: Rehabilitation length of stay, discharge FIM motor and cognitive ratings, discharge setting, and scheduled home health services at discharge. Results: Mean age +/- SD of the sample was 79 7 years, and 47% were women. In multivariable models, higher age was associated with shorter lengths of stay (P<.001), lower discharge FIM motor and cognitive ratings (P<.001), and greater odds of home health services at discharge (P<.001). Women demonstrated shorter lengths of stay (P=.006) and greater odds of being scheduled for home health services at discharge (P<.001) than men. The sex-by-age interaction term was not significant in any outcome model. Sex differences and trends were consistent across the entire age range of the sample. Conclusions: Sex and age patterns in rehabilitation outcomes among older adults with TBI varied by outcome. The current findings related to rehabilitation length of stay may be helpful for facility-level resource planning. Additional studies are warranted to identify the factors associated with returning to home and to assess the long-term benefits of combined inpatient rehabilitation and home health services for older adults with TBI.	[Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Radice-Neumann, Dawn M.; Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Reistetter, Timothy A.] E Carolina Univ, Dept Occupat Therapy, Greenville, NC USA; [Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Granger, Carl V.] SUNY Buffalo, Dept Rehabil Med, Buffalo, NY 14260 USA	Graham, JE (corresponding author), Univ Texas Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	jegraham@utmb.edu	Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research [H133G080163]; National Institutes of Health, National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute for Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12-H0055929]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055929] Funding Source: NIH RePORTER	Supported in part by the National Institute on Disability and Rehabilitation Research (grant no. H133G080163) and the National Institutes of Health, National Institute for Child Health and Human Development and National Institute for Neurological Disorders and Stroke (grant no. K12-H0055929).	Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; Kraemer HC, 2004, INT J METH PSYCH RES, V13, P141, DOI 10.1002/mpr.170; KRAUS IF, 2000, NEUROSURG FOCUS, V8, pE5; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lum TY, 2005, J GERONTOL SOC WORK, V45, P3, DOI 10.1300/J083v45n04_02; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Scharlach AE, 2006, J GERONTOL SOC WORK, V47, P133, DOI 10.1300/J083v47n01_09; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tieves Kelly S, 2005, WMJ, V104, P22; *UB FDN ACT, 2004, IRF PAI TRAIN MAN; *UDSMR, 2009, UN DAT SYST MED REH; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	34	36	36	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2010	91	1					43	50		10.1016/j.apmr.2009.09.017			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	592YG	WOS:000277417300007	20103395	Green Accepted			2021-06-18	
J	Gwin, JT; Chu, JJ; Diamond, SG; Halstead, PD; Crisco, JJ; Greenwald, RM				Gwin, Joseph T.; Chu, Jeffery J.; Diamond, Solomon G.; Halstead, P. David; Crisco, Joseph J.; Greenwald, Richard M.			An Investigation of the NOCSAE Linear Impactor Test Method Based on In Vivo Measures of Head Impact Acceleration in American Football	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; CONCUSSION; COLLEGIATE; PLAYERS; EPIDEMIOLOGY	The performance characteristics of football helmets are currently evaluated by simulating head impacts in the laboratory using a linear drop test method. To encourage development of helmets designed to protect against concussion, the National Operating Committee for Standards in Athletic Equipment recently proposed a new headgear testing methodology with the goal of more closely simulating in vivo head impacts. This proposed test methodology involves an impactor striking a helmeted headform, which is attached to a nonrigid neck. The purpose of the present study was to compare headform accelerations recorded according to the current (n = 30) and proposed (n = 54) laboratory test methodologies to head accelerations recorded in the field during play. In-helmet systems of six single-axis accelerometers were worn by the Dartmouth College men's football team during the 2005 and 2006 reasons (n = 20,733 impacts; 40 players). The impulse response characteristics of a subset of laboratory test impacts (n = 27) were compared with the impulse response characteristics of a matched sample of in vivo head accelerations (n = 24). Second- and third-order underdamped, conventional, continuous-time process models were developed for each impact. These models were used to characterize the linear head/headform accelerations for each impact based ore frequency domain parameters. Headform linear accelerations generated according to the proposed test method were less similar to in vivo head accelerations than headform accelerations generated by the current linear drop test method. The nonrigid neck currently utilized was not developed to simulate sport-related direct head impacts and appears to be a source of the discrepancy between frequency characteristics of in vivo and laboratory head/headform accelerations. In vivo impacts occurred 37% snore frequently on helmet regions, which are tested in the proposed standard than on helmet regions tested currently. This increase was largely due to the addition of the facemask test location. For the proposed standard, impactor velocities as high as 10.5 m/s were needed to simulate the highest energy impacts recorded in vivo. The knowledge gained from. this study may provide the basis for improving sports headgear test apparatuses with regard to mimicking in vivo linear head accelerations. Specifically, increasing the,stiffness of the neck is recommended. In addition, this study may provide a basis for selecting appropriate test impact energies for the standard performance specification to accompany the proposed standard linear impactor test method. [DOI: 10.1115/1.4000249]	[Gwin, Joseph T.; Chu, Jeffery J.; Greenwald, Richard M.] Simbex, Lebanon, NH 03766 USA; [Gwin, Joseph T.; Diamond, Solomon G.; Greenwald, Richard M.] Dartmouth, Thayer Sch Engn, Hanover, NH 03755 USA; [Gwin, Joseph T.] Univ Michigan, Div Kinesiol, Ann Arbor, MI 48109 USA; [Halstead, P. David] Univ Tennessee, Sports Biomech Impact Res Lab, Rockford, TN 37853 USA; [Crisco, Joseph J.] Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI 02903 USA	Gwin, JT (corresponding author), Simbex, Lebanon, NH 03766 USA.	jgwin@umich.edu		Diamond, Solomon/0000-0002-7589-2942	National Operating Committee for Standards in Athletic Equipment (NOCSAE); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048638]; NIH Small Business Innovation Research (SBIR) award [R44HD40473]; Riddell, Inc. (Chicago, IL); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	This work was funded in part by the National Operating Committee for Standards in Athletic Equipment (NOCSAE) and the National Institutes of Health (NIH) (Grant No. R01 HD048638). The HIT System was developed by Simbex (Lebanon, NH) through a NIH Small Business Innovation Research (SBIR) award (Grant No. R44HD40473). In addition, this work was supported by research and development funding from Riddell, Inc. (Chicago, IL). Analog Devices (Cambridge, MA) provided sensors and expertise in sensor integration. We appreciate and acknowledge our colleagues Tom McAllister, MD and Tina Duhaime, MD from Dartmouth Hitchcock Medical Center, Lebanon NH, Mel Cook, Southern Impact Research Center, Rockford TN, for performing laboratory helmet testing, Jeff Frechette and Scott Roy, Dartmouth College Sports Medicine, for invaluable insight and daily monitoring of the in vivo data acquisition system, and the engineering team at Simbex, including Jonathan Beckwith, Siena Calabro, Lindley Brainard, and Dan Leonard, for manufacturing and supporting the instrumented helmets. Additionally, we would like to thank the players, athletic training staff, equipment staff, and coaches from the Dartmouth College football team for their ongoing support and cooperation.	BRAZARIAN JJ, 2005, BRAIN INJURY, V19, P85; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P1; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; CRISCO JJ, 2004, ASME, V126, P849; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Foster J.K., 1977, P 21 STAPP CAR CRASH; Gadd CW, 1966, P 10 STAPP CAR CRASH; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gwin JT, 2009, AM SOC TEST MATER, V1516, P244, DOI 10.1520/JAI101848; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hodgson VR, 1970, P 14 STAPP CAR CRASH; HODGSON VR, 1982, ATHLETIC INJURIES HE, P27; King AI, 2003, INT RES COUNC BIOM I; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; *NOCSAE, 2006, 08104M04 NOCSAE; *NOCSAE, 2005, 00298M05 NOCSAE; *NOCSAE, 2007, 00106M07 NOCSAE; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosner B., 1990, FUNDAMENTALS BIOSTAT; ROWSON S, 2009, ASME, V131; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; ZERBE GO, 1982, AM J PHYSIOL, V242, pR178	38	36	36	0	13	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JAN	2010	132	1							011006	10.1115/1.4000249			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	550CW	WOS:000274106900006	20524744				2021-06-18	
J	Hajek, CA; Yeates, KO; Taylor, HG; Bangert, B; Dietrich, A; Nuss, KE; Rusin, J; Wright, M				Hajek, Christine A.; Yeates, Keith Owen; Taylor, H. Gerry; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Rusin, Jerome; Wright, Martha			Relationships among post-concussive symptoms and symptoms of PTSD in children following mild traumatic brain injury	BRAIN INJURY			English	Article						Pediatric; closed head injury; outcome	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; CONSEQUENCES; ADOLESCENTS; AMNESIA	Primary objective: To investigate the occurrence of post-concussive symptoms (PCS) and symptoms of post-traumatic stress disorder (PTSD) in children following mild traumatic brain injuries (TBI). Research design: Longitudinal study comparing the outcomes of mild TBI and orthopaedic injuries (OI) in children aged 8-15. Methods and procedures: One hundred and eighty-six children with mild TBI and 99 with OI were recruited prospectively. Parents rated children's PCS and symptoms of PTSD at 2 weeks, 3 months and 12 months post-injury. One hundred and sixty-seven with mild TBI and 84 with OI completed all assessments. Main outcomes and results: Controlling for symptoms of PTSD, the mild TBI group demonstrated more PCS than the OI group, although the magnitude of group differences diminished with time. Controlling for PCS, the OI group displayed more symptoms of PTSD than the mild TBI group at baseline, but not thereafter. Symptoms of PTSD and PCS were correlated significantly, but more highly in the OI group than the mild TBI group. Conclusions: Although PCS and symptoms of PTSD are correlated, children with mild TBI are more distinguishable from children with OI based on PCS than on symptoms of PTSD. The latter symptoms, moreover, do not account for increased PCS following mild TBI in children.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Hajek, Christine A.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Hajek, Christine A.; Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn E.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Columbus, OH USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; National Center for Medical Rehabilitation Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	The research reported here served as the basis for a thesis submitted by the first author to The Ohio State University in partial fulfilment of the requirements for a master's degree. Portions of the research were presented at the annual meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 2008 and the annual meeting of the Society for Developmental and Behavioral Pediatrics, Cincinnati, Ohio, October 2008. The larger study on which the research was based was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development and the National Center for Medical Rehabilitation Research to Keith Owen Yeates. The authors wish to acknowledge the contributions of Lauren Ayr, Anne Birnbaum, Amy Clemens, Taryn Fay, Kalaichelvi Ganesalingham, Amanda Lininger, Melissa Ginn, Katie Pestro, Elizabeth Roth, Elizabeth Shaver and Heidi Walker in conducting the study.	Aaron J, 1999, J PEDIATR PSYCHOL, V24, P335, DOI 10.1093/jpepsy/24.4.335; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; *AM MED ASS, 1997, INT CLASS DIS; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Davis L, 2000, Clin Child Fam Psychol Rev, V3, P135, DOI 10.1023/A:1009564724720; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Foa EB, 2001, J CLIN CHILD PSYCHOL, V30, P376, DOI 10.1207/S15374424JCCP3003_9; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Keppel-Benson JM, 2002, J CHILD PSYCHOL PSYC, V43, P203, DOI 10.1111/1469-7610.00013; KIRKWOOD MW, 2007, CLIN NEUROPSYCHOL, V24, P1; Landolt MA, 2003, J CHILD PSYCHOL PSYC, V44, P1199, DOI 10.1111/1469-7610.00201; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McNally RJ, 1996, J SCHOOL PSYCHOL, V34, P147, DOI 10.1016/0022-4405(96)00004-0; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Strand VC, 2005, TRAUMA VIOLENCE ABUS, V6, P55, DOI 10.1177/1524838004272559; TAYLOR HG, NEUROPSYCHO IN PRESS; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	39	36	36	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	2					100	109		10.3109/02699050903508226			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500005	20085447	Green Accepted			2021-06-18	
J	Lescot, T; Fulla-Oller, L; Po, C; Chen, XR; Puybasset, L; Gillet, B; Plotkine, M; Meric, P; Marchand-Leroux, C				Lescot, Thomas; Fulla-Oller, Lawrence; Po, Chrystelle; Chen, Xiao Ru; Puybasset, Louis; Gillet, Brigitte; Plotkine, Michel; Meric, Philippe; Marchand-Leroux, Catherine			Temporal and Regional Changes after Focal Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; nuclear magnetic resonance; nuclear magnetic resonance spectroscopy; traumatic brain injury		Magnetic resonance imaging (MRI) is widely used to evaluate the consequences of traumatic brain injury (TBI) in both experimental and clinical studies. Improved assessment of experimental TBI using the same methods as those used in clinical investigations would help to translate laboratory research into clinical advances. Here our goal was to characterize lateral fluid percussion-induced TBI, with special emphasis on differentiating the contused cortex from the pericontusional subcortical tissue. We used both in vivo MRI and proton magnetic resonance spectroscopy (H-1-MRS) to evaluate adult male Sprague-Dawley rats 24 h and 48 h and 7 days after TBI. T2 and apparent diffusion coefficient (ADC) maps were derived from T2-weighted and diffusion-weighted images, respectively. Ratios of N-acetylaspartate (NAA), choline compounds (Cho), and lactate (Lac) over creatine (Cr) were estimated by H-1-MRS. T2 values were high in the contused cortex 24 h after TBI, suggesting edema development; ADC was low, consistent with cytotoxic edema. At the same site, NAA/Cr was decreased and Lac/Cr elevated during the first week after TBI. In the ipsilateral subcortical area, NAA/Cr was markedly decreased and Lac/Cr was elevated during the first week, although MRI showed no evidence of edema, suggesting that H-1-MRS detected "invisible" damage. H-1-MRS combined with MRI may improve the detection of brain injury. Extensive assessments of animal models may increase the chances of developing successful neuroprotective strategies.	[Lescot, Thomas; Chen, Xiao Ru; Plotkine, Michel; Marchand-Leroux, Catherine] Univ Paris 05, Fac Sci Pharmaceut & Biol, EA 2510, Equipe Rech Pharmacol Circulat Cerebrale, F-75006 Paris, France; [Fulla-Oller, Lawrence; Puybasset, Louis] Grp Hosp Pitie Salpetriere, AP HP, Reanimat Neurochirurg Dept Anesthesie Reanimat, F-75634 Paris, France; [Fulla-Oller, Lawrence; Puybasset, Louis] Univ Paris 06, Paris, France; [Fulla-Oller, Lawrence; Po, Chrystelle; Gillet, Brigitte; Meric, Philippe] CNRS, Inst Chim Subst Nat, Lab Resonance Magnet Nucl Biol, Gif Sur Yvette, France	Lescot, T (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, EA 2510, Equipe Rech Pharmacol Circulat Cerebrale, 4 Ave Observ, F-75006 Paris, France.	thomas.lescot@psl.aphp.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Po, Chrystelle/0000-0001-9785-9572	Fondation des Gueules Cassees	The authors are very grateful to Dr. Antoinette Wolfe for helping to prepare the manuscript, and to Dr. Yannick Le Manach for expert statistical assistance. This work was supported by the nonprofit organization Fondation des Gueules Cassees (grants to T. L. and L.F.O.).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alessandri B, 2000, NEUROL RES, V22, P705; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BEDERSON JB, 1986, J NEUROSURG, V64, P795, DOI 10.3171/jns.1986.64.5.0795; BERRY I, 1986, ACTA RADIOL S, P338; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; GUIMARAES AR, 1995, NEUROSCIENCE, V69, P1095, DOI 10.1016/0306-4522(95)00300-8; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Le Bihan D, 2006, J MAGN RESON IMAGING, V24, P478, DOI 10.1002/jmri.20683; LEBIHAN D, 1988, MAGNET RESON MED, V7, P346, DOI 10.1002/mrm.1910070312; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1990, ACTA NEUROCHIR S, P263; Naressi A, 2001, COMPUT BIOL MED, V31, P269, DOI 10.1016/S0010-4825(01)00006-3; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Rudkin TM, 1999, ARCH NEUROL-CHICAGO, V56, P919, DOI 10.1001/archneur.56.8.919; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; VIAN MR, 2005, NMR BIOMED, V8, P507; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	38	36	42	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					85	94		10.1089/neu.2009.0982			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200007	19705964				2021-06-18	
J	Yu, Z; Morrison, B				Yu, Zhe; Morrison, Barclay, III			Experimental Mild Traumatic Brain Injury Induces Functional Alteration of the Developing Hippocampus	JOURNAL OF NEUROPHYSIOLOGY			English	Article							PAIRED-PULSE FACILITATION; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; IN-VITRO; SLICE CULTURES; ORGANOTYPIC CULTURES; CA1 AREA; POSTNATAL ONTOGENESIS; SYNAPTIC-TRANSMISSION	Yu Z, Morrison B. Experimental mild traumatic brain injury induces functional alteration of the developing hippocampus. J Neurophysiol 103: 499-510, 2010. First published November 18, 2009; doi: 10.1152/jn.00775.2009. It is estimated that similar to 1.5 million Americans suffer a traumatic brain injury (TBI) every year, of which similar to 80% are considered mild injuries. Because symptoms caused by mild TBI last less than half an hour by definition and apparently resolve without treatment, the study of mild TBI is often neglected resulting in a significant knowledge gap for this wide-spread problem. In this work, we studied functional (electrophysiological) alterations of the neonatal/juvenile hippocampus after experimental mild TBI. Our previous work reported significant cell death after in vitro injury >10% biaxial deformation. Here we report that biaxial deformation as low as 5% affected neuronal function during the first week after in vitro mild injury of hippocampal slice cultures. These results suggest that even very mild mechanical events may lead to a quantifiable neuronal network dysfunction. Furthermore, our results highlight that safe limits of mechanical deformation or tolerance criteria may be specific to a particular outcome measure and that neuronal function is a more sensitive measure of injury than cell death. In addition, the age of the tissue at injury was found to be an important factor affecting posttraumatic deficits in electrophysiological function, indicating a relationship between developmental status and vulnerability to mild injury. Our findings suggest that mild pediatric TBI could result in functional deficits that are more serious than currently appreciated.	[Yu, Zhe; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 1210 Amsterdam Ave,351 Engn Terrace, New York, NY 10027 USA.	bm2119@columbia.edu	Yu, Zhe/K-6180-2013; Morrison, Barclay/B-7132-2008	Yu, Zhe/0000-0002-1401-2294; Morrison, Barclay/0000-0001-7676-0864	Southern Consortium for Injury Biomechanics; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 052794]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS052794] Funding Source: NIH RePORTER	This work was supported by the Southern Consortium for Injury Biomechanics and National Institute of Neurological Disorders and Stroke Grant R21 052794.	Abr`amoff M.D., 2005, BIOPHOTONICS INT, V11, P36, DOI [10.1117/1.3589100, DOI 10.1117/1.3589100]; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Amaral D G, 1993, Curr Opin Neurobiol, V3, P225, DOI 10.1016/0959-4388(93)90214-J; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Bishop Naomi B, 2006, Curr Probl Pediatr Adolesc Health Care, V36, P318, DOI 10.1016/j.cppeds.2006.05.004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BUCHS PA, 1993, DEV BRAIN RES, V71, P81, DOI 10.1016/0165-3806(93)90108-M; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Buzsaki G, 2004, NAT NEUROSCI, V7, P446, DOI 10.1038/nn1233; Cao R, 2006, NEUROSCI LETT, V401, P136, DOI 10.1016/j.neulet.2006.03.005; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Collin C, 1997, J NEUROPHYSIOL, V77, P1614; Cronin AF, 2001, AM J OCCUP THER, V55, P377, DOI 10.5014/ajot.55.4.377; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; EVANS RW, 1992, NEUROL CLIN, V10, P815; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fiala JC, 2003, J COMP NEUROL, V465, P90, DOI 10.1002/cne.10825; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GAHWILER BH, 1984, NEUROSCIENCE, V11, P751, DOI 10.1016/0306-4522(84)90192-1; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graudejus O, 2009, J ELECTROCHEM SOC, V156, pP85, DOI 10.1149/1.3115465; Huang FS, 2007, EUR J NEUROSCI, V25, P3253, DOI 10.1111/j.1460-9568.2007.05539.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; KIERNAN JA, 1971, EXP NEUROL, V32, P111, DOI 10.1016/0014-4886(71)90169-5; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mori-Kawakami F, 2003, J PHYSIOL-LONDON, V553, P37, DOI 10.1113/jphysiol.2003.045948; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; MULLER D, 1993, DEV BRAIN RES, V71, P93, DOI 10.1016/0165-3806(93)90109-N; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; *NAT CTR INJ PREV, 2005, TRAUM BRAIN INJ US A; Pena F, 2002, NEUROPHARMACOLOGY, V42, P807, DOI 10.1016/S0028-3908(02)00024-2; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; POKORNY J, 1981, BRAIN RES BULL, V7, P121, DOI 10.1016/0361-9230(81)90076-9; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; RAPHAELY RC, 1980, PEDIATR CLIN N AM, V27, P715; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Sanchez JC, 2006, EXP NEUROL, V198, P31, DOI 10.1016/j.expneurol.2005.10.031; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; SHARONOVA I N, 1982, Byulleten' Eksperimental'noi Biologii i Meditsiny, V93, P14; Shimono K, 2002, J NEUROSCI METH, V120, P193, DOI 10.1016/S0165-0270(02)00202-9; Sirvio J, 1996, NEUROSCIENCE, V74, P1025, DOI 10.1016/S0306-4522(96)00170-4; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Thomson AM, 2000, TRENDS NEUROSCI, V23, P305, DOI 10.1016/S0166-2236(00)01580-0; Villablanca JR, 1998, DEV BRAIN RES, V105, P309, DOI 10.1016/S0165-3806(97)00187-9; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wirth C, 2004, J NEUROPHYSIOL, V91, P1635, DOI 10.1152/jn.00950.2003; WU LG, 1994, J NEUROSCI, V14, P645; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Yu Z, 2007, NANO LETT, V7, P2188, DOI 10.1021/nl070291a; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810	86	36	37	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	JAN	2010	103	1					499	510		10.1152/jn.00775.2009			12	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	542VD	WOS:000273526000047	19923245	Green Published			2021-06-18	
J	Allon, N; Amir, A; Manisterski, E; Rabinovitz, I; Dachir, S; Kadar, T				Allon, Nahum; Amir, Adina; Manisterski, Eliau; Rabinovitz, Ishay; Dachir, Shlomit; Kadar, Tamar			Inhalation exposure to sulfur mustard in the guinea pig model: Clinical, biochemical and histopathological characterization of respiratory injuries	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Sulfur mustard; Guinea pig; LCt(50); FTIR; Respiratory parameters; Clinical symptoms; Histopathological evaluation; BAL; Abnormal epithelial regeneration; Recurrent lung injury	IRANIAN VETERANS; ADDUCTS; ASTHMA; MICE; DNA; COMPLICATIONS; HEMOGLOBIN; DRUGS	Guinea pigs (GP) were exposed (head only) in individual plethysmographs to various concentrations of sulfur Mustard vapor, determined online, using FTIR attached to flow chamber. The LCt(50) and the inhaled LD50 were calculated at different time points post exposure. Surviving animals were monitored for clinical symptoms, respiratory parameters and body weight changes for up to 30 days. Clinical symptoms were noted at 3 h post exposure, characterized by erythematic and swelling nose with extensive mucous secretion (with or without bleeding). At 6 h post exposure most of the guinea pigs had breathing difficulties, rhonchi and dyspnea and few deaths were noted. These symptoms peaked at 48 h and were noted up to 8 days, associated with few additional deaths. Thereafter, a spontaneous healing was noted, characterized by recovery of respiratory parameters and normal weight gain with almost complete apparent healing within 2 weeks. Histopathological evaluation Of lungs and trachea in the surviving GPs at 4 weeks post exposure revealed a dose-dependent residual injury in both lung and trachea expressed by abnormal recovery of the tracheal epithelium concomitant with a close-dependent increase in cellular volume in the lungs. These abnormal epithelial regeneration and lung remodeling were accompanied with significant changes in protein, LDH, differential cell count and glutathione levels in the bronchoalveolar lavage (BAL). It is suggested that the abnormal epithelial growth and cellular infiltration into the lung as well as the continuous lung inflammation Could cause recurrent lung injury similar to that reported for HD exposed human casualties. (C) 2009 Elsevier Inc. All rights reserved.	[Allon, Nahum; Amir, Adina; Manisterski, Eliau; Rabinovitz, Ishay; Dachir, Shlomit; Kadar, Tamar] Israel Inst Biol Res, Dept Pharmacol, IL-74100 Ness Ziona, Israel	Allon, N (corresponding author), Israel Inst Biol Res, Dept Pharmacol, POB 19, IL-74100 Ness Ziona, Israel.	nahuma@iibr.gov.il					Allon N, 1998, TOXICOL SCI, V43, P121; ALLON N, 1993, P 1993 MED DEF BIOSC, P133; Amir A, 2000, J APPL TOXICOL, V21, pS109; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Balali M., 1984, ARCH BELG S, P254; Balali-Mood M, 2005, FUND CLIN PHARMACOL, V19, P713, DOI 10.1111/j.1472-8206.2005.00364.x; Balali-Mood M, 2006, BASIC CLIN PHARMACOL, V99, P273, DOI 10.1111/j.1742-7843.2006.pto_429.x; Beheshti J, 2006, PATHOL RES PRACT, V202, P739, DOI 10.1016/j.prp.2006.04.008; BITRON MD, 1978, AM IND HYG ASSOC J, V39, P129, DOI 10.1080/0002889778507726; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; CALVET JH, 1994, J APPL PHYSIOL, V76, P681; Canning BJ, 2008, PULM PHARMACOL THER, V21, P702, DOI 10.1016/j.pupt.2008.01.004; Casillas RP, 1997, TOXICOL METHOD, V7, P381; Castranova V, 2002, INT IMMUNOPHARMACOL, V2, P163, DOI 10.1016/S1567-5769(01)00169-2; Dachir S, 2002, HUM EXP TOXICOL, V21, P197, DOI 10.1191/0960327102ht229oa; Fidder A, 1996, CHEM RES TOXICOL, V9, P788, DOI 10.1021/tx9502150; FREITAG L, 1991, CHEST, V100, P1436, DOI 10.1378/chest.100.5.1436; Gao X, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-17; GECKEL PT, 1951, COLORIMETRIC METHOD; Guyton AC, 2005, TXB MED PHYSL; Hasenfuss G, 1998, CARDIOVASC RES, V39, P60, DOI 10.1016/S0008-6363(98)00110-2; HENDERSON RF, 1988, FUND APPL TOXICOL, V11, P546, DOI 10.1016/0272-0590(88)90119-4; Kumar O, 1998, J APPL TOXICOL, V18, P257, DOI 10.1002/(SICI)1099-1263(199807/08)18:4<257::AID-JAT501>3.0.CO;2-4; Langenberg JP, 1998, DRUG CHEM TOXICOL, V21, P131, DOI 10.3109/01480549809007407; Niu TQ, 1996, CHEM-BIOL INTERACT, V100, P77, DOI 10.1016/S0009-2797(96)03690-3; Noort D, 1997, ARCH TOXICOL, V71, P171, DOI 10.1007/s002040050372; PAPIRMEISTER B, 1991, TOXIC MECH PHARM IMP, P133; Rao PVL, 1999, TOXICOLOGY, V139, P39, DOI 10.1016/S0300-483X(99)00097-9; REES J, 1991, LANCET, V337, P430, DOI 10.1016/0140-6736(91)91208-C; Sohrabpour H, 1984, Arch Belg, VSuppl, P291; SOHRABPOUR H, 2004, MED J ISLAM REPUB IR, V1408, P32; SOMANI SM, 1989, INT J CLIN PHARM TH, V27, P419; van Helden HPM, 2004, INHAL TOXICOL, V16, P537, DOI 10.1080/08958370490442520; VIJAYARAGHAVAN R, 1997, ARCH TOXICOL, V69, P35; West KL, 2004, CARDIOVASC DRUG REV, V22, P55	36	36	36	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	DEC 1	2009	241	2					154	162		10.1016/j.taap.2009.08.006			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	518SD	WOS:000271712600004	19682477				2021-06-18	
J	Helling, TS; Kaswan, S; Miller, SL; Tretter, JF				Helling, Thomas S.; Kaswan, Sumesh; Miller, S. Lee; Tretter, James F.			Practice Patterns in the Use of Retrievable Inferior Vena Cava Filters in a Trauma Population: A Single-Center Experience	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Inferior vena cava filter; Anticoagulation; Trauma center	PULMONARY-EMBOLISM; VENOUS THROMBOEMBOLISM; DATA-BANK; PREVENTION; TERM	Background: The use of permanent inferior vena cava filters (IVCFs) offers protection against pulmonary embolism (PE) but increases the long-term risk of deep vein thrombosis (DVT) and does not affect long-term mortality. The use of retrievable IVCFs in trauma patients offers the dual advantage of protection against PE during the risk period and the option of filter removal thus avoiding complications of DVT. Despite the safety of removal, it is likely that many of these retrievable filters are not removed. Methods: This was a retrospective, single-center, observational cohort study at a rural level I trauma center. We sought to investigate the number of patients and the circumstances under which retrievable IVCFs were placed and removed. Results: During a 4-year period, 3,455 trauma patients were admitted and 125 patients had retrievable IVCFs placed (71 therapeutic and 54 prophylactic). The most common indications were traumatic brain and spinal cord injuries (66%). During in-hospital filter use, there were 36 new incidences (29%) of PE (1) and DVT (35). Nine patients died before removal. In 40 patients (32%), removal was attempted, and 32 (26%) retrievable IVCFs were successfully removed and in most patients (76%) within 180 days of insertion. Seventeen patients were transferred out of the area for extended care and lost to follow-Lip. In 55 patients, the filters were not removed. In 20 patients, the surgeon decided against removal. Thirty patients were transferred to extended care or rehabilitation within the community, but they did not return for removal. Thus, of 108/125 patients with follow-up, 76 patients (70%) did not have their IVCFs removed, and 50 patients did not have their IVCFs removed because of the choice of the surgeon, extended care, or rehabilitation. Conclusions: The use of retrievable IVCFs, when necessary, produced predictable protection against PE and DVT complications. Despite the opportunity for removal, most patients, in fact, did not have their filters removed, even when posthospital care could be tracked. The practices of the surgeon, the transfer to extended-care facilities, near or far, and the reluctance to remove long-standing IVCFs contributed to the high-retention rate.	[Helling, Thomas S.; Kaswan, Sumesh; Miller, S. Lee; Tretter, James F.] Conemaugh Mem Med Ctr, Dept Surg, Johnstown, PA USA	Helling, TS (corresponding author), Conemaugh Mem Med Ctr, Dept Surg, 1086 Franklin St, Johnstown, PA USA.	thelling@conemaugh.org					Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Berczi V, 2007, CARDIOVASC INTER RAD, V30, P820, DOI 10.1007/s00270-007-9153-z; Binkert CA, 2006, J VASC INTERV RADIOL, V17, P299, DOI 10.1097/01.RVI.0000195153.32491.37; COON WW, 1976, SURG GYNECOL OBSTET, V143, P385; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Fox MA, 2008, J VASC INTERV RADIOL, V19, P981, DOI 10.1016/j.jvir.2008.03.022; GREENFIELD LJ, 1988, SURGERY, V104, P706; Hoppe H, 2007, CHEST, V132, P31, DOI 10.1378/chest.06-2897; Johnson ON, 2009, J VASC SURG, V49, P410, DOI 10.1016/j.jvs.2008.09.004; Karmy-Jones R, 2007, J TRAUMA, V62, P17, DOI 10.1097/TA.0b013e31802dd72a; Knudson M Margaret, 2004, Curr Opin Crit Care, V10, P539, DOI 10.1097/01.ccx.0000144941.09650.9f; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Neuerburg JM, 2001, CARDIOVASC INTER RAD, V24, P418, DOI 10.1007/s00270-001-0066-y; Offner PJ, 2003, ARCH SURG-CHICAGO, V138, P591, DOI 10.1001/archsurg.138.6.591; Rogers FB, 2001, SURGERY, V130, P1, DOI 10.1067/msy.2001.114558; Shackford SR, 2007, J TRAUMA, V63, P764, DOI 10.1097/01.ta.0000240444.14664.5f; Stefanidis D, 2006, AM J SURG, V192, P789, DOI 10.1016/j.amjsurg.2006.08.046; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020	18	36	36	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2009	67	6					1293	1296		10.1097/TA.0b013e3181b0637a			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	531IL	WOS:000272658100034	20009680				2021-06-18	
J	Terpolilli, NA; Zweckberger, K; Trabold, R; Schilling, L; Schinzel, R; Tegtmeier, F; Plesnila, N				Terpolilli, Nicole A.; Zweckberger, Klaus; Trabold, Raimund; Schilling, Lothar; Schinzel, Reinhard; Tegtmeier, Frank; Plesnila, Nikolaus			The Novel Nitric Oxide Synthase Inhibitor 4-amino-tetrahydro-L-biopterine Prevents Brain Edema Formation and Intracranial Hypertension following Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; nitric oxide; nitric oxide synthase inhibitor; tetrahydrobiopterine (BH4); traumatic brain injury	CONTROLLED CORTICAL IMPACT; ENDOTHELIN RECEPTOR ANTAGONIST; CEREBRAL-BLOOD-FLOW; L-ARGININE; SELECTIVE-INHIBITION; HEAD-INJURY; CEREBROVASCULAR CHARACTERIZATION; SECONDARY EXPANSION; CEREBROSPINAL-FLUID; OXYGEN REDUCTION	Brain edema formation, resulting in increased intracranial pressure (ICP), is one of the most deleterious consequences of traumatic brain injury (TBI). Nitric oxide (NO) has previously been shown to be involved in the damage of the blood-brain barrier (BBB) and, thus, in the formation of post-traumatic brain edema; however, this knowledge never resulted in a clinically relevant therapeutic option because available NO synthase inhibitors have serious side effects in man. The aim of the current study was to investigate the therapeutic efficacy of VAS203, a novel tetrahydrobiopterine (BH3)-based NOS inhibitor, in experimental TBI. When added to isolated vessels rings obtained from rat basilar and middle cerebral arteries (n - 32-35) VAS203 showed the same vasoconstrictive effect as the classical NO synthase inhibitor L-(G)-nitro-arginine-methylester (L-NAME). VAS203 passed the BBB both in healthy and traumatized mouse brain (C57/BL6, n = 5 per group) and did not show any systemic side effects at therapeutic concentrations. When administered 30 min after experimental TBI (controlled cortical impact, 2.2 mg/kg/min i.v., n = 7 per group), VAS203 prevented any further increase in ICP or deterioration of cerebral blood flow. This effect was dose-dependent and long-lasting (i.e., 24 h after trauma, brain edema formation was still significantly reduced [-40%, p < 0.008; n = 7 per group] and functional improvements were present up to 7 days after TBI [p < 0.02 on post-trauma day 6; n = 8 per group]). Therefore, VAS203 may represent a promising candidate for the treatment of acute intracranial hypertension following TBI.	[Terpolilli, Nicole A.; Zweckberger, Klaus; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany; [Terpolilli, Nicole A.; Zweckberger, Klaus; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich Med Ctr Grosshadern, Inst Surg Res, Munich, Germany; [Schilling, Lothar] Heidelberg Univ, Klinikum Mannheim, Dept Neurosurg, Mannheim, Germany; [Schinzel, Reinhard; Tegtmeier, Frank] Vasopharm GmbH, Wurzburg, Germany	Plesnila, N (corresponding author), RCSI, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Terpolilli, Nicole/AAG-3598-2021; Plesnila, Nikolaus/T-7522-2019				Avontuur JAM, 1998, SHOCK, V9, P451, DOI 10.1097/00024382-199806000-00010; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Bahrami S, 2000, SHOCK, V13, P386, DOI 10.1097/00024382-200005000-00007; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Chang CP, 2004, J PHARMACOL SCI, V95, P56, DOI 10.1254/jphs.95.56; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Cosentino F, 1998, EUR HEART J, V19, pG3; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Forstermann U, 2006, BIOL CHEM, V387, P1521, DOI 10.1515/BC.2006.190; Frohlich LG, 1999, J MED CHEM, V42, P4108, DOI 10.1021/jm981129a; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Gibraeil HD, 2000, BRIT J PHARMACOL, V131, P1757, DOI 10.1038/sj.bjp.0703752; Guix FX, 2005, PROG NEUROBIOL, V76, P126, DOI 10.1016/j.pneurobio.2005.06.001; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Ridger VC, 1997, BRIT J PHARMACOL, V122, P1083, DOI 10.1038/sj.bjp.0701498; Rinecker M, 2003, ACTA NEUROCHIR, V145, P977, DOI 10.1007/s00701-003-0131-1; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schmidt K, 1999, EUR J BIOCHEM, V259, P25, DOI 10.1046/j.1432-1327.1999.00003.x; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vatter H, 2005, J NEUROSURG, V102, P1101, DOI 10.3171/jns.2005.102.6.1101; Vatter H, 2005, J NEUROSURG, V102, P1108, DOI 10.3171/jns.2005.102.6.1108; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Walker G, 1997, J BIOL CHEM, V272, P16679, DOI 10.1074/jbc.272.26.16679; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Werner ER, 2003, EXP BIOL MED, V228, P1291; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	63	36	37	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1963	1975		10.1089/neu.2008.0853			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600012	19514849				2021-06-18	
J	Rochat, L; Ammann, J; Mayer, E; Annoni, JM; Van der Linden, M				Rochat, Lucien; Ammann, Jussara; Mayer, Eugene; Annoni, Jean-Marie; Van der Linden, Martial			Executive disorders and perceived socio-emotional changes after traumatic brain injury	JOURNAL OF NEUROPSYCHOLOGY			English	Article							ECOLOGICAL VALIDITY; IMPAIRMENTS; DEFICITS; DAMAGE; DEPRESSION; ATTENTION; SEQUELAE; TESTS; BADS	Although socio-emotional changes are very frequently encountered after traumatic brain injury (TBI), the psychological mechanisms underlying these disorders are still poorly understood. This study aimed to explore the relationships between dysexecutive syndrome (assessed with the Behavioural Assessment of the Dysexecutive Syndrome [BADS]) and socio-emotional changes assessed by the Iowa scales of personality change (ISPC) in patients with TBI. The BADS was thus administered to 25 patients with TBI and to 25 healthy controls. Simultaneously, a close relative of each patient was given the ISPC in order to assess socio-emotional changes. Results indicated that patients displayed significantly lower executive performances than controls and experimented significant socio-emotional changes. The Modified Six Elements Test was the only subtask of the BADS to be significantly related to behavioural changes, and more specifically to externalizing disorders. It is concluded that executive functions, and especially multitasking, encompass processes whereby one can consciously control one's emotional reactions and behaviours.	[Rochat, Lucien; Van der Linden, Martial] Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, CH-1205 Geneva, Switzerland; [Ammann, Jussara; Mayer, Eugene; Annoni, Jean-Marie] Univ Hosp Geneva, Neuropsychol Unit, Geneva, Switzerland; [Van der Linden, Martial] Univ Liege, Cognit Psychopathol Unit, Liege, Belgium	Rochat, L (corresponding author), Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, 40 Blvd Pont Arve, CH-1205 Geneva, Switzerland.	Lucien.Rochat@unige.ch		Rochat, Lucien/0000-0002-9992-2720			Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; BARRASH J, 1997, 25 ANN M INT NEUR SO; BENI C, 2007, PROPRIETES PSY UNPUB; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Burgess P. W., 2005, MEASURING MIND SPEED, P217, DOI DOI 10.1093/ACPR0F:0S0/9780198566427.003.0009; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collette F, 2006, NEUROSCIENCE, V139, P209, DOI 10.1016/j.neuroscience.2005.05.035; Derryberry D, 2002, SELF IDENTITY, V1, P105, DOI 10.1080/152988602317319276; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; ELSASS L, 1989, P 14 ANN BRAIN IMP C; Finset A, 2000, BRAIN INJURY, V14, P887; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; GAINOTTI G, 1999, HDB CLIN EXPT NEUROP, P613; Gilbert SJ, 2005, EUR J NEUROSCI, V21, P1423, DOI 10.1111/j.1460-9568.2005.03981.x; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; icton TW, 2006, CEREB CORTEX, V12, P1; Johnstone B, 1995, Appl Neuropsychol, V2, P24, DOI 10.1207/s15324826an0201_4; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JUILLERAT AC, 1998, ADAPTATION FRA UNPUB; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Krueger RF, 1999, ARCH GEN PSYCHIAT, V56, P921, DOI 10.1001/archpsyc.56.10.921; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; MAZAUX JM, 2000, TRAITE NEUROPSYCHOLO, V2, P31; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014	53	36	37	0	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	SEP	2009	3		2				213	227		10.1348/174866408X397656			15	Psychology; Psychology, Experimental	Psychology	504GV	WOS:000270605100005	19338726				2021-06-18	
J	Gao, X; Chen, JH				Gao, Xiang; Chen, Jinhui			Conditional Knockout of Brain-Derived Neurotrophic Factor in the Hippocampus Increases Death of Adult-Born Immature Neurons following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain-derived neurotrophic factor; cell death; conditional knockout; postnatal-born neuron; traumatic brain injury	REDUCES INFARCT SIZE; SPINAL-CORD-INJURY; RAT HIPPOCAMPUS; CORTICAL IMPACT; NERVOUS-SYSTEM; DENTATE GYRUS; MELANOCORTIN SYSTEM; OXIDATIVE DAMAGE; MESSENGER-RNAS; POTENTIAL ROLE	It has been reported that the hippocampus is particularly vulnerable to traumatic brain injury (TBI), the consequence of which results in hippocampal-dependent cognitive impairment. In the previous study we found that adult-born immature neurons in the hippocampal dentate gyrus are the most vulnerable cell type to moderate TBI insult. However, the molecular mechanisms that regulate the survival of adult-born immature neurons in the hippocampus following TBI are still not well understood. Here, we conditionally knocked out brain-derived neurotrophic factor (BDNF) in the hippocampal dentate gyrus and examined the death of adult-born immature neurons following moderate TBI. The results showed that the amount of adult-born immature neuron death in the hippocampal dentate gyrus significantly increased in the BDNF conditional knockout mice. This result suggests that BDNF is involved in regulating the survival of adult-born immature neurons in the hippocampus following TBI, and potentially might be a useful target for preventing the adult-born immature neurons from death following TBI.	[Chen, Jinhui] Indiana Univ, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA	Chen, JH (corresponding author), Indiana Univ, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, 950 W Walnut St, Indianapolis, IN 46202 USA.	jchen@uky.edu	Chen, Jinhui/A-7138-2009	Chen, Jinhui/0000-0002-6864-7121	Indiana University.	This work was supported by startup funding provided by Indiana University.	Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; Cone RD, 1999, TRENDS ENDOCRIN MET, V10, P211, DOI 10.1016/S1043-2760(99)00153-8; Conover JC, 1997, REV NEUROSCIENCE, V8, P13; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; DEWIED D, 1987, ANN NY ACAD SCI, V512, P328, DOI 10.1111/j.1749-6632.1987.tb24971.x; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GAO X, 2008, J NEUROSCI RES; Gao X, 2007, J NEUROSCI, V27, P14317, DOI 10.1523/JNEUROSCI.3206-07.2007; Goodfellow VS, 2003, CURR TOP MED CHEM, V3, P855, DOI 10.2174/1568026033452212; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jagasia R, 2006, TRENDS MOL MED, V12, P400, DOI 10.1016/j.molmed.2006.07.006; Jakeman LB, 1998, EXP NEUROL, V154, P170, DOI 10.1006/exnr.1998.6924; Kempermann G, 2006, P NATL ACAD SCI USA, V103, P780, DOI 10.1073/pnas.0510291103; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; Krude H, 2000, TRENDS ENDOCRIN MET, V11, P15, DOI 10.1016/S1043-2760(99)00213-1; Lu P, 2001, J COMP NEUROL, V436, P456, DOI 10.1002/cne.1080; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MEMBERG SP, 1995, MOL CELL NEUROSCI, V6, P323, DOI 10.1006/mcne.1995.1025; Overstreet LS, 2004, J NEUROSCI, V24, P3251, DOI 10.1523/JNEUROSCI.5173-03.2004; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; RUBINSTEIN M, 1993, NEUROENDOCRINOLOGY, V58, P373, DOI 10.1159/000126566; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; TIMMUSK T, 1994, ANAL TRANSCRIPTIONAL, V199, P27; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Webster MJ, 2002, DEV BRAIN RES, V139, P139, DOI 10.1016/S0165-3806(02)00540-0; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	65	36	36	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1325	1335		10.1089/neu.2008.0744			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900015	19203227				2021-06-18	
J	Li, V; Brustovetsky, T; Brustovetsky, N				Li, Viacheslav; Brustovetsky, Tatiana; Brustovetsky, Nickolay			Role of cyclophilin D-dependent mitochondrial permeability transition in glutamate-induced calcium deregulation and excitotoxic neuronal death	EXPERIMENTAL NEUROLOGY			English	Article							CEREBELLAR GRANULE CELLS; PERMEANT CA2+ CHELATORS; TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; CEREBRAL-ISCHEMIA; AMINO-ACIDS; PORE; INHIBITION; NEUROTOXICITY; DYSFUNCTION	In the present study we tested the hypothesis that the cyclophilin D-dependent (CyD) mitochondrial permeability transition (CyD-mPT) plays an important role in glutamate-triggered delayed calcium deregulation (DCD) and excitotoxic neuronal death. We used Cultured cortical neurons from wild-type C57BL/6 and cyclophilin D-knockout mice (Ppif(-/-)). Induction of the mPT was identified by following the rapid secondary acidification of mitochondrial matrices monitored with mitochondrially targeted pH-sensitive yellow fluorescent protein. Suppression of the CyD-mPT due to genetic CyD ablation deferred DCD and mitochondrial depolarization, and increased the survival rate after exposure of neurons to 10 mu m glutamate, but not to 100 mu M glutamate. Ca2+ influx into Ppif(-/-) neurons was not diminished in comparison with WT neurons judging by Ca-45 accumulation. In both types of neurons, 100 mu M glutamate produced greater Ca2+ influx than 10 mu M glutamate. We hypothesize that greater Ca2+ influx produced by higher glutamate rapidly triggered the CyD-independent mPT in both WT and Ppif(-/-) neurons equalizing their responses to supra-physiologic excitotoxic insults. In neurons exposed to moderate but pathophysiologically-relevant glutamate concentrations, an induction of the CyD-mPT appears to play an important role in mitochondrial injury contributing to DCD and cell death. (C) 2009 Elsevier Inc. All rights reserved.	[Li, Viacheslav; Brustovetsky, Tatiana; Brustovetsky, Nickolay] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Brustovetsky, Nickolay] Indiana Univ, Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA	Brustovetsky, N (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, 635 Barnhill Dr,Med Sci Bldg Room 547, Indianapolis, IN 46202 USA.	nbrous@iupui.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 050131]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050131] Funding Source: NIH RePORTER	We are thankful to Dr. Jeffery D. Molkentin (University of Cincinnati) and Cincinnati Children's Research Foundation for providing us with cyclophilin D-knockout mice. Dr. Natalia Shalbuyeva is gratefully acknowledged for help with mitochondrial experiments. This work was supported by the NIH/NINDS R01 NS 050131 to NB.	Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bernardi P, 1999, PHYSIOL REV, V79, P1127; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BERNSTEIN P, 1993, ANIM BEHAV CONSULTAN, V10, P1; Bolshakov AP, 2008, CELL CALCIUM, V43, P602, DOI 10.1016/j.ceca.2007.10.005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Brustovetsky T, 2004, EXP NEUROL, V189, P222, DOI 10.1016/j.expneurol.2004.03.021; Budd SL, 1996, J NEUROCHEM, V67, P2282; Castilho RF, 1998, J NEUROSCI, V18, P10277; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chinopoulos C, 2004, J NEUROCHEM, V91, P471, DOI 10.1111/j.1471-4159.2004.02732.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; CROMPTON M, 1988, BIOCHEM J, V255, P357; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; DUBINSKY JM, 1995, J NEUROSCI, V15, P7071; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Isaev NK, 1996, FEBS LETT, V392, P143, DOI 10.1016/0014-5793(96)00804-6; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; KIEDROWSKI L, 1995, MOL PHARMACOL, V47, P140; Korde AS, 2007, J NEUROTRAUM, V24, P895, DOI 10.1089/neu.2006.0122; Kristian T, 2007, J NEUROCHEM, V102, P1346, DOI 10.1111/j.1471-4159.2007.04626.x; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MANEV H, 1989, MOL PHARMACOL, V36, P106; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakayama R, 2002, ANESTHESIOLOGY, V96, P705, DOI 10.1097/00000542-200203000-00029; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Shalbuyeva N, 2007, J BIOL CHEM, V282, P18057, DOI 10.1074/jbc.M702134200; Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; THAYER SA, 1990, J PHYSIOL-LONDON, V425, P85, DOI 10.1113/jphysiol.1990.sp018094; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; TYMIANSKI M, 1994, J NEUROPHYSIOL, V72, P1973; TYMIANSKI M, 1993, NEURON, V11, P221, DOI 10.1016/0896-6273(93)90180-Y; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Van Hemelrijek A, 2005, J NEUROSCI METH, V144, P63, DOI 10.1016/j.jneumeth.2004.10.013; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Vergun O, 2003, EXP NEUROL, V183, P682, DOI 10.1016/S0014-4886(03)00243-7; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; White RJ, 1996, J NEUROSCI, V16, P5688; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; ZENKE G, 1993, ANN NY ACAD SCI, V685, P330, DOI 10.1111/j.1749-6632.1993.tb35882.x	85	36	36	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2009	218	2			SI		171	182		10.1016/j.expneurol.2009.02.007			12	Neurosciences	Neurosciences & Neurology	472GE	WOS:000268117400002	19236863	Green Accepted			2021-06-18	
J	Goodrich-Hunsaker, NJ; Hopkins, RO				Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.			Word Memory Test Performance in Amnesic Patients With Hippocampal Damage	NEUROPSYCHOLOGY			English	Article						symptom validity test; amnesia; declarative memory; hippocampus	MEDIAL TEMPORAL-LOBE; TRAUMATIC BRAIN-INJURY; RECOGNITION MEMORY; EXTERNAL INCENTIVES; DECLARATIVE MEMORY; SPATIAL MEMORY; ITEM MEMORY; VALIDITY	Many symptom validity tests (SVTs) assess performance validity via declarative memory paradigms. One widely used SVT, the Word Memory Test (WMT), uses a variety of memory tests to assess performance. It is well known that declarative memory requires the hippocampus and related medial temporal lobe structures. In the present study, WMT performance was examined in nonlitigating amnesic subjects (n = 3) with well-documented focal bilateral hippocampal atrophy who were nondemented and otherwise cognitively unimpaired compared with matched controls. The amnesic subjects had no external incentives. Amnesic subjects performed significantly below the level of matched comparison subjects but above established cutoff scores on the immediate recognition and delay recognition subtests and consistency component. In contrast, the amnesic subjects were impaired relative to our comparison subjects on the multiple-choice, paired associate, free-recall, and long delay free-recall subtests and had extremely low performance on these measures. Thus, there was a differential effect of hippocampal damage on WMT performance where the recognition subtests were performed within the normal range, yet the free recall was profoundly impaired in amnesic subjects. Such an approach where SVT performance is assessed in populations with well-known cognitive impairments adds breadth to SVT clinical interpretations.	[Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Dept Physiol, Provo, UT 84602 USA; [Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Dev Biol & Neurosci Ctr, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Crit Care Med, Murray, UT USA	Goodrich-Hunsaker, NJ (corresponding author), Brigham Young Univ, Dept Psychol, 1082 SWKT, Provo, UT 84602 USA.	naomihunsaker@mac.com					Aggleton JP, 2005, NEUROPSYCHOLOGIA, V43, P1810, DOI 10.1016/j.neuropsychologia.2005.01.019; Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064; Chun MM, 1999, NAT NEUROSCI, V2, P844, DOI 10.1038/12222; Davachi L, 2008, CURR DIR PSYCHOL SCI, V17, P112, DOI 10.1111/j.1467-8721.2008.00559.x; Dickerson BC, 2007, HIPPOCAMPUS, V17, P1060, DOI 10.1002/hipo.20338; Dodrill CB, 2008, EPILEPSIA, V49, P691, DOI 10.1111/j.1528-1167.2007.01457.x; Eichenbaum H, 2007, ANNU REV NEUROSCI, V30, P123, DOI 10.1146/annurev.neuro.30.051606.094328; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Gold JJ, 2006, P NATL ACAD SCI USA, V103, P9351, DOI 10.1073/pnas.0602716103; Gold JJ, 2006, LEARN MEMORY, V13, P644, DOI 10.1101/lm.258406; Green P, 2003, WORD MEMORY TEST WIN; Hopkins RO, 2004, NEUROPSYCHOLOGIA, V42, P524, DOI 10.1016/j.neuropsychologia.2003.09.005; Manns JR, 2003, NEURON, V37, P171, DOI 10.1016/S0896-6273(02)01147-9; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Milner B, 2005, PSYCHIAT CLIN N AM, V28, P599, DOI 10.1016/j.psc.2005.06.002; Ofen N, 2007, NAT NEUROSCI, V10, P1198, DOI 10.1038/nn1950; Sarter M, 2006, BRAIN RES REV, V51, P145, DOI 10.1016/j.brainresrev.2005.11.002; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shrager Y, 2007, P NATL ACAD SCI USA, V104, P2961, DOI 10.1073/pnas.0611233104; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Vanderploeg RD, 2001, NEUROREHABILITATION, V16, P245; Wais PE, 2006, NEURON, V49, P459, DOI 10.1016/j.neuron.2005.12.020; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Westerberg CE, 2006, NEUROPSYCHOLOGY, V20, P193, DOI 10.1037/0894-4105.20.2.193	32	36	36	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2009	23	4					529	534		10.1037/a0015444			6	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	472IA	WOS:000268122600011	19586216				2021-06-18	
J	Park, SK; Chun, HJ; Kim, DW; Im, TH; Hong, HJ; Yi, HJ				Park, Sang-Kyu; Chun, Hyoung-Joon; Kim, Dong-Won; Im, Tai-Ho; Hong, Hyun-Jong; Yi, Hyeong-Joong			Acute Physiology and Chronic Health Evaluation II and Simplified Acute Physiology Score II in Predicting Hospital Mortality of Neurosurgical Intensive Care Unit Patients	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						APACHE; Intensive Care Units; Mortality; Simplified Acute Physiologic Score; Subarachnoid Hemorrhage; Brain Injuries	APACHE-II; SAPS-II; SEVERITY; MULTICENTER; SURVIVAL; PROGNOSIS; ABILITY; COST; BIAS	We study the predictive power of Acute Physiology and Chronic Health Evaluation II (APACHE II) and Simplified Acute Physiology Score II (SAPS II) in neurosurgical intensive care unit (ICU) patients. Retrospective investigation was conducted on 672 consecutive ICU patients during the last 2 yr. Data were collected during the first 24 hours of admission and analyzed to calculate predicted mortality. Mortality predicted by two systems was compared and, multivariate analyses were then performed for subarachnoid hemorrhage (SAH) and traumatic brain injury (TBI) patients. Observed mortality was 24.8% whereas predicted mortalities were 37.7% and 38.4%, according to APACHE II and SAPS II. Calibration curve was close to the line of perfect prediction. SAPS II was not statistically significant according to a Lemeshow-Hosmer test, but slightly favored by area under the curve (AUC). In SAH patients, SAPS II was an independent predictor for mortality. In TBI patients, both systems had independent prognostic implications. Scoring systems are useful in predicting mortality and measuring performance in neurosurgical ICU setting. TBI patients are more affected by systemic insults than SAH patients, and this discrepancy of predicting mortality in each neurosurgical disease prompts us to develop a more specific scoring system targeted to cerebral dysfunction.	[Chun, Hyoung-Joon; Hong, Hyun-Jong; Yi, Hyeong-Joong] Hanyang Univ, Med Ctr, Dept Neurosurg, Seoul 133792, South Korea; [Kim, Dong-Won] Hanyang Univ, Med Ctr, Dept Anesthesia & Pain Med, Seoul 133792, South Korea; [Im, Tai-Ho] Hanyang Univ, Med Ctr, Dept Emergency Med, Seoul 133792, South Korea; [Park, Sang-Kyu] Ajou Univ Hosp, Dept Neurosurg, Suwon, South Korea	Yi, HJ (corresponding author), Hanyang Univ, Med Ctr, Dept Neurosurg, 17 Haengdang Dong, Seoul 133792, South Korea.	hjyi8499@hanyang.ac.kr	Yi, Hyeong-Joong/AAR-2685-2020				Blot F, 1997, EUR J CANCER, V33, P1031, DOI 10.1016/S0959-8049(97)00042-7; BROWN MC, 1995, CRIT CARE MED, V23, P848, DOI 10.1097/00003246-199505000-00012; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; CHU DY, 1993, CRIT CARE CLIN, V9, P89; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; COWEN JS, 1994, CRIT CARE CLIN, V10, P53; ElSolh AA, 1996, CHEST, V110, P1299, DOI 10.1378/chest.110.5.1299; Goldhill DR, 1998, CRIT CARE MED, V26, P1337, DOI 10.1097/00003246-199808000-00017; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEADLEY J, 1992, CANCER-AM CANCER SOC, V70, P497, DOI 10.1002/1097-0142(19920715)70:2<497::AID-CNCR2820700220>3.0.CO;2-H; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; MOREAU R, 1989, CRIT CARE MED, V17, P409, DOI 10.1097/00003246-198905000-00006; Murthy J M, 2001, Neurol India, V49 Suppl 1, pS91; Pierpont GL, 1999, CLIN CARDIOL, V22, P366, DOI 10.1002/clc.4960220514; PITTET D, 1993, INTENS CARE MED, V19, P265, DOI 10.1007/BF01690546; RAPOPORT J, 1994, CRIT CARE MED, V22, P1385, DOI 10.1097/00003246-199409000-00006; ROWAN KM, 1994, CRIT CARE MED, V22, P1392, DOI 10.1097/00003246-199409000-00007; SARMIENTO J, 1991, CRIT CARE MED, V19, P867, DOI 10.1097/00003246-199107000-00007; Schuiling WJ, 2005, NEUROSURGERY, V57, P230, DOI 10.1227/01.NEU.0000166536.42876.9C; Schuster HP, 1997, INTENS CARE MED, V23, P1056, DOI 10.1007/s001340050456; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Tunnell RD, 1998, ANAESTHESIA, V53, P1045, DOI 10.1046/j.1365-2044.1998.00566.x; VASSAR MJ, 1992, J TRAUMA, V32, P490, DOI 10.1097/00005373-199204000-00014; Yi HJ, 2006, NEUROSURGERY, V59, P838, DOI 10.1227/01.NEU.0000232976.22414.D9; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010	31	36	40	0	6	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	JUN	2009	24	3					420	426		10.3346/jkms.2009.24.3.420			7	Medicine, General & Internal	General & Internal Medicine	462IA	WOS:000267343400010	19543503	Green Published, Bronze			2021-06-18	
J	Petridis, AK; Dorner, L; Doukas, A; Eifrig, S; Barth, H; Mehdorn, M				Petridis, A. K.; Doerner, L.; Doukas, A.; Eifrig, S.; Barth, H.; Mehdorn, M.			Acute Subdural Hematoma in the Elderly; Clinical and CT Factors Influencing the Surgical Treatment Decision	CENTRAL EUROPEAN NEUROSURGERY			English	Article						acute subdural hematoma; Glasgow Coma Scale; Glasgow Outcome Score; midline shift	PROGNOSTIC-FACTORS; OUTCOME PREDICTION; BRAIN-DAMAGE; HEMORRHAGE; INJURY; MODEL; RAT	Objective: Acute subdural hematomas (aSDH) are severe traumatic brain injuries. Older patients have a higher mortality rate. In the present study the computed tomography (CT) and neurological deficits caused by aSDH were used as prognostic factors to define the outcome and surgical treatment indication in older patients. Methods: The affect of the Glasgow Coma Scale (GCS) score on initial presentation, pupil abnormalities, parenchymal lesions, SDH-thickness, midline shift and intracranial pressure (ICP) in the outcome of older patients (>= 65 years old) admitted to our hospital between 1993 and 2006 with aSDH was evaluated. The outcome was assessed with the Glasgow Outcome Scale (GOS). The data were collected retrospectively. Statistical analysis was performed with Chi-square test and ANOVA. Results: Older patients have a high mortality after aSDH. A low GCS score (3-8), pupil abnormalities, the presence of contusions and subarachnoid bleeding, midline shift > aSDH thickness as well as a highly elevated ICP > 40 mmHg are unfavorable factors in the prognosis of aSDH. Conclusion: Patients with a GCS of 13-15 can be observed clinically (the expected outcome is very good). Comatose patients (GCS 3-8) with bilateral dilatation of the pupils should not be operated (very high mortality rate). if the GCS score is < 13 and both pupils or only one are reactive to light and the midline shift < 10 mm, surgery is indicated. If the midline shift is > 10 mm and aSDH thickness > midline shift, surgery is also indicated. If in the same patient group midline shift > SDH thickness and ICP > 40 mmHg, surgery is not indicated.	[Petridis, A. K.; Doerner, L.; Doukas, A.; Eifrig, S.; Barth, H.; Mehdorn, M.] UKSH, Dept Neurosurg, D-24106 Kiel, Germany	Petridis, AK (corresponding author), UKSH, Dept Neurosurg, Campus Kiel,Schittenhelmstr 10, D-24106 Kiel, Germany.	opticdisc@aol.com	Mehdorn, Maximilian/D-2495-2010				Alessandri B, 2006, BRAIN RES, V1111, P196, DOI 10.1016/j.brainres.2006.06.105; D'Amato L, 2007, J Neurosurg Sci, V51, P107; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Domenicucci M, 1998, NEUROSURGERY, V42, P51, DOI 10.1097/00006123-199801000-00010; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KURODA Y, 1992, NEUROSURGERY, V30, P687; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	19	36	36	1	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	1868-4904	1868-4912		CENT EUR NEUROSURG	Cent. Eur. Neurosurg.	MAY	2009	70	2					73	78		10.1055/s-0029-1224096			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	449MG	WOS:000266334100003	19711259				2021-06-18	
J	Banerjee, S; Barry, MJ; Paterson, JMH				Banerjee, Sughran; Barry, M. J.; Paterson, J. Mark H.			Paediatric pelvic fractures: 10 years experience in a trauma centre	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Pelvic fractures; Paediatric fractures; Road traffic accident	INJURIES; CLASSIFICATION; PATTERNS; CHILDREN	Fractures of the skeletally immature pelvis are relatively rare. We performed a retrospective analysis of 10 years experience of paediatric pelvic fractures in patients admitted a Level 1 Trauma Centre in London. All patients evacuated to the Royal London Hospital by the Helicopter Emergency Medical Service (HEMS) were entered on a comprehensive trauma database. This contains data about the time, date and mechanism of injury; nature of the injuries sustained; Injury Severity Score (ISS), Revised Trauma Score (RTS) and Glasgow Coma Scale (GCS). Patients were studied to obtain the following information in addition to that available from the trauma database: management of the pelvic fracture, length of stay in the intensive care unit and on the ward, and clinical outcome. Pelvic fractures were classified as open type or closed type and stable or unstable type in the database. 44 patients with pelvic fracture were admitted via HEMS in 10 years and seven patients died in that group. The mean age was 11.4 (range 6-16) and 28 male and 16 female patients. Commonest mechanism of injury was pedestrian hit by the car and predominantly stable type of injury was found in skeletally immature pelvis. Commonest associated injury was long bone fracture followed by head injury. ISS, GCS and RTS were significantly (p < 0.05) altered in the non-survivors compared to the surviving group. All patients save one were treated conservatively allowing gradual mobilisation. In conclusion, pelvic fractures in children may themselves have a good long term outcome with conservative management, but they are an indicator of serious other bodily injuries which carry a high mortality. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.	[Banerjee, Sughran] Univ London Imperial Coll Sci Technol & Med, London E11 1PW, England; [Barry, M. J.; Paterson, J. Mark H.] Royal London Hosp, London, England	Banerjee, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, 23 Malcolm Way, London E11 1PW, England.	sughran@gmail.com					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Batislam E, 1997, J TRAUMA, V42, P285, DOI 10.1097/00005373-199702000-00018; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRYAN WJ, 1979, J TRAUMA, V19, P799, DOI 10.1097/00005373-197911000-00001; Demetriades D, 2003, J TRAUMA, V54, P1146, DOI 10.1097/01.TA.0000044352.00377.8F; Grisoni N, 2002, J ORTHOP TRAUMA, V16, P458, DOI 10.1097/00005131-200208000-00003; Guillamondegui OD, 2003, J TRAUMA, V55, P236, DOI 10.1097/01.TA.0000079250.80811.D1; HARDER JA, 1981, CAN J SURG, V24, P409; Heeg M, 2000, CLIN ORTHOP RELAT R, P80; Ismail N, 1996, J PEDIATR SURG, V31, P82, DOI 10.1016/S0022-3468(96)90324-3; Junkins EP, 2001, J TRAUMA, V51, P64, DOI 10.1097/00005373-200107000-00010; Karunakar MA, 2005, J PEDIATR ORTHOPED, V25, P34, DOI 10.1097/00004694-200501000-00009; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; NOVKOV H, 1998, ORTOP TRAVMATOL, V34, P152; Quicke Donald L. J., 2005, Journal of Hymenoptera Research, V14, P96; Quinby W C Jr, 1966, J Pediatr Surg, V1, P353, DOI 10.1016/0022-3468(66)90338-1; Schlickewei W, 2005, INJURY, V36, pA57, DOI 10.1016/j.injury.2004.12.014; Signorino PR, 2005, J PEDIATR SURG, V40, P107, DOI 10.1016/j.jpedsurg.2004.09.018; Silber JS, 2002, J PEDIATR ORTHOPED, V22, P22; Silber JS, 2001, J PEDIATR ORTHOPED, V21, P446, DOI 10.1097/00004694-200107000-00006; SILBER JS, 2001, J PAEDIAT ORTHOP, P148; Smith I. W. G., 2004, NZ J ARCHAEOLOGY, V24, P5; Smith W, 2005, J BONE JOINT SURG AM, V87A, P2423, DOI 10.2106/JBJS.C.01244v; TEASDALE G, 1974, LANCET, V2, P81; Tile M, 1999, J BONE JOINT SURG BR, V81B, P941, DOI 10.1302/0301-620X.81B6.10474; TORODE I, 1985, J PEDIATR ORTHOPED, V5, P76, DOI 10.1097/01241398-198501000-00014; TORODE I, 1985, J PEDIAT ORTHOP; Vitale MG, 2005, J PEDIATR ORTHOPED, V25, P581, DOI 10.1097/01.bpo.0000175112.91122.41; WIERMAN MJ, 1996, INJURY, V27, P163	29	36	42	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	APR	2009	40	4					410	413		10.1016/j.injury.2008.10.019			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	435SC	WOS:000265362600014	19232592				2021-06-18	
J	Brenner, LA; Ladley-O'Brien, SE; Harwood, JEF; Filley, CM; Kelly, JP; Homaifar, BY; Adler, LE				Brenner, Lisa A.; Ladley-O'Brien, Susan E.; Harwood, Jeri E. F.; Filley, Christopher M.; Kelly, James P.; Homaifar, Beeta Y.; Adler, Lawrence E.			An Exploratory Study of Neuroimaging, Neurologic, and Neuropsychological Findings in Veterans With Traumatic Brain Injury and/or Posttraumatic Stress Disorder	MILITARY MEDICINE			English	Article							VIETNAM VETERANS; COMBAT VETERANS; MILD; MEMORY; PTSD; IRAQ; AFGHANISTAN; DEFICITS	Seventy-two veterans with traumatic brain injury (TB!), posttraumatic stress disorder (PTSD), or both participated in assessment procedures to evaluate between group differences. Half the sample was randomly selected for magnetic resonance imaging (MRI). Neurologic examinations were conducted using the Neurologic Rating Scale (NRS). Neuropsychological measures included the Paced Auditory Serial Addition Test (PASAT), Rey Auditory Verbal Learning Test (RAVLT), Conners' Continuous Performance Test II (CPT II), and Halstead Impairment Index (HII) including the Booklet Category Test (BCT). Data were analyzed using linear regression. Participants with moderate/severe TBI were significantly more likely to have trauma-related imaging findings, and more severe TBI predicted lower scores on the NRS. No significant between-group differences were identified on the HI!, PASAT, RAVLT, or CPT II. TBI group performance was significantly better on the BCT. More severe TBI predicted abnormal imaging findings and lower NRS scores. Hypothesized between-group differences on neuropsychological measures were not supported.	[Brenner, Lisa A.; Homaifar, Beeta Y.; Adler, Lawrence E.] Educ & Clin Ctr MIRECC, VA VISN 19 Mental Illness Res, Denver, CO 80220 USA; [Brenner, Lisa A.; Filley, Christopher M.; Homaifar, Beeta Y.; Adler, Lawrence E.] Univ Colorado Denver, Dept Psychiat, Sch Med, Aurora, CO 80045 USA; [Brenner, Lisa A.; Ladley-O'Brien, Susan E.; Kelly, James P.] Univ Colorado Denver, Dept Phys Med & Rehabil, Sch Med, Aurora, CO 80045 USA; [Brenner, Lisa A.; Filley, Christopher M.] Univ Colorado Denver, Dept Neurol, Sch Med, Aurora, CO 80045 USA; [Harwood, Jeri E. F.] Univ Colorado Denver, Dept Pediat, Sch Med, Aurora, CO 80045 USA; [Kelly, James P.] Univ Colorado Denver, Dept Neurosurg, Sch Med, Aurora, CO 80045 USA	Brenner, LA (corresponding author), Educ & Clin Ctr MIRECC, VA VISN 19 Mental Illness Res, 1055 Clermont St, Denver, CO 80220 USA.		Brenner, Lisa A./AAG-2442-2019				Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bremner JD, 1995, PSYCHIAT RES, V59, P97; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; CONDER R, 1992, MANUAL COMPUTERIZED; Conners C., 2000, CONNERS CONTINUOUS P; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; DeFilippis NA, 1997, BOOKLET CATEGORY TES; *DEP VET AFF, 2004, VETEESA138 SP DEP VE, V138; Feinstein A, 2002, J NEUROPSYCH CLIN N, V14, P25, DOI 10.1176/appi.neuropsych.14.1.25; Fennema-Notestine C, 2002, BIOL PSYCHIAT, V52, P1089, DOI 10.1016/S0006-3223(02)01413-0; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Gilbertson MW, 2007, BIOL PSYCHIAT, V62, P513, DOI 10.1016/j.biopsych.2006.12.023; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Gurvits TV, 2006, ARCH GEN PSYCHIAT, V63, P571, DOI 10.1001/archpsyc.63.5.571; Heaton RK, 2004, REVISED COMPREHENSIV; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McCullagh S, 2005, TXB TRAUMATIC BRAIN, P321; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; Reitan R.M., 1993, HALSTEADREITAN NEURO; SIPE JC, 1984, NEUROLOGY, V34, P1368, DOI 10.1212/WNL.34.10.1368; Spitzer R. l., 1995, STRUCTURED CLIN INTE; Spreen O., 1998, COMPENDIUM NEUROPSYC; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; Thurman DJ., 1995, GUIDELINES SURVEILLA; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Twamley EW, 2004, PSYCHIAT RES, V126, P265, DOI 10.1016/j.psychres.2004.01.008; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137	39	36	37	0	12	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	APR	2009	174	4					347	352		10.7205/MILMED-D-01-5808			6	Medicine, General & Internal	General & Internal Medicine	601LB	WOS:000278059600005	19485102	Bronze			2021-06-18	
J	Wachter, D; Gundling, K; Oertel, MF; Stracke, H; Boker, DK				Wachter, Dorothee; Guendling, Katja; Oertel, Matthias F.; Stracke, Hilmar; Boeker, Dieter-Karsten			Pituitary insufficiency after traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						CT scan; Hypopituitarism; Intracranial hemorrhage; Quality of life; Traumatic brain injury	GROWTH-HORMONE DEFICIENCY; SUBARACHNOID HEMORRHAGE; GH DEFICIENCY; HEAD TRAUMA; HIGH-RISK; HYPOPITUITARISM; DYSFUNCTION; PREVALENCE; TBI; DIAGNOSIS	After traumatic brain injury (TBI), patients present with psychological disorders that may be explained by post-traumatic pituitary insufficiency (PI). The goal of this study was to determine the relationship between hypopituitarism, neuropsychological changes and findings on CT scans after TBI. Hospital charts of 55 TBI patients were screened for age, Glasgow Coma Scale (GSC) score, hypoxia or hypotension. The first two CT scans were analyzed for hemorrhagic lesions. Basal levels of the following hormones were recorded: cortisol, prolactin, estradiol, testosterone, insulin-like growth factor 1 and free thyroxine. Hormonal stimulation tests were performed either if the basal hormone screening revealed an abnormality or if the patient answered "yes" to at least one question in the non-evaluated neuropsychological questionnaire. Overall, 14 out of 55 patients (25.4%) presented with PI; one of them with two hormonal deficits. Growth hormone deficit, hypothyroidism and hypocortisolism were found in one, one and two patients, respectively. Neuropsychological complaints were present in 67% of the patients and were associated with intracerebral hemorrhagic lesions and not PI. Neuropsychological complaints after TBI are more frequent than PI. Brain tissue damage is most important than PI in the development of psychological changes after TBI. (C) 2008 Published by Elsevier Ltd.	[Wachter, Dorothee; Guendling, Katja; Oertel, Matthias F.; Boeker, Dieter-Karsten] Univ Hosp, Dept Neurosurg, D-35385 Giessen, Germany; [Stracke, Hilmar] Univ Hosp, Dept Endocrinol, D-35385 Giessen, Germany	Oertel, MF (corresponding author), Univ Hosp, Dept Neurosurg, Klin Str 29, D-35385 Giessen, Germany.	matthias.oertel@neuro.med.uni-giessen.de					Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Aimaretti G, 1998, J ENDOCRINOL INVEST, V21, P506, DOI 10.1007/BF03347336; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; CONSENSUS G, 1998, J CLIN ENDOCR METAB, V83, P379; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kreutzer J, 2001, J CLIN ENDOCR METAB, V86, P4072, DOI 10.1210/jc.86.9.4072; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lippert-Gruener M, 2007, BRAIN INJURY, V21, P1001, DOI 10.1080/02699050701468933; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mulligan T, 2006, INT J CLIN PRACT, V60, P762, DOI 10.1111/j.1742-1241.2006.00992.x; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Popovic V, 2005, FRONT HORM RES, V33, P33, DOI 10.1159/000088399; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Salehi F, 2007, BRAIN INJURY, V21, P651, DOI 10.1080/02699050701426956; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Yehuda R, 1999, Semin Clin Neuropsychiatry, V4, P256	39	36	39	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	FEB	2009	16	2					202	208		10.1016/j.jocn.2008.01.009			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	418XA	WOS:000264181900005	19097906				2021-06-18	
J	Griffin, JM; Friedemann-Sanchez, G; Hall, C; Phelan, S; van Ryn, M				Griffin, Joan M.; Friedemann-Sanchez, Greta; Hall, Carmen; Phelan, Sean; van Ryn, Michelle			Families of patients with polytrauma: Understanding the evidence and charting a new research agenda	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						caregiving; families; Family Care Map; information needs; polytrauma; rapid assessment process; recovery; rehabilitation; resilience; stress; traumatic brain injury	TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; INTENSIVE-CARE-UNIT; DEMENTIA CAREGIVERS; HEALTH-CARE; NEEDS; REHABILITATION; PERSPECTIVES; INFORMATION; RESILIENCE	Although research shows that caring for a family member with chronic disease or disability can cause significant distress for caregivers, it also shows that families that function well and adequately support patients can improve the quality of life and health outcomes for their ill or disabled family member. Currently, little knowledge exists about how families function and cope after a loved one has sustained polytrauma, the multiple traumatic injuries that often include traumatic brain injury (TBI). We summarize the polytrauma and TBI research about family needs during rehabilitation and recovery, describe current efforts to improve family-centered care, and detail approaches for understanding family resilience and the long-term consequences of injuries on families. We conclude with recommendations for future research in inpatient and outpatient settings where evidence has been limited for families of patients with TBI and is nonexistent for families of patients with polytrauma. Understanding many of these issues will help to better inform families of policies for benefits and resources and help researchers and clinicians plan for appropriate interventions.	[Griffin, Joan M.; Hall, Carmen] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Dept Vet Affairs, VA Hlth Serv Res Ctr Excellence, Minneapolis, MN 55417 USA; [Griffin, Joan M.] Univ Minnesota, Sch Med, Dept Med, Div Gen Internal Med, Minneapolis, MN 55455 USA; [Friedemann-Sanchez, Greta] Univ Minnesota, Hubert H Humphrey Inst Publ Affairs, Minneapolis, MN 55455 USA; [Phelan, Sean] Univ Minnesota, Sch Publ Hlth, Dept Epidemiol & Community Med, Minneapolis, MN USA; [van Ryn, Michelle] Univ Minnesota, Sch Med, Dept Med, Div Family Med & Community Hlth, Minneapolis, MN 55455 USA	Griffin, JM (corresponding author), Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Dept Vet Affairs, VA Hlth Serv Res Ctr Excellence, 1 Vet Dr, Minneapolis, MN 55417 USA.	joangriffin2@va.gov	Griffin, Jillian/F-9415-2010; VAN RYN, MICHELLE/B-1664-2010	Friedemann-Sanchez, Greta/0000-0002-0493-7218	VA Health Services Research and Development ServiceUS Department of Veterans Affairs [RRP 06149, SDR 07-044]; VA PT/BRI QUERI	This material was based on work supported by VA Health Services Research and Development Service (grants RRP 06149 and SDR 07-044) and the VA PT/BRI QUERI.	Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Bamm EL, 2008, ARCH PHYS MED REHAB, V89, P1618, DOI 10.1016/j.apmr.2007.12.034; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; Bensink M, 2006, J TELEMED TELECARE, V12, P8, DOI 10.1258/135763306779380174; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; Buckley Kathleen M, 2004, Online J Issues Nurs, V9, P9; Burr G, 1998, Intensive Crit Care Nurs, V14, P161, DOI 10.1016/S0964-3397(98)80473-4; Caron W, 1999, PSYCHIATRY, V62, P347, DOI 10.1080/00332747.1999.11024882; Chin MH, 2007, MED CARE, V45, P1135, DOI 10.1097/MLR.0b013e31812da80e; Chiu YL, 2004, J CLIN NURS, V13, P655, DOI 10.1111/j.1365-2702.2004.00844.x; Coon DW, 2004, AGING MENT HEALTH, V8, P330, DOI 10.1080/13607860410001709683; Darkins A, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.03.0029; DAVISMARTIN S, 1994, HEART LUNG, V23, P515; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; *DEP DEF, 2009, DOD PRESS RES; Dunn MS, 2006, PEDIATRICS, V118, pS95, DOI 10.1542/peds.2006-0913F; Engli M, 1993, J Neurosci Nurs, V25, P78; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P144; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Friedemann-Sanchez G, 2008, REHABIL NURS, V33, P206, DOI 10.1002/j.2048-7940.2008.tb00229.x; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Gottlieb BH, 2004, AGING MENT HEALTH, V8, P364, DOI 10.1080/13607860410001709719; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hawley DR, 1996, FAM PROCESS, V35, P283, DOI 10.1111/j.1545-5300.1996.00283.x; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Holland Daniel, 2002, Issues Compr Pediatr Nurs, V25, P73, DOI 10.1080/01460860290042512; Horbar JD, 2004, BMJ-BRIT MED J, V329, P1004, DOI 10.1136/bmj.329.7473.1004; Horbar JD, 2003, PEDIATRICS, V111; Institute for Healthcare Improvement, 2003, BREAKTHR SER IHIS CO; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; King G, 2003, CHILD HEALTH CARE, V32, P191, DOI 10.1207/S15326888CHC3203_2; King S, 2004, CHILD HEALTH CARE, V33, P35, DOI 10.1207/s15326888chc3301_3; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Langley GJ, 1996, IMPROVEMENT GUIDE PR; Lesar TS, 2007, JT COMM J QUAL PATIE, V33, P73, DOI 10.1016/S1553-7250(07)33009-2; LEVINE C, 1998, ROUGH CROSSINGS FAMI; Luthar SS, 2000, DEV PSYCHOPATHOL, V12, P857, DOI 10.1017/S0954579400004156; McCubbin H. I., 1998, RESILIENCY AFRICAN A; McCubbin H. I., 1999, DYNAMICS RESILIENT F; McCubbin H.I., 1998, RESILIENCY NATIVE AM; McCubbin H.I., 1982, FAMILY STRESS COPING; McCubbin H.I., 1983, MARRIAGE FAM REV, V6, P7, DOI [10.1300/J002v06n01_02, DOI 10.1300/J002V06N01_02]; McCubbin H. I., 1987, FAMILY ASSESSMENT IN, P3; MCCUBBIN HI, 1988, FAM RELAT, V37, P247, DOI 10.2307/584557; McCubbin HI, 1980, FAMILY CHANGE, P89; MCCUBBIN HI, 1997, AM ASS FAM CONS SCI; MCCUBIN HI, 1975, J MARRIAGE FAM, V37, P471, DOI 10.2307/350511; Meade MA, 2004, REHABIL PSYCHOL, V49, P150, DOI 10.1037/0090-5550.49.2.150; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4; Paterson B, 2001, Rehabil Nurs, V26, P48; Patterson JM, 2002, J MARRIAGE FAM, V64, P349, DOI 10.1111/j.1741-3737.2002.00349.x; Ramritu PL, 1999, INT J NURS STUD, V36, P209, DOI 10.1016/S0020-7489(99)00016-4; Rosenbaum P., 1998, PHYS OCCUP THER PEDI, V18, P1, DOI DOI 10.1080/J006V18N01; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Sorensen S, 2002, GERONTOLOGIST, V42, P356, DOI 10.1093/geront/42.3.356; Spatt L, 1986, QRB Qual Rev Bull, V12, P16; STRINGER E, 1999, ACTION RES HDB PRACT; Taylor E J, 1993, Oncol Nurs Forum, V20, P919; TAYLOR HG, 1995, TRAUMATIC HEAD INJUR; Testani-Dufour L, 1992, J Neurosci Nurs, V24, P317; Vaccaro MJ, 2002, NEUROREHABILITATION, V17, P169; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Verhaeghe S, 2005, J CLIN NURS, V14, P501, DOI 10.1111/j.1365-2702.2004.01081.x; Veterans Health Administration, 2005, VHA HDB; Ward K, 2001, Pediatr Nurs, V27, P281; Warden DL, 2005, NEW ENGL J MED, V353, P633; Wearden AJ, 2000, CLIN PSYCHOL REV, V20, P633, DOI 10.1016/S0272-7358(99)00008-2	76	36	36	1	13	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					879	891		10.1682/JRRD.2008.08.0104			13	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100017	20104409	Bronze			2021-06-18	
J	Hoane, MR; Kaufman, N; Vitek, MP; McKenna, SE				Hoane, Michael R.; Kaufman, Nicholas; Vitek, Michael P.; McKenna, Suzanne E.			COG1410 Improves Cognitive Performance and Reduces Cortical Neuronal Loss in the Traumatically Injured Brain	JOURNAL OF NEUROTRAUMA			English	Article						apoE; behavioral recovery; neuronal degeneration; neuroprotection; recovery of function; TBI; trauma	SYSTEM INFLAMMATORY RESPONSE; FLUID PERCUSSION INJURY; CLOSED-HEAD INJURY; E-DEFICIENT MICE; E-BASED PEPTIDE; APOLIPOPROTEIN-E; CONTUSION INJURY; WORKING-MEMORY; MURINE MODEL; FUNCTIONAL RECOVERY	We have previously shown that a single dose of COG1410, a small molecule ApoE-mimetic peptide derived from the apolipoprotein E (ApoE) receptor binding region, improves sensorimotor and motor outcome following cortical contusion injury (CCI). The present study evaluated a regimen of COG1410 following frontal CCI in order to examine its preclinical efficacy on cognitive recovery. Animals were prepared with a bilateral CCI of the frontal cortex. A regimen of COG1410 (0.8 mg/kg intravenously [IV]) was administered twice, at 30 min and again at 24 h post-CCI. Starting on day 11, the animals were tested for their acquisition of a reference memory task in the Morris water maze (MWM), followed by a working memory task in the MWM on day 15. Following CCI, the animals were also tested on the bilateral tactile adhesive removal test to measure sensorimotor dysfunction. On all of the behavioral tests the COG1410 group was no different from the uninjured sham group. Administration of the regimen of COG1410 significantly improved recovery on the reference and working memory tests, as well as on the sensorimotor test. Lesion analysis revealed that COG1410 significantly reduced the size of the injury cavity. Administration of COG1410 also reduced the number of degenerating neurons, as measured by Fluoro-Jade C staining, in the frontal cortex at 48 h post-CCI. These results suggest that a regimen of COG1410 appeared to block the development of significant behavioral deficits and reduced tissue loss. These combined findings suggest that COG1410 appears to have strong preclinical efficacy when administered following traumatic brain injury (TBI).	[Hoane, Michael R.; Kaufman, Nicholas] So Illinois Univ, Ctr Integrat Res Cognit & Neural Sci, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA; [Vitek, Michael P.; McKenna, Suzanne E.] Cognosci Inc, Res Triangle Pk, NC USA; [Vitek, Michael P.] Duke Univ, Med Ctr, Div Neurol, Dept Med, Durham, NC 27710 USA; [Vitek, Michael P.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol Life Sci 2, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657; Vitek, Michael/0000-0001-8140-8048	Cognosci Inc [R44NS048689, R44AG020473]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: NIH RePORTER	The research was supported by Cognosci Inc. and by grants R44NS048689 and R44AG020473 from the National Institutes of Health. Dr. Vitek is an Associate Professor of Neurology and an Adjunct Professor of Neurobiology at Duke University Medical Center, and is also Chief Executive Officer of Cognosci, Inc. Cognosci, Inc. has filed for patent protection for COG1410.	Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Fitch RH, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-45; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gay EA, 2006, J PHARMACOL EXP THER, V316, P835, DOI 10.1124/jpet.105.095505; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2005, RESTOR NEUROL NEUROS, V23, P67; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; Means LW, 1996, PHYSIOL BEHAV, V60, P1239, DOI 10.1016/S0031-9384(96)00129-1; MEANS LW, 1993, NEUROBEHAVIORAL PLAS, P67; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Schulteis G, 2008, ALCOHOL, V42, P459, DOI 10.1016/j.alcohol.2008.05.002; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129; Zareparsi S, 2002, AM J MED GENET, V107, P156, DOI 10.1002/ajmg.10111	41	36	42	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2009	26	1					121	129		10.1089/neu.2008.0565			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	409OW	WOS:000263516700010	19119914	Green Published, Green Accepted			2021-06-18	
J	Stern, S; Rice, J; Philbin, N; McGwin, G; Arnaud, F; Johnson, T; Flournoy, WS; Ahlers, S; Pearce, LB; McCarron, R; Freilich, D				Stern, Susan; Rice, Jennifer; Philbin, Nora; McGwin, Gerald; Arnaud, Francoise; Johnson, Todd; Flournoy, W. Shannon; Ahlers, Stephen; Pearce, L. Bruce; McCarron, Richard; Freilich, Daniel			RESUSCITATION WITH THE HEMOGLOBIN-BASED OXYGEN CARRIER, HBOC-201, IN A SWINE MODEL OF SEVERE UNCONTROLLED HEMORRHAGE AND TRAUMATIC BRAIN INJURY	SHOCK			English	Article						Hemoglobin-based oxygen carrier; HBOC-201; hemorrhagic shock; traumatic brain injury; resuscitation	BOVINE POLYMERIZED HEMOGLOBIN; CEREBRAL-BLOOD-FLOW; HYPERTONIC SALINE DEXTRAN; LACTATED RINGERS SOLUTION; LOW-VOLUME RESUSCITATION; CROSS-LINKED HEMOGLOBIN; CLOSED-HEAD TRAUMA; INTRACRANIAL-PRESSURE; INTRAVASCULAR MACROPHAGES; HYPOTENSIVE RESUSCITATION	The purpose of this investigation was to compare the effects of initial resuscitation with HBOC-201 to that of lactated Ringer (LR) solution in the setting of uncontrolled hemorrhage and traumatic brain injury (TBI). Anesthetized immature swine underwent fluid-percussion TBI and liver laceration. During a 75-min "prehospital phase," the animals were resuscitated with HBOC-201, LR solution, or nothing (NON). Upon "hospital arrival," the animals were provided blood and 0.9% NaCl as needed, and the liver injury was repaired. Surviving animals were killed 6 h after injury. Brain tissue was processed for blood flow, and gross, light microscopic, and immunohistochemical analyses. Mean TBI force (2.6 +/- 0.6 atm) and blood loss (64.4 +/- 3.4 mL/kg) were similar between groups. Six-hour survival was significantly greater in HBOC-201 (8 of 13 [62%]) versus LR solution (1 of 11 [9%]) and NON (11 of 8 [3%]) animals (P < 0.02). Mean arterial pressures, cardiac indices, cerebral perfusion pressures, and brain tissue oxygen tension were significantly greater, and lactate and base deficit were lower in HBOC-201 as compared with LR solution animals. Blood transfusion requirements were reduced in HBOC-201 (3.6 +/- 0.6 mL/kg per survival hour) as compared to 7.1 +/- 1.2 mL/kg per survival hour. Severity of subarachnoid and intraparenchymal hemorrhages was statistically greater in LR solution-treated animals, but these differences were not likely to be clinically significant. There were no differences in glial fibrillary acidic protein and microtubule-associated protein 2. In this model of combined uncontrolled hemorrhage and TBI, initial resuscitation with HBOC-201 resulted in significant improvements in survival and systemic and cerebrovascular physiological parameters, as well as a reduction in transfusion requirements.	[Stern, Susan] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Rice, Jennifer; Philbin, Nora; Arnaud, Francoise; Johnson, Todd; Ahlers, Stephen; McCarron, Richard; Freilich, Daniel] Naval Med Res Ctr, Silver Spring, MD USA; [McGwin, Gerald] Univ Alabama Birmingham, Birmingham, AL USA; [Flournoy, W. Shannon] Walter Reed Army Inst Res, Silver Spring, MD USA; [Pearce, L. Bruce] Biopure Corp, Cambridge, MA USA	Stern, S (corresponding author), Univ Michigan, Dept Emergency Med, TC B1 354,Box 0303,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	suestern@umich.edu			US Government (Office of Naval Research)Office of Naval Research [604771N.9595.001.A0315]	The studies described herein were entirely funded by the US Government (Office of Naval Research work unit no. 604771N.9595.001.A0315). The Naval Medical Research Center and Biopure Corp. have a Cooperative Research and Development Agreement for evaluation of HBOC-201 in trauma clinical trials. No Naval Medical Research Center or other authors (with the exception of L.B.P. of Biopure Corp.) have financial or other competing interests related to this article. Hemoglobin-based oxygen carrier formulations were provided by Biopure Corp. (under Materials Transfer Agreements). There were no transfers of funds in ally of these agreements. Dr. Bruce Pearce is in employee of Biopure Corp. and has financial interest in the subject material. HBOC-201. Dr. Pearce's contribution to this article was limited to study design, protocol authorship, and editorial review.; The opinions expressed in this article are those of the authors and do not reflect the official policy of the Departments of the Navy, Army, and Defense. or the US Government.; D.F. is a military service member (or employee of the US government). This work was prepared as part of my official duties. Title 17 U.S.C 105 provides that "Copyright protection under this title is not available for any work of the United States Government." Title 17 U.S.C 101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties.	Alspaugh DM, 2000, J TRAUMA, V48, P851, DOI 10.1097/00005373-200005000-00008; *AM ASS NEUR, 1995, JOINT SECT TRAUM CRI; *AM COLL SURG COT, 1997, ADV TRAUM LIF SUPP P; Arnaud F, 2006, TRANSFUSION MED, V16, P290, DOI 10.1111/j.1365-3148.2006.00678.x; Asano Y, 1998, AM J PHYSIOL-HEART C, V275, pH1313; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Caswell JE, 2005, AM J PHYSIOL-HEART C, V288, pH1796, DOI 10.1152/ajpheart.00905.2004; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Doucet JJ, 1999, J TRAUMA, V47, P956, DOI 10.1097/00005373-199911000-00027; Driessen B, 2003, CRIT CARE MED, V31, P1771, DOI 10.1097/01.CCM.0000063476.79749.C1; DUNHAM CM, 1991, CRIT CARE MED, V19, P231, DOI 10.1097/00003246-199102000-00020; ENZAN K, 1991, J APPL PHYSIOL, V71, P2231; Feldman Z, 1997, J TRAUMA, V43, P667, DOI 10.1097/00005373-199710000-00017; Fitzpatrick MCM, 2005, J TRAUMA, V59, P273, DOI 10.1097/01.ta.0000174730.62338.88; FLAIM SF, 1991, INVEST RADIOL, V26, pS122, DOI 10.1097/00004424-199111001-00041; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; George I, 2006, AM J PHYSIOL-HEART C, V291, pH1126, DOI 10.1152/ajpheart.00076.2006; Gow AJ, 1998, NATURE, V391, P169; GROSS D, 1989, J TRAUMA, V29, P79, DOI 10.1097/00005373-198901000-00016; GROSSLIGHT K, 1985, ANESTHESIOLOGY, V63, P533, DOI 10.1097/00000542-198511000-00011; Gulati A, 1996, CRIT CARE MED, V24, P137, DOI 10.1097/00003246-199601000-00023; GUNNAR W, 1988, SURGERY, V103, P398; Gurney J, 2004, J TRAUMA, V57, P726, DOI 10.1097/01.TA.0000147520.84792.B4; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johnson SB, 1996, J TRAUMA, V40, P921; Kasper SM, 1996, ANESTH ANALG, V83, P921; Kaufmann CR, 2005, J TRAUMA, V59, P281; Kerby JD, 2007, SHOCK, V27, P652, DOI 10.1097/01.shk.0000248584.10400.dc; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; Lee SK, 2002, ACAD EMERG MED, V9, P969; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; Matsuoka T, 1996, J TRAUMA, V40, P915, DOI 10.1097/00005373-199606000-00009; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; McNeil JD, 2001, J TRAUMA, V50, P1063, DOI 10.1097/00005373-200106000-00015; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MIYAMOTO K, 1988, J APPL PHYSIOL, V64, P1143; OLSON DA, 2004, E MED; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Pearce LB, 2003, ADV EXP MED BIOL, V530, P261; Philbin N, 2005, RESUSCITATION, V66, P367, DOI 10.1016/j.resuscitation.2005.03.019; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Rebel A, 2002, AM J PHYSIOL-HEART C, V282, pH832, DOI 10.1152/ajpheart.00880.2001; Reinhardt CP, 2001, AM J PHYSIOL-HEART C, V280, pH108; Rice J, 2005, SHOCK, V23, P20; Rice J, 2006, J TRAUMA, V61, P1085, DOI 10.1097/01.ta.0000236640.62893.fa; Rice J, 2006, SHOCK, V26, P302, DOI 10.1097/01.shk.0000226338.48033.c2; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; SCHULTZ SC, 1993, J LAB CLIN MED, V122, P301; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 2005, J TRAUMA, V59, P560; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; SHOEMAKER WC, 1979, CRIT CARE MED, V7, P424, DOI 10.1097/00003246-197909000-00015; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Sondeen JL, 2003, J TRAUMA, V54, pS110, DOI 10.1097/01.TA.0000047220.81795.3D; SPAHN DR, 1994, ANESTH ANALG, V78, P1000; STAUB N C, 1988, Chest, V93, p84S, DOI 10.1378/chest.93.3_Supplement.84S; STERN S, 1996, ACAD EMERG MED, V3, P545; STERN SA, 1995, AM J EMERG MED, V13, P269, DOI 10.1016/0735-6757(95)90198-1; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; STERN SA, 1995, ACAD EMERG MED, V2, P89, DOI 10.1111/j.1553-2712.1995.tb03167.x; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; Talmor D, 1999, ANESTH ANALG, V89, P950, DOI 10.1097/00000539-199910000-00024; Torres LN, 2004, AM J PHYSIOL-HEART C, V286, pH1811, DOI 10.1152/ajpheart.00837.2003; Tsai AG, 2001, TRANSFUSION, V41, P1290, DOI 10.1046/j.1537-2995.2001.41101290.x; Ulatowski JA, 1998, AM J PHYSIOL-HEART C, V274, pH1933; VLAHAKES GJ, 1990, J THORAC CARDIOV SUR, V100, P379; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WANG Y, 1993, AM REV RESPIR DIS, V147, P927, DOI 10.1164/ajrccm/147.4.927; WINKLER GC, 1985, J LEUKOCYTE BIOL, V38, P471; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F; YUAN XQ, 1991, CIRC SHOCK, V35, P231; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	87	36	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JAN	2009	31	1					64	79		10.1097/SHK.0b013e3181778dc3			16	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	385LO	WOS:000261815900010	18497706				2021-06-18	
J	Vallat-Azouvi, C; Pradat-Diehl, P; Azouvi, P				Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe			Rehabilitation of the central executive of working memory after severe traumatic brain injury: Two single-case studies	BRAIN INJURY			English	Article						Cognitive rehabilitation; executive functioning; attention; traumatic brain injury	DUAL-TASK PERFORMANCE; DIVIDED ATTENTION; SELECTIVE IMPAIRMENT; DEFICITS; COMPONENT; CHILDREN; LOAD	Background/objective: A deficit of the central executive of working memory is a frequent finding in patients with severe traumatic brain injury (TBI). The objective of the present study was to assess the efficacy of a rehabilitation programme of the central executive after severe TBI. Method: An experimental single-case design was used in two patients with remote severe TBI suffering from an isolated central executive deficit. Outcome was assessed with specific working memory tests (spans, Brown Peterson, n-back), non-specific cognitive tasks requiring working memory (dual-task, arithmetic solving problem), an ecological questionnaire to assess generalization to everyday life and non-target tasks not requiring working memory, to assess the specificity of the therapy. Results: Performance was stable on two baseline sessions before therapy. For both patients, an improvement was found for target measures, mainly for central executive tasks, and for the questionnaire on attention failures in everyday life. In opposition, no change was found for non-target measures. Discussion: Improvement was not seemingly related to spontaneous recovery, nor to re-test effects. This study suggests that specific cognitive training may improve the central executive of working memory in patients with remote severe TBI.	[Azouvi, Philippe] Hop Raymond Poincare, Serv Med Phys & Readapt, AP HP, F-92380 Garches, France; [Vallat-Azouvi, Claire] Hop Raymond Poincare, UGECAM Antenne UEROS, F-92380 Garches, France; [Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe] INSERM, U731, Paris, France; [Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe] UPMC, Fac Med, Lab Physiol & Physiopathol Motricite, Paris, France; [Pradat-Diehl, Pascale] Hop La Pitie Salpetriere, AP HP, Serv Med Phys & Readapt, Paris, France; [Azouvi, Philippe] Univ Versailles St Quentin, Versailles, France	Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readapt, AP HP, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr					Allain P, 2001, BRAIN COGNITION, V45, P21, DOI 10.1006/brcg.2000.1249; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A. D., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Baddeley A. D., 1986, WORKING MEMORY; BROOKS D N, 1975, Cortex, V11, P329; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; Duval J, 2008, NEUROPSYCHOL REHABIL, V18, P430, DOI 10.1080/09602010701573950; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Le Gall C., 2007, Annales de Readaptation et de Medecine Physique, V50, P5, DOI 10.1016/j.annrmp.2006.06.007; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; WECHSLER D, 1997, WAIS 3 MANUEL ECHELL; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767; Wilson B.A, 1987, REHABILITATION MEMOR; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; ZIMMERMANN P, 1992, BATTERIE TESTS NEURO; Zimmermann P, 1995, TEST ATTENTIONAL PER	52	36	38	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					585	594	PII 911809129	10.1080/02699050902970711			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800012	19484632				2021-06-18	
J	Weichel, EA; Colyer, MH; Bautista, C; Bower, KS; French, LM				Weichel, Eric A.; Colyer, Marcus H.; Bautista, Charisma; Bower, Kraig S.; French, Louis M.			Traumatic Brain Injury Associated With Combat Ocular Trauma	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed-globe; ocular trauma; open-globe; Operation Iraqi Freedom; traumatic brain injury	UNITED-STATES; REHABILITATION; IRAQ; WAR; AFGHANISTAN; IMPAIRMENT; DEPRESSION; MANAGEMENT; OUTCOMES; SYSTEM	Purpose: To determine the impact of traumatic brain injury (TBI) on visual outcomes in combat ocular trauma (COT) and determine the association between TBI severity and types of ocular injuries. Participants: One hundred fifty-two US casualties sustained 207 globe/oculoplastic combat injuries. Methods: Retrospective, hospital-based cross-sectional study of US service members injured during Operations Iraqi Freedom and Enduring Freedom were treated by the Ophthalmology Service at Walter Reed Army Medical Center and screened for TBI by the Defense and Veterans Brain Injury Center from August 2004 to October 2006. Main Outcome Measures: The main outcome measure was best-corrected visual acuity (BCVA). Secondary outcome measures included the severity and frequency of TBI with globe, oculoplastic, and/or neuro-ophthalmic injury. Results: The frequency of COT with positive TBI screening was 101 of 152 cases (66%) in comparison with negative TBI screening, which was 51 of 152 (34%) cases. The Defense and Veterans Brain Injury Center found TBI with concomitant ocular trauma in 101 of 474 (21%) consecutive casualties. Explosive fragmentary munitions accounted for 79% of TBI-associated COT The median follow-up was 185 days. Traumatic brain injury severity did not correlate with worse final BCVA (Spearman coefficient, r = 0.12). The odds that BCVA worse than 20/200 was present with TBI was not statistically significant (OR: 1.5; 95% CI, 0.9-2.6; P =. 10). The presence of TBI in COT was not associated with worse visual outcome (Mann-Whitney U test,P = .10). Globe injuries were more common than oculoplastic or neuro-ophthalmic injury. Closed-globe injuries were more likely to have TBI than open-globe injuries (OR: 2.17; 95% CI, 1.12-4.21; P = .03). Traumatic brain injury severity associated with COT included mild TBI (31%), moderate TBI (30%), severe TBI (25%), and penetrating TBI (14%). Severe TBI is more frequently associated with COT Conclusion: Traumatic brain injury occurs in two thirds of all COT and ocular trauma is a common finding in all TBI cases. Closed-globe injuries are at highest risk for TBI while TBI does not appear to lead to poorer visual outcomes. Every patient with COT needs TBI screening. Those service members who are screened TBI positive need a referral to a TBI rehabilitation specialist.	[Weichel, Eric A.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA; [French, Louis M.] Def & Vet Brain Injury Ctr, Washington, DC USA; [Weichel, Eric A.] NEI, NIH, Bethesda, MD 20892 USA; [Bautista, Charisma; Bower, Kraig S.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Weichel, EA (corresponding author), Walter Reed Army Med Ctr, Ophthalmol Serv, 6900 Georgia Ave, Washington, DC 20307 USA.	eweichel@hotmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Andermahr J, 2006, J NEUROTRAUM, V23, P708, DOI 10.1089/neu.2006.23.708; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; *DEP DEF PERS PROC, GLOB WAR TERR OP END; *DEP DEF PERS PROC, 2003, OP IR FREED MIL WOUN; DUKEELDER S, 1972, SYSTEM OPHTHALMOLOGY, V14, P50; Elovic EP, 2008, ARCH PHYS MED REHAB, V89, pS21, DOI 10.1016/j.apmr.2007.12.012; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Flanagan SR, 2008, ARCH PHYS MED REHAB, V89, pS9, DOI 10.1016/j.apmr.2007.12.010; Frucht SJ, 2002, ADV NEUROL, V89, P85; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; *GOVTRACK US S, 1999, 110 C BILL PROV EST; GUNDERSEN T, 1947, T AM ACAD OPHTHALMOL, V52, P604; Harlan J B Jr, 2002, Ophthalmol Clin North Am, V15, P153, DOI 10.1016/S0896-1549(02)00006-8; HEIER JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P795, DOI 10.1001/archopht.1993.01090060083028; HORNBLASS A, 1981, International Ophthalmology Clinics, V21, P121, DOI 10.1097/00004397-198102140-00008; Jacobs JM, 2005, AGING CLIN EXP RES, V17, P281; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kuhn F, 1996, GRAEF ARCH CLIN EXP, V234, P399, DOI 10.1007/BF00190717; Kuhn F, 2004, J FR OPHTALMOL, V27, P206, DOI 10.1016/S0181-5512(04)96122-0; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P139, DOI 10.1016/S0896-1549(02)00004-4; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P163, DOI 10.1016/S0896-1549(02)00007-X; Kwasnica C, 2008, ARCH PHYS MED REHAB, V89, pS15, DOI 10.1016/j.apmr.2007.12.006; LOWREY A, 1954, Trans Pac Coast Otoophthalmol Soc Annu Meet, V35, P39; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Naraghi FF, 1996, ORTHOPEDICS, V19, P145; Parsons J., 1941, T OPHTHAL SOC UK, V61, P157; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; STONE W, 1950, JAMA-J AM MED ASSOC, V142, P151, DOI 10.1001/jama.1950.02910210007002; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; Winter CD, 2005, SURG-J R COLL SURG E, V3, P329, DOI 10.1016/S1479-666X(05)80112-X	47	36	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					41	50		10.1097/HTR.0b013e3181956ffd			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500007	19158595				2021-06-18	
J	Yang, CC; Hua, MS; Tu, YK; Huang, SJ				Yang, Chi-Cheng; Hua, Mau-Sun; Tu, Yong-Kwang; Huang, Sheng-Jean			Early clinical characteristics of patients with persistent post-concussion symptoms: A prospective study	BRAIN INJURY			English	Article						Persistent post-concussion symptoms; early predictors; prospective study	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; COMA SCALE SCORE; QUALITY-OF-LIFE; POSTCONCUSSION SYMPTOMS; DIAGNOSTIC-CRITERIA; MODERATE; MANAGEMENT; DISABILITY; PREDICTION	Primary objective: To identify the early clinical features of patients with mild traumatic brain injury (mTBI) that are predictive of the presence of persistent post-concussion symptoms (PPCS). Research design: A prospective study was conducted at a level I trauma centre. Methods and procedures: One hundred and eighty mTBI patients participated in this study. The post-concussion symptoms (PCS) were evaluated with a PCS checklist. All patients were examined at 1, 2 and 8 weeks post-injury. The chi-square test was used to evaluate the associations of each PCS and the logistic regression was used to identify potential predictors of mTBI patients who might suffer from PPCS. Main outcomes and results: Less than one-tenth of the mTBI patients examined complained of PPCS at 2 months after head trauma. Patients with PPCS are more likely to suffer from intracranial lesions. Moreover, clinical symptoms at 1 and 2 weeks post-injury, especially physical ones including headache, dizziness and fatigue, were reported significantly more often by patients with PPCS. Conclusions: This study showed that early clinical symptoms and intracranial lesions may be strongly associated with the presence of PPCS. Thus, those specific characteristics may be used as early indicators of long-term difficulties.	[Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Neurosurg, Taipei 100, Taiwan; [Huang, Sheng-Jean] Natl Taiwan Univ, Dept Surg, Taipei, Taiwan; [Yang, Chi-Cheng; Tu, Yong-Kwang; Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan; [Yang, Chi-Cheng; Hua, Mau-Sun] Natl Taiwan Univ, Dept Psychol, Taipei, Taiwan	Huang, SJ (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, 7 Chung San S Rd, Taipei 100, Taiwan.	d92227007@ntu.edu.tw		Tu, Yong-kwang/0000-0003-2113-1176			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chi H. T., 2005, CLASSIFICATION MED R; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Department of Health, 2005, HLTH NAT HLTH INS AN; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Granacher Jr RP, 2003, TRAUMATIC BRAIN INJU, P25; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; HSIANG JN, 2005, LONG TERM EFFECTS ME, V15, P153; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; KRAUS JF, 1996, NEUROTRAUMA, P13; LEE LH, 1992, CHIN MED J TAPIEI, V50, P219; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MCCREA MA, 2007, MILD TRAUMATIC BRAIN, P153; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Tellier A, 1999, BRAIN INJURY, V13, P463; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Von Wild K, 2001, BRAIN INJURY, V15, P273; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Zasler N. D., 2007, BRAIN INJURY MED PRI, P779; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	56	36	37	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	4					299	306	PII 909975018	10.1080/02699050902788543			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000004	19330593				2021-06-18	
J	Ost, M; Nylen, K; Csajbok, L; Blennow, K; Rosengren, L; Nellgard, B				Ost, M.; Nylen, K.; Csajbok, L.; Blennow, K.; Rosengren, L.; Nellgard, B.			Apolipoprotein E polymorphism and gender difference in outcome after severe traumatic brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						Apolipoprotein E; brain injuries; child; female; Glasgow outcome scale; male; survival rate	AMYLOID BETA-PROTEIN; ALZHEIMERS-DISEASE; E GENOTYPE; APOE IMMUNOREACTIVITY; CEREBROSPINAL-FLUID; TRANSGENIC MICE; NEURONAL DAMAGE; ASSOCIATION; ALLELE; HEMORRHAGE	Background: Traumatic brain injury (TBI) is one of the most common causes of death and dismal outcome among children and young adults. The morbidity and mortality differ but more aggressive monitoring and more designated neuro intensive care units have improved the results. Studies have demonstrated a connection between apolipoprotein E (APOE) genotype and outcome after TBI, but few are prospective and none is from northern Europe. APOE has three alleles: epsilon 2, epsilon 3 and epsilon 4. Methods: A total of 96 patients with Glasgow coma score (GCS) <= 8 were prospectively and consecutively included. APOE genotypes were all analyzed at the same laboratory from blood samples by polymerase chain reaction-restriction fragment length polymorphism. Results: All patients were assessed at 1 year with Glasgow outcome scale extended (GOSE), National Institute of Health Stroke Scale (NIHSS) and the Barthel daily living index. The genotype was available in all patients. Twenty-six patients expressed APOE epsilon 4 while 70 patients did not. Outcome demonstrated that patients with APOE epsilon 4 had worse outcome vs. those lacking this allele. When subdividing patients into gender, males with APOE epsilon 4 did worse, a difference not detected among female patients. Conclusions: APOE epsilon 4 correlated to worse outcome in TBI patients. We also found that males with APOE epsilon 4 had poor outcome while females did not. Thus, the results indicate that genetic polymorphism may influence outcome after TBI.	[Ost, M.; Csajbok, L.; Nellgard, B.] Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41135 Gothenburg, Sweden; [Nylen, K.; Rosengren, L.] Sahlgrens Univ Hosp, Dept Neurol, S-41135 Gothenburg, Sweden; [Blennow, K.] Sahlgrens Univ Hosp, Dept Neurochem, S-41135 Gothenburg, Sweden	Ost, M (corresponding author), Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41135 Gothenburg, Sweden.	martin.ost@gmail.com	Ost, Martin/AAY-5827-2020	Rosengren, Lars/0000-0003-0505-8896	Laerdal Foundation; Mattson's Memorial Foundation; Swedish Medical Grants [S-160 00]	We wish to thank Ingrid Eiving, Ingrid Pettersson and Catherine Ritzen for their excellent contribution to the study. This study was supported by Laerdal Foundation, Mattson's Memorial Foundation and Swedish Medical Grant S-160 00.	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Blennow K, 2000, J NEURAL TRANSM, V107, P1065, DOI 10.1007/s007020070052; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corder EH, 2000, ANN NY ACAD SCI, V908, P295; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Erbagci AB, 2002, ACTA CARDIOL, V57, P197, DOI 10.2143/AC.57.3.2005389; Farace E, 2000, Neurosurg Focus, V8, pe6; Gerdes LU, 2003, CLIN CHEM LAB MED, V41, P628, DOI 10.1515/CCLM.2003.094; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jaramillo-Correa JP, 2001, HUM HERED, V52, P14, DOI 10.1159/000053351; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Lambert JC, 2005, J NEUROL NEUROSUR PS, V76, P928, DOI 10.1136/jnnp.2004.048983; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MAHONEY F I, 1965, Md State Med J, V14, P61; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McCarron MO, 1999, J NEUROPATH EXP NEUR, V58, P711, DOI 10.1097/00005072-199907000-00005; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; PEACOCK ML, 1994, NEUROLOGY, V44, P339, DOI 10.1212/WNL.44.2.339; Qiu C, 2004, J NEUROL NEUROSUR PS, V75, P828, DOI 10.1136/jnnp.2003.021493; Thelandersson A, 2006, ACTA ANAESTH SCAND, V50, P937, DOI 10.1111/j.1399-6576.2006.01037.x; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	38	36	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2008	52	10					1364	1369		10.1111/j.1399-6576.2008.01675.x			6	Anesthesiology	Anesthesiology	361ME	WOS:000260131000011	19025529				2021-06-18	
J	Curtis, KL; Thompson, LK; Greve, KW; Bianchini, KJ				Curtis, Kelly L.; Thompson, Laura K.; Greve, Kevin W.; Bianchini, Kevin J.			Verbal fluency indicators of malingering in traumatic brain injury: Classification accuracy in known groups	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	25th Annual Meeting of the National-Academy-of-Neuropsychology	OCT 19-22, 2005	Tampa, FL	Natl Acad Neuropsychol		COWAT : known-groups; malingering; traumatic brain injury; verbal fluency	WORD-ASSOCIATION TEST; FRONTAL-LOBE LESIONS; CARD SORTING TEST; NEUROCOGNITIVE DYSFUNCTION; ALZHEIMERS TYPE; PERFORMANCE; DEMENTIA; RELIABILITY	A known-groups design was used to determine the classification accuracy of verbal fluency variables in detecting Malingered Neurocognitive Dysfunction (MND) in traumatic brain injury (TBI). Participants were 204 TBI and 488 general clinical patients. The Slick et al. (1999) criteria were used to classify the TBI patients into non-MND and MND groups. An educationally corrected FAS Total Correct word T-score proved to be the most accurate of the several verbal fluency indicators examined. Classification accuracy of this variable at specific cutoffs is presented in a cumulative frequency table. This variable accurately differentiated non-MND from MND mild TBI patients but its accuracy was unacceptable in moderate/severe TBI. The clinical application of these findings is discussed.	[Curtis, Kelly L.; Thompson, Laura K.; Greve, Kevin W.; Bianchini, Kevin J.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Baldo JV, 1998, NEUROPSYCHOLOGY, V12, P259, DOI 10.1037/0894-4105.12.2.259; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Benton A., 1994, MULTILINGUAL APHASIA; BIANCHINI KJ, 2001, CLIN NEUROPSYCHOL, V17, P255; BINDER LM, 1993, PORTLAND DIGIT RECOG; BOLLA KI, 1990, J CLIN PSYCHOL, V46, P623, DOI 10.1002/1097-4679(199009)46:5<623::AID-JCLP2270460513>3.0.CO;2-C; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; CHERTKOW H, 1990, BRAIN, V113, P397, DOI 10.1093/brain/113.2.397; Demakis GJ, 2003, CLIN NEUROPSYCHOL, V17, P322, DOI 10.1076/clin.17.3.322.18081; Demakis GJ, 1999, ARCH CLIN NEUROPSYCH, V14, P401, DOI 10.1016/S0887-6177(98)00039-0; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton RK, 2004, REVISED COMPREHENSIV; Hennekens CH, 1987, EPIDEMIOLOGY MED; Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Loonstra A S, 2001, Appl Neuropsychol, V8, P161, DOI 10.1207/S15324826AN0803_5; MARGOLIN DI, 1990, J CLIN EXP NEUROPSYC, V12, P597, DOI 10.1080/01688639008401004; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; MITTENBERG W, 1995, PROFESSIONAL PSYCHOL, V26, P492; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Ross TP, 2003, ARCH CLIN NEUROPSYCH, V18, P153, DOI 10.1016/S0887-6177(01)00192-5; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O., 1991, COMPENDIUM NEUROPSYC; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Tombaugh TN, 1996, TEST MEMORY MALINGER	41	36	37	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	5					930	945		10.1080/13854040701563591			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	342HP	WOS:000258775500012	18756393				2021-06-18	
J	Di Giorgio, AM; Hou, YJ; Zhao, XR; Zhang, B; Lyeth, BG; Russell, MJ				Di Giorgio, Anthony M.; Hou, Yongjin; Zhao, Xueren; Zhang, Bin; Lyeth, Bruce G.; Russell, Michael J.			Dimethyl sulfoxide provides neuroprotection in a traumatic brain injury model	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						DMSO; curcumin; traumatic brain injury; antioxidant; neuroprotection	ACUTE NEURONAL DEGENERATION; FOCAL CEREBRAL-ISCHEMIA; FLUORO-JADE; OXIDATIVE STRESS; BEHAVIORAL DEFICITS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; SPINAL-CORD; CURCUMIN; RAT	Purpose: The objective of this study was to evaluate the neuroprotective potential of the antioxidant, curcumin compared to alpha-tocopherol in a rat model of traumatic brain injury (TBI). Methods: Male Sprague-Dawley rats were administered curcumin (3, 30, 300 mg/kg), alpha-tocopherol (100 mg/kg), DMSO vehicle, or saline, 30 min prior to and 30 and 90 min after moderate lateral fluid percussion TBI. Rats were euthanized at 24 hours after injury and coronal brain sections were stained with Fluoro-Jade to identify degenerating neurons. Degenerating neurons in the CA2-3 sector of the dorsal hippocampus were quantified in 10 sections spaced 300 mu m apart in each rat. Results: One way ANOVA revealed a significant difference (p = 0.01) between groups. The curcumin, alpha-tocopherol, and DMSO groups had significantly reduced numbers of degenerating neurons compared to the saline-treated group. No significant differences were observed between any of the drug treatment groups or the DMSO group. Conclusions: Since protection in the DMSO vehicle group was equal to that of the experimental groups, no conclusions about neuroprotection regarding alpha-tocopherol or curcumin can be made from this study. The results suggest that DMSO may be acting as an overriding neuroprotectant in this experiment. We conclude that DMSO is a viable neuroprotective agent against secondary cell death in TBI.	[Zhao, Xueren; Zhang, Bin; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Di Giorgio, Anthony M.; Hou, Yongjin; Russell, Michael J.] AAaken Labs, Davis, CA USA; [Zhang, Bin] Shandong Univ, Sch Med, Dept Pharmacol, Jinan 250100, Shandong, Peoples R China	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 45136]; Aaken Laboratories; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136] Funding Source: NIH RePORTER	This research was supported in part by NIH NS 45136 ( BGL) and Aaken Laboratories ( MJR).	Bardutzky J, 2005, J CEREBR BLOOD F MET, V25, P968, DOI 10.1038/sj.jcbfm.9600095; BROMONT C, 1989, STROKE, V20, P918, DOI 10.1161/01.STR.20.7.918; Butterfield DA, 2002, J NUTR BIOCHEM, V13, P444, DOI 10.1016/S0955-2863(02)00205-X; CLEMENS JA, 1991, STROKE, V22, P1048, DOI 10.1161/01.STR.22.8.1048; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; Cuzzocrea S, 2000, J PINEAL RES, V29, P217, DOI 10.1034/j.1600-0633.2002.290404.x; DELATORRE JC, 1991, CAN J PHYSIOL PHARM, V69, P191, DOI 10.1139/y91-028; DIKSHIT M, 1995, INDIAN J MED RES, V101, P31; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Ghoneim AI, 2002, PHARMACOL RES, V46, P273, DOI 10.1016/S1043-6618(02)00123-8; HALL ED, 1992, J NEUROTRAUM, V9, pS165; Hulsmann S, 1999, NEUROSCI LETT, V261, P1, DOI 10.1016/S0304-3940(98)00999-9; Ikeda K, 2003, TOXICOLOGY, V189, P55, DOI 10.1016/S0300-483X(03)00152-5; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Langbein John H., 2006, TRAUMATIC BRAIN INJU, P1; Lim GP, 2001, J NEUROSCI, V21, P8370; LITTLE JR, 1983, ANN NY ACAD SCI, V411, P269, DOI 10.1111/j.1749-6632.1983.tb47308.x; LITTLE JR, 1981, NEUROSURGERY, V9, P34, DOI 10.1227/00006123-198107000-00006; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR M, 1996, DMSO MANY USES MUCH, P230; Osakada F, 2003, EUR J PHARMACOL, V465, P15, DOI 10.1016/S0014-2999(03)01495-X; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Perez-Pasten R, 2006, TOXICOL LETT, V161, P167, DOI 10.1016/j.toxlet.2005.09.001; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rajakrishnan V, 1999, PHYTOTHER RES, V13, P571, DOI 10.1002/(SICI)1099-1573(199911)13:7&lt;571::AID-PTR494&gt;3.0.CO;2-7; REITER RJ, 1995, FASEB J, V9, P526; REPINE JE, 1981, P NATL ACAD SCI-BIOL, V78, P1001, DOI 10.1073/pnas.78.2.1001; SABEL BA, 1985, EXP NEUROL, V88, P95, DOI 10.1016/0014-4886(85)90116-5; SABEL BA, 1982, PHYSIOL BEHAV, V28, P1017, DOI 10.1016/0031-9384(82)90169-X; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SAWADA M, 1975, ANN NY ACAD SCI, V243, P337, DOI 10.1111/j.1749-6632.1975.tb25375.x; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4; Shoskes DA, 1998, TRANSPLANTATION, V66, P147, DOI 10.1097/00007890-199807270-00001; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Simonyi A, 2005, MOL NEUROBIOL, V31, P135, DOI 10.1385/MN:31:1-3:135; SREEJAYAN, 1994, J PHARM PHARMACOL, V46, P1013, DOI 10.1111/j.2042-7158.1994.tb03258.x; SRIMAL RC, 1973, J PHARM PHARMACOL, V25, P447, DOI 10.1111/j.2042-7158.1973.tb09131.x; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; TORRE JCDL, 1976, STROKE, V7, P577; Wang Q, 2005, J NEUROSCI RES, V82, P138, DOI 10.1002/jnr.20610; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	53	36	36	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2008	26	6					501	507					7	Neurosciences	Neurosciences & Neurology	390KO	WOS:000262162900007	19096138				2021-06-18	
J	Ruocco, AC; Swirsky-Sacchetti, T; Chute, DL; Mandel, S; Platek, SM; Zillmer, EA				Ruocco, Anthony C.; Swirsky-Sacchetti, Thomas; Chute, Douglas L.; Mandel, Steven; Platek, Steven M.; Zillmer, Eric A.			Distinguishing between neuropsychological malingering and exaggerated psychiatric symptoms in a neuropsychological setting	CLINICAL NEUROPSYCHOLOGIST			English	Article						malingering; neuropsychology; personality; symptom validity	CLINICAL MULTIAXIAL INVENTORY; PERSONAL-INJURY LITIGANTS; MMPI-2 VALIDITY SCALES; CLOSED-HEAD INJURY; FAKE BAD SCALE; NEUROCOGNITIVE DYSFUNCTION; DISORDER SYMPTOMATOLOGY; COGNITIVELY INTACT; MODIFIER INDEXES; NORMATIVE DATA	It is unclear whether symptom validity test (SVT) failure in neuropsychological and psychiatric domains overlaps. Records of 105 patients referred for neuropsychological evaluation, who completed the Test of Memory Malingering (TOMM), Reliable Digit Span (RDS), and Millon Clinical Multiaxial Inventory-III (MCMI-III), were examined. TOMM and RDS scores were uncorrelated with MCMI-III symptom validity indices and factor analysis revealed two distinct factors for neuropsychological and psychiatric SVTs. Only 3.5% of the sample failed SVTs in both domains, 22.6% solely failed the neuropsychological SVT, and 6.1% solely failed the psychiatric SVT. The results support a dissociation between neuropsychological malingering and exaggeration of psychiatric symptoms in a neuropsychological setting.	[Ruocco, Anthony C.; Chute, Douglas L.; Platek, Steven M.; Zillmer, Eric A.] Drexel Univ, Dept Psychol, Neuropsychol Program, Philadelphia, PA 19102 USA; [Swirsky-Sacchetti, Thomas; Mandel, Steven] Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA	Ruocco, AC (corresponding author), Drexel Univ, Dept Psychol, Neuropsychol Program, 245 N 15th St,Mail Stop 626, Philadelphia, PA 19102 USA.	acr32@drexel.edu	Ruocco, Anthony C./B-4915-2010; Ruocco, Anthony Charles/AAM-4794-2021	Ruocco, Anthony C./0000-0002-1942-7181; 			Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BAGBY RM, 1991, PSYCHOL ASSESSMENT J, V3, P496, DOI DOI 10.1037/1040-3590.3.3.496; BAGBY RM, 1990, BEHAV SCI LAW, V8, P93; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Blais MA, 1995, J CLIN PSYCHOL, V51, P783, DOI 10.1002/1097-4679(199511)51:6<783::AID-JCLP2270510609>3.0.CO;2-8; BOONE KB, 1995, J CLIN PSYCHOL, V51, P457, DOI 10.1002/1097-4679(199505)51:3<457::AID-JCLP2270510322>3.0.CO;2-7; Bunce SC, 2005, PROC SPIE, V5769, P24, DOI 10.1117/12.600601; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher JN., 1989, MMPI 2 MINNESOTA MUL; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Choca J.P., 2004, INTERPRETIVE GUIDE M, V3rd; Daubert SD, 2000, PSYCHOL ASSESSMENT, V12, P418, DOI 10.1037/1040-3590.12.4.418; FALSSTEWART W, 1995, J PERS ASSESS, V64, P540, DOI 10.1207/s15327752jpa6403_11; Graham JR., 2000, MMPI 2 ASSESSING PER; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCaffrey R. J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; MCNEIL K, 1990, J CLIN PSYCHOL, V46, P755, DOI 10.1002/1097-4679(199011)46:6<755::AID-JCLP2270460609>3.0.CO;2-J; Millon T, 1997, MANUAL MILLON CLIN M; Millon T., 1983, MILLON CLIN MULTIAXI; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morgan CD, 2002, J PERS ASSESS, V78, P288, DOI 10.1207/S15327752JPA7802_05; Nunez JM, 2005, NEUROIMAGE, V25, P267, DOI 10.1016/j.neuroimage.2004.10.041; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; RETZLAFF PD, 1991, J PERS ASSESS, V55, P219; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ruocco AC, 2003, ARCH CLIN NEUROPSYCH, V18, P737; RUOCCO AC, 2006, UNPUB ASSESSING PERS; Ruocco AC, 2007, J NEUROPSYCH CLIN N, V19, P27, DOI 10.1176/appi.neuropsych.19.1.27; Schoenberg MR, 2004, J PERS ASSESS, V82, P273, DOI 10.1207/s15327752jpa8203_03; Schoenberg MR, 2003, PSYCHOL ASSESSMENT, V15, P198, DOI 10.1037/1040-3590.15.2.198; Slick D., 1997, VSVT VICTORIA SYMPTO; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; SMITH D, 1988, J CLIN PSYCHOL, V44, P165, DOI 10.1002/1097-4679(198803)44:2<165::AID-JCLP2270440212>3.0.CO;2-E; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; VANGORP WG, 1986, J CLIN PSYCHOL, V42, P742, DOI 10.1002/1097-4679(198609)42:5<742::AID-JCLP2270420510>3.0.CO;2-3; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Wise EA, 2002, PSYCHOL REP, V90, P760, DOI 10.2466/PR0.90.3.760-766; Zago S, 2004, CORTEX, V40, P519, DOI 10.1016/S0010-9452(08)70144-8	55	36	36	0	22	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	3					547	564		10.1080/13854040701336444			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	298LU	WOS:000255690000193	17853126				2021-06-18	
J	Wenke, RJ; Theodoros, D; Cornwell, P				Wenke, Rachel J.; Theodoros, Deborah; Cornwell, Petrea			The short- and long-term effectiveness of the LSVT (R) for dysarthria following TBI and stroke	BRAIN INJURY			English	Article						dysarthria; TBI; stroke; treatment	INTENSIVE VOICE TREATMENT; TRAUMATIC BRAIN-INJURY; HYPOKINETIC-SPASTIC DYSARTHRIA; SOUND PRESSURE LEVEL; PARKINSON-DISEASE; SPEECH TREATMENT; PRINCIPLED APPROACH; SPEAKING RATE; INTELLIGIBILITY; INDIVIDUALS	Objectives: To examine the effectiveness of Lee Silverman Voice Treatment (LSVT (R)) for the treatment of 10 individuals with dysarthria following TBI and stroke. Research design: ABAA experimental research design. Methods: Participants received 4 weeks of the standard LSVT (R) programme. To measure the effects of intervention, participants were assessed using perceptual and acoustic speech measures and everyday communication outcome measures prior to, immediately post and 6 months post-treatment. Results: Following treatment, participants demonstrated statistically and clinically significant improvements to several acoustic and perceptual parameters. This included increased vocal loudness in sustained phonation and connected speech, increased vocal frequency range and improved word and sentence intelligibility. Improved ratings of communication initiation and participation and well-being were also found on the AusTOMs and items on participant questionnaires post-LSVT (R). The majority of treatment effects were maintained 6 months following treatment. Conclusions: LSVT (R) has the potential to be a viable treatment option for individuals with dysarthria featuring respiratory-phonatory impairments following TBI and stroke.	[Wenke, Rachel J.; Theodoros, Deborah; Cornwell, Petrea] Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia; [Cornwell, Petrea] Princess Alexandra Hosp, Speech Pathol Dept, Brisbane, Qld 4102, Australia	Wenke, RJ (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia.	r.wenke@uq.edu.au	Cornwell, Petrea/AAE-5547-2019; Theodoros, Deborah/F-1362-2010				ARBOIX A, 1990, STROKE, V21, P842, DOI 10.1161/01.STR.21.6.842; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Ballard KJ, 2001, J COMMUN DISORD, V34, P3, DOI 10.1016/S0021-9924(00)00038-1; BINDER LM, 1987, REHABIL PSYCHOL, P65; Cahill LM, 2004, J HEAD TRAUMA REHAB, V19, P241, DOI 10.1097/00001199-200405000-00005; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; COUNTRYMAN S, 1994, J MED LANGUAGE PATHO, V3, P211; De Bodt MS, 2002, J COMMUN DISORD, V35, P283, DOI 10.1016/S0021-9924(02)00065-5; DEPIJPER JR, 2007, SEMITONE CONVERSIONS; Dromey C, 1998, J SPEECH LANG HEAR R, V41, P1003, DOI 10.1044/jslhr.4105.1003; Dromey C, 2000, J MED SPEECH-LANG PA, V8, P155; Duffy JR, 2019, MOTOR SPEECH DISORDE; Eadie TL, 2006, AM J SPEECH-LANG PAT, V15, P307, DOI 10.1044/1058-0360(2006/030); El Sharkawi A, 2002, J NEUROL NEUROSUR PS, V72, P31; ENGEN T, 1972, WOODWORTH SCHLOSBERG, P478; Fairbanks G., 1960, VOICE ARTICULATION D, V, 2nd ed; Fox CM., 1997, AM J SPEECH LANG PAT, V6, P85, DOI 10.1044/1058-0360.0602.85; Fox Cynthia M., 2006, Seminars in Speech and Language, V27, P283, DOI 10.1055/s-2006-955118; Hokkanen LSK, 2006, EUR J NEUROL, V13, P161, DOI 10.1111/j.1468-1331.2006.01157.x; Huber JE, 2006, J SPEECH LANG HEAR R, V49, P1368, DOI 10.1044/1092-4388(2006/098); KEATLEY A, 1994, EUR J DISORDER COMM, V29, P183; Kent R., 1996, AM J SPEECH LANG PAT, V5, P7, DOI DOI 10.1044/1058-0360.0503.07; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Knock TR, 2000, APHASIOLOGY, V14, P653, DOI 10.1080/026870300401379; LEFFORGE A, 2005, EAGLE FEATHER, V2, P1; MAAS E, IN PRESS AM J SPEECH; MCHENRY MA, 1994, J MED SPEECH-LANG PA, V2, P59; MILENKOVIC P, 2002, TF32 COMPUTER SOFTWA; Palmer R, 2007, INT J LANG COMM DIS, V42, P61, DOI 10.1080/13682820601173296; Perry A, 2004, INT J QUAL HEALTH C, V16, P285, DOI 10.1093/intqhc/mzh059; Prigatano GP, 2005, ACT NEUR S, V93, P39; Ramig L., 1994, J MED SPEECH LANG PA, V2, P191; Ramig L. O., 1992, INTELLIGIBILITY SPEE, DOI [10.1075/sspcl.1.05ram, DOI 10.1075/SSPCL.1.05RAM]; Ramig L. O, 1995, LEE SILVERMAN VOICE; Ramig LO, 1996, NEUROLOGY, V47, P1496, DOI 10.1212/WNL.47.6.1496; Ramig LO, 2001, J NEUROL NEUROSUR PS, V71, P493, DOI 10.1136/jnnp.71.4.493; RAMIG LO, 1995, J SPEECH HEAR RES, V38, P1232, DOI 10.1044/jshr.3806.1232; Robertson S, 2001, INT J LANG COMM DIS, V36, P292, DOI 10.3109/13682820109177900; RUSSELL NK, 1988, J SPEECH HEAR RES, V31, P146, DOI 10.1044/jshr.3102.146; Saldert C, 2007, CLIN LINGUIST PHONET, V21, P637, DOI 10.1080/02699200701431056; Sapir S, 2003, AM J SPEECH-LANG PAT, V12, P387, DOI 10.1044/1058-0360(2003/085); Sapir S, 2001, J MED SPEECH-LANG PA, V9, P141; SAPIR S, J SPEECH LANGUAGE HE, V50, P899; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Schmidt R.A., 1999, MOTOR CONTROL LEARNI, V3rd ed; SCHMIDT RA, 1992, PSYCHOL SCI, V3, P207, DOI 10.1111/j.1467-9280.1992.tb00029.x; SCHMIDT RA, 1991, MOTOR LEARNING HUMAN; Sellars C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002088.pub2; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SMITH ME, 1995, J VOICE, V9, P453, DOI 10.1016/S0892-1997(05)80210-3; Solomon NP, 2004, J MED SPEECH-LANG PA, V12, P213; Solomon NP, 2001, AM J SPEECH-LANG PAT, V10, P51, DOI 10.1044/1058-0360(2001/008); Solomon NP, 2000, J VOICE, V14, P331; Spencer KA., 2002, 3 AC NEUR COMM DIS S; SPIELMAN J, 2000, AM SPEECH LANG HEAR; Stevens S. S., 1975, PSYCHOPHYSICS; TANNER DC, 2003, PSYCHOL NEUROGENIC C; Tasko SM, 2004, J SPEECH LANG HEAR R, V47, P85, DOI 10.1044/1092-4388(2004/008); Theodoros DG, 2001, TRAUMATIC BRAIN INJU, P155; Tjaden K, 2004, J SPEECH LANG HEAR R, V47, P766, DOI 10.1044/1092-4388(2004/058); Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001; Ward EC, 2000, J MED SPEECH-LANG PA, V8, P331; WARLOW CP, 1996, STROKE PRACTICAL GUI; Weismer G, 2002, J SPEECH LANG HEAR R, V45, P421, DOI 10.1044/1092-4388(2002/033); Weismer G., 1992, INTELLIGIBILITY SPEE, P68; Whitehill TL, 2002, J SPEECH LANG HEAR R, V45, P80, DOI 10.1044/1092-4388(2002/006); Williams LS, 2006, STROKE, V37, P2081, DOI 10.1161/01.STR.0000230583.10311.9f; Wohlert AB, 2000, J SPEECH LANG HEAR R, V43, P1229, DOI 10.1044/jslhr.4305.1229; Wood RL, 2001, BRAIN DAM B, P3; Yorkston K. M., 1984, ASSESSMENT INTELLIGI; Yorkston KM., 1999, MANAGEMENT MOTOR SPE; YORKSTON KM, 2005, PRACTICE GUIDELINES; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	74	36	37	0	40	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	4					339	352		10.1080/02699050801960987			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	279HS	WOS:000254346900007	18365848				2021-06-18	
J	Kirov, I; Fleysher, L; Babb, JS; Silver, JM; Grossman, RI; Gonen, O				Kirov, Ivan; Fleysher, Lazar; Babb, James S.; Silver, Jonathan M.; Grossman, Robert I.; Gonen, Oded			Characterizing 'mild' in traumatic brain injury with proton MR spectroscopy in the thalamus: Initial findings	BRAIN INJURY			English	Article						mild traumatic brain injury (mTBI); 3D proton MR spectroscopy ((1)H-MRS); thalamus; N-acetylaspartate (NAA); metabolic imaging	MAGNETIC-RESONANCE-SPECTROSCOPY; HEAD-INJURY; AXONAL INJURY; MISERABLE MINORITY; MAJOR DEPRESSION; UNITED-STATES; SEVERITY; DISORDER; ATROPHY; HUMANS	Objective: Although most mild traumatic brain injury ( mTBI) patients suffer any of several post- concussion symptoms suggestive of thalamic involvement, they rarely present with any MRI- visible pathology. The aim here, therefore, is to characterize their thalamic metabolite levels with proton MR spectroscopy ((1)H- MRS) compared with healthy controls. Methods: T(1)- weighted MRI and multi- voxel (1)H- MRS were acquired at 3 Tesla from 20 mTBI ( Glasgow Coma Scale score of 15 - 13) patients, 19 - 59 years old, 0 - 7 years post- injury; and from 17 age and gender matched healthy controls. Mixed model regression was used to compare patients and controls with respect to the mean absolute N- acetylaspartate ( NAA), choline ( Cho) and creatine ( Cr) levels within each thalamus. Results: The mTBI- induced thalamic metabolite concentration changes were under +/- 13.0% for NAA, +/- 13.5% for Cr and +/- 18.8% for Cho relative to their corresponding concentrations in the controls: NAA: 10.08 +/- 0.30 ( mean +/- standard error), Cr: 5.62 +/- 0.18 and Cho: 2.08 +/- 0.09mM. These limits represent the minimal detectable differences between the two cohorts. Conclusion: The change in metabolic levels in the thalamus of patients who sustained clinically defined mTBI could be an instrumental characteristic of 'mildness'. (1)H- MRS could, therefore, serve as an objective laboratory indicator for differentiating 'mild' from more severe categories of head- trauma, regardless of the presence or lack of current clinical symptoms.	NYU, Sch Med, Dept Radiol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA	Gonen, O (corresponding author), NYU, Sch Med, Dept Radiol, 650 1st Ave, New York, NY 10016 USA.	oded.gonen@med.nyu.edu	Kirov, Ivan/I-2792-2019	Kirov, Ivan/0000-0001-5641-8578; Gonen, Oded/0000-0002-3148-2028; Babb, James/0000-0003-1798-1186	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001015] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39135] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Cihangiroglu M, 2002, NEUROL RES, V24, P7, DOI 10.1179/016164102101199440; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Goelman G, 2006, MAGN RESON MED, V56, P34, DOI 10.1002/mrm.20942; Gonen O, 1998, MAGN RESON MED, V39, P34, DOI 10.1002/mrm.1910390108; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreis R, 1997, PROG NUCL MAG RES SP, V31, P155, DOI 10.1016/S0079-6565(97)00014-9; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Son BC, 2000, ACT NEUR S, V76, P13; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE G, 1974, LANCET, V2, P81; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	46	36	38	0	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2007	21	11					1147	1154		10.1080/02699050701630383			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WX	WOS:000250329900006	17882630				2021-06-18	
J	Ganesalingam, K; Yeates, KO; Sanson, A; Anderson, V				Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Sanson, Ann; Anderson, Vicki			Social problem-solving skills following childhood traumatic brain injury and its association with self-regulation and social and behavioural functioning	JOURNAL OF NEUROPSYCHOLOGY			English	Article							RATING-SCALE; HEAD-INJURY; ATTENTION; COMPETENCE; CHILDREN; RECOVERY; OUTCOMES; DELAY; TERM	This study examines social problem-solving skills following childhood traumatic brain injury (TBI) and its association with self-regulation, and social and behavioural functioning. Participants included 65 children with moderate to severe TBI and 65 children without TBI, all between 6 and 11 years of age. Social problem-solving, self-regulation, and social and behavioural functioning were assessed 2-5 years following injury. Children were administered a newly developed semi-structured task to assess their solutions to hypothetical situations involving social problems or dilemmas. When compared with uninjured children, those with TBI suggested avoidant and aggressive solutions more often and assertive solutions less often in response to the hypothetical situations. Children's self-regulatory skills, as measured by the Matching Familiar Figures Test (MFFT), Test of Everyday Attention for Children (TEA-Ch) and the Delay of Gratification Task (DGT), collectively accounted for significant variance in their solutions to social problems, such that better self-regulation predicted more assertive solutions and fewer aggressive solutions. Assertive solutions were positively related to parent- and teacher-rated social and behavioural outcomes, whereas aggressive solutions were negatively related to the outcomes. The difficulties in social problem-solving skills demonstrated by children with TBI may help account for their poor social and behavioural functioning.	[Ganesalingam, Kalaichelvi] Columbus Childrens Hosp, Childrens Res Inst, Columbus, OH 43205 USA; [Ganesalingam, Kalaichelvi; Sanson, Ann; Anderson, Vicki] Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Anderson, Vicki] Murdoch Childrens Res Ctr, Melbourne, Vic, Australia	Ganesalingam, K (corresponding author), Columbus Childrens Hosp, Childrens Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	GanesaKa@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Sanson, Ann/0000-0003-4910-3310; Yeates, Keith/0000-0001-7680-2892			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; *AUSTR BUR STAT, 2001, POP AUSTR NZ COMP; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Daniel A. E., 1983, POWER PRIVILEGE PRES; Davis P., 1997, NZ SOCIOECONOMIC IND; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DODGE KA, 1986, MINN SYM CHILD PSYCH, V18, P77; EYBERG SM, 1983, J CLIN CHILD PSYCHOL, V12, P347, DOI 10.1207/s15374424jccp1203_19; FUNDERBURK BW, 1989, BEHAV ASSESS, V11, P297; Gresham F. M., 1990, SOCIAL SKILLS RATING; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; MANLY T, 1999, TEST EVEYDAY ATTENTI; Mariani MA, 1997, DEV NEUROPSYCHOL, V13, P111, DOI 10.1080/87565649709540671; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MISCHEL W, 1970, J PERS SOC PSYCHOL, V16, P329, DOI 10.1037/h0029815; *NAT HLTH INF MAN, 2001, NAT HLTH PLAN AUSTR; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; RUBIN KH, 1984, J CONSULT CLIN PSYCH, V52, P17, DOI 10.1037/0022-006X.52.1.17; RUBIN KH, 1992, HDB SOCIAL DEV; Sethi A, 2000, DEV PSYCHOL, V36, P767, DOI 10.1037//0012-1649.36.6.767; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Shields A., 1998, EMOTION REGULATION C; SHIELDS AM, 1994, DEV PSYCHOPATHOL, V6, P57, DOI 10.1017/S0954579400005885; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	33	36	36	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	SEP	2007	1		2				149	170		10.1348/174866407X185300			22	Psychology; Psychology, Experimental	Psychology	V06HD	WOS:000207183800002	19331015				2021-06-18	
J	Beebe, DW; Krivitzky, L; Wells, CT; Wade, SL; Taylor, HG; Yeates, KO				Beebe, Dean W.; Krivitzky, Lauren; Wells, Carolyn T.; Wade, Shari L.; Taylor, H. Gerry; Yeates, Keith Owen			Brief report: Parental report of sleep behaviors following moderate or severe pediatric traumatic brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	33rd Annual Meeting of the International-Neuropsychological-Society	FEB 03, 2005	St Louis, MO	Int Neuropsychol Soc		brain injury; children; longitudinal; orthopedic injury; pediatrics; sleep	SHORT-TERM; CHILDREN; DISTURBANCES; ADOLESCENTS; OUTCOMES; SYMPTOMS	Objective Determine the effect of moderate and severe traumatic brain injuries (TBI) on the sleep of school-aged children. Methods A concurrent cohort-prospective design compared children aged 6-12 years who sustained moderate TBI (baseline n = 56), severe TBI (n = 53), or only orthopedic injuries (n = 80). Retrospective parental report of pre-injury sleep was collected about 3 weeks post-injury. Post-injury assessments occurred prospectively a mean of 6, 12, and 48 months later. Results Growth curve analyses compared the groups over time. The moderate TBI group had worse pre-injury sleep than the other groups. The moderate TBI and orthopedic injury groups displayed a small decline in sleep problems from pre- to post-injury. Children with severe TBI displayed increased post-injury sleep problems. Conclusions Children who sustain severe TBI are at elevated risk for post-injury sleep problems. Because sleep problems may result in daytime impairments and family distress, additional clinical and research attention is warranted.	Cincinnati Childrens Hosp Med Ctr, Div Psychol MLC 3015, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Childrens Natl Med Ctr, Washington, DC 20010 USA; Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Ohio State Univ, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH 43205 USA	Beebe, DW (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Psychol MLC 3015, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	dean.beebe@cchmc.org	Sanguansri, Luz/B-6630-2011; Yeates, Keith/AAJ-4223-2020	Sanguansri, Luz/0000-0003-1908-7604; Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Blunden SL, 2006, SLEEP MED REV, V10, P109, DOI 10.1016/j.smrv.2005.11.003; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; Gregory AM, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200208000-00015; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mindell J.A., 2003, CLIN GUIDE PEDIAT SL; NAKAYAMA DK, 1990, J TRAUMA, V30, P1390, DOI 10.1097/00005373-199011000-00012; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Singer J.D., 2003, APPL LONGITUDINAL DA; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Wiggs L, 2000, SLEEP MED REV, V4, P299, DOI 10.1053/smrv.1999.0094; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	21	36	36	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2007	32	7					845	850		10.1093/jpepsy/jsm003			6	Psychology, Developmental	Psychology	193JT	WOS:000248271000010	17442693	Green Published, Green Accepted			2021-06-18	
J	Hoane, MR; Pierce, JL; Holland, MA; Birky, ND; Dang, T; Vitek, MP; McKenna, SE				Hoane, Michael R.; Pierce, Jeremy L.; Holland, Michael A.; Birky, Nicholas D.; Dang, Tan; Vitek, Michael P.; McKenna, Suzanne E.			The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury	JOURNAL OF NEUROTRAUMA			English	Article						apoE; behavioral recovery; GFAP; neuroprotection; recovery of function; TBI; trauma	TRAUMATIC BRAIN-INJURY; APOE GENOTYPE; MURINE MODEL; NEUROPROTECTION; INFLAMMATION; ACTIVATION; DISABILITY; EXPRESSION; THERAPY; DISEASE	It has previously been shown that small peptide molecules derived from the apolipoprotein E ( ApoE) receptor binding region are anti-inflammatory in nature and can improve outcome following head injury. The present study evaluated the preclinical efficacy of COG1410, a small molecule ApoE-mimetic peptide (1410 daltons), following cortical contusion injury (CCI). Animals were prepared with a unilateral CCI of the sensorimotor cortex (SMC) or sham procedure. Thirty mins post-CCI the animals received i.v. infusions of 0.8 mg/kg COG1410, 0.4 mg/kg COG1410, or vehicle. Starting on day 2, the animals were tested on a battery of behavioral measures to assess sensorimotor (vibrissae-forelimb placing and forelimb use-asymmetry), and motor (tapered balance beam) performance. Administration of the 0.8 mg/kg dose of COG1410 significantly improved recovery on the vibrissae-forelimb and limb asymmetry tests. However, no facilitation was observed on the tapered beam. The low dose (0.4 mg/kg) of COG1410 did not show any significant differences compared to vehicle. Lesion analysis revealed that the 0.8 mg/kg dose of COG1410 significantly reduced the size of the injury cavity compared to the 0.4 mg/kg dose and vehicle. The 0.8 mg/kg dose also reduced the number of glial fibrillary acid protein (GFAP(+)) reactive cells in the injured cortex. These results suggest that a single dose of COG1410 facilitates behavioral recovery and provides neuroprotection in a dose and task-dependent manner. Thus, the continued clinical development of ApoE based therapeutics is warranted and could represent a novel strategy for the treatment of traumatic brain injuries.	So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA; Cognosci Inc, Res Triangle Pk, NC USA; Duke Univ, Med Ctr, Div Neurol, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657; Vitek, Michael/0000-0001-8140-8048	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048689] Funding Source: Medline		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gay EA, 2006, J PHARMACOL EXP THER, V316, P835, DOI 10.1124/jpet.105.095505; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129; Zareparsi S, 2002, AM J MED GENET, V107, P156, DOI 10.1002/ajmg.10111	43	36	38	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1108	1118		10.1089/neu.2006.0254			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200003	17610351				2021-06-18	
J	Haileyesus, T; Annest, JL; Dellinger, AM				Haileyesus, Tadesse; Annest, Joseph L.; Dellinger, Ann M.			Cyclists injured while sharing the road with motor vehicles	INJURY PREVENTION			English	Article								Objective: To provide national estimates of non-fatal cyclist injuries treated in US hospital emergency departments (EDs) resulting from an encounter with a motor vehicle (MV) on the road. Methods: Non-fatal injury data for 2001 - 4 from the National Electronic Injury Surveillance System All Injury Program were analyzed. Results: An estimated 62 267 persons (21.5 per 100 000 population; 95% CI 14.3 to 28.7) were treated annually in US hospital EDs for unintentional non-fatal cyclist injuries involving an MV on the road. Among these cases, children aged 10 14 years (65.8 per 100 000) and males (35.3 per 100 000) had the highest injury rates. Many injuries involved the extremities (41.9%). The head was the primary body part affected for 38.6% of hospitalized/ transferred patients, of which about 84.7% had a principal diagnosis of a concussion or internal head injury. Conclusions: Effective road environmental interventions (eg, bicycle- friendly roadway design, intersections and crossings) along with efforts to promote safe personal behavior ( eg, helmet use and following rules of the road) are needed to help reduce injuries among cyclists while sharing the road.	Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30340 USA; Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Annest, JL (corresponding author), Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, 4770 Buford Highway MS K59, Atlanta, GA 30340 USA.	lannest@cdc.gov					*AM AC PED COMM AC, 1990, PEDIATRICS, V85, P229; C. for Disease Control Prevention, 2003, WEB BAS INJ STAT QUE; *CDC, 2004, US CENS POP BRIDG RA; *CDC, 1995, J SCH HLTH, V65, P133; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P340; EilertPetersson E, 1997, ACCIDENT ANAL PREV, V29, P363, DOI 10.1016/S0001-4575(97)00002-X; *FED HIGHW ADM, 1998, PUBL FED HIGHW ADM; *FED HIGHW ADM, 2003, DES GUID ACC BIC PED; Gerberich S G, 1994, Minn Med, V77, P27; Jacobsen PL, 2003, INJURY PREV, V9, P205, DOI 10.1136/ip.9.3.205; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Karkhaneh M, 2006, INJURY PREV, V12, P76, DOI 10.1136/ip.2005.010942; KIBURZ D, 1986, AM J SPORT MED, V14, P416, DOI 10.1177/036354658601400516; Kwan I., 2009, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003438, 10.1002/14651858.CD003438]; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; *NAT BIC DEAL ASS, 2005, IND OV 2005; *NAT CTR STAT AN, 2005, PED TRAFF SAF FACTS; Quinlan KP, 1999, ANN EMERG MED, V34, P637, DOI 10.1016/S0196-0644(99)70166-6; SCHROEDER T, 2001, NEISS ALL INJURY PRO; SCOTT D, 2005, INJURY B         APR; Stutts JC, 1999, ACCIDENT ANAL PREV, V31, P505, DOI 10.1016/S0001-4575(99)00007-X; *US BUR CENS, 2006, AM FACTFINDER; Vaa, 2004, HDB ROAD SAFETY MEAS; Watson L., 2006, 251 MON U ACC RES CT	24	36	36	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	JUN	2007	13	3					202	206		10.1136/ip.2006.014019			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	178MO	WOS:000247225000014	17567979	Green Published			2021-06-18	
J	O'Keeffe, FM; Dockree, PM; Moloney, P; Carton, S; Robertson, IH				O'Keeffe, F. M.; Dockree, P. M.; Moloney, P.; Carton, S.; Robertson, I. H.			Characterising error-awareness of attentional lapses and inhibitory control failures in patients with traumatic brain injury	EXPERIMENTAL BRAIN RESEARCH			English	Article						traumatic brain injury; errors; attention; response inhibition; frontal dysfunction	SUSTAINED ATTENTION; SELF-AWARENESS; EXECUTIVE FUNCTIONS; IMPAIRED AWARENESS; HEAD-INJURY; ADULTS; SENSITIVITY; DYSFUNCTION; RELATIVES; BEHAVIOR	Awareness deficits are a significant problem following traumatic brain injury (TBI). This study examined error processing as candidate marker of awareness and compared the performance of 18 TBI participants and 18 controls using an online error-monitoring task while participants performed simple go/no-go tasks. Error-monitoring performance was compared where the no-go target was part of (a) a predictive sequence, (b) predictive sequence plus a dual-task element and (c) a random sequence. Results showed that the TBI participants, in contrast to control participants, were significantly impaired at monitoring their errors during both predictive sequence tasks but were not impaired on the random sequence task. These findings suggest that following TBI, when an error is more impulsive it may be more easily monitored, whereas when an error is characterised by attentional drift, subsequent error-processing mechanisms may fail to engage. Higher levels of online error-awareness were also associated with lower levels of anxiety, fewer symptoms of frontal dysfunction and greater competence in everyday functioning.	Univ Dublin Trinity Coll, Trinity Coll Inst Neurosci, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Natl Rehabil Hosp, Dept Clin Neuropsychol, Dun Laoghaire, Co Dublin, Ireland	Robertson, IH (corresponding author), Univ Dublin Trinity Coll, Trinity Coll Inst Neurosci, Dublin 2, Ireland.	iroberts@tcd.ie		Robertson, Ian H/0000-0001-8637-561X			Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Barco P.P., 1991, COGNITIVE REHABILITA, P129; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Grace J, 2002, FRONTAL SYSTEMS BEHA; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Markova IS, 2006, NEUROPSYCHOL REHABIL, V16, P439, DOI 10.1080/09602010500373396; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; OKEEFE F, IN PRESS BRAIN; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOLOGI; Robertson IH, 2004, COGNITIVE NEUROSCIENCES III, THIRD EDITION, P631; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P563, DOI 10.1016/j.neuropsychologia.2003.11.004; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; STUSS DT, 1998, NEUROBEHAVIOURAL REC; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	36	36	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JUN	2007	180	1					59	67		10.1007/s00221-006-0832-9			9	Neurosciences	Neurosciences & Neurology	181SO	WOS:000247456600006	17216412				2021-06-18	
J	Fee, DB; Swartz, KR; Joy, KM; Roberts, KN; Scheff, NN; Scheff, SW				Fee, Dominic B.; Swartz, Karin R.; Joy, Kelly M.; Roberts, Kelly N.; Scheff, Nicole N.; Scheff, Stephen W.			Effects of progesterone on experimental spinal cord injury	BRAIN RESEARCH			English	Article						progesterone; spinal cord injury; contusion; neurotrauma; gender; BBB	FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; BRAIN; RAT; EXPRESSION; CONTUSION; PROTEIN; NEUROPROTECTION; STEROIDS; RECEPTOR	Progesterone has been proposed to be protective to the central nervous system following injury. This study assessed progesterone supplementation in the setting of contusional spinal cord injury in male and female rats. Short-term (S days of either 4 or 8 mg/kg progesterone) and long-term (14 days of either 8 or 16 mg/kg progesterone) therapy failed to show any significant alteration in locomotor functioning and injury morphometrics after 21 days. This study does not support progesterone as a potential therapeutic agent in spinal cord injury. (c) 2006 Elsevier B.V. All rights reserved.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Div Neurosurg, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Fee, DB (corresponding author), KY Clin, Dept Neurol, Rm L-55, Lexington, KY 40536 USA.	dbfee2@email.uky.edu					Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gintzler A R, 2001, Prog Brain Res, V133, P83; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; MACLUSKY NJ, 1978, NATURE, V274, P276, DOI 10.1038/274276a0; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rabchevsky AG, 2003, J NEUROTRAUM, V20, P659, DOI 10.1089/089771503322144572; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Robel P, 1995, CRIT REV NEUROBIOL, V9, P383; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; YU WHA, 1989, BRAIN RES, V491, P379, DOI 10.1016/0006-8993(89)90075-9	29	36	37	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 16	2007	1137	1					146	152		10.1016/j.brainres.2006.12.024			7	Neurosciences	Neurosciences & Neurology	145EY	WOS:000244849300017	17204255				2021-06-18	
J	Mitra, B; Cameron, P; Butt, W				Mitra, Biswadev; Cameron, Peter; Butt, Warwick			Population-based study of paediatric head injury	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Article						craniocerebral trauma; Emergency Medicine; Epidemiology; Neurosurgery	TRAUMATIC BRAIN-INJURY; CHILDREN; MORTALITY	Aim: There is a paucity of population-based studies regarding the spectrum of paediatric head injury from mild through serious to fatal paediatric head injury. The aims of the present study were to determine the incidence, demographics and outcome of significant head injury in a state-wide population of children aged 0-15 years. A secondary aim was to determine if any serious head injuries were being missed under the current management protocols of the state-wide trauma system. Methods: A retrospective review of significant head injury in all paediatric patients over a period of 2 years was undertaken. Data were collected from the Victorian State Trauma Outcome Registry and Monitoring database, the Victorian Emergency Minimum Dataset and from the Victorian Institute of Forensic Medicine. Results: The incidence of paediatric head injury in Victoria over the 2-year period was 765 per 100 000 per year. The incidence of admitted head injuries was 75 per 100 000 per year and the incidence of significant head injury was seven per 100 000 or 151 children. Forty-one per cent of these injuries required surgical intervention. Mortality was 1.6 children per 100 000. All patients who died presented with a Glasgow Coma Score (GCS) of 3 and had multiple other risk factors. There were no deaths in patients discharged from hospital. Demographic and clinical factors associated with higher mortality and morbidity was determined. Conclusion: The incidence of significant paediatric head injury was low. Deaths occurred early and were always associated with significant early clinical features of severe head injury. This highlights the importance of strategies for the prevention of head injuries. There appeared to be no serious head injuries missed during the study period.	Monash Univ, Alfred Emergency & Trauma Ctr, Melbourne, Vic 3004, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia; Royal Childrens Hosp, Intens Care Unit, Melbourne, Vic, Australia; Alfred Hosp, Intens Care Unit, Melbourne, Vic, Australia; Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Mitra, B (corresponding author), Monash Univ, Alfred Emergency & Trauma Ctr, Commercial Rd, Melbourne, Vic 3004, Australia.	b.mitra@alfred.org.au	Mitra, Biswadev/AAC-3724-2019	Mitra, Biswadev/0000-0002-0508-2450; Cameron, Peter/0000-0002-1443-557X			Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; Brown L, 2003, AM J EMERG MED, V21, P467, DOI 10.1016/S0735-6757(03)00174-8; Cameron P, 1995, AUST NZ J SURG, V65, P848, DOI 10.1111/j.1445-2197.1995.tb00574.x; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; COOKSLEY D, 2006, TXB PAEDIAT EMERGENC, P63; COOKSLEY D, 2006, TXB PAEDIAT EMERGENC, P62; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Gabbe BJ, 2005, ANZ J SURG, V75, P650, DOI 10.1111/j.1445-2197.2005.03484.x; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hirsch W, 2002, PAEDIATR ANAESTH, V12, P337, DOI 10.1046/j.1460-9592.2002.00837.x; INABA A, 1991, EMERG MED CLIN N AM, V9, P290; International Liaison Committee on Resuscitation, 2005, Resuscitation, V67, P271; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; MULLICK P, 2004, INDIAN J ANAEST, V48, P111; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ratan Simmi K., 2002, Indian Journal of Pediatrics, V69, P573, DOI 10.1007/BF02722680; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Sanchez JI, 1999, SURG CLIN N AM, V79, P1503, DOI 10.1016/S0039-6109(05)70090-6; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Sharma M, 1994, Indian Pediatr, V31, P733; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Tsai WC, 2004, J CLIN NEUROSCI, V11, P126, DOI 10.1016/S0967-5868(03)00156-5; Williamson LM, 2002, J EPIDEMIOL COMMUN H, V56, P285, DOI 10.1136/jech.56.4.285	25	36	36	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1034-4810	1440-1754		J PAEDIATR CHILD H	J. Paediatr. Child Health	MAR	2007	43	3					154	159		10.1111/j.1440-1754.2007.01035.x			6	Pediatrics	Pediatrics	132WT	WOS:000243974300012	17316189				2021-06-18	
J	Rusnak, M; Janciak, I; Majdan, M; Wilbacher, I; Mauritz, W				Rusnak, Martin; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Mauritz, Walter		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria VI: Effects of guideline-based management	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; guidelines; compliance; resuscitation; mannitol; ICP; barbiturates; corticosteroids; hyperventilation; lengths of stay; monitoring; outcome	SEVERE HEAD-INJURY; CARE MANAGEMENT; UNITED-STATES; SCALE; PROTOCOL; OUTCOMES; SCORE	OBJECTIVES: The goal of this paper is to report relations between health outcomes and implementation of individual recommendations of the guidelines. PATIENTS AND METHODS: Data sets from 405 patients included by 5 Austrian hospitals were available. The analysis focused on the compliance of treatment modalities to TBI guidelines recommendations. Compliance was evaluated based on scores developed specifically for this purpose. To evaluate the relations between the TBI guidelines compliance and outcomes the estimation of odds ratios was computed using multiple as well as logistic regression with age, ISS and initial GCS used to control confounding. RESULTS: The option on prehospital resuscitation was followed in 84%, the guideline on early resuscitation was followed in 79%. The guideline on intracranial pressure treatment threshold was the most closely followed one (89%). The option on cerebral perfusion pressure was followed in less than 30% of patients. Only the scores on resuscitation of blood pressure and oxygenation and on cerebral perfusion pressure were positively and statistically significantly related to ICU survival. Positive relations were also found for adherence to the recommendations on the type of monitoring, hyperventilation (guideline), prophylactic use of anti-seizure drugs, and the total of scores. The other recommendations were negatively related to ICU survival, but computed odds ratios were statistically not significant. Analysis of relations between compliance scores and length of ICU and hospitals stay in survivors showed that adherence to the recommendations on type of monitoring was related to a reduction of length of stay in ICU and hospital, adherence to the hyperventilation guideline was related to shortened ICU, but increased hospital stay, and adherence to the guideline on mannitol was related to reduced days in hospital, but not to days in ICU. Implementing the standard on corticosteroid use was related to a reduction of days both in hospital and ICU. Using the standard on prophylactic use of anti-seizure drugs was related to a reduction in ICU days. If all the recommendations were closely followed an increase of days in ICU would be observed, while the length of stay in hospital would be reduced. CONCLUSIONS: The relatively strong relation between initial resuscitation in the hospital and ICU survival provides a firm basis for future efforts of emergency teams. The positive influence of some of the recommendations on reduction of ICU or hospital days may provide economic incentives to promote guidelines implementation.	INRO, Med Advisory Board, Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, Vienna, Austria	Rusnak, M (corresponding author), INRO, Med Advisory Board, Vienna, Austria.		Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016	Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Drobetz H, 2000, ANASTH INTENSIV NOTF, V35, P630, DOI 10.1055/s-2000-7365; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hurwitz B, 1999, BRIT MED J, V318, P661, DOI 10.1136/bmj.318.7184.661; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Mcilvoy L, 2001, J Neurosci Nurs, V33, P72; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; ROSENBERG J, 1992, NEUROLOGY, V42, P1110, DOI 10.1212/WNL.42.5.1110; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Scottish Intercollegiate Guidelines Network SIGN, GUID DEV HDB; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; WALTERS BC, 1998, NEUROSURGERY TRANSIT, P99	23	36	39	0	10	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					64	71		10.1007/s00508-006-0765-0			8	Medicine, General & Internal	General & Internal Medicine	142GQ	WOS:000244637800012	17318752				2021-06-18	
J	Cheung, PSY; Lam, JMY; Yeung, JHH; Graham, CA; Rainer, TH				Cheung, Phoebe S. Y.; Lam, Jenny M. Y.; Yeung, Janice H. H.; Graham, Colin A.; Rainer, Timothy H.			Outcome of traumatic extradural haematoma in Hong Kong	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						extradural haematoma; head injury; major trauma; emergency department; neurosurgery; mortality; outcome; pupils; Glasgow Coma Score	PRACTICAL SCALE; CRANIOTOMY; ADULT	Aim: Traumatic extradural haematoma (EDH) is a neurosurgical emergency and timely surgical intervention for significant EDH is the gold standard. This study aims to determine the incidence and mortality of consecutive patients with traumatic EDH admitted to the Emergency Department (ED) of Prince of Wales Hospital (PWH), a University Hospital Trauma Centre in Hong Kong. Patients and methods: Retrospective analysis of prospectively collected data for all consecutive trauma cases admitted through the ED during 2001-2004. EDH was diagnosed by CT in all cases. Both primary and delayed onset EDH were included, as were patients with combined EDH and other intracranial lesions (e.g. subdural haematoma). Age, sex, cause of injury, associated intracranial lesions, skull fracture, Glasgow Coma Scale, pupil reactivity, treatment, length of stay and clinical outcome were determined. Results: Two thousand and two hundred and eight patients were in the trauma registry for 2001-2004. Total 1080 head injured patients; 89 patients had traumatic EDH, mean of 1.9 patients per month. Seventy (79%) patients were mate, with a mean age of 37.7 years. Fifty (56%) patients were from road traffic crashes, 27 (30%) sustained falls, 10 (11%) had direct head trauma. On admission, 62 (70%) patients were GCS 13-15, 9 (10%) GCS 9-12 and 18 (20%) GCS 3-8. Sixty-six (74%) patients had a skull fracture. Thirty (34%) patients underwent neurosurgical operation. Overall, nine patients (10%) died; eight patients were GCS<8; five had bilateral fixed and dilated pupils; one had a single fixed and dilated pupil. Four patients died after neurosurgical operation, three of whom had fixed dilated pupils and were GCS 3 prior to surgery. Median length of hospital stay for survivors was 10.4 days. Conclusion: Survival from traumatic EDH was 90% (80/89) and 91% (73/80) of survivors had a Glasgow Outcome Score of 4 or 5 (good or moderate). The combination of bilateral fixed dilated pupils and GCS 3 suggests severe primary brain injury. Emergency evacuation of intracranial haematomas is unlikely to improve the outcome for these patients. Even in an urban environment with short prehospital times and rapid access to neurosurgery, outcome in patients who are GCS 3 following EDH is likely to be poor. (C) 2006 Elsevier Ltd. All rights reserved.	Prince Wales Hosp, Trauma & Emergency Ctr, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Accid & Emergency Med Acad Unit, Trauma & Emergency Ctr, Shatin, Hong Kong, Peoples R China	Graham, CA (corresponding author), Prince Wales Hosp, Trauma & Emergency Ctr, Shatin, Hong Kong, Peoples R China.	cagraham@cuhk.edu.hk	Graham, Colin A/B-4535-2013; Rainer, Timothy H/I-2591-2013	Graham, Colin A/0000-0002-4381-7470; Rainer, Timothy H/0000-0003-3355-3237			BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Hutchinson J., 1867, LOND HOSP REP, V4, P51; Jacobson WHA, 1886, GUYS HOSP REP, V43, P147; JENNETT B, 1975, LANCET, V1, P480; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; LEUNG GKK, 2001, ASIAN J SURG, V24, P305; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; PATERNITI S, 1994, ACTA NEUROCHIR, V131, P207, DOI 10.1007/BF01808614; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; TEASDALE G, 1974, LANCET, V2, P81	13	36	38	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JAN	2007	38	1					76	80		10.1016/j.injury.2006.08.059			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	130XA	WOS:000243831100012	17097656				2021-06-18	
J	Mandalis, A; Kinsella, G; Ong, B; Anderson, V				Mandalis, Anna; Kinsella, Glynda; Ong, Ben; Anderson, Vicki			Working memory and new learning following pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; PREFRONTAL CORTEX; TASK-PERFORMANCE; YOUNG-CHILDREN; FUNCTIONAL MRI; ADOLESCENTS; ATTENTION; RECOVERY; ABILITIES; DISEASE	Working memory (WM), the ability to monitor, process and maintain task relevant information on-line to respond to immediate environmental demands, is controlled by frontal systems (D'Esposito et al., 2006), which are particularly vulnerable to damage from a traumatic brain injury (TBI). This study employed the adult-based Working Memory model of Baddeley and Hitch (1974) to examine the relationship between working memory function and new verbal learning in children with TBI. A cross-sectional sample of 36 school-aged children with a moderate to severe TBI was compared to age-matched healthy Controls on a series of tasks assessing working memory subsystems: the Phonological Loop (PL) and Central Executive (CE). The TBI group performed significantly more poorly than Controls on the PL measure and the majority of CE tasks. On new learning tasks, the TBI group consistently produced fewer words than Controls across the learning and delayed recall phases. Results revealed impaired PL function related to poor encoding and acquisition on a new verbal learning task in the TBI group. CE retrieval deficits in the TBI group contributed to general memory dysfunction in acquisition, retrieval and recognition memory. These results suggest that the nature of learning and memory deficits in children with TBI is related to working memory impairment.	Murdoch Childrens Res Inst, Murdoch, WA, Australia; Royal Childrens Hosp, Dept Psychol, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia	Mandalis, A (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	anna.mandalis@childneuropsychology.com.au	Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; ANDERSON V, 1995, NEUROPSYCHOLOGICAL A; Anderson VA, 2000, BRAIN INJURY, V14, P679; Baddeley A, 2001, J EXP PSYCHOL GEN, V130, P641, DOI 10.1037//0096-3445.130.4.641; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Baddeley A.D., 1999, MODELS WORKING MEMOR, P28, DOI DOI 10.1017/CBO9781139174909.005; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 2001, FRONTAL LOBES, P246; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; D'Esposito M, 2006, J INT NEUROPSYCH SOC, V12, P248, DOI 10.1017/S1355617706060322; D'Esposito M, 1998, NEUROIMAGE, V8, P274, DOI 10.1006/nimg.1998.0364; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Garth J, 1997, Pediatr Rehabil, V1, P99; GATHERCOLE SE, 1993, DEV PSYCHOL, V29, P770, DOI 10.1037/0012-1649.29.4.770; Gathercole SE, 2005, J CHILD PSYCHOL PSYC, V46, P598, DOI 10.1111/j.1469-7610.2004.00379.x; HALPERIN JM, 1989, J CLIN EXP NEUROPSYC, V11, P518, DOI 10.1080/01688638908400910; HARTMAN A, 1992, CLIN REHABIL, V6, P133; HITCH GJ, 1983, PHILOS T ROY SOC B, V302, P325, DOI 10.1098/rstb.1983.0058; HITCH GJ, 1988, MEM COGNITION, V16, P120, DOI 10.3758/BF03213479; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Jarrold C, 2004, J MEM LANG, V50, P134, DOI 10.1016/j.jml.2003.10.004; Jarrold C, 2001, Downs Syndr Res Pract, V7, P17, DOI 10.3104/reviews.110; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LEZAK M, 2004, NEUROPSYCHOLOGY ASSE; Logie RH, 2004, NEUROPSYCHOLOGY, V18, P504, DOI 10.1037/0894-4105.18.3.504; Loose R, 2003, HUM BRAIN MAPP, V18, P249, DOI 10.1002/hbm.10082; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P85, DOI 10.1080/13854049308401890; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rowe JB, 2001, NEUROPSYCHOLOGIA, V39, P315, DOI 10.1016/S0028-3932(00)00109-3; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Spreen O., 1998, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Wechsler D., 1991, WECHSLER INTELLIGENC; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	52	36	36	0	10	LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS	PHILADELPHIA	325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2007	32	2					683	701		10.1080/87565640701376045			19	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	212NJ	WOS:000249603000005	17931125				2021-06-18	
J	Niechwiej-Szwedo, E; Inness, EL; Howe, JA; Jaglal, S; McIlroy, WE; Verrier, MC				Niechwiej-Szwedo, E.; Inness, E. L.; Howe, J. A.; Jaglal, S.; McIlroy, W. E.; Verrier, M. C.			Changes in gait variability during different challenges to mobility in patients with traumatic brain injury	GAIT & POSTURE			English	Article						traumatic brain injury; gait; variability; dynamic stability	STRIDE VARIABILITY; OLDER ADULTS; HEAD-INJURY; WALKING; DISEASE; BALANCE; LENGTH; FALLS	Postural stability may be compromised in patients who have sustained a traumatic brain injury (TBI). The purpose of the present study was to examine dynamic stability during gait by measuring spatial and temporal variability of foot placement, and to determine the effect of increased difficulty of the walking task on gait variability in patients with TBI. It was hypothesized that patients with TBI will show increased variability in step time, step length, and step width in comparison to healthy controls and that such differences would be accentuated by increased task difficulty. Participants (patients: n = 20, controls: n = 20) were asked to walk across a pressure sensitive mat at their preferred pace (PW), as fast as possible (FW), and with their eyes closed (EC). In accordance with the hypotheses, patients had significantly greater variability in step time and step length in comparison to healthy controls, and when the complexity of the gait task increased (FW and EC tasks). Although step width variability showed no significant difference between the groups, both control and patient groups had increased step width variability in the EC task. It is proposed that such increases in variability reflect greater challenges to maintaining dynamic stability during gait among individuals with TBI and when performing more difficult tasks. (C) 2006 Elsevier B.V. All rights reserved.	Univ Toronto, Grad Dept Rehabil Sci, Restorat Motor Control Lab, Toronto, ON M5G 1V7, Canada; Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; Toronto Rehabil Inst, Restorat Motor Control Lab, Toronto, ON, Canada	Verrier, MC (corresponding author), Univ Toronto, Grad Dept Rehabil Sci, Restorat Motor Control Lab, 500 Univ Ave, Toronto, ON M5G 1V7, Canada.	m.verrier@utoronto.ca		Jaglal, Susan/0000-0002-2930-1443; Inness, Elizabeth L./0000-0002-9217-4619			Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; BASFORD JR, 2003, ARCH PHYS MED REHAB, V84, P249; Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X; Danion F, 2003, GAIT POSTURE, V18, P69, DOI 10.1016/S0966-6362(03)00030-4; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hausdorff JM, 2003, EXP BRAIN RES, V149, P187, DOI 10.1007/s00221-002-1354-8; HEITMANN DK, 1989, PHYS THER, V69, P923, DOI 10.1093/ptj/69.11.923; INNESS EL, 2004, ARCH PHYS MED REHAB, V85, pE11; Langlois JA, 1997, AM J PUBLIC HEALTH, V87, P393, DOI 10.2105/AJPH.87.3.393; MacKay-Lyons M, 1998, PHYS THER, V78, P1083, DOI 10.1093/ptj/78.10.1083; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Nakamura T, 1996, GERONTOLOGY, V42, P108, DOI 10.1159/000213780; Patla AE, 1998, ECOL PSYCHOL, V10, P287, DOI 10.1207/s15326969eco103&4_7; TOWNSEND MA, 1985, J BIOMECH, V18, P21, DOI 10.1016/0021-9290(85)90042-9; van Emmerik REA, 2002, EXERC SPORT SCI REV, V30, P177, DOI 10.1097/00003677-200210000-00007; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45; Zar J. H., 1984, BIOSTATISTICAL ANAL, V3	20	36	36	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	JAN	2007	25	1					70	77		10.1016/j.gaitpost.2006.01.002			8	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	127RS	WOS:000243604600010	16490355				2021-06-18	
J	Trokel, M; Discala, C; Terrin, NC; Sege, RD				Trokel, Matthew; Discala, Carla; Terrin, Norma C.; Sege, Robert D.			Patient and injury characteristics in abusive abdominal injuries	PEDIATRIC EMERGENCY CARE			English	Article						child abuse; blunt abdominal injury	TRAUMATIC BRAIN-INJURY; CHILD-ABUSE; YOUNG-CHILDREN; BLUNT TRAUMA; HEAD-INJURY; FRACTURES; INFANTS; MECHANISMS; HOSPITALS; ACCIDENT	Objective: To identify patient and injury characteristics associated with suspected child abuse in the setting of blunt abdominal trauma. Patients: We extracted from the National Pediatric Trauma Registry phases 2 and 3 (October 1995 to April 2001; N = 106,135) all-cases of blunt abdominal injury, excluding motor vehicle injuries, in patients aged 0 to 4 years. Main Outcome Measures: Independent variables included age, mortality, nutritional status, and injury type. The dependent variable was suspected child abuse. Results: Six hundred sixty-four cases were analyzed. The median age of patients was 2.6 years; 11.4% were undernourished. The 3 most common mechanisms of injury were suspected child abuse (40.5%), fall (36.6%), and struck-not child abuse (9.7%). Hepatic injury (46.1%) was the most common intra-abdominal injury, followed by splenic (26%), hollow viscous (17.9%), and pancreatic (8.6%) injuries. Eighty-four percent of deaths were related to suspected child abuse. There was a greater proportion of children with suspected child abuse in every patient and injury characteristics studied than all other mechanisms combined. In a regression model including age, undernourishment, pancreatic injury, hollow viscous injury, traumatic brain injury, and mortality, all variables were significantly associated with suspected abuse. Hollow viscous injury had the highest odds ratio (OR, 9.5; confidence limits, 5.7, 15.8), whereas traumatic brain injury had the lowest (OR, 3.6; confidence limits, 2.4, 5.6). Conclusions: Young children with severe pancreatic or hollow viscous injuries or severe abdominal injuries in the context of either brain injury or undernourishment should be evaluated for the possibility that these injuries resulted from abuse. Increasing the awareness of the possibility of child abuse associated with a set of injury characteristics may allow for more consistent and complete medical evaluation.	Boston Med Ctr, Dept Pediat, Boston, MA USA; Floating Hosp, Pediat & Adolescent Hlth Res Ctr, Boston, MA USA; Tufts New England Med Ctr, Biostat Res Ctr, Boston, MA USA; Tufts New England Med Ctr, Div Clin Care Res, Boston, MA USA	Sege, RD (corresponding author), Tufts Univ New England Med Ctr, Pediat & Adolescent Hlth Res Ctr, Box 351,750 Washington St, Boston, MA 02111 USA.	rsege@tufts-nemc.org		Sege, Robert/0000-0003-1260-4787	AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS000060] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32 HS0060-09] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR1186-03] Funding Source: Medline		Arkovitz MS, 1997, J TRAUMA, V42, P49, DOI 10.1097/00005373-199701000-00009; Athey J, 2001, PEDIATR EMERG CARE, V17, P170, DOI 10.1097/00006565-200106000-00005; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CANIANO DA, 1986, ANN SURG, V203, P219, DOI 10.1097/00000658-198602000-00017; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; *CHILD WELF INF GA, CHILD AB NEGL FAT ST; COBB LM, 1986, J TRAUMA, V26, P461, DOI 10.1097/00005373-198605000-00009; COOPER A, 1994, J PEDIATR SURG, V29, P33, DOI 10.1016/0022-3468(94)90518-5; COOPER A, 1988, J TRAUMA, V28, P1483, DOI 10.1097/00005373-198810000-00015; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; GORNALL P, 1972, ARCH DIS CHILD, V47, P211, DOI 10.1136/adc.47.252.211; HAMPTON RL, 1985, AM J PUBLIC HEALTH, V75, P56, DOI 10.2105/AJPH.75.1.56; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; KARP RJ, 1989, CLIN PEDIATR, V28, P317, DOI 10.1177/000992288902800704; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; LEDBETTER DJ, 1988, ARCH SURG-CHICAGO, V123, P1101; NAKAYAMA DK, 1992, J PEDIATR SURG, V27, P427, DOI 10.1016/0022-3468(92)90328-5; Nance ML, 2000, J PEDIATR SURG, V35, P1300, DOI 10.1053/jpsu.2000.9301; *NAT CTR HLTH STAT, CDC GROWTH CHARTS US; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; PENA SDJ, 1973, J PEDIATR-US, V83, P1026, DOI 10.1016/S0022-3476(73)80542-6; Rex C, 2000, J PEDIATR ORTHOPED, V20, P411; Scherl SA, 2000, CLIN ORTHOP RELAT R, P96; Shaw BA, 1997, J PEDIATR ORTHOPED, V17, P293, DOI 10.1097/00004694-199705000-00005; Skuse D H, 1995, J Med Screen, V2, P145; Tepas Joseph J. Iii, 1993, Current Opinion in Pediatrics, V5, P317	30	36	36	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	OCT	2006	22	10					700	704		10.1097/01.pec.0000238734.76413.d0			5	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	096HQ	WOS:000241368600002	17047468				2021-06-18	
J	Moein, H; Khalili, HA; Keramatian, K				Moein, Houshang; Khalili, Hossein A.; Keramatian, Kamyar			Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Ritalin; methylphenidate; severe traumatic brain injury; moderate traumatic brain injury	CONTROLLED-TRIAL; DISORDERS	Objective: Traumatic brain injury is one of the major causes of death and disability among young people. Methylphenidate, a neural stimulant and protective drug, which has been mainly used for childhood attention deficit/hyperactivity disorder, has shown some benefits in late psychosocial problems in patients with traumatic brain injury. Its effect on arousal and consciousness has been also revealed in the sub-acute phase of traumatic brain injury. We studied its effect on the acute phase of moderate and severe traumatic brain injury (TBI) in relation to the length of ICU and hospital admission. Patients and methods: Severely and moderately TBI patients (according to inclusion and exclusion criteria) were randomized to treatment and control groups. The treatment group received methylphenidate 0.3 mg/kg per dose PO BID by the second day of admission until the time of discharge, and the control group received a placebo. Admission information and daily Glasgow Coma Scale (GCS) were recorded. Medical, surgical, and discharge plans for patients were determined by the attending physician, blinded to the study. Results: Forty patients with severe TBI (GCS = 5-8) and 40 moderately TBI patients (GCS = 9-12) were randomly divided into treatment and control groups on the day of admission. In the severely TBI patients, both hospital and ICU length of stay, on average, were shorter in the treatment group compared with the control group. In the moderately TBI patients while ICU stay was shorter in the treatment group, there was no significant reduction of the period of hospitalization. Conclusion: There were no significant differences between the treatment and control groups in terms of age, sex, post resuscitation GCS, or brain CT scan findings, in either severely or moderately TBI patients. Methylphenidate was associated with reductions in ICU and hospital length of stay by 23% in severely TBI patients (P = 0.06 for ICU and P = 0.029 for hospital stay time). However, in the moderately TBI patients who received methylphenidate, there was 26% fall (P = 0.05) only in ICU length of stay. (c) 2005 Elsevier B.V. All rights reserved.	Isfahan Univ Med Sci, Dept Neurosurg, Esfahan, Iran; Univ British Columbia, Dept Neurosci, Vancouver, BC V5Z 1M9, Canada	Khalili, HA (corresponding author), Kashani Hosp, Dept Neurosurg, Esfahan, Iran.	khalilih@yahoo.com; keramatian@gmail.com	Khalili, Hosseinali/I-1087-2016	Khalili, Hosseinali/0000-0002-3390-4212; Keramatian, Kamyar/0000-0003-4958-6025			Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Burke DT, 2003, AM J PHYS MED REHAB, V82, P493, DOI 10.1097/00002060-200307000-00001; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Forsyth R., 2003, COCHRANE DB SYST REV, V1; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Husson I, 2004, NEUROSCIENCE, V125, P163, DOI 10.1016/j.neuroscience.2004.01.010; Jin C, 2004, CNS SPECTRUMS, V9, P217, DOI 10.1017/S1092852900009019; Kajs-Wyllie Marylyn, 2002, J Neurosci Nurs, V34, P303; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rosati DL, 2002, AM J PHYS MED REHAB, V81, P90, DOI 10.1097/00002060-200202000-00003; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Worzniak M, 1997, J FAM PRACTICE, V44, P495; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	18	36	36	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2006	108	6					539	542		10.1016/j.clineuro.2005.09.003			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	082EJ	WOS:000240369200003	16226371				2021-06-18	
J	Mysiw, WJ; Bogner, JA; Corrigan, JD; Fugate, LP; Clinchot, DM; Kadyan, V				Mysiw, W. Jerry; Bogner, Jennifer A.; Corrigan, John D.; Fugate, Lisa P.; Clinchot, Daniel M.; Kadyan, Vivek			The impact of acute care medications on rehabilitation outcome after traumatic brain injury	BRAIN INJURY			English	Article						brain trauma; rehabilitation; agitation; post traumatic amnesia	HEAD-INJURY; RECOVERY; AGITATION; STROKE; NOREPINEPHRINE; DOPAMINE; DRUGS; EDEMA	Objectives: To examine the impact of medications with known central nervous system (CNS) mechanisms of action, given during the acute care stages after traumatic brain injury (TBI), on the extent of cognitive and motor recovery during inpatient rehabilitation. Design: Retrospective extraction of data utilizing an inception cohort of moderate and severe TBI survivors. Methods: The records of 182 consecutive moderate and severe TBI survivors admitted to a single, large, Midwestern level I trauma centre and subsequently transferred for acute inpatient rehabilitation were abstracted for the presence of 11 categories of medication, three measures of injury severity (worst 24 hour Glasgow Coma Scale, worst pupillary response, intra-cranial hypertension), three measures of outcome (Function Independence Measure (FIM) Motor and Cognitive scores at both rehabilitation admission and discharge and duration of post-traumatic amnesia (PTA)). Main outcome and results: The narcotics, benzodiazepines and neuroleptics were the most common categories of CNS active medications (92%, 67% and 43%, respectively). The three categories of medications appeared to have no significant outcome on the FIM outcome variables. The neuroleptics affected cognitive recovery with almost 7 more days required to clear PTA in the neuroleptic treated group. The presence of benzodiazepines did tend to obscure the impact of neuroleptics on PTA duration but the negative impact of neuroleptics on PTA duration remained significant. Conclusions: The results suggest that the use of neuroleptics during the acute care stage of recovery has a negative impact on recovery of cognitive function at discharge from inpatient rehabilitation. Due to the paucity of subjects with hemiplegia in this cohort, conclusions could not be drawn as to the impact of acute care medications on motor recovery.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Mysiw, WJ (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 W 9th Ave,Dodd Hall, Columbus, OH 43210 USA.	mysiw.1@osu.edu	Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011; Bogner, Jennifer/E-2773-2011	Clinchot, Daniel/0000-0002-2810-7227			Beaumont A, 2000, ACT NEUR S, V76, P147; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Centers for Disease Control, 2001, TRAUM BRAIN INJ US R; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Dam M, 1996, STROKE, V27, P2145; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goldstein LB, 2000, NEUROPHARMACOLOGY, V39, P852, DOI 10.1016/S0028-3908(99)00249-X; Goldstein LB, 1999, REV NEUROL-FRANCE, V155, P731; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GOLDSTEIN LB, 1995, J NEUROL NEUROSUR PS, V58, P753, DOI 10.1136/jnnp.58.6.753; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; O'Neill MJ, 1998, EUR J PHARMACOL, V352, P37, DOI 10.1016/S0014-2999(98)00333-1; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	20	36	36	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2006	20	9					905	911		10.1080/02699050600743972			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100003	17062422				2021-06-18	
J	Richardson, RM; Holloway, KL; Bullock, MR; Broaddus, WC; Fillmore, HL				Richardson, RM; Holloway, KL; Bullock, MR; Broaddus, WC; Fillmore, HL			Isolation of neuronal progenitor cells from the adult human neocortex	ACTA NEUROCHIRURGICA			English	Article						adult human brain; neuronal progenitor cell; autologous transplantation; traumatic brain injury	NEURAL STEM-CELLS; HUMAN BRAIN; ZONE; NEUROGENESIS; HIPPOCAMPUS; PRECURSORS; FOREBRAIN; PRIMATES; REGIONS; CULTURE	Background. The reliability of harvesting neuronal progenitor cells (NPCs) from the adult human neocortex has not been established, with respect to preparing autologous cell cultures for transplantation in stroke and traumatic brain injured patients. Method. Enriched NPC cultures have been generated from nonneurogenic regions of the adult rodent brain by buoyancy-dependent fractionation, but the feasibility of using such a method to isolate NPCs from the adult human cortex has not been reported previously. To determine if a starter population of human adult cortical NPCs could be isolated for in vitro expansion using this method, tissue samples from five patients undergoing cortical resection for either epilepsy or trauma were assayed. Findings. Cultured cells generated from all patients predominately expressed both the NPC marker nestin and neuron-specific beta-tubulin III. The presence of NPCs was verified by in vitro BrdU/beta-tubulin III co-labeling and increasing beta-tubulin expression in differentiating conditions. Despite the formation of aggregates in monolayer culture, cell proliferation as measured by BrdU incorporation was not as prevalent as that reported from rodent cultures generated by this protocol. Conclusions. NPCs isolated from the adult human neocortex using this method expressed beta-tubulin III in larger percentages than has been previously reported for NPCs isolated using other methods. As such, these data suggest the possibility of culturing dividing neuroblasts from the adult neocortex for further manipulation as transplantable cells.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Neurosurg, Richmond, VA USA; McGuire Dept Vet Affairs Med Ctr, Neurosurg Serv, Richmond, VA USA; McGuire Dept Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Richmond, VA USA	Richardson, RM (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Rm M779, San Francisco, CA 94143 USA.	robertmark.richardson@ucsfmedctr.org	Messier, Claude/A-2322-2008; Richardson, R Mark/C-6819-2016; Broaddus, William/ABF-8984-2020	Messier, Claude/0000-0002-4791-1763; Richardson, R Mark/0000-0003-2620-7387; Broaddus, William/0000-0001-9614-8162; Fillmore, Helen/0000-0003-4131-579X; Holloway, Kathryn/0000-0003-3777-0060	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA16059] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS042420-04, F31 NS042420-01, F31 NS042420-03, NS12587, F31 NS042420, F31 NS042420-02, F31NS42420] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587, F31NS042420] Funding Source: NIH RePORTER		Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; Gritti A, 1999, J NEUROSCI, V19, P3287; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Lie DC, 2002, J NEUROSCI, V22, P6639; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Richardson RM, 2005, MOL CELL NEUROSCI, V28, P674, DOI 10.1016/j.mcn.2004.11.013; Richardson RM, 2005, BRAIN RES, V1032, P11, DOI 10.1016/j.brainres.2004.10.043; Richardson RM, 2004, J NEUROSURG, V100, P659, DOI 10.3171/jns.2004.100.4.0659; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 2000, NAT MED, V6, P271; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Westerlund U, 2003, EXP CELL RES, V289, P378, DOI 10.1016/S0014-4827(03)00291-X	24	36	37	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUL	2006	148	7					773	777		10.1007/s00701-006-0778-5			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	058SR	WOS:000238685400013	16708171				2021-06-18	
J	Greenspan, AI; Stringer, AY; Phillips, VL; Hammond, FM; Goldstein, FC				Greenspan, Arlene I.; Stringer, Anthony Y.; Phillips, V. L.; Hammond, Flora M.; Goldstein, Felicia C.			Symptoms of post-traumatic stress: Intrusion and avoidance 6 and 12 months after TBI	BRAIN INJURY			English	Article						post-traumatic stress symptoms; impact of events scale; amnesia; traumatic brain injury; risk factors; follow-up studies	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; DISORDER SYMPTOMS; MAJOR TRAUMA; EVENT SCALE; PSYCHIATRIC CONSEQUENCES; CONVERGENT VALIDITY; RECOVERY PROJECT; PTSD; PREDICTORS	Primary objectives: (1) To examine survivors with traumatic brain injury (TBI) for symptoms of avoidance and intrusion, two dimensions of post-traumatic stress (PTS) at 6 and 12 months post-injury. (2) To identify risk factors associated with these symptoms. Research design: Prospective follow-up study. Methods and procedures: Georgia and North Carolina Model Brain Injury Systems participants (n = 198) with mild (19%), moderate (21%) and severe (60%) TBI were interviewed by telephone at 6 and 12 months post-injury. The Impact of Event Scale (IES) was used to identify intrusion and avoidance symptoms. Results: Symptoms consistent with severe PTS increased from 11% at 6 months to 16% 12 months post-injury (p < 0.003). African-Americans (p < 0.01) and women (p < 0.05) reported greater symptomatology at 12 months compared to their counterparts. TBI severity and memory of the event were not associated with PTS-like symptoms. Symptoms increased over time when examined by race, injury intent, gender and age (p < 0.05). Conclusions: Regardless of severity, survivors with TBI are at risk for developing symptoms consistent with PTS. Amnesia for the injury event was not protective against developing these symptoms. African-Americans appear to be at greatest risk.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Charlotte Inst Rehabil, Charlotte, NC USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Greenspan, AI (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop K-63, Atlanta, GA 30341 USA.	agreenspan@cdc.gov					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BLANCHARD EB, 1997, CRASH ASSESSMENT TRE; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 1999, AM J PSYCHIAT, V156, P902, DOI 10.1176/ajp.156.6.902; BRESLAU N, 1995, AM J PSYCHIAT, V152, P529; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Corneil W, 1999, J Occup Health Psychol, V4, P131, DOI 10.1037/1076-8998.4.2.131; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Greenspan AI, 2002, J TRAUMA, V53, P709, DOI 10.1097/00005373-200210000-00015; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holbrook TL, 2002, J TRAUMA, V53, P882, DOI 10.1097/00005373-200211000-00012; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kornblith AB, 1996, HEAD NECK-J SCI SPEC, V18, P323, DOI 10.1002/(SICI)1097-0347(199607/08)18:4<323::AID-HED3>3.0.CO;2-#; KORNBLITH AB, 1992, CANCER, V70, P2508, DOI 10.1002/1097-0142(19921115)70:10<2508::AID-CNCR2820701020>3.0.CO;2-V; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCFALL ME, 1990, AM J PSYCHIAT, V147, P645; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050150209110; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NEAL LA, 1994, J TRAUMA STRESS, V7, P447, DOI 10.1002/jts.2490070310; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Richmond TS, 1998, J TRAUMA, V44, P635, DOI 10.1097/00005373-199804000-00012; Ruchkin VV, 1998, CHILD ABUSE NEGLECT, V22, P889, DOI 10.1016/S0145-2134(98)00064-7; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Sundin EC, 2003, PSYCHOSOM MED, V65, P870, DOI 10.1097/01.PSY.0000084835.46074.F0; TEASDALE G, 1974, LANCET, V2, P81; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407; Zlotnick C, 2004, J NERV MENT DIS, V192, P153, DOI 10.1097/01.nmd.0000110287.16635.8e; Zlotnick C, 2001, J NERV MENT DIS, V189, P404, DOI 10.1097/00005053-200106000-00011; 1999, J HEAD TRAUMA REHABI, V14, P189	55	36	36	1	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2006	20	7					733	742		10.1080/02699050600773276			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200008	16809206				2021-06-18	
J	Stevens, ST; Lassonde, M; de Beaumont, L; Keenan, JP				Stevens, S. T.; Lassonde, M.; de Beaumont, L.; Keenan, J. P.			The effect of visors on head and facial injury in National Hockey League players	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						concussions; head injuries; ice hockey; National Hockey League (NHL); face visor; visor	ICE-HOCKEY; CONCUSSIONS; NECK	There has been an increase in the number of concussions sustained by players in the National Hockey League (NHL). White wearing a helmet is now required by the NHL, the face visor-remains optional. It is unknown to what degree face visors influence concussion, other head injury and eye-injury rates at the professional level. Data from the 2001-2002 NHL season were examined. It was found that wearing a face visor did not significantly influence the prevalence of concussion. Visor protection did, however, minimise eye-injuries and other, non-concussion head injuries. These data suggest that, white a visor may prevent some head and eye-injuries, other measures may be necessary to reduce the number of concussions. (c) 2006 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	Montclair State Univ, Cognit Neuroimaging Lab, Montclair, NJ 07043 USA; Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada	Keenan, JP (corresponding author), Montclair State Univ, Cognit Neuroimaging Lab, 219 Dickson Hall, Montclair, NJ 07043 USA.	keenanj@mail.montclair.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barth JT, 2001, J ATHL TRAINING, V36, P253; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Deady B, 1996, J Emerg Med, V14, P645, DOI 10.1016/S0736-4679(96)00134-5; DIAMOND D, 2003, TOTAL NHL; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FISCHLER S, 1996, GREAT BOOK HOCKEY; Ing E, 2002, CAN J OPHTHALMOL, V37, P161, DOI 10.1016/S0008-4182(02)80058-8; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Menard S., 1995, APPL LOGISTIC REGRES; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; Pashby T J, 1979, Am J Sports Med, V7, P254, DOI 10.1177/036354657900700410; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Voyer D., 1998, Journal of Sport Behavior, V21, P456; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; 2003, HOCKEY REGISTER 2003; 2004, HOCKEY NEWS, V57, P4	22	36	36	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUN	2006	9	3					238	242		10.1016/j.jsams.2006.03.025			5	Sport Sciences	Sport Sciences	061TE	WOS:000238894700008	16716662				2021-06-18	
J	Rassovsky, Y; Satz, P; Alfano, MS; Light, RK; Zaucha, K; McArthur, DL; Hovda, D				Rassovsky, Y; Satz, P; Alfano, MS; Light, RK; Zaucha, K; McArthur, DL; Hovda, D			Functional outcome in TBI I: Neuropsychological, emotional, and behavioral mediators	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; MILD HEAD; PSYCHOSOCIAL ADJUSTMENT; HIV-1 INFECTION; SCALE; SCHIZOPHRENIA; RETURN; WORK; ADOLESCENTS	Literature exists to suggest that the severity of traumatic brain injury (TBI) is positively associated with the severity of functional impairment. However, potential mediators of this relationship have not been studied systematically. In the present study, we evaluated a model hypothesized to explain the relationship between TBI severity and functional impairment in 87 patients with moderate-to-severe TBI, studied longitudinally. Using structural equation modeling, we found that only neuropsychological status (but not emotional or behavioral difficulties) consistently mediated the relationship between TBI severity and functional outcome at 12-months post-injury. These findings suggest that, of the factors examined here, neurocognitive compromise plays the most prominent role in mediating post-TBI adaptive functioning in moderate-to-severe TBI, which has important implications for post-injury interventions.	Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Daniel Freeman Mem Hosp, Inglewood, CA USA; Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Child Psychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA	Rassovsky, Y (corresponding author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Room C8-747,760 Westwood Plaza, Los Angeles, CA 90024 USA.	yurir@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Rassovsky, Yuri/0000-0002-6362-9944			ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BENTLER PM, 1996, EQS STRUCTURAL EQUAT; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; Brekke JS, 1997, SCHIZOPHRENIA BULL, V23, P19, DOI 10.1093/schbul/23.1.19; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; DELIA LF, 1996, COLOR TRAILS TEST AD; DEROGATIS LR, 1983, SYMPTOM CHECKLIST 90, V2; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; GENNARELLI T, 1984, ALMANAC         1009, P6; GIACINO JT, 1999, J HEAT TRAUMA REHABI, V14, P277; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GOLDSTEIN FC, 1990, TRAUMATIC BRAIN INJU; Goodkin K, 2001, PSYCHIAT ANN, V31, P37, DOI 10.3928/0048-5713-20010101-09; Green MF, 1999, SCHIZOPHRENIA BULL, V25, P309, DOI 10.1093/oxfordjournals.schbul.a033380; Green MF, 1996, AM J PSYCHIAT, V153, P321; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; KlOve H, 1963, MED CLIN N AM; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; KURTZKE JF, 1984, ANN NEUROL, V16, P265, DOI 10.1002/ana.410160302; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; ODDY M, 1984, CLOSED HEAD INJURY; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; Rey A, 1964, EXAMEN CLIN PSYCHOL; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Sohlberg M. M., 2001, COGNITIVE REHABILITA; *STAT U NEW YORK, 1993, AD FUNCT IND MEAS VE; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Ullman J. B., 2001, USING MULTIVARIATE S, V4th, P653; Vogenthaler D R, 1987, Brain Inj, V1, P113; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilkie FL, 1998, J NEUROPSYCH CLIN N, V10, P125, DOI 10.1176/jnp.10.2.125	57	36	36	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2006	28	4					567	580		10.1080/13803390500434466			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	033MX	WOS:000236853600008	16624784				2021-06-18	
J	Sviri, GE; Soustiel, JF; Zaaroor, M				Sviri, GE; Soustiel, JF; Zaaroor, M			Alteration in brain natriuretic peptide (BNP) plasma concentration following severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						brain natriuretic peptide; head injury; intracranial hypertension; subarachnoid hemorrhage	CEREBRAL VASOSPASM; SUBARACHNOID HEMORRHAGE; EDEMA; HYPONATREMIA; SYSTEM	Background. Brain natriuretic peptide (BNP) is a potent natriuretic and vasodilator factor which, by its systemic effects, can decrease cerebral blood flow (CBF). In aneurysmal subarchnoid hemorrhage (aSAH), BNP plasma concentrations were found to be associated with hyponatremia and were progressively elevated in patients who eventually developed delayed ischemic deficit secondary to vasospasm. The purpose of the present study was to evaluate trends in BNP plasma concentrations during the acute phase following severe (traumatic brain injury) TBI. Methods. BNP plasma concentration was evaluated in 30 patients with severe isolated head injury (GCS < 8 on admission) in four time periods after the injury (period 1: days 1-2; period 2: days 4-5; period 3: days 7-8; period 4: days 10-11). All patients were monitored for ICP during the first week after the injury. Findings. The initial BNP plasma concentrations (42 +/- 36.9 pg/ml) were 7.3 fold (p < 0.01) higher in TBI patients as compared to the control group (5.78 +/- 1.90pg/ml). BNP plasma concentrations were progressively elevated through days 7-8 after the injury in patients with diffused SAH as compared to patients with mild or no SAH (p < 0.001) and in patients with elevated ICP as compared to patients without elevated ICP (p < 0.001). Furthermore, trends in BNP plasma concentrations were significantly and positively associated with poor outcome. Interpretation. BNP plasma concentrations are elevated shortly after head injury and are continuously elevated during the acute phase in patients with more extensive SAH and in those with elevated ICP, and correlate with poor outcomes. Further studies should be undertaken to evaluate the role of BNP in TBI pathophysiology.	Technion Israel Inst Technol, Dept Neurosurg, Rambam Maimonides Med Ctr, Haifa, Israel	Sviri, GE (corresponding author), Rambam Maimonides Med Ctr, Dept Neurol Surg, POB 9602, IL-31096 Haifa, Israel.						Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; Donati-Genet PCM, 2001, J PEDIATR SURG, V36, P1094, DOI 10.1053/jpsu.2001.24770; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fukui S, 2004, J CLIN NEUROSCI, V11, P507, DOI 10.1016/S0967-5868(03)00111-5; HOFFMAN A, 1991, AM J HYPERTENS, V4, P597, DOI 10.1093/ajh/4.7.597; JENNETT B, 1975, LANCET, V1, P480; Kuwahara K, 1998, J CARDIOVASC PHARM, V31, pS354, DOI 10.1097/00005344-199800001-00099; Levin ER, 1998, NEW ENGL J MED, V339, P321; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; MINAMIKAWA J, 1994, ACTA NEUROCHIR, P104; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V155, P740, DOI 10.1016/S0006-291X(88)80557-6; MORINAGA K, 1992, Neurological Surgery, V20, P45; Morinaga K, 1994, No To Shinkei, V46, P545; ROSENBERG GA, 1995, STROKE, V26, P874, DOI 10.1161/01.STR.26.5.874; Sviri GE, 2000, STROKE, V31, P118, DOI 10.1161/01.STR.31.1.118; Sviri GE, 2001, ACT NEUR S, V77, P41; TEASDALE G, 1974, LANCET, V2, P81; Tomida M, 1998, STROKE, V29, P1584, DOI 10.1161/01.STR.29.8.1584; Tsubokawa T, 2004, NEUROL RES, V26, P893, DOI 10.1179/016164104225017776; WEI CM, 1993, CIRCULATION, V88, P1004, DOI 10.1161/01.CIR.88.3.1004; Wijdicks EFM, 1997, J NEUROSURG, V87, P275, DOI 10.3171/jns.1997.87.2.0275; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P540, DOI 10.1016/S0003-9993(97)90173-8	23	36	46	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAY	2006	148	5					529	533		10.1007/s00701-005-0666-4			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	034GG	WOS:000236916400009	16322908				2021-06-18	
J	Sheldon, AL; Gonzalez, MI; Robinson, MB				Sheldon, AL; Gonzalez, MI; Robinson, MB			A carboxyl-terminal determinant of the neuronal glutamate transporter, EAAC1, is required for platelet-derived growth factor-dependent trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN-KINASE-C; PERINUCLEAR STORAGE COMPARTMENT; TRAUMATIC BRAIN-INJURY; GABA SYNTHESIS; AMINO; ACTIVATION; SUBTYPE; GLUT4; EXCITOTOXICITY	The neuronal glutamate transporter, EAAC1 ( excitatory amino acid carrier 1), undergoes rapid regulation after treatment with platelet-derived growth factor (PDGF) or phorbol ester in C6 glioma cells and neurons. A large intracellular pool of EAAC1 exists, from which transporters are redistributed to the cell surface in response to these signals. Here we show that PDGF had no effect on subcellular localization of the glial glutamate transporter, GLT-1, after transfection into C6 glioma cells. Chimeras consisting of domains from EAAC1 or GLT-1 were used to investigate structural motifs involved in PDGF-dependent redistribution of EAAC1. PDGF did not induce trafficking of an EAAC1 chimera containing the carboxyl- terminal domain of GLT-1; however, it did induce trafficking of a GLT-1 chimera containing the carboxyl- terminal domain of EAAC1. A truncated mutant of EAAC1 lacking 10 carboxyl-terminal amino acids was responsive to PDGF, whereas a mutant lacking 20 residues was not. Alanine substitution mutagenesis in this region revealed a short motif, (YVN504)-Y-502, necessary for regulated trafficking. This motif was also involved in protein kinase C-dependent trafficking, as mutant transporters exhibited an attenuated response to phorbol ester. Interestingly, the presence of YVN in the homologous region of a nonresponsive chimera was not sufficient to confer regulated trafficking; however, the presence of a 12-amino acid motif starting at this Tyr residue was sufficient to confer responsiveness to PDGF. These studies identify a novel motif within the carboxyl terminus of EAAC1 which is required for regulated trafficking. The possibility that this motif targets EAAC1 to an intracellular, "regulated pool" is discussed.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Neurosci, Philadelphia, PA 19104 USA	Robinson, MB (corresponding author), Dept Pediat, 502N Abramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30-HD29679] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5-T32-GM07517] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1-F31-MH1071008-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39011, NS29868] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R13HD029679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039011, R01NS029868] Funding Source: NIH RePORTER		BECKMANN ML, 2005, NEUROPHARMACOL C, V15; Cheng CL, 2002, J NEUROSCI, V22, P10643; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Diamond JS, 2001, J NEUROSCI, V21, P8328; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; He Y, 2000, J COMP NEUROL, V418, P255; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Mathews GC, 2003, J NEUROSCI, V23, P2040; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Palacios S, 2001, J BIOL CHEM, V276, P3371, DOI 10.1074/jbc.M006739200; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Tsvetkov E, 2004, NEURON, V41, P139, DOI 10.1016/S0896-6273(03)00800-6; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	32	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4876	4886		10.1074/jbc.M504983200			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	013RF	WOS:000235426200038	16368696	Other Gold			2021-06-18	
J	Prado, GR; Ross, JD; DeWeerth, SP; LaPlaca, MC				Prado, Gustavo R.; Ross, James D.; DeWeerth, Stephen P.; LaPlaca, Michelle C.			Mechanical trauma induces immediate changes in neuronal network activity	JOURNAL OF NEURAL ENGINEERING			English	Article								During a traumatic insult to the brain, tissue is subjected to large stresses at high rates which often surpass cellular thresholds leading to cell dysfunction or death. The acute response of neurons to a mechanical trauma, however, is poorly understood. Plasma membrane disruption may be the earliest cellular outcome from a mechanical trauma. The increase in membrane permeability due to such disruptions may therefore play an important role in the initiation of deleterious cascades following brain injury. The immediate consequences of an increase in plasma membrane permeability on the electrophysiological behavior of a neuronal network exposed to the trauma have not been elucidated. We have developed an in vitro model of traumatic brain injury (TBI) that utilizes a novel device capable of applying stress at high rates to neuronal cells cultured on a microelectrode array. The mechanical insult produced by the device caused a transient increase in neuronal plasma membrane permeability, which subsided after 10 min. We were able to monitor acute spontaneous electrophysiological activity of injured cultures for at least 10 min following the insult. Firing frequency, average burst interval and spikes within burst were assessed before and after injury. The electrophysiological responses to the insult were heterogeneous, although an increase in burst intervals and in the variability of the assessed parameters were common. This study provides a multi-faceted approach to elucidate the role of neuronal plasma membrane disruptions in TBI and its functional consequences.	[Prado, Gustavo R.; Ross, James D.; DeWeerth, Stephen P.; LaPlaca, Michelle C.] Georgia Inst Technol, Emory Coulter Dept Biomed Engn, Georgia Tech, Lab Neuroengn, 313 Ferst Dr, Atlanta, GA 30332 USA	Prado, GR (corresponding author), Georgia Inst Technol, Emory Coulter Dept Biomed Engn, Georgia Tech, Lab Neuroengn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NIBIB/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB00786]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000786] Funding Source: NIH RePORTER	Funding was provided through NIBIB/NINDS (EB00786).	Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Doebler JA, 2000, TOXICOL LETT, V114, P27, DOI 10.1016/S0378-4274(99)00193-9; GALLANT PE, 1992, J NEUROPATH EXP NEUR, V51, P220, DOI 10.1097/00005072-199203000-00011; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; MILLS LR, 1990, NEURON, V4, P149, DOI 10.1016/0896-6273(90)90451-K; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; SAWYER DB, 1989, BIOCHEMISTRY-US, V28, P6571, DOI 10.1021/bi00442a007; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1999, J NEUROSCI, V19, P4263; Tateno T, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.051924; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	18	36	37	0	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1741-2560	1741-2552		J NEURAL ENG	J. Neural Eng.	DEC	2005	2	4					148	158	PMID 16317239	10.1088/1741-2560/2/4/011			11	Engineering, Biomedical; Neurosciences	Engineering; Neurosciences & Neurology	V43HN	WOS:000209672600017	16317239				2021-06-18	
J	Hoane, MR; Wolyniak, JG; Akstulewicz, SL				Hoane, MR; Wolyniak, JG; Akstulewicz, SL			Administration of riboflavin improves behavioral outcome and reduces edema formation and glial fibrillary acidic protein expression after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						vitamin B-2; Recovery of Function; GFAP; Rat; sensorimotor behavior; antioxidant	FOCAL CEREBRAL-ISCHEMIA; MAGNESIUM THERAPY; OXIDATIVE INJURY; WISTAR RATS; NICOTINAMIDE; INFARCTION; APOPTOSIS; RADICALS; RECOVERY; DEFICITS	Previous studies have shown that administration of riboflavin, vitamin B-2, significantly reduced edema formation following experimental stroke. The present study evaluated the ability of B-2 to improve behavioral function, reduce edema formation, and limit glial fibrillary acidic protein (GFAP) expression following frontal cortex contusion injury. Groups of rats were assigned to B-2 (7.5 mg/kg) or saline (1.0 ml/kg) treatment conditions and received contusion injuries or sham procedures. Drug treatment was administered 15 min and 24 h following injury. Rats were examined on a variety of tests to measure sensorimotor performance (bilateral tactile removal test), and cognitive ability (acquisition of reference and working memory) in the Morris water maze. Administration of B-2 following injury significantly reduced the behavioral impairments observed on the bilateral tactile removal test and improved the acquisition of both reference and working memory tests compared to saline-treated rats. The lesion analysis showed that B-2 reduced the size of the lesion. Examination of GFAP expression around the lesion revealed that B-2 significantly reduced the number of GFAP(+) astrocytes. Edema formation following injury was also significantly reduced by B-2 administration. These findings are the first to show that B-2 administration significantly improved behavioral outcome and reduced lesion volume, edema formation, and the expression of GFAP following traumatic brain injury. These findings suggest that B-2 may have therapeutic potential for the treatment of TBI.	So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS045647-01] Funding Source: Medline		Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BETZ AL, 1994, ACTA NEUROCHIR, P314; CHRISTENSEN HN, 1993, NUTR REV, V51, P149; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; HALL ED, 1993, RES P ARNMD, V71, P81; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Hoane Michael R, 2004, Clin Calcium, V14, P65; Hoane MR, 2005, RESTOR NEUROL NEUROS, V23, P67; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; HULTQUIST DE, 1993, AM J HEMATOL, V42, P13, DOI 10.1002/ajh.2830420105; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Ksendzova GA, 2004, FREE RADICAL RES, V38, P1183, DOI 10.1080/10715760400016162; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Lin YP, 2004, NEUROREPORT, V15, P2241, DOI 10.1097/00001756-200410050-00020; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; McCord JM, 2004, J NUTR, V134, p3171S; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MODUDAI T, 2000, STROKE, V31, P1679; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; PAXINOS G, 1997, RAT BRAIN STEROTAXIC; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; van den Heuvel Corinna, 2004, Clin Calcium, V14, P9; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; WASE AW, 1956, ARCH BIOCHEM BIOPHYS, V61, P174, DOI 10.1016/0003-9861(56)90329-0	41	36	40	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1112	1122		10.1089/neu.2005.22.1112			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600007	16238487				2021-06-18	
J	Willer, B; Kroetsch, B; Darling, S; Hutson, A; Leddy, J				Willer, B; Kroetsch, B; Darling, S; Hutson, A; Leddy, J			Injury rates in house league, select, and representative youth ice hockey	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						injury prevention; injury severity; concussion; sports	HIGH-SCHOOL; SPORTS	Purpose: The purpose of this study was to determine injury rates in a youth ice hockey program over two seasons (2002-2004). Injury rates for age groups (4-18 yr) and for different levels of competition were compared. Another purpose was to determine the effect of body checking on injury rates among these youths. Methods: A prospective injury report form was completed by a volunteer trainer for each injury that caused a loss of player time and resulted in evaluation by a physician. The injury form documented age group, type of injury, length of time that the player missed action due to the injury, location of the injury, and circumstances that led to the injury. Participants included 2632 boys aged 4-18 who played in the 2002-2003 season and 2639 boys who played in the 2003-2004 season. Results: Injuries were four times more likely to occur in games than practices. Boys who played in the most advanced levels of competition are 6.1 times more likely to be injured than boys playing in house leagues. Injury rates during games showed a trend toward increasing with the age of the player. Injury rates spiked the first year that body checking was introduced in two different competition levels. Injury rates also spiked with the onset of adolescence (age 13). Conclusion: The study findings suggest that the introduction of body checking at age 9 to competitive youth hockey causes an immediate but relatively short-term increase in injury rates. The period of adjustment that accompanies body checking should be taken into account when determining the age at which body checking is introduced.	SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA; Joseph Brant Mem Hosp, Rehabil Serv, Burlington, ON, Canada	Willer, B (corresponding author), SUNY Buffalo, Dept Psychiat, G96 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	willer@vaxxine.com					*AAP, 2000, PEDIATRICS, V105, P657; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 1999, PHYSICIAN SPORTSMED, V27, P35, DOI 10.3810/psm.1999.08.945; DAFFNER RH, 1977, J FAM PRACTICE, V4, P225; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Roberts WO, 1999, PHYSICIAN SPORTSMED, V27, P35, DOI 10.3810/psm.1999.11.1102; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; Stuart MJ, 2000, AM SOC TEST MATER, V1341, P19, DOI 10.1520/STP15224S; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605	13	36	36	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	OCT	2005	37	10					1658	1663		10.1249/01.mss.0000181839.86170.06			6	Sport Sciences	Sport Sciences	980XM	WOS:000233051500003	16260964				2021-06-18	
J	Poggi, G; Liscio, M; Adduci, A; Galbiati, S; Massimino, M; Sommovigo, M; Zettin, M; Figini, E; Castelli, E				Poggi, G; Liscio, M; Adduci, A; Galbiati, S; Massimino, M; Sommovigo, M; Zettin, M; Figini, E; Castelli, E			Psychological and adjustment problems due to acquired brain lesions in childhood: A comparison between post-traumatic patients and brain tumour survivors	BRAIN INJURY			English	Article						brain injury; brain tumours; psychological problems; social adjustment	CLOSED-HEAD-INJURY; PRACTICAL SCALE; CHILDREN; MEDULLOBLASTOMA; DEPRESSION; DISORDERS; SEQUELAE; ADHD	Objective: To define and differentiate psychological and adjustment problems due to brain injury or brain tumour in children and adolescents. Methods: Two groups of patients with acquired brain lesions (24 post-traumatic patients and 22 brain tumour survivors), ranging in age between 8-15 years, received a psychological evaluation, including the Child Behaviour Checklist for Ages 4-18 (CBCL) and the Vineland Behaviour Adaptive Scales (VABS). Results: Both groups showed psychological and social adjustment problems. Post-traumatic patients were more impaired than brain tumour survivors. Social adjustment problems were associated to externalizing problems in post-traumatic patients and internalizing problems in brain tumour surviving patients. Conclusions: These differences in psychological and behavioural disorders between the two groups must necessarily be considered when developing psychological treatment, rehabilitation plan and social re-entry.	IRCCS Eugenio Medea, I-23842 Bosisio Parini, LC, Italy; Natl Tumour Inst, Milan, Italy; Univ Turin, I-10124 Turin, Italy	Poggi, G (corresponding author), IRCCS Eugenio Medea, Via Don Luigi Monza 20, I-23842 Bosisio Parini, LC, Italy.	gpoggi@bp.lnf.it	Galbiati, Sara/AAA-7115-2020; Poggi, Geraldina/K-4490-2016; Castelli, Enrico/J-1887-2012; massimino, maura/K-7310-2016	Galbiati, Sara/0000-0001-6810-359X; Poggi, Geraldina/0000-0003-0589-6347; massimino, maura/0000-0002-5506-2001			Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; BLOOM HJG, 1969, AMER J ROENTGENOL RA, V105, P43, DOI 10.2214/ajr.105.1.43; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; DANOFF BF, 1982, CANCER, V48, P1580, DOI 10.1002/1097-0142(19820415)49:8<1580::AID-CNCR2820490810>3.0.CO;2-7; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fossen A, 1998, PEDIATR HEMAT ONCOL, V15, P479, DOI 10.3109/08880019809018309; Fuemmeler BF, 2002, CLIN PSYCHOL REV, V22, P547, DOI 10.1016/S0272-7358(01)00120-9; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Green ML, 1998, J PEDIATR PSYCHOL, V23, P289, DOI 10.1093/jpepsy/23.5.289; HIRSCH JF, 1979, ACTA NEUROCHIR, V48, P1, DOI 10.1007/BF01406016; JENNETT B, 1975, LANCET, V1, P480; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; MULHERN RK, 1993, J PEDIATR PSYCHOL, V18, P339, DOI 10.1093/jpepsy/18.3.339; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; RIS MD, 2002, J CLIN EXPT NEUROPSY, V16, P21; ROBIN AH, 1999, ARCH PHYS MED REHAB, V80, P991; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sherwin ED, 2000, BRAIN INJURY, V14, P267; Siffert J, 1999, CHILD ADOL PSYCH CL, V8, P879; Sparrow S., 1984, VINELAND ADAPTIVE BE; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, MANUAL WECHSLER INTE	33	36	36	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2005	19	10					777	785		10.1080/0269905500110132			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800004	16175838				2021-06-18	
J	Slomine, BS; Salorio, CF; Grados, MA; Vasa, RA; Christensen, JR; Gerring, JP				Slomine, BS; Salorio, CF; Grados, MA; Vasa, RA; Christensen, JR; Gerring, JP			Differences in attention, executive functioning, and memory in children with and without ADHD after severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						attention deficit hyperactivity disorder; brain injuries; cognition; pediatrics; learning; neuropsychology	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; ADOLESCENTS; PERFORMANCE; SCALE; TESTS; COMA	Although the development of Attention Deficit Hyperactivity Disorder (ADHD) after traumatic brain injury (TBI) has been described, it is unknown whether children with TBI and ADHD have greater neuropsychological impairments than children with TBI alone. This study examines attention, executive functioning, and memory in children with TBI-only and TBI + ADHD. Caregivers of 82 children with severe TBI completed structured psychiatric interviews at enrollment to diagnose premorbid ADHD and one-year after injury to diagnose post-injury ADHD. Children underwent neuropsychological testing one year after injury. One memory measure significantly differentiated children with TBI-only from children with newly developed ADHD [secondary ADHD (S-ADHD)] and those with premorbid ADHD that persisted after injury [persisting ADHD (P-ADHD)]. Compared with the TBI-only group, children with TBI + ADHD had worse performance on measures of attention, executive functioning, and memory. Results reveal that in children with severe TBI, the behavioral diagnosis of ADHD is associated with more difficulty in attention, executive functioning, and memory. Additionally, results suggest greater deficits in memory skills in the S-ADHD group compared with the P-ADHD group. Although findings provide preliminary support for distinguishing P-ADHD from S-ADHD, further research is needed to investigate neuropsychological differences between these subgroups of children with severe TBI.	Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Kennedy Krieger Inst, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21218 USA; Kennedy Krieger Inst, Dept Psychiat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Slomine, BS (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21205 USA.	Slomine@Kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD 24061] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Barkley RA, 1997, J DEV BEHAV PEDIATR, V18, P271; Benton AL, 1983, MULTILINGUAL APHASIA; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cahn DA, 1995, CHILD NEUROPSYCHOL, V1, P158, DOI 10.1080/09297049508402247; DELIS D, 1994, CALIFORNIA VERBAL LE; Dennis M, 1995, TRAUMATIC HEAD INJUR; Durston S, 2003, MENT RETARD DEV D R, V9, P184, DOI 10.1002/mrdd.10079; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; Heaton R., 1993, WISCONSIN CARD SORTI; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; Kaplan BJ, 1998, J CLIN EXP NEUROPSYC, V20, P518, DOI 10.1076/jcen.20.4.518.1477; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Leark R, 1996, TOVA TEST VARIABLES; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1995, TRAUMATIC HEAD INJUR; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wechsler D., 1991, WECHSLER INTELLIGENC; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	35	36	36	1	15	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2005	11	5					645	653		10.1017/S1355617705050769			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	968TJ	WOS:000232185000016	16212692				2021-06-18	
J	Chen, WH; Tzeng, SF				Chen, WH; Tzeng, SF			Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury	NEUROSCIENCE LETTERS			English	Article						pituitary adenylyl cyclase-activating polypeptide; spinal cord injury; neuroprotection	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; CEREBELLAR GRANULE CELLS; NEUROTROPHIC FACTOR; GENE-TRANSFER; CYCLIC-AMP; RAT-BRAIN; REGENERATION; PACAP; RECEPTOR; EXPRESSION	Pituitary adenylyl cyclase-activating polypeptide (PACAP) is a potent factor in the regulation of neurotransmission, neuroprotection, neurogenesis and anti-inflammation. We here examined the neuroprotective effect of PACAP on injury to the spinal cord tissue of adult rats, induced by dropping a 10 g NYU impactor from the height of 25 mm (moderate injury) or 50 mm (severe injury). PACAP was found to effectively attenuate cell apoptosis in the spinal cord with moderate injury. However, treatment with PACAP had a lesser effect on decreasing DNA fragmentation in the lesion center of the spinal cord with severe contusion injury. Yet, greater extended neural fibers and motor neurons were observed in the rostral and caudal regions of the PACAP-treated spinal cord when compared to that seen in the PBS-treated control. Our findings indicate the beneficial effect of PACAP for the treatment of spinal cord injury (SCI). (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Natl Cheng Kung Univ, Dept Life Sci, Tainan 70101, Taiwan	Tzeng, SF (corresponding author), Natl Cheng Kung Univ, Dept Life Sci, 1 Ta Hsueh Rd, Tainan 70101, Taiwan.	stzeng@mail.ncku.eud.tw					Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Chang JY, 1997, NEUROCHEM INT, V31, P161, DOI 10.1016/S0197-0186(96)00145-3; Cheng H, 2002, J NEUROSCI RES, V69, P397, DOI 10.1002/jnr.10303; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; HARMAR T, 1994, TRENDS PHARMACOL SCI, V15, P97, DOI 10.1016/0165-6147(94)90042-6; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Horner P, 2002, ARCH NEUROL-CHICAGO, V59, P1717, DOI 10.1001/archneur.59.11.1717; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Lee M, 2001, J NEUROSCI, V21, P3849, DOI 10.1523/JNEUROSCI.21-11-03849.2001; Lindholm D, 1998, ANN NY ACAD SCI, V865, P189, DOI 10.1111/j.1749-6632.1998.tb11178.x; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; PINCUS DW, 1990, BRAIN RES, V514, P355, DOI 10.1016/0006-8993(90)91433-H; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; Tai MH, 2003, EXP NEUROL, V183, P508, DOI 10.1016/S0014-4886(03)00130-4; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/S0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2003, J NEUROSCI RES, V72, P303, DOI 10.1002/jnr.10530; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; Waschek JA, 1996, ANN NY ACAD SCI, V805, P290; YOUNG W, 1993, ADV NEUROL, V59, P249	25	36	38	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 12	2005	384	1-2					117	121		10.1016/j.neulet.2005.04.070			5	Neurosciences	Neurosciences & Neurology	943MF	WOS:000230357400023	15913892				2021-06-18	
J	Shore, AD; Mccarthy, ML; Serpi, T; Gertner, M				Shore, AD; Mccarthy, ML; Serpi, T; Gertner, M			Validity of administrative data for characterizing traumatic brain injury-related hospitalizations	BRAIN INJURY			English	Article						traumatic brain injury; administrative data sources; injury epidemiology	ACCURACY	Primary objective: To examine the validity of Maryland Hospital Discharge (MHD) data for identifying and characterizing traumatic brain injury (TBI)-related hospitalizations. Methods: All TBI-related hospitalizations in 1999 were identified using MHD and Maryland Trauma Registry (MTR) data. In addition, a sample of records were abstracted to compare agreement between MHD and chart data. Results: The MHD file identified fewer TBI cases (61%) compared to the MTR (95%). Overall, TBI-related hospitalization rates based on MHD were significantly fewer ( 95; 95% CI 92, 98) vs MHD and MTR ( 144; 95% CI 140, 147). There was good agreement between the MHD and chart data regarding skull fractures or intracranial lesions (kappa = 0.73 and 0.83, respectively), but poor agreement for neurologic abnormalities or amnesia. The MHD significantly underestimated TBI severity. Conclusions: TBI cases, especially mild ones, were under-reported by MHD data. MHD data are better at detecting anatomic injuries compared to TBI symptoms and sequella.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA; Maryland Inst Emergency Med Serv Syst, Baltimore, MD 21201 USA	Shore, AD (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 637, Baltimore, MD 21205 USA.	ashore@jhsph.edu			ODCDC CDC HHS [U17/CCU314059-04] Funding Source: Medline		*CDCP, 2001, RR1350 US DEP HHS CD; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; Hunt JP, 2000, J TRAUMA, V49, P679, DOI 10.1097/00005373-200010000-00016; Hunt JP, 1999, SURGERY, V126, P191, DOI 10.1067/msy.1999.98749; Johnson RL, 1997, AM J EPIDEMIOL, V146, P266; LANGLOIS JA, 2003, 52SS04 CDCP; Lilienfeld A.M., 1980, FDN EPIDEMIOLOGY; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MCCARTHY ML, 2004, IN PRESS J TRAUMA; MULLINS RJ, 1995, J TRAUMA, V39, P941, DOI 10.1097/00005373-199511000-00020; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P25; *SAS I, 1998, SAS SYST WIND REL 7; Sox HC, 1996, ANNU REV MED, V47, P463; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wynn A, 2001, J TRAUMA, V51, P464, DOI 10.1097/00005373-200109000-00007	18	36	37	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2005	19	8					613	621		10.1080/02699050400013568			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700006	16175815				2021-06-18	
J	Straume-Naesheim, TM; Andersen, TE; Bahr, R				Straume-Naesheim, TM; Andersen, TE; Bahr, R			Reproducibility of computer based neuropsychological testing among Norwegian elite football players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; COGNITIVE IMPAIRMENT; HEAD-INJURIES; CONCUSSIONS; SCORES; IMPACT	Background: Head injuries account for 4-22% of all football injuries. The rate of brain injuries is difficult to assess, due to the problem of defining and grading concussion. Thus computerised testing programs for cognitive function have been developed. Objective: To assess the reliability of a computerised neuropsychological test battery (CogSport) among Norwegian professional football players. Methods: Norwegian professional football league players (90.3% participation) performed two consecutive baseline Cogsport tests before the 2004 season. CogSport consists of seven different subtasks: simple reaction time (SRT), choice reaction time (ChRT), congruent reaction time (CgRT), monitoring (MON), one-back (OBK), matching (Match) and learning (Learn). Results: There was a small but significant improvement from repeated testing for the reaction time measurements of all seven subtasks (SRT: 0.7%, ChRT: 0.4%, CgRT: 1.2%, MON: 1.3%, OBK: 2.7%, Match: 2.0%, Learn: 1.1%). The coefficient of variation (CV) ranged from 1.0% to 2.7%; corresponding intraclass correlation coefficients ranged from 0.45 (0.34 to 0.55) to 0.79 (0.74 to 0.84). The standard deviation data showed higher CVs, ranging from 3.7% (Learn) to 14.2% (SRT). Thus, the variance decreased wit increasing complexity of the task. The accuracy data displayed uniformly high CV (10.4-12.2) and corresponding low intraclass correlation coefficient (0.14 (0.01 to 0.26) to 0.31 (0.19 to 0.42)). Conclusion: The reproducibility for the mean reaction time measures was excellent, but less good for measures of accuracy and consistency. Consecutive testing revealed a slight learning effect from test 1 to test 2, and double baseline testing is recommended to minimise this effect.	Oslo Sports Trauma & Res Ctr, Oslo, Norway; Norwegian Univ Sport & Phys Educ, Oslo, Norway	Straume-Naesheim, TM (corresponding author), Oslo Sports Trauma & Res Ctr, Oslo, Norway.	truls.straume-nesheim@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237; Andersen, Thor Einar/0000-0003-4172-4518			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BENESTAD HB, 2004, FORSKNINGSMETODE MED, P83; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLIE A, 2005, SPORTS NEUROPSYCHOLO; COLLIE A, 2004, BRIT J SPORT MED, V38, P254; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; ERLANGER DM, 2001, BRIT J SPORT MED, V35, P367; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; MULLER R, 1994, STAT MED, V13, P2465, DOI 10.1002/sim.4780132310; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sale DG, 1990, PHYSL TESTING HIGH P, P21; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Westerman R, 2001, ADF HLTH, V2, P29	34	36	36	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I64	I69		10.1136/bjsm.2005.019620			6	Sport Sciences	Sport Sciences	954KI	WOS:000231153600009	16046358	Green Published, Bronze			2021-06-18	
J	Graham, DI; Adams, JH; Murray, LS; Jennett, B				Graham, DI; Adams, JH; Murray, LS; Jennett, B			Neuropathology of the vegetative state after head injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the International-Neuropsychological-Society/German-Society-for-Neuropsychology	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc, German Soc Neuropsychol			CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN-INJURY; CARDIAC-ARREST; WHITE-MATTER; DAMAGE; DEATH; PATHOLOGY; SURVIVAL	A detailed neuropathological study of patients identified clinically after head injury as either severely disabled (SD, n = 30) or vegetative (VS, n = 35) has been carried out to determine the nature and frequency of the various pathologies that form the basis of these clinical states. Patients who were SD were older (SD median 49.5 yrs vs. VS median 38 yrs, p = .04), more likely to have a lucid interval (SD 31% vs. VS 9%, p = .03), and to have had an acute intracranial haematoma (SD 70% vs. VS 26%, p < .001). SD patients less often had severe, Grades (2 or 3) of traumatic diffuse axonal injury (SD 30% vs. VS 71%, p = .001) and less often had thalamic damage (SD 37% vs. VS 80%, p < .001). Similar features of both focal and diffuse damage were present in some SD and VS cases with both groups having considerable damage to white matter and to the thalamus. It is concluded that the principal structural basis of both SD and VS is diffuse traumatic axonal injury (DAI) with widespread damage to white matter and changes in the thalami. However, both ischaemic brain damage and the vascular complications of raised intracranial pressure contributed to the clinical signs and symptoms.	Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland	Graham, DI (corresponding author), So Gen Hosp, Inst Neurol Sci, Acad Univ Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	d.graham@clinmed.gla.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1966, BRAIN, V89, P235, DOI 10.1093/brain/89.2.235; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; [Anonymous], 2003, Clin Med (Lond), V3, P249; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Auer R., 2002, GREENFIELDS NEUROPAT, V7th, P233; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRIERLEY JB, 1971, LANCET, V2, P560; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; COLE G, 1987, CLIN NEUROPATHOL, V6, P104; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P727, DOI 10.1001/archneurpsyc.1952.02320240002001; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1995, BRAIN PATHOL, V5, P117; Ingvar D H, 1978, Ann N Y Acad Sci, V315, P184; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JELLINGER KA, 1994, NEW ENGL J MED, V331, P1378; Jellinger KA, 1977, APALLIC SYNDROME, P88; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; JENNETT B, 2002, VEGETATIVE STATE; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; PETERS G, 1977, APALLIC SYNDROME, P78; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; REILLY PL, 1975, LANCET, V2, P375; RELKIN NR, 1990, ANN NEUROL, V28, P221; RINK A, 1995, AM J PATHOL, V147, P1575; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031	43	36	36	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					198	213		10.1080/09602010443000452			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900007	16350963				2021-06-18	
J	Uzan, M; Tanriverdi, T; Baykara, O; Kafadar, A; Sanus, GZ; Tureci, E; Ozkara, C; Uysal, O; Buyra, N				Uzan, M; Tanriverdi, T; Baykara, O; Kafadar, A; Sanus, GZ; Tureci, E; Ozkara, C; Uysal, O; Buyra, N			Association between interleukin-1 beta (IL-1 ss) gene polymorphism and outcome after head injury: an early report	ACTA NEUROCHIRURGICA			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress-of-Neurological-Surgeons	APR 30-MAY 01, 2003	SAN DIEGO, CA	Amer Assoc Neurol Surg		head injury; interleukin; interleukin-1 beta; outcome; polymorphism	AMYLOID PROTEIN DEPOSITION; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; RECEPTOR ANTAGONIST; CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; PRECURSOR PROTEIN; TEMPORAL PROFILE; EXPRESSION; CYTOKINES	Background. Recent studies focusing on the genetic influences on outcome after head injury (HI) have suggested that different alleles of certain genes are associated with different outcomes. Interleukin-1 beta (IL-1 beta) gene, especially beta 2 polymorphism, is frequently observed in Alzheimer's disease, a remarkable degenerative state in which HI is among the known risk factors. Therefore, the aim of this paper was to search for the possible association between the outcome and IL-1 beta gene polymorphism in human HI. Methods. The study group was composed of the 69 patients admitted to the neurosurgery department after HI. The severity of the initial injury was evaluated by means of the Glasgow Coma Scale and outcome six months later was assessed by means of the Glasgow Outcome Scale. IL-1 beta genotypes were determined from blood samples by standard methods. Findings. Fourteen of 25 (56%) patients with IL-1 beta +3953 allele 2 had an unfavourable outcome (dead, vegetative state or severe disability) compared with eight of 44 (18.1%) patients without IL-1 beta 3953 (p = 0.0004). Similarly, 20 of 28 (71.4%) patients with IL-1 beta allele 2 had an unfavourable outcome compared with two of 41 (4.8%) patients without IL-1 beta -511 (p = 0.005). Patients who had a composite of IL-1 beta 2/2 or 1/2 genotype from both -511 and +3953 region of the chromosome 2 were more prone to have bad prognosis. Conclusion. Results of our study demonstrated that there might be a significant association between IL-1 beta gene polymorphism and outcome after HI, supporting the hypothesis of a genetically determined influence.	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Reanimat & Anaesthesiol, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Biostat, Istanbul, Turkey	Uzan, M (corresponding author), POB 5,Cerrahpasa, TR-34301 Istanbul, Turkey.	uzan@istanbul.edu.tr	Kafadar, Ali/AAH-9387-2019; Uzan, Mustafa/D-6571-2019; Sanus, Galip Zihni/D-6715-2019; Ozkara, Cigdem/AAA-2562-2020; Baykara, Onur/V-5990-2018; Tanriverdi, Taner/C-9003-2019; Buyru, Nur/D-1810-2019	Kafadar, Ali/0000-0002-3312-3192; Ozkara, Cigdem/0000-0003-0548-1838; Baykara, Onur/0000-0002-9754-8456; Buyru, Nur/0000-0002-6920-1455; uysal, omer/0000-0002-8833-697X; Uzan, Mustafa/0000-0001-7214-380X			Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; DERESKI MO, 1992, NEUROSCI RES COMMUN, V11, P179; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; GARCIA JH, 1995, AM J PATHOL, V147, P1477; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Griffin WST, 2002, J LEUKOCYTE BIOL, V72, P233; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HONG XY, 1993, PAINT COATINGS IND, V1, P1; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Huang D, 1998, J NEUROIMMUNOL, V81, P76, DOI 10.1016/S0165-5728(97)00161-6; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A; Kinouchi T, 2002, BIOL GROW ANIM, V1, P203, DOI 10.1016/S1877-1823(09)70123-7; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637, DOI 10.1016/0016-5085(94)90696-3; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Mrak RE, 2000, J NEUROPATH EXP NEUR, V59, P471, DOI 10.1093/jnen/59.6.471; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Muller N, 1998, PROG NEURO-PSYCHOPH, V22, P1, DOI 10.1016/S0278-5846(97)00179-6; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; REIER PJ, 1986, ASTROCYTES, P263; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; ROTHWELL N, 1997, J CLIN INVEST, V100, P2658; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; Santtila S, 1998, SCAND J IMMUNOL, V47, P195; Sciacca FL, 1999, NEUROLOGY, V52, P1896, DOI 10.1212/WNL.52.9.1896; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155	46	36	39	0	7	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUL	2005	147	7					715	720		10.1007/s00701-005-0529-z			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	938AK	WOS:000229972100006	15891809				2021-06-18	
J	Pannu, R; Singh, AK; Singh, I				Pannu, R; Singh, AK; Singh, I			A novel role of lactosylceramide in the regulation of tumor necrosis factor alpha-mediated proliferation of rat primary astrocytes - Implications for astrogliosis following neurotrauma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; LIPID RAFTS; REACTIVE ASTROCYTES; ERK/MAP KINASE; MESSENGER-RNA; CELL-LINE; TNF-ALPHA; EXPRESSION	The present study describes the role of glycosphingolipids in neuroinflammatory disease and investigates tumor necrosis factor alpha (TNF alpha)-induced astrogliosis following spinal cord injury. Astrogliosis is the hallmark of neuroinflammation and is characterized by proliferation of astrocytes and increased glial fibrillary acidic protein (GFAP) gene expression. In primary astrocytes, TNF alpha stimulation increased the intracellular levels of lactosylceramide (LacCer) and induced GFAP expression and astrocyte proliferation. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol.HCl (PDMP), a glucosylceramide synthase and LacCer synthase (GalT-2) inhibitor, inhibited astrocyte proliferation and GFAP expression, which were reversed by exogenous supplementation of LacCer but not by other glycosphingolipids. TNF alpha caused a rapid increase in the activity of GalT-2 and synthesis of LacCer. Silencing of GalT-2 gene using antisense oligonucleotides also attenuated the proliferation of astrocytes and GFAP expression. The PDMP and antisense-mediated inhibition of proliferation and GFAP expression was well correlated with decreased Ras/ERK1/2 pathway activation. Furthermore, TNF alpha-mediated astrocyte proliferation and GFAP expression was also inhibited by LY294002, a phosphatidylinositol 3-kinase inhibitor, which was reversed by exogenous LacCer. LY294002 also inhibited TNF alpha-induced GalT-2 activation and LacCer synthesis, suggesting a phosphatidylinositol 3-kinase-mediated regulation of GalT-2. In vivo, PDMP treatment attenuated chronic ERK1/2 activation and spinal cord injury (SCI)-induced astrocyte proliferation with improved functional recovery post-SCI. Therefore, the in vivo studies support the conclusions drawn from cell culture studies and provide evidence for the role of LacCer in TNF alpha-induced astrogliosis in a rat model of SCI. To our knowledge, this is the first report demonstrating the role of LacCer in the regulation of TNF alpha-induced proliferation and reactivity of primary astrocytes.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Dept Pediat, Charleston, SC USA; Ralph H Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC USA	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 316 Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA.	singhi@musc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS022576, R01NS034741, R37NS022576, R01NS040144, R01NS037766] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-40144, NS-22576, NS-34741, NS-37766] Funding Source: Medline		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BARNA BP, 1990, J NEUROIMMUNOL, V30, P239, DOI 10.1016/0165-5728(90)90108-Y; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BETHEA JR, 1990, J NEUROIMMUNOL, V30, P1, DOI 10.1016/0165-5728(90)90047-Q; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ENG LF, 1992, PROG BRAIN RES, V94, P353; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fern R, 2001, Prog Brain Res, V132, P405; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; Giri S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0798com; Gong NL, 2004, P NATL ACAD SCI USA, V101, P6490, DOI 10.1073/pnas.0308684101; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Houle JD, 2003, EXP NEUROL, V182, P247, DOI 10.1016/S0014-4886(03)00029-3; Iwabuchi K, 2002, BLOOD, V100, P1454, DOI 10.1182/blood.V100.4.1454.h81602001454_1454_1464; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Moon LDF, 2000, EXP NEUROL, V161, P49, DOI 10.1006/exnr.1999.7230; MUCKE L, 1993, FASEB J, V7, P1226; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pannu R, 2004, J NEUROSCI, V24, P5942, DOI 10.1523/JNEUROSCI.1271-04.2004; Parkin ET, 2001, BIOCHEM J, V358, P209, DOI 10.1042/0264-6021:3580209; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rabchevsky AG, 2001, ARCH NEUROL-CHICAGO, V58, P721, DOI 10.1001/archneur.58.5.721; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Steeves JD, 1998, ANN NY ACAD SCI, V860, P412, DOI 10.1111/j.1749-6632.1998.tb09065.x; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tatagiba M, 1997, NEUROSURGERY, V40, P541, DOI 10.1097/00006123-199703000-00023; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Won JS, 2004, J NEUROCHEM, V88, P583, DOI 10.1046/j.1471-4159.2003.02165.x; Won JS, 2001, BRAIN RES, V903, P207, DOI 10.1016/S0006-8993(01)02452-0; YAJIMA K, 1979, LAB INVEST, V41, P385; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yanase H, 2001, PIGM CELL RES, V14, P103, DOI 10.1034/j.1600-0749.2001.140205.x; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang L, 2000, NEUROREPORT, V11, P409, DOI 10.1097/00001756-200002070-00037	50	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13742	13751		10.1074/jbc.M411959200			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	912QW	WOS:000228095500070	15668227	Other Gold			2021-06-18	
J	Mauler, F; Horvath, E				Mauler, F; Horvath, E			Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						5-HT1A; middle cerebral artery occlusion; neuroprotection; repinotan hydrochloride; subdural hematoma; traumatic brain injury	BAY X 3702; CEREBRAL-ARTERY OCCLUSION; THERAPEUTIC TIME WINDOW; ACUTE SUBDURAL-HEMATOMA; IN-VIVO; GLUTAMATE RELEASE; CULTURED NEURONS; RAT HIPPOCAMPUS; TRANSIENT; ISCHEMIA	Repinotan is a highly potent 5-HT1A receptor agonist with strong neuroprotective efficacy in animal models of middle cerebral artery occlusion and traumatic brain injury. In this study, we characterized the time window for neuroprotective effects of repinotan in animal models. In the permanent middle cerebral artery occlusion model, repinotan showed neuroprotective efficacy when administered as a triple bolus injection (0.3-100 mu g/kg) or an intravenous infusion (0.3-100 mu g/ kg per hour). A 73% reduction in infarct volume was observed with a 3 mu g/kg intravenous bolus, and a 65% reduction was observed with a 3 and 10 mu g/kg per hour intravenous infusion. When delayed until 5 hours after occlusion, repinotan (10 mu g/kg per hour) reduced infarct volume by 43%. In the transient middle cerebral artery occlusion model, repinotan (10 mu g/kg per hour) administered immediately after occlusion reduced infarct volume by 97%, and a delay to 5 hours reduced infarct volume by 81%. In the acute subdural hematoma model, repinotan (3 and 10 mu g/kg per hour) reduced infarct volume by 65%. In this model, repinotan (3 mu g/kg per hour) administered 5 hours after occlusion reduced infarct volume by 54%. The favorable neuroprotective efficacy, broad doseresponse curve, and prolonged therapeutic window observed in all models strongly suggest that repinotan is a promising candidate for treating acute ischemic stroke in humans.	Bayer Hlth Care, Global Drug Safety, PH R EU CNS, D-42096 Wuppertal, Germany	Mauler, F (corresponding author), Bayer Hlth Care, Global Drug Safety, PH R EU CNS, Aprather Weg 18A, D-42096 Wuppertal, Germany.	frank.mauler@bayerhealthcare.com					Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahlemeyer B, 1999, EUR J PHARMACOL, V370, P211, DOI 10.1016/S0014-2999(99)00136-3; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; Casanovas JM, 2000, N-S ARCH PHARMACOL, V362, P248, DOI 10.1007/s002100000291; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dong JM, 1998, J PHARMACOL EXP THER, V286, P1239; Furuichi Y, 2003, BRAIN RES, V965, P137, DOI 10.1016/S0006-8993(02)04151-3; GERLACH I, 1998, J NEUROTRAUM, V15, P870; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Horikawa N, 2001, BIOL PHARM BULL, V24, P767, DOI 10.1248/bpb.24.767; Horvath E., 1997, Society for Neuroscience Abstracts, V23, P1923; HORVATH E, 1997, J NEUROTRAUM, V14, P800; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Kukley M, 2001, NEUROSCIENCE, V107, P405, DOI 10.1016/S0306-4522(01)00369-4; LEES KR, 1997, NEUROLOGY S4, V49, P66; Lipton P, 1999, PHYSIOL REV, V79, P1431; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; Mauler F, 2003, CNS DRUG REV, V9, P343; Mauler F, 2003, BRAIN RES, V989, P99, DOI 10.1016/S0006-8993(03)03376-6; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Mohr J.P., 1986, STROKE PATHOPHYSIOLO, P377; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Schaper C, 2000, BRAIN RES, V883, P41, DOI 10.1016/S0006-8993(00)02876-6; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SHIMIZU H, 1993, BRAIN RES, V605, P33, DOI 10.1016/0006-8993(93)91353-T; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; Takahashi M, 1998, J PHARMACOL EXP THER, V287, P559; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; WAHL F, 1994, J NEUROCHEM, V63, P1003; Wardlaw JM., 2003, THROMBOLYSIS ACUTE I; Yenari MA, 1998, CLIN NEUROPHARMACOL, V21, P28; ZHAO Q, 1995, TRANSIENT MIDDLE CER	51	36	36	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2005	25	4					451	459		10.1038/sj.jcbfm.9600038			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	915CH	WOS:000228274700005	15674237	Bronze			2021-06-18	
J	Bhambhani, Y; Rowland, G; Farag, M				Bhambhani, Y; Rowland, G; Farag, M			Effects of circuit training on body composition and peak cardiorespiratory responses in patients with moderate to severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						aerobic exercise; body composition; brain injuries; rehabilitation	METABOLIC-RATE; EXERCISE; RELIABILITY; DEPRESSION; HUMANS	Objective: To examine the time course of the changes in body composition and peak cardiorespiratory fitness resulting from routine brain injury rehabilitation program (BIRP) activities and circuit training in patients with moderate to severe traumatic brain injury (TBI). Design: Time-series design spanning 18 weeks. Trials T1 and T2 were completed in weeks 1 and 2, respectively, to establish reliability of the measurements, followed by trial 3 (T3) 4 weeks later to evaluate changes resulting from the BIRP. Setting: A BIRP in a community rehabilitation hospital. Setting: A BIRP in a community rehabilitation hospital. Participants: Fourteen inpatients with moderate to severe acquired TBI (Glasgow Coma Scale score, 4.6+/-1.4; time since injury, 17.2+/-17mo). Interventions: Twelve-week circuit-training program designed to enhance muscular strength and endurance and aerobic fitness. Subjects were tested midway (T4) through the program and at the end (T5) of 12 weeks. The patients completed an average of 32 supervised sessions, each lasting 1 hour. Main Outcome Measures: Changes in body composition and peak cardiorespiratory responses. Results: No significant changes were observed in the body mass or percentage body fat during the study. The peak values of power output, oxygen uptake, and ventilation rate increased significantly as a result of training, with no concomitant increases in peak heart rate or blood lactate (T5>T3, T2, T1; P<.05). No significant changes were evident midway through training. Conclusions: In a heterogeneous sample of patients with moderate to severe TBI, (1) body composition and peak cardiorespiratory responses remained fairly stable during 6 weeks of BIRP activities, (2) improvements in peak cardiorespiratory fitness required more than 6 weeks of circuit training, and (3) a 12-week course of circuit training without controlling caloric intake was not effective in reducing body weight or percentage body fat.	Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada; Alberta Hosp Ponoka, Brain Injury Rehabil Provincial Program, Ponoka, AB, Canada	Bhambhani, Y (corresponding author), Univ Alberta, Fac Rehabil Med, Rm 373,Corbett Hall, Edmonton, AB T6G 2G4, Canada.	yagesh.bhambhani@ualberta.ca					*AM COLL SPORTS ME, 2001, GUID EX TEST PRESCR; [Anonymous], 1990, Med Sci Sports Exerc, V22, P265; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Bhambhani Y, 1985, Can J Appl Sport Sci, V10, P44; Bhambhani Y, 2003, ARCH PHYS MED REHAB, V84, P1629, DOI 10.1053/S0003-9993(03)00343-5; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Dulloo AG, 1998, AM J CLIN NUTR, V68, P599; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Greenleaf J E, 1982, Exerc Sport Sci Rev, V10, P84; Henson Martha B., 1993, Brain Injury, V7, P169, DOI 10.3109/02699059309008170; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; McArdle WD, 2001, EXERCISE PHYSL ENERG; MCLEAN KP, 2002, ACSM RESOURCES CLIN, P98; NEUFER PD, 1989, SPORTS MED, V8, P302, DOI 10.2165/00007256-198908050-00004; NOVACK TA, 1988, REHABIL COUNS BULL, V31, P313; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; Pinnington H, 2001, J SCI MED SPORT, V4, P129, DOI 10.1016/S1440-2440(01)80014-1; Raggueneau J L, 1979, Anesth Analg (Paris), V36, P439; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; Saltin B, 1968, CIRCULATION       S7, V38, pVII1, DOI DOI 10.1161/01; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Topp Robert, 2002, AACN Clin Issues, V13, P263, DOI 10.1097/00044067-200205000-00011; U. S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; VITALE AE, 1995, PERCEPT MOTOR SKILL, V80, P57, DOI 10.2466/pms.1995.80.1.57; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; Wiercisiewski DR, 1998, J HEAD TRAUMA REHAB, V13, P28, DOI 10.1097/00001199-199802000-00006; Wolman RL, 1994, CLIN REHABIL, V8, P253; Young B, 1991, Neurosurg Clin N Am, V2, P301	37	36	38	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2005	86	2					268	276		10.1016/j.apmr.2004.04.022			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	894UY	WOS:000226818300013	15706553				2021-06-18	
J	Howes, H; Benton, D; Edwards, S				Howes, H; Benton, D; Edwards, S			Women's experience of brain injury: An interpretative phenomenological analysis	PSYCHOLOGY & HEALTH			English	Article						brain injury; women; adaptation; qualitative	SEVERE HEAD-INJURY; DISABILITY; REHABILITATION; RELATIVES; SELF	Acquired traumatic brain injury (TBI) can leave the survivor with a complex range of psychological sequalae. This study aims to investigate the experience from the perspective of women with acquired TBI. Using a qualitative research method, six women with a TBI were interviewed about their experience, and the interviews were transcribed verbatim and analysed according to Interpretative Phenomenological Analysis (IPA). The major themes that emerged were: awareness of change; the emotional reaction; struggling to make sense; adaptation and acceptance. This article describes the process of adaptation, and the implications for rehabilitation are discussed. It is suggested that an intervention based on these themes might be an effective tool in rehabilitation.	Univ Coll Swansea, Dept Psychol, Swansea SA2 8PP, W Glam, Wales	Howes, H (corresponding author), Univ Coll Swansea, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	hannah.howes@nbt.nhs.uk					BOWLBY J, 1981, SADNESS DEPRESSION, V3; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHARMAZ K, 1989, STUD SYM IN, V10, P127; CIOCCA CL, 1995, DISS ABSTR INT B, V56, P2846; DIENER E, 1994, SOC INDIC RES, V31, P103, DOI 10.1007/BF01207052; Dombrowski LK, 2000, REHABIL PSYCHOL, V45, P299, DOI 10.1037/0090-5550.45.3.299; Drench M E, 1994, Rehabil Nurs, V19, P31; EARLL L, 1995, HEALTH PSYCHOL, P283; Folkman S, 2000, AM PSYCHOL, V55, P647, DOI 10.1037//0003-066X.55.6.647; FOLKMAN S, 1997, PL S STRESS, P293; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fortune DG, 2002, BRIT J CLIN PSYCHOL, V41, P157, DOI 10.1348/014466502163949; GOFFMAN, 1963, SOCIETY; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HAHN H, 1983, SOCIETY, V20, P36, DOI 10.1007/BF02700073; HARRELL MM, 1991, COGNITIVE REHABILITA, V9, P12; Imrie R, 1997, DISABIL REHABIL, V19, P263, DOI 10.3109/09638289709166537; JACKSON LA, 1988, SEX ROLES, V19, P429, DOI 10.1007/BF00289717; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Judd D. P., 1999, COUNS PSYCHOL, V14, P4; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Littlewood J., 1992, ASPECTS GRIEF BEREAV; Maker C, 2003, PSYCHOL HEALTH, V18, P403, DOI 10.1080/0887044031000069343; MCKEE KJ, 1998, J BRIT SOC GERONTOLO, V8, P11; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCKNIGHT JL, 1990, MAPPING COMMUNITY CA, P9; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; MOSKOWITZ J, 1998, ANN M AM PSYCH ASS S; Moskowitz JT, 2003, DEATH STUD, V27, P471, DOI 10.1080/07481180390197624; Moustakas C., 1994, PHENOMENOLOGICAL RES; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PARKES CM, 1998, BEREAVEMENT STUDIES; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M, P157; RUSSELL DM, 2001, DISS ABSTR INT B, V61, P3860; SALTER S, 1997, ALTERED BODY IMAGE, P1; Smith JA, 2000, PSYCHOL HEALTH, V15, P1, DOI 10.1080/08870440008400284; Smith JA, 1996, PSYCHOL HEALTH, V11, P261, DOI 10.1080/08870449608400256; Smith JA, 1999, BRIT J SOC PSYCHOL, V38, P409, DOI 10.1348/014466699164248; Stroebe M.S., 2001, HDB BEREAVEMENT RES; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANZOMEREN EAH, 2002, EVV REH COGN DEF C C; WESTBROOK MT, 1990, AUSTR SOCIAL WORK, V43, P27; WILLIAMS CA, 2002, BRIT J HEALTH PSYCH, V2, P153; WILSONBARNETT J, 1980, NURSING, V2, P432	50	36	36	1	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0887-0446	1476-8321		PSYCHOL HEALTH	Psychol. Health	JAN	2005	20	1					129	142		10.1080/0887044042000272903			14	Public, Environmental & Occupational Health; Psychology, Multidisciplinary	Public, Environmental & Occupational Health; Psychology	889ZW	WOS:000226482500009					2021-06-18	
J	Nelson, DW; Bellander, BM; MacCallum, RM; Axelsson, J; Alm, M; Wallin, M; Weitzberg, E; Rudehill, A				Nelson, DW; Bellander, BM; MacCallum, RM; Axelsson, J; Alm, M; Wallin, M; Weitzberg, E; Rudehill, A			Cerebral microdialysis of patients with severe traumatic brain injury exhibits highly individualistic patterns as visualized by cluster analysis with self-organizing maps	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; brain metabolism; microdialysis; intracranial pressure; cerebral perfusion pressure; cluster analysis; neural network	POSITRON-EMISSION-TOMOGRAPHY; AMINO-ACID RELEASE; SEVERE HEAD-INJURY; PERFUSION-PRESSURE; INTRACEREBRAL MICRODIALYSIS; EXTRACELLULAR GLUTAMATE; SUBSTRATE DELIVERY; ENERGY-METABOLISM; NEURAL NETWORKS; ISCHEMIA	Objective: To analyze patterns of cerebral microdialysis in patients with traumatic brain injury and, with a neural network methodology, investigate pattern relationships to intracranial pressure and cerebral perfusion pressure. Design: Retrospective. Setting. University hospital, adult neurosurgical intensive care unit. Patients: Twenty-six patients with severe traumatic brain injury. All consecutive traumatic brain injured patients (Glasgow Coma Scale less than or equal to8) with microdialysis monitoring, analyzing glutamate, lactate, pyruvate, and glucose in both penumbral and nonpenumbral tissue. Interventions: None; patients received the unit's standard neurointensive care procedure. Measurements and Main Results: We used 2084 hrs of complete microdialysis data sets (eight markers) to train Kohonen self-organizing maps. The self-organizing map algorithm is a data-clustering method that reduces high-dimensional information to a two-dimensional representation on a grid (map), retaining local relationships in the data. Maps were colored (overlaid) for intracranial pressure, cerebral perfusion pressure, and outcome, to explore relationships with underlying microdialysis patterns. The maps exhibited a striking clustering of patients, with unique microdialysis patterns that were recognizable throughout the analysis period. This also held true for most microdialysis patterns characteristic of ischemia. These patients with ischemic patterns can have good outcomes, suggesting a disparity between microdialysis values and severity of traumatic brain injury. Conclusion. Using an artificial neural network-like clustering technique, Kohonen self-organizing maps, we have shown that cerebral microdialysis, in traumatic brain injury, exhibits strikingly individualistic patterns that are identifiable throughout the analysis period. Because patients form their own clusters, microdialysis patterns, during periods of increased intracranial pressure or decreased cerebral perfusion pressure, will be found within these clusters. Consequently, no common pattern of microdialysis can be seen among patients within the range of our data. We suggest that these individualistic patterns reflect not only metabolic states of traumatic brain injury but also local gradients seen with small volume sampling. Future investigation should focus on relating these patterns, and movement within and from clusters, to metabolic states of the complex pathophysiology of traumatic brain injury.	Karolinska Univ Hosp, Dept Anaesthesiol & Intens Care, Stockholm, Sweden; Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; Stockholm Univ, Stockholm Bioinformat Ctr, S-10691 Stockholm, Sweden; Karolinska Inst, Dept Biomed Engn, Huddinge, Sweden	Nelson, DW (corresponding author), Karolinska Univ Hosp, Dept Anaesthesiol & Intens Care, Stockholm, Sweden.						Baxt WG, 2002, ANN EMERG MED, V40, P575, DOI 10.1067/mem.2002.129171; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; CHENG B, 1994, STAT SCI, V9, P2, DOI 10.1214/ss/1177010638; Dybowski R, 1996, LANCET, V347, P1146, DOI 10.1016/S0140-6736(96)90609-1; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gopinath SP, 2000, ACT NEUR S, V76, P437; Gurney K., 1997, INTRO NEURAL NETWORK; Hanson CW, 2001, CRIT CARE MED, V29, P427, DOI 10.1097/00003246-200102000-00038; Hillered L, 2003, SCAND CARDIOVASC J, V37, P13, DOI 10.1080/14017430310006974; Hillered L, 1999, ACT NEUR S, V75, P3; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; JENNETT B, 1975, LANCET, V1, P480; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Koura SS, 1998, ACT NEUR S, V71, P244; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; Mjolsness E, 2001, SCIENCE, V293, P2051, DOI 10.1126/science.293.5537.2051; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; PRESNELL SR, 1993, ANNU REV BIOPH BIOM, V22, P283, DOI 10.1146/annurev.bb.22.060193.001435; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1998, NEUROL RES, V20, pS91; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Whittle IR, 1998, NEUROREPORT, V9, P2821, DOI 10.1097/00001756-199808240-00025; 2000, ARTIFICIAL NEURAL NE, P45	52	36	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2004	32	12					2428	2436		10.1097/01.CCM.0000147688.08813.9C			9	Critical Care Medicine	General & Internal Medicine	881NG	WOS:000225873600010	15599147				2021-06-18	
J	Bryant, RA; Marosszeky, JE; Crooks, J; Gurka, JA				Bryant, RA; Marosszeky, JE; Crooks, J; Gurka, JA			Elevated resting heart rate as a predictor of posttraumatic stress disorder after severe traumatic brain injury	PSYCHOSOMATIC MEDICINE			English	Article						posttraumatic stress disorder; traumatic brain injury; heart rate; fear conditioning	ANXIETY; PTSD; FEAR	Objective: This study indexed the relationship between resting heart rates (HRs) after injury and subsequent posttraumatic stress disorder (PTSD) in patients who sustained severe traumatic brain injury (TBI). Methods: Patients who sustained a severe TBI (N = 68) had their resting HR assessed 1 week and 1 month after injury, and they were assessed for PTSD 6 months after injury with the PTSD Inter-view, a structured clinical interview based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Results: PTSD was diagnosed in 23% of patients. PTSD participants had higher HRs at 1 week but not at 1 month after trauma than non-PTSD participants. This difference remained significant when the effect of posttraumatic amnesia was controlled, but it was not significant when the effect of Glasgow Coma Scale was controlled. Conclusion: These findings accord with the proposal that fear conditioning can occur outside the level of awareness and contribute to PTSD development.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Dept Rehabil Med, Sydney, NSW, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			Blanchard EB, 2002, J TRAUMA STRESS, V15, P199, DOI 10.1023/A:1015299126858; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.ne.15.030192.002033; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; LEDOUX JE, 1988, J NEUROSCI, V8, P2517; Pitman R. K., 2000, NEW COGNITIVE NEUROS; PITMAN RK, 1990, J ABNORM PSYCHOL, V99, P49, DOI 10.1037/0021-843X.99.1.49; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P	12	36	36	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0033-3174			PSYCHOSOM MED	Psychosom. Med.	SEP-OCT	2004	66	5					760	761		10.1097/01.psy.0000138121.13198.84			2	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	856UJ	WOS:000224070300021	15385703				2021-06-18	
J	Chen, SF; Richards, HK; Smielewski, T; Johnstrom, P; Salvador, R; Pickard, JD; Harris, TG				Chen, SF; Richards, HK; Smielewski, T; Johnstrom, P; Salvador, R; Pickard, JD; Harris, TG			Relationship between flow-metabolism uncoupling and evolving axonal injury after experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						uncoupling; autoradiography; blood flow; glucose metabolism; cortical contusion injury	CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; POSITRON EMISSION TOMOGRAPHY; FLUID-PERCUSSION INJURY; GLUCOSE-UTILIZATION; HEAD-INJURY; WHITE-MATTER; QUANTITATIVE ASSESSMENT; ARTERY OCCLUSION; ISCHEMIC-INJURY	Blood flow-metabolism uncoupling is a well-documented phenomenon after traumatic brain injury, but little is known about the direct consequences for white matter. The aim of this study was to quantitatively assess the topographic interrelationship between local cerebral blood flow (LCBF) and glucose metabolism (LCMRglc) after controlled cortical impact injury and to determine the degree of correspondence with the evolving axonal injury. LCMRglc and LCBF measurements were obtained at 3 hours in the same rat from F-18-fluorodeoxyglucose and C-14-iodoantipyrine coregistered autoradiographic images, and compared to the density of damaged axonal profiles in adjacent sections and in an additional group at 24 hours using beta-amyloid precursor protein (beta-APP) immunohistochemistry. LCBF was significantly reduced over the ipsilateral hemisphere by 48 +/- 15% compared with shamcontrols, whereas LCMRglc was unaffected, apart from foci of elevated LCMRglc in the contusion margin. Flow-metabolism was uncoupled, indicated by a significant 2-fold elevation in the LCMRglc/LCBF ratio within most ipsilateral structures. There was a significant increase in beta-APP-stained axons from 3 to 24 hours, which was negatively correlated with LCBF and positively correlated with the LCMRglc/LCBF ratio at 3 hours in the cingulum and corpus callosum. Our study indicates a possible dependence of axonal outcome on flow-metabolism in the acute injury stage.	Univ Cambridge, Acad Neurosurg, Ctr Brain Repair, Cambridge, England; Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge, England; Univ Cambridge, Clin Pharmacol Unit, Cambridge, England	Harris, TG (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, 100 UCLA Medplaza Suite 219,Box 718424, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu	Chen, Szu-Fu/K-5040-2012	Harris, Neil/0000-0002-1965-6750; Salvador, Raymond/0000-0001-5557-1562; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Belayev L, 1997, J CEREBR BLOOD F MET, V17, P1266, DOI 10.1097/00004647-199712000-00002; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GINSBERG MD, 1987, NEUROLOGY, V37, P11, DOI 10.1212/WNL.37.1.11; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INGVAR M, 1991, J CEREBR BLOOD F MET, V11, P926, DOI 10.1038/jcbfm.1991.157; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KIRINO T, 1985, PROG BRAIN RES, V63, P39; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEAR JL, 1989, METAB BRAIN DIS, V4, P95, DOI 10.1007/BF00999387; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lythgoe MF, 2003, BRIT MED BULL, V65, P235, DOI 10.1093/bmb/65.1.235; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NAKAI H, 1987, STROKE, V18, P158, DOI 10.1161/01.STR.18.1.158; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1981, FED PROC, V40, P2311; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; STUDHOLME C, 1997, MED PHYS, V6, P334; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1994, ACTA NEUROCHIR, P446; TOMIMOTO H, 1994, J CEREBR BLOOD F MET, V14, P565, DOI 10.1038/jcbfm.1994.70; Valeriani V, 2000, J CEREBR BLOOD F MET, V20, P765, DOI 10.1097/00004647-200005000-00002; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; Whalen MJ, 1998, ACT NEUR S, V71, P212; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAO H, 1995, J CEREBR BLOOD F MET, V15, P398, DOI 10.1038/jcbfm.1995.50; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	70	36	36	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2004	24	9					1025	1036		10.1097/01.WCB.0000129415.34520.47			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	853CO	WOS:000223804100008	15356423	Bronze			2021-06-18	
J	Juttler, E; Potrovita, I; Tarabin, V; Prinz, S; Tuan, DS; Fink, G; Schwaninger, M				Juttler, E; Potrovita, I; Tarabin, V; Prinz, S; Tuan, DS; Fink, G; Schwaninger, M			The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B)	NEUROPHARMACOLOGY			English	Article						cannabinoid; inflammation; dexanabinol; apoptosis; nuclear factor-kappa B	FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; RECEPTOR MESSENGER-RNA; CLOSED-HEAD INJURY; RAT-BRAIN; NEUROPROTECTIVE ANTIOXIDANTS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CB1 RECEPTOR; CELL-DEATH	Exogenous and endogenous cannabinoids have been shown to have neuroprotective effects in vitro and in vivo. Although many of the pharmacological effects of cannabinoids have been identified, the mechanism of neuroprotection still represents a controversy. Here we demonstrate for the first time protective effects of the synthetic cannabinoid dexanabinol by inhibiting apoptosis in a neuron-like cell line using nuclear staining and FACS analysis and in primary neurons. We provide further evidence of inhibition of nuclear factor-kappakappa B (NF-kappaB) by dexanabinol: Dexanabinol inhibits (1) phosphorylation and degradation of the inhibitor of NF-kappaB IkappaBalpha and translocation of NF-kappaB to the nucleus; dexanabinol reduces (2) the transcriptional activity of NF-kappaB and (3) mRNA accumulation of the NF-kappaB target genes tumor necrosis factor-alpha and interleukin-6 (TNF-alpha and IL-6). Dexanabinol does not bind to cannabinoid (CB) receptors I and 2. To investigate the mechanism of action, we employed the non-antioxidant CBI receptor agonist WIN 55,212-2 and the antioxidant cannabinol, which binds to CBI receptors only weakly. Both cannabinoids mimicked the effect of dexanabinol on NF-kappaB and apoptosis. This suggests that neither the antioxidant properties of cannabinoids nor binding to CB1 or CB2 receptors are responsible for the inhibition of NF-kappaB activity and apoptosis. Our results clearly demonstrate that dexanabinol inhibits NF-kappaB. NF-kappaB has been shown to be involved in brain damage and to promote neuronal cell death in vitro and in in vivo models of ischemic and neurodegenerative neurological diseases. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; Pharmos Ltd Kiryat, Rehovot, Israel	Juttler, E (corresponding author), Univ Heidelberg, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	eric_juettler@med.uni-heidelberg.de		Fink, George/0000-0002-0713-527X			Abood ME, 2001, NEUROSCI LETT, V309, P197, DOI 10.1016/S0304-3940(01)02065-1; Achiron A, 2000, J NEUROIMMUNOL, V102, P26, DOI 10.1016/S0165-5728(99)00149-6; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bass R, 1996, J INFECT DIS, V173, P735, DOI 10.1093/infdis/173.3.735; Bauerle PA, 1996, CELL, V87, P13; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; Breivogel CS, 1999, J NEUROCHEM, V73, P2447, DOI 10.1046/j.1471-4159.1999.0732447.x; BURNETTECURLEY D, 1995, P SOC EXP BIOL MED, V210, P64, DOI 10.3181/00379727-210-43926; Chan GCK, 1998, J NEUROSCI, V18, P5322; Chen YQ, 2000, J PHARMACOL EXP THER, V293, P807; Childers SR, 1998, DRUG ALCOHOL DEPEN, V51, P173, DOI 10.1016/S0376-8716(98)00075-1; Cowling RT, 2002, J BIOL CHEM, V277, P5719, DOI 10.1074/jbc.M107515200; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Di Marzo V, 2000, FASEB J, V14, P1432, DOI 10.1096/fj.14.10.1432; DROUET C, 1991, J IMMUNOL, V147, P1694; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Filbert MG, 1999, ANN NY ACAD SCI, V890, P505, DOI 10.1111/j.1749-6632.1999.tb08032.x; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 2000, ANN NY ACAD SCI, V899, P274, DOI 10.1111/j.1749-6632.2000.tb06193.x; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Herring AC, 1999, J PHARMACOL EXP THER, V291, P1156; Huang CJ, 2002, INT J DEV NEUROSCI, V20, P289, DOI 10.1016/S0736-5748(02)00022-9; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Jack DB, 1997, DRUG NEWS PERSPECT, V10, P440; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kittler JT, 2000, PHYSIOL GENOMICS, V3, P175; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nagayama T, 1999, J NEUROSCI, V19, P2987; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ouyang YL, 1998, MOL PHARMACOL, V53, P676; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Schneider A, 1999, NAT MED, V5, P554; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; Shen MX, 1998, MOL PHARMACOL, V54, P459; Shen MX, 1996, J NEUROSCI, V16, P4322; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Simpson CS, 2000, J BIOL CHEM, V275, P16879, DOI 10.1074/jbc.275.22.16879; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; van der Stelt M, 2001, J NEUROSCI, V21, P6475; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Won SJ, 1999, NEUROSCIENCE, V94, P83, DOI 10.1016/S0306-4522(99)00196-7; Xu L, 2002, BIOCHEM BIOPH RES CO, V299, P14, DOI 10.1016/S0006-291X(02)02573-1; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	59	36	37	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	SEP	2004	47	4					580	592		10.1016/j.neuropharm.2004.05.009			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	858WU	WOS:000224223900009	15380375				2021-06-18	
J	Riley, GA; Brennan, AJ; Powell, T				Riley, GA; Brennan, AJ; Powell, T			Threat appraisal and avoidance after traumatic brain injury: why and how often are activities avoided?	BRAIN INJURY			English	Article							HEAD-INJURY; STRESS; MODEL	Objective: Goldstein emphasized the anxiety-related avoidance of activities after brain injury, but such avoidance has rarely been systematically investigated. This study aimed to compile a list of specific threat appraisals that may lead to avoidance and to obtain data on the frequency with which these appraisals and consequent avoidance occur. Design: Survey. Method: Qualitative methodology was used to obtain an account of threat appraisals. These data were then used to compile two questionnaires that asked about the experience of these appraisals and consequent avoidance. Fifty individuals with a TBI completed the questionnaires. Results: A varied list of threat appraisals was obtained. Appraisals and consequent avoidance were frequent in the sample. Males and those whose TBI resulted from an assault reported more avoidance. Conclusions: A core aim of rehabilitation is to facilitate participation in valued roles and activities. Threat appraisals and avoidance deserve more attention in research and practice because they may constitute a significant obstacle to achieving this.	Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England	Riley, GA (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	rileyga@bham.ac.uk	riley, gerard/AAP-1439-2020; Riley, Gerard Anthony/J-1646-2012; Riley, Gerard/A-4328-2008	Riley, Gerard Anthony/0000-0002-1167-8023; Powell, Theresa/0000-0002-3351-9453			BUCK M, 1963, J REHABIL, V29, P37; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dey I, 1993, QUALITATIVE DATA ANA; Finset A, 2000, BRAIN INJURY, V14, P887; FOLKMAN S, 1984, J PERS SOC PSYCHOL, V46, P839, DOI 10.1037/0022-3514.46.4.839; FREEDMAN LR, 1987, DOCTORS GET SICK, P131; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Goldstein K., 1939, ORGANISM; Goldstein K, 1942, EFFECTS BRAIN INJURY; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; HINCKLEDAY NS, 1990, BRAIN INJURY, V47, P50; KAPUR N, 1998, INJURED BRAINS MED M; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kline Paul., 2000, PSYCHOMETRICS PRIMER; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lazarus R.S., 1984, STRESS APPRAISAL COP; LINGE FR, 1990, CAN J PSYCHOL, V44, P116, DOI 10.1037/h0084383; LINGE FR, 1980, CANADAS MENTAL HLTH, V28, P317; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MOORE AD, 1994, CANADIAN J REHABILIT, V7, P193; NEWBORNE B, 1997, RETURN ITHACA; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; QUINN DA, 1998, CONQUERING DARKNESS; Rimel RW, 1990, REHABILITATION ADULT, P8; Syder D., 1993, SHEFFIELD SCREENING; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218	26	36	36	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2004	18	9					871	888		10.1080/02699050410001671829			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700003	15223740				2021-06-18	
J	Dimopoulou, I; Tsagarakis, S; Douka, E; Zervou, M; Kouyialis, AT; Dafni, U; Thalassinos, N; Roussos, C				Dimopoulou, I; Tsagarakis, S; Douka, E; Zervou, M; Kouyialis, AT; Dafni, U; Thalassinos, N; Roussos, C			The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome	INTENSIVE CARE MEDICINE			English	Article						head trauma; stroke; critical illness; cortisol; low-dose corticotropin stimulation test; outcome prediction	SEPTIC SHOCK; ADRENAL INSUFFICIENCY; CORTISOL RESPONSE	Objective. To investigate adrenal responses to the low-dose corticotropin (ACTH) stimulation test in acute traumatic or non-traumatic brain injury (BI) and to assess its value in predicting outcome. Design. Prospective study. Setting. Intensive care unit (ICU) in a university hospital. Patients and participants. Seventy-five patients with acute BI, with a median age of 45 years were investigated. BI was due to trauma (n=51), ischemic stroke (n=17), subarachnoid hemorrhage (n=4) or intracerebral hemorrhage (n=3). Interventions. Blood was taken on day 16 (median) after admission to the ICU to determine baseline cortisol and ACTH. Thereafter, a low-dose stimulation test (LDST) was performed: 1 mug of tetracosactrin was injected and 30 min later a second blood specimen was obtained to measure stimulated cortisol. Patients having a stimulated cortisol below 500 nmol/l were defined as non-responders to the LDST. Measurements and results. Median baseline and stimulated cortisol were 491 nmol/l and 690 nmol/l, respectively. The median increment in cortisol was 154 nmol/l (range 5-579 nmol/l). Mean ACTH was 46+/-21 pg/ml. Ten (13%) patients were non-responders to the LDST; these had a higher mortality rate compared to patients with adequate cortisol production (70 vs 32%, p=0.034). Logistic regression analysis revealed that APACHE II (p<0.001), Glasgow Coma Scale (GCS) (p=0.04) and age (p=0.02) were independent outcome predictors. In contrast, the increment in cortisol (p=0.26) did not add to outcome prediction. Conclusions. Adrenal hypo-responsiveness in the setting of acute traumatic or non-traumatic BI is not an independent outcome predictor in the presence of high APACHE II, low GCS and older age.	Natl & Kapodistrian Univ Athens, Dept Crit Care Med, Evangelismos Hosp, Sch Med, Athens 10675, Greece; Natl & Kapodistrian Univ Athens, Dept Endocrinol Diabet & Metab, Evangelismos Hosp, Sch Med, Athens 10675, Greece	Dimopoulou, I (corresponding author), Natl & Kapodistrian Univ Athens, Dept Crit Care Med, Evangelismos Hosp, Sch Med, Athens 10675, Greece.	idimo@otenet.gr	Dafni, Ourania/AAH-4453-2019	Dafni, Ourania/0000-0003-4367-4497			Ambrosi B, 1998, EUR J ENDOCRINOL, V139, P575, DOI 10.1530/eje.0.1390575; Beishuizen A, 2001, INTENS CARE MED, V27, P1584, DOI 10.1007/s001340101073; BOACHOUR G, 1995, INTENS CARE MED, V21, P57; Bourne RS, 2003, ANAESTHESIA, V58, P591, DOI 10.1046/j.1365-2044.2003.03183.x; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; DIMOPOULOU I, 2004, CRIT CARE MED, V32, P404; GRINSPOON SK, 1994, J CLIN ENDOCR METAB, V79, P923, DOI 10.1210/jc.79.4.923; Hoen S, 2002, ANESTHESIOLOGY, V97, P807, DOI 10.1097/00000542-200210000-00010; LEDINGHAM IM, 1983, LANCET, V1, P1270; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; OLSSON T, 1992, STROKE, V23, P1573, DOI 10.1161/01.STR.23.11.1573; ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7; SALEM M, 1994, ANN SURG, V219, P416, DOI 10.1097/00000658-199404000-00013; Tordjman K, 2000, CLIN ENDOCRINOL, V52, P633, DOI 10.1046/j.1365-2265.2000.00984.x	15	36	40	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2004	30	6					1216	1219		10.1007/s00134-004-2297-2			4	Critical Care Medicine	General & Internal Medicine	825BF	WOS:000221730300033	15103462				2021-06-18	
J	Delaney, JS				Delaney, JS			Head injuries presenting to Emergency Departments in the United States from 1990 to 1999 for ice hockey, soccer, and football	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article; Proceedings Paper	1st International Symposium on Concussion in Sport	NOV, 2001	Vienna, AUSTRIA			head injuries; concussions; skull fractures; emergency department; ice hockey; soccer; football	TRAUMATIC BRAIN-INJURY; ATHLETIC NECK INJURY; HIGH-SCHOOL; MULTIVARIATE-ANALYSIS; COLLEGE FOOTBALL; CERVICAL-SPINE; PLAYERS; CONCUSSION; SPORT; EPIDEMIOLOGY	Study Objective: To examine the number and rates of head injuries occurring in the community as a whole for the team sports of ice hockey, soccer, and football by analyzing data from patients presenting to US emergency departments (EDs) from 1990 to 1999. Design: Retrospective analysis. Main Outcome Measures: Data compiled for the US Consumer Product Safety Commission using the National Electronic Injury Surveillance System were used to generate estimates for the total number of head injuries, concussions, internal head injuries, and skull fractures occurring on a national level from the years 1990 to 1999. These data were combined with yearly participation figures to generate rates of injuries presenting to the ED for each sport. Results: There were an estimated 17,008 head injuries from ice hockey, 86,697 from soccer, and 204,802 from football that presented to US EDs from 1990 to 1999. The total number ofconcussions presenting to EDs in the United States over the same period was estimated to be 4820 from ice hockey, 21,715 from soccer, and 68,861 from football. While the rates of head injuries, concussions, and combined concussions/internal head injuries/skull fractures presenting to EDs per 10,000 players were not always statistically similar for all 3 sports in each year data were available, they were usually comparable. Conclusion: While the total numbers of head injuries, concussions, and combined concussions/skull fractures/internal head injuries presenting to EDs in the United States are different for ice hockey, soccer, and football for the years studied, the yearly rates for these injuries are comparable among all 3 sports.	McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ H2W 1S4, Canada; McGill Univ, Sport Med Clin, Montreal, PQ H2W 1S4, Canada	Delaney, JS (corresponding author), McGill Univ, Ctr Hlth, Dept Emergency Med, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	j.delaney@staff.mcgill.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; Cantu RC., 1997, AM COLL SPORTS MED E, P345; Clarke KS, 1998, CLIN SPORT MED, V17, P1, DOI 10.1016/S0278-5919(05)70056-9; Clarke KS, 1998, CLIN SPORT MED, V17, P83, DOI 10.1016/S0278-5919(05)70063-6; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gillogly S D, 2000, J Med Assoc Ga, V89, P39; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; GOTTESFELD SH, 2000, EMERG MED PRACT, V2, P1; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Kraus J F, 1970, Med Sci Sports, V2, P162; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; MONTGOMERY DL, 1988, SPORTS MED, V5, P99, DOI 10.2165/00007256-198805020-00003; Mueller F O, 1991, Exerc Sport Sci Rev, V19, P261; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; *PED TAAO, 1988, PHYSICIAN SPORTSMED, V16, P165; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Schneider R., 1973, HEAD NECK INJURIES F; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; STRANG I, 1978, INJURY, V10, P154; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196	67	36	36	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2004	14	2					80	87		10.1097/00042752-200403000-00005			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	943BO	WOS:000230327000005	15014341				2021-06-18	
J	Korinthenberg, R; Schreck, J; Weser, J; Lehmkuhl, G				Korinthenberg, R; Schreck, J; Weser, J; Lehmkuhl, G			Post-traumatic syndrome after minor head injury cannot be predicted by neurological investigations	BRAIN & DEVELOPMENT			English	Article						minor head injury; childhood; prognosis; post-traumatic syndrome; electroencephalography; neurological examination	BEHAVIORAL SEQUELAE; PAROXYSMAL ACTIVITY; NORMAL CHILDREN; MILD; TRAUMA; ELECTROENCEPHALOGRAM; TERM; INTERVENTION; RECOVERY; FOLLOW	The aim of this study is to investigate predictive factors of post-traumatic syndrome in children with minor head injury. Prospective neurological, electroencephalographic and psychological investigations were performed in 98 children aged 3 - 13 years within 24 h after the trauma and 4-6 weeks later. Inclusion criteria for mild head injury were unconsciousness < 10 min or none at all, lack of overt neurological symptoms and other complications requiring intensive care. Twenty-six of the children had been unconscious for a short period. Ten had suffered a skull fracture. Within the first 24 h, nearly all children reported acute symptoms of concussion and 64 of 98 showed abnormal EEG findings. After 4-6 weeks, 23 of 98 still exhibited post-traumatic complaints with headache, fatigue, sleep disturbances, anxiety and affect instability. Such post-traumatic symptoms did not correlate with somatic, neurological or electroencephalographic findings observed immediately after the injury or at the follow-up investigation. As opposed to the situation in more severe head trauma, post-traumatic syndrome after minor head injury in children is apparently not due to central nervous injury detectable by neurological examination or electroencephalography. Irrespective of the necessity of neuroradiological investigations and repeated EEGs in more severe and complicated head trauma, we discourage the routine EEG examination in very slight head injury and instead rather recommend parent and patient counselling. (C) 2003 Elsevier B.V. All rights reserved.	Univ Hosp, Div Neuropaediat & Muscular Dis, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany; Univ Hosp, Dept Child & Adolescent Psychiatry, D-50931 Cologne, Germany	Korinthenberg, R (corresponding author), Univ Hosp, Div Neuropaediat & Muscular Dis, Dept Pediat & Adolescent Med, Mathildenstrassw 1, D-79106 Freiburg, Germany.	rudokori@kikli.ukl.uni-freiburg.de	Korinthenberg, Rudolf/A-9796-2009	Korinthenberg, Rudolf/0000-0002-4638-3460			BIJUR PE, 1990, PEDIATRICS, V86, P337; BLACK P, 1981, BRAIN DYSFUNCTION CH; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1987, PEDIATRICS, V80, P159; DUSSER A, 1989, ELECTROEN CLIN NEURO, V73, P85, DOI 10.1016/0013-4694(89)90187-9; Edna T H, 1987, J Oslo City Hosp, V37, P101; EEGOLOFSSON O, 1971, NEUROPADIATRIE, V2, P375, DOI 10.1055/s-0028-1091791; ENOMOTO T, 1986, CHILD NERV SYST, V2, P72; Esser G., 1989, MANNHEIMER ELTERNINT; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; Fellick JM, 2001, ARCH DIS CHILD, V85, P371, DOI 10.1136/adc.85.5.371; HUGENHOLTZ H, 1987, CHILD NERV SYST, V3, P266, DOI 10.1007/BF00271820; JONES RK, 1974, SURG NEUROL, V2, P101; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KOUFEN H, 1977, EEG-EMG-Z ELEK ELEKT, V8, P29; KOUFEN H, 1977, MED KLIN, V72, P739; KRAUS F, 1990, AM J DIS CHILD, V44, P684; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MASUZAWA H, 1988, CHILD NERV SYST, V4, P198, DOI 10.1007/BF00270914; PETERSEN I, 1971, NEUROPADIATRIE, V2, P247, DOI 10.1055/s-0028-1091786; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; RAEGRANT AD, 1991, ELECTROEN CLIN NEURO, V79, P349, DOI 10.1016/0013-4694(91)90199-E; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; RUMPL E, 1999, ELECTROENCEPHALOGRAP, P393; RUTHERFORD WH, 1977, LANCET, V1, P1; SANFORD RA, 1988, SEMIN NEUROL, V8, P108, DOI 10.1055/s-2008-1041362; SILVERMAN D, 1962, NEUROLOGY, V12, P273, DOI 10.1212/WNL.12.4.273; SLATER EJ, 1989, J ADOLESCENT HEALTH, V10, P237, DOI 10.1016/0197-0070(89)90240-4; Stallard P, 1998, BRIT MED J, V317, P1619, DOI 10.1136/bmj.317.7173.1619; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Touwen B.C.L., 1979, EXAMINATION CHILD MI	34	36	39	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2004	26	2					113	117		10.1016/S0387-7604(03)00110-4			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	801VH	WOS:000220122900007	15036430				2021-06-18	
J	Nolle, C; Todt, I; Seidl, RO; Ernst, A				Nolle, C; Todt, I; Seidl, RO; Ernst, A			Pathophysiological changes of the central auditory pathway after blunt trauma of the head	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; hearing disorder; MTBI; otoacoustic emissions	EVOKED OTOACOUSTIC EMISSIONS; CONTRALATERAL ACOUSTIC STIMULATION; HEARING-LOSS; AXONAL INJURY; SUPPRESSION; CONCUSSION; DIZZINESS; TINNITUS; HUMANS; NOISE	It is the aim of the present paper to correlate clinical symptoms of auditory dysfunction (tinnitus, hyperacusis, hearing loss) one year on average after a blunt trauma of the head with objective audiological test results (otoacoustic emission and auditory brainstem response testing, impedance audiometry) and to compare these findings to controls without history of head trauma. Thirty-one patients (24-56 years) were included. They were largely female (n = 26). The clinical and otolaryngological examination (including otoscopy) of all patients revealed no pathological abnormalities. Pure-tone audiograms were normal with one exception (pre-existing noise-induced hearing loss) as well as tympanograms. The main auditory symptoms were tinnitus (n = 9), hyperacusis (n = 2) and a reported transient hearing loss immediately after the trauma (n = 16) (which had improved at the time of examination). The results of testing the central auditory pathway showed that the transiently evoked otoacoustic emissions (otoemissions) revealed statistically significant differences between amplitude differences of all patients as well as patients with tinnitus and controls in the linear, but not in the non-linear stimulation mode. A complete loss of stapedial reflex responses was found in 12 of the patients and a partial (irregular) loss (in at least more than two frequencies) in four additional patients. Auditory brainstem responses (ABR) were normal in all patients, but 76% had lowered loudness discomfort levels (LDL). Blunt trauma of the head can lead to auditory dyfunction, probably as a result of diffuse axonal injury of the central auditory pathway. An initial sensorineural hearing loss after the trauma (as a result of the inner ear fluid concussion) was transiently reported only. Auditory symptoms play a minor role in the so-called "post-concussive syndrome," but should be considered and evaluated fully.	UKB, Dept Otolaryngol, D-12683 Berlin, Germany; Hosp Univ Berlin, UKB, Dept Otolaryngol, D-12683 Berlin, Germany	Ernst, A (corresponding author), UKB, Dept Otolaryngol, Warener Str 7, D-12683 Berlin, Germany.	ArneborgE@ukb.de					Anari M, 1999, SCAND AUDIOL, V28, P219, DOI 10.1080/010503999424653; Bamiou DE, 2000, AUDIOLOGY, V39, P168; BERLIN CI, 1995, HEARING RES, V87, P96, DOI 10.1016/0378-5955(95)00082-F; BERLIN CI, 1993, HEARING RES, V71, P1, DOI 10.1016/0378-5955(93)90015-S; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Brors M, 2001, NEURORADIOLOGY, V43, P144, DOI 10.1007/PL00006045; Ceranic BJ, 1998, J NEUROL NEUROSUR PS, V65, P523, DOI 10.1136/jnnp.65.4.523; Cohen M, 1996, SCAND AUDIOL, V25, P133, DOI 10.3109/01050399609047995; COLLET L, 1994, BRIT J AUDIOL, V28, P213, DOI 10.3109/03005369409086570; De Ceulaer G, 2001, OTOL NEUROTOL, V22, P350, DOI 10.1097/00129492-200105000-00013; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; FRANKLIN DJ, 1992, EAR HEARING, V13, P417, DOI 10.1097/00003446-199212000-00008; GELFAND SA, 1982, J EAR HEAR, V3, P93; JANNI NN, 1991, J NEUROSURG, V29, P206; Katzenell U, 2001, OTOL NEUROTOL, V22, P321, DOI 10.1097/00129492-200105000-00009; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meriot P, 1999, J RADIOL, V80, P1780; Nolle C, 2000, OTO RHINO LARYN NOVA, V10, P194, DOI 10.1159/000054817; NORMAN M, 1993, BRIT J AUDIOL, V27, P281, DOI 10.3109/03005369309076705; PLINKERT PK, 1992, LARYNGO RHINO OTOL, V71, P74, DOI 10.1055/s-2007-997249; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRASHER D, 1994, BRIT J AUDIOL, V28, P247, DOI 10.3109/03005369409086574; RAJAN R, 1990, J HEAR RES, V45, P137; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SOUSTIEL JF, 1995, BRAIN INJURY, V9, P805, DOI 10.3109/02699059509008236; VEUILLET E, 1991, J NEUROPHYSIOL, V65, P724; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WILLIAMS EA, 1994, ACTA OTO-LARYNGOL, V114, P121, DOI 10.3109/00016489409126029	31	36	39	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					251	258		10.1089/089771504322972040			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600003	15115600				2021-06-18	
J	Aare, M; Kleiven, S; Halldin, P				Aare, M; Kleiven, S; Halldin, P			Injury tolerances for oblique impact helmet testing	INTERNATIONAL JOURNAL OF CRASHWORTHINESS			English	Article						injury tolerances; oblique impacts; helmet; head injuries and FE (finite element)	DIFFUSE AXONAL INJURY; HUMAN HEAD	The most frequently sustained severe injuries in motorcycle crashes are injuries to the head, and many of these are caused by rotational force. Rotational force is most commonly the result of oblique impacts to the head. Good testing methods for evaluating the effects of such impacts are currently lacking. There is also a need for improving our understanding of the effects of oblique impacts on the human head. Helmet standards currently in use today do not measure rotational effects in test dummy heads. However rotational force to the head results in large shear strains arising in the brain, which has been proposed as a cause of traumatic brain injuries like diffuse axonal injuries (DAI). This paper investigates a number of well-defined impacts, simulated using a detailed finite element (FE) model of the human head, an FE model of the Hybrid III dummy head and an FE model of a helmet. The same simulations were performed on both the FE human head model and the FE Hybrid III head model, both fitted with helmets. Simulations on both these heads were performed to describe the relationship between load levels in the FE Hybrid III head model and strains in the brain tissue in the FE human head model. In this study, the change in rotational velocity and the head injury criterion (HIC) value were chosen as appropriate measurements. It was concluded that both rotational and translational effects are important when predicting the strain levels in the human brain.	CTV, Div Neuron Engn, Royal Inst Technol, SE-14157 Huddinge, Sweden; Karolinska Inst, S-10401 Stockholm, Sweden	Aare, M (corresponding author), CTV, Div Neuron Engn, Royal Inst Technol, Novum Res Pk, SE-14157 Huddinge, Sweden.	aare@kth.se					AARE M, 1999, INJ CONTR SAF PROMOT, V10, P131, DOI DOI 10.1076/ICSP.10.3.131.14556; AARE M, 2003, NEW LAB RIG EVALUATI, V4, P240; BAIN BC, 1996, AGARD AMP; BAIN BC, 2000, J BIOMECH ENG, V16, P615; Beusenberg M, 2001, IRCOBI C 2001 ISL MA, P295; *BRIT STAND I, 1985, PROT HELM VEH US; DiMasi F. P., 1995, 952718 SAE; DONNELLY BR, 1998, P 26 INT WORKSH, P47; FREDRIKSSON LA, 1996, 447 DIV SOL MECH DEP; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli T.A., 1987, 872197 SAE, P49; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HALLQUIST JO, 1998, LSDYNA3D THEOR MAN L; HARDY WN, 2001, 45 STAPP CAR CRASH J, P337; Hering A. M, 2000, IRCOBI C MONTP FRANC, P307; Holbourn AHS, 1943, LANCET, V2, P438; KING AI, 2002, 4 WORLD C BIOM AUG 2; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; KLEIVEN S, 2002, 02S76 SAE; KLEIVEN S, 2003, P RTO SPEC M NATO CO; KLEIVEN S, 2001, IRCOBI C 2001 ISL MA, P161; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; NEWMAN JA, 2000, 200101SC16 SAE; *NHTSA DOT, 1972, OCC CRAST PROT HEAD; OTTE D, 1999, 327 COST; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; UENO K, 1995, J BIOMECH ENG-T ASME, V117, P319, DOI 10.1115/1.2794187; *UN EC COMM EUR, 1999, WORK PART WP29 CONST; YETTRAM AL, 1994, PLAST RUB COMPOS PRO, V22, P215; 2003, VISIBLE HUMAN PROJEC; 1997, FMV218	32	36	36	1	15	WOODHEAD PUBL LIMITED	LETCHWORTH	BLACKHORSE RD, LETCHWORTH SG6 1HN, HERTS, ENGLAND	1358-8265			INT J CRASHWORTHINES	Int. J. Crashworthiness		2004	9	1					15	23		10.1533/ijcr.2004.0268			9	Engineering, Manufacturing; Engineering, Mechanical	Engineering	771DF	WOS:000188769800002					2021-06-18	
J	Arundine, M; Chopra, GK; Wrong, A; Lei, SB; Aarts, MM; Macdonald, JF; Tymianski, M				Arundine, M; Chopra, GK; Wrong, A; Lei, SB; Aarts, MM; Macdonald, JF; Tymianski, M			Enhanced vulnerability to NMDA toxicity in sublethal traumatic neuronal injury in vitro	JOURNAL OF NEUROTRAUMA			English	Article						excitotoxicity; F-actin; in vitro model; microtubules; NMDA receptor; stretch injury; trauma	STRETCH-INDUCED INJURY; HIPPOCAMPAL-NEURONS; RECEPTOR ACTIVATION; GENE-EXPRESSION; ALPHA-ACTININ; BRAIN-INJURY; CALCIUM; NEUROTOXICITY; CHANNEL; DAMAGE	Traumatic brain injury causes neuronal disruption and triggers secondary events leading to additional neuronal death. To study injuries triggered by secondary events, we exposed cultured cortical neurons to sublethal mechanical stretch, thus eliminating confounding death from primary trauma. Sublethally stretched neurons maintained cell membrane integrity, viability, and electrophysiological function. However, stretching induced in the cells a heightened vulnerability to subsequent challenges with L-glutamate or NMDA. This heightened vulnerability was specifically mediated by NMDA receptors (NMDARs), as stretched neurons did not become more vulnerable to either kainate toxicity or to that induced by the Call ionophore A23187. Stretch-enhanced vulnerability to NMDA occurred independently of endogenous glutamate release, but required Ca2+ and Na+ influx through NMDARs. Stretch did not affect the electrophysiological properties of NMDARs nor excitatory synaptic activity, indicating that specificity of enhanced vulnerability to NMDA involves postsynaptic mechanisms downstream from NMDARs. To test whether this specificity requires physical interactions between NMDARs and cytoskeletal elements, we perturbed actin filaments and microtubules, both of which are linked to NMDARs. This had no effect on the stretch-induced vulnerability to NMDA, suggesting that sublethal stretch does not affect cell survival through the cytoskeleton. Our data illustrate that sublethal in vitro stretch injury triggers distinct signaling pathways that lead to secondary injury, rather than causing a generalized increase in vulnerability to secondary insults.	Toronto Western Hosp, Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	Tymianski, M (corresponding author), Toronto Western Hosp, Res Inst, Toronto, ON M5T 2S8, Canada.	mike_t@uhnres.utoronto.ca	Aarts, Michelle/C-5766-2008	Aarts, Michelle/0000-0002-9171-0571; Tymianski, Mike/0000-0002-6311-9565	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039060] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39060] Funding Source: Medline		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; Allison DW, 1998, J NEUROSCI, V18, P2423; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Brenman JE, 1998, J NEUROSCI, V18, P8805; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; *CDCP, 2001, TRAUM INJ US INT REP; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; David JC, 1996, J NEUROSCI, V16, P200; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Ehlers MD, 1998, J NEUROSCI, V18, P720; EIMERL S, 1994, J NEUROCHEM, V62, P1223; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faddis BT, 1997, J NEUROSCI, V17, P951; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE G, 1986, NEUROSCIENCE, V18, P437, DOI 10.1016/0306-4522(86)90164-8; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kaech S, 1997, J NEUROSCI, V17, P9565; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Li S, 1999, J Neurosci, V19, pRC16; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Lu WY, 1999, NAT NEUROSCI, V2, P331; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MADDEN KP, 1990, BRAIN RES, V537, P256, DOI 10.1016/0006-8993(90)90366-J; MARCOUX FW, 1989, CEREBROVASC DIS, P135; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; *NAT CTR HLTH STAT, 1997, DAT FIL DOC NAT HOSP; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Passafaro M, 1999, NAT NEUROSCI, V2, P1063; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shorte SL, 1997, J NEUROPHYSIOL, V78, P1135; Smith DH, 1999, J NEUROSCI, V19, P4263; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; TANKE HJ, 1982, J IMMUNOL METHODS, V52, P91, DOI 10.1016/0022-1759(82)90353-2; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Tymianski M, 1996, ADV NEUROL, V71, P85; Tymianski M, 1996, NEUROSURGERY, V38, P1176; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; WANG LY, 1995, J PHYSIOL-LONDON, V486, P83, DOI 10.1113/jphysiol.1995.sp020792; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505	76	36	36	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1377	1395		10.1089/089771503322686166			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700009	14748985				2021-06-18	
J	Ruff, RM				Ruff, RM			A friendly critique of neuropsychology: facing the challenges of our future	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	21st Annual Conference of the National-Academy-of-Neuropsychology	OCT 31-NOV 03, 2001	SAN FRANCISCO, CA	Natl Acad Neuropsychol		neuropsychological testing; history of neuropsychology; cognitive treatment	TRAUMATIC BRAIN-INJURY; UNIFIED DEFINITION; SEARCH	Neuropsychology emerged as a discipline in the 1940s when prior to performing a craniotomy, neurosurgeons based their localization on EEGs, X-rays and neuropsychological test results. This practice ended in the mid 1970s when computerized tomography became available. As the neuropsychologists' role in localizing has become miniscule, the referral questions have shifted to obtaining quantitative descriptions of the patient's cognitive status. The current paper explores future directions for neuropsychology on the basis of asking the following question: Are we meeting the needs of the patients? The answer is clear: Patients' needs are not met by merely diagnosing cognitive deficits. There is a growing need to advance services that maintain cognitive health, since modem societies place increasing value on highly educated and skilled work forces. Thus, the time has come for neuropsychologists to identify as caretakers for cognitive health. Just as we expect from the disciplines responsible for physical and emotional health, we must provide a combination of diagnostic and treatment services for cognitive health. (C) 2003 National Academy of Neuropsychology. Published. by Elsevier Ltd. All rights reserved.	St Marys Hosp, San Francisco, CA 94117 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Stanford Univ, Stanford, CA 94305 USA	Ruff, RM (corresponding author), St Marys Hosp, 450 Stanyan St, San Francisco, CA 94117 USA.	ronuff@mindpring.com					[Anonymous], 1996, Neurology, V47, P592; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; Baldo Juliana V, 2002, Appl Neuropsychol, V9, P193, DOI 10.1207/S15324826AN0904_1; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Broca P., 1865, B SOC ANTHROPOL PAR, V6, P337; Friston KJ, 1997, TRENDS COGN SCI, V1, P21, DOI 10.1016/S1364-6613(97)01001-2; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; GRANT I, 1996, NEUROPSYCHOLOGICAL A; HARTMAN DE, 1995, NEUROPSYCHOLOGICAL T; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Levin HS, 1989, MILD HEAD INJURY; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Pribram K. H., 1971, LANGUAGES BRAIN; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P99; Ruff RM, 1999, BRAIN INJURY, V13, P943; SQUIRE LR, 1987, MEMORY BRAIN; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; SWEET J, 2001, INITIAL RESULTS D40; TARTER RE, 1988, MED NEUROPSYCHOLOGY; Teuber HL, 1955, ANNU REV PSYCHOL, V6, P267, DOI 10.1146/annurev.ps.06.020155.001411; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Weiskrantz L., 1991, PERSPECTIVES COGNITI; WERNICKE C, 1874, APHASISCHE SYMPTOMKO; Wilson B., 1987, BEHAV INATTENTION TE; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; World Health Organization, 1980, INT CLASS IMP DIS HA	27	36	36	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2003	18	8					847	864		10.1016/j.acn.2003.07.002			18	Psychology, Clinical; Psychology	Psychology	747WZ	WOS:000186830200003	14609580	Bronze			2021-06-18	
J	Glomsda, BA; Blaheta, RA; Hailer, NP				Glomsda, BA; Blaheta, RA; Hailer, NP			Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil	SPINAL CORD			English	Article						mycophenolic acid; adhesion molecules; immunosuppression; mononuclear cells; spinal cord; mycophenolate metabolism	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; P-SELECTIN; NITRIC-OXIDE; IN-VITRO; INFLAMMATORY RESPONSE; QUINOLINIC ACID	Study design: In vitro study on the effects of mycophenolate mofetil (MMF) on isolated human monocytes and endothelial cells. Objectives: Haematogenous macrophages play an essential role in the development of secondary damage following spinal cord injury (SCI), and there is evidence that the use of immunosuppressants such as MMF can reduce monocyte invasion and neuronal damage. Setting: University Hospital for Orthopaedic Surgery, Frankfurt am Main, Germany. Methods: The effects of MMF on the adhesion of human monocytes to human umbilical vein endothelial cells (HUVEC), monocyte binding to immobilised E-selectin, and monocyte expression of intercellular adhesion molecule (ICAM)-1, sialyl Lewis X (sLeX) and major histocompatibility complex (MHC)-II were studied. The binding of monocytes to E-selectin was examined by using purified and immobilised E-selectin fusion protein. Adhesion molecule expression was investigated by flow cytometry. Results: The binding of monocytes to HUVEC was significantly reduced by 30.1% after treatment of monocytes with MMF (10 mug/ml), whereas the pretreatment of HUVEC with MMF did not result in significant changes in monocyte adhesion. MMF forcefully inhibited monocyte binding to immobilised E-selectin by 55.7%. Furthermore, MMF significantly inhibited the upregulation of ICAM-1- and MHC-II-expression on monocytes stimulated with either lipopolysaccharide or interferon-gamma, whereas the expression of sLeX was not impaired. Toxic effects were excluded by propidium-iodide staining and measurement of fluorescein-diacetate metabolism. Conclusion: MMF can downregulate important monocytic adhesion molecules and inhibits monocyte adhesion to endothelial cells, thus indicating that treatment with MMF could be beneficial after SCI. Sponsorship: This study was supported by the DFG (Ha 2721/1-3), the Paul und Ursula KleinStiftung and the Stiftung Friedrichsheim.	Univ Hosp Orthopaed Surg Friedrichsheim, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Clin Pediat, Interdisciplinary Lab, D-6000 Frankfurt, Germany	Hailer, NP (corresponding author), Univ Hosp Orthopaed Surg Friedrichsheim, Marienburgstr 2, D-60528 Frankfurt, Germany.			Hailer, Nils/0000-0002-3233-2638			ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; ALLISON AC, 1993, CLIN TRANSPLANT, V7, P96; ALLISON AC, 1993, TRANSPLANT P, V25, P67; Baer PC, 2000, NEPHROL DIAL TRANSPL, V15, P184, DOI 10.1093/ndt/15.2.184; Blaheta RA, 1998, TRANSPL IMMUNOL, V6, P251, DOI 10.1016/S0966-3274(98)80015-4; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; CANNELLA B, 1990, J EXP MED, V172, P1521, DOI 10.1084/jem.172.5.1521; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; CHOI DW, 1990, J NEUROSCI, V10, P2493; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Davies SJA, 1997, NATURE, V390, P680; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DEVRIES HE, 1994, J NEUROIMMUNOL, V52, P1, DOI 10.1016/0165-5728(94)90155-4; DIJKSTRA CD, 1992, J NEUROIMMUNOL, V40, P183, DOI 10.1016/0165-5728(92)90132-5; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Engelhardt B, 1997, BLOOD, V90, P4459, DOI 10.1182/blood.V90.11.4459.4459_4459_4472; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HAUSER SL, 1983, J NEUROIMMUNOL, V5, P197, DOI 10.1016/0165-5728(83)90010-3; Heemann U, 1996, Transpl Immunol, V4, P64, DOI 10.1016/S0966-3274(96)80039-6; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; Laurent AF, 1996, EXP HEMATOL, V24, P59; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; Navratil E, 1997, NEUROPATH APPL NEURO, V23, P68, DOI 10.1046/j.1365-2990.1997.8298082.x; NOWAK I, 1995, CLIN CHEM, V41, P1011; OEHMICHEN M, 1983, PROG NEUROPATH, V5, P277; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Schwab JM, 2000, J NEUROIMMUNOL, V111, P122, DOI 10.1016/S0165-5728(00)00372-6; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Wittig BM, 1996, INT J CANCER, V67, P80, DOI 10.1002/(SICI)1097-0215(19960703)67:1<80::AID-IJC14>3.0.CO;2-G; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; Zhang RL, 1996, J CEREBR BLOOD F MET, V16, P1126, DOI 10.1097/00004647-199611000-00006	50	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	NOV	2003	41	11					610	619		10.1038/sj.sc.3101512			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	734TP	WOS:000186074300003	14569262	Bronze			2021-06-18	
J	Rosenkranz, KA; Sheridan, RL				Rosenkranz, KA; Sheridan, RL			Trauma to adult bicyclists: a growing problem in the urban environment	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							SAFETY HELMETS	The proportion of adults involved in serious bicycle accidents has increased in the last two decades. The majority of the bicycle injury prevention efforts, however, are directed toward child riders. The authors performed a retrospective review of injury statistics from the Massachusetts Hospital Discharge Data Set, 1994-1999, the Massachusetts Emergency Department Injury Surveillance System, 1999, and the trauma registry of an Urban Level I Trauma Centre, 1993-2000. Massachusetts's state-wide injury data reveals a 30% increase in hospital charges between 1994 and 1999 for adults following bicycle falls and collisions with concomitant stability in the charges for children. In the years 1993-2000, 60% of patients requiring inpatient care at the Study Centre for Bicycle Related Injuries were over 16 years of age. Fifty-one percent of patients were without a helmet. Positive blood alcohol tests were present in 35 (16%) of the 222 patients. Forty-six (75%) of patients suffering closed head injury were not helmeted. Adult bicycle trauma is a significant health and financial problem in the urban state of Massachusetts. Bicycle education and legislation emphasising safe bicycling practice, the protective effects of helmets, and the danger of cycling under the influence of alcohol may help alleviate this problem. (C) 2003 Elsevier Science Ltd. All rights reserved.	Massachusetts Gen Hosp, Dept Surg, Div Trauma & Burns, Clin 108, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Dartmouth Hitchcock Med Ctr, Dept Surg, Boston, MA 02114 USA	Sheridan, RL (corresponding author), Massachusetts Gen Hosp, Dept Surg, Div Trauma & Burns, Clin 108, Boston, MA 02114 USA.						FORESTER J, 1994, BICYCLE TRANSPORTER, P41; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; STUTTS J, 1999, INJURIES PEDESTRIAN; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON DC, 2002, COCHRANE LIB; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101	6	36	37	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	NOV	2003	34	11					825	829	PII S0020-1383(02)00389-3	10.1016/S0020-1383(02)00389-3			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	745DJ	WOS:000186673400004	14580814				2021-06-18	
J	Hoffman, SW; Virmani, S; Simkins, RM; Stein, DG				Hoffman, SW; Virmani, S; Simkins, RM; Stein, DG			The delayed administration of dehydroepiandrosterone sulfate improves recovery of function after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; controlled cortical impact injury; DHEAS; medical rehabilitation; neuroplasticity; neurosteroids; recovery of function	METHYL-D-ASPARTATE; INDUCED LEARNING IMPAIRMENT; CONTROLLED CORTICAL IMPACT; ENHANCE MEMORY RETENTION; FLUID-PERCUSSION INJURY; REDUCED EVOKED RELEASE; CLOSED-HEAD INJURY; LONG-TERM; PREFRONTAL CORTEX; CONTUSION INJURY	The goal of the current study was to test the hypothesis that dehydroepiandrosterone-sulfate (DHEAS), a pro-excitatory neurosteroid, could facilitate recovery of function in male rats after delayed treatment following TBI. DHEAS has been found to play a major role in brain development and aging by influencing the migration of neurons, arborization of dendrites, and formation of new synapses. These characteristics make it suitable as a potential treatment to enhance neural repair in response to CNS injury. In our study, behavioral tests were conducted concurrently with DHEAS administration (0, 5, 10, or 20 mg/kg) starting seven days post-injury (PI). These assays included 10 days of Morris Water Maze testing (MWM; 7d PI), 10 days of Greek-Cross (GC; 21d PI), Tactile Adhesive Removal task (TAR; PI days: 6, 13, 20, 27, 34), and spontaneous motor behavior testing (SMB; PI days: 2, 4, 6, 12, 19, 26, 33). Brain-injured rats showed an improvement in performance in all tasks after 5, 10, or 20 mg/kg DHEAS. The most effective dose of DHEAS in the MWM was 10 mg/kg, while in the GC it was 20 mg/kg, in TAR 5 mg/kg, and all doses, except for vehicle, were effective at reducing injury-induced SMB hyperactivity. In no task did DHEAS-treated animals perform worse than the injured controls. In addition, DHEAS had no significant effects on behavioral performance in the sham-operates. These results can be interpreted to demonstrate that after a 7-day delay, the chronic administration of DHEAS to injured rats significantly improves behavioral recovery on both sensorimotor and cognitive tasks.	Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Hoffman, SW (corresponding author), Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA.	swhoffm@emory.edu	Stein, Donald/AAJ-5139-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD040295] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R03 HD 040295] Funding Source: Medline		BARTH TM, 1990, STROKE, V21, P153; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Bergeron R, 1996, J NEUROSCI, V16, P1193; BERGERON R, 1995, N-S ARCH PHARMACOL, V351, P252, DOI 10.1007/BF00233244; Borromei A, 1997, FUNCT NEUROL, V12, P89; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; CARBARY TJ, 2002, J NEUROTRAUM, V19, P1323; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Debonnel G, 1996, J ENDOCRINOL, V150, pS33; Devan BD, 1999, J NEUROSCI, V19, P2789; Diamond DM, 1996, NEUROSCI LETT, V202, P204, DOI 10.1016/0304-3940(95)12233-8; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; Dorner G, 2001, NEUROENDOCRINOL LETT, V22, P403; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 1997, ADV NEUROL, V73, P383; FINGER S, 1985, BRAIN RES REV, V10, P177, DOI 10.1016/0165-0173(85)90023-2; FINGER S, 1982, BRAIN DAMAGE RECOVER; FLOOD JF, 1988, BRAIN RES, V448, P178, DOI 10.1016/0006-8993(88)91116-X; FLOOD JF, 1988, BRAIN RES, V447, P269, DOI 10.1016/0006-8993(88)91129-8; Frye CA, 1999, PHYSIOL BEHAV, V66, P85, DOI 10.1016/S0031-9384(98)00256-X; FRYE CA, 1995, NEUROBIOL LEARN MEM, V64, P83, DOI 10.1006/nlme.1995.1046; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goodyer IM, 2001, BRIT J PSYCHIAT, V179, P243, DOI 10.1192/bjp.179.3.243; Hoffman S. W, 2001, ACAD EMERG MED, V8, P496; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hoffman SW, 1997, RESTOR NEUROL NEUROS, V11, P1, DOI 10.3233/RNN-1997-111201; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; KOLB B, 1982, BEHAV BRAIN RES, V6, P365, DOI 10.1016/0166-4328(82)90018-3; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Lee I, 2003, J NEUROSCI, V23, P1517; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Li SY, 1997, ENDOCRINE, V6, P265, DOI 10.1007/BF02820502; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; MAJEWSKA MD, 1990, BRAIN RES, V526, P143, DOI 10.1016/0006-8993(90)90261-9; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Marx CE, 2000, BRAIN RES, V871, P104, DOI 10.1016/S0006-8993(00)02452-5; Maurice T, 1999, JPN J PHARMACOL, V81, P125, DOI 10.1254/jjp.81.125; Maurice T, 2000, EUR J PHARMACOL, V390, P145, DOI 10.1016/S0014-2999(00)00015-7; MCDANIEL WF, 1995, BEHAV BRAIN RES, V70, P165, DOI 10.1016/0166-4328(95)80006-9; McIntosh TK, 1996, LAB INVEST, V74, P315; Melchior CL, 1996, PHARMACOL BIOCHEM BE, V53, P51, DOI 10.1016/0091-3057(95)00197-2; Migues PV, 2002, NEUROSCIENCE, V109, P243, DOI 10.1016/S0306-4522(01)00471-7; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MUIZELAAR JP, 1994, ADV EXP MED BIOL, V366, P389; Nieto-Escamez FA, 2002, BEHAV BRAIN RES, V134, P93, DOI 10.1016/S0166-4328(01)00458-2; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Pham J, 2000, PHYSIOL BEHAV, V70, P431, DOI 10.1016/S0031-9384(00)00286-9; Ragozzino ME, 2002, NEUROBIOL LEARN MEM, V77, P29, DOI 10.1006/nlme.2001.4003; Reddy DS, 1998, BRAIN RES, V799, P215, DOI 10.1016/S0006-8993(98)00419-3; Rhodes ME, 1997, BRAIN RES, V773, P28, DOI 10.1016/S0006-8993(97)00867-6; Rhodes ME, 1996, BRAIN RES, V733, P284, DOI 10.1016/0006-8993(96)00751-2; ROBERTS E, 1987, BRAIN RES, V406, P357, DOI 10.1016/0006-8993(87)90807-9; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, SOC NEUR MIAM BEACH; ROOF RL, 1997, J NEUROTRAUM, V14, P760; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SPIVAK CE, 1994, SYNAPSE, V16, P113, DOI 10.1002/syn.890160205; STEFFENSEN SC, 1995, HIPPOCAMPUS, V5, P320, DOI 10.1002/hipo.450050405; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Urani A, 1998, BRAIN RES, V799, P64, DOI 10.1016/S0006-8993(98)00469-7; UYLINGS HBM, 1990, 16 INT SUMM SCH BRAI; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Watson RR, 1996, DRUG AGING, V9, P274, DOI 10.2165/00002512-199609040-00005; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1; Yoo A, 1996, EXP NEUROL, V137, P151, DOI 10.1006/exnr.1996.0015	83	36	36	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2003	20	9					859	870		10.1089/089771503322385791			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	725BB	WOS:000185521800005	14577864				2021-06-18	
J	Albensi, BC; Janigro, D				Albensi, BC; Janigro, D			Traumatic brain injury and its effects on synaptic plastic	BRAIN INJURY			English	Article							LONG-TERM POTENTIATION; FLUID PERCUSSION INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; ANIMAL-MODELS; RISK FACTOR; HIPPOCAMPUS; INVOLVEMENT; MEMORY; POTASSIUM	Animal models have been used to simulate the effects of human head trauma. Some of these models have been further utilized to explore how trauma affects specific mechanisms of synaptic plasticity, a cellular model for memory consolidation. Unfortunately, these studies have been more limited in number in spite of their importance for understanding alterations in synaptic plasticity and memory impairments in trauma patients. Research in this area includes well characterized trauma models, genetically engineered animals and neuroprotective studies. One largely ignored but important idea that is entertained here is that trauma may be a crucial aetiological factor for the loss of potassium homeostasis. Moreover, high extracellular potassium has been shown to promote abnormal expression of hippocampal synaptic plasticity due to K+-induced glutamate release, thus showing important relationships among trauma, glia, potassium and synaptic plasticity. Collectively, this mini review surveys investigations of head trauma involving altered mechanisms of synaptic plasticity and how trauma may be related to increased risk for dementia.	Cleveland Clin Fdn, Dept Neurol Surg, Cleveland, OH 44195 USA	Albensi, BC (corresponding author), Cleveland Clin Fdn, Dept Neurol Surg, NB20,9500 Euclid Ave, Cleveland, OH 44195 USA.		Albensi, Benedict/AAJ-2359-2021; Albensi, Benedict C/F-7304-2010	Albensi, Benedict/0000-0002-7884-9261; Janigro, Damir/0000-0003-2165-5826			Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Albensi BC, 2000, SYNAPSE, V35, P151; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; BIROS MH, 1991, RESUSCITATION, V22, P283, DOI 10.1016/0300-9572(91)90036-X; BLACK JA, 1992, PROG BRAIN RES, V94, P89; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIETZEL I, 1989, GLIA, V2, P25, DOI 10.1002/glia.440020104; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1994, NEUROBIOLOGY CENTRAL, P3; Foster TC, 1999, BRAIN RES REV, V30, P236, DOI 10.1016/S0165-0173(99)00017-X; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Golarai G, 2001, J NEUROSCI, V21, P8523; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Holscher C, 1999, J NEUROSCI RES, V58, P62; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Janigro D, 1997, J NEUROSCI, V17, P2813; KUFFLER SW, 1967, PROC R SOC SER B-BIO, V168, P1, DOI 10.1098/rspb.1967.0047; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; ORKAND R, 1986, ANN NY ACAD SCI, V4, P269; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sastry B R, 1990, Adv Exp Med Biol, V268, P377; SASTRY BR, 1988, CAN J PHYSIOL PHARM, V66, P841, DOI 10.1139/y88-135; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Sontheimer H, 1996, TRENDS NEUROSCI, V19, P325, DOI 10.1016/0166-2236(96)10039-4; SONTHEIMER H, 1994, GLIA, V11, P156, DOI 10.1002/glia.440110210; SONTHEIMER H, 1992, CAN J PHYSIOL PHARM, V70, P223; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.3.CO;2-Z; Toth Z, 1997, J NEUROSCI, V17, P8106; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	53	36	36	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					653	663		10.1080/0269905031000107142			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500003	12850950				2021-06-18	
J	Tyack, ZF; Ziviani, J				Tyack, ZF; Ziviani, J			What influences the functional outcome of children at 6 months post-burn?	BURNS			English	Article						paediatric burn; functional outcome; functioning and disability; parents; children; burn injury; pre-morbid functioning	PEDIATRIC BURN SURVIVORS; TRAUMATIC BRAIN INJURY; SOCIAL SUPPORT; ADJUSTMENT; STRESS; FAMILY; SEQUELAE; QUESTIONNAIRE; PREDICTORS; 80-PERCENT	The contribution of demographic, injury, pre-morbid, and parent factors to a child's functional outcome at 6 months post-burn injury was examined. Sixty-eight children, aged 5-14 years with percent total body surface area (%TBSA) burns ranging from <1 to 35%, and their primary caregivers participated in the study. It was expected that pre-morbid and parent factors but not injury factors would have a significant impact on the functional outcome of children at 6 months post-burn. Injury factors included the percent of total body surface area burned, number of operative procedures, and source of the burn (i.e. flame burn, scald burn). Pre-morbid child factors included the presence or absence of behaviour problems. psychological or psychiatric problems, learning difficulty or developmental delay. Parent factors included anxiety. depression, coping processes, and social support. Whilst investigating the contribution of these factors to functional outcome, the effect of demographic factors (i.e. age, gender, family socioeconomic status, and the number of previous hospitalizations) was controlled for and investigated. Analyses included two hierarchical multiple regression analyses that supported the expected results. R was significantly different front zero at the end of each step in both hierarchical regression analyses, indicating that each group of factors added significantly to the fit of the model. After step 4 in the final regression model with all independent variables in the equation, R = 0.85, F(18, 49) = 6.89, P < 0.001. (C) 2003 Published by Elsevier Science Ltd and ISBI.	Univ Queensland, St Lucia, Qld, Australia	Ziviani, J (corresponding author), Univ Queensland, St Lucia, Qld, Australia.		tyack, zephanie/A-7810-2015; Ziviani, Jenny M/C-1708-2010; Tyack, Zephanie/Z-4135-2019	tyack, zephanie/0000-0003-3376-5731; Tyack, Zephanie/0000-0003-3376-5731			ATKINSON M, 1993, PSYCHOL REP, V72, P1159, DOI 10.2466/pr0.1993.72.3c.1159; *AUSTR BUR STAT, 1997, 12200 AUSTR BUR STAT; Beck A.T., 1996, BDI 2 MANUAL; Blakeney P, 1998, J TRAUMA, V44, P625, DOI 10.1097/00005373-199804000-00011; Blakeney Patricia, 1993, Journal of Burn Care and Rehabilitation, V14, P65, DOI 10.1097/00004630-199301000-00015; Byrne C, 1986, J Burn Care Rehabil, V7, P247, DOI 10.1097/00004630-198605000-00011; CELLA DF, 1988, J PEDIATR PSYCHOL, V13, P87, DOI 10.1093/jpepsy/13.1.87; COHEN J, 1993, APPL MULTIPLE REGRES; COMPAS BE, 1990, AM J COMMUN PSYCHOL, V18, P525, DOI 10.1007/BF00938058; CROMES CF, 1998, J BURN CARE REHABI 2, V19, pS178; Davey RB, 1999, BURNS, V25, P62, DOI 10.1016/S0305-4179(98)00059-X; FLEMING JM, 1996, THESIS U QUEENSLAND; FOLKMAN S, 1987, PSYCHOL AGING, V2, P171, DOI 10.1037/0882-7974.2.2.171; Folkman S., 1988, WAYS COPING QUESTION; Gorga D, 1999, J BURN CARE REHABIL, V20, P171; HALEY SM, 1991, PHYS MED REH CLIN N, V2, P689; HARTFORD CE, 1996, TOTAL BURN CARE, P78; Heaman D J, 1995, J Pediatr Nurs, V10, P311, DOI 10.1016/S0882-5963(05)80049-1; HU XH, 1994, J TRAUMA, V37, P209, DOI 10.1097/00005373-199408000-00010; JOHNSTON MV, 1993, REHABILITATION MED P, P240; Kent L, 2000, BURNS, V26, P317, DOI 10.1016/S0305-4179(99)00172-2; KOWALSKE K, 1998, J BURN CARE REHABIL, V19, pS150; LAMONTAGNE LL, 1990, HEART LUNG, V19, P416; LIBBER SM, 1984, J TRAUMA, V24, P245, DOI 10.1097/00005373-198403000-00011; Lund CCBN, 1944, SURG GYNECOL OBSTET, V79, P352; MAHER M, 2000, J BURN CARE REHABI 2, V21, pS251; MASON S, 1993, BURNS, V19, P507, DOI 10.1016/0305-4179(93)90008-V; MCCOLL MA, 1995, DISABIL REHABIL, V17, P24, DOI 10.3109/09638289509166624; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Meyer W. J. Iii, 1995, Journal of Burn Care and Rehabilitation, V16, P511, DOI 10.1097/00004630-199509000-00009; Meyer Walter J., 1994, Journal of Burn Care and Rehabilitation, V15, P62, DOI 10.1097/00004630-199401000-00012; Meyer WJ, 2000, J BURN CARE REHABIL, V21, P179, DOI 10.1097/00004630-200021020-00019; Meyers-Paal R, 2000, J BURN CARE REHABIL, V21, P43, DOI 10.1097/00004630-200021010-00009; Ottenbacher KJ, 1999, AM J OCCUP THER, V53, P181, DOI 10.5014/ajot.53.2.181; PERRIN EC, 1993, J DEV BEHAV PEDIATR, V14, P94; Pruitt Basil A. Jr., 1996, P5; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; ROHE DE, 1993, REHABILITATION MED P, P131; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; SCHOR EL, 1995, PEDIATR CLIN N AM, V42, P89; SPARROW SS, 1984, INTERVIEW EDITION SU; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Staley M, 1999, J BURN CARE REHABIL, V20, P91, DOI 10.1097/00004630-199901001-00023; Staley Marlys, 1996, Journal of Burn Care and Rehabilitation, V17, P362, DOI 10.1097/00004630-199607000-00014; Tabachnick BG, 2013, USING MULTIVARIATE S; TARNOWSKI KJ, 1991, CLIN PSYCHOL REV, V11, P371, DOI 10.1016/0272-7358(91)90114-A; TARNOWSKI KJ, 1989, J PEDIATR PSYCHOL, V14, P607, DOI 10.1093/jpepsy/14.4.607; TYACK ZF, 2001, THESIS U QUEENSLAND; Warden Glenn D., 1996, P523; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015; WILLIAMSON GG, 1993, FRAMES REFERENCE PED, P395; World Health Organization, 2001, INT CLASS FUNCT DIS; Zeitlin REK, 1998, BURNS, V24, P3, DOI 10.1016/S0305-4179(97)00052-1	53	36	39	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179			BURNS	Burns	AUG	2003	29	5					433	444		10.1016/S0305-4179(03)00045-7			12	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	709AU	WOS:000184603200005	12880722				2021-06-18	
J	Broglio, SP; Ju, YY; Broglio, MD; Sell, TC				Broglio, SP; Ju, YY; Broglio, MD; Sell, TC			The efficacy of soccer headgear	JOURNAL OF ATHLETIC TRAINING			English	Article						soccer heading; impact force; head injury	BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PROTECTIVE HEADGEAR; PLAYERS; IMPACT; CONCUSSION; BALL	Objective: The potential for risks associated with chronic soccer heading has led some soccer leagues to mandate the use of soccer headgear. Although manufacturers have designed and promoted these headbands to decrease the forces associated with heading a soccer ball, their efficacy has not been tested. Therefore, we investigated the efficacy of 3 brands of soccer headgear: Headers, Headblast, and Protector, as compared with a non-headband condition. Design and Setting: A force platform was mounted vertically with each headband attached with a length of hook-and-loop tape. A JUGS Soccer Machine projected balls at the platform and headband at 56.45 kph (35 mph). Measurements: We measured vertical ground reaction force for 50 trials of each condition and calculated peak force, time to peak force, and impulse. Results: We found a significant reduction in peak force of impact with all 3 headbands. The Protector headband also showed the greatest decrease in time to peak force and impulse, whereas the Headers headband showed a significant increase in impulse. Conclusions: All 3 headbands were effective at reducing the peak impact force. The Protector headband appeared the most effective at reducing time to peak force and impulse within the design of this study. The clinical effectiveness of these products remains to be seen.	Univ Pittsburgh, Pittsburgh, PA 15213 USA	Broglio, SP (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15213 USA.						ARMSTRONG C, 1994, SCIENCE FOOTBALL, P394; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Broglio SP, 2001, ATHLET THER TODAY, V6, P28, DOI 10.1123/att.6.1.28; CARMACK B, 2000, NAT ATHL TRAIN ASS 5; Carroll EJ, 1936, AM J MED SCI, V191, P706, DOI 10.1097/00000441-193619150-00014; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DAILEY SW, 1992, PHYSICIAN SPORTSMED, V20, P79, DOI 10.1080/00913847.1992.11947468; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Dvorak J, 2000, AM J SPORT MED, V28, pS3; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GROSS L, 2001, SPORTS INJURIES, P320; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lees K., 1988, SCI FOOTBALL, P385; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; LOHNES JH, 2001, SPORTS INJURIES, P703; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Pettersen JA, 2002, BRIT J SPORT MED, V36, P19, DOI 10.1136/bjsm.36.1.19; REID SE, 1975, J TRAUMA, V15, P150, DOI 10.1097/00005373-197502000-00007; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	31	36	36	0	18	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2003	38	3					220	224					5	Sport Sciences	Sport Sciences	732CJ	WOS:000185923000009	14608431				2021-06-18	
J	Boivin, DB; James, FO; Santo, JB; Caliyurt, O; Chalk, C				Boivin, DB; James, FO; Santo, JB; Caliyurt, O; Chalk, C			Non-24-hour sleep-wake syndrome following a car accident	NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; PHASE SYNDROME	The authors report the case of a 39-year-old sighted woman who displayed non-24-hour sleep-wake cycles following a car accident. The phase relationship between endogenous circadian markers such as plasma melatonin and 6-sulfatoxymelatonin rhythms and self-selected sleep times was abnormal. A laboratory investigation indicated that she was sensitive to bright light as a circadian synchronizer. MRI and brain CT scans were normal, but microscopic brain damage in the vicinity of the suprachiasmatic nucleus or its output pathways is plausible.	Douglas Hosp, Res Ctr, Ctr Study & Treatment Circadian Rhythms, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Psychiat, Montreal, PQ, Canada; McGill Univ, Montreal Gen Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada	Boivin, DB (corresponding author), Douglas Hosp, Res Ctr, Ctr Study & Treatment Circadian Rhythms, 6875 LaSalle Blvd,Suite F-1127, Verdun, PQ H4H 1R3, Canada.		Caliyurt, Okan/ABE-7339-2020	Caliyurt, Okan/0000-0002-0513-0619			Alexander MP, 1998, NEUROLOGY, V51, P336, DOI 10.1212/WNL.51.2.336; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN RA, 1991, NEUROLOGY, V41, P726, DOI 10.1212/WNL.41.5.726; CZEISLER CA, 1995, NEW ENGL J MED, V332, P6, DOI 10.1056/NEJM199501053320102; McArthur AJ, 1996, SLEEP, V19, P544, DOI 10.1093/sleep/19.7.544; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Smits MG, 2000, NEUROLOGY, V55, P902, DOI 10.1212/WNL.55.6.902; Uchiyama M, 2002, SLEEP, V25, P83, DOI 10.1093/sleep/25.1.83	10	36	37	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JUN 10	2003	60	11					1841	1843		10.1212/01.WNL.0000061482.24750.7C			4	Clinical Neurology	Neurosciences & Neurology	688DT	WOS:000183418400027	12796546				2021-06-18	
J	Chua, K; Chuo, A; Kong, KH				Chua, K; Chuo, A; Kong, KH			Urinary incontinence after traumatic brain injury: incidence, outcomes and correlates	BRAIN INJURY			English	Article							STROKE; REHABILITATION	Objectives: To document the incidence and outcome of urinary incontinence (UI) and urinary retention (UR) during acute traumatic brain injury (TBI) rehabilitation and determine associated clinical variables. Methods: Retrospective case series. Results: Eighty-four patients (mean age 44.7+/-17.9 years; 66 males, 18 females) with first-ever TBI within 6 weeks of injury. On admission, UI was present in 52 (62%). UR defined as post-void residual urine volumes of >100 mls was present in eight (9.5%). Forty-six (54.8%) needed external collecting devices and six (7.1%) used indwelling catheters. Bilateral lesions, diabetes mellitus and faecal impaction were present in 70.2, 10.7 and 6.0%, respectively. UI was associated with poorer functional status (measured by the modified Barthel index) and presence of bilateral lesions (p<0.01). UR was associated with diabetes mellitus and faecal impaction (p<0.01). On discharge, 31 (36.9%) remained incontinent. Conclusion: UI is common after acute TBI and is associated with poorer functional outcome.	Tan Tock Seng Hosp, Dept Rehabil Med, Singapore 569766, Singapore; Changi Gen Hosp, Dept Geriatr Med, Singapore, Singapore	Chua, K (corresponding author), Tan Tock Seng Hosp, Dept Rehabil Med, 17,Ang Mo Kio Ave 9, Singapore 569766, Singapore.						ABRAMS P, 1999, CONSENSUS REPORT THE; BENBOW S, 1991, LANCET, V338, P1602, DOI 10.1016/0140-6736(91)92439-9; Brittain KR, 1998, STROKE, V29, P524, DOI 10.1161/01.STR.29.2.524; BROCKLEHURST JC, 1985, J AM GERIATR SOC, V33, P540, DOI 10.1111/j.1532-5415.1985.tb04618.x; GARCIA J G, 1990, Brain Injury, V4, P203, DOI 10.3109/02699059009026167; GELBER DA, 1993, STROKE, V24, P378, DOI 10.1161/01.STR.24.3.378; Gross JC, 2000, ARCH PHYS MED REHAB, V81, P22, DOI 10.1016/S0003-9993(00)90216-8; JONGBLOED L, 1986, STROKE, V17, P65; KHAN Z, 1990, UROLOGY, V35, P265, DOI 10.1016/0090-4295(90)80048-R; KHAN Z, 1981, J UROLOGY, V126, P86, DOI 10.1016/S0022-5347(17)54392-X; Kong K. H., 1994, Annals Academy of Medicine Singapore, V23, P319; Kong KH, 2000, ARCH PHYS MED REHAB, V81, P1464, DOI 10.1053/apmr.2000.9630; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; OOSTRA K, 1995, BRAIN INJURY, V10, P459; Owen D C, 1995, Rehabil Nurs, V20, P197; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; WADE D, 1995, ARCH PHYS MED REHAB, V64, P24; WADE DT, 1985, Q J MED, V56, P601; Ween JE, 1996, NEUROLOGY, V47, P659, DOI 10.1212/WNL.47.3.659; YOUNGSON HA, 1994, BRAIN INJURY, V8, P23, DOI 10.3109/02699059409150956	22	36	37	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2003	17	6					469	478		10.1080/02699050210154268			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	672GG	WOS:000182512400002	12745703				2021-06-18	
J	Inamasu, J; Nakamura, Y; Ichikizaki, K				Inamasu, J; Nakamura, Y; Ichikizaki, K			Induced hypothermia in experimental traumatic spinal cord injury: an update	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						hypothermia; local cooling; systemic cooling; temperature; traumatic spinal cord injury	SYSTEMIC HYPOTHERMIA; COMPRESSION INJURY; BRAIN INJURY; MILD HYPOTHERMIA; LOCOMOTOR FUNCTION; RAT; HYPERTHERMIA; TEMPERATURE; DAMAGE; IMMUNOHISTOCHEMISTRY	The use of induced hypothermia in the treatment of traumatic spinal cord injury (SCI) has been studied extensively between the 1960s and 1970s. Although the treatment showed some promise, it became less popular by the 1980s, mainly because of its adverse effects. However, a revival of hypothermia in the treatment of traumatic brain injury (TBI) in the last decade has encouraged neuroscientists to conduct experiments to reevaluate the potential benefits of hypothermia in traumatic SCI. All laboratory investigations studying the mechanisms of action and/or the efficacy of induced hypothermia in treating experimental traumatic SCI published in the last decade were reviewed. Although efficacy of hypothermia in improving functional outcome of mild to moderate traumatic SCI has been demonstrated, hypothermia may not be protective against severe traumatic SCI. At present, induced hypothermia has yet to be recognized or approved as a potential treatment having therapeutic value for traumatic SCI in humans. The continued search for a possible synergistic effect of induced hypothermia and pharmacological therapy may yield some promise. It has also been deduced from these laboratory studies that hyperthermia is deleterious and rigorous measures to prevent hyperthermia should be taken to minimize the propagation of secondary neuronal damage after traumatic SCI. (C) 2002 Elsevier Science B.V All rights reserved.	Natl Tokyo Med Ctr, Dept Neurosurg, Tokyo 1528902, Japan	Inamasu, J (corresponding author), Natl Tokyo Med Ctr, Dept Neurosurg, Higashigaoka 2-5-1, Tokyo 1528902, Japan.	GInamasu@aol.com	Inamasu, Joji/R-7314-2019				Amar AP, 1999, J AM COLL SURGEONS, V188, P550, DOI 10.1016/S1072-7515(99)00013-7; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bricolo A, 1976, Surg Neurol, V6, P101; Cambria R P, 2000, Semin Vasc Surg, V13, P315; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; Fijen J W, 1997, Ned Tijdschr Geneeskd, V141, P1390; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Hindman BJ, 1999, NEUROSURGERY, V44, P23, DOI 10.1097/00006123-199901000-00009; Inamasu J, 2002, ANN EMERG MED, V40, P220, DOI 10.1067/mem.2002.123697; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kuchner E F, 1976, Surg Neurol, V6, P371; Kuchner EF, 2000, J SPINAL DISORD, V13, P391, DOI 10.1097/00002517-200010000-00004; LUNDGREN J, 1994, EXP BRAIN RES, V99, P43; Marsala M, 1997, J NEUROSCI METH, V74, P97, DOI 10.1016/S0165-0270(97)02270-X; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MENARD MR, 1991, ARCH PHYS MED REHAB, V72, P421; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Tator C H, 1973, Trans Am Neurol Assoc, V98, P107; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; Westergren H, 2001, SPINAL CORD, V39, P74, DOI 10.1038/sj.sc.3101127; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 1999, NEUROPATHOLOGY, V19, P172, DOI 10.1046/j.1440-1789.1999.00227.x; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206	41	36	39	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	MAY 15	2003	209	1-2					55	60		10.1016/S0022-510X(02)00463-X			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	672VN	WOS:000182543800009	12686402				2021-06-18	
J	Kirchner, TR; Sayette, MA				Kirchner, TR; Sayette, MA			Effects of alcohol on controlled and automatic memory processes	EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY			English	Article							PROCESS-DISSOCIATION PROCEDURE; IN-PROCESS DISSOCIATION; APPRAISAL-DISRUPTION MODEL; CLOSED-HEAD INJURY; DIVIDED ATTENTION; IMPLICIT MEMORY; EXPLICIT MEMORY; STRESS; VIOLATIONS; RECOLLECTION	The authors used the process-dissociation procedure (L. L. Jacoby, 1998) to examine the effects of alcohol on controlled and automatic influences on memory performance. Participants studied 1 of 2 word lists and subsequently were cued with word stems to recall the words from both lists. Fifty-four men were administered either a moderate dose of alcohol (0.82 g/kg) or placebo prior to studying the word list. Results indicated that alcohol decreased estimates of controlled contributions to performance on the task. In contrast, alcohol did not appear to affect automatic influences on this task. Integrated with recent findings using a different cognitive task, these data suggest that alcohol impairs performance on implicit, conceptually driven tasks but not on implicit, perceptually driven tasks.	Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA	Sayette, MA (corresponding author), Univ Pittsburgh, Dept Psychol, 604 Old Engn Hall, Pittsburgh, PA 15260 USA.	sayette@pitt.edu					BALOTA DA, 1986, J EXP PSYCHOL LEARN, V12, P336, DOI 10.1037/0278-7393.12.3.336; Birnbaum I. M., 1977, ALCOHOL HUMAN MEMORY, P99; BIRNBAUM IM, 1980, J EXP PSYCHOL-HUM L, V6, P293, DOI 10.1037/0278-7393.6.3.293; BLAXTON TA, 1992, MEM COGNITION, V20, P549, DOI 10.3758/BF03199587; CURRAN HV, 2000, OXFORD HDB MEMORY, P245; CURRAN T, 1995, J EXP PSYCHOL LEARN, V21, P531, DOI 10.1037/0278-7393.21.3.531; Curran T, 1997, J EXP PSYCHOL LEARN, V23, P496, DOI 10.1037/0278-7393.23.2.496; Fillmore MT, 1999, EXP CLIN PSYCHOPHARM, V7, P372, DOI 10.1037/1064-1297.7.4.372; Grattan KE, 2001, ALCOHOL CLIN EXP RES, V25, P192, DOI 10.1111/j.1530-0277.2001.tb02198.x; HARRISON G, 1985, ANN INTERN MED, V103, P489; HASHTROUDI S, 1984, J EXP PSYCHOL LEARN, V10, P156, DOI 10.1037/0278-7393.10.1.156; Hay JF, 1996, J EXP PSYCHOL LEARN, V22, P1323, DOI 10.1037/0278-7393.22.6.1323; HOLENDER D, 1986, BEHAV BRAIN SCI, V9, P1, DOI 10.1017/S0140525X00021269; Hull J., 1987, PSYCHOL THEORIES DRI, P272; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P505, DOI 10.1037/0278-7393.23.2.505; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; Jacoby LL, 1998, J EXP PSYCHOL LEARN, V24, P3, DOI 10.1037/0278-7393.24.1.3; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; Jacoby LL, 1997, CARN S COGN, P13; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P484, DOI 10.1037/0278-7393.23.2.484; Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8; MARTIN CS, 1993, J STUD ALCOHOL, V54, P750, DOI 10.15288/jsa.1993.54.750; Mulligan NW, 1998, J EXP PSYCHOL LEARN, V24, P27, DOI 10.1037/0278-7393.24.1.27; Neely J.H., 1991, BASIC PROCESSES READ, V11, P264; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; PERRUCHET P, 1989, MEM COGNITION, V17, P77, DOI 10.3758/BF03199559; REINGOLD EM, 1990, MIND LANG, V5, P9, DOI DOI 10.1111/J.1468-0017.1990.TB00150.X; Robins RW, 2001, J PERS SOC PSYCHOL, V80, P340, DOI 10.1037//0022-3514.80.2.340; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; ROHSENOW DJ, 1981, ADDICT BEHAV, V6, P107, DOI 10.1016/0306-4603(81)90003-4; ROOM R, 1983, NATL I ALCOHOL ABUSE, V12; ROSEN LJ, 1976, J ABNORM PSYCHOL, V85, P309, DOI 10.1037/0021-843X.85.3.309; RYBACK RS, 1970, PSYCHON SCI, V20, P353, DOI 10.3758/BF03335686; SAYETTE MA, 1991, J ABNORM PSYCHOL, V100, P56, DOI 10.1037/0021-843X.100.1.56; SAYETTE MA, 1993, PSYCHOL BULL, V114, P459, DOI 10.1037/0033-2909.114.3.459; Sayette MA, 1996, J CLIN EXP NEUROPSYC, V18, P678, DOI 10.1080/01688639608408291; Sayette MA, 2001, EXP CLIN PSYCHOPHARM, V9, P409, DOI 10.1037/1064-1297.9.4.409; Sayette MA, 2001, J STUD ALCOHOL, V62, P247, DOI 10.15288/jsa.2001.62.247; SAYETTE MA, 1999, PSYCHOL THEORIES DRI, P247; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schmitter-Edgecombe M, 1999, MEM COGNITION, V27, P512, DOI 10.3758/BF03211545; Schmitter-Edgecombe M, 2000, NEUROPSYCHOLOGY, V14, P559; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; Schneider W., 1984, VARIETIES ATTENTION, P1; Sher K. J., 1999, PSYCHOL THEORIES DRI, P54; Shiffrin R. M., 1988, STEVENS HDB EXPT PSY, V2, P739; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; STADLER MA, 1995, J EXP PSYCHOL LEARN, V21, P674, DOI 10.1037/0278-7393.21.3.674; STEELE CM, 1988, J ABNORM PSYCHOL, V97, P196, DOI 10.1037/0021-843X.97.2.196; SteMarie DM, 1996, CLIN NEUROPSYCHOL, V10, P25, DOI 10.1080/13854049608406660; TIFFANY ST, 1991, BRIT J ADDICT, V86, P617; Tolstoy Leo, 1982, WAR PEACE; TOTH JP, 2000, OXFORD HDB MEMORY, P245; Tracy JI, 1999, NEUROPSYCHOLOGY, V13, P282, DOI 10.1037/0894-4105.13.2.282; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; Vidailhet P, 1996, PSYCHOPHARMACOLOGY, V127, P63, DOI 10.1007/BF02805976; VONHIPPEL W, 1994, EFFECTS ALCOHOL SOCI	57	36	36	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1064-1297			EXP CLIN PSYCHOPHARM	Exp. Clin. Psychopharmacol.	MAY	2003	11	2					167	175		10.1037/1064-1297.11.2.167			9	Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry	Psychology; Pharmacology & Pharmacy; Psychiatry	677DM	WOS:000182791700006	12755461				2021-06-18	
J	Limbrick, DD; Sombati, S; DeLorenzo, RJ				Limbrick, DD; Sombati, S; DeLorenzo, RJ			Calcium influx constitutes the ionic basis for the maintenance of glutamate-induced extended neuronal depolarization associated with hippocampal neuronal death	CELL CALCIUM			English	Article							EXCITATORY AMINO-ACIDS; LARGE ASPINY INTERNEURONS; INTRACELLULAR CALCIUM; CELL-DEATH; IN-VITRO; STRIATAL NEURONS; CORTICAL-NEURONS; NA+/CA2+ EXCHANGE; RECEPTOR FUNCTION; RAT	Excessive activation of neuronal glutamate receptors has been implicated in the pathophysiology of stroke, epilepsy, and traumatic brain injury. Previously, it has been demonstrated that excitotoxic glutamate exposure results in the induction of an extended neuronal depolarization (END), as well as protracted elevations in free intracellular calcium ([Ca2+](i)). Both END and the prolonged [Ca2+](i) elevations were shown to correlate with subsequent neuronal death. In the current study, we used whole-cell current-clamp electrophysiology and fura-ff Ca2+ imaging to determine the electrophysiological basis of END. We found that removal of extracellular Ca2+ but not Na+ in the post-glutamate period resulted in complete reversal of END, allowing neurons to rapidly repolarize to their initial resting membrane potential (RMP). In addition, removal of extracellular Ca-2+ was sufficient to eliminate the protracted [Ca2+](i) elevations induced by excitotoxic glutamate exposure. To investigate the mechanism through which extracellular Ca-2+ was effecting these changes, pharmacolgical antagonists of well-characterized routes of Ca-2+ entry were tested for their effects on END. Antagonists of glutamate receptors and voltage-gated Ca2+ channels (VGCCs) had no significant effect on the membrane potential of neurons in END. Likewise, inhibitors of the Na+/Ca2+ exchange (NCX) were ineffective. In contrast, addition of 500 muM ZnCl2 or 100 muM GdCl3 to control extracellular medium (containing normal levels of exctracellular Ca2+) in the post-glutamate period resulted in rapid and complete reversal of END. Addition of 1 mM CdCl2 to control medium had only modest effects on END. These data provide the first direct evidence that END induced by excitotoxic glutamate exposure is caused by an influx of extracellular Ca2+ and demonstrate that the previously irreversible condition of END can be reversed by removing extracellular Ca2+. In addition, understanding the electrophysiological basis of this novel Ca2+-induced extended depolarization may provide an insight into the pathophysiology of stroke, traumatic brain injury, and other forms of neuronal injury. (C) 2003 Elsevier Science Ltd. All rights reserved.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	DeLorenzo, RJ (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	rdeloren@hsc.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023350, P50NS025630] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS25630, R01-NS23350] Funding Source: Medline		Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; Arias C, 1998, Neurobiology (Bp), V6, P33; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bittigau P, 1997, J CHILD NEUROL, V12, P471, DOI 10.1177/088307389701200802; BOLAND LM, 1991, BRAIN RES, V563, P142, DOI 10.1016/0006-8993(91)91527-8; Borgdorff AJ, 2000, J NEUROPHYSIOL, V83, P81; CALABRESI P, 1995, BRAIN, V118, P1027, DOI 10.1093/brain/118.4.1027; Calabresi P, 1999, STROKE, V30, P1687, DOI 10.1161/01.STR.30.8.1687; Calabresi P, 1997, J NEUROSCI, V17, P1940; Chen QX, 1997, J NEUROSCI, V17, P4032; Chen QX, 1998, J NEUROPHYSIOL, V79, P1124; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; Coulter D A, 1999, Adv Neurol, V79, P725; COULTER DA, 1992, J NEUROPHYSIOL, V68, P362; deLorenzo RJ, 1998, P NATL ACAD SCI USA, V95, P14482, DOI 10.1073/pnas.95.24.14482; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; DUBINSKY JM, 1993, ANN NY ACAD SCI, V679, P34, DOI 10.1111/j.1749-6632.1993.tb18287.x; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; EIMERL S, 1994, J NEUROCHEM, V62, P1223; FLEISCHER JE, 1989, J CEREBR BLOOD F MET, V9, P795, DOI 10.1038/jcbfm.1989.113; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P2139; GRAHAM SH, 1993, NEUROSCI LETT, V160, P21, DOI 10.1016/0304-3940(93)90907-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Hoyt KR, 1998, MOL PHARMACOL, V53, P742; Hyrc K, 1997, J NEUROSCI, V17, P6669; Hyrc KL, 1998, CELL CALCIUM, V24, P165, DOI 10.1016/S0143-4160(98)90126-9; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; Kim AH, 2000, BRAIN RES, V886, P99, DOI 10.1016/S0006-8993(00)02944-9; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; Limbrick DD, 2001, BRAIN RES, V894, P56, DOI 10.1016/S0006-8993(00)03303-5; Lipton P, 1999, PHYSIOL REV, V79, P1431; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; LONDON RE, 1994, AM J PHYSIOL, V266, pC1313; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; Meldrum BS, 1999, EPILEPSY RES, V36, P189, DOI 10.1016/S0920-1211(99)00051-0; MILLER RJ, 1995, BIOCHEM SOC T, V23, P629, DOI 10.1042/bst0230629; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; Morgans CW, 1998, J NEUROSCI, V18, P2467; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NISHIMURA T, 1995, J AUTONOM NERV SYST, V51, P213, DOI 10.1016/0165-1838(94)00134-6; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pisani A, 1999, J NEUROPHYSIOL, V81, P2508; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Read SJ, 1999, DRUG AGING, V14, P11, DOI 10.2165/00002512-199914010-00002; Sacchi O, 1999, J NEUROPHYSIOL, V82, P1662; Scheyer RD, 1998, PROG BRAIN RES, V116, P359, DOI 10.1016/S0079-6123(08)60448-3; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sherwin AL, 1999, NEUROCHEM RES, V24, P1385, DOI 10.1023/A:1022580506443; Small DL, 1999, PROG CARDIOVASC DIS, V42, P185, DOI 10.1016/S0033-0620(99)70002-2; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; Smothers CT, 1997, J PHARMACOL EXP THER, V283, P1214; SOMBATI S, 1991, BRAIN RES, V566, P316, DOI 10.1016/0006-8993(91)91716-E; SOMBATI S, 1995, J NEUROPHYSIOL, V73, P1706; Storozhevykh TP, 1996, INT J NEUROSCI, V88, P199, DOI 10.3109/00207459609000615; Stout AK, 1999, NEUROSCIENCE, V89, P91, DOI 10.1016/S0306-4522(98)00441-2; Tanaka E, 1999, J NEUROPHYSIOL, V81, P1872; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Teasdale GM, 1999, ACT NEUR S, V73, P111; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; Tymianski M, 1996, ADV NEUROL, V71, P85; Vaughan J, 1999, STROKE THERAPY, P3; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WU AF, 1994, J NEUROCHEM, V63, P2136; Yamamoto S, 1997, J NEUROPHYSIOL, V78, P903; Yu SP, 1997, EUR J NEUROSCI, V9, P1273, DOI 10.1111/j.1460-9568.1997.tb01482.x	72	36	39	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0143-4160	1532-1991		CELL CALCIUM	Cell Calcium	FEB	2003	33	2					69	81	PII S0143-4160(02)00054-4	10.1016/S0143-4160(02)00054-4			13	Cell Biology	Cell Biology	647LL	WOS:000181094200001	12531183				2021-06-18	
J	Sander, AM; Sherer, M; Malec, JF; High, WM; Thompson, RN; Moessner, AM; Josey, J				Sander, AM; Sherer, M; Malec, JF; High, WM; Thompson, RN; Moessner, AM; Josey, J			Preinjury emotional and family functioning in caregivers of persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; caregivers; family; rehabilitation	BLUNT HEAD-INJURY; RELATIVES; BURDEN; RELIABILITY; PREDICTORS; AWARENESS; DISTRESS	Objective: To characterize the preinjury family functioning, emotional distress, and social support of caregivers of persons with traumatic brain injury (TBI). Design: Inception cohort. Setting: Three Traumatic Brain Injury Model Systems centers' inpatient rehabilitation facilities. Participants: One hundred ninety-one caregivers, primarily white and female, of persons with TBI. Interventions: Not applicable. Main Outcome Measures: The Brief Symptom Inventory, Family Assessment Device, Multidimensional Scale of Perceived Social Support, and history of medical and psychiatric illness. Results: Thirty-seven percent of caregivers indicated symptoms of emotional distress consistent with psychiatric diagnoses for the month before injury, whereas 27% reported a history of psychiatric or psychologic treatment at some point in the past. Between 25% and 33% of caregivers reported unhealthy family functioning in 1 or more areas for the month before injury. Persons with an annual income less than $10,000 reported less healthy preinjury family functioning. Caregivers reported good satisfaction with preinjury social support, and very few caregivers reported a history of substance abuse. Conclusion: A substantial proportion of caregivers reported emotional distress and/or unhealthy family functioning before injury. Such difficulties may make them more vulnerable to the stress associated with injury and result in greater coping difficulties.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; TIRR, Houston, TX USA; Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA; Mayo Med Ctr & Med Sch, Dept Psychiat & Psychol, Rochester, MN USA; Mayo Med Ctr & Med Sch, Dept Phys Med & Rehabil, Rochester, MN USA	Sander, AM (corresponding author), Brain Injury Res Ctr, 2455 S Braeswood, Houston, TX 77030 USA.	sandea@tirr.tmc.edu					ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DEROGATIS LR, 1982, BRIEF SYMPTON INVENT; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LIVINGSTON MG, 2001, BRAIN INJURY, V1, P33; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; SANDER A, 1999, REHABILITATION ADULT, P199; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SIMON GE, 1995, J CLIN EPIDEMIOL, V48, P1109, DOI 10.1016/0895-4356(95)00010-2; TEASDALE G, 1974, LANCET, V2, P81; United States Department of Health and Human Services, 2001, MENT HLTH REP SURG G; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	40	36	36	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					197	203		10.1053/apmr.2003.50105			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700008	12601650				2021-06-18	
J	Otani, N; Nawashiro, H; Fukui, S; Nomura, N; Shima, K				Otani, N; Nawashiro, H; Fukui, S; Nomura, N; Shima, K			Temporal and spatial profile of phosphorylated mitogen activated protein kinase pathways after lateral fluid percussion injury in the cortex of the rat brain	JOURNAL OF NEUROTRAUMA			English	Article						c-Jun NH2-terminal kinase; double immunostaining; extracellular signal-regulated kinase; immunohistochemistry; mitogen-activated protein kinase; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; REACTIVE ASTROCYTES; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; ERK/MAP KINASE; MESSENGER-RNA; MOUSE-BRAIN; MAP KINASES; APOPTOSIS; SIGNAL	Mitogen-activated protein kinases (MAPK) play a crucial role in signal transduction that regulates gene expression through transcriptional factor activity. The purpose of this study was to investigate the temporal expression and topographic distribution of the activated MAPK pathways including extracellular signal-regulated protein kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 MAPK following traumatic brain injury (TBI) in the cortex of the rat brain. Adult male Sprague-Dawley rats (300-400 g) were subjected to lateral fluid percussion injury of moderate severity (3.5-4.0 atm) using the Dragonfly device model (no. HPD-1700). Phosphorylated-MAPK protein levels were quantified using Western blot analysis. Topographic distribution of immunoreactivity for phosphorylated-MAPK was examined using immunohistochemistry. Our findings showed that TBI significantly increased the phosphorylated-ERK (p-ERK) and -JNK (p-JNK) levels, but not the -p38 (p-p38) protein levels in the cortex surrounding the injury site. The immunoreactivity for p-ERK and p-JNK immediately after TBI were localized in neurons. The immunoreactivity for p-JNK was uniformly but only transiently induced and returned to control levels I h after TBE The immunoreactivity for p-ERK was confirmed up until 30 min after TBI in the superficial neuronal layers. Double immunostaining using a glial-specific marker demonstrated that p-ERK was prominent in astrocytes 6 h after TBI. The current results suggest that the ERK and JNK pathways, but not the p38 MAPK pathways are involved in signal transduction in the cortex following TBI.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan	Otani, N (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.						BALASINGAM V, 1994, J NEUROSCI, V14, P846; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Conti AC, 1998, J NEUROSCI, V18, P5663; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DIETRICH DW, 1994, J NEUROTRAUM, V13, P289; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; Hayashi T, 2000, NEUROSCI LETT, V284, P195, DOI 10.1016/S0304-3940(00)01024-7; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; JOHANSON SO, 1995, BRAIN RES, V690, P55, DOI 10.1016/0006-8993(95)00587-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KURINO M, 1995, J NEUROCHEM, V65, P1282; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; SEGER R, 1995, FASEB J, V9, P726; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wu DC, 2000, J CEREBR BLOOD F MET, V20, P1320, DOI 10.1097/00004647-200009000-00007; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang L, 2000, NEUROREPORT, V11, P409, DOI 10.1097/00001756-200002070-00037	40	36	40	1	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1587	1596		10.1089/089771502762300247			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700006	12542859				2021-06-18	
J	Cernak, I; Chapman, SM; Hamlin, GP; Vink, R				Cernak, I; Chapman, SM; Hamlin, GP; Vink, R			Temporal characterisation of pro- and anti-apoptotic mechanisms following diffuse traumatic brain injury in rats	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						apoptosis; diffuse axonal injury; neurotrauma; caspases	CEREBRAL-ARTERY OCCLUSION; HYPOXIA-INDUCED APOPTOSIS; CORTICAL IMPACT INJURY; PROGRAMMED CELL-DEATH; NEURONAL APOPTOSIS; BCL-X; CASPASE-3 ACTIVATION; ANTIOXIDANT PATHWAY; TRANSGENIC MICE; AXONAL INJURY	Few studies have characterised apoptosis in a brain injury model that causes a significant degree of diffuse axonal injury. Such characterisation is essential from a clinical viewpoint since diffuse axonal injury is a major component of human head injury. The present study therefore, examines the expression of active and proactive caspase-3, and the bax, bcl-2 and bcl-x members of the bcl-2 family, to characterise the temporal profile of apoptosis in a model of traumatic brain injury in rats that produces significant diffuse axonal injury. Pentobarbital anaesthetised male Sprague-Dawley rats were injured using the 2 m impact-acceleration model of diffuse traumatic brain injury. After injury, diffuse trauma resulted in an increased bax expression followed by induction of caspase-3. The increase in caspase-3 was simultaneous with an increase in anti-apoptotic bcl-2 expression. Bcl-x levels were increased after induction of caspase-3 and the increased levels of bcl-x were sustained to the end of the 5-day observation period. Increased active caspase-3 expression was associated with the appearance of TUNEL positive cells. These cells were detected in different brain regions at different times, with some regions showing no apoptotic cells until 3 days after injury. No TUNEL positive cells were detected at 7 and 14 days after injury. DNA electrophoresis confirmed that DNA fragmentation was maximal at 3 days after injury. Increased active caspase-3 levels were also significantly correlated with increased bcl-2 levels (r=0.80; P < 0.001) suggesting that the apoptotic cascade after diffuse traumatic brain injury is a carefully controlled cellular homeostatic response. Pharmacological manipulation of this balance may offer a therapeutic approach for preventing cell death and improving outcome after diffuse traumatic brain injury. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia; Georgetown Univ, Dept Neurosci, Washington, DC USA	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	robert.vink@adelaide.edu.au	Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Allen JW, 1999, FASEB J, V13, P1875; Antonawich FJ, 1998, J CEREBR BLOOD F MET, V18, P882, DOI 10.1097/00004647-199808000-00008; Banasiak KJ, 1999, MOL BRAIN RES, V72, P214, DOI 10.1016/S0169-328X(99)00189-8; Bossenmeyer-Pourie C, 1999, MOL BRAIN RES, V71, P225, DOI 10.1016/S0169-328X(99)00190-4; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Charriaut-Marlangue C., 1999, Annales Pharmaceutiques Francaises, V57, P309; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cregan SP, 1999, J NEUROSCI, V19, P7860; Ellis RE, 1992, CURR OPIN GENET DEV, V2, P635, DOI 10.1016/S0959-437X(05)80184-4; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Isenmann S, 1998, BRAIN PATHOL, V8, P49; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krebs JF, 1999, J CELL BIOL, V144, P915, DOI 10.1083/jcb.144.5.915; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Michel PP, 1999, CLIN NEUROPHARMACOL, V22, P137; Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Ravishankar S, 2001, BRAIN RES, V901, P23, DOI 10.1016/S0006-8993(01)02109-6; RINK A, 1995, AM J PATHOL, V147, P1575; Rudin CM, 1997, ANNU REV MED, V48, P267; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; StClair EG, 1997, J BIOL CHEM, V272, P29347; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921	55	36	41	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	SEP	2002	9	5					565	572		10.1054/jocn.2002.1132			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	609YL	WOS:000178933900016	12383417				2021-06-18	
J	Frazier, JL; Wang, PP; Patel, SH; Benson, JE; Cameron, DE; Hoon, AH; Avellino, AM				Frazier, JL; Wang, PP; Patel, SH; Benson, JE; Cameron, DE; Hoon, AH; Avellino, AM			Unusual migration of the distal catheter of a ventriculoperitoneal shunt into the heart: Case report	NEUROSURGERY			English	Article						heart; hydrocephalus; ventriculoperitoneal shunt	FOREIGN-BODIES; COMPLICATIONS; REMOVAL; CHEST	OBJECTIVE AND IMPORTANCE: Placement of a ventriculoperitoneal (VP) shunt is the most common form of treatment for hydrocephalus. Thoracic complications with VP shunts are rare, but we present the second documented case of the distal migration of the distal catheter of a VP shunt into the heart. CLINICAL PRESENTATION: A 14-year-old boy, who underwent placement of a right occipital VP shunt at another institution after closed-head injury, presented with hypertension. Plain chest x-rays and computed tomography revealed the distal catheter to be in the right ventricle of the heart. INTERVENTION: A joint surgical procedure was performed with the cardiac surgery team. The cardiac surgeons created a pericardial window through a subxyphoid incision. Simultaneously, a right occipital incision was made to access the distal catheter, which was then Slowly pulled out with the pericardium under direct visualization. No hemorrhage or change in the pericardium was observed, and, therefore, the need for a thoracotomy was eliminated. A new distal catheter was placed into the peritoneal cavity. CONCLUSION: The migration of the distal catheter probably occurred during the initial VP shunt placement. The internal jugular vein probably was perforated by the tunneler during the creation of the distal catheter tract. Slow venous flow and negative inspiratory pressure may have gradually pulled the catheter up into the right atria and ventricle. As demonstrated by our case report, the catheter can be extracted safely in a joint procedure with cardiac surgeons, and a thoracotomy is not always necessary. The patient did not experience postoperative complications, and his hypertension was alleviated.	Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cardiac Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Avellino, AM (corresponding author), Johns Hopkins Univ Hosp, Dept Neurosurg, Harvey 811,600 N Wolfe St, Baltimore, MD 21287 USA.	avellino@jhmi.edu					COOPER JR, 1978, J NEUROSURG, V48, P146, DOI 10.3171/jns.1978.48.1.0146; Fischer G, 1983, Zentralbl Neurochir, V44, P155; FISHER RG, 1978, AM J ROENTGENOL, V130, P541, DOI 10.2214/ajr.130.3.541; FUKAMACHI A, 1982, ACTA NEUROCHIR, V64, P159, DOI 10.1007/BF01405628; GAUDIO R, 1988, NEUROSURGERY, V23, P768, DOI 10.1227/00006123-198812000-00017; GRABENWOEGER F, 1988, BRIT J RADIOL, V61, P1014, DOI 10.1259/0007-1285-61-731-1014; GROSFELD JL, 1974, PEDIATRICS, V54, P791; Haralampopoulos F, 1996, SURG NEUROL, V46, P21, DOI 10.1016/0090-3019(96)00052-3; HLAVIN ML, 1990, NEUROSURGERY, V26, P526, DOI 10.1097/00006123-199003000-00024; James CA, 1997, PEDIATR RADIOL, V27, P330, DOI 10.1007/s002470050142; Kang JK, 1996, CHILD NERV SYST, V12, P176, DOI 10.1007/BF00266827; LOURIE H, 1985, NEUROSURGERY, V17, P324, DOI 10.1227/00006123-198508000-00014; Mori Takahisa, 1993, Neurologia Medico-Chirurgica, V33, P713, DOI 10.2176/nmc.33.713; NISHIJIMA M, 1980, Neurological Surgery, V8, P679; PATEL CD, 1973, J NEUROSURG, V38, P761, DOI 10.3171/jns.1973.38.6.0761; PORTNOY HD, 1974, CLIN J NEUROSURGERY, V39, P775; Schulhof L A, 1975, Surg Neurol, V3, P265; TAUB E, 1994, NEUROSURGERY, V34, P181; UFLACKER R, 1986, RADIOLOGY, V160, P731, DOI 10.1148/radiology.160.3.3737911	19	36	37	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2002	51	3					819	822		10.1097/00006123-200209000-00042			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	592FH	WOS:000177925700058	12188965				2021-06-18	
J	Davis, CH				Davis, CH			Self-perception in mild traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						mild traumatic brain injury; concussion; misattribution; postconcussive syndrome	POSTCONCUSSION SYMPTOMS; HEAD-INJURY	Objective: The objectives of this study were (1) to describe a procedure for measuring preinjury and postinjury symptoms, (2) to compare these symptoms with normal controls and individuals with non-head related traumas, (3) to describe patterns in persistent symptomatology after mild traumatic brain injury, and (4) to document trends in self-perception as measured by retrospective ratings of symptoms after trauma. Design: A total of 102 individuals with mild traumatic brain injury and 69 individuals with non-head-related traumas completed preinjury and postinjury symptom questionnaires 1 wk after trauma. Symptoms were compared with 115 normal controls. Three months after injury, a subgroup of the mild traumatic brain injury group completed symptom questionnaires again. A factor analysis and subsequent discriminant function analysis of the symptoms differentiated the groups. Results: Retrospective ratings of preinjury symptoms by the two trauma groups were significantly less than the normal controls, implying misattribution. Most symptoms were somatic at 1 wk postinjury in both trauma groups. At 3 mo, the mild traumatic brain injury group endorsed more recall symptoms. Conclusions: The procedure was useful in differentiating groups by symptom patterns and increasing our knowledge of persistent symptomatology after mild traumatic brain injury. Misattribution, the unrealistic self-perception of symptoms after the event of a trauma, was detected in both the head and non-head trauma groups.	Univ Calif Davis, Med Ctr, Phys Med & Rehabil Ambulatory Care Ctr, Sacramento, CA 95817 USA	Davis, CH (corresponding author), Univ Calif Davis, Med Ctr, Phys Med & Rehabil Ambulatory Care Ctr, 4860 Y St,Suite 1100, Sacramento, CA 95817 USA.						ALVES W, 1992, PHYSICAL MED REHABIL, P21; BARSKY AJ, 1983, AM J PSYCHIAT, V140, P273; BERROL S, 1992, REHABILITATION POST, P1; Davis CH, 1999, ARCH CLIN NEUROPSYCH, V14, P28, DOI 10.1093/arclin/14.1.28a; FERGUSON R, 1993, MILD HEAD INJURY SYM; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gwin RD, 1998, ARCH CLIN NEUROPSYCH, V13, P133; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schacter DL, 1999, AM PSYCHOL, V54, P182, DOI 10.1037/0003-066X.54.3.182; TAFOYA S, 2000, CALIFORNIA COUNTYS P, V1	17	36	36	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2002	81	8					609	618	UNSP 0894-9115/02/8108-0609/0	10.1097/00002060-200208000-00009			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	577EE	WOS:000177047900009	12172071				2021-06-18	
J	Rudehill, A; Bellander, BM; Weitzberg, E; Bredbacka, S; Backheden, M; Gordon, E				Rudehill, A; Bellander, BM; Weitzberg, E; Bredbacka, S; Backheden, M; Gordon, E			Outcome of traumatic brain injuries in 1,508 patients: Impact of prehospital care	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Coma Scale; Glasgow Outcome Scale; prehospital care; traumatic brain injury	SEVERE HEAD-INJURY; PROGNOSTIC FACTORS; ADULT PATIENTS; MANAGEMENT; GUIDELINES; PREDICTION; HEMATOMAS	This article describes the outcome of 1,508 patients with traumatic brain injuries (TBI) treated in a single neurosurgical unit over an 8-year period. Our aim has been to compare those outcomes with our previous results and with other large patient series. Another important goal was to evaluate the effect of the introduction of a 4-year ongoing study initiated in January 1993 using a new strategy of prehospital care on postresuscitation Glasgow Coma Score (GCS) and Glasgow Outcome Score (GOS). Results from the 1,508 patients showed good recovery or moderate disability in 69%, severe disability or vegetative state in 11%, and a mortality rate of 20%. When outcome of the most severely injured patients (GCS less than or equal to 8) was compared with those of our previous and other large international patient series, more favorable outcome figures were shown in the present study. To evaluate the impact of the improved prehospital care after half of the study period, a logistic regression analysis showed after January 1993 a significantly increased expected odds/ratio for a postresuscitation GCS 8-15 rather than a GCS 3-4 (odds/ratio: 2.2; p < 0.001). For patients with postresuscitation GCS 5-7 and 8-15, the expected odds/ratio for a GOS 4-5 instead of GOS 1 increased significantly (odds/ratio: 2.2 and 1.7, respectively; p < 0.05-0.01). For patients with GCS 3-4, an increased expected odds/ratio (2.0; p < 0.05) for a GOS 2-3 rather than a GOS I was seen. The principal conclusion is that outcome for the severely injured patients in the present study is more favorable than in other large series of TBI. We posit that the introduction of effective prehospital care most likely contributed to the improved postresuscitation neurological status and consequently to the better outcome observed after January 1993.	Karolinska Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Neurosurg, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Med Stat, S-17176 Stockholm, Sweden; Karolinska Inst, S-10401 Stockholm, Sweden	Rudehill, A (corresponding author), Karolinska Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden.						Alberts KA, 1999, EUR J SURG, V165, P426; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Bullock MR, 1996, J NEUROTRAUM, V13, P643; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; GORDON E, 1979, MANAGEMENT ACUTE INT, P188; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Marshall SB, 1991, J NEUROSURG S, V75, P14; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 1997, ACTA NEUROCHIR, V139, P273, DOI 10.1007/BF01808821; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; Vollmer DG, 1991, J NEUROSURG S, V75, P37	21	36	38	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					855	868		10.1089/08977150260190447			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700005	12184855				2021-06-18	
J	Hicks, RR; Keeling, KL; Yang, MY; Smith, SA; Simons, AM; Kotwal, GJ				Hicks, RR; Keeling, KL; Yang, MY; Smith, SA; Simons, AM; Kotwal, GJ			Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; complement; fluid percussion injury; inflammation; memory loss; Morris Water Maze; vaccinia virus complement control protein	HEAD-INJURY; SYSTEM; INFLAMMATION; ACTIVATION; BINDING; RAT; PROTEOGLYCANS; ACCUMULATION; DYSFUNCTION; INHIBITION	Inflammation is a major contributor to the neuropathological consequences of traumatic brain injury (TBI). Previous studies have shown that proinflammatory complement activation fragments are present in the injured brain within the first 24 h after trauma. To investigate whether complement activation within the injured brain leads to the neuropathology and subsequent functional impairment associated with TBI, we examined what effect administration of a complement inhibitor, the vaccinia virus complement control protein (VCP), would have on spatial learning and memory in brain injured rats, as measured using the Morris Water Maze (MWM) procedure. Animals were subjected to a lateral fluid percussion brain injury of moderate severity and, 15 min later, received a 10-muL injection of either full-length VCP, a truncated version of VCP (VCPt), which lacks the complement inhibitory activity but retains the heparin binding activity of VCP, or saline directly into the cortex. Results of such intervention indicated that, at 2 weeks postinjury, both VCP and VCPt treatment attenuated impairments in spatial memory, but not neuropathological damage, as compared to the saline treated controls. These results were surprising and suggest that the neuroprotective effects following administration of VCP after acute brain injury are mediated by mechanisms other than complement inhibition. Potential mechanisms are discussed.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Grad Program Neurobiol & Behav, Seattle, WA 98195 USA; Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY USA	Kotwal, GJ (corresponding author), Univ Cape Town, Div Med Virol, ZA-7925 Cape Town, South Africa.	GJKOTW01@yahoo.com					Al-Mohanna F, 2001, TRANSPLANTATION, V71, P796, DOI 10.1097/00007890-200103270-00019; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Dunzendorfer S, 2001, BLOOD, V97, P1079, DOI 10.1182/blood.V97.4.1079; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Fernaud-Espinosa I, 1998, J NEUROBIOL, V36, P16, DOI 10.1002/(SICI)1097-4695(199807)36:1<16::AID-NEU2>3.0.CO;2-D; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Harris JA, 2001, NEURON, V30, P315, DOI 10.1016/S0896-6273(01)00300-2; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kesner RP, 2000, HIPPOCAMPUS, V10, P483, DOI 10.1002/1098-1063(2000)10:4<483::AID-HIPO15>3.0.CO;2-Z; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; Kotwal G, 1998, 10TH INTERNATIONAL CONGRESS ON IMMUNOLOGY, VOLS 1 AND 2, P315; Kotwal GJ, 2000, IMMUNOL TODAY, V21, P242, DOI 10.1016/S0167-5699(00)01606-6; Kotwal GJ, 1998, MOL CELL BIOCHEM, V185, P39, DOI 10.1023/A:1006844624825; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; Kotwal GJ, 1997, J LEUKOCYTE BIOL, V62, P415; Lalonde R, 1997, INT REV NEUROBIOL, V41, P191, DOI 10.1016/S0074-7742(08)60352-9; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MARTIN D, 1998, NEUROINFLAMMATION ME, P197; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; Miller CG, 1997, VIROLOGY, V229, P126, DOI 10.1006/viro.1996.8396; Molinari M, 1997, INT REV NEUROBIOL, V41, P217, DOI 10.1016/S0074-7742(08)60353-0; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; Nieto-Sampedro M, 1999, ADV EXP MED BIOL, V468, P207; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; OTT L, 1998, NEUROINFLAMMATION ME, P221; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; REYNOLDS DN, 1999, ADV ANIMAL VIROLOGY, P343; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000; Soares HD, 1995, J NEUROSCI, V15, P8223; SPIEGEL K, 1998, NEUROINFLAMMATION ME, P129; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21	49	36	36	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2002	19	6					705	714		10.1089/08977150260139093			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	569EZ	WOS:000176588900003	12165132				2021-06-18	
J	Gurkin, MA; Parikshak, M; Kralovich, KA; Horst, HM; Agarwal, V; Payne, N				Gurkin, MA; Parikshak, M; Kralovich, KA; Horst, HM; Agarwal, V; Payne, N			Indicators for tracheostomy in patients with traumatic brain injury	AMERICAN SURGEON			English	Article; Proceedings Paper	44th Annual Meeting of the Midwest-Surgical-Association	AUG 12-15, 2001	LAKE GENEVA, WI	Midwest Surg Assoc			GLASGOW COMA SCALE; MECHANICAL VENTILATION; HEAD-INJURY; MANAGEMENT; PREDICTION; SCORE	Our objective was to develop criteria to identify patients with traumatic brain injury (TBI) who require a tracheostomy (TR). From January 1994 to May 2000 all TBI patients requiring intubation on presentation and who survived >7 days were identified from our trauma registry. Demographics, Glasgow Coma Score (GCS), Injury Severity Score (ISS), and ventilator days, ICU days, hospital days, need for TR, and development of pneumonia were statistically analyzed. Of 246 patients with TBI 211 without TR and 35 with TR were identified (mean time to TR 13.3 +/- 7.0 days). Logistic regression analysis identified presenting GCS less than or equal to8, ISS greater than or equal to25, and ventilator days >7 as significant predictors for TR. Applying these three predictors to our population identified 48 patients (21 with TR, 18 without TR, and nine who died on the ventilator without TR) with a sensitivity of 60 per cent, a specificity of 87 per cent, a positive predictive value of 44 per cent, and a negative predictive value of 93 per cent. Patients with TR had lower presenting GCS and higher ventilator, ICU, and hospital days (P < 0.05). Pneumonia rates were similar. Time to neurologic recovery (GCS >= 9) was longer for the TR patients as compared with the patients without TR. We conclude that patients with TBI presenting with a GCS <= 8, an ISS >= 25, and ventilator days >7 are more likely to require TR. Performing TR late did not reduce pneumonia rates or ventilator, ICU, or hospital days. By identifying the at-risk population early TR could be performed in an attempt to decrease morbidity and length of stay.	Henry Ford Hosp, Div Trauma & Crit Care, Detroit, MI 48202 USA	Horst, HM (corresponding author), Henry Ford Hosp, Div Trauma & Crit Care, Clara Ford Pavil,4th Floor,2799 W Grand Blvd, Detroit, MI 48202 USA.						DAMELIO LF, 1994, AM SURGEON, V60, P180; Gibbons KJ, 2000, CRIT CARE MED, V28, P1663, DOI 10.1097/00003246-200005000-00076; GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; HEFFNER JE, 1993, AM REV RESPIR DIS, V147, P768, DOI 10.1164/ajrccm/147.3.768; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Koh WY, 1997, ANAESTH INTENS CARE, V25, P365, DOI 10.1177/0310057X9702500407; LESNIK I, 1992, AM SURGEON, V58, P346; MARSH HM, 1989, CHEST, V96, P190, DOI 10.1378/chest.96.1.190; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PLUMMER AL, 1989, CHEST, V96, P178, DOI 10.1378/chest.96.1.178; Qureshi AI, 2000, CRIT CARE MED, V28, P1383, DOI 10.1097/00003246-200005000-00020; RODRIGUEZ JL, 1990, SURGERY, V108, P655; Scheinhorn DJ, 1998, CRIT CARE CLIN, V14, P819, DOI 10.1016/S0749-0704(05)70032-4	14	36	40	0	2	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	APR	2002	68	4					324	328					5	Surgery	Surgery	536DE	WOS:000174684800005	11952241				2021-06-18	
J	Givner, A; Gurney, J; O'Connor, D; Kassarjian, A; LaMorte, WW; Moulton, S				Givner, A; Gurney, J; O'Connor, D; Kassarjian, A; LaMorte, WW; Moulton, S			Reimaging in pediatric neurotrauma: Factors associated with progression of intracranial injury	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	32nd Annual Meeting of the American-Pediatric-Surgical-Association	MAY 20-23, 2001	NAPLES, FL	Amer Pediatr Surg Assoc		pediatric trauma; craniocerebral trauma; head injury; computed tomography; craniotomy	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; BRAIN INJURY; TRAUMA; CHILDREN; PREDICTORS; MODERATE; HEMATOMA	Purpose: The purpose of this study was to characterize the radiologic changes that are seen in the first 24 to 48 hours after head injury and to correlate those changes with clinical findings, to determine which children are at greatest risk for progression of their neurologic injury. Methods: The authors identified 104 children (less than or equal to17 years of age) who had a second computed tomography (CT) scan of the head within 24 to 48 hours of admission. CT scans were evaluated systematically in a blinded fashion. Mechanism of injury, findings on physical examination, therapeutic measures, and changes in management were recorded from hospital medical records. The 50 children whose second CT scan showed progression of injury were compared with the 54 patients whose intracranial injuries were unchanged or improved on their second CT. Results: Twenty-six percent of patients (13 of 50) with radiographic progression of injury had an admission Glasgow coma score of 15. Progression of injury was more common, however, in patients with lower Glasgow coma scores, averaging 9 on admission and 10 at the time of the second CT. Progression of injury also was more common if the initial head CT showed 3 or more intracranial injuries, mass effect, intraventricular hemorrhage, or an epidural hematoma. Conclusions: Children with an intracranial injury identified on their initial head CT scan should undergo a second scan 24 hours after injury, especially if the initial CT shows 3 or more intracranial injuries, mass effect, intraventricular hemorrhage, or an epidural hematoma. J Pediatr Surg 37:381-385. Copyright (C) 2002 by W.B. Saunders Company.	Walter Reed Army Med Ctr, Dept Surg, Boston, MA USA; Boston Univ, Sch Med, Dept Radiol, Div Neuroradiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Radiol, Div Pediat Surg, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Surg, Div Pediat Surg, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Surg, Div Neuroradiol, Boston, MA 02118 USA	Moulton, S (corresponding author), Dowling 2419,1 Boston Med Ctr Pl, Boston, MA 02118 USA.			LaMorte, Wayne/0000-0002-7813-9809; Kassarjian, Ara/0000-0002-9969-3227			BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; BRUNETTI J, 1979, NEURORADIOLOGY, V18, P43, DOI 10.1007/BF00346211; JAIMOVICH R, 1992, PEDIATR NEUROSURG, V17, P25, DOI 10.1159/000120562; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; WINCHELL RJ, 1995, ANN EMERG MED, V25, P737, DOI 10.1016/S0196-0644(95)70200-8	16	36	37	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	MAR	2002	37	3					381	385		10.1053/jpsu.2002.30825			5	Pediatrics; Surgery	Pediatrics; Surgery	526ZZ	WOS:000174160700024	11877652				2021-06-18	
J	Otto, VI; Gloor, SM; Frentzel, S; Gilli, U; Ammann, E; Hein, AE; Folkers, G; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Otto, VI; Gloor, SM; Frentzel, S; Gilli, U; Ammann, E; Hein, AE; Folkers, G; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			The production of macrophage inflammatory protein-2 induced by soluble intercellular adhesion molecule-1 in mouse astrocytes is mediated by src tyrosine kinases and p42/44 mitogen-activated protein kinase	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; macrophage inflammatory protein-2; p42/44 mitogen-activated protein kinase; soluble intercellular adhesion molecule-1; src tyrosine kinases	CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; TNF-ALPHA; CHEMOTACTIC ACTIVITY; HELICOBACTER-PYLORI; CEREBROSPINAL-FLUID; SIGNALING PATHWAYS; CIRCULATING ICAM-1; EPITHELIAL-CELLS	Severe traumatic brain injury stimulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) into CSF. Studies in cultured mouse astrocytes suggest that sICAM-1 induces the production of macrophage inflammatory protein-2 (MIP-2). In the present study, we investigated the underlying mechanisms for MIP-2 induction. sICAM-1 induced MIP-2 in astrocytes lacking membrane-bound ICAM-1, indicating that its action is due to heterophilic binding to an undescribed receptor rather than homophilic binding to surface ICAM-1. Signal transduction may be mediated by src tyrosine kinases, as the src tyrosine kinase inhibitors herbimycin A and PP2 abolished MIP-2 induction by sICAM-1. Phosphorylation of p42/44 mitogen-activated protein kinase (MAPK), but not of p38 MAPK, occurred further downstream, as evidenced by western blot analysis combined with the use of herbimycin A and specific MAPK inhibitors. By contrast, induction of MIP-2 by tumour necrosis factor-alpha (TNF-alpha) involved both p42/44 MAPK and p38 MAPK. Following stimulation with either sICAM-1 or TNF-alpha, astrocyte supernatants promoted chemotaxis of human neutrophils and incubation of these supernatants with anti-MIP-2 antibodies more efficiently suppressed the migration induced by sICAM-1 than by TNF-alpha. These results show that sICAM-1 induces the production of biologically active MIP-2 in astrocytes by heterophilic binding to an undefined receptor and activation of src tyrosine kinases and p42/44 MAPK.	Univ Zurich Hosp, Div Res, Dept Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Internal Med, Lab Transplantat Immunol, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, ETH, Inst Biochem, Zurich, Switzerland; Novartis Pharma Res, Basel, Switzerland; Swiss Fed Inst Technol, Dept Appl Biosci, ETH, Div Pharmaceut Sci, Zurich, Switzerland	Otto, VI (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, BRC 417,975 NE 10th St, Oklahoma City, OK 73104 USA.			Morganti-Kossmann, Cristina/0000-0002-0807-2063; Folkers, Gerd/0000-0002-3620-705X; Otto, Vivianne/0000-0002-1157-0186			BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; Beales ILP, 1997, CYTOKINE, V9, P514, DOI 10.1006/cyto.1996.0195; Ding SZ, 1997, BIOCHEM BIOPH RES CO, V240, P561, DOI 10.1006/bbrc.1997.7699; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 1999, J IMMUNOL, V163, P668; Franchini M, 1998, VET IMMUNOL IMMUNOP, V66, P53, DOI 10.1016/S0165-2427(98)00178-0; Gho YS, 1999, CANCER RES, V59, P5128; HASKARD D, 1986, J IMMUNOL, V137, P2901; Holland J, 1997, J BIOL CHEM, V272, P9108; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Janabi N, 1999, J IMMUNOL, V162, P1701; Keane MP, 2000, CRIT CARE MED, V28, pN13, DOI 10.1097/00003246-200004001-00003; KING PD, 1995, J IMMUNOL, V154, P6080; KUBY J, 1997, IMMUNOLOGY, P357; Kusterer K, 1998, AM J PHYSIOL-GASTR L, V275, pG377; Lacy P, 1999, BLOOD, V94, P23, DOI 10.1182/blood.V94.1.23.413k13_23_32; Lawson C, 1999, J IMMUNOL, V162, P2990; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; LUKACS NW, 1994, BLOOD, V83, P1174; Matsumoto K, 1998, J ALLERGY CLIN IMMUN, V101, P825, DOI 10.1016/S0091-6749(98)70311-2; MCCABE SM, 1993, CELL IMMUNOL, V150, P364, DOI 10.1006/cimm.1993.1204; MEYER DM, 1995, J IMMUNOL, V155, P3578; MEYER JD, 1988, ARCH SURG-CHICAGO, V123, P1454; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; MROWIETZ U, 1988, BIOCHEM BIOPH RES CO, V153, P1223, DOI 10.1016/S0006-291X(88)81358-5; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Sano H, 1998, BIOCHEM BIOPH RES CO, V250, P694, DOI 10.1006/bbrc.1998.9385; Saunders J, 1999, DRUG DISCOV TODAY, V4, P80, DOI 10.1016/S1359-6446(98)01280-X; Schmal H, 1998, J IMMUNOL, V161, P3685; SEEBACH J, 1995, J IMMUNOL, V155, P4367; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shrikant P, 1996, J IMMUNOL, V157, P1819; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Su SB, 1996, J LEUKOCYTE BIOL, V59, P420; VAN SG, 1990, J IMMUNOL, V144, P4579; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Wolff B, 1998, J EXP MED, V188, P1757, DOI 10.1084/jem.188.9.1757; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; Zu YL, 1998, J IMMUNOL, V160, P1982	45	36	41	0	6	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2002	80	5					824	834		10.1046/j.0022-3042.2001.00748.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	527CY	WOS:000174169500013	11948246	Bronze			2021-06-18	
J	Fisk, GD; Novack, T; Mennemeier, M; Roenker, D				Fisk, GD; Novack, T; Mennemeier, M; Roenker, D			Useful field of view after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						divided attention; driving; peripheral vision; processing speed; selective attention	CLOSED-HEAD-INJURY; ATTENTIONAL DEFICITS; DRIVING PERFORMANCE; VISUAL-SEARCH; OLDER ADULTS; OF-VIEW; CRASHES; DRIVERS; AGE	Background: Traumatic brain injury (TBI) survivors often have sensory and cognitive impairments that may interfere with driving ability. The Useful Field of View (UFOV) is a measure of visual information processing that is a good predictor of vehicle crash risk in older adults. Objective: The objective of this study was to explore the possibility that UFOV is compromised after TBI Design: UFOV performance of 23 TBI survivors and 18 young adults without neurological impairment were compared, Conclusion: TBI survivors had higher UFOV scores than young adults, which indicated a greater functional loss of peripheral vision, The results suggest that the UFOV may be a valuable instrument for assessing driving readiness in TBI survivors.	Georgia SW State Univ, Dept Psychol & Sociol, Americus, GA 31709 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA; Western Kentucky Univ, Dept Psychol, Bowling Green, KY 42101 USA	Fisk, GD (corresponding author), Georgia SW State Univ, Dept Psychol & Sociol, 800 Wheatley St, Americus, GA 31709 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420-06] Funding Source: Medline		BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K., 1992, J AM OPTOM ASSOC, V64, P71; BALL K, 1999, USEFUL FIELD VIEW MA; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; BALL KK, 1990, DEV ATTENTION RES TH, P489, DOI DOI 10.1016/S0166-4115(08)60472-0; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; DELIS D, 1987, CALIFORNIA VERBAL LE; Fisk GD, 1998, BRAIN INJURY, V12, P683; FISK GD, 2002, ARCH PHYS MED REHABI, V83; Fox G K, 1992, Disabil Rehabil, V14, P140; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; Geldmacher DS, 1997, BRAIN INJURY, V11, P59, DOI 10.1080/026990597123818; HANDLER BS, 1995, J REHABIL, V61, P43; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; IKEDA M, 1975, PERCEPT PSYCHOPHYS, V18, P255, DOI 10.3758/BF03199371; Korner-Bitensky N, 2000, AM J PHYS MED REHAB, V79, P253, DOI 10.1097/00002060-200005000-00007; MATTHEWS CG, 1964, INSTRUCTION MANUAL A; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Myers RS, 2000, PERCEPT MOTOR SKILL, V91, P279, DOI 10.2466/PMS.91.5.279-290; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; OWSLEY C, 1995, VISION RES, V35, P579, DOI 10.1016/0042-6989(94)00166-J; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REITAN RM, 1985, HAISTAN REITAN NEURO; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Seiple W, 1996, VISION RES, V36, P1859, DOI 10.1016/0042-6989(95)00288-X; Sekuler AB, 2000, EXP AGING RES, V26, P103, DOI 10.1080/036107300243588; SEKULER R, 1986, J OPTOM SOC AM, V3, P861; Slosson R.L., 1991, SLOSSON INTELLIGENCE; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; ZACHARY RA, 1987, SHIPLEY I LIVING SCA; Zar J.H., 1974, BIOSTATISTICAL ANAL	39	36	37	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2002	17	1					16	25		10.1097/00001199-200202000-00004			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	519MM	WOS:000173730100005	11860326				2021-06-18	
S	Morrison, RS; Kinoshita, Y; Johnson, MD; Ghatan, S; Ho, JT; Garden, G		Alzheimer, C		Morrison, RS; Kinoshita, Y; Johnson, MD; Ghatan, S; Ho, JT; Garden, G			Neuronal survival and cell death signaling pathways	MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS	Advances in Experimental Medicine and Biology		English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; TRAIL-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CYCLIN-DEPENDENT KINASES; TRANSGENIC MOUSE MODEL; N-TERMINAL KINASE; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; BCL-X-L	Neuronal viability is maintained through a complex interacting network of signaling pathways that can be perturbed in response to a multitude of cellular stresses. A shift in the balance of signaling pathways after stress or in response to pathology can have drastic consequences for the function or the fate of a neuron. There is significant evidence that acutely injured and degenerating neurons may die by an active mechanism of cell death. This process involves the activation of discrete signaling pathways that ultimately compromise mitochondrial structure, energy metabolism and nuclear integrity. In this review we examine recent evidence pertaining to the presence and activation of anti- and pro-cell death regulatory pathways in nervous system injury and degeneration.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA	Morrison, RS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA.			Garden, Gwenn/0000-0002-8753-6515			Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Anderson CNG, 1999, J NEUROSCI, V19, P664; Araki T, 1998, BRAIN RES, V794, P239, DOI 10.1016/S0006-8993(98)00231-5; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Attardi LD, 2000, GENE DEV, V14, P704; Ay I, 2001, MOL BRAIN RES, V87, P71, DOI 10.1016/S0169-328X(00)00285-0; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Balass M, 1997, P NATL ACAD SCI USA, V94, P6054, DOI 10.1073/pnas.94.12.6054; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barker V, 2001, NAT NEUROSCI, V4, P1194, DOI 10.1038/nn755; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Behrens A, 1999, NAT GENET, V21, P326; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bruckner SR, 2001, J NEUROCHEM, V78, P298, DOI 10.1046/j.1471-4159.2001.00400.x; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Busser J, 1998, J NEUROSCI, V18, P2801; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chakravarthy BR, 1999, J NEUROCHEM, V72, P933, DOI 10.1046/j.1471-4159.1999.0720933.x; Chechlacz M, 2001, J NEUROCHEM, V78, P141, DOI 10.1046/j.1471-4159.2001.00380.x; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chen RW, 1999, J NEUROSCI, V19, P9654; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Coovert DD, 2000, J MED GENET, V37, P536, DOI 10.1136/jmg.37.7.536; Copani A, 1999, FASEB J, V13, P2225; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cregan SP, 1999, J NEUROSCI, V19, P7860; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Culmsee C, 2001, MOL BRAIN RES, V87, P257, DOI 10.1016/S0169-328X(01)00008-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; D'Mello SR, 2000, J NEUROSCI RES, V59, P24, DOI 10.1002/(SICI)1097-4547(20000101)59:1<24::AID-JNR4>3.0.CO;2-8; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Aguilar JLG, 2000, NEUROBIOL DIS, V7, P406, DOI 10.1006/nbdi.2000.0295; de la Monte SM, 1998, LAB INVEST, V78, P401; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Ding XL, 2000, AM J PATHOL, V157, P1983, DOI 10.1016/S0002-9440(10)64837-7; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Droin N, 2000, CANCER RES, V60, P7039; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Eggert A, 2000, MED PEDIATR ONCOL, V35, P603, DOI 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Elovaara I, 1999, ACTA NEUROPATHOL, V98, P355, DOI 10.1007/s004010051094; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Enokido Y, 1996, NEUROSCI LETT, V203, P1, DOI 10.1016/0304-3940(95)12247-8; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Faddis BT, 1997, J NEUROSCI, V17, P951; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 1997, NEUROREPORT, V8, P2483, DOI 10.1097/00001756-199707280-00014; Ferri CC, 1998, J NEUROBIOL, V34, P1; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Frade JM, 1999, DEVELOPMENT, V126, P683; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Frank S, 1999, BIOCHEM BIOPH RES CO, V257, P454, DOI 10.1006/bbrc.1999.0493; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Gendron TF, 2001, J NEUROCHEM, V78, P316, DOI 10.1046/j.1471-4159.2001.00423.x; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guegn C, 2001, J NEUROSCI, V21, P6569; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Harris CA, 2001, J BIOL CHEM, V276, P37754; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Herdegen T, 1998, J NEUROSCI, V18, P5124; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; Hirata H, 1997, J NEUROCHEM, V69, P780; Hisahara S, 2001, J EXP MED, V193, P111, DOI 10.1084/jem.193.1.111; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jin KL, 2001, J NEUROCHEM, V77, P1508, DOI 10.1046/j.1471-4159.2001.00361.x; Jo M, 2000, NAT MED, V6, P564; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan J, 1997, J NEUROSCI, V17, P1397; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Khursigara G, 2001, J NEUROSCI, V21, P5854; Kim GM, 2001, J NEUROSCI, V21, P6617; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kowaltowski AJ, 2000, AM J PHYSIOL-CELL PH, V279, pC852; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kuechle MK, 2001, CELL DEATH DIFFER, V8, P868, DOI 10.1038/sj.cdd.4400897; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Kuntz C, 2000, EXP NEUROL, V165, P184, DOI 10.1006/exnr.2000.7464; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; LaFerla FM, 1996, J CLIN INVEST, V98, P1626, DOI 10.1172/JCI118957; Lakkaraju A, 2001, J BIOL CHEM, V276, P32000, DOI 10.1074/jbc.M100138200; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee Y, 2001, J NEUROSCI, V21, P6687; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Leonard JR, 2001, DEV BRAIN RES, V128, P187, DOI 10.1016/S0165-3806(01)00174-2; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1033.2001.02024.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin LJ, 2000, NEUROBIOL DIS, V7, P613, DOI 10.1006/nbdi.2000.0314; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Martinou I, 1998, NEUROREPORT, V9, P15, DOI 10.1097/00001756-199801050-00004; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 2001, TRENDS NEUROSCI, V24, P255, DOI 10.1016/S0166-2236(00)01838-5; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; McGinnis KM, 1999, J NEUROCHEM, V72, P1899, DOI 10.1046/j.1471-4159.1999.0721899.x; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; McShea A, 1997, AM J PATHOL, V150, P1933; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIYASHITA T, 1994, CANCER RES, V54, P3131; Morishima Y, 2001, J NEUROSCI, V21, P7551; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Morrison RS, 1996, J NEUROSCI, V16, P1337; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Namura S, 1998, J NEUROSCI, V18, P3659; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Nath R, 2001, CELL MOL BIOL LETT, V6, P173; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Prudlo J, 2000, BRAIN RES, V879, P183, DOI 10.1016/S0006-8993(00)02745-1; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Qin ZH, 1999, J NEUROSCI, V19, P4023; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Reimann-Philipp U, 2001, J NEUROSCI RES, V64, P654, DOI 10.1002/jnr.1119; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sadoul R, 1998, CELL DEATH DIFFER, V5, P805, DOI 10.1038/sj.cdd.4400438; SAEIPPER CD, 2001, DEVELOPMENT, V128, P137; Saito M, 2000, NAT CELL BIOL, V2, P553; Sakhi S, 1996, NEUROREPORT, V8, P233, DOI 10.1097/00001756-199612200-00047; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sawa A, 1999, J NEURAL TRANSM-SUPP, P87; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sedel F, 1999, EUR J NEUROSCI, V11, P3904, DOI 10.1046/j.1460-9568.1999.00814.x; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Seidl R, 1999, NEUROSCI LETT, V260, P9, DOI 10.1016/S0304-3940(98)00945-8; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shibata M, 2000, J CLIN INVEST, V106, P643, DOI 10.1172/JCI10203; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; Smith CD, 2002, PROTEIN SCI, V11, P625, DOI 10.1110/ps.37802; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Sun YF, 2001, J BIOL CHEM, V276, P16240, DOI 10.1074/jbc.M010419200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tamami M, 1996, J BIOL CHEM, V271, P24551, DOI 10.1074/jbc.271.40.24551; Tenneti L, 2000, J NEUROCHEM, V74, P134, DOI 10.1046/j.1471-4159.2000.0740134.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; Tong X, 2000, INT J RADIAT BIOL, V76, P1387; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.t01-1-00218.x; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Uberti D, 1998, EUR J NEUROSCI, V10, P246, DOI 10.1046/j.1460-9568.1998.00042.x; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Vemuri MC, 2001, CELL DEATH DIFFER, V8, P245, DOI 10.1038/sj.cdd.4400806; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Vincent I, 2001, NEUROSCIENCE, V105, P639, DOI 10.1016/S0306-4522(01)00219-6; Vincent I, 1997, J NEUROSCI, V17, P3588; Vogel KS, 1998, MOL CELL NEUROSCI, V11, P19, DOI 10.1006/mcne.1998.0670; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang Y, 1999, NEUROSCIENCE, V94, P1153, DOI 10.1016/S0306-4522(99)00264-X; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Whalen MJ, 2000, ACT NEUR S, V76, P61; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wiese S, 1999, EUR J NEUROSCI, V11, P1668, DOI 10.1046/j.1460-9568.1999.00585.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOOD KA, 1995, J NEUROSCI, V15, P5851; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 1998, J NEUROSCI, V18, P1363; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamagishi S, 2001, J BIOL CHEM, V276, P5129, DOI 10.1074/jbc.M007258200; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeung MC, 1998, AIDS, V12, P349, DOI 10.1097/00002030-199804000-00002; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	394	36	38	1	3	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598	2214-8019	0-306-47414-X	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2002	513						41	86					46	Medicine, Research & Experimental	Research & Experimental Medicine	BW92A	WOS:000183600500002	12575817				2021-06-18	
J	Grundy, PL; Harbuz, MS; Jessop, DS; Lightman, SL; Sharples, PM				Grundy, PL; Harbuz, MS; Jessop, DS; Lightman, SL; Sharples, PM			The hypothalamo-pituitary-adrenal axis response to experimental traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; glucocorticoids; HPA axis; rat; traumatic brain injury	CORTICOTROPIN-RELEASING FACTOR; PARVOCELLULAR NEUROSECRETORY NEURONS; INSITU HYBRIDIZATION HISTOCHEMISTRY; FLUID-PERCUSSION MODEL; MESSENGER-RNA; HEAD-INJURY; PARAVENTRICULAR NUCLEUS; ARGININE-VASOPRESSIN; GLUCOCORTICOID ENDANGERMENT; PLASMA-CORTISOL	Alterations in the hypothalamo-pituitary-adrenal (HPA) axis following traumatic brain injury have not been documented in detail. We used fluid percussion injury (FPI) to evaluate the early changes in components of the HPA axis following experimental traumatic brain injury. Wistar rats were sacrificed at 2 or 4 h following sham or FRI surgery. In situ hybridization histochemistry was used to determine the expression of mRNAs of corticotrophin releasing hormone (CRH) and arginine vasopressin (AVP) in the hypothalamus and pro-opiomelanocortin (POMC) in the pituitary. A group of animals undergoing no surgery were used as control. Repeated blood sampling from an indwelling catheter demonstrated that plasma corticosterone (CORT) levels peaked 30 min following surgery in sham and FPI animals but there was no significant difference in CORT concentration between these groups at any time. Pituitary POMC expression was increased following sham and FPI surgery (compared with control non-operated animals) but with no significant difference between the two groups undergoing surgery. Hypothalamic CRH mRNA expression was significantly higher in animals undergoing FPI compared with sham surgery. Hypothalamic AVP mRNA expression was not significantly increased when compared with control nonoperated animals. These data indicate that the anaesthesia and/or surgery associated with FPI or sham surgery induces a generalised activation of the HPA axis. The selective increase in CRH mRNA in animals undergoing FPI may be due to specific effects of traumatic brain injury rather than a general stress response and may suggest an additional neurotransmitter role for CRH following head injury. The absence of an AVP response suggests that the effects of FPI may be mediated through the CRH-alone-containing subpopulation of neurons.	Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England; Univ Bristol, Res Ctr Neuroendocrinol, Bristol, Avon, England; Univ Bristol, Div Child Hlth, Bristol, Avon, England	Grundy, PL (corresponding author), Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England.	p.l.grundy@doctors.org.uk		Lightman, Stafford/0000-0002-8546-9646			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; ANTONI FA, 1986, ENDOCR REV, V7, P351, DOI 10.1210/edrv-7-4-351; Armstead WM, 1996, J NEUROTRAUM, V13, P115, DOI 10.1089/neu.1996.13.115; BARTANUSZ V, 1993, ENDOCRINOLOGY, V132, P895, DOI 10.1210/en.132.2.895; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BOUZARTH WF, 1968, SURG GYNECOL OBSTETR, V126, P995; BROWNSTEIN MJ, 1986, PROG BRAIN RES, V68, P161, DOI 10.1016/S0079-6123(08)60237-X; BUCKINGHAM JC, 1994, PHARMACOL RES, V30, P35, DOI 10.1016/1043-6618(94)80085-5; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; Chiolero R, 1994, New Horiz, V2, P432; CHOWDREY HS, 1995, BRIT J PHARMACOL, V116, P2417, DOI 10.1111/j.1476-5381.1995.tb15089.x; CUNNINGHAM ET, 1991, TRENDS NEUROSCI, V14, P406, DOI 10.1016/0166-2236(91)90032-P; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GOLDMAN H, 1993, ANN EMERG MED, V22, P1035, DOI 10.1016/S0196-0644(05)82747-7; GOLDMAN H, 1993, J NEUROTRAUM, V10, P385, DOI 10.1089/neu.1993.10.385; Grossman A, 1997, ANN NY ACAD SCI, V823, P225, DOI 10.1111/j.1749-6632.1997.tb48394.x; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HARBUZ MS, 1992, ENDOCRINOLOGY, V130, P1394, DOI 10.1210/en.130.3.1394; HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705; Ikeda Y, 1997, ACTA NEUROCHIR, V139, P1173, DOI 10.1007/BF01410978; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; Kinoshita H, 2000, J NEUROENDOCRINOL, V12, P255; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Kovacs KJ, 1996, J NEUROSCI, V16, P262; LEVY A, 1988, J ENDOCRINOL, V118, P205, DOI 10.1677/joe.0.1180205; LIGHTMAN SL, 1993, ANN NY ACAD SCI, V697, P28, DOI 10.1111/j.1749-6632.1993.tb49920.x; MASTERS JN, 1989, ENDOCRINOLOGY, V124, P3083, DOI 10.1210/endo-124-6-3083; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NAVARRA P, 1991, ENDOCRINOLOGY, V128, P37, DOI 10.1210/endo-128-1-37; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SAPOLSKY RM, 1994, ANN NY ACAD SCI, V746, P294; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; SAWCHENKO PE, 1984, P NATL ACAD SCI-BIOL, V81, P1883, DOI 10.1073/pnas.81.6.1883; SAWCHENKO PE, 1984, J NEUROSCI, V4, P1118; Sawchenko PE, 1996, PROG BRAIN RES, V107, P201; SAWCHENKO PE, 1989, CORTICOTROPIN RELEAS, P29; Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Stratakis CA, 1995, ANN NY ACAD SCI, V771, P1, DOI 10.1111/j.1749-6632.1995.tb44666.x; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; WHITNALL MH, 1987, NEUROENDOCRINOLOGY, V45, P420, DOI 10.1159/000124768; WHITNALL MH, 1985, NATURE, V317, P248, DOI 10.1038/317248a0; WHITNALL MH, 1988, NEUROENDOCRINOLOGY, V47, P176, DOI 10.1159/000124910; WHITNALL MH, 1988, J COMP NEUROL, V275, P13, DOI 10.1002/cne.902750103; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wotjak CT, 1996, J NEUROSCI, V16, P7725; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; YOUNG WS, 1986, NEUROSCI LETT, V70, P198; YOUNG WS, 1986, BRAIN RES, V387, P231	56	36	39	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2001	18	12					1373	1381		10.1089/08977150152725669			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	504RE	WOS:000172869000007	11780867				2021-06-18	
J	Ray, SK; Matzelle, DD; Wilford, GG; Hogan, EL; Banik, NL				Ray, SK; Matzelle, DD; Wilford, GG; Hogan, EL; Banik, NL			Inhibition of calpain-mediated apoptosis by E-64 d-reduced immediate early gene (IEG) expression and reactive astrogliosis in the lesion and penumbra following spinal cord injury in rats	BRAIN RESEARCH			English	Article						spinal cord injury; E-64-d; calpain-cleaved alpha-fodrin; immediate early gene; reactive astrogliosis; apoptosis	PROGRAMMED CELL-DEATH; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN INJURY; ACTIVATED NEUTRAL PROTEASE; CENTRAL-NERVOUS-SYSTEM; C-FOS; NEURONAL APOPTOSIS; OXIDATIVE STRESS; MESSENGER-RNA; ENDOGENOUS INHIBITOR	Upregulation of calpain, a Ca2+ -activated cysteine protease, has been implicated in apoptosis and tissue degeneration in spinal cord injury (SCI) that over time spreads from the site of injury to the surrounding regions. We examined calpain content and activity, regulation of immediate early genes (IEGs) such as c-jun and c-fos, reactive astrogliosis as the expression of glial fibrillary acidic protein (GFAP), and apoptosis-related features such as caspase-3 mRNA expression and internucleosomal DNA fragmentation in 1-cm long spinal cord segments (S1, distant rostral; S2, adjacent rostral; S3, lesion or injury; S4, adjacent caudal; and S5, distant caudal) following SCI in rats. Calpain content and production of 150 kD calpain-cleaved alpha -fodrin fragment, expression of IEGs, reactive astrogliosis, and apoptotic features were highly increased in the lesion (S3), moderately in adjacent areas (S2 and S4), and slightly in distant areas (SI and S5) in SO rats when compared to sham animals. Administration of the calpain- specific inhibitor E-64-d (1 mg/kg) to SCI rats continuously for 24 h inhibited calpain activity and other factors contributing to apoptosis in the lesion and surrounding areas, indicating that calpain played a key role in the pathophysiology of SCI. The results obtained from this animal model of SCI suggest that calpain inhibitor can provide neuroprotection in patients with SCI. (C) 2001 Published by Elsevier Science B.V.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 96 Jonathan Lucas St,Suite 309,POB 250606, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041088, R01NS031622, R01NS038146] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-41088, NS-38146, NS-31622] Funding Source: Medline		Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arnold PM, 2000, J NEUROCHEM, V74, pS73; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; BONDY SC, 1993, FREE RADICAL BIO MED, V14, P633, DOI 10.1016/0891-5849(93)90144-J; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CHAKRABARTI AK, 1988, J NEUROSCI RES, V20, P351, DOI 10.1002/jnr.490200309; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chen J, 1998, J NEUROSCI, V18, P4914; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROALL DE, 1991, PHYSIOL REV, V71, P813; CURRAN T, 1987, ONCOGENE, V2, P79; CURTIS CR, 1990, J AM VET MED ASSOC, V197, P838; DRAGUNOW M, 1994, MOL BRAIN RES, V25, P19, DOI 10.1016/0169-328X(94)90274-7; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FEINSTEIN DL, 1992, J NEUROSCI RES, V32, P1, DOI 10.1002/jnr.490320102; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; Juan TSC, 1996, ONCOGENE, V13, P749; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; KOISTINAHO J, 1993, NEUROREPORT, V4, P37, DOI 10.1097/00001756-199301000-00009; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Liu XZ, 1997, J NEUROSCI, V17, P5395; MANN MD, 1991, LAB ANIM SCI, V41, P6; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; MILLIGAN CE, 1994, J NEUROBIOL, V25, P1005, DOI 10.1002/neu.480250809; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; MOTSENBOCKER MA, 1988, J BIOLUM CHEMILUM, V2, P9, DOI 10.1002/bio.1170020104; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NEUMANHAEFELIN T, 1994, J CEREB BLOOD FLOW M, V4, P206; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; O'CALLAGHAN J P, 1991, Biomedical and Environmental Sciences, V4, P197; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Park DS, 1998, J NEUROSCI, V18, P830; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; PERSSON H, 1991, NEUROSCI LETT, V130, P81, DOI 10.1016/0304-3940(91)90232-I; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Ray SK, 2000, NEUROCHEM RES, V25, P1191, DOI 10.1023/A:1007631826160; Ray SK, 2000, BRAIN RES PROTOC, V5, P305, DOI 10.1016/S1385-299X(00)00027-1; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; Reier PJ, 1986, ASTROCYTES, V3, P263; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; SAKAI M, 1989, CANCER RES, V49, P5633; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; Tong LQ, 1998, J NEUROCHEM, V71, P447; Vanderluit JL, 2000, EUR J NEUROSCI, V12, P3469, DOI 10.1046/j.1460-9568.2000.00241.x; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	85	36	43	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 19	2001	916	1-2					115	126		10.1016/S0006-8993(01)02874-8			12	Neurosciences	Neurosciences & Neurology	486HL	WOS:000171812300014	11597598				2021-06-18	
J	Ferrari, R; Obelieniene, D; Russell, AS; Darlington, P; Gervais, R; Green, P				Ferrari, R; Obelieniene, D; Russell, AS; Darlington, P; Gervais, R; Green, P			Symptom expectation after minor head injury. A comparative study between Canada and Lithuania	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						minor head injury; mild traumatic brain injury; concussion; symptom expectation	SEQUELAE; WHIPLASH; TRAUMA	Objectives: The purpose of the present study is to compare the frequency and nature of expected symptoms in Lithuania (a country where the chronic post-concussive syndrome is largely unknown) with that in Canada. Methods: A symptom checklist was administered to two subject groups selected from local companies in Kaunas, Lithuania, and Edmonton, Canada, respectively. Subjects were asked to imagine having suffered head trauma with loss of consciousness in a motor vehicle accident, and to check off symptoms they expected might arise from the injury. For symptoms they anticipated, they were asked to select the period of time they expected those symptoms to persist. Results: In both the Lithuanian and Edmontonian groups,, the pattern or symptoms anticipated closely resembled the acute symptoms commonly reported by accident victims with minor head injury. Yet, while many, Edmontonians also anticipated symptoms to last months or years, very few Lithuanian subjects selected any symptoms as being likely to persist in a chronic manner. Conclusions: In Lithuania, despite the frequent experience of minor head injury in motor vehicle accidents, there is a very low rate of expectation of any chronic sequelae from such an injury, contrasting greatly with the response shown in Canada, where the prevalence of the chronic post-concussive syndrome is higher. Symptom expectation in some countries may be all important factor in the development of the chronic post-concussive syndrome. (C) 2001 Elsevier Science B.V. All rights reserved.		Ferrari, R (corresponding author), 12779-50 St, Edmonton, AB T5A 4L8, Canada.	rferrari@powersurfr.com		Obelieniene, Diana/0000-0002-7356-7150			AUBREY JB, 1989, J NEUROL NEUROSUR PS, V52, P842, DOI 10.1136/jnnp.52.7.842; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; DADOLENE JH, 2001, 16 EULAR C PRAG CZEC; DADONLENE JH, 2001, 16 EULAR C PRAG CZEC; FERRARI R, IN PRESS ARTHRITIS C; FERRARI R, 1999, WHIPLASH ENCY FACTS; Hewlett S, 1995, Arthritis Care Res, V8, P4, DOI 10.1002/art.1790080104; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KAY T, 1992, NEUROPSYCHOLOGY, V6, P341; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MADIANOS MG, 1993, PSYCHOTHER PSYCHOSOM, V60, P177, DOI 10.1159/000288691; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Obelieniene D, 1998, CEPHALALGIA, V18, P559, DOI 10.1046/j.1468-2982.1998.1808559.x; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107	19	36	36	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	OCT	2001	103	3					184	190		10.1016/S0303-8467(01)00143-3			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	476YC	WOS:000171255500011	11532561				2021-06-18	
J	Pyne, GJ; Cadoux-Hudson, TAD; Clark, JF				Pyne, GJ; Cadoux-Hudson, TAD; Clark, JF			Magnesium protection against in vitro cerebral vasospasm after subarachnoid haemorrhage	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cerebral vasospasm; magnesium; stroke; subarachnoid haemorrhage	INTRACELLULAR-FREE MAGNESIUM; TRAUMATIC BRAIN INJURY; SMOOTH-MUSCLE CELLS; GUINEA-PIG CECUM; HEMORRHAGE; CALCIUM; SULFATE; TAENIA; PHOSPHORYLATION; RELEASE	Mg2+ has recently been proposed for the treatment of cerebral vasospasm and is known to dilate vessels. In this study, we examine the effects of Mg2+ on in vitro vasospasm using CSF from vasospastic subarachnoid haemorrhage patients with vasospasm (CSFv). Oxygen consumption and isometric force measurements in the porcine carotid artery were used to assess the contractile and metabolic status of the vessels' responses to CSFv and the effect of Mg2+. Mg2+ caused a dose dependant decrease in tension following contraction by CSFv. Mg2+ (12 mM) caused a normalization of relaxation rate in tissue exposed to CSFv, caused a significant decrease in basal oxygen consumption, as well as significantly decreasing the rate of oxygen consumption of the porcine carotid artery when stimulated by CSF (0.70 +/- 0.12 versus. 0.46 +/- 0.1 mmol O-2 min(-1) g(-1)). Acute Mg2+ addition demonstrated the most effective protection using an assay based on CSFv contraction. These results suggest that Mg2+ can protect vascular smooth muscle exposed to CSFv by benefiting contractile behaviour and metabolism of the arteries.	Univ Oxford, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX1 3QU, England; MRC, Ctr Collaborat, London NW7 1AD, England	Clark, JF (corresponding author), Univ Cincinnati, Med Ctr, Dept Neurol, Cincinnati, OH 45267 USA.						Altura BT, 1997, NEUROSCI LETT, V230, P37, DOI 10.1016/S0304-3940(97)00471-0; ARHEDEN H, 1992, BIOPHYS J, V61, P1480, DOI 10.1016/S0006-3495(92)81954-9; BARANY K, 1985, J BIOL CHEM, V260, P7126; Bearchell MC, 1998, AM J OBSTET GYNECOL, V179, P1534, DOI 10.1016/S0002-9378(98)70020-1; Boet R, 2000, NEUROSURGERY, V47, P602, DOI 10.1097/00006123-200009000-00014; Cadoux-Hudson TAD, 2001, ACTA NEUROCHIR, V143, P65, DOI 10.1007/s007010170140; CADOUXHUDSON TAD, 1999, EMERGING THERAPEUTIC, V3, P439; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; DULEY L, 1995, LANCET, V345, P1455; ENDO S, 1977, STROKE, V8, P702, DOI 10.1161/01.STR.8.6.702; FORD GD, 1986, AM J PHYSIOL, V251, pC687; HEALY M D, 1984, Magnesium, V3, P63; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; HORN E, 1906, MED REV, V32, P264; Lazard EM, 1933, AM J OBSTET GYNECOL, V26, P647, DOI 10.1016/S0002-9378(33)90285-9; MACDONALD RL, 1994, FREE RADICAL BIO MED, V16, P633; MCCLEAN RM, 1994, AM J MED, V96, P63; MORELAND RS, 1981, ARCH BIOCHEM BIOPHYS, V208, P325, DOI 10.1016/0003-9861(81)90516-6; MORELAND S, 1987, PFLUG ARCH EUR J PHY, V408, P139, DOI 10.1007/BF00581343; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; NAKAYAMA S, 1991, J PHYSIOL-LONDON, V435, P559, DOI 10.1113/jphysiol.1991.sp018525; NAKAYAMA S, 1994, J GEN PHYSIOL, V103, P833, DOI 10.1085/jgp.103.5.833; NAKAYAMA S, 1990, J PHYSIOL-LONDON, V421, P363, DOI 10.1113/jphysiol.1990.sp017949; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; POE M, 1969, ARCH BIOCHEM BIOPHYS, V132, P377, DOI 10.1016/0003-9861(69)90379-8; Pyne GJ, 2000, BBA-GEN SUBJECTS, V1474, P283, DOI 10.1016/S0304-4165(00)00030-1; Pyne GJ, 2001, ACTA NEUROCHIR, V143, P59, DOI 10.1007/s007010170139; RAM Z, 1991, STROKE, V22, P922, DOI 10.1161/01.STR.22.7.922; RUSSELL WE, 1973, EUR J BIOCHEM, V33, P459, DOI 10.1111/j.1432-1033.1973.tb02703.x; SJOGREN A, 1988, PHARMACOL TOXICOL, V62, P17; SLOANE BF, 1978, ARCH BIOCHEM BIOPHYS, V189, P409, DOI 10.1016/0003-9861(78)90228-X; STRAUSS JD, 1996, BIOCH SMOOTH MUSCLE, P345; STULL JT, 1986, ENZYMES, P113; TAYLOR JS, 1991, P NATL ACAD SCI USA, V88, P6810, DOI 10.1073/pnas.88.15.6810; VARSOS VG, 1983, J NEUROSURG, V58, P11, DOI 10.3171/jns.1983.58.1.0011; WEBER A, 1969, BIOCHEMISTRY-US, V8, P2266, DOI 10.1021/bi00834a005; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; WEIR B, 1995, BRIT J NEUROSURG, V9, P375, DOI 10.1080/02688699550041386; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4; WINGARD CJ, 1995, J PHYSIOL-LONDON, V488, P729, DOI 10.1113/jphysiol.1995.sp021004; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6	42	36	37	0	0	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2001	15	5					409	415		10.1080/02688690120082413			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	486MP	WOS:000171821800005	11708544				2021-06-18	
J	Stancin, T; Kaugars, AS; Thompson, GH; Taylor, HG; Yeates, KO; Wade, SL; Drotar, D				Stancin, T; Kaugars, AS; Thompson, GH; Taylor, HG; Yeates, KO; Wade, SL; Drotar, D			Child and family functioning 6 and 12 months after a serious pediatric fracture	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	60th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 11-15, 2000	SAN ANTONIO, TX	Amer Assoc Surg Trauma		injuries; fractures; child and family outcomes	TRAUMATIC BRAIN INJURY; ACQUIRED LIMB DEFICIENCIES; SEVERITY SCALE; HEAD-INJURY; MORBIDITY; BURDEN; STRESS; IMPACT	Background: Previous findings indicate that pediatric fractures can have adverse consequences for child adjustment and family functioning immediately after injury. However, longer term effects of the fractures are unknown. The purposes of the present prospective study were to examine the child and family outcomes of pediatric traumatic fractures at 6 months and 1 year after injury, and to identify injury and treatment factors associated with these outcomes. Methods: We evaluated 57 children 6 to 12 years of age with traumatic fractures requiring hospitalization. Using standardized measures and parent interview, we obtained measures of pre- and postinjury child and family functioning. Results: Although outcomes were primarily positive at 1 year after injury, child functional limitations and family stress were observed up to 6 months after injury. Lower extremity fractures had a more negative impact on families across all three assessment points. Children with fracture interventions that involved prolonged immobilization had more functional limitations at 6 months than children who were ambulatory. Family burden was higher at 1 month for the immobilized children, but not at later follow-up, Conclusion: some children and families experience adverse effects during the year after a serious pediatric fracture, especially if sustained in a lower extremity, Fracture stabilization that allows for greater ambulation may offer some benefits related to functional outcomes and family impact.	Metrohlth Med Ctr, Dept Pediat, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA; Univ Hosp, Dept Orthopaed, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Cleveland, OH USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Childrens Hosp, Columbus, OH 43205 USA; Univ Cincinnati, Dept Phys Med & Rehabil Med, Cincinnati, OH USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	Stancin, T (corresponding author), Metrohlth Med Ctr, Dept Pediat, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.	tstancin@metrohealth.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; CRAMER KE, 1995, CLIN ORTHOP RELAT R, P125; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EISEN M, 1980, RAND CORPORATION PUB; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; HUGHES BF, 1995, J PEDIATR ORTHOPED, V15, P457, DOI 10.1097/01241398-199507000-00009; Joy D, 2000, J TRAUMA, V48, P490, DOI 10.1097/00005373-200003000-00020; KASHANI JH, 1981, BRIT J PSYCHIAT, V138, P21, DOI 10.1192/bjp.138.1.21; Loder R T, 1987, J Orthop Trauma, V1, P48; LODER RT, 1995, J PEDIATR ORTHOPED, V15, P41, DOI 10.1097/01241398-199501000-00010; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MAYER T, 1984, J TRAUMA, V24, P31, DOI 10.1097/00005373-198401000-00004; MOOS R, 1988, LIFE STRESSORS SOCIA; *NAT CTR HLTH STAT, 1980, US DEP HHS SER, V10; Shindi J, 1983, Int J Soc Psychiatry, V29, P292, DOI 10.1177/002076408302900409; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; VARNI JW, 1989, PEDIATRICS, V84, P323; VARNI JW, 1989, J DEV BEHAV PEDIATR, V10, P13; VARNI JW, 1989, J PEDIATR PSYCHOL, V14, P515, DOI 10.1093/jpepsy/14.4.515; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; YEATES KO, 1977, J INT NEUROL SOC, V3, P617	36	36	36	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2001	51	1					69	76		10.1097/00005373-200107000-00011			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	453FL	WOS:000169905800012	11468470				2021-06-18	
J	Schmidt, RH; Scholten, KJ; Maughan, PH				Schmidt, RH; Scholten, KJ; Maughan, PH			Cognitive impairment and synaptosomal choline uptake in rats following impact acceleration injury	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic neurons; choline uptake; impact acceleration injury; learning and memory; traumatic brain injury; water maze	TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION INJURY; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; MORRIS WATER MAZE; ACETYLCHOLINE SYNTHESIS; EVOKED RELEASE; DEFICITS; MEMORY; ACETYLTRANSFERASE	Traumatic brain injury is well known to cause deficits in learning and memory, which typically improve with time. Animal studies with fluid percussion or controlled cortical impact injury have identified transient disturbances in forebrain cholinergic innervation which may contribute to such cognitive problems, This study examines the extent to which water maze performance and forebrain synaptosomal choline uptake are affected one week after injury using the newly developed impact acceleration injury model. Injury or sham injury was delivered to adult male Sprague-Dawley rats under halothane anesthesia using a 500-g 2,1-m weight drop. Based on righting reflex, injured rats were divided irate moderate (less than or equal to 12 min) or severe (>12 min) groups. Water maze testing was performed on days 5-7 postinjury, On day 7, choline uptake was determined in synaptosomes from hippocamppus, a parietal cortex, and entorhinal cortex. Maze learning was severely impaired in the severe injury group but not in the moderate injury group. Learning retention was slightly impaired in the moderate injury group and severely affected in the severe injury group. There was a very strong correlation between the severity of injury as determined by prolongation of righting times and disruption of maze learning at 1 week postinjury, There was no change in synaptosomal choline uptake in any of the forebrain regions in the severe injury group, but a slight (14%) decrease in the hippocampus and parietal cortex of the moderate injury group. Correlation analysis showed no relationship between synaptosomal choline uptake in any brain region and performance in either water maze learning or retention. This study shows that the impact acceleration model produces cognitive impairments equivalent to those seen with fluid percussion injury and controlled cortical impact. Compared with those models, the impact acceleration model does not produce a similar disruption of forebrain cholinergic nerve terminals.	Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA	Schmidt, RH (corresponding author), Univ Utah, Dept Neurosurg, 50 N Med Dr, Salt Lake City, UT 84132 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01866] Funding Source: Medline		BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; COOPER JR, 1994, J NEUROCHEM, V63, P395; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DACY RG, 1993, HEAD INJURY, P159; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon C. E., 1995, Society for Neuroscience Abstracts, V21, P762; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, PSYCHOLOGICAL EFFECT; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hayes R. L., 1992, J HEAD TRAUMA REHAB, V7, P16; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JOPE RS, 1979, BRAIN RES REV, V1, P313, DOI 10.1016/0165-0173(79)90009-2; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LAPCHAK PA, 1988, J NEUROCHEM, V50, P58, DOI 10.1111/j.1471-4159.1988.tb13229.x; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin H., 1987, HEAD INJURY, P442; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; SHAPIRO SM, 1993, MINOR HEAD TRAUMA, P1; SIMON JR, 1976, J NEUROCHEM, V26, P909, DOI 10.1111/j.1471-4159.1976.tb06472.x; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	47	36	39	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2000	17	12					1129	1139		10.1089/neu.2000.17.1129			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	379MB	WOS:000165644900002	11186227				2021-06-18	
J	Del Bigio, MR				Del Bigio, MR			Calcium-mediated proteolytic damage in white matter of hydrocephalic rats?	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	29th Annual Meeting of the Society-for-Neuroscience	OCT 23-28, 1999	MIAMI BEACH, FLORIDA	Soc Neurosci		axon; calpain; hydrocephalus; kaolin; proteolytic enzyme	TRAUMATIC BRAIN INJURY; KAOLIN-INDUCED HYDROCEPHALUS; FOCAL CEREBRAL-ISCHEMIA; INDUCED AXONAL INJURY; IMMATURE RATS; CALPAIN-I; NEONATAL HYDROCEPHALUS; CEREBROSPINAL-FLUID; SPINAL-CORD; CELL-DEATH	Hydrocephalus is a pathological dilatation of the cerebrospinal fluid (CSF)-containing ventricles of the brain. Damage to periventricular white matter is multifactorial with contributions by chronic ischemia and gradual physical distortion. Acute ischemic and traumatic brain injuries are associated with calcium-dependent activation of proteolytic enzymes. We hypothesized that hydrocephalus is associated with calcium ion accumulation and proteolytic enzyme activation in cerebral white matter Hydrocephalus was induced in immature and adult rats by injection of kaolin into the cisterna magna and several different experimental approaches were used. Using the glyoxal bis (2-hydroxyanil) method, free calcium ion was detected in periventricular white matter at sites of histological injury. Western blot determinations showed accumulation of calpain I (mu -calpain) and immunoreactivity for calpain I was increased in periventricular axons of young hydrocephalic rats. Proteolytic cleavage of a fluorogenic calpain substrate was demonstrated in white matter. Immunoreactivity for spectrin breakdown products was detected in scattered callosal axons of young hydrocephalic rats. The findings support the hypothesis that periventricular white matter damage associated with experimental hydrocephalus is due, at least in part, to calcium-activated proteolytic processes. This may have implications for supplemental drug treatments of this disorder.	Univ Manitoba, Dept Pathol, Winnipeg, MB R3E 0W3, Canada	Del Bigio, MR (corresponding author), Univ Manitoba, Dept Pathol, D212-770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.			Del Bigio, Marc/0000-0001-8366-0394			BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BENUCK M, 1993, LIFE SCI, V52, P877, DOI 10.1016/0024-3205(93)90517-7; Blomgren K, 1997, ANN NY ACAD SCI, V825, P104, DOI 10.1111/j.1749-6632.1997.tb48420.x; BRUNI JE, 1985, BRAIN RES REV, V9, P1, DOI 10.1016/0165-0173(85)90016-5; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CLARK G, 1981, STAINING PROCEDURES, P188; Del Bigio MR, 1998, EXP NEUROL, V154, P157, DOI 10.1006/exnr.1998.6922; DelBigio MR, 1997, J NEUROPATH EXP NEUR, V56, P1053, DOI 10.1097/00005072-199709000-00010; DelBigio MR, 1997, EXP NEUROL, V148, P256, DOI 10.1006/exnr.1997.6644; DELBIGIO MR, 1989, NEUROSURGERY, V25, P416, DOI 10.1227/00006123-198909000-00016; DELBIGIO MR, 1995, GLIA, V14, P1, DOI 10.1002/glia.440140102; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; Frim DM, 1998, NEUROSURG CLIN N AM, V9, P105; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Hansen AR, 1998, NEUROSURG CLIN N AM, V9, P95; HOCHWALD GM, 1985, P SOC EXP BIOL MED, V178, P1; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KASHIWA HK, 1963, J HISTOCHEM CYTOCHEM, V11, P258, DOI 10.1177/11.2.258; KASHIWA HK, 1970, CLIN ORTHOP RELAT R, P200; KEEP RF, 1989, J NEUROL SCI, V91, P119, DOI 10.1016/0022-510X(89)90081-6; KENESSEY A, 1991, NEUROCHEM RES, V16, P1001, DOI 10.1007/BF00965843; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Li JH, 1998, MOL BRAIN RES, V53, P174, DOI 10.1016/S0169-328X(97)00295-7; LI ZH, 1995, BRAIN RES, V697, P112; Liebetrau M, 1999, NEUROREPORT, V10, P529, DOI 10.1097/00001756-199902250-00016; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASLIAH E, 1990, BRAIN RES, V531, P36, DOI 10.1016/0006-8993(90)90755-Z; Massicotte EM, 2000, J NEUROSURG, V92, P442, DOI 10.3171/jns.2000.92.3.0442; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister JP, 1998, NEUROSURG CLIN N AM, V9, P73; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SEUBERT P, 1988, BRAIN RES, V459, P226, DOI 10.1016/0006-8993(88)90638-5; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Stys PK, 1996, NEUROSCIENCE, V71, P27, DOI 10.1016/0306-4522(95)00430-0; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Thompson VF, 2000, BIOCHEM BIOPH RES CO, V267, P495, DOI 10.1006/bbrc.1999.2001; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Verkhratsky A, 1998, PHYSIOL REV, V78, P99; Wells GJ, 1998, EXPERT OPIN THER PAT, V8, P1707, DOI 10.1517/13543776.8.12.1707; WOLTERS GHJ, 1979, HISTOCHEMISTRY, V62, P137, DOI 10.1007/BF00493315; WOLTERS GHJ, 1979, HISTOCHEMISTRY, V62, P1, DOI 10.1007/BF00537002; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441; Zalewska T, 1998, MOL CHEM NEUROPATHOL, V33, P185, DOI 10.1007/BF02815181; Zhang YW, 1998, NEUROSCIENCE, V86, P847, DOI 10.1016/S0306-4522(98)00080-3	59	36	36	0	0	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2000	59	11					946	954		10.1093/jnen/59.11.946			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	371UT	WOS:000165198200002	11089572	Bronze			2021-06-18	
J	Umehara, F; Abe, M; Koreeda, Y; Izumo, S; Osame, M				Umehara, F; Abe, M; Koreeda, Y; Izumo, S; Osame, M			Axonal damage revealed by accumulation of beta-amyloid precursor protein in HTLV-I-associated myelopathy	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						HTLV-I; HTLV-I-associated myelopathy; axonal damage; beta-amyloid precursor protein; axonal flow; HAM/TSP	SPINAL-CORD LESIONS; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; MULTIPLE-SCLEROSIS LESIONS; T-LYMPHOCYTES; HEAD-INJURY; HUMAN BRAIN; EXPRESSION; APP; IMMUNOREACTIVITY	We investigated the localization and extent of beta-amyloid precursor protein (APP) immunoreactivity as a sensitive marker for impairment of fast axonal transport in the spinal cords of patients with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP). The results from this study show that APP, used as a marker of early axonal damage in HAM/TSP lesions, is more intensively expressed in areas of active-inflammatory lesions than those of inactive-chronic lesions. The close localization to the areas containing inflammation (activation of macrophage/microglia) is striking and suggests that axonal damage is closely associated with inflammation in active-chronic lesions. Although inflammatory cell infiltration in the central nervous system (CNS) is rarely found in inactive-chronic lesions, a few clusters of APP+ axons are found in the spinal cord white matter in some cases. The presence of APP+ axons without relation to inflammatory cells in inactive-chronic lesions, suggest that soluble neurotoxic factors might induce axonal changes in the CNS of HAM/TSP. The occasional myelinated fibers in the anterior and posterior spinal roots in lower thoracic to lumbar levels had APP+ axons, suggesting that spinal nerve roots can be affected in HAM/TSP, especially in lower thoracic to lumbar levels. Impairment of fast axonal transport may contribute to the development of disability in patients with HAM/TSP. (C) 2000 Elsevier Science B.V. All rights reserved.	Kagoshima Univ, Sch Med, Dept Internal Med 3, Kagoshima 890, Japan; Kagoshima Univ, Chron Viral Dis Res Ctr, Div Mol Pathol, Kagoshima 890, Japan	Umehara, F (corresponding author), Kagoshima Univ, Sch Med, Dept Internal Med 3, Sakuragaoka 8-35-1, Kagoshima 890, Japan.						Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; AMARATUNGA A, 1995, J NEUROCHEM, V64, P2374; An SF, 1997, J NEUROPATH EXP NEUR, V56, P1262, DOI 10.1097/00005072-199711000-00011; ARIMURA K, 1995, MUSCLE NERVE, V18, P248, DOI 10.1002/mus.880180219; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; COCHRAN E, 1991, AM J PATHOL, V139, P485; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; GEHRMANN J, 1995, GLIA, V15, P141, DOI 10.1002/glia.440150206; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GESSAIN A, 1985, LANCET, V2, P407; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; GRIFFIN JW, 1987, J NEUROPATHOL EXP NE, V36, P214; IWASAKI Y, 1990, J NEUROL SCI, V96, P103, DOI 10.1016/0022-510X(90)90060-Z; Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016; KATAOKA A, 1993, J NEUROL NEUROSUR PS, V56, P1213, DOI 10.1136/jnnp.56.11.1213; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MOORE GRW, 1989, ANN NEUROL, V26, P523, DOI 10.1002/ana.410260405; Moritoyo T, 1996, ANN NEUROL, V40, P84, DOI 10.1002/ana.410400114; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; REFOLO LM, 1991, J NEUROSCI, V11, P3888; Sasaki S, 1999, ACTA NEUROPATHOL, V97, P463, DOI 10.1007/s004010051015; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Tsujino A, 1997, J NEUROIMMUNOL, V73, P191, DOI 10.1016/S0165-5728(96)00198-1; Umehara F, 1996, ACTA NEUROPATHOL, V91, P343, DOI 10.1007/s004010050435; UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P72, DOI 10.1097/00005072-199401000-00009; Umehara F, 1998, J NEUROPATH EXP NEUR, V57, P839, DOI 10.1097/00005072-199809000-00005; UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P617, DOI 10.1097/00005072-199411000-00009; UMEHARA F, 1993, J NEUROPATH EXP NEUR, V52, P424, DOI 10.1097/00005072-199307000-00010; UMEHARA F, 1990, ACTA NEUROPATHOL, V80, P563, DOI 10.1007/BF00294621	34	36	36	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUN 15	2000	176	2					95	101		10.1016/S0022-510X(00)00324-5			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	350BP	WOS:000089081100003	10930590				2021-06-18	
J	Hoffman, SW; Rzigalinski, BA; Willoughby, KA; Ellis, EF				Hoffman, SW; Rzigalinski, BA; Willoughby, KA; Ellis, EF			Astrocytes generate isoprostanes in response to trauma or oxygen radicals	JOURNAL OF NEUROTRAUMA			English	Article						antioxidants; cultured astrocytes; deferoxamine; 8-epi-prostaglandin; hydroxyl radical; lipid peroxidation; trauma	STRETCH-INDUCED INJURY; BRAIN INJURY; SUPEROXIDE-DISMUTASE; ARACHIDONIC-ACID; PROSTAGLANDINS; CELLS; NONCYCLOOXYGENASE; METABOLISM; RECOVERY; F2-ALPHA	Previous studies have shown that oxygen radical scavengers prevent the reduced cerebral blood flow that occurs following experimental traumatic brain injury. The exact chemical species responsible for the posttraumatic reduction in flow is unknown. We tested whether isoprostanes, which are formed by non-cyclooxygenase-dependent free radical attack of arachidonic acid and are vasoconstrictors of the cerebral circulation, are increased in astrocytes following stretch-induced trauma or injury with a free radical generating system. Isoprostane (8-epi-prostaglandin F-2 alpha) was analyzed in cells and in media by immunoassay, Confluent rat cortical astrocytes in culture were injured by a hydroxyl radical generating system consisting of hydrogen peroxide and ferrous sulfate or by rapid stretch of astrocytes grown on a deformable silastic membrane. Some cells were treated with the iron chelator deferoxamine for 1 h before injury. The hydroxyl generating system caused free and cell-bound isoprostanes to increase to more than 400% of control. After trauma, free and membrane bound isoprostanes increased to 321 +/- 34% and 229 +/- 23% of control, respectively, and posttraumatic increases were prevented by deferoxamine. Since astrocytes are in close proximity to cerebral vessels, posttraumatic free radical formation may increase the formation of isoprostanes, which in turn produce vasoconstriction and decrease cerebral blood flow.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Ellis, EF (corresponding author), Box 980613,MCV Stn, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214, NS-07288] Funding Source: Medline		AHMED SM, 2000, IN PRESS J NEUROCHEM; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Aoshima H, 1997, BBA-LIPID LIPID MET, V1345, P35, DOI 10.1016/S0005-2760(96)00159-2; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; Ferrari R, 1996, J CARDIOVASC PHARM, V28, pS1; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619; Hall CB, 1993, CONT PEDIAT, V10, P92; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; KAYGANICHHARRISON KA, 1993, J LIPID RES, V34, P1229; Lamb RG, 1997, J NEUROCHEM, V68, P1904; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mobert J, 1997, J CARDIOVASC PHARM, V29, P789, DOI 10.1097/00005344-199706000-00012; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MORRIS HC, 1992, THEOR PSYCHOL, V2, P89, DOI 10.1177/0959354392021005; MORROW JD, 1991, ADV PROSTAG THROMB L, V21, P125; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Schapira AHV, 1996, CURR OPIN NEUROL, V9, P260, DOI 10.1097/00019052-199608000-00003; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	29	36	38	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2000	17	5					415	420		10.1089/neu.2000.17.415			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	316BB	WOS:000087146500004	10833060				2021-06-18	
J	Grandas, OH; Klar, M; Goldman, MH; Filston, HC				Grandas, OH; Klar, M; Goldman, MH; Filston, HC			Deep venous thrombosis in the pediatric trauma population: an unusual event: Report of three cases	AMERICAN SURGEON			English	Article; Proceedings Paper	67th Annual Meeting of the Southeastern Surgical Congress	FEB 13-17, 1999	TAMPA, FLORIDA	SE Surg Congress			ACTIVATED PROTEIN-C; VEIN THROMBOSIS; PULMONARY-EMBOLISM; RISK-FACTORS; THROMBOEMBOLIC COMPLICATIONS; CHILDREN; RESISTANCE; DIAGNOSIS; ADOLESCENTS; PROPHYLAXIS	The incidence of deep venous thrombosis (DVT) in the pediatric population has been reported to be lower than in adults. Pediatric trauma patients have predisposing risk factors for DVT similar to those in the general trauma population, We reviewed the records of 2746 children under 16 years of age admitted to our Level I pediatric trauma service from 1989 to 1997. Only three cases of DVT were documented, all adolescents. DVT was located in the upper (n = 1) and lower (n = 1) extremity venous system. One patient presented with pulmonary embolism alone without identifiable DVT. Risk factors found were venous system manipulations, including atriocaval shunt, subclavian central line, and hyperinflated medical antishock trousers garment. Therapy consisted of heparin followed by warfarin anticoagulation, A vena cava filter was inserted in one patient for whom systemic anticoagulation was contraindicated, No DVT was seen in 1123 closed head injury patients or 29 spinal cord injury patients without associated risk factors, The thrombotic risk in pediatric trauma patients is low. Routine screening or prophylaxis is not indicated except for patients who are likely to remain immobile for an extended period of time and require prolonged rehabilitation, have venous manipulations, or present with clinical symptoms. Hematologic evaluation in patients with diagnosed DVT is necessary to identify individual risk factors.	Univ Tennessee, Med Ctr, Div Pediat Surg, Knoxville, TN 37920 USA; Univ Tennessee, Med Ctr, Dept Surg, Div Vasc Surg, Knoxville, TN 37920 USA; Univ Tennessee, Grad Sch Med, Dept Surg, Knoxville, TN USA	Grandas, OH (corresponding author), Univ Tennessee, Med Ctr, Dept Surg, Div Vasc Surg, Box U-11,1924 Alcoa Highway, Knoxville, TN 37920 USA.						ANDREW M, 1994, BLOOD, V83, P1251, DOI 10.1182/blood.V83.5.1251.1251; BERMAN D A, 1989, Pediatric Emergency Care, V5, P102; BERNSTEIN D, 1986, AM J DIS CHILD, V140, P667, DOI 10.1001/archpedi.1986.02140210065028; BLANCO A, 1994, AM J HEMATOL, V45, P330, DOI 10.1002/ajh.2830450411; Britt LD, 1996, AM J SURG, V172, P13, DOI 10.1016/S0002-9610(96)00079-7; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; Criado E, 1997, SURGERY, V122, P578, DOI 10.1016/S0039-6060(97)90131-8; CROYLE PH, 1979, JAMA-J AM MED ASSOC, V241, P827, DOI 10.1001/jama.241.8.827; Dahlback B, 1996, HAEMOSTASIS, V26, P301; DAVID M, 1995, THROMB HAEMOSTASIS, V74, P791; DAVID M, 1993, J PEDIATR-US, V123, P337, DOI 10.1016/S0022-3476(05)81730-5; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; HORATTAS MC, 1988, SURGERY, V104, P561; Kahn SR, 1998, ARCH INTERN MED, V158, P2315, DOI 10.1001/archinte.158.21.2315; MancoJohnson MJ, 1997, THROMB HAEMOSTASIS, V78, P710; MCBRIDE WJ, 1994, J TRAUMA, V37, P913, DOI 10.1097/00005373-199412000-00007; MEYER CS, 1995, ANN VASC SURG, V9, P109, DOI 10.1007/BF02015324; NGUYEN LT, 1986, J PEDIATR SURG, V21, P640, DOI 10.1016/S0022-3468(86)80422-5; PETAJA J, 1995, J PEDIATR-US, V127, P103, DOI 10.1016/S0022-3476(95)70266-0; Petaja J, 1997, J CARDIOTHOR VASC AN, V11, P889, DOI 10.1016/S1053-0770(97)90129-4; RADECKI RT, 1994, ARCH PHYS MED REHAB, V75, P248, DOI 10.1016/0003-9993(94)90023-X; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; Rohrer MJ, 1996, J VASC SURG, V24, P46, DOI 10.1016/S0741-5214(96)70143-X; Rosendaal FR, 1997, THROMB HAEMOSTASIS, V78, P1; Satiani B, 1997, ANN VASC SURG, V11, P626, DOI 10.1007/s100169900101; Schulman S, 1997, THROMB HAEMOSTASIS, V78, P693; SOBUS KM, 1994, ARCH PHYS MED REHAB, V75, P362, DOI 10.1016/0003-9993(94)90044-2; SOBUS KM, 1993, ARCH PHYS MED REHAB, V74, P547, DOI 10.1016/0003-9993(93)90123-R; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TRACY T, 1988, J PEDIATR SURG, V23, P529, DOI 10.1016/S0022-3468(88)80362-2; vonScheven E, 1996, J PEDIATR-US, V129, P339, DOI 10.1016/S0022-3476(96)70064-1; ZIONTS LE, 1983, J BONE JOINT SURG AM, V65, P839, DOI 10.2106/00004623-198365060-00018	32	36	36	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	MAR	2000	66	3					273	276					4	Surgery	Surgery	298EZ	WOS:000086127500013	10759198				2021-06-18	
J	Al-Noori, S; Swann, JW				Al-Noori, S; Swann, JW			A role for sodium and chloride in kainic acid-induced beading of inhibitory interneuron dendrites	NEUROSCIENCE			English	Article						varicose swellings; explant cultures; kainate; excitotoxicity; glutamate; sodium channels	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; RAT HIPPOCAMPUS; RECEPTOR ACTIVATION; PYRAMIDAL NEURONS; IONIC DEPENDENCE; IN-VITRO; GLUTAMATE; NEUROTOXICITY	Excitotoxic injury of the dendrites of inhibitory interneurons could lead to decreases in their synaptic activation and explain subsequent local circuit hyperexcitability and epilepsy. A hallmark of dendrotoxicity, at least in principal neurons of the hippocampus and cortex, is focal or varicose swellings of dendritic arbors. In experiments reported here, transient (1 h) exposure of hippocampal explant cultures to kainic acid produced marked focal swellings of the dendrites of parvalbumin-immunoreactive pyramidal basket cells in a highly reproducible and dose-dependent manner. AL 5 mM kainic acid, more than half of the immunopositive apical dendrites in area CA, had a beaded appearance, However, the somal volumes of these cells were unaltered by the same treatment. The presence of focal swellings was reversible with kainate washout and was not accompanied by interneuronal cell death. In contrast, exposure to much higher concentrations (300 mM) of kainic acid resulted in the total loss of parvalbumin-positive interneurons from explants. Surprisingly, kainic acid-induced dendritic beading does not appear to be mediated by extracellular calcium. Beading was unaltered in the presence of N-methyl-D-aspartate receptor antagonists, the L-type calcium channel antagonist, nimodipine, cadmium, or by removing extracellular calcium. However, blockade of voltage-gated sodium channels by either tetrodotoxin or lidocaine abolished dendritic beading, while the activation of existing voltage-gated sodium channels by veratridine mimicked the kainic acid-induced dendritic beading. Finally, the removal of extracellular chloride prevented the kainic acid-induced dendritic beading. Thus, we suggest that the movement of Na+ and Cl-, rather than Ca2+, into cells underlies the focal swellings of interneuron dendrites in hippocampus, (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Baylor Coll Med, Cain Fdn Labs, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Swann, JW (corresponding author), Baylor Coll Med, Cain Fdn Labs, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS18309, NS37171] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037171, R01NS018309] Funding Source: NIH RePORTER		ALNOORI S, 1998, NEUR ABSTR, V24, P1933; ALNOORI S, 2000, IN PRESS NEUR ABSTR; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; Bernard C, 1998, EPILEPSY RES, V32, P93, DOI 10.1016/S0920-1211(98)00043-6; BEST N, 1993, NEUROSCI LETT, V155, P1, DOI 10.1016/0304-3940(93)90660-D; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Colbert CM, 1996, J NEUROSCI, V16, P6676; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.physiol.58.1.349; Faddis BT, 1997, J NEUROSCI, V17, P951; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; FROTSCHER M, 1995, PROG NEUROBIOL, V45, P143, DOI 10.1016/0301-0082(94)00040-O; HAUSER WA, 1984, EPILEPSIA, V25, P666; HILLE B, 1984, CALCIUM CHANNELS ION; Inglefield JR, 1997, HIPPOCAMPUS, V7, P511, DOI 10.1002/(SICI)1098-1063(1997)7:5<511::AID-HIPO7>3.3.CO;2-V; Isokawa M, 1997, J NEUROPHYSIOL, V77, P3355; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; KATO K, 1991, J PHARMACOL EXP THER, V256, P402; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Martina M, 2000, SCIENCE, V287, P295, DOI 10.1126/science.287.5451.295; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; OBENAUS A, 1993, J NEUROSCI, V13, P4470; OLNEY JW, 1979, BRAIN RES, V176, P91, DOI 10.1016/0006-8993(79)90872-2; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Paul L A, 1986, Adv Neurol, V44, P775; PURPURA DP, 1982, DEV BRAIN RES, V5, P287, DOI 10.1016/0165-3806(82)90128-6; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; SIMAN R, 1989, J NEUROSCI, V9, P1579; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; SLOVITER RS, 1985, BRAIN RES BULL, V15, P39, DOI 10.1016/0361-9230(85)90059-0; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; STARMER CF, 1984, BIOPHYS J, V46, P15, DOI 10.1016/S0006-3495(84)83994-6; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Zhang YL, 1999, J NEUROSCI, V19, P3307	46	36	36	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	101	2					337	348		10.1016/S0306-4522(00)00384-5			12	Neurosciences	Neurosciences & Neurology	378BX	WOS:000165562800009	11074157				2021-06-18	
J	Marsigny, B; Lecoq-Jammes, F; Cauchy, E				Marsigny, B; Lecoq-Jammes, F; Cauchy, E			Medical mountain rescue in the Mont-Blanc massif	WILDERNESS & ENVIRONMENTAL MEDICINE			English	Article						mountaineering; multiple trauma; brain concussion; hypothermia; lightning; rescue work; air ambulance	INJURY	Because of its peculiar geographic location beneath Mont-Blanc, the Chamonix Hospital plays an important role in the management of mountaineering- and skiing-related traumatic injuries. The authors. thanks to the study of 5200 mountain rescue medical reports, set out to explain the different aspects of this activity: epidemiology, specific equipment, care in the field. reception and primary survey, dispatching, common therapeutic attitudes, progress, and results. In the dangerous environment of the high mountains, emphasis is put on the physicians' experience, allowing an early evacuation in the best conditions to the hospital. Diagnosis at the scene of the accident is very basic, and the initial treatment is based on immobilization, analgesia, and sedating. In the case of resuscitation, only the vital maneuvers are performed. these actions are carried on during the short flight and improved in the crash rooms. Finally, different specific pathologies are mentioned, including cold- or heat-related injuries, exhaustion, lightning strikes, and mountain sickness.	Hosp Chamonix, Emergency Unit, F-74400 Les Bossons, Chamonix, France	Marsigny, B (corresponding author), Hosp Chamonix, Emergency Unit, 509 Route Pelerins,BP 30, F-74400 Les Bossons, Chamonix, France.						DEMARTINES N, 1991, HELV CHIR ACTA, V58, P223; DURRER B, 1993, THER UMSCH, V30, P228; FORAY J, 1982, CHIRURGIE, V108, P724; Koizumi T, 1996, J SPORT MED PHYS FIT, V36, P72; MAIR P, 1997, INT J INTENSIVE CARE, V3, P20; MALACRIDA RL, 1993, INJURY, V24, P451, DOI 10.1016/0020-1383(93)90147-X; MARTINEZ JY, 1995, THESIS LYON I U FRAN; MCLENNAN JG, 1983, AM J SPORT MED, V11, P160, DOI 10.1177/036354658301100310; Meier R, 1993, Z Unfallchir Versicherungsmed, VSuppl 1, P85; MOESCHLER O, 1992, J TRAUMA, V33, P754, DOI 10.1097/00005373-199211000-00027; Philadelphy M, 1991, Fortschr Kiefer Gesichtschir, V36, P43; RANE A, 1989, 7 JOURN NAC MED MONT, P75; REID WA, 1986, J CLIN PATHOL, V39, P1217, DOI 10.1136/jcp.39.11.1217; Rousseau JM, 1997, ANN FR ANESTH, V16, P885, DOI 10.1016/S0750-7658(97)89838-3; STERETT WI, 1994, J ORTHOP TRAUMA, V8, P310, DOI 10.1097/00005131-199408000-00006	15	36	36	0	2	WILDERNESS MEDICAL SOC	COLORADO SPRINGS	3595 E FOUNTAIN BLVD, STE A1, COLORADO SPRINGS, CO 80910 USA	1080-6032			WILD ENVIRON MED	Wildern. Environ. Med.	FAL	1999	10	3					152	156		10.1580/1080-6032(1999)010[0152:MMRITM]2.3.CO;2			5	Public, Environmental & Occupational Health; Sport Sciences	Public, Environmental & Occupational Health; Sport Sciences	252CR	WOS:000083483600004	10560308	Bronze			2021-06-18	
J	Slavik, RS; Rhoney, DH				Slavik, RS; Rhoney, DH			Indomethacin: A review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients	NEUROLOGICAL RESEARCH			English	Article						indomethacin; intracranial pressure; traumatic brain injury; cerebral blood flow; cerebral perfusion pressure; non-steroidal anti-inflammatory agent	SEVERE HEAD-INJURY; CARBON-DIOXIDE REACTIVITY; PATENT DUCTUS-ARTERIOSUS; HEALTHY-VOLUNTEERS; INTENSIVE MANAGEMENT; AGGRESSIVE TREATMENT; PREMATURE-INFANTS; HYPERTENSION; METABOLISM; HYPOTHERMIA	Traumatic brain injury (TBI) causes about 75,000 deaths and leaves approximately 200,000 people disabled in USA each year. Brain swelling and increased intracranial pressure (ICP) contribute to this morbidity and mortality. Aggressive management protocols,including ICP control, have been shown to reduce the overall mortality from 50% to 36% following severe head injury. Despite these encouraging results, new and improved pharmacologic strategies to control ICP are required. Indomethacin (IND) is a non-steroidal anti-inflammatory agent with unique effects on cerebral blood flow physiology which may be of benefit in reducing elevated ICP in TBI patients. Data from animal models and randomized, controlled studies with pre-term infants have shown that i.v. IND produces rapid, significant reductions in cerebral blood flow (CBF). Controlled studies of i.v. IND in normal volunteers show a reduction in CBF from 26%-40%. Case series involving severe TBI patients suggest that IND i.v. boluses of 30-50 mg reduce ICP by 37%-52%, reduce CBF by 22%-26%, with a modest 14% increase in cerebral perfusion pressure (CPP). Despite these encouraging results, i.v. IND should only be considered an experimental treatment for control of refractory ICP in TBI patients. Larger, well-designed randomized trials in TBI patients will provide more efficacy and safety data and delineate the effects of IND alone or in combination with other proven, effective, or experimental therapies. Once these concerns have been addressed, larger outcome studies will ultimately be needed to determine the role of IND for ICP control in TBI patients.	Wayne State Univ, Detroit Receiving Hosp & Univ Hlth Ctr, Dept Pharm Serv, Coll Pharm, Detroit, MI 48201 USA; Wayne State Univ, Coll Pharm & Allied Hlth Profess, Dept Pharm Practice, Detroit, MI 48201 USA; Vancouver Hosp & Hlth Sci Ctr, Dept Pharmaceut Sci, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada	Rhoney, DH (corresponding author), Wayne State Univ, Detroit Receiving Hosp & Univ Hlth Ctr, Dept Pharm Serv, Coll Pharm, 4201 St Antoine, Detroit, MI 48201 USA.						Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; BOREL C, 1990, CHEST, V98, P180, DOI 10.1378/chest.98.1.180; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Cold GE, 1996, ANESTHESIOLOGY, V85, P1499; COWAN F, 1986, J PEDIATR-US, V109, P341, DOI 10.1016/S0022-3476(86)80398-5; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dahl B, 1996, ACTA NEUROCHIR, V138, P265, DOI 10.1007/BF01411736; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; ERIKSSON S, 1983, GEN PHARMACOL, V14, P179, DOI 10.1016/0306-3623(83)90096-4; EVANS DH, 1987, DEV MED CHILD NEUROL, V29, P776; FRIEDMAN PL, 1981, NEW ENGL J MED, V305, P1171, DOI 10.1056/NEJM198111123052002; HAMMERMAN C, 1995, PEDIATRICS, V95, P244; Jensen K, 1996, J NEUROSURG ANESTH, V8, P111, DOI 10.1097/00008506-199604000-00002; JENSEN K, 1993, ACTA NEUROCHIR, V124, P114, DOI 10.1007/BF01401132; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; KRAAIER V, 1992, ELECTROEN CLIN NEURO, V82, P208, DOI 10.1016/0013-4694(92)90169-I; KRISCH JR, 1986, ARCH INTERN MED, V146, P1415; Luer MS, 1996, PHARMACOTHERAPY, V16, P830; MARDOUM R, 1991, J PEDIATR-US, V118, P112, DOI 10.1016/S0022-3476(05)81860-8; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARKUS HS, 1994, STROKE, V25, P1760, DOI 10.1161/01.STR.25.9.1760; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Monro Alexander, 1783, OBSERVATIONS STRUCTU; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NITTER WH, 1995, PHARMACOLOGY, V51, P48, DOI 10.1159/000139316; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PICKARD JD, 1973, NATURE-NEW BIOL, V245, P187; PICKLES H, 1984, J NEUROL NEUROSUR PS, V47, P51, DOI 10.1136/jnnp.47.1.51; PRYDS O, 1988, EUR J PEDIATR, V147, P315, DOI 10.1007/BF00442705; QUANDT CM, 1984, DRUG INTEL CLIN PHAR, V18, P105, DOI 10.1177/106002808401800203; SAKABE T, 1979, ACTA PHYSIOL SCAND, V107, P283, DOI 10.1111/j.1748-1716.1979.tb06476.x; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Simko A, 1994, J Perinatol, V14, P29; THERKELSEN K, 1994, SCAND J CLIN LAB INV, V54, P441, DOI 10.3109/00365519409085468; WENNMALM A, 1981, CLIN PHYSIOL, V1, P227, DOI 10.1111/j.1475-097X.1981.tb00891.x; WENNMALM A, 1984, ARCH TOXICOL, P350	46	36	37	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	1999	21	5					491	499					9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	218JU	WOS:000081550100010	10439431				2021-06-18	
J	Schurr, MJ; Ebner, KA; Maser, AL; Sperling, KB; Helgerson, RB; Harms, B				Schurr, MJ; Ebner, KA; Maser, AL; Sperling, KB; Helgerson, RB; Harms, B			Formal swallowing evaluation and therapy after traumatic brain injury improves dysphagia outcomes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	58th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Trauma-Association-of-Canada	SEP 24-26, 1998	BALTIMORE, MARYLAND	Amer Assoc Surg Trauma, Trauma Assoc Canada		speech pathology; aspiration pneumonia; videofluoroscopic swallow study; closed head injury		Background: The incidence of swallowing dysfunction after brain injury is unknown. The efficacy of dysphagia therapy is also unknown. We reviewed our experience to define the incidence of swallowing dysfunction and efficacy of therapeutic intervention, Methods: Patients with brain injury sustained between January of 1996 and December of 1997 were reviewed. All were screened with trials of oral intake. Abnormal findings were confirmed with a videofluoroscopic swallow study. Standard therapies included diet, posture, and behavior modifications. Results: A total of 47 patients were evaluated. Bedside evaluations were normal in 14 patients, 2 patients had overt aspiration and underwent gastrostomy, and 31 patients were referred for a videofluoroscopic swallow study (66%), The videofluoroscopic swallow study was abnormal in 22 of 31 patients (71%). Of these, 4 additional patients required gastrostomy, 13 patients had laryngeal penetration or minor aspiration responsive to dysphagia therapy and were fed. Five other patients had silent aspiration and were fed by means of nasogastric tube; these five patients responded to dysphagia therapy and were able to resume oral intake. Conclusion: Dysphagia is common after severe head injury. With formal swallowing service intervention, aspiration is avoided. Therapeutic interventions can be used to restore oral intake.	Univ Wisconsin Hosp, Dept Surg, Madison, WI 53792 USA; Univ Wisconsin Hosp, Swallowing Serv, Madison, WI 53792 USA; Univ Wisconsin Hosp, Dept Rehabil Med, Madison, WI 53792 USA	Schurr, MJ (corresponding author), Univ Wisconsin Hosp, Dept Surg, 600 Highland Ave, Madison, WI 53792 USA.						Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; DELARMINAT V, 1995, CRIT CARE MED, V23, P486, DOI 10.1097/00003246-199503000-00012; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Kaye GM, 1997, ANN OTO RHINOL LARYN, V106, P705, DOI 10.1177/000348949710600817; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; Logemann JA, 1997, OTOLARYNG HEAD NECK, V116, P335, DOI 10.1016/S0194-5998(97)70269-9; LOGEMANN JA, 1989, J HEAD TRAUMA REHAB, V4, P24; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167	9	36	40	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1999	46	5					817	821		10.1097/00005373-199905000-00009			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	196EA	WOS:000080295000017	10338398				2021-06-18	
J	Skele, A; Schwartz, O				Skele, A; Schwartz, O			Traumatic injuries of the teeth in connection with general anaesthesia and the effect of use of mouthguards	ENDODONTICS & DENTAL TRAUMATOLOGY			English	Article						endoscopy; incidence; intubation; mouthguards; traumatic injuries	TRACHEAL INTUBATION; COMPLICATIONS	The aim of the present study was to describe the frequency of dental injuries over a 10-year period, where a mouthguard was used in approximately 10% of intubation cases or endoscopying. The types of injury are presented and the use of different types of mouthguard is discussed. Among 120086 procedures involving anaesthesia carried out in the period 1983-1992 at Bispebjerg Hospital, Copenhagen, 75 cases of dental trauma occurred. The incidence of dental traumatic injuries was 0.06%. Although eight patients had used mouthguards they were registered with traumatic injuries to the teeth in connection with general anaesthesia. Of the patients, 58% were women and 42% men, with a mean age of 61 years. Seventy-eight percent of the injuries were located in the maxilla and 91% of these involved the incisor area of the maxilla. Forty-one percent were classified as lateral luxations or mobile teeth, 47% were classified as fractured teeth, 10% tooth avulsions and the remaining 2% were classified as concussions. Because of the low frequency of traumatic dental injuries in connection with general anaesthesia and the non-significant effect of the use of mouthguards, routine use of mouthguards is not recommended. Only when a patient is to have an endoscopy done under general anaesthesia, and the surgeon or anaesthesiologist foresees problems (restricted mouth opening, extensive fixed prosthetics, extensive loss of marginal bone) is use of an individually made mouthguard indicated.	Copenhagen Hosp Corp, Rigshosp, Ctr Head & Orthopaed, Dept Oral & Maxillofacial Surg, DK-2100 Copenhagen, Denmark; Bispebjerg Hosp, Dept Oral & Maxillofacial Surg, DK-2400 Copenhagen, Denmark	Skele, A (corresponding author), Copenhagen Hosp Corp, Rigshosp, Ctr Head & Orthopaed, Dept Oral & Maxillofacial Surg, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.						Andreasen JO., 1994, TXB COLOR ATLAS TRAU, V3; BAMFORTH BJ, 1963, ANESTH ANALG, V42, P727; BLANC VF, 1974, ANESTH ANALG, V53, P202; BONSING E, 1976, UGESKRIFT LAEGER, V5, P278; BUNKER PG, 1962, ANN OTO RHINOL LARYN, V71, P1073, DOI 10.1177/000348946207100421; DAVIS FO, 1971, ANESTH ANAL CURR RES, V50, P203; Evers W, 1967, Can Anaesth Soc J, V14, P123, DOI 10.1007/BF03003633; GRONDAHL H, 1974, GOTEBORGS TANDLAKAR, V384, P38; HAGELSTEN J O, 1968, Nordisk Medicin, V80, P1717; HENRY PJ, 1964, J AM DENT ASSOC, V68, P569, DOI 10.14219/jada.archive.1964.0140; HENRY PJ, 1969, MED J AUSTRALIA, V1, P911, DOI 10.5694/j.1326-5377.1969.tb49783.x; HYDO M, 1971, MASUI, V20, P1064; LOCKHART PB, 1986, J AM DENT ASSOC, V112, P480, DOI 10.14219/jada.archive.1986.0035; MCCARTHY G, 1977, ACTA OTO-LARYNGOL, V84, P450, DOI 10.3109/00016487709123991; NOYEK AM, 1976, J OTOLARYNGOL, V5, P468; POWELL JB, 1965, ANESTH ANAL CURR RES, V44, P357; ROSENBERG M, 1968, ANESTH ANAL CURR RES, V47, P34; WASMUTH C E, 1956, Cleve Clin Q, V23, P32; WASMUTH C E, 1960, Anesth Analg, V39, P138; Wright R B, 1974, Anesth Analg, V53, P405	20	36	38	0	2	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0109-2502			ENDOD DENT TRAUMATOL	Endod. Dent. Traumatol.	FEB	1999	15	1					33	36					4	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	161FP	WOS:000078278800006	10219152				2021-06-18	
J	Iverson, GL; Franzen, MD; Lovell, MR				Iverson, GL; Franzen, MD; Lovell, MR			Normative comparisons for the controlled Oral Word Association Test following acute traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS	The Controlled Oral Word Association Test (COWAT) is widely used in clinical neuropsychology as a measure of verbal fluency. It is important for psychologists to realize that using the recently published normative data will result in different clinical conclusions because the updated normative sample performed better than the original normative sample. The purpose of this study was to compare the original and updated norms in a large sample of patients with acute traumatic brain injuries (N=669). The percentages of patients who scored below the 5th centile in each system varied as a function of brain injury severity. Moreover, a substantially larger number of patients scored in the impaired range according to the updated normative data.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2B4, Canada; Riverview Hosp, Neuropsychiat Unit, Vancouver, BC, Canada; Allegheny Gen Hosp, Dept Psychiat, Pittsburgh, PA 15212 USA; Henry Ford Hosp, Div Behav Sci, Detroit, MI USA; Henry Ford Hosp, Neuropsychiat Unit, Detroit, MI USA; Allegheny Gen Hosp, Neuropsychiat Unit, Pittsburgh, PA 15212 USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2B4, Canada.			Iverson, Grant/0000-0001-7348-9570			BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; BENTON AL, 1994, MULTLINGUAL APHASIA; DLATON JE, 1986, VA PRACTITIONER, P37; Hart R P, 1988, Arch Clin Neuropsychol, V3, P313, DOI 10.1016/0887-6177(88)90044-3; Jones R. D., 1992, NEUROPSYCHOLOGY, V6, P13; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; PEYSER JM, 1990, ARCH NEUROL-CHICAGO, V47, P94, DOI 10.1001/archneur.1990.00530010120030; RASKIN S A, 1990, Neuropsychology Review, V1, P185, DOI 10.1007/BF01112571; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; SKORASZEWSKI MJ, 1991, J CLIN EXP NEUROPSYC, V13, P278, DOI 10.1080/01688639108401043; Smith-Seemiller L, 1996, Appl Neuropsychol, V3, P41, DOI 10.1207/s15324826an0301_6; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TOMBAUGH TN, 1998, COMPENDIUM NEUROPSYC, P453; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; YEUDALL LT, 1986, J CLIN PSYCHOL, V42, P918, DOI 10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2-Y	16	36	36	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		1999	13	4					437	441		10.1076/1385-4046(199911)13:04;1-Y;FT437			5	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	310PP	WOS:000086836800007	10806456				2021-06-18	
J	Alexeeva, N; Broton, JG; Calancie, B				Alexeeva, N; Broton, JG; Calancie, B			Latency of changes in spinal motoneuron excitability evoked by transcranial magnetic brain stimulation in spinal cord injured individuals	ELECTROMYOGRAPHY AND MOTOR CONTROL-ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						H-reflex; transcranial magnetic stimulation; spinal cord injury; human; central motor conduction	MOTOR CORTEX STIMULATION; LOWER-LIMB MOTONEURONS; ELECTRICAL-STIMULATION; PRESYNAPTIC INHIBITION; MULTIPLE-SCLEROSIS; H-REFLEXES; INTACT MAN; CONDUCTION; MUSCLE; DEMYELINATION	Objectives: To examine the basis for delay in the excitatory effects of transcranial magnetic stimulation (TMS) of motor cortex on motoneuron pools of muscles left partially-paralyzed by traumatic spinal cord injury (SCI). Methods: The effect of subthreshold transcranial magnetic stimulation (TMS) on just-suprathreshold H-reflex amplitude was examined in subjects (n = 10) with incomplete cervical SCI, and in able-bodied (AB) subjects (n = 20) for comparison. EMG activity was recorded from the soleus and the abductor hallucis muscles, and H-reflex was elicited by stimulation of the tibial nerve behind the knee. Comparison of the peak-to-peak amplitude of the TMS-conditioned H-reflex to that of the H-reflex alone (i.e. unconditioned H-reflex) was made for different conditioning-test intervals with multivariate analysis of variance and (when called for) t testing. Results: The absolute latencies of motor responses to suprathreshold TMS delivered during a weak voluntary contraction of the soleus and abductor hallucis were significantly prolonged in the SCI group relative to AB subjects. For the TMS-conditioned H-reflex, the timecourse effect of TMS on the H-reflex amplitude in different AB subjects included an early effect (typically facilitation, but occasionally inhibition) seen between -5 and 0 ms, followed by a later period (i.e. >5 ms) of H-reflex facilitation. In contrast, the earliest indication of a TMS effect on H-reflex excitability in SCT subjects was between 5 and 10 ms after TMS. This difference between SCI and AB subjects of approximately 10 ms was similar to the prolongation of TMS-evoked response latencies in the soleus and the abductor hallucis muscles of the SCI subjects. Conclusions: The results suggest that motor conduction slowing after traumatic SCI most likely occurs across the population of the descending tract axons mediating the TMS-evoked motor responses. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Calancie, B (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, 1600 NW 10th Ave,R-48, Miami, FL 33136 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036542] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS36542] Funding Source: Medline		ADVANI A, 1990, CAN J PHYSIOL PHARM, V68, P1231, DOI 10.1139/y90-185; Alexeeva N, 1997, EXP NEUROL, V148, P399, DOI 10.1006/exnr.1997.6689; ALEXEEVA N, 1997, P INT S BRAIN MOV ST, P21; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; BROUWER B, 1992, EXP BRAIN RES, V89, P649; BROUWER B, 1992, J NEUROL NEUROSUR PS, V55, P20, DOI 10.1136/jnnp.55.1.20; BUNGE RP, 1993, ADV NEUROL, V59, P75; BURKE D, 1993, J PHYSIOL-LONDON, V470, P383, DOI 10.1113/jphysiol.1993.sp019864; CALANCIE B, 1993, ELECTROEN CLIN NEURO, V89, P177, DOI 10.1016/0168-5597(93)90131-8; Calancie Blair, 1995, Journal of Neurotrauma, V12, P361; CHANG CW, 1991, MUSCLE NERVE, V14, P990, DOI 10.1002/mus.880141010; CLARKE CE, 1994, PARAPLEGIA, V32, P554, DOI 10.1038/sc.1994.87; COWAN JMA, 1986, J PHYSIOL-LONDON, V377, P333, DOI 10.1113/jphysiol.1986.sp016190; Dimitrijevic M R, 1983, Adv Neurol, V39, P915; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; HAYES KC, 1992, ELECTROEN CLIN NEURO, V85, P102, DOI 10.1016/0168-5597(92)90075-M; ILES JF, 1992, J PHYSIOL-LONDON, V455, P425, DOI 10.1113/jphysiol.1992.sp019309; LEWKO JP, 1995, RESTOR NEUROL NEUROS, V7, P225, DOI 10.3233/RNN-1994-7405; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; NIELSEN J, 1995, J PHYSIOL-LONDON, V484, P777, DOI 10.1113/jphysiol.1995.sp020703; NIELSEN J, 1993, J PHYSIOL-LONDON, V471, P223, DOI 10.1113/jphysiol.1993.sp019899; NIELSEN J, 1995, J PHYSIOL-LONDON, V484, P791, DOI 10.1113/jphysiol.1995.sp020704; PRIORI A, 1993, ELECTROEN CLIN NEURO, V89, P131, DOI 10.1016/0168-5597(93)90095-7; QUENCER RM, 1992, NEURORADIOLOGY, V34, P85, DOI 10.1007/BF00588148; ROTHWELL JC, 1987, BRAIN, V110, P1173, DOI 10.1093/brain/110.5.1173; ROTHWELL JC, 1991, EXP PHYSIOL, V76, P159, DOI 10.1113/expphysiol.1991.sp003485; ROTHWELL JC, 1987, NEUROSURGERY, V20, P156; ROTHWELL JC, 1984, EXP BRAIN RES, V54, P382; THOMPSON PD, 1991, ELECTROEN CLIN NEURO, V81, P397, DOI 10.1016/0168-5597(91)90029-W; UGAWA Y, 1995, CAN J NEUROL SCI, V22, P36, DOI 10.1017/S0317167100040476; VALLSSOLE J, 1994, NEUROSCI LETT, V170, P149, DOI 10.1016/0304-3940(94)90261-5; VANDERKAMP W, 1991, ANN NEUROL, V29, P6, DOI 10.1002/ana.410290104; WAXMAN SG, 1994, PROG BRAIN RES, V100, P233; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; Wolfe DL, 1996, J NEUROTRAUM, V13, P281, DOI 10.1089/neu.1996.13.281	35	36	37	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0924-980X			ELECTROMYOGR MOTOR C	Electromyogr. Mot. Control-Electroencephalogr. Clin. Neurophysiol.	AUG	1998	109	4					297	303		10.1016/S0924-980X(98)00021-6			7	Engineering, Biomedical; Neurosciences	Engineering; Neurosciences & Neurology	116LA	WOS:000075725100003	9751291				2021-06-18	
J	Radomisli, TE; Rosen, AL				Radomisli, TE; Rosen, AL			Controversies regarding radial neck fractures in children	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							PERCUTANEOUS REDUCTION; ELBOW FRACTURES; FIXATION	Fractures of the radial neck in children are not uncommon, yet several aspects of their management remain controversial. Until a consensus is reached regarding the determination of displacement, acceptability of initial angulation, treatment, and outcome, the complication rate of these fractures will remain high. The authors recommend measuring the displacement as the angle between a line perpendicular to the articular surface of the radial head with a line down the shaft of the proximal radius. Fractures that are angulated less than 30 degrees require immobilization alone. Fractures angulated more than 30 degrees should be treated with an attempt at closed reduction, If closed reduction fails, a percutaneous reduction should be attempted before open reduction. Internal fixation should be performed using an oblique extraarticular Kirshner wire for all unstable fractures. Grading outcome based on range of motion and the presence or absence of pain is recommended. It is hoped that once the controversies surrounding these fractures are resolved, the long term results of these troublesome injuries will improve.	CUNY Mt Sinai Sch Med, Dept Orthopaed Surg, New York, NY 10029 USA	Radomisli, TE (corresponding author), CUNY Mt Sinai Sch Med, Dept Orthopaed Surg, Box 1188,1 Gustave L Levy Pl, New York, NY 10029 USA.						BERNSTEIN SM, 1993, J PEDIATR ORTHOPED, V13, P85, DOI 10.1097/01241398-199301000-00017; CREASMAN C, 1984, CLIN ORTHOP RELAT R, P40; DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P232; FAHEY J J, 1960, Instr Course Lect, V17, P13; FOWLES JV, 1986, J PEDIATR ORTHOPED, V6, P51; GASTON SR, 1953, AM J SURG, V85, P266, DOI 10.1016/0002-9610(53)90608-4; Green NE, 1994, SKELETAL TRAUMA CHIL, P213; HENRIKSON B, 1969, ACTA ORTHOP SCAND, V40, P246, DOI 10.3109/17453676908989505; JONES E R L, 1971, Journal of Bone and Joint Surgery British Volume, V53, P429; KAUFMAN B, 1989, J BONE JOINT SURG BR, V71, P66; LANDIN LA, 1986, ACTA ORTHOP SCAND, V57, P309, DOI 10.3109/17453678608994398; MCBRIDE ED, 1960, CLIN ORTHOP RELAT R, V16, P264; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; NUSSBAUM AJ, 1983, J TRAUMA, V23, P40, DOI 10.1097/00005373-198301000-00008; Ortega R, 1996, J PEDIATR ORTHOPED, V16, P651, DOI 10.1097/01241398-199609000-00019; PETERS CL, 1995, J BONE JOINT SURG AM, V77A, P1070, DOI 10.2106/00004623-199507000-00014; Praemer A, 1992, MUSCULOSKELETAL COND; RANG M, 1983, CHILDRENS FRACTURES, P182; REIDY JA, 1963, J BONE JOINT SURG AM, V45, P1355, DOI 10.2106/00004623-196345070-00002; Rodriguez-Merchan EC, 1991, ORTHOPEDICS, V14, P697; RODRIGUEZMERCHA.EC, 1994, J TRAUMA, V37, P812; Sharrard WJW, 1971, PAEDIATRIC ORTHOPAED, P972; SPONSELLER PD, 1994, HAND CLIN, V10, P495; STEELE JA, 1992, J BONE JOINT SURG BR, V74, P760; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; Tachdjian MO, 1990, PAEDIATRIC ORTHOPAED, P3137; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P100, DOI 10.2106/00004623-198163010-00013; VAHVANEN V, 1978, ACTA ORTHOP SCAND, V49, P32, DOI 10.3109/17453677809005720; WATSONJONES R, 1955, FRACTURES JOINT INJU, P515	29	36	38	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1998		353					30	39					10	Orthopedics; Surgery	Orthopedics; Surgery	113GH	WOS:000075541700005	9728157				2021-06-18	
J	Soustiel, JF; Bruk, B; Shik, B; Hadani, M; Feinsod, M				Soustiel, JF; Bruk, B; Shik, B; Hadani, M; Feinsod, M			Transcranial Doppler in vertebrobasilar vasospasm after subarachnoid hemorrhage	NEUROSURGERY			English	Article						basilar artery; head injury; subarachnoid hemorrhage; transcranial Doppler; vasospasm	CEREBRAL BLOOD-FLOW; HEAD-INJURY; ULTRASOUND; SONOGRAPHY; ULTRASONOGRAPHY; HEMODYNAMICS; ENDOTHELIN; VELOCITIES; ARTERIES; SPASM	OBJECTIVE: The primary objective of this study was to assess the incidence of vertebrobasilar vasospasm after subarachnoid hemorrhage (SAH) by means of transcranial Doppler ultrasonography and to evaluate the clinical significance of this phenomenon. The secondary objective was to analyze the different factors influencing the development, the severity, and the duration of vertebrobasilar vasospasm. METHODS: Fifty-seven patients with traumatic SAH and 44 patients with spontaneous SAH were evaluated and monitored by means of transcranial Doppler ultrasonography. Vasospasm of the anterior and middle cerebral arteries was defined by mean flow velocities (FVs) exceeding 120 cm per second and at least three times the FV of the internal carotid artery. Vasospasm of the basilar and vertebral arteries was defined by a mean FV exceeding 60 cm per second. RESULTS: Vasospasm of the anterior or middle cerebral arteries was found in 27 patients and was associated with vertebrobasilar spasm in 20 patients. FVs in anterior circulation vessels were neither related to the cause of the SAH nor did they correlate with the outcome. Forty-six patients (45.5%) had FVs exceeding 60 cm per second and 25 (24.8%) had FVs exceeding 85 cm per second. In 10 of these patients, direct or computed tomographic angiography showed arterial narrowing involving the vertebrobasilar system, whereas in 21 more patients, computed tomography disclosed a cerebral infarction involving the vertebrobasilar vascular territory. Vertebral artery FVs in this group were twice that of the ipsilateral carotid artery. Vertebrobasilar vasospasm was significantly more frequent after head injury, although it was not related to the type of intracranial lesion or the Glasgow Coma Scale score at admission. It did correlate, however, with outcome (P < 0.0001) and with the intensity of SAH (P < 0.0001). Delayed neurological deterioration occurred in 14 patients and was significantly more frequent in patients with basilar artery FVs above 85 cm per second (P < 0.001). Prognosis, however, could not be reliably predicted by FVs in the basilar artery, even when an FV of 110 cm per second was chosen for prediction criterion. CONCLUSION: These results suggest that vertebrobasilar vasospasm is more common than previously thought, especially in association with head injury, with which it may significantly contribute to brain stem ischemic lesions and therefore justify specific therapeutic measures.	Technion Israel Inst Technol, Rambam Maimonides Med Ctr, Dept Neurosurg, Brain Injury Appl Res Ctr, IL-31096 Haifa, Israel; Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Dept Neurosurg, IL-69978 Tel Aviv, Israel	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Maimonides Med Ctr, Dept Neurosurg, Brain Injury Appl Res Ctr, POB 9102, IL-31096 Haifa, Israel.						AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; ALEXANDER MJ, 1994, ACTA NEUROCHIR, P479; Barker F G 2nd, 1990, Neurosurg Clin N Am, V1, P277; CHUI M, 1983, NEUROSURGERY, V12, P542, DOI 10.1227/00006123-198305000-00011; ECHLIN FA, 1965, J NEUROSURG, V23, P1, DOI 10.3171/jns.1965.23.1.0001; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fujioka KA., 1992, TRANSCRANIAL DOPPLER, P9; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; HASSLER W, 1988, J NEUROSURG, V68, P745; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; LAUMER R, 1993, NEUROSURGERY, V33, P1, DOI 10.1227/00006123-199307000-00001; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; NEWELL DW, 1992, TRANSCRANIAL DOPPLER, P109; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; Sahs AL, 1969, INTRACRANIAL ANEURYS; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; SLOAN MA, 1994, STROKE, V25, P2187, DOI 10.1161/01.STR.25.11.2187; SMITH RR, 1985, NEUROSURGERY, P1355; STEINMEIER R, 1993, NEUROSURGERY, V33, P10; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Wozniak MA, 1996, J NEUROIMAGING, V6, P87, DOI 10.1111/jon19966287	29	36	38	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	1998	43	2					282	291		10.1097/00006123-199808000-00061			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	103VX	WOS:000074979500054	9696081				2021-06-18	
J	Hilsabeck, RC; Gouvier, WD; Bolter, JE				Hilsabeck, RC; Gouvier, WD; Bolter, JE			Reconstructive memory bias in recall of neuropsychological symptomatology	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SOCIAL SUPPORT; HEAD-INJURY; BASE RATES; DEPRESSION; SYMPTOMS; PERSPECTIVE; ETIOLOGY	Subjective recall of symptoms among nonlitigants with closed-head and back injuries and non-injured participants with high and low levels of life stressors was evaluated. All participants completed a demographic questionnaire, the Brief Symptom Inventory, and a symptom checklist. Recall of symptoms by participants with closed-head and back injuries was consistent with perceptions of being worse now than they were before their injuries. The results further suggest that these participants tend to overestimate the actual degree of change that has taken place by recalling fewer pre-injury symptoms than control participants. In addition, participants with closed-head injuries, but not with back injuries, showed significantly higher levels of symptom endorsement now than controls.	Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA; Neuromed Ctr, Baton Rouge, LA USA	Gouvier, WD (corresponding author), Louisiana State Univ, Dept Psychol, 236 Audubon Hall, Baton Rouge, LA 70803 USA.		Hilsabeck, Robin/ABC-5093-2020				BAHRICK HP, 1984, PHYSIOL PSYCHOL, V12, P53; BARCLAY CR, 1988, PRACTICAL ASPECTS ME, V1, P289; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BLANEY PH, 1986, PSYCHOL BULL, V99, P229, DOI 10.1037/0033-2909.99.2.229; BRESLOW R, 1981, AM J PSYCHIAT, V138, P227; CASSEL J, 1974, INT J HEALTH SERV, V4, P471, DOI 10.2190/WF7X-Y1L0-BFKH-9QU2; CONWAY M, 1984, J PERS SOC PSYCHOL, V47, P738, DOI 10.1037/0022-3514.47.4.738; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1977, SCL 90 MANUAL, V1; DUNBAR GC, 1984, BRIT J PSYCHIAT, V144, P376, DOI 10.1192/bjp.144.4.376; FIENBERG SE, 1985, MILBANK FUND Q, V63, P582, DOI 10.2307/3349849; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HARTLAGE LC, 1989, MANUAL BEHAV CHANGE; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lees-Haley P.R., 1988, AM J FORENSIC PSYCHO, V6, P3; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LeesHaley PR, 1996, PSYCHOL REP, V79, P811, DOI 10.2466/pr0.1996.79.3.811; LEWINSOHN PM, 1980, J ABNORM PSYCHOL, V89, P203, DOI 10.1037/0021-843X.89.2.203; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINDSAY DS, 1994, APPL COGNITIVE PSYCH, V8, P281, DOI 10.1002/acp.2350080403; Loftus E. F., 1982, GS HALL LECTURES, P119; LOFTUS EF, 1983, MEM COGNITION, V11, P114, DOI 10.3758/BF03213465; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NADOLNE M, 1996, 16 ANN M NAT AC NEUR; NEISSER U, 1981, COGNITION, V9, P1, DOI 10.1016/0010-0277(81)90011-1; Rattan G, 1987, Arch Clin Neuropsychol, V2, P257, DOI 10.1016/0887-6177(87)90013-8; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSS M, 1986, HDB MOTIVATION COGNI, P122; WEBSTER JD, 1993, DEV REV, V13, P54, DOI 10.1006/drev.1993.1003; YARROW MR, 1970, MONOGRAPH SOC RES CH, V5	34	36	36	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1998	20	3					328	338		10.1076/jcen.20.3.328.813			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	142MM	WOS:000077204300007	9845160				2021-06-18	
J	Keren, O; Ben-Dror, S; Stern, MJ; Goldberg, G; Groswasser, Z				Keren, O; Ben-Dror, S; Stern, MJ; Goldberg, G; Groswasser, Z			Event-related potentials as an index of cognitive function during recovery from severe closed head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							P300 COMPONENT; STIMULI; LATENCY	Objective: To evaluate the utility and neuropsychological correlates of serially performed recordings of event-related potentials (ERPs) in patients recovering from a severe closed head injury (CHI). Design: Prospective longitudinal study. Setting: Brain injury rehabilitation unit based in a national rehabilitation hospital. Subjects: Sixteen patients with severe CHI (significant degree of impaired consciousness greater than 24 hours) subclassified into two severity groups according to initial Glasgow Coma Scale (GCS) score: those with initial GCS score < 9, consistent with a more severe injury; and those with initial GCS score > 8, indicating a less severe injury. Methods: ERPs were elicited using the standard auditory P300 "oddball" detection paradigm. ERP recordings were carried out three times: 2 months after injury, 1 month later, and 2.5 months or more after the initial study. Parameters analyzed included latencies and amplitudes of the P3, N2, P2, and N1 components of the ERPs. Correlations between changes in these ERP parameters and specific neuropsychological test results were evaluated. Results: Initial P3 latencies in the more severely injured group were significantly longer (P < .05) than those recorded in the less severely injured patients. In subsequent recordings, P3 latency was found to be significantly shorter compared with the initial P3 latency, and the difference in P3 latency between the two patient groups was no longer statistically significant by the time of the third recording. For the group as a whole, P3 latency decreased significantly on each repeated recording. N2 latency was found to be significantly shorter (P < .05) between the first and third recordings. Cognitive performance significantly improved between the first and third recordings. P3 latency shortening was correlated with improvement in neuropsychological test scores for short-term and long-term story recall and for word recall. N2 latency shortening was correlated with improvement in the neuropsychological test scores for word recall only. Conclusion: ERP recordings performed in the subacute stage after CHI may assist in evaluating injury severity. Moreover, serially performed recordings of P3 latency may be used as a physiologic index of brain activity that correlates with recovery from CHI.	Loewenstein Hosp, Rehabil Ctr, Dept Brain Injury Rehabil, IL-43100 Raanana, Israel; Loewenstein Rehabil Hosp, Sect Psychiat, IL-43100 Raanana, Israel; MossRehab Hosp, Drucker Brain Injury Ctr, Dept Psychotherapy, Philadelphia, PA USA; Tel Aviv Univ, Sackler Fac Med, Dept Phys Med & Rehabil, IL-69978 Tel Aviv, Israel	Groswasser, Z (corresponding author), Loewenstein Hosp, Rehabil Ctr, Dept Brain Injury Rehabil, POB 3, IL-43100 Raanana, Israel.						ARMITAGE SG, 1946, PSYCHOL MONOGR, V60, P277; BADDELEY A, 1982, AGING, V19; BRECHER M, 1987, ELECTROEN CLIN NEURO, V66, P369; Buchwald JS., 1990, EVENT RELATED BRAIN; CAMPBELL K, 1986, CEREBRAL PSYCHOPHYSI; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; CURRY SH, 1980, MOTIVATION MOTOR SEN; DEACONELLIOTT DL, 1987, CURRENT TRENDS EVENT; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DRAKE ME, 1990, SEMIN NEUROL, V10, P196, DOI 10.1055/s-2008-1041269; Goldberg G, 1987, Electromyogr Clin Neurophysiol, V27, P455; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; HIRATA K, 1991, EUR ARCH PSY CLIN N, V240, P240, DOI 10.1007/BF02189533; HOFFMAN JE, 1990, EVENT RELATED BRAIN; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MCCALLUM WC, 1968, ELECTROEN CLIN NEURO, V25, P319, DOI 10.1016/0013-4694(68)90172-7; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; Meier M. J., 1987, NEUROPSYCHOLOGICAL R; OBERT AD, 1990, AM J OTOL, V11, P447; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; Picton T., 1988, HUMAN EVENT RELATED; PICTON TW, 1990, CURRENT PRACTICE CLI; POLICH J, 1985, J GERONTOL, V40, P721, DOI 10.1093/geronj/40.6.721; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Rappaport M, 1990, J Neuropsychiatry Clin Neurosci, V2, P399; RAPPAPORT M, 1996, MED REHABILITATION T; RAPPAPORT M, 1994, J HEAD TRAUMA REHAB, V9, P94; Raven J., 1960, GUIDE STANDARD PROGR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; RUCHKIN DS, 1994, BRAIN, V117, P289, DOI 10.1093/brain/117.2.289; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; SKLARE DA, 1984, ELECTROEN CLIN NEURO, V59, P420, DOI 10.1016/0168-5597(84)90043-1; SQUIRES K, 1980, AGING 1980S; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; WHYTE J, 1988, PRINCIPLES PRACTICE	41	36	39	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1998	13	3					15	30					16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZT046	WOS:000074042200003	9582176				2021-06-18	
J	Tateishi, A; Soejima, Y; Taira, Y; Nakashima, K; Fujisawa, H; Tsuchida, E; Maekawa, T; Ito, H				Tateishi, A; Soejima, Y; Taira, Y; Nakashima, K; Fujisawa, H; Tsuchida, E; Maekawa, T; Ito, H			Feasibility of the titration method of mild hypothermia in severely head-injured patients with intracranial hypertension	NEUROSURGERY			English	Article						body temperature; central nervous system injury; head injury; induced hypothermia; intracranial pressure	TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; PROTECTION; ISOFLURANE; ISCHEMIA; RELEASE; RAT	OBJECTIVE: Clinical strategy to maximize effectiveness and to minimize adverse influences remains to be determined for mild hypothermia therapy for traumatic brain injury. This study was conducted to evaluate the clinical feasibility of the titration method of mild hypothermia in severely head-injured patients in whom a reduction in intracranial pressure was regarded as the target effect. METHODS: Nine consecutive patients with severe head injury were studied. Patient age ranged between 18 and 66 years, Glasgow Coma Scale scores were equal to or less than 8, and intracranial pressures were equal to or greater than 20 mm Hg despite removal of intracranial hematoma and drugs, including glycerol and thiopental. During a maximum of 6 days of hypothermia therapy, jugular venous blood or cerebrospinal fluid temperature was titrated to reduce intracranial pressure to less than 20 mm Hg by means of repeated intragastric cooling with our nasoduodenal tube and surface cooling. The feasibility and the effects on systemic complications of this titration method of mild hypothermia were evaluated. RESULTS: Intracranial pressure variably decreased from before to 3 hours after the beginning of all procedures of cooling. The mean intracranial pressure significantly decreased from 24 to 15 mm Hg with cooling, while temperature reduced an average of 2.0 degrees C. Four patients had systemic infection complications. Increased C-reactive protein and decreased platelet count were observed in all patients during hypothermia. The incidence of good recovery and moderate disability according to the Glasgow Outcome Scale was seven of nine patients. CONCLUSION: The titration method of mild hypothermia to control intracranial hypertension in severely head-injured patients is clinically feasible. However, the method failed to reduce the incidence of infectious and hematological complications.	Yamaguchi Univ Hosp, Div Intens Care Med, Ube, Yamaguchi 755, Japan; Yamaguchi Univ Hosp, Dept Anesthesiol, Ube, Yamaguchi 755, Japan; Yamaguchi Univ Hosp, Dept Neurosurg, Ube, Yamaguchi 755, Japan; Yamaguchi Univ Hosp, Dept Emergency Med, Ube, Yamaguchi 755, Japan; Yamaguchi Univ Hosp, Div Gen Med, Ube, Yamaguchi 755, Japan	Tateishi, A (corresponding author), Yamaguchi Univ Hosp, Div Gen Med, 1144 Kogushi, Ube, Yamaguchi 755, Japan.						BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DAVSON H, 1962, EXP NEUROL, V6, P118, DOI 10.1016/0014-4886(62)90082-1; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HESSEL EA, 1980, J SURG RES, V28, P23, DOI 10.1016/0022-4804(80)90078-5; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; MOSS G, 1966, ARCH SURG-CHICAGO, V92, P80; Nakashima K, 1996, ANESTHESIOLOGY, V85, P161, DOI 10.1097/00000542-199607000-00022; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; ROSOMOFF HL, 1955, AM J PHYSIOL, V183, P19; SANO T, 1992, ANESTHESIOLOGY, V76, P221, DOI 10.1097/00000542-199202000-00011; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; TATEISHI A, 1981, ANESTHESIOLOGY, V54, P335, DOI 10.1097/00000542-198104000-00016; YAMASHITA K, 1991, STROKE, V22, P1574, DOI 10.1161/01.STR.22.12.1574	20	36	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1998	42	5					1065	1069		10.1097/00006123-199805000-00066			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZK454	WOS:000073322500058	9588551				2021-06-18	
J	McCleary, C; Satz, P; Forney, D; Light, R; Zaucha, K; Asarnow, R; Namerow, N				McCleary, C; Satz, P; Forney, D; Light, R; Zaucha, K; Asarnow, R; Namerow, N			Depression after traumatic brain injury as a function of Glasgow outcome score	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; SCALE; MOOD	One hundred and five patients with traumatic brain injury (TBI) were assessed for depressive symptomatology at 6 months postinjury and 66 of those patients were examined again at 12 months postinjury. At 6 months, 42% of the patients with TBI and 20% of the Other Injury Control Group (OIC) were identified as depressed. Individuals with poor outcome las measured by Glasgow Outcome Score [GOS]) had a higher frequency of depressive symptomatology than those with good GOS outcome. At 12 months, 36% of the patients with TBI and 288 of the OIC group were identified as depressed. At 12 months, there was no difference in terms of frequency of depressive symptomatology among patients with TBI with poor, moderate, or good outcome.	Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA; Daniel Freeman Mem Hosp, Los Angeles, CA USA	McCleary, C (corresponding author), Univ So Calif, Sch Med, Dept Neurol, 1510 San Pablo St,Suite 268, Los Angeles, CA 90033 USA.						*ASS ADV AUT MED, 1990, ABBR INJ SCAL 1990; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Derogatis L.R., 1983, SCL 90 R; DICKSON WJ, 1983, INTRO STAT ANAL; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; GAULTIERI C, 1991, BRAIN INJURY, V5, P219; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; ROBINSON RG, 1985, CRC CR REV CL NEUROB, V1, P285; SATZ P, IN PRESS BRAIN INJUR; TEASDALE G, 1974, LANCET, V2, P81; *U NY, 1993, GUID UN DAT SYST MED; WETZLER S, 1993, J PERS ASSESS, V60, P1, DOI 10.1207/s15327752jpa6001_1	19	36	37	1	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1998	20	2					270	279		10.1076/jcen.20.2.270.1172			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	122GG	WOS:000076063100015	9777481				2021-06-18	
J	Hinchliffe, FJ; Murdoch, BE; Chenery, HJ				Hinchliffe, FJ; Murdoch, BE; Chenery, HJ			Towards a conceptualization of language and cognitive impairment in closed-head injury: use of clinical measures	BRAIN INJURY			English	Article							VERBAL IMPAIRMENT; MEMORY; COMPREHENSION; PERFORMANCE; SKILLS	Language deficits following closed-head injury (CHI) are widely considered as impairments secondary to the cognitive disruptions common to closed-head injury. In addition, the use of standardized measures to assess the functioning of the language: system in closed-head injury has mostly been limited to aphasia test batteries which examine primary language functions only. This has resulted in generalizations as to the integrity of the language system following dosed-head injury, and as a consequence, consideration of the contribution of the language system to the achievement of communicative competence in this population has been minimized. This paper presents a framework in which the functional language system is identified as a hierarchical system containing primary and higher-order language processes involved in reciprocal relationships with cognitive functions at each level. A group of 25 closed-head injury subjects and 23 demographically matched control subjects were examined for linguistic proficiency using a battery of standardized tests which investigated the language system across a hierarchy of complexity, structure and predicability. In addition, 23 of the closed-head subjects were administered a comprehensive neuropsychological test battery in order to determine the nature and extent of concomitant impairments in cognitive processes and their relationship with impairments in the language system. The language battery was found to consistently discriminate between the control and clinical groups indicating that the linguistic system is significantly impaired following CHI, with the lexical-semantic system being the most vulnerable to disruption. A strong influential relationship between language and cognitive processes was statistically confirmed and the nature of the relationship between aspects of language and cognition further delineated.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia	Hinchliffe, FJ (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia.		Chenery, Helen J/F-5194-2010; Murdoch, Bruce E/C-1397-2012				ADAMOVICH BB, 1990, FOLIA PHONIATR, V42, P11, DOI 10.1159/000266015; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; *ASLHA, 1987, AM SPEECH HEARING AS, P53; BAKER L, 1982, TOPICS LEARNING LEAR, V2, P26; BENJAMIN L, 1989, THEORY FUNCTION BRID, P57; Bloom L., 1978, LANGUAGE DEV LANGUAG; BRAUN CMJ, 1987, CLIN APHASIOLOGY, P326; BRYAN KL, 1989, RIGHT HEMISPHERE LAN; BUTLERHINZ S, 1990, J SPEECH HEAR RES, V33, P269, DOI 10.1044/jshr.3302.269; CHAPMAN S, 1992, BRAIN LANG, V43, P4; CHAPMAN SB, 1995, HDB NEUROLOGICAL SPE, P387; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; GESCHWIND N, 1971, NEW ENGL J MED, V284, P654, DOI 10.1056/NEJM197103252841206; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Graham D. I., 1987, HEAD INJURY, P72; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HOLLAND AL, 1982, CLIN APHASIOLOGY, V12, P345; HOLM S, 1979, SCAND J STAT, V6, P65; Huisingh R, 1990, WORD TEST REVISED; Irvine L, 1986, S Afr J Commun Disord, V33, P49; Kaplan E., 1983, BOSTON NAMING TEST; KENNEDY MRT, 1991, COMMUNICATION DISORD, P123; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEZAK M, 1996, NEUROPSCYHOLOGICAL A; MALKMUS D, 1989, COMMUNICATION DISORD, P123; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McNeil M. R., 1978, REVISED TOKEN TEST; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Morse P, 1992, CLIN SYNDROMES ADULT, P85; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; NORUSIS MJ, 1990, SPSS PC PLUS STAT 4; PAIGET J, 1969, PSYCHOL CHILD; Pang D, 1985, HEAD INJURY REHABILI, P3; PARSONS C, 1989, AUSTR J HUMAN COMMUN, V17, P237; PAYNEJOHNSON JC, 1986, J COMMUN DISORD, V19, P237, DOI 10.1016/0021-9924(86)90030-4; PEACH RK, 1992, J SPEECH HEAR RES, V35, P810, DOI 10.1044/jshr.3504.810; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P18; REITAN RM, 1987, TRAUMATIC BRAIN INJU, pR2; Reitan RM., 1985, HALSTEAD REITAN NEUR; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; Secord, 1989, TEST LANGUAGE COMPET; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spreen O., 1991, COMPENDIUM NEUROPSYC; Spreen O, 1969, NEUROSENSORY CTR COM; Tabachnick B.G., 1995, USING MULTIVARIATE S; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Vygotsky L. S., 1962, THOUGHT LANGUAGE; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MOMORY SCAL; Wiig E, 1992, TEST WORD KNOWLEDGE; Wiig E. H., 1984, TOP LANG DISORD, V4, P1; WIIG EH, 1974, PERCEPT MOTOR SKILL, V38, P171, DOI 10.2466/pms.1974.38.1.171; WIIG EH, 1984, TOP LANG DISORD, V4, P41; Yorkston K.M., 1981, ASSESSMENT INTELLIGI	72	36	36	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1998	12	2					109	132		10.1080/026990598122746			24	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YV073	WOS:000071786900002	9492959				2021-06-18	
J	Beringer, DC; Weiner, DS; Noble, JS; Bell, RH				Beringer, DC; Weiner, DS; Noble, JS; Bell, RH			Severely displaced proximal humeral epiphyseal fractures: A follow-up study	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						children's fractures; humeral epiphyseal fractures	CHILDREN; GROWTH	Forty-eight patients with severely displaced proximal, humeral epiphyseal fractures were reviewed. Twenty-one patients were followed up for an average of 9 years after injury with a personal interview, examination, and radiographs. Average age was 14.1 years, half of whom were age 15 years or older. Initial head-shaft displacement averaged 80%, and 31 fractures were displaced by greater than or equal to 80%. All underwent attempted closed reduction. Radiographs for all except three were sufficient to judge the adequacy of reduction. Twenty-six of 45 attempted closed reductions failed to improve displacement significantly. Nine patients underwent operative treatment, and the remainder had a closed reduction. In the operative group, complications occurred in three of nine patients. No complications occurred in the nonoperative group. No patients seen at late follow-up identified any activity or employment restrictions as a result of their injuries. Several patients incurred humeral shortening or imperfect radiographic remodeling, but this did not correlate with clinical outcome. Comparing the operative complications with the excellent late results after nonoperative treatment in this series supports previous recommendations to avoid operative intervention with few exceptions. The magnitude of displacement alone does not appear to justify operative treatment.	Childrens Hosp, Med Ctr, Dept Pediat Orthopaed Surg, Akron, OH 44308 USA	Weiner, DS (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat Orthopaed Surg, 1 Perkins Sq,Ste 250,Locust Bldg, Akron, OH 44308 USA.						Aitken A., 1936, J BONE JOINT SURG, V18, P1036; BAXTER MP, 1986, J BONE JOINT SURG BR, V68, P570; BLOUND WP, 1954, FRACTURES CHILDREN; BOURDILLON JF, 1950, J BONE JOINT SURG BR, V32, P35; Crenshaw A.H., 1992, CAMPBELLS OPERATIVE; CURTIS RJ, 1990, ORTHOP CLIN N AM, V21, P315; DAMERON TB, 1969, J BONE JOINT SURG AM, VA 51, P289, DOI 10.2106/00004623-196951020-00008; HOHL JC, 1976, ORTHOP CLIN N AM, V7, P557; JEFFERY CC, 1953, SURG GYNECOL OBSTET, V96, P205; KOHLER R, 1983, J PEDIATR ORTHOPED, V3, P326, DOI 10.1097/01241398-198307000-00010; LARSEN CF, 1990, ACTA ORTHOP SCAND, V61, P255, DOI 10.3109/17453679008993512; McBride E D, 1965, Clin Orthop Relat Res, V38, P143; Neer C S 2nd, 1965, Clin Orthop Relat Res, V41, P24; Nilsson S, 1965, Acta Chir Scand, V130, P433; PETERSON CA, 1972, J TRAUM, V12, P275, DOI 10.1097/00005373-197204000-00002; Rockwood C, 1991, FRACTURES CHILDREN; SMITH FM, 1956, AM J SURG, V91, P627, DOI 10.1016/0002-9610(56)90296-3	17	36	39	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0271-6798			J PEDIATR ORTHOPED	J. Pediatr. Orthop.	JAN-FEB	1998	18	1					31	37		10.1097/00004694-199801000-00007			7	Orthopedics; Pediatrics	Orthopedics; Pediatrics	ZG845	WOS:000073045800007	9449098				2021-06-18	
J	Glaser, DL; Rocke, DM; Kaplan, FS				Glaser, DL; Rocke, DM; Kaplan, FS			Catastrophic falls in patients who have fibrodysplasia ossificans progressiva	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article								There have been numerous anecdotal reports of catastrophic falls in patients with fibrodysplasia ossificans progressiva, To determine the incidence of serious morbidity and mortality associated with falls in this patient population, the authors surveyed the 135 patient members of the International Fibrodysplasia Ossificans Progressiva Association and an age and gender matched control group, Eighty-one percent of the fibrodysplasia ossificans progressiva population suffered a fall resulting in injury compared with 44% of the controls, Sixty-seven percent of the falls initiated a painful flareup of fibrodysplasia ossificans progressiva leading to permanent loss of movement in almost all patients, Fifty-four percent of all falls suffered by the fibrodysplasia ossificans progressiva group led to permanent disability compared with 4% of all falls in the control group, Although trauma to the head was a common site of injury in both groups, the injury profile in the fibrodysplasia ossificans progressiva group included traumatic brain injuries, intracranial hemorrhage and death whereas the control group suffered mostly minor soft tissue lacerations. Deficiencies in coordinate gait and protective function likely accounted for the severity of injuries especially to the head in the fibrodysplasia ossificans progressiva population, Precautions are recommended that are intended to minimize the risk of injury without compromising a patient's functional level and independence, These recommendations include limitation of high risk activities, protective head gear, safety improvements in living environments, and augmentation of stabilizing and protective functions.	Univ Penn, Sch Med, Dept Orthopaed Surg, Div Metab Bone Disorders & Mol Orthopaed, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Calif Davis, Grad Sch Management, Davis, CA USA	Kaplan, FS (corresponding author), Univ Penn, Sch Med, Dept Orthopaed Surg, Div Metab Bone Disorders & Mol Orthopaed, 3400 Spruce St,Silverstein 2, Philadelphia, PA 19104 USA.		Rocke, David M/I-7044-2013	Rocke, David M/0000-0002-3958-7318			COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; Everitt B, 1977, ANAL CONTINGENCY TAB; ROCKE DM, 1994, CLIN ORTHOP RELAT R, P243	3	36	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	JAN	1998		346					110	116					7	Orthopedics; Surgery	Orthopedics; Surgery	YT798	WOS:000071646100016	9577417				2021-06-18	
J	Nagtegaal, JE; Kerkhof, GA; Smits, MG; Swart, ACW; van der Meer, YG				Nagtegaal, JE; Kerkhof, GA; Smits, MG; Swart, ACW; van der Meer, YG			Traumatic brain injury-associated delayed sleep phase syndrome	FUNCTIONAL NEUROLOGY			English	Article						brain injury; delayed sleep phase syndrome; melatonin	MELATONIN	A 15-year-old girl developed a prominent delayed sleep phase syndrome (DSPS) following traumatic brain injury. Several physiological markers of the sleep-wake rhythm: plasma melatonin, body temperature, wrist activity and sleep architecture (EEG) were delayed almost half a day, returning to normal after treatment with 5 mg melatonin. This report suggests an association between traumatic brain injury and DSPS. Awareness of this phenomenon may result in better possibilities for treatment of patients with brain injury.	Hosp Gelderse Vallei, Dept Clin Pharm, Bennekon, Netherlands; Hosp Gelderse Vallei, Dept Neurol, Bennekon, Netherlands; Hosp Gelderse Vallei, Dept Clin Chem, Bennekon, Netherlands; Acad Hosp Leiden, Dept Physiol, Leiden, Netherlands			Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604			Arendt J., 1995, MELATONIN MAMMALIAN, P161; DAHLITZ M, 1991, LANCET, V337, P1121, DOI 10.1016/0140-6736(91)92787-3; *DIAGN CLASS STEER, 1990, INT CLASS SLEEP DIS, P128; KNEISLEY LW, 1978, J NEURAL TRANSM, P311; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; Middleton BA, 1996, LANCET, V348, P551, DOI 10.1016/S0140-6736(05)64715-0; MINORS D S, 1984, Chronobiology International, V1, P205, DOI 10.3109/07420528409063897; NAGTEGAAL E, 1995, LANCET, V346, P1299, DOI 10.1016/S0140-6736(95)91901-5; NAGTEGAAL JE, 1995, BIOL RHYTHM RES, V26, P426; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015	10	36	37	0	3	C I C-EDIZIONI INTERNAZIONALI SRL	ROME	VIA L SPALLANZANI 11, 00161 ROME, ITALY	0393-5264			FUNCT NEUROL	Funct. Neurol.	NOV-DEC	1997	12	6					345	348					4	Clinical Neurology	Neurosciences & Neurology	YT888	WOS:000071656300006	9503198				2021-06-18	
J	Max, JE; Lindgren, SD; Knutson, C; Pearson, CS; Ihrig, D; Welborn, A				Max, JE; Lindgren, SD; Knutson, C; Pearson, CS; Ihrig, D; Welborn, A			Child and adolescent traumatic brain injury: psychiatric findings from a paediatric outpatient speciality clinic	BRAIN INJURY			English	Article							HEAD-INJURIES; SCALE; COMA	A record review focused on children and adolescents, with a history of traumatic brain injury, who were consecutively admitted to a brain injury clinic in which all new patients are psychiatrically evaluated. The development of a 'novel' psychiatric disorder (not present before injury) occurred in 76% (38/50) of the cohort and was correlated significantly with family psychiatric history and family function, but not with severity of injury, preinjury psychiatric status, intellectual/educational functioning, or socioeconomic status. Psychiatric consultation is often necessary in this paediatric population even though much of the psychopathology, particularly following mild injury, may not be directly related to brain trauma.	UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242				Ihrig, Damien/0000-0002-5083-5853			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HARRINGTON JA, 1958, J MENT SCI, V104, P1205; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jastak S, 1984, WIDE RANGE ACHIEVEME; JEFFREY R, 1986, IOWAS SEVERITY RATIN; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEMKUHL G, 1991, BRAIN BEHAV CHILD PS, P267; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MARTINI DR, 1992, SCI P 39 ANN M AM AC, V8; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SHAFFER D, 1975, CIBA FDN S, V34; *SPSS INC, 1995, SPSS WIND PROF STAT; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1991, WECHSLER INTELLIGENC	26	36	36	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1997	11	10					699	711					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XY415	WOS:A1997XY41500001	9354246				2021-06-18	
J	Cicerone, KD; Kalmar, K				Cicerone, KD; Kalmar, K			Does premorbid depression influence post-concussive symptoms and neuropsychological functioning?	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; BRAIN INJURY; MEMORY; COMPLAINTS	We examined the contribution of premorbid affective disturbance to persistent post-concussive symptoms and neuropsychological functioning following a mild traumatic brain injury. No differences were observed on self-reported post-concussive symptoms, MMPI scales, or neuropsychological measures between two case-matched soups of patients with and without a history of pre-injury depression. Clinicians are urged to use caution in attributing post-concussive symptoms or neuropsychological deficits to the presence of a pre-existing affective disorder.		Cicerone, KD (corresponding author), JFK JOHNSON REHABIL INST,DEPT NEUROPSYCHOL,2048 OAK TREE RD,EDISON,NJ 08820, USA.						ALEXANDER MP, 1992, J HEAD TRAUMA REHABI, V7, P90; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GUILMETTE TJ, 1995, NEUROPSYCHOLOGY, V9, P338, DOI 10.1037/0894-4105.9.3.338; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; OCONNOR DW, 1990, ARCH GEN PSYCHIAT, V47, P224; OTTO MW, 1994, ARCH CLIN NEUROPSYCH, V9, P81, DOI 10.1016/0887-6177(94)90016-7; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; Wilkinson L., 1989, SYSTAT SYSTEM STAT; ZAPPALA G, 1992, ARCH CLIN NEUROPSYCH, V7, P145, DOI 10.1016/0887-6177(92)90008-B	14	36	38	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					643	648		10.1080/026990597123197			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600003	9376832				2021-06-18	
J	Hymel, KP; Rumack, CM; Hay, TC; Strain, JD; Jenny, C				Hymel, KP; Rumack, CM; Hay, TC; Strain, JD; Jenny, C			Comparison of intracranial computed tomographic (CT) findings in pediatric abusive and accidental head trauma	PEDIATRIC RADIOLOGY			English	Article							HIGH-FIELD MR; CHILD-ABUSE; MAGNETIC-RESONANCE; CRANIOCEREBRAL TRAUMA; SUBDURAL HEMATOMAS; BRAIN TRAUMA; INJURY; HEMORRHAGE; LESIONS; FALX	Background. Child abuse specialists rely heavily on diagnostic neuroimaging. Objectives. Study objectives were: (1) to compare the frequencies of six specific intracranial CT abnormalities in accidental and nonaccidental pediatric head trauma, and (2) to assess interobserver agreement regarding these CT findings. Materials and methods. Three pediatric radiologists blindly and independently reviewed cranial CT scans of pediatric patients who sustained closed head trauma between 1991 and 1994. All patients were less than 4 years of age. Study cases included thirty-nine (50 %) with nonaccidental head trauma and thirty-nine (50 %) with accidental head trauma. Each scan was evaluated for the presence or absence of the following six intracranial findings: (1) interhemispheric falx hemorrhage, (2) subdural hemorrhage, (3) large (non-acute) extra-axial fluid, (4) basal ganglia edema, (5) posterior fossa hemorrhage, and (6) frontal-parietal shearing tear(s). Interobserver agreement was calculated as the percentage of total cases in which all reviewers agreed a specific CT finding was present or absent. Diagnosis required independent agreement by all three pediatric radiologists. The frequencies of these six intracranial CT abnormalities were compared between the two study groups by Chi-square analysis and Fisher's exact test. Results. Interobserver agreement between radiologists was greater than 80 % for all. lesions evaluated, with the exception of frontal-parietal shearing tear(s). Interhemispheric fair hemorrhage, subdural hemorrhage, large (non-acute) extra-axial fluid, and basal ganglia edema were discovered significantly more frequently in non-accidental trauma (P less than or equal to.05). Conclusion. Although not specific for child abuse, discovery of these intracranial CT abnormalities in young patients should prompt careful evaluation of family and injury circumstances for indicators of nonaccidental trauma.	UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80218 USA				Hymel, Kent/0000-0002-1422-182X			ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; AOKI N, 1986, NEUROSURGERY, V18, P475, DOI 10.1227/00006123-198604000-00017; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; CHEAH IGS, 1994, ANN TROP PAEDIATR, V14, P325, DOI 10.1080/02724936.1994.11747737; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; FELDMAN KW, 1995, CHILD ABUSE NEGLECT, V19, P307, DOI 10.1016/S0145-2134(94)00130-8; FOBBEN ES, 1989, AM J ROENTGENOL, V153, P589, DOI 10.2214/ajr.153.3.589; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HALLER J D, 1991, Pediatrics, V87, P262; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HARWOODNASH DC, 1992, AM J NEURORADIOL, V13, P569; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MERTEN DF, 1990, PEDIATR CLIN N AM, V37, P815; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OSBORN AG, 1980, RADIOLOGY, V134, P421, DOI 10.1148/radiology.134.2.7352222; PACKER RJ, 1985, PEDIATRICS, V76, P84; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TSAI FY, 1980, CT-J COMPUT TOMOGR, V4, P277; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215; ZIMMERMAN RD, 1982, AM J NEURORADIOL, V3, P635	34	36	36	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	SEP	1997	27	9					743	747		10.1007/s002470050215			5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	XX554	WOS:A1997XX55400004	9285736				2021-06-18	
J	Togher, L; Hand, L; Code, C				Togher, L; Hand, L; Code, C			Measuring service encounters with the traumatic brain injury population	APHASIOLOGY			English	Article; Proceedings Paper	26th Clinical Aphasiology Conference	JUN, 1996	NEWPORT, RI					Functional therapy tasks are frequently cited as being important for the successful carry-over of treatment objectives. Service encounters, such as shopping or enquiring for information on the telephone, are typical community integration activities used with the traumatically brain injured (TBI) population. This paper explores the use of systemic functional linguistics in the measurement of performance in service encounters using Generic Structure Potential (GSP) analysis. Results are presented for GSP analysis of service encounters on the telephone to a bus timetable information service, and the police, for five TBI individuals and five matched controls. Service encounters differed according to the complexity of information requested and the interpersonal, or tenor relationships between participants. Differences were evident between TBI and control interactions in the use of generic structural elements. Variation in generic structure was demonstrated across the two types of service encounter. The potential of GSP to measure the dynamic linguistic patterns in everyday TBT interactions is discussed.	LIVERPOOL AREA HLTH SERV,BRAIN INJURY UNIT,SYDNEY,NSW,AUSTRALIA	Togher, L (corresponding author), UNIV SYDNEY,FAC HLTH SCI,SCH COMMUN DISORDERS,POB 170,LIDCOMBE,NSW 2141,AUSTRALIA.		Togher, Leanne/AAC-7083-2019; Code, Chris/F-4259-2010	Togher, Leanne/0000-0002-4518-6748			Armstrong E., 1993, APHASIA TREATMENT WO, P263; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brennan M., 1994, CLEARTALK POLICE RES; Eggins S., 1990, THESIS U SYDNEY; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Halliday MAK, 1985, LANGUAGE CONTEXT TEX; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley Leila L., 1992, Seminars in Speech and Language, V13, P264, DOI 10.1055/s-2008-1064202; HASAN R, 1984, NOTTINGHAM LINGUISTI, V13, P71; Hasan R., 1985, LANGUAGE CONTEXT TEX, P52; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Kress G., 1982, LEARNING WRITE; Martin J. R., 1985, FACTUAL WRITING EXPL; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; ODDY M, 1984, CLOSED HEAD INJURY P, P108; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SLADE D, 1994, AUST REV APPL LING S, V11, P47; SOHLBERG MM, 1989, TOP LANG DISORD, V9, P15, DOI 10.1097/00011363-198903000-00004; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; VENTOLA E, 1979, J PRAGMATICS, V3, P267, DOI 10.1016/0378-2166(79)90034-1; Ventola E., 1987, STRUCTURE SOCIAL INT; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	24	36	38	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	APR-MAY	1997	11	4-5					491	504		10.1080/02687039708248486			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	WU481	WOS:A1997WU48100015					2021-06-18	
J	Mautes, AEM; Fukuda, K; Noble, LJ				Mautes, AEM; Fukuda, K; Noble, LJ			Cellular response in the cerebellum after midline traumatic brain injury in the rat	NEUROSCIENCE LETTERS			English	Article						fluid percussion injury; immunocytochemistry; microglia; Purkinje cells; vermis	NITRIC-OXIDE; EDEMA; CELLS	We evaluated the response of microglia and Purkinje cells in the cerebellum at 1, 2, 3, 7 and 10 days after a midline fluid percussion brain injury. There was marked activation of microglia and a significant loss of Purkinje cells in the vermis by 7 days postinjury. These findings emphasize the vulnerability of the cerebellum to midline traumatic brain injury.	UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; FUKUDA K, 1996, IN PRESS J NEUROTRAU; IKEDA Y, 1990, NEUROSURGERY, V27, P1; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; NAKASHIMA MN, 1995, CELL MOL NEUROBIOL, V15, P341, DOI 10.1007/BF02089944; OHEARN E, 1993, NEUROREPORT, V4, P299, DOI 10.1097/00001756-199303000-00018; OZAWA H, 1994, BRAIN RES, V651, P345, DOI 10.1016/0006-8993(94)90717-X; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; ZIAI R, 1986, P NATL ACAD SCI USA, V83, P8420, DOI 10.1073/pnas.83.21.8420	12	36	36	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 23	1996	214	2-3					95	98		10.1016/0304-3940(96)12916-5			4	Neurosciences	Neurosciences & Neurology	VF281	WOS:A1996VF28100006	8878092				2021-06-18	
J	Hawkins, ML; Lewis, FD; Medeiros, RS				Hawkins, ML; Lewis, FD; Medeiros, RS			Serious traumatic brain injury: An evaluation of functional outcomes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	55th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 27-30, 1995	HALIFAX, CANADA	Amer Assoc Surg Trauma		serious traumatic brain injury; functional independence measure; Glasgow Coma Scale; injury severity score; outcomes measurement	REHABILITATION	Objectives: Evaluate independent living, productivity, and social outcomes of patients with serious traumatic brain injury (TBI) after inpatient rehabilitation, Methods: Fifty-five adults with serious TBI (Abbreviated Injury Scale score greater than or equal to 3) were admitted to a Level I trauma center and subsequently transferred to a comprehensive inpatient rehabilitation hospital (Walton Rehabilitation Hospital), Functional Independence Measures were obtained at admission (Adm), discharge (D/C), and at 3- (n = 52) and 1-year (n = 51) follow-up, Results: At 1 year, 90% of the patients were living at home. Eight (16%) required full-time supervision, while 41 (82%) were independent of supervision throughout most of the day, Thirteen (25%) patients had returned to work, eight full time and five with reduced responsibility and fewer hours than before injury, Nineteen shared household duties, while eight (16%) had primary responsibility. Fourteen (27%) patients demonstrated socially inappropriate or disruptive behavior at least weekly. [GRAPHICS] Conclusion: Although cognitive skills were diminished for the majority of patients, many achieved a substantial reduction in disability within 18 months after TBI.	WALTON REHABIL HOSP,AUGUSTA,GA	Hawkins, ML (corresponding author), MED COLL GEORGIA,1120 15TH ST,ROOM BA 4411,AUGUSTA,GA 30912, USA.						*AM COLL SURG, 1993, ATLS INSTR MAN, P9; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Di Donato B A, 1994, Rehabil Nurs, V19, P219; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Gronwall D, 1989, MILD HEAD INJURY, P153; Haffey W. J., 1990, NEUROPSYCHOLOGY EVER, P99; JACOBS HE, 1987, J HEAD TRAUMA REHAB, V2, P37; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LONG WB, 1994, ARCH PHYS MED REHAB, V75, P144; MALKMUS D, 1974, ASSESSMENT MANUAL; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1987, BNI Q, V31, P10; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; STRAX TE, 1994, ARCH PHYS MED REHAB, V75, pSC1	19	36	36	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	1996	41	2					257	263		10.1097/00005373-199608000-00010			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VC511	WOS:A1996VC51100015	8760533				2021-06-18	
J	Mathew, P; Bullock, R; Teasdale, G; McCulloch, J				Mathew, P; Bullock, R; Teasdale, G; McCulloch, J			Changes in local microvascular permeability and in the effect of intervention with 21-aminosteroid (Tirilazad) in a new experimental model of focal cortical injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						autoradiography; focal injury; microvascular permeability; rodent; 21-aminosteroid	BLOOD-BRAIN-BARRIER; OXYGEN-FREE-RADICALS; CEREBROVASCULAR PERMEABILITY; LIPID-PEROXIDATION; HEAD-INJURY; EDEMA; DISRUPTION; TRANSPORT; RESPONSES; SYSTEM	In a new, reproducible model of rodent focal cortical injury, we have shown that in the absence of early traumatic disruption of the microvasculature and subsequent hemorrhage, delayed perivascular protein leakage and polymorphonuclear leukocyte infiltration of the injured cortex occur. In this study we employed a sensitive quantitative autoradiographic technique (using alpha-aminoisobutyric acid as a tracer) to investigate the focal changes in microvascular permeability with time and to determine the effects of administration of a 21-aminosteroid (Tirilazad) initiated 5 min after induction of the cortical injury. At all time points studied, there was a significant increase in perilesional blood-brain barrier permeability in lesioned animals treated with vehicle, compared to sham-operated animals, with the most marked increase in blood-brain barrier permeability at 4 h postinjury (mean K-i +/- SE = 19.2 +/- 2.4/1000 min with cortical injury, 1.5 +/- 0.3/1000 min in shams) (mean volume +/- SE = 15.48 +/- 0.7 mm(3)). In animals with cortical injury treated with Tirilazad (10 mg/kg), there was a significant reduction in microvascular permeability at the site of injury (K-i = 3.1 +/- 0.5, p < 0.001) and a significant reduction in volume of increased permeability (4.86 +/- 0.7 mm(3), p < 0.01) at 4 h postinjury. In this model of cortical injury, a delayed increase in microvascular permeability occurs, which is significantly attenuated by postinjury treatment with Tirilazad.	SO GEN HOSP, INST NEUROL SCI, DEPT NEUROSURG, GLASGOW G51 4TF, LANARK, SCOTLAND; UNIV GLASGOW, WELLCOME SURG INST, GLASGOW G61 1QH, LANARK, SCOTLAND					Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; Blasberg R G, 1980, Adv Neurol, V28, P255; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P8, DOI 10.1038/jcbfm.1983.2; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BROSNAN CF, 1989, J NEUROIMMUNOL, V25, P227, DOI 10.1016/0165-5728(89)90141-0; BULLOCK R, 1990, ACT NEUR S, V51, P286; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; COLTRAN RS, 1987, J IMMUNOL, V139, P1833; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DUMLICH RVW, 1990, ADV NEUROL, V52, P365; ELLISON MD, 1990, J NEUROIMMUNOL, V28, P249, DOI 10.1016/0165-5728(90)90018-I; HADLEY DM, 1991, NEURORADIOLOGY S, V33, P86; HALL ED, 1992, J NEUROTRAUM, V9, pS425; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JOO F, 1994, ACT NEUR S, V60, P76; KLATZO I, 1994, ACTA NEUROCHIR, P3; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1989, INTRACRANIAL PRESSUR, V7, P787; LOSSINSKY AS, 1979, ACTA NEUROPATHOL, V47, P105, DOI 10.1007/BF00717032; MATHEW P, 1994, ACTA NEUROCHIR, P428; MATHEW P, 1993, J NEUROTRAUMA S1, V1, P80; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MITCHELL J, 1979, ACTA NEUROPATHOL, V46, P45, DOI 10.1007/BF00684803; OHNO K, 1978, AM J PHYSIOL, V235, pH299; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Smith SL, 1996, J NEUROSURG, V84, P229, DOI 10.3171/jns.1996.84.2.0229; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TODD NV, 1990, ACT NEUR S, V51, P296; TOMITA H, 1994, ACTA NEUROCHIR, P558; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TYSON GW, 1982, J NEUROSURG, V57, P186, DOI 10.3171/jns.1982.57.2.0186; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; WEI EP, 1986, AM J PHYSIOL, V251, pH693; ZALESKA MM, 1985, NEUROCHEM RES, V10, P397, DOI 10.1007/BF00964608; ZUCCARELLO M, 1989, STROKE, V20, P367, DOI 10.1161/01.STR.20.3.367	39	36	37	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1996	13	8					465	472		10.1089/neu.1996.13.465			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VH009	WOS:A1996VH00900004	8880610				2021-06-18	
J	Glisky, EL; Delaney, SM				Glisky, EL; Delaney, SM			Implicit memory and new semantic learning in posttraumatic amnesia	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						dosed head injury; implicit memory; posttraumatic amnesia; rehabilitation; semantic learning	CLOSED HEAD-INJURY; IMPAIRED PATIENTS; PRACTICAL SCALE; RETENTION; ACQUISITION; KNOWLEDGE; DURATION	Whether cognitive rehabilitation should be begun in patients with closed head injury before posttraumatic amnesia (PTA) has resolved has been a matter of debate. This article reports two studies that demonstrate that PTA patients are capable of learning during PTA. The first study establishes that PTA patients show significant priming in an implicit stem completion task. The second study indicates that PTA patients can learn new semantic information using the method of vanishing cues. These results suggest that some memory systems remain functional during PTA and that early interventions may be beneficial.		Glisky, EL (corresponding author), UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85721 USA.						ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BROOKS N, 1989, ASSESSMENT BEHAV CON; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CORKIN SH, 1987, NEUROBEHAVIOURAL REC; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GABRIELI JDE, 1995, PSYCHOL SCI, V6, P76, DOI 10.1111/j.1467-9280.1995.tb00310.x; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; GLISKY EL, 1994, COGNITIVE NEUROPSYCH; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Kucera H, 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1992, NEUROPSYCHOLOGY MEMO; Overton DA, 1978, DRUG DISCRIMINATION; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SAINTCYR JA, 1992, NEUROPSYCHOLOGY MEMO; Schacter D. L., 1994, MEMORY SYSTEMS 1994; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1990, ANN NY ACAD SCI, V608, P543, DOI 10.1111/j.1749-6632.1990.tb48909.x; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1987, NEUROPSYCHOLOGIA, V25, P195, DOI 10.1016/0028-3932(87)90131-X; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1991, J EXP PSYCHOL LEARN, V17, P595, DOI 10.1037/0278-7393.17.4.595; Wilson B.A., 1992, CLIN MANAGEMENT MEMO, V2nd; Wilson B.A., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [10.1080/09602019208401410, DOI 10.1080/09602019208401410]; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Winocur G, 1996, NEUROPSYCHOLOGY, V10, P57, DOI 10.1037/0894-4105.10.1.57	42	36	36	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					31	42		10.1097/00001199-199604000-00004			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400004					2021-06-18	
J	Parker, RS; Rosenblum, A				Parker, RS; Rosenblum, A			IQ loss and emotional dysfunctions after mild head injury incurred in a motor vehicle accident	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							WHIPLASH INJURY; WAIS-R; CEREBRAL CONCUSSION; NECK; COMPENSATION; DEFICITS; SYMPTOMS; STRESS; IMPACT	Intelligence and personality dysfunctions after minor traumatic brain injury (TBI) (whiplash; slight head impact) incurred in a motor vehicle accident (MVA) were studied in adults after an average interval of 20 months. There was a mean loss of 14 points of Full Scale IQ from estimated preinjury baseline IQ determined from the standardization group (WAIS-R) without evidence for recovery. Personality dysfunctions included cerebral personality disorder, psychiatric diagnosis (30 of 33 patients), post-traumatic stress disorders, persistent altered consciousness, and psychodynamic reactions to impairment. Cognitive loss is caused by interaction of brain injury with distractions such as pain and emotional distress. Unreported head impact and altered consciousness at the time of accident contribute to the underestimation of brain trauma after minor TBI.	NATL DEV RES INST INC,NEW YORK,NY	Parker, RS (corresponding author), NYU,MED CTR,NEW YORK,NY 10012, USA.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; AUER RN, 1994, J NEUROL NEUROSUR PS, V57, P500, DOI 10.1136/jnnp.57.4.500; Becker DP, 1989, TXB HEAD INJURY, P1; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1993, ACTA NEUROL BELG, V93, P23; BOONE DE, 1992, J CLIN PSYCHOL, V48, P72, DOI 10.1002/1097-4679(199201)48:1<72::AID-JCLP2270480111>3.0.CO;2-0; CARETTE S, 1994, NEW ENGL J MED, V330, P1083, DOI 10.1056/NEJM199404143301512; COLLUM CM, 1991, FORENSIC NEUROPSYCHO, P141; CORNES P, 1992, INJURY, V23, P256, DOI 10.1016/S0020-1383(05)80011-7; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; EVANS RW, 1992, NEUROL CLIN, V10, P815; FARR SP, 1986, HDB CLIN NEUROPSYCHO, V2, P213; GALASKO D, 1993, NEUROLOGY, V43, P1559, DOI 10.1212/WNL.43.8.1559; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GLOVER H, 1992, J TRAUMA STRESS, V5, P643, DOI 10.1007/BF00979232; GOTTEN N, 1956, JAMA-J AM MED ASSOC, V162, P865, DOI 10.1001/jama.1956.02970260015005; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GREGORY R, 1987, ADULT INTELLECTUAL A; GURDJIAN ES, 1975, SURG GYNECOLOGY OBST, V146, P805; HIRSCH AD, 1968, 287 DEP NAV NAV SHIP, V19, P352; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KHURANA RK, 1986, HEADACHE, V26, P183, DOI 10.1111/j.1526-4610.1986.hed2604183.x; Kirkpatrick J B, 1983, Acta Neurochir Suppl (Wien), V32, P115; LEE J, 1993, J PSYCHOSOM RES, V37, P105, DOI 10.1016/0022-3999(93)90076-R; LEE MS, 1994, NEUROLOGY, V44, P1374, DOI 10.1212/WNL.44.8.1374; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; MATARAZZO JD, 1984, J CONSULT CLIN PSYCH, V52, P631, DOI 10.1037/0022-006X.52.4.631; MAYOU R, 1992, International Review of Psychiatry, V4, P45, DOI 10.3109/09540269209066301; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V6, P32, DOI DOI 10.1080/13854049208404115; MILLER L, 1994, PSYCHOTHERAPY, V31, P161, DOI 10.1037/0033-3204.31.1.161; MILLER L, 1993, J COGNITIVE REHA JUL, P18; Ommaya A. K., 1990, NEUROLOGICAL SURG, V3, P1877; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKER R, 1990, TRAUMATIC BRAIN INJU; PARKER RS, 1994, GUIDE ANAL UNDERSTAN, P79; PARKER RS, 1994, J NEUROL ORTH MED S, V15, P123; PARMAR HV, 1993, INJURY, V24, P75, DOI 10.1016/0020-1383(93)90191-8; PEARCE JMS, 1994, NEUROLOGY, V44, P1993, DOI 10.1212/WNL.44.11.1993; PEARCE JMS, 1992, HEADACHE Q-CURR TREA, V3, P45; PENNIE B, 1991, INJURY, V22, P57, DOI 10.1016/0020-1383(91)90166-C; PILOWSKY I, 1985, BRIT J PSYCHIAT, V147, P310, DOI 10.1192/bjp.147.3.310; PORTER KM, 1989, BRIT MED J, V298, P973, DOI 10.1136/bmj.298.6679.973; PRIGATANO GP, 1991, AWARENESS DEFICIT BR, P110; PUTNAM SH, 1992, PSYCHOL ASSESSMENT, V4, P312; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADANOV BP, 1994, BRIT J RHEUMATOL, V33, P442; ROSS ED, 1993, NEUROL CLIN, V11, P9; RYAN JJ, 1991, J CLIN PSYCHOL, V47, P104, DOI 10.1002/1097-4679(199101)47:1<104::AID-JCLP2270470117>3.0.CO;2-2; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Van Der Kolk B.A., 1988, J TRAUMA STRESS, V1, DOI [DOI 10.1007/BF00974765, 10.1002/jts.2490010302, DOI 10.1002/JTS.2490010302]; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	60	36	37	0	1	CLINICAL PSYCHOLOGY PUBL CO	BRANDON	4 CONANT SQUARE, BRANDON, VT 05733	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	JAN	1996	52	1					32	43		10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y			12	Psychology, Clinical	Psychology	TY363	WOS:A1996TY36300005	8682910				2021-06-18	
J	YANG, K; MU, XS; XUE, JJ; PEREZPOLO, JR; HAYES, RL				YANG, K; MU, XS; XUE, JJ; PEREZPOLO, JR; HAYES, RL			REGIONAL AND TEMPORAL PROFILES OF C-FOS AND NERVE GROWTH-FACTOR MESSENGER-RNA EXPRESSION IN RAT-BRAIN AFTER LATERAL CORTICAL IMPACT INJURY	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						GENE EXPRESSION; IMMEDIATE EARLY GENE; C-FOS; NGF; BRAIN INJURY	FACTOR MESSENGER-RNA; DIFFERENTIAL REGULATION; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; FACTOR GENE; HIPPOCAMPUS; TRANSCRIPTION; NGF; INDUCTION; INCREASE	Lesion-induced increases in NGF mRNA are thought to be mediated by c-fos gene expression. Conversely, NGF induction of c-fos expression has been reported following administration of exogenous NGF. However, the relationship between c-fos and NGF gene expression after traumatic injury to the intact brain is not known. Thus, we applied in situ hybridization and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) methods to determine temporal profiles of c-fos and NGF mRNA expression in rat brains after controlled impact to the exposed cortex. Using alternate sections from the same rat brains, in situ hybridization studies showed that in neocortex, c-fos mRNA transiently increased at 30 min, 1 hr, and 3 hr after injury, while there were no increases of NGF mRNA at these postinjury time points. In the hippocampus, in situ hybridization showed that c-fos mRNA increased at 30 min, 1 hr and 3 hr postinjury, while NGF mRNA increased at 1 hr, 3 hr but not at 30 min after injury. RT-PCR studies in hippocampus confirmed that c-fos mRNA increased as early as 5 min after injury, peaked at 30 min postinjury, and remained elevated 5 hr postinjury, Levels of hippocampal NGF mRNA expression increased by 1 hr after injury and plateaued until 3 and 5 hr postinjury. These data are consistent with the possible regulatory role of endogenous c-fos on NGF expression following traumatic brain injury. (C) 1995 Wiley-Liss, Inc.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550			Perez-Polo, Jose R./B-6250-2009		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458, P01 NS31998] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DASH PK, 1995, IN PRESS J NEUROSCI; DEKOSKY ST, 1995, IN PRESS EXP NEUROL; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1994, UNPUB REDUCED EVOKED; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL C, 1991, EPILEPSY RES S, V4, P225; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GIORDANO T, 1992, MOL BRAIN RES, V16, P239, DOI 10.1016/0169-328X(92)90231-Y; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GWAG BJ, 1994, BRAIN RES, V647, P23, DOI 10.1016/0006-8993(94)91394-3; HASHIMOTO Y, 1992, NEUROSCI LETT, V139, P45, DOI 10.1016/0304-3940(92)90853-Y; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERRERA DG, 1993, BRAIN RES, V602, P99, DOI 10.1016/0006-8993(93)90247-K; JEHAN F, 1993, J NEUROCHEM, V60, P1843, DOI 10.1111/j.1471-4159.1993.tb13411.x; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAMINSKA B, 1993, NEUROSCI LETT, V153, P189, DOI 10.1016/0304-3940(93)90319-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LADENHEIM RG, 1993, J NEUROCHEM, V60, P260, DOI 10.1111/j.1471-4159.1993.tb05846.x; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MOCCHETTI I, 1989, P NATL ACAD SCI USA, V86, P3891, DOI 10.1073/pnas.86.10.3891; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; PENG ZC, 1993, BRAIN RES, V632, P57, DOI 10.1016/0006-8993(93)91138-I; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PRASAD MR, 1995, IN PRESS J NEUROCHEM; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHOZUHARA H, 1992, J NEUROCHEM, V59, P175, DOI 10.1111/j.1471-4159.1992.tb08888.x; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMITH DH, 1993, J NEUROSCI, V13, P5383; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; VARON S, 1994, J NEUROTRAUM, V11, P473, DOI 10.1089/neu.1994.11.473; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7	45	36	39	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	NOV 1	1995	42	4					571	578		10.1002/jnr.490420415			8	Neurosciences	Neurosciences & Neurology	TC837	WOS:A1995TC83700014	8568943				2021-06-18	
J	ROSNER, MJ				ROSNER, MJ			INTRODUCTION TO CEREBRAL PERFUSION-PRESSURE MANAGEMENT	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article							SEVERE HEAD-INJURY; PHENYLEPHRINE-INDUCED HYPERTENSION; TRAUMATIC BRAIN INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; AUTO-REGULATION; EXPANDING MASS; PLATEAU WAVES; MANNITOL; ISCHEMIA	This article offers a broad review of cerebral autoregulation to help understand the principles of cerebral perfusion pressure (CPP) management. Discussed are cerebral autoregulation, Poiseuille's law, mannitol-induced hypertension and CPP, prognosis by CPP, management of CPP, and a summary of physiologic basis for CPP management.		ROSNER, MJ (corresponding author), UNIV ALABAMA, DIV NEUROL SURG, UNIV STN, BIRMINGHAM, AL 35294 USA.						ASHWAL S, 1992, NEUROLOGY, V42, P739, DOI 10.1212/WNL.42.4.739; BISHOP R, 1994, INTRACRANIAL PRESSUR, V9, P189; BOREL CO, 1987, AM J PHYSIOL, V253, pH1342; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLD GE, 1981, ACTA ANAESTH SCAND, V25, P332, DOI 10.1111/j.1399-6576.1981.tb01662.x; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DRUMMOND JC, 1991, J NEUROSURG ANESTH, V3, P4, DOI 10.1097/00008506-199103000-00002; DRUMMOND JC, 1989, STROKE, V20, P1538, DOI 10.1161/01.STR.20.11.1538; ELADAWY Y, 1988, INTRACRANIAL PRESSUR, P829; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FEIN JM, 1983, J NEUROSURG, V59, P51, DOI 10.3171/jns.1983.59.1.0051; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOH D, 1993, ARCH DIS CHILD, V68, P111, DOI 10.1136/adc.68.1.111; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; GUYTON AC, 1986, TXB MED PHYSL, P206; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; JONES MD, 1981, AM J PHYSIOL, V240, pH209; KAJITA Y, 1994, J NEUROSURG, V80, P476, DOI 10.3171/jns.1994.80.3.0476; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KAUFMANN GE, 1970, J NEUROSURG, V33, P145, DOI 10.3171/jns.1970.33.2.0145; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Langfitt T W, 1969, Clin Neurosurg, V16, P436; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1964, J NEUROSURG, V21, P989, DOI 10.3171/jns.1964.21.11.0989; LANGFITT TW, 1964, J NEUROSURG, V21, P998, DOI 10.3171/jns.1964.21.11.0998; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MATSUDA M, 1979, J NEUROSURG, V50, P483, DOI 10.3171/jns.1979.50.4.0483; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MCPHERSON RW, 1988, AM J PHYSIOL, V255, pH1516; MOORE FD, 1975, MANUAL SURGICAL NUTR, P169; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1992, AM J PHYSIOL, V262, pH949; NAKATANI S, 1983, INTRACRANIAL PRESSUR, V5, P784; NELSON RJ, 1992, NEUROSURGERY, V31, P705; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PIEK J, 1988, ACTA NEUROCHIR, V93, P129, DOI 10.1007/BF01402894; POLLAY M, 1983, J NEUROSURG, V59, P945, DOI 10.3171/jns.1983.59.6.0945; PROCTOR HJ, 1984, SURGERY, V96, P273; ROSENWASSER RH, 1989, J NEUROSURG, V71, P503, DOI 10.3171/jns.1989.71.4.0503; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; Rosner Michael J., 1993, P57; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROSNER MJ, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P293; Rosner MJ, 1993, INTRACRANIAL PRESSUR, P540; ROSNER MJ, 1995, J NEUROSURG; ROSNER MJ, 1986, INTRACRANIAL PRESSUR, V6, P37; ROSNER MJ, 1994, INTRACRANIAL PRESSUR, P218; ROSNER MJ, 1994, NEUROSURGICAL EMERGE, P5; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P414; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P686; ROSNER MJ, 1993, P INT C RECENT ADV N, P313; SCHETTINI A, 1972, ANESTHESIOLOGY, V36, P4, DOI 10.1097/00000542-197201000-00002; SCHRADER H, 1985, ACTA NEUROL SCAND, V71, P453; SCHRADER H, 1985, ACTA NEUROL SCAND, V71, P114; SHALMON E, 1995, INTRACRANIAL PRESSUR, V9, P357; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SULLIVAN HG, 1987, J NEUROSURG, V67, P525, DOI 10.3171/jns.1987.67.4.0525; SYROGIANNOPOULOS GA, 1987, PEDIATR RES, V22, P118, DOI 10.1203/00006450-198708000-00002; TAKAGI H, 1983, INTRACRANIAL PRESSUR, V5, P729; TRAUB YM, 1982, CLIN EXP HYPERTENS A, V4, P1193, DOI 10.3109/10641968209060783; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; WEINSTEI.JD, 1968, J NEUROSURG, V28, P513, DOI 10.3171/jns.1968.28.6.0513; WEINSTEIN JD, 1967, SURG FORUM, V18, P430; WOISCHNECK D, 1989, INTRACRANIAL PRESSUR, V7, P850; Wolff HG, 1928, ARCH NEURO PSYCHIATR, V20, P1035, DOI 10.1001/archneurpsyc.1928.02210170142002; YOSHIDA A, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P309; ZEMAN FJ, 1983, CLIN NUTRITION DIETE, P555	96	36	38	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	1995	6	4					761	+					1	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RZ142	WOS:A1995RZ14200016	8527917				2021-06-18	
J	DIXON, CE; BAO, J; JOHNSON, KM; YANG, K; WHITSON, J; CLIFTON, GL; HAYES, RL				DIXON, CE; BAO, J; JOHNSON, KM; YANG, K; WHITSON, J; CLIFTON, GL; HAYES, RL			BASAL AND SCOPOLAMINE-EVOKED RELEASE OF HIPPOCAMPAL ACETYLCHOLINE FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE LETTERS			English	Article						BRAIN INJURY; ACETYLCHOLINE; MICRODIALYSIS; SCOPOLAMINE; RAT	CONTROLLED CORTICAL IMPACT; DEAFFERENTATION	This study employed in vivo microdialysis in awake, freely-moving Sprague-Dawley rats to examine acetylcholine (ACh) release in the dorsal hippocampus at 14 days following lateral controlled cortical impact. Extracellular levels of ACh were measured prior to and after an intraperitoneal administration of scopolamine (1 mg/kg), which evokes ACh release by blocking autoreceptors. At 14 days post injury there were no differences in basal ACh levels. However, injury produced a significant reduction in scopolamine-evoked ACh release. The data suggest that cholinergic neurotransmission remains chronically compromised, and thus may contribute to previously documented post traumatic spatial memory deficits.	UNIV TEXAS, MED BRANCH, DEPT PHARMACOL & TOXICOL, GALVESTON, TX 77555 USA	DIXON, CE (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT NEUROSURG, 6431 FANNIN ST, SUITE 7148, HOUSTON, TX 77030 USA.		Johnson, Kenneth/E-7944-2014		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, NS21458] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR303547] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		AMMASSARITEULE M, 1993, BEHAV BRAIN RES, V54, P145, DOI 10.1016/0166-4328(93)90073-Y; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; CARROLL PT, 1980, SCIENCE, V210, P641, DOI 10.1126/science.7433989; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; Dixon C. E., 1995, Journal of Neurotrauma, V12, P491; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1995, IN PRESS BEHAV BIOCH; DIXON CE, 1995, IN PRESS BEHAV BRAIN; DUTAR P, 1986, BRAIN RES, V365, P325, DOI 10.1016/0006-8993(86)91644-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; LEANZA G, 1993, BRAIN RES, V615, P147, DOI 10.1016/0006-8993(93)91126-D; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; MORTIMER JA, 1991, INT J EPIDEMIOL S2, V20, P528; POSTMANTUR RM, UNPUB J NEUROPATHOL; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STARKE K, 1989, PHYSIOL REV, V69, P864; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; VANDERZEE EA, 1994, BRAIN RES, V652, P263, DOI 10.1016/0006-8993(94)90236-4	20	36	37	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 29	1995	198	2					111	114		10.1016/0304-3940(95)11979-7			4	Neurosciences	Neurosciences & Neurology	TA406	WOS:A1995TA40600011	8592633				2021-06-18	
J	LI, GH; BAKER, SP; FOWLER, C; DISCALA, C				LI, GH; BAKER, SP; FOWLER, C; DISCALA, C			FACTORS RELATED TO THE PRESENCE OF HEAD-INJURY IN BICYCLE-RELATED PEDIATRIC TRAUMA PATIENTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HELMET USE; CHILDREN	Using data from the National Pediatric Trauma Registry, this study examined the characteristics of bicycle-related head injury, factors related to the presence of head injury, and different outcomes of head injury up to the time of discharge. Of the 2,333 patients ages 0 to 14 years who were admitted to trauma centers because of bicycle-related injury during 1989 through 1992, more than one-half (54%) sustained head injury, predominantly concussions and skull fractures. With adjustment for age, sex, and motor vehicle involvement, children who had pre-existing mental disorders, who did not wear a helmet at the time of injury, or who were injured on roads had a significantly increased likelihood of sustaining head injuries. Patients with a head injury were four times as likely as patients with no head injury to be treated in intensive care units, and were almost twice as likely to develop complications. Head injury was associated with an increased risk of inhospital fatality and high prevalence rates of communication and behavior impairments at discharge. Although it is urgent to increase helmet use substantially by child bicyclists, special attention should be paid to high-risk groups, such as children with mental disorders and children who are likely to ride in traffic.	TUFTS UNIV NEW ENGLAND MED CTR,RES & TRAINING CTR REHABIL & CHILDHOOD TRAUMA,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111	LI, GH (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR INJURY RES & POLICY,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R29AA009963] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R29AA09963-01] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR302486, H133B344] Funding Source: Medline		Baker SP, 1993, INJURIES BICYCLISTS; BERGMAN AB, 1990, AM J DIS CHILD, V144, P727, DOI 10.1001/archpedi.1990.02150300127033; BUNTAIN WL, 1985, P AM ASS AUT MED, V29, P307; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; CUSHMAN R, 1991, AM J PUBLIC HEALTH, V81, P1044, DOI 10.2105/AJPH.81.8.1044; DANNENBERG AL, 1993, AM J PUBLIC HEALTH, V83, P667, DOI 10.2105/AJPH.83.5.667; DANNENBERG AL, 1993, PUBLIC HEALTH REP, V108, P212; EWING CL, 1983, IMPACT INJURY HEAD S; FRIEDE AM, 1985, PEDIATR CLIN N AM, V32, P141; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; NAKAYAMA DK, 1990, J TRAUMA, V30, P1390, DOI 10.1097/00005373-199011000-00012; RIVARA FP, 1994, PEDIATRICS, V93, P567; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; TEPAS JJ, 1989, J PEDIATR SURG, V24, P156, DOI 10.1016/S0022-3468(89)80237-4; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WEISS BD, 1992, PEDIATRICS, V89, P78; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; YEARGINALLSOPP M, 1992, PEDIATRICS, V89, P624; 1994, DIAGNOSTIC STATISTIC; 1986, SUGI SUPPLEMENTAL LI	22	36	36	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Inf. Crit. Care	JUN	1995	38	6					871	875		10.1097/00005373-199506000-00007			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	RG548	WOS:A1995RG54800007	7602626				2021-06-18	
J	LIU, DX; YANG, JP; LI, LP; MCADOO, DJ				LIU, DX; YANG, JP; LI, LP; MCADOO, DJ			PARAQUAT - A SUPEROXIDE GENERATOR - KILLS NEURONS IN THE RAT SPINAL-CORD	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						MICRODIALYSIS; NEUROTRAUMA; PEROXIDATION; REACTIVE OXYGEN SPECIES; SPINAL CORD; SUPEROXIDE; FREE RADICALS	CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; NITRIC-OXIDE; OXYGEN RADICALS; HIPPOCAMPAL SLICES; PRIMARY AMINES; BRAIN-DAMAGE; INJURY; DISMUTASE; MICRODIALYSIS	Microdialysis was used to administer paraquat into the spinal cord of the anesthetized rat to determine the effects of the in vivo generation of the superoxide anion (O-2(.-)) on neurons. Exposure to paraquat caused blockage of axonal conduction, destruction of the cell bodies of neurons, and a general release of amino acids. Thus, paraquat is quite harmful to neuronal tissue. Similarities between paraquat-induced damage and that previously observed from the hydroxyl radical are consistent with paraquat, causing damage by generation of reactive oxygen species and the widespread belief that generation of O-2(.-) initiates the formation of destructive reactive oxygen species in a wide variety of traumas and other disorders.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	LIU, DX (corresponding author), UNIV TEXAS, MED BRANCH, INST MARINE BIOMED, 200 UNIV BLVD, GALVESTON, TX 77555 USA.			liu, danxia/0000-0001-8172-2344	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS11255] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS011255] Funding Source: NIH RePORTER		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BAGETTA G, 1992, PHARMACOL TOXICOL, V71, P443, DOI 10.1111/j.1600-0773.1992.tb00575.x; BAUKNIGHT GC, 1992, STROKE, V23, P1512, DOI 10.1161/01.STR.23.10.1512; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; Bus JS, 1977, BIOCH MECHANISMS PAR, P157; CAZEVIEILLE C, 1993, FREE RADICAL BIO MED, V14, P389, DOI 10.1016/0891-5849(93)90088-C; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; CORASANITI MT, 1992, HUM EXP TOXICOL, V11, P535, DOI 10.1177/096032719201100616; DEMONTIGNY P, 1987, ANAL CHEM, V59, P1096, DOI 10.1021/ac00135a007; DYKSTRA KH, 1992, J NEUROCHEM, V58, P931, DOI 10.1111/j.1471-4159.1992.tb09346.x; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HAYASHIN, 1990, ACTA NEUROCHIR S, V51, P31; HIRAISHI H, 1992, J BIOL CHEM, V267, P14812; HUGHES JT, 1988, NEUROTOXICOLOGY, V9, P243; IMAIZUMI S, 1990, ACT NEUR S, V51, P236; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU D, 1990, Journal of Neurotrauma, V7, P219, DOI 10.1089/neu.1990.7.219; LIU D, IN PRES FREE RADIC B; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; LIU TH, 1989, AM J PHYSIOL, V256, pH589; MATUSZEWSKI BK, 1987, ANAL CHEM, V59, P1102, DOI 10.1021/ac00135a008; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; PELLEGRINIGIAMPIETRO DE, 1988, J NEUROCHEM, V51, P1960, DOI 10.1111/j.1471-4159.1988.tb01187.x; PELLMAR TC, 1992, BRAIN RES, V569, P189, DOI 10.1016/0006-8993(92)90630-R; Pereira B M, 1990, Adv Neurol, V52, P97; SION A, 1989, BIOCHEM PHARMACOL, V38, P3903, DOI 10.1016/0006-2952(89)90666-7; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TOGASHI H, 1991, HEPATOLOGY, V14, P707, DOI 10.1002/hep.1840140422; TOMITA M, 1992, BIOCHIM BIOPHYS ACTA, V1128, P174, DOI 10.1016/0005-2760(92)90304-E	50	36	38	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAY	1995	18	5					861	867		10.1016/0891-5849(94)00214-5			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	QP569	WOS:A1995QP56900004	7797093				2021-06-18	
J	YOSHIHARA, M; BANDOH, K; MARMAROU, A				YOSHIHARA, M; BANDOH, K; MARMAROU, A			CEREBROVASCULAR CARBON-DIOXIDE REACTIVITY ASSESSED BY INTRACRANIAL-PRESSURE DYNAMICS IN SEVERELY BEAD INJURED PATIENTS	JOURNAL OF NEUROSURGERY			English	Article						CARBON DIOXIDE REACTIVITY; INTRACRANIAL PRESSURE; HEAD INJURY; CEREBROVASCULAR REACTIVITY; PRESSURE VOLUME INDEX; BLOOD VOLUME RESPONSIVITY	CEREBRAL BLOOD-FLOW; CLOSED HEAD-INJURY; TRANSCRANIAL DOPPLER; CO2 REACTIVITY; BRAIN INJURY; ACUTE PHASE; ULTRASOUND; VELOCITY; HEMODYNAMICS; CIRCULATION	Appropriate management of intracranial pressure (ICP) in severely head injured patients depends in part on the cerebral vessel reactivity to PCO2; loss of CO2 reactivity has been associated with poor outcome. This study describes a new method for evaluating vascular reactivity in head-injured patients by determining the sensitivity of ICP change to alterations in PCO2. This method was combined with measurements of the pressure volume index (PVI), which allowed calculation of blood volume change necessary to alter ICP. The objective of this study was to investigate the ICP response and the blood volume change corresponding to alterations in PCO2 and to examine the correlation of responsivity and outcome as measured on the Glasgow Outcome Scale. The PVI and ICP at different end-tidal PCO2 levels produced by mild hypo- and hyperventilation were obtained in 49 patients with Glasgow Coma Scale scores of less than 8 and over a wide range of PCO2 (25 to 40 mm Hg) in eight patients. Given the assumption that the PVI remained constant during alteration of PaCO2, the estimated blood volume change per torr change of PCO2 was calculated by the following equation: BVR = PVI X Delta log(ICP)/Delta PCO2, where BVR = blood volume reactivity. The data in this study showed that PVI remained stable with changes in PCO2, thus validating the assumption used in the blood volume estimates. Moreover, the response of ICP to PCO2 alterations followed an exponential curve that could be described in terms of the responsivity indices to capnic stimuli. It was found that responsivity to hypocapnia was reduced by 50% compared to responsivity to hypercapnia measured within 24 hours of injury (p < 0.01). The sensitivity of ICP to estimated blood volume changes in patients with a PVI of less than 15 ml was extremely high with only 4 ml of blood required to raise ICP by 10 mm Hg. The authors conclude from these data that, following traumatic injury, the resistance vessels are in a state of persistent vasoconstriction, possibly due to vasospasm or compression. Furthermore, BVR correlates with outcome on the Glasgow Coma Scale, indicating that assessment of cerebrovascular response within the first 24 hours of injury may be of prognostic value.		YOSHIHARA, M (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,POB 508,MCV STN,RICHMOND,VA 23298, USA.						BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BURKI NK, 1983, CHEST, V83, P666, DOI 10.1378/chest.83.4.666; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; COMPTON JS, 1987, J NEUROL NEUROSUR PS, V50, P1499, DOI 10.1136/jnnp.50.11.1499; DALY C, 1962, BIOMETRICS, V18, P114, DOI 10.2307/2527714; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GOTOH F, 1961, EXP NEUROL, V4, P48, DOI 10.1016/0014-4886(61)90077-2; GREENBERG JH, 1978, CIRC RES, V43, P324, DOI 10.1161/01.RES.43.2.324; Hayes T M, 1969, Surg Forum, V20, P421; JENNETT B, 1975, LANCET, V1, P480; Kindt G. W., 1972, INTRACRANIAL PRESSUR, P210; KONTOS HA, 1977, STROKE, V8, P226, DOI 10.1161/01.STR.8.2.226; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; LANGFITT TW, 1966, HEAD INJURY, P172; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LUNDAR T, 1990, ACTA NEUROCHIR, V102, P85, DOI 10.1007/BF01405419; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1988, INTRACRANIAL PRESSUR, V7, P688; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; OBRIST WD, 1984, J NEUROSURG, V61, P251; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PAUL RL, 1972, J NEUROSURG, V36, P714, DOI 10.3171/jns.1972.36.6.0714; REIVICH M, 1964, AM J PHYSIOL, V206, P25; ROUGHTON FJW, 1946, BIOCHEM J, V40, P319, DOI 10.1042/bj0400319; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SHIGEMORI M, 1990, ACTA NEUROCHIR, V107, P5, DOI 10.1007/BF01402605; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Takagi H, 1980, INTRACRANIAL PRESSUR, VIV, P163; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, ACTA NEUROCHIR, V104, P121, DOI 10.1007/BF01842829; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	39	36	37	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	1995	82	3					386	393		10.3171/jns.1995.82.3.0386			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QJ311	WOS:A1995QJ31100002	7861215				2021-06-18	
J	JIANG, JY; LYETH, BG; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ				JIANG, JY; LYETH, BG; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ			MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN RAT-BRAIN AT 15 DAYS FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						QUINUCLIDINYLBENZILATE; RECEPTOR BINDING; HOMOGENATE; HIPPOCAMPUS; BRAIN-STEM; NEOCORTEX; FLUID PERCUSSION; TRAUMATIC BRAIN INJURY	SUPPRESSION; INCREASE; DEFICITS; BEHAVIOR; MEMORY	Laboratory studies indicate that activation of muscarinic cholinergic receptors (mAChRs) at or soon after traumatic brain injury (TBI) significantly contributes to behavioral morbidity. Recent research has demonstrated that pre-injury treatment with the muscarinic antagonist scopolamine significantly reduces spatial memory deficits at 11-15 days post-TBI. In the present study, we examined mAChR binding kinetics in brain regions at 15 days after moderate (1.95 atm) fluid percussion TBI in untreated and scopolamine-treated rats. Three groups were examined: untreated TBI (n = 8), TBI with pre-injury scopolamine treatment (1.0 mg/kg, i.p., 15 min prior to injury) (n = 11), and sham-injury (n = 7). The affinity (K-d) and maximum number of binding sites (B-max) of mAChRs in hippocampus, neocortex, and brainstem were determined by [H-3]QNB binding. B-max values in TBI animals were significantly higher in hippocampus (4061 +/- 494 fmol/mg protein) and neocortex (4272 +/- 640 fmol/mg protein), but not in brainstem (833 +/- 39 fmol/mg protein) compared to sham-injured controls (hipp. 2812 +/- 218 fmol/mg/protein; neoctx. 2850 +/- 129 fmol/mg protein; brainstem 794 +/- 26 fmol/mg protein) (P < 0.05). At 15 days after injury, B-max values of mAChRs in TBI animals with pre-injury scopolamine treatment (hipp. 2850 +/- 129 fmol/mg protein; neoctx. 2948 +/- 123 fmol/mg protein) did not differ from control. In all brain regions, K-d values did not differ between groups. These results demonstrate that TBI significantly alters the binding sites of mAChRs in hippocampus and neocortex for as long as 15 days after TBI. Furthermore, these results indicate that a pharmacological treatment that improves motor and memory function outcome also normalizes aspects of mAChRs physiology. These data suggest that excessive activation of mAChRs at or soon after TBI impact contributes to long-term pathophysiological processes in TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,RICHMOND,VA 23298				Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R01NS029995, P50NS012587] Funding Source: NIH RePORTER		ASANUMA M, 1992, ARCH INT PHARMACOD T, V315, P16; BELDHUIS HJA, 1993, NEUROSCIENCE, V55, P965, DOI 10.1016/0306-4522(93)90311-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CLIFTON GL, 1991, STROKE, V20, P1545; DEUTSCH JA, 1971, SCIENCE, V174, P788, DOI 10.1126/science.174.4011.788; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON ED, 1993, 2 GLASG INT NEUR S, P167; DIXON ED, 1992, ROLE NEUROTRANSMITTE, P213; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1993, J COGN BRAIN RES, V1, P223; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; Jiang J. Y., 1993, Society for Neuroscience Abstracts, V19, P1879; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEYER MR, 1982, MOL PHARMACOL, V21, P280; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NODA Y, 1982, EXP NEUROL, V78, P91, DOI 10.1016/0014-4886(82)90191-1; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SIMAN RG, 1979, P NATL ACAD SCI USA, V76, P4141, DOI 10.1073/pnas.76.8.4141; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725	38	36	36	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 18	1994	651	1-2					123	128		10.1016/0006-8993(94)90687-4			6	Neurosciences	Neurosciences & Neurology	NX150	WOS:A1994NX15000014	7922558				2021-06-18	
J	PRAYER, L; WIMBERGER, D; ODER, W; KRAMER, J; SCHINDLER, E; PODREKA, I; IMHOF, H				PRAYER, L; WIMBERGER, D; ODER, W; KRAMER, J; SCHINDLER, E; PODREKA, I; IMHOF, H			CRANIAL MR-IMAGING AND CEREBRAL TC-99M HM-PAO-SPECT IN PATIENTS WITH SUBACUTE OR CHRONIC SEVERE CLOSED-HEAD INJURY AND NORMAL CT EXAMINATIONS	ACTA RADIOLOGICA			English	Article						HEAD INJURIES, CT; MR; EMISSION CT	TRAUMATIC BRAIN INJURY; MAGNETIC-RESONANCE; COMPUTERIZED-TOMOGRAPHY; TECHNETIUM-99M-HMPAO SPECT; INITIAL EXPERIENCE; BLOOD-FLOW; FIELD MR; IMAGES; PERFUSION; PET	Eighteen patients in the subacute or chronic state following severe closed head injury with normal cranial CT scans were examined by MR and Tc-99m HM-PAO SPECT. Correlations were sought between these 2 imaging modalities and the clinical outcome, as defined by the Glasgow Outcome Scale (GOS) score. Both MR and SPECT revealed cerebral damage in all patients examined but structural and functional alterations did not coincide topographically in 64.9% of lesions. Nevertheless, complementary injury patterns suggesting poor recovery were found; cortical contusions and diffuse axonal injury (MR) in conjunction with cortical and thalamic hypoperfusion (SPECT) were noticed in 8 out of 12 patients with unfavorable outcome (GOS=III and IV). The synthesis of MR and SPECT information clearly enhanced the ability both to accurately assess posttraumatic brain damage and to improve patients' outcome pre prediction.	UNIV VIENNA,ALLGEMEINES KRANKENHAUS,DEPT NEUROL,A-1010 VIENNA,AUSTRIA; UNIV VIENNA,ALLGEMEINES KRANKENHAUS,MR INST,A-1010 VIENNA,AUSTRIA	PRAYER, L (corresponding author), UNIV VIENNA,ALLGEMEINES KRANKENHAUS,DEPT RADIOL,DIV NEURORADIOL,WAHRINGER GURTEL 18-20,A-1097 VIENNA,AUSTRIA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1984, RECENT ADV HISTOPATH, P1; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; CHEVENET TL, 1990, RADIOLOGY, V117, P401; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; FUMEYA H, 1990, ACT NEUR S, V51, P283; GENARELLI TA, 1982, ANN NEUROL, V12, P564; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GHETTI B, 1989, NEUROLOGY, V39, P1453, DOI 10.1212/WNL.39.11.1453; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; HESSELINK JR, 1988, AM J NEURORADIOL, V9, P269; HOLMAN BL, 1991, J NUCL MED, V32, P1478; JENNETT B, 1975, LANCET, V1, P480; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN DN, 1989, RADIOLOGY, V172, P783, DOI 10.1148/radiology.172.3.2788893; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; MURASE K, 1992, J NUCL MED, V33, P135; NADJMI M, 1981, KRANIELLE COMPUTERTO, P56; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; PELIZZARI CA, 1989, J COMPUT ASSIST TOMO, V13, P20, DOI 10.1097/00004728-198901000-00004; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; PODREKA I, 1987, J NUCL MED, V28, P1657; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; ROPER SN, 1991, J NUCL MED, V32, P1684; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; WALDEMAR G, 1991, J CEREBR BLOOD F MET, V11, P508, DOI 10.1038/jcbfm.1991.95; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WOLFF SD, 1991, RADIOLOGY, V179, P133, DOI 10.1148/radiology.179.1.2006263; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	37	36	37	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0284-1851			ACTA RADIOL	Acta Radiol.	NOV	1993	34	6					593	599					7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	MJ632	WOS:A1993MJ63200012	8240895				2021-06-18	
J	WRENN, K; RODEWALD, L; LUMB, E; SLOVIS, C				WRENN, K; RODEWALD, L; LUMB, E; SLOVIS, C			THE USE OF STRUCTURED, COMPLAINT-SPECIFIC PATIENT ENCOUNTER FORMS IN THE EMERGENCY DEPARTMENT	ANNALS OF EMERGENCY MEDICINE			English	Article						PATIENT SATISFACTION		Study objective: To assess the effect of preprinted, structured, complaint-specific patient encounter forms on documentation, use of testing, and treatment compared with free-text record keeping. Design: Nonrandomized case-control trial. Setting: University-affiliated, tertiary referral hospital emergency department. Methods: The records of all patients with lacerations, pharyngitis, asthma, or isolated closed-head injury during an eight-month period were reviewed. Intervention: Use of structured complaint-specific patient encounter forms versus traditional free-text record keeping. Main outcome measure: The null hypothesis was that there would be no differences in documentation, test use, or practice when the structured forms were used compared with free-text record keeping. Results: Differences in documentation that favored the use of the structured forms for all four problems studied were seen consistently. Not only was documentation improved, but test use also was affected in a way that decreased use. In addition, in certain areas (eg, treatment of pharyngitis), clinical practice also was changed. Conclusion: Structured, problem-specific ED records improve documentation and affect both resource use and clinical practice. These forms may be useful for improving communication and reimbursement as well as for medicolegal documentation. They provide a method for standardized quality assurance review and clinical data abstraction. Finally, they provide a method for active dissemination of clinical standards.		WRENN, K (corresponding author), VANDERBILT UNIV,MED CTR,DEPT EMERGENCY MED,ROOM 1368,NASHVILLE,TN 37232, USA.		Wrenn, Keith/AAI-7651-2020	Rodewald, Lance/0000-0003-2593-542X				0	36	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAY	1993	22	5					805	812		10.1016/S0196-0644(05)80796-6			8	Emergency Medicine	Emergency Medicine	KZ091	WOS:A1993KZ09100007	8470837				2021-06-18	
J	BOHNEN, N; JOLLES, J; TWIJNSTRA, A; MELLINK, R; SULON, J				BOHNEN, N; JOLLES, J; TWIJNSTRA, A; MELLINK, R; SULON, J			COPING STYLES, CORTISOL REACTIVITY, AND PERFORMANCE IN A VIGILANCE TASK OF PATIENTS WITH PERSISTENT POSTCONCUSSIVE SYMPTOMS AFTER A MILD HEAD-INJURY	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						COGNITIVE IMPAIRMENT; CORTISOL; MILD HEAD INJURY; POSTCONCUSSIVE SYMPTOMS; STRESS	CONCUSSION		UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS; CHU SART TILMAN,STEROIDES LAB,LIEGE,BELGIUM	BOHNEN, N (corresponding author), UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Bohnen, Nicolaas/A-1312-2007				ANSSEAU M, 1984, PSYCHIAT RES, V13, P201; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1990, BIOL PSYCHOL, V31, P107, DOI 10.1016/0301-0511(90)90011-K; BOHNEN N, 1991, J PSYCHOSOM RES, V35, P141, DOI 10.1016/0022-3999(91)90068-Y; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GRONWALL D, 1974, LANCET, V2, P605; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Holroyd K.A., 1982, HDB STRESS THEORETIC; HUBERT W, 1989, Journal of Clinical Chemistry and Clinical Biochemistry, V27, P235; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Long C J, 1983, Psychiatr Med, V1, P35; Luteijn F., 1983, Handleiding Groninger Intelligentie Test [Manual Groningen Intelligence Test]; MENAGHAN E, 1982, J HEALTH SOC BEHAV, V23, P220, DOI 10.2307/2136631; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; SCHIFFRIN RM, 1977, PSYCHOL REV, V84, P127; SCHREURS PJG, 1987, UTRECHTSE COPING LIJ; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1981, THESIS U GRONINGEN N; Verhage R., 1964, INTELLIGENTIE LEEFTI; VINING RF, 1986, CRIT REV CL LAB SCI, V23, P95, DOI 10.3109/10408368609165797; 1985, USERS GUIDE STATISTI	27	36	36	0	2	GORDON BREACH SCI PUBL LTD	READING	C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL	0020-7454			INT J NEUROSCI	Int. J. Neurosci.		1992	64	1-4					97	105		10.3109/00207459209000536			9	Neurosciences	Neurosciences & Neurology	JB934	WOS:A1992JB93400008	1342053				2021-06-18	
J	EYSEL, UT; SCHMIDTKASTNER, R				EYSEL, UT; SCHMIDTKASTNER, R			NEURONAL DYSFUNCTION AT THE BORDER OF FOCAL LESIONS IN CAT VISUAL-CORTEX	NEUROSCIENCE LETTERS			English	Article						THERMOLESION; VISUAL CORTEX; SINGLE CELL RECORDING; HYPOACTIVITY; HYPEREXCITATION	TRAUMATIC BRAIN INJURY; NMDA RECEPTORS; STRIATE CORTEX; INHIBITION; GLUTAMATE; DAMAGE; ISCHEMIA; INACTIVATION; PARVALBUMIN; CONNECTIONS	Traditional concepts assume that traumatic or ischemic brain lesions are surrounded by regions with depressed neuronal function. More recently hyperactivity gained increasing attention as excitotoxic mechanisms become effective at certain stages of neuronal injury. Single cell recordings in the surrounding of small focal lesions in the cat visual cortex revealed both types of functional pathology 1-30 days after lesioning. A rim of suppressed neurons surrounded a completely silent core. Cells further away from the lesion showed bursts and long lasting hyperactivity with extremely high discharge rates. Consequently, the volume of disturbed tissue was considerably larger than the region of initial cell death. This halo of dysfunction may be important for neurological symptoms evoked by cortical lesions.		EYSEL, UT (corresponding author), RUHR UNIV BOCHUM,FAK MED,NEUROPHYSIOL ABT,GEBAUDE MA4-149,W-4630 BOCHUM 1,GERMANY.			Eysel, Ulf/0000-0001-6087-957X			ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; CELIO MR, 1988, CELL CALCIUM, V9, P81, DOI 10.1016/0143-4160(88)90027-9; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; EYSEL UT, 1988, J PHYSIOL-LONDON, V399, P657; EYSEL UT, 1990, EXP BRAIN RES, V80, P626; EYSEL UT, 1987, EXP BRAIN RES, V68, P606; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FINGER S, 1985, BRAIN RES REV, V10, P177, DOI 10.1016/0165-0173(85)90023-2; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GILBERT CD, 1983, J NEUROSCI, V3, P1116; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1963, J PHYSIOL-LONDON, V165, P559, DOI 10.1113/jphysiol.1963.sp007079; Klatzo I, 1980, Adv Neurol, V28, P359; LINDSBERG PJ, 1991, J CEREBR BLOOD F MET, V11, P88, DOI 10.1038/jcbfm.1991.10; MATSUBARA JA, 1987, BRAIN RES BULL, V18, P121, DOI 10.1016/0361-9230(87)90040-2; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHMIDTKASTNER R, 1988, ACTA NEUROPATHOL, V76, P411, DOI 10.1007/BF00686979; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; STICHEL CC, 1987, J COMP NEUROL, V262, P563, DOI 10.1002/cne.902620409; SUZUKI R, 1983, ACTA NEUROPATHOL, V60, P217, DOI 10.1007/BF00691869; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WORGOTTER F, 1988, J NEUROSCI METH, V25, P135, DOI 10.1016/0165-0270(88)90150-1; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	33	36	36	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 30	1991	131	1					45	48		10.1016/0304-3940(91)90333-O			4	Neurosciences	Neurosciences & Neurology	GK153	WOS:A1991GK15300011	1791978				2021-06-18	
J	EIDSON, M; LYBARGER, JA; PARSONS, JE; MACCORMACK, JN; FREEMAN, JI				EIDSON, M; LYBARGER, JA; PARSONS, JE; MACCORMACK, JN; FREEMAN, JI			RISK-FACTORS FOR TORNADO INJURIES	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article							DISASTERS	Tornadoes in North and South Carolina on 28 March 1984 caused 252 people to be injured seriously enough to require hospitalization and 59 to be killed. To evaluate risk factors, we gathered information on 238 (94%) of those hospitalized and 46 (78%) of those killed. Those hospitalized or decreased had statistically significantly more deep cuts, concussions, unconsciousness and broken bones than those with them at the time of the tornado who were not hospitalized or killed. People living in mobile homes were more likely to be hospitalized or die than people occupying conventional houses. Other risk factors for hospitalization or death included advanced age (60+ years), no physical protection (not having been covered with a blanket or other object), having been struck by broken window glass or other falling objects, home lifted off its foundation, collapsed ceiling or floor, or walls blown away. More awareness of the tornado risk before it strikes and better adherence to tornado protection guidelines could reduce injuries and deaths in the future.	N CAROLINA DEPT HUMAN RESOURCES,DIV HLTH SERV,RALEIGH,NC 27609; CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,DIV FIELD SERV,ATLANTA,GA 30333							AHEARN FL, 1984, 841311 NAT I MENT HL; BELVILLE JD, 1987, ANN EMERG MED, V16, P1078, DOI 10.1016/S0196-0644(87)80762-X; BINDER S, 1987, ANN EMERG MED, V16, P1081, DOI 10.1016/S0196-0644(87)80763-1; DYNES RR, 1977, B AM METEOROL SOC, V58, P689; FUJITA TT, 1981, J ATMOS SCI, V38, P1511, DOI 10.1175/1520-0469(1981)038<1511:TADITC>2.0.CO;2; GLASS RI, 1980, SCIENCE, V207, P734, DOI 10.1126/science.207.4432.734; GORDON P, 1982, SPECIAL STATISTICAL; Leibovich M, 1983, J Ark Med Soc, V80, P98; LINEHAN UJ, 1957, 30 US DEP COMM WEATH, P47; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; LUBIN JH, 1981, COMPUTERS BIOMED RES; LUBIN JH, 1981, PARAMETER ESTIMATION; MACCONNON G, 1985, SELECTED BIBLIO EMER; MAHONEY LE, 1987, ANN EMERG MED, V16, P1085, DOI 10.1016/S0196-0644(87)80764-3; MANDELBAUM I, 1966, J TRAUM, V6, P353, DOI 10.1097/00005373-196605000-00005; SANDERS WW, 1975, 2ND P NAT C WIND ENG; SANDERSON LM, 1989, PUBLIC HLTH CONSEQUE, P39; SIMMS JH, 1972, SCIENCE, V176, P1386; WOLDETINSAE AM, 1985, J CLIM APPL METEOROL, V24, P699, DOI 10.1175/1520-0450(1985)024<0699:WAOTBO>2.0.CO;2; 1987, B AM METEOROL SOC, V68, P687; 1985, B AM METEOROL SOC, V66, P570; 1985, B AM METEOROL SOC, V66, P857; 1988, MORB MORT WEEKLY REP, V37, P454; 1981, GUIDE EMERGENCY HLTH; 1972, DISASTER PREPAREDNES, P35; 1985, MORB MORT WEEKLY REP, V34, P205; 1983, MED SUPPLY MANAGEMEN; 1988, B AM METEOROL SOC, V69, P422	28	36	37	0	2	OXFORD UNIV PRESS UNITED KINGDOM	OXFORD	WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	DEC	1990	19	4					1051	1056		10.1093/ije/19.4.1051			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	ET595	WOS:A1990ET59500040	2083989				2021-06-18	
J	WEST, M; PARKINSON, D; HAVLICEK, V				WEST, M; PARKINSON, D; HAVLICEK, V			SPECTRAL-ANALYSIS OF THE ELECTROENCEPHALOGRAPHIC RESPONSE TO EXPERIMENTAL CONCUSSION IN THE RAT	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT NEUROSURG,WINNIPEG R3E 0W3,MANITOBA,CANADA	WEST, M (corresponding author), UNIV MANITOBA,FAC MED,DEPT PHYSIOL,WINNIPEG R3E 0W3,MANITOBA,CANADA.						BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; FRANTZEN E, 1958, ACTA PSYCH NEUROL, V33, P417, DOI 10.1111/j.1600-0447.1958.tb03529.x; HAVLICEK V, 1977, NEUROPADIATRIE, V8, P360, DOI 10.1055/s-0028-1091532; JOSEPH PD, 1971, BRAIN RES, V26, P15; LARSSON LE, 1954, ACTA PSYCHIAT SCAND, V95, P1; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; MEYER JS, 1955, ELECTROENCEPH CLIN N, V7, P520; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OLEARY JL, 1966, CLIN NEUROSURG, V12, P171; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1977, MAYO CLIN PROC, V52, P492; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; PLUM F, 1972, DIAGNOSIS STUPOR COM, P286; POVISHOCK JT, 1978, BRAIN RES, V153, P223; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; ROTHMAN JE, 1968, 8143 DIG EQ CORP; ROWBOTHAM G. F., 1961, BRIT JOUR SURG, V48, P400, DOI 10.1002/bjs.18004821008; Shetter A G, 1979, Adv Neurol, V22, P5; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SYMONDS C, 1962, LANCET, V1, P1; SYMONDS CP, 1974, BROCKS INJURIES BRAI, P100; WARD AA, 1966, CLIN NEUROSURG, V12, P95	23	36	36	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.		1982	53	2					192	200		10.1016/0013-4694(82)90023-2			9	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	NE396	WOS:A1982NE39600006	6174291				2021-06-18	
J	FRIEDE, RL				FRIEDE, RL			EXPERIMENTAL CONCUSSION ACCELERATION - PATHOLOGY AND MECHANICS	ARCHIVES OF NEUROLOGY			English	Article																BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BRODAL A, 1954, J NEUROPHYSIOL, V17, P484; Brodal A, 1956, RETICULAR FORMATION; CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DOW S, 1945, J NEUROPHYSIOL, V8, P161; FRIEDE R, 1955, Monatsschr Unfallheilkd Versicherungsmed, V58, P361; FRIEDE R, 1955, Zentralbl Neurochir, V15, P73; FRIEDE RL, 1960, J NEUROPATH EXP NEUR, V19, P266, DOI 10.1097/00005072-196004000-00007; FRIEDE RL, 1959, EXP NEUROL, V1, P441, DOI 10.1016/0014-4886(59)90043-3; GERNANDT BE, 1960, J NEUROPHYSIOL, V23, P269; GOVONS R, 1944, SURGERY, V1, P606; GROAT RA, 1944, J NEUROSURG, V2, P26; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; GROSS AG, 1958, AVIAT MED, P725; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Gurdjian ES, 1944, SURGERY, V16, P381; HALLERVORDEN J, 1957, DEUT MED WOCHENSCHR, V82, P129, DOI 10.1055/s-0028-1114649; HESSLER DC, UAFC; Holbourn AHS, 1944, J NEUROSURG, V1, P190, DOI 10.3171/jns.1944.1.3.0190; Holbourn AHS, 1943, LANCET, V2, P438; HOLLISTER NR, WADC TR 58-193; Jakob A., 1912, HISTOL HISTOPATH ARB, V5, P182; KOENIG H, 1945, STAIN TECHNOL, V20, P13, DOI 10.3109/10520294509107124; KREMS A. D., 1942, PROC SOC EXP BIOL AND MED, V49, P73; LIVINGSTON WK, 1939, WESTERN J SURG, V54, P131; LOMBARD CHARLES F., 1951, JOUR AVIATION MED, V22, P109; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; PETERS G, 1943, ZBL NEUROCHIR, V8, P172; POLIS A, 1924, REV CHIR LY, P273; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; SCHARENBERG K, 1952, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V188, P430, DOI 10.1007/BF00353219; Shelden CH, 1944, J NEUROSURG, V1, P67, DOI 10.3171/jns.1944.1.1.0067; SPIEGEL EA, 1948, J NEUROPATH EXP NEUR, V7, P162, DOI 10.1097/00005072-194804000-00004; SPIEGELADOLF M, 1947, J NERV MENT DIS, V106, P359, DOI 10.1097/00005053-194710630-00011; WALKER EA, 1944, J NEUROSURG, V1, P103; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349; WARD JW, 1948, J NEUROPHYSIOL, V11, P59; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; WINDLE W. F., 1944, TRANS AMER NEUROL ASSOC, V70, P117; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; Witkowski L., 1877, ARCH PATH ANAT, V69, P498; WRIGHT DR, 1946, SURGERY, V19, P661	46	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1961	4	4					449	&		10.1001/archneur.1961.00450100097012			0	Clinical Neurology	Neurosciences & Neurology	5674A	WOS:A19615674A00005	13701949				2021-06-18	
J	Sherman, EMS; Slick, DJ; Iverson, GL				Sherman, Elisabeth M. S.; Slick, Daniel J.; Iverson, Grant L.			Multidimensional Malingering Criteria for Neuropsychological Assessment: A 20-Year Update of the Malingered Neuropsychological Dysfunction Criteria	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; exaggeration; malingered neurocognitive dysfunction; feigning; performance validity; symptom validity; effort; response bias; PVT; SVT	SYMPTOM VALIDITY TEST; RESPONSE BIAS SCALE; SOMATIC PERCEPTION QUESTIONNAIRE; HENRY-HEILBRONNER INDEX; COGNITIVE IMPAIRMENT IMPLICATIONS; MEMORY COMPLAINTS INVENTORY; RESTRUCTURED FORM MMPI-2-RF; TRAUMATIC BRAIN-INJURY; FALSE-POSITIVE RATES; FORCED-CHOICE TEST	Objectives: Empirically informed neuropsychological opinion is critical for determining whether cognitive deficits and symptoms are legitimate, particularly in settings where there are significant external incentives for successful malingering. The Slick, Sherman, and Iversion (1999) criteria for malingered neurocognitive dysfunction (MND) are considered a major milestone in the field's operationalization of neurocognitive malingering and have strongly influenced the development of malingering detection methods, including serving as the criterion of malingering in the validation of several performance validity tests (PVTs) and symptom validity tests (SVTs) (Slick, D.J., Sherman, E.M.S., & Iverson, G. L. (1999). Diagnostic criteria for malingered neurocognitive dysfunction: Proposed standards for clinical practice and research. The Clinical Neuropsychologist, 13(4), 545-561). However, the MND criteria are long overdue for revision to address advances in malingering research and to address limitations identified by experts in the field. Method: The MND criteria were critically reviewed, updated with reference to research on malingering, and expanded to address other forms of malingering pertinent to neuropsychological evaluation such as exaggeration of self-reported somatic and psychiatric symptoms. Results: The new proposed criteria simplify diagnostic categories, expand and clarify external incentives, more clearly define the role of compelling inconsistencies, address issues concerning PVTs and SVTs (i.e., number administered, false positives, and redundancy), better define the role of SVTs and of marked discrepancies indicative of malingering, and most importantly, clearly define exclusionary criteria based on the last two decades of research on malingering in neuropsychology. Lastly, the new criteria provide specifiers to better describe clinical presentations for use in neuropsychological assessment. Conclusions: The proposed multidimensional malingering criteria that define cognitive, somatic, and psychiatric malingering for use in neuropsychological assessment are presented.	[Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] Spaulding Res Inst, Charlestown, MA USA; [Iverson, Grant L.] Home Base, Charlestown, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Charlestown, MA USA	Sherman, EMS (corresponding author), Sherman Consulting & Assessment Inc, 3553 31 St NW,Suite 262, Calgary, AB T2L 2K7, Canada.	drsherman@drshermanbrainhealth.com					Aita SL, 2018, ARCH CLIN NEUROPSYCH, V33, P832, DOI 10.1093/arclin/acx113; Ali Shahid, 2015, Innov Clin Neurosci, V12, P12; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2017, APPL NEUROPSYCH-ADUL, V24, P190, DOI 10.1080/23279095.2015.1132219; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P725, DOI 10.1093/arclin/acs071; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P101, DOI 10.1093/arclin/acr081; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Balasanyan M, 2018, CLIN NEUROPSYCHOL, V32, P165, DOI 10.1080/13854046.2017.1330421; Bass Christopher, 2019, Pract Neurol, V19, P96, DOI 10.1136/practneurol-2018-001950; BEABER RJ, 1985, AM J PSYCHIAT, V142, P1478; Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; Bender S.D., 2018, CLIN ASSESSMENT MALI, V4, P42; Berry DTR, 2010, PSYCHOL INJ LAW, V3, P295, DOI 10.1007/s12207-010-9087-7; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2018, PSYCHOL ASSESSMENT, V30, P857, DOI 10.1037/pas0000532; Bianchini KJ, 2014, CLIN NEUROPSYCHOL, V28, P1376, DOI 10.1080/13854046.2014.986199; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Binder LM, 2014, CLIN NEUROPSYCHOL, V28, P1366, DOI 10.1080/13854046.2014.978383; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2017, NEUROPSYCHOLOGICAL E; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Boone KB, 2011, PSYCHOL INJ LAW, V4, P157, DOI 10.1007/s12207-011-9106-3; Boussahba-Bravard M, 2018, ROUTL RES GEND HIST, P1; Brooks L, 2012, CLIN NEUROPSYCHOL, V26, P816, DOI 10.1080/13854046.2012.662999; Buddin WH, 2014, CLIN NEUROPSYCHOL, V28, P525, DOI 10.1080/13854046.2014.906658; Burton V, 2012, ARCH CLIN NEUROPSYCH, V27, P262, DOI 10.1093/arclin/acs026; Butcher J. N., 2001, MANUAL ADM SCORING A; Carone D.A., 2013, MILD TRAUMATIC BRAIN; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Chafetz M, 2014, CHILD ABUSE NEGLECT, V38, P1755, DOI 10.1016/j.chiabu.2014.08.015; Chafetz M, 2011, APPL NEUROPSYCHOL, V18, P143, DOI 10.1080/09084282.2011.570619; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Chafetz MD, 2013, ARCH CLIN NEUROPSYCH, V28, P205, DOI 10.1093/arclin/act015; Chafetz MD, 2012, CLIN NEUROPSYCHOL, V26, P1358, DOI 10.1080/13854046.2012.730674; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; Chmielewski M, 2017, PSYCHOL ASSESSMENT, V29, P199, DOI 10.1037/pas0000328; Crighton AH, 2014, SPINE J, V14, P2042, DOI 10.1016/j.spinee.2014.04.012; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1224, DOI 10.1080/13854046.2014.987167; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Dickens S. E., 1992, STRUCTURED INTERVIEW; Dionysus KE, 2011, ARCH CLIN NEUROPSYCH, V26, P81, DOI 10.1093/arclin/acq096; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Fazio RL, 2018, ARCH CLIN NEUROPSYCH, V33, P1069, DOI 10.1093/arclin/acy001; Fazio RL, 2015, ARCH CLIN NEUROPSYCH, V30, P293, DOI 10.1093/arclin/acv024; Feldman MD., 2018, Dying to be ill: true stories of medical deception; Ferrari R., 2016, J RHEUMATOL, V43, P11; Ferrari R, 2014, EUR J RHEUMATOL, V1, P150, DOI 10.5152/eurjrheumatol.2014.140061; Gaasedelen OJ, 2019, CLIN NEUROPSYCHOL, V33, P1467, DOI 10.1080/13854046.2019.1612947; Gaillard N. D., 2018, CLIN ASSESSMENT MALI, P174; Garcia-Willingham N. E., 2018, CLIN ASSESSMENT MALI, P329; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2018, PSYCHOL ASSESSMENT, V30, P410, DOI 10.1037/pas0000506; Gillard ND., 2010, STRUCTURED INTERVIEW; Gottfried E, 2016, ASSESSMENT, V23, P672, DOI 10.1177/1073191115599640; Green D, 2012, INT J FORENSIC MENT, V11, P181, DOI 10.1080/14999013.2012.723665; Green P., 2003, GREENS WORD MEMORY T; Green P., 2004, MEMORY COMPLAINTS IN; Green P, 2015, APPL NEUROPSYCH-ADUL, V22, P293, DOI 10.1080/23279095.2014.925903; Greene R. L., 2008, CLIN ASSESSMENT MALI, P159; Greiffenstein M, 2013, CLIN NEUROPSYCHOL, V27, P138, DOI 10.1080/13854046.2012.722686; Greve K. W., 2012, FORENSIC NEUROPSYCHO, P302; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; Grossi LM, 2017, PSYCHOL ASSESSMENT, V29, P531, DOI 10.1037/pas0000364; Gu W, 2017, J PERS ASSESS, V99, P286, DOI 10.1080/00223891.2016.1149483; Gualtieri C. T., 2015, FRONTIERS, V4, P1; Hall RCW, 2006, GEN HOSP PSYCHIAT, V28, P525, DOI 10.1016/j.genhosppsych.2006.08.011; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry GK, 2006, CLIN NEUROPSYCHOL, V20, P786, DOI 10.1080/13854040500287749; Henry GK, 2014, BRAIN INJURY, V28, P357, DOI 10.3109/02699052.2013.865272; Henry GK, 2013, CLIN NEUROPSYCHOL, V27, P509, DOI 10.1080/13854046.2012.739644; Heyanka DJ, 2015, ARCH CLIN NEUROPSYCH, V30, P369, DOI 10.1093/arclin/acv025; Hirst RB, 2017, ARCH CLIN NEUROPSYCH, V32, P456, DOI 10.1093/arclin/acx009; Jaffe Robert J, 2016, Prim Care Companion CNS Disord, V18, DOI 10.4088/PCC.16l01934; Johnson-Greene D, 2013, CLIN NEUROPSYCHOL, V27, P148, DOI 10.1080/13854046.2012.733732; Jones A, 2016, ARCH CLIN NEUROPSYCH, V31, P786, DOI 10.1093/arclin/acw035; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kemp S, 2008, J PSYCHOSOM RES, V65, P319, DOI 10.1016/j.jpsychores.2008.02.010; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P853, DOI 10.1080/13803395.2015.1064864; Lange RT, 2013, J CLIN EXP NEUROPSYC, V35, P192, DOI 10.1080/13803395.2012.761677; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee G.J., 2012, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; McGuire C, 2019, ARCH CLIN NEUROPSYCH, V34, P114, DOI 10.1093/arclin/acy012; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Merten T, 2013, PSYCHOL INJ LAW, V6, P122, DOI 10.1007/s12207-013-9155-x; Messer JM, 2007, J FORENSIC PSYCHOL P, V7, P33, DOI 10.1300/J158v07n03_02; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; Musso MW, 2014, J ATTEN DISORD, V18, P186, DOI 10.1177/1087054712441970; Nguyen CT, 2015, CLIN NEUROPSYCHOL, V29, P255, DOI 10.1080/13854046.2015.1033020; Nijdam-Jones A, 2017, PSYCHOL ASSESSMENT, V29, P1321, DOI 10.1037/pas0000438; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Pankratz L., 1990, CLIN NEUROPSYCHOL, V4, P379; Pearson, 2009, ADV CLIN SOL WAIS 4; Peck CP, 2013, CLIN NEUROPSYCHOL, V27, P693, DOI 10.1080/13854046.2013.779032; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Pierre JM, 2019, J AM ACAD PSYCHIATRY, V47, P448, DOI 10.29158/JAAPL.003867-19; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Resnick P. J., 2018, CLIN ASSESSMENT MALI, P188; Ricker J.H., 2018, TXB CLIN NEUROPSYCHO; Roberson CJ, 2013, CLIN NEUROPSYCHOL, V27, P495, DOI 10.1080/13854046.2012.737027; Rogers R., 2018, CLIN ASSESSMENT MALI, P422; Rogers R., 2018, CLIN ASSESSMENT MALI, V4, P592; Rogers R, 2011, PSYCHOL INJ LAW, V4, P163, DOI 10.1007/s12207-011-9108-1; Rogers R, 2011, PSYCHOL INJ LAW, V4, P147, DOI 10.1007/s12207-011-9107-2; Ruff RM, 2016, PSYCHOL INJ LAW, V9, P143, DOI 10.1007/s12207-016-9259-1; Schroeder RW, 2016, CLIN NEUROPSYCHOL, V30, P515, DOI 10.1080/13854046.2016.1177118; Schroeder RW, 2012, CLIN NEUROPSYCHOL, V26, P129, DOI 10.1080/13854046.2011.639314; Sellbom M., 2018, FORENSIC APPL MMPI 2; Sellbom M, 2012, PSYCHIAT RES, V197, P295, DOI 10.1016/j.psychres.2011.12.043; Sherman E.M., 2013, MILD TRAUMATIC BRAIN, P57; Sherman E. M. S., 2015, VALIDITY TESTING CHI, P23; Sherman E. M. S., COMPENDIUM NEUROPSYC; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick D. J., 2012, VALIDITY TESTING CHI; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith G., 2018, CLIN ASSESSMENT MALI, P449; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Sullivan KA, 2013, APPL NEUROPSYCH-ADUL, V20, P20, DOI 10.1080/09084282.2012.670149; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Teodoro T, 2018, J NEUROL NEUROSUR PS, V89, P1308, DOI 10.1136/jnnp-2017-317823; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tuck NL, 2019, J PAIN, V20, P133, DOI 10.1016/j.jpain.2018.07.002; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Vilar-Lopez R, 2008, J CLIN EXP NEUROPSYC, V30, P710, DOI 10.1080/13803390701684562; Weiss Kenneth J, 2017, J Am Acad Psychiatry Law, V45, P339; Whitney KA, 2013, APPL NEUROPSYCH-ADUL, V20, P83, DOI 10.1080/09084282.2012.670167; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wisdom NM, 2010, ARCH CLIN NEUROPSYCH, V25, P118, DOI 10.1093/arclin/acp110; Wodushek TR, 2020, APPL NEUROPSYCH-ADUL, V27, P9, DOI 10.1080/23279095.2018.1473251; Worley C. B., 2009, PSYCHIAT TIMES, V26; Wygant DB, 2011, PSYCHOL INJ LAW, V4, P13, DOI 10.1007/s12207-011-9098-z; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730	164	35	35	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2020	35	6					735	764		10.1093/arclin/acaa019			30	Psychology, Clinical; Psychology	Psychology	OW5NS	WOS:000592933700009	32377667	Other Gold, Green Published	Y	N	2021-06-18	
J	Kochanek, PM; Tasker, RC; Carney, N; Totten, AM; Adelson, PD; Selden, NR; Davis-O'Reilly, C; Hart, EL; Bell, MJ; Bratton, SL; Grant, GA; Kissoon, N; Reuter-Rice, KE; Vavilala, MS; Wainwright, MS				Kochanek, Patrick M.; Tasker, Robert C.; Carney, Nancy; Totten, Annette M.; Adelson, P. David; Selden, Nathan R.; Davis-O'Reilly, Cynthia; Hart, Erica L.; Bell, Michael J.; Bratton, Susan L.; Grant, Gerald A.; Kissoon, Niranjan; Reuter-Rice, Karin E.; Vavilala, Monica S.; Wainwright, Mark S.			Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						critical care; evidence-based medicine; guidelines; pediatrics; systematic review; traumatic brain injury	EARLY DECOMPRESSIVE CRANIECTOMY; COMMON DATA ELEMENTS; REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL PERFUSION-PRESSURE; THERAPEUTIC HYPOTHERMIA; HYPERTONIC SALINE; HEAD-INJURY; SINGLE-CENTER; CHILDREN; OUTCOMES	Objectives: The purpose of this work is to identify and synthesize research produced since the second edition of these Guidelines was published and incorporate new results into revised evidence-based recommendations for the treatment of severe traumatic brain injury in pediatric patients. Methods and Main Results: This document provides an overview of our process, lists the new research added, and includes the revised recommendations. Recommendations are only provided when there is supporting evidence. This update includes 22 recommendations, nine are new or revised from previous editions. New recommendations on neuroimaging, hyperosmolar therapy, analgesics and sedatives, seizure prophylaxis, temperature control/hypothermia, and nutrition are provided. None are level I, three are level II, and 19 are level III. The Clinical Investigators responsible for these Guidelines also created a companion algorithm that supplements the recommendations with expert consensus where evidence is not available and organizes possible interventions into first and second tier utilization. The purpose of publishing the algorithm as a separate document is to provide guidance for clinicians while maintaining a clear distinction between what is evidence based and what is consensus based. This approach allows, and is intended to encourage, continued creativity in treatment and research where evidence is lacking. Additionally, it allows for the use of the evidence-based recommendations as the foundation for other pathways, protocols, or algorithms specific to different organizations or environments. The complete guideline document and supplemental appendices are available electronically from this journal. These documents contain summaries and evaluations of all the studies considered, including those from prior editions, and more detailed information on our methodology. Conclusions: New level II and level III evidence-based recommendations and an algorithm provide additional guidance for the development of local protocols to treat pediatric patients with severe traumatic brain injury. Our intention is to identify and institute a sustainable process to update these Guidelines as new evidence becomes available.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Anesthesiol Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02115 USA; [Carney, Nancy; Totten, Annette M.; Davis-O'Reilly, Cynthia; Hart, Erica L.] Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosci, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosurg, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Bell, Michael J.] Childrens Natl Med Ctr, Crit Care Med, Washington, DC 20010 USA; [Bratton, Susan L.] Univ Utah, Pediat, Salt Lake City, UT USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, British Columbias Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Kissoon, Niranjan] Univ British Columbia, Child & Family Res Inst, Vancouver, BC, Canada; [Reuter-Rice, Karin E.] Duke Univ, Dept Pediat, Div Pediat Crit Care Med, Sch Nursing,Sch Med, Durham, NC 27706 USA; [Vavilala, Monica S.] Univ Washington, Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, HIPRC, Seattle, WA 98195 USA; [Wainwright, Mark S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Anesthesiol Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Totten, Annette/P-7909-2019; Kissoon, Niranjan/AAC-6140-2021; Tasker, Robert C/R-5837-2019; Adelson, David/W-2083-2019	Totten, Annette/0000-0002-9100-8678; Kissoon, Niranjan/0000-0001-8847-9973; Reuter-Rice, Karin/0000-0003-1501-8994	U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911 QY-14-C-0086]; Brain Trauma Foundation	Supported, in part, by the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to Stanford University (W911 QY-14-C-0086) and a subcontract awarded to Oregon Health & Science University. Prior editions were supported, in part, by funding from multiple sources through the Brain Trauma Foundation.	Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Bata SC, 2014, ANZ J SURG, V84, P438, DOI 10.1111/ans.12582; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bell MJ, 2017, CHILD NERV SYST, V33, P1663, DOI 10.1007/s00381-017-3530-y; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chin KH, 2015, PEDIATR CRIT CARE ME, V16, P352, DOI 10.1097/PCC.0000000000000344; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Crompton E, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002565; Crompton EM, 2017, CRIT CARE MED, V45, P575, DOI 10.1097/CCM.0000000000002205; Csokay A, 2012, CHILD NERV SYST, V28, P441, DOI 10.1007/s00381-011-1661-0; de Andrade AF, 2011, ARQ NEURO-PSIQUIAT, V69, P79, DOI 10.1590/S0004-282X2011000100016; Desgranges FP, 2014, CHILD NERV SYST, V30, P1393, DOI 10.1007/s00381-014-2417-4; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Ferguson NM, 2016, PEDIATR CRIT CARE ME, V17, P444, DOI 10.1097/PCC.0000000000000709; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2010, NEUROCRIT CARE, V12, P430, DOI 10.1007/s12028-010-9344-3; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, pS1, DOI 10.1097/PCC.0000000000001735; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kurz JE, 2016, PEDIATR CRIT CARE ME, V17, P649, DOI 10.1097/PCC.0000000000000765; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mhanna MJ, 2015, J NEUROSURG PEDIAT, V16, P1; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piper BJ, 2015, ANAESTH INTENS CARE, V43, P204, DOI 10.1177/0310057X1504300210; Prasad GL, 2015, BRAIN INJURY, V29, P1; Roumeliotis N, 2016, CHILD NERV SYST, V32, P2363, DOI 10.1007/s00381-016-3231-y; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Taha AA, 2011, J NEUROSCI NURS, V43, P291, DOI 10.1097/JNN.0b013e318234e9b2; Tasker RC, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002526; Tasker RC, 2017, PEDIATR CRIT CARE ME, V18, P355, DOI 10.1097/PCC.0000000000001098; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Webster DL, 2015, J CRIT CARE, V30, P1267, DOI 10.1016/j.jcrc.2015.07.022; Welch TP, 2016, CRIT CARE MED, V44, P809, DOI 10.1097/CCM.0000000000001558	63	35	39	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2019	20	3					280	289		10.1097/PCC.0000000000001736			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	HN4QS	WOS:000460169200017	30830016				2021-06-18	
J	Wang, JM; Jiang, C; Zhang, K; Lan, X; Chen, XM; Zang, WD; Wang, ZY; Guan, FX; Zhu, CL; Yang, XL; Lu, H; Wang, J				Wang, Junmin; Jiang, Chao; Zhang, Kun; Lan, Xi; Chen, Xuemei; Zang, Weidong; Wang, Zhongyu; Guan, Fangxia; Zhu, Changlian; Yang, Xiuli; Lu, Hong; Wang, Jian			Melatonin receptor activation provides cerebral protection after traumatic brain injury by mitigating oxidative stress and inflammation via the Nrf2 signaling pathway	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Chronotherapy; Inflammation; NF-E2-related factor; Oxidative stress; Ramelteon; Traumatic brain injury	MONONUCLEAR-CELL TRANSPLANTATION; INTRACEREBRAL HEMORRHAGE; RAT MODEL; POSSIBLE INVOLVEMENT; RAMELTEON TAK-375; UP-REGULATION; NEUROINFLAMMATION; NEUROPROTECTION; AGONIST; SLEEP	Traumatic brain injury (TBI) is a principal cause of death and disability worldwide. Melatonin, a hormone made by the pineal gland, is known to have anti-inflammatory and antioxidant properties. In this study, using a weight-drop model of TBI, we investigated the protective effects of ramelteon, a melatonin MT1/MT2 receptor agonist, and its underlying mechanisms of action. Administration of ramelteon (10 mg/kg) daily at 10:00 a.m. alleviated TBI-induced early brain damage on day 3 and long-term neurobehavioral deficits on day 28 in C57BL/6 mice. Ramelteon also increased the protein levels of interleukin (IL)-10, IL-4, superoxide dismutase (SOD), glutathione, and glutathione peroxidase and reduced the protein levels of IL-1 beta, tumor necrosis factor, and malondialdehyde in brain tissue and serum on days 1, 3, and 7 post-TBI. Similarly, ramelteon attenuated microglial and astrocyte activation in the perilesional cortex on day 3. Furthermore, ramelteon decreased Keap 1 expression, promoted nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear accumulation, and increased levels of downstream proteins, including SOD-1, heme oxygenase-1, and NQO1 on day 3 post-TBI. However, in Nrf2 knockout mice with TBI, ramelteon did not decrease the lesion volume, neuronal degeneration, or myelin loss on day 3; nor did it mitigate depression-like behavior or most motor behavior deficits on day 28. Thus, timed ramelteon treatment appears to prevent inflammation and oxidative stress via the Nrf2-antioxidant response element pathway and might represent a potential chronotherapeutic strategy for treating TBI.	[Wang, Junmin; Guan, Fangxia; Lu, Hong] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Henan, Peoples R China; [Wang, Junmin; Chen, Xuemei; Zang, Weidong] Zhengzhou Univ, Coll Basic Med Sci, Dept Anat, Zhengzhou 450000, Henan, Peoples R China; [Wang, Junmin; Guan, Fangxia; Zhu, Changlian] Zhengzhou Univ, Affiliated Hosp 3, Zhengzhou 450052, Henan, Peoples R China; [Wang, Junmin; Lan, Xi; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Jiang, Chao] Zhengzhou Univ, Affiliated Hosp 5, Dept Neurol, Zhengzhou 450052, Henan, Peoples R China; [Zhang, Kun; Guan, Fangxia] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450000, Henan, Peoples R China; [Wang, Zhongyu] Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol, Zhengzhou 450000, Henan, Peoples R China; [Zhu, Changlian] Zhengzhou Univ, Inst Neurosci, Henan Key Lab Child Brain Injury, Zhengzhou 450052, Henan, Peoples R China; [Zhu, Changlian] Univ Gothenburg, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil, S-40530 Gothenburg, Sweden; [Yang, Xiuli] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA	Wang, JM; Lu, H (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Henan, Peoples R China.; Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.	wangjunmin@zzu.edu.cn; zzu_luhong@163.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019; Zhu, Changlian/AAN-6205-2020	Wang, Jian/0000-0003-2291-640X; Zhu, Changlian/0000-0002-5029-6730	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81671165]	The authors thank the Wang lab members for technical expertise and insightful input. This research was supported by a grant from the National Natural Science Foundation of China (Grant No. 81671165 to CJ).	Babaee A, 2015, IRAN J BASIC MED SCI, V18, P867; Otalora BB, 2012, CHRONOBIOL INT, V29, P822, DOI 10.3109/07420528.2012.699119; Bin Sayeed MS, 2017, J NEUROIMMUNOL, V313, P46, DOI 10.1016/j.jneuroim.2017.10.007; CAN A, 2012, JOVE J VIS EXP JAN, DOI DOI 10.3791/3769; Cardinali DP, 2012, J PINEAL RES, V52, P365, DOI 10.1111/j.1600-079X.2011.00962.x; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Cheng T, 2015, CELL MOL NEUROBIOL, V35, P641, DOI 10.1007/s10571-015-0159-9; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dong W. W., 2017, P 12 BIENN C CHIN NE, P754; Emet M, 2016, EURASIAN J MED, V48, P135, DOI 10.5152/eurasianjmed.2015.0267; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Fisher SP, 2008, J PINEAL RES, V45, P125, DOI 10.1111/j.1600-079X.2008.00565.x; Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x; Greenblatt DJ, 2007, J CLIN PHARMACOL, V47, P485, DOI 10.1177/0091270006298602; Han X., 2018, J CEREB BLOOD FLOW M; Han XN, 2016, J CEREBR BLOOD F MET, V36, P1059, DOI 10.1177/0271678X15606462; Hirai K, 2005, J BIOL RHYTHM, V20, P27, DOI 10.1177/0748730404269890; Jiang C, 2017, MOL NEUROBIOL, V54, P571, DOI 10.1007/s12035-015-9651-y; Jiang C, 2016, NEUROBIOL AGING, V42, P13, DOI 10.1016/j.neurobiolaging.2016.02.029; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Kasahara T, 2010, P NATL ACAD SCI USA, V107, P6412, DOI 10.1073/pnas.0914399107; Kast RE, 2015, WSPOLCZESNA ONKOL, V19, P157, DOI 10.5114/wo.2015.51421; Kragel PA, 2018, NAT NEUROSCI, V21, P283, DOI 10.1038/s41593-017-0051-7; Lan X, 2017, MOL NEUROBIOL, V54, P7898, DOI 10.1007/s12035-016-0271-y; Lan X, 2017, BRAIN BEHAV IMMUN, V61, P326, DOI 10.1016/j.bbi.2016.12.012; Laudon M, 2014, INT J MOL SCI, V15, P15924, DOI 10.3390/ijms150915924; Lauterbach EC, 2010, J NEUROPSYCH CLIN N, V22, P8, DOI 10.1176/appi.neuropsych.22.1.8; Lequerica A, 2015, ARCH PHYS MED REHAB, V96, P1802, DOI 10.1016/j.apmr.2015.05.011; Li B. X., 2017, P 12 BIENN C CHIN NE, P755; Li DP, 2016, CELL MOL NEUROBIOL, V36, P1045, DOI 10.1007/s10571-015-0295-2; Li Q, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90777; Li Q, 2017, NEUROBIOL DIS, V108, P173, DOI 10.1016/j.nbd.2017.08.011; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev-pharmtox-010814-124742; Miyamoto M, 2006, NEUROSCI LETT, V402, P201, DOI 10.1016/j.neulet.2006.02.049; Pan LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099526; Pandi-Perumal S. R., 2010, SLEEP MENTAL ILLNESS, P119; Shimizu N, 2013, RES REP UROL, V5, P113, DOI 10.2147/RRU.S44502; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; Vivien-Roels B, 1998, J BIOL RHYTHM, V13, P403, DOI 10.1177/074873098129000228; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang JP, 2017, NEUROSCIENCE, V364, P202, DOI 10.1016/j.neuroscience.2017.09.025; Wang JP, 2016, MOL NEUROBIOL, V53, P6057, DOI 10.1007/s12035-015-9512-8; Wang JP, 2015, BRAIN BEHAV IMMUN, V45, P98, DOI 10.1016/j.bbi.2014.12.015; Wang JP, 2014, BEHAV BRAIN RES, V265, P171, DOI 10.1016/j.bbr.2014.02.033; Wang WZ, 2017, BRAIN BEHAV IMMUN, V64, P344, DOI 10.1016/j.bbi.2017.04.019; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wisor JP, 2009, BRAIN RES, V1296, P46, DOI 10.1016/j.brainres.2009.07.103; Wu G, 2016, MED SCI MONITOR, V22, P2161, DOI 10.12659/MSM.896568; Wu H, 2017, J CEREBR BLOOD F MET, V37, P39, DOI 10.1177/0271678X15625351; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang YQ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00580; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3; Zhang H, 2017, J CEREBR BLOOD F MET, V37, P3422, DOI 10.1177/0271678X17690165; Zhang L, 2018, MOL NEUROBIOL, V55, P1773, DOI 10.1007/s12035-017-0456-z; Zhu W, 2018, BRAIN BEHAV IMMUN, V69, P568, DOI 10.1016/j.bbi.2018.02.004; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423	68	35	36	2	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	FEB 1	2019	131						345	355		10.1016/j.freeradbiomed.2018.12.014			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	HG7TX	WOS:000455199300033	30553970				2021-06-18	
J	Halstead, ME; Walter, KD; Moffatt, K				Halstead, Mark E.; Walter, Kevin D.; Moffatt, Kody		Council Sports Med Fitness	Sport-Related Concussion in Children and Adolescents	PEDIATRICS			English	Article							HIGH-SCHOOL FOOTBALL; TRAUMATIC BRAIN-INJURY; ERROR SCORING SYSTEM; COMPUTERIZED NEUROCOGNITIVE TEST; DEFICIT HYPERACTIVITY DISORDER; EMERGENCY-DEPARTMENT VISITS; CATASTROPHIC HEAD-INJURIES; TEST-RETEST RELIABILITY; STATES HIGH-SCHOOL; RETURN-TO-PLAY	Sport-related concussion is an important topic in nearly all sports and at all levels of sport for children and adolescents. Concussion knowledge and approaches to management have progressed since the American Academy of Pediatrics published its first clinical report on the subject in 2010. Concussion's definition, signs, and symptoms must be understood to diagnose it and rule out more severe intracranial injury. Pediatric health care providers should have a good understanding of diagnostic evaluation and initial management strategies. Effective management can aid recovery and potentially reduce the risk of long-term symptoms and complications. Because concussion symptoms often interfere with school, social life, family relationships, and athletics, a concussion may affect the emotional well-being of the injured athlete. Because every concussion has its own unique spectrum and severity of symptoms, individualized management is appropriate. The reduction, not necessarily elimination, of physical and cognitive activity is the mainstay of treatment. A full return to activity and/or sport is accomplished by using a stepwise program while evaluating for a return of symptoms. An understanding of prolonged symptoms and complications will help the pediatric health care provider know when to refer to a specialist. Additional research is needed in nearly all aspects of concussion in the young athlete. This report provides education on the current state of sport-related concussion knowledge, diagnosis, and management in children and adolescents.	[Halstead, Mark E.] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Walter, Kevin D.] Med Coll Wisconsin, Dept Orthopaed Surg, Pediat Sports Med, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Moffatt, Kody] Creighton Univ, Sch Med, Omaha, NE USA	Halstead, ME (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.	mehalstead@wustl.edu					Agel J, 2010, CAN J SURG, V53, P319; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Alsalaheen B, 2016, BRAIN INJURY, V30, P914, DOI 10.3109/02699052.2016.1146965; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2014, PEDIATRICS, V134, P1224, DOI 10.1542/peds.2014-2984; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Ashbaugh A, 2016, CURR SPORT MED REP, V15, P16, DOI 10.1249/JSR.0000000000000219; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baker A, 2015, ACCIDENT ANAL PREV, V79, P50, DOI 10.1016/j.aap.2015.03.014; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barrett EC, 2014, ADV NUTR, V5, P268, DOI 10.3945/an.113.005280; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bey T, 2009, WEST J EMERG MED, V10, P6; Biederman J, 2015, J NERV MENT DIS, V203, P813, DOI 10.1097/NMD.0000000000000375; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; BOND GR, 1995, PEDIATRICS, V95, P487; Bonow RH, 2017, J NEUROTRAUM, V34, P2706, DOI 10.1089/neu.2017.4970; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Brandenburg MA, 2002, CLIN J SPORT MED, V12, P360, DOI 10.1097/00042752-200211000-00007; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner JS, 2014, PEDIATRICS, V133, P1151, DOI 10.1542/peds.2014-0692; Brett BL, 2016, ARCH CLIN NEUROPSYCH, V31, P904, DOI 10.1093/arclin/acw055; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks MA, 2017, JAMA PEDIATR, V171, P670, DOI 10.1001/jamapediatrics.2017.0592; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; Buzas D, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114528460; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Carl RL, 2014, CLIN PEDIATR, V53, P689, DOI 10.1177/0009922814526979; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Caswell S, 2017, BRIT J SPORT MED, V51, P305; Caswell SV, 2002, J ATHL TRAINING, V37, P164; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Clark JM, 2016, ANN BIOMED ENG, V44, P3693, DOI 10.1007/s10439-016-1686-3; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins CL, 2016, AM J SPORT MED, V44, P1382, DOI 10.1177/0363546516629626; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Comstock D, 2012, EPIDEMIOLOGY PREVENT; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Concannon LG, 2016, PHYS MED REH CLIN N, V27, P513, DOI 10.1016/j.pmr.2015.12.006; Concannon LG, 2014, CURR SPORT MED REP, V13, P365, DOI 10.1249/JSR.0000000000000098; Council on Sports Medicine and Fitness, 2015, PEDIATRICS, V136; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Currie DW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2447; Cusimano MD, 2010, BRIT J SPORT MED, V44, P781, DOI 10.1136/bjsm.2009.070573; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Denny-Brown D E, 1941, Proc R Soc Med, V34, P691; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Downey Daniel J, 2007, Curr Sports Med Rep, V6, P328; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Eckner JT, 2014, AM J SPORT MED, V42, P566, DOI 10.1177/0363546513517869; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Elbin RJ, 2015, RES SPORTS MED, V23, P203, DOI 10.1080/15438627.2015.1005293; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Ellis MJ, 2017, J NEUROSURG-PEDIATR, V19, P38, DOI 10.3171/2016.7.PEDS16310; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Fishman M, 2017, J PEDIATR-US, V184, P19, DOI 10.1016/j.jpeds.2017.01.048; Fukuda O, 2007, NEUROL MED-CHIR, V47, P491, DOI 10.2176/nmc.47.491; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giola G, 2006, ACUTE CONCUSSION EVA; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Graham R., 2014, SPORTS RELATED CONCU; Green L., 2014, LEGAL PERSPECTIVES R; Greenhill DA, 2016, SPORTS HEALTH, V8, P238, DOI 10.1177/1941738116639027; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Grubenhoff JA, 2016, J PEDIATR-US, V174, P27, DOI 10.1016/j.jpeds.2016.03.027; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hansen C, 2017, CLIN J SPORT MED, V27, P64, DOI 10.1097/JSM.0000000000000293; Hansen C, 2016, CLIN J SPORT MED, V26, P497, DOI 10.1097/JSM.0000000000000285; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Heyer GL, 2014, PEDIATR NEUROL, V50, P464, DOI 10.1016/j.pediatrneurol.2014.01.040; Higgins KL, 2017, ARCH CLIN NEUROPSYCH, V32, P259, DOI 10.1093/arclin/acw108; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Huang WY, 2014, BRIT J CANCER, V110, P2354, DOI 10.1038/bjc.2014.103; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kerr ZY, 2017, AM J PREV MED, V53, P914, DOI 10.1016/j.amepre.2017.05.017; Kerr ZY, 2016, JAMA PEDIATR, V170, P647, DOI 10.1001/jamapediatrics.2016.0073; Khanna NK, 2015, SPORTS HEALTH, V7, P341, DOI 10.1177/1941738115571508; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P458, DOI 10.1097/PEC.0000000000000161; Kinnaman KA, 2013, ACTA PAEDIATR, V102, pE424, DOI 10.1111/apa.12315; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1633; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Kostyun RO, 2015, AM J SPORT MED, V43, P633, DOI 10.1177/0363546514560727; Kriz PK, 2016, J PEDIATR-US, V171, P234, DOI 10.1016/j.jpeds.2015.12.006; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Lee Bruce, 2005, NeuroRx, V2, P372; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Lin AC, 2015, SPORTS HEALTH, V7, P124, DOI 10.1177/1941738115571570; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Littleton AC, 2015, ARCH CLIN NEUROPSYCH, V30, P683, DOI 10.1093/arclin/acv043; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; Mannings C, 2014, J TRAUMA ACUTE CARE, V77, pS18, DOI 10.1097/TA.0000000000000371; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer C, 1930, ORAL HYG, V20, P298; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McGuine T, 1996, 1305 ASTM STP, P83; McGuine TA, 2014, AM J SPORT MED, V42, P2470, DOI 10.1177/0363546514541926; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McLendon LA, 2016, PEDIATR NEUROL, V62, P9, DOI 10.1016/j.pediatrneurol.2016.03.009; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mihalik JP, 2017, MED SCI SPORT EXER, V49, P247, DOI 10.1249/MSS.0000000000001089; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Mrazik M, 2015, J HEAD TRAUMA REHAB, V30, P219, DOI 10.1097/HTR.0000000000000018; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Mueller FO, 2001, J ATHL TRAINING, V36, P312; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Parker EM, 2015, J HEAD TRAUMA REHAB, V30, P198, DOI 10.1097/HTR.0000000000000097; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Petraglia Anthony L, 2011, Surg Neurol Int, V2, P146, DOI 10.4103/2152-7806.85987; Pfaller AY, 2016, AM J SPORT MED, V44, P2941, DOI 10.1177/0363546516651821; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Preece MHW, 2010, NEUROPSYCHOLOGY, V24, P493, DOI 10.1037/a0018903; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Purcell L, 2016, CLIN PEDIATR, V55, P452, DOI 10.1177/0009922815589915; Randolph C, 2005, J ATHL TRAINING, V40, P139; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Reisner A, 2017, J PEDIATR-US, V184, P26, DOI 10.1016/j.jpeds.2017.01.045; Root JM, 2016, J PEDIATR-US, V174, P39, DOI 10.1016/j.jpeds.2016.03.020; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Rowhani-Rahbar A, 2016, J NEUROTRAUM, V33, P784, DOI 10.1089/neu.2015.4100; Sabatino M, 2016, AM AC PED NAT C EXH; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2014, J ATHL TRAINING, V49, P659, DOI 10.4085/1062-6050-49.3.37; Schatz P, 2014, ARCH CLIN NEUROPSYCH, V29, P625, DOI 10.1093/arclin/acu041; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneider DK, 2017, BRIT J SPORT MED, V51, P1473, DOI 10.1136/bjsports-2015-095645; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Simon LM, 2016, CURR SPORT MED REP, V15, P161, DOI 10.1249/JSR.0000000000000268; Singh GD, 2009, DENT TRAUMATOL, V25, P515, DOI 10.1111/j.1600-9657.2009.00808.x; Snedden TR, 2017, CLIN J SPORT MED, V27, P462, DOI 10.1097/JSM.0000000000000389; Stache S, 2016, CLIN J SPORT MED, V26, P381, DOI 10.1097/JSM.0000000000000270; Stein CJ, 2016, CLIN J SPORT MED, V26, P386, DOI 10.1097/JSM.0000000000000268; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stocker RPJ, 2017, ARCH CLIN NEUROPSYCH, V32, P349, DOI 10.1093/arclin/acx003; Stoller J, 2014, CAN FAM PHYSICIAN, V60, P548; Sufrinko A, 2016, NEUROPSYCHOLOGY, V30, P484, DOI 10.1037/neu0000250; Sufrinko AM, 2017, J PEDIATR-US, V185, P167, DOI 10.1016/j.jpeds.2017.02.072; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Taubman B, 2016, J CHILD NEUROL, V31, P1607, DOI 10.1177/0883073816667194; Terwilliger VK, 2016, J NEUROTRAUM, V33, P761, DOI 10.1089/neu.2015.4082; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Trojian TH, 2011, CURR SPORT MED REP, V10, P180, DOI 10.1249/JSR.0b013e31822458d5; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vaughan CG, 2014, AM J SPORT MED, V42, P1716, DOI 10.1177/0363546514531732; Vernau BT, 2015, DEV NEUROPSYCHOL, V40, P7, DOI 10.1080/87565641.2014.971955; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Wallace J, 2017, J ATHL TRAINING, V52, P682, DOI 10.4085/1062-6050-52.3.06; Wallace J, 2017, J ATHL TRAINING, V52, P228, DOI 10.4085/1062-6050-52.1.07; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; WATTS G, 1954, J AM DENT ASSOC, V49, P7, DOI 10.14219/jada.archive.1954.0132; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Winters Jackson, 2014, General Dentistry, V62, P34; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; WITHNALL C, 2005, BR J SPORTS MED S1, V39, P48; World Health Organization, 1992, ICD 10 CLASS MENT BE; Xiang J, 2014, AM J SPORT MED, V42, P2082, DOI 10.1177/0363546514539914; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zemek R, 2014, PAED CHILD HEALT-CAN, V19, P474, DOI 10.1093/pch/19.9.475; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	268	35	35	1	25	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2018	142	6							e20183074	10.1542/peds.2018-3074			24	Pediatrics	Pediatrics	HB8WO	WOS:000451372200058	30420472	Bronze			2021-06-18	
J	Zanier, ER; Bertani, I; Sammali, E; Pischiutta, F; Chiaravalloti, MA; Vegliante, G; Masone, A; Corbelli, A; Smith, DH; Menon, DK; Stocchetti, N; Fiordaliso, F; De Simoni, MG; Stewart, W; Chiesa, R				Zanier, Elisa R.; Bertani, Ilaria; Sammali, Eliana; Pischiutta, Francesca; Chiaravalloti, Maria Antonietta; Vegliante, Gloria; Masone, Antonio; Corbelli, Alessandro; Smith, Douglas H.; Menon, David K.; Stocchetti, Nino; Fiordaliso, Fabio; De Simoni, Maria-Grazia; Stewart, William; Chiesa, Roberto			Induction of a transmissible tau pathology by traumatic brain injury	BRAIN			English	Article						traumatic brain injury; tau pathology; prion; neurological dysfunction; neurodegeneration	CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; MOUSE-BRAIN; NEUROFIBRILLARY TANGLES; IN-VIVO; MODEL; MICE; ENCEPHALOPATHY; TAUOPATHIES; PROPAGATION	Traumatic brain injury is a risk factor for subsequent neurodegenerative disease, including chronic traumatic encephalopathy, a tauopathy mostly associated with repetitive concussion and blast, but not well recognized as a consequence of severe traumatic brain injury. Here we show that a single severe brain trauma is associated with the emergence of widespread hyperphosphorylated tau pathology in a proportion of humans surviving late after injury. In parallel experimental studies, in a model of severe traumatic brain injury in wild-type mice, we found progressive and widespread tau pathology, replicating the findings in humans. Brain homogenates from these mice, when inoculated into the hippocampus and overlying cerebral cortex of naive mice, induced widespread tau pathology, synaptic loss, and persistent memory deficits. These data provide evidence that experimental brain trauma induces a self-propagating tau pathology, which can be transmitted between mice, and call for future studies aimed at investigating the potential transmissibility of trauma associated tau pathology in humans.	[Zanier, Elisa R.; Bertani, Ilaria; Sammali, Eliana; Pischiutta, Francesca; Chiaravalloti, Maria Antonietta; Vegliante, Gloria; Masone, Antonio; De Simoni, Maria-Grazia; Chiesa, Roberto] IRCCS, Ist Ric Farmacol Mario Negri, Dept Neurosci, Via G La Masa 19, I-20156 Milan, Italy; [Sammali, Eliana] Fdn IRCCS, Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy; [Corbelli, Alessandro; Fiordaliso, Fabio] IRCCS, Ist Ric Farmacol Mario Negri, Dept Cardiovasc Res, I-20156 Milan, Italy; [Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Perelman Sch Med, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge CB2 2QQ, England; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, I-20122 Milan, Italy; [Stocchetti, Nino] Osped Maggiore, Policlin Milano, Fdn IRCCS Ca Granda, I-20122 Milan, Italy; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TE, Lanark, Scotland	Zanier, ER; Chiesa, R (corresponding author), IRCCS, Ist Ric Farmacol Mario Negri, Dept Neurosci, Via G La Masa 19, I-20156 Milan, Italy.	elisa.zanier@marionegri.it; roberto.chiesa@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; Chiaravalloti, Maria Antonietta/ABI-5305-2020; Fiordaliso, Fabio/AAA-7161-2020; Chiesa, Roberto/Q-4295-2019; Zanier, Elisa/AAA-8095-2020; Corbelli, Alessandro/ABG-3900-2020; Pischiutta, Francesca/AAA-7927-2020; Sammali, Eliana/AAA-2464-2019	De Simoni, Maria Grazia/0000-0001-6695-5297; Chiaravalloti, Maria Antonietta/0000-0002-5355-1346; Fiordaliso, Fabio/0000-0002-0172-4030; Chiesa, Roberto/0000-0002-3842-3733; Corbelli, Alessandro/0000-0001-8545-8050; Pischiutta, Francesca/0000-0002-7151-0812; Zanier, Elisa/0000-0002-3011-8718; Masone, Antonio/0000-0001-8357-5931; Bertani, Ilaria/0000-0003-3175-8677; Stewart, William/0000-0003-2199-2582	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH NS094003, NS038104]; NHS Research Scotland Career-Researcher Fellowship; Alzheimer's AssociationAlzheimer's Association [AARG-18532633]; National Institute for Health Research (UK)National Institute for Health Research (NIHR); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094003, R01NS038104] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (NIH NS094003 and NS038104) (D.H.S., W.S.); by NHS Research Scotland Career-Researcher Fellowship (W.S.); and the Alzheimer's Association (AARG-18532633) (E.R.Z., R.C.); D.K.M. was supported by a Senior Investigator award from the National Institute for Health Research (UK).	Ahmed Z, 2014, ACTA NEUROPATHOL, V127, P667, DOI 10.1007/s00401-014-1254-6; Bouybayoune I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004796; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Chiesa R, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004745; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gerson J, 2016, J NEUROTRAUM, V33, P2034, DOI 10.1089/neu.2015.4262; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goedert M, 2017, MOL BRAIN, V10, DOI 10.1186/s13041-017-0298-7; Goedert M, 2017, BRAIN, V140, P266, DOI 10.1093/brain/aww230; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo JL, 2016, J EXP MED, V213, P2635, DOI 10.1084/jem.20160833; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Heise C, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00106; Holmes BB, 2014, J BIOL CHEM, V289, P19855, DOI 10.1074/jbc.R114.549295; Iba M, 2015, ACTA NEUROPATHOL, V130, P349, DOI 10.1007/s00401-015-1458-4; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kaufman SK, 2016, NEURON, V92, P796, DOI 10.1016/j.neuron.2016.09.055; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Makinde HM, 2017, SHOCK, V48, P276, DOI 10.1097/SHK.0000000000000859; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mudher A, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0488-7; Narasimhan S, 2017, J NEUROSCI, V37, P11406, DOI 10.1523/JNEUROSCI.1230-17.2017; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Petry FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094251; Pischiutta F, 2018, EXP NEUROL, V300, P167, DOI 10.1016/j.expneurol.2017.11.003; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 2012, SCIENCE, V336, P1511, DOI 10.1126/science.1222951; Sanders DW, 2014, NEURON, V82, P1271, DOI 10.1016/j.neuron.2014.04.047; Sekino Y, 2017, ADV EXP MED BIOL, V1006, P183, DOI 10.1007/978-4-431-56550-5_11; Senatore A, 2012, NEURON, V74, P300, DOI 10.1016/j.neuron.2012.02.027; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Woerman AL, 2016, P NATL ACAD SCI USA, V113, pE8187, DOI 10.1073/pnas.1616344113; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041	51	35	36	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2018	141		9				2685	2699		10.1093/brain/awy193			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GW0IX	WOS:000446548100023	30084913	Green Published, Green Accepted			2021-06-18	
J	Chen, XR; Wang, HD; Zhou, ML; Li, X; Fang, ZN; Gao, HZ; Li, YS; Hu, WP				Chen, Xiangrong; Wang, Handong; Zhou, Mengliang; Li, Xiang; Fang, Zhongning; Gao, Hongzhi; Li, Yasong; Hu, Weipeng			Valproic Acid Attenuates Traumatic Brain Injury-Induced Inflammation in Vivo: Involvement of Autophagy and the Nrf2/ARE Signaling Pathway	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						traumatic brain injury; valproic acid; HDAC3; microglia; inflammatory; autophagy; Nrf2/ARE pathway	HEMORRHAGIC-SHOCK; RATS; APOPTOSIS; CELLS; NEUROPROTECTION; NEUROGENESIS; SUPPRESSION; ACTIVATION; INHIBITION; EXPRESSION	Microglial activation and the inflammatory response in the central nervous system (CNS) play important roles in secondary damage after traumatic brain injury (TBI). Transcriptional activation of genes that limit secondary damage to the CNS are mediated by a cis-acting element called the antioxidant responsive element (ARE). ARE is known to associate with the transcription factor NF-E2-related factor 2 (Nrf2), a transcription factor that is associated with histone deacetylases (HDACs). This pathway, known as the Nrf2/ARE pathway, is a critical antioxidative factor pathway that regulates the balance of oxygen free radicals and the inflammatory response, and is also related to autophagic activities. Although valproic acid (VPA) is known to inhibit HDACs, it is unclear whether VPA plays a role in the microglia-mediated neuroinflammatory response after TBI via regulating oxidative stress and autophagy induced by the Nrf2/ARE signaling pathway. In this study, we demonstrate that microglial activation, oxidative stress, autophagy, and the Nrf2/ARE signaling pathway play essential roles in secondary injury following TBI. Treatment with VPA alleviated TBI-induced secondary brain injury, including neurological deficits, cerebral edema, and neuronal apoptosis. Moreover, VPA treatment upregulated the occurrence of autophagy and Nrf2/ARE pathway activity after TBI, and there was an increase in H3, H4 histone acetylation levels, accompanied by decreased transcriptional activity of the HDAC3 promoter in cortical lesions. These results suggest that VPA-mediated up-regulation of autophagy and antioxidative responses are likely due to increased activation of Nrf2/ARE pathway, through direct inhibition of HDAC3. This inhibition further reduces TBI-induced microglial activation and the subsequent inflammatory response, ultimately leading to neuroprotection.	[Chen, Xiangrong; Wang, Handong; Zhou, Mengliang; Li, Xiang] Southern Med Univ, Jinling Hosp, Nanjing Sch Clin Med, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Chen, Xiangrong; Fang, Zhongning; Gao, Hongzhi; Li, Yasong; Hu, Weipeng] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou, Peoples R China	Wang, HD (corresponding author), Southern Med Univ, Jinling Hosp, Nanjing Sch Clin Med, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.	njhdwang@hotmail.com	zhang, chuengji/AAD-4591-2020	Zhou, Meng-liang/0000-0002-1165-5489	Natural Science Foundation of Fujian ProvinceNatural Science Foundation of Fujian Province [2015J01443]; Key Medical Subjects of Jiangsu Province [ZDXKB2016023]	This work was supported by grants from the Natural Science Foundation of Fujian Province (Grant No. 2015J01443) for XC and the Key Medical Subjects of Jiangsu Province (Grant No. ZDXKB2016023).	Bai Y, 2017, EXP BIOL MED, V242, P527, DOI 10.1177/1535370216685433; Bonay M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.256; Cha HY, 2016, CANCER LETT, V372, P65, DOI 10.1016/j.canlet.2015.12.016; Chen S, 2014, NEUROCHEM RES, V39, P1621, DOI 10.1007/s11064-014-1241-2; Chen X., 2017, RNA BIOL, V2017, P1, DOI DOI 10.1155/2017/5196958; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Chhor V, 2017, BRAIN BEHAV IMMUN, V63, P197, DOI 10.1016/j.bbi.2016.11.001; Chu TC, 2015, REGEN MED, V10, P193, DOI [10.2217/RME.14.86, 10.2217/rme.14.86]; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Gao YY, 2017, AM J TRANSL RES, V9, P887; Genet GF, 2017, J NEUROTRAUM, V34, P1054, DOI 10.1089/neu.2016.4574; Guadagno J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.151; He RN, 2015, AUTOPHAGY, V11, P740, DOI 10.1080/15548627.2015.1034404; Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8; Jang J, 2016, CELL, V165, P410, DOI 10.1016/j.cell.2016.02.014; Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Lastres-Becker I, 2014, BRAIN, V137, P78, DOI 10.1093/brain/awt323; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Nikolian VC, 2018, J TRAUMA ACUTE CARE, V84, P459, DOI 10.1097/TA.0000000000001765; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Penas C, 2011, NEUROSCIENCE, V178, P33, DOI 10.1016/j.neuroscience.2011.01.012; Rajendran P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0132-y; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Sillesen M, 2016, J TRAUMA ACUTE CARE, V80, P26, DOI 10.1097/TA.0000000000000896; Sinha SP, 2017, BRAIN BEHAV IMMUN, V61, P353, DOI 10.1016/j.bbi.2017.01.006; Suda S, 2015, BRAIN RES, V1606, P1, DOI 10.1016/j.brainres.2015.02.013; Sun Z, 2009, MOL CELL BIOL, V29, P2658, DOI 10.1128/MCB.01639-08; Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133; Tang CH, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/2923182; Vlahakis A, 2017, AUTOPHAGY, V13, P1256, DOI 10.1080/15548627.2017.1299314; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wasik U, 2017, SCI REP-UK, V7, DOI 10.1038/srep44769; Wilson CB, 2014, BEHAV BRAIN RES, V268, P72, DOI 10.1016/j.bbr.2014.03.029; Xue F, 2016, BEHAV BRAIN RES, V309, P1, DOI 10.1016/j.bbr.2016.04.045; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yang XY, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00131; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763; Zhang RR, 2017, MOL NEUROBIOL, V54, P6006, DOI 10.1007/s12035-016-0111-0; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915	49	35	36	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	APR 17	2018	11								117	10.3389/fnmol.2018.00117			14	Neurosciences	Neurosciences & Neurology	GD0WQ	WOS:000430222100001	29719500	DOAJ Gold, Green Published			2021-06-18	
J	Servadei, F; Rossini, Z; Nicolosi, F; Morselli, C; Park, KB				Servadei, Franco; Rossini, Zefferino; Nicolosi, Federico; Morselli, Carlotta; Park, Kee B.			The Role of Neurosurgery in Countries with Limited Facilities: Facts and Challenges	WORLD NEUROSURGERY			English	Article						Education; Global surgery; Lancet Commission; LMICs; Neurosurgical care; Training; WFNS	TRAUMATIC BRAIN-INJURY; EMERGENCY NEUROSURGERY; DEVELOPING-WORLD; EPIDEMIOLOGY; MANAGEMENT; RESOURCE; TUMORS; CARE; HYDROCEPHALUS; TELEMEDICINE	The Lancet Commission on Global Surgery has recently focused its attention on the lack of surgical care worldwide. Like other surgical subspecialties, neurosurgical care needs to be better distributed around the world, with a major focus on low- to middle-income countries. Neurosurgical diseases like hydrocephalus, traumatic brain injury, and brain tumors have a high impact on families, individual quality of life, and cost for the society. Implementation of neurosurgical care in poor settings is not easy. More than other surgeries, neurosurgery requires great amounts of human resources, dedicated environments, and specialized postoperative care. It is responsibility of the neurosurgical community to identify major areas of current gaps and outline strategies for intervention.	[Servadei, Franco] Humanitas Univ, Dept Neurosurg, Pieve Emanuele, MI, Italy; [Servadei, Franco; Rossini, Zefferino; Nicolosi, Federico; Morselli, Carlotta] Humanitas Clin & Res Ctr, Dept Neurosurg, Rozzano, MI, Italy; [Servadei, Franco] World Federat Neurosurg Soc, Nyon, Switzerland; [Park, Kee B.] Harvard Med Sch, Program Global Surg & Social Change, Boston, MA USA	Servadei, F (corresponding author), Humanitas Univ, Dept Neurosurg, Pieve Emanuele, MI, Italy.; Servadei, F (corresponding author), Humanitas Clin & Res Ctr, Dept Neurosurg, Rozzano, MI, Italy.	franco.servadei@hunimed.eu		Morselli, Carlotta/0000-0003-1031-4874			Adams LP, 1998, PHOTOGRAMM REC, V16, P259, DOI 10.1111/0031-868X.00125; Adeleye AO, 2016, J NEUROL SURG PART A, V77, P167, DOI 10.1055/s-0035-1566115; Adeleye AO, 2012, WORLD NEUROSURG, V78, DOI [10.1016/j.wneu.2011.07.015, 10.1016/J.WNEU.2011.07.015]; Adeloye A, 1997, E AFR MED J, V74, P263; Azad TD, 2015, WORLD NEUROSURG, V84, P1832, DOI 10.1016/j.wneu.2015.07.074; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cherian I, 2016, WORLD NEUROSURG, V89, P51, DOI 10.1016/j.wneu.2016.01.072; Dadlani R, 2014, WORLD NEUROSURG, V82, P270, DOI 10.1016/j.wneu.2014.05.027; Dewan MC, 2017, PEDIATR NEUROSURG, V52, P401, DOI 10.1159/000452809; Ellegala DB, 2014, J NEUROSURG, V121, P1526, DOI 10.3171/2014.7.JNS122153; Ezzat S, 2016, J NEURO-ONCOL, V126, P371, DOI 10.1007/s11060-015-1979-7; Ganapathy K, 2002, SURG NEUROL, V58, P388, DOI 10.1016/S0090-3019(02)00924-2; Griswold D, 2016, WORLD NEUROSURG, V93, P474, DOI 10.1016/j.wneu.2016.06.044; Gupta S, 2017, WORLD NEUROSURG, V100, P267, DOI 10.1016/j.wneu.2016.12.104; Howe KL, 2013, WORLD NEUROSURG, V80, pE171, DOI [10.1016/j.wneu.2013.02.087, 10.1016/j.wneu.2013.07.003]; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Luck T, 2015, ANZ J SURG, V85, P610, DOI 10.1111/ans.13138; Mainthia R, 2009, J NEUROSURG-PEDIATR, V4, P4, DOI 10.3171/2009.1.PEDS08193; Meara JG, 2014, LANCET, V383, P12, DOI 10.1016/S0140-6736(13)62345-4; Mock CN, 2015, LANCET, V385, P2209, DOI 10.1016/S0140-6736(15)60091-5; Muir RT, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16273; Ng-Kamstra JS, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2015-000011; Ojo O A, 2015, Niger Postgrad Med J, V22, P45; Okazaki T, 2016, WORLD NEUROSURG, V93, P336, DOI 10.1016/j.wneu.2016.06.070; Owler BK, 2015, J NEUROSURG-PEDIATR, V16, P340, DOI 10.3171/2015.2.PEDS14310; Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048; Piquer J, 2015, J NEUROSURG-PEDIATR, V15, P552, DOI 10.3171/2014.10.PEDS14318; Rasul FT, 2012, BRIT J NEUROSURG, V26, P736, DOI 10.3109/02688697.2012.690909; Ravindra VM, 2015, WORLD NEUROSURG, V84, P1458, DOI 10.1016/j.wneu.2015.06.046; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2015, ANZ J SURG, V85, P600, DOI 10.1111/ans.13207; Servadei F, 2003, INJURY PREV, V9, P257, DOI 10.1136/ip.9.3.257; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Smart LR, 2017, WORLD NEUROSURG, V105, P238, DOI 10.1016/j.wneu.2017.05.101; Srivastava PV, 2014, INT J STROKE, V9, P133, DOI 10.1111/ijs.12326; Stagno V, 2014, CHILD NERV SYST, V30, P137, DOI 10.1007/s00381-013-2297-z; Stahl I, 2017, SPINE J, V17, P161, DOI 10.1016/j.spinee.2016.08.021; Thapa A, 2016, WORLD NEUROSURG, V95, P270, DOI 10.1016/j.wneu.2016.08.001; United Nations, 2015, MILL DEV GOAL 8 TAK; Warf BC, 2005, J NEUROSURG, V102, P358, DOI 10.3171/ped.2005.102.4.0358; Warf BC, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2010.09.021; WHO (World Health Organization), 2015, GLOB STAT REP ROAD S; Wong JM, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12179	43	35	36	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	APR	2018	112						315	321		10.1016/j.wneu.2018.01.047			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG8FH	WOS:000432932700172	29366998				2021-06-18	
J	del-Pino-Casado, R; Frias-Osuna, A; Palomino-Moral, PA; Ruzafa-Martinez, M; Ramos-Morcillo, AJ				del-Pino-Casado, Rafael; Frias-Osuna, Antonio; Palomino-Moral, Pedro A.; Ruzafa-Martinez, Maria; Ramos-Morcillo, Antonio J.			Social support and subjective burden in caregivers of adults and older adults: A meta-analysis	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; FAMILY CAREGIVERS; INFORMAL CAREGIVERS; PUBLICATION BIAS; ALZHEIMERS-DISEASE; PERCEIVED BURDEN; MENTAL-HEALTH; NURSING-HOME; DEMENTIA	Background & para;& para;Despite the generally accepted belief that social support improves caregiver adjustment in general and subjective burden in particular, the literature shows mixed findings, and a recent review concluded that the predictive strength of caregiver social support in determining caregiver burden is less evident, due to the conceptual diversity of this determinant.& para;& para;Objective & para;& para;The purpose of this review is to analyse the relationship of perceived and received social support with subjective burden among informal caregivers of an adult or older adult.& para;& para;Methods & para;& para;A systematic search was carried out up to September 2017 in the following databases: MEDLINE (PubMed), CINAHL, EMBASE, PsycINFO), Scopus and ISI Proceedings, and a meta-analysis was performed with the results of the selected and included studies.& para;& para;Results & para;& para;Fifty-six studies were included in the meta-analysis, which provided 46 independent comparisons for perceived support and 16 for received support. Most of these studies were cross-sectional. There was a moderate, negative association of perceived social support on subjective burden (r =-0.36; CI 95%=-0.40,-0.32) and a very small, negative association of received support on subjective burden (r =-0.05; CI 95%=-0.095,-0.001). & para;& para;Conclusions & para;& para;1) perceived and received support are not redundant constructs, 2) the relationships between social support and subjective burden depend on whether the social support is measured as perceived or received, 3) the relationship of perceived social support with subjective burden has a bigger effect size than that of received social support, the relation between received support and subjective burden being clinically irrelevant, 4) perceived social support may be a good predictor of subjective burden.& para;& para;Implications of key findings & para;& para;Our findings broadly support interventions promoting social support in caregivers to prevent or alleviate subjective burden, and specifically, to intervene on the promotion of perceived social support more than on the promotion of received social support when preventing or alleviating burden.& para;& para;Implications of key findings & para;& para;Our findings broadly support interventions promoting social support in caregivers to prevent or alleviate subjective burden, and specifically, to intervene on the promotion of perceived social support more than on the promotion of received social support when preventing or alleviating burden.	[del-Pino-Casado, Rafael; Frias-Osuna, Antonio; Palomino-Moral, Pedro A.] Univ Jaen, Fac Hlth Sci, Dept Nursing, Jaen, Spain; [Ruzafa-Martinez, Maria; Ramos-Morcillo, Antonio J.] Univ Murcia, Fac Nursing, Dept Nursing, Murcia, Spain	del-Pino-Casado, R (corresponding author), Univ Jaen, Fac Hlth Sci, Dept Nursing, Jaen, Spain.	rdelpino@ujaen.es	del-Pino-Casado, Rafael/L-3733-2018; Ruzafa-Martinez, Maria/AAB-5248-2019; Ramos-Morcillo, Antonio Jesus/J-2195-2016	del-Pino-Casado, Rafael/0000-0003-2263-2415; Ruzafa-Martinez, Maria/0000-0001-6570-738X; Ramos-Morcillo, Antonio Jesus/0000-0002-3490-3326			Adriaansen JJE, 2011, PATIENT EDUC COUNS, V85, pE48, DOI 10.1016/j.pec.2010.12.011; Alvarez-Ude F, 2004, J NEPHROL, V17, P841; Aneshensel C.S., 1995, PROFILES CAREGIVING; Annisa F, 2015, THAI PHARM HLTH SCI, V10, P87; Artaso B., 2003, Revista Espanola de Geriatria y Gerontologia, V38, P212; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bainbridge D, 2009, AGING MENT HEALTH, V13, P537, DOI 10.1080/13607860802607322; Barrera Jr M., 1983, CONNECTIONS, V3, P8; Barusch A. S., 1994, J GERONTOL SOC WORK, V21, P197; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Blake H, 2000, CLIN REHABIL, V14, P307, DOI 10.1191/026921500667530134; Boyle MH., 1998, EVID BASED MENTAL HL, V1, P37, DOI DOI 10.1136/EBMH.1.2.37; Burton Allison M, 2008, Palliat Support Care, V6, P149, DOI 10.1017/S1478951508000230; Carretero S, 2009, ARCH GERONTOL GERIAT, V49, P74, DOI 10.1016/j.archger.2008.05.004; Cassidy T, 2013, PSYCHOL HEALTH, V28, P250, DOI 10.1080/08870446.2012.717623; Chang BL, 2001, WOMEN HEALTH, V33, P39, DOI 10.1300/J013v33n01_04; Cheng ST, 2013, GERONTOLOGIST, V53, P998, DOI 10.1093/geront/gns195; Chiou CJ, 2009, ARCH GERONTOL GERIAT, V48, P419, DOI 10.1016/j.archger.2008.04.001; CLAIR JM, 1995, SOCIOL PERSPECT, V38, P195, DOI 10.2307/1389290; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; Cohen S, 2004, AM PSYCHOL, V59, P676, DOI 10.1037/0003-066X.59.8.676; Cooper C, 2007, INT PSYCHOGERIATR, V19, P175, DOI 10.1017/S1041610206004297; Cooper H, 2009, HDB RES SYNTHESIS ME; Cotelo Natalia Verez, 2015, Pharm Pract (Granada), V13, P521; Dam AEH, 2016, MATURITAS, V85, P117, DOI 10.1016/j.maturitas.2015.12.008; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; del-Pino-Casado R, 2014, J NURS SCHOLARSHIP, V46, P176, DOI 10.1111/jnu.12070; del-Pino-Casado R, 2011, J ADV NURS, V67, P2311, DOI 10.1111/j.1365-2648.2011.05725.x; Dorfman LT, 1996, FAM RELAT, V45, P46, DOI 10.2307/584769; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Edwards Nancy E, 2002, J Neurosci Nurs, V34, P184; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elvish R, 2013, PSYCHOL INTERVENTION; FOLKMAN S, 1994, J CONSULT CLIN PSYCH, V62, P746, DOI 10.1037/0022-006X.62.4.746; Gallart A, 2013, J ADV NURS, V69, P642, DOI 10.1111/j.1365-2648.2012.06049.x; Gold DP, 1995, INT J AGING HUM DEV, V41, P183, DOI 10.2190/RGYJ-5KA2-7THX-7BQ5; Goldsworthy B, 2008, J GERONTOL B-PSYCHOL, V63, pP372, DOI 10.1093/geronb/63.6.P372; Goris S, 2016, HOLIST NURS PRACT, V30, P227, DOI 10.1097/HNP.0000000000000153; Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001; Greenberger H, 2003, J ADV NURS, V41, P332, DOI 10.1046/j.1365-2648.2003.02531.x; Greene MC, 2013, AIDS BEHAV, V17, P1775, DOI 10.1007/s10461-012-0396-6; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; Kahriman Fatma, 2015, Asian Pac J Cancer Prev, V16, P3313; Kaur N, 2014, DELHI PSYCHIAT J, V17, P337; Kim H, 2012, J ADV NURS, V68, P846, DOI 10.1111/j.1365-2648.2011.05787.x; Kruithof WJ, 2016, PATIENT EDUC COUNS, V99, P1632, DOI 10.1016/j.pec.2016.04.007; Lazarus R.S., 1984, STRESS APPRAISAL COP; LECHNER VM, 1993, SOC WORK, V38, P461; Leibach G, 2013, EXAMINING RELATIONS; Liu Y, 2012, NURS RES, V61, P39, DOI 10.1097/NNR.0b013e31823bc451; Lopez S.R., 2005, ENFERMERIA COMUNITAR, V1, P12; Losada A, 2010, AGING MENT HEALTH, V14, P193, DOI 10.1080/13607860903167838; Losada A, 2010, ARCH GERONTOL GERIAT, V50, P347, DOI 10.1016/j.archger.2009.06.001; Lubben J, 2006, GERONTOLOGIST, V46, P503, DOI 10.1093/geront/46.4.503; Majerovitz SD, 2007, AGING MENT HEALTH, V11, P323, DOI 10.1080/13607860600963380; Manso Martínez Mª Esperanza, 2013, Clínica y Salud, V24, P37, DOI 10.5093/cl2013a5; Marwit SJ, 2002, GERONTOLOGIST, V42, P751, DOI 10.1093/geront/42.6.751; Meader N, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-82; Meiland FJM, 2001, SCAND J PUBLIC HEALT, V29, P113, DOI 10.1177/14034948010290020801; Melrose KL, 2015, PERS INDIV DIFFER, V77, P97, DOI 10.1016/j.paid.2014.12.047; Moller-Leimkuhler AM, 2012, EUR ARCH PSY CLIN N, V262, P157, DOI 10.1007/s00406-011-0215-5; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Molina Linde JM, 2005, PSICOLOGIA SALUD, V15, P33; Moral Serrano M S, 2003, Aten Primaria, V32, P77, DOI 10.1157/13049173; Bermejo LM, 2015, REV ROL ENFERM, V38, P852; Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Prati G, 2010, J COMMUNITY PSYCHOL, V38, P403, DOI 10.1002/jcop.20371; REIS MF, 1994, INT J AGING HUM DEV, V39, P257, DOI 10.2190/6LYN-YFWQ-P87D-MKWX; Riemsma RP, 1999, PSYCHOL HEALTH, V14, P773, DOI 10.1080/08870449908407347; Robinson K M, 1990, Sch Inq Nurs Pract, V4, P189; Rodakowski J, 2012, ARCH PHYS MED REHAB, V93, P2229, DOI 10.1016/j.apmr.2012.07.004; Roe B, 2007, REVIEWING RESEARCH EVIDENCE FOR NURSING PRACTICE: SYSTEMATIC REVIEWS, P9, DOI 10.1002/9780470692127.ch2; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Ryan KA, 2012, DEMENT GERIATR COGN, V34, P206, DOI 10.1159/000339955; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Schoenmakers B, 2010, MATURITAS, V66, P191, DOI 10.1016/j.maturitas.2010.02.009; Shieh SC, 2012, J NURS SCHOLARSHIP, V44, P223, DOI 10.1111/j.1547-5069.2012.01453.x; Smerglia VL, 2007, AGING MENT HEALTH, V11, P205, DOI 10.1080/13607860600844515; Son Gwi-Ryung, 2003, J Gerontol Nurs, V29, P19; Stevens LF, 2013, AM J PHYS MED REHABI; Stommel M., 1990, J AGING HEALTH, V2, P81, DOI DOI 10.1177/089826439000200106; Tang Y, 2006, OBLIGATION FILIAL PI; Teixeira RJ, 2013, PSYCHO-ONCOLOGY, V22, P1587, DOI 10.1002/pon.3173; THOMPSON EH, 1993, J GERONTOL, V48, pS245, DOI 10.1093/geronj/48.5.S245; Uchino BN, 2012, SOC SCI MED, V74, P949, DOI 10.1016/j.socscimed.2011.11.023; van der Lee J, 2014, AGEING RES REV, V15, P76, DOI 10.1016/j.arr.2014.03.003; Verbakel E, 2016, CAREGIVING OLDER ADU; Viswanathan M., 2013, ASSESSING RISK BIAS; Vrabec N J, 1997, Image J Nurs Sch, V29, P383, DOI 10.1111/j.1547-5069.1997.tb01062.x; Wang Hsiu-Hung, 2003, Kaohsiung Journal of Medical Sciences, V19, P345, DOI 10.1016/S1607-551X(09)70436-X; Wang Li-Chieh, 2011, Hu Li Za Zhi, V58, P54; Wittenberg-Lyles E, 2014, HEALTH COMMUN, V29, P901, DOI 10.1080/10410236.2013.815111; Yuksel MM, 2013, WELL BEING SIBLINGS; Yurtsever S., 2013, J NURSING ED PRACTIC, V3, DOI [10.5430/jnep.v3n9p1, DOI 10.5430/JNEP.V3N9P1]; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649; Zegwaard MI, 2011, J CLIN NURS, V20, P2233, DOI 10.1111/j.1365-2702.2010.03524.x	101	35	35	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2018	13	1							e0189874	10.1371/journal.pone.0189874			18	Multidisciplinary Sciences	Science & Technology - Other Topics	FR5JA	WOS:000419101600038	29293522	DOAJ Gold, Green Published			2021-06-18	
J	Rose, CR; Ziemens, D; Untiet, V; Fahlke, C				Rose, Christine R.; Ziemens, Daniel; Untiet, Verena; Fahlke, Christoph			Molecular and cellular physiology of sodium-dependent glutamate transporters	BRAIN RESEARCH BULLETIN			English	Article						EAAT; GLAST; GLT-1; Anion conductance; Astrocyte; Tripartite synapse	AMINO-ACID TRANSPORTER; BERGMANN GLIAL-CELLS; SYNAPTICALLY RELEASED GLUTAMATE; CEREBELLAR PURKINJE-CELLS; AMYOTROPHIC-LATERAL-SCLEROSIS; RAT HIPPOCAMPAL ASTROCYTES; PLASMA-MEMBRANE VESICLES; NMDA RECEPTOR ACTIVATION; TRAUMATIC BRAIN-INJURY; GATED CHLORIDE CHANNEL	Glutamate is the major excitatory transmitter in the vertebrate brain. After its release from presynaptic nerve terminals, it is rapidly taken up by high-affinity sodium-dependent plasma membrane transporters. While both neurons and glial cells express these excitatory amino acid transporters (EAATs), the majority of glutamate uptake is accomplished by astrocytes, which convert synaptically-released glutamate to glutamine or feed it into their own metabolism. Glutamate uptake by astrocytes not only shapes synaptic transmission by regulating the availability of glutamate to postsynaptic neuronal receptors, but also protects neurons from hyper-excitability and subsequent excitotoxic damage. In the present review, we provide an overview of the molecular and cellular characteristics of sodium-dependent glutamate transporters and their associated anion permeation pathways, with a focus on astrocytic glutamate transport. We summarize their functional properties and roles within tripartite synapses under physiological and pathophysiological conditions, exemplifying the intricate interactions and interrelationships between neurons and glial cells in the brain. (C) 2016 Elsevier Inc. All rights reserved.	[Rose, Christine R.; Ziemens, Daniel] Heinrich Heine Univ Dusseldorf, Fac Math & Nat Sci, Inst Neurobiol, Univ Str 1, D-40225 Dusseldorf, Germany; [Untiet, Verena; Fahlke, Christoph] Forschungszentrum Julich, Inst Complex Syst, Zellullare Biophys ICS 4, Julich, Germany	Rose, CR (corresponding author), Heinrich Heine Univ Dusseldorf, Fac Math & Nat Sci, Inst Neurobiol, Univ Str 1, D-40225 Dusseldorf, Germany.	rose@uni-duesseldorf.de	Fahlke, Christoph/G-3635-2013; Untiet, Verena/AAZ-4783-2020	Fahlke, Christoph/0000-0001-8602-9952; Untiet, Verena/0000-0002-1888-6378	German Research FoundationGerman Research Foundation (DFG) [Ro2327/8-1]	We thank Lisa Felix, Institute of Neurobiology, for critical comments on the manuscript and Dr. Jan-Philipp Machtens, Institute of Complex Systems, for helpful discussion and providing figures 2 and 3. This work was supported by the German Research Foundation (Ro2327/8-1).	Abrahamsen B, 2013, J NEUROSCI, V33, P1068, DOI 10.1523/JNEUROSCI.3396-12.2013; Adamczyk A, 2011, PSYCHIAT GENET, V21, P90, DOI 10.1097/YPG.0b013e328341a307; Al Awabdh S, 2016, GLIA, V64, P1252, DOI 10.1002/glia.22997; Albrecht J, 2010, BIOCHEM PHARMACOL, V80, P1303, DOI 10.1016/j.bcp.2010.07.024; Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; AMATO A, 1994, J NEUROPHYSIOL, V72, P1686; Anderson CM, 2000, GLIA, V32, P1; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Arnth-Jensen N, 2002, NAT NEUROSCI, V5, P325, DOI 10.1038/nn825; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Asztely F, 1997, NEURON, V18, P281, DOI 10.1016/S0896-6273(00)80268-8; Azarias G, 2011, J NEUROSCI, V31, P3550, DOI 10.1523/JNEUROSCI.4378-10.2011; Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471-4159.2006.03913.x; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Bellamy TC, 2005, GLIA, V52, P325, DOI 10.1002/glia.20248; Ben-Ari Y, 2001, TRENDS NEUROSCI, V24, P353, DOI 10.1016/S0166-2236(00)01813-0; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Benediktsson AM, 2012, GLIA, V60, P175, DOI 10.1002/glia.21249; Bennay M, 2008, GLIA, V56, P1138, DOI 10.1002/glia.20685; Bergles DE, 2002, J NEUROSCI, V22, P10153; Bergles DE, 1999, CURR OPIN NEUROBIOL, V9, P293, DOI 10.1016/S0959-4388(99)80043-9; Bergles DE, 1997, P NATL ACAD SCI USA, V94, P14821, DOI 10.1073/pnas.94.26.14821; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Bernardinelli Y, 2004, P NATL ACAD SCI USA, V101, P14937, DOI 10.1073/pnas.0405315101; Billups D, 2013, J NEUROSCI, V33, P17429, DOI 10.1523/JNEUROSCI.1466-13.2013; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; Bordey A, 2003, J NEUROPHYSIOL, V89, P979, DOI 10.1152/jn.00904.2002; Bordey A, 1997, J NEUROPHYSIOL, V78, P461; Borre L, 2004, J BIOL CHEM, V279, P2513, DOI 10.1074/jbc.M311446200; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; BOWMAN CL, 1984, NATURE, V311, P656, DOI 10.1038/311656a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Broer A, 2002, J PHYSIOL-LONDON, V539, P3, DOI 10.1013/jphysiol.2001.013303; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Carmona MA, 2009, P NATL ACAD SCI USA, V106, P12524, DOI 10.1073/pnas.0903328106; Cater RJ, 2016, J GEN PHYSIOL, V148, P13, DOI 10.1085/jgp.201511556; Cauli O, 2009, METAB BRAIN DIS, V24, P69, DOI 10.1007/s11011-008-9115-4; Chan H, 2003, NEUROCHEM INT, V43, P525, DOI 10.1016/S0197-0186(03)00043-3; Chatton JY, 2016, GLIA, V64, P1667, DOI 10.1002/glia.22971; Chatton JY, 2000, EUR J NEUROSCI, V12, P3843, DOI 10.1046/j.1460-9568.2000.00269.x; Chatton JY, 2001, BRAIN RES, V893, P46, DOI 10.1016/S0006-8993(00)03286-8; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Chen JC, 2005, NEUROPHARMACOLOGY, V49, P703, DOI 10.1016/j.neuropharm.2005.05.002; Chen S, 2002, J NEUROSCI, V22, P2165, DOI 10.1523/JNEUROSCI.22-06-02165.2002; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Cholet N, 2002, CEREB CORTEX, V12, P515, DOI 10.1093/cercor/12.5.515; Clark BA, 2002, J NEUROSCI, V22, P4428, DOI 10.1523/JNEUROSCI.22-11-04428.2002; COOPER AJL, 1987, NEUROCHEM PATHOL, V6, P67, DOI 10.1007/BF02833601; COOPER AJL, 1979, J BIOL CHEM, V254, P4982; Crisman TJ, 2009, P NATL ACAD SCI USA, V106, P20752, DOI 10.1073/pnas.0908570106; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Deitmer JW, 2010, BRAIN RES REV, V63, P113, DOI 10.1016/j.brainresrev.2009.10.006; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; Diamond JS, 2005, J NEUROSCI, V25, P2906, DOI 10.1523/JNEUROSCI.5125-04.2005; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dvorzhak A, 2016, J NEUROSCI, V36, P4959, DOI 10.1523/JNEUROSCI.0316-16.2016; Escartin C, 2006, J NEUROSCI, V26, P5978, DOI 10.1523/JNEUROSCI.0302-06.2006; Ewers D, 2013, P NATL ACAD SCI USA, V110, P12486, DOI 10.1073/pnas.1300772110; Fahlke C, 2016, PFLUG ARCH EUR J PHY, V468, P491, DOI 10.1007/s00424-015-1768-3; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Filosa A, 2009, NAT NEUROSCI, V12, P1285, DOI 10.1038/nn.2394; Fontana ACK, 2015, J NEUROCHEM, V134, P982, DOI 10.1111/jnc.13200; Foran E, 2014, GLIA, V62, P1241, DOI 10.1002/glia.22677; Furness DN, 1997, EUR J NEUROSCI, V9, P1961, DOI 10.1111/j.1460-9568.1997.tb00763.x; Furuta A, 1997, J NEUROSCI, V17, P8363; Gameiro A, 2011, BIOPHYS J, V100, P2623, DOI 10.1016/j.bpj.2011.04.034; Garaschuk O, 1998, J PHYSIOL-LONDON, V507, P219, DOI 10.1111/j.1469-7793.1998.219bu.x; Gegelashvili G, 2001, Prog Brain Res, V132, P267; Gegelashvili G, 2014, J NEUROCHEM, V131, P712, DOI 10.1111/jnc.12957; Genda EN, 2011, J NEUROSCI, V31, P18275, DOI 10.1523/JNEUROSCI.3305-11.2011; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; Genoud C, 2006, PLOS BIOL, V4, P2057, DOI 10.1371/journal.pbio.0040343; Giaume C, 2010, NAT REV NEUROSCI, V11, P87, DOI 10.1038/nrn2757; GINSBERG SD, 1995, J NEUROCHEM, V65, P2800; Glowatzki E, 2006, J NEUROSCI, V26, P7659, DOI 10.1523/JNEUROSCI.1545-06.2006; Gonzalez-Gonzalez IM, 2009, J NEUROCHEM, V110, P264, DOI 10.1111/j.1471-4159.2009.06125.x; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grewer C, 2005, BIOCHEMISTRY-US, V44, P11913, DOI 10.1021/bi050987n; Grewer C, 2003, J BIOL CHEM, V278, P2585, DOI 10.1074/jbc.M207956200; Grewer C, 2008, IUBMB LIFE, V60, P609, DOI 10.1002/iub.98; Grewer C, 2012, J BIOL CHEM, V287, P26921, DOI 10.1074/jbc.M112.364059; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Hanelt I, 2015, J BIOL CHEM, V290, P15962, DOI 10.1074/jbc.M115.656876; Hanson E, 2015, GLIA, V63, P1784, DOI 10.1002/glia.22844; Hartfuss E, 2001, DEV BIOL, V229, P15, DOI 10.1006/dbio.2000.9962; Hasegawa J, 2006, NEURON, V50, P63, DOI 10.1016/j.neuron.2006.02.022; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Herman MA, 2007, J NEUROSCI, V27, P9736, DOI 10.1523/JNEUROSCI.3009-07.2007; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; Holmseth S, 2012, J NEUROSCI, V32, P6000, DOI 10.1523/JNEUROSCI.5347-11.2012; Huang H, 2004, J NEUROSCI, V24, P5659, DOI 10.1523/JNEUROSCI.1338-04.2004; Huang YHH, 2004, CURR OPIN NEUROBIOL, V14, P346, DOI 10.1016/j.conb.2004.05.007; Huang YHH, 2004, J NEUROSCI, V24, P103, DOI 10.1523/JNEUROSCI.4473-03.2004; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jen JC, 2005, NEUROLOGY, V65, P529, DOI 10.1212/01.WNL.0000172638.58172.5a; Jensen AA, 2015, CURR OPIN PHARMACOL, V20, P116, DOI 10.1016/j.coph.2014.10.008; Jensen AA, 2009, J MED CHEM, V52, P912, DOI 10.1021/jm8013458; Jensen S, 2013, NAT STRUCT MOL BIOL, V20, P1224, DOI 10.1038/nsmb.2663; Kafitz KW, 2008, J NEUROSCI METH, V169, P84, DOI 10.1016/j.jneumeth.2007.11.022; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P3143, DOI 10.1021/bi00256a017; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Karus C, 2015, GLIA, V63, P936, DOI 10.1002/glia.22793; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Kelly T, 2010, J NEUROCHEM, V115, P1123, DOI 10.1111/j.1471-4159.2010.07009.x; Kelly T, 2009, GLIA, V57, P921, DOI 10.1002/glia.20817; KETTENMANN H, 1984, NEUROSCI LETT, V52, P25, DOI 10.1016/0304-3940(84)90345-8; Kirischuk S, 2007, PFLUG ARCH EUR J PHY, V454, P245, DOI 10.1007/s00424-007-0207-5; Kirischuk S, 2016, GLIA, V64, P1655, DOI 10.1002/glia.22943; Koch HP, 2007, J NEUROSCI, V27, P2943, DOI 10.1523/JNEUROSCI.0118-07.2007; Kovermann P, 2010, J BIOL CHEM, V285, P23676, DOI 10.1074/jbc.M110.126557; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; Kugler P, 2004, HIPPOCAMPUS, V14, P975, DOI 10.1002/hipo.20015; Langer J, 2017, GLIA, V65, P293, DOI 10.1002/glia.23092; Langer J, 2009, J PHYSIOL-LONDON, V587, P5859, DOI 10.1113/jphysiol.2009.182279; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; Leary GP, 2007, J NEUROSCI, V27, P2938, DOI 10.1523/JNEUROSCI.4851-06.2007; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1997, BRAIN RES, V744, P129, DOI 10.1016/S0006-8993(96)01022-0; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Linden DJ, 1997, NEURON, V18, P983, DOI 10.1016/S0896-6273(00)80337-2; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Machtens JP, 2015, CELL, V160, P542, DOI 10.1016/j.cell.2014.12.035; MACVICAR BA, 1989, J NEUROSCI, V9, P3577; Magistretti PJ, 2005, J NEURAL TRANSM, V112, P77, DOI 10.1007/s00702-004-0171-6; Maragakis NJ, 2004, NEUROBIOL DIS, V15, P461, DOI 10.1016/j.nbd.2003.12.007; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Marcaggi P, 2004, GLIA, V47, P217, DOI 10.1002/glia.20027; Marcaggi P, 2003, J PHYSIOL-LONDON, V552, P89, DOI 10.1113/jphysiol.2003.044263; Marcaggi P, 2001, PROG NEUROBIOL, V64, P157, DOI 10.1016/S0301-0082(00)00043-5; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Matsugami TR, 2006, P NATL ACAD SCI USA, V103, P12161, DOI 10.1073/pnas.0509144103; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Meier SD, 2008, GLIA, V56, P1127, DOI 10.1002/glia.20684; Melzer N, 2005, P NATL ACAD SCI USA, V102, P19214, DOI 10.1073/pnas.0508837103; Melzer N, 2003, J BIOL CHEM, V278, P50112, DOI 10.1074/jbc.M307990200; Mennerick S, 1998, J NEUROSCI, V18, P4490; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mim C, 2005, J GEN PHYSIOL, V126, P571, DOI 10.1085/jgp.200509365; Mim C, 2007, BIOCHEMISTRY-US, V46, P9007, DOI 10.1021/bi7005465; Minelli A, 2001, NEUROSCIENCE, V108, P51, DOI 10.1016/S0306-4522(01)00375-X; MONGIN AA, 2015, PFLUGERS ARCH, V468, P421, DOI DOI 10.1007/s00424-015-1765-6; Morel L, 2014, J NEUROSCI, V34, P10950, DOI 10.1523/JNEUROSCI.1167-14.2014; Moretto MB, 2005, EXP NEUROL, V195, P400, DOI 10.1016/j.expneurol.2005.06.005; MULLER T, 1994, J NEUROSCI, V14, P2503; Munch C, 2002, J NEUROCHEM, V82, P594, DOI 10.1046/j.1471-4159.2002.01012.x; Murphy-Royal C, 2015, NAT NEUROSCI, V18, P219, DOI 10.1038/nn.3901; Nakagawa T, 2008, EUR J NEUROSCI, V28, P1719, DOI 10.1111/j.1460-9568.2008.06494.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Nothmann D, 2011, J BIOL CHEM, V286, P3935, DOI 10.1074/jbc.M110.187492; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Otis TS, 2000, J NEUROSCI, V20, P2749; Overstreet LS, 1999, J NEUROSCI, V19, P9663; Owe SG, 2006, J PHYSIOL-LONDON, V577, P591, DOI 10.1113/jphysiol.2006.116830; Pannasch U, 2014, NAT NEUROSCI, V17, P549, DOI 10.1038/nn.3662; Parinejad N, 2016, J NEUROSCI, V36, P7640, DOI 10.1523/JNEUROSCI.0197-16.2016; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Pellerin L, 1997, J NEUROCHEM, V69, P2132; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Petr GT, 2015, J NEUROSCI, V35, P5187, DOI 10.1523/JNEUROSCI.4255-14.2015; Phillis JW, 1996, BRAIN RES, V730, P150; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Pow DV, 2000, NEUROSCI LETT, V280, P21, DOI 10.1016/S0304-3940(99)00988-X; Rao KVR, 2012, NEUROCHEM INT, V61, P575, DOI 10.1016/j.neuint.2012.01.012; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Raponi E, 2007, GLIA, V55, P165, DOI 10.1002/glia.20445; Rauen T, 2004, NEUROCHEM INT, V45, P1095, DOI 10.1016/j.neuint.2004.04.006; Rauen T, 2000, AMINO ACIDS, V19, P53, DOI 10.1007/s007260070033; Reyes N, 2009, NATURE, V462, P880, DOI 10.1038/nature08616; Rimmele TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109243; Rivera C, 2005, J PHYSIOL-LONDON, V562, P27, DOI 10.1113/jphysiol.2004.077495; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Rose CR, 2016, GLIA, V64, P1611, DOI 10.1002/glia.22964; Rose CR, 1996, J NEUROSCI, V16, P5393; Rose EM, 2009, J NEUROSCI, V29, P8143, DOI 10.1523/JNEUROSCI.1081-09.2009; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rusakov DA, 1998, J NEUROSCI, V18, P3158; Ryan RM, 2010, J NEUROCHEM, V114, P565, DOI 10.1111/j.1471-4159.2010.06796.x; Schlag BD, 1998, MOL PHARMACOL, V53, P355; Schneider N, 2014, J BIOL CHEM, V289, P1815, DOI 10.1074/jbc.M113.517177; Schousboe A, 2003, NEUROCHEM RES, V28, P347, DOI 10.1023/A:1022397704922; Schousboe A, 2004, NEUROCHEM INT, V45, P521, DOI 10.1016/j.neuint.2003.11.001; Schousboe A, 2014, ADV NEUROBIOL, V11, P13, DOI 10.1007/978-3-319-08894-5_2; Schreiner A. E., 2013, ISRN NEUROL; Schreiner AE, 2014, J COMP NEUROL, V522, P204, DOI 10.1002/cne.23450; Shibata T, 1997, J NEUROSCI, V17, P9212; Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Somjen GG, 2002, NEUROSCIENTIST, V8, P254, DOI 10.1177/1073858402008003011; Soni N, 2014, PHARMACOL BIOCHEM BE, V127, P70, DOI 10.1016/j.pbb.2014.10.001; SONNEWALD U, 1993, J NEUROCHEM, V61, P1179, DOI 10.1111/j.1471-4159.1993.tb03641.x; Sonnewald U, 2014, J NEUROCHEM, V131, P399, DOI 10.1111/jnc.12812; Stephan J, 2012, GLIA, V60, P965, DOI 10.1002/glia.22328; Stolzenberg S, 2012, J PHYS CHEM B, V116, P5372, DOI 10.1021/jp301726s; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Sullivan R, 2004, GLIA, V45, P155, DOI 10.1002/glia.10317; Swanson RA, 1997, J NEUROSCI, V17, P932; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; Takasaki C, 2008, J NEUROSCI, V28, P4995, DOI 10.1523/JNEUROSCI.0861-08.2008; Takayasu Y, 2005, J NEUROSCI, V25, P8788, DOI 10.1523/JNEUROSCI.1020-05.2005; Takayasu Y, 2009, ACTA PHYSIOL, V197, P1, DOI 10.1111/j.1748-1716.2009.02019.x; Takumi Y, 1997, NEUROSCIENCE, V79, P1137, DOI 10.1016/S0306-4522(97)00025-0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Torres-Salazar D, 2007, J BIOL CHEM, V282, P34719, DOI 10.1074/jbc.M704118200; Tzingounis AV, 2007, NAT REV NEUROSCI, V8, P935, DOI 10.1038/nrn2274; Ullensvang K, 1997, EUR J NEUROSCI, V9, P1646, DOI 10.1111/j.1460-9568.1997.tb01522.x; Ullian EM, 2004, GLIA, V47, P209, DOI 10.1002/glia.20082; Untiet V, 2017, GLIA, V65, P388, DOI 10.1002/glia.23098; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Uwechue NM, 2012, J PHYSIOL-LONDON, V590, P2317, DOI 10.1113/jphysiol.2011.226605; Vallejo-Illarramendi A, 2005, J NEUROCHEM, V95, P341, DOI 10.1111/j.1471-4159.2005.03370.x; van Amen-Hellebrekers C. J., 2016, EUR J MED GENET; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Vandenberg RJ, 2013, PHYSIOL REV, V93, P1621, DOI 10.1152/physrev.00007.2013; Venkatesan S, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004551; Verbich D, 2012, GLIA, V60, P1067, DOI 10.1002/glia.22335; Verdon G, 2014, ELIFE, V3, DOI 10.7554/eLife.02283; Verdon G, 2012, NAT STRUCT MOL BIOL, V19, P355, DOI 10.1038/nsmb.2233; Vermeiren C, 2005, J NEUROCHEM, V94, P405, DOI 10.1111/j.1471-4159.2005.03216.x; Veruki ML, 2006, NAT NEUROSCI, V9, P1388, DOI 10.1038/nn1793; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Watzke N, 2000, J GEN PHYSIOL, V116, P609, DOI 10.1085/jgp.116.5.609; Watzke N, 2001, J GEN PHYSIOL, V117, P547, DOI 10.1085/jgp.117.6.547; Wersinger E, 2006, J PHYSIOL-LONDON, V577, P221, DOI 10.1113/jphysiol.2006.118281; Winter N, 2012, BRAIN, V135, P3416, DOI 10.1093/brain/aws255; WRIGHT EM, 1977, PHYSIOL REV, V57, P109; Yang YJ, 2009, NEURON, V61, P880, DOI 10.1016/j.neuron.2009.02.010; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; ZHANG YM, 1994, J BIOL CHEM, V269, P19573; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751; Zhang Z, 2007, P NATL ACAD SCI USA, V104, P18025, DOI 10.1073/pnas.0704570104; Zheng KY, 2008, BIOPHYS J, V95, P4584, DOI 10.1529/biophysj.108.129874; Zhou JZ, 2004, J NEUROSCI, V24, P6301, DOI 10.1523/JNEUROSCI.1404-04.2004; Zhou M, 2006, J NEUROPHYSIOL, V95, P134, DOI 10.1152/jn.00570.2005; Zhou Y, 2014, J NEUROSCI, V34, P13472, DOI 10.1523/JNEUROSCI.2282-14.2014; Zomot E, 2007, NATURE, V449, P726, DOI 10.1038/nature06133	264	35	35	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JAN	2018	136				SI		3	16		10.1016/j.brainresbull.2016.12.013			14	Neurosciences	Neurosciences & Neurology	FU2AX	WOS:000423651700002	28040508				2021-06-18	
J	Wu, Q; Gao, C; Wang, HC; Zhang, XM; Li, QQ; Gu, ZY; Shi, XY; Cui, YC; Wang, T; Chen, XP; Wang, X; Luo, CL; Tao, LY				Wu, Qiong; Gao, Cheng; Wang, Haochen; Zhang, Xinmu; Li, Qianqian; Gu, Zhiya; Shi, Xiuyu; Cui, Yongchun; Wang, Tao; Chen, Xiping; Wang, Xin; Luo, Chengliang; Tao, Luyang			Mdivi-1 alleviates blood-brain barrier disruption and cell death in experimental traumatic brain injury by mitigating autophagy dysfunction and mitophagy activation	INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY			English	Article						Dynamin-related protein 1; Traumatic brain injury; Autophagy; Mitophagy; Blood-brain barrier	INTRACEREBRAL HEMORRHAGE MODEL; MITOCHONDRIAL FISSION; IN-VITRO; MEMBRANE PERMEABILIZATION; PROTECTS MITOCHONDRIA; CORTICAL-NEURONS; DAMAGE; PATHWAY; MICE; DRP1	Dynamin-related protein 1 (Drp1) is a key regulator of mitochondrial fission. Our previous studies proved that the inhibition of Drpl may help attenuate traumatic brain injury (TBI)-induced functional outcome and cell death through maintaining normal mitochondrial morphology and inhibiting activation of apoptosis. However, the molecular mechanisms of Drpl after TBI remain poorly understood. In this study, we investigated the role of mitochondrial division inhibitor 1 (Mdivi-1), a small molecule inhibitor of Drpl, in underlying mechanisms of general autophagy and mitochondria autophagy (mitophagy) after experimental TBI. In vivo, we found that autophagosomes accumulated in cortical neurons at 24 h after TBI, owing to the enhanced autophagy indicated by the accumulation of LC3 and the decrease of p62; but Mdivi-1 reversed the enhancement. Mdivi-1 also alleviated the number of LC3 puncta and TUNEL-positive structures in cells, indicating that autophagy maybe involved in Mdivi-l's anti-apoptosis effects. Then, the expression level of mitochondrial dynamics related and mitophagy related proteins was assessed using the isolated mitochondria. The results showed that TBI-induced mitochondrial fission (represented by Drpl), mtDNA concentration down-regulation and PTEN induced putative kinase 1 (PINK1)-Parkin mediated mitophagy activation were all inhibited by Mdivi-1. In addition, TBI-induced blood-brain barrier (BBB) disruption and matrix metalloproteinases (MMP)-9 expression up-regulation were inhibited following Mdivi-1 treatment. In vitro, Mdivi-1 significantly alleviated the scratch injury-induced cell death, loss of mitochondrial membrane potential, reactive oxygen species (ROS) production and ATP reduction in primary cortical neurons (PCNs). Additionally, the lysosome inhibitor chloroquine (CQ) abrogated the Mdivi1-induced decrease in autophagosomes accumulation and cell death at 24 h both in the basal state and under the conditions of scratch cell injury. Together, these data demonstrate that Mdivi-1 mitigates TBI-induced BBB disruption and cell death at least in part by a mechanism involving inhibiting autophagy dysfunction and mitophagy activation.	[Wu, Qiong; Gao, Cheng; Wang, Haochen; Gu, Zhiya; Wang, Tao; Chen, Xiping; Luo, Chengliang; Tao, Luyang] Soochow Univ, Coll Med, Dept Forens Med, 178 Ganjiang East St, Suzhou 215123, Peoples R China; [Zhang, Xinmu; Wang, Xin; Luo, Chengliang] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Li, Qianqian] Wannan Med Coll, Dept Forens Med, Wuhu 241002, Peoples R China; [Shi, Xiuyu] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Cui, Yongchun] Chinese Acad Med Sci, Fu Wai Hosp, State Key Lab Cardiovasc Dis, Beijing 100037, Peoples R China; [Cui, Yongchun] Chinese Acad Med Sci, Fu Wai Hosp,Natl Ctr Cardiovasc Dis, Beijing Key Lab Preclin Res & Evaluat Cardiovasc, Ctr Cardiovasc Expt Study & Evaluat, Beijing 100037, Peoples R China; [Cui, Yongchun] Peking Union Med Coll, Beijing 100037, Peoples R China	Luo, CL; Tao, LY (corresponding author), Soochow Univ, Coll Med, Dept Forens Med, 178 Ganjiang East St, Suzhou 215123, Peoples R China.	clluo@suda.edu.cn; taoluyang@suda.edu.cn	Zhang, Xinmu/G-8128-2018; Cui, Yong/AAF-9300-2020		National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81530062, 81400999, 81373251, 81601643]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M551660]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Beijing Natural Science FoundationBeijing Natural Science Foundation [7172181]	This work was supported by the National Science Foundation of China (Nos. 81530062, 81400999, 81373251, and 81601643), China Postdoctoral Science Foundation (No. 2014M551660), a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and Beijing Natural Science Foundation (7172181).	Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Chang CR, 2010, ANN NY ACAD SCI, V1201, P34, DOI 10.1111/j.1749-6632.2010.05629.x; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985; Fukui K, 2012, FREE RADICAL RES, V46, P184, DOI 10.3109/10715762.2011.647689; Gao Y, 2017, MOL NEUROBIOL, V54, P3879, DOI 10.1007/s12035-016-9947-6; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Herrmann JM, 2012, ADV EXP MED BIOL, V748, P41, DOI 10.1007/978-1-4614-3573-0_3; Iwai-Kanai E, 2008, AUTOPHAGY, V4, P322, DOI 10.4161/auto.5603; Ji J, 2012, J NEUROTRAUM, V29, P776, DOI 10.1089/neu.2010.1602; Jin YC, 2015, WORLD NEUROSURG, V84, P420, DOI 10.1016/j.wneu.2015.03.039; Kang JW, 2016, J PINEAL RES, V60, P383, DOI 10.1111/jpi.12319; Kim T, 2016, J NEUROSCI, V36, P7055, DOI 10.1523/JNEUROSCI.1241-16.2016; Knott AB, 2008, ANN NY ACAD SCI, V1147, P283, DOI 10.1196/annals.1427.030; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Luo CL, 2015, J MOL NEUROSCI, V56, P988, DOI 10.1007/s12031-015-0568-8; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Purnell PR, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-86; Qiu X, 2013, NEUROSCIENCE, V245, P157, DOI 10.1016/j.neuroscience.2013.04.019; Rambold AS, 2011, AUTOPHAGY, V7, P1568, DOI 10.4161/auto.7.12.17992; Saito T, 2015, CIRC RES, V116, P1477, DOI 10.1161/CIRCRESAHA.116.303790; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Song JX, 2012, CHIN MED-UK, V7, DOI 10.1186/1749-8546-7-1; Song Y, 2015, NEUROSCI J, V2015; Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang DB, 2013, J NEUROSCI, V33, P1357, DOI 10.1523/JNEUROSCI.3365-12.2013; Wang T, 2015, J MOL NEUROSCI, V55, P240, DOI 10.1007/s12031-014-0313-8; Wu Q, 2017, HISTOL HISTOPATHOL, V32, P551, DOI 10.14670/HH-11-841; Wu Q, 2016, BRAIN RES, V1630, P134, DOI 10.1016/j.brainres.2015.11.016; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241; Zhang WH, 2008, STROKE, V39, P455, DOI 10.1161/STROKEAHA.107.496810; Zuo W, 2016, BRIT J PHARMACOL, V173, P1665, DOI 10.1111/bph.13468; Zuo W, 2014, NEUROPHARMACOLOGY, V86, P103, DOI 10.1016/j.neuropharm.2014.07.002	45	35	37	3	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1357-2725	1878-5875		INT J BIOCHEM CELL B	Int. J. Biochem. Cell Biol.	JAN	2018	94						44	55		10.1016/j.biocel.2017.11.007			12	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	FU5JJ	WOS:000423888700007	29174311				2021-06-18	
J	Yang, LD; Tucker, D; Dong, Y; Wu, CY; Lu, YJ; Li, Y; Zhang, J; Liu, TCY; Zhang, QG				Yang, Luodan; Tucker, Donovan; Dong, Yan; Wu, Chongyun; Lu, Yujiao; Li, Yong; Zhang, Juan; Liu, Timon Cheng-Yi; Zhang, Quanguang			Photobiomodulation therapy promotes neurogenesis by improving post-stroke local microenvironment and stimulating neuroprogenitor cells	EXPERIMENTAL NEUROLOGY			English	Article						Photobiomodulation; Ischemic stroke; Neurogenesis; Inflammation; Mitochondrial function	LEVEL LASER THERAPY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TERM NEUROLOGICAL DEFICITS; CYTOCHROME-C-OXIDASE; STEM-CELLS; MITOCHONDRIAL-FUNCTION; CORTICAL NEUROGENESIS; INFLAMMATORY RESPONSES; PHOTOTHROMBOTIC STROKE	Recent work has indicated that photobiomodulation (PBM) may beneficially alter the pathological status of several neurological disorders, although the mechanism currently remains unclear. The current study was designed to investigate the beneficial effect of PBM on behavioral deficits and neurogenesis in a photothrombotic (PT) model of ischemic stroke in rats. From day 1 to day 7 after the establishment of PT model, 2-minute daily PBM (CW, 808 nm, 350 mW/cm(2), total 294 J at scalp level) was applied on the infarct injury area (1.8 mm anterior to the bregma and 2.5 mm lateral from the midline). Rats received intraperitoneal injections of 5-bromodeoxyuridine (BrdU) twice daily (50 mg/kg) from day 2 to 8 post-stoke, and samples were collected at day 14. We demonstrated that PBM significantly attenuated behavioral deficits and infarct volume induced by PT stroke. Further investigation displayed that PBM remarkably enhanced neurogenesis and synaptogenesis, as evidenced by immunostaining of BrdU, Ki67, DCX, MAP2, spinophilin, and synaptophysin. Mechanistic studies suggested beneficial effects of PBM were accompanied by robust suppression of reactive gliosis and the production of pro-inflammatory cytokines. On the contrary, the release of anti-inflammatory cytokines, cytochrome c oxidase activity and ATP production in peri-infarct regions were elevated following PBM treatment. Intriguingly, PBM could effectively switch an M1 microglial phenotype to an anti-inflammatory M2 phenotype. Our novel findings indicated that PBM is capable of promoting neurogenesis after ischemic stroke. The underlying mechanisms may rely on: 1) promotion of proliferation and differentiation of internal neuroprogenitor cells in the peri-infarct zone; 2) improvement of the neuronal microenvironment by altering inflammatory status and promoting mitochondrial function. These findings provide strong support for the promising therapeutic effect of PBM on neuronal repair following ischemic stroke.	[Yang, Luodan; Wu, Chongyun; Liu, Timon Cheng-Yi; Zhang, Quanguang] South China Normal Univ, Coll Phys Educ & Sports Sci, Lab Laser Sports Med, Guangzhou, Guangdong, Peoples R China; [Yang, Luodan; Tucker, Donovan; Dong, Yan; Lu, Yujiao; Li, Yong; Zhang, Juan; Zhang, Quanguang] Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, 1120 15th St, Augusta, GA 30912 USA	Zhang, QG (corresponding author), Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, 1120 15th St, Augusta, GA 30912 USA.	qzhang@augusta.edu			National Institute of Neurological Disorders and Stroke, National Institutes of Health, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS086929]; American Heart AssociationAmerican Heart Association [15GRNT25240004]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61575065, 11604104]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086929] Funding Source: NIH RePORTER	This study was supported by Research Grant NS086929 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, USA; an American Heart Association Grant-in-Aid 15GRNT25240004, and National Natural Science Foundation of China: 61575065 & 11604104.	Ahmed ME, 2016, NEUROSCIENCE, V336, P39, DOI 10.1016/j.neuroscience.2016.08.036; Alcantara CC, 2013, LASER SURG MED, V45, P246, DOI 10.1002/lsm.22129; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Andrabi SS, 2017, DIS MODEL MECH, V10, P787, DOI 10.1242/dmm.025692; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barakat R, 2016, MED PRIN PRACT, V25, P3, DOI 10.1159/000435858; Bernstein BW, 2003, J NEUROSCI, V23, P1; Bolanos JP, 2006, ANTIOXID REDOX SIGN, V8, P955, DOI 10.1089/ars.2006.8.955; Braeuninger Stefan, 2009, Exp Transl Stroke Med, V1, P8, DOI 10.1186/2040-7378-1-8; Chen YM, 2013, NEUROSCI LETT, V553, P99, DOI 10.1016/j.neulet.2013.07.049; Choi JY, 2017, EXP NEUROBIOL, V26, P33, DOI 10.5607/en.2017.26.1.33; Couch Y., 2017, STROKE; da Silva CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142816; Demidova-Rice TN, 2007, LASER SURG MED, V39, P706, DOI 10.1002/lsm.20549; Demyanenko SV, 2015, BIOCHEMISTRY-MOSCOW+, V80, P790, DOI 10.1134/S0006297915060152; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Eissa M., 2017, LASERS MED SCI; Esenwa CC, 2016, NAT REV NEUROL, V12, P594, DOI 10.1038/nrneurol.2016.125; Ferraresi C, 2015, PHOTOCHEM PHOTOBIOL, V91, P411, DOI 10.1111/php.12397; Fike JR, 2009, SEMIN RADIAT ONCOL, V19, P122, DOI 10.1016/j.semradonc.2008.12.003; Fukuoka CY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169443; Giannakopoulou A, 2017, J NEUROSCI RES, V95, P1446, DOI 10.1002/jnr.23982; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang YY, 2013, J BIOPHOTONICS, V6, P829, DOI 10.1002/jbio.201200157; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kawamura R, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0334-z; Kim JY, 2014, CURR MED CHEM, V21, P2076, DOI 10.2174/0929867321666131228205146; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Landes T, 2011, BBA-MOL CELL RES, V1813, P540, DOI 10.1016/j.bbamcr.2011.01.021; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2016, BRAIN RES, V1646, P125, DOI 10.1016/j.brainres.2016.04.039; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Li M, 2016, STROKE, V47, P187, DOI 10.1161/STROKEAHA.115.009687; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu YJ, 2017, J ALZHEIMERS DIS, V56, P1469, DOI 10.3233/JAD-160869; Lu YJ, 2017, NEUROBIOL AGING, V49, P165, DOI 10.1016/j.neurobiolaging.2016.10.003; Mantineo M, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.9.098002; Medeiros DM, 2002, J BIOENERG BIOMEMBR, V34, P389, DOI 10.1023/A:1021206220851; Miao YP, 2016, BRAIN RES BULL, V121, P9, DOI 10.1016/j.brainresbull.2015.11.019; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Narne P, 2017, MOL CELL NEUROSCI, V82, P176, DOI 10.1016/j.mcn.2017.05.008; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Ozturk S, 2014, WORLD NEUROSURG, V81, pE35, DOI 10.1016/j.wneu.2012.10.074; Parent JM, 1997, J NEUROSCI, V17, P3727; PASTORE D, 1994, BIOCHEM MOL BIOL INT, V34, P817; Pevsner PH, 2001, J PHARMACOL TOXICOL, V45, P227, DOI 10.1016/S1056-8719(01)00153-8; Plane JM, 2004, NEUROBIOL DIS, V16, P585, DOI 10.1016/j.nbd.2004.04.003; Salehpour F, 2017, NEUROBIOL AGING, V58, P140, DOI 10.1016/j.neurobiolaging.2017.06.025; Schmidt Antje, 2012, Exp Transl Stroke Med, V4, P13, DOI 10.1186/2040-7378-4-13; Schroeter M, 2002, J NEUROSCI METH, V117, P43, DOI 10.1016/S0165-0270(02)00072-9; Shanina EV, 2005, BEHAV BRAIN RES, V158, P69, DOI 10.1016/j.bbr.2004.08.007; Sharp WW, 2014, FASEB J, V28, P316, DOI 10.1096/fj.12-226225; Shimazaki Takuya, 2008, Tanpakushitsu Kakusan Koso, V53, P311; Sieber MW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026288; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Thunshelle C, 2016, PHOTOMED LASER SURG, V34, P587, DOI 10.1089/pho.2015.4051; Trensz F, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395-016-0109-3; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Voloboueva LA, 2011, J NEUROSCI RES, V89, P1989, DOI 10.1002/jnr.22768; Wang LL, 2017, INT J DEV NEUROSCI, V57, P77, DOI 10.1016/j.ijdevneu.2017.01.002; Wang Q, 2015, INT J DEV NEUROSCI, V43, P50, DOI 10.1016/j.ijdevneu.2015.04.009; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Winklewski PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0213-4; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2016, J BIOPHOTONICS, V9, P1263, DOI 10.1002/jbio.201500336; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yan T, 2015, NEUROSCI BULL, V31, P717, DOI 10.1007/s12264-015-1567-z; Yang XD, 2017, BRAIN BEHAV IMMUN, V64, P162, DOI 10.1016/j.bbi.2017.03.003; Yu B, 2014, INT J MOL SCI, V15, P4142, DOI 10.3390/ijms15034142; Yuan JC, 2017, ONCOTARGET, V8, P19855, DOI 10.18632/oncotarget.15774; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhao N., 2016, MOL NEUROBIOL; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547; Zuo W, 2016, BRIT J PHARMACOL, V173, P1665, DOI 10.1111/bph.13468	86	35	35	1	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.		2018	299		A				86	96		10.1016/j.expneurol.2017.10.013			11	Neurosciences	Neurosciences & Neurology	FR7PD	WOS:000419261500008	29056360	Green Accepted, Bronze			2021-06-18	
J	Manning, KY; Schranz, A; Bartha, R; Dekaban, GA; Barreira, C; Brown, A; Fischer, L; Asem, K; Doherty, TJ; Fraser, DD; Holmes, J; Menon, RS				Manning, Kathryn Y.; Schranz, Amy; Bartha, Robert; Dekaban, Gregory A.; Barreira, Christy; Brown, Arthur; Fischer, Lisa; Asem, Kevin; Doherty, Timothy J.; Fraser, Douglas D.; Holmes, Jeff; Menon, Ravi S.			Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; DIFFUSION TENSOR; FUNCTIONAL RECOVERY; VULNERABILITY; CONNECTIVITY; MYELOPATHY; MOTOR; TBI	Objective: To determine whether multiparametric MRI data can provide insight into the acute and long-lasting neuronal sequelae after a concussion in adolescent athletes. Methods: Players were recruited from Bantam hockey leagues in which body checking is first introduced (male, age 11-14 years). Clinical measures, diffusion metrics, resting-state network and region-to-region functional connectivity patterns, and magnetic resonance spectroscopy absolute metabolite concentrations were analyzed from an independent, age-matched control group of hockey players (n = 26) and longitudinally in concussed athletes within 24 to 72 hours (n = 17) and 3 months (n = 14) after a diagnosed concussion. Results: There were diffusion abnormalities within multiple white matter tracts, functional hyper-connectivity, and decreases in choline 3 months after concussion. Tract-specific spatial statistics revealed a large region along the superior longitudinal fasciculus with the largest decreases in diffusivity measures, which significantly correlated with clinical deficits. This region also spatially intersected with probabilistic tracts connecting cortical regions where we found acute functional connectivity changes. Hyperconnectivity patterns at 3 months after concussion were present only in players with relatively less severe clinical outcomes, higher choline concentrations, and diffusivity indicative of relatively less axonal disruption. Conclusions: Changes persisted well after players' clinical scores had returned to normal and they had been cleared to return to play. Ongoing white matter maturation may make adolescent athletes particularly vulnerable to brain injury, and they may require extended recovery periods. The consequences of early brain injury for ongoing brain development and risk of more serious conditions such as second impact syndrome or neural degenerative processes need to be elucidated.	[Manning, Kathryn Y.; Schranz, Amy; Bartha, Robert; Menon, Ravi S.] Univ Western Ontario, Dept Med Biophys, London, ON, Canada; [Dekaban, Gregory A.; Barreira, Christy] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; [Brown, Arthur] Univ Western Ontario, Dept Anat & Cell Biol, London, ON, Canada; [Doherty, Timothy J.] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada; [Holmes, Jeff] Univ Western Ontario, Sch Occupat Therapy, London, ON, Canada; [Manning, Kathryn Y.; Bartha, Robert; Menon, Ravi S.] Robarts Res Inst, Ctr Funct & Metab Mapping, London, ON, Canada; [Dekaban, Gregory A.; Barreira, Christy; Brown, Arthur] Robarts Res Inst, Mol Med, London, ON, Canada; [Fischer, Lisa; Asem, Kevin] Fowler Kennedy Sport Med, Family Med, Primary Care Sport Med, London, ON, Canada; [Fraser, Douglas D.] London Hlth Sci Ctr, Paediat Crit Care Med, London, ON, Canada	Menon, RS (corresponding author), Univ Western Ontario, Dept Med Biophys, London, ON, Canada.; Menon, RS (corresponding author), Robarts Res Inst, Ctr Funct & Metab Mapping, London, ON, Canada.	rmenon@robarts.ca	Fischer, Lisa K/H-3999-2015; Bartha, Robert/K-3611-2013; Brown, Arthur/K-8328-2013; Menon, Ravi S/K-5500-2013; Dekaban, Gregory A./L-1987-2013	Fischer, Lisa K/0000-0001-5992-0176; Bartha, Robert/0000-0002-7118-9096; Brown, Arthur/0000-0002-8725-3195; Menon, Ravi S/0000-0002-7916-0263; Dekaban, Gregory A./0000-0002-3087-4660	Children's Health Foundation; Western University Schulich School of Medicine and Dentistry	Funding was provided by a grant from the Children's Health Foundation to Dr. D.D. Fraser and a grant from the Western University Schulich School of Medicine and Dentistry (co-principal investigators: Dr. D.D. Fraser and G.A. Dekaban).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bartha R, 1999, NMR BIOMED, V12, P205, DOI 10.1002/(SICI)1099-1492(199906)12:4<205::AID-NBM558>3.0.CO;2-1; Bartha R, 2000, MAGN RESON MED, V44, P641, DOI 10.1002/1522-2594(200010)44:4<641::AID-MRM19>3.0.CO;2-G; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Borich M, 2015, J NEUROTRAUM, V32, P265, DOI 10.1089/neu.2013.3269; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058868; Czerniak SM, 2015, BRAIN IMAGING BEHAV, V9, P323, DOI 10.1007/s11682-014-9312-1; Daley M, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1131-5; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Goncalves S, 2016, J NEUROSURG-SPINE, V25, P436, DOI 10.3171/2016.2.SPINE15944; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Iraji A, 2014, J NEUROTRAUM, V1045, P1; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kowalczyk I, 2012, BRAIN, V135, P461, DOI 10.1093/brain/awr328; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Maddock Richard J, 2012, Curr Top Behav Neurosci, V11, P199; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; Mori S, 2009, CURR OPIN NEUROL, V22, P362, DOI 10.1097/WCO.0b013e32832d954b; Morton SM, 2004, NEUROSCIENTIST, V10, P247, DOI 10.1177/1073858404263517; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shin SS, 2017, BRAIN IMAGING BEHAV, V11, P591, DOI 10.1007/s11682-017-9684-0; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Westfall DR, 2015, J PEDIATR REHAB MED, V8, P297, DOI 10.3233/PRM-150348; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wright AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150215	39	35	35	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 21	2017	89	21					2157	2166		10.1212/WNL.0000000000004669			10	Clinical Neurology	Neurosciences & Neurology	FP5RF	WOS:000417677500009	29070666	Other Gold, Green Published			2021-06-18	
J	Esterov, D; Greenwald, BD				Esterov, Dmitry; Greenwald, Brian D.			Autonomic Dysfunction after Mild Traumatic Brain Injury	BRAIN SCIENCES			English	Article						mild traumatic brain injury; mild TBI; concussion; autonomic dysfunction; dysautonomia; heart rate variability; graded exercise testing; post concussive syndrome	HEART-RATE-VARIABILITY; NERVOUS-SYSTEM; CONCUSSION RECOVERY; MANAGEMENT; DISORDERS; HISTORY; IMPACT	A mild traumatic brain injury (mTBI) is a complex pathophysiologic process that has a systemic effect on the body aside from solely an impairment in cognitive function. Dysfunction of the autonomic nervous system (ANS) has been found to induce abnormalities in organ systems throughout the body, and may contribute to cardiovascular dysregulation and increased mortality. Autonomic dysfunction, also known as dysautonomia, has been studied in moderate and severe TBI, and has emerged as a major contributing factor in the symptomatology in mTBI as well. Analysis of the ANS has been studied through changes in heart rate variability (HRV), pupillary dynamics, eye pressure, and arterial pulse wave in those with mild TBI. Graded exercise testing has been studied as both a method of diagnosis and as a means of recovery in those with mild TBI, especially in those with persistent symptoms. Given the studies showing persistence of autonomic dysfunction after symptomatic resolution of concussions, further research is needed to establish return to play protocols	[Esterov, Dmitry] JFK Johnson Rehabil Inst, Edison, NJ 08820 USA; [Greenwald, Brian D.] JFK Johnson Rehabil Inst, JFK Ctr Head Injuries, Edison, NJ 08820 USA	Esterov, D (corresponding author), JFK Johnson Rehabil Inst, Edison, NJ 08820 USA.; Greenwald, BD (corresponding author), JFK Johnson Rehabil Inst, JFK Ctr Head Injuries, Edison, NJ 08820 USA.	desterov@jfkhealth.org; BGreenwald@jfkhealth.org					Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; AGGARWAL A, 1994, GASTROENTEROLOGY, V106, P945, DOI 10.1016/0016-5085(94)90753-6; Albalawi T., 2017, J NEUROTRAUM, DOI [10.1089/neu.2017.506028537493, DOI 10.1089/NEU.2017.506028537493]; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alvares GA, 2016, J PSYCHIATR NEUROSCI, V41, P89, DOI 10.1503/jpn.140217; Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Bishop S, 2017, BRAIN INJURY, V31, P247, DOI 10.1080/02699052.2016.1226385; Blake TA, 2016, BRAIN INJURY, V30, P132, DOI 10.3109/02699052.2015.1093659; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; Dobson JL, 2017, AM J PHYSIOL-REG I, V312, pR575, DOI 10.1152/ajpregu.00499.2016; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Fountaine M. F. L., 2016, FRONT NEUROL, V7, P13, DOI [10.3389/fneur.2016.0001326925028, DOI 10.3389/FNEUR.2016.0001326925028]; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Henden PL, 2014, J NEUROSURG ANESTH, V26, P50, DOI 10.1097/ANA.0b013e3182a47b62; Hilz MJ, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0584-5; Hilz MJ, 2015, J NEUROTRAUM, V32, P1796, DOI 10.1089/neu.2014.3842; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Kenney MJ, 2014, COMPR PHYSIOL, V4, P1177, DOI 10.1002/cphy.c130051; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lal A., 2017, AM J SPORTS MED, DOI [10.1177/036354651770613728570092, DOI 10.1177/036354651770613728570092]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy J, 2010, CLIN J SPORT MED, V20, P166, DOI 10.1097/01.jsm.0000369407.44192.40; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Lim HB, 2007, ANAESTHESIA, V62, P474, DOI 10.1111/j.1365-2044.2007.04998.x; McCorry LK, 2007, AM J PHARM EDUC, V71, DOI 10.5688/aj710478; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2010, CLIN J SPORT MED, V20, P332, DOI 10.1097/JSM.0b013e3181e92350; Senthinathan A, 2017, CLIN J SPORT MED, V27, P288, DOI 10.1097/JSM.0000000000000337; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; Truong JQ, 2016, BRAIN INJURY, V30, P1378, DOI 10.1080/02699052.2016.1195922; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9	34	35	38	1	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-3425			BRAIN SCI	Brain Sci.	AUG	2017	7	8							100	10.3390/brainsci7080100			8	Neurosciences	Neurosciences & Neurology	FF4DL	WOS:000408881300008	28800081	DOAJ Gold, Green Published			2021-06-18	
J	Tucker, R; Raftery, M; Kemp, S; Brown, J; Fuller, G; Hester, B; Cross, M; Quarrie, K				Tucker, Ross; Raftery, Martin; Kemp, Simon; Brown, James; Fuller, Gordon; Hester, Ben; Cross, Matthew; Quarrie, Ken			Risk factors for head injury events in professional rugby union: a video analysis of 464 head injury events to inform proposed injury prevention strategies	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS INJURIES; WORLD CUP; CONCUSSION; EPIDEMIOLOGY; FOOTBALL; SURVEILLANCE; PLAYERS	Objectives The tackle is responsible for the majority of head injuries during rugby union. In order to address head injury risk, risk factors during the tackle must first be identified. This study analysed tackle characteristics in the professional game in order to inform potential interventions. Methods 464 tackles resulting in a head injury assessment (HIA) were analysed in detail, with tackle type, direction, speed, acceleration, nature of head contact and player body position the characteristics of interest. Results Propensity to cause an HIA was significantly greater for active shoulder tackles, front-on tackles, high speeder tackles and an accelerating tackler. Head contact between a tackler's head and ball carrier's head or shoulder was significantly more likely to cause an HIA than contact below the level of the shoulder (incident rate ratio (IRR) 4.25, 95% CI 3.38 to 5.35). The tackler experiences the majority (78%) of HIAs when head-to-head contact occurs. An upright tackler was 1.5 times more likely to experience an HIA than a bent at the waist tackler (IRR 1.44, 95% CI 1.18 to 1.76). Conclusions This study confirms that energy transfer in the tackle is a risk factor for head injury, since direction, type and speed all influence HIA propensity. The study provides evidence that body position and the height of tackles should be a focus for interventions, since lowering height and adopting a bent at the waist body position is associated with reduced risk for both tacklers and ball carriers. To this end, World Rugby has implemented law change based on the present data.	[Tucker, Ross; Raftery, Martin; Hester, Ben; Cross, Matthew] World Rugby, Dublin, Ireland; [Kemp, Simon] Rugby Football Union, Twickenham, England; [Brown, James] Univ Cape Town, Cape Town, South Africa; [Fuller, Gordon] Univ Sheffield, Sheffield, S Yorkshire, England; [Cross, Matthew] Univ Bath, Dept Hlth, Bath, Avon, England; [Quarrie, Ken] New Zealand Rugby, Wellington, New Zealand	Tucker, R (corresponding author), World Rugby Pty Ltd, Dublin, Ireland.	ross.tucker@mweb.co.za	Brown, James Craig/H-7637-2019	Brown, James Craig/0000-0002-7778-7783; Kemp, Simon/0000-0002-3250-2713; Fuller, Gordon Ward/0000-0001-8532-3500	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Bahr R, 2003, BRIT J SPORT MED, V37, P384, DOI 10.1136/bjsm.37.5.384; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2016, BRIT J SPORT MED, V50, P682, DOI 10.1136/bjsports-2016-096043; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Hendricks S, 2017, J SPORTS SCI, V7, P1; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Kemp S, ENGLAND PROFESSIONAL; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; Mercy J A, 1988, Violence Vict, V3, P285; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Tucker R, BRIT J SPORTS MED BJ; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	23	35	35	1	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2017	51	15					1152	1157		10.1136/bjsports-2017-097895			6	Sport Sciences	Sport Sciences	FA9US	WOS:000405792300012	28642222	Green Accepted			2021-06-18	
J	Kirkpatrick, B; Mucci, A; Galderisi, S				Kirkpatrick, Brian; Mucci, Armida; Galderisi, Silvana			Primary, Enduring Negative Symptoms: An Update on Research	SCHIZOPHRENIA BULLETIN			English	Article						deficit schizophrenia; nosology; negative symptoms; psychopathology; schizophrenia	NON-DEFICIT SCHIZOPHRENIA; WHITE-MATTER ALTERATIONS; TRAUMATIC BRAIN-INJURY; NAIVE PATIENTS; DIMINISHED EXPRESSION; NEUROIMAGING EVIDENCE; INTERSTITIAL-CELLS; APATHY; IMPAIRMENTS; PSYCHOSIS	We previously proposed that people with schizophrenia who have primary, enduring negative symptoms have a disease-deficit schizophrenia (DS)-that is separate from that affecting people with schizophrenia without these features. Additional evidence consistent with the separate disease hypothesis has accumulated in recent years. White matter changes may be widespread in deficit compared to nondeficit patients and may relate to problems in early brain migration. These 2 patient groups also appear to differ on metabolic measures prior to antipsychotic treatment. Studies of reward and defeatist beliefs provide the basis for future treatment trials. The 2 factors or groups within negative symptoms broadly defined (both primary and secondary) have also been found in DS, and recent evidence suggests these 2 symptom groups have different correlates and reflect the existence of 2 groups with in DS. Negative symptoms are found in disorders other than schizophrenia, and excess summer birth, a deficit risk factor, has been found in a non-patient group with deficit-like features. It may be useful in future research to determine whether findings in DS extend to patients with other neuropsychiatric disorders who also have negative symptoms.	[Kirkpatrick, Brian] Univ Nevada, Reno Sch Med, Dept Psychiat & Behav Sci, 1664 North Virginia St,Mail Stop 0354, Reno, NV 89557 USA; [Mucci, Armida] Univ Naples SUN, Dept Psychiat, Naples, Italy; [Galderisi, Silvana] Univ Campania Luigi Vanvitelli SUN, Dept Psychiat, Naples, Italy; [Galderisi, Silvana] Univ Hosp SUN, Naples, Italy	Kirkpatrick, B (corresponding author), Univ Nevada, Reno Sch Med, Dept Psychiat & Behav Sci, 1664 North Virginia St,Mail Stop 0354, Reno, NV 89557 USA.	bkirkpatrick2@aol.com			Genentech/RocheRoche HoldingGenentech; Minerva Neurosciences; ProPhase LLC; Decision Resources, Inc; Walsh Medical Media; Physicians Postgraduate Press, Inc.; LundbeckLundbeck Corporation; Janssen PharmaceuticalsJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc; Hoffman-La Roche; Angelini-Acraf; OtsukaOtsuka Pharmaceutical; Pierre Fabre; Gedeon-Richter; PfizerPfizer	B.K. has received licensing royalties from ProPhase LLC for use of the Brief Negative Symptom Scale (BNSS) by for-profit groups; these fees are donated to the Brain and Behavior Research Foundation. B.K. has also received consulting fees and travel support from Genentech/Roche, Minerva Neurosciences, and ProPhase LLC, some of the fees for teaching the BNSS to pharmaceutical company raters; he has also received consulting fees from anonymized pharmaceutical companies through Decision Resources, Inc. and L.E.K. Consulting, and from an investment capital company through Guideposts. B.K. also receives fees from Walsh Medical Media for editorial services, and received fees for editorial services from Physicians Postgraduate Press, Inc. S.G. received honoraria or advisory board/consulting fees from the following companies: Lundbeck, Janssen Pharmaceuticals, Hoffman-La Roche, Angelini-Acraf, Otsuka, Pierre Fabre and Gedeon-Richter. A.M. received honoraria or advisory board/consulting fees from the following companies: Janssen Pharmaceuticals, Otsuka, Pfizer and Pierre Fabre.	Ahmed AO, 2015, SCHIZOPHRENIA BULL, V41, P879, DOI 10.1093/schbul/sbu163; Arango C, 1999, AM J PSYCHIAT, V156, P1097; Arango C, 2011, EUR NEUROPSYCHOPHARM, V21, P867, DOI 10.1016/j.euroneuro.2011.03.005; Beck AT, 2013, SCHIZOPHRENIA BULL, V39, P43, DOI 10.1093/schbul/sbr040; Blanchard JJ, 2005, SCHIZOPHR RES, V77, P151, DOI 10.1016/j.schres.2005.03.022; Blanchard JJ, 2006, SCHIZOPHRENIA BULL, V32, P238, DOI 10.1093/schbul/sbj013; Blanchard JJ, SCHIZOPHR RES; Bucci P, 2016, SCHIZOPHR RES, V174, P172, DOI 10.1016/j.schres.2016.01.032; Campellone TR, 2016, SCHIZOPHRENIA BULL, V42, P1343, DOI 10.1093/schbul/sbw026; Cascella NG, 2010, SCHIZOPHR RES, V120, P63, DOI 10.1016/j.schres.2010.03.039; Cohen AS, 2007, SCHIZOPHRENIA BULL, V33, P1201, DOI 10.1093/schbul/sbl066; Dantas CR, 2011, SCHIZOPHR RES, V128, P124, DOI 10.1016/j.schres.2011.01.023; De Rossi P, 2016, PSYCHIAT RES-NEUROIM, V254, P48, DOI 10.1016/j.pscychresns.2016.06.004; Fernandez-Egea E, 2012, PSYCHIAT RES-NEUROIM, V203, P109, DOI 10.1016/j.pscychresns.2011.09.016; Fervaha G, 2015, SCHIZOPHR RES, V168, P483, DOI 10.1016/j.schres.2015.07.023; Fischer BA, 2012, SCHIZOPHR RES, V136, P51, DOI 10.1016/j.schres.2012.01.030; Galderisi S, 2002, AM J PSYCHIAT, V159, P983, DOI 10.1176/appi.ajp.159.6.983; Galderisi S, 2015, EUR ARCH PSY CLIN N, V265, P543, DOI 10.1007/s00406-015-0590-4; Galderisi S, 2014, WORLD PSYCHIATRY, V13, P275, DOI 10.1002/wps.20167; Galderisi S, 2013, SCHIZOPHR RES, V147, P157, DOI 10.1016/j.schres.2013.03.020; Garcia-Rizo C, 2012, PSYCHIAT RES, V198, P212, DOI 10.1016/j.psychres.2011.08.014; Grant PM, 2009, SCHIZOPHRENIA BULL, V35, P798, DOI 10.1093/schbul/sbn008; Hong LE, 2003, SCHIZOPHR RES, V63, P39, DOI 10.1016/S0920-9964(02)00388-2; Kimhy D, 2006, SCHIZOPHRENIA BULL, V32, P274, DOI 10.1093/schbul/sbi064; Kirkpatrick B, 2001, ARCH GEN PSYCHIAT, V58, P165, DOI 10.1001/archpsyc.58.2.165; KIRKPATRICK B, 1993, PSYCHIAT RES, V47, P47, DOI 10.1016/0165-1781(93)90054-K; Kirkpatrick B, 2006, SCHIZOPHRENIA BULL, V32, P214, DOI 10.1093/schbul/sbj053; KIRKPATRICK B, 1989, PSYCHIAT RES, V30, P119, DOI 10.1016/0165-1781(89)90153-4; Kirkpatrick B, 2003, J NERV MENT DIS, V191, P563, DOI 10.1097/01.nmd.0000087181.61164.e1; Kirkpatrick B, 1999, SYNAPSE, V34, P95, DOI 10.1002/(SICI)1098-2396(199911)34:2<95::AID-SYN2>3.0.CO;2-I; Kirkpatrick B, 2008, WORLD PSYCHIATRY, V7, P143; Kirkpatrick B, 2008, SCHIZOPHR RES, V103, P151, DOI 10.1016/j.schres.2007.12.479; Kirkpatrick B, 2009, SCHIZOPHR RES, V107, P122, DOI 10.1016/j.schres.2008.09.023; Kirschner M, 2016, J PSYCHIATR NEUROSCI, V41, P152, DOI 10.1503/jpn.140383; Kranz TM, 2016, EBIOMEDICINE, V6, P206, DOI 10.1016/j.ebiom.2016.03.008; Lei W, 2015, PSYCHIAT RES-NEUROIM, V234, P219, DOI 10.1016/j.pscychresns.2015.09.015; Lei W, 2015, SCI REP-UK, V5, DOI 10.1038/srep12994; Li Z, 2013, ASIA-PAC PSYCHIAT, V5, P69, DOI 10.1111/appy.12030; Santos JL, 2010, SCHIZOPHR RES, V119, P183, DOI 10.1016/j.schres.2010.01.010; Marder SR, 2017, WORLD PSYCHIATRY, V16, P14, DOI 10.1002/wps.20385; Messias E, 2004, ARCH GEN PSYCHIAT, V61, P985, DOI 10.1001/archpsyc.61.10.985; Mucci A, 2015, EUR PSYCHIAT, V30, P641, DOI 10.1016/j.eurpsy.2015.01.014; Mucci A, 2015, PSYCHOL MED, V45, P1765, DOI 10.1017/S0033291714002943; Nakaya M, 2008, PSYCHIAT RES, V158, P256, DOI 10.1016/j.psychres.2007.10.008; Nemeth G, 2017, LANCET, V389, P1103, DOI [10.1016/S0140-6736(17)30060-0, 10.1016/s0140-6736(17)30060-0]; Nkam I, 2010, BIOL PSYCHIAT, V67, P992, DOI 10.1016/j.biopsych.2009.11.029; Pegoraro LFL, 2013, SCHIZOPHR RES, V147, P91, DOI 10.1016/j.schres.2013.02.041; Peralta V, 2014, SCHIZOPHRENIA BULL, V40, P214, DOI 10.1093/schbul/sbs152; Pillny M, 2016, PSYCHIAT RES, V244, P117, DOI 10.1016/j.psychres.2016.07.018; Rao V, 2007, PSYCHOSOMATICS, V48, P217, DOI 10.1176/appi.psy.48.3.217; Rethelyi JM, 2012, EUR ARCH PSY CLIN N, V262, P107, DOI 10.1007/s00406-011-0224-4; Rowland LM, 2009, NEUROPSYCHOPHARMACOL, V34, P1514, DOI 10.1038/npp.2008.207; Spalletta G, 2015, PSYCHIAT RES-NEUROIM, V231, P252, DOI 10.1016/j.pscychresns.2014.12.006; Strauss GP, 2008, SCHIZOPHR RES, V102, P76, DOI 10.1016/j.schres.2008.01.014; Strauss GP, 2013, J PSYCHIATR RES, V47, P783, DOI 10.1016/j.jpsychires.2013.01.015; Strauss GP, 2012, SCHIZOPHR RES, V142, P96, DOI 10.1016/j.schres.2012.09.007; Strauss GP, 2012, SCHIZOPHR RES, V135, P134, DOI 10.1016/j.schres.2011.11.007; Strauss GP, 2010, SCHIZOPHRENIA BULL, V36, P860, DOI 10.1093/schbul/sbn178; Strauss GP, 2010, SCHIZOPHRENIA BULL, V36, P788, DOI 10.1093/schbul/sbn167; Takayanagi M, 2013, SCHIZOPHR RES, V150, P484, DOI 10.1016/j.schres.2013.07.036; Takayanagi Y, 2013, J NEUROPSYCH CLIN N, V25, P292, DOI 10.1176/appi.neuropsych.12040093; Telfer S, 2011, ACTA PSYCHIAT SCAND, V124, P357, DOI 10.1111/j.1600-0447.2011.01751.x; Trotman HD, 2011, SCHIZOPHR RES, V126, P252, DOI 10.1016/j.schres.2010.08.024; Vaskinn A, 2015, PSYCHIAT RES, V228, P803, DOI 10.1016/j.psychres.2015.05.019; Vogel SJ, 2013, SCHIZOPHR RES, V151, P97, DOI 10.1016/j.schres.2013.07.052; Voineskos AN, 2013, JAMA PSYCHIAT, V70, P472, DOI 10.1001/jamapsychiatry.2013.786; Wheeler AL, 2015, JAMA PSYCHIAT, V72, P446, DOI 10.1001/jamapsychiatry.2014.3020; Yu M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138357	68	35	37	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	JUL	2017	43	4					730	736		10.1093/schbul/sbx064			7	Psychiatry	Psychiatry	EX6HU	WOS:000403344200011	28575513	Bronze, Green Published			2021-06-18	
J	Roos, KG; Wasserman, EB; Dalton, SL; Gray, A; Djoko, A; Dompier, TP; Kerr, ZY				Roos, Karen G.; Wasserman, Erin B.; Dalton, Sara L.; Gray, Aaron; Djoko, Aristarque; Dompier, Thomas P.; Kerr, Zachary Y.			Epidemiology of 3825 injuries sustained in six seasons of National Collegiate Athletic Association men's and women's soccer (2009/2010-2014/2015)	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							HIGH-SCHOOL SOCCER; SURVEILLANCE SYSTEM; FEMALE SOCCER; DESCRIPTIVE EPIDEMIOLOGY; DATA-COLLECTION; AMATEUR SOCCER; UNITED-STATES; TEAM SPORTS; PLAYERS; DEFINITIONS	Aim To describe the epidemiology of National Collegiate Athletic Association (NCAA) men's and women's soccer injuries during the 2009/2010-2014/ 2015 academic years. Methods This descriptive epidemiology study used NCAA Injury Surveillance Program (NCAA-ISP) data during the 2009/2010-2014/2015 academic years, from 44 men's and 64 women's soccer programmes (104 and 167 team seasons of data, respectively). Non-time-loss injuries were defined as resulting in <24 h lost from sport. Injury counts, percentages and rates were calculated. Injury rate ratios (RRs) and injury proportion ratios (IPRs) with 95% CIs compared rates and distributions by sex. Results There were 1554 men's soccer and 2271 women's soccer injuries with injury rates of 8.07/1000 athlete exposures (AE) and 8.44/1000AE, respectively. Injury rates for men and women did not differ in competitions (17.53 vs 17.04/1000AE; RR=1.03; 95% CI 0.94 to 1.13) or practices (5.47 vs 5.69/1000AE; RR=0.96; 95% CI 0.88 to 1.05). In total, 47.2% (n=733) of men's soccer injuries and 47.5% (n=1079) of women's were non-time loss. Most injuries occurred to the lower extremity and were diagnosed as sprains. Women had higher concussion rates (0.59 vs 0.34/1000AE; RR=1.76; 95% CI 1.32 to 2.35) than men. Conclusions Non-time-loss injuries accounted for nearly half of the injuries in men's and women's soccer. Sex differences were found in competition injuries, specifically for concussion. Further study into the incidence, treatment and outcome of non-time-loss injuries may identify a more accurate burden of these injuries.	[Roos, Karen G.; Dalton, Sara L.; Djoko, Aristarque; Dompier, Thomas P.; Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA; [Wasserman, Erin B.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Gray, Aaron] Univ Missouri, Sch Med, Dept Family Med, Columbia, MO USA; [Gray, Aaron] Univ Missouri, Sch Med, Dept Orthoped, Columbia, MO USA	Roos, KG (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	kroos@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259; Gray, Aaron/0000-0001-7879-1867; , Karen/0000-0003-1444-2646; Wasserman, Erin/0000-0001-5957-5878	NCAA	The NCAA Injury Surveillance Program data were provided by the Datalys Center for Sports Injury Research and Prevention. The Injury Surveillance Program was funded by the NCAA.	Agel J, 2007, J ATHL TRAINING, V42, P270; Andersen CA, 2013, BRIT J SPORT MED, V47, P857, DOI 10.1136/bjsports-2013-092397; Arendt EA, 1999, J ATHL TRAINING, V34, P86; Brito J, 2012, J ATHL TRAINING, V47, P191; Brooks JHM, 2006, SPORTS MED, V36, P459, DOI 10.2165/00007256-200636060-00001; Clarsen B, 2014, BRIT J SPORT MED, V48, P754, DOI 10.1136/bjsports-2012-092087; Clarsen B, 2014, BRIT J SPORT MED, V48, P510, DOI 10.1136/bjsports-2013-093297; Clausen MB, 2014, AM J SPORT MED, V42, P2487, DOI 10.1177/0363546514541224; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dick R, 2007, J ATHL TRAINING, V42, P278; Dick R, 2007, J ATHL TRAINING, V42, P173; DiStefano LJ, 2009, AM J SPORT MED, V37, P495, DOI 10.1177/0363546508327542; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Gutierrez GM, 2014, PEDIATR EXERC SCI, V26, P33, DOI 10.1123/pes.2013-0102; Herrero H, 2014, AM J SPORT MED, V42, P78, DOI 10.1177/0363546513507767; Hewett TE, 2010, N AM J SPORTS PHYS T, V5, P234; Hodgson L, 2007, CLIN J SPORT MED, V17, P188, DOI 10.1097/JSM.0b013e3180547513; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Irick E, 2014, NCAA SPORTS SPONSORS; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Kerr ZY, 2016, J ATHL TRAINING, V51, P57, DOI 10.4085/1062-6050-51.1.10; Kerr ZY, 2015, BRIT J SPORT MED, V49, P465, DOI 10.1136/bjsports-2014-094423; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; Mercer TH, 2003, EUR J APPL PHYSIOL, V89, P506, DOI 10.1007/s00421-003-0830-6; Mufty S, 2015, ACTA ORTHOP BELG, V81, P289; Orchard J, 2007, CLIN J SPORT MED, V17, P192, DOI 10.1097/JSM.0b013e3180547527; Orchard JW, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2014-094272; Powell JW, 2004, J ATHL TRAINING, V39, P56; Roos KG, 2015, AM J SPORT MED, V43, P1790, DOI 10.1177/0363546515580790; Stubbe JH, 2015, J ATHL TRAINING, V50, P211, DOI 10.4085/1062-6050-49.3.64; Sutton KM, 2013, J AM ACAD ORTHOP SUR, V21, P41, DOI 10.5435/JAAOS-21-01-41; Swenson DM, 2013, MED SCI SPORT EXER, V45, P462, DOI 10.1249/MSS.0b013e318277acca; U.S. Youth Soccer, WHAT IS YOUTH SOCC; van Beijsterveldt AMC, 2015, J SCI MED SPORT, V18, P145, DOI 10.1016/j.jsams.2014.02.004; Yang JZ, 2012, J ATHL TRAINING, V47, P198; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047	40	35	35	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2017	51	13					1029	U70		10.1136/bjsports-2015-095718			7	Sport Sciences	Sport Sciences	EY5KJ	WOS:000404015800011	27190140				2021-06-18	
J	Namjoshi, DR; Cheng, WH; Bashir, A; Wilkinson, A; Stukas, S; Martens, KM; Whyte, T; Abebe, ZA; McInnes, KA; Cripton, PA; Wellington, CL				Namjoshi, Dhananjay R.; Cheng, Wai Hang; Bashir, Asma; Wilkinson, Anna; Stukas, Sophie; Martens, Kris M.; Whyte, Tom; Abebe, Zelalem A.; McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.			Defining the biomechanical and biological threshold of murine mild traumatic brain injury using CHIMERA (Closed Head Impact Model of Engineered Rotational Acceleration)	EXPERIMENTAL NEUROLOGY			English	Article						CHIMERA; Traumatic brain injury; Closed head injury; Animal model of traumatic brain injury; Biomechanics; Behavior; Neuropathology	CLINICAL MANAGEMENT; CONCUSSION; FOOTBALL; MECHANISMS; DIAGNOSIS	CHIMERA (Closed Head Impact Model of Engineered Rotational Acceleration) is a recently described animal model of traumatic brain injury (TBI) that primarily produces diffuse axonal injury (DAI) characterized by white matter inflammation and axonal damage. CHIMERA was specifically designed to reliably generate a variety of TBI severities using precise and quantifiable biomechanical inputs in a nonsurgical user-friendly platform. The objective of this study was to define the lower limit of single impact mild TBI (mTBI) using CHIMERA by characterizing the dose-response relationship between biomechanical input and neurological, behavioral, neuropathological and biochemical outcomes. Wild-type male mice were subjected to a single CHIMERA TBI using six impact energies ranging from 0.1 to 0.7 J, and post-TBI outcomes were assessed over an acute period of 14 days. Here we report that single TBI using CHIMERA induces injury dose- and time-dependent changes in behavioral and neurological deficits, axonal damage, white matter tract microgliosis and astrogliosis. Impact energies of 0.41 or below produced no significant phenotype (subthreshold), 0.5 J led to significant changes for one or more phenotypes (threshold), and 0.6 and 0.7 J resulted in significant changes in all outcomes assessed (mTBI). We further show that linear head kinematics are the most robust predictors of duration of unconsciousness, severity of neurological deficits, white matter injury, and microgliosis following single TBI. Our data extend the validation of CHIMERA as a biofidelic animal model of DAI and establish working parameters to guide future investigations of the mechanisms underlying axonal pathology and inflammation induced by mechanical trauma. Crown Copyright (C) 2017 Published by Elsevier Inc.	[Namjoshi, Dhananjay R.; Cheng, Wai Hang; Bashir, Asma; Wilkinson, Anna; Stukas, Sophie; Martens, Kris M.; Wellington, Cheryl L.] Univ British Columbia, Dept Pathol & Lab Med, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; [Whyte, Tom; Abebe, Zelalem A.; McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Mech Engn, Vancouver, BC, Canada; [Whyte, Tom; Abebe, Zelalem A.; McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC, Canada	Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	dnamjoshi@gmail.com; chengwh@mail.ubc.ca; asmab@mail.ubc.ca; wanna@mail.ubc.ca; stukas@mail.ubc.ca; krismmartens@gmail.com; tom@mech.ubc.ca; cripton@mech.ubc.ca; wcheryl@mail.ubc.ca	Cripton, Peter/AAC-8268-2020	Cripton, Peter/0000-0002-5067-0833; McInnes, Kurt/0000-0001-5931-2963; Bashir, Asma/0000-0002-3616-9436; Cheng, Wai Hang/0000-0002-3408-9184; Namjoshi, Dhananjay/0000-0003-1753-5581; Stukas, Sophie/0000-0001-8819-8821	Alzheimer Society Research Program Doctoral Award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao; Canadian Institutes for Health Research Graduate Fellowship; University of British Columbia Doctoral Fellowship; Weston Brain Institute	Operating funding for this project was supplied by a Transformational Grant from the Weston Brain Institute to C.L.W. W H.C. is supported by Alzheimer Society Research Program Doctoral Award and Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao. A.B. is supported by Canadian Institutes for Health Research Graduate Fellowship and University of British Columbia Doctoral Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allsop D., 1991, FORCE DEFLECTION FRA; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bogoslovsky T, 2016, DIAGNOSTICS, V6, DOI 10.3390/diagnostics6040037; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Coats B, 2017, J NEUROTRAUM, V34, P235, DOI 10.1089/neu.2015.4352; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Cullen DK, 2016, METHODS MOL BIOL, V1462, P289, DOI 10.1007/978-1-4939-3816-2_17; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hodgson V.R., 1971, COMPARISON HEAD ACCE; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kamins J, 2016, NEUROSURG CLIN N AM, V27, P441, DOI 10.1016/j.nec.2016.05.005; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Ommaya A.K., 1967, SCALING EXPT DATA CE; Oresic M, 2016, EBIOMEDICINE, V12, P118, DOI 10.1016/j.ebiom.2016.07.015; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; SINHA JN, 1968, JPN J PHARMACOL, V18, P519, DOI 10.1254/jjp.18.519; Szabo T.J., 1996, HUMAN SUBJECT KINEMA; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; TEASDALE G, 1974, LANCET, V2, P81; United Sates Departments of Defense and Veterans Affairs, 2008, COMM DEF TBI; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	37	35	35	1	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2017	292						80	91		10.1016/j.expneurol.2017.03.003			12	Neurosciences	Neurosciences & Neurology	ET5FR	WOS:000400310100008	28274861	Other Gold			2021-06-18	
J	Hutchison, MG; Mainwaring, L; Senthinathan, A; Churchill, N; Thomas, S; Richards, D				Hutchison, Michael G.; Mainwaring, Lynda; Senthinathan, Arrani; Churchill, Nathan; Thomas, Scott; Richards, Doug			Psychological and Physiological Markers of Stress in Concussed Athletes Across Recovery Milestones	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; emotions; heart rate variability; mild traumatic brain injury; physiological; psychological; recovery; sport; stress	HEART-RATE-VARIABILITY; TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; PARTIAL LEAST-SQUARES; RECURRENT CONCUSSION; HIGH-SCHOOL; GENDER; FMRI; SYMPTOMS	Background: Sport-related concussions are associated with a range of physical, cognitive, and behavioral disturbances that are highly variable across individuals. Much remains unknown about the effects of sport concussion, and changes in markers of psychological and physiological stress over the recovery timeline. Objective: To examine psychological (mood, stress, sleep quality, and symptoms) and physiological (heart rate variability and salivary cortisol) measures in concussed athletes over clinical recovery milestones. Setting: University athletic program, sport medicine clinic, Canada. Participants: A sample of 52 interuniversity athletes (32 male and 20 female), 26 with concussion and 26 healthy controls. Design: Case-control repeated measures study at 3 time points of the clinical recovery process. Measures were administered to a matched control sample of uninjured athletes as well. Main Measures: Physiological measures were heart rate variability and salivary cortisol; psychological measures were mood, perceived stress, and quality of sleep. Results: Psychological measures were significantly worse for concussed athletes relative to controls at the symptomatic phase (acute injury), but significantly better at return-to-play (RTP). Multivariate analysis of heart rate variability identified main effects of sex and concussion, with reduced high-frequency heart rate variability for females and concussed athletes extending into the post-RTP phase. An interaction effect was also observed, showing the cardiac response of female athletes was more sensitive to concussion compared with males. Conversely, male athletes showed greater suppression of low-frequency heart rate variability associated with mood disturbances. Conclusion: This integrated study of psychological and physiological markers in concussed athletes confirmed the resolution of mood disturbances, symptoms, and sleep quality by RTP, but identified autonomic nervous system disturbances, as measured by depressed heart rate variability beyond RTP.	[Hutchison, Michael G.; Mainwaring, Lynda; Senthinathan, Arrani; Thomas, Scott; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Hutchison, Michael G.; Churchill, Nathan] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada	Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Thomas, Scott G/G-4522-2012	Thomas, Scott G/0000-0002-5564-4271	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [2012-ABI-CAT1-971]	This study was supported by a grant from Canadian Institute of Health Research (CIHR)-2012-ABI-CAT1-971 awarded to L. Mainwaring.	Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Antelmi I, 2004, AM J CARDIOL, V93, P381, DOI 10.1016/j.amjcard.2003.09.065; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Bashirelahi KB, 2014, J NEUROTRAUM, V31, pA39; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berntson GG, 2004, DYNAMIC ELECTROCARDIOGRAPHY, P57, DOI 10.1002/9780470987483.ch7; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; Critchley HD, 2005, J COMP NEUROL, V493, P154, DOI 10.1002/cne.20749; Dart AM, 2002, CARDIOVASC RES, V53, P678, DOI 10.1016/S0008-6363(01)00508-9; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Hutchison MG, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00046; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kemp AH, 2010, BIOL PSYCHIAT, V67, P1067, DOI [10.1016/j.biopsych.2009.12.012, 10.1016/j.biopsych.2009.11.019]; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kostyun RO, 2015, AM J SPORT MED, V43, P633, DOI 10.1177/0363546514560727; La Fountaine MF, 2011, J ATHL TRAINING, V46, P230; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; LIAO DP, 1995, AM J CARDIOL, V76, P906, DOI 10.1016/S0002-9149(99)80260-4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nguyen DV, 2002, BIOINFORMATICS, V18, P1216, DOI 10.1093/bioinformatics/18.9.1216; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rosipal R, 2006, LECT NOTES COMPUT SC, V3940, P34, DOI 10.1007/11752790_2; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Tolkunov D, 2010, NEUROIMAGE, V50, P72, DOI 10.1016/j.neuroimage.2009.12.021; Vrijkotte TGM, 2000, HYPERTENSION, V35, P880, DOI 10.1161/01.HYP.35.4.880; Wilberger J, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P45, DOI 10.1007/0-387-32565-4_3; Zhang L, 2002, ANAL CHEM, V74, P4097, DOI 10.1021/ac020023r; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	61	35	35	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E38	E48		10.1097/HTR.0000000000000252			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900011	27603761				2021-06-18	
J	Yang, B; Hamilton, JA; Valenzuela, KS; Bogaerts, A; Xi, XP; Aronowski, J; Mays, RW; Savitz, SI				Yang, Bing; Hamilton, Jason A.; Valenzuela, Krystal S.; Bogaerts, Annelies; Xi, XiaoPei; Aronowski, Jaroslaw; Mays, Robert W.; Savitz, Sean I.			Multipotent Adult Progenitor Cells Enhance Recovery After Stroke by Modulating the Immune Response from the Spleen	STEM CELLS			English	Article						Rat model; Adult human bone marrow; Bone marrow stromal cells; Cellular therapy	REGULATORY T-CELLS; MARROW MONONUCLEAR-CELLS; HYPOXIC-ISCHEMIC INJURY; TRAUMATIC BRAIN-INJURY; INTERFERON-GAMMA; RAT-BRAIN; INFLAMMATION; THERAPY; SIZE; TRANSPLANTATION	Stem cell therapy modulates not only the local microenvironment of the brain but also the systemic immune responses. We explored the impact of human multipotent adult progenitor cells (MAPC) modulating splenic activation and peripheral immune responses after ischemic stroke. Hundred twenty-six Long-Evans adult male rats underwent middle cerebral artery occlusion. Twenty-four hours later, they received IV MAPC or saline treatment. At 3 days after infusion, RNA was isolated from the injured cortex and spleen for microarray analysis. Spleen mass, splenocyte phenotype, and releasing cytokines were measured. Serum cytokines, MAPC biodistribution, brain lesion sizes and neurofunctional deficits were compared in rats treated with MAPC or saline with and without spleens. Stroked animals treated with MAPC exhibited genes that more closely resembled animals with sham surgery. Gene categories downregulated by MAPC included leukocyte activation, antigen presentation, and immune effector processing, associated with the signaling pathways regulated by TNF-, IL-1, IL-6, and IFN- within the brain. MAPC treatment restored spleen mass reduction caused by stroke, elevated Treg cells within the spleen, increased IL-10 and decreased IL-1 released by splenocytes. MAPC reduced IL-6 and IL-1 and upregulated IL-10 serum levels. Compared with saline, MAPC enhance stroke recovery in rats with intact spleens but had no effects in rats without spleens. MAPC restores expression of multiple genes and pathways involved in immune and inflammatory responses after stroke. Immunomodulation of the splenic response by the intravenous administration of MAPC may create a more favorable environment for brain repair after stroke. Stem Cells2017;35:1290-1302	[Yang, Bing; Valenzuela, Krystal S.; Xi, XiaoPei; Aronowski, Jaroslaw; Savitz, Sean I.] UT Hlth Houston, McGovern Med Sch, Stroke Program, 6431 Fannin St, Houston, TX 77030 USA; [Hamilton, Jason A.; Mays, Robert W.] Athersys, Cleveland, OH USA; [Hamilton, Jason A.] Novartis Pharmaceut, E Hanover, NJ USA; [Bogaerts, Annelies] ReGenesys, Leuven, Belgium	Savitz, SI (corresponding author), UT Hlth Houston, McGovern Med Sch, Stroke Program, 6431 Fannin St, Houston, TX 77030 USA.	sean.i.savitz@uth.tmc.edu			Athersys Inc.	This work was supported by a grant sponsored by Athersys Inc.	Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Bao Y, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-92; Becker KJ, 2010, STROKE, V41, pS75, DOI 10.1161/STROKEAHA.110.592881; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Blomster LV, 2013, EXP NEUROL, V247, P226, DOI 10.1016/j.expneurol.2013.05.002; Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198; Burr SP, 2013, IMMUNOL CELL BIOL, V91, P12, DOI 10.1038/icb.2012.60; Burrows GG, 2013, STEM CELL TRANSL MED, V2, P745, DOI 10.5966/sctm.2013-0031; Busch SA, 2011, J NEUROSCI, V31, P944, DOI 10.1523/JNEUROSCI.3566-10.2011; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; de Bilbao F, 2009, J NEUROCHEM, V110, P12, DOI 10.1111/j.1471-4159.2009.06098.x; del Zoppo GJ, 2001, ARCH NEUROL-CHICAGO, V58, P669, DOI 10.1001/archneur.58.4.669; DePaul MA, 2015, SCI REP-UK, V5, DOI 10.1038/srep16795; Gao L, 2014, INT J MOL SCI, V15, P4431, DOI 10.3390/ijms15034431; Golden JE, 2012, TRANSL STROKE RES, V3, P491, DOI 10.1007/s12975-012-0208-3; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Hess DC, 2014, INT J STROKE, V9, P381, DOI 10.1111/ijs.12065; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Hurn PD, 2007, J CEREBR BLOOD F MET, V27, P1798, DOI 10.1038/sj.jcbfm.9600482; Illoh K, 2006, J CEREBR BLOOD F MET, V26, P1538, DOI 10.1038/sj.jcbfm.9600308; Jacobs SA, 2013, CELL TRANSPLANT, V22, P1915, DOI 10.3727/096368912X657369; Jellema RK, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0459-5; Kasam M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032793; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li PY, 2013, ANN NEUROL, V74, P458, DOI 10.1002/ana.23815; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Liu ZJ, 2015, CNS NEUROSCI THER, V21, P320, DOI 10.1111/cns.12361; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Ostrowski RP, 2012, TRANSL STROKE RES, V3, P473, DOI 10.1007/s12975-012-0206-5; Pennypacker KR, 2015, J CEREBR BLOOD F MET, V35, P186, DOI 10.1038/jcbfm.2014.212; Reading JL, 2015, MOL THER, V23, P1783, DOI 10.1038/mt.2015.131; Reading JL, 2013, J IMMUNOL, V190, P4542, DOI 10.4049/jimmunol.1202710; Robert W, 2010, J EXP STROKE TRANSL, V3, P3; Ross Amy Miner, 2007, J Stroke Cerebrovasc Dis, V16, P203, DOI 10.1016/j.jstrokecerebrovasdis.2007.05.002; Sahota P, 2013, INT J STROKE, V8, P60, DOI 10.1111/ijs.12022; Seifert HA, 2012, J NEUROIMMUNE PHARM, V7, P1017, DOI 10.1007/s11481-012-9406-8; Seifert HA, 2012, METAB BRAIN DIS, V27, P131, DOI 10.1007/s11011-012-9283-0; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Yan J, 2012, J NEUROIMMUNOL, V243, P89, DOI 10.1016/j.jneuroim.2011.12.019; Yang B, 2011, J NEUROSCI RES, V89, P833, DOI 10.1002/jnr.22614; Yasuhara T, 2006, REV NEUROSCIENCE, V17, P215; Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; Zeng LL, 2013, NEUROSCI LETT, V548, P4, DOI 10.1016/j.neulet.2013.04.037	50	35	36	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2017	35	5					1290	1302		10.1002/stem.2600			13	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	ET1HC	WOS:000400017200015	28263009	Bronze			2021-06-18	
J	Dayan, PS; Ballard, DW; Tham, E; Hoffman, JM; Swietlik, M; Deakyne, SJ; Alessandrini, EA; Tzimenatos, L; Bajaj, L; Vinson, DR; Mark, DG; Offerman, SR; Chettipally, UK; Paterno, MD; Schaeffer, MH; Wang, J; Casper, TC; Goldberg, HS; Grundmeier, RW; Kuppermann, N				Dayan, Peter S.; Ballard, Dustin W.; Tham, Eric; Hoffman, Jeff M.; Swietlik, Marguerite; Deakyne, Sara J.; Alessandrini, Evaline A.; Tzimenatos, Leah; Bajaj, Lalit; Vinson, David R.; Mark, Dustin G.; Offerman, Steve R.; Chettipally, Uli K.; Paterno, Marilyn D.; Schaeffer, Molly H.; Wang, Jun; Casper, T. Charles; Goldberg, Howard S.; Grundmeier, Robert W.; Kuppermann, Nathan		PECARN; Clinical Res Emergency; Trumatic Brain Injury-Knowledge	Use of Traumatic Brain Injury Prediction Rules With Clinical Decision Support\	PEDIATRICS			English	Article							BLUNT HEAD TRAUMA; COMPUTED-TOMOGRAPHY USE; EMERGENCY-DEPARTMENT; RADIATION-EXPOSURE; MULTICENTER TRIAL; CHILDREN; IMPLEMENTATION; RISK; ASSOCIATION; MANAGEMENT	OBJECTIVES: We determined whether implementing the Pediatric Emergency Care Applied abstract Research Network (PECARN) traumatic brain injury (TBI) prediction rules and providing risks of clinically important TBIs (ciTBIs) with computerized clinical decision support (CDS) reduces computed tomography (CT) use for children with minor head trauma. METHODS: Nonrandomized trial with concurrent controls at 5 pediatric emergency departments (PEDs) and 8 general EDs (GEDs) between November 2011 and June 2014. Patients were <18 years old with minor blunt head trauma. Intervention sites received CDS with CT recommendations and risks of ciTBI, both for patients at very low risk of ciTBI (no Pediatric Emergency Care Applied Research Network rule factors) and those not at very low risk. The primary outcome was the rate of CT, analyzed by site, controlling for time trend. RESULTS: We analyzed 16 635 intervention and 2394 control patients. Adjusted for time trends, CT rates decreased significantly (P <.05) but modestly (2.3%-3.7%) at 2 of 4 intervention PEDs for children at very low risk. The other 2 PEDs had small (0.8%-1.5%) nonsignificant decreases. CT rates did not decrease consistently at the intervention GEDs, with low baseline CT rates (2.1%-4.0%) in those at very low risk. The control PED had little change in CT use in similar children (from 1.6% to 2.9%); the control GED showed a decrease in the CT rate (from 7.1% to 2.6%). For all children with minor head trauma, intervention sites had small decreases in CT rates (1.7%-6.2%). CONCLUSIONS: The implementation of TBI prediction rules and provision of risks of ciTBIs by using CDS was associated with modest, safe, but variable decreases in CT use. However, some secular trends were also noted.	[Dayan, Peter S.] Columbia Univ, Dept Pediat, Coll Phys & Surg, Div Emergency Med, 3959 Broadway,CHN 1-116, New York, NY 10032 USA; [Ballard, Dustin W.] Kaiser Permanente, San Rafael Med Ctr, San Rafael, CA USA; [Ballard, Dustin W.; Vinson, David R.] Kaiser Permanente, Div Res, Oakland, CA USA; [Tham, Eric; Bajaj, Lalit] Univ Colorado, Dept Pediat, Sect Emergency Med, Aurora, CO USA; [Hoffman, Jeff M.] Nationwide Childrens Hosp, Columbus, OH USA; [Swietlik, Marguerite; Deakyne, Sara J.] Childrens Hosp Colorado, Dept Res Informat, Aurora, CO USA; [Alessandrini, Evaline A.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; [Vinson, David R.] Kaiser Permanente, Roseville Med Ctr, Roseville, CA USA; [Mark, Dustin G.] Kaiser Permanente, Oakland Med Ctr, Oakland, CA USA; [Offerman, Steve R.] Kaiser Permanente, South Sacramento Med Ctr, Sacramento, CA USA; [Chettipally, Uli K.] Kaiser Permanente, South San Francisco Med Ctr, San Francisco, CA USA; [Paterno, Marilyn D.; Goldberg, Howard S.] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA USA; [Schaeffer, Molly H.; Goldberg, Howard S.] Partners HealthCare Syst, Informat Syst, Boston, MA USA; [Wang, Jun; Casper, T. Charles] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Grundmeier, Robert W.] Childrens Hosp Philadelphia, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA; [Grundmeier, Robert W.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Dayan, PS (corresponding author), Columbia Univ, Dept Pediat, Coll Phys & Surg, Div Emergency Med, 3959 Broadway,CHN 1-116, New York, NY 10032 USA.	psd6@columbia.edu	Vinson, David R/AAK-3227-2020	Vinson, David R/0000-0001-6559-1858	American Recovery and Reinvestment Act, Office of the Secretary [S02MC19289-01-00]; Health Resources and Services Administration, Maternal and Child Health Bureau, Emergency Medical Services for Children Program [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	This work was supported by American Recovery and Reinvestment Act, Office of the Secretary grant S02MC19289-01-00. The Pediatric Emergency Care Applied Research Network is supported by the Health Resources and Services Administration, Maternal and Child Health Bureau, Emergency Medical Services for Children Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685.	Atabaki SM, 2016, ACAD EMERG MED, V23, P566, DOI 10.1111/acem.12923; Bates DW, 2003, J AM MED INFORM ASSN, V10, P523, DOI 10.1197/jamia.M1370; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Curran JA, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-25; Dayan PS, 2015, PEDIATRICS, V135, P504, DOI 10.1542/peds.2014-2695; Dayan PS, 2014, ANN EMERG MED, V64, P153, DOI 10.1016/j.annemergmed.2014.02.003; Dayan PS, 2014, ANN EMERG MED, V63, P657, DOI 10.1016/j.annemergmed.2014.01.009; Deakyne SJ, 2015, APPL CLIN INFORM, V6, P521, DOI 10.4338/ACI-2015-02-RA-0019; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Goldberg HS, 2016, INT J MED INFORM, V87, P101, DOI 10.1016/j.ijmedinf.2015.12.002; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee LK, 2014, JAMA PEDIATR, V168, P837, DOI 10.1001/jamapediatrics.2014.361; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Marin JR, 2014, ACAD EMERG MED, V21, P987, DOI 10.1111/acem.12458; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Mooney JS, 2011, EMERG MED J, V28, P778, DOI 10.1136/emj.2009.083360; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Nigrovic LE, 2013, PEDIATRICS, V132, pE689, DOI 10.1542/peds.2013-0909; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Nishijima DK, 2015, JAMA PEDIATR, V169, P1141, DOI 10.1001/jamapediatrics.2015.2743; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Roshanov PS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f657; Sheehan B, 2013, J BIOMED INFORM, V46, P905, DOI 10.1016/j.jbi.2013.07.005; Sittig DF, 2010, QUAL SAF HEALTH CARE, V19, pI68, DOI 10.1136/qshc.2010.042085; Stanley RM, 2014, J PEDIATR-US, V165, P1201, DOI 10.1016/j.jpeds.2014.08.008; Stanley RM, 2014, J PEDIAT, V165, pe2; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Tavender EJ, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0264-7; Tham E, 2016, APPL CLIN INFORM, V7, P534, DOI 10.4338/ACI-2015-10-CR-0144	36	35	35	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2017	139	4							e2 0162709	10.1542/peds.2016-2709			10	Pediatrics	Pediatrics	ER2CU	WOS:000398602400021	28341799	Bronze			2021-06-18	
J	Lane, SM; Briffa, M				Lane, Sarah M.; Briffa, Mark			The price of attack: rethinking damage costs in animal contests	ANIMAL BEHAVIOUR			English	Article						animal contests; cumulative assessment model; damage costs; injurious contests; self-inflicted damage	RECURRENT CONCUSSION; ACTINIA-EQUINA; FOOTBALL; AGGRESSION; STRATEGY; BEHAVIOR; SPIDER; SELF	Theoretical models of injurious animal contests, such as the cumulative assessment model (CAM), predict that an individual's decision to give up and retreat from a fight is determined by reaching a maximum cost threshold (C-max). Under this model, an individual gives up when the accumulated costs of persisting exceed this threshold. CAM predicts that the velocity with which C-max is reached depends on both the energetic (physiological) costs of remaining in the fight and the damage costs of injuries received. Here we propose that damage costs are accumulated not only by receiving injuries, but in some cases also by inflicting injury (attacking). We argue that these self-inflicted damage costs need to be incorporated into theoretical frameworks to fully understand what drives an individual to make the decision to give up, and we call for further research into this area. (C) 2017 The Association for the Study of Animal Behaviour. Published by Elsevier Ltd. All rights reserved.	[Lane, Sarah M.; Briffa, Mark] Plymouth Univ, Marine Biol & Ecol Res Ctr, Davy 620,Drake Circus, Plymouth PL4 8AA, Devon, England	Lane, SM (corresponding author), Plymouth Univ, Marine Biol & Ecol Res Ctr, Davy 620,Drake Circus, Plymouth PL4 8AA, Devon, England.	sarah.lane@plymouth.ac.uk	Lane, Sarah M/O-3153-2017; Briffa, Mark/M-9041-2013	Lane, Sarah M/0000-0002-3797-3178; Briffa, Mark/0000-0003-2520-0538	BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M019772/1]; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M019772/1] Funding Source: researchfish	We thank Ian C.W. Hardy and an anonymous referee for helpful comments on the manuscript. This work was supported by BBSRC grant BB/M019772/1.	BANKS WJ, 1968, ANAT REC, V162, P387, DOI 10.1002/ar.1091620401; Bartosz G, 2008, TOXICON, V51, P1038, DOI 10.1016/j.toxicon.2008.01.017; Batchelor TP, 2012, ANIM BEHAV, V83, P111, DOI 10.1016/j.anbehav.2011.10.014; Batchelor TP, 2011, P ROY SOC B-BIOL SCI, V278, P3243, DOI 10.1098/rspb.2011.0062; Batchelor TP, 2010, ANIM BEHAV, V80, P443, DOI 10.1016/j.anbehav.2010.05.030; BIGGER CH, 1982, J MORPHOL, V173, P259, DOI 10.1002/jmor.1051730303; BIGGER CH, 1980, BIOL BULL, V159, P117, DOI 10.2307/1541013; Bonnin J. P., 1964, Bull Biol, V98, P225; BRACE RC, 1979, ANIM BEHAV, V27, P553, DOI 10.1016/0003-3472(79)90190-8; Briffa M, 2009, ANIM BEHAV, V77, P759, DOI 10.1016/j.anbehav.2008.11.010; CLUTTONBROCK TH, 1982, BEHAVIOUR, V79, P108, DOI 10.1163/156853982X00201; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Davidson DW, 2007, BIOTROPICA, V39, P468, DOI 10.1111/j.1744-7429.2007.00304.x; Davidson DW, 2012, ACTA ZOOL-STOCKHOLM, V93, P487, DOI 10.1111/j.1463-6395.2011.00523.x; Edmonds E, 2016, BIOL LETTERS, V12, DOI 10.1098/rsbl.2015.0884; Goubault M, 2008, BIOL J LINN SOC, V94, P837, DOI 10.1111/j.1095-8312.2008.01022.x; Goubault M, 2006, P ROY SOC B-BIOL SCI, V273, P2853, DOI 10.1098/rspb.2006.3655; Green C. M., 2007, SCANDINAVIAN J MED S, V17, P20; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hurst A., 1917, MED DIS WAR, P308; Johnson HE, 2007, EUR J WILDLIFE RES, V53, P9, DOI 10.1007/s10344-006-0060-4; Johnson SA, 1999, ANIM BEHAV, V57, P957, DOI 10.1006/anbe.1998.1058; McCullough EL, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0696; McCullough EL, 2013, ANIM BEHAV, V86, P977, DOI 10.1016/j.anbehav.2013.08.017; McCullough EL, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0197; Murray M. G., 1987, ANIM BEHAV, V38, P186; Nuchter T, 2006, CURR BIOL, V16, pR316, DOI 10.1016/j.cub.2006.03.089; Palaoro AV, 2017, BEHAV ECOL, V28, P328, DOI 10.1093/beheco/arw163; PARKER GA, 1981, ANIM BEHAV, V29, P221, DOI 10.1016/S0003-3472(81)80170-4; Patek SN, 2004, NATURE, V428, P819, DOI 10.1038/428819a; Payne RJH, 1998, ANIM BEHAV, V56, P651, DOI 10.1006/anbe.1998.0835; Rudin FS, 2011, BEHAV ECOL, V22, P1278, DOI 10.1093/beheco/arr125; Ryan A J, 1991, Br J Sports Med, V25, P81; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Shackleton K, 2015, BEHAV ECOL SOCIOBIOL, V69, P273, DOI 10.1007/s00265-014-1840-6; Shorter J. R., 2015, INSECT SOC, V59, P1; SMITH JM, 1976, ANIM BEHAV, V24, P159, DOI 10.1016/S0003-3472(76)80110-8; Sobotnik J, 2012, SCIENCE, V337, P436, DOI 10.1126/science.1219129; Stabili L, 2015, MAR DRUGS, V13, P5276, DOI 10.3390/md13085276; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Szinicz L, 2005, TOXICOLOGY, V214, P167, DOI 10.1016/j.tox.2005.06.011; Taylor PW, 2003, ANIM BEHAV, V65, P787, DOI 10.1006/anbe.2003.2104; Uematsu K, 2007, SOCIOBIOLOGY, V50, P711; Uematsu K, 2010, CURR BIOL, V20, P1182, DOI 10.1016/j.cub.2010.04.057; Varnon J., 1995, SWAFS J, V17, P19; Wilde G J, 1998, Inj Prev, V4, P89; WILKINSON PF, 1976, ANIM BEHAV, V24, P756, DOI 10.1016/S0003-3472(76)80004-8; WILLIAMS RB, 1978, J MAR BIOL ASSOC UK, V58, P787	49	35	35	0	27	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0003-3472	1095-8282		ANIM BEHAV	Anim. Behav.	APR	2017	126						23	29		10.1016/j.anbehav.2017.01.015			7	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	ET6LH	WOS:000400402700004					2021-06-18	
J	Stewart, WF; Kim, N; Ifrah, CS; Lipton, RB; Bachrach, TA; Zimmerman, ME; Kim, M; Lipton, ML				Stewart, Walter F.; Kim, Namhee; Ifrah, Chloe S.; Lipton, Richard B.; Bachrach, Tamar A.; Zimmerman, Molly E.; Kim, Mimi; Lipton, Michael L.			Symptoms from repeated intentional and unintentional head impact in soccer players	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL IMPAIRMENT; UNITED-STATES; YOUTH SOCCER; ENCEPHALOPATHY; POLYMORPHISM; ASSOCIATION; CONCUSSIONS; SPORTS	Objective: To determine the rate and differential contribution of heading vs unintentional head impacts (e.g., head to head, goal post) to CNS symptoms in adult amateur soccer players. Methods: Amateur soccer players completed baseline and serial on-line 2-week recall questionnaires (HeadCount) and reported (1) soccer practice and games, (2) heading and unintentional soccer head trauma, and (3) frequency and severity (mild to very severe) of CNS symptoms. For analysis, CNS symptoms were affirmed if one or more moderate, severe, or very severe episodes were reported in a 2-week period. Repeated measures logistic regression was used to assess if 2-week heading exposure (i.e., 4 quartiles) or unintentional head impacts (i.e., 0, 1, 21) were associated with CNS symptoms. Results: A total of 222 soccer players (79% male) completed 470 HeadCount questionnaires. Mean (median) heading/2 weeks was 44 (18) for men and 27 (9.5) for women. One or more unintentional head impacts were reported by 37% of men and 43% of women. Heading-related symptoms were reported in 20% (93 out of 470) of the HeadCounts. Heading in the highest quartile was significantly associated with CNS symptoms (odds ratio [OR] 3.17, 95% confidence interval [CI] 1.57-6.37) when controlling for unintentional exposure. Those with 21 unintentional exposures were at increased risk for CNS symptoms (OR 6.09, 95% CI 3.33-11.17) as were those with a single exposure (OR 2.98, 95% CI 1.69-5.26) when controlling for heading. Conclusions: Intentional (i.e., heading) and unintentional head impacts are each independently associated with moderate to very severe CNS symptoms.	[Stewart, Walter F.] Sutter Hlth Res, Walnut Creek, CA USA; [Kim, Namhee; Ifrah, Chloe S.; Bachrach, Tamar A.; Lipton, Michael L.] Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10467 USA; [Kim, Namhee; Ifrah, Chloe S.; Bachrach, Tamar A.; Lipton, Michael L.] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA; [Lipton, Richard B.; Zimmerman, Molly E.] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; [Lipton, Richard B.; Kim, Mimi] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10467 USA; Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Zimmerman, Molly E.] Fordham Univ, Bronx, NY 10458 USA	Lipton, ML (corresponding author), Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA.; Lipton, ML (corresponding author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10467 USA.	Michael.Lipton@einstein.yu.edu	Lipton, Richard B/B-5060-2011		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS082432]; Dana Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082432] Funding Source: NIH RePORTER	Study funded by NIH (R01 NS082432) and Dana Foundation.	Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Dart J, GUARDIAN; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KAHNEMAN D, 1993, PSYCHOL SCI, V4, P401, DOI 10.1111/j.1467-9280.1993.tb00589.x; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Koutures CG, 2010, PEDIATRICS, V125, P410, DOI 10.1542/peds.2009-3009; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Robinson MD, 2002, J PERS SOC PSYCHOL, V83, P198, DOI 10.1037//0022-3514.83.1.198; Rodrigues AC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00038; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	38	35	35	2	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 28	2017	88	9					901	908		10.1212/WNL.0000000000003657			8	Clinical Neurology	Neurosciences & Neurology	EP4HH	WOS:000397341100021	28148633	Green Published			2021-06-18	
J	Wang, ZC; Nong, J; Shultz, RB; Zhang, ZL; Kim, T; Tom, VJ; Ponnappan, RK; Zhong, YH				Wang, Zhicheng; Nong, Jia; Shultz, Robert B.; Zhang, Zhiling; Kim, Taegyo; Tom, Veronica J.; Ponnappan, Ravi K.; Zhong, Yinghui			Local delivery of minocycline from metal ion-assisted self-assembled complexes promotes neuroprotection and functional recovery after spinal cord injury	BIOMATERIALS			English	Article						Spinal cord injury; Minocycline; Drug delivery; Neuroprotection; Inflammation; Secondary injury	INTRACEREBRAL-HEMORRHAGE; PROVIDES NEUROPROTECTION; CELL-DEATH; APOPTOSIS; OLIGODENDROCYTES; CONTUSION; MICROGLIA; BRAIN; PROLIFERATION; NEUROTOXICITY	Many mechanisms contribute to the secondary injury cascades following traumatic spinal cord injury (SCI). However, most current treatment strategies only target one or a few elements in the injury cascades, and have been largely unsuccessful in clinical trials. Minocycline hydrochloride (MH) is a clinically available antibiotic and anti-inflammatory drug that has been shown to target a broad range of secondary injury mechanisms via its anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, MH is only neuroprotective at high concentrations. The inability to translate the high doses of MH used in experimental animals to tolerable doses in human patients limits its clinical efficacy. In addition, the duration of MH treatment is limited because long-term systemic administration of high doses of MH has been shown to cause liver toxicity and even death. We have developed a drug delivery system in the form of hydrogel loaded with polysaccharide-MH complexes self-assembled by metal ions for controlled release of MH. This drug delivery system can be injected into the intrathecal space for local delivery of MH with sufficient dose and duration, without causing any additional tissue damage. We show that local delivery of MH at a dose that is lower than the standard human dose (3 mg/kg) was more effective in reducing secondary injury and promoting locomotor functional recovery than systemic injection of MH with the highest dose and duration reported in experimental animal SCI (90-135 mg/kg). (C) 2016 Elsevier Ltd. All rights reserved.	[Wang, Zhicheng; Nong, Jia; Shultz, Robert B.; Zhang, Zhiling; Zhong, Yinghui] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA; [Kim, Taegyo; Tom, Veronica J.] Drexel Univ, Spinal Cord Res Ctr, Dept Neurobiol & Anat, Coll Med, Philadelphia, PA 19129 USA; [Ponnappan, Ravi K.] Drexel Univ, Coll Med, Dept Orthopaed Surg, Philadelphia, PA 19102 USA	Zhong, YH (corresponding author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	yz348@drexel.edu		Nong, Jia/0000-0002-9210-7707	National Institute of Neurological Disorders And Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS084379]; Drexel-Coulter Translational Research Partnership; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS084379] Funding Source: NIH RePORTER	We thank Dr. Narayan Avadhani (Department of Animal Biology, University of Pennsylvania) for kindly providing RAW264.7 macrophages. This work was supported by the National Institute of Neurological Disorders And Stroke of the National Institutes of Health under Award Number R21NS084379 and the Drexel-Coulter Translational Research Partnership.	Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Anderberg L, 2007, UPSALA J MED SCI, V112, P259, DOI 10.3109/2000-1967-200; Audet JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034932; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Ek CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012021; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Ghica MV, 2011, PHARMAZIE, V66, P853, DOI 10.1691/ph.2011.1061; Goulden V, 1996, BRIT J DERMATOL, V134, P693, DOI 10.1111/j.1365-2133.1996.tb06972.x; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Iannotti CA, 2011, EXP NEUROL, V230, P3, DOI 10.1016/j.expneurol.2010.03.010; JOSHI YM, 1981, BIOPHYS CHEM, V13, P65, DOI 10.1016/0301-4622(81)80026-9; Kashi TSJ, 2012, INT J NANOMED, V7, P221, DOI 10.2147/IJN.S27709; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Koda M, 2002, J NEUROTRAUM, V19, P777, DOI 10.1089/08977150260139147; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; LAMBS L, 1984, AGENTS ACTIONS, V14, P743, DOI 10.1007/BF01978919; Leal EC, 2015, AM J PATHOL, V185, P1638, DOI 10.1016/j.ajpath.2015.02.011; Lee JHT, 2010, SPINE, V35, P2041, DOI 10.1097/BRS.0b013e3181d2d6c5; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Garcia-Martinez EM, 2010, BIOCHEM PHARMACOL, V79, P239, DOI 10.1016/j.bcp.2009.07.028; Milane A, 2007, CHROMATOGRAPHIA, V65, P277, DOI 10.1365/s10337-006-0167-5; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Papa S, 2016, BIOMATERIALS, V75, P13, DOI 10.1016/j.biomaterials.2015.10.015; Papa S, 2013, ACS NANO, V7, P9881, DOI 10.1021/nn4036014; Paquette David W, 2002, Compend Contin Educ Dent, V23, P15; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Pinney SP, 2003, J CARDIOVASC PHARM, V42, P469, DOI 10.1097/00005344-200310000-00003; Sandrow HR, 2008, EXP NEUROL, V210, P489, DOI 10.1016/j.expneurol.2007.11.029; Shoichet MS, 2007, PROG BRAIN RES, V161, P385, DOI 10.1016/S0079-6123(06)61027-3; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Singh A, 2014, J NEUROSCI METH, V226, P124, DOI 10.1016/j.jneumeth.2014.01.001; Soliman GM, 2010, MACROMOL BIOSCI, V10, P278, DOI 10.1002/mabi.200900259; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sung JH, 2010, INT J PHARMACEUT, V392, P232, DOI 10.1016/j.ijpharm.2010.03.024; Takeda M, 2011, SPINE, V36, P1919, DOI 10.1097/BRS.0b013e3181ffda29; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka T. M., 2001, J NEUROCHEM, V91, P568; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhang ZL, 2015, BIOFABRICATION, V7, DOI 10.1088/1758-5090/7/1/015006	57	35	37	5	61	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JAN	2017	112						62	71		10.1016/j.biomaterials.2016.10.002			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	ED9CB	WOS:000389166700006	27744221	Green Accepted			2021-06-18	
J	Ma, J; Xiao, WJ; Wang, JR; Wu, J; Ren, JD; Hou, J; Gu, JW; Fan, KH; Yu, BT				Ma, Jie; Xiao, Wenjing; Wang, Junrui; Wu, Juan; Ren, Jiandong; Hou, Jun; Gu, Jianwen; Fan, Kaihua; Yu, Botao			Propofol Inhibits NLRP3 Inflammasome and Attenuates Blast-Induced Traumatic Brain Injury in Rats	INFLAMMATION			English	Article						blast-induced traumatic brain injury; propofol; NLRP3 inflammasome; inflammation; oxidative stress	NALP3 INFLAMMASOME; NEUROINFLAMMATION; CONTRIBUTES; EXPRESSION; DAMAGE	Increasing evidence has demonstrated that inflammatory response plays a crucial role in the pathogenesis of secondary injury following blast-induced traumatic brain injury (bTBI). Propofol, a lipid-soluble intravenous anesthetic, has been shown to possess therapeutic benefit during neuroinflammation on various brain injury models. Recent findings have proved that the NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome involved in the process of the inflammatory response following brain trauma, may probably be a promising target in the treatment of bTBI. Rats were randomly divided into six groups (n = 8): normal group; bTBI-12 and 24 h group; bTBI-12 h and bTBI-24 h group treated with propofol; and bTBI treated with control dimethyl sulfoxide (DMSO) group. The effect of propofol on the expression and activation of NLRP3 inflammasome and the degree of oxidative stress and inflammatory cascades, as well as the brain trauma biomarkers were evaluated in rats suffering from bTBI. The enhanced expressions and activation of NLRP3 inflammasome in the cerebral cortex of bTBI rats were substantially suppressed by the administration of propofol, which was paralleled with the decreased oxidative stress, cytokines production, and the amelioration of cerebral cortex damage. Our results have, for the first time, revealed that over-activation of NLRP3 inflammasome in the cerebral cortex may be involved in the process of neuroinflammation during the secondary injury of bTBI in rats. Propofol might relieve the inflammatory response and attenuate brain injury by inhibiting ROS and reluctant depressing NLRP3 inflammasome activation and pro-inflammatory cytokines maturation.	[Ma, Jie; Xiao, Wenjing; Wu, Juan; Ren, Jiandong; Hou, Jun; Fan, Kaihua; Yu, Botao] Chengdu Mil Gen Hosp, Dept Pharm, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China; [Wang, Junrui] Chengdu Second Peoples Hosp, Dept Orthopaed, Chengdu 610017, Sichuan, Peoples R China; [Gu, Jianwen] 306th Hosp PLA, Dept Neurosurg, 9 Anxiang Beili, Beijing 100101, Peoples R China; [Gu, Jianwen] Chengdu Mil Gen Hosp, Dept Neurosurg, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China	Gu, JW (corresponding author), 306th Hosp PLA, Dept Neurosurg, 9 Anxiang Beili, Beijing 100101, Peoples R China.; Gu, JW (corresponding author), Chengdu Mil Gen Hosp, Dept Neurosurg, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China.	gujianwen5000@sina.com; fankh2012@sina.com; botao_yu@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501658]; Chengdu Military General Hospital Project [2013YG-B033]	This study was funded by a grant from the National Natural Science Foundation of China (Grant No. 81501658) and Chengdu Military General Hospital Project (Grant No. 2013YG-B033).	Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cai JS, 2011, NEUROCHEM RES, V36, P1724, DOI 10.1007/s11064-011-0487-1; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Ding ZY, 2013, CELL BIOCHEM BIOPHYS, V67, P615, DOI 10.1007/s12013-013-9549-0; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Grasshoff C, 2005, EUR J ANAESTH, V22, P467, DOI 10.1017/S0265021505000803; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hampton T, 2011, JAMA-J AM MED ASSOC, V306, P477, DOI 10.1001/jama.2011.1092; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Ma Jie, 2009, Yaoxue Xuebao, V44, P344; Marik PE, 2004, CURR PHARM DESIGN, V10, P3639, DOI 10.2174/1381612043382846; Pedra JHF, 2009, CURR OPIN IMMUNOL, V21, P10, DOI 10.1016/j.coi.2009.01.006; Ren JD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930894; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003; Taylor PA, 2014, BRAIN INJURY, V28, P879, DOI 10.3109/02699052.2014.888478; Thomas S, 2000, ACT NEUR S, V76, P397; Tsuchiya M, 2002, AM J RESP CRIT CARE, V165, P54, DOI 10.1164/ajrccm.165.1.2010134; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xi HJ, 2011, BRAIN RES, V1410, P24, DOI 10.1016/j.brainres.2011.06.060; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	38	35	38	0	13	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	DEC	2016	39	6					2094	2103		10.1007/s10753-016-0446-8			10	Cell Biology; Immunology	Cell Biology; Immunology	EC4MX	WOS:000388106800025	27696022				2021-06-18	
